<SEC-DOCUMENT>0001564590-21-014169.txt : 20210318
<SEC-HEADER>0001564590-21-014169.hdr.sgml : 20210318
<ACCEPTANCE-DATETIME>20210318162543
ACCESSION NUMBER:		0001564590-21-014169
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210318
DATE AS OF CHANGE:		20210318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALX ONCOLOGY HOLDINGS INC
		CENTRAL INDEX KEY:			0001810182
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				850642577
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39386
		FILM NUMBER:		21754660

	BUSINESS ADDRESS:	
		STREET 1:		866 MALCOLM ROAD, SUITE 100
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
		BUSINESS PHONE:		650-466-7125

	MAIL ADDRESS:	
		STREET 1:		866 MALCOLM ROAD, SUITE 100
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>alxo-10k_20201231.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alxo-10k_20201231.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:center;border-top:Double 2.25pt;padding-top:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:15pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 10-K<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Mark&#160;One) </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 </p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December 31, 2020</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">OR </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:4%;">
<p style="margin-top:3pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Segoe UI Symbol;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:96%;">
<p style="margin-top:2pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934 FOR THE TRANSITION PERIOD FROM&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; TO &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Commission File Number&#160;001-39386 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALX ONCOLOGY HOLDINGS INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of Registrant as specified in its Charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">85-0642577</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Identification No.)</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">866 Malcolm Road, Suite 100</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Burlingame, California</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">94010</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="bottom"  style="width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Registrant&#8217;s telephone number, including area code: 650-466-7125  </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:46.15%;margin-right:46.15%;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title of each class</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Trading</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Symbol(s)</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Name of each exchange on which registered</p></td>
</tr>
<tr>
<td valign="top"  style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, par value $0.001 per share</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:20%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALXO</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:39%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Nasdaq Global Select Market</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: <font style="font-weight:bold;">None </font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section&#160;13 or 15(d) of the Act. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the Registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the Registrant was required to submit such files). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr style="height:10.8pt;">
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated&#160;filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:56.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:21.56%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td colspan="2" valign="top"  style="width:2.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated filer</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9744;</p></td>
</tr>
<tr style="height:1.9pt;">
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:2pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:19.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:55.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Segoe UI Symbol;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#9746;</p></td>
<td valign="top"  style="width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:20.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:2.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant has filed a report on and attestation to its management&#8217;s assessment of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <font style="font-family:Segoe UI Symbol;">&#9744;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). &#160;YES&#160;<font style="font-family:Segoe UI Symbol;">&#9744;</font> NO&#160;<font style="font-family:Segoe UI Symbol;">&#9746;</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the common stock held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The Nasdaq Stock Market on December 31, 2020, was $1.5 billion. The Registrant has elected to use December 31, 2020 as the calculation date, which was the last trading date of the Registrant&#8217;s most recently completed fiscal year, because on June 30, 2020 (the last business day of the Registrant&#8217;s most recently completed second fiscal quarter), the Registrant was a privately held company. Shares of common stock owned by each executive officer, director, and holder of more than 5% of the Registrant&#8217;s common stock have been excluded in that such persons may be deemed to be affiliates of the Registrant. This calculation does not reflect a determination that certain persons are affiliates of the Registrant for any other purpose.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of Registrant&#8217;s Common Stock outstanding as of March 12, 2021 was 40,127,198. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain portions of the registrant's definitive proxy statement relating to the Company's 2021 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</p>
<p style="border-bottom:Double 2.25pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Table of Contents</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART I</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1_BUSINESS"><font style="text-decoration:underline;">Business</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1A_RISK_FACTORS"><font style="text-decoration:underline;">Risk Factors</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_1B_UNRESOLVED_STAFF_COMMENTS"><font style="text-decoration:underline;">Unresolved Staff Comments</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_2_PROPERTIES"><font style="text-decoration:underline;">Properties</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_3_LEGAL_PROCEEDINGS"><font style="text-decoration:underline;">Legal Proceedings</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_4_MINE_SAFETY_DISCLOSURES"><font style="text-decoration:underline;">Mine Safety Disclosures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"><font style="text-decoration:underline;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_6_SELECTED_FINANCIAL_DATA"><font style="text-decoration:underline;">Selected Financial Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"><font style="text-decoration:underline;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"><font style="text-decoration:underline;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"><font style="text-decoration:underline;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"><font style="text-decoration:underline;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9A_CONTROLS_PROCEDURES"><font style="text-decoration:underline;">Controls and Procedures</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_9B_OR_INFORMATION"><font style="text-decoration:underline;">Other Information</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;III</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"><font style="text-decoration:underline;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_11_EXECUTIVE_COMPENSATION"><font style="text-decoration:underline;">Executive Compensation</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"><font style="text-decoration:underline;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"><font style="text-decoration:underline;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"><font style="text-decoration:underline;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;IV</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"><font style="text-decoration:underline;">Exhibits, Financial Statement Schedules</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;16.</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:underline;">Form 10-K Summary</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:94.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:underline;">SIGNATURES</font></a></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.9%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Annual Report on Form 10-K contains forward-looking statements. All statements other than statements of historical facts contained in this report, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. Forward-looking statements contained in this Annual Report include, but are not limited to, statements about: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our financial performance; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and our ability to grow a sales team; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the implementation of our strategic plans for our business and product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to obtain and maintain regulatory approval of our product candidates and the timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations, such as orphan drug designation, for our product candidates for various diseases; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our reliance on third parties to conduct preclinical research activities, and for the manufacture of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the progress and focus of our current and future clinical trials, and the reporting of data from those trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to advance product candidates into and successfully complete clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the ability of our clinical trials to demonstrate the safety and efficacy of our product candidates, and other positive results; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the success of competing therapies that are or may become available; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">developments relating to our competitors and our industry, including competing product candidates and therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our plans relating to the further development and manufacturing of our product candidates, including additional indications that we may pursue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">existing regulations and regulatory developments in the United States and other jurisdictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our potential and ability to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the scope of protection we are able to establish and maintain for intellectual property rights, including our technology platform and product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to retain the continued service of our key personnel and to identify, hire, and then retain additional qualified personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our expectations regarding the impact of the COVID-19 pandemic on our business; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">and our anticipated use of our existing cash and cash equivalents.</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ii</a></p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this Annual Report on Form 10-K and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this Annual Report, whether as a result of any new information, future events or otherwise.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, statements that &#8220;we believe&#8221; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iii</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a><a name="PART_I"></a>PART I</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1_BUSINESS"></a><a name="ITEM_1_BUSINESS"></a>Item 1. Business. </p>
<p style="text-align:center;margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">BUSINESS</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage immuno-oncology company focused on helping patients fight cancer by developing therapies that focus on the CD47-SIRP&#945; checkpoint pathway and bridge the innate and adaptive immune system. Cancer cells leverage CD47, a cell surface protein, as a &#8220;don&#8217;t eat me&#8221; signal, to evade detection by the immune system. Our lead program is a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, ALX148, will have a wide therapeutic window to block the &#8220;don&#8217;t eat me&#8221; signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. We have dosed over 170 subjects with ALX148 across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. We intend to continue clinical development for the treatment of a range of solid tumor indications and for the treatment of hematologic malignancies, including myelodysplastic syndromes, or MDS, and acute myeloid leukemia, or AML. We plan to initiate additional studies in combination with leading anti-cancer agents. In solid tumors, we intend to initiate randomized Phase 2 trials of ALX148 for the treatment of first-line head and neck cancer and second-line gastric/gastroesophageal junction, or GEJ, cancer and a Phase 1 trial for the treatment of breast cancer in 2021. In hematologic malignancies, we have dosed the first subjects for the treatment of MDS and intend to advance ALX148 into clinical development for the treatment of AML in the second half of 2021. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability and our clinical development plans, our strategy is to pursue ALX148 as a potentially critical component for future combination treatments in oncology. Our second program combines our company&#8217;s SIRP&#945; antibodies with Tallac Therapeutics&#8217; toll-like receptor 9 agonist antibody conjugate to deliver a potent immune activator to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anti-cancer agents, including many chemotherapies, other small molecules and anti-cancer antibodies, can stimulate immune cells such as macrophages to engulf and kill cancer cells, a process known as phagocytosis, by providing so-called &#8220;eat me&#8221; signals on cancer cells. In response, cancer cells frequently overexpress CD47 to counteract these &#8220;eat me&#8221; signals. As a result, high expression of CD47 on cancer cells has been associated with reduced patient survival in multiple cancers. The therapeutic blockade of CD47 in combination with an &#8220;eat me&#8221; signal enables the immune system to detect and phagocytose cancer cells. However, healthy blood cells and nearly all other cells in the body also express CD47 as a way to protect against pathologic phagocytosis by immune cells. There have been a number of approaches to blocking CD47, including monoclonal antibodies and fusion proteins that include an active Fc region. These approaches have encountered limitations, including limited dosing and therapeutic window, limited ability to combine with other anti-cancer agents, limited efficacy in solid tumors and limited indications due to patient selection, that have challenged their ability to maximize the full potential of CD47 blockade. In addition, most of these therapeutic approaches to CD47 blockade have resulted in the destruction of patients&#8217; healthy blood cells, causing cytopenias that limit the dosing and therapeutic potential of those molecules. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALX Oncology was founded by Corey Goodman, Ph.D., K. Christopher Garcia, Ph.D., and Jaume Pons, Ph.D. to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target. We have developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities. All competing clinical data to date have come from product candidates that incorporate an active antibody Fc region in addition to a CD47 blocking region. The Fc region provides a positive, pro-phagocytic &#8220;eat me&#8221; signal to macrophages and other cells of the immune system. Since healthy blood cells also express CD47, these competing therapeutic approaches can cause a reduction in the number of blood cells in the body, resulting in anemia, thrombocytopenia and neutropenia, which can be dangerous to patients and may limit the ability to combine these agents with other anti-cancer medicines. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, ALX148, is a next-generation CD47 blocking therapeutic that we believe has significantly enhanced properties compared to competing CD47 blocking approaches. ALX148 is a fusion protein that combines a high-affinity CD47 binding domain with a proprietary inactivated Fc domain. The CD47 binding domain of ALX148 is an affinity enhanced extracellular domain of SIRP</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#945;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a protein that is the natural receptor to CD47 found on myeloid cells. We have engineered the Fc domain of ALX148 so that it does not provide a pro-phagocytic signal while still maintaining an antibody-like half-life for the molecule. We believe our inactive Fc approach improves tolerability when compared to other CD47 blocking approaches that have an Fc domain that engages activating receptors on macrophages, causing phagocytosis and death of healthy cells in addition to cancer cells. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALX148&#8217;s design has several advantages that we believe will make it broadly applicable to treating a number of oncology indications. Due to the inactive Fc, ALX148 is specifically designed for use in combination with other anti-cancer agents that provide a positive immune-stimulating signal. We believe ALX148 has a favorable tolerability profile that may enable higher dosing levels and greater combination potential with other leading anti-cancer agents. Additionally, the molecular weight of ALX148 is half that of a typical antibody. The relatively smaller size of our molecule may facilitate increased penetrance into the tumor microenvironment. We believe these properties may enable ALX148 to provide superior therapeutic benefits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical data to date in ALX148 have not shown dose-dependent hematologic toxicities, which are characteristic of other CD47 blockers that incorporate an active Fc domain. At least 170 subjects have been treated with ALX148 in combination with targeted anti-cancer agents, small molecules, and checkpoint inhibitors as of December 31, 2020. ALX148 has not reached a maximum tolerated dose in any of the combinations evaluated to date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, we began enrollment in subjects with MDS and plan to advance ALX148 for the treatment of AML. In our Phase 1b trial of ALX148 in combination with an anti-CD20 agent to treat subjects with relapsed/refractory non-Hodgkin&#8217;s lymphoma, or NHL, ALX148 demonstrated a higher response rate at higher doses and achieved a 70.0% objective response rate, or ORR, in the highest dose (15 mg/kg once per week, or QW) cohort as compared to a 40.9% ORR at the lower dose (10 mg/kg QW) cohort. We view this ORR as compelling evidence for the role of ALX148 in treating hematologic malignancies and as a favorable comparison to outcomes reported by other CD47 blocking agents in a similar patient population. Furthermore, other CD47 blocking agents in development have demonstrated clinical evidence supporting the role of CD47 blockade in treating hematologic malignances, specifically in both MDS and AML, albeit with high rates of cytopenias. We have conducted preclinical studies of ALX148 combined with azacitidine or venetoclax that support our clinical development plan in MDS and AML. Azacitidine is a standard of care agent for the treatment of MDS. Azacitidine and venetoclax are both standard of care regimen components for the treatment of AML in older patients and those who are not candidates for intensive induction chemotherapy due to comorbidities. We have conducted preclinical studies that show that azacitidine and venetoclax increase both the display of the &#8220;eat me&#8221; signal calreticulin and the &#8220;don&#8217;t eat me&#8221; signal CD47 on AML cells, suggesting that a CD47 blocking agent could maximize the activity of venetoclax and azacitidine in these models. Additionally, we have shown that azacitidine and ALX148 in combination produce increased phagocytosis in vitro and anti-tumor activity in mouse models compared to azacitidine alone. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, we have demonstrated that combination treatment of ALX148 with azacitidine or venetoclax leads to tumor elimination and prolonged survival in leukemia mouse models. In October 2020, the first subjects received ALX148 in a Phase 1b/2 trial in combination with azacitidine for the treatment of subjects with higher-risk MDS. We also plan to advance ALX148 into a Phase 1b/2 trial in combination with venetoclax and azacitidine for the first-line treatment of subjects with AML in the second half of 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALX148 has also generated clinical data in solid tumors in various combinations, including with a leading tumor antigen targeting antibody, a leading checkpoint inhibitor and chemotherapy. We believe that ALX148 induces multiple responses that bridge innate and adaptive immunity. We are investigating ALX148 for the treatment of head and neck squamous cell carcinoma, or HNSCC, human epidermal growth factor receptor 2, or HER2-positive gastric/GEJ carcinoma, and HER2-expressing breast cancer and other solid tumors. In Phase 1b clinical trials, ALX148 has demonstrated both objective clinical response per the Response Evaluation Criteria in Solid Tumors, or RECIST, criteria and tolerability in combination with other broadly used cancer agents. Based on these results, the Food&#160;and Drug Administration, or FDA, has granted Fast Track designation for ALX148 for both the treatment of patients with HNSCC in the first-line setting and for patients with HER2-positive advanced gastric </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or GEJ carcinoma in the second-line setting. While other CD47 blockers have failed to achieve meaningful clinical activity in the treatment of solid tumors, we believe ALX148&#8217;s properties, including favorable tolerability and ability to escalate to higher doses, coupled with high affinity and small size for enhanced solid tumor penetration, may underlie the observed anti-tumor activity in solid tumors. We are planning to advance ALX148 into two </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">randomized </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2 trials in patients with previously untreated advanced HNSCC in combination with pembrolizumab, marketed as Keytruda, the market leading anti-programmed cell death protein-1, or PD-1, checkpoint inhibitor, with or without chemotherapy in the first half of 2021. These trials will be conducted in collaboration with Merck. We are also planning to advance ALX148 into </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">randomized </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2 trials in subjects with previously treated advanced HER2-positive gastric/GEJ carcinoma in combination with trastuzumab, marketed as Herceptin, the market-leading anti-HER2 antibody, with the second line standard of care, ramucirumab, marketed as Cyramza, plus paclitaxel in the second half of 2021. We have also entered into a clinical trial collaboration with Zymeworks to initiate a Phase&#160;1 trial of ALX148 in combination with Zymeworks&#8217; HER2-targeted bispecific antibody zanidatamab for the treatment of patients with HER2-expressing breast cancer. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our team of industry veterans plans to continue to advance a broad development plan for ALX148 that balances speed to market, scale of unmet need and existing clinical evidence for ALX148&#8217;s combination mechanisms. Members of our management team have brought multiple drugs to FDA approval. Our President, Chief Executive Officer and founder, Jaume Pons, Ph.D., was Chief Science Officer of Rinat (a subsidiary of Pfizer), invented fremanezumab (FDA approved in 2018), tanezumab (Biologics License Application, or BLA, filed in 2020) and additional antibodies in late-stage development at Pfizer and advanced nine more drugs into human trials. Our Chief Medical Officer, Sophia Randolph, M.D., Ph.D., was the global clinical franchise lead for Ibrance at Pfizer, where she oversaw the program from first-in-human trials to regulatory approval. Our Executive Chairman and founder, Corey Goodman, Ph.D., an elected member of the National Academy of Sciences, has co-founded seven biopharmaceutical companies, including Exelixis and Labrys (acquired by Teva Pharmaceuticals in 2014), and led Pfizer&#8217;s Biotherapeutics and Bioinnovation Center. Our Chief Financial Officer, Peter Garcia, has over 20 years of experience guiding public and private life science companies and has raised over $2.0&#160;billion in debt and equity offerings. We have funded ALX Oncology to date primarily through the issuance and sale of our convertible preferred stock and the issuance and sale of our common stock through an initial public offering in July 2020 and a follow-on public offering in December 2020. We own global rights to all of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Strategy </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our goal is to transform treatment options for patients with cancer by developing ALX148 as a foundational checkpoint immunotherapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Key elements of our strategy to support this goal include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Advance our lead product candidate, ALX148, through clinical development for MDS and AML.&#160;&#160;&#160;&#160;</font><font style="font-size:10pt;color:#000000;">We have initiated a</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">Phase 1b/2 trial of ALX148, in combination with azacitidine, for the treatment of patients with higher-risk MDS and plan to initiate a Phase 1b/2 trial in combination with venetoclax and azacitidine for the first-line treatment of patients with AML in the second half of 2021. Given the limitations of current treatment options for patients with MDS, preclinical activity of ALX148 in combination with azacitidine, clinical data from competitor programs and the differentiated tolerability profile of ALX148, we intend to pursue a strategy in which we will leverage the data generated from this Phase 1b/2 trial to request from the FDA that ALX148 be a candidate for accelerated approval in the first-line treatment of higher risk MDS. Similarly, we believe ALX148 combination therapies could address the significant unmet need for more active tolerable regimens in the majority of patients with AML who are not fit for intensive induction chemotherapy. While we plan to seek accelerated approval by the FDA for the use of ALX148 in higher risk MDS, and potentially AML, and may do so opportunistically for other indications in the future, there is no assurance that this approach will be successful for these as well as other indications. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Expanding the therapeutic potential of CD47 blockade into solid tumors.&#160;&#160;&#160;&#160;</font><font style="font-size:10pt;color:#000000;">We believe ALX148 can overcome the limitations</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">of other CD47 blocking approaches in solid tumors. We have generated encouraging data in subjects with HNSCC treated with ALX148 in combination with a PD-1 checkpoint inhibitor with and without chemotherapy as well as in subjects with HER2-positive gastric/GEJ cancer, who have progressed on prior HER2-targeted therapy, treated in combination with a HER2-targeted antibody with and without chemotherapy. The FDA has granted ALX148 Fast Track designation in first-line HNSCC and second-line HER2-positive gastric/GEJ cancer. We intend to pursue a strategy in which we will leverage the data generated from our planned</font><font style="font-size:10pt;color:#000000;"> randomized</font><font style="font-size:10pt;color:#000000;"> Phase 2 trials of ALX148 and pembrolizumab with and without chemotherapy to request from the FDA that ALX148 be a candidate for accelerated approval in the first-line treatment of HNSCC. We are also planning a </font><font style="font-size:10pt;color:#000000;">randomized </font><font style="font-size:10pt;color:#000000;">Phase 2 trial of ALX148, trastuzumab and chemotherapy in second-line HER2-positive gastric/GEJ cancer and plan to request from the FDA that ALX148 be a candidate for accelerated approval in the second-line treatment of gastric/GEJ cancer. We also plan to initiate an additional Phase 1 trial of ALX148 in patients with HER2-expressing breast cancer and other solid tumors in combination with zanidatamab. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Continuing development of a pipeline of innovative therapeutics based on our protein engineering expertise and knowledge of the immune system and cancer biology.&#160;&#160;&#160;&#160;</font><font style="font-size:10pt;color:#000000;">We</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">specialize in designing and developing drug candidates that engage the immune system. We continue to develop a pipeline of immuno-oncology programs that represent complementary, but differentiated, approaches to engaging the innate and adaptive immune systems. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Continuing to develop strategic partnerships to broaden the potential impact of our current and future product candidates across patient populations.&#160;&#160;&#160;&#160;</font><font style="font-size:10pt;color:#000000;">In order to advance treatment options for the most patients, we have in the past and may in the future partner with other companies with</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">complementary resources that will maximize the value of our current and future product candidates. Such partnerships may allow us to pair ALX148 and any future product candidates with other novel agents owned fully or in part by strategic partners. Partnerships may and will also help realize the full potential of our product candidates in markets where we are unlikely to pursue development or commercialization on our own. We intend to maintain significant economic interest in our product candidates and selectively consider partnership opportunities. In September 2020, we announced a clinical trial collaboration with Merck on a Phase&#160;2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer. In November 2020, we announced a clinical trial collaboration with Zymeworks on a Phase&#160;1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pipeline </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our initial programs are focused on targeting CD47 across various oncology indications. Many forms of cancer use CD47 expression as a means of evading immune response. We are targeting the hematologic malignancies and solid tumor indications where we believe we have the greatest potential to address large markets and unmet medical needs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The chart below summarizes the development status of our product candidate pipeline. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000001.jpg" title="" alt="" style="width:624px;height:292px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have a preclinical program focused on developing a SIRP&#945; TRAAC that may offer additional ways to engage the innate and adaptive immune response to cancer.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CD47 Scientific Background </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer immunotherapies targeting adaptive immune system checkpoints, notably those related to T cells, have transformed the standard of care in oncology across multiple cancer types. Initial clinical successes in this area have focused on stimulating the adaptive immune system. However, emerging evidence demonstrates that the innate immune system plays a crucial role in the first line of defense to eliminate transformed malignant cells and the subsequent activation of the adaptive immune system. Dendritic cells and macrophages are a type of myeloid cell and are important parts of the innate immune system. These cells eliminate cancer cells by phagocytosis and present tumor-derived antigens to T cells, a process known as cross-priming, which activates the adaptive immune system. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer cells evade phagocytosis by up-regulating CD47, a transmembrane protein that mainly functions as an anti-phagocytic &#8220;don&#8217;t eat me&#8221; signal for healthy cells. CD47 interacts with its cognate receptor SIRP&#945;, a regulatory membrane glycoprotein, that is expressed on macrophages and other myeloid cells and serves to prevent phagocytosis when bound to CD47. By overexpressing CD47, cancer cells are able to avoid phagocytosis by macrophages and thereby evade subsequent detection by the adaptive immune system. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">High CD47 expression in cancer cells has been shown to be a prognostic indicator of decreased survival in multiple oncology indications. A study published by Majeti, et al. in 2009, assessed this association in a validation cohort of 137 subjects with AML. As shown in the figure below, normal karyotype AML, or NK-AML, subjects with high levels of CD47 expression had shorter median overall survival, or mOS, of 9.1 months compared to subjects with low levels of CD47 expression who had an mOS of 22.1 months. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000002.jpg" title="" alt="" style="width:444px;height:250px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CD47 as a therapeutic checkpoint target </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Data generated by our and other studies in the field have demonstrated that activating the immune system against cancer requires both blocking phagocytosis checkpoints and inducing pro-phagocytic signals. This can be achieved by combining CD47 blockade with either conventional chemotherapies or targeted therapies, which together promote phagocytosis by macrophages and maximize adaptive immune system response. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Existing anti-cancer therapeutics can increase &#8220;eat me&#8221; signals on cancer cells. For example, the hypomethylating agent, or HMA, azacitidine activates the immune system by increasing display of calreticulin, a multifunctional protein, on cancer cells. Calreticulin is an important example of a pro-phagocytic &#8220;eat me&#8221; signal that potentiates immune response when expressed on cancer cells. Therapeutic antibodies that target tumor-specific antigens, such as the HER2 receptor, also induce cellular phagocytosis, but through a slightly different mechanism. These antibodies direct macrophages to cancer cells by binding to the tumor-specific antigen and activating the macrophage by engaging the Fc&#947; receptors to induce phagocytosis. However, if CD47 is not blocked, the &#8220;don&#8217;t eat me&#8221; signal can limit the activity of this mechanism. CD47 blocking therapies can therefore maximize a combination agent&#8217;s clinical efficacy by overcoming the &#8220;don&#8217;t eat me&#8220; signal that is co-opted by cancer cells. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our lead product candidate targets CD47 to maximize phagocytosis of cancer cells and activation of the adaptive immune system. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000003.jpg" title="" alt="" style="width:624px;height:240px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancer cells can also modulate their environment to suppress detection by immune cells. Overexpression of CD47 helps cancer cells avoid innate immune system detection by dendritic cells and subsequent antigen presentation to T cells, thereby limiting anti-tumor immune response. PD(L)-1 targeting immunotherapies are designed to reduce the suppression of T cells but do not address the initial evasion of the innate immune system by cancer cells. By removing the suppression of dendritic cells, CD47 blocking therapies in combination with PD(L)-1 targeted therapies can complement their T cell stimulatory activities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Limitations of Current Approaches to Blocking CD47 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been a number of approaches to blocking CD47, including monoclonal antibodies and fusion proteins that include an active Fc region. These approaches have encountered limitations that have challenged their ability to maximize the full potential of CD47 blockade. These include: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Limited dosing and therapeutic window</font><font style="font-size:10pt;color:#000000;">:&#160;&#160;&#160;&#160;All clinical data to date from other CD47 blocking agents have come from approaches</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">that incorporate an active Fc region that provides an &#8220;eat me&#8221; signal to macrophages. Given that healthy blood cells express CD47, the presence of an &#8220;eat me&#8221; signal coupled with CD47 binding in a single-agent leads to destruction of blood cells. This mechanism is illustrated in the figure below. The trials of these other CD47 blocking agents have resulted in frequent occurrence of treatment-related cytopenias that we believe limits the therapeutic window of these agents. In addition to limiting the dosing, cytopenias can be dangerous for patients undergoing treatment for cancer as they may already have a compromised immune system related to intensive treatment regimens and disease progression. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Limited ability to combine with other anti-cancer agents</font><font style="font-size:10pt;color:#000000;">:&#160;&#160;&#160;&#160;Combination therapies continue to play an important role in treating</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">patients with cancer. Overlapping toxicities of these agents dictate which agents can and cannot be combined. The overlapping toxicity profiles of other CD47 blocking agents and most other anti-cancer agents create challenges for combination dosing. When combination dosing is possible, the therapeutic benefit of the combination is limited due to the minimal amount of the CD47 blocking agent that can be safely dosed. Moreover, many combinations are precluded entirely due to overlapping toxicity. In addition, an active Fc domain can compete with anti-cancer antibodies when used in combination treatments and can prevent such antibodies from binding with Fc&#947; receptors on immune cells. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Limited efficacy in solid tumors</font><font style="font-size:10pt;color:#000000;">:&#160;&#160;&#160;&#160;To date, other CD47 blocking agents have failed to achieve meaningful clinical activity in the</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">treatment of solid tumors, as the balance between managing cytopenias and maximizing efficacy may lead to tolerable doses that are too low to facilitate tumor penetration and efficacy. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Limited indications due to patient selection</font><font style="font-size:10pt;color:#000000;">: Toxicities associated with other CD47 blocking agents may require careful patient</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">selection when evaluating potential indications. In some cases, only subjects with lower risk of hematologic complications have been selected for treatment for other CD47 blocking agents due to drug related risk of severe cytopenias. Sponsors have chosen to initially develop these investigational medicines in indications such as MDS, where patients are often already cytopenic upon presentation and receive regular transfusions, potentially obscuring the side effects of their CD47 blocking approaches. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000004.jpg" title="" alt="" style="width:616px;height:248px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Advantages of ALX&#8217;s Approach to Blocking CD47 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We founded ALX Oncology because we believed the limitations described above would prevent CD47 blockade from reaching its full potential as a therapy for patients with cancer. From the company&#8217;s inception, we designed ALX148 to overcome these limitations and to maximize the utility of CD47 blockade as an effective anti-cancer therapeutic for a broad range of tumors. Specifically, we believe ALX148 may provide the following significant advantages: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Broader therapeutic window</font><font style="font-size:10pt;color:#000000;">:&#160;&#160;&#160;&#160;We believe ALX148&#8217;s broader therapeutic window will allow for greater drug exposure than other</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">CD47 blocking agents potentially translating into improved efficacy across a range of cancers, including MDS and AML, compared to other CD47 blocking agents. To date, we have not yet reached a maximum tolerated dose, or MTD, for ALX148. Furthermore, flexibility in dosing could allow for several administration schedules (weekly, bi-weekly, every three weeks, monthly) that are more amenable to combination therapy dosing schedules, potentially improving a patient&#8217;s quality of life. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Strong potential for combination with other anti-cancer agents</font><font style="font-size:10pt;color:#000000;">:&#160;&#160;&#160;&#160;CD47 blocking agents are combined with other therapeutics in</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">order to maximize their potential in treating patients with cancer. Unlike other CD47 blocking agents, ALX148 was specifically designed to be combined with other anti-cancer agents. We believe ALX148&#8217;s favorable toxicity profile will enable it to be combined with a wider range of anti-cancer agents, including chemotherapy and cytotoxic containing regimens, compared to other CD47 blocking agents. Furthermore, we believe that ALX148&#8217;s inactive Fc domain will neither compete with nor potentially limit the efficacy of anti-cancer antibodies when used in combination treatments. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Encouraging responses in solid tumors</font><font style="font-size:10pt;color:#000000;">:&#160;&#160;&#160;&#160;ALX148 has demonstrated meaningful Phase 1b clinical data in the treatment of solid</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">tumors. While other CD47 blocking agents have failed to demonstrate meaningful clinical activity in solid tumors, ALX148&#8217;s differentiated properties may underlie its encouraging results. Based on the data generated with ALX148 in combination with anti-cancer antibodies and checkpoint inhibitors with and without chemotherapy, our strategy is to pursue ALX148 as a potentially critical component for future combination treatment of solid tumors. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-weight:bold;font-size:10pt;color:#000000;">Broader potential indications</font><font style="font-size:10pt;color:#000000;">:&#160;&#160;&#160;&#160;We believe ALX148&#8217;s tolerability profile will allow for broad treatment of patient populations in a</font><font style="font-weight:bold;font-size:10pt;color:#000000;"> </font><font style="font-size:10pt;color:#000000;">wide range of oncology indications. Toxicities such as cytopenias associated with other CD47 blocking agents may potentially constrain their development strategies. While initial activity of other CD47 blocking agents has been reported in indications such as MDS and AML where many patients already suffer from disease-induced cytopenias, their development in oncology indications that do not include associated cytopenias may be challenged. We believe ALX148 is well positioned to expand the therapeutic potential of CD47 blockade across a broad spectrum of hematologic and solid tumor indications. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ALX148 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, ALX148, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including MDS, AML, HNSCC, gastric/GEJ and breast cancer. We engineered ALX148 to maximize CD47 blockade and to avoid hematologic toxicities. We believe ALX148 enhances the efficacy of both anti-cancer targeted antibodies, numerous small molecule drugs and T cell checkpoint inhibitors and exhibits no dose-dependent cytopenias. ALX148 has demonstrated encouraging clinical responses in combination with multiple anti-cancer regimens for both hematologic and solid malignancies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other companies have pursued CD47 blocking approaches that prioritize single-agent activity, albeit with limited success. Rather than designing a molecule for monotherapy activity that has been associated with cytopenias, we designed ALX148 for use in combination with anti-cancer agents. Our product candidate exclusively blocks the &#8220;don&#8217;t eat me&#8221; pathway. A combination anti-cancer agent provides a specific pro-phagocytic signal on cancer cells. This approach may both increase the specificity to cancer cells and avoid dose-dependent destruction of healthy blood cells. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fusion Protein Design </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALX148 is a fusion protein designed to provide a high CD47 blocking potency while potentially eliminating any associated toxicities. Our fusion protein comprises an engineered CD47-binding domain of SIRP&#945; that has been genetically linked to a modified human immunoglobulin-derived Fc domain that does not bind to Fc&#947; receptors. We engineered ALX148 in two important ways: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We mutated the binding domain to optimize CD47 affinity. ALX148 binding domain demonstrates an affinity that is over 3,000 times stronger than wildtype SIRP&#945;. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We fused the CD47-binding region of SIRP&#945; to an inactive Fc domain. Incorporating an inactive Fc domain was intended to eliminate single-agent activation of macrophages while still maintaining an antibody-like pharmacokinetic, or PK, profile. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The successful design of ALX148 required in-house generation of approximately 280 different protein constructs to thoroughly evaluate and optimize the impact of differing designs on multiple important evaluation criteria. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to optimize ALX148&#8217;s properties we conducted the following processes: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Design of the high-affinity CD47 binding domain: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Optimization of binding affinity for human CD47; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Optimization of cross-reactivity to rodent and monkey CD47 to enable key translational experiments; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Elimination of partially glycosylated sites in SIRP&#945; to remove heterogeneity and enable consistent manufacturing. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Design of the optimal fusion combination for PK extension: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Selection of an immunoglobulin isotype to prevent hemagglutination; and </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Selection of mutations to immunoglobulin G1, or IgG1, to functionally eliminate Fc&#947; binding and avoid associated cytopenias while maintaining neonatal Fc receptor binding that enables antibody-like PK. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As illustrated in the figure below, ALX148 comprises: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">A SIRP&#945; binding domain optimized to bind to CD47 with high affinity at a picomolar level; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">An inactive Fc domain that reduces cytopenias while preserving the desired PK properties of antibodies with an active Fc domain. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The resulting fusion protein has approximately one-half the molecular weight of a typical antibody. ALX148&#8217;s lower molecular weight enables it to deliver the molar equivalent of an antibody at one half the dose. For example, a 30 mg/kg dose of ALX148, the highest level that we have dosed to date, is approximately equivalent to a 60 mg/kg dose of an antibody. ALX148&#8217;s lower molecular weight may also facilitate increased solid tumor penetration and provide greater potency within the tumor microenvironment. Furthermore, ALX148 can be efficiently and consistently produced at high yield at commercial scale utilizing standard monoclonal antibody manufacturing techniques. We believe ALX148&#8217;s differentiated properties potentially overcome the limitations of other CD47 blocking agents and may have utility as a combination agent in oncology. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Our lead candidate is a fusion protein that potently and selectively binds CD47 to block the SIRP<font style="font-style:normal;">&#945;</font> interaction. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000005.jpg" title="" alt="" style="width:622px;height:263px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Pre-Clinical Differentiation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our preclinical studies of ALX148 support a target product profile of favorable tolerability, the ability to be dosed in high levels and increased anti-tumor activity as compared to other CD47 blocking agents. These data include the following. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Lack of hematologic side effects </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our preclinical data demonstrate that CD47 blocking agents with an active Fc domain directly cause adverse hematologic side effects. To support this hypothesis, we engineered a fusion protein with a SIRP&#945; CD47-binding domain identical to ALX148&#8217;s binding domain but fused to an active, wild-type IgG1 Fc domain, ALX377. We administered 30 mg/kg ALX148 and 30 mg/kg ALX377 in mouse models and measured red blood cell, or RBC, platelet and white blood cell (lymphocyte, monocytes and granulocytes) counts. As shown in the figure below, mice treated with ALX148 having an inactive Fc domain showed blood count levels that were similar to the pre-dose baseline. In contrast, mice treated with ALX377 having an active Fc domain showed average decreases of 34% in RBC count, 70% in platelet count and 67% in white blood cell count three days post-dosing as compared to baseline counts. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The inactive Fc domain on ALX148 is responsible for improved hematologic tolerability in preclinical models. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000006.jpg" title="" alt="" style="width:624px;height:170px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">***</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">p&lt;0.001 </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">****</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">p&lt;0.0001 </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To further evaluate ALX148&#8217;s preclinical tolerability, cynomolgus monkeys were treated by weekly intravenous injections at doses of zero (control), 10, 30 and 100 mg/kg for five consecutive weeks. No toxicity or adverse findings related to CD47 blockade by ALX148 were seen in analysis of RBCs, white blood cells, platelets, body weight, ophthalmic examination, cytokine analysis, ECG parameters and anatomical pathology assessment. The no-observable-adverse-effect-level in the study was the highest dose tested, 100 mg/kg. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Together, these preclinical studies demonstrate that inactivation of the Fc domain of ALX148 avoids adverse effects on normal blood cells seen on other CD47 blocking agents with an active Fc domain. They also supported our expectation that ALX148&#8217;s lack of overlapping toxicities with other anti-cancer therapies would result in fewer adverse outcomes in a clinic when combined with these therapies than combinations with conventional CD47 blocking agents. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ALX148 elicits superior phagocytosis in combination with anti-cancer antibodies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The inactive Fc of ALX148 does not compete with the active Fc domain of other therapeutic antibodies for binding with Fc&#947; receptors on effector cells of the immune system. This fact, coupled with the high-affinity CD47 binding of our agent, results in enhanced phagocytosis from ALX148 in combination with other anti-cancer antibodies to a greater extent than other CD47 blockers. We believe this will allow us to explore ALX148 in combination with a higher number of leading anti-cancer antibodies compared to other CD47 blocking agents in both hematologic malignancies and solid tumors. In order to investigate the potential effects of the Fc domain and CD47 binding affinity on phagocytic activity, we produced two CD47 blocking agents with either an IgG4 or IgG1 active Fc domain, based on published sequences from two other clinical CD47 blockade programs. We combined these agents and ALX148 with cetuximab, an epidermal growth factor receptor, or EGFR, inhibitor that is FDA approved for several solid tumors, to assess phagocytic activity as compared to single-agent cetuximab. Both cetuximab and the active Fc domain of a CD47 blocking agent bind to the same cell surface Fc&#947; receptors on a macrophage, potentially creating competition. IgG1 binds to receptors with higher affinity than IgG4 does, and ALX148&#8217;s inactive Fc does not bind. This experiment shows that CD47 blocking agents with active Fc domains and lower affinity, combined with cetuximab result in lower phagocytic activity from macrophages as compared to ALX148 with cetuximab. This experiment suggests ALX148, the only clinical CD47 blocking agent with an inactive Fc domain and high-affinity CD47 binding, may be unique in its anti-tumor activity when combined with anti-tumor antibodies. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ALX148 has shown superior antibody-dependent cellular phagocytosis, or ADCP, of solid tumor cells compared to CD47 blockers with an active Fc domain and lower CD47 affinity when combined with an anti-tumor antibody. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000007.jpg" title="" alt="" style="width:624px;height:278px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical Data </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Favorable tolerability profile </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials to date continue to support ALX148&#8217;s differentiated approach to CD47 blockade. ALX148 has been administered in over 170 subjects with advanced solid or hematologic malignancies, including in combination with a range of standard of care anti-cancer regimens. ALX148 has been consistently well-tolerated, with low occurrences of cytopenias and other toxicities. Adverse events are reported as of April&#160;1, 2020 for ALX148 combined with Keytruda and Herceptin and as of October&#160;1, 2020 for ALX148 combined with Rituxan, Keytruda plus chemotherapy and Herceptin plus chemotherapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not yet reached a maximum tolerated dose in any trial of ALX148 and are continuing to test higher doses. Because the half-life of ALX148 is longer with higher dose levels, such dosing may allow up to every four weeks, or Q4W, administration schedule. Furthermore, ALX148&#8217;s tolerability profile could potentially result in a broad therapeutic window. We believe its tolerability profile to date supports initiation of trials in combination with highly effective, but more toxic, standard of care agents, such as chemotherapies that can cause cytopenias. Many other CD47 blocking agents are unable to combine with these anti-cancer agents due to overlapping toxicity profiles. We believe ALX148 may be uniquely positioned in its ability to combine with standard of care agents including those with associated cytopenias. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Initial data suggests that ALX148 demonstrates a consistent tolerability profile in Phase 1 trial cohorts. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000008.jpg" title="" alt="" style="width:624px;height:274px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Treatment related adverse events occurring in &#8805;2 subjects in all histologies at 10 &amp; 15 mg/kg QW.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*Data cut off: April 1, 2020 for combination cohorts of ALX148 plus Keytruda and Herceptin; October 1, 2020 for combination cohorts of ALX148 plus Rituxan, Keytruda and chemotherapy (5FU, platinum) and Herceptin and chemotherapy (ramucirumab, paclitaxel). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Single-digit to no incident rates of treatment-related grade three and higher cytopenias occurred in more than 2 subjects across each of the combination cohorts in this heavily pre-treated group who are typical participants in early stage cancer trials and are often hematologically fragile at baseline. Additionally, the majority of treatment-related adverse events were of low-grade and were easily managed. Overall, ALX148 was well tolerated in an advanced cancer population and can be combined with a wide range of anti-cancer therapeutics. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All other CD47 blockers that have reported clinical data have reported high rates of both all grade and high grade cytopenias. A magrolimab clinical trial in solid tumors resulted in 56% anemia in the first 48 subjects dosed, despite each subject receiving an initial priming dose to mitigate anemia. A recent trial of magrolimab in 68 subjects with higher-risk MDS or AML presented in November 2020 (Sallman, SITC 2020, Session 304) reported over 35% grade 3 or 4 treatment-related anemia, over 15% grade 3 or 4 treatment-related neutropenia and over 10% grade 4 treatment-related thrombocytopenia. Such a tolerability profile could present challenges to the administration of this compound as a single agent and in combination. In contrast, ALX148&#8217;s tolerability profile may enhance the breadth of clinical development by providing better treatment options for patients with cancer. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical PK and PD Data </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Initial clinical trials have confirmed that ALX148 exhibits favorable PK, and CD47 target occupancy, or TO. Human PK following intravenous, or IV, doses of ALX148 ranging from 0.3 to 30 mg/kg either as a single-agent, or in combination with pembrolizumab, trastuzumab or rituximab have been characterized in 159 subjects as of October&#160;1, 2020. ALX148 single agent PK profiles showed a trend of non-linear PK with faster clearance at lower doses and slower clearance at higher doses of 10&#160;mg/kg QW and 30&#160;mg/kg once every other week, or QOW, indicating saturation of target mediated clearance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The pharmacodynamics, or PD, following AXL148 IV infusion either as a single-agent or in combination with pembrolizumab, trastuzumab or rituximab have been characterized in 156 subjects as of October&#160;1, 2020. Target engagement has been confirmed based on CD47 TO in peripheral blood T lymphocytes and erythrocytes measured by a flow cytometry assay. At lower doses of 0.3 mg/kg and 1 mg/kg ALX148 monotherapy, dose dependent increase of TO was observed. Increased TO was observed following the subsequent IV dosing compared to the first IV dose. Complete TO in periphery across the dosing interval, where TO &gt;85%, was observed at ALX148 single </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agent doses </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8805;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 mg/kg QW and at doses of 30 mg/kg QOW. Complete TO in periphery was observed with ALX148 at doses of 10 mg/kg QW in combination with trastuzumab, or at doses of 10mg/kg QW or 15 mg/kg QW in combination with trastuzumab, ramucirumab and paclitaxel. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In our Phase 1b expansion trial to date, we have observed a statistically significant positive ALX148 exposure-response relationship in subjects with NHL. While our data support full TO in the periphery at 10 mg/kg, enhanced tumor penetration may explain the higher response rate seen at 15 mg/kg in the clinic. Given the favorable tolerability observed to date at doses up to 15 mg/kg QW, we plan to evaluate these higher doses of ALX148. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Clinical Development of ALX148 in Hematologic Malignancies </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The potential therapeutic role of CD47 blockade to date has been clearly demonstrated in hematologic malignancies. This includes both our trials of ALX148 as well as trials by other CD47 blockade programs. We have initiated a clinical trial of ALX148 in patients with MDS and are planning to initiate a trial in the second half of 2021 in patients with AML based on our initial trials in the relapsed/refractory NHL clinical setting, preclinical studies and evidence for the clinical utility of the CD47 blockade from other programs. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">NHL Proof-of-Principle </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALX148&#8217;s initial hematologic clinical trial was a Phase 1b expansion trial in combination with rituximab to treat subjects with relapsed/refractory NHL. This was an open-label, multisite trial to assess safety. Subjects received ALX148 10 mg/kg QW or 15 mg/kg QW in combination with rituximab 375 mg/m2 administered as an intravenous infusion QW for four doses followed by once monthly for eight doses. In order to meet inclusion criteria, subjects must have had no curative therapy or standard approved therapy option available to them. Across all cohorts, as of October&#160;1, 2020, subjects had received a median of three lines of therapy prior to enrollment in the ALX148 trial. These were heavily pre-treated subjects, all of whom had progressed on previous rituximab-containing regimens. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Responses were evaluated according to the Lugano 2014 response criteria and reported as of October&#160;1, 2020. As of October&#160;1, 2020, ALX148 had been administered to 33&#160;subjects. Thirty-two subjects were response evaluable. Eleven subjects had indolent lymphomas and 22 had aggressive lymphomas. There were 11&#160;subjects enrolled to the higher dose 15&#160;mg/kg QW cohort, 10 of whom were response evaluable. This cohort achieved an ORR of 70.0% (7/10). The ORR reported in the lower dose 10&#160;mg/kg QW cohort was 40.9% (9/22). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000009.jpg" title="" alt="" style="width:624px;height:300px;"></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aggressive includes relapsed/refractory Diffuse Large B&#160;Cell and Mantle Cell Lymphomas. Indolent includes Follicular and Marginal Zone</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lymphomas; N: Response evaluable patients; ORR: Objective response rate (complete + partial response rates). Data cut-off: October&#160;1, 2020.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000010.jpg" title="" alt="" style="width:624px;height:272px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Data Cutoff October&#160;1, 2020; Response evaluable patients; Responses include metabolic response per Lugano Response Criteria. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#94; more than 80% increase from baseline. * patient with rapid fatal progressive disease not represented in plot </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We view ALX148&#8217;s initial activity in heavily pre-treated subjects with NHL as compelling evidence for the role of ALX148 in treating hematologic malignancies and as a favorable comparison to outcomes reported by other CD47 blocking agents in similar subjects. We believe the initial data in our 10 and 15 mg/kg QW cohorts, which showed a statistically significant exposure-dependent response, demonstrates ALX148&#8217;s activity and supports higher dose administration in trials for subjects with MDS. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Based on the activities seen at the 10 and 15 mg/kg QW doses coupled with a favorable tolerability profile, we are intending to test higher doses, up to 60 mg/kg Q4W in MDS. We believe this dosing schedule may be unique among CD47 blockade programs and can potentially provide a more convenient regimen in combination with monthly azacitidine for patients. This data set also supported our decision to advance ALX148 into solid tumor indications at higher doses of 45 mg/kg once every three weeks, or Q3W, in combination with standard agents also administered Q3W. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ALX148 for the Treatment of MDS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our development of ALX148 in hematologic indications is initially focused on MDS. There are approximately 70,000 people living with diagnosed MDS in the U.S. Patients with MDS have a wide range of expected outcomes that can be estimated from their Revised International Prognostic Scoring System, or IPSS-R, risk category. Patients with very low IPSS-R have an mOS of 8.8 years, whereas those with very high IPSS-R have an mOS of under ten months. Since nearly 75% of new cases are in patients aged 70 or older, balancing a patient&#8217;s age at prognosis with potential treatment-related impact on quality of life is important in considering treatment options. Regardless of age, treatment goals for patients with MDS are a balance of improved survival, symptom alleviation and quality of life. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For patients with higher-risk MDS (intermediate, high and very high IPSS-R), standard of care treatments include stem cell transplant, or SCT, high and low-intensity chemotherapy regimens and HMAs. SCT is the only therapy that is potentially curative; however, the procedure is difficult to tolerate, especially for older patients, and has a non-relapse mortality rate of approximately 40% at 200 days for all patients with MDS. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For patients who are ineligible for SCT, azacitidine, an HMA, is a standard backbone therapy for combination treatment regimens in MDS. The drug continues to be used in combination with investigational agents in a number of current MDS trials. Single-agent azacitidine is one of the few FDA-approved agents for patients with MDS. However, its FDA label indicates a complete response, or CR, rate of only 5.6% and an mOS of 2.0 years. A clinical complete response comprises normalizing peripheral blood counts, resolution of bone marrow dysplasia and reduction in the percentage of immature blood cells, or myeloblasts, to less than 5%. CD47 blockade in combination with azacitidine has shown early clinical evidence that suggests it may improve CR rates in MDS. For patients with higher-risk MDS, achieving a CR and improving overall survival are the central treatment goals. Treatment goals for patients with lower-risk MDS are different. The primary goal for those patients is resolution of cytopenias. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Red blood cell transfusions are a key element of treatment intended to address cytopenias in patients with MDS. The majority of patients have a hemoglobin count of less than 10 g/dL and approximately one-third of patients are RBC transfusion dependent. Transfusions impose significant time and cost burdens on patients and also cause clinical sequelae such as iron overload and associated liver fibrosis and cardiomyopathy. Therefore, achieving transfusion independence is an important secondary goal of treating patients with higher-risk MDS. A competitive CD47 blocking agent has generated encouraging clinical data, however, it is associated with high rates of anemia that may require additional transfusions upon treatment initiation, mitigating any success in peripheral blood count normalization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current clinical experience with CD47 blocking agents in MDS underscores the need for combination therapy to increase CR rates above that seen with standard of care azacitidine monotherapy. As previously discussed, pro-phagocytic signals in ALX148-based combinations can be provided by drugs that increase display of the &#8220;eat me&#8221; signal calreticulin on the surface of tumor cells. We have conducted preclinical studies that showed that azacitidine and venetoclax increase both the display of the &#8220;eat me&#8221; signal calreticulin and the &#8220;don&#8217;t eat me&#8221; signal CD47 on AML cells, suggesting that a CD47 blocking agent could maximize the activity of venetoclax and azacitidine in these models. Additionally, we have shown that ALX148 with venetoclax or azacitidine in combination produces increased phagocytosis in vitro and anti-tumor activity in mouse models compared to azacitidine or venetoclax alone. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, combination treatment of ALX148 with azacitidine or venetoclax led to tumor elimination and prolonged survival in leukemia mouse models. Azacitidine and ALX148 monotherapies produced moderate tumor growth inhibition with all mice succumbing to disease by day 85 post inoculation. In contrast, the combination of ALX148 and azacitidine completely eliminated tumor growth with 100% animal survival up to study termination on day 147. We have also demonstrated in preclinical studies that ALX148 when combined with venetoclax, a BCL-2 inhibitor that is FDA approved for the treatment of patients with AML, led to tumor elimination in a leukemia tumor model. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000011.jpg" title="" alt="" style="width:624px;height:366px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recent data from a competitive CD47 blockade program, magrolimab, further support trials of ALX148 for treatment of MDS. Magrolimab was studied both as a single-agent and in combination with azacitidine in subjects with higher-risk MDS or AML. As reported at ASCO 2020, magrolimab plus azacitidine achieved a 42% CR rate in previously untreated MDS and a 40% CR in previously untreated AML. As a single-agent, magrolimab achieved no CRs in relapsed/refractory MDS and AML, suggesting that a separate pro-phagocytic signal is required for the observed clinical activity. Despite the high rate of CRs achieved in combination, over 38% of subjects in these trials have experienced grade 3 or higher treatment-related anemia. Notwithstanding these limitations, magrolimab&#8217;s data support the potential role of CD47 blockade in treating these subjects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our strategy is to pursue ALX148 as a potentially critical component for future combination treatment options for patients with higher-risk MDS. Our preclinical models, activity of ALX148 in NHL where magrolimab has reported similar data and available CD47 clinical data in this indication support a potential role for ALX148 for treatment of patients with MDS. Baseline characteristics of subjects in a recent trial of azacitidine plus venetoclax in treatment-na&#239;ve higher-risk MDS illustrated the need for therapies that do not induce cytopenias. Prior to treatment, 56% of subjects had grade 3 or higher neutropenia, 33% had grade 3 or higher thrombocytopenia, 40% had grade&#160;3 or higher leukopenia and 12% had grade 3 or higher anemia. We believe that it is important to develop a CD47 blocking therapy that does not exacerbate cytopenias that patients may already exhibit pre-treatment. ALX148&#8217;s tolerability profile to date suggests it may address this unmet need in patients who suffer from MDS. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2020, we initiated a Phase 1b/2 trial of ALX148 in combination with azacitidine for the treatment of subjects with higher-risk MDS. The Phase 1b portion of the trial will seek to evaluate up to 60&#160;mg/kg Q4W of ALX148 plus standard azacitidine in subjects with relapsed/refractory and previously untreated MDS. The Phase&#160;2 portion of the trial will assess the combination of ALX148 and azacitidine in subjects with previously untreated higher-risk MDS. The primary endpoint will be complete remission rate by six months. We intend to pursue a strategy in which we will leverage the data generated from the Phase&#160;1b/2 trial to request from the FDA that ALX148 be a candidate for accelerated approval in the treatment of MDS. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ALX148 for the treatment of AML </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our preclinical studies and clinical trials from competing CD47 agents support the potential role of ALX148 in the treatment of patients with AML. In the United States, there are over 35,000 people living with AML with an expected 20,000 newly diagnosed cases and over 11,000 deaths from the disease in 2020. Overall survival for patients with AML is generally worse than patients with higher-risk MDS. Median overall survival for patients with AML ranges from approximately 15 months for patients with favorable cytogenetic risk factors to less than 5 months for those with adverse risk factors. Similar to MDS, patients tend to be older with a median age at diagnosis of 68. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First-line treatment options for patients can be broadly stratified into high-intensity and low-intensity induction regimens. High-intensity induction chemotherapy is typically cytarabine plus an anthracycline (so called &#8220;7+3&#8221;) administered over a 28-day cycle. While patients can derive long term benefit from 7+3, the risks of the regimen are substantial. 60-day treatment-related mortality from 7+3 induction have been as high as 27% and have declined to 6-8% in recent years, likely due in part to more stringent patient selection and the decreased average age of patients who receive 7+3. Patients who are not candidates for intensive induction chemotherapy due to preference, performance status, or other reasons are likely to receive low-intensity regimens characterized by the use of HMAs, venetoclax or combined HMA plus venetoclax. In the past decade, the percentage of patients 65 and older who receive first-line high-intensity treatment has declined from approximately 70% to 40%, while the use of HMAs in this population increased from 11% to 44%. Venetoclax combined with an HMA recently received approval from the FDA for use in adults who are 75 years or older or who have comorbidities that exclude the use of intensive induction chemotherapy. In the Phase 3 VIALE-A trial, venetoclax achieved a 37% CR rate in combination with azacitidine and a median duration of CR of 18.0 months. Despite these results, we believe there is a significant unmet need for more effective and well-tolerated first-line treatment options for patients who are not candidates for high-intensity therapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mechanistic rationale for combining ALX148 with azacitidine in AML is similar to the rationale for MDS. Preclinical studies show that azacitidine increases the display of calreticulin, a pro-phagocytic signal, on cancer cells in AML models. The preclinical studies that support the use of ALX148 combinations in MDS also support its use in AML. Clinically, the CD47 agent magrolimab has achieved a 40% CR rate in untreated AML when used in combination with azacitidine. In a separate study in patients 65 and older with untreated AML, single-agent azacitidine as achieved a 20% CR rate. We believe this indicates CD47 agents could increase the activity of HMAs above their single-agent levels. Furthermore, our preclinical data of ALX148 in combination with venetoclax supports the combination with this agent that is increasingly being used in the treatment of patients with AML. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to initiate a Phase 1b/2 trial of ALX148 in combination with venetoclax and azacitidine for the first-line treatment of patients with AML in the second half of 2021. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ALX148 in Solid Tumors </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have generated clinical data with ALX148 in combination with multiple anti-cancer agents in solid tumors. We believe the smaller molecular weight of ALX148 as compared to a typical antibody may facilitate greater penetration into solid tumors. In addition, we believe the favorable tolerability profile of ALX148 will allow for higher administered doses in a range of combination strategies with leading therapies for solid tumors. Solid tumors represent the largest markets within oncology and many of these oncology indications are poorly served by current therapies, both in front-line as well as in the relapsed and refractory settings. We have demonstrated proof of concept with ALX148 in combination treatment in two solid tumor settings in initial clinical trials: HNSCC and HER2-positive gastric/GEJ cancer. We believe these indications offer registration pathways in combination with existing approved therapies and we intend to advance ALX148 into randomized Phase 2 trials in both oncology indications in 2021. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALX148 can be combined with PD-1/programmed death-ligand 1, or PD-(L)1, agents in a broad range of solid tumors. As part of our development strategy, we are exploring the use of ALX148 in combination with a PD-1 inhibitor with and without chemotherapy in HNSCC. PD-(L)1 inhibitors are currently approved by the FDA for 18 indications and had over $20&#160;billion in 2019 sales. Other CD47 blocking approaches may be limited in their ability to combine with PD-(L)1 inhibitors due to cumulative or overlapping toxicities. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We investigated ALX148 in subjects with solid tumors in additional cohorts as part of an extensive Phase 1 trial. Part 1 was a dose escalation trial of single-agent ALX148 intended to examine tolerability and recommended dosing and was not expected to show single-agent activity. Sixteen subjects with solid tumors received ALX148 as a single-agent on a QW schedule at doses ranging from 0.1 mg/kg to 10 mg/kg and 12 subjects received ALX148 as a single-agent on a QoW dosing schedule at a dose of 30 mg/kg. The maximum tolerated dose was not determined on either schedule. However, the maximum administered dose was 30 mg/kg for the Q2W dosing schedule and 10 mg/kg for the QW schedule. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part 2 was comprised of ALX148 escalation and expansion cohorts. In subjects with solid tumors, ALX148 was combined with various anti-cancer agents including pembrolizumab, trastuzumab and chemotherapy. Adverse events from these cohorts are reported above. As previously discussed, ALX148 has consistently displayed a favorable tolerability profile. Many of the reported adverse events have been associated with either pembrolizumab or trastuzumab. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In HNSCC, our initial Phase 1b expansion trial combined ALX148 with pembrolizumab, an anti-PD-1 agent, which is a standard of care for subjects with HNSCC. Final results from the cohort of ALX148 combined with pembrolizumab were reported at the 2020 American Society of Clinical Oncology, Virtual Scientific Program, or ASCO 2020, and provided the first demonstration of ALX148&#8217;s ability to enhance checkpoint inhibitor antibody activity in solid tumors and is the basis for FDA Fast Track designation in first-line treatment of HNSCC. Data from this trial supported our second trial in HNSCC that adds chemotherapy (5-fluoropyrimidine plus cisplatin) to the combination of pembrolizumab and ALX148 and preliminary data for this cohort was presented at the Society for Immunotherapy of Cancer&#8217;s 35<sup style="font-size:85%;line-height:120%;vertical-align:top">th</sup> Anniversary Annual Meeting, or SITC 2020. We also recently entered into a clinical trial collaboration with Merck to study the combination of ALX148 and pembrolizumab with and without chemotherapy in a randomized Phase 2 trial. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In HER2-positive gastric/GEJ cancer, our Phase 1b expansion trial included a combination with trastuzumab, an anti-HER2 agent, that is the standard of care for subjects with HER2-positive gastric/GEJ cancer and is FDA-approved for other HER2-expressing tumors. Final results from the cohort of ALX148 combined with trastuzumab were reported at ASCO 2020 and provided the first demonstration of ALX148 activity with an anti-tumor targeted antibody in subjects with solid tumors. Data from this trial formed the basis for FDA Fast Track designation in second-line subjects with advanced HER2-positive gastric/GEJ cancer and supported our second trial in gastric/GEJ cancer that adds second-line standard of care agents (ramucirumab plus paclitaxel) to the combination of trastuzumab and ALX148. Preliminary data for this cohort was also presented at SITC 2020. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also plan to advance ALX148 into a Phase 1 clinical trial in combination with zanidatamab, an investigational anti-HER2 bispecific antibody, in patients with HER2-expressing breast cancer and other solid tumors. We recently entered into a clinical trial collaboration with Zymeworks, the developer of zanidatamab, to explore this combination. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Overall, we believe our development plan for ALX148 in solid tumors has significant potential and represents a strong complement to our program in hematologic malignancies. With encouraging data in multiple drug combinations initially evaluated in the clinic, we plan to advance trials to assess efficacy in the solid tumor indications with substantial unmet medical need. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ALX148 in HNSCC </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disease background </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are estimated to be over 38,000 people living in the United States with metastatic HNSCC, with over 50,000 newly incident cases at all stages estimated to be diagnosed in 2020. Five-year survival is 85% for patients diagnosed with localized disease but decreases to only 40% for those diagnosed with metastatic disease, underlying the need for improved treatment options. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA-approved and National Comprehensive Cancer Network, or NCCN, recommended therapies for the first-line treatment of recurrent/metastatic disease include pembrolizumab monotherapy, pembrolizumab combined with chemotherapy, platinum and fluorouracil, and cetuximab, an anti-epidermal growth factor receptor antibody, combined with chemotherapy among other treatments. The KEYNOTE-048 clinical trial led to the FDA approval of pembrolizumab monotherapy as a first-line treatment in patients with HNSCC whose tumors express PD-L1 on a Combined Positive Score, or CPS, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8805;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 and approval of pembrolizumab plus chemotherapy as a first-line treatment in patients with HNSCC regardless of CPS . In KEYNOTE-048, pembrolizumab monotherapy achieved 17% ORR with a median progression-free survival, or mPFS, of 2.3 months in subjects with HNSCC regardless of CPS. Of particular note, in subjects with CPS &lt;1 pembrolizumab monotherapy only achieved a 5% ORR. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pembrolizumab monotherapy in previously treated HNSCC was reported in the Phase 3 KEYNOTE-040 trial. Subjects were excluded if they had prior therapy with an anti-PD-1 or anti-PD-L1 therapy. In KEYNOTE-040, pembrolizumab achieved a 15% ORR, mPFS of only 2.1 months and mOS of 8.4 months. While we believe pembrolizumab is an important treatment option for both first- and second-line HNSCC, the majority of patients do not have an objective response to pembrolizumab-based therapy. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the recent approval of pembrolizumab, we believe that there is significant unmet need remaining for patients with HNSCC. The addition of ALX148 to pembrolizumab, or pembrolizumab plus chemotherapy, may have the potential to improve response rates and provide additional clinical benefit to patients with metastatic HNSCC. We have evaluated ALX148 in subjects with metastatic HNSCC and continue to develop ALX148 in this setting. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Trial design </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALX148 was investigated in two combinations and lines of therapy in subjects with recurrent/metastatic HNSCC. First, ALX148 was investigated in combination with pembrolizumab in subjects with recurrent/metastatic HNSCC who had received at least one prior systemic therapy. The clinical evaluation of ALX148 in HNSCC was an open-label, multisite expansion of our Phase 1 trial to assess safety and tolerability with response rate and duration as secondary endpoints. There was no requirement for PD-L1 expression. Subjects received ALX148 10 mg/kg QW in combination with pembrolizumab 200 mg on a Q3W dosing schedule. Subject response was evaluated based on RECIST version 1.1. Twenty subjects were dosed with ALX148 and as of October&#160;1, 2020, all subjects in the ALX148 with pembrolizumab HNSCC expansion cohort were response evaluable. Because standard of care in first-line HNSCC was evolving during the course of this trial to include checkpoint inhibitors, 50% (10) of the subjects who enrolled were checkpoint inhibitor na&#239;ve and 50% (10) had previously received a checkpoint inhibitor. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, ALX148 was investigated in the ongoing trial of ALX148 in combination with pembrolizumab, 5FU and platinum therapy in subjects with recurrent/metastatic HNSCC who had received no prior treatment for advanced disease. As of October&#160;1, 2020, five subjects had been dosed and four were response evaluable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Outcomes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary objective of the trial was to assess safety. Final results of the fully enrolled ALX148 with pembrolizumab cohort and partially enrolled ALX148 plus pembrolizumab and chemotherapy cohort were reported at SITC 2020. As reported above in the summary tables of treatment-related adverse events from all ALX148 trials, the combination was well tolerated. As of October&#160;1, 2020, ALX148 with pembrolizumab achieved an ORR of 40% (4/10) in checkpoint inhibitor na&#239;ve subjects while maintaining a tolerability profile consistent with earlier trials. Some of the 20 subjects had a CPS of zero and response was also observed within this subject population. We believe the addition of ALX148 to pembrolizumab represents a potentially significant advance over pembrolizumab monotherapy based on a review of the KEYNOTE-040 trial results that showed an ORR of 15% in a similar checkpoint inhibitor therapy na&#239;ve population. Based on our clinical trial data, the FDA granted ALX148 Fast Track designation for first-line treatment of subjects with HNSCC. ALX148 with pembrolizumab and chemotherapy </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">achieved an ORR of 75% (3/4), including a complete response, in subjects who had received no prior treatment for advanced disease. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000012.jpg" title="" alt="" style="width:624px;height:260px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000013.jpg" title="" alt="" style="width:614px;height:262px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notes: Data Cutoff October&#160;1, 2020. Subjects who received at least one dose of ALX148 in the expansion phase, had a baseline assessment, and at least one post-baseline disease assessment. ORR = Overall Response Rate. DCR = disease control rate. DOR = duration of response. mPFS = median progression free survival. mOS = median overall survival. NC = not calculated. CI = confidence interval. ITT Intent to treat population in chemotherapy cohort: HNSCC (10+15 mg/kg) N=5; HNSCC (15mg/kg) N=2 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also analyzed paired pre- and on-treatment tumor biopsies from subjects for the presence of CD8+ T cells, CD68+ and CD163+ myeloid cells. After treatment with ALX148, tumor samples showed increased infiltration of CD8+, CD68+ and CD163+ cells in the tumor, which suggests that ALX148 also engages the innate and adaptive immune system consistent with its mechanism of action. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical development plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our HNSCC development plan is to build on the initial results of ALX148 in checkpoint inhibitor na&#239;ve patients in combination with pembrolizumab. Given the results of KEYNOTE-048, we expect pembrolizumab, or pembrolizumab plus chemotherapy, to continue to be widely used in the first-line treatment of metastatic HNSCC. Therefore, our future plans will be focused on establishing additional efficacy, in the context of acceptable safety </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and tolerability, over pembrolizumab alone, or pembrolizumab plus chemotherapy, in the front-line metastatic HNSCC setting. In January 2020, we initiated a Phase 1b trial that is evaluating ALX148 plus pembrolizumab plus chemotherapy in subjects with no PD-L1 expression requirements. In addition to our initial dosing of 10 mg/kg QW, a higher dosing will be explored with 15 mg/kg QW dosing planned. In September 2020, we announced a clinical trial collaboration with Merck to evaluate ALX148 in combination with pembrolizumab with and without chemotherapy in two randomized Phase 2 trials in subjects with HNSCC who have not received prior therapy for advanced disease. The first trial will evaluate the efficacy of ALX148 in combination with pembrolizumab for the first-line treatment of patients with PD-L1 expressing metastatic or unresectable, recurrent HNSCC. The second trial will evaluate ALX148 in combination with pembrolizumab and standard chemotherapy for the first-line treatment of patients with metastatic or unresectable, recurrent HNSCC. In December 2020, the FDA verbally informed us, that given our planned initiation of two </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">randomized </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phase 2 HNSCC clinical trials that could be potentially registrational, they require completion of a routine non-clinical safety study that we currently have in process. The FDA noted that for any drug development program moving swiftly through development, this non-clinical study is still required prior to the initiation of a clinical trial that could be considered pivotal. We are allowed to initiate both Phase 2 HNSCC clinical trials with the enrollment capped at a total of 50 subjects treated with ALX148 across both trials (excluding safety lead-in cohorts) pending acceptance of the non-clinical safety study report. We expect to provide the required report to the FDA prior to reaching the 50-patient enrollment cap. While this cap on enrollment is defined as a partial clinical hold, no delays are anticipated in our current clinical trial timelines. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ALX148 in HER2-Positive Gastric/GEJ </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Disease background </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Over 25,000 people are estimated to be living in the United States with diagnosed metastatic gastric/GEJ carcinoma. A large, international Phase 3 trial of trastuzumab in gastric/GEJ cancer found that of the nearly 4,000 subjects screened for inclusion in the trial, 17% of them were HER2-positive, which suggests a general HER2-positive rate for patients with gastric/GEJ cancer. In East Asian countries, gastric/GEJ cancer is much more common than in the United States, with incidence rates 4-10 times higher. China alone has a diagnosed incidence of over 900,000 patients with gastric/GEJ cancer per year. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First-line standard of care treatment is trastuzumab combined with the chemotherapy agents platinum and fluoropyrimidine. Trastuzumab, marketed as Herceptin, is an anti-HER2 antibody that has multiple FDA approvals in patients with HER2-positive cancers. In the second-line HER2-positive gastric setting, there are no HER2 targeted FDA-approved therapies. As such, the standard of care regimen in the U.S. is ramucirumab, marketed as Cyramza, a vascular endothelial growth factor 2 receptor monoclonal antibody, in combination with paclitaxel, a widely used chemotherapy. In a Phase 3 trial leading to FDA approval, ramucirumab plus paclitaxel achieved a 28% ORR with a 9.6 month mOS in subjects with previously treated gastric/GEJ cancer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">HER2-positive patients with gastric/GEJ cancers in second-line treatment are likely to have received an anti-HER2 antibody-based treatment in their first line of treatment. A recently reported prospective clinical trial studied trastuzumab plus paclitaxel compared to paclitaxel alone in previously treated HER2-positive subjects with gastric/GEJ cancer. Subjects were required to have progressed during the first line of treatment with trastuzumab plus chemotherapy (fluoropyrimidine plus platinum). The objective of this trial was to assess the clinical effect of trastuzumab after patients had progressed on prior trastuzumab treatment. The trial results showed that the addition of trastuzumab added no meaningful clinical benefit over paclitaxel alone. There was no significant improvement in mOS, mPFS or ORR compared to the paclitaxel arm. Based on these data, we hypothesized that we could attribute any observed responses when treating a similar subject population with ALX148 paired with trastuzumab, to a combination effect of the two agents and not simply a response to trastuzumab alone. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Trial design </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALX148 was investigated in two combinations in subjects with HER2-positive gastric/GEJ cancer. First, ALX148 was investigated with trastuzumab in subjects with relapsed/refractory HER2-positive gastric/GEJ cancer. This trial was an open-label, multisite expansion of our Phase 1 trial to assess safety and tolerability with response rate and duration as secondary endpoints. Twenty subjects from the gastric/GEJ expansion cohort received ALX148 10 mg/kg QW in combination with trastuzumab at an initial dose of 8 mg/kg followed by 6 mg/kg intravenous infusion Q3W. As of October&#160;1, 2020, 19 subjects were response evaluable. One of the twenty subjects administered ALX148 discontinued the trial due to clinical symptoms of progression prior to their first scheduled on trial scan and therefore was not response evaluable per protocol definition. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of April&#160;1, 2020, in our trial of ALX148 plus trastuzumab, 18 of 19 response evaluable subjects from the gastric/GEJ expansion cohort, including all subjects who achieved a response, had been treated with at least one HER2-containing regimen prior to enrollment. Multiple subjects also received an investigational anti-HER2 agent and a PD-1 checkpoint inhibitor as prior treatment. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, ALX148 was investigated with trastuzumab, ramucirumab and paclitaxel in subjects with relapsed/refractory HER2-postive gastric/GEJ cancer who had progressed on prior trastuzumab, fluoropyrimidine or platinum. As of October&#160;1, 2020, 14 subjects had enrolled, all of whom were response evaluable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Outcomes </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000014.jpg" title="" alt="" style="width:624px;height:258px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000015.jpg" title="" alt="" style="width:618px;height:224px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Data Cutoff October 1, 2020. Subjects who received at least one dose of ALX148 in the expansion phase, had a baseline assessment, and at least one post-baseline disease assessment. One subject administered ALX148+pembrolizumab with rapid fatal clinical progression is not included in plots. ORR = Overall Response Rate. DOR = duration of response. mPFS = median progression free survival. mOS = median overall survival. CI = confidence interval. ND = Not Done. HER2 Score retrospectively assessed using archival tissue by a central IHC lab. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The primary objective of the trial was to assess safety and the combination regimen was well tolerated. Final results of the fully enrolled cohort were reported at SITC 2020. Importantly, ALX148 with trastuzumab achieved an ORR of 21.1% (4/19) in subjects treated with the doublet and an ORR of 64.3% (9/14) in subjects treated with ALX148 with trastuzumab, ramucirumab and paclitaxel. The FDA granted ALX148 Fast Track designation for second-line treatment of advanced HER2-positive gastric/GEJ carcinoma partly due to the data for ALX148 in combination with trastuzumab alone for the treatment of gastric cancer. Based on prior studies, one of which is </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">described above, any observed response can likely be attributed to the combination effect and not a response to single-agent trastuzumab. As described above, ramucirumab and paclitaxel in a second-line setting resulted in an ORR of 28% in a Phase 3 trial leading to FDA approval. We believe that an ORR of 64.3% in this second-line or later population supports further development of ALX148 in HER2-positive cancers. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Clinical development plans </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to initiate a randomized Phase 2 trial of ALX148 with trastuzumab and chemotherapy for subjects with HER2-positive gastric/GEJ cancer adenocarcinoma with disease progression on or after prior trastuzumab (or other HER2-directed therapy), and fluoropyrimidine or platinum-containing chemotherapy as the first line of therapy for advanced disease, by the second half of 2021. Data from this trial would confirm whether ALX148 improves the response rate to anti-HER2-based therapy in patients with HER2-positive gastric/GEJ cancer. Of note, there are multiple emerging agents, predominantly antibody-based therapies, in development for patients with HER2-positive cancer. Because these agents target HER2 as does trastuzumab, we believe that ALX148 has the potential to maximize the anti-cancer activity of these novel agents should they supplant trastuzumab in the treatment paradigm for these patients. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ALX148 in HER2-expressing breast cancer and other solid tumors </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to continue developing ALX148 in a broad range of tumor types and in novel combinations. In November 2020, we announced a clinical trial collaboration with Zymeworks to investigate ALX148 in combination with Zymeworks&#8217; HER2-targeted bispecific antibody, zanidatamab, in patients with advanced HER2-expressing tumors. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, Zymeworks will conduct an open label, multi-center Phase 1b trial to assess the safety and efficacy of the combination of zanidatamab and ALX148 in a two-part trial. The first part of the trial will evaluate the safety of the combination treatment. The second part of the trial will evaluate the safety, tolerability and anti-tumor activity of the combination in separate cohorts of subjects with HER2-overexpressing breast cancer, HER2-low breast cancer and non-breast HER2-expressing solid tumors. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Research Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have a preclinical program focused on developing a SIRP&#945; TRAAC that may offer additional ways to engage the innate and adaptive immune response to cancer. SIRP&#945; TRAAC is complementary to our CD47 blocker approach. SIRP&#945; is expressed on myeloid cells and dendritic cells which have TLR9, an intracellular receptor present in a wide variety of immune cells, including B-cells, myeloid cells and dendritic cells. TRAAC, or TLR9 agonist antibody conjugate, is designed specifically for compatibility with antibody conjugation, superior pharmacokinetics, receptor-mediated uptake, and TLR9 stimulation with the potential for intravenous administration. SIRP&#945; TRAAC is an agonistic molecule targeting myeloid cells and directly activates them, resulting in cytokine release, antigen presentation, and initiation of a coordinated innate and adaptive immune response against cancer. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Licensing and Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our current and future product candidates, novel discoveries, product development technologies and knowhow and to operate without infringing on the proprietary rights of others. We seek to protect our proprietary position by, among other methods, filing or in-licensing U.S. and foreign patents and patent applications related to technology, inventions and improvements that are important to the development and implementation of our business. Our patent portfolio is intended to cover our product candidates and related components, their methods of use and processes for their manufacture and any other inventions that are commercially important to our business. We also rely on trademarks, trade secrets, knowhow, continuing technological innovation and confidential information to develop and maintain our proprietary position. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 1, 2021, we own two issued U.S. patents, nine pending U.S. nonprovisional patent applications, twelve pending U.S. provisional patent applications and a portfolio of national patent application filings in a variety of non-U.S. jurisdictions, including Europe, Hong Kong, Brazil, Mexico, New Zealand, Japan, Australia, Canada, China, India, Israel, Republic of Korea, Singapore and Russia. Of these patents and patent applications, the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">following relate to ALX148: two issued U.S. patents, six pending U.S. nonprovisional patent applications, twelve pending U.S. provisional patent applications and a portfolio of national patent application filings in a variety of non-U.S. jurisdictions, including Europe, Hong Kong, Brazil, Mexico, New Zealand, Japan, Australia, Canada, China, India, Israel, Republic of Korea, Singapore and Russia. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term of individual patents depends upon the legal term for patents in the countries in which they are granted. Our two U.S. issued patents and, if issued as U.S. patents, our ten U.S. nonprovisional patent applications and twelve U.S. provisional patent applications are expected to expire between August 2036 and February 2042, excluding any additional term for patent term adjustments or patent term extensions, with an expiration of between August 2036 and December 2041 with respect to our patent and patent applications related to ALX148, excluding any additional term for patent term extensions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We obtained a worldwide, royalty-bearing, sublicensable license from the Board of Trustees of the Leland Stanford Junior University, or Stanford, under certain patents relating to high-affinity SIRP&#945; variant polypeptides, to develop, manufacture and commercialize products for use in certain licensed fields, the scope of which would include the application of the licensed intellectual property in oncology. Our portfolio of exclusively licensed patents from Stanford includes six issued patents (one of which is in the United States) and applications are pending in five jurisdictions (including the United States and the European Patent Office). For more information regarding our license agreement with Stanford, please see &#8220;&#8212;Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University.&#8221;  </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our patent portfolio exclusively licensed from Stanford contains patent families relating to high-affinity SIRP&#945; variant polypeptides, which includes one issued patent in each of U.S., Australia, China, Europe, Hong Kong and Japan, one pending U.S. patent application and one pending European patent application. The European patent has been validated as national patents in 37 different European countries. These patents and patent applications are subject to retained rights by Stanford to allow academic and nonprofit research institutions to practice the licensed technology and patents for noncommercial purposes. In addition, these patents are subject to certain pre-existing rights that Stanford has granted to two third parties. These patents are expected to expire in 2033 excluding any extension of patent term that may be available. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of a revoked European patent (EP 2 429 574) owned by UHN and The Hospital for Sick Children that may encompass certain therapies for the treatment of cancer using polypeptides comprising soluble human SIRP&#945;, or a CD47-binding fragment thereof. This revoked patent related to the treatment of cancer with polypeptides comprising soluble human SIRP&#945;, or a CD47-binding fragment thereof. This patent was revoked by the European Patent Office and UHN and The Hospital for Sick Children have appealed the decision.&nbsp;&nbsp;If UHN and the Hospital for Sick Children win their appeal of the European Patent Office decision revoking their European patent, the resulting patent claims could potentially limit our ability to pursue ALX148 in certain new indications or geographies in the future. The U.S. counterpart was recently granted as US patent 10,907,209.&nbsp;&nbsp;However, we believe that we do not infringe claims listed in this U.S. patent.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For more information regarding the risks related to our intellectual property, including the above referenced intellectual property proceedings, see &#8220;Risk Factors&#8212;Risks Related to Our Intellectual Property.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2015, we entered into a license agreement, or the Stanford Agreement, with Stanford under which we obtained a worldwide, royalty-bearing, sublicensable license under certain patents relating to our current product candidates, to develop, manufacture and commercialize products for use in certain licensed fields, the scope of which would include the application of the licensed intellectual property in oncology. The license granted to us in the Stanford Agreement includes an exclusive grant, subject to certain pre-existing non-exclusive or exclusive rights that Stanford retained for grant to third parties with respect to certain categories of the licensed patents in certain fields of use and retained rights by Stanford and all other nonprofit institutions to use and practice the licensed patents and technology for internal research and other nonprofit purposes. The license granted to us in the Stanford Agreement also includes non-exclusive grants to certain Stanford patents. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the rights granted to us under the Stanford Agreement, we paid Stanford a nonrefundable license royalty and reimbursed Stanford for past patent expenses, together totaling less than $0.1&#160;million, and granted Stanford a specified number of our common stock. In addition, we are obligated to pay Stanford ongoing </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patent expenses and an annual license maintenance fee, which are nominal and will be creditable against any royalties payable to Stanford in the applicable year. We are required to make milestone payments up to an aggregate of $5.0&#160;million in respect of a specified number of licensed products that successfully satisfy certain clinical and regulatory milestones. No milestone payments have been made through December&#160;31, 20</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. We also agreed to pay Stanford tiered royalties on a specified percentage of net sales made by us, our affiliates and our sublicensees of licensed products at rates ranging within low single-digit percentages, subject to certain reductions and offsets. Our license, on a licensed product-by-licensed product and country-by-country basis, shall become royalty-free and fully paid-up upon the later of the date on which the last valid claim included in the exclusively or non-exclusively licensed patents expires and ten years after the first commercial sale of the licensed product in such country. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may terminate the Stanford Agreement, on a licensed product-by-licensed product basis, at any time for any reason by providing at least 60 days&#8217; written notice to Stanford. Stanford may terminate the Stanford Agreement if we are in breach of any provision of the Stanford Agreement and fail to remedy such breach within 60 days after written notice of such breach by Stanford. In addition, Stanford has the right to terminate the Stanford Agreement, on a licensed product-by-licensed product basis, if we are not diligently developing and commercializing such licensed product under certain conditions or if we fail to achieve specified development milestones for such licensed product by certain dates, subject to our extension rights. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Third-Party Agreements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into license agreements with third parties related to the development and commercialization of our product candidates, including ALX148, and SIRP&#945; antibodies which we are exploring in our research program. In consideration of the foregoing, we have agreed to customary payments terms in these agreements, including certain milestone payments upon the achievement of clinical and commercial milestones and low single-digit royalties. See the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Contractual Obligations and Commitments&#8212;License and Collaboration Agreements.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commercialization </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to retain significant development and commercial rights to our product candidates and, if marketing approval is obtained, to commercialize our product candidates on our own, or potentially with a partner, in the United States and other regions. We currently have no sales, marketing or commercial product distribution capabilities and have no experience as a company commercializing products. We intend to build the necessary infrastructure and capabilities over time for the United States, and potentially other regions, following further advancement of our product candidates. Clinical data, the size of the addressable patient population, the size of the commercial infrastructure and manufacturing needs may all influence or alter our commercialization plans. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing and Supply </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not own or operate and do not intend to establish our own manufacturing facilities. We rely on, and will continue to rely on, CMOs for both drug substance and drug product. Both ALX148 bulk drug substance and finished drug product are produced in accordance with current good manufacturing practices, or cGMPs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our existing supply of ALX148 drug product is sufficient to complete our clinical trials through the first half of 2021. We plan to manufacture additional supplies with our existing CMOs to produce ALX148 drug product sufficient to complete the ongoing and planned clinical trials described in this document. We first entered into an engagement with KBI Biopharma, Inc. in 2015 for analytical method development, formulation development, bulk drug manufacturing, release and stability testing. We first entered into a drug product manufacturing agreement with Lyophilization Services of New England, Inc. in 2016 and have subsequently used them for all ALX148 drug product used in clinical trials to date. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Competition </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new product candidates is highly competitive. We face competition with respect to ALX148 and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical, specialty pharmaceutical and biotechnology companies among others. We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immune-oncology therapies for the treatment of cancer. There are other companies working to develop immuno-oncology therapies for the treatment of cancer including divisions of large pharmaceutical and biotechnology companies of various sizes. The large pharmaceutical and biotechnology companies that have commercialized and/or are developing immuno-oncology treatments for cancer include AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Merck, Novartis, Pfizer and Roche/Genentech. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, including with respect to the targeting of CD47 pathway and others are based on entirely different approaches. We are aware that Apexigen, Arch Therapeutics, Bristol Myers Squibb, Gilead Sciences (through its recent acquisition of Forty Seven), I-Mab, Innovent, Kahr, Novimmune, OSE Immunotherapeutics and Trillium Therapeutics, among others, are developing drugs targeting the CD47 pathway that may have utility for the treatment of indications that we are targeting. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and enrolling subjects for our clinical trials and in acquiring technologies complementary to, or necessary for, our programs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could see a reduction or elimination of our commercial opportunity if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or foreign regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience and price, if required, the level of biosimilar or generic competition and the availability of reimbursement from government and other third-party payors. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the FDA, regulates biologic products under the Food, Drug, and Cosmetic Act, or FDCA, and Public Health Service Act, or PHSA. Biologic products and substances are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, record keeping, approval, advertising, promotion, marketing, post-approval monitoring and post approval reporting of biologics such as those we are developing. We, along with third-party contractors, will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we wish to conduct studies or seek approval or licensure of our product candidates. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Biologics Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any future product candidates must be approved by the FDA through the BLA process before they may be legally marketed in the United States. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The process generally involves the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Completion of extensive preclinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s current Good Laboratory Practices, or GLP, regulation. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Submission to the FDA of an investigational new drug, or IND, application, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before the trial is commenced. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Performance of adequate and well-controlled human clinical trials in accordance with the applicable IND regulations, good clinical practice, or GCP, requirements to establish the safety, purity and potency (</font><font style="font-style:italic;font-size:10pt;color:#000000;">i.e.</font><font style="font-size:10pt;color:#000000;">, safety and effectiveness) of the proposed biologic product candidate for its intended purpose. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Preparation of and submission to the FDA of a BLA after completion of all pivotal clinical trials. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">A determination by the FDA within 60 days of its receipt of a BLA to file the application for review. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Satisfactory completion of any FDA audit of preclinical studies and/or clinical trial sites that generated the data in support of the BLA. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the proposed product is produced to assess compliance with cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s continued safety, purity and potency, and of selected clinical investigation sites to assess compliance with GCPs. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Satisfactory completion of an FDA Advisory Committee review, if applicable. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">FDA review and approval of a BLA to permit commercial marketing of the product for particular indications for use in the United States. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preclinical and Clinical Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The data required to support a BLA are generated in two distinct developmental stages: preclinical and clinical. The preclinical and clinical testing and approval process require substantial time, effort and financial resources, and we cannot be certain that any approvals for any future product candidates will be granted on a timely basis, or at all. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preclinical developmental stage generally involves laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animals, including pharmacology, PK, toxicokinetic and metabolism studies, that support subsequent clinical testing in humans. The sponsor must submit the results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Preclinical studies include laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to beginning the first clinical trial with a product candidate, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new biopharmaceutical product to humans. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical trials. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises any concerns or questions about the proposed clinical trial(s) and places the trial(s) on clinical hold. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the trial until completed. Regulatory authorities, the IRB, or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, which provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing preclinical studies and clinical trials and clinical trial results to public registries. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For purposes of BLA approval, human clinical trials are typically conducted in three sequential phases that may overlap. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase 1. For biologics being studied in oncology indications, the investigational product is initially introduced into patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, to identify possible side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase 2. The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks and additional information on PK and PD. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Phase 3. The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, purity and potency for an intended use, and generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials after a product is approved to gain more information about the product. These so-called Phase 4 trials may be made a condition to approval of the BLA. Concurrent with clinical trials, companies may complete additional animal studies and develop additional information about the biological characteristics of the product candidate and must finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product, or for biologics, the safety, purity and potency. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">BLA Submission and Review </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, nonclinical studies and clinical trials are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications. The BLA must include all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s chemistry, manufacturing, controls and proposed labeling, among other things. The submission of a BLA requires payment of a substantial application user fee to the FDA, unless a waiver or exemption applies. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a BLA has been submitted, the FDA&#8217;s goal is to review standard applications within ten months after it accepts the application for filing, or, if the application qualifies for priority review, six months after the FDA accepts the application for filing. In both standard and priority reviews, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA reviews a BLA to determine, among other things, whether a product is safe, pure and potent and the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its biopharmaceutical substance will be produced, the FDA may issue an approval letter or a Complete Response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A Complete Response letter will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the Complete Response letter without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. In issuing the Complete Response letter, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-marketing testing and surveillance to monitor safety or efficacy of a product. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may entail limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the BLA with a REMS to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may require one or more Phase 4 post-market trials and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization and may limit further marketing of the product based on the results of these post-marketing studies. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Expedited Development and Review Programs </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA offers a number of expedited development and review programs for qualifying product candidates. The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for Fast Track designation if they are intended to treat patients with a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for frequent interactions with the review team during product development and, once a BLA is submitted, the product may be eligible for priority review. A fast track product may also be eligible for rolling review, where the FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A product intended to treat patients with a serious or life-threatening disease or condition may also be eligible for breakthrough therapy designation to expedite its development and review. A product can receive breakthrough therapy designation if preliminary clinical evidence indicates that the product, alone or in combination with one or more other drugs or biologics, may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance beginning as early as Phase 1 and an organizational commitment to expedite the development and review of the product, including involvement of senior managers. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any marketing application for a biologic submitted to the FDA for approval, including a product with a Fast Track designation and/or breakthrough therapy designation, may be eligible for other types of FDA programs intended to expedite the FDA review and approval process, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide a significant improvement in the treatment, diagnosis or prevention of a serious disease or condition. For original BLAs, priority review designation means the FDA&#8217;s goal is to take action on the marketing application within six months of the 60-day filing date (as compared to ten months under standard review). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, products studied for their safety and effectiveness in treating patients with serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of accelerated approval, the FDA will generally require the sponsor to perform adequate and well-controlled post-marketing clinical trials to verify and describe the anticipated effect on irreversible morbidity or mortality or other clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval preapproval of promotional materials, which could adversely impact the timing of the commercial launch of the product. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fast track designation, breakthrough therapy designation and priority review do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Orphan Drug Designation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat patients with a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusive approval (or exclusivity), which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity or if the FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application fee. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Post-Approval Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any products manufactured or distributed by us pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to facility registration, biopharmaceutical product listing, record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved BLA. Biologic manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMPs, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance. Further, if there are any modifications to the drug or biologic, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new BLA or a supplement submission, which may require the development of additional preclinical studies, clinical trials, data and/or assays, such as comparability protocols. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Fines, warning letters or holds on post-approval clinical trials. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Product seizure or detention, or refusal of the FDA to permit the import or export of products. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Mandated modification of promotional materials and labeling and the issuance of corrective information. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA closely regulates the marketing, labeling, advertising and promotion of biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Biosimilars and Reference Product Exclusivity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Patient Protection and Affordable Care Act, or ACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA approved reference biological product. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing that applicant&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, which are governed by state pharmacy law. Additionally, prescribing physicians are free to specify &#8220;Do Not Substitute&#8221; in prescriptions, which would prohibit pharmacists from substituting a branded biologic product for a biosimilar product. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, government proposals have sought to reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. As a result, the ultimate impact, implementation and impact of the BPCIA are subject to uncertainty. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Healthcare Laws and Compliance Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Biopharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Research, manufacturing, sales, promotion and other activities following product approval are subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the U.S. Centers for Medicare&#160;&amp; Medicaid Services, or CMS, other divisions of the Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&#160;&amp; Health Administration, the Environmental Protection Agency, and state and local governments. For example, in the United States, sales, marketing and scientific and educational programs also must comply with state and federal fraud and abuse laws, false claims laws, transparency laws, government price reporting and health information privacy and security laws. These laws include the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Moreover, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act, or FCA. In addition, the intent standard under the federal Anti-Kickback Statute was amended by the ACA to eliminate the need to prove specific intent and actual knowledge to establish an Anti-Kickback Statute violation. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal civil and criminal false claims, including the FCA that can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The civil monetary penalties laws impose penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, also imposes obligations, including mandatory contractual terms, on certain covered healthcare providers, health plans, and healthcare clearinghouses and their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information as well as their covered subcontractors, with respect to safeguarding the privacy, security and transmission of individually identifiable health information. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, medical devices, biologics and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians, as defined by such law, and teaching hospitals as well as information regarding ownership and investment interests held by physicians and their immediate family members. Additionally, President Trump signed into law in 2018 the &#8220;Substance Use-Disorder Prevention that Promoted Opioid Recovery and Treatment for Patients and Communities Act&#8221; which, under the provision entitled &#8220;Fighting the Opioid Epidemic with Sunshine,&#8221; in part, extends the reporting and transparency requirements under the Physician Payments Sunshine Act to physician assistants, nurse practitioners and other mid-level practitioners, with reporting requirements beginning in 2022 for payments made or ownership or investment interests held in 2021. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, price reporting, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. Pricing and rebate programs must also comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. For example, products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, if any, and to devise and maintain an adequate system of internal accounting controls for international operations. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Analogous state and foreign laws and regulations, such as state anti-kickback, anti-referral and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, state laws that require biotechnology or pharmaceutical companies to comply with the biotechnology or pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report certain information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, state laws that require biotechnology companies to report information on the pricing of certain drug products, state and local laws that require the registration of pharmaceutical sales representatives, and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and state laws related to insurance fraud in the case of claims involving private insurers. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions or safe harbors, it is possible that some of our activities, such as stock-option compensation paid to physicians, could be subject to challenge under one or more of such laws. The growth of our business and sales organization and our expansion outside of the United States may increase the potential of violating these laws or our internal policies and procedures. Any action brought against us for violations of these laws or regulations, even successfully defended, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. Also, we may be subject to private &#8220;qui tam&#8221; actions brought by individual whistleblowers on behalf of the federal or state governments. If our operations are found to be in violation of any of the federal, state and foreign laws described above or any other current or future fraud and abuse or other healthcare laws and regulations that apply to us, we may be subject to penalties, including significant civil, criminal and administrative penalties, including damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts, and we could be required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Coverage and Reimbursement </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the availability of coverage and adequate reimbursement from third-party payors. Third-party payors include government programs such as Medicare or Medicaid, managed care plans, private health insurers and other organizations. These third-party payors may deny coverage or reimbursement for a product or therapy in whole or in part if they determine that the product or therapy was not medically appropriate or necessary. Third-party payors may attempt to control costs by limiting coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drug products for a particular indication, and by limiting the amount of reimbursement for particular procedures or drug treatments. Additionally, coverage and reimbursement for drug products can differ significantly from payor to payor. The Medicare and Medicaid programs are often used as models by private payors and other governmental payors to develop their coverage and reimbursement policies for drugs and biologics. However, one third-party payor&#8217;s decision to cover a particular drug product does not ensure that other payors will also provide coverage for the product or will provide coverage at an adequate reimbursement rate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cost of pharmaceuticals continues to generate substantial governmental and third-party payor interest. We expect that the pharmaceutical industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care organizations and additional legislative proposals. Third-party payors are increasingly challenging the price and examining the medical necessity and cost effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products to obtain third-party payor coverage, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some third-party payors also require pre-approval of coverage for new or innovative drug therapies before they will reimburse healthcare providers who use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted or otherwise implemented in the future, these requirements or any announcement or adoption of such proposals could have a material adverse effect on our ability to obtain adequate prices for our product candidates and to operate profitably. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. There can be no assurance that our products will be considered medically reasonable and necessary for a specific indication, that our products will be considered cost-effective by third-party payors, that coverage or an adequate level of reimbursement will be available or that third-party payors&#8217; reimbursement policies will not adversely affect our ability to sell our products profitably. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other Healthcare Laws </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">U.S. Healthcare Reform </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system. There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by federal and state legislative initiatives, including those designed to limit the pricing, coverage and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA, which was enacted in March 2010, substantially changed the way healthcare is financed by both governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The ACA contains a number of provisions of particular import to the pharmaceutical and biotechnology industries, including, but not limited to, those governing enrollment in federal healthcare programs, a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected, a new licensure framework for follow on biologic products, and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. There remain judicial and Congressional challenges to certain aspects of the ACA, as well as efforts by the Trump administration to repeal or replace certain aspects of the ACA. Since January 2017, President Trump has signed Executive Orders and other directives designed to delay the implementation of certain provisions of the ACA or otherwise circumvent some of the requirements for health insurance mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the ACA have passed. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;22, 2017, President Trump signed into law new federal tax legislation commonly referred to as the Tax Cuts and Jobs Act, or Tax Act, which includes a provision repealing, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; In addition, the 2020 federal spending package permanently eliminates, effective January&#160;1, 2020, the ACA mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January&#160;1, 2021, also eliminates the health insurer tax. The Bipartisan Budget Act of 2018, or BBA, among other things, amended the ACA, effective January&#160;1, 2019, to close the coverage gap in most Medicare Part D drug plans. In December 2018, CMS published a new final rule permitting further collections and payments to and from certain ACA-qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. However, on April&#160;27, 2020, the U.S. Supreme Court reversed a Federal Circuit decision that previously upheld Congress&#8217; denial of $12&#160;billion in &#8220;risk corridor&#8221; funding. On December&#160;14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December&#160;18, 2019, the U.S Court of Appeals for the Fifth Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. In November 2020, the United States Supreme Court held oral arguments and is expected to issue a decision by mid-2021. It is uncertain how the Supreme Court will rule on this case. We cannot predict how this decision or future litigation will impact our business, or what other healthcare measures and regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation may have on our business.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of up to 2% per fiscal year</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which&nbsp;&nbsp;went into effect in April 2013 and</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will remain in effect through 2030, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2021, unless additional action is taken by Congress.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Additionally, it is possible that additional governmental action is taken to address the COVID-19 pandemic, resulting in a material adverse effect on our business. For example, on August 6, 2020, the Trump administration issued another executive order that instructs the federal government to develop a list of &#8220;essential&#8221; medicines and then buy them and other medical supplies from U.S. manufacturers instead of from companies around the world, including China. The order is meant to reduce regulatory barriers to domestic pharmaceutical manufacturing and catalyze manufacturing technologies needed to keep drug prices low and the production of drug products in the United States. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January&#160;1, 2020, codifying a policy change that was effective January&#160;1, 2019. In 2020, the U.S. Department of Health and Human Services and CMS issued various rules that are expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, importation of prescription drugs from Canada and other countries, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Multiple lawsuits have been brought against the HHS challenging various aspects of these new rules. In January 2021, the Biden administration issued a &#8220;regulatory freeze&#8221; memorandum that directs department and agency heads to review new or pending rules of the prior administration. It is unclear whether these new regulations will be withdrawn or when they will become fully effective under the current administration. The impact of these lawsuits as well as legislative, executive, and administrative actions of the current administration on us and the biopharmaceutical industry as a whole is unclear.  At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. These and other new laws and regulations may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our biopharmaceutical products, if approved, and accordingly, our financial operations. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Right to Try Act, which was enacted on May&#160;30, 2018, provides a federal framework for certain patients with life-threatening diseases to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Employees and Human Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 23 employees, 11 of whom hold Ph.D. or M.D. degrees and 12 of whom were engaged in research and development activities. None of our employees are represented by a labor union and we believe we maintain good relations with our employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our objectives. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Corporate Information</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our predecessor company, ALX Oncology Limited, an Irish private company limited by shares, was initially incorporated in Ireland on March&#160;13, 2015 under the name Alexo Therapeutics Limited and changed its name to ALX Oncology Limited on October&#160;11, 2018. We were then incorporated in Delaware on April&#160;1, 2020 under the name ALX Oncology Holdings Inc. and completed a reorganization effective as of the same date whereby ALX Oncology Limited became our wholly-owned subsidiary and all of the shareholders, warrantholders and optionholders of ALX Oncology Limited became our stockholders, warrantholders and optionholders, holding the same number of corresponding shares, warrants and/or options in ALX Oncology Holdings Inc. as they did in ALX Oncology Limited immediately prior to the reorganization. We present the information included in this Annual Report on Form 10-K as that of ALX Oncology Holdings Inc. unless such information refers to a date prior to April 1, 2020, in which case it will reflect that of our predecessor company.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal executive offices are located at 866 Malcolm Road, Suite 100, Burlingame, California 94010. Our telephone number is 650-466-7125. Our website address is http://alxoncology.com.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We use ALX Oncology and other marks as trademarks in the United States and other countries. This Annual Report on Form 10-K contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the &#174; or TM symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available Information</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our Annual Reports on Form 10&#8209;K, Quarterly Reports on Form 10&#8209;Q, Current Reports on Form 8&#8209;K, proxy and information statements and amendments to reports filed pursuant to Sections 13(a), and 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act) are filed with the U.S. Securities and Exchange Commission (SEC). We are subject to the informational requirements of the Exchange Act and file or furnish reports, proxy statements and other information with the SEC. The SEC maintains an Internet site that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC at www.sec.gov. Such documents and other information filed by us with the SEC are available free of charge on the Investor section of our website (ir.alxoncology.com) when such reports are available on the SEC&#8217;s website.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investors and others should note that we may announce material information to the public through filings with the SEC, our website (alxoncology.com), press releases, public conference calls, and public webcasts. We encourage our investors and others to review the information disclosed through such channels as such information could be deemed to be material information. Please note that this list may be updated from time to time.</p><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1A_RISK_FACTORS"></a>Item 1A. Ris</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">k Factors. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RISK FACTORS </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, together with the other information contained elsewhere in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes, Part II, Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our other filings with the Securities and Exchange Commission, or SEC, before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations and the market price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risk Factors Summary </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investing in our common stock involves a high degree of risk because our business is subject to numerous risks and uncertainties, as fully described below. These risks include, but are not limited to, the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We have incurred significant net losses since our inception, and we expect to continue to incur significant net losses for the foreseeable future; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We will require substantial additional capital to finance our operations, such capital may not be available to us or may only be available on terms that are unfavorable to us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We have a limited operating history and have no products approved for commercial sale; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The price of our stock may be volatile, and you could lose all or part of your investment; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We are substantially dependent on the success of our lead product candidate, ALX148, which is in clinical development and which has not completed a pivotal trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Our product candidates may cause significant adverse events or other undesirable side effects when used alone or in combination with other treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Clinical trials of our product candidates are expensive, time consuming and difficult to design and implement and may fail to demonstrate adequate safety, efficacy and potency of our product candidates or provide the basis for marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, which could lead to our inability to generate product revenue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">If we are unable to obtain, maintain and enforce patent protection and other intellectual property for our product candidates and related technology, our business could be materially harmed; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating, and retaining highly qualified personnel, we may not be able to successfully implement our business strategy; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Our preclinical research is conducted solely by a third party service provider, Tallac Therapeutics, Inc. (formerly known as Tollnine, Inc.), or Tallac Therapeutics, and we are dependent on Tallac Therapeutics to perform its contractual research obligations on an effective and timely basis; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The COVID-19 pandemic could adversely impact our business including our ongoing and planned clinical trials and preclinical research; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">We have identified material weaknesses in our internal control over financial reporting. If remediation measures are not effective, investors may lose confidence in our financial reports. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Financial Position and Need for Additional Capital </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred significant net losses since our inception, and we expect to continue to incur significant net losses for the foreseeable future. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred significant net losses in each reporting period since our inception, have not generated any revenue to date and have financed our operations principally through private placements of our convertible preferred stock. Our net losses were $45.7 million, $19.2&#160;million and $13.7 million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. As of December&#160;31, 2020, we had an accumulated deficit of $118.5&#160;million. We have devoted substantially all of our resources and efforts to research and development. Our lead product candidate, ALX148, is in early-stage clinical trials. Our other programs are in preclinical discovery and research stages. As a result, we expect that it will be several years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses in order to discover, develop and market additional potential products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital, our ability to fund the development of our product candidates and our ability to achieve and maintain profitability and the performance of our stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek marketing approval for ALX148 and advance our other programs. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution activities. Our expenses could increase beyond expectations if we are required by the FDA, the European Medicines Agency, or EMA, or other regulatory agencies to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. Because the design and outcome of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amount of resources and funding that will be necessary to successfully complete the development and commercialization of any product candidate we develop. We have incurred and expect to continue to incur additional costs associated with operating as a public company and comply with legal, accounting and other regulatory requirements. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations. If we are unable to raise capital when needed or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had cash and cash equivalents of $434.2&#160;million. Based on our current operating plan, we believe that our existing cash and cash equivalents, will be sufficient to fund our operations through 2024. Our estimate as to how long we expect our existing cash and cash equivalents to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to use </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our cash and cash equivalents </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to advance the clinical development of ALX148, as well as for working capital and other general corporate purposes. This may include additional pre-clinical research, clinical development, hiring additional personnel, capital expenditures, the potential acquisition of businesses or assets and the costs of operating as a public company, as well as for working capital and other general corporate purposes. Advancing the development of ALX148 and our other programs will require a significant amount of capital. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">O</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ur current cash and cash equivalents on hand, may not be sufficient to fund all of the actions that are necessary to complete the development of ALX148 or our other programs. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, which may dilute our stockholders or restrict our operating activities. We do not have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt financing may result in imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through upfront payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and viability. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We were incorporated and commenced operations in 2015, have no products approved for commercial sale and have not generated any revenue. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, identifying and developing potential product candidates and conducting preclinical and clinical trials of our product candidates, including a Phase 1 clinical trial of ALX148. We have not yet demonstrated our ability to successfully complete any large-scale, pivotal clinical trials, obtain marketing approvals, manufacture a commercial-scale drug or arrange for a third party to do so on our behalf or conduct sales and marketing activities. As a result, it may be more difficult for you to accurately predict our likelihood of success and viability than it could be if we had a longer operating history. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields. We also may need to transition from a company with a research focus to a company capable of supporting commercial activities. We have not yet demonstrated an ability to successfully overcome such risks and difficulties or to make such a transition. If we do not adequately address these risks and difficulties or successfully make such a transition, our business will suffer. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business depends entirely on the successful development and commercialization of our product candidates. We currently generate no revenue from any product sales, licenses or collaborations and do not expect to generate any revenue from the sale of product candidates in the foreseeable future. We have no products approved for commercial sale and do not anticipate generating any revenue from product sales for the next several years, if ever. Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve a number of objectives, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">successful and timely completion of preclinical and clinical development of our lead product candidate, ALX148, and our other future product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establishing and maintaining relationships with CROs and clinical sites for the clinical development of ALX148 and our other future product candidates; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we successfully complete clinical development; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">developing an efficient and scalable manufacturing process for ALX148 and any future product candidates, including establishing and maintaining commercially viable supply and manufacturing relationships with third parties to obtain finished products that are appropriately packaged for sale; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for our product candidates, if approved; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">successful commercial launch following any marketing approval, including the development of a commercial infrastructure, whether in-house or with one or more collaborators; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">a continued acceptable safety profile following any marketing approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">commercial acceptance of ALX148 and any future product candidates as viable treatment options by patients, the medical community and third-party payors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining favorable coverage and adequate reimbursement by third-party payors for our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">addressing any competing therapies and technological and market developments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">identifying, assessing, acquiring and developing new product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">protecting our rights in our intellectual property portfolio, including our licensed intellectual property; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">defending against third-party interference or infringement claims, if any; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">entering into, on favorable terms, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">negotiating favorable terms in any collaboration, licensing or other arrangements that may be necessary to develop, manufacture or commercialize our product candidate; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">attracting, hiring and retaining qualified personnel. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may never be successful in achieving our objectives and, even if we do, may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business and/or continue our operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to the Discovery, Development and Commercialization of Our Product Candidates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are substantially dependent on the success of our lead product candidate, ALX148, which is in clinical development and which has not completed a pivotal trial. If we do not obtain regulatory approval for and successfully commercialize ALX148 in one or more indications, or we experience significant delays in doing so, we may never generate any revenue or become profitable. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any products that have received regulatory approval and may never be able to develop marketable product candidates. We expect that a substantial portion of our efforts and expenses over the next several years will be devoted to the development of our lead product candidate, ALX148, in our ongoing clinical trials. As a result, our business currently depends heavily on the successful development, regulatory approval and, if approved, commercialization of ALX148 in one or more of these indications, such as MDS, AML, HNSCC, or gastric/ GEJ carcinoma. We cannot be certain that ALX148 will receive regulatory approval or will be successfully commercialized even if it receives regulatory approval. The research, testing, manufacturing, safety, efficacy and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">potency, labeling, approval, sale, marketing and distribution of ALX148 is, and will remain, subject to comprehensive regulation by the FDA and similar foreign regulatory authorities. Our failure to timely complete clinical trials, obtain regulatory approval or, if approved, commercialize ALX148 or any of our future product candidates, would materially harm our business, financial condition and results of operations. We are not permitted to market or promote ALX148, or any other product candidate, before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals. If we do not receive marketing approvals for ALX148, we may not be able to continue our operations. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities. The clinical trials of our product candidates may not produce positive results or demonstrate adequate safety, purity and efficacy and potency to the satisfaction of regulatory authorities. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy/potency of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many years to complete, and its ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain approval of their drugs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Positive or timely results from preclinical or early-stage trials do not ensure positive or timely results in future clinical trials or registrational clinical trials because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety, purity and efficacy and potency to the satisfaction of the FDA or comparable international regulatory authorities, despite having progressed through preclinical studies or initial clinical trials. In addition, the FDA or any comparable international regulatory authorities may conclude that the results from our clinical trials are insufficient to support any accelerated approval that we may seek with respect to ALX148 or any of our future product candidates in general or with respect to any specific indications. Product candidates that have shown promising results in early clinical trials may still suffer significant setbacks in subsequent clinical trials or registration clinical trials. For example, a number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Clinical trials of our product candidates are expensive, time consuming and difficult to design and implement and may fail to demonstrate adequate safety, purity and efficacy and potency of our product candidates or provide the basis for marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct preclinical development and then extensive clinical trials to demonstrate their safety, purity and efficacy and potency. Clinical trials are expensive and difficult to design and implement. Clinical trials can take many years to complete, and their ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. We will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe, pure and effective or potent for use in a diverse patient population before we can seek regulatory approvals for their commercial sale. Our clinical trials may produce negative or inconclusive results and we may decide, or regulators may require us, to conduct additional and expansive preclinical or clinical testing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not know whether our future clinical trials will begin on time or enroll subjects on time or whether our ongoing and/or future clinical trials will be completed on schedule or at all. Clinical trials can be delayed for a variety of reasons, including delays related to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining approval to commence a clinical trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">obtaining institutional review board approval at each clinical trial site; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">adding necessary new clinical trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">recruiting suitable subjects to participate in a trial; failing in having clinical trial sites or subjects comply with trial protocols; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">suffering clinical trial sites or subjects dropping out of trials; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">manufacturing sufficient quantities of product candidate for use in clinical trials. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent receipt of marketing approval or our ability to commercialize our product candidates, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">receipt of feedback from regulatory authorities that requires us to modify the design of our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">negative or inconclusive clinical trial results that may require us to conduct additional clinical trials or abandon certain drug development programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the number of subjects required for clinical trials being larger than anticipated, enrollment in these clinical trials being slower than anticipated or subjects dropping out of these clinical trials at a higher rate than anticipated; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in clinical trials due to outbreaks or public health crises, such as the COVID-19 pandemic, that impact both trial site operations and subject selection; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">third-party contractors failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the suspension or termination of our clinical trials for various reasons, including non-compliance with regulatory requirements, a finding that our product candidates have undesirable side effects or other unexpected characteristics or risks; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of clinical trials of our product candidates are greater than anticipated; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates being insufficient or inadequate; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulators revising the requirements for approving our product candidates. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of any of these delays or other circumstances, we may incur unplanned costs, not obtain or be delayed in obtaining marketing approval, receive more limited or restrictive marketing approval, be subject to additional post-marketing testing requirements or have our drug removed from the market after obtaining marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the FDA verbally informed us, that given our planned initiation of two Phase 2 HNSCC clinical trials that could be potentially registrational, they require completion of a routine non-clinical safety study that we currently have in process. The FDA noted that for any drug development program moving swiftly through development, this non-clinical study is still required prior to the initiation of a clinical trial that could be considered pivotal. We are allowed to initiate both Phase 2 HNSCC clinical trials with the enrollment capped at a total of 50 subjects treated with ALX148 across both trials (excluding safety lead-in cohorts) pending acceptance of the non-clinical safety study report. We expect to provide the required report to the FDA prior to reaching the 50-patient enrollment cap. While this cap on enrollment is defined as a partial clinical hold, no delays are anticipated in our current clinical trial timelines. Delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our drugs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate safety, purity and efficacy and potency sufficient to obtain marketing approval or our product candidates or to market our drugs after any such approval. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we experience delays or difficulties in the enrollment of subjects in clinical trials and/or retention of subjects in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible subjects to participate in these trials as required by the FDA or comparable international regulatory authorities. Subject enrollment is a significant factor in the timing of clinical trials. In particular, because certain of our clinical trials of ALX148 are focused on indications with small patient populations, our ability to enroll eligible subjects may be limited or may result in slower enrollment than we anticipate. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enrollment of subjects in our clinical trials may be delayed or limited if our clinical trial sites limit their onsite staff or temporarily close as a result of the COVID-19 pandemic. In addition, subjects may not be able to visit clinical trial sites for dosing or data collection purposes due to limitations on travel and physical distancing imposed or recommended by federal or state governments or subjects&#8217; reluctance to visit the clinical trial sites during the pandemic. The drop-out rates in our clinical trials may be increased during the pandemic. Subjects who enroll in our clinical trials and then who become infected with the COVID-19 virus may complicate the clinical trial data, procedures and analysis. These factors resulting from the COVID-19 pandemic could delay the anticipated readouts from our clinical trials and our regulatory submissions and increase the costs associated of the clinical trials. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject enrollment may also be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; product candidates. Subject enrollment may also be affected by other factors, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">size and nature of the patient population; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">severity of the disease under investigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">availability and efficacy or potency of approved drugs for the disease under investigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">patient eligibility criteria for the trial in question; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">perceived risks and benefits of the product candidate under study; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">efforts to facilitate timely enrollment in clinical trials by us and the clinical trial sites; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">patient referral practices of physicians; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the ability to monitor subjects adequately during and after the clinical trial; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">proximity of clinical trial sites to prospective subjects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">risk of subjects enrolled in clinical trials dropping out before completion; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">inability or delay in enrollment of subjects due to a variety of reasons, including outbreaks and public health crises, such as the COVID-19 pandemic. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our inability to enroll a sufficient number of subjects for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our drugs. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more subject data become available and are subject to audit and verification procedures that could result in material changes in the final data. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials. These interim updates are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. Further, interim, topline and preliminary data include certain assumptions, estimations, calculations and conclusions as part of our analyses of data available at that time, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as subject enrollment continues and more subject data become available. Adverse changes between interim data and final data could significantly harm our business and prospects. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common stock. You or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the preliminary or topline data that we report differ from late, final or actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If ALX148 or any of our other product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. For example, we have observed single-digit incident rates of treatment-related grade three and higher cytopenias across each of the trial cohorts in our ALX148 combination clinical trials with pembrolizumab, trastuzumab and rituximab in a heavily pre-treated group of subjects who are typical participants in early stage cancer trials and are often hematologically fragile at baseline. Subjects in our ALX148 combination clinical trials experienced a number of treatment-related adverse events that were low-grade and manageable, including fatigue, rash, aspartate aminotransferase, or AST, increase, platelets decrease, alanine aminotransferase, or ALT, increase, pruritus, pyrexia, decreased appetite, anemia, infusion reaction, neutropenia, nausea, alkaline phosphate increase, arthralgia, white blood cell decrease and myalgia. Treatment-related side effects could also affect subject recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any adverse events as a result of ALX148 or any of our future product candidates, including in combination therapy, may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We face substantial competition which may result in others discovering, developing or commercializing products before or more successfully than we do. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The development and commercialization of new product candidates is highly competitive. We face competition with respect to ALX148 and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical, specialty pharmaceutical and biotechnology companies among others. We compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immuno-oncology therapies for the treatment of cancer. There are other companies working to develop immuno-oncology therapies for the treatment of cancer including divisions of large pharmaceutical and biotechnology companies of various sizes. The large pharmaceutical and biotechnology companies that have commercialized and/or are developing immuno-oncology treatments for cancer include AstraZeneca, Bristol Myers Squibb, Gilead Sciences, Merck, Novartis, Pfizer and Roche/Genentech. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of these competitive products and therapies are based on scientific approaches that are the same as or similar to our approach, including with respect to the targeting of CD47 pathway and others are based on entirely different approaches. We are aware that Apexigen, Arch Therapeutics, Bristol Myers Squibb, Gilead Sciences (through its acquisition of Forty Seven), I-Mab, Innovent, Kahr, Novimmune, OSE Immunotherapeutics and Trillium Therapeutics, among others, are developing drugs targeting the CD47 pathway that may have utility for the treatment of indications that we are targeting. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are already a variety of available drug therapies marketed for cancer and some of the currently approved drug therapies are branded and subject to patent protection and others are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use of generic products. We expect that if ALX148 and any of our other future product candidates are approved, they will be priced at a significant premium over competitive generic products. This may make it difficult for us to achieve our business strategy of using our product candidates in combination with existing therapies or replacing existing therapies with our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved drugs than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and enrolling subjects for our clinical trials and in acquiring technologies complementary to, or necessary for, our programs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could see a reduction or elimination of our commercial opportunity if our competitors develop and commercialize products that are safer, more effective, more convenient or less expensive than any products that we or our collaborators may develop. Our competitors also may obtain FDA or foreign regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. The key competitive factors affecting the success of all our product candidates, if approved, are likely to be their efficacy, safety, convenience, price, the level of biosimilar or generic competition and the availability of reimbursement from government and other third-party payors. The inability to compete with existing or subsequently introduced drugs would harm our business, financial condition and results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even after approval, our manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our approved products will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and current good clinical practices, or cGCPs, for any clinical trials that we conduct post-approval. Regulatory approvals may contain significant limitations related to use restrictions for specific target population subsets, <font style="font-style:italic;">e.g.</font>, age groups, warnings, precautions or contraindications, or may include costly and burdensome post-approval study or risk management requirements and regulatory inspection. For example, the FDA may require a REMS as a condition for approval of our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk mitigation tools. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with a contract supplier, vendor, or facility where the product is manufactured or processed, a regulatory agency may impose restrictions on that product, the manufacturing facility or contractor, or us, including requiring recall or withdrawal of the product from the market </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or suspension of manufacturing. In addition, failure to comply with FDA, EMA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions or enforcement actions, including: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in or the rejection of product approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">restrictions on the products, manufacturers or manufacturing process; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">warning or untitled letters; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">civil and criminal penalties; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">injunctions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">suspension or withdrawal of regulatory approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">product seizures, detentions or import bans; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">voluntary or mandatory product recalls and publicity requirements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">total or partial suspension of production; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">imposition of restrictions on operations, including costly new manufacturing requirements. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any of these sanctions, enforcement actions or penalties described above may inhibit our ability to commercialize our product candidates, even if approved, and generate revenue. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We rely on Tallac Therapeutics, a third-party service provider, to conduct substantially all of our preclinical research activities. If Tallac Therapeutics does not successfully carry out its contractual duties or meet expected deadlines, there may be disruptions or delays to our development pipeline and our business could be substantially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have the ability to independently conduct our preclinical research activities as we rely on a third-party service provider to conduct all of our preclinical research activities. Effective as of July&#160;1, 2020, we transferred all of our preclinical research capabilities and nine of our employees, including our former Chief Scientific Officer, Dr.&#160;Hong Wan, to Tallac Therapeutics, and entered into a research and development services agreement, or the Tallac Services Agreement, with Tallac Therapeutics. Under the terms of the Tallac Services Agreement, Tallac Therapeutics will provide preclinical research services to us for the cost of these services plus a mark-up equal to 10.0% of such costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Tallac Therapeutics does not successfully carry out its contractual obligations or meet expected deadlines, if Tallac Therapeutics needs to be replaced or if the quality or accuracy of the preclinical data Tallac Therapeutics obtains is compromised due to its failure to adhere to its or our preclinical protocols, regulatory requirements or for other reasons, our preclinical research efforts and studies may be extended, delayed or terminated, and there may be disruptions or delays to our development pipeline. As a result, our product candidate research and development efforts may be delayed or harmed, and our costs could increase and our future ability to generate revenues could be delayed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, Tallac Therapeutics&#8217; employees are not our employees, and we will not be able to control, other than by contract, the amount of resources, including time, that they devote to our preclinical research efforts and studies. If Tallac Therapeutics fails to devote sufficient resources to the research and development of our preclinical research programs and studies, or if its performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, we must disclose our proprietary information to Tallac Therapeutics, which could increase the risk that this information will be misappropriated or that disputes related to our intellectual property with Tallac Therapeutics may occur, including the risks discussed below related to intellectual property matters. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If our relationship with Tallac Therapeutics terminates, we may not be able to enter into arrangements with alternative providers or do so in a timely manner or on commercially reasonable terms. If the Tallac Services Agreement is terminated, replacing Tallac Therapeutics or adding additional preclinical research providers will involve additional costs and divert our management&#8217;s time and focus. In addition, there is a natural transition period when a new service provider commences work. As a result, delays may occur, which can materially impact our ability to meet our desired preclinical timelines. Since Tallac Therapeutics is an early-stage company with a limited operating history, it may face challenges to its business and cease to operate, and we may need to engage replacement service providers on an accelerated timeline and on even less favorable terms. There can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and results of operations. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends, in part, on our ability to conduct our research and develop our product pipeline without infringing the intellectual property and other proprietary rights of third parties. If we ever become involved in any dispute with Tallac Therapeutics over ownership of intellectual property or proprietary rights in the future because of the access that Tallac Therapeutics had to our intellectual property, including trade secrets, we may need to negotiate or engage in litigation to preserve our intellectual property rights, which may be time-consuming, expensive and ultimately unsuccessful. In addition, our former employees who are now employees of Tallac Therapeutics may possess our proprietary information. Although these former employees have signed confidentiality and invention assignment agreements with us, we cannot guarantee that they will not breach these agreements in the future. If these former employees disclose our proprietary information to Tallac Therapeutics or other third parties, we may not be able to obtain adequate remedies for such breaches. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We contract with third parties for the manufacture of our product candidates for preclinical development and clinical trials, and we expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently own or operate, nor do we have any plans to establish in the future, any manufacturing facilities or personnel. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical development and clinical testing, as well as for the commercial manufacture of our drugs if any of our product candidates receive marketing approval. No assurance can be given that long-term, scalable manufacturers can be identified or that they can make clinical and commercial supplies of our product candidates that meet the product specifications of previously manufactured batches, or are of a sufficient quality, or at an appropriate scale and cost to make it commercially feasible. Such third-party manufacturers may also be subject to delays due to circumstances outside of their control for a variety of reasons, including outbreaks and public health crises, such as the COVID-19 pandemic, that could shut down or cause limited staffing of their facilities. Our reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. If they are unable to do so, it could have a material adverse impact on our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The facilities used by contract manufacturers to manufacture our product candidates must be approved by the FDA or any applicable foreign regulatory authority pursuant to inspections that may be conducted after we submit our marketing applications to the FDA or any such foreign regulatory authority. We do not control the manufacturing process of, and will be completely dependent on, our contract manufacturers for compliance with cGMPs in connection with the manufacture of our product candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or any applicable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact, including causing substantial delay, in our ability to develop, obtain regulatory approval for or market our product candidates. Further, our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of drug candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business and supplies of our product candidates. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates and any drugs that we may develop may compete with other product candidates and approved drugs for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also expect to rely on other third parties to store and distribute product candidate supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or marketing approval of any future product candidates or commercialization of our products, producing additional losses and depriving us of potential drug revenue. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any performance failure on the part of our existing or future manufacturers could delay clinical development, marketing approval or commercial drug supply after marketing approval. If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers causing additional costs and delays in identifying and qualifying any such replacement. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Material modifications in the methods of product candidate manufacturing or formulation may result in additional costs or delay. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented. Also, as product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing, suppliers and formulation, are altered in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the modified manufacturing, materials or process. This could delay completion of clinical trials, require the conduct of additional clinical trials, such as bridging studies to demonstrate the product is substantially equivalent to product used during earlier clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lack of third-party combination drugs may materially and adversely affect demand for our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates may be administered in combination with drugs of other pharmaceutical companies as one regimen. In addition, we plan to use third-party drugs in our development and clinical trials as controls for our studies, such as our current plans to conduct Phase 2 clinical trials of ALX148 in combination with pembrolizumab for HNSCC and trastuzumab for gastric/GEJ carcinoma. As a result, both the results of our clinical trials and the sales of our drugs may be affected by the availability of these third-party drugs. For instance, we entered into clinical trial collaboration and supply agreements with Merck and Zymeworks, pursuant to which Merck and Zymeworks will supply doses of pembrolizumab and zanidatamab, respectively, for use in certain of our clinical trials. If these agreements are terminated before our trials are completed, we may need to find another source of pembrolizumab or zanidatamab in order to continue our trial. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If other pharmaceutical companies discontinue these drugs for combination therapies in the future, regimens that use these combination drugs may no longer be prescribed, and we may not be able to introduce or find an alternative drug to be used in combination with our drugs at all or in a timely manner and on a cost-effective basis. Use of new combination drugs with our approved product candidates will require further regulatory approval before we can promote such new combination therapies. As a result, demand for our product candidates may be lowered, which would in turn materially and adversely affect our business and results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to obtain regulatory approval for our product candidates or commercialize any product candidates that may result from our development efforts, or may miss expected deadlines, if we are not able to maintain or secure agreements with the third parties that conduct the activities related to our clinical trials on acceptable terms, if these third parties do not perform their services as contractually required, or if these third parties fail to timely transfer any regulatory information held by them to us. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on entities outside of our control, which may include academic institutions, CROs, hospitals, clinics and other third-party strategic partners, to monitor, support, conduct and oversee preclinical studies and clinical trials of our current and future product candidates. As a result, we have less control over the timing and cost of these studies and the ability to recruit trial subjects than if we conducted these trials with our own personnel. If we are unable to maintain or enter into agreements with these third parties on acceptable terms, or if any such engagement is terminated prematurely, we may be unable to enroll subjects on a timely basis or otherwise conduct our clinical trials as planned. In addition, there is no guarantee that these third parties will devote adequate time and resources to our clinical trials or perform as required by our contract or in accordance with regulatory requirements, including maintenance of clinical trial information regarding our product candidates. For example, these third parties may be adversely impacted by the COVID-19 pandemic. If these third parties fail to meet expected deadlines, fail to transfer to us any regulatory information in a timely manner, fail to adhere to protocols or fail to act in accordance with regulatory requirements or our agreements with them, or if they otherwise perform in a substandard manner or in a way that compromises the quality or accuracy of their activities or the data they obtain, then clinical trials of our product candidates may be extended or delayed with additional costs incurred, or our data may be rejected by the FDA or other regulatory agencies. Ultimately, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We and our CROs are required to comply with cGCPs, regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these cGCPs through periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we or any of our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and our submission of marketing applications may be delayed, or the FDA or foreign regulatory authority may require us to perform additional clinical trials before approving our marketing applications. Upon inspection, the FDA or foreign regulatory authority could determine that any of our clinical trials fail or have failed to comply with applicable cGCPs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business also may be implicated if any of our CROs violates fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our third-party clinical trial sites terminate for any reason, we may experience the loss of follow-up information on subjects enrolled in our ongoing clinical trials unless we are able to transfer the care of those subjects to another qualified clinical trial site. Further, our CROs are not required to work indefinitely or exclusively with us. Our existing agreements with our CROs may be subject to termination by the counterparty upon the occurrence of certain circumstances. If any CRO terminates its agreement with us, the research and development of the relevant product candidate would be suspended, and our ability to research, develop and license future product candidates would be impaired. We may be required to devote additional resources to the development of our product candidates or seek a new CRO partner, and the terms of any additional arrangements that we establish may not be favorable to us. Switching or adding CROs or other service providers can involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a new CRO or service provider commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. If we are required to seek alternative arrangements, the resulting delays and potential inability to find suitable replacements could materially and adversely impact our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive marketing approval for any of our product candidates, we may not achieve market acceptance, which would limit the revenue that we can generate from sales of any of our approved product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the FDA and applicable foreign regulatory authorities approve the marketing of any product candidates that we develop, physicians, patients, third-party payors or the medical community may not accept or use our product candidates. Efforts to educate the medical community and third-party payors on the benefits of our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">product candidates may require significant resources and may not be successful. Market acceptance of ALX148 and any other product candidates, if any are approved, will depend on a number of factors, including, among others: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the ability of ALX148 and our other product candidates to treat cancer or other applicable targeted diseases, as compared with other available drugs, treatments or therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing of market introduction of the product candidate as well as competitive products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the clinical indications for which a product candidate is approved; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the approval of other new therapies for the same indications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the prevalence and severity of any adverse side effects associated with ALX148 and our other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">limitations or warnings contained in the labeling approved for ALX148 or our other product candidates by the FDA or foreign regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">availability of alternative treatments and the potential and perceived advantages of our product candidates over alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the size of the target patient population and the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the strength and effectiveness of marketing and distribution support and timing of market introduction of competitive products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">publicity for our product candidates and competing products and treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">pricing and cost-effectiveness in relation to alternative treatments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">relative convenience and ease of administration; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to obtain sufficient third-party coverage or reimbursement, and the willingness of patients to pay out-of-pocket in the absence of third-party coverage; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the likelihood that the FDA or any foreign regulatory authority may impose additional requirements that limit the promotion, advertising, distribution or sales of our product candidates. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adverse events in clinical trials for our product candidates or in clinical trials of others developing similar products and the resulting publicity, as well as any other adverse events in the field of immuno-oncology that may occur in the future, could result in a decrease in demand for ALX148 or any other product candidate that we may develop. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our therapies or those of our competitors, our products may not be accepted by the general public or the medical community. Future adverse events in immuno-oncology or the biopharmaceutical industry generally could also result in greater governmental regulation and stricter labeling requirements. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates is approved but does not achieve an adequate level of acceptance by patients, physicians and third-party payors, we may not generate sufficient revenue to become or remain profitable and our business may be harmed. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have never commercialized a product candidate and we may lack the necessary expertise, personnel and resources to successfully commercialize any of our products that receive regulatory approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have no marketing and sales organization and we have never commercialized a product candidate. To achieve commercial success of our product candidates, if any are approved, we will have to develop our own sales, marketing and supply capabilities or outsource these activities to a third party. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates ultimately receives regulatory approval, we may choose to establish an internal marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming. We have no prior experience as a company in the marketing, sale and distribution of pharmaceutical products and there are significant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">risks involved in building and managing a sales organization. Factors that may affect our ability to commercialize our product candidates on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our product candidates and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization requires significant investment, is time-consuming and could delay the launch of our product candidates. We may not be able to build an effective sales and marketing organization in the United States, the European Union or other key global markets. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may have difficulties generating revenue from them. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenue and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses. We have no internal sales, marketing or distribution capabilities. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The market opportunities for the product candidates we develop, if approved, may be limited to certain smaller patient subsets. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is no guarantee that the product candidates we develop, even if approved, would be approved for the currently proposed indications. We may have to conduct additional clinical trials that may be costly, time-consuming and subject to risk. Regulators, like FDA, may require us to narrow our indications to smaller patient subsets, and the number of patients in such subsets may turn out to be lower than expected. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our current and future product candidates may have undesirable side effects that may delay or prevent marketing approval or, if approval is received, require them to be taken off the market, require them to include new safety warnings, contraindications or precautions, or otherwise limit their sales. No regulatory agency has made a determination that any of our product candidates are safe, pure, potent or effective for use by the target patient population for any indication. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our lead product candidate, ALX148, is at an early stage of clinical development and not all adverse effects can be predicted or anticipated. Unforeseen side effects from ALX148 or any of our future product candidates may arise at any time during clinical development or, if approved by regulatory authorities, after the approved drug product has been marketed. Any undesirable or unacceptable side effects of ALX148 or our future product candidates could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA or comparable international regulatory authorities, or result in marketing approval from the FDA or comparable international regulatory authorities with restrictive label warnings or for limited patient populations. Ultimately, such side effects could result in product liability claims. No regulatory agency has made any determination that any of our product candidates or discovery programs is safe or effective for use by the general public for any indication. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if any of our product candidates receive marketing approval, if we or others later identify undesirable or unacceptable side effects caused by such products: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory authorities may require us to take our approved product off the market; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory authorities may require the addition of labeling statements, specific warnings, contraindication, precaution or field alerts to physicians and pharmacies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be required to change the way the product is administered, limit the patient population who can use the product or conduct additional clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be subject to limitations on how we may promote the product; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">sales of the product may decrease significantly; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be subject to litigation or product liability claims; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our reputation may suffer. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating revenue from the sale of any future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford products such as our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our product candidates. Coverage under certain government programs, such as Medicare, Medicaid and TRICARE, may not be available for certain of our product candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates and other therapies as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy and potency or improved convenience of administration with our product candidates, pricing of existing drugs may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on products that we may develop. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Obtaining and maintaining reimbursement status is time-consuming and costly. No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, has become very intense. As a result, increasingly high barriers are being erected to the entry of new </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products. The continuing efforts of the government, insurance companies, managed care organizations and other payors of health care services to contain or reduce costs of health care may adversely affect: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the demand for any products for which we may obtain regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to set a price that we believe is fair for our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to obtain and maintain coverage and adequate reimbursement for a product; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to generate revenue and achieve or maintain profitability; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the level of taxes that we are required to pay. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA strictly regulates manufacturers&#8217; promotional claims of drug products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the FDA-approved labeling. The FDA, the Department of Justice, the Inspector General of the Department of Health and Human Services, or HHS, among other government agencies, actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability, including large civil and criminal fines, penalties and enforcement actions. The FDA has also imposed consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed for companies that engaged in such prohibited activities. If we cannot successfully manage the promotion of our approved product candidates, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Government Regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we receive regulatory approval to commercialize any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review with respect to our drugs, which will result in significant additional expense. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed, or subject to certain conditions of approval and may contain requirements for potentially costly post-approval trials and surveillance to monitor the safety, purity and efficacy/potency of the marketed product. For any approved drug, we will be subject to ongoing regulatory obligations and extensive oversight by regulatory authorities, including with respect to manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product. These requirements include submissions of safety and other post-approval information and reports, as well as continued compliance with cGMPs and cGCP for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with a drug, including adverse events of unanticipated severity or frequency, or with third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">restrictions on the marketing or manufacturing of the drug; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">withdrawal of the drug from the market or voluntary or mandatory product recalls; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">adverse publicity, fines, warning letters or holds on clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">refusal by the FDA or any other applicable regulatory authority to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">drug product seizure or detention, or refusal to permit the import or export of product candidates; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The occurrence of any of the foregoing could have a material and adverse effect on our business and results of operations. Further, the policies of the FDA or other comparable foreign regulatory authorities may change, and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates or impact any already approved drugs. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to generate revenue or achieve or sustain profitability. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, which could lead to our inability to generate product revenue. Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which would limit our ability to realize their full market potential. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The time required to obtain approval by the FDA and comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. Seeking foreign regulatory approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. Our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA and comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested. We have not submitted for or obtained regulatory approval for any product candidate and it is possible that ALX148 or any product candidates we may seek to develop in the future will ever obtain regulatory approval. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or comparable international regulatory authorities may disagree with the design, implementation or results of our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or comparable international regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and potency and safety in the full population for which we seek approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or comparable international regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a Biologics License Application, New Drug Application or other submission or to obtain regulatory approval in the United States or elsewhere; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may be unable to demonstrate to the FDA or comparable international regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the FDA or comparable international regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the approval policies or regulations of the FDA or international foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order to market any product candidates outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy and potency and approval standards. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, government shutdowns, including as a result of budget delays or other circumstances like the COVID-19 pandemic and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">While we have received certain FDA Fast Track designations, such Fast Track designations may not lead to a faster development or regulatory review or approval process, and does not increase the likelihood that the drug will receive marketing approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the FDA granted Fast Track designations to ALX148 for first-line HNSCC and for second-line treatment of advanced HER2-positive gastric/GEJ carcinoma. If a product candidate is intended for the treatment of a serious condition and preclinical or clinical data demonstrate the potential to address unmet medical need for such condition, a sponsor may apply for FDA Fast Track designation. Even though we received these Fast Track designations for ALX148, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we decide to seek orphan drug designation for one or more of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with such orphan drug designation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. We may seek Orphan Drug Designation for certain indications for our product candidates in the future. Orphan Drug Designation neither shortens the development time or regulatory review time of a product candidate nor gives the product candidate any advantage in the regulatory review or approval process. Generally, if a product candidate with an Orphan Drug Designation subsequently receives the first marketing approval for the indication for which it has such designation, the drug is entitled to a period of marketing exclusivity that precludes the FDA from approving another marketing application for the same drug for the same indication for seven years. Therefore, if our competitors are able to obtain orphan product exclusivity for their product candidates in the same indications we are pursuing, we may not be able to have competing product candidates approved in those indications by the FDA for a significant period of time. There are also limited circumstances where the FDA may reduce the seven-year exclusivity for a product candidate with an orphan drug designation where other product candidates show clinical superiority to the product with orphan exclusivity or if the FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. However, even if one of our product candidates receives orphan exclusivity, the FDA can still approve </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other drugs that have a different active ingredient for use in treating the same indication or disease. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture a sufficient supply of our product. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Current and future legislation may increase the difficulty and cost for us to commercialize our products, if approved, and affect the prices we may obtain. We may face difficulties from changes to current regulations and future legislation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the demand for our drugs, if we obtain regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to receive or set a price that we believe is fair for our drugs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to generate revenue and achieve or maintain profitability; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the level of taxes that we are required to pay; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the availability of capital. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively ACA, was enacted in 2010 and includes measures that have significantly changed the way healthcare is financed by both governmental and private insurers. The ACA continues to impact the U.S. pharmaceutical industry. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. In December 2018, the Centers for Medicare&#160;&amp; Medicaid Services, or CMS, published a new final rule permitting further collections and payments to and from certain ACA-qualified health plans, or QHPs, and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On April&#160;27, 2020, the United States Supreme Court reversed a Federal Circuit decision that previously upheld Congress&#8217; denial of $12&#160;billion in &#8220;risk corridor&#8221; funding. Further, in December 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by the U.S. Congress as part of a tax act. Additionally, in December 2019, the U.S. Court of Appeals for the 5th Circuit upheld the district court ruling that the individual mandate was unconstitutional and remanded the case back to the district court to determine whether the remaining provisions of the ACA are invalid as well. The U.S. Supreme Court held oral arguments in November 2020 and is expected to issue a decision by mid-2021, although it is uncertain how the Supreme Court will rule. It is unclear how such litigation and other efforts to repeal and replace the ACA will impact the ACA and our business. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2030, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. Additionally, it is possible that additional governmental action is taken in response to the COVID-19 pandemic, resulting in a material adverse effect on our business. For example, on August 6, 2020, the Trump administration issued another executive order that instructs the federal government to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop a list of &#8220;essential&#8221; medicines and then buy them and other medical supplies from U.S. manufacturers instead of from companies around the world, including China. The order is meant to reduce regulatory barriers to domestic pharmaceutical manufacturing and catalyze manufacturing technologies needed to keep drug prices low and the production of drug products in the United States. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There also has recently been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their drugs, which has resulted in several U.S. congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. For example, in May 2019, CMS issued a final rule to allow Medicare Advantage plans the option to use step therapy for Part B drugs beginning January&#160;1, 2020, codifying a policy change that was effective January&#160;1, 2019. In 2020, the U.S. Department of Health and Human Services and CMS issued various rules that are expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, importation of prescription drugs from Canada and other countries, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements. Multiple lawsuits have been brought against the HHS challenging various aspects of these new rules. In January 2021, the Biden administration issued a &#8220;regulatory freeze&#8221; memorandum that directs department and agency heads to review new or pending rules of the prior administration. It is unclear whether these new regulations will be withdrawn or when they will become fully effective under the current administration. The impact of these lawsuits as well as legislative, executive, and administrative actions of the current administration on us and the biopharmaceutical industry as a whole is unclear. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage importation from other countries and bulk purchasing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ACA, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, lower reimbursement and new payment methodologies. This could lower the price that we receive for any approved drug product. Any denial in coverage or reduction in reimbursement from Medicare or other government funded programs may result in a similar denial or reduction in payments from private payors, which may prevent us from being able to generate sufficient revenue, attain profitability or commercialize our product candidates, if approved. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our current or any future products. In addition to continuing pressure on prices, price controls and cost containment measures, legislative developments at the European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs. In international markets, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. Our future product candidates, if any, might not be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, an adequate level of reimbursement might not be available for such product candidates and third-party payors&#8217; reimbursement policies might adversely affect our ability to sell any future product candidates profitably. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay the commercial launch of the product candidate, possibly for lengthy time periods, and negatively impact the revenue that are generated from the sale of the product in that country. If reimbursement of such product candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, or if there is competition from lower-priced cross-border sales, our profitability will be negatively affected. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States, particularly in light of the recent presidential election, or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, our product candidates may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business operations and current and future relationships with investigators, health care professionals, consultants, third-party payors and customers will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we do not currently have any products on the market, our operations may be directly, or indirectly through our prescribers, consultants, customers and third-party payors, subject to various U.S. federal and state healthcare laws and regulations, including, without limitation, the U.S. federal Anti-Kickback Statute, the U.S. federal civil and criminal false claims laws and the Physician Payments Sunshine Act and regulations. Healthcare providers and others play a primary role in the recommendation and prescription of any products for which we obtain marketing approval. These laws may impact, among other things, our current business operations, including our clinical research activities and proposed sales, marketing and education programs and constrain the business of financial arrangements and relationships with healthcare providers, physicians and other parties through which we market, sell and distribute our products for which we obtain marketing approval. In addition, we may be subject to patient data privacy and security regulation by both the U.S. federal government and the states in which we conduct our business. Finally, we may be subject to additional healthcare, statutory and regulatory requirements and enforcement by foreign regulatory authorities in jurisdictions in which we conduct our business. The laws that may affect our ability to operate are described in the following paragraphs: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The U.S. federal Anti-Kickback Statute prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. Moreover, the ACA provides that the government may assert that a violation of the federal Anti-Kickback Statute also constitutes a false or fraudulent claim for purposes of the civil FCA. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal civil and criminal false claims, including the civil FCA, that can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. No specific intent to defraud is required under the civil FCA. The criminal FCA provides for criminal penalties for submitting false claims, including imprisonment and criminal fines. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The Civil Monetary Penalty Act of 1981 and implementing regulations impose penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">HIPAA imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, as amended again by the Modifications to the HIPAA Privacy, Security, Enforcement and Breach Notification Rules Under HITECH and the Genetic Information Nondiscrimination Act and Other Modifications to the HIPAA Rules, commonly referred to as the Final HIPAA Omnibus Rule, published in January 2013, impose certain obligations, including mandatory contractual terms, on covered entities subject to the Final HIPAA Omnibus Rule, </font><font style="font-style:italic;font-size:10pt;color:#000000;">i.e.</font><font style="font-size:10pt;color:#000000;">, health plans, healthcare clearinghouses and healthcare providers, and their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information as well as their covered subcontractors with respect to safeguarding the privacy, security and transmission of individually identifiable health information. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The U.S. Federal Food, Drug and Cosmetic Act prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, medical devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians, as defined by such law, and teaching hospitals as well as information regarding ownership and investment interests held by physicians and their immediate family members. Additionally, President Trump signed into law in 2018 the &#8220;Substance Use-Disorder Prevention that Promoted Opioid Recovery and Treatment for Patients and Communities Act&#8221; which, under the provision entitled &#8220;Fighting the Opioid Epidemic with Sunshine,&#8221; in part, extends the reporting and transparency requirements under the Physician Payments Sunshine Act to physician assistants, nurse practitioners and other mid-level practitioners, with reporting requirements beginning in 2022 for payments made or ownership or investment interests held in 2021. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, price reporting, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. Pricing and rebate programs must also comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">Analogous state laws and regulations impose additional obligations, including: state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">European and other foreign law equivalents of each of the laws also impose legal requirements, including reporting requirements detailing interactions with and payments to healthcare providers. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual damages, reputational harm, diminished profits, additional reporting requirements and oversight, and the delay, reduction, termination or restructuring of our operations. Further, defending against any such actions can be costly and time-consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to operate our business and our results of operations. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we, our employees, independent contractors, principal investigators, consultants, vendors or agents acting on our behalf fail to comply with healthcare laws and regulatory requirements, we could be subject to fines, penalties or enforcement actions, or incur costs that could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of employee fraud or other misconduct as well as risks of noncompliance by contractors or agents acting on our behalf. Misconduct by employees and independent contractors, such as principal investigators, consultants and vendors, could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with health care fraud and abuse laws, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, research, sales, marketing and business arrangements in the health care industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of research, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Employee and independent contractor misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a written code of business conduct and ethics, but it is not always possible to identify and deter employee or independent contractor misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines, exclusion from participation in government-funded healthcare programs, or other sanctions. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development involve, and may in the future involve, the use of potentially hazardous materials and chemicals. Our operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain workers&#8217; compensation insurance as prescribed by the State of California to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional laws and regulations affecting our operations may be adopted in the future. Current or future laws and regulations may impair our research, development or commercialization efforts. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels and the ability to hire and retain key personnel. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as recent furloughs or government shutdowns, may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our business activities may be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws, as well as U.S. and certain foreign export controls, trade sanctions and import laws and regulations, all of which can subject us to criminal liability and other serious consequences for violations. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other countries in which we operate. These laws generally prohibit companies and their employees and third party business partners, representatives and agents from engaging in corruption and bribery, including offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a government official or commercial party in order to influence official action, direct business to any person, gain any improper advantage, or obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business is heavily regulated and therefore involves significant interaction with government officials, including officials of non-U.S. governments. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, in many countries, healthcare providers are employed by the government, and the purchasers of biopharmaceuticals are government entities. As a result, our dealings with these providers and purchasers are subject to regulation and such healthcare providers and employees of such purchasers may be considered &#8220;foreign officials&#8221; as defined in the FCPA. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology companies. In addition to our own employees, we leverage third parties to conduct our business abroad, such as obtaining government licenses and approvals. We and our third-party business partners, representatives and agents may have direct or indirect interactions with officials and employees of government agencies, state-owned or affiliated entities and we may be held liable for the corrupt or other illegal activities of our employees, our third-party business partners, representatives and agents, even if we do not explicitly authorize such activities. There is no certainty that our employees or the employees of our third-party business partners, representatives and agents will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in whistleblower complaints, adverse media coverage, investigations, loss of export privileges, debarment from U.S. government contracts, substantial diversion of management&#8217;s attention, significant legal fees and fines, severe criminal or civil sanctions against us, our officers or our employees, disgorgement and other penalties and remedial measures and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, financial condition and stock price. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our business. Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Data collection under European and U.S. laws is governed by restrictive regulations addressing the collection, use, processing and, in the case of Europe, cross-border transfer, of personal information. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may collect, process, use or transfer personal information from individuals located in the European Union in connection with our business, including in connection with conducting clinical trials in the European Union. Additionally, if any of our product candidates are approved, we may seek to commercialize those products in the European Union. The collection and use of personal health data in the European Union is governed, in part, by the provisions of the General Data Protection Regulation (EU) 2016/679, or the GDPR. This legislation imposes requirements relating to having legal bases for processing personal information relating to identifiable individuals and transferring such information outside of the European Economic Area, including to the United States, providing details to those individuals regarding the processing of their personal information, keeping personal information secure, having data processing agreements with third parties who process personal information, responding to individuals&#8217; requests to exercise their rights in respect of their personal information, reporting security breaches involving personal data to the competent national data protection authority and affected individuals, appointing data protection officers, conducting data protection impact assessments and record-keeping. The GDPR imposes </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">additional responsibilities and liabilities in relation to personal data that we process, and we may be required to put in place additional mechanisms ensuring compliance. Failure to comply with the requirements of the GDPR and related national data protection laws of the member states of the European Union may result in substantial fines, other administrative penalties and civil claims being brought against us, which could have a material adverse effect on our business, financial condition and results of operations. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">European data protection laws also generally prohibit the transfer of personal data from Europe, including the European Economic Area, United Kingdom and Switzerland, to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. One of the primary safeguards used for transfers of personal data from the European Union to the United States, namely, the Privacy Shield framework administered by the U.S. Department of Commerce, was recently invalidated by a decision of the European Union&#8217;s highest court. The same decision also cast doubt on the ability to use one of the primary alternatives to the Privacy Shield, namely, the European Commission&#8217;s Standard Contractual Clauses, to lawfully transfer personal data from Europe to the United States and most other countries. At present, there are few if any viable alternatives to the Privacy Shield and the Standard Contractual Clauses. To the extent that we were to rely on the EU-U.S. Privacy Shield Framework or the Standard Contractual Clauses, we will not be able to do so in the future, which could increase our costs and limit our ability to process personal data from the EU. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, Brexit has created uncertainty with regard to data protection regulation in the UK. In particular, while the Data Protection Act of 2018, that &#8220;implements&#8221; and complements the GDPR achieved Royal Assent on May&#160;23, 2018 and is now effective in the United Kingdom, it is still unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under GDPR. During the period of &#8220;transition&#8221; (i.e., until December&#160;31, 2020), EU law continued to apply in the UK, including the GDPR. In 2021, the UK became a &#8220;third country&#8221; under the GDPR. We may, however, incur liabilities, expenses, costs, and other operational losses under GDPR and applicable EU Member States and the United Kingdom privacy laws in connection with any measures we take to comply with them. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, U.S. states are adopting new laws or amending existing laws, requiring attention to frequently changing regulatory requirements related to personal information. For example, California enacted the California Consumer Privacy Act, or the CCPA, in 2018, which took effect on January&#160;1, 2020 and has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined and which can include any of our current or future employees who may be California residents or any other California residents whose data we collect or process) and provide such residents new ways to opt out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Additionally, a new privacy law, the California Privacy Rights Act, or the CPRA, was approved by California voters in the election on November&#160;3, 2020. The CPRA will modify the CCPA significantly, potentially resulting in further uncertainty and requiring us to incur additional costs and expenses in an effort to comply. As we expand our operations, preclinical studies and clinical trials, the CCPA and CPRA may increase our compliance costs and potential liability. Other states are beginning to consider and pass similar laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Privacy and data security laws and regulations are not consistent across jurisdictions, and they may impose conflicting or uncertain obligations. Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous, costly and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with new and changing data protection obligations under these laws and regulations. Actual or alleged noncompliance with any such laws and regulations may lead to regulatory investigations, enforcement actions, claims and litigation, and if we fail to comply with any such laws or regulations, we may face significant fines and penalties. Any of these could adversely affect our business, financial condition and results of operations. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Intellectual Property </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to obtain, maintain and enforce patent protection for our product candidates and related technology, our business could be materially harmed. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our strategy depends on our ability to identify, seek, obtain and maintain patent protection for our product candidates and other research and development discoveries. Our patent portfolio is relatively small compared to many large and more established pharmaceutical and biotechnology companies. As our patent portfolio grows, we expect patent protection will continue to be an important part of our strategy. The patent protection process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and enforce any patents that may issue from such patent applications, at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we will fail to identify patentable aspects of our research and development discoveries before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we have licensed from third parties. Therefore, our in-licensed patents and patent applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our current and future product candidates in the United States or in foreign countries or may fail to effectively prevent third parties from commercializing competitive product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent position of biotechnology companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation. We may be subject to a third-party pre-issuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, and such prior art may affect the scope of any claims we ultimately get allowed or it may prevent our patent applications from issuing as patents. Further, the issuance of a patent does not ensure that it is valid or enforceable, nor is the issuance conclusive as to inventorship or the scope of any claims. Third parties may challenge the validity, enforceability or scope of our issued patents or claim that they should be inventors on such patents, and such patents may be narrowed, invalidated, circumvented or deemed unenforceable and such third parties may gain rights to such patents. We could also become involved in reexamination, <font style="font-style:italic;">inter partes</font> review, post-grant review, opposition or derivation proceedings challenging our patent rights or the patent rights of others. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, changes in law may introduce uncertainty in the enforceability or scope of patents owned by us. If our patents are narrowed, invalidated or held unenforceable, third parties may be able to commercialize our technology or products and compete directly with us without payment to us. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, and such prior art could potentially invalidate one or more of our patents or prevent a patent from issuing from one or more of our pending patent applications. There is also no assurance that there is no prior art that may ultimately be found to affect the validity or enforceability of a claim. Furthermore, even if our patents are unchallenged, they may not adequately protect our intellectual property, provide exclusivity for our product candidates, prevent others from designing around our claims or provide us with a competitive advantage. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with patents to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For all of the foregoing reasons, the issuance, validity, enforceability, scope and commercial value of our patents in the United States and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to protect our intellectual property rights throughout the world. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies to develop their own products in jurisdictions where we have not obtained patent protection and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our current or future products, if any, and our patents or other intellectual property rights may not be valid or sufficient to prevent them from competing. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the requirements for patentability may differ in certain countries. For example, in India, unlike the United States, there is no link between regulatory approval of a drug and its patent status, and patenting of medical uses of a claimed drug are prohibited. In addition to India, certain countries in Europe and other countries, including China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we and our licensors may have limited remedies if patents are infringed or if we or our licensors are compelled to grant a license to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents or applications. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees automatically when due, but we must notify the provider of any new patents or applications. Additionally, the USPTO and various foreign patent offices require compliance with many procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The patent positions of biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. We cannot predict the breadth of claims that may be allowed or found to be enforceable in our patents or in third-party patents. The United States has enacted and implemented wide-ranging patent reform legislation. Further, recent U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the validity, scope and value of patents, once obtained. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For our U.S. patent applications containing a priority claim after March&#160;16, 2013, there is a higher level of uncertainty in the patent law. In September 2011, the Leahy-Smith America Invents Act, also known as the America Invents Act, or AIA, was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The AIA and its implementation may increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have an adverse effect on our business. An important change introduced by the AIA is that, as of March&#160;16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties disclosing or claiming the same invention. A third party that has filed, or does file a patent application in the USPTO after March&#160;16, 2013 but before us, could be awarded a patent covering a given invention, even if we had made the invention before it was made by the third party. This requires us to be cognizant going forward of the time from invention to filing of a patent application. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to file third party submissions of prior art to the USPTO during patent prosecution and to challenge any issued patent in the USPTO (<font style="font-style:italic;">e.g.</font>, via post-grant reviews or <font style="font-style:italic;">inter partes</font> reviews). Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that may weaken our and our licensors&#8217; ability to obtain new patents or to enforce existing patents we and our licensors or partners may obtain in the future. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our patents covering one or more of our product candidates could be found invalid or unenforceable if challenged. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of our intellectual property rights could be challenged or invalidated despite measures we take to obtain patent and other intellectual property protection with respect to our product candidates and proprietary technology. For example, if we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States and in some other jurisdictions, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld material information from the USPTO, or the applicable foreign counterpart, or made a misleading statement, during prosecution. A litigant or the USPTO itself could challenge our patents on this basis even if we believe that we have conducted our patent prosecution in accordance with the duty of candor and in good faith. The outcome following such a challenge is unpredictable. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to challenges to the validity of our patents, for example, there might be invalidating prior art, of which the patent examiner and we were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on a product candidate. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others. The cost of defending such a challenge, particularly in a foreign jurisdiction, and any resulting loss of patent protection could have a material adverse impact on one or more of our product candidates and our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enforcing our intellectual property rights against third parties may also cause such third parties to file other counterclaims against us, which could be costly to defend, particularly in a foreign jurisdiction, and could require us to pay substantial damages, cease the sale of certain products or enter into a license agreement and pay royalties (which may not be possible on commercially reasonable terms or at all). Any efforts to enforce our intellectual property rights are also likely to be costly and may divert the efforts of our scientific and management personnel. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent protection, prosecution, assertion and defense for some of our product candidates may be dependent on third parties. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There may be times in the future when certain patents that relate to our product candidates or any approved products are controlled by our licensees or licensors, such as with respect to our Stanford license agreements. Although we may, under such arrangements, have rights to consult with our strategic partners on actions taken as well as back-up rights of prosecution and enforcement, we have in the past and may in the future relinquish rights to prosecute and maintain patents and patent applications within our portfolio as well as the ability to assert such patents against infringers. If any current or future licensee or licensor with rights to prosecute, assert or defend patents related to our product candidates fails to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, or if patents covering any of our product candidates are asserted against infringers or defended against claims of invalidity or unenforceability in a manner which adversely affects such coverage, our ability to develop and commercialize any such product candidate may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to protect the confidentiality of our trade secrets and proprietary information or obtain proper assignment of such intellectual property, the value of our technology and products could be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets and other proprietary information. Trade secrets and know-how can be difficult to protect. Trade secrets and know-how can also in some instances be independently derived or reverse-engineered by a third party. We maintain the confidentiality of trade secrets and proprietary information in part by entering into confidentiality agreements with our employees, consultants, other service providers, including Tallac Therapeutics, strategic partners and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies in addition to our service provider agreements, such as the Tallac Services Agreement, also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and even when we obtain these agreements, individuals with whom we have these agreements may not comply with their terms. Any of the parties to these agreements may breach such agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. We may also become involved in inventorship disputes relating to inventions and patents developed by our employees, consultants, contractors and other service providers, such as Tallac Therapeutics, under such agreements. To the extent that our employees, consultants, contractors or other service providers use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent such third party, or those to whom they communicate such technology or information, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or if we otherwise lose protection for our trade secrets or proprietary know-how, the value of this information may be greatly reduced, and our business and competitive position could be harmed. Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may become involved in lawsuits to protect or enforce our patents and trade secrets, which could be expensive, time-consuming and unsuccessful. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may seek approval to market their own products similar to or otherwise competitive with our product candidates or biosimilar versions of any approved product candidates. In these circumstances, we may need to defend or assert our patents, including by filing lawsuits alleging patent infringement. If we were to initiate legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for an invalidity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products sufficient to achieve our business objectives. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even after they have issued, our patents and any patents that we license may be challenged, narrowed, invalidated or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect our competitive business position, business prospects and financial condition. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may initiate litigation or other proceedings against third parties to enforce our patent and trade secret rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or patents licensed to us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">third parties may initiate opposition or other proceedings challenging the validity or scope of our patent rights, requiring us and/or licensors to participate in such proceedings to defend the validity and scope of our patents; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">there may be a challenge or dispute regarding inventorship or ownership of patents or trade secrets currently identified as being owned by or licensed to us, including disputes that may arise from our reliance on Tallac Therapeutics as the current sole provider of our preclinical research services and the intellectual property generated under the Tallac Services Agreement; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">third parties may seek approval to market biosimilar versions of our future approved products prior to the expiration of relevant patents owned by or licensed to us under the Biologics Price Competition and Innovation Act of 2009, requiring us to defend our patents, including by filing lawsuits alleging patent infringement. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any litigation or other proceedings would be costly and could affect our results of operations and divert the attention of our management and scientific personnel. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. There is a risk that a court would decide that we are infringing the third party&#8217;s patents and would order us to stop the activities covered by the patents. In that event, we may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved drug. In addition, there is a risk that a court will order us to pay third party damages or some other monetary award, depending upon the jurisdiction. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties, potentially including treble damages and attorneys&#8217; fees if we are found to have willfully infringed, and we may be required to cease using the technology that is at issue or to license the technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. We may not be able to prevent, alone or with our licensors, infringement or misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or on our business, results of operations, financial condition and prospects. Any of these outcomes could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information of our employees&#8217; or consultants&#8217; former employers or their clients. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ individuals who were previously or concurrently employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, trade secrets or other proprietary information could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products. Such license may not be available on commercially reasonable terms or at all. A loss of key research personnel or their work product could limit our ability to commercialize, or prevent us from commercializing, our current or future technologies or product candidates, which could materially harm our business. Even if we are successful in defending against these claims, litigation would expose us to the risk described above under &#8220;&#8212; We may become involved in lawsuits to protect or enforce our patents and trade secrets, which could be expensive, time consuming and unsuccessful.&#8221; </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position. Our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are aware of third-party patents and patent applications containing claims in the immuno-oncology field based on scientific approaches that are the same as or similar to our approach, including with respect to the targeting of the CD47 and signal regulatory protein alpha, or SIRP&#945;, pathways, and others that are based on entirely different approaches. These patents and applications could potentially be construed to cover our product candidates and their use. For example, we are aware of U.S. patent 10,907,209 and patent application 16/118,038 owned by University Health Network, or UHN, and The Hospital for Sick Children that may encompass certain therapies for the treatment of cancer using polypeptides comprising soluble human SIRP&#945;. This patent and patent application relate to the treatment of cancer with polypeptides comprising soluble human SIRP&#945;. Trillium Therapeutics, our competitor, has an exclusive license to the U.S. patent and application. The European counterpart patent (EP 2 429 574) was revoked by the European Patent Office and UHN and The Hospital for Sick Children have appealed the decision. The patent claims under the European patent, if the appeal by UHN and The Hospital for Sick Children is successful, could potentially limit our ability to pursue ALX148 in certain new indications or geographies in the future. However, we believe that we do not infringe claims listed in U.S. patent 10,907,209. As the biotechnology industry expands and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights of third parties. There is no assurance that there are not third-party patents or patent applications of which we are aware, but which we do not believe are relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing product candidates. These patents may not expire before we receive any marketing approval for our product candidates, and they could delay the commercial launch of one or more future product candidates. If our product candidates were to be found to infringe any such patents, and we were unable to invalidate those patents, or if licenses for them are not available on commercially reasonable terms or at all, our business, financial condition and results of operations could be materially harmed. Furthermore, even if a license is available, it may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. Our failure to maintain a license to any technology that we require may also materially harm our business, financial condition and results of operations, and we would be exposed to a threat of litigation. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any litigation resulting from claims of infringement or failure to license patents and proprietary rights of others would expose us to the risk described above under &#8220;&#8212;We may become involved in lawsuits to protect or enforce our patents and trade secrets, which could be expensive, time consuming and unsuccessful.&#8221; Any of the aforementioned threats to our competitive advantage could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our intellectual property rights will not necessarily provide us with competitive advantages. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we own or have exclusively licensed; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">others may independently develop similar or alternative technologies without infringing our intellectual property rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">issued patents that we own or have exclusively licensed may not provide us with competitive advantages, or may be held invalid or unenforceable, as a result of legal challenges by our competitors; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may obtain patents for product candidates many years before we obtain marketing approval for such product candidates and because patents have a limited life, which may begin to run prior to the commercial sale of the related product, the commercial value of our patents may be limited; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">we may fail to develop additional proprietary technologies that are patentable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the laws of certain foreign countries may not protect our intellectual property rights to the same extent as the laws of the United States, or we may fail to apply for or obtain adequate intellectual property protection in all the jurisdictions in which we operate; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the patents of others may have an adverse effect on our business, for example by preventing us from marketing one or more of our product candidates for one or more indications. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of the aforementioned threats to our competitive advantage could have a material adverse effect on our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We will need to obtain FDA approval for any proposed product candidate names, and any failure or delay associated with product candidate name approval may adversely affect our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any proprietary name or trademark we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal trademark registration from the USPTO. The FDA typically conducts a review of proposed product candidate names, including an evaluation of the potential for confusion with other product names and potential pharmacy dispensing errors. The FDA may also object to a product name if it believes the name inappropriately implies certain medical claims or contributes to an overstatement of efficacy. If the FDA objects to any product candidate names we propose, we may be required to adopt an alternative name for our product candidates. If we adopt an alternative name, we would lose the benefit of any existing trademark applications for such product candidate and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. We may be unable to build a successful brand identity for a new trademark in a timely manner or at all, which would limit our ability to commercialize our product candidates. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our rights to develop and commercialize our product candidates may be subject, in part, to the terms and conditions of agreements with others. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current agreements do not, and future agreements we may enter into in the future may not, provide exclusive rights to use certain intellectual property and technology retained by a collaborator in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors or other third parties from developing and commercializing competitive products that utilize technology retained by such collaborators to the extent such products are not also covered by our intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may need to obtain additional intellectual property rights from others to advance our research or allow commercialization of product candidates we may develop. We may be unable to obtain additional intellectual property rights at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates or future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which could be significant. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our current or our future collaborators&#8217; patents may be subject to a reservation of rights by one or more third parties. The U.S. government may have certain rights to resulting intellectual property. When new technologies are developed with U.S. government funding, the U.S. government generally obtains certain rights in any resulting patents, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. The U.S. government&#8217;s rights may also permit it to disclose the funded inventions and technology to third parties and to exercise march-in rights to use or allow third parties to use the technology developed using U.S. government funding. The U.S. government may exercise its march-in rights if it determines that action is necessary because we fail to achieve the practical application of the government funded technology, or because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in facilities in the United States in certain circumstances and if this requirement is not waived. Any exercise by the U.S. government of such rights or by any third-party of its reserved rights could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in agreements under which we option or license intellectual property rights from collaborators or licensors or otherwise experience disruptions to our business relationships with future collaborators or licensors, we could lose intellectual property rights that are important to our business. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current agreements do and our future agreements may impose various economic, development, diligence, commercialization and other obligations on us. Such agreements may also require us to meet development timelines, or to exercise commercially reasonable efforts to develop and commercialize licensed products. It might be concluded that we have materially breached our obligations under such agreements and licensors or collaborators might therefore terminate or seek damages under the agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these agreements. Termination of these agreements could cause us to lose the rights to certain patents or other intellectual property, or the underlying patents could fail to provide the intended exclusivity, and competitors or other third parties may have the freedom to seek regulatory approval of, and to market, products similar to or identical to ours and we may be required to cease our development and commercialization of certain of our product candidates. Any of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and growth prospects. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, disputes may arise regarding intellectual property subject to a collaboration agreement, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the scope of the option or license rights granted under the agreement and other interpretation-related issues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the extent to which our technology and processes infringe on intellectual property of the collaborator that is not subject to the option or license rights granted under the agreement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the sublicensing of patent and other rights under our collaborative development relationships; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our diligence obligations under the agreement and what activities satisfy those diligence obligations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our collaborators and us and our other partners; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the priority of invention of patented technology. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may enter into agreements to option or license intellectual property or technology from third parties that are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and growth prospects. Moreover, if disputes over intellectual property that we have optioned or licensed prevent or impair our ability to maintain such arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and growth prospects. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Our Operations </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, we had 23&#160;employees, including 12 employees engaged in research and development. In order to successfully implement our development and commercialization plans and strategies, and as we continue to transition into operating as a public company, we expect to need additional managerial, scientific, technical, medical, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">identifying, recruiting, integrating, maintaining and motivating additional employees; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">managing our internal development efforts effectively, including the clinical and FDA review process for ALX148 and any other future product candidates, while complying with any contractual obligations to contractors and other third parties we may have; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">improving our operational, financial and management controls, reporting systems and procedures. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future financial performance and our ability to successfully develop and, if approved, commercialize ALX148 and any other future product candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on specific independent organizations, advisors and consultants to provide certain services, including substantially all aspects of clinical management and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third-party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of ALX148 and any other future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third-party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third-party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize ALX148 and other future product candidates and, accordingly, may not achieve our research, development and commercialization goals. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates are based on a novel technology, which makes it difficult to predict the time and cost of product candidate development. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have concentrated our product research and development efforts on our novel immuno-oncology approach, and our future success depends on the successful development of our lead product candidate, ALX148, and any future product candidates that we develop. There can be no assurance that any development problems we experience in the future related to our novel immuno-oncology approach will not cause significant delays or unanticipated costs or that such development problems can be solved. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our clinical trials or commercializing our product candidates on a timely or profitable basis, if at all. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete in the highly competitive biotechnology and life science industries depends upon our ability to attract, motivate and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management and our scientific, technical, business and medical personnel. The loss of the services </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided by any of our executive officers, other key employees and other scientific and medical advisors, and our inability to find suitable replacements, could result in delays in the development of our product candidates and harm our business. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conduct our operations at our facility in the San Francisco Bay Area of California, a region that is headquarters to many other biopharmaceutical companies and many academic and research institutions. To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, manufacturing and sales and marketing personnel, and we face significant competition for experienced personnel. In addition, we will need to expand and effectively manage our managerial, operational, financial, development and other resources in order to successfully pursue our research, development and commercialization efforts for our existing and future product candidates. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited talent pool in our industry due to the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize products. Competition for skilled personnel is intense and the turnover rate can be high, which may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all. We expect that we may need to recruit talent from outside of our region and doing so may be costly and difficult. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many of the other biotechnology companies that we compete against for qualified personnel have considerably more financial and other resources, different risk profiles and a more extended history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we can offer. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition to competition for personnel, the San Francisco Bay Area in particular is characterized by a high cost of living. We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts. To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided equity grants that vest over time. The value to employees of these equity grants that vest over time may be significantly affected by movements in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. If we are unable to attract and incentivize quality personnel on acceptable terms, or at all, it may cause our business and operating results to suffer. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our international operations may expose us to business, regulatory, political, operational, financial, pricing and reimbursement risks associated with doing business outside of the United States. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our predecessor company, which after our internal reorganization is now our wholly-owned subsidiary, was an Irish private company limited by shares. Our business is subject to risks associated with conducting business internationally. Some of our subsidiaries and operations, in addition to suppliers, industry partners and clinical study centers, are located outside of the United States. Furthermore, our business strategy incorporates potential international expansion as we seek to obtain regulatory approval for, and commercialize, our product candidates in patient populations outside the United States. If approved, we expect to hire sales representatives and conduct physician and patient association outreach activities outside of the United States. Doing business internationally involves a number of risks and complexities, including but not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">multiple, conflicting and changing laws and regulations such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses, including within the European Union and in the United Kingdom as a result of Brexit; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure by us to obtain and maintain regulatory approvals for the use of our products in various countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">rejection or qualification of foreign clinical trial data by the competent authorities of other countries; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">complexities and difficulties in obtaining, maintaining, protecting and enforcing our intellectual property, including as a result of potentially relevant third-party patent rights; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">difficulties in staffing and managing foreign operations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">limits in our ability to penetrate international markets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our drugs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">exposure to foreign currency exchange rate fluctuations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">political and economic instability, including wars, terrorism and political unrest, boycotts, curtailment of trade and other business restrictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">natural disasters, outbreaks or public health crises, such as the COVID-19 pandemic; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">certain expenses including, among others, expenses for travel, translation and insurance; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall within the purview of the FCPA, its accounting provisions or its anti-bribery provisions, or provisions of anti-corruption or anti-bribery laws in other countries. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any of these factors could harm our future international expansion and operations and, consequently, our results of operations. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If any of the third parties that we rely on for various operational and administrative aspects of our business fail to provide timely, accurate and ongoing service or if the technology systems and infrastructure suffer outages that we are unable to mitigate, our business may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely upon third-party consultants and contractors to provide specific operational and administrative services, including research and clinical consultation and management. The failure of any of these third parties to provide accurate and timely service may adversely impact our business operations. In addition, if such third-party service providers were to cease operations, temporarily or permanently, face financial distress or other business disruption, increase their fees or if our relationships with these providers deteriorate, we could suffer increased costs until an equivalent provider could be found, if at all, or we could develop internal capabilities, if ever. In addition, if we are unsuccessful in choosing or finding high-quality partners, if we fail to negotiate cost-effective relationships with them, or if we ineffectively manage these relationships, it could have an adverse impact on our business and financial performance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, our operations depend on the continuing and efficient operation of our information technology, communications systems and infrastructure, and on cloud-based platforms. Any of these systems and infrastructure are vulnerable to damage or interruption from earthquakes, vandalism, sabotage, terrorist attacks, floods, fires, power outages, telecommunications failures, computer viruses or other deliberate attempts to harm the systems. The occurrence of a natural or intentional disaster, any decision to close a facility we are using without adequate notice, or particularly an unanticipated problem at a cloud-based virtual server facility, could result in harmful interruptions in our service, resulting in adverse effects to our business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may become exposed to costly and damaging product liability claims, either when testing our product candidates in the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing and use of pharmaceutical products. We currently have no products that have been approved for commercial sale. However, the current and future use of product candidates by us in clinical trials and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. In addition, we have agreed to indemnify various counterparties related to our product candidates against certain liability claims and any agreements or collaborations in the future may include such indemnification obligations. Any claims against us, or with respect to which we are obligated to provide indemnification, regardless of their merit, could be difficult and costly to defend or settle and could compromise the market acceptance of our product candidates or any prospects for commercialization of our product candidates, if approved. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although the clinical trial process is designed to identify and assess potential side effects, it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If any of our product candidates were to cause adverse side effects during clinical trials or after approval of the product candidate, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects or that certain patients should not use our drugs for various reasons. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. As the expense of insurance coverage is increasing, we may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because we have limited financial and managerial resources, we focus on research programs that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial therapies or profitable market opportunities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our spending on current and future research and development programs, such as ALX148, for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The COVID-19 pandemic could adversely impact our business including our ongoing and planned clinical trials and preclinical research. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, COVID-19 was reported to have surfaced in Wuhan, China. Since then, the virus has spread to most other countries across the world, including all 50 states within the United States, resulting in the World Health Organization characterizing COVID-19 as a pandemic. As a result of measures imposed by the governments in affected regions, many commercial activities, businesses and schools have been suspended as part of quarantines and other measures intended to contain this pandemic. The extent to which the COVID-19 pandemic ultimately impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, such as the duration of the outbreak, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease and to address its impact, including on financial markets or otherwise. As the COVID-19 pandemic continues to spread around the globe, we may experience disruptions that could severely impact our business, current and planned clinical trials and preclinical research, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays or difficulties in enrolling and retaining subjects, particularly elderly subjects, who are at a higher risk of severe illness or death from COVID-19, in our ongoing clinical trial of ALX148 and our future clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">difficulties interpreting data from our clinical trials due to the possible effects of COVID-19 on subjects; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">limitations in resources, including our employees, that would otherwise be focused on the conduct of our business or our current or planned clinical trials or preclinical research, including because of </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="font-size:10pt;color:#000000;">sickness, the desire to avoid contact with large groups of people, or restrictions on movement or access to our facility as a result of government-imposed &#8220;shelter in place&#8221; or similar working restrictions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruptions, difficulties or delays arising in our existing operations and company culture as a result of all of our employees working remotely, including those hired during the COVID-19 pandemic; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in receiving approval from regulatory authorities to initiate our clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruptions in preclinical studies due to restricted or limited operations at the CROs conducting such studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruptions or delays in the operations of the FDA or other domestic or foreign regulatory authorities, which may impact review and approval timelines; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in receiving the supplies, materials and services needed to conduct clinical trials and preclinical research; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">changes in regulations as part of a response to the COVID-19 pandemic which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs or require us to discontinue the clinical trial altogether; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">interruptions or delays to our development pipeline; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">delays in necessary interactions with regulators, ethics committees and other important agencies and contractors due to limitations in employee resources or forced furlough of government or contractor personnel; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">refusal of the FDA to accept data from clinical trials in affected geographies outside of the United States. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are still assessing the impact that the COVID-19 pandemic may have on our ability to effectively conduct our business operations as planned and there can be no assurance that we will be able to avoid a material impact on our business from the spread of COVID-19 or its consequences, including disruption to our business and downturns in business sentiment generally or in our industry or due to shutdowns that may be requested or mandated by federal, state and local governmental authorities. For example, in August 2020, California implemented the Blueprint for a Safer Economy, which uses COVID-19 case rates and test positivity rates in each county to determine the extent to which businesses may reopen. Under the Blueprint for a Safer Economy, most business operations in San Mateo County, where our primary operations are located, remain restricted. As a result, the majority of our employees are currently telecommuting, which may impact certain of our operations over the near term and long term. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, certain third parties with whom we engage or may engage, including collaborators, contract organizations, third-party manufacturers, suppliers, clinical trial sites, regulators and other third parties are similarly adjusting their operations and assessing their capacity in light of the COVID-19 pandemic. If these third parties experience shutdowns or continued business disruptions, our ability to conduct our business in the manner and on the timelines presently planned could be materially and negatively impacted. For example, as a result of the COVID-19 pandemic, there could be delays in the procurement of materials or manufacturing supply chains for one or more of our product candidates, which could delay or otherwise impact our preclinical studies and our planned clinical trials. Additionally, all of our preclinical studies are conducted by CROs, which could be discontinued or delayed as a result of the pandemic. It is also likely that the disproportionate impact of COVID-19 on hospitals and clinical sites will have an impact on recruitment and retention for our planned clinical trials. CROs have also made certain adjustments to the operation of such trials in an effort to ensure the monitoring and safety of patients and minimize risks to trial integrity during the pandemic in accordance with the guidance issued by the FDA and may need to make further adjustments in the future that could impact the timing or enrollment of our clinical trials. Many of these adjustments are new and untested, may not be effective, may increase costs and may have unforeseen effects on the enrollment, progress and completion of these trials and the findings from these trials. While we are currently continuing our clinical trials and preclinical studies, we may experience delays in the completion of our clinical trials, preclinical activities and subject enrollment, may need to suspend our clinical trials and may encounter other negative impacts to such trials due to the effects of the COVID-19 pandemic. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, as a result of the COVID-19 pandemic, the extent and length of which is uncertain, we may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from the COVID-19 virus, which may include using telemedicine visits, remote monitoring of subjects and clinical sites and measures to ensure that data from clinical trials that may be disrupted as a result of the pandemic are collected pursuant to the study protocol and consistent with GCPs, with any material protocol deviation reviewed and approved by the site Institutional Review Board. Subjects who may miss scheduled appointments, any interruption in study drug supply, or other consequences that may result in incomplete data being generated during a clinical trial as a result of the pandemic must be adequately documented and justified. For example, in March 2020, the FDA issued a guidance, which the FDA subsequently updated, on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report contingency measures implemented to manage the trial, and any disruption of the trial as a result of the COVID-19 pandemic; a list of all subjects affected by the COVID-19-pandemic related study disruption by unique subject identifier and by investigational site and a description of how the individual&#8217;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (</font><font style="font-style:italic;">e.g.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the clinical trial. In June 2020, the FDA also issued a guidance on good manufacturing practice considerations for responding to COVID-19 infection in employees in drug products manufacturing, including recommendations for manufacturing controls to prevent contamination of drugs. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The COVID-19 pandemic continues to rapidly evolve. While the extent of the impact of the COVID-19 pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the COVID-19 pandemic could have a material negative impact on our business, financial condition and operating results. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent the COVID-19 pandemic adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this section and in this &#8220;Risk Factors&#8221; section. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may seek to enter into collaborations, including strategic collaborations, licenses and other similar arrangements related to our product candidates and may not be successful in doing so, and even if we are, we may not be able to maintain or realize the benefits of such relationships. If we are not able to establish future collaborations, we may have to alter some of our future development and commercialization plans and our business could be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may seek to enter into collaborations, licenses and other similar arrangements for the development or commercialization of our product candidates, due to strategic advantages to partnering with third parties and capital costs required to develop or commercialize the product candidate in such markets. For instance, we recently entered into a collaboration agreement with Tallac Therapeutics pursuant to which we expect to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. We may not be successful in our efforts to establish such collaborations for our product candidates because our product candidates may be deemed to be at too early of a stage of development for collaborative effort or third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators. We cannot be certain that, following a strategic transaction or license, we will achieve an economic benefit that justifies such transaction. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or of a product candidate is delayed, the safety of a product candidate is questioned or sales of an approved product are unsatisfactory. We also may not be able to realize the benefit of such collaborations if we are unable to successfully integrate them with our existing operations and company culture. In any such collaborations, we may likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. We cannot predict the success of any collaboration that we may enter into. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face significant competition in seeking appropriate collaborators and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA or similar foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.29%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to negotiate further collaborations on a timely basis, on acceptable terms, or at all. We also may find that our programs require the use of proprietary rights held by third parties, and the growth of our business may depend in part on our ability to acquire, in-license or use these proprietary rights. Even if we are able to obtain a license to intellectual property of interest, we may not be able to secure exclusive rights, in which case others could use the same rights and compete with us. Our future collaboration partners may not prioritize our product candidates or otherwise not effectively pursue the development of our product candidates which may delay, reduce or terminate the development of such product candidate, reduce or delay its development program, or delay its potential commercialization. Further, if we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to delay, reduce or terminate the development of such product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities or increase our expenditures and undertake development or commercialization activities at our own expense. Any of the foregoing factors would likely harm our ability to execute our business plans. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may acquire businesses or assets and we may not realize the benefits of such acquisitions. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may acquire businesses or assets or create joint ventures with third parties that we believe may complement our existing product candidates. We may not be able to realize the benefit of acquiring such businesses or joint ventures if we are not able to successfully integrate them with our existing operations and company culture. We may encounter difficulties in developing, manufacturing and marketing any new product candidates resulting from an acquisition or that delay or prevent us from realizing their expected benefits. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Also, the anticipated benefit of any joint venture or acquisition may not materialize or such joint venture or acquisition may be prohibited. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the U.S. Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage points change (by value) in the ownership of its equity over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income and taxes may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future, in either case as a result of subsequent shifts in our stock ownership, some of which are outside our control. As of December 31, 2020, we had net operating loss carryforwards of approximately $7.9 million and $71.4 million for U.S. federal and state income tax purposes, respectively. Our ability to utilize those net operating loss carryforwards could be limited by an &#8220;ownership change&#8221; as described above, which could result in increased tax liability to our company. The federal net operating losses carries forward indefinitely while the state net operating loss will begin to expire beginning in 2038.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020, we had Irish net operating loss carryforwards of approximately $5.1&#160;million. These Irish net operating loss carryforwards do not expire but may not be fully utilized unless we generate sufficient income in Ireland. Under Irish law, where a company makes a loss in its trade, it can carry that loss forward to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">subsequent accounting periods and offset the loss against profits or gains of the same trade. The utilization of carried forward losses is disallowed where (i)&#160;the trade that gave rise to the losses is discontinued or (ii)&#160;within any period of three years, there is both a change in the ownership of a company and (whether earlier or later in that period or at the same time) a major change in the nature or conduct of a trade carried on by the company or (iii)&#160;at any time after the scale of the activities in a trade carried on by a company has become small or negligible and before any considerable revival of the trade, there is a change in ownership of the company. There are no legislative explanations of what constitutes a major change in the nature or conduct of a trade. Relevant case law indicates that there must be a difference in the kind of trade/goods (and not just a quantitative difference) or a major difference in client outlets or markets of the trade but whether there has been a major change in the nature or conduct of a trade is a qualitative matter, and one which is to be judged on the facts of any particular set of circumstances. We may experience ownership changes in the future as a result of subsequent movements in our share ownership, some of which are outside of our control. If we also experience a major change in the nature or conduct of our trade or our trade becomes small or negligible, we may be limited in the amount of loss carryforwards that we can use in the future to offset taxable income for Irish corporation tax purposes. Furthermore, in the event we incur net income in certain jurisdictions but incur losses (or have loss carryforwards) in other jurisdictions, we cannot offset the income from one jurisdiction with the loss from another, which could increase our effective tax rate. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Related to Ownership of Our Common Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not know whether an active, liquid and orderly trading market will be sustained for our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering, no market for shares of our common stock existed. Although our common stock is listed on the Nasdaq Global Select Market, the market for our shares has demonstrated varying levels of trading activity. It is possible that in one or more future periods our results of operations and progression of our product pipeline may not meet the expectations of public market analysts and investors, and, as a result of these and other factors, the price of our common stock may fall. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">The price of our stock may be volatile, and you could lose all or part of your investment. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading price of our common stock may be highly volatile and subject to wide fluctuations in response to various factors, some of which are beyond our control. In addition to those discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this Annual Report on Form 10-K, the following factors may cause the market price of our common stock to fluctuate: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">results and timing of our preclinical studies and clinical trials and studies and trials of our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure or discontinuation of any of our development programs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">issues in manufacturing our product candidates or any future approved products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">regulatory developments or enforcement in the United States and foreign countries with respect to our product candidates or our competitors&#8217; products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">competition from existing products or new products that may emerge; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">actual or anticipated changes in our growth and development relative to our competitors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">developments or disputes concerning patents or other proprietary rights; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">introduction of new product candidates or technological innovations by us or our competitors; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">announcements by us, our future strategic partners or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">actual or anticipated changes in estimates or recommendations by securities analysts, if any cover our common stock; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">fluctuations in the valuation of companies perceived by investors to be comparable to us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">public concern over our product candidates or any future approved products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">litigation; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">future sales of our common stock by us, our insiders or our other stockholders; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expiration of market stand-off or lock-up agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">additions or departures of key personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">changes in the structure of health care payment systems in the United States or overseas; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">failure of any of our product candidates, if approved, to achieve commercial success; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">economic and other external factors such as macroeconomic, disasters, crises or health matters, including the impact of the COVID-19 pandemic; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">period-to-period fluctuations in our financial condition and results of operations, including the timing of payment or receipt of any future milestone or other payments under commercialization or licensing agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">announcements or expectations of additional financing efforts; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">overall fluctuations in U.S. equity markets, general market conditions and market conditions for biotechnology stocks; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">other factors that may be unanticipated or out of our control. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the stock market has recently experienced significant volatility, particularly with respect to biotechnology and other life sciences company stocks as a result of the COVID-19 pandemic and the U.S. presidential election. The volatility of biotechnology and other life sciences company stock often does not relate to the operating performance of the companies presented by the stock. In addition, in the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit and divert the time and attention of our management, which could seriously harm our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our quarterly and annual operating results may fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our board of directors, and recognize the cost as an expense over the employee&#8217;s requisite service period. As the variables that we use as a basis for valuing these </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">awards change over time, including our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing and cost of, and level of investment in, research and development activities relating to our current product candidates and any future product candidates and research-stage programs, which will change from time to time; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to enroll subjects in clinical trials and the timing of enrollment; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the cost of manufacturing our current product candidates and any future product candidates, which may vary depending on FDA, EMA or other comparable foreign regulatory authority guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">expenditures that we will or may incur to acquire or develop additional product candidates and technologies or other assets; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the timing and outcomes of clinical trials for ALX148, and any of our other product candidates, or competing product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">competition from existing and potential future products that compete with ALX148 and any of our other product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any delays in regulatory review or approval of ALX148 or any of our other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the level of demand for ALX148 and any of our other product candidates, if approved, which may fluctuate significantly and be difficult to predict; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with ALX148 and any of our other product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to commercialize ALX148 and any of our other product candidates, if approved, inside and outside of the United States, either independently or working with third parties; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to establish and maintain collaborations, licensing or other arrangements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">our ability to adequately support future growth; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">potential unforeseen business disruptions that increase our costs or expenses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">future accounting pronouncements or changes in our accounting policies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the COVID-19 pandemic; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">the changing and volatile global economic and political environment. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. As of December 31, 2020, we had 39,844,522 shares of our common stock outstanding. If our stockholders sell, or the market perceives that our stockholders intend to sell, substantial amount of our common stock in the public market, the market price of our common stock could decline significantly. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules and Rule 144 and Rule 701 under the Securities Act. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, on July&#160;17, 2020, we filed a registration statement on Form S-8 to register 3,563,962 shares of our common stock reserved for future issuance under our equity compensation plans. As a result, shares registered under this registration statement on Form S-8 will be available for sale in the public market subject to the satisfaction of applicable vesting arrangements and the exercise of such options and, in the case of our affiliates, the restrictions of Rule 144. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Moreover, holders of an aggregate of 24,429,399 shares of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act would result in the shares becoming freely tradeable in the public market, subject to the restrictions of Rule 144 in the case of our affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock depends on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. We cannot assure you that analysts will cover us or provide favorable coverage. If no or few securities or industry analysts commence coverage of us, the trading price for our stock would be negatively impacted. If one or more of the analysts who cover us downgrade our stock or change their opinion of our common stock, our share price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred and will continue to incur significant increased costs and management resources as a result of operating as a public company. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred and will continue to incur significant legal, accounting, compliance and other expenses as a public company and these expenses may increase even more after we are no longer an &#8220;emerging growth company.&#8221; Our management and other personnel need to devote a substantial amount of time and incur significant expense in connection with compliance initiatives. For example, as a public company, we must adopt additional internal controls and disclosure controls and procedures and have retained a transfer agent and adopted an insider trading policy. As a public company, we bear all of the internal and external costs of preparing and distributing periodic public reports in compliance with our obligations under the securities laws. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we anticipate implementing an enterprise resource planning, or ERP, system for our company. An ERP system is intended to combine and streamline the management of our financial, accounting, human resources, sales and marketing and other functions, enabling us to manage operations and track performance more effectively. However, an ERP system would likely require us to complete many processes and procedures for the effective use of the system or to run our business using the system, which may result in substantial costs. Additionally, in the future, we may be limited in our ability to convert any business that we acquire to the ERP. Any disruptions or difficulties in using an ERP system could adversely affect our controls and harm our business, including our ability to forecast or make sales and collect our receivables. Moreover, such disruption or difficulties could result in unanticipated costs and diversion of management attention. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act, or SOX, and the related rules and regulations implemented by the SEC and the Nasdaq Stock Market LLC, or Nasdaq, have and will continue to increase legal and financial compliance costs and make some compliance activities more time-consuming. We have invested and will continue to invest additional resources to comply with evolving laws, regulations and standards, and this investment will result in increased general and administrative expenses and may divert management&#8217;s time and attention from our other business activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us, and our business may be harmed. In connection with our initial public offering, we increased our directors&#8217; and officers&#8217; insurance coverage, which substantially increased our insurance cost. In the future, it may be more expensive or more difficult for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to emerging growth companies could make our common stock less attractive to investors. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section&#160;404(b), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an &#8220;emerging growth company&#8221; for up to five years following the completion of our initial public offering, although, if we have more than $1.07&#160;billion in annual revenue, if the market value of our common stock held by non-affiliates exceeds $700&#160;million as of June&#160;30 of any year, or we issue more than $1.0&#160;billion of non-convertible debt over a three-year period before the end of that five-year period, we would cease to be an &#8220;emerging growth company&#8221; as of the following December 31. Investors could find our common stock less attractive if we choose to rely on these exemptions. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have elected to use this extended transition period. As a result, our consolidated financial statements may not be comparable to companies that comply with the new or revised accounting standards as of public company effective dates. If some investors find our common stock less attractive as a result of any of our reliance on these exemptions, there may be a less active trading market for our common stock and our share price may be more volatile. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March&#160;12, 2021, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 58.9% of our outstanding voting stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Therefore, this group of stockholders, if they act together, will have the ability to control us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other material corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their common stock, and might affect the prevailing market price for our common stock. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not anticipate paying cash dividends and, accordingly, stockholders must rely on share appreciation for any return on their investment. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never paid any dividends on our capital stock. We currently intend to retain our future earnings, if any, to fund the development and growth of our businesses and do not anticipate that we will declare or pay any cash dividends on our capital stock in the foreseeable future. See the section titled &#8220;Dividend Policy.&#8221; As a result, capital appreciation, if any, of our common stock will be your sole source of gain on your investment for the foreseeable future. Investors seeking cash dividends should not invest in our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available, may involve fixed payment obligations or agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through partnerships, collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our clinical or discovery programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provisions in our amended and restated certificate of incorporation and bylaws may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our charter documents: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">establish that our board of directors is divided into three classes, with each class serving staggered three-year terms; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">provide that our directors may only be removed for cause; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">eliminate cumulative voting in the election of directors; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">authorize our board of directors to issue shares of convertible preferred stock and determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created directorship; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">permit stockholders to only take actions at a duly called annual or special meeting and not by written consent; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">prohibit stockholders from calling a special meeting of stockholders; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="text-decoration:none;Background-color:#auto;font-size:10pt;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">authorize our board of directors to amend the bylaws; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person who together with its affiliates owns, or within the last three years has owned, 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any provision of our amended and restated certificate of incorporation, amended and restated bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our common stock. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, another State court in Delaware or the federal district court for the District of Delaware) is the exclusive forum for the following (except for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of such court (and the indispensable party does not consent to the personal jurisdiction of such court within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court or for which such court does not have subject matter jurisdiction): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any derivative action or proceeding brought on behalf of us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any action asserting a claim of breach of a fiduciary duty; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any action asserting a claim against us arising under the Delaware General Corporation Law, or DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws (as either may be amended from time to time); and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:'Times New Roman';"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#9642;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:12pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;"></font><font style="font-size:10pt;color:#000000;">any action asserting a claim against us that is governed by the internal affairs doctrine. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This provision would not apply to suits brought to enforce a duty or liability created by the Securities Exchange Act of 1934, as amended, or Exchange Act, or any other claim for which the U.S. federal courts have exclusive jurisdiction. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws further provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These exclusive-forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#8217; charter documents has been challenged in legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find either exclusive-forum provision in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">In the past, we have identified material weaknesses in our internal control over financial reporting, and if we are unable to implement and maintain effective internal control over financial reporting in the future, investors may lose confidence in the accuracy and completeness of our financial reports, and the market price of our common stock may be materially adversely affected</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have never conducted a review of our internal control for the purpose of providing the reports required by the Sarbanes-Oxley Act of 2002. During our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. In the past, we and our independent registered public accounting firm identified two material weaknesses in our internal control over financial reporting, all of which have since been remediated. We did not identify any material weakness as of December 31, 2020.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, if in the future, we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our consolidated financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Select Market or other adverse consequences that would materially harm our business. In addition, we could become subject to investigations by the stock exchange on which our securities are listed, the SEC, and other regulatory authorities, and become subject to litigation from investors and stockholders, which could harm our reputation and our financial condition, or divert financial and management resources from our core business.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud, which would harm our business and the trading price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&#160;404(a) of SOX or any subsequent testing by our independent registered public accounting firm in connection with Section&#160;404(b) of SOX, may reveal deficiencies in our internal controls over financial reporting that are deemed to be significant deficiencies or material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement. As discussed above, we have identified material weaknesses in the past which we are in the process of remedying. However, our efforts to remediate previous material weaknesses may not be effective or prevent any future deficiency in our internal control over financial reporting. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with our evaluation of our internal controls over financial reporting, we expect to upgrade our finance and accounting systems and team. If we are unable to accomplish these objectives in a timely and effective manner, our ability to comply with the financial reporting requirements and other rules that apply to reporting companies could be adversely impacted. Any failure to maintain effective internal control over financial reporting could have a material adverse effect on our business, financial condition and results of operations and the trading price of our common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We will be required to disclose material changes made in our internal controls over financing reporting and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. Beginning with our second annual report on Form 10-K after we become a public company, we will be required to make a formal assessment of the effectiveness of our internal control over financial reporting, and once we cease to be an emerging growth company, we will be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, for as long as we are an &#8220;emerging growth company&#8221; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&#160;404(b). </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To achieve compliance with Section&#160;404(a) within the prescribed period, we will be engaging in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of our internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are designed and operating effectively and implement a continuous reporting and improvement process for internal control over financial reporting. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We could be an &#8220;emerging growth company&#8221; for up to five years. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not identify. Undetected material weaknesses in our internal controls could lead to consolidated financial statement restatements and require us to incur the expense of remediation. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are organized in a holding company structure and we are, and will be, dependent upon the results of operations and cash flows of our subsidiaries and distributions we receive from our subsidiaries. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALX Oncology Holdings Inc. is a holding company that currently has no material assets other than cash and our ownership of all of the equity issued by ALX Oncology Limited. As such, ALX Oncology Holdings Inc. will have no independent means of generating revenue or cash flow, and our ability to pay our taxes and operating expenses or declare and pay dividends in the future, if any, will be dependent upon the results of operations and cash flows of ALX Oncology Limited and its consolidated subsidiaries, including any distributions we receive from ALX Oncology Limited. There can be no assurance that our direct and indirect subsidiaries will generate sufficient cash flow to distribute funds to us or that applicable law and contractual restrictions, such as negative covenants in any debt instruments, will permit such distributions. In addition, in the event that the board of directors and stockholders of ALX Oncology Holdings Inc. were to approve a sale of all of our equity in ALX Oncology Limited or any of our other indirect subsidiaries, your equity interest would be in a holding company with no material assets other than those assets and other consideration received in such transaction. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">General Risks </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If any of the third parties that we rely on for various operational and administrative aspects of our business fail to provide timely, accurate and ongoing service or if the technology systems and infrastructure suffer outages that we are unable to mitigate, our business may be adversely affected. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently rely upon third-party consultants and contractors to provide specific operational and administrative services, including research and clinical consultation and management. The failure of any of these third parties to provide accurate and timely service may adversely impact our business operations. In addition, if such third-party service providers were to cease operations, temporarily or permanently, face financial distress or other business disruption, increase their fees or if our relationships with these providers deteriorate, we could suffer increased costs until an equivalent provider could be found, if at all, or we could develop internal capabilities, if ever. In addition, if we are unsuccessful in choosing or finding high-quality partners, if we fail to negotiate cost-effective relationships with them, or if we ineffectively manage these relationships, it could have an adverse impact on our business and financial performance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, our operations depend on the continuing and efficient operation of our information technology, communications systems and infrastructure, and on cloud-based platforms. Any of these systems and infrastructure are vulnerable to damage or interruption from earthquakes, vandalism, sabotage, terrorist attacks, floods, fires, power outages, telecommunications failures, computer viruses or other deliberate attempts to harm the systems. The occurrence of a natural or intentional disaster, any decision to close a facility we are using without adequate notice, or particularly an unanticipated problem at a cloud-based virtual server facility, could result in harmful interruptions in our service, resulting in adverse effects to our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our operations, and those of our service providers and suppliers and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical or public health crises, such as the COVID-19 pandemic, and other natural or man-made disasters or business interruptions, for which we are partly uninsured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidates. Our ability to obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The majority of our operations including our corporate headquarters are located in the San Francisco Bay Area in California. Damage or extended periods of interruption to our corporate, development or research facilities due to fire, natural disaster, power loss, communications failure, unauthorized entry or other events could cause us to cease or delay development of some or all of our product candidates. Although we maintain property damage and business interruption insurance coverage on these facilities, our insurance might not cover all losses under such circumstances and our business may be seriously harmed by such delays and interruption. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may experience disruptions and delays or incur financial damages as a result of system failures or security breaches. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Despite the implementation of security measures, any of the internal computer systems belonging to us or our third-party service providers are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. Any system failure, accident or security breach that causes interruptions in our own or in third-party service providers&#8217; operations could result in a material disruption of our drug discovery and development programs. A system failure or security breach that causes the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs in order to recover or reproduce the lost data. In addition, to the extent that any disruption or security breach results in a loss or damage to our data or applications or inappropriate disclosure of confidential or proprietary information, including personal information related to the subjects in our clinical trial, we may incur liability as a result, our drug discovery programs and competitive position may be adversely affected and further development of our product candidates may be delayed. Any such disruption, failure or security breach could also cause us to incur additional costs to remedy the damages that arise from such disruption, failure or security breach. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to securities litigation, which is expensive and could divert management attention. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The market price of our common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a><a name="ITEM_1B_UNRESOLVED_STAFF_COMMENTS"></a>Item 1B. Unresolved Staff Comments. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_2_PROPERTIES"></a><a name="ITEM_2_PROPERTIES"></a>Item 2. Properties. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our principal executive office is located in Burlingame, California. We currently sub-lease 2,856 square feet of office space in Burlingame, California, under a lease that expires in 2023. We believe that this space is sufficient to meet our needs for the foreseeable future and that any additional space we may require will be available on commercially reasonable terms.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_3_LEGAL_PROCEEDINGS"></a><a name="ITEM_3_LEGAL_PROCEEDINGS"></a>Item 3. Legal Proceedings. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not currently a party to any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a><a name="ITEM_4_MINE_SAFETY_DISCLOSURES"></a>Item 4. Mine Safety Disclosures.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not applicable. </p><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> II</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a><a name="ITEM_5_MARKET_FOR_REGISTRANTS_COMMON_EQU"></a>Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Market Information for Our Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock has been listed on the Nasdaq Global Select Market under the symbol &#8220;ALXO&#8221; since July 17, 2020. Prior to that date, there was no public trading market for our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Holders of Record</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 12, 2021, there were 89 holders of record of our common stock. Certain shares are held in "street" name and, accordingly, the number of beneficial owners of such shares is not known or included in the foregoing number.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Dividend Policy</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements and contractual restrictions of then-existing debt instruments and other factors that our board of directors deems relevant.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unregistered Sales of Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Stock Performance Graph</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities under that Section, and shall not be deemed to be incorporated by reference into any of our filings under the Securities Act, except to the extent that we specifically incorporate this information by reference therein, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following&#160;graph compares the cumulative total return to stockholder on our common stock relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. An investment of $100 is assumed to have been made in our common stock and each index on July </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020 (the first day of trading of our common stock&#160;with a closing price on that date of $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.0</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) and its relative performance is tracked through </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 3</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020. Pursuant to applicable SEC rules, all values assume reinvestment of the full amount of all dividends; however</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> no dividends have been declared on our common stock to date. The stockholder returns shown on the graph below are based on&#160;historical results and are not indicative of future performance, and we do not make or endorse any predictions as to future stockholder returns.</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><img src="gvvh0m1pmdf2000016.jpg" title="" alt="" style="width:554px;height:370px;"></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Proceeds from Initial Public Offering of Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we closed the sale of 9,775,000 shares of common stock, which includes the additional overallotment of 1,275,000 shares exercised by the underwriters in the initial public offering, to the public at an initial public offering price of $19.00 per share. The aggregate offering price for shares sold in our initial public offering was $185.7 million. The offer and sale of the shares in the initial public offering was registered under the Securities Act pursuant to registration statements on Form S-1 (File No. 333- 239490), which was filed with the SEC on June 26, 2020 and amended subsequently and declared effective on July 16, 2020, and Form S-1MEF, which was filed with the SEC on July 16, 2020 and became effective on July 16, 2020. The underwriters of the offering were Jefferies LLC, Credit Suisse Securities (USA) LLC, Piper Sandler &amp; Co. and Cantor Fitzgerald &amp; Co.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We received approximately $169.5 million in net proceeds after deducting underwriting discounts and commissions of approximately $13.0 million and offering-related expenses of $3.2 million. No offering expenses were paid directly or indirectly to any of our directors or officers (or their associates) or persons owning ten percent or more of any class of our equity securities or to any other affiliates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We invested the funds received in accordance with our investment policy. None of such payments were direct or indirect payments to any of our directors or officers (or their associates), to persons owning ten percent or more of our common stock or to any other affiliates. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC on July 17, 2020 pursuant to Rule 424(b)(4). </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Issuer Purchases of Equity Securities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_6_SELECTED_FINANCIAL_DATA"></a>Item 6. Selected </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Data. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following tables set forth selected financial and other data. Our historical results are not necessarily indicative of the results that may be expected in the future. You should read the financial and other data below in conjunction with Item 7. "Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and Item 8. "Financial Statements" in this Annual Report on Form 10-K. <font style="Background-color:#FFFFFF;color:#000000;">The selected data in this section is not intended to replace the Consolidated Financial Statements. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated<font style="font-family:Calibri;">&#160;</font>Statements&#160;of&#160;Operations&#160;and Comprehensive Loss Data:</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party revenue</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,796</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,067</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,961</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,270</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,809</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,313</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,601</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of services for related-party revenue</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,075</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,360</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,880</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,845</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,979</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,751</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,663</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,684</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(811</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(404</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on early debt extinguishment</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(621</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,499</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,686</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax provision</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(241</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and comprehensive loss</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,740</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,243</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,731</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative dividends allocated to preferred</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,202</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,028</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,671</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,942</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,271</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders, basic and diluted<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.76</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7.56</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.33</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; used to compute net loss per share</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; attributable to common stockholders, basic</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; and diluted<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,485,343</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076,461</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,750,838</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">See Note 11 to our audited consolidated financial statements included elsewhere in this Annual Report for an explanation of the method used to calculate historical net loss per share and the weighted-average number of shares used in the computation of the per share amounts.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31,</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consolidated Balance Sheet Data:</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.3%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">434,219</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,262</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429,788</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,825</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,335</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436,054</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,676</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,164</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,209</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,952</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,009</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,363</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,933</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,522</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,782</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,539</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity (deficit)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,639</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,778</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">(1)</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">We define working capital as current assets less current liabilities. See our consolidated financial statements for further details regarding our current assets and current liabilities.</font></p></td></tr></table></div><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7_MANAGEMENTS_DISCUSSION_ANALYSIS_F"></a>Item 7. Management&#8217;s Discussion and Analysis of </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial Condition and Results of Operations. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">You should read the following discussion of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis, including information with respect to our plans and strategy for our business, include forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. Cancer cells leverage CD47, a cell surface protein, as a &#8220;don&#8217;t eat me&#8221; signal to evade detection by the immune system. Our company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, ALX148, will have a wide therapeutic window to block the &#8220;don&#8217;t eat me&#8221; signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. As of December 31, 2020, we have dosed over 170 subjects with ALX148 across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. We plan to initiate additional studies in combination with leading anti-cancer agents. In hematologic malignancies, we have dosed the first subjects for the treatment of MDS and intend to advance ALX148 into clinical development for the treatment of AML in the second half of 2021. In solid tumors, we intend to initiate randomized Phase 2 trials of ALX148 for the treatment of first-line head and neck cancer, second line gastric/GEJ cancer and a Phase 1 trial for the treatment of breast cancer in 2021. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability and our clinical development plans, our strategy is to pursue ALX148 as a potentially critical component for future combination treatments in oncology.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our predecessor company, ALX Oncology Limited, an Irish private company limited by shares, was initially incorporated in Ireland on March 13, 2015 under the name Alexo Therapeutics Limited and changed its name to ALX Oncology Limited on October 11, 2018. We were then incorporated in Delaware on April 1, 2020 under the name ALX Oncology Holdings Inc. and completed an internal reorganization effective as of the same date whereby ALX Oncology Limited became our wholly-owned subsidiary and all of the stockholders, warrant holders and option holders of ALX Oncology Limited became our stockholders, warrant holders and option holders, holding the same number of corresponding shares, warrants and/or options in us as they did in ALX Oncology Limited immediately prior to the internal reorganization. The information included herein are presented as that of ALX Oncology Holdings Inc., unless such information refers to a date prior to April 1, 2020, in which case it will reflect that of our predecessor company. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our founding, we have devoted substantially all of our resources to identifying and developing ALX148, advancing preclinical programs, scaling up manufacturing, conducting clinical trials and providing general and administrative support for these operations. We have no products approved for marketing and we have never received any revenue from drug product sales. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In&#160;July&#160;2020, we consummated our initial public offering, raising net proceeds of&#160;$169.5 million, after deducting underwriting discounts and commissions of $13.0 million and offering-related expenses of $3.2 million. In&#160;December&#160;2020, we consummated a follow-on public offering, raising net proceeds of&#160;$194.9 million, after deducting underwriting discounts and commissions of $12.5 million and offering-related expenses of $0.7 million. From inception through December 31, 2020, we have raised an aggregate of $545.3 million to fund our operations, of which $175.1 million were net proceeds from sales of our convertible preferred stock, $5.8 million were net proceeds from borrowings under a term loan, $169.5 million were net proceeds from our initial public offering and $194.9 million were net proceeds from our follow-on public offering. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses in each year since inception. Our net losses were $45.7 million, $19.2 million and $13.7 million for the years ended December 31, 2020, 2019 and 2018, respectively. As of December 31, 2020, we had an accumulated deficit of $118.5 million. Substantially all of our operating losses are a result of expenses incurred in connection with our research and development programs, primarily ALX148, and from general and administrative expenses associated with our operations.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to incur significant expenses and increasing operating losses over at least the foreseeable future. We expect our expenses will increase substantially in connection with our ongoing activities, as we:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">advance ALX148 through multiple clinical trials in multiple indications;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">pursue regulatory approval of ALX148 in hematological malignancies and solid tumors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">continue our discovery and preclinical and clinical development efforts;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtain and maintain patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">manufacture supplies for our preclinical studies and clinical trials; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">continue to add operational, financial and management information systems to support ongoing operations as a public company.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Components of Results of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Related-Party Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, we have not generated any revenue from product sales, licenses or collaborations and do not expect to generate any revenue from the sale of products in the foreseeable future. We recognized related-party revenue related to research and development services to Tallac Therapeutics, which ceased as of July 1, 2020, as further described in &#8220;&#8212;License and Collaboration Agreements&#8212;Related-Party Agreement&#8221; below. If our clinical development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue from future product sales. If we enter into license or collaboration agreements for any of our product candidates or intellectual property, we may generate revenue in the future from payments as a result of such license or collaboration agreements. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates including ALX148. We may never succeed in obtaining regulatory approval for any of our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses consist primarily of costs incurred for the development of our lead product candidate, ALX148, which include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">expenses incurred in connection with the preclinical and clinical development, including expenses incurred under agreements with contract research organizations, or CROs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">employee-related expenses, including salaries, related benefits, travel and stock-based compensation expense for employees engaged in research and development functions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">expenses related to production of clinical materials, including fees paid to contract manufacturing organizations, or CMOs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">laboratory and vendor expenses related to the execution of preclinical studies and clinical trials; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">facilities and other expenses, which include expenses for rent and maintenance of facilities, depreciation and amortization expense and other supplies.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expense research and development costs as incurred. Nonrefundable advance payments for goods or services to be received in future periods for use in research and development activities are deferred and capitalized. The capitalized amounts are then expensed as the related goods are delivered or as services are performed. We record accruals for estimated costs of research, preclinical studies and clinical trials and manufacturing development, which are a significant component of research and development expenses. We determine the estimated costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fees to be paid for such services.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research and development expenses consist primarily of costs associated with the development of our lead product candidate ALX148 and include external costs, such as fees paid to consultants, central laboratories, contractors, CMOs and CROs in connection with our preclinical and clinical development activities. We allocate expenses, such as employee salaries, benefits, facilities, travel and other miscellaneous expenses, based on an estimated percentage of time worked on each program. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Almost all of our research and development expenses to date related to the clinical development of our lead product candidate, ALX148. We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, as our product candidates advance into later stages of development and as we begin to conduct larger clinical trials. The process of conducting the necessary clinical trials to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. As a result, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of any of our product candidates. In addition, we will incur expenses related to the preclinical research services that we contract from Tallac Therapeutics, as further described in &#8220;&#8212;License and Collaboration Agreements&#8212;Related-Party Agreement&#8221; below.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The successful development of our current and future product candidates is highly uncertain. This is due to the numerous risks and uncertainties, including the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">successful completion of preclinical studies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">delays in regulators or institutional review boards authorizing us or our investigators to commence our clinical trials or in our ability to negotiate agreements with clinical trial sites or CROs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the number and location of clinical sites included in the trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">raising additional funds necessary to complete clinical development of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">contracting with third-party manufacturers for clinical supplies of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">protecting and enforcing our rights in our intellectual property portfolio, including, if necessary, litigation; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">maintaining a continued acceptable safety profile of the products following approval.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A change in the outcome of any of these variables with respect to the development of our product candidates may significantly impact the costs and timing associated with the development of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development activities are central to our business model. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. In addition, future regulatory factors beyond our control may impact the success, cost or timing of our clinical development programs.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">General and Administrative Expenses</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of personnel-related expenses, business development expenses, facilities expenses, depreciation and amortization expenses and professional services expenses, including legal, human resources, audit, accounting and tax-related services, and directors and officers liability insurance premiums. Personnel and related costs consist of salaries, benefits and stock-based compensation expense. Facilities costs consist of rent and maintenance of facilities.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate that our general and administrative expenses will continue to increase as a result of increased headcount, expanded infrastructure and higher consulting, legal, tax and regulatory-related services associated with maintaining compliance with stock exchange listing and SEC requirements, audit and investor relations costs, director and officer insurance premiums and other costs associated with being a public company.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Services for Related-Party Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We incur costs associated with related-party contract research services including direct labor and associated employee benefits, laboratory supplies and other expenses. These costs are recorded in cost of services for related-party transactions as a component of total operating expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest Expense</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our interest expense consists primarily of interest expense on the term loan and amortization of deferred debt issuance costs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Other Expense, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our other expense, net, consists of interest income on cash balances, changes in the fair value of our convertible preferred stock warrant liability and compound derivative liability, gain on assignment of lease, and foreign currency re-measurement and transaction gains and losses. Prior to our initial public offering, the underlying shares of our Series B convertible preferred stock warrants were contingently redeemable, and we accounted for these warrants as a liability at fair value and re-measured the fair value at each balance sheet date. As a result of the completion of our initial public offering, the Series B convertible preferred stock warrant liability was&#160;reclassified&#160;to stockholders&#8217; equity and re-measurement was no longer required. The compound derivative liability was extinguished upon the extinguishment of the host instrument in December 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Loss&#160;on&#160;Early&#160;Debt&#160;Extinguishment&#160;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we used approximately $6.5 million of the net proceeds from our follow-on public offering to repay the outstanding principal amount of $6.0 million and early extinguish the outstanding Term Loan with SVB and WestRiver. As a result of the early repayment, we recognized a $0.6 million loss on early debt extinguishment, representing the difference between the&#160;reacquisition&#160;price of debt and the net carrying amount of the loan as of the date of the payoff. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations and Net Loss</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comparisons of the Years Ended December 31, 2020, 2019 and 2018</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our results of operations for the years ended December 31, 2020, 2019 and 2018 (<font style="font-style:italic;">dollars in thousands</font>):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 vs 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 vs 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,796</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,067</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,614</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,729</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,961</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,270</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,655</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,036</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,809</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,313</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,601</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,496</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">347</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of services for related-party</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,075</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,360</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,880</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,285</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(75</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,480</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,845</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,979</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,751</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,866</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,228</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,663</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,684</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,480</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,499</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(811</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(790</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/M</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/M</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(404</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(399</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/M</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">150</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on early debt extinguishment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(621</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(621</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/M</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/M</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,499</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,686</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,290</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,523</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax provision</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(241</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(207</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">609</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,740</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,243</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,731</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,497</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,512</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative dividends allocated to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,202</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,028</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,671</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,174</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(357</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,942</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,271</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,671</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,869</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">N/M - not meaningful</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Related-Party Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party revenue for the years ended December 31, 2020, 2019 and 2018 was $1.2 million, $4.8 million and $2.1 million, respectively, which was generated solely from payments received for reimbursement of research and development expenses pursuant to the Research and Development Services Agreement with Tallac Therapeutics, or the Tollnine Agreement, as further described in Note 10 to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K. The decrease of $3.6 million from 2019 to 2020 relates to decreased fee-for-service hours provided to Tallac Therapeutics as a result of winding down the Tollnine Agreement, which was terminated on July 1, 2020. The increase of $2.7 million from 2018 to 2019 relates to increased fee-for-service hours provided to Tallac Therapeutics during 2019. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our research and development expenses incurred for the years ended December 31, 2020, 2019 and 2018 (<font style="font-style:italic;">dollars in thousands</font>):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 vs 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 vs 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical and development costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,743</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,011</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,654</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,732</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,357</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel and related costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,504</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,127</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,312</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,377</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,185</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,551</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,446</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/M</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other research and development costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">163</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(42</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,961</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,270</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,655</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,036</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">N/M - not meaningful</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses for the year ended December 31, 2020 were $29.0 million, compared to $16.3 million for the year ended December 31, 2019. The increase of $12.7 million was primarily attributable to an increase of $7.7 million in clinical and development costs due to higher expenses associated with increased pre-clinical, clinical and other research costs in advancement of our current lead product candidate, ALX148, as well as an increase of $2.4 million in stock-based compensation expense primarily resulting from additional stock option awards granted in 2020 at higher fair values and the modification of stock option awards for former employees who transferred to Tallac Therapeutics, which increased stock-based compensation expense by $1.3 million. In addition, we incurred increased personnel-related costs of $2.4 million due to higher headcount.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses for the year ended December 31, 2019 was $16.3 million, compared to $11.3 million for the year ended December 31, 2018. The increase of $5.0 million was primarily due to increases in external research and development expenses related to our lead product candidate, as we significantly increased trial recruitment for our Phase 1 clinical trials for ALX 148 in the year ended December 31,2019. In addition, in the year ended December 31, 2019, we incurred increased costs for additional preclinical studies and CMC manufacturing.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes our general and administrative expenses incurred for the years ended December 31, 2020, 2019 and 2018 (<font style="font-style:italic;">dollars in thousands</font>):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24.74%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020 vs 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019 vs 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Personnel and related costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,893</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">834</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">695</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,059</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">487</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,885</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,852</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/M</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other general and administrative costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,031</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,446</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,890</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,585</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">556</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total general and administrative</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; expenses</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,809</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,313</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,601</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,496</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">347</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.86%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">N/M - not meaningful</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.86%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses for the year ended December 31, 2020 were $14.8 million, compared to $3.3 million for the year ended December 31, 2019. The increase of $11.5 million was primarily attributable to an increase in personnel-related costs of $4.1 million due to higher headcount, an increase in stock-based compensation expense of $2.9 million, which consists of $0.4 million related to the modification of stock option awards for former employees as well as additional stock option awards&#160;granted in 2020 at higher fair values, and an increase in other general and administrative costs of $4.6 million, which includes higher professional service fees of $2.8 million associated with increased accounting, legal and recruiting activities, as well as $1.0 million of directors and officers liability insurance premium. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses for the year ended December 31, 2019 was $3.3 million, compared to $2.6 million during the year ended December 31, 2018. This increase of $0.7 million was due to increased administrative costs supporting the increased activities in connection with our Phase 1 clinical trials for ALX 148, resulting in increased other general and administrative expenses of $0.6 million, which included increases in business development activities, legal, accounting and audit services, as well as increased personnel-related costs of $0.1 million. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Cost of Services for Related-Party Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of services for related-party revenue for the years ended December 31, 2020, 2019 and 2018 was $1.1 million, $4.4 million and $1.9 million, respectively. The decrease of $3.3 million from 2019 to 2020 was attributable to decreased fee-for-service hours provided to Tallac Therapeutics as a result of winding down the Tollnine Agreement, which was terminated on July 1, 2020. The increase of $2.5 million from 2018 to 2019 was attributable to an increase in services rendered to Tallac Therapeutics.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Loss on Early Debt Extinguishment</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year-ended December 31, 2020 we recognized a $0.6 million loss on early debt extinguishment, representing the difference between the&#160;reacquisition&#160;price of debt and the net carrying amount of the loan as of the date of the payoff. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources; Plan of Operations</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Sources of Liquidity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since our inception, we have incurred significant operating losses and have not generated any product revenue. We have not yet commercialized any of our product candidates and we do not expect to generate revenue from sales of any product candidates for several years, if at all, subject to marketing approval of any of our product candidates. To date, we have funded our operations with proceeds from the sales of shares of our common stock and convertible preferred stock and borrowings under our term loan. Through December 31, 2020, we have received net proceeds from sales of our convertible preferred stock, borrowings under our term loan, our initial public offering and our follow-on public offering of $175.1 million, $5.8 million, $169.5 million and $194.9 million, respectively. As of December 31, 2020, we had cash and cash equivalents of $434.2 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Debt Extinguishment</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we used approximately $6.5 million of the net proceeds from our follow-on public offering to repay the outstanding principal amount of $6.0 million and early extinguish the outstanding Term Loan with SVB and WestRiver. As a result, we recognized a $0.6 million loss on early debt extinguishment, representing the difference between the&#160;reacquisition&#160;price of debt and the net carrying amount of the loan as of the date of the payoff. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Funding Requirements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred losses and negative cash flows from operations since inception and anticipate that we will continue to incur net losses for the foreseeable future. As of December 31, 2020, we had an accumulated deficit of $118.5 million. We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials for our product candidates in development. In addition, we expect to incur additional costs associated with operating as a public company. Management recognizes the need to raise additional capital to fully implement its business plan. The timing and amount of such future capital requirements are difficult to forecast and will depend on many factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the timing and progress of preclinical and clinical development activities;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">successful enrollment in and completion of clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the timing and outcome of regulatory review of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our ability to establish agreements with third-party manufacturers for clinical supply for our clinical trials and, if any of our product candidates are approved, commercial manufacturing;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">addition and retention of key research and development personnel;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">our efforts to enhance operational, financial and information management systems, and hire additional personnel, including personnel to support development of our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we obtain marketing approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the legal patent costs involved in prosecuting patent applications and enforcing patent claims and other intellectual property claims;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone and royalty payments thereunder; and</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="text-decoration:none;Background-color:#auto;font-family:'Times New Roman';"></font><font style="color:#000000;"></font><font style="color:#000000;">the impact of the COVID-19 pandemic, which may exacerbate the magnitude of the factors discussed above.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not currently have any committed external source of funds. Our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions and the recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from the ongoing COVID-19 pandemic. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or drug candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market drug candidates that we would otherwise prefer to develop and market ourselves.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, we completed our initial public offering pursuant to a registration statement on Form S-1. In the initial public offering, we issued and sold an aggregate of&#160;9,775,000&#160;shares of common stock, including the underwriters&#8217; exercise in full of their overallotment option, under the registration statement at a public offering price of&#160;$19.00&#160;per share. Net proceeds were approximately&#160;$169.5 million, after deducting underwriting discounts and commissions of $13.0 million and offering-related expenses of $3.2 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, we completed our follow-on public offering pursuant to a registration statement on Form S-1. In the follow-on public offering, we issued and sold an aggregate of&#160;2,737,000&#160;shares of common stock, including the underwriters&#8217; exercise in full of their overallotment option, under the registration statement at a public offering price of&#160;$76.00&#160;per share. Net proceeds were approximately&#160;$194.9 million, after deducting underwriting discounts and commissions of $12.5 million and offering-related expenses of $0.7 million. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements through 2024. We have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash Flows</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents a summary of the net cash flow activity for the years ended December 31, 2020, 2019 and 2018:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in):</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,289</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,249</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,190</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">610</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(353</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(653</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">462,881</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,357</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">425,202</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">755</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,842</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Operating Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the year ended December 31, 2020, cash used in operating activities of $38.3 million was attributable to a net loss of $45.7 million and a net change of $0.2 million in our net operating assets and liabilities, partially offset </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by $7.2 million in non-cash charges. The non-cash charges consisted of stock-based compensation</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> expense</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of $5.4 million, change in fair value of Series B convertible preferred stock warrant liability and term loan compound derivative of $0.7 million, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a loss on debt extinguishment of $0.6 million</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">amortization of term loan discount and issuance costs of $0.4 million</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">depreciation and amortization of $0.2 million, partially offset by a gain on assignment of lease of $0.1 million. The change in operating assets and liabilities was primarily due to a $3.7 million decrease in accounts payable</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $1.5 million increase in prepaid expenses</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other current assets</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, partially offset by a $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million increase in accrued expenses</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and other current liabilities</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which was</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> primarily due to timing of cash payments for clinical-related activities</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the year ended December 31, 2019, cash used in operating activities of $14.2 million was attributable to a net loss of $19.2 million and a net change of $4.3 million in our net operating assets and liabilities, partially offset by $0.7 million in non-cash charges. The non-cash charges primarily consisted of stock-based compensation expense of $0.3 million and depreciation and amortization expense of $0.4 million. The change in operating assets and liabilities was primarily due to a $3.0 million increase in accounts payable, a $0.7 million decrease in prepaid expenses and other current assets and a $0.4 million decrease in receivables due from a related-party. The increase in accounts payable is primarily due to the timing of cash payments and increased activities to support overall business growth. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the year ended December 31, 2018, cash used in operating activities of $13.2 million was attributable to a net loss of $13.7 million partially offset by $0.7 million in non-cash charges and a net change of $0.2 million in our net operating assets and liabilities. The non-cash charges consisted of stock-based compensation expense of $0.3 million and depreciation and amortization expense of $0.4 million. The change in operating assets and liabilities was primarily due to a $0.9 million increase in receivables due from a related-party and $0.3 million decrease in accounts payable. This was partially offset by a $0.9 million decrease in prepaid expenses and other current assets resulting from the timing of prepayments made for research and development activities.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Investing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the year ended December 31, 2020, cash provided by investing activities of $0.6 million was primarily related to proceeds from the sale of certain lab equipment and other assets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the year ended December 31, 2019, cash used in investing activities of $0.4 million was related to capital expenditures on the purchase of property and equipment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the year ended December 31, 2018, cash used in investing activities of $0.7 million was related to capital expenditures on the purchase of property and equipment.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financing Activities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the year ended December 31, 2020, cash provided by financing activities was $462.9 million, primarily from the net proceeds from our common stock offerings of $368.3 million, the net proceeds from the sale and issuance of Series C convertible preferred stock of $104.7 million and the proceeds from exercise of common stock options under equity incentive plans of $0.3 million. These cash inflows were partially offset by payments for early debt extinguishment of $6.5 million and payments of offering costs of $3.8 million.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the year ended December 31, 2019, cash provided by financing activities of $15.4 million was related to net proceeds of $9.4 million from the issuance of Series B convertible preferred shares and $5.9 million from the net proceeds from a term loan entered into in December 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the year ended December 31, 2018, cash provided by financing activities was nominal. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commitments</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have contractual obligations from our operating lease, manufacturing and service contracts and other research and development activities. The following table aggregates our material expected contractual obligations and commitments as of December 31, 2020 (in thousands):</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:4.91%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022 - 2023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2024 - 2025</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.9%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligations<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">346</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.9%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing and service contracts<sup style="font-size:85%;line-height:120%;vertical-align:top"> (2)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,320</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,292</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,028</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.9%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,666</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,432</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,234</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-right:4.91%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Payments due for the office space in Burlingame, California under a single operating sub-lease agreement that expires in 2023. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In November 2015, we entered into a Master Service Agreement, or the MSA, with KBI Biopharma, Inc. relating to formulation development, process development and cGMP manufacturing of ALX148 for use in clinical trials on a project basis. The MSA had an initial term of three years with successive one-year renewal periods, is cancellable upon notice and is non-exclusive. Statements of work under the MSA commit us to certain purchase obligations of approximately $9.9 million. In addition, we have commitments with a second drug product manufacturer that commits us to certain purchase obligations of approximately $0.4 million. These amounts are based on non-cancellable commitments and forecasts that include estimates of future market demand, quantity discounts and manufacturing efficiencies that may impact timing of purchases.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We enter into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation. These payments are not included in the table of contractual obligations above.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">License and Collaboration Agreements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2015, we entered into the Stanford Agreement with the Board of Trustees of Stanford, under which we obtained a worldwide, royalty-bearing, sublicensable license under certain patents relating to our current product candidates, to develop, manufacture and commercialize products for use in certain licensed fields, the scope of which would include the application of the licensed intellectual property in oncology. The license granted to us in the Stanford Agreement includes an exclusive grant, subject to certain pre-existing non-exclusive or exclusive rights that Stanford retained for grant to third parties with respect to certain categories of the licensed patents in certain fields of use and retained rights by Stanford and all other nonprofit institutions to use and practice the licensed patents and technology for internal research and other nonprofit purposes. The license granted to us in the Stanford Agreement also includes non-exclusive grants to certain Stanford patents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the rights granted to us under the Stanford Agreement, we paid Stanford a nonrefundable license royalty and reimbursed Stanford for past patent expenses, together totaling less than $0.1 million, and granted Stanford a specified number of our common stock. In addition, we are obligated to pay Stanford ongoing patent expenses and an annual license maintenance fee, which are nominal and will be creditable against any royalties payable to Stanford in the applicable year. We are required to make milestone payments up to an aggregate of $5.0 million in respect of a specified number of licensed products that successfully satisfy certain clinical and regulatory milestones. No milestone payments have been made through December 31, 2020. We also agreed to pay Stanford tiered royalties on a specified percentage of net sales made by us, our affiliates and our sublicensees of licensed products at rates ranging within low single-digit percentages, subject to certain reductions and offsets. Our license, on a licensed product-by-licensed product and country-by-country basis, shall become royalty-free and fully paid-up upon the later of the date on which the last valid claim included in the exclusively or non-exclusively licensed patents expires and ten years after the first commercial sale of the licensed product in such country.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may terminate the Stanford Agreement, on a licensed product-by-licensed product basis, at any time for any reason by providing at least 60 days&#8217; written notice to Stanford. Stanford may terminate the Stanford Agreement, if </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in breach of any provision of the Stanford Agreement and fail to remedy such breach within 60 days after written notice of such breach by Stanford. In addition, Stanford has the right to terminate the Stanford Agreement, on a licensed product-by-licensed product basis, if </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we are</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not diligently developing and commercializing such licensed product under certain conditions or if </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">we </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fail to achieve specified development milestones for such licensed product by certain dates, subject to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> extension rights.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Commercial License Agreement with Selexis SA</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, we entered into a license agreement with Selexis SA, or Selexis, under which we obtained a worldwide, royalty-bearing, sublicensable license under certain patents, know-how and other intellectual property, to use Selexis generated cell lines to manufacture ALX148 and to make, use and sell licensed products containing such compound in all fields of use. The rights granted under this agreement include the rights to grant sublicenses to contractors or other collaboration partners, in each case to develop production processes or manufacture licensed products, containing ALX148.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the rights granted to us under the agreement, we paid Selexis a nominal one-time fee and will pay Selexis an annual maintenance fee. We also agreed to pay Selexis milestone payments up to an aggregate of 1.2 million Swiss Francs in respect of all licensed products developed and/or commercialized under the grant, that successfully satisfies certain milestone events. We also agreed to pay Selexis a flat royalty of a very low single-digit percentage on net sales made by us, our affiliates and our sublicensees of products. This royalty obligation, on a product-by-product and country-by-country basis, shall terminate and become fully paid-up upon the passing of ten years after the first commercial sale of the product in such country or our exercise of the royalty buyout option, exercisable at any time prior to the first commercial sale of a licensed product.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may terminate the license agreement at any time for any reason with at least 60 days&#8217; written notice to Selexis. Either party may terminate the license agreement if the other party enters into a bankruptcy event or in the event of a material breach of the agreement (that cannot be cured or remains uncured for 60 days after the date that the defaulting party is provided with written notice of such breach). Our obligations to make payments that are accrued or accruable will survive any termination of the agreement, and in certain circumstances the licenses granted under the agreement will terminate unless they have become fully paid up as described in the previous paragraph.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Commercial Antibody Agreement with Crystal Bioscience, Inc. (Now a Subsidiary of Ligand Pharmaceuticals Incorporated)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, we entered into an agreement with Crystal Bioscience, Inc. (now a subsidiary of Ligand Pharmaceuticals Incorporated), or Crystal, under which we obtained an assignment of certain patents, covering certain SIRP&#945; antibodies. Under this agreement, we also received a worldwide, royalty-bearing non-exclusive license, with the right to grant sublicenses through multiple tiers of sublicenses, under certain of Crystal&#8217;s background patents and know-how necessary to commercialize the rights under the assigned patents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the rights granted to us under the agreement, we agreed to pay Crystal milestone payments up to $11.1 million in respect of all licensed products developed under the assigned patents, that successfully satisfy certain clinical and regulatory milestones, each milestone being paid only once for all products. We also agreed to pay Crystal tiered royalties on net sales of licensed products made by us, our affiliates and our sublicensees of products at rates ranging within low single-digit percentages, subject to certain potential reductions. This royalty obligation, on a product-by-product and country-by-country basis, shall terminate and become fully paid-up upon the later of the date on which the last valid claim included in the licensed patents expires and ten years after the first commercial sale of the product in such country.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We agreed to use commercially reasonable efforts to develop and commercialize licensed products, including meeting defined development milestones by certain specified dates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may terminate the agreement at any time for any reason with at least 60 days&#8217; written notice to Crystal. Either party may terminate the agreement if the other party enters into a bankruptcy event or in the event of material breach of the agreement (that remains uncured for 60 days after the date that it is provided with written notice of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such breach). Our obligations to pay royalties and milestone payments which accrued pre-termination or accrue post- termination will survive any termination.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Related-Party Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, we entered into the Tollnine Agreement with Tallac Therapeutics, a related-party, to provide research and development services to Tallac Therapeutics. From June 2018 to April 2020, our Chief Executive Officer was also the Chief Executive Officer of Tallac Therapeutics and currently two of our investors are also investors in Tallac Therapeutics. In April 2020, Dr. Hong Wan, our former Chief Scientific Officer, replaced our Chief Executive Officer to become the Chief Executive Officer of Tallac Therapeutics. As such, Tallac Therapeutics was deemed to be a related-party. The services under the Tollnine Agreement were provided at a price based on the costs incurred by us plus a mark-up equal to 10.0% of such costs. We recognized revenue when Tallac Therapeutics, as our customer, obtained control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2020, 2019 and 2018, we recognized related-party revenues of $1.2 million, $4.8 million and $2.1 million, respectively, under the Tollnine Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, 2019 and 2018, we had outstanding related-party receivables from Tallac Therapeutics of zero, $0.5 million and $0.9 million, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective as of July 1, 2020, we terminated the Tollnine Agreement and entered into the Tallac Services Agreement with Tallac Therapeutics, pursuant to which Tallac Therapeutics will provide certain research and development services to us. The Tallac Services Agreement has an initial term of four years, to be automatically renewed for additional one-year terms unless terminated by either party. The services are to be provided at a price based on the costs incurred by Tallac Therapeutics plus a mark-up equal to 10.0% of such costs. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Off-Balance Sheet Arrangements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the period presented, we did not have, nor do we currently have, any off-balance sheet arrangements, as defined in the rules and regulations of the SEC.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Significant Judgments and Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses during the reporting periods. These items are monitored and analyzed by us for changes in facts and circumstances, and material changes in these estimates could occur in the future. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which they become known. Actual results may differ significantly from these estimates under different assumptions or conditions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While our significant accounting policies are more fully described in the notes to our audited consolidated financial statements elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies related to accrued expenses and equity-based compensation are most critical to understanding and evaluating our reported financial results.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical and Manufacturing Accruals</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We record accruals for estimated costs of research, preclinical studies and clinical trials, and manufacturing development, which are a significant component of research and development expenses. A substantial portion of our ongoing research and development activities are conducted by third-party service providers, including CROs and contract manufacturing organizations, or CMOs. Our contracts with CROs generally include pass-through fees such as regulatory expenses, investigator fees, travel costs and other miscellaneous costs, including shipping and printing fees. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">result in payment flows that do not match the periods over which materials or services are provided to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">us</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> under such contracts. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accrue the costs incurred under agreements with these third parties based on estimates of actual work completed in accordance with the respective agreements. </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> determine the estimated costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fees to be paid for such services.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We make significant judgments and estimates in determining the accrual balance at the end of each reporting period. As actual costs become known, we adjust our accruals. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in our reporting amounts that are too high or too low in any particular period. To assist in its estimates we rely upon the receipt of timely and accurate reporting from our clinical and non-clinical studies and other third-party vendors. Through December 31, 2020, there have been no material differences from our accrued estimated expenses to the actual clinical trial expenses. However, variations in the assumptions used to estimate accruals, including, but not limited to, the number of patients enrolled, the rate of patient enrollment, and the actual services performed, and related costs may vary from our estimates, resulting in adjustments to clinical trial expense in future periods. Changes in these estimates that result in material changes to our accruals could materially affect its financial position and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-Based Compensation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense represents the grant-date fair value of awards recognized over the requisite service period of the awards (usually the vesting period) on a straight-line basis. For stock options and shares purchased under our Employee Stock Purchase Plan, or ESPP, we estimate the grant-date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Black-Scholes option-pricing model requires the derivation and use of subjective assumptions to determine the estimated fair value of stock option awards. These assumptions include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Expected Term&#8212;We have concluded that our stock option exercise history does not provide a reasonable basis upon which to estimate expected term, and therefore we use the simplified method for estimating the expected term of stock option grants. Under this approach, the weighted-average expected term is presumed to be the average of the vesting term and the contractual term of the option.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Expected Volatility&#8212;Since we do not have significant trading history for our common stock, the expected volatility is estimated based on the average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. The comparable companies were chosen based on their similar size, stage in the life cycle or area of specialty.&#160;We will continue to use comparable company information until the historical volatility of our common stock is sufficient to measure expected volatility for future option grants.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Risk-Free Interest Rate&#8212;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the time of grant for periods corresponding with the expected term of the award.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.08%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Dividend Yield&#8212;We have not paid dividends on our common stock and do not anticipate paying dividends for the foreseeable future, and we therefore used an expected dividend yield of zero.</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the Black-Scholes assumptions, we include the effect of forfeitures as they occur.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect the impact of our stock-based compensation expense to grow in future periods due to the potential increases in the value of our common stock and the number of awards we expect to grant.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We issue incentive and non-statutory stock options and under the 2020 Amended and Restated Equity Incentive Plan, or 2020 Plan, to certain directors, officers, employees and consultants in consideration for services provided to us. To date, all incentive stock options have provided for vesting over a four year period from either the date of grant or the commencement of service. To date, all non-statutory stock options have provided for vesting over periods ranging from one to four years from either the date of grant or commencement of service. To date, all non-statutory stock options have been granted to directors and vest over a three year period from the award's date of grant, or the date of the Company&#8217;s next annual meeting of stockholders that occurs following the date of grant. The 2020 Plan does not allow the option holders to exercise their options prior to vesting.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to our initial public offering, </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the fair value of the common stock underlying our stock-based awards </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> determined on each grant date by our board of directors, with input from management, considering our most recently available third-party valuation of common shares. In the absence of a public trading market for our common stock,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">our board of directors made a reasonable determination of the fair value of our common stock based on the information known to us on the date of grant, upon a review of any recent events and their potential impact on the estimated fair value per share of the common stock, and timely valuations from an independent third-party valuation in accordance with guidance provided by the American Institute of Certified Public Accountants Practice Aid, </font><font style="font-style:italic;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or Practice Aid. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">See &#8220;Note 2. Significant Accounting Policies&#8221; of the Notes to Consolidated Financial Statements in &#8220;Item&#160;8. Financial Statements and Supplementary Data&#8221; for a full description of recent accounting pronouncements, including the respective expected dates of adoption and estimated effects, if any, on our consolidated financial statements.</font><font style="color:#000000;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a><a name="ITEM_7A_QUANTITATIVE_QUALITATIVE_DISCLOS"></a>Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Interest Rate Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. As of December 31, 2020, we had cash and cash equivalents of $434.2 million. We generally hold our cash and cash equivalents in interest-bearing bank accounts and money market funds. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. An immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash and cash equivalents. <font style="Background-color:#FFFFFF;color:#000000;">To date, we have not experienced a loss of principal on any of our cash equivalents and as of&#160;December 31, 2020, we did not record any allowance for credit loss from our cash equivalents.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financial Institution Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Substantially all of our cash and cash equivalents is held with a single financial institution. Due to its size, this financial institution represents a minimal credit risk. Cash amounts held at financial institutions are insured by the Federal Deposit Insurance Corporation up to $250,000. At December 31, 2020, we had $434.0 million in excess of this insured limit.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Currency Risk</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our expenses are generally denominated in U.S. dollars. However, we have entered into a limited number of contracts with vendors for services with payments denominated in foreign currencies, primarily the Euro. We are subject to foreign currency transaction gains or losses on our contracts denominated in foreign currencies. To date, foreign currency transaction gains and losses have not been material to our consolidated financial statements, and we have not had a formal hedging program with respect to foreign currency. A 10.0% increase or decrease in current exchange rates would not have a material effect on our financial results.</p><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_8_FINANCIAL_STATEMENTS_SUPPLEMENTAR"></a>Item 8. Financial Statement</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">s and Supplementary Data. </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO FINANCIAL STATEMENTS</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"><font style="text-decoration:underline;">Report of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_BALANCE_SHEETS"><font style="text-decoration:underline;">Consolidated Balance Sheets</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"><font style="text-decoration:underline;">Consolidated Statements of Comprehensive Loss and Comprehensive Loss</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"><font style="text-decoration:underline;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CONSOLIDATED_STATEMENTS_CASH_FLOWS"><font style="text-decoration:underline;">Consolidated Statements of Cash Flows</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:93.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"><font style="text-decoration:underline;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.42%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a><a name="REPORT_INDEPENDENT_REGISTERED_PUBLIC_ACC"></a>Report of Independent Registered Public Accounting Firm</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the Stockholders and Board of Directors<br />ALX Oncology Holdings Inc.:</p>
<p style="margin-bottom:5pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Opinion on the Consolidated Financial Statements</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of ALX Oncology Holdings Inc.&#160;and subsidiaries (the Company) as of December&#160;31,&#160;2020 and 2019, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years in the three-year period ended December&#160;31,&#160;2020, and the related notes (collectively, the consolidated financial statements).&#160;In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31,&#160;2020 and 2019, and the results of its operations and its cash flows for each of the years in the three-year period ended December&#160;31,&#160;2020, in conformity with U.S. generally accepted accounting principles.</p>
<p style="margin-bottom:5pt;margin-top:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Basis for Opinion</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 2016.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, California<br />March&#160;18,&#160;2021</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALX ONCOLOGY HOLDINGS INC.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_BALANCE_SHEETS"></a><a name="CONSOLIDATED_BALANCE_SHEETS"></a>Consolidated Balance Sheets</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share data)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:31.56%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Assets</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">434,219</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivables due from related-party</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">536</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,773</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">256</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">435,992</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,809</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436,054</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,676</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,748</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,200</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,236</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,204</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,984</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term loan - non-current</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,421</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current liabilities</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">547</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,209</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,952</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies (Note 12)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock, $0.001 par value; zero shares authorized,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued and outstanding as of December 31, 2020; 9,421,633 shares authorized</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; as of December 31, 2019; 9,297,081 shares issued and outstanding as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019; aggregate liquidation preference of $73,571 as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,933</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series B convertible preferred stock, $0.001 par value; zero shares authorized,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued and outstanding as of December 31, 2020; 2,145,370 shares authorized</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; as of December 31, 2019; 1,016,727 shares issued and outstanding as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019; aggregate liquidation preference of $10,014 as of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2019</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,430</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders&#8217; equity (deficit)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred stock, $0.001 par value; 100,000,000 shares authorized, no shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issued or outstanding</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.001 par value; 1,000,000,000 and 1,519,618,271 shares</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; authorized as of December 31, 2020 and 2019, respectively; 39,844,522 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 3,166,946 shares issued and outstanding as of December 31, 2020 and 2019,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; respectively</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548,327</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,140</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,522</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,782</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders&#8217; equity (deficit)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,639</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities, convertible preferred stock and stockholders&#8217; equity</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; (deficit)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">436,054</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,676</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p><a name="_AEIOULastRenderedPageBreakAEIOU10"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALX ONCOLOGY HOLDINGS INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a><a name="CONSOLIDATED_STATEMENTS_OPERATIONS_COMPR"></a>Consolidated Statements of Operations and Comprehensive Loss</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share and per share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Related-party revenue</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,182</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,796</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,067</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,961</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,306</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,270</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,809</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,313</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,601</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of services for related-party revenue</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,075</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,360</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,880</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,845</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,979</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,751</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,663</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,684</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest expense</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(811</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other expense, net</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(404</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on early debt extinguishment</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(621</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,499</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,686</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax provision</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(241</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(34</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss and comprehensive loss</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,740</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,243</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,731</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative dividends allocated to preferred stockholders</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,202</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,028</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,671</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,942</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,271</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,402</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders, basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.76</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7.56</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.33</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock used to compute net</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; loss per share attributable to common stockholders, basic and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; diluted</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,485,343</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076,461</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,750,838</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALX ONCOLOGY HOLDINGS INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"></a><a name="CONSOLIDATED_STATEMENTS_CONVERTIBLE_PREF"></a>Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share amounts)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-style:italic;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Convertible Preferred</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.36%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' Equity (Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.72%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.72%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-In</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.72%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.86%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity (Deficit)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,297,081</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,933</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,205,421</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,390</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,808</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,415</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; under equity incentive plans</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,914</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase of common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43,689</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of early exercised stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Repurchase of unvested early</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; exercised stock options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,899</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,731</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,731</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,297,081</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,933</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,161,747</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,758</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(53,539</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51,778</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,016,727</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,430</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; under equity incentive plans</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,199</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of early exercised stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; options</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,243</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,243</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313,808</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,363</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,166,946</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,140</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,782</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70,639</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock, net of</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,055,966</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,680</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification of warrants</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; from liability to equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stock into</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,369,774</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(175,043</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,369,774</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,043</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cumulative dividends</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,564,759</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock in</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; connection with equity</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; offerings, net of underwriter</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; discounts and issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,512,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364,387</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364,400</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; upon net exercise of warrants</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,932</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; under equity incentive plans</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">182,111</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of early exercised stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.6%; border-left:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-right:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-left:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:26.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance as of December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-right:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.6%; border-left:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,844,522</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">548,327</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118,522</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8.5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429,845</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALX ONCOLOGY HOLDINGS INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a><a name="CONSOLIDATED_STATEMENTS_CASH_FLOWS"></a>Consolidated Statements of Cash Flows</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating activities</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,243</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,731</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,436</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of term loan discount and issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">421</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in fair value of compound derivative liability and warrants</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">650</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gain on assignment of lease</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(126</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss on early debt extinguishment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">621</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Changes in operating assets and liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Receivables due from related-party</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">536</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">396</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(932</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,514</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">744</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">897</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,744</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,976</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(269</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses and other current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,983</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other non-current liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:41.05pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38,289</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,249</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,190</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Investing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchase of property and equipment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(353</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(653</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from assets held for sale</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">641</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) investing activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">610</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(353</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(653</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from common stock offerings, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">368,256</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payments of offering costs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,848</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from exercise of common stock under equity incentive plans</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">299</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of convertible preferred stock, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,680</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,430</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for repurchase of common stock</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of term loan, net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,917</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for early debt extinguishment</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,506</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">462,881</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,357</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">425,202</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">755</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,842</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at beginning of year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,262</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,104</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents at end of year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">434,219</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,262</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for interest</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">427</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of non-cash investing and financing</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; activities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vesting of early exercised stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of property and equipment in accounts payable and accrued</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Debt issuance costs in accounts payable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Conversion of convertible preferred stock into common stock upon</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; closing of initial public offering</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">175,043</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated dividend on convertible preferred stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying notes are an integral part of these consolidated financial statements. </p><a name="_AEIOULastRenderedPageBreakAEIOU13"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ALX ONCOLOGY HOLDINGS INC.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a><a name="NOTES_TO_CONSOLIDATED_FINANCIAL_STATEMEN"></a>Notes to Consolidated Financial Statements</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1) ORGANIZATION</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Organization</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALX Oncology Holdings Inc., or the Company, was formed as a Delaware corporation on April&#160;1, 2020, or Inception. The Company was formed for the purpose of completing the Company&#8217;s initial public offering of its common stock and related transactions in order to carry on the business of ALX Oncology Limited. After Inception, ALX Oncology Limited became a wholly-owned subsidiary of the Company as a result of the internal reorganization. As part of the internal reorganization, all of the equity, option and warrant holders of ALX Oncology Limited became equity, option and warrant holders of the Company, holding the same number of corresponding shares, options and/or warrants in the Company as they did in ALX Oncology Limited immediately prior to the internal reorganization. The information included herein is presented as that of ALX Oncology Holdings Inc. unless such information refers to a date prior to April 1, 2020, in which case it will reflect that of ALX Oncology Limited, the predecessor company. The Company is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company owns subsidiaries, consisting of ALX Oncology Limited, incorporated in Ireland; ALX Oncology Inc., incorporated in the United States, Alexo International Holdings Ltd, incorporated in Malta; Alexo Therapeutics International, incorporated in the Cayman Islands, which is a wholly-owned subsidiary of Alexo International Holdings Ltd., and Sirpant Therapeutics, incorporated in the Cayman Islands, which is a wholly-owned subsidiary of Alexo Therapeutics International, or collectively, the Subsidiaries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of&#160;December 31, 2020, the Company has devoted substantially all of its efforts to the formation and financing of the Company, as well as product development, and has not realized product revenues from its planned principal operations. The Company has no manufacturing facilities and all manufacturing related activities are contracted out to third-party service providers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management expects to incur additional losses in the future to conduct product candidate research and development and to conduct pre-commercialization activities and recognizes that the Company will likely raise additional capital to fully implement its business plan. The Company intends to raise such capital through the sale of additional equity, debt financings or strategic alliances with third parties. However, there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms acceptable to the Company. If the Company is unsuccessful in its efforts to raise additional financing, the Company could be required to significantly reduce operating expenses and delay, reduce the scope of or eliminate some of its development programs or its future commercialization efforts, out-license intellectual property rights to its product candidates and sell unsecured assets, or a combination of the above, any of which may have a material adverse effect on the Company&#8217;s business, results of operations, financial condition and/or its ability to fund its scheduled obligations on a timely basis or at all. <font style="Background-color:#FFFFFF;color:#000000;">The Company believes that the existing capital resources will be sufficient to fund the projected operating requirements for at least the next twelve months.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2) SIGNIFICANT ACCOUNTING POLICIES</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Preparation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, and the applicable rules and regulations of the U.S. Securities and Exchange Commission, or SEC.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reverse Stock Split</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, the Company&#8217;s board of directors approved an amendment to the Company&#8217;s certificate of incorporation to effect a 1-for-6.5806 reverse split of its common stock and convertible preferred stock. The par values of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All authorized, issued and outstanding common stock, convertible preferred stock, stock options, warrants, and related per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. The reverse stock split was effected on July 9, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, Series B convertible preferred stock warrant liability, term loan compound derivative liability, term loan, valuation of the Company&#8217;s common stock, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company holds its cash and cash equivalents in checking and money market accounts. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and are stated at fair value.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Credit Losses and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits, and invests in money market funds. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents. The Company has not experienced any losses on its deposits of cash and cash equivalents. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s potential product candidates, uncertainty of market acceptance of the Company&#8217;s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives of the assets. Upon sale or retirement of assets, the cost and related accumulated depreciation or amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations and comprehensive loss. Maintenance and repairs are charged to the consolidated statement of operations and comprehensive loss as incurred.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Offering Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in capital generated as a result of the equity financing. &#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the asset or asset group are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds its fair value. Fair value is determined using various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. The Company has not recorded impairment of any long-lived assets. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the consolidated financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Where observable prices or inputs are not available valuation models are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments&#8217; complexity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of cash and cash equivalents, receivables due from related-party, accounts payable, the term loan compound derivative liability and the Series B convertible preferred stock warrant liability. The term loan compound derivative liability and the Series B convertible preferred stock warrant liability are re-measured at the end of every period and carried at fair value (Note 3). The recorded value of the Company&#8217;s receivables due from related-party and accounts payable approximates its current fair value due to the relatively short-term nature of these items.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Term Loan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for the Loan and Security Agreement, dated as of December 20, 2019, as amended, with Silicon Valley Bank, or SVB, and WestRiver Innovation Lending Fund VIII, LP, or WestRiver, collectively as lenders, and SVB, as administrative agent and collateral agent, as a liability measured at net proceeds less debt discount and is accreted to the face value of the term loan over its expected term using the effective interest method. The Company considers whether there are any embedded features in its debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to Accounting Standards Codification, or ASC, Topic 815, <font style="font-style:italic;">Derivatives and Hedging</font>.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">118</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records convertible preferred stock net of issuance costs on the dates of issuance, which represents the carrying value. In the event of a change of control of the Company, proceeds will be distributed in accordance with the liquidation preferences set forth in its organization documents unless the holders of convertible preferred stock have converted their convertible preferred stock into common stock. Convertible preferred stock is classified outside of stockholders&#8217; equity (deficit) on the accompanying consolidated balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. The Company has elected not to adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because of the uncertainty of whether or when such an event would occur. Upon the consummation of the Company&#8217;s initial public offering in July 2020, all shares of convertible preferred stock outstanding and accrued cumulative dividends automatically converted into&#160;23,934,533&#160;shares of common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Series B Convertible Preferred Stock Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has issued freestanding warrants to purchase its Series B convertible preferred stock. Freestanding warrants for the Company&#8217;s convertible preferred stock that are classified outside of permanent equity are recorded at fair value, and are subject to re-measurement at the end of every period until the earlier of the exercise of the warrants or the completion of a liquidation event, including the completion of an initial public offering. Upon exercise, the Series B convertible preferred stock warrant liability would be reclassified to additional paid-in capital, with any change in fair value recognized as a component of other expense, net. Following the Company&#8217;s initial public offering, the warrants were automatically converted to warrants to purchase shares of common stock (Note 5). The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance to additional paid-in capital with no further re-measurement required as common stock warrants are considered permanent equity. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the Company has derived revenue from providing research and development services on a time and materials basis to a related-party.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes such revenues over time as services are delivered, and invoices the customer as the work is incurred in arrears.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (Topic 606), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the Company&#8217;s consideration as to whether the Company has entered into a contract with a customer, it considers whether it is probable that it will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">119</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Services for Related-Party Revenue</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurs costs associated with related-party services including direct labor and associated employee benefits, laboratory supplies, and other expenses. These costs are recorded in cost of services for related-party revenue as a component of total operating expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and consist primarily of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to nonemployees and entities that conduct certain research and development activities on behalf of the Company and expenses incurred in connection with license agreements (Note 9). Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and recorded in prepaid expenses and other current assets, and then expensed as the related goods are delivered or the services are performed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical and Manufacturing Accruals</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records accruals for estimated costs of research, preclinical studies and clinical trials, and manufacturing development, which are a significant component of research and development expenses. A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including contract research organizations, or CROs, and contract manufacturing organizations, or CMOs. The Company&#8217;s contracts with CROs generally include pass-through fees such as regulatory expenses, investigator fees, travel costs and other miscellaneous costs, including shipping and printing fees. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company accrues the costs incurred under agreements with these third parties based on estimates of actual work completed in accordance with the respective agreements. The Company determines the estimated costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fees to be paid for such services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company makes significant judgments and estimates in determining the accrual balance at the end of each reporting period. As actual costs become known, the Company adjusts its accruals. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in the Company reporting amounts that are too high or too low in any particular period. To assist in its estimates the Company relies upon the receipt of timely and accurate reporting from its clinical and non-clinical studies and other third-party vendors. Through December 31, 2020, there have been no material differences from the Company&#8217;s accrued estimated expenses to the actual clinical trial expenses. However, variations in the assumptions used to estimate accruals, including, but not limited to, the number of patients enrolled, the rate of patient enrollment, and the actual services performed, and related costs may vary from the Company&#8217;s estimates, resulting in adjustments to clinical trial expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect its financial position and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-based Compensation Expense </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all stock-based payments made to employees, directors and non-employees based on estimated grant-date fair values. The Company uses the straight-line method to allocate compensation expense to reporting periods over each optionee&#8217;s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards using the Black-Scholes option-pricing model. The Black-Scholes model requires the input of subjective assumptions, including expected volatility, expected dividend yield, expected term, risk-free rate of return and the estimated fair value of the underlying common stock on the date of grant. Prior to the Company&#8217;s initial public offering, the fair value of the common stock underlying the stock-based awards was determined on each grant date by the board of directors, with input from management, considering the most recently available third-party valuation of common shares. The Company accounts for the effect of forfeitures as they occur. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Currency Transactions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of the Company&#8217;s operation and each of its subsidiaries is U.S. dollars. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate prevailing on the balance sheet date. Expenses are translated at the average exchange rates prevailing during the applicable period. Foreign currency transaction gains and losses are included in the consolidated statement of operations and comprehensive loss and recorded in other expense, net, and were immaterial for the years December 31, 2020, 2019 and 2018.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for the period in which the temporary differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is equal to net loss for all periods presented.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share Attributable to Common Stockholders</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method to compute basic and diluted net loss per share when it has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires net loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all net loss for the period had been distributed. The Company&#8217;s convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), <font style="font-style:italic;">Leases</font> (ASU 2016-02). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU No. 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. In June 2020, the FASB issued ASU No. 2020-05, which extends the effective date of ASU No. 2016-02 for non-public business entities, including smaller reporting companies, to fiscal years beginning after December 15, 2021. The new standard is effective for the Company beginning January 1, 2022 (or earlier if the Company ceases to be an emerging growth company). Early adoption is permitted. The Company is currently evaluating the effects of the adoption of this guidance on its consolidated financial statements and related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2021. ASU 2019-12 is effective for the Company beginning January 1, 2022. Early adoption is permitted. The Company is currently in the process of evaluating the effects of the adoption of this guidance on the Company&#8217;s financial statements and does not expect it to have a material impact on its consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Accounting Pronouncements Recently Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. The Company early adopted this guidance on January 1, 2020. <font style="Background-color:#FFFFFF;color:#000000;">For trade receivables and other instruments, the Company uses a new forward-looking </font><font style="color:#000000;">expected loss model that generally results in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses are recognized as allowances rather than as reductions in the amortized cost of the securities. </font><font style="Background-color:#FFFFFF;color:#000000;">The adoption of the guidance did not have a material impact on the Consolidated Financial Statements and related disclosures and there was&#160;no&#160;allowance for losses for the year ended December 31, 2020.</font> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement. The FASB issued final guidance that eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. Under the ASU, entities will no longer be required to disclose the amount of transfers between Level 1 and Level 2 of the fair value hierarchy. Public companies will be required to disclose changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. ASU 2018-13 is effective for public business entities for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2019, with early adoption permitted. The Company adopted this guidance on January 1, 2020. The adoption of ASU 2018-13 did not have a material impact on its consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(3) FAIR VALUE OF FINANCIAL INSTRUMENTS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the Company&#8217;s financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC Topic 820, Fair Value Measurements and Disclosures. ASC Topic 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Observable inputs, such as quoted prices in active markets;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs, other than the quoted prices in active markets, which are observable either directly or indirectly such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#8217;s anticipated life</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; and</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of cash and cash equivalents, receivables due from related-party, accounts payable, the term loan compound derivative liability and the Series B convertible preferred stock warrant liability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are reported at their respective fair values on the Company&#8217;s consolidated balance sheets. Where quoted prices are available in an active market, securities are classified as Level 1. The Company classifies money market funds as Level 1. When quoted market prices are not available for the specific security, then the Company estimates fair value by using quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third-party data providers, including but not limited to benchmark yields, reported trades and broker/dealer quotes. Where applicable the market approach utilizes prices and information from market transactions for similar or identical assets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its Series B convertible preferred stock warrant liability and term loan compound derivative liability at fair value on a recurring basis and these are classified as Level 3 liabilities. The fair value of the Series B convertible preferred stock warrant liability was determined using an option-pricing model. The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance to additional paid-in capital with no further re-measurement required as the common stock warrants are considered permanent equity effective with the completion of the initial public offering. The Company calculated the fair value of the term loan compound derivative liability by computing the difference between the fair value of the term loan with the compound derivative using the &#8220;with and without&#8221; method under the income approach, and the fair value of the term loan without the compound derivative. The valuation methodology and underlying assumptions are discussed further in Note 5. The compound derivative liability was extinguished upon the extinguishment of the host instrument in December 2020 (Note 5).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Cash equivalents</font></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424,115</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424,115</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Non-current liabilities</font></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compound derivative liability</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.56%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">123</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table is a reconciliation of all financial liabilities measured at fair value using Level 3 unobservable inputs (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compound</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrant</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at beginning of year</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">658</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification to equity</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of compound derivative liability upon extinguishment of host instrument</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at end of year</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no transfers of assets or liabilities between the fair value measurement levels during the years ended December 31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of the Company&#8217;s financial instruments, such as accounts payable and accrued expenses and other current liabilities, approximate fair value due to the short-term nature of these items.&#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(4) BALANCE SHEET COMPONENTS</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the components of property and equipment, net as of December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk64885239"></a>&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware and software</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,698</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,309</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,449</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense was $0.2 million, $0.4 million and $0.4 million for years ended December 31, 2020, 2019 and 2018, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 2020, certain lab equipment and other assets for an aggregated net book value of $0.6 million relating to the asset transfer with Tallac Therapeutics, Inc. (formerly known as Tollnine, Inc., or Tollnine), or Tallac Therapeutics, a related-party (Note 10), met the criteria as assets held for sale. Those assets were reported at the lower of carrying value or fair value less costs to sell. In July 2020, the Company received $0.6 million cash in exchange for the transfer of such assets. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Expenses and Other Current Liabilities</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the components of accrued expenses and other current liabilities as of December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,974</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">924</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical and nonclinical study costs</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,473</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued contract manufacturing</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,123</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued federal income tax</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,200</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,236</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(5) TERM LOAN</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s wholly-owned subsidiaries Alexo Therapeutics International and Sirpant Therapeutics, as borrowers, entered into a Loan and Security Agreement, or the Loan Agreement, dated as of December 20, 2019, with SVB and WestRiver, collectively as lenders, and SVB, as administrative agent and collateral agent. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the internal reorganization, in May 2020 the Company entered into a Joinder and First Amendment to the Loan and Security Agreement, or the Joinder Amendment, and Amended and Restated Warrants to Purchase Stock, or the Amended Warrants. The purpose for entering into the Joinder Amendment was to add the newly established ALX Oncology Holdings Inc. as additional borrower to the Term Loan. Concurrently, the Company modified the Amended Warrants to change the issuer from ALX Oncology Limited to ALX Oncology Holdings Inc. The Company accounted for the First Amendment to the Loan and Security Agreement as a modification.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Loan Agreement provided for term loans in an aggregate principal amount of up to $10.0 million funded in two tranches, subject to the satisfaction of a certain milestone. The first tranche, in the amount of $6.0 million, was funded on the closing date of the Loan Agreement in December 2019. A second tranche of $4.0 million was available on or before March 31, 2020, upon the Company&#8217;s achievement of an equity financing resulting in net cash proceeds in an amount of at least $30.0 million to the Company. The Company elected not to draw down on the second tranche, which is no longer available.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loans under the Loan Agreement bore interest at a floating per annum interest rate equal to the greater of 7.0% or 2.0% plus the prime rate as reported in The Wall Street Journal.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was required to make interest-only payments for the first 12 months after the closing of the Loan Agreement, followed by consecutive equal monthly payments of principal and interest commencing on January 1, 2021 and continuing through the maturity date of September 1, 2022. The Loan Agreement also provided for a final payment equal to 6.0% multiplied by the aggregate principal amount of the term loans funded, which was due on the maturity date, upon the acceleration of the term loans, or upon prepayment of the term loans. If the Company elected to prepay the term loans, there was also a prepayment fee of between 1.0% and 3.0% of the principal amount being prepaid depending on the timing and circumstances of prepayment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the Loan Agreement, the Company issued warrants to purchase 61,292 Series B convertible preferred stock to SVB and WestRiver with an exercise price of $9.4972 per share. Following the Company&#8217;s initial public offering, these warrants were automatically converted to warrants to purchase 61,292 shares of common stock at an exercise price of $9.4972 per share. The estimated fair value of the warrants at the date of issuance was approximately $0.4 million. The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance of $1.0 million to additional paid-in capital with no further re-measurement required as the common stock warrants are considered permanent equity effective July 16, 2020. The fair value of the common stock warrant </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was determined using a Black-Scholes option-pricing model with the following assumptions: an expected term of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.8 years</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a volatility of</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 84.2</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%, a dividend rate of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">zero</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and a risk-free rate of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.6</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%. The changes in fair value in warrant liability </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">recognized as a component of other expense, net in the accompanying consolidated statement of operations and comprehensive loss. On August 17, 2020, SVB and WestRiver delivered the Notice of Exercise for net exercise of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,292</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> warrants at an exercise price of $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4972</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> per share. Accordingly, the Company issued </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,932</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of the Company&#8217;s common stock (Note 6</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loans under the Loan Agreement were secured by substantially all of the Company&#8217;s assets, except the Company&#8217;s intellectual property, which is the subject of a negative pledge.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that certain loan features were embedded derivatives requiring bifurcation and separate accounting. Those embedded derivatives were bundled together as a single, compound embedded derivative and then bifurcated and accounted for separately from the host contract. The Company recorded a term loan compound derivative liability of approximately $51,000 which was marked-to-market until the extinguishment of the host instrument. The Company calculated the fair value of the compound derivative by computing the difference between the fair value of the term loan with the compound derivative using the &#8220;with and without&#8221; method under the income approach, and the fair value of the term loan without the compound derivative. The Company calculated the fair values using a probability-weighted discounted cash flow analysis. The key valuation assumptions used consist of the discount rate and the probability of the occurrence of a change in control event. The term loan compound derivative liability was re-measured at each financial reporting period with any changes in fair value being recognized as a component of other expense, net in the consolidated statement of operations and comprehensive loss. The compound derivative liability was extinguished upon the extinguishment of the host instrument in December 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of Series B convertible preferred stock warrant liability at issuance, fair value of embedded derivatives, which were bifurcated and other debt issuance costs were treated as debt discounts on the Company&#8217;s consolidated balance sheet and together with the final payment were amortized to interest expense throughout the life of the term loan using the effective interest rate method.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company used approximately $6.5 million of the net proceeds from the Company&#8217;s follow-on public offering to repay the outstanding principal amount of $6.0 million and early extinguish the outstanding Term Loan with SVB and WestRiver. As a result, the Company recognized a $0.6 million loss on early debt extinguishment, representing the difference between the&#160;reacquisition&#160;price of debt and the net carrying amount of the loan as of the date of the payoff. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(6) STOCKHOLDERS&#8217; EQUITY <font style="font-style:italic;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On&#160;July 21, 2020, the Company&#8217;s amended and restated certificate of incorporation became effective, authorizing 1,000,000,000&#160;shares of common stock and&#160;100,000,000&#160;shares of undesignated preferred stock. As of&#160;December 31, 2020&#160;and&#160;2019, the Company had&#160;39,844,522&#160;and&#160;3,166,946&#160;shares of common stock outstanding, respectively. As of&#160;December 31, 2020&#160;and&#160;2019, the Company had zero and 10,313,808 shares of preferred stock outstanding, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In&#160;July&#160;2020, the Company consummated its initial public offering and issued&#160;9,775,000&#160;shares of common stock for net proceeds of approximately&#160;$169.5 million, after deducting underwriting discounts and commissions of $13.0 million and offering-related expenses of $3.2 million. Upon the closing of the initial public offering, all shares of convertible preferred stock outstanding and accrued cumulative dividends were automatically converted into 23,934,533 shares of common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In&#160;December&#160;2020, the Company consummated its follow-on public offering and issued&#160;2,737,000&#160;shares of common stock for net proceeds of approximately&#160;$194.9 million, after deducting underwriting discounts and commissions of $12.5 million and offering-related expenses of $0.7 million. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">126</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance, on an as if converted basis, as of </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2020 and 2019, consists of the following:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock issued and outstanding</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313,808</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857,308</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,745</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options authorized for future issuance</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,835,443</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants issued and outstanding</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,292</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants authorized for future issuance</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,646</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,692,751</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,156,391</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, the Company&#8217;s convertible preferred stock consisted of the following (in thousands, except share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued And</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Proceeds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preference</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Shares designated as:</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,421,633</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,297,081</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,933</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,571</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series&#160;B convertible preferred stock</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145,370</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,016,727</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,430</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,014</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,567,003</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313,808</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,363</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,585</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net proceeds are gross proceeds from the offerings net of issuance costs</p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:9pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Series C Convertible Preferred Stock Issuance</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:4pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company entered into a Series C Preferred Stock Purchase Agreement, or the Series C Agreement, with certain existing investors, employees and new investors, or collectively, the Series C Investors. Under the terms of the Series C Agreement, the Company authorized the sale and issuance of up to 11,055,981 Series C convertible preferred stock at a purchase price of $9.4972 per share. All authorized Series C convertible preferred stock have been purchased with gross proceeds of $105.0&#160;million.&nbsp;&nbsp;The Series C convertible preferred stock and related accumulated dividends automatically converted into shares of the Company&#8217;s common stock upon the consummation of the Company&#8217;s initial public offering.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preferred Stock Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 21, 2020, the warrants to purchase 61,292 Series B convertible preferred stock issued to SVB and WestRiver with an exercise price of $9.4972 per share were automatically converted to warrants to purchase 61,292 shares of common stock at an exercise price of $9.4972 per share. The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance to additional paid-in capital with no further re-measurement required as the common stock warrants are considered permanent equity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 17, 2020, SVB and WestRiver delivered the Notice of Exercise to net exercise 61,292 warrants at an exercise price of $9.4972 per share. Accordingly, the Company issued&#160;48,932&#160;shares of the Company&#8217;s common stock. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s initial public offering, cumulative dividends of 6.0% per annum of the original issue price for each convertible preferred stock series were payable when and as declared by the Company&#8217;s Board of Directors, or Board of Directors, upon the occurrence of a liquidation event or upon a contingent mandatory conversion of the convertible preferred stock in connection with a qualified initial public offering as described </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">127</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">below. The Series A original issue price </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.58</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, and the Series B and Series C original issue price </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.4972</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. The original issue price </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">was</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> subject to adjustment in the event of any share dividend, share split, combination, consolidation or other recapitalization. The dividends </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">accrued </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from day to day from the issue date of such preferred stock whether or not declared and </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cumulative. In addition, the preferred stockholders participate</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> on an as-converted basis in any dividends payable to </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">common stockholders</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. As of July 20, 2020, there were approximately $</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.0</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> million of accrued cumulative dividends on the Series A, Series B and Series C convertible preferred stock, which became payable upon the consummation of the Company&#8217;s initial public offering and automatically converted into </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,564,759</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shares of the Company&#8217;s common stock.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(7) STOCK-BASED COMPENSATION </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Incentive Plans</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2015 Share Award Scheme</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2015, the Company adopted an equity compensation plan, the 2015 Share Award Scheme, or the 2015 Share Award Scheme, for eligible employees, officers, directors, advisors, and consultants. The 2015 Share Award Scheme provided for the grant of incentive and non-statutory share options. The 2015 Share Award Scheme permitted the Company to grant up to 2,143,117 common stock awards, including incentive share options, non-statutory share options, conditional share awards and restricted share awards.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2020 Equity Incentive Plan</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2020, the Board of Directors approved a new equity incentive plan, or the 2020 Equity Incentive Plan, that replaced the 2015 Share Award Scheme. The 2020 Equity Incentive Plan is for employees, non-employee directors and consultants covering 4,379,139 shares of the Company&#8217;s common stock and authorizes the award of stock options, restricted stock awards, stock appreciation rights and restricted stock units.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2020 Amended and Restated Equity Incentive Plan</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company adopted the Amended and Restated 2020 Equity Incentive Plan, or the 2020 Plan. The 2020 Plan replaced the Company&#8217;s 2020 Equity Incentive Plan and&#160;a total of 7,874,862&#160;shares were reserved under the 2020 Plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the stock option agreements, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the 2020 Plan. The term of the options generally expire, upon the earliest of (i) termination of continuous service for cause (ii) three months after the termination of continuous service for reasons other than cause, death or disability (iii) twelve months after the termination of continuous service due to disability (iv) eighteen months after the employee&#8217;s death if the employee died during the period of continuous service (v) expiration date in the grant notice or (vi) the day before the tenth anniversary of the date of grant. The exercise price of the incentive share options must equal at least the fair market value of the share on the date of grant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All awards that are canceled, forfeited or expired are returned to the 2020 Plan and are available for grant in conjunction with the issuance of new awards. Share options granted are exercisable over a maximum term of 10 years from the date of grant and generally vest over an agreed service period, usually four years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain share options granted under the 2020 Plan provide option holders the right to elect to exercise unvested options in exchange for common stock. Such unvested common stock is subject to a repurchase right held by the Company at the original issuance price in the event the optionee&#8217;s service to the Company is terminated either voluntarily or involuntarily. The right lapses as the underlying repurchase right expires. These repurchase terms are considered to be a forfeiture provision. The cash received from employees for exercise of unvested options is treated as a refundable deposit and is classified as a liability on the consolidated balance sheets. At December 31, 2020 and 2019, there were unvested early exercised options of 63 and 34,024, respectively, and the liability related to these unvested options was approximately $0 and $27,000, respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Option Modification</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the transfer of employees to Tallac Therapeutics, Dr. Hong Wan, the Company&#8217;s former Chief Scientific Officer, and eight of the Company&#8217;s employees, or Transferred Employees, terminated their employment with the Company effective as of June 30, 2020 and became employees of Tallac Therapeutics effective as of July 1, 2020. The options to purchase shares of the Company&#8217;s common stock that were previously granted to the Transferred Employees will continue to vest and be exercisable subject to the Transferred Employees remaining service providers under the original terms of the award. The Company evaluated the change in status from an employee to a consultant in accordance with ASC 718. While the Company concluded that the change in status did not affect the vesting condition or the classification of the initial awards, the significant reduction in the level of services that the grantees were expected to provide under the original awards as compared to the level of services expected under the Tallac Services Agreement will no longer meet the substantive service condition requirements and therefore the compensation cost for the unvested awards was recognized immediately with no future service requirement. In September 2020, in connection with the resignation of the Company&#8217;s former Chief Business Officer and the entry into a consulting agreement with him, the Company evaluated the change in status from an employee to a consultant in accordance with ASC 718. While the Company concluded that the change in status did not affect the vesting condition or the classification of the initial awards, the significant reduction in the level of services that the grantee was expected to provide under the original awards as compared to the level of services expected under the consulting agreement will no longer meet the substantive service condition requirements and therefore the compensation expense for the unvested awards expected to vest during the consultancy was recognized immediately with no future service requirement. The Company recorded $1.7 million in stock-based compensation expenses related to the modifications for the year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Board of Directors and stockholders approved the ALX Oncology Holdings Inc. 2020 Employee Stock Purchase Plan, or the ESPP. The ESPP allows eligible employees to have up to&#160;15&#160;percent&#160;of their eligible compensation withheld and used to purchase common stock, subject to a maximum of&#160;$25,000&#160;worth of stock purchased in a calendar year or no more than&#160;3,000&#160;shares in an offering period, whichever is less. An offering period consists of a&#160;six-month purchase period, with a look back feature to our stock price at the commencement of the offering period. Eligible employees can purchase the Company&#8217;s common stock at the end of the offering period at&#160;85%&#160;of the lower of the closing price of our common stock on The Nasdaq Global Select Market on the first and last day of the offering periods.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial number of shares of common stock available for issuance under the ESPP, was&#160;400,000. Unless the Board of Directors provides otherwise, beginning on January 1, 2021, the maximum number of shares which shall be made available for sale under the ESPP will automatically increase on the first trading day in January of each calendar year during the term of the ESPP by an amount equal to the least of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.65%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">800,000 shares; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.65%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">one percent of the outstanding shares of our common stock on the last day of our immediately preceding fiscal year; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:8.65%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:'Times New Roman';text-transform:none;font-variant: normal;letter-spacing:0pt;"></font><font style="font-size:10pt;font-family:'Times New Roman'">&#8226;</font></p></td>
<td valign="top">
<p style="text-align:left;margin-top:0pt;margin-bottom:0pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">such number of shares as our board of directors may determine no later than the last day of our immediately preceding fiscal year.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Board of Directors approved the first offering period beginning February 1, 2021. As of&#160;December 31, 2020, there were&#160;no purchases under the ESPP.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">129</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock </font><font style="font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Option Activity</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a summary of share option activity under the Plan and related information:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available&#160;to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,745</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.06</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,124,217</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,857,655</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,857,655</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.92</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(182,111</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.65</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled/forfeited</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,981</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,981</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.99</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,835,443</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857,308</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.94</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.86</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375,270</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,776,399</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.85</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.65</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,999</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, there was unrecognized share-based compensation expense of $25.0 million, related to unvested share options which the Company expects to recognize over a weighted-average period of 3.2 years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic values represent the total pre-tax intrinsic value, of options outstanding and exercisable calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of December 31, 2020 and 2019. The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018 were $4.4 million, immaterial and immaterial, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-based Compensation Expenses</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation cost for share options granted is based on the grant-date fair value estimated and is recognized over the vesting period of the applicable option on a straight-line basis. The weighted-average grant-date fair value per share for share options granted during the years ended December 31, 2020, 2019 and 2018 was $7.74, $1.27 and $1.14, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense includes share options granted to employees and nonemployees and has been reported in the Company&#8217;s consolidated statements of operations and comprehensive loss as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,551</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,885</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of services for related-party revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,436</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Option Valuation Assumptions</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option pricing model to determine the estimated fair value of stock options at the date of the grant, and stock-based compensation is adjusted for actual forfeitures as they occur. The </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">fair value of each option grant during the years ended December 31, 20</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, 2019 and 2018</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> was estimated with the</font><font style="letter-spacing:-0.4pt;"> </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">following</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> assumptions</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="5" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 - 6.1</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4 - 6.0</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2 - 6.0</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3% - 0.8%</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7% - 2.1%</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6% - 3.0%</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend rate</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected stock price volatility</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78.7% - 89.0%</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.2% - 80.5%</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.5% - 68.7%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term. <font style="font-style:normal;">The expected term of the options represents the average period the share options are expected to remain outstanding. As the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior, the expected term of options granted is derived from the average midpoint between the weighted average vesting and the contractual term, also known as the simplified method.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Free Interest Rate. <font style="font-style:normal;">The risk-free interest rate is based on the yield of U.S. Treasury notes as of the grant date with terms commensurate with the expected term of the option.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dividend Yield. <font style="font-style:normal;">The expected dividends assumption is based on the Company&#8217;s expectation of not paying dividends in the foreseeable future.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Volatility. <font style="font-style:normal;">Since the Company does not have sufficient trading history for its common stock, the expected volatility is based on the historical volatilities of the common shares of comparable publicly traded companies. The Company selected companies with comparable characteristics, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the Company&#8217;s share-based awards.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value<font style="font-style:normal;">. Historically, for all periods prior to our initial public offering, the fair value of the shares of common stock underlying our stock option was determined by the Company&#8217;s board of directors. Because there was no public market for the Company&#8217;s common stock, the board of directors determined fair value of the common stock at the time of grant of the options by considering a number of objective and subjective factors including important developments in the Company&#8217;s operations, valuations performed by an independent third party, sales of convertible preferred stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company&#8217;s common stock, among other factors. Since the completion of our initial public offering, the fair value of each share of common stock underlying stock option grants is based on the closing price of our common stock on the Nasdaq Global Select Market as reported on the date of grant.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(8) INCOME TAXES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. domestic and international components of pre-tax loss for the years ending December 31, 2020, 2019 and 2018 are as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,457</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">813</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">855</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,042</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,541</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,499</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,209</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,686</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal and state provision for income taxes consist of the following (in thousands):</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Current provision for income taxes:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax provision:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the effective tax for the years ended December 31, 2020, 2019 and 2018 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk65586399"></a>&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At federal statutory income tax rate</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,555</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,034</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,874</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,098</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,875</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(332</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; Development credits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(512</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(861</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(499</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,710</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,733</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">732</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign rate differential</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,380</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,886</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,899</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior period true ups</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(950</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets as of December 31, 2020 and 2019 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,283</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,259</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; other credits</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,861</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,260</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">696</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,299</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,852</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,288</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,686</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realization of deferred tax assets is dependent upon the Company generating future taxable income, the timing and amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $4.6 million and $4.5 million for the years ended December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses and tax credit carryforwards as of December 31, 2020 are as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration Years</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, federal (Post December 31, 2017)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,919</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Do Not Expire</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, state</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,363</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2038-2040</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits, federal</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,327</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2039-2040</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits, state</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,893</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, foreign</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,086</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the Company&#8217;s U.S. net operating loss and credit carryforwards may be subject to substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitation could result in the expiration of the U.S. net operating loss and credit carryforwards before utilization. To date, the Company has not performed an analysis to determine whether there would be a substantial annual limitation due to a change in ownership.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unrecognized Tax Benefits</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations and comprehensive loss. If the Company is eventually able to recognize its uncertain tax positions, the Company&#8217;s effective tax rate would be reduced. The Company currently has a full valuation allowance against its net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unrecognized tax benefits as of December 31, 2020, 2019 and 2018 were $0.8 million, $0.7 million and $0.4 million, respectively. Future changes in the unrecognized tax benefits will not impact the effective tax rate due to the Company's full valuation allowance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will file income tax returns in the U.S. federal and California jurisdiction, is not currently under examination, and all years since inception are open to examination. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the following activity relating to unrecognized tax benefits (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:89.6%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">247</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions/reversals based on tax positions of prior years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to the current year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lapses in statutes of limitations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">842</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next 12 months due to tax examination changes, settlement activities, expirations of statute of limitations or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months. During the years ended December 31, 2020, 2019 and 2018, no interest or penalties were required to be recognized relating to unrecognized tax benefits.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">133</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">9</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">) LICENSE AGREEMENT</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2015, the Company entered into a license agreement, or the Stanford Agreement, with the Board of Trustees of the Leland Stanford Junior University, or Stanford, under which the Company obtained a worldwide, royalty-bearing, sublicensable license under certain patents relating to the Company&#8217;s current product candidates, to develop, manufacture and commercialize products for use in certain licensed fields, the scope of which would include the application of the licensed intellectual property in oncology. The license granted to the Company in the Stanford Agreement includes an exclusive grant, subject to certain pre-existing non-exclusive or exclusive rights that Stanford retained for grant to third parties with respect to certain categories of the licensed patents in certain fields of use and retained rights by Stanford and all other nonprofit institutions to use and practice the licensed patents and technology for internal research and other nonprofit purposes. The license granted to the Company in the Stanford Agreement also includes non-exclusive grants to certain Stanford patents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the rights granted to the Company under the Stanford Agreement, the Company paid Stanford a nonrefundable license royalty and reimbursed Stanford for past patent expenses, together totaling less than $0.1 million, and granted Stanford a specified number of shares of common stock of the Company. In addition, the Company is obligated to pay Stanford ongoing patent expenses and an annual license maintenance fee, which are nominal and will be creditable against any royalties payable to Stanford in the applicable year. The Company is required to make milestone payments up to an aggregate of $5.0 million in respect of a specified number of licensed products that successfully satisfy certain clinical and regulatory milestones. No milestone payments have been made through December 31, 2020. The Company also agreed to pay Stanford tiered royalties on a specified percentage of net sales made by the Company, its affiliates and its sublicensees of licensed products at rates ranging within low single-digit percentages, subject to certain reductions and offsets. The license, on a licensed product-by-licensed product and country-by-country basis, shall become royalty-free and fully paid-up upon the later of the date on which the last valid claim included in the exclusively or non-exclusively licensed patents expires and ten years after the first commercial sale of the licensed product in such country.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may terminate the Stanford Agreement, on a licensed product-by-licensed product basis, at any time for any reason by providing at least 60 days&#8217; written notice to Stanford. Stanford may terminate the Stanford Agreement, if the Company is in breach of any provision of the Stanford Agreement and fails to remedy such breach within 60 days after written notice of such breach by Stanford. In addition, Stanford has the right to terminate the Stanford Agreement, on a licensed product-by-licensed product basis, if the Company is not diligently developing and commercializing such licensed product under certain conditions or if the Company fails to achieve specified development milestones for such licensed product by certain dates, subject to the Company&#8217;s extension rights.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Commercial License Agreement with Selexis SA</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Company entered into a license agreement with Selexis SA, or Selexis, under which the Company obtained a worldwide, royalty-bearing, sublicensable license under certain patents, know-how and other intellectual property, to use Selexis generated cell lines to manufacture ALX148 and to make, use and sell licensed product containing such compound in all fields of use. The rights granted under this agreement include the rights to grant sublicenses to contractors or other collaboration partners, in each case to develop production processes or manufacture licensed product containing ALX148.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the rights granted to the Company under the agreement, the Company paid Selexis a nominal one-time fee and will pay Selexis an annual maintenance fee. The Company also agreed to pay Selexis milestone payments up to an aggregate of 1.2 million Swiss Francs in respect of all licensed products developed and/or commercialized under the grant that successfully satisfies certain milestone events. The Company also agreed to pay Selexis a flat royalty of a very low single-digit percentage on net sales made by the Company, its affiliates and sublicensees of products. This royalty obligation, on a product-by-product and country-by-country basis, shall terminate and become fully paid-up upon the passing of ten years after the first commercial sale of the product in such country, or the Company&#8217;s exercise of the royalty buyout option exercisable at any time prior to the first commercial sale of a licensed product.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may terminate the license agreement at any time for any reason with at least </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60 days</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217; written notice to Selexis. Either party may terminate the license agreement if the other party enters into a bankruptcy event or in the event of a material breach of the agreement (that cannot be cured or remains uncured for </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60 days</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> after the date that the defaulting party is provided with written notice of such breach). The Company&#8217;s obligations to pay royalties that are accrued or accruable will survive any termination of the agreement, and in certain circumstances the licenses granted under the agreement will terminate unless they have become fully paid up as described in the previous paragraph.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Commercial Antibody Agreement with Crystal Bioscience Inc. (Now a Subsidiary of Ligand Pharmaceuticals Incorporated)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, the Company entered into an agreement with Crystal Bioscience Inc. (now a subsidiary of Ligand Pharmaceuticals Incorporated), or Crystal, under which the Company obtained an assignment of certain patents, covering certain SIRP&#945; antibodies. Under this agreement, the Company also received a worldwide, royalty-bearing non-exclusive license, with the right to grant sublicenses through multiple tiers of sublicenses, under certain of Crystal&#8217;s background patents and know-how necessary to commercialize the rights under the assigned patents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the rights granted to the Company under the agreement, it agreed to pay Crystal milestone payments up to $11.1 million in respect of all licensed products developed under the assigned patents, that successfully satisfy certain clinical and regulatory milestones, each milestone being paid only once for all products. The Company also agreed to pay Crystal tiered royalties on net sales made by the Company, its affiliates and sublicensees of products at rates ranging within low single-digit percentages, subject to certain potential reductions. This royalty obligation, on a product-by-product and country-by-country basis, shall terminate and become fully paid-up upon the later of the date on which the last valid claim included in the licensed patents expires and ten years after the first commercial sale of the product in such country.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company agreed to use commercially reasonable efforts to develop and commercialize licensed products, including meeting defined development milestones by certain specified dates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may terminate the agreement at any time for any reason with at least 60 days&#8217; written notice to Crystal. Either party may terminate the agreement if the other party enters into a bankruptcy event or in the event of material breach of the agreement (that remains uncured for 60 days after the date that it is provided with written notice of such breach). The Company&#8217;s obligations to pay royalties and milestone payments which accrued pre-termination or accrue post-termination will survive any termination.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(10) RELATED-PARTY TRANSACTIONS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Related-party revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company entered into a Research and Development Services Agreement, or Tollnine Agreement, with Tollnine, a related-party of the Company, to provide research and development services to Tollnine. The Company&#8217;s Chief Executive Officer was also the Chief Executive Officer of Tollnine until April 2020 and two of the Company&#8217;s investors are also investors in Tollnine. As such, Tollnine was deemed to be a related-party. The Tollnine Agreement had an initial term of 3 years, to be automatically renewed for additional one-year terms unless terminated by either party. The services were to be provided at a price based on the costs incurred by the Company plus a mark-up equal to 10% of such costs. The Company recognized revenue when Tollnine, as the Company&#8217;s customer, obtained control of promised goods or services, in an amount that reflects the consideration which the Company expected to receive in exchange for those goods or services. The Company recognized related-party revenues of $1.2 million, $4.8 million and $2.1 million for the years ended December 31, 2020, 2019 and 2018, respectively, under the Tollnine Agreement. Effective as of July 1, 2020, the Company terminated the Tollnine Agreement and entered into the Tallac Services Agreement with Tallac Therapeutics. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Receivables due from related-party</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company had outstanding related-party receivables from Tollnine of zero and $0.5 million, respectively.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Tallac Service Agreement</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into a research and development services agreement, or the Tallac Services Agreement, with Tallac Therapeutics effective as of July 1, 2020. The Tallac Services Agreement provides that Tallac Therapeutics will provide certain preclinical research services to the Company for a service fee based on the costs incurred by Tallac Therapeutics plus a mark-up equal to 10.0% of such costs. The Tallac Services Agreement has an initial term of four years and is renewed automatically for additional one year terms thereafter. The Company records the payments for the research and development services as research and development costs within the consolidated statement of operations and comprehensive loss. The Company has recorded $0.6 million as research and development costs for the year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Tallac Collaboration Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 4, 2021, the Company entered into a Collaboration Agreement with Tallac Therapeutics pursuant to which the Company and Tallac Therapeutics expect to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. T<font style="color:#000000;">he key economic components of the collaboration transaction include that both parties </font>will share equally (a) in the cost and expenses of research and development and (b) any profit or loss.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(11) NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,740</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,243</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,731</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: cumulative preferred dividends allocated to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stockholders</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,202</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,028</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,671</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,942</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,271</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,402</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,485,343</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076,461</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,750,838</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders, basic and diluted</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.76</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7.56</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods presented as the inclusion of all potential common stock outstanding would have been anti-dilutive. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive securities were excluded from the computation of diluted net loss per share for the years ended December 31, 2020, 2019 and 2018, because including them would have been anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313,808</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,297,081</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase convertible preferred stock</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,292</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,024</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229,912</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857,308</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,745</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">864,819</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857,371</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,592,869</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,391,812</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(12) COMMITMENTS AND CONTINGENCIES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Guarantees and Indemnifications</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company also has indemnification obligations to its officers and directors for specified events or occurrences, subject to some limits, while they are serving at the Company&#8217;s request in such capacities. There have been no claims to date and the Company has director and officer insurance that may enable the Company to recover a portion of any amounts paid for future potential claims. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be a party to various claims in the normal course of business. Legal fees and other costs associated with such actions will be expensed as incurred. The Company will assess, in conjunction with its legal counsel, the need to record a liability for litigation and contingencies. Reserve estimates will be recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. For the years ended December 31, 2020, 2019 and 2018, the Company had no pending or threatened litigation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Other Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has contractual obligations from its operating lease, manufacturing and service contracts and other research and development activities. The following table aggregates the Company&#8217;s material expected contractual obligations and commitments as of December 31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022 - 2023</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2024 - 2025</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligations<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">346</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing and service contracts<sup style="font-size:85%;line-height:120%;vertical-align:top"> (2)</sup></p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,320</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,292</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,028</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,666</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,432</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,234</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Payments due for the office space in Burlingame, California under a single operating sub-lease agreement that expires in 2023. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In November 2015, the Company entered into a Master Service Agreement, or the MSA, with KBI Biopharma, Inc. relating to formulation development, process development and cGMP manufacturing of ALX148 for use in clinical trials on a project basis. The MSA had an initial term of three years with successive one-year renewal periods, is cancellable upon notice and is non-exclusive. Statements of work under the MSA commit the Company to certain purchase obligations of approximately $9.9 million. In addition, the Company has commitments with a second drug product manufacturer that commits the Company to certain purchase obligations of approximately $0.4 million. These amounts are based on non-cancellable commitments and forecasts that include estimates of future market demand, quantity discounts and manufacturing efficiencies that may impact timing of purchases.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation. These payments are not included in the table of contractual obligations above.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Facilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, the Company entered into a lease agreement for office space for a period of five years and four months, commencing February 1, 2018 and ending May 31, 2023.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company (i) assigned to Tallac Therapeutics</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, a related party</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (Note </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">,</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the Company&#8217;s lease with respect to the premises located at 866 Malcolm Road, Burlingame, California, and (ii) received a sub-lease for premises from Tallac Therapeutics.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum rent payments under operating leases are recognized on a straight-line basis over the term of the lease including any periods of free rent. Rent expense was $0.6 million, $0.8 million and $1.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. Sub-lease expenses are recorded within rent expense. &#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(13) SUBSEQUENT EVENTS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Tallac Collaboration Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 4, 2021, the Company entered into a Collaboration Agreement with Tallac Therapeutics pursuant to which the Company and Tallac Therapeutics expect to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. The collaboration builds on the Company&#8217;s expertise in developing therapies that block the CD47 checkpoint pathway and expands its immuno-oncology pipeline. The companies will leverage their respective scientific and technical expertise to advance an anti-SIRP&#945; antibody conjugated to a Toll-like receptor 9, or TLR9, agonist for targeted activation of both the innate and adaptive immune systems. T<font style="color:#000000;">he key economic components of the collaboration transaction include that both parties </font>will share equally (a) in the cost and expenses of research and development and (b) any profit or loss. The Company is currently evaluating the accounting for the collaboration.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(14) SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following presents certain unaudited quarterly consolidated financial information for the&#160;years ended December 31,&#160;2020&#160;and&#160;2019. This information has been prepared on the same basis as the audited consolidated financial statements and includes all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the unaudited quarterly results of operations set forth herein. Net loss per share for all periods presented has been retroactively adjusted to reflect the 1-for-6.5806 reverse stock split effected on July 8, 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q1</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q2</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q3</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q4</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,897</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,314</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,809</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,825</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,437</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,972</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,759</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,774</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.41</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.36</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q1</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q2</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q3</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q4</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,259</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,484</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,290</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,946</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,143</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,178</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,115</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,835</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.71</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.68</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.33</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a><a name="ITEM_9_CHANGES_IN_DISAGREEMENTS_WITH_ACC"></a>Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9A_CONTROLS_PROCEDURES"></a><a name="ITEM_9A_CONTROLS_PROCEDURES"></a>Item 9A. Controls and Procedures. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of our &#8220;disclosure controls and procedures&#8221; as of the end of the period covered by this report, pursuant to Rules&#160;13a-15(b) and 15d-15(b) under the Exchange Act.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms as of&#160;December 31, 2020. For the purpose of this review, disclosure controls and procedures means controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. These disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit is accumulated and communicated to management, including our Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Report on Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Annual Report on Form 10-K does not include a report of management&#8217;s assessment regarding internal control over financial reporting or an attestation report of our independent registered public accounting firm due to a transition period established by the rules of the SEC for newly public companies.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Material Weakness in Internal Control over Financial Reporting</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the audit of our consolidated financial statements as of and for the years ended December&#160;31, 2019 and 2018, we identified material weaknesses in our internal control over financial reporting resulting from a lack of sufficient qualified personnel. For the year ended December 31, 2019, the material weaknesses related to (i) independent reviews of journal entries not being performed prior to posting, (ii) account reconciliations not being performed and independently reviewed on a timely basis and (iii) lack of independent review of technical accounting matters. During 2020, we have undertaken specific remediation actions to address the control deficiencies in our financial reporting. We have established more robust processes related to the review of complex accounting transactions, the preparation of account reconciliations and the review of journal entries. These remediation actions included hiring a full time Chief Financial Officer in January 2020, a Vice President, Finance and Chief Accounting Officer in March 2020 and a Controller in August 2020, all of whom have extensive experience in developing and implementing internal controls and executing plans to remediate control deficiencies. We added new control activities, modified existing controls, and enhanced the documentation that evidences that controls are performed. We concluded that the control deficiencies have been remediated as of December 31, 2020, as the applicable controls have operated for a sufficient period of time and we have concluded that these controls are operating effectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_9B_OR_INFORMATION"></a><a name="ITEM_9B_OR_INFORMATION"></a>Item 9B. Other Information. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a>PART </font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">III </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain information required by Part III is omitted from this Annual Report on Form 10-K and is incorporated herein by reference to our definitive Proxy Statement for our next Annual Meeting of Stockholders (the &#8220;Proxy Statement&#8221;), which we intend to file pursuant to Regulation 14A of the Securities Exchange Act of 1934, as amended, within 120 days after December 31, 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a><a name="ITEM_10_DIRECTORS_EXECUTIVE_FICERS_CORPO"></a>Item 10. Directors, Executive Officers and Corporate Governance. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item concerning our directors, executive officers, corporate governance, Section 16 reporting compliance and code of business conduct and ethics is incorporated by reference to the Proxy Statement. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a><a name="ITEM_11_EXECUTIVE_COMPENSATION"></a>Item 11. Executive Compensation. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item regarding executive compensation is incorporated by reference to the Proxy Statement. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a><a name="ITEM_12_SECURITY_OWNERSHIP_CERTAIN_BENEF"></a>Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item regarding security ownership of certain beneficial owners and management is incorporated by reference to the Proxy Statement. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a><a name="ITEM_13_CERTAIN_RELATIONSHIPS_RELATED_TR"></a>Item 13. Certain Relationships and Related Transactions, and Director Independence. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item regarding executive compensation is incorporated by reference to the Proxy Statement. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a><a name="ITEM_14_PRINCIPAL_ACCOUNTING_FEES_SERVIC"></a>Item 14. Principal Accounting Fees and Services. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this Item regarding principal accountant fees and services is incorporated by reference to the Proxy Statement.</p><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a>PART</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> IV </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a><a name="ITEM_15_EXHIBITS_FINANCIAL_STATEMENT_SCH"></a>Item 15. Exhibits, Financial Statement Schedules. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The following documents are filed as part of this Annual Report on Form 10-K: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:10.47%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements filed as part of this Annual Report on Form 10-K are listed in the &#8220;Index to Financial Statements&#8221; under Part II, Item 8 of this Annual Report on Form 10-K. </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statement Schedules</p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:10.47%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial statement schedules have been omitted as the information required is not applicable or the information is presented in the financial statements or related notes included in Part II, Item 8 of this Annual Report on Form 10-K.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:10.47%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:18pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)</font></p></td>
<td valign="top">
<p style="margin-top:18pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Exhibits </p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:10.61%;text-indent:-0.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The exhibits listed below are filed as part of this Annual Report on Form 10-K, or are incorporated herein by reference, in each case as indicated below.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.71%;text-indent:-5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Exhibit Index</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:8%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:30%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td colspan="7" valign="bottom"  style="width:5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">INCORPORATED BY REFERENCE</p></td>
<td valign="bottom"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">NUMBER</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:30%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT TITLE</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">FORM</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:11%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">FILE NO.</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:6%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT</p></td>
<td valign="bottom"  style="width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">FILING<br />DATE</p></td>
<td valign="bottom"  style="width:1%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:8%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">FILED<br />HEREWITH</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520196288/d47591dex31.htm"><font style="text-decoration:underline;">Amended and Restated Certificate of Incorporation of the Registrant. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39386</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.1</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 21, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520196288/d47591dex32.htm"><font style="text-decoration:underline;">Amended and Restated Bylaws of the Registrant. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8-K</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">001-39386</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 21, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520181021/d913838dex41.htm"><font style="text-decoration:underline;">Amended and Restated Investors&#8217; Rights Agreement among the Registrant and certain of its stockholders, dated April 1, 2020. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.1</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 26, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520181021/d913838dex42.htm"><font style="text-decoration:underline;">Specimen common stock certificate of the Registrant. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 26, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.3</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alxo-ex43_312.htm"><font style="text-decoration:underline;">Description of Securities.</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1+</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520181021/d913838dex101.htm"><font style="text-decoration:underline;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.1</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 26, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2+</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520191500/d913838dex102.htm"><font style="text-decoration:underline;">Amended and Restated 2020 Equity Incentive Plan and forms of agreements thereunder. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.2</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 13, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3+</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520191500/d913838dex103.htm"><font style="text-decoration:underline;">2020 Employee Stock Purchase Plan. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.3</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 13, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4+</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520191500/d913838dex104.htm"><font style="text-decoration:underline;">Confirmatory Offer Letter between the Registrant and Jaume Pons, Ph.D. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.4</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 13, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6+</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520191500/d913838dex106.htm"><font style="text-decoration:underline;">Confirmatory Offer Letter between the Registrant and Peter Garc&#237;a. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.6</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 13, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7+</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520191500/d913838dex107.htm"><font style="text-decoration:underline;">Confirmatory Offer Letter between the Registrant and Steffen Pietzke.</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.7</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 13, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8+</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520191500/d913838dex108.htm"><font style="text-decoration:underline;">Confirmatory Offer Letter between the Registrant and Sophia Randolph, M.D., Ph.D. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.8</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 13, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9+</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520191500/d913838dex109.htm"><font style="text-decoration:underline;">Executive Incentive Compensation Plan. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.9</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 13, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10+</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520191500/d913838dex1010.htm"><font style="text-decoration:underline;">Outside Director Compensation Policy. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.10</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 13, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11+</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520191500/d913838dex1011.htm"><font style="text-decoration:underline;">Form of Change in Control and Severance Agreement. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1/A</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.11</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July 13, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12+</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520181021/d913838dex1012.htm"><font style="text-decoration:underline;">Exclusive (Equity) Agreement between the Registrant and The Board of Trustees of the Leland Stanford Junior University, effective as of March 24, 2015, as amended on April 24, 2015 and May 15, 2015. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.12</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 26, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520181021/d913838dex1013.htm"><font style="text-decoration:underline;">Loan and Security Agreement, dated as of December 20, 2019, among the Registrant, certain of its affiliates, Silicon Valley Bank and WestRiver Innovation Lending Fund VIII, L.P., as amended by the Joinder and First Amendment to Loan and Security Agreement on May 21, 2020. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.13</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 26, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520181021/d913838dex1014.htm"><font style="text-decoration:underline;">Conformed Copy of Amended and Restated Research and Development Services Agreement, dated as of June 18, 2018, between ALX Oncology Inc. and Tollnine, Inc., incorporating Amendment No. 1, dated as of May 3, 2019. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.14</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 26, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520181021/d913838dex1015.htm"><font style="text-decoration:underline;">Research and Development Services Agreement, dated as of June 25, 2020, between the Registrant and Tallac Therapeutics, Inc. (formerly known as Tollnine, Inc.). </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.15</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 26, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#0000EE;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1810182/000119312520181021/d913838dex211.htm"><font style="text-decoration:underline;">List of subsidiaries of Registrant. </font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">S-1</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">333-239490</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.1</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June 26, 2020</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alxo-ex231_746.htm"><font style="text-decoration:underline;">Consent of KPMG LLP, Independent Registered Public Accounting Firm.</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#POWER_ATTORNEY"><font style="text-decoration:underline;">Power of Attorney.</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.1</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alxo-ex311_311.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31.2</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alxo-ex312_310.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.1*</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alxo-ex321_309.htm"><font style="text-decoration:underline;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</font></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32.2*</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="alxo-ex322_308.htm"><font style="text-decoration:underline;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">143</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:30%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:5%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:11%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:6%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:12%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:8%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">X</p></td>
</tr>
</table></div>
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:100%;text-indent:0%;font-size:6pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">+</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates management contract or compensatory plan.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The certifications attached as Exhibit 32.1 and 32.2 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing. </p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>Item 16. Form 10-K Summary</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p><a name="_AEIOULastRenderedPageBreakAEIOU44"></a>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">144</a></p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNA</font><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">TURES</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated<font style="font-weight:bold;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALX ONCOLOGY HOLDINGS INC.</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 18, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jaume Pons</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jaume Pons, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="POWER_ATTORNEY"></a><a name="POWER_ATTORNEY"></a>POWER OF ATTORNEY</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Dr. Jaume Pons and Peter Garcia, jointly and severally, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form&#160;10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Signature</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Title</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.58%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.58%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jaume Pons</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">President, Chief Executive Officer and Director</font><br /><font style="Background-color:#FFFFFF;">(</font><font style="font-style:italic;Background-color:#FFFFFF;">Principal Executive Officer</font><font style="Background-color:#FFFFFF;">)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jaume Pons, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Peter Garcia</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Chief Financial Officer</font><br /><font style="Background-color:#FFFFFF;">(</font><font style="font-style:italic;Background-color:#FFFFFF;">Principal Financial Officer</font><font style="Background-color:#FFFFFF;">)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Peter Garcia</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Steffen Pietzke</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Vice President, Finance and Chief Accounting&#160;Officer</font><br /><font style="font-style:italic;Background-color:#FFFFFF;">(Principal Accounting Officer)</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.58%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Steffen Pietzke</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.58%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Corey Goodman</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Executive Chairman of the Board of Directors</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Corey Goodman, Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Rekha Hemrajani</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Director</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Rekha Hemrajani</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jason Lettmann</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Director</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jason Lettmann</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jack Nielsen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Director</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jack Nielsen</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Sophia Randolph</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Director</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Sophia Randolph, M.D., Ph.D.</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:5pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Graham Walmsley</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.52%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Director</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.26%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 18, 2021</p></td>
<td style="border:none;padding:0;"></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.86%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Graham Walmsley</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.52%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.26%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td style="border:none;padding:0;"></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145</a></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>alxo-ex43_312.htm
<DESCRIPTION>EX-4.3
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alxo-ex43_312.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 4.3</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DESCRIPTION OF REGISTRANT&#8217;S SECURITIES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">REGISTERED PURSUANT TO SECTION 12 OF THE</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES EXCHANGE ACT OF 1934</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The authorized capital stock of ALX Oncology Holdings Inc., consists of 1,000,000,000 shares of common stock, par value $0.001 per share, and 100,000,000 shares of convertible preferred stock, par value $0.001 per share. We have one class of securities registered under Section 12 of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), our common stock, which is listed on the Nasdaq Global Select Market under the symbol &#8220;ALXO&#8221;. For purposes of this exhibit, unless the context otherwise requires, the work &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and &#8220;our company&#8221; refer to ALX Oncology Holdings Inc. a Delaware corporation.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Common Stock</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">General</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;;font-style:normal;color:#auto;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">The following summary sets forth some of the general terms of our common stock. Because this is a summary, it does not contain all of the information that may be important to you. For a more detailed description of our common stock, you should read our amended and restated certificate of incorporation and the amended and rested bylaws, each of which is an exhibit to our Annual Report on Form 10-K to which this summary is also an exhibit, and the applicable provisions of the Delaware General Corporation Law (the DGCL&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Voting Rights</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. Our certificate of incorporation and bylaws do not provide for cumulative voting rights. Because of this, the holders of a plurality of the shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they should so choose. With respect to matters other than the election of directors, at any meeting of the stockholders at which a quorum is present or represented, the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at such meeting and entitled to vote on the subject matter shall be the act of the stockholders, except as otherwise required by law. The holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dividends</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to preferences that may be applicable to any then-outstanding convertible preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Liquidation</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the holders of any then-outstanding shares of convertible preferred stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Rights and Preferences</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our convertible preferred stock that we may designate in the future.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fully Paid and Nonassessable</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All of our outstanding shares of common stock are, and the shares of common stock to be issued in this offering, upon payment and delivery in accordance with the underwriting agreement, will be fully paid and nonassessable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description of Preferred Stock</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our board of directors has the authority, without further action by the stockholders, to issue up to 100,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control or other corporate action. No shares of preferred stock are outstanding, and we have no present plan to issue any shares of preferred stock.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;"><a name="_cp_text_1_3"></a>&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Registration Rights</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_4"></a>We are party to an amended and restated investors&#8217; rights agreement that provides that certain holders of our common stock have certain registration rights as set forth below. The registration of shares of our common stock by the exercise of registration rights described below would enable the holders to sell these shares without restriction under the&#160;Securities Act of 1933 (the &#8220;Securities Act&#8221;)&#160;when the applicable registration statement is declared effective. Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions, to limit the number of shares such holders may include.</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_5"></a>Demand Registration Rights</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_6"></a>The holders of an aggregate of 24,429,399 shares of our common stock are entitled to certain demand registration rights. At any time beginning 180 days after the effective date of our initial public offering and before the three-year anniversary of the date of the investors&#8217; rights agreement, the holders of at least 50% of the shares in the aggregate may request that we file a registration statement to register all or a portion of their shares. Such request for registration must cover at least 40% of the shares or shares with an anticipated aggregate public offering price, net of underwriting discounts and expenses, of at least $15.0 million.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_7"></a>S-3&#160;Registration Rights</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_8"></a>The holders of an aggregate of 24,429,399 shares of our common stock are entitled to certain Form&#160;S-3&#160;registration rights. At any time when we are eligible to file a registration statement on Form&#160;S-3,&#160;the holders of at least 10% of these shares can make a request that we register their shares on Form&#160;S-3&#160;if such request covers shares with an anticipated aggregate public offering price, net of underwriting discounts and expenses, of at least $1.0 million.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_9"></a>Piggyback Registration Rights</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_10"></a>In connection with this offering, the holders of an aggregate of 24,429,399 shares of our common stock were entitled to, and the necessary percentage of holders waived, their rights to notice of this offering and to include their shares of registrable securities in this offering. After this offering, in the event that we propose to register any of our securities under the&#160;Securities Act, either for our own account or for the account of other security holders, the holders of these shares will be entitled to certain piggyback registration rights allowing the holder to include their shares in such registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the&#160;Securities Act, the holders of these shares are entitled to notice of the registration and have the right to include their shares in the registration, subject to limitations that the underwriters may impose on the number of shares included in the offering.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_11"></a>Indemnification</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_12"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated investors&#8217; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them.</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_13"></a>Expenses of Registration</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_14"></a>We will pay the registration expenses, other than underwriting discounts and commissions, of the shares registered by the demand, Form S-3 and piggyback registrations described above.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_15"></a>Termination of Registration Rights</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_16"></a>The demand, Form&#160;S-3&#160;and piggyback registration described above will expire upon the earliest of (1) the fifth anniversary after the closing of our initial public offering, (2) a deemed liquidation event (as defined in our amended and restated certificate of incorporation, in effect prior to the completion of our initial public offering) and (3) such time after the completion of our initial public offering that such stockholder can sell all of its shares entitled to registration rights under Rule&#160;144&#160;of the&#160;Securities Act.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.33%;margin-right:10.26%;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Anti-Takeover Effects of Certain Provisions of Delaware Law, Our Amended and Restated Certificate of Incorporation and Our Amended and Restated Bylaws</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain provisions of Delaware law and certain provisions that are included in our amended and restated certificate of incorporation and amended and restated bylaws summarized below may be deemed to have an anti-takeover effect and may delay, deter or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, including attempts that might result in a premium being paid over the market price for the shares held by stockholders.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Preferred Stock</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation contains provisions that permit our board of directors to issue, without any further vote or action by the stockholders, shares of preferred stock in one or more series and, with respect to each such series, to fix the number of shares constituting the series and the designation of the series, the voting rights (if any) of the shares of the series and the powers, preferences or relative, participation, optional and other special rights, if any, and any qualifications, limitations or restrictions, of the shares of such series.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Classified Board</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that our board of directors is divided into three classes, designated Class I, Class II and Class III. Each class will be an equal number of directors, as nearly as possible, consisting of one-third of the total number of directors constituting the entire board of directors. The term of initial Class I directors shall terminate on the date of the 2021 annual meeting, the term of the initial Class II directors shall terminate on the date of the 2022 annual meeting, and the term of the initial Class III directors shall terminate on the date of the 2023 annual meeting. At each annual meeting of stockholders beginning in 2021, successors to the class of directors whose term expires at that annual meeting will be elected for a three-year term.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Removal of Directors</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that stockholders may only remove a director for cause by a vote of no less than a majority of the shares present in person or by proxy at the meeting and entitled to vote.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Director Vacancies</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation authorizes only our board of directors to fill vacant directorships.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">No Cumulative Voting</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation provides that stockholders do not have the right to cumulate votes in the election of directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Special Meetings of Stockholders</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that, except as otherwise required by law, special meetings of the stockholders may be called only by an officer at the request of a majority of our board of directors, by the Chair of our board of directors or by our Chief Executive Officer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Advance Notice Procedures for Director Nominations</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that stockholders seeking to nominate candidates for election as directors at an annual or special meeting of stockholders must provide timely notice thereof in writing. To be timely, a stockholder&#8217;s notice generally will have to be delivered to and received at our principal executive offices before notice of the meeting is issued by the secretary of the company, with such notice being served not less than 90 nor more than 120 days before the meeting. Although the amended and restated bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates to be elected at an annual meeting, the amended and restated bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the company.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Action by Written Consent</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and amended and restated bylaws provide that any action to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by written consent.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Amending our Certificate of Incorporation and Bylaws</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation may be amended or altered in any manner provided by the DGCL. Our amended and restated bylaws may be adopted, amended, altered or repealed by stockholders only upon approval of at least majority of the voting power of all the then outstanding shares of the common stock, except for any amendment of the above provisions, which would require the approval of a two-thirds majority of our then outstanding common stock. Additionally, our amended and restated certificate of incorporation provides that our bylaws may be amended, altered or repealed by the board of directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Authorized but Unissued Shares</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our authorized but unissued shares of common stock and preferred stock are available for future issuances without stockholder approval, except as required by the listing standards of Nasdaq, and may be utilized for a variety of corporate purposes, including future offerings to raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock may render more difficult or discourage an attempt to obtain control of the company by means of a proxy contest, tender offer, merger or otherwise.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive Jurisdiction</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim arising pursuant to the DGCL, any action regarding our amended and restated certificate of incorporation or amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. This provision does not apply to suits brought to enforce a duty or liability created by the Exchange Act or </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any other claim for which the U.S. federal courts have exclusive jurisdiction. Our amended and restated bylaws further provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed to have notice of and consented to these provisions. Although we believe these provisions benefit us by providing increased consistency in the application of law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers. For additional information, please also see the section titled &#8220;Risk Factors&#8212;Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.&#8221;</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Business Combinations with Interested Stockholders</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are governed by Section 203 of the DGCL. Subject to certain exceptions, Section 203 of the DGCL prohibits a public Delaware corporation from engaging in a business combination (as defined in such section) with an &#8220;interested stockholder&#8221; (defined generally as any person who beneficially owns 15% or more of the outstanding voting stock of such corporation or any person affiliated with such person) for a period of three years following the time that such stockholder became an interested stockholder, unless (i) prior to such time the board of directors of such corporation approved either the business combination or the transaction that resulted in the stockholder becoming an interested stockholder; (ii) upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of such corporation at the time the transaction commenced (excluding for purposes of determining the voting stock of such corporation outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (A) by persons who are directors and also officers of such corporation and (B) by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer); or (iii) at or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of stockholders (and not by written consent) by the affirmative vote of at least 66 2/3% of the outstanding voting stock of such corporation not owned by the interested stockholder.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we must indemnify our directors and officers to the fullest extent authorized by the DGCL. We are expressly authorized to, and do, carry directors&#8217; and officers&#8217; insurance providing coverage for our directors, officers and certain employees for some liabilities. We believe that these indemnification provisions and insurance are useful to attract and retain qualified directors and executive directors.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The limitation on liability and indemnification provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Listing</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;ALXO.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;;color:#231F20;font-family:Times New Roman;font-style:italic;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Transfer Agent and Registrar</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s address is 250 Royal Street, Canton, Massachusetts 02021.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>alxo-ex231_746.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alxo-ex231_746.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors<br />ALX Oncology Holdings Inc.:</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the registration statement (No. 333-239927) on Form S-8 of ALX Oncology Holdings Inc. and subsidiaries of our report dated March&#160;18, 2021, with respect to the consolidated balance sheets of ALX Oncology Holdings Inc. and subsidiaries as of December&#160;31, 2020 and 2019, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#8217; equity (deficit), and cash flows for each of the years in the three-year period ended December&#160;31, 2020, and the related notes, which report appears in the December&#160;31, 2020 annual report on Form 10-K of ALX Oncology Holdings Inc. and subsidiaries.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ KPMG LLP</p>
<p style="margin-bottom:10pt;margin-top:10pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, California<br />March 18, 2021</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:23.72%;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>alxo-ex311_311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alxo-ex311_311.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Jaume Pons, Ph.D., certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of ALX Oncology Holdings Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 18, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jaume Pons</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jaume Pons, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>alxo-ex312_310.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alxo-ex312_310.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Peter Garcia, certify that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">1.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">I have reviewed this Annual Report on Form 10-K of ALX Oncology Holdings Inc.;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">2.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">3.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">4.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;"><font style="font-weight:normal;font-style:normal;text-decoration:none;Background-color:#auto;color:#auto;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;letter-spacing:0pt;">5.</font></p></td>
<td valign="top">
<p style="text-align:left;margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;color:#auto;text-transform:none;font-variant: normal;letter-spacing:0pt;font-family:Times New Roman;font-size:10pt;"><font style="Background-color:#auto;text-decoration:none;"></font><font style="color:#000000;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:49%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 18, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Peter Garcia</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Peter Garcia</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>alxo-ex321_309.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alxo-ex321_309.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of ALX Oncology Holdings Inc. (the &#8220;Company&#8221;), on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 18, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Jaume Pons</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Jaume Pons, Ph.D.</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>alxo-ex322_308.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
alxo-ex322_308.htm
</title>
</head>
<!-- NG Converter v5.0.2.50 -->
<body>

<p style="text-align:right;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.2</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CERTIFICATION PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</p>
<p style="text-align:center;Background-color:#FFFFFF;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Annual Report of ALX Oncology Holdings Inc. (the &#8220;Company&#8221;), on Form 10-K for the fiscal year ended December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-top:12pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 18, 2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;Peter Garcia</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Peter Garcia</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Chief Financial Officer</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gvvh0m1pmdf2000006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (4!YX# 2(  A$! Q$!_\0
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MN;='$:M]QW^\">_04 >N^-/%6A:WX#UV'3-5MKJ1+5RRQ/DC@US_ .S_ /\
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MQTH ^KK>Y@NH$FMY5DB<95E/!%2U@>$+"UTSPW86EE<BZMXX_DF!X89-;](
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHUNLD;;E."<'\30!A_""TU6S\%1)JF\!G+6R.>5BP,#';G->@4Q(U0*%& .
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M'PSH^H364]\6GA<I($4G:?3I6GX:\9Z/XH:4:==J\D1&Z(@AA[\T =+1110
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MZPPHB1(-JHBX51Z 5X]\%](EO[G4_%=W@S7,C*GXG+'\P*]D1=JXH =1110
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MX_&NDK@/A%-?R^ ++[>I^5BL.1UC &T_SKOA2 6BBB@ HHHH **** "BBB@
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M.AR&'J#4] 'GMK\%_!]I.)1;7$NWHLTVX?EBNQO-&M+[2FTR9?\ 12H38O'
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M]NM '0T5!:W,5W;QW$$BR12*&5E/!%3T %%%% !1110 4444 %%%% !1110
M4444 %%%<]XE\8:9X2M8KG5GD2.9MJ>6FXD_3\: .AIK*&!![U2MM8L;JX%O
M%=1-.5#>4&^8#&>GTJ_0!S]GX-T6PU>75+>S1;R7[\A&3^%;IB5EVL,C%/HH
M YNV\#:#9WMU=P6NR:Z#+*0>&!.2*S!\)O" '_(-'7L?_K5V]% '&6OPN\*V
M=W'<PZ>JRQMN5O0UUIMHVC\ME!3&-IZ8J:HY)!&I=F"JHR2: ,'1_!.BZ%?R
M7NGV_DRRYWXZ-]:DUKPAH^OWEO=ZA;"6:WQY;'^'!S5G3/$.E:S-+%INH6UV
M\7^L$,@;;VYQ6H/>@!B1B-%1>%48'TK/US0;#Q%8_8]2A$L&[=M]ZU** ,2\
M\*Z1J&APZ/=VB26<*A8T(^Y@8!'H<5RT?P5\'QW"RBWN6P<[&FROY8Z5Z)5*
M]U2RT\JMU=0PE^0)& R* );>SAM+:.WMHUBAC 5$48  ]*L=JRH?$.E3S)#%
MJ-L\DAPJK(,D^@K4).* %HKF]?\ &FE^&KZSM-2:9'O&"1,L65R3CD]JZ".0
M2 ,#D$9!H DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"[MH[VTEMI<F
M.52C@'J#P16'XE\9Z3X46W.I22 SL5C6)-[$_2MJWN/M%O',N0LBAE##!YH
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M,L+%9(9%VNN.^/3WH Z.BD'(S2T %%%% !1110 4444 %%%% !1110 4444
M%%,D<1H69@ .YKF-&^(&A:Y]K^S7+1K:G;*TR[ #G% '55CZ]X9TOQ+;0P:I
M;B:.)_,53ZUI6US#=VZ3P2++$_*NAR#4U $%O:QVMO%!"-D<2!$4=E P!67K
MGA31_$0A_M*T25X6S&^/F7Z&MNB@#E=3^'GAW6)HY=0M#/)'&L:L[9.T=*H_
M\*F\(;@?[-''O7<44 9.A^'--\.V;6FEVZP0LY<J/4__ *JK:[X.T7Q')%)J
M=FDTD?"N1R!Z9K?K)U#Q'I&E745K?ZE;6T\W^K260*6R<# ^M %R&QC@M%M4
M+&)5V#<<G&,8JCHOAO3?#XNETZ$1"YE\V7W;UK55]P5@05(R#3Z &&/L3QZ5
MD6'A72=,U*[U"UMPMS=L6F<_Q$G)K:HH XC6?A1X4UR]-W/9/#*V2_V=_+W'
MU/')K4\,^!]$\)^8=*MRCR !G<[F(^M="S*B%F(50,DGM66?$VBC_F*6F1V\
MT4 :U%5K2]M[Z/S;:>.:/INC;(S3KNY6SM)KB3=LB0N=HR2 ,\#UH GHK#\/
M>*=.\3VDESIDC.D3^7('7:RMCH16V,[1F@!:*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@!#TYZ5X7X@F?QK\9+70W+/I]@?F
MB+@JQ4Y8_B,?E7NC<@BO&? ]Y!!\8_$UG-"WVBY),+$?="Y)_/- 'H'B_64\
M.>$;N[5A$4B\N''9CPN/QQ7A7AV:^\&^)-#UZ_>26'50S2)G:5W,R<YZ_P!Z
MNF^,6NKJNM67ANSBN;C[.WFW*VPRS?[(&#R ,_C65XV\2R>(_#%KIZ>$=4MF
MLP#'<21'Y0.IX'H#0![Y<:A;VFG-?33+':HF]G8X %>:7?QRTN*^:*STN\O+
M4,!]H5MOUXQVKD->\7W>N?!^S2"28-!.+:^")\NT#*Y..GW?QKU7P#I>E1^#
M=,-M:VKJT09F"ALL>O/US0!P7B3XIV]SXOT&;3[R]ATV/=]LC\DC?Z<$9/X5
MT/BS5O"'BWP@NHZG/J$6FQ7 4-'$5;?SC@@\=:S_ (@1V=M\4O!VY((H29-^
M0%7MU[5J?&J.*'X>%88U0"[CX10.S4P-#1O&/AK3!HWARUN+G=/!']D\R(_.
MI^[D],UN>)/%NF>%+.*YU65XHY&VH40N2?H*\B\7Z1+_ ,*S\+>(;4A9;&)
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MPSI.AP^'; :;!%+:>2OER/&-S CJ>.IKS3Q%;0C]H+2HE@01&"'Y @VGD]J
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MZW1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <WXYT
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M_9KA25A"L'^9,#VK0TKP9=:=\0=8\1M<1-#?*H6( [EP /IVKL4C"# _"GT
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MELXZ8^E=M10 U!M0+Z"O+_$?PIO+G7Y=;\.ZL-,NISF5"#M/T %>I4A&1@T
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M![E169HMO?6>FQ0:A=BZN%^]-C&[\*OB13_$OYT 244SS%_O+^='F+_>7\Z
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M13/,7^\OYT>8O]Y?SH ?13/,7^\/SH\Q?[P_.@!]%(#D9&*6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **YOQ=8:_J$5G'H5^ED5D)N)&Z[<<8'?F
MO/9=?\5^$O'NE:9J6J+?6EX"6&SG'(_#F@#V:BO(+OQ)XF\5^-[O1]"O$L(+
M"-V=_O&3! I/#?Q'U.VT#Q!#K">?J.DD[6'&[D@@^F* /8**\%.K?$1?!O\
MPE3ZB/*9A)Y(3_EGUW?2O8/"^M#Q!X=LM4&!Y\08J#T/<4 ;5%1B1?4?G2^8
MO]X?G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q
M?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q
M?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q
M?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q
M?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q
M?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q
M?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q
M?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q
M?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q
M?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q?[R_G0 ^BF>8O]Y?SH\Q
M?[R_G0 ^BF>8O]Y?SI1(/[P_.@!U%%% !1@'M110!Y+X>X^/GB7_ *Y)_P"@
M+6KXZ^(-OI+'1]'*W>MW!\L1J<B//][\*Z6V\(:;9^*KSQ%$9_MUV L@9\I@
M #@8XZ>M<]JGP?\ #>K:K/J-R]^)YFW,8YP!GV^6@!/ 7@M= T>\EU&5)-1U
M %[EQ_!G.0/SKC?%/PTT7P[X5FUO2-1GBNK5?-C?S/O^@%>@Z#\-]'\.7,]Q
M92WLC3P&!Q--N&T^G'7BN9@^!VE)J!DGOKJ:S!X@+\^V3W_*@#JOAUJ%WJO@
M>PN;Z4S3E-K.>K<=36W_ &+ 226;D]ZLZ=I]OI=E%9VL8C@A0(B#L!TJW0!E
M_P!BV_\ >-']B0?WC6I0>G2@#+_L6W_O&C^Q;?\ O&N$\3_%P>&O$%UI7]A3
M7)@(!E6; ;(!_NGUK'_X7V/^A9N/_ @?_$T >I_V+;_WC1_8MO\ WC7EG_"^
MU_Z%FX_\"!_\31_POM?^A9N/_ @?_$T >I?V);?WC1_8MN>K&O+?^%]K_P!"
MS<?^! _^)H_X7VO_ $+-Q_X$#_XF@#U+^Q+;^\:7^Q;?'WC7EG_"^U_Z%FX_
M\"!_\31_POM?^A9N/_ @?_$TP/4O[%M_[QH_L2W/\1KRW_A?:_\ 0LW'_@0/
M_B:/^%]K_P!"S<?^! _^)H ]3_L6W_O&C^Q;?^\:\L_X7VO_ $+-Q_X$#_XF
MC_A?:_\ 0LW'_@0/_B:0'J?]BV_]XT?V+;_WC7EG_"^U_P"A9N/_  ('_P 3
M1_POM?\ H6;C_P "!_\ $T >I_V+;_WC1_8MO_>-9?@WQ4/%VD-J L9+/]X4
M\MSDG !SG R.:ZCM0!E_V+;_ -XT?V+;_P!XUJ44 9?]BV_]XT?V+;_WC6I1
M0!E_V+;_ -XT?V+;_P!XUJ44 9?]BV_]XT?V+;_WC6I10!E_V+;_ -XT?V+;
M_P!XUJ44 9?]BV_]XT?V+;_WC6I10!E_V+;_ -XT?V+;_P!XUJ44 9?]BV_]
MXT?V+;_WC6I10!E_V+;_ -XT?V+;_P!XUJ44 9?]BV_]XT?V+;_WC6I10!E_
MV+;_ -XT?V+;_P!XUJ44 9?]BV_]XT?V)!_>-:;=.:9GB@+&?_8MO_>-']BV
M_P#>-:*D=S3LCUH S/[%M_[QH_L6W_O&M L,T#(/)Z]*!V,_^Q;?^\:/[%M_
M[QK4HH$9?]BV_P#>-']BV_\ >-:E% &7_8MO_>-']BV_]XUJ44 9?]BV_P#>
M-']BV_\ >-:E% &7_8MO_>-']BV_]XUJ44 9?]BV_P#>-']BV_\ >-:E% &7
M_8MO_>-']BV_]XUJ44 9?]BV_P#>-']BV_\ >-:E% &=%I$$4JN&.5.:T:**
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS'XXX_X0;C_GJO\ ,5Z<
M>G%87B3PO8^*=-^P:@9?)W;OW3;3_(T 4_L-IJ7P\LK&^D\NWFLH$=LXQ\JX
MKR3QYX2TWP%;V6I:%J$L5X95'EM+\S*!SCVR!7L^K>&+35/##:%(TRVYB6(,
MC88!<8Y_ 5Q>A_!71M/NDNM0N)[Z2-PT:LV$'U'.: .8MK^6[^,6AZI>@1->
MV,#8(P"Y0$@?2KVJQG6OC[8?865OL2)).V< !.N/?FN\\7^ M-\76JB<-#=1
M#]S<1\%?;Z5#X-^'EAX0\V:*22XNYAM>60]!Z 4 =3=6:784.2-ISQ5;^Q;?
M^\:U** ,O^Q;?^\:/[%M_P"\:U** ,O^Q;?^\:/[%M_[QK4HH R_[%M_[QH_
ML6W_ +QK4HH R_[%M_[QH_L6W_O&M2B@#+_L6W_O&C^Q;?\ O&M2B@#+_L6W
M_O&C^Q;?^\:U** ,O^Q;?^\:/[%M_P"\:U** ,O^Q;?^\:/[%M_[QK4HH R_
M[%M_[QH_L6W_ +QK4HH R_[%M_[QH_L6W_O&M2B@#+_L6W_O&C^Q;?\ O&M2
MB@#+_L6W_O&C^Q;?^\:U** ,O^Q;?^\:/[%M_P"\:U** ,O^Q;?^\:/[%M_[
MQK4HH R_[%M_[QH_L6W_ +QK4HH R_[%M_[QH_L6W_O&M2B@#+_L6W_O&C^Q
M;?\ O&M2B@#+_L6W_O&C^Q;?^\:U** ,O^Q;?^\:/[%M_P"\:U** ,O^Q;?^
M\:/[%M_[QK4HH R_[%M_[QH_L6W_ +QK4HH R_[%M_[QH_L6W_O&M.EH R_[
M%M_[QH_L6W_O&M2B@#+_ +%M_P"\:/[%M_[QK4HH R_[%M_[QH_L6W_O&M2B
M@#+_ +%M_P"\:/[%M_[QK4HH R_[%M_[QH_L6W_O&M2B@#+_ +%M_P"\:/[%
MM_[QK4HH R_[%M_[QH_L6W_O&M2B@#+_ +%M_P"\:/[%M_[QK4HH R_[$M_[
MQH.B6_JU:E% $%K MM#Y:<@5/110 4444 %%%% !1110 4444 %%%% !1110
M 4444 <WXR\76'A'26N[J0&9AB&$'F1O\*\[\#Z%?>+O$;^,?$8CVGFTAZ=.
M!QZ8_7FO0/%O@32/&1@;4S<YA&$$,@7\^#6+IOP@\.Z9?07D$VHB6!MR*UP"
MOXC% '.?#:ZM=/\ '_BC3[K"W<MP\R.>FS=TS^(_*N9GE%Y-\0'A6-U8N%,2
MXW8;K[_6O3O%OPOTOQ1?-J'F36U\RA3)&WRD 8Y'?\ZTO#?@/2/#V@RZ7'#Y
MRW _TEY.3*??VH XF36[!/V?T03AF:R%IA.2),=#Z5U/PJA9?AUIH=67>F1D
M=1ZUC/\ !'0FU43B>Y%EU^RAN-WL?3VQ7I%C90:?:0VEK$L5O"@6-%'"CTH
MJ?V+ 222W)SS1_8MO_>-:E% &7_8MO\ WC1_8MO_ 'C6I10!E_V+;_WC1_8M
MO_>-:E% &7_8MO\ WC1_8MO_ 'C6I10!E_V+;_WC1_8MO_>-:E% &7_8MO\
MWC1_8MO_ 'C6I10!E_V+;_WC1_8MO_>-:E% &7_8MO\ WC1_8MO_ 'C6I10!
ME_V+;_WC1_8MO_>-:E% &7_8MO\ WC1_8MO_ 'C6I10!E_V+;_WC1_8MO_>-
M:E% &7_8MO\ WC1_8MO_ 'C6I10!E_V+;_WC1_8MO_>-:E% &7_8MO\ WC1_
M8MO_ 'C6I10!E_V+;_WC1_8MO_>-:E% &7_8MO\ WC1_8MO_ 'C6I10!E_V+
M;_WC1_8MO_>-:E% &7_8MO\ WC1_8MO_ 'C6I10!E_V+;_WC1_8MO_>-:E%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH R?MU__ ,^3_G1]NO\ _GR?\ZUJ* ,G[=?_ //D_P"='VZ__P"?)_SK6HH
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M%_\ R,Y_ZY'^8KB*[?X7_P#(SG_KD?YBE+8Y\7_!D>VCI2T@Z4M9GRX4444
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M;X>:!JGAWP_]CU6XAEE5R$V( 50= 3WSUKC?^$^^)7_0I6G_ 'Q)_P#%4?\
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M%R/2SX05]6>X\F.X0A8 -SG!XY/2O,=&\=>'?#R>;9>$!O3&7ERY3T.6)Q3
MZ#PQ\6=<MM0T_3O$NG.4N6""X,91R2< XX'Y"O;8R&0$'@\UP6BII7Q.TFQU
M>^T]H6LYR8%#%<'CGCJ*[Y%V(% X P*0#Z*** "BBB@ HHHH *#THH/2@#QC
MQG_R-=[]5_\ 016!6_XT_P"1KO?JO_H(K KOA\*/$J_&_46BBBJ,Q*[SX9?\
M?M__ +B?S-<&:[SX9?\ '[?_ .XG\S6=7X#HPW\1'I7>BCO17$>N%%%% !11
M10 4444 %&:*P[[Q3I>FW36]Q.%D7J,&FDWL)R2W-O-&17.#QOH9_P"7H?\
M?)J>Q\3Z5?72P6]QND;H,&CE9*J1?4W:*:IS3J11R7Q"_P"19;_KJM>3#K7K
M'Q"_Y%EO^NJUY/WKLH? >9C/XOR%HHHK4Y J[HW_ "&;3_KH*I5=T;_D,VG_
M %T%*6S*A\2/=^U+2=J6O//<04444#$/6LG7_P#D!7?_ %S-:QZUDZ__ ,@*
M[_ZYF@TI_&CYSE_US_[QIM.E_P!<_P#O&FUJ?51V04444%!7OG@7_D5[?Z5X
M'7OG@7_D5[?Z5$SS<S_AHE\;_P#(I7O^Z/YU\_5] ^-_^12O?]T?SKY^IPV)
MRS^&_4****H]0*GL_P#C]B_WA4%3V?\ Q^Q?[PH>Q,_A9](:?_R#;?\ W!7!
M_%O_ )!EE_UT-=YI_P#R#;?_ '!7!_%O_D&67_70UFMSYW"_[PO4\DHHHK0^
MD"BBB@#H_!'_ "-%K_O5[\O;Z5X#X(_Y&BU_WJ]^7M]*SEN>%F7\1'B_Q1_Y
M&5/^N(_F:X:NY^*/_(RI_P!<1_,UPU7'8]3"?P8A1113.D*[?X7_ /(SG_KD
M?YBN(KM_A?\ \C.?^N1_F*4MCGQ?\&1[:.E+2#I2UD?+A1113 **** "BBB@
M HHHH **** "BBB@ J.4*4(;IC!J2HI@I0@\ @Y/M0!\[>.M'\$Z7J-U<:?K
M-Q'J>3(L,!)"L>GS?_7K*\+?$'QCI2@VYGU"RC))CDC+CWRP&?UI;VZ\)Z%X
MFU/S+"ZU>,2["\GR(IR>1M/0^_I7H7@[XAV&NZRGA^'P]'9)*C!@D83C'?'K
M0!VG@3Q8OC#0%U'REBF1S%/&H.%<<X&?8BNJW#UK'\/^&=.\,VDUOID31Q32
MF9@7+?,?K]*\U^)'Q2U'0-2FTG2+66*:!AYMS+&"C9 /R]?7% 'L6]1^-&]<
M9STKD]7\3OHGP^CUZ=?.G^RQR;1@;F8#^IKS5_'7CW2;73->U183I-W*=T7E
MJ"JG.,G&>G(Q0![N6 &:-P]:\H\8?$#5)=4TW1O"!CEN[R-9_-*@X1AE>&XP
M0<_A5KPCXOUH>+[GPGXF\F2]13)%=1X57 [8XZ]N* /3J*;N]J6@!:*:V.])
MDB@!]%,!R,]*7\:+@.HIOXTGXT7 =FEIF['O2JV>QH =1244 +1244 +1244
M +1244 +6#XP_P"1:O/]T?S%;M8/C$_\4U>?[H_F*J'Q(SJ? R_HG_($LO\
MK@G_ *"*T*SM$/\ Q)++_K@G_H(K1S2>Y4?A04T]"12FD+8'-(H\VU;QMJ-C
MK%S;1QQE(WVC-9ESXWO+M=D]I;R+Z$5F>).?$=_C_GJ:RZ[8PC9,\BI6GS-7
M-"^U4WFP&T@CVMNR@QFK<?B,Q!-NGVVY,8.WTK$I*NRM8R4Y)W.O_P"%B:J%
MP(H?RKK/!NOW>NI<M<*@$14#;[Y_PKR0]*]&^&/_ !ZZA_OI_(UC4A%1NCJH
M5IRFDV>@44E%<IZ0M%)10 M)FD8\4W*CGO2'8DS135/>ER*!"T9I,BD)&*=P
M#</6FMZCK31CL*7)W'CM2'8\O\2^/-3TC69;:!4*KZBL@?%#63SLA_*LSQY_
MR-%Q]:YFM$E8^AH8:E*FFT='K'C*_P!9\O[0J9C;<,"M*'XEZQ#"(U2+ 'I7
M%44[(W>'IM<K6AW'_"T-:_N1?E7<^!?$EYXB@N)+H(#&V!BO#J]9^$G_ !Y7
MG^^*4DCBQN'IPI-Q6IZ4#ZT;AZU!=2F."1AU52:\9O?'VL0WTT4<@"JY X%0
MCS*&&E6^$]M+#;G-<)XG/_%::/\ 0UPQ^(FM8'[P?D*H7?B[4KR_@O)''F0_
M=XI\K.RE@*D'<^@ 1^E/##'6O"Q\1-9!/[P?E2?\+#UK_GJ,?2CE9G_9U0]V
MR,5B>(]0FTO1IKF$ L@R,TWPI?S:EX>M;J<YD=<DU6\;'_BF+GC^&D<M.%JJ
MBSSH_%#602 D6/I3?^%G:STV0_E7$GJ?K25IRH^@6%I?RG0Q>+;R+7Y-75$\
MYUP1VK6_X6=K/]R'\JXBBCE13P].6Z.]A^)NLRS1QLD6&8#@5[#;,SP([8RP
MR:^:+3_C[A_WQ7TM:?\ 'I%_NBHDK'E9A2A3MRJQ8HI*,^U(\L6BD!ZTM !1
M110 4444 %%%% !1110 4444 %<!\2]+\-:CI<#^);TV:1.?(E7);G&<*.O0
M=J[^O)OC7;Z.=/T^YU2:XWQ.WDP0*"9"<9R3T P.GK0!Y"-9NM U$+X5UN[E
MB!_=H5)(_P" XQ^E>F^$_BSJDNLVFD^(M/,37!"I-L*L2>!D'WKF-%^('A[0
M(S]B\**&4 >;(-[ _5LXKUC3=%T;QO;:-XIO+%H[Q4#Q+O*[,,<9 /K0!VT8
MQ3Z100,'FEH J7%A;73H]Q;12LGW6DC#$?3-6B"5P.*6B@"J+.W^V?:C;1>>
M!M$NP;L?7K5JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** #O7#_$K_D%V_\ OG^E=QWKA_B5_P @NW_WS_2M*?QHPQ'\
M-GF5%%%=QY 4444"+FD_\ABU_P"N@KW9>WTKPG2?^0Q:_P#705[LO;Z5RXC=
M'I8+X6/HHHKG.T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** . ^*VAZAKWA-(-.M6N)H[
MA)/*7&2!G/6O,/$T>L6-W?M!H.^RUBU6%5P#Y#\XQMSAAG]:UO%&N^+O%/CZ
M\\/>'+J6UCMF,9*2E!P<$DCM6)>^&OB!X TS[2FINE@CEG6TN&8*>Y*X I@>
MM_"G2=0T?P5!;ZB&29F+B-CRBG&!^E=Q6)X2U=M=\,6&INH5[B(,R[LX-;=(
M HHHH **** "BBB@ H/2BD/2@#QGQI_R-=[]5_\ 016!VK?\:?\ (UWOU7_T
M$5@"N^'PH\2K\;]0XHXI:*L@3M7>?#+_ (_;_P#W$_F:X3M7=_#+_C]O_P#<
M3^9K*K\)OAOXB/2N]%'>BN(]<**** "BBB@ I">*6JFH71LK.6X";A&A;'KB
M@5[%C?[&L^XT;3[J8RSVD3L>K,@)KCF^)FUB/[/!Q_TT_P#K4A^)A(_Y!P_[
M^?\ UJU5*:,'B:3W+,NCV/\ PFL5L+:/RO*SLVC'Y5U<&BZ?;2"2&TA1QT8(
M,BO-F\:$Z^NI?9!E4V[-_7WZ5K?\+-;_ *!X_P"_G_UJJ5.;,X5Z2N>@Y"TH
M;->>-\2V./\ B7KUY/F?_6KM].O1?Z;;787;YR!L>F:RE"4=SHA5A-VB8'Q"
M_P"19;_KJM>35ZQ\0?\ D6&_ZZK7D]=-#X#S\9_%^04<4M%;'()5[1O^0S:?
M]=!5*KNC?\AFT_ZZ"E+9E0^)'N_:EI.U+7GGN(****!B'K63K_\ R KO_KF:
MUCUK*U__ ) 5W_US-!I3^-'SE+_KG_WC3:?+_KG_ -XTRM3ZJ.R"BBB@H*]\
M\"_\BO;_ $KP.O?/ O\ R*]O]*F9YN9_PT2^-_\ D4KW_='\Z^?J^@?&_P#R
M*5Y_NC^=?/U$-A99_#?J%%%%4>F%3V?_ !^Q?[PJ"I[/_C]B_P!X4/8F?PL^
MD-/_ .0;;_[@K@_BW_R#++_KH:[S3O\ D&V_^X*X/XM_\@RR_P"NAK..Y\[A
M?]X7J>24445H?2!1110!T?@C_D:+7_>KWY>WTKP'P1_R-%K_ +U>_#M]*SEN
M>%F7\1'B_P 4?^1E3_KB/YFN&KN/BE_R,J?]<1_,UP]7'8]3"?P8A1113.D*
M[?X7_P#(SG_KD?YBN(KM_A?_ ,C.?^N1_F*4MCGQ?\&1[:.E+2=J6LCY<***
M*8!1110 4444 %%%% !1110 4444 %17 +1LHQD@CFI:XKXI>(KCPWX,FN;3
M_CYFD$",&P4+9^8?3% 'D>I^!]?M;?Q%9OIXV3W$<L,Q88D"%B=G<YS6OX'7
M6-?^)%OK,FC"PCM;?R9W085V&>3TR3_2L^V\"_$CQ!!9ZI-J>)(SYEM]HNF#
MQD]QP<=!70?#7Q9KUOXONO#'B.>2:8*=K2L2RE>3R>N>*8'M/5>O45Y;\<+>
M)?!9F"+YID52^.2,CC->I?P\>G>N5\<^%CXQT#^SOM/D9<-O"YZ4@.&^)L-W
M)\+O#DD"N8(A UR0> GE@<^V<4?$V6"7X3:2\$BLI$(4J>#^[KT:[\.6NI>$
MUT"]S)"+9(2P']T#!_,5Y]!\&3MM[&[U^XFTVW<R1VGEX3.<^O7F@#FO#A$?
MQ0\-NYVJ^EVRJ2.I\L=*U?$*BZ^/VD_9@)#$8VEV<[<=<UVOB?P!;:['I\ME
M<OIE[IX"VLML/]6N.@'&.@J+P?\ #N/PWK%UK%U>RZAJ-QG,\BXZ]>YR3Q0!
MVUS;-<(JK,T6/[O>JO\ 94G_ #_3_G6G10!EG2'/_+]/^?\ ]>L7Q,EUI6BS
M74-[,77  )]Q76]JYCQU_P BO<?5?YBG'XE<BH[0;1YZOB[6E&/MA/X4O_"8
M:U_S]G\JPZ*[O9Q['D>VJ?S&Y_PE^M?\_9_*C_A+]:_Y^S^58=%'LX]@]M4[
MFW_PENM$\WAY]J]1M=-EDMHY&OY\LH)YKQ,=17OMC_QX0?\ 7,?RK"M%+8[,
M).4F^9W*G]E2?\_T_P"?_P!>C^RI/^?Z?\__ *]:=%<YW&9_94G_ #_3_G_]
M>C^RI/\ G^G_ #_^O6G10!F?V5)_S_3_ )__ %Z/[*D_Y_I_SK3HH R_[*D_
MY_I_SH_LJ3_G^G_.M(U@:UXLLM$NE@N5E+,N[Y%SQ32;T1,I**NW8N_V5+_S
M_3_G6-XIT]X?#UTYNY7 4?*?J*B_X6-I'_/.X_[X'^-9FO>-M.U/2)[2!)@[
M@8+(,=?K5QIRYEH8U*U-P:3.CTG3I'T>S?[9,N84X';@5=_LR3_G^G_.N8TW
MQ]IEKIUO Z3EHXU4X08R!CUJR/B-I/\ SSN/^^!_C2=.=]BHUZ2BKLWO[,D_
MY_I_S_\ KTO]E2#I?S?G531?%%GKLSQVRR H,G>N*W>U0TT[,UC)25XGAWB!
M#'K]ZI8L1+U/?BLVM7Q+_P C)?\ _74_R%95>A'9'BU/C8G%%+13($/2N]^'
M=HUS;7VV=XL.GW>_!K@CTKT?X8_\>VH?[Z?R-9U?A-\-_$1UG]E2?\_T_P"?
M_P!>C^RI/^?Z?\__ *]:=%<1ZYF?V5)_S_3_ )__ %Z/[*D_Y_I_S_\ KUIT
M4 99TES_ ,OT_P"?_P!>O./'&M:IH&K1VUM>R,I3=R:]:->,?%7_ )&*'_KG
M36YVX",95;2V,4^.-=R<7C_G1_PG&O?\_CUSG>BKLCW/JU+^4Z/_ (3C7O\
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M_AY9QW=S?))NP%0@J?<UE5^$WPW\1'I/VN'/^N2C[9#_ ,]DJI_8=KG[TO\
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M%_USIK<[LN_CG!]Z*.YHK0^B"BBBF!VOPQ_Y&Q?^N;?R->W&O$/AC_R-B_\
M7-OY&O;C64MSY[,?XQX)X\_Y&>X^M<Q73^//^1GN/K7,5:V/:P_\)!1113-P
M'6O6?A)_QY7O^^*\F'6O6?A)_P >5[_OBE+8X<P_@,]!OO\ CSF_W#_*OG#4
MO^0E<_\ 70U]'WW_ !YS?[A_E7SAJ7_(2N?^NAJ8G)E?4J44459[(4444"9[
M]X"_Y%"R_P!VE\;?\BQ<_P"[2> O^10L?]VE\;?\BQ<_[M9/<^;_ .8GYG@)
MZGZTE*>I^M)6I](M@HHHH&3VG_'W#_OBOI:S_P"/2+_=%?--I_Q]P_[XKZ6L
M_P#CTB_W142/'S3[)8HHHJ3QPHHHH **** "BBB@ HHHH **** "BBB@"M=_
MZF7C.4../:OF[PYJ7C7PFUT--T-B]P^Z222W+,V,XY_&OH77].DU71KRQBE\
MIYXBBOC.T^M>(1ZE\1_ 3M#=6;7UDA"[FC,BHH_NL.A_.@"KKOBGX@^(=*FT
MZ]T(B&4?,5MB"/UKV'X;6\UEX T>UN8FBGCA(=&&"#N;K7F8^*GC#4C]GTWP
M\&N3T @9\COP*ZOX>>&/$\.LS:_XDNV,TBE$MV.2%Q^G7IB@#TZBBB@ HHHH
M **** "BBB@ HHI,CL: .?\ &5OK%UX?EBT6]6SN,Y>8\%4 R<'L>E?.,7B+
M7I?&4=\-1B%W,/LB7[\(5'&[/Y<U]3W=O%>6LEM,H>*1=K*>XKEH/ASX=@TR
M/3Q9EK9+G[2%9@<-SQTZ<]* ,S6K#Q5;^![6-?$"6UQ;+ONKPO@L /7TZYKQ
M;P_J^O7GBV>:VU"*TO\ 5&V-=R-MSV^4^IKZ<OM.M=3L)+*[@66VD78\;#@B
ML>V\":!:V>GVOV(21V#%H=_)W''S$]SP* .<\:CQ38>&+*_BUP6KV$9DN&4X
M$[=E//(.!^=>1>!KKQ!/KTD.FZA'IUQJ!\QI7.TR8;.%^I%?2>LZ'9:]I4NF
MW\6^WE7:0#ROH0?6J$?@K0HY;"5;!?,L(Q' V.5&2?YDT ;MD)EM8EN'WS!%
M$C#NV.?UJQ4:<,2?PJ3(H **** "BBB@ HHHH **** "BBB@ [UP_P 2O^07
M;_[Y_I7<=ZX;XE?\@NW_ -\_TK2G\:,<1_#9YG1117<>.%%%% %S2?\ D,6O
M_705[LO;Z5X3I/\ R&+7_KH*]V7M]*Y<1NCT<%\+'T445SG:%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4TL!UI<TAYXH!
M#=W.,4[\:RM=O+NPTR2>QMS/,N,(!G-<+<^/?$5E%YESH[1IZLI%"-Z="51>
MZ>G_ (TT$XR>U>;0>-_$MRB.FC.T;]&537H%C++/:0R3(4=D!92.AH%4HRI_
M$6T)(S3J:M.H,0HHHH C=XR-CX((.01P167::KH-Y="WLKRPEN,9"0R(S8]<
M#FN/^,=[=67@DFW<Q[[A$=T."%.<]*\3LUTW2M9U,V>H22P2:9-]FG8E6+D<
M#C&#3 ^L8SU&0<<4^O/?@U<75QX%1KN261Q,P5I,DE<#N>O>O0J0!7/:YX/T
MOQ#>VUUJ$;2/;',0#< YS70T4 5Y8%DA:(J-C*5(]CQ7$K\)?#BS^8T4TB97
M$3R91<>@KOJ* (K>%+>%8HXU1%& %&!4M%% !0:*#TH \8\:?\C7>_5?_016
M#6]XS_Y&N]^J_P#H(K KOA\*/$J_&_46BDXHXJR KO/AE_Q^W_\ N)_,UP?:
MN\^&7_'[?_[B?S-95?@-\-_$1Z5WHI"<4SS5QU'YUQ'KF7K5MJD_EG3KA(B/
MO;AG-<=JVI>(])OK>UFO$=IOND+[UZ+O')R*\_\ &C[O$>EGT']:UI.[L<^(
M5H\US;LK3Q(MU$]Q?0O"#EE"]1^==,N[O3%88!XZ4[>N<DUFW=FT8V1)6;KG
M_(%OO^N+?RJ\D@?..U4=;.=$O?\ KBW\C1'<)_"SPUOO'ZTE#??/UI*]$\,6
MBDXHH .X^M>Y>'/^1;T__K@O\J\-[CZU[EX<_P"1;T__ *X+_*N>OL=F"^)F
M+\0?^19;_KJM>3UZQ\0?^18;_KJM>3]ZJA\!.,_B_(6BCBDXK4Y1:NZ-_P A
MFT_ZZ"J-7M&_Y#-I_P!=!2ELQP^)'N_:EI.U+7GGN(****!C3UK+U_\ Y 5W
M_P!<S6J>M9.O_P#("N_^N9H-*?QH^<Y?]<_^\:;3I?\ 7/\ [QIM:GU4=@HH
MHH*"O?/ O_(K6_TKP.O?/ O_ "*]O]*F9YN9_P -$OC?_D4KS_='\Z^?J^@?
M&_\ R*5[_NC^=?/U$-A99_#?J%%%%4>F%3V?_'[%_O"H*GL_^/V+_>%#V)G\
M+/I'3O\ D&V_^X*X+XM_\@RR_P"NAKO=._Y!MO\ [@K@OBW_ ,@RR_ZZ&LX[
MGSN%_P!X7J>24445H?2!1110!T?@C_D:+7_>KWX=OI7@/@C_ )&BU_WJ]^7M
M]*SEN>%F7\1'B_Q2_P"1E3_KB/YFN&KN?BC_ ,C*G_7$?S-<-5QV/5PG\&(4
M444SH"NW^%__ ",__;(_S%<17;_"_P#Y&<_]<C_,4I;'-B_X,CVT=*6D'2EK
M,^8"BBB@ HHHH **** "BBB@ HHHH **** "F/GH#3ZCF.V,L!D@&@#/O[_1
MM/9/[2N+.W:3.PW+*N['IGK5VWGMI8$>V>-X6&4:,@J1[8KY1\3W;:QJ.N7V
MIW4JWD-RHAMLG&&)W8!Z8P*[/P3J,4OQ$T:#3;F5H18XN4W,5\T9SQTZ8Z<4
M ?05% Z44 %%%% !1110 4444 !Z5R_CG_D5KCZK_,5U!Z5R_CK_ )%:X^J_
MS%5'XD15_AL\BHI*.*[SQ!:*2B@!1U%>^V/_ !XP?]<Q_*O AU%>^V/_ !XP
M?]<Q_*N>N=V"W98HHHKF/0"BBB@ HHHH 3M7E?Q&_P"0_#_UP'\S7JG:O*_B
M-_R'X?\ K@/YFM:'QG-B_P"&<?12<4<5V'E"T4E% '<_#?\ Y"%S_NBO3*\S
M^&W_ "$+G_=%>F5Q5OC9ZV%_A(\0\2_\C'?_ /74_P JRJU?$O\ R,=__P!=
M36579'9'F5/C844G%%,@#TKT?X8_\>U__OI_(UYP>E>C_#'_ (]K_P#WT_D:
MSJ_";X;^(COZ***XCUPHHHH 0]*\8^*O_(Q0_P#7.O9STKQ?XJ_\C%#_ -<Z
M:W.[+OXYP?<T4=Z*T/H@HHHH [7X8_\ (V+_ -<V_D:]M->)?#'_ )&M?^N;
M?R->VFLY;GSV8_QCP3QY_P C/<?6N8KI_'G_ "-%Q]:YBK6Q[6'_ (2"BBBF
M;@.M>L_"3_CRO?\ >%>35ZS\)/\ CRO?]X4I;'#F'\!GH-]_QYS?[A_E7SAJ
M7_(2N?\ KH:^C[[_ (\YO]P_RKYPU+_D)7/_ %T-1$Y<KZE2BBBM3V HHHI"
M9[]X"_Y%"Q_W:7QM_P BQ<_[M)X"_P"10LO]VE\;?\BS<_[M9/<^;_YB?F>
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MH 0XP<UY1K?BWXAVFL7,&FZ#;S6D;XBD:)R6'KP:]8INTYR* /&O^$V^*?\
MT+5K_P!^'_\ BJ/^$V^*?_0M6O\ WX?_ .*KV>CF@#QC_A-OBG_T+5K_ -^'
M_P#BJ/\ A-OBG_T+5K_WX?\ ^*KV?FCF@#QC_A-OBG_T+5K_ -^'_P#BJ/\
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M%[RUFG2)DC;!!.>1R*\.\2Z+X8\+>(TLT;4-06("2:-MH4C^[Q@_C7N7Q-T
M>(/"$L"W<5LT4@F$DK87C/%>+Z)IVDN=4-[XBL+K4;N!K:#>96Y<$$DLO4<4
MQGO/@*^TW4/"5E-I4/D6H3:(2<F,^A/>NGKC?AGH,_A[PC':7$\,[.YD#PG*
MX( Z_A794@"BBB@ HHHH **** "@]**#TH \8\9_\C7>_5?_ $$5@5O^-/\
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M_'[%_O"A[$S^%GTAI_\ R#;?_<%<'\6_^099?]=#7>:?_P @VW_W!7!_%O\
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MH."7X->OKIE]QBY'3^\:Y<1NCT<%\+-O=[&C=[&L;^S+_P#Y^1_WT:/[,O\
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M&<_]<C_,5Q%=O\+_ /D9S_UR/\Q2EL<^+_@R/;1TI:3M2UD?+A1113 ****
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MW#UK&^U:G_SQ'_?!H^U:G_SQ'_?!I#-@D9ZUE:^1_85WS_RS-1FZU3_GBO\
MWP:S=:N=1;1[D20J%*'/R&@TI?&CPF7_ %S_ .\:;3I/]:_^\:;6I]5'9!11
M104%>]^!2/\ A%K?GM7@E>T^#[B_3P[ L,09 .NTFIF>;F?\-&OXW(/A*]Y_
MA'\Z^?Z]M\77%^_AF[6:(!-O)VGUKQ*B&PLL_AL****H],*GL_\ C]B_WA4%
M3VF?M<>.NX4/8F?PL^D-/(_LZVY_@%<'\6B#IEE_UT-=)8W6I_8(-L*[=HQ\
MAKC?B9+=R:=:_:8PH#G&%Q6<=SY["_[PO4\RHHHK0^C"BBB@#H_!'_(SVO\
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MK7'U7^8KJ#TKE_'/_(K7'U7^8JH?$B*O\-GD-%%+7H'B"44M%( '45[[8_\
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MW#_OBOI:S_X](O\ =%1(\?-/LEBBBBI/'"BBB@ HHHH **** "BBB@ HHHH
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MBC_R,J?]<1_,UP]=S\4?^1E3_KB/YFN&JX['JX3^#$****9T!7;?##GQ.?\
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ME+0,[CX;_P#(0N?]T5Z97F?PW_Y"%S_NBO2ZXJWQL];"_P -'B/B7_D9+_\
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M:S_X](O]T5\TVG_'W#_OBOI>T_X](O\ =%1(\?-/LD]%%%2>.%%%% !1110
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M3_6-]:J![65_#(;1115GK!3E^^OUIM.7_6+]:"9;'T5X7_Y%^U_W!6-\2/\
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MLM/O].U+4TCMH'!@69@,9SG!_ 5J:C\#M,U+4KB^EU:Z5IY#(P6,8!/I5?\
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MW6F:ZD\4\J^=AAF/!&=V.,<U]":?XAT>^>."UU"WEF89V(^2:\Q_X4!HY/\
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M_P ]U_[Y%<5\-_\ D(7/T%>F5Q5OC9ZV%_A(\,U\.-?O1(<OYG)K.K5\2_\
M(R7_ /UU/\JRJ[([(\NI\;"BBBF0(>E=U\/4O&M[W[+(% 9,@CV-<*>E>C_#
M'_CVO_\ ?3^1K.K\)T8;^(CJ/*U;_GNOY"CRM6_Y[K^0K7HKB/7,CRM6_P">
MZ_D*/*U;_GNOY"M>B@#(\K5O^?A?^^17DOQ)6X778A<,&;R^,5[@:\7^*O\
MR,4/_7.G'<[LN_C(X/O11WHK0^B"BBB@#KOAV)V\2@0-M?8><>QKUXPZM_SW
M7\A7E'PQ_P"1L7_KFW\C7MQJ);GS^8_QCY^\:"0>(IA*07[D5SM=/X\_Y&BX
M^M<Q5+8]G#_PT%%%%4;A7IOPP2\:SO/LT@0;AGBO,J]9^$G_ !Y7O^\*F6QP
MYA_!9UMW%JOV64M.I&T]A7@>HY_M&XSUWG-?2%]_QY3?[A_E7SAJ7_(2N?\
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M+_C]O_\ <3^9K@^U=Y\,O^/V_P#]Q/YFLZOP'1AOXB/1W^Z:\#O?^/\ N/\
MKJW\Z]\?[IKP.]_X_P"X_P"NK?SK*ANSIQNR(*.***ZCS@XH-%!I >L?#O\
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M5?YBNH/2N7\<_P#(K7'U7^8JH?$B*O\ #9Y#1Q117>>('%%%% "CJ*]]L?\
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M2,D8KN?[8M/[Y_*N*K\1[&&_AHT**S_[8L_^>A_*C^V+/_GH?RK,W-"BL_\
MMBS_ .>A_*C^V+/_ )Z'\J -"BL_^V+/_GH?RH_MBS_YZ'\J *_BC_D7KO\
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M_P!=3_*LJNR.R/+J?&PI*6BF2(:]'^&/_'M?_P"^G\C7G!Z5Z/\ #'_CVO\
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M9[]X"_Y%"Q_W:7QM_P BQ<_[M)X"_P"10LO]VE\;?\BQ<_[M9/<^;_YB?F>
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M8KI_'G_(SW'UKF*N.Q[6'_AH****9N%>L_"3_CRO?]X5Y,.M>L_"3_CRO?\
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M"CBBBF(*]F\&?\BO9_[M>-=Z]E\&?\BM9_[M<]?8[<%\;)O$XQX>N_\ </\
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MY_N#^M>OUF]SYS,/X["BBBD<04444 %%%% !1110 4444 %%%% !0>E%!Z4
M>,>,_P#D:[WZK_Z"*P*W_&?_ "-=[]5_]!%8 KOA\*/$J_&_46BBBJ,Q#7>?
M#+_C]O\ _<3^9K@Z[SX9?\?M_P#[B?S-9U?@9T8;^(CT=_NFO [W_C_N/^NK
M?SKWQ_NFO [W_C_N/^NK?SK+#[LZ<;M$AHHHKJ/."D-+24@/6/AW_P BV?\
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MKW9>WTKFQ&Z/2P7PL?1117.=H4E+24 4-9_Y ]U_UR:OFR3_ %C?6OI/6?\
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M^E9=3YO_ )B?F> GJ?K24K Y/UI*U/I$] HHHH&3VG_'W#_OBOI:S_X](O\
M=%?--H#]KA_WQ7TK9G_18N/X142/'S3[)9HHI"<=JD\<6BD!S2T %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4=J*IZAJ$&G6,]W</LAA3>[>@
MH MY!I:\@7XU[7-ZVA71T8RF)+L'"D_EU]J]3T[4K?5;""]M'\R"= Z-Z@T
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M4*,W"]/^^J]A* T! *3DWN7&G&&J1XOJNG_%O6+,VMQIVG^63GBX3_XJL$>
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ML:5);Z/IUQ8VUD5C$<\87.1G/!Y]S78T@"BBB@ HHHH **** "BBB@ HHHH
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M.K;4+*W\ZX2WA4(P/7"BO)?"GBK3;/6IM=\1Z?J=_JTK'81"&2+GC&3_ $H
M^@-#CN(-$T^*Z+>>EO&LFXY.X*,Y/?FM*J=A=+?6EM=*K*LT2R!6Z@$9JY0
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M10!QFM^$]5\)ZY>ZKJFB)?:6T[$D_,H0MD'/8]!7O?@+7+;7_!]G>VEH;6
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M9LX5M[6*!,[8D" GK@#%("Q1110 4444 %%%% !1110 4444 %%%% !1110
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MIA^!VB>7L_M'42@Y"F4$?EBNBN?AQH-QX5AT'RGCMXFWAU;Y]W<YZ=AVI@>
M^);5X;#3-0M=!.E6\GS0R[MS.P[YP*Z?QI;2^&/%OA_Q+'RMS!#)*^WOM ;\
M<"NNMO@A:/:>3J>LW4Y1B(O+;:JKZ8(/-9/Q;U?1WT^/POY$[ZE9"-;9QT/
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M^R^7J^L3W.P_NO)&P(.XP<^U=)K?PMTK5M L;!)Y8)]/A\JWN,C/'3=QS^E
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MT!Q^=%% $N!Z4444 %&!Z444 %%%% !@>E%%% !@>E&!Z444 )@>E+@>E%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1@>
ME%% !@>E026-I++YDEK \G]YHP3^=%% $V .@%+@>E%% "8&,8X-1PVUO;@B
M""*('J$0+G\J** ):3 ]*** %HHHH **** # ]*,#THHH **** "DP/0444
M+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gvvh0m1pmdf2000005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,V!Y@# 2(  A$! Q$!_\0
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MIEU(+(1\RB/(!^N:]6\Q/[PH\Q/[P_.DZDF-48(\L_X5 W_04_\ (7_UZ/\
MA4#?]!3_ ,A?_7KU/S$_O#\Z/,7^\/SI<\BO9P['EG_"H&_Z"G_D+_Z]'_"H
M&_Z"G_D+_P"O7J?F+_>'YT>8O]X?G1SR#V<.QY9_PJ!O^@I_Y"_^O1_PJ!O^
M@I_Y"_\ KUZGYB_WA^='F+_>'YT<\@]G#L>6?\*@;_H*?^0O_KT?\*@;_H*?
M^0O_ *]>I^8O]X?G1YB_WA^='/(/9P['EG_"H&_Z"G_D+_Z]'_"H&_Z"G_D+
M_P"O7J?F+_>'YT>8O]X?G1SR#V<.QY9_PJ!O^@I_Y"_^O1_PJ!O^@I_Y"_\
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M"G_D+_Z]>I^8O]X4>8O]X4<\A^SAV/+/^%0-_P!!3_R%_P#7H_X5 W_04_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% '#^"O'!\17#65V@CO%4L-@^5@/Y5VY(49->)_"W_D<S_U[/_,5
M[1,?D ]:TJ)*6AA0DY4[LA=RQYZ4VBBI*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \
M1^%O_(Z'_KVD_F*]HGZ"O%_A;_R.9_Z]I/YBO:)^@K6K\9S8;^&044=J*@T"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#"\9?\BAJ?\ UQ-<W\+/^09<_P"_
M72>,O^11U/\ ZXFN;^%G_(,N?]^K7PF;^-'I,'W:EJ*#[M2UFSH6P4444AA1
M110 4444 !Z5YA\%/^0-KG_85E_D*]//2O,/@I_R!M<_["LO\A0!Z?1110 4
M444 %%%% !1110 4444 %%&:* "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHS0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!XC\+?^1S/_ %[2?S%>T3]!7B_PM_Y'
M,_\ 7M)_,5[1/T%:U?C.;#_PR"BBBH- HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO"'CF?Q-K$UJUHD,:1[P0^2>0/2FXR2N"J0;L=W1114EA1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >(_"W_D<S_P!>TG\Q7M$_05XO\+?^1S/_
M %[2?S%>T3]!6M7XSFP_\,@HH[45!H%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% 7"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** N%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHTPWPLCF16B;<,\=Z\+TQ%/Q-C7'R_;6X_$U[O(?W;?2O"]+_P"2GI_U_/\
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M7"#G+E13\9>,X?#T!@@99+YQ\J=E]S7EVEZ3JWC/5F<NS9.9)GZ+4>D:9?\
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M3(DP^#@8[GFNY^ A_P"*>U;_ *^E_P#0:S/AF?\ B[OB,^\__HT46"YK^/\
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M8I'&N6^8=CCI^-8'Q'\:W?@VQM+BTMH9S,Q#"4GC&/0^]>#VVJZHGQ"_M1+
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M_P \SD[@O8?[Q_I2N-QN>IY%+D5XSXN^*.L#Q1/X>\.VBBXCF\E9' W,X."
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M444AA1110 4444 !Z5YA\%/^0-KG_85E_D*]//2O,/@I_P @;7/^PK+_ "%
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M$88$#Z9KO/"_@O2?",=RFEI(OV@J9-[ELXSCK]:W+6UM[*W2WMH4BA085$7
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M:14(W'&:0-:CZ*8DJR#*$,,XR#2[\'!IA9CJ*C\U>F1GTI6<*<-Q]: L/HI
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M5))[D2DULCUO^U]/_P"?R'_OJC^U]/\ ^?R'_OJO)?\ A7/B7^[#_P!_Z/\
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M,/Y(<H-XP<C'^-<^_P +/#KR,P^U("?NI* !^E;%G9Z3X-TCRUE,%KYF2\K
MY8\<FE+E^R5#GO[VQX[XIL)/#GC!VA4JJRB>'<<Y&<_S!K7^&^FMJOB>;4I@
M=L.Y^G#,W;]<T_XEZOI6JSVGV&1)ITSOE3D;>PS]<UW/P^T4:5X9B9E99[G]
MY(#V]/TQ5.7NF48+VGD=8.E+116)UA1110!XC\+?^1S/_7M)_,5[1/T%>+_"
MW_D<S_U[2?S%>T3]!6M7XSFP_P##(****@T"BBB@ HHHH \P^+WB'4;&VL=%
MTMWCN=0<KO3K@8^7\<_I68WPFU#3]$COM-UR[_MR%1("7_=LPYP >GXT_P",
MZWEC>Z'KELF4LY3N?&0I.,?R-=5=_$SP_:^%O[6BO8YG,8V0*?G9L=-O4<U'
M4TZ:'G7P5NA8:CXENKMO]3 KRGZ,Q-&A:;K'Q4U^]O\ 4-3EATJWD*(L#;?H
M%_,'GUJ#X16YUF3Q9;J2GVRTV9_N[BW/ZUI?"S7+/PIJ&I>&]7;[+,TY=)9?
ME5L #&3TX&>:&,J:U8:Q\)]>M-0LM1EGTBXD",LS;B>.0?7C)!%6_B]?W%U'
MX=N;&:1&N4#Q[6*_>Y&?SIOQ9URU\47NF>'='/VR=9Q(TD7S*"1C''7@YH^)
MUJUB/!]J^-\ BC;'J" :!$.O?#J_TOP9/K]UK-RVK1?Z1, QV<GH!ZY(YZ5)
MX1\-:I\1M*;5M=UF[VQYBMQ$X7)'4G]*]&^(_P#R3G6_^O?^HK&^"W_)/(_^
MOB7^8IV"YE_"*74K75M?T2]O'GCL'1$W'(!^;./R%3^*_"5I?^)9[KQ!XM^R
MV[C_ $:W2<1,@_'K3?AV<?$'QGZ^>O\ -JX;P=;:1X@\9ZE)XRNRS1D^7%=2
M;%8Y.<],8&/2D.VIHZ%>KX-^)=K86&N-J6EW>%(64/RWR@,1W!YK2^*]Q/%\
M1_#*1S2(K"+*JQ /[TUR]^_A[_A:6DQ>&[=(;.*>)7V%B&??R02?3%=)\6_^
M2E>%_I%_Z.--"8WXURWB^*M"AL[B2*22+"[6P-V_BK&K?"V^M_#<^JMJ][-K
M*IYS+YN$+=3Q^=0_&/\ Y'OPS]%_]&5[%J:A])N\_P#/!S_XZ:+7%>QRGPL\
M07/B#P?#+>R>9<PN8V;&,@=#]:[29_+C9N@ )->9? W_ )%";_KN?YFO2[I2
M]O(H."RD TUL#7O'AFGOJ7Q9\57GGWL]KI5EC;#$V&&2<'/<\4>(]+U7X57]
MMJNDW]S<V,QV2I,2V,>I]\\4_P"&VLIX,\4:IH6O.+4RN#$TBX7.3D[O0\<Y
MQ5[XJ^)[?Q!%;>&=$>.]N)Y5,GE\A<$8PW3KUJ2B]XZ\(VNL:#/XF-[=I*UN
MLGE+)A.GI4?PK\$6K:-I7B3[;>"X^<^3YG[OJR],5U/BBW>U^&%Q!)]^.U"M
M['%+\*/^2:Z3_NR?^AM32U"3T.S/W:\*\4>&_$7@OQA/XET&.2Y@N9&:150L
M1N.XA@.=N>_M7NI( R>E<G=_$7PO!=7-E<7X2:!BDBM&W4=>W--DQ;,?P1\4
M;#Q/+'I]VGV74ROW2<*Y[X_PZUROBW_DX'0_K;_S-8]I<V7B/XU6-UH,6+2-
MU9BJ;>%ZMC\:U_%G_)P.A_6W_F:2&RC\4;I['XN:7=1P/.\,4#B)/O.0[<#W
MJ'QG\0;_ ,56T7AQ=*?3Y+B9%;[2<'J,=<8YK0^(&#\;M"![BW_]&-74?%SP
MK_:GAI=1LTVW5B?-^3 RO\1)Z\#FD"-C3=%D\/?"Z;3)I1+)!8S99>AR&/'Y
MUY5\./B)IGA'0KJUO(I9)9)-ZA/I]*]&\->)X_$WPOO9=P-S;V4L,X ( 8(<
M=>O&#6'\$M.L[OPU>/<6L,K"? +Q@GI[T]P,;PK!?>,OB6OBT6;V=C;CS"6&
M0V%VX!]>]:YU7Q?XZ\1:C#X?U/\ LO3].8QL^ Q=L\9'O@_2O5IK*/\ L^:V
M@C2)71E C 7&17D'PJU/3_#&J>(M&U&\2"X6?*M.V X3(/)XSR*+6'>Y1OO%
MGC)-9T_PE+>R6VJ+,(WNDP1*IZ$C\#7NL61&H8Y;')KPFU\0Z3JOQJ&K7>(K
M *8K::3A2ZD8;/XU[I;3Q7-ND\,B21.,JZ'((]0:(DS1+1115$!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^&K2\>&V$PM=IX7?G!)]:;)2/:[7Q/HEY<+!;ZM92RL<*J3J2?PS6E/=6]K
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M+Q5=:)9W9MUNG<RGLRJ2:]_\ >#G\&:3<637 G\Z;S=P&,< 8_2A,322.N)
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M*2]@N'WDR$;DXQ@@ 8_&N['2J1#"BBB@04444 %%%% !1110!A^,?^12U/\
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M#TKX8Z7I]ZES-)+<%#E48C;[9XKND4(H50 !P *=13;;W!12V"BBBD,****
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M>\\-3"["_/'',^"WM\W2OH>#3K*VM/LL%K#';\_NE0!>>O'2J'_"*Z!YF_\
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M *XFN/\ A-TU3_MG_P"S5HO@9C+^(CU2#[IJ6HH/NFI:R9U+8****0PHHHH
M****  ]*\P^"G_(&US_L*R_R%>GGI7F'P4_Y VN?]A67^0H ]/HHHH ****
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M &%9?Y"O3STKS#X*?\@;7/\ L*R_R% 'I]%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!XC\+?^1S/_7M)_,5[1/T%>+_  M_Y',_]>TG\Q7M$_05K5^,YL/_
M  R#M1114&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A^,?^12U/_KB:Y#X3
M=-4_[9_^S5U_C'_D4M3_ .N)KC_A+TU3_MG_ .S5HO@9C+^(CU.#[M35#!]V
MIJR9U+8****0PHHHH ****  ]*\P^"G_ "!M<_["LO\ (5Z>>E>8?!3_ ) V
MN?\ 85E_D* /3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q'X6_P#(YG_K
MVD_F*]HGZ"O%_A;_ ,CH?^O9_P"8KVB?H*UJ_$<N'_AD%%%%0:A1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%4M5U.VT?2[C4;Q]EO;IO=J +M%<5X3^(EOXLOQ;V^E7]O&\32QS3H K!2
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M5&EV[$=VC!)H]P$JC6IQ?_"V;KMI47_?T_X4R7XFZO)'B+3%C;L>6_I7>?\
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M["4EN&*/U#S 9HY ]I?9'KFX=S4$]];6Z;IID09QR:\D_P"$ \4N0'* #O\
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M(0#E449_V:OX]J,47'RE/R6S]T_6G"-\_=JW12N/E16\E_:CR7]JLT47#E1
M(#W.*/L_N/RJ>BBX^5$7D#'6CR%]ZEHI7"R(_*6G>6G]T4ZB@+#?+4'[HI<
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M*U%%%26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !2Y/K244 .\Q_[QH\Q_P"\:;10 _S'_O&D\Q_[QIM% QWF/_>-
M)D^M)10%PHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.>.O^10OO]VN
M6^$W35/^V?\ [-75^-XS)X0U#G[L>ZN5^$O35/\ MG_[-6D?A9E/^(CU.#[I
MJ6HH/NFI:R9TK8****0PHHHH ****  ]*\P^"G_(&US_ +"LO\A7IYZ5YA\%
M/^0-KG_85E_D* /3Z*** "BBB@ HHHH *SM?_P"1<U3_ *])?_0#6C6=K_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 444C,JJ2S  =230%NPM%<[JOC/1-*)6:]5Y ,A(_FS^(KE+OXN1;=
MMEITC.3QYAX/Y&BYO##5)*Z1Z;17E ^(OB:X/[C11CMB)R*LQ^+/&LL7F)HJ
M[?<$'^=*YI]3EU:/3J*\M_X6!XF@&9]"RN>2(WJ_:_%2S,B17UC/;L3AF(X'
MX=:+DO"U.AZ'165IGB+2M5 -I>QOG^$G!_(UJ]>E,PE!QW"BBB@D**** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH PO&7_(H:G_UQ-<C\)NFJ?]L__9JZ[QE_R*.I_P#7$UR/
MPFZ:I_VS_P#9JTC\+,I?Q$>IP?=-2U%!]TU+63.E;!1112&%%%% !1110 'I
M7F'P4_Y VN?]A67^0KT\]*\P^"G_ "!M<_["LO\ (4 >GT444 %%%% !1110
M 5G:_P#\BYJG_7I+_P"@&M&L[7_^1<U3_KTE_P#0#0!RGPA_Y)]8_P"])_Z&
MU=Y7!_"'_DGMC_OR?^AM7>4H[#EN%%%%,04444 %%%% !1110!7O)4@MY)9
M2BJ20!GBN*O?#_AOQ=I#:C90H967(DC.&!]".WY5W,R"2-D89!&#7E>BNWA;
MXB76CNVRRO?FB7MD_=%'4Z:%[-Q>J..?PK%YNU+EE /)89J_:_#Y+K[NMVRG
M_;0K_.MW4[;[)J4\'9'('N*J5?+<]:\I133"'X5*S R:Y:E<\[#S6U:_#/PW
M;L'N-1>4CDJTB@&L<.PZ,P_&D+,>K$_C2Y492IU);R.S@_X1/P^I6SMHBX_N
MJ6)/UYJCJ'C"XG!CLXQ"I_B/)KF:*:2%'#13O+4=)(\SEY'9F/4DTVBBJ.A*
MVQSUWG3M?CN,8BFX//>O:_"NHB_TF,%LO'\I.>M>1:[:?:=.8K]^/YA71_#C
M6_WD<;M]\;&SV(Z5#1SXJGST[KH>KTM)UI:D\8**** "BBB@ HHHH **** "
MBBB@ I.]+2=Z %KC/B1KITCPS)'&Q6>Y_=I]._Z9KLB0.M>"_$W7!JGB-K:)
MB8;0;.O!/4G]<4'3A:?/41S.B:=)JVLVUD@+&60 _3J?TKW/Q)<1Z1H4.G0<
M901@=]H'_P!:N+^$NBB2XN-6E7Y8QLCR._<_TK1\2W_V_5I,']W&=J_A3BM3
MNJ?O*RCT1D4445H=8UHT<@NBL1ZBC^R- O%"W-FUNV>9+=N?Q!S3J*5D3)70
MC?#S2+T9T_6O+]1<@#^@H7X2W+C*:S:,OL#2_C4BS2J,+*X'LQI<IGR5.DA(
M_A(R8:YUB )_%M&#^%+I^E^ M.U V]S>2W4R':PD4[=P]" *J:EJ,MM822-,
MY.,*"QZUP*^9+.#DEW;K[U+5@]E.7Q2/<QXELK%5MM(M$2,D '&!_C17/>&+
M)IM1LX'^;9@N?I13T1R552IOE9A?#?\ Y'&W_P!T_P Q7NDW^KKPOX;_ /(X
MV_\ NG^8KW2;[E54^(\:A\!6HHHJ2PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5:^%F4OXB/4X/NFI:B@^Z:EK-G2M@HHHI#"BBB@ HHHH #TKS#X*?\@;7/\
ML*R_R%>GGI7F'P4_Y VN?]A67^0H ]/HHHH **** "BBB@ K.U__ )%S5/\
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M-261HH[F20;&P=P)]O>L?P1\/]#US7?$=M>).8["Z"0[' XRW7CV%=A\&?\
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M>/;RQU&Z?3@]U)F8DKL!)()]CQ^==7>^!/#ZQAYO&D%QA@JJL@D;).!@9]Z
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ME*H(2N""1UR#Z5K2^&+:;P;_ ,(TTTHMOLPMO,&-^T#&>F,\5N44!=G(^#?
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M[F>(J<D&SM+:%8+>.)1@(H J;M1VHJ3P6[NX4444 >#_  W_ .1QM_\ =/\
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M:*Y+5_B/X9T>\>TGU!&G0[9$3G:<9YKH-)U2TUG3(=0L91+;S E''?!P?U%
MK.Q+>WD&GV4MW<R".&)=SL1T%5M&UJPUZP6]TVX6>W8D!P".1UZU0\<?\B5J
MO_7'^HKSSX<>,]$\,^ +.+4KQ(Y'EE81CEB-U)L:6A['6;/KFFVVH)837D27
M3XVQ$\G-5/#_ (OT3Q*CG3+U)63AD/WA6#K>C^$F\<Z?>ZA=&+6BR"VCWM\Q
M!XXZ=Z+Z: EKJ=T#FEK+O]?TK1Y[:WO[V."6Y;;$'_C-<]=?%/PG;W7D?VDC
M\X+J#M%%T%F=K14%O>6]U:1W,$JO"Z[E<'@BN3U'XG>%],OVM)-1#R+PVP9"
MFBXE%F[>^(M-L=8MM*GN0EY=?ZF(@Y?UJ6]US3M.FBAN[N.&67[BL>6KRK5M
M9L-=^+'A*]T^X2>%MXW*>^#76>,].\)W.LZ;+XAO/)NUS]E7<PW<C/3\*E-E
MN*3U.Y!S2UC:OXFT7PX84U6_CM?.SY?F9^;'7^8K$NOBEX3MKW[,VIHQZ%U!
MV@U5R+':453T[4K/5+&*\LKA)[>0961#P:YW6/B/X;T6]>TNK]#/&VUT3DK]
M:=PLSKJ*Y6U^(OA2Z6,QZQ#NED$:J<YW'H.E=4#D9'>@&K!1574=1M-*LI+R
M]G6"WC&6D;H*Y*+XK>$Y;OR/[25><"0K\II7!*YV]%1)<0R1+(DBM&PRK \&
MN3U/XE^%]+N6MI=21Y4;:ZQ\[33NAI,[&CCUKC=;\?Z):^&I;ZVU2%99K=VM
M"03N< X[>M<C\,/B';RV=U'XBUA?MT]X/)20GD%5  ].:5PY6>HW&KV5K>QV
M<]U&EQ*,I&3RU7A7&ZY9>%YO&>F7&HW935U0_98]Q&X<]NGK6W8>)M&U#4YM
M,M+Z.6\@!\R+D,,'!ZCUI)ZC:TT-BJ%YK-AI\\<%W=1PRR_ZM6ZM3=7UW3-"
MM1<:G=I;0EP@9\_>/;]*Y/Q*G@[6+W1=1U34-LL@+V)#,!)TYQ^76FWV%%7W
M.[5P5!/&1T-.KS#XF>.K33-"GLM)U.-=7CD5#& =RKWJ_P" ?'&D7?AG3[6Z
MU=9=32W+SJY9GXR23Z\47!H] HK,TCQ#I.O1R2:9>QW*QML<IG@^G-1ZEXGT
M;1]0M["_OXX+JXQY4;9RV3@?K1<1KT444Q!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% $5S<1VMM)/*VV.-2S'T KG_P#A/?#O_013_OEO
M\*W-0M!?:=<6I8H)HV0L!G&1BN!'PGM_^@G-_P!^A_C5)1ZDR<T_=1T7_">^
M'?\ H(K_ -\M_A1_PGOAW_H(K_WRW^%<[_PJ:V_Z"DW_ 'Z'^-'_  J>V_Z"
MDW_?H?XT[0[D\U3L=%_PGOAW_H(K_P!\M_A1_P )[X=_Z"*_]\M_A7._\*GM
MO^@I-_WZ'^-'_"IK;_H*3?\ ?H?XT6AW#FJ=CHO^$]\._P#017_OEO\ "C_A
M/?#O_017_OEO\*YW_A4]M_T%)O\ OT/\:/\ A4UM_P!!2;_OT/\ &BT.X<U3
ML=%_PGOAW_H(K_WRW^%'_">^'?\ H(K_ -\M_A7._P#"I[;_ *"DW_?H?XT?
M\*GMO^@I-_WZ'^-%H=PYJG8Z+_A/?#O_ $$5_P"^6_PH_P"$]\._]!%?^^6_
MPKG?^%36W_04F_[]#_&C_A4]M_T%)O\ OT/\:+0[AS5.QT7_  GOAW_H(K_W
MRW^%)_PGGAW_ *""?]\M_A7/?\*FMO\ H*3?]^A_C37^$\&P[-4E+=LQ@#^=
M%H]PO4[%;Q&?!NMNUS%J*V]T1RRHV&/N,?K7/Z%XKO?#5\T,<_VNR#;2N3@C
MU7/2M/4? 5II4!FN]8CC4=B.37%3K$LS+"[/&#PS#!-:12>AC-R3N]#Z&TO5
M;;6+*.ZM9 \;#D#J#Z&KU>8?"N&^6>ZE(=;,J,9Z,WM^E>GUBU9G3&7,KA11
M12&%%%% !1110 4444 <=\2[99_"<KG.8F#K]>G]:XOX4,!XBN!ZVY_F*])\
M7V9OO"]_ OWC'D?@0:\F^&UXMIXMB1A_KT,?X\'^E)[GIT/>PTHGNG:O(+F%
M[?XL1><,>9>*Z^X)KU_M7D_Q$CGT_P 56FI*,*578?=>O\ZT@W>R/(JI6NQ/
M&:,GB.8L,;@&'TI_@K2UU/7H_-3=#"/,;G'/;]:L>,D6[%CJT+AXIX@H(]O_
M -=5?".O0:#?32W$;O'(@7Y.QK>[<-#AM%5M=BUX[U62\UIK+;MAM<!<'J2.
MOZU<\#ZC#'IVIV$DBQLZ%P[G Z8KE/$.IVUUJ]S>1DK%(V5#=>@KEKF_DN&V
MQY5>@QU-3-J,+';A<-4KU7-;=S0GUBXTZ\D6RN"KH2AD0\'Z5%:Z'J%_;2:C
M*KBW!^::3^(GMZFM?PCX5L]9G9+^^^S2$XBCVY+FO7[KPY;R^&X-):8110A<
MNH S@8K%ZRO(]252GAZ;IX??N>+0PK;JHC !4Y!K:UC7[O6EMUN=H\E<#:.I
M[FNJUZ3PSI6CW&GVL<4UV5*@A0S*?=JX'M75&S5TCYVLYJ6KO<Z/PA)Y]S/I
M$IS!=QD?-R$;!P0/6L"XB-O<RPGDHQ6IM-OFT[48;M &,; D>HI=3NDOM2GN
MHXA$LK;M@Z#BJ2:D0VG"W4I-]T_2NA^%JY\07C>EN?\ T(5S<[[(6/M7=?"J
MUVV%Y=-%AG<*CD=1W_6LZKTL;89>]<]#)Q7@7CR\^W>,+QNOEGRA_P !XKWB
MZE$-O)(> BEOTKYTFDDUGQ$TJ(2]S/N"CW.:Y&?19?'5R/=?"$)M_"FFQ%2I
M$"Y!]:W*AMH_)@2,#A5P*FIG!4=Y-A103BN0U?XC^&='O'M;C44::,X=$&2I
M]Z5R4F=?17)VWQ%\,S::=0;4HXK;S/*W.#P^,XZ>E;VEZQI^M6*WNG7*7%NQ
M(#IT)'!IW"S+U&1GJ*Y]?&_AR34VTU-4A:\1BC1 '((ZCI7CGQ!^)5Y/K_V7
M0=7!TS:C>9""#N_B^;K2N-1/H.BL31?%&CZS9--8ZA%,L*CS&!.%^N:PKOXJ
M^%+2X,7]HB7'5D&11<.5G<45D:'XDTGQ# TNF7L5P$.&"]5-07/C/P]9ZI+I
MMQJD$=Y$,O$Q.1QN_E1<5F;U%<-!\5_"<UT(3J 7+;0Y'R__ *J[$WUL++[8
M9D^S!-_F9XV^M%T#3+%%<+-\6?"44VP:@)!_?0<5U6E:SI^L:>MY8W4<\!'W
MT/2BX[,T**Y63XC>%%MYYEUB!U@(#A<YR>@Z>U0:5\2O#6KWR6<%^JRR$+&K
MC&X^@HN@Y6;6M^)=(\.Q1R:M>I:K*VU"ZD[C^ -:-M<)=0QS1-OCD4.K8Z@\
M@UPOQ.TK0-4L;!==UC^S8TD)C;;NWG'2NF_M+3- \-VUS=7BI8Q0HJSL#RN
M ?QXHN.QM45P8^+?A,R[/MYQG&[;Q]:[*PU"TU*SCNK.=)X)!E74\&BXFK%J
MBBBF2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!A>,O^10U/_KB:Y#X2]-4_P"V?_LU=?XR_P"10U/_
M *XFN/\ A,>=3'_7/_V:M%\+,I?Q$>J0_=J:H8/N_C4U9'2M@HHHI#"BBB@
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MR11D1@9_ 8KU4=*X?P/8DR37C=!\BUV]#/%QDE*I9=!:***DY0HHHH ****
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MLZIZ$/MS^0KV+3%:/2;17!5EA4$'J"!7C_PZT#58?$7BL7%I-;+=P2I#+(F
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M<P/^]M))VB)&0"J BJ?PA\,Z7XBL]2U?6+.*]N)+@IB= RC@'(![Y-=#\-M
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MYQC],TO(>ECT5?NTM'2BK,@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IKC*D D$]_2G44 >-
MZ[X)\0R:PQ&^]21\+.6)(7MN]*WM ^&<,16?5W\QP<B*/[OXGO7HN!Z"EQ5\
MSL0J2O<AM;6&SMT@MXUCB0855& *FHHJ"PHHHH **** "BBB@ HHHH BN(Q-
M!)$>CJ5/XU\^2))X<\7D+\OV:X.W/]W/^%?0Y&:\H^*NALEU%J\2_(X$<I]Q
MT_0&DSOP,TI.#ZGJ5O<)=01S1'*2*&4^H-<O\0=(&H>'))T4&6U_>*>X'?\
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M94#QN"&4C@BIJ2@+V/ O&W@VX\.7[7=JC-8NVY&'6,^AJMI?B".1!%=L%D'
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MQ7&(+: YAMRN",'@;>J\\U[-[4M%"5@;N(0",$#GBFK%'']R-%SUV@"GT4Q
M !T%,>*.3&^-'_WES3Z* $5550%  '8#%-:&)F#-&A8="5'%/HH%J)@9S@?E
M2\444#U$ &. *" 3R <4M% 7#\*8L,:$LL: GN%I]% 'BVL6OC/X@WUOI-YI
MDEAIL$N9Y&4H)0&ZC/L!QZU[!86<=A8P6L0Q'$@0?@*LT4DAN5PHHHIDA111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]2XD_E6A;Z#J%Y-)%9VDTA"@K)*AB7_Q[K2<T.-*3=D4K2TFOKE+>W0R2,>
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MA?G_ %>WI]:]7HI-:#3L1K#$"&\I WJ%%2444Q7&-#$Y&^)&],J*<JJJ[5
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M%% !1110 4444 %9VO\ _(N:G_UZ2_\ H!K1J&\MDO;*>UD)"31M&Q'4 C%
M'#_"%U'P_L1D9W2<?\#:N\WK_>%>8K\$-$3(CU?5XUSG:DX 'Z4[_A2>C_\
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MI_6OKC3[N._T^WNXO]7-&L@_$9KY_P#CIX?6RUZWU>"!(XKI=DK \O(.^/\
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M/!L/AZ#S9]LEZX^9NR#T%;&B>'=/T&V$5I JM_%(>6/XUL4TB:^*YER0T0@
M%+113.$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKG_85E_D* /3Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P \JVG%N6ART9Q4;-G745R4?Q(\/2-CS9T]VCP/YU?A\:>'YD#?VE N>SN
M:AQ:+4T]F;U%8P\6: >FK6GT\P5H1:C9SA3%<1N&Z;6ZT68TT]BS12;UZT9%
M(8M%)D=:,YH 6BDS2T %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML+K.ENP5-2M&8] )E.?UHLQW1>HJ)+B"3[DT;?[K U("#T(I#%HHR/6CKTH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBBD 4444 *&*G(X-5?%=FFI:(-00?Z3;_?QW7UJS5BUC6Y66TD.(YXRC"F
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M7Q-9R/\ 9PYQ_%%+MS^M/E7<'.6]CV;<.V#^-+FO%?\ A&O&BGB.]Q_U\_\
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M:=;?]]-3Y&+VL4>KYHR*\AE^)FLS[Q#;11ENFT%MM5!XR\7R %9)B.Q%L/\
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M_P"^O\:]%A\+Z/;OO2PASC'S+G^=6QH^F@8&GVO_ 'Y7_"GS1[ HS_F/(O\
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M![CZ#^8KF/#C%==MAZOBF2>UCI2T@Z"EJB0HHHH **** "BBB@ HHHH \O\
M@]_J=4_WH_\ V:O2KCHM>:_![_4ZI_O1_P#LU>DW'\-:3^(PI? 0T445)044
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 +N;^\?SI=
M[_WC3:*!C_-?UI?.?VJ.B@+DHG;N,T[[1_L_K4%% 7)Q..ZT[SU]ZK44AW+/
MG)[THE7UJK118.8M^8G]X4NX'O5.BBP<Q=S15*EWMV-%A\Q<HJIYC_WC2^8_
M]XT6#F+5%5O.?VI1,W?%%@YD6**@\_VH\_\ V?UHLQW1/147GKCD8I1.GO2"
MZ)**C\U?6E\Q/[PH"X^BFAU/0BG4 &****!A1110 4444 %%%% !1110 444
M4 %%%% !1110 W:#U%'EI_=%.HH$,\I#VI/)2I**=PLB+R%]Z:;<=C^E3T47
M"R*_V;T;]*0V[9]:LT47"Q5-N_M33;$CE<U<HHNQ<J,J;2;6<GS;5'R,'<O6
MJ#>$=")RVCVA^L0KI**?,Q."9R$_@;P_.N#I\<?O& IJBWPT\/L20EP,^DM=
M[BDP#U%-2:)=*+/-KKX6:;(F+:ZFA;/5AOK//PH7&1JI/_;'_P"O7K&Q#_"*
M3RD_NBG[1B]C'L>,3_"[4U+>1<0OC[NX[<U5/PT\0+T%L?I(?\*]O\E,YQ1Y
M">_YT>T9/L([GA%Q\/\ Q#;1>9]F63G[L39/\JK)X9\40C:FGWBCK\JFO?S;
MKZTW[,,]?TIJH)T-3P]8/'<(PHU1!Z D4I'CQA@MJI'^\:]O-OQD')IOV=O[
MHHY_(?L?-GAD^F>,[H#SK?49 .0&R:K#PGXDN),R:;<@GNXKWSR']!1Y+^@I
MJIY$NC?J>)K\-O$)&=MLO'>4_P"%6K;X7ZL[#[1-!$O?8=Q_I7LGV?(Y-+]G
M_P!K]*GVC*]@CRP?"=3UU4_]^?\ Z]:%I\+-,C0?:;J:9L\E1LXKT3[..YI?
M(7WHYV-48K9'##X9^'@"-ER?^VO_ -:K4'@#P_ X86GF8[2'(KL/)2E\M/[M
M+G8U278YH>$- '_,)M#C_ID*L0>'=(M6+0:;;1DC!*Q@5O;$S]T4N!Z4N8KV
M:W,Z.VB0 )&J@=,"I1$>R\?2KF!Z4M',Q\J*?E-_=-*(7ST(JW12N/E*H@>E
M$+=ZLT47#E1!Y'^U2^1[U-11<=D1>0G>CR$]ZEHHN%D1B)/2E\M/[HI^:*06
M&A5'04ZBB@=@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD) Z
MFF[T_O"@5Q]%1^:G]X4&=!ZT!<DHJ+STI//_ -G]:+!=$U%0_:/]G]::9SV
MIV"Z+%%5O.?VI/-;UHL+F1:HJIYC?WC1O8]2:+!S%O(I,CUJIFDS18.8MEU'
M5A2>8F/O"JM%%A<Q:,J>OY4WST]ZKT46#F+!G'89IOVC_9_6H:*8KDWGG'W:
M;YS^WY5'10%R3SG]J:9'/\5-HH"X[>_]X_G2$GUI** N%%%% @HHHH ****
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M*00=HX/XUU-(H****0!1110 5/9_\?</^]4%36QVW,9)P-U '!>)?^1COO\
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M** "BBB@ HHHH **** "BBB@ ILG^K;Z4ZFR?ZMOI0!Y=\&_]?XN_P"PJ_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** N%%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQV%-(3.#\)>!-!O?B9XETR>V9K73O+:W7S#\IXK>BLH9?B[JMB0?)?3_ "L
M_P )7'\JGO?!_C#2_'&H:YX9N['RM1"FX6ZZC'8<'TZUM:?X6U2'XASZ_<-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(**** "BBB@ HHHH **** /+_@]_J=4_WH__ &:O2;C^&O-O@]_J=4_WH_\
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MCQOXE6V&K^(-,E6%B8_E9,$_1?:B["QU/Q \>7'@Y=.F@MH[B"Y?#[B00O\
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M0,^O'2LOX2ZCXH32;"TM])A?13,XDO#( R\G/&?7VKH_$V__ (4?.) 0PT^
M<CW2I/@P ?AW;?\ 7:7_ -"-.PCT(=*\0\07%A;?'**74O*%J($W&50RCD]C
M7N XKP[Q'H]EKWQPCL-0C,EO) NY0Q7/)[BE+<(;'HUEK'@RXO88;(Z<URS
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M:.%;8"-PXY],Y[4E>XG:QW]%%%69A1110 4444 %%%% !1110 4444 %%%%
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M HHHH **** "BBB@ HHHH **** "BBB@#"\9?\BCJ?\ UQ-<C\)NFJ?]L_\
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M5BJ("BBB@ HHHH **** "BBB@#R_X/?ZG5/]Z/\ ]FKTFX_AKS;X/?ZG5/\
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MT&.E=5X%\&IX/TV:W\YIYIY/,ED8=3BNMHHL',PHHHIDA1110 4444 %%%%
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M_"SM>]+;_OU_]>O1_P#A#_#_ /T"+;\J/^$/\/\ _0(MORHYX]@]E/N><?\
M"SM>]+;_ +]?_7H_X6=KWI;?]^O_ *]>C_\ "'^'_P#H$6WY4?\ "(>'_P#H
M$6WY4<\>P>RGW/./^%G:]Z6W_?K_ .O1_P +.U[TMO\ OU_]>O1_^$/\/_\
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MW4GUJ$I<US64HN"5M26HQ"]U?VMJDAC\Z0)N SC)Q4E12)+YT4T,ACDC;<K
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MQ\+WEY/) \1@8J&88DXZ#US4%F'IGC0^(_AWJ6L69:WNK>WD#8_@D5,\?I7
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MIWND? "QO=/N&M[B.,;9%QD9E(-6=+_X2WQ3\-M&NM-UIH-0:1VGG8#+J&8
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MH*7[5!_ST%>F_P#"M/#_ /<N/^_IH_X5IX?_ +EQ_P!_31[9!]4D>9?:H/\
MGH*3[5!_ST%>G?\ "M/#_P#<N/\ OZ:/^%:>'_[EQ_W]-'MD'U27<\R^U0?\
M]!4JY<@("Q/0"O21\-?#_>*X/_;4UN6'A[2]/,9M[.)6C&%<J-WYT>V0?5)=
M3E_!OAF6*5-2O$VXYB0]?K7>T45A*7,[G7""A&R"BBBI+"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"
M\9?\BAJ?_7$UQWPF^_J7_;/^M=CXR_Y%#4_^N)KCOA-]_4OI'_[-5KX3*7\1
M'JT'W:EJ*#[M2UD=*V"BBB@84444 %%%%  >E>8?!3_D#:Y_V%9?Y"O3STKS
M#X*?\@;7/^PK+_(4 >GT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !39/]6WTIU-D_U;?2@#R[X-_P"O\7?]A5_YFO4Z\J^#
MLB)<>+=SJO\ Q-7ZG'<UZA]HA_YZI_WT*2&]R6@C-%%,1S/B[P\NKV?G0J!=
M1#*X'+>U>?Z=K$^EN;>Y1C&IY4]5^E>RD USVO\ A2SUI?,XAN!_RT49S]:3
M0TS"MM2M+M<Q2J3CD=Q5L8(R"#7%:GX;U/2G)E@+1CI(G(JD+^^B&!<3+CH-
MQI%'H)*@9) ^M4KS5[2S4[I S=E6N)DOKN9=LEQ(X]"U-AM9[F0)#"[N>@ Z
MT 6]3U>;47P1LB!X2KOAOP]-J]VK,A%NA^9B.M:NB> [JY82ZCF"/^Y_$?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB(9-/AW+T.WFM1(UC4*H 'H*DHH$%%%% !1110 4444 %%%% !1110 4444
M>7_![_4ZI_O1_P#LU>DW'\->;?![_4ZI_O1_^S5Z3<?PU<_B,*7P$-%%%(H*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,+QC_P BCJ?_ %Q-<=\)OOZE_P!L
M_P#V:NQ\8_\ (HZG_P!<37'?";[^I_\ ;/\ ]FJU\#,I?Q$>K0?=-2U%!]TU
M+6;.E;!1112&%%%% !1110 'I7F'P4_Y VN?]A67^0KT\]*\P^"G_(&US_L*
MR_R% 'I]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MFCD7</:OL>R9HS7C?F^/?^HG^9H\WQ[_ -1/\S1R+N'M7V/9,T9KQOS?'O\
MU$_S-'F^/?\ J)_F:.1=P]J^Q[)FC->-^;X]_P"HG^9H\WQ[_P!1/\S1R+N'
MM7V/9,T9KQOS?'O_ %$_S-'F^/?^HG^9HY%W#VK['LF:,UXWYOCW_J)_F:/-
M\>_]1/\ ,T<B[A[5]CV3-&:\;\WQ[_U$_P S1YOCW_J)_F:.1=P]J^Q[)FC-
M>-^;X]_ZB?YFCS?'O_43_,T<B[A[5]CV3-&:\;\WQ[_U$_S-'F^/?^HG^9HY
M%W#VK['LF:,UXWYOCW_J)_F:/-\>_P#43_,T<B[A[5]CV3-&:\;\WQ[_ -1/
M\S1YOCW_ *B?YFCD7</:OL>R9HS7C?F^/?\ J)_F:/-\>_\ 43_,T<B[A[5]
MCV3-&:\;\WQ[_P!1/\S2>9X]_P"HG^9HY%W#VK['LN:,UXWYOCW_ *B?YFCS
M?'O_ %$_S-'(NX>U?8]DS1FO&_-\>_\ 43_,TGF>/?\ J)_F:.1=P]J^Q[+F
MC->-^;X]_P"HG^9H\WQ[_P!1/\S1R+N'M7V/9,T9KQOS?'O_ %$_S-'F^/?^
MHG^9HY%W#VK['LF:,UXWYOCW_J)_F:/-\>_]1/\ ,T<B[A[5]CV3-&:\;\WQ
M[_U$_P S1YOCW_J)_F:.1=P]J^Q[)FC->-^;X]_ZB?YFCS?'O_43_,T<B[A[
M5]CV3-&:\;\WQ[_U$_S-'F^/?^HG^9HY%W#VK['LF:,UXWYOCW_J)_F:/-\>
M_P#43_,T<B[A[5]CV3-&:\;\WQ[_ -1/\S1YOCW_ *B?YFCD7</:OL>R9HS7
MC?F^/?\ J)_F:/-\>_\ 43_,T<B[A[5]CV3-&:\;\WQ[_P!1/\S1YOCW_J)_
MF:.1=P]J^Q[)FC->-^;X]_ZB?YFCS?'O_43_ #-'(NX>U?8]DS1FO&_-\>_]
M1/\ ,T>;X]_ZB?YFCD7</:OL>R9HS7C?F^/?^HG^9H\WQ[_U$_S-'(NX>U?8
M]DS1FO&_-\>_]1/\S1YOCW_J)_F:.1=P]J^Q[)FC->-^;X]_ZB?YFCS?'O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
;%%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gvvh0m1pmdf2000015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" *\!XT# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVEQZ7;F4Q.Y?D#&<>OTKE-:L?B?J_A^#PI<:;%]F7:K72L-S@=,\XKZ$XHH
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M4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
MM%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4E+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBT O6-#_ (2_0/\ H)P_K_A1_P )?H'_ $$X?U_PK/\ ^%>>'?\ GT/YT?\
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M]^30>//#TYV_V@B$] P/^%;MO?6UV@>WGCD!_NMFN9D^'/A]A@6S#Z-6;=^
M)-+1KGP_?303K\WEECM>E:#V'S58_$CT'-%<?X1\5/J,DFFZFGDZE!PRG^+W
M%=>.14--;FT)J:NAU%)2TBPHHHH ***0]* ,G5O$FD:&R+J=_%;&3[H?//Y5
MG_\ "PO"?_0;MOR;_"N;\7:=::G\3?#]M>P1SPM$^4D7(/![5U'_  @GA?\
MZ =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L
M?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_
M  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?D
MW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C
M_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @G
MA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"_
M_0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;M
MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@
MW;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_
MPH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_
M  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A
M!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?
M_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3
M_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_
M]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO
M^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_P
MJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"
MP_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X
M6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^
M@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['
M_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;
M\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^
M%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH
M C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_""
M>%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\
MT ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\
MT&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;
M?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^
M5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%
M'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/
M"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_
M"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_
M^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C
M_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*
M_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3
M_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'
M_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%
MA^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\
MZ =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L
M?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_
M  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?D
MW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C
M_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @G
MA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"_
M_0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;M
MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@
MW;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_
MPH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_
M  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A
M!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?
M_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3
M_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_
M]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO
M^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_P
MJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"
MP_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X
M6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^
M@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['
M_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;
M\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^
M%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH
M C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_""
M>%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\
MT ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\
MT&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;
M?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^
M5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%
M'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/
M"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_
M"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_
M^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C
M_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*
M_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3
M_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'
M_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%
MA^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\
MZ =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L
M?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_
M  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?D
MW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C
M_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @G
MA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"_
M_0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;M
MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@
MW;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_
MPH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_
M  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A
M!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?
M_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3
M_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_
M]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO
M^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_P
MJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"
MP_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X
M6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^
M@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['
M_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;
M\F_PJ3_A!/"__0#L?^_*_P"%'_"">%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^
M%'_"P_"?_0;MOR;_  J3_A!/"_\ T ['_ORO^%'_  @GA?\ Z =C_P!^5_PH
M C_X6'X3_P"@W;?DW^%'_"P_"?\ T&[;\F_PJ3_A!/"__0#L?^_*_P"%'_""
M>%_^@'8_]^5_PH C_P"%A^$_^@W;?DW^%'_"P_"?_0;MOR;_  J3_A!/"_\
MT ['_ORO^%'_  @GA?\ Z =C_P!^5_PH C_X6'X3_P"@W;?DW^%'_"P_"?\
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M TC3I/XA=@?^.FNST)_,T.R?UA3^0K27PIG-3TJR1HTM)2UF=(4444 %%%%
M'GWB#_DJ_AW_ *Y/_(UZ#7GWB#_DJ_AW_KD_\C7H- !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 &:6FT9H =13:* '44"B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "D-+2&@#SWXM#.B:>/6['_H
M)KL- 79H-BOI G\A7(?%G_D"Z=_U^#_T$UV.B?\ ($LO^N*_R%:/X$<T?X[-
M"EHHK,Z0HHHH **** //O$/_ "5?P[_UR?\ D:]!KS[Q#_R5?P[_ -<G_D:]
M!H **** "BBB@ HHHH ***,T %%)D4M !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%!Z57N;C[.BL1G+8H L44@/&:6@ HHHH
M ***@N9Q;H'(SD@4 3T4@Y /K2T %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !137.U"?3FHK>83Q"0# )Q0!/1110 4444 %%%%
M !12$XI,T .HIH-+D4 +11FFYYH =1249'K0 M%)D4M !1110 4444 %%%%
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M=M4=F Q#DVI,ZTUY?XW:V3Q]H[7FW[,"#)NZ8KT_->:>+X([GXBZ)#,@>-W
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M?,O_ /GC'^='F7__ #QC_.@"]15'S+__ )XQ_G1YE_\ \\8_SH O451\R_\
M^>,?YT>9?_\ /&/\Z +U%4?,O_\ GC'^='F7_P#SQC_.@"]15'S+_P#YXQ_G
M1YE__P \8_SH O451\R__P">,?YT>9?_ //&/\Z +U%4?,O_ /GC'^='F7__
M #QC_.@"]15'S+__ )XQ_G1YE_\ \\8_SH O451\R_\ ^>,?YT>9?_\ /&/\
MZ +U%4?,O_\ GC'^='F7_P#SQC_.@"]15'S+_P#YXQ_G1YE__P \8_SH O45
M1\R__P">,?YT>9?_ //&/\Z +U%4?,O_ /GC'^='F7__ #QC_.@"]15'S+__
M )XQ_G1YE_\ \\8_SH O451\R_\ ^>,?YT>9?_\ /&/\Z +U%4?,O_\ GC'^
M='F7_P#SQC_.@"]15'S+_P#YXQ_G1YE__P \8_SH O451\R__P">,?YT>9?_
M //&/\Z +U%4?-O_ /GC'^=(9+\_\LH_Q)H O4M06YG(/G*H/;;4] !1110
M4444 %%%(: #-&:\\\6?$T^'/%']A0Z1<7L_D+/^ZYX.??VK<\)>,]/\5Z2]
M_!F#RF*2I+\NPCUH ZBBJMO?VEUG[/=038Z^7(&Q^51G6--#;3J%H&)P!YRY
MSZ=: +U)FH3=0B1(VFC#R?<4L,M]!WJEJ^KQ:=IUY.CQR3VT1D,089_$=: -
M/-&:YOPIXICU[PM;:S=F*T$V<AW  _$UIW>M6%KILM^;J%[>-<EDD4C\Z -'
M-%<:WCRVNO!L^OZ5$MR8QD0%P&_'GBM[3]8BGT:UO[QHK7SD#$22  'TSF@#
M5HJNE[;20F:.XB>(?QJX*C\:CCU2PED$45];/(>B+,I)_#- %RBD!I: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"J&J?\>Z?[XJ_5'4_P#CW3_?% %Q?NBG4B_=%+0 4449H *HZG_Q[K_OC^=7
MJHZG_P >Z_[X_G0!<3[H^E.I%^X/I2T %%%% !1110 4449H **** "BBB@
MHI,TN: "BBB@ HHHH **** "BBB@!DG^K;Z&JVG?\>:_4_SJS)_JF^AJMIW_
M !Z+]3_.@"Y1110 4444 %%%)0!R'Q*UB\T+P7>7]A)Y=Q'C:V*YGX?_ !!F
MU+P-J-YJTH^V6"L7W<$_+D?SK=^+%I<7W@&^@M87FE;&$09)KRK7/"&MPZEI
MUMIT$RV>L0P"\"KPI4C.?3@4 =/\+O'^I:QJ6O3:Y=;;2UB\Y PQL7(Q^AKH
M]-^+VA:CJT-D(KF&.=RD%Q(A"2'VX]JXVU\&W\NJ^--,MK>2%)K.*.!\85RH
M3@'\*YKPUX71K[3]/OM,UI;Z";YB1^Z0C/(.: /5/$/Q7TK3;R\TZ"VN[IH%
M*S3P(2L38[\>M<[H6NS3?#K2+R[U2YC>74E02)@L^0WRGCI6; =3\$:KXDTZ
M;0)]0_M)W>WE2/<I!SU/XT:=HNI1_"W0+5[*<3QZM&[Q[#E5PW- 'HOB7XB6
M'AB\%K/97=PP0.[Q1G:@/<G&*75OB5HFDZ3IVIOYLUOJ&?(\M"22,=L>]>5^
M/K+6[KQ?J:7EKJ<L#Q[;);1?D8<_>_2M&VT:^D\._#^)["8FVN29U:,_(,IU
MH ])\*^/M/\ %5Y<6<5O/:W< #-!.N&VGH:ZX=*\YL=&N8/C%-J"VK):/9!3
M(!\I;YN*]&'2@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH 1ONFN!^&G_ !\^(_\ L)2_^A-7?-]TUP/PT_X^?$?_ &$I?_0FH [^BBB@
M IIZ4ZD/0T ]CSCP)_R.GB3_ 'D_F:]'KS7P,Q'CCQ"OJ5_F:]*JZGQ&&'^$
M*J:D_EZ;<,.T;']*MU3U1=^EW*^L3?RJ8[FLOA9X-/(RVEIZ3/*Q/K\YJ"4X
MB8^@ZT3M\EI&6^X\HQZ?.:2;_4O]*]>G\)\M6^,E\/N1K,1/\463^E:7B*8F
M2RQPNXG'TQ6=X=7=JJ-U"PU=\0=;%CTW,"?RJ'N:KX3,@D,L>XCO5>[)W!<]
MCFI;/_4#'K4%X<3?\!K5['-'XCJ]&DSH87/*HW]:YT#R4A.<^<68_@2/Z5T&
MC1E='P>IB/'YUS\C!H[0 \H74C\2:R6YT5-8:CY3B)B#VK9^'DCKXM@(;[\9
M!^G%8LW^I?Z5O?#F+S?%L9Z^7#N_E17^%A@_XJ/;:S;G1+*[U&"_FB#7$!S&
MV>E:5+7E*Z/IFDU9E'4=+M-5M3;7D0DC)S@U%/H=A<:<MC- LD"#"JPSBM.B
MFFQ.*9S5KX(T2UN8YX[;YXR&3)) (J74?".DZG=M=7,!:1OO$,1FN@I*?-(E
M4HVM8X?QGI,5KX0-I8V^$5UPB#WJQ8^"M&N["UFGM,2-$N\ D9..XKKG"E?F
M (]Z1&4KE""OL:?.[$^QCS79!;V-O:VJVT,2I"HP$ XK%F\#Z%-<&8V@!8Y(
M4X!_"NDXI:E-EN$7NBC'IEI%8_8DA5("NW:!CBG6.GV^FVHMK5-D0.0*N4UF
M"C). .]%VQJ*1EQ^'].C:Z98!FZ_UO\ M52M?!6BVETMPEMF13E=Q)Q70JP8
M94@CU!I2<=:.9BY(]C,U30M/UB-4O;=9-OW3CD?C573?"6DZ5<BYMH")5& Q
M).*VU=7!*L#]*=VHYGL')&]["BEI**18M%)10 M%)1F@ I:9F@,#T(/TH"X^
MBDHS0 M%)UHS0 M%-S2T +124M !1110 4444 %%%% !1110 4444 %%%% !
M1110 4AI:0T >>_%G_D"Z=_U^#_T$UV6B?\ (%L_^N*_RKC?BS_R!=._Z_!_
MZ":[+1/^0+9_]<5_E6C^!'-'^,S1HHHK,Z0HHHH **** //O$/\ R5?P[_UR
M?^1KT&O/O$/_ "5?P[_UR?\ D:]!H **** "BBB@ HHHH @N+6"Z79/#'*O7
M;(@8?K2"U@$'DB&,0XQY84;<?2K%% $%O:P6R[+>&.).NV- H_2IZ** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH 2EHHH ****
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZG_Q[Q_[XJ]5'5/\
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M  I:I_VG;_[?_?!H_M.W_P!O_O@T 7,T9JG_ &E;_P"W_P!\&C^T[?\ V_\
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M +M4=3_X]Q_OC^=+_:=O_M_]\&JE]?0RP@+NSN'53ZT :R_='TI<U274K<*
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MU3_M.W_V_P#O@T?VG;_[?_?!H NTT\BJG]IV_P#M_P#?!I#J-O\ [?\ WP:
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M% !1110 4444 %%%% "-]TUP/PT_X^?$?_82E_\ 0FKOF^Z:X'X:?\?/B/\
M["4O_H34 =_1110 4AZ4M(>E ,\O\%_\E#UKZ_XUZ@*\O\%_\E#UKZ_XUZ>*
MTJ[G-AOA8[O1249K,Z1:*3-&: %HI,TM !1129H 6BDS1F@!:*3-+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0 4M%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MAI:0T >>_%G_ ) NG?\ 7X/_ $$UV6B?\@6S_P"N*_RKC?BS_P @73O^OP?^
M@FNRT3_D"V?_ %Q7^5:/X$<T?XS-&BBBLSI"BBB@ HHHH \^\0_\E7\._P#7
M)_Y&O0:\^\0?\E7\._\ 7)_Y&O0: "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU/\ X]U_WQ_.@"TJ)M'RCIZ4[RT_NC\J5?N#Z4M #?+3^Z/RH\M/[H_*G44
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M%%% !1110 C?=-<#\-/^/GQ'_P!A*7_T)J[YONFN!^&G_'SXC_["4O\ Z$U
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M*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H
M6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*** "BDS1F@!:*3-&: %HI,T9H 6
MBDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-+0 4444 %%%% !24M-[T 8U[X6
MT/4KHW5YI=K-,>"[Q G\Z7_A&M$.G&P_LVU-H6W>5Y8VY]<5P'B_7->\0>.X
M_!^@W9L4CC\RYN1][Z#Z8J=/MOPO4WFKZO?:S9W;I$"X_P!0V>O7H<_I0!WF
MF^&]&TB=I]/TZVMY&&"T<84D?A5V[L[:^MV@NH(YXFX*2*&!_ US&H>/;&QU
M>/3D@EGD-FUXQ3!"H 3SSUXK*\/?%*'Q$\CVVC7ZVR*Y,Y4;<J"<=?:@#HK'
MP/X;TV\6[M=)MDG4Y5M@./I5S5?#FD:V -2L+>X(Z,\8+#\>M<EI_P 5;.XU
MRVTR]TVZL3=,5ADEVX;\B:KZA\7;.PU34+-=)OI_L#8GDC4;5&<9ZT =YI>C
MV&BVWV;3K:."'.2J# S4U[8VVHVS6]W"DT+?>1UR#^%<!IWQ>TW4-1LX/[/O
M(;>\8K!<NHV.1^-,U[XMQ>'KUX;S0M05!)L63:N'/MS0!Z'!:06UJEM#$B0(
M-JQJ, #TQ6:_A/098/(?2K1HBY?88EQN/4XQ[5A:S\0DTF"UD&D7D[3P^<RH
M%&P>^2*V_"WB:S\5Z,FIV081EBC*W56'4?K0!&G@GPW$P9-%L@00>(5ZC\*T
MKW2;#4K5;:\M8IX5((1T! QTJ]2T 9]QI%A=6:6<]K%);IC;&R@@8Z5<1%C1
M40 *HP!CH*?BEH SHM%TV%[AX[*!6N23,?+'[SZ^M4+'P;X?TV]^UVFE6T4^
M<AQ&/E^GI7044 ,QZU572[)-1;4%MHQ=,NUI0HW$>F:NT4 ,>,2(5894C!'K
M52VTNRLK5[6WMHHH7SNC50 <]>*O44 98T'2_P"SVL/L%O\ 97Y:'RQM/X57
MT_PGH>E"866G01><NU\(/F'I]*V\48H J6^GV=K9BT@MXTM@,")5 7'TK-LO
M"&A:?>O>6FFP0SN""40#@]1BMW%&* ,&'P;X?M=1^WPZ7;)<!MP81C@^H%<S
M9?#2SE\2:YJ.LVUM=1WMT9H  =RCT/%>B$<48H S9M$TRXTL:;+90M9@8$6P
M;1^%0P>%]%M8;>*+3X EN^^(;!\C>HK9Q10!GQ:/80/</#:0HUS_ *XJ@&_M
MSZU+8Z=:Z;;^19P1P1 Y"(N!5NB@"I?:=::E"(KR".:,,&"NH(!%3HBHH50
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M^/WBY//7U!KTL5YWX#^&[^$M1FOKJ_-W)Y7DP97&Q,D_GR:]#!H =129HS0
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M7^S\[<8Z?>KH-2\ _;_AW;^%A>%/)C1!-M_NC'3-8-K\-_%UG%'##XZOTBC
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ML]O^?J?_ +Z-7:* *7]GM_S]3_\ ?1H_L]O^?J?_ +Z-7:* *7]GM_S]3_\
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M^'].N+'3+IHM60C'R9&.:ZOP;XOL/%6G*UK*TDT2+YV5QS47CGPA;^+M$EL
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M^= "T4F]?[P_.C>O]X?G0 M%)O7^\/SHWK_>'YT +12;U_O#\Z-Z_P!X?G0
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MM-MKO&WSHE?'ID9KDOBM;RW'PZOX88F>1FAPJC)XD7M72^'U9/#VGHP(9;=
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M4 4O[,M_[K?]]&C^S+?^ZW_?1J[10!2_LRW_ +K?]]&C^S+?^ZW_ 'T:NT4
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M ,>:_4_SH ;_ &9;_P!UO^^C1_9EO_=;_OHU=HH I?V9;_W6_P"^C1_9EO\
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MAUV[2ZU6Y79\@PL:=<#CV%>@4E #5C1,[55<]<#&:'B25-LB*RGLPR*=D4M
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M&1TI:7-&: (3;0&3S##&7_O;1G\ZS?$=MJMSI$D>BW,=O>Y!1W7(_D:U\T4
M>3:CX:\?^);3^R]1N[&ULY#BX>%?FD7\J](TC1[;2-&M=,B4-#;1A%W#TK0[
MTI8"@!,&HWM+=Y-[P1,P[E 35:]U>QTZ:"*\N8X7N"5B#'[Q'7'YBKH(.".]
M #9+>*5=LD2.H[,H- @B$?EB) G]W:,?E4F:3- #(H(81B*)(P>NU0*26WAF
MQYL228Z;E!JM!K%A<W\MC#=(]U$,O&#RM7LT ,6-44*BA1Z 8IOV:#S/,\F/
M>?XM@S^=48-?TVYU2XTZ&Z5KJV&Z6,=5%36.J66IH[V5PDRQMM8J>A]* +:Q
MI&N$4*.^T8IV*0$4N: (EM8$D,BPQASU8*,T]HU?&Y5;'3(SBG9HH :T:NN&
M4,OH1FE  &!P/04M&: .%\1>#[O5OB!HNNQO&+>R1ED4]3FNTCMX8FW1PQH3
MU*J!FI,CI3NE #/*3?OV+O\ [V.:'C1QM=58>XI^:* &E RX(!'3!%,CMX8<
M^5%''GKM4#-4O[=TX:W_ &1]I7[=L\SRN^WU_2M+- #/*4N&*J6'0XYI])FD
MR"3C'% "-$CL&9%)'0D=*<5!!! (/7-4K;5K&[NYK2"Y1YX?]8@/*U=!H 18
MU1=J*JKZ 8J/[);[]X@BW_WM@S4V:,T ,,2%@Q12PZ$BEVYZ]Z=FC- $26L"
M2>8D,:N>K!1FDEMH)N988W(Z%E!J7-+0!RGCKPY/XD\,2Z99F.-V8$9''!K6
MT?2H[+1["VFBB>:W@2,N5R<@ =:U<48H ,#%1+;0)NV0QKNZX4#-344 1&&,
MIL,:;1_#CBG-&K+M905]"*?10 U55!M4  = !2FEI#0!Y[\6?^0+IW_7X/\
MT$UV6B?\@6S_ .N*_P JXWXL_P#(%T[_ *_!_P"@FNRT3_D"V?\ UQ7^5:/X
M$<T?XS-&BBBLSI"BBB@ HHHH \^\0_\ )5_#O_7)_P"1KT&O/O$/_)5_#O\
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M'6IR7T8_X2$7+EF=#YN[?QSZ8S75^'+5O$/B&PNVR;31=,"(".LCJ#G\-IH
MZ_P=XN&L^&TU+4Y(+:1IVB"[L9QCI^=;]WK&G6#(MW>P0L_W0[@$UX)X(06N
MJV,_B"-GTEIW%H6&4CER/O#\JZ1AH%QXY\1_\)3'O!B7[*94W+L^;[GH: .W
M\3^+7T2&QU&V\FYTQ[A8;AT;.S<0 >/K75PR+-$DBG*NH8?0UX;H\]K#\#KI
M' 99;HQP*>I8D!?Z5[+H,;Q:%8QR9WK"N<_2@#2HHHH **** "BBB@ HHHH
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M()__ %4 ;M%%% #)/]4WT-5M._X]%^I_G5F3_5-]#5;3O^/1?J?YT 7****
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MG'Y5Y?JUC,GPA\,6U\I_>7BX5AT0D<5Z-\3+*YE^%EW!8*05B0[5'\('/Z4
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M,\]Q-"KPK$,EB<@#]*P_BM_R.'@@_P#3W)_[)3K^*.7X]:674,5T[(SV^]0
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MUCSD8_QKA/"T0_X2OQ^D:]9SP![M4WPAUO3K'P)<1W=W%"]O=2F17;&T<<T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4V/0;W0])O1;W=SJ+M#LB@D?@<'IUJUX&L+O2_!VGV=]%Y5R@<NF<XR['^M
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MDU473H48,"^1[U-- LR;6R!GL: )00>AI:@@MTMP0A)SZFIZ "BBB@ HHHH
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MO4?^>\7_ 'Q_]>JM]'>B$>9+&PW#HOO]:V:HZG_Q[K_OC^= #%CU#:,3Q?\
M?/\ ]>G>7J'_ #WB_P"^?_KU=4?(OTIU %#RM0_Y[Q?]\_\ UZ/*U#_GO%_W
MS_\ 7J_10!0\K4/^>\7_ 'S_ /7H\K4/^>\7_?/_ ->K]% %#RM0_P">\7_?
M'_UZ/)U#_GO%_P!\?_7J_24 4?*U#_GO%_WQ_P#7I#%?_P#/>+_OC_Z]8'B'
MQ3?6FM0:+H]B+N_D3S'+-A8U]3^E-U'Q3J.B:';RZC8HVIW$ODPV\3<,W./P
MP* .A\O4/^>\7_?'_P!>CRM0_P">\7_?'_UZS]!NM?N#(-:LH+? !3RGSGZ\
MTS6]2UVSN,:=IL5Q;A,F1Y0N#^- &GY6H#_EO%_WQ_\ 7H\K4#_RWB_[Y_\
MKUQ5A\1I[KP;?Z[-IP3R)#%$JOD2-]:ET[XA-)H>I7%]9B.^LI/*$*'/F.0"
MH'USB@#L?*U#_GO%_P!\_P#UZ/*U#_GO%_WS_P#7IVF37-QIT$UW&(YW0,R#
M^'-7!TH H^5J'_/:+_OC_P"O2>3?_P#/:+_OG_Z]:%% %#RM0_Y[Q?\ ?/\
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M3A7 Y(]ZF7+T+IN:TD:]+2#I2U!L%%%% !1110 4444 %%%% !1110 4444
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MQIM,04444 %%%% &_H/^HD^M;%8^@_ZB3ZUL4AA1110 4444 %%%% !1110
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M1+:[,<-OY:%67?CGC-:]GJ_B/P_XFTM-1U5M0AU6T:=H610(6V[L+@ ]L<T
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MS*BJ6+ *.I)Z4J.KJ&1@RGH0<T /HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!&^Z:X'X:?\?/B/\ ["4O_H35WS?=-<#\-/\ CY\1_P#8
M2E_]":@#OZ*** "D/2EI#TH!GE_@K_DH>M?7_&O3Q7F'@K_DH>M?7_&O3Q6E
M7<YL-\+'=Z*.]%9G2)1F@\5!<7,5M \LSA$49)-"$W97&7M[!86KW%PX2-!D
MDUR=DZZUJBZAJ<@C@1O]&MF_]"852O\ 43K5PMW*I%A$V883_P MC_>(]/\
M&J4DC2R%V/)K>%.ZU.&KB/>/3%V[1M(QVQ6+KUKHZQ"^U&%"T/S(V/F)].*P
M+#Q(^F1G[0^^!1U)Z"KFFI+XJO(]3NQML(6S;P?WC_>-2X.+U-8UHU%9;FSH
M=U>WMJ;BZA$"-_JH^X7MFM<4@&  !P*?63.E*R$Q2T44#"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M10 4444 %%%% !36^X?I3J:WW#]* .,E_P!<_P#O&FTZ7_7/_O&FTQ!1110
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MJK#(-$-O';Q+%#&L<:\*JC %344 %%%% !1110 4444 %%%% !1110 4444
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M 6BDS2T %%%% !1110 4444 %%%(30 M%-S3J "BBB@ HHHH **** "BBB@
MHI":!0 M%)2T %%%% !1110 4444 %%-S1F@!U%)FEH **** "BBB@ HHHH
M**3-)F@!U%)FC- "T444 %%%% !1110 44F:,B@!:*3-&: %HHHH ***0T +
M16'#XEM9_%$^@JC_ &F"$3,Q'&#C_&H[CQ79V_BJ/P^R.;F2$S!@.,#'^- '
M045P ^)\,UW<06FB:A<B"8Q-)'&2NX''7%7M=\>V^B7MI9MIUW<7%S'YBQQ*
M20!USQ[T =C17*:3XZT[6=,O+JUAN#-9C]]:M&1(#Z8JA8?$>"75[?3M3TB\
MTMKD[8)+@';(?3H,&@#NJ*0'-+0 C?=-<#\-/^/GQ'_V$I?_ $)J[YONFN!^
M&G_'SXC_ .PE+_Z$U '?T444 %(>E+2'I0#/+_!7_)0]:^O^->GBO,/!7_)0
M]:^O^->GBM*NYS8;X6+364,"" 0>QI](:S.D8J!1QP*?5>[N[>R@:XN95BA7
M[SN< 5'I^IV6J1&6RN8YT!P2C XH NT50O-7T_3YHX;N[BA>3[BNP!:K,LR0
MQ-+(P5%&23V% $U%4+#6-.U/?]BO(I]GWMC XICZWIT=^+!KR(71Z1;AN_*@
M#2HJG>ZA::= 9[RXC@C'\3L!3[2\M[ZV2YM95FA?[KH<@T 6:*SM0UG3M**?
M;KR& O\ =WN!FI3J-F+(7IN8A;%=PE+ +CZT 7**YZU\:>';VX%O!JUN\I.
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M?%G_ ) NG?\ 7X/_ $$UV.B?\@6S_P"N*_R%:/X$<T?XS-&BD%+69TA1110
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M4?C(SSR?99/#)U6W=,(ZNH*-[Y(K'_X0"?4?ATFF7W_(12-A%F1L)D<#@\T
M>AVEY%>P)+%(CAE#?*P.,U9%8V@:%9Z%9K%:QLA91OR[-D@>YK8!H =1244
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M%)24 .K/U=-0>PD337BCN6X5I 2!5[-8GBN[U.T\/W$FCVOVB^(VQKG&,]Z
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M1@RGH0<@T^JME:0V%K';6ZE8T& "Q/\ .K&: '44W-+F@!:*2B@!:0T9I,T
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M?#^B6?\ :-QY:?:)%/R0C ZFL+XR::D'@W0-,B)C1+I(59>"/EQFLOP1<?\
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M/_BJ](HK,W/-_P#A/_%G_0C7G_?Q/_BJ/^$_\6?]"->?]_$_^*KTBB@#S?\
MX3_Q9_T(UY_W\3_XJC_A/_%G_0C7G_?Q/_BJ](HH \=MM=U36OBEHC:GHLVF
M-'&^T2,IW<'T)KV(5Y_X@'_%U_#O_7)_Y&O0!0 5PWCC6-/TS4;"2\MM3E=
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M_.HY8"D;,)'X&>M6ZCG_ -0_^Z:2+6YX7??$[7+?4+F!#&5CE9!D=@2*K_\
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M+/\ D5=2_P"N#5\PGJ?K5Q1ZN7TH5$^97.X_X6IK_P#TS_*C_A:>O_\ 3/\
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M>EX9]S7TEVPG5@W0C'TXS0!]( TM4M*6:/2[5+A@\RQJ'8'J<=:NT (WW37
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M7EO/;:-\.A;:M.IC,I@4"/=P2#^->D^$? MII6CZ.;^%7U"QB*J^?N[B6/\
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M/PW_ ,BY8?\ 7$5K5D^&_P#D7+#_ *XBM>L7N?)U/C85#<?\>\O^Z:FJ&?\
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MP_IRZ?:^)]$>WC)$:R/RH]*]0TQIGTZ%KB6*64K\SQ?=)]J +E%%% !1110
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M=._Y^9OR%=OBC%6JLTK)G//"TIOFDCB/^%:Z=_S\S?D*/^%:Z=_S\S?D*[?
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M'V9^8?6M6C%3.K*:M(UI86G2=X(*6BBLSH&M7C/C7_D:+G\/ZU[,U>,>-?\
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M M"U/PY!HEW;>;;VZ[8F)^9/<&LG0?A-H^@W$\T%Y>RB:%H2DKY4*P(./SH
M\L\-_P#)OFL?]=/_ &>M>.)7_9HE?RPS*C$'&2/GKTRS^'.B67A6X\.Q+)]B
MG.7!;GKFM'3_  CI>G^%SX>2+S+ J5*.>H)S0!YQX0\066@_!9;]$MYKB&(@
MQ\;C]>]<O?:AKFL_#2]U6[U'2;6PEB94LTC&\CL!SUKTK2/@_P"'](GN#'+<
MRP3(8VMY'R@!]/RJ"U^"?AFW:02&YGA8';!)(=B>X H YS2+[2(OV>@=4 DA
M\IHU7N7QQBO+? P33/&FBW&OPS#39&S;^9G:,GY3SVS7T+/\*]!N=$M='D:<
MV-NQ=(@V 2<=?RJ_K_P^T+Q%I]I9W5L$2T_U+1G!6@#R3XAM>M\8=+>.>VB1
MK<?99+D?NAUQW'>M27P=K^I>,]*U>_UG1Q/ 0%6W(!=<YZ;N:]&UKX>Z)KVC
MVUA?QO(;9=L4^<2+^-9_A[X5:-X?U2/4%N;R[FC_ -7Y\F0OY4 <5X:S_P -
M#ZOGKY(S_P!\BO<A7-6G@G2K/Q9<>(XE?[=.NUR3Q_GBNE% "T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %(:6D- 'GOQ9_Y NG?]?@_]!-=EHG_
M "!;/_KBO\JXWXL_\@73O^OP?^@FNRT3_D"V?_7%?Y5H_@1S1_C,T:***S.D
M**** "BBB@#S[Q#_ ,E7\._]<G_D:]!KS[Q#_P E7\._]<G_ )&O0: "JE_<
M_9+&>XVE_+0MM'>K5>>_$'1X-5U;2;676-2LGN&:-5M&4*W3EL@T 9^F#Q9X
MQTF'4T?1HK67YXH98"Y0>^#UKTC3HKB&PACNFC:95PYC7"Y]A7F?_"J+/0-'
MFDB\0ZR8X5+E5D49_2N]\*W$-UX:L9H))9(FC^5Y3ECSWH VJ*** "BBB@ H
MHHH ***3- "T4F:6@ HHHH **** "BBB@ HHI,T +129HS0 M%)FB@!:*3-&
M: %HI,TM !1244 +129I: "BBB@ HHHH **** "BC-)0 M%)2T %%%)F@!:*
M2C- "T444 %%)FC- "T4F:,T +1249H 6BDS1F@!:*** "BBB@ J.?\ U#_[
MIJ2HI_\ 4O\ [IH''<^5]6_Y#%[_ -?$G_H1JG5O5O\ D,WO_7Q)_P"A&J=;
M'UE/X$+124=:"Q:*3C%% 'L/P7_X]K__ 'A7K Z5Y-\%S_H^H?[PKUG-9RW/
MF<;_ !F+249HS4G*>-_&G_C\T[_<;^8KRH5ZK\:/^/S3O]QOYBO*JU6Q])@/
MX*%HI,T4SL%HI** -;PU_P C+I__ %W7^=?42_<%?+OAG_D9=/\ ^NR_SKZB
M7[HJ)'A9G_$0ZBBDS4'F&-XL_P"15U+_ *X-7S ?O'ZU]/>+/^15U+_K@U?,
M)/S'ZUI$]G*]F)2TE%4>N+124<4 !KZ#^%G_ ")=O_OM_.OGOUKZ$^%G_(E0
M?[[?SJ9;'F9G_#1VU!HHK,\(#TKYQ^(__([WW^\/Y5]&GI7SE\1S_P 5M??[
MP_E5Q/1RW^*<K12459[XM(:*3B@!:[;X5?\ ([1?]<7_ *5Q-=M\*O\ D=HO
M^N+_ -*3V.?%?P9'T'VI:0&BLCY<.U<#\6_^10/_ %T'\Z[ZN!^+7_(HG_KH
M/YTUN;X;^+$\$%+3:6M3ZD6BDHH ****!/8^H_#?_(N6'_7$5K5D^&_^1<L/
M^N(K6S6+/DZGQ,6H;C_CWE_W34N>*BN/^/>3_=-'4E;GRUK7_(<OO^N[_P Z
MH\5=UK_D-WW_ %V?^=4.*V/K*?P(=13>U+^-!H+24E'% CUOX*_?U'Z#^E>P
M5X_\%OOZC^']*]?K.6Y\UCOXS%[T=Z2BI.0\B^-'W=/^K?TKR2O6_C1]W3_J
MW]*\C[5K'8^CP'\%"T4E'%,[1:*2B@#1T'_D/67_ %U%?4R?=%?+.@?\AZRS
M_P ]17U,GW143/#S3XT/[4G>BBH/+,SQ'_R+NH_]>TG_ *":^6F_UC?6OJ3Q
M&?\ BG-1_P"O>3_T$U\MOQ(WU-:0/9ROJ%%-R*451ZXM%)FB@!:]\^$W_(F+
M_P!=F_D*\"KWWX3?\B8O_7=OY"E+8\W,_P"$=X*6D%&:R/! UX3\7_\ D9X?
M^N->[&O"?B__ ,C/#G_GC51W.[+_ .,>>T4G:BM#Z(6BDHH #7H?P>_Y&>;_
M *Y?XUYY7H?P>_Y&:;_KE_C2>QRXS^#(]VHH[4"LCYD6BBB@ HHHH **** "
MBBB@!&^Z:X'X:?\ 'SXC_P"PE+_Z$U=\WW37 _#3_CY\1_\ 82E_]":@#OZ*
M** "D/2EI#T- ,\O\%?\E#UKZ_XUZ>*\P\%?\E#UKZ_XUZ>*TJ[G-AOA8[O3
M68*"3T%.[TA /6LSI*O]H6W]\Y_W31_:%M_?/_?)J?R8_P#GFOY4ODQ_\\U_
M*@"O_:%M_?/_ 'R:/[0MO[Y_[Y-6/*C_ +B_E1Y4?]Q?RH K_P!HV_\ ?/\
MWR:/[0MO[_\ XZ:L>5'_ '%_*CRH_P"XOY4 5_[0MO[Y_P"^31_:%M_?/Y&K
M'E1_W%_*CRH_[B_E0!7_ +0MO[Y_[Y-']H6W]\_]\FK'E1_W%_*CRH_[B_E0
M!7_M"V_O_P#CIH_M"V_OG_ODU8\J/^XOY4>5'_<7\J *_P#:%M_?/_?)I/[0
MMO[Y_P"^35GRH_[B_E1Y4?\ <7\J *WV^V_OG\C2_P!H6W]\_P#?)JQY4?\
M<7\J/*C_ +B_E0!7_M"V_OG_ +Y-']H6W]\_]\FK'E1_W%_*CRH_[B_E0!7_
M +1M_P"^?^^31_:-O_?/_?)JQY4?]Q?RH\J/^XOY4 5_[1M_[Y_[Y-']HV_]
M\_\ ?)JQY4?]Q?RH\J/^XOY4 5_[1M_[Y_[Y-']HV_\ ?/\ WR:L>5'_ '%_
M*CRH_P"XOY4 5_[1M_[Y_P"^31_:-O\ WS_WR:L>5'_<7\J/*C_N+^5 %?\
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M_P"^?^^31_:-O_?/_?)JQY4?]Q?RH\J/^XOY4 5_[1M_[Y_[Y-']HV_]\_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!*CE!,;@=2,"I*".: ZW/ +_P"&OB*?4KJ5+92D
MDSLIW=B2:@_X5AXE_P"?9/SKZ&HJN9G>LQJI6/GG_A6'B7_GV7_OJC_A5_B7
M_GV3_OJOH;%&*.9C_M*L?//_  J_Q+_S[)_WU2?\*O\ $O\ S[)_WU7T/BBC
MF#^TJQY[\-/#6I>'8;M=0C"&0C;@UZ%28%+2;.*I4=27,Q:2EI#2(/&_C1_Q
M]Z=_N-_,5Y37JWQH'^EZ=_N-_,5Y5S6JV/H\ U[%7"C\:,&C!IG9=!BEQ28-
M&#0.Z-;PS_R,FG_]=E_G7U$OW1]*^7?#(/\ PDFG_P#7=?YU]0J?E%1(\+,_
MXB'#K2TE+4'F&)XL_P"15U+_ *X-7S"?O'ZU]/>+/^15U+_K@U?,)^\?K6D#
MV<KV8E&***H]<,4N*2EH 3%?0?PK_P"1*M_]]OYU\^5]!_"O_D2X/]]OYU,M
MCS<S_A([:@T4&LSP1#TKYR^(_P#R.U]_O#^5?1QZ5\X_$?\ Y':^_P!X?RJX
MGHY;_%.5HH[T59[XF*,4M)0 5VWPJ_Y':+_KB_\ 2N)KMOA5_P CM%_UQ?\
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M^: 3%HJ*25(HR[L%0<DDXQ2Q2I-&LD;!D89!!ZT#N244F:,T .HHHH ****
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M'VN#_GJGYT 2XHJ+[7!_SU3\Z/M<'_/5/SH FHJ'[7!_SU3\Z/M<'_/5/SH
MFI,5%]K@_P">J?G1]K@_YZI^= $N*,5%]K@_YZI^='VN#_GJGYT 34E1?:X/
M^>J?G2?:K?\ YZI^= %'5- TW6'1K^U28H,*6&<5G_\ "#>'/^@9#_WS6_\
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M-D3Q(H[# J6[G+B<:JT>6Q=HJO\ ;;;_ )[)^='VVV_Y[)^=2<!.:^<OB/\
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MJ9;'FYG_  CT(4M5/[1M?^>HH_M&U_YZBLSP2U7A/Q>_Y&>'_KE7MG]HVO\
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MJNJV'AE+J^@B^PP6Y=&4_,V,^]-MU+?"E@ 3_HY_E6CX:OM,NO!MO!//$R+
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M^S[3_GB/S-.%W;_\]X_^^A3DGBD;"2(Q] P-.P^5HC_LZT_YXC\S2C3[4?\
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MK5% %?[%;_\ /):/L5O_ ,\EJQ10!7^Q6_\ SR6C[%;_ //):L44 5_L5O\
M\\EH^Q6__/):L44 5_L5O_SR6C[%;_\ /):L44 5_L5O_P \EH^Q6_\ SR6K
M%% %?[%;_P#/):/L5O\ \\EJQ10!7^Q6_P#SR6C[%;_\\EJQ10!7^Q6__/):
M/L5O_P \EJQ10!7^QV__ #R6C[%;_P#/):L44 5_L=O_ ,\EH^Q6_P#SR6K%
M% %?[%;_ //):/L5O_SR6K%% %?[%;_\\EH^Q6__ #R6K%% %?[%;_\ /):/
ML5O_ ,\EJQ10!7^Q6_\ SR6C[%;_ //):L44 5_L=O\ \\EH^QV__/):L44
M0"S@_P">2T?9(/\ GDM3T4 0?9(/^>2T?9(/^>2U/10!!]D@_P">2T?9(/\
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M2H?^%+VO_03G_(?X5K<]^&/I**39X[17L7_"E[7_ *"<_P"0_P */^%+VO\
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MZ:]$^#__ ",TW_7'_&D]CEQO\%GN/D1?\\U_*E6)%.510?I3Z!61\R+1110
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M;>R E!R"SEL?F:T&T:RDU2/4F@'VJ-=J29/ K0HHNP4(K9"#I2T44B@HHHH
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MB3K13/*/[2OO^?RX_P"_IKT+X275S<>(YUFN)9%$60&<FO,Z]&^#Y_XJ6?\
MZXU3V/;QD8JC*R/7_$-U/8^'=0NK=]DT,#NC8!P0*\IC\4>+]%T/2==O=<@U
M&&\>,/:F-%8!O3 %>I>*4:3PKJB(I9FMG  '7Y37&^"/A[HZZ#I-_=P7$ETD
M2OLGF9E5L?W2<"LSYLV=8^(VEZ+>BVN+:\; !DD2%BL>?4XJ?6?'^AZ';VD]
MS,[K>)OM_*0L9!QTP/>O-/$NHWE]<^((=2N[^!XV:.VM;>$[95R<$D=>/6M#
M2M.FE?X=^=:NR0VB^8&3[IPO7- &GK'Q>AM+_2XK>PNQ'</^^\RW<,%XZ#')
MKJK?6([OQ/:JEY(JS6OF"V9,>O)XK"^(^ZTUWPSJ312-:VMPQE:-"VW.W' ^
MAI\L\MSX[M]3LX7>-M.9HRRD GG H MS_$[1;;5/L4T5VB>8(_M#0,(]QXZX
MIEM?W$OQ6DMA<,;7[ )%CS\N23S7E.N7=UJGAR1[V]U&34C<?-9) 1''@^W%
M>E:);3K\2HIVB?RO[*C7>1QGGB@"_P#$_6]4T30K232KP6D\]U'"92BMM#$#
M/(/K6'H_B?Q!IWCVS\/7^J0:Q;W*%FGA0#RL#/.T 5I?%JRDU#0].@2%Y5:_
MA#A!_#N&:QDT3_A"/B)ML;1WT_5K=HM^-QA?'7/7M^M '2:C\4= T[4Y+-C/
M*L3[)IXHF:.,^A.*DU;XDZ)IFHPV*&:[FE028MHR^U3T)P.G->5Z?I<=BNL:
M3KE_J5D9+EV,45OO68%B0<UHZY86/AYK.]\/W=]'K,4$:"-H2RS)@8#=0.E
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M'QZX-=,#7EW@K3=,NO%LNK6NJ7]Y=+;[7:>#RQCCCW->H#I0 ZBBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P#(S3?]<O\ &O.S7HGP?_Y&:;_KE_C2>QRXW^"SW6BBBLCYD6BBB@ HHHH
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M1V I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MB@ HHHH **** $;[IK@?AI_Q\^(_^PE+_P"A-7?-]TUP/PT_X^?$?_82E_\
M0FH [^BBB@ I#TI:0]* 9Y?X*_Y*'K7U_P :]/%>8>"O^2AZU]?\:]/%:5=S
MFPWPL6BBDK,Z0HQQ1FCB@#)UKPYIFOQQIJ5JLRQG*Y.,4S2O"^CZ-:RV]C8Q
M1QRC]X,9W?6MKBB@#E8_AWX7CN#,NE0@DYQSC/TK<MM)LK33/[.@@2.TVE/*
M'3!ZBKV12=J *6G:59Z3:?9;&!88<YVKTK'O_ 'AK4KMKJXTR+SG^\RY&[\J
MZ7-07-[;6:JUS<10JQP#(X4$_C0!!8:/8Z78?8K.V2*V (\L=#FL>/PGH6A7
M,NL66F*+E 7Q'G)/L*Z56#*&4@J>012D \?I0!Y!I6EWWC3XG1^)KO2I+&QL
MH]L8F&&=N,?R->O >M 55Z #Z"G"@"AJFD6.L6AMM0MHYXCSM<5F:5X(\/Z-
M>?:K+3XDG'1SDD?3-=%1Q0!G:EHMAJPA^W6RS>2XDCW?PL.0:OJN!@= ,"G<
M44 9FKZ!IFNP"'4;..X4<C<.15?2?"FCZ)%-'8V:(LXQ(#D[A^-;>11Q0!RK
M?#OPLUW]H.E1;MV[ SC/TK9OM#T[4;!;&ZM8Y+5<8C(X&.E:/%'>@"C?:18Z
MEIYL+NW66V( ,;=.*2\TBQOM-_L^YMUDM< >6>G%7^*.* ,>\\-:1?VUK;75
ME%+#:Y,*,.%S6?;?#[PS:WJW<6EQ"53N7.2 ?:NGXI,XH HWFC6&H3VTUS;)
M));-NB)_A/M0VC6#:JNJ-;(;Q5VB4]0*GAO[2YFDA@N89)(_OHC@E?KCI5F@
M#/N]'L;Z\MKRXMUDGMCNBD/536;JO@G0=:O?M=]I\<D^,;^03^5;-U>VMF%-
MS<Q0ACA3(X7)_&IP?>@#(TSPOH^CW)N+"PBMY2NPLG<5!J'@O0=3U(:A=:?&
M]T"#Y@R"<>M= ,44 9Z:+81ZE_:26R"[V>7YO?;Z51U?PAHFNRK+?V$4LH_C
MZ']*WN*,4 9>E>'],T2V:WT^SC@C;[VT=:?IFBZ?I'G_ &"W2'SW\R3;_$WK
M6E28H SX-&L+;4Y=1AME2[F&UY!U(K1I,4M !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4AI:0T >>_%G_D"Z=_U^#_ -!-=EHG
M_(%L_P#KBO\ *N-^+/\ R!=._P"OP?\ H)KLM$_Y MG_ -<5_E6C^!'-'^,S
M1HHHK,Z0HHHH **** //O$'_ "5?P[_UR?\ D:]!KS[Q!_R5?P[_ -<G_D:]
M!H **** "BBB@ HHHH **0M2;J '44T-3J $K(UR62)(=CE<DYQ6O6+X@_U<
M'U/]* ,C[7/_ ,]6_.M+1IY9+I@[E@!WK(K4T+_C[?\ W:8%[Q#>26'A^_NX
M3B6*!G3Z@5Y4OBKQEH>E:1KU_J%G>V-\R!K<(5=-WISS7I_BM2WA35%4%B;9
MP !R?E-<'X'^&FCMHNDZG>?:IYUB600S2,51L?W:0'6-X^T1-5_LSS97NPP5
MD2)CM^OH*-2^(&@Z9?26DMP\DD1Q*8HRZQ_[Q'3\:R/"FEH?$7BBX:W FDF"
MJ[K['H:Y;P[J^F^$;77=+\16DQOY+B1U/V=I//4DXP0#0!Z=>>+-'LM'CU22
M[0VLN/+*')<^P[U4TKQWHNKWPLK>61;HH9#%)&48 >H->4+IU[HVB^$M5U&S
MG;3;:XD>>WV%C&K;=N5'/&#6W9ZWIFN_%F.XTRWD6-;"13(T)3?P>@(&: .\
MT[QWH>JWK6UI.\A4$NX0[$QUR>@J&+XB^'IM06U6Z;YG\M92A$;-Z!NE8'A?
M1&/PNOX;6#R[VZ28Y*X8L<@<UY]I"6UYH5GHFJ:S>VTT4Z@V8LN0X?(^8)G&
M<<YH ]G'CK16U@Z9%-)-,&V,T4995;T+#@4Z/QMI$^M'2HGFDG5MC,D9*!O0
MMC%>5_:;?PQXNB'AFZGN9+NX1+RREMF('0%PQ7TYZU:CU)=#\?K!X<N)KN.]
MO&%Y9RVS 1'G+ABOJ/7O0!V.E>*[/31J]QJ&L&ZA2_,"XC($!).%_3K[5T][
MXBTW3KVTL[B<+-= M$H[@=3^M>7^'?#[:SHWCVQFB=#+J4CQ,RXY#,015'PM
M9ZIXP^W:C<QR13:;8?885<=9"!N8?]\?K0!Z/'\1O#LE^MJMTV&?RUF*'RRW
MINZ5I^*+^;3?"FJ:A:L!-!;/)&?<#(KPG0X8+GP];:'JVL7MI-'*%^Q_8LG<
M.AW;,_CFO:?%T+1_#G5X02["P=0<<GY: .)TS4/B#+X8MO$T5_97MO)%YS6A
MB*L%!.1G/7BNAE\4)K7A_1=2MM1&GFXND1U*[BQW %/;/]:Y7P]\0]*TKX<V
M&E1)=7&J+;&,6Z6SGYB3WQBD;0;W2_"/AJ.XB8W$NJ1SR(!]S,BG^5 'H+^-
M]'36CI2/++<*P1_+B+*A/J0,"C5/'>B:5?-:33222IS)Y,9<1C_:(Z?C7F^I
MWL/AWQS(_AZ\GGN+RZ5;NQ>V8KV!8-M]/>L>&.ZT/7]>M-:U2YT[[7*TBE;7
MS5D1N0 =I['% 'M5[XLTNRTF#4C*\MO/CRS"A<MD9Z"H;?QMHMSI%QJ8NBD%
ML<2AU*LI],'G->77FHW7A[3O#^F6>H7$&DW"O*^H&UWNISP-I4XX/I531H[&
M_L/%']KW=\]A+(FR[:V*L3SAMH4?RH ]:L/&VCWVG75\)9(+>V ,C3QE.N<8
MS]*31O'.BZW?BSMII$G89C65"F\>HSUKQV6ZUK7/!&M:; )+VTL)$,-T("C3
M(-W; SCCM6YX92QU[Q3HMP==O)[NT^=8&L_*"CC()" =J /:Q2T@I: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@!I%)MI]% #<>U+CV%+10 W'THQ]*=10 W%&*=10 E+28
MI: $->$?%[_D9X?^N5>[FO"?B]_R,\/_ %QJHG=E_P#&//:**2M#Z(6BDHH
M*]#^#W_(S3?]<O\ &O/*]#^#W_(S3?\ 7+_&D]CEQG\&1[MVHHHK(^9%HHHH
M **** "BBB@ HHHH 1ONFN!^&G_'SXC_ .PE+_Z$U=\WW37 _#3_ (^?$?\
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M^)/BB;PKX6DO;:!99G<1J' *C/<T 9G_  MBTAN81?Z1?V=K,P5;B6/"Y/\
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M>:>W_CHH ]NB?S(U?!&X XJ2FJ,#'I3J "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "D-+2&@#SWXL_\ (%T[_K\'
M_H)KLM$_Y MG_P!<5_E7'?%K_D"Z=_U^#_T$UV.B?\@6S_ZXK_*M'\".:/\
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M:8/^>J?G1]I@_P">J?G4/]FVO_/(?G1_9MK_ ,\A^= $WVF#_GJGYT?:8/\
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M7\Z;]@MO^>*T?8+;_GBM #OMEO\ \]5_.C[9;_\ /5?SIOV"V_YXK1]@MO\
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MLL'_ #PB_P"^!0!%_:5I_P ]EH_M*T_Y[+4OV6#_ )X1?]\"C[+!_P \(O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 (WW37 _#3_CY\1_\ 82E_]":N^;[IK@?AI_Q\>)/^PE)_Z$U
M'?T444 %-;I2T$4 >:>#[6>+Q_K,CPNJGD,5P#UKTH4P1(KE@BACU(')J2JD
M[F=.'(K :YGQ-XH?PZT7^@37"R#[R=!]:Z;%,DBCDX>-7'^T,TEH5)-K1GGG
M_"TA_P! >Y_S^%'_  M/_J#W/^?PKO\ [';?\^\7_? H^Q6O_/O%_P!\"KYH
M]C'V=7^8X#_A:?\ U![G_/X4?\+3_P"H/<_Y_"N_^Q6W_/O%_P!\"C[%;?\
M/O%_WP*.:/8/9U?YC@/^%I_]0>Y_S^%'_"T_^H/<_P"?PKO_ +%;?\^\7_?
MH^Q6W_/O%_WP*.:/8/9U?YC@/^%I_P#4'N?\_A1_PM/_ *@]S_G\*[_[%;?\
M^\7_ 'P*/L5M_P ^\7_? HYH]@]G5_F. _X6G_U![G_/X4?\+3_Z@]S_ )_"
MN_\ L5M_S[Q?]\"C[%;?\^\7_? HYH]@]G5_F. _X6G_ -0>Y_S^%'_"T_\
MJ#W/^?PKO_L5M_S[Q?\ ? H^Q6W_ #[Q?]\"CFCV#V=7^8X#_A:?_4'N?\_A
M1_PM/_J#W/\ G\*[_P"Q6W_/O%_WP*/L5M_S[Q?]\"CFCV#V=7^8X#_A:?\
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M]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <K_P +;\)?\_=Q_P"
MS_X4?\+;\)?\_=Q_X#/_ (5U7]BZ9_T#[;_OV*/[%TS_ *!]M_W[% '*_P#"
MV_"7_/W<?^ S_P"%'_"V_"7_ #]W'_@,_P#A75?V+IG_ $#[;_OV*/[%TS_H
M'VW_ '[% '*_\+;\)?\ /W<?^ S_ .%'_"V_"7_/W<?^ S_X5U7]BZ9_T#[;
M_OV*/[%TS_H'VW_?L4 <K_PMOPE_S]W'_@,_^%'_  MOPE_S]W'_ (#/_A75
M?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <K_P +;\)?\_=Q_P" S_X4?\+;\)?\
M_=Q_X#/_ (5U7]BZ9_T#[;_OV*/[%TS_ *!]M_W[% '*_P#"V_"7_/W<?^ S
M_P"%'_"V_"7_ #]W'_@,_P#A75?V+IG_ $#[;_OV*/[%TS_H'VW_ '[% '*_
M\+;\)?\ /W<?^ S_ .%'_"V_"7_/W<?^ S_X5U7]BZ9_T#[;_OV*/[%TS_H'
MVW_?L4 <K_PMOPE_S]W'_@,_^%'_  MOPE_S]W'_ (#/_A75?V+IG_0/MO\
MOV*/[%TS_H'VW_?L4 <K_P +;\)?\_=Q_P" S_X4?\+;\)?\_=Q_X#/_ (5U
M7]BZ9_T#[;_OV*/[%TS_ *!]M_W[% '*_P#"V_"7_/W<?^ S_P"%'_"V_"7_
M #]W'_@,_P#A75?V+IG_ $#[;_OV*/[%TS_H'VW_ '[% '*_\+;\)?\ /W<?
M^ S_ .%'_"V_"7_/W<?^ S_X5U7]BZ9_T#[;_OV*/[%TS_H'VW_?L4 <K_PM
MOPE_S]W'_@,_^%'_  MOPE_S]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'V
MW_?L4 <K_P +;\)?\_=Q_P" S_X4?\+;\)?\_=Q_X#/_ (5U7]BZ9_T#[;_O
MV*/[%TS_ *!]M_W[% '*_P#"V_"7_/W<?^ S_P"%'_"V_"7_ #]W'_@,_P#A
M75?V+IG_ $#[;_OV*/[%TS_H'VW_ '[% '*_\+;\)?\ /W<?^ S_ .%'_"V_
M"7_/W<?^ S_X5U7]BZ9_T#[;_OV*/[%TS_H'VW_?L4 <K_PMOPE_S]W'_@,_
M^%'_  MOPE_S]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <K_P +
M;\)?\_=Q_P" S_X4?\+;\)?\_=Q_X#/_ (5U7]BZ9_T#[;_OV*/[%TS_ *!]
MM_W[% '*_P#"V_"7_/W<?^ S_P"%'_"V_"7_ #]W'_@,_P#A75?V+IG_ $#[
M;_OV*/[%TS_H'VW_ '[% '*_\+;\)?\ /W<?^ S_ .%'_"V_"7_/W<?^ S_X
M5U7]BZ9_T#[;_OV*/[%TS_H'VW_?L4 <K_PMOPE_S]W'_@,_^%'_  MOPE_S
M]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <K_P +;\)?\_=Q_P"
MS_X4?\+;\)?\_=Q_X#/_ (5U7]BZ9_T#[;_OV*/[%TS_ *!]M_W[% '*_P#"
MV_"7_/W<?^ S_P"%'_"V_"7_ #]W'_@,_P#A75?V+IG_ $#[;_OV*/[%TS_H
M'VW_ '[% '*_\+;\)?\ /W<?^ S_ .%'_"V_"7_/W<?^ S_X5U7]BZ9_T#[;
M_OV*/[%TS_H'VW_?L4 <K_PMOPE_S]W'_@,_^%'_  MOPE_S]W'_ (#/_A75
M?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <K_P +;\)?\_=Q_P" S_X4?\+;\)?\
M_=Q_X#/_ (5U7]BZ9_T#[;_OV*/[%TS_ *!]M_W[% '*_P#"V_"7_/W<?^ S
M_P"%'_"V_"7_ #]W'_@,_P#A75?V+IG_ $#[;_OV*/[%TS_H'VW_ '[% '*_
M\+;\)?\ /W<?^ S_ .%'_"V_"7_/W<?^ S_X5U7]BZ9_T#[;_OV*/[%TS_H'
MVW_?L4 <K_PMOPE_S]W'_@,_^%'_  MOPE_S]W'_ (#/_A75?V+IG_0/MO\
MOV*/[%TS_H'VW_?L4 <K_P +;\)?\_=Q_P" S_X4?\+;\)?\_=Q_X#/_ (5U
M7]BZ9_T#[;_OV*/[%TS_ *!]M_W[% '*_P#"V_"7_/W<?^ S_P"%'_"V_"7_
M #]W'_@,_P#A75?V+IG_ $#[;_OV*/[%TS_H'VW_ '[% '*_\+;\)?\ /W<?
M^ S_ .%'_"V_"7_/W<?^ S_X5U7]BZ9_T#[;_OV*/[%TS_H'VW_?L4 <K_PM
MOPE_S]W'_@,_^%'_  MOPE_S]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'V
MW_?L4 <K_P +;\)?\_=Q_P" S_X4?\+;\)?\_=Q_X#/_ (5U7]BZ9_T#[;_O
MV*/[%TS_ *!]M_W[% '*_P#"V_"7_/W<?^ S_P"%'_"V_"7_ #]W'_@,_P#A
M75?V+IG_ $#[;_OV*/[%TS_H'VW_ '[% '*_\+;\)?\ /W<?^ S_ .%'_"V_
M"7_/W<?^ S_X5U7]BZ9_T#[;_OV*/[%TS_H'VW_?L4 <K_PMOPE_S]W'_@,_
M^%'_  MOPE_S]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <K_P +
M;\)?\_=Q_P" S_X4?\+;\)?\_=Q_X#/_ (5U7]BZ9_T#[;_OV*/[%TS_ *!]
MM_W[% '*_P#"V_"7_/W<?^ S_P"%'_"V_"7_ #]W'_@,_P#A75?V+IG_ $#[
M;_OV*/[%TS_H'VW_ '[% '*_\+;\)?\ /W<?^ S_ .%'_"V_"7_/W<?^ S_X
M5U7]BZ9_T#[;_OV*/[%TS_H'VW_?L4 <K_PMOPE_S]W'_@,_^%'_  MOPE_S
M]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <K_P +;\)?\_=Q_P"
MS_X4?\+;\)?\_=Q_X#/_ (5U7]BZ9_T#[;_OV*/[%TS_ *!]M_W[% '*_P#"
MV_"7_/W<?^ S_P"%'_"V_"7_ #]W'_@,_P#A75?V+IG_ $#[;_OV*/[%TS_H
M'VW_ '[% '*_\+;\)?\ /W<?^ S_ .%'_"V_"7_/W<?^ S_X5U7]BZ9_T#[;
M_OV*/[%TS_H'VW_?L4 <K_PMOPE_S]W'_@,_^%'_  MOPE_S]W'_ (#/_A75
M?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <K_P +;\)?\_=Q_P" S_X4?\+;\)?\
M_=Q_X#/_ (5U7]BZ9_T#[;_OV*/[%TS_ *!]M_W[% '*_P#"V_"7_/W<?^ S
M_P"%'_"V_"7_ #]W'_@,_P#A75?V+IG_ $#[;_OV*/[%TS_H'VW_ '[% '*_
M\+;\)?\ /W<?^ S_ .%'_"V_"7_/W<?^ S_X5U7]BZ9_T#[;_OV*/[%TS_H'
MVW_?L4 <K_PMOPE_S]W'_@,_^%'_  MOPE_S]W'_ (#/_A75?V+IG_0/MO\
MOV*/[%TS_H'VW_?L4 <K_P +;\)?\_=Q_P" S_X4?\+;\)?\_=Q_X#/_ (5U
M7]BZ9_T#[;_OV*/[%TS_ *!]M_W[% '*_P#"V_"7_/W<?^ S_P"%'_"V_"7_
M #]W'_@,_P#A75?V+IG_ $#[;_OV*/[%TS_H'VW_ '[% '*_\+;\)?\ /W<?
M^ S_ .%'_"V_"7_/W<?^ S_X5U7]BZ9_T#[;_OV*/[%TS_H'VW_?L4 <K_PM
MOPE_S]W'_@,_^%'_  MOPE_S]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'V
MW_?L4 <K_P +;\)?\_=Q_P" S_X4?\+;\)?\_=Q_X#/_ (5U7]BZ9_T#[;_O
MV*/[%TS_ *!]M_W[% '*_P#"V_"7_/W<?^ S_P"%'_"V_"7_ #]W'_@,_P#A
M75?V+IG_ $#[;_OV*/[%TS_H'VW_ '[% '*_\+;\)?\ /W<?^ S_ .%'_"V_
M"7_/W<?^ S_X5U7]BZ9_T#[;_OV*/[%TS_H'VW_?L4 <K_PMOPE_S]W'_@,_
M^%'_  MOPE_S]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <K_P +
M;\)?\_=Q_P" S_X4?\+;\)?\_=Q_X#/_ (5U7]BZ9_T#[;_OV*/[%TS_ *!]
MM_W[% '*_P#"V_"7_/W<?^ S_P"%'_"V_"7_ #]W'_@,_P#A75?V+IG_ $#[
M;_OV*/[%TS_H'VW_ '[% '*_\+;\)?\ /W<?^ S_ .%'_"V_"7_/W<?^ S_X
M5U7]BZ9_T#[;_OV*/[%TS_H'VW_?L4 <K_PMOPE_S]W'_@,_^%'_  MOPE_S
M]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <K_P +;\)?\_=Q_P"
MS_X4?\+;\)?\_=Q_X#/_ (5U7]BZ9_T#[;_OV*/[%TS_ *!]M_W[% '*_P#"
MV_"7_/W<?^ S_P"%'_"V_"7_ #]W'_@,_P#A75?V+IG_ $#[;_OV*/[%TS_H
M'VW_ '[% '*_\+;\)?\ /W<?^ S_ .%'_"V_"7_/W<?^ S_X5U7]BZ9_T#[;
M_OV*/[%TS_H'VW_?L4 <K_PMOPE_S]W'_@,_^%'_  MOPE_S]W'_ (#/_A75
M?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <K_P +;\)?\_=Q_P" S_X4?\+;\)?\
M_=Q_X#/_ (5U7]BZ9_T#[;_OV*/[%TS_ *!]M_W[% '*_P#"V_"7_/W<?^ S
M_P"%'_"V_"7_ #]W'_@,_P#A75?V+IG_ $#[;_OV*/[%TS_H'VW_ '[% '*_
M\+;\)?\ /W<?^ S_ .%'_"V_"7_/W<?^ S_X5U7]BZ9_T#[;_OV*/[%TS_H'
MVW_?L4 <K_PMOPE_S]W'_@,_^%'_  MOPE_S]W'_ (#/_A75?V+IG_0/MO\
MOV*/[%TS_H'VW_?L4 <K_P +;\)?\_=Q_P" S_X4?\+;\)?\_=Q_X#/_ (5U
M7]BZ9_T#[;_OV*/[%TS_ *!]M_W[% '*_P#"V_"7_/W<?^ S_P"%'_"V_"7_
M #]W'_@,_P#A75?V+IG_ $#[;_OV*/[%TS_H'VW_ '[% '*_\+;\)?\ /W<?
M^ S_ .%'_"V_"7_/W<?^ S_X5U7]BZ9_T#[;_OV*/[%TS_H'VW_?L4 <K_PM
MOPE_S]W'_@,_^%'_  MOPE_S]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'V
MW_?L4 <K_P +;\)?\_=Q_P" S_X4?\+;\)?\_=Q_X#/_ (5U7]BZ9_T#[;_O
MV*/[%TS_ *!]M_W[% '*_P#"V_"7_/W<?^ S_P"%'_"V_"7_ #]W'_@,_P#A
M75?V+IG_ $#[;_OV*/[%TS_H'VW_ '[% '*_\+;\)?\ /W<?^ S_ .%'_"V_
M"7_/W<?^ S_X5U7]BZ9_T#[;_OV*/[%TS_H'VW_?L4 <K_PMOPE_S]W'_@,_
M^%'_  MOPE_S]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <K_P +
M;\)?\_=Q_P" S_X4?\+;\)?\_=Q_X#/_ (5U7]BZ9_T#[;_OV*/[%TS_ *!]
MM_W[% '*_P#"V_"7_/W<?^ S_P"%'_"V_"7_ #]W'_@,_P#A75?V+IG_ $#[
M;_OV*/[%TS_H'VW_ '[% '*_\+;\)?\ /W<?^ S_ .%'_"V_"7_/W<?^ S_X
M5U7]BZ9_T#[;_OV*/[%TS_H'VW_?L4 <K_PMOPE_S]W'_@,_^%'_  MOPE_S
M]W'_ (#/_A75?V+IG_0/MO\ OV*/[%TS_H'VW_?L4 <HWQ:\)D$"ZN/_  &?
M_"JGPJN$O(M<O(@_DW%^[QEE*D@LQZ&NV_L73/\ H'VW_?L58@M8;5-D$*1K
MZ(H% $PI:04M !24M% !1110 4E+10 E+110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gvvh0m1pmdf2000001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .1!YX# 2(  A$! Q$!_\0
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M%%% !129HS0 M%)FEH **** "BBB@ HI"<#-&X8S0 M%&<T4 %%%% !1110
M44F:,T +129I: "BBB@ HHHH ***3- "T4F:6@ HHHH **** "BBB@ HI,\G
MVHS0 M%%% !1110 44F:,T +1110 44F11D4 +129YQ1F@!:*** "BBB@ HI
M,BC- "T444 %%%% !129HW"@!:*3-+0 4444 %%%% !129HS0 M%)D49XH 6
MBDR,XHW"@!:*3(_.C/% "T444 %%%% !11FC- !129I: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***\^^)GC+5/"ATG^S?)_P!*N/+D
M\U-W&.U 'H-%51>PQP1O<S11,R@_.X7/YT1ZC9RL$CNX'8]ED!- %CO0:CEG
MB@&Z:6.,>KL /UKR;X@>(+F+QYX=M]/U-A#+*!+'!-PW!ZXH ]='6G5S=\-=
M.L61M-6TZ"R(!EMYXBTK_P"Z<_TK<EO;:W(6:XA1O1W"_P Z +%%5C?6OE>;
M]IA$9X#;QC/UJO<ZU86]M),;NW;8,[1*N3^M &C17*>%/'%GXMT^:X@5;1T<
MH$EE4DGGGCZ5;T(ZV+B[.JZKIUY#N_<K:Q[3&,GAN30!T%%5#J=B#@WEOGT\
MU?\ &GR7MO$H,EQ"@;[I9P : +%%54U"SE<)'=0.Q[+(":L@YH 6BBB@ HHH
MH **** "BBB@ HHHH ****  ]*:1WIU)CG- '+Z5K-U=>.M7TIV4VMM;121C
M'(9B<\_A74UP^A #XJ>(?^O*W_FU=Q0 4444 %(:6D/0T 9TVMZ1;S-%/JME
M'(IY1[A%(^H)J>UO;.^7?9W4-P@ZM%(' _*O&O#^G:-?_%;Q"NL6]G,@8;?M
M 7 ^4>M2^!O(M/B?JD/A]I&T-$)=5^X'P<@=NM 'M(IU>96WQ;EU#Q#>:-IG
MA:]O)K1RCLDZ <'&>:W_ !#X\M_#>DVMS>V4HO;D?)8A@7)YXST[4 ==2=S7
MGS_$^2PO;.+7/#EWI<%WCRYY9E=<G& <>N:=??%"W&MG2M%TJXUB=4WOY$@4
M(,=\T =#XC\7:3X56U.JRR(+J3RHMD9;+8SSCI6B=4L$DBBDO((YI@"D;R ,
MWT!YKP?XC^+X_%-MI .GSV-Q;W^V2&;DCY>N<8-=OXG\5Z#X?UK1X;_0!>7C
MP"2*X^7,>#CN,T >F\?A4%Q=06D7FW4\4$0ZO*X4?F:\QTWXS2:Q]J.G^$;^
M>.U#&1Q.@  SGJ/:M"[^(.A:QX FURYTDWELC[);.0@D'('.1CO0!Z#!-%<1
M+-#*DD3#*NC!@1[$5**\]N/B-HV@^&-(EM=-;?>1@VVGPD @<\=,=JL:?\1V
MEU==.U70+W2V:,R*\C"0$#']T>] '=U@>(O%ND^&'M1J<LB?:I/+BV1ELM[X
MZ5SA^)=Y-'=7&G^$[^[LK<MNN!,J [<YX;GM7 >/_%EGXPT[PUJ-HC0_Z<5>
M)SDJ0!P: /?D<.H<=",BGU#;\VT7^Z*FH **** &DXKF;O6;N+Q_IFD(P^R7
M%M-)(".2RXQS^-=.17$ZA_R5O0_^O*X_D* .V'2EHHH **** "H9IXK>)I9Y
M4BB499W8*!^)J:N,^*8_XMSK'_7N: .J%[:&U^U"YA-OU\T.-OY]*+>\MKR/
M?:7,,Z$_>B<,/S%>4:?_ ,F_/SC_ $>3^M<I\*M7O?!FH6EGJ<G_ !*=37,,
MI^ZKXSC\R!0!] QWUI+.UO'=0O,GWHUD!9?J.M5I-=TB&1XI=6L8Y$."CSHI
M4^X)KRKPDP/QH\2$'@Q\8_WC5'P9H^FZQ\6?%":E8P7:+(2!,@8#A?6@#VFT
MU*POMWV.]M[G;][RI5?'Y&K8/XUXMX^\/IX"NK7Q'X<DDLT>XC2YM8SA'R<=
M![5Z9>^)+;2?":Z[>@B,0K(5'7)'2@#=)XSVI,?G7G&G?%9[UM,DF\,7UO9Z
MB<17)E5U'!/( SVKFM?\7^(H/BE8Q0Z7?"'RR19K<*!/R.?3VYH ]NI:X>_\
M?W-BUM;?\(Y>RZG/D_8UD7* =RWW:SU^+EK9ZS)I>O:1<:1.L?F+YTJN&Z_W
M?I0!Z117E5S\9V@TG^UE\*WTFG,VU+D3H WX=:T9?BK&JV4$6AW,VIW8W+8I
M,NX#U)Z>GYT >B45PVF_$9)O$"Z+K&D7&D7;C,8FD5P_TVUW&: %HHHH *0T
MM% ',>+-8N](ET06K*OVO48[>7(SE#G/\JZ85QGC\8G\,?\ 89A_K79XH 6B
MBB@ HHHH 0TTD*A8L .I)[4XU3U3_D&7&?[AH K?\)%H:D@ZQ8#G!S<IG^=.
MU'7-.TW2)-4FG#V<8R9(?G_+%>-_#S2/"UUX2UB?6K:R9UEDS)(%W@9;IWJE
MH4ER?AMXD3S)6TU92+3S,_=W'I^&* /<M$UNR\0Z9#J.GN[6\PRA9"I_*M$5
MX3X ^(USH_@-"OAF^N;2Q0>;<I*JKV&<'DUZA'XXTZ3P>OB-$D:!H]XB49;/
MIP/:@#J**\UO?BM=Z981ZE?^$;^WT^1POVAITP 3UQUJWJOQ2M+34+"PT[3)
M]2N[R(3)'%($PI&1RU '?T5P5K\4;#^RK^\U.PN--ELW*-;S')8C'0@8[U4?
MXIW5MIL.J7GA.^M],D;'VIIT(4>I YH ]'-4[G4;&Q91=WMO 6X ED5=WTR:
M-/U"WU:PBN[5P\,J[E(]Q7C'QD\(65E;6VK_ &N^FN7N00L\^]$Y'08XZT >
MXQLKH&1@RGH0<@T^LS0.-!LO^N0K2H 6BBB@ HHHH *Y[QMJMUHG@_4M1LV"
MW$,8*$C(SN _K70UR7Q-X^'.M'_IDO\ Z&M '2VC&2TA<]6C4GZD58JO8C_0
M+;_KDO\ (58H **** "@T44 -[_2J-UJVFV4HCN]0M8)",A99E0X_$U?KQCQ
M/::?>?&O38M2A@DMS!RL^-OWO>@#UNUU33[]MMG?6MPPZB*96(_(UEZ=XPT?
M4]<NM&M996O+;F16C( Z]_PKRZ]M[#3OB]IT'A3$2D?Z9';C]V!E?3CI63IO
MB2;0/B]JPM]*N-2EG.U8X6"XP3U)H ^AL4ZN*\+_ !!@\0ZO>Z3<:=/IU]9_
MZR&9PQ/..HJ*?XAW+ZI=6>D>&K[4EMFVR2I(L8S[;J .ZHKSNR^+NDW/AW4-
M5GLYK:2Q?RY;9V!;<<X&0,<XHT_XI/<W5@M[X;O;&UO@6CNFE5U QGD+0!Z)
M17 M\2VO-6NK#0O#]UJPMO\ 630S*B@_\"K5\)^.+/Q6)HD@>TO(&VS6TK99
M#^% &]=7]E88:[NX+=6Z&:4)G\Z2UU&QO\_8[VWN-O)\F57Q]<&L;6_!>D:_
MJD-_J:RS^2,+"SYB_%:\[\.VJ6/QGN[70(C'IJQ+]H2/A%.6[?7% 'L_TI1T
MI.,4Z@ HHHH **** *NHRO!IUU-']^.)W'U )%9'@O5+G6O"FG:A>,#<3PAY
M"%P,FM75O^0/??\ 7O)_Z":Y[X:?\D^T?_KW6@#K!2T44 %%%% !3>].I,4
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M,K[WM3 NT_CUIVC_  OTS3+?6()[F2\BU-R[JZ ;"23QCTS0!SN@_#CP]?\
MP[BOKJ%9=0N(//-ZQ^=6QGBO*[F:Z\1VVCZ5?WLDD:W(MQ*IYV\U[3%\+[VW
MTM])M?%U]%IKG_CV%NA 'INSFK$_PHTISI(MKF2V&G,&4*@/F$9ZY^M '">-
M?#.G^"[_ ,,WFB*UK,9$21D/,H+#.:]VLW,MI#(WWF0$_E7,^*_ T'BHZ>9K
MV6#[$ZNNU =V#FNH@B\B".(-NV*%R>] $M%%% !1110 4444 %%%% !1110
M4444 %%%% '#Z%_R5/Q#_P!>5O\ S:NXKA]"_P"2I^(?^O*W_FU=Q0 4444
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MC /Z58H .U%%% !1110!Q?Q _P!?X8_[#,/]:[2N+^('^O\ #'_89A_K7:4
M%%%% !1110 AJGJG_(,N/]PU=I" 1@@$4 >)_"OP7X=US1KZXU32+>YF%RP#
MR YQN;WKM_']K!8_#N]MK6$1PQQA51!T%=G%#%""(HDC!Y(10*5XTD0I(BNI
MZAAD4 >3>'$/_"BG&#DVH[<]JPM(US4_#WP36[TR!I)AE68#F(<_-7NBP0K%
MY2Q((^FP*,?E2"UMQ"8A!$(SU38,?E0!\U^,=:LKOP4N/&^H:E=RE&>Q+*54
M]^W:MA+SPU)9Z);ZJUUHNH16J-%JJ  ?=Z9.?Y=Z]V_LO3_^?"U_[\K_ (4]
M["SD #VD#!> &C!Q0!\SZ[+XF\5:+>PP32ZKI>FW9=-1ZNXP!].^>E;MY?Z!
M>>&8X)O'6LWIE41OID;(6STQC']:]]CM;>*,QQV\21MU54 !_"HQIE@K;A8V
MP8=Q$O\ A0!D>#=,@T?PK:6UNMPD2KN47&-X!YYQ7FGQE\4Z'>Z5#86NI02W
M4%S^\B0G<F",YKVO  P!QZ56;3;%V+/96S,>23$I)_2@##\'>(=(UG1[>+3[
M^*YDAC D5#RIKI0:BAM;>WSY%O%%GKL0+_*IJ "BBB@ HHHH *Y+XF_\DXUK
M_KDO_H:UUM<E\3?^2<:U_P!<E_\ 0UH Z:Q_Y!]M_P!<E_D*GJ"Q_P"0?;?]
M<E_D*GH **** "BBB@!*\9\4:18ZS\:=.M=1M$N;=K?E'!P?FKV>HS!"91*8
MHS(.CE1D?C0!DZ-X7T3PZ9/[)TV"T\P@OY8/->9>"%)^,&O$@]!U'NU>SU$M
MO DAD2&-9&ZL% )_&@#QS2MR?'#6&523Y65!'!.X\5EVOC";4]:U?^W_ !5>
M^''MYMD5I"0-PP/4&O=Q;P"4RB&,2'J^T9_.HWTZQD<N]G;LQZLT2DG]* /F
MGP9J&F16OB6;4[2ZU33Y)E5GP"W.[YST'O6NVM2V-SIMAX,UZ?68[M'1M-E(
M(@!7IP!T^O:OH!;"S1&1+2!5;J!& #1'864+AXK2!''1EC (_2@#YT\&0IX=
M?4=,UWQ9J'AVY24MY<94+)TYY!YKN_A?INES:YJ&M6$^J7;.=C75T%V2\=1C
MZ5ZA)86<SEY;2"1CU9HP34D4$4";88DC7T10!^E 'FWQ*^((\/R1Z+:3)!>7
M/#3OG;"IZDX[X-2> -3\&Z7$MC9Z_:WNJW1W32 G=(QY/:O0I;*TN&W36L,C
M>KQ@G]:;'I]E$X>.SMT8=&6)01^E %C\*6BB@ HHHH **** *>K?\@>^_P"O
M>3_T$USWPT_Y)]H__7NM=#JW_('OO^O>3_T$USWPT_Y)]H__ %[K0!UM%%%
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ML-GY?E_9(-F<[?+&,_2GRVMO.H6:"*11T#H"!0!XEX[U:S\>ZYI]CX<$=_\
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M*X?0O^2I^(?^O*W_ )M7<4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5Q.H_\E;T3_KRN/Y"NVKB=1_Y*WHG_ %Y7'\A0
M!VU%%% !1110 4444 %%%% !1110 4444 %%%% !2$4M% #<<TN#WI:* $'2
MEHHH **** "BBB@#B_B!_K_#'_89A_K7:5Q?Q _U_AC_ +#,/]:[2@ HHHH
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M%%% !1110 5Q6E?\E-UG_KG'_P"@5VM<5I7_ "4W6?\ KG'_ .@4 =K1110
M4444 %%%% !1110 444UNG>@!<C&:,BO$_'-SK^H?%&ST/3=;NK"WD3<_ER$
M# QGIWJ;79-8^'_BK2'37;V_L;Q_*>&[E+\XY/ZT >S9HR*\P\8W2IXD5=5\
M8'3;';E+:RWK*?J0"*P? ?BJX'Q+N]&@UFXU329(R\4ER6+J1CUQZGM0![;D
M5C:OXJTG0[VTM+Z9TFNWV0@(2"<9ZUY1/_;WB'XQ76C)X@O;2P2(.8X92O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124
M<9\0/]?X8_[#,/\ (UVE<7\0/]?X8_[#,/\ (UVE !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %<E\3?\ DG.L_P#7)?\
MT-:ZVN2^)W_).=9_ZY+_ .AK0!TUC_R#[;_KDO\ (5/4%C_R#[;_ *Y+_(5/
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M%/5O^0/??]>\G_H)KGOAI_R3[1_^O=:Z'5O^0/??]>\G_H)KGOAI_P D^T?_
M *]UH ZVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** .)^'7_'KJ_P#V$[C_ -"KMJXGX=?\>NK_ /83N/\ T*NVH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KBM
M*_Y*;K/_ %SC_P#0*[6N*TK_ )*;K/\ USC_ /0* .UHHHH **** "BBB@ H
MHHH *0TM-(H \%\?P:M<_&*PCT6=(;P)N5I#A2!C(/UKJV\$>(_$7BFRU/Q-
M+9);V>#'!:.S MCDG</I7:7'A72+KQ!%K4ML3?1KM63>1C\/PK:QW[T >8W?
M@GQ)8^/K[Q%H[V%VEVN#%?,0(^<X&!4'AOP#XFMOB)-XGUF:QVR(5\JW8_+T
MZ9'M7JN.O/'I1B@#@=+\$ZA9?$^Z\2R2P&TEBV*H)W [<4_XA>#=1\1SZ9>Z
M3/"EW8RF0+,2%/&.U=Y[=:.G:@#S'7/!OB?Q+JVC:C?_ -G0R64H9UA=B"!G
MU[\UH^._!>H>)YM(>UD@064BM)YA(S@YXKO.>E'.0<<T >6VOP_USPQXAFU+
MPX;">.Z4>?#>DA=WM@>IK5T[PWXJN)=0GUJ_MU6>,K#:6W,2'ZD9KOOQHQVH
M XKX:^$KWP?H<]G?20R222[PT1)&*[8=*3FE'2@!:*** "BBB@ HHHH ****
M /G^35O$<DC.-79=QZ 'C]:;_:?B/_H,/Q]?\:/?UH[5Z:HPL>"\74ON']I^
M(_\ H,/^O^-']I^(_P#H,/\ K_C12T>Q@+ZW4[B?VGXC_P"@R_Z_XT?VGXC_
M .@R_P"O^-+^=%'L8=@^MU.XG]I^(_\ H,/^O^-']I^(_P#H,/\ K_C1^=%'
ML8] ^MU2YI,_B&_U:UM'UIPLL@4G!_QKOO\ A#-8Q_R,$O\ X]_C7%>&C_Q4
MNG]?]<*]K%<>(CRRLCT\%-SB[G$_\(;K'_0P2_\ CW^-'_"&:Q_T,$O_ (]_
MC7;T5@=AQ'_"&:Q_T,$O_CW^-'_"&:Q_T,$O_CW^-=Q10!P__"&:Q_T,$O\
MX]_C1_PAFL?]#!+_ ./?XUW%% '#_P#"&:Q_T,$O_CW^-'_"&:Q_T,$O_CW^
M-=Q10!P__"&:Q_T,$O\ X]_C1_PAFL?]#!+_ ./?XUW%% '#_P#"&:Q_T,$O
M_CW^-'_"&:Q_T,$O_CW^-=Q10!P__"&:Q_T,$O\ X]_C1_PAFL?]#!+_ ./?
MXUW%% '#_P#"&:Q_T,$O_CW^-'_"&:Q_T,$O_CW^-=Q10!P__"&:Q_T,$O\
MX]_C1_PAFL?]#!+_ ./?XUW%% '#_P#"&:Q_T,$O_CW^-'_"&:Q_T,$O_CW^
M-=Q10!P__"&:Q_T,$O\ X]_C1_PAFL?]#!+_ ./?XUW%% '#_P#"&:Q_T,$O
M_CW^-'_"&:Q_T,$O_CW^-=Q10!P__"&:Q_T,$O\ X]_C1_PAFL?]#!+_ ./?
MXUW%% '#_P#"&:Q_T,$O_CW^-'_"&:Q_T,$O_CW^-=Q10!P__"&:Q_T,$O\
MX]_C1_PAFL?]#!+_ ./?XUW%% '#_P#"&:Q_T,$O_CW^-'_"&:Q_T,$O_CW^
M-=Q10!P__"&:Q_T,$O\ X]_C1_PAFL?]#!+_ ./?XUW%% '#_P#"&:Q_T,$O
M_CW^-'_"&:Q_T,$O_CW^-=Q10!P__"&:Q_T,$O\ X]_C1_PAFL?]#!+_ ./?
MXUW%% '#_P#"&:Q_T,$O_CW^-'_"&:Q_T,$O_CW^-=Q10!P__"&:Q_T,$O\
MX]_C1_PAFL?]#!+_ ./?XUW%% '#_P#"&:Q_T,$O_CW^-'_"&:Q_T,$O_CW^
M-=Q10!P__"&:Q_T,$O\ X]_C1_PAFL?]#!+_ ./?XUW%% '#_P#"&:Q_T,$O
M_CW^-'_"&:Q_T,$O_CW^-=Q10!P__"&:Q_T,$O\ X]_C1_PAFL?]#!+_ ./?
MXUW%% '#_P#"&:Q_T,$O_CW^-)_PANLY_P"1@D_\>_QKN:81WQS0!XWIOAO4
MS\0=9MDUF19([6%FD^;+9+>]=1_PB>L_]#!+_P"/?XT:3_R5/Q!_UY6_\VKL
MJI$-LXW_ (1/6?\ H/R_^/?XT?\ ")ZS_P!!^7_Q[_&NRYHH%=G&_P#")ZS_
M -!^7_Q[_&C_ (1/6?\ H/R_^/?XUV5'-%@YF<;_ ,(GK/\ T'Y/_'O\:/\
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MB>L_]!^7_P >_P :[+FCFBP7.-_X1/6?^@_+_P"/?XT?\(GK/_0?E_\ 'O\
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M_P"/?XT?\(GK/_0?E_\ 'O\ &NRYHYHL',SC?^$3UG_H/R_^/?XT?\(GK/\
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M2_\ CW^-=Q10!P__  AFL?\ 0P2_^/?XT?\ "&:Q_P!#!+_X]_C7<44 </\
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MAFL?]#!+_P"/?XT?\(9K'_0P2?\ CW^-=Q10!P__  AFL?\ 0P2_^/?XT?\
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M;;_H'Q_G_P#6H^KR#Z_#N>E_\)!I'_00M_\ ONC_ (2#2/\ H(6__?=>:?\
M"0VW_0/C_/\ ^M1_PD-M_P! ^/\ /_ZU'U>0?7X=STO_ (2#2/\ H(6__?='
M_"0:1_T$+?\ [[KS7_A(;;_H'Q_G_P#6I/\ A(;;_H'Q_G_]:CZO(/K\.YZ7
M_P )!I'_ $$+?_ONC_A(-(_Z"%O_ -]UYI_PD-M_T#X_S_\ K4?\)#;?] ^/
M\_\ ZU'U>0?7X=STO_A(-(_Z"%O_ -]T?\)!I'_00M_^^Z\T_P"$AMO^@?'^
M?_UJ/^$AMO\ H'Q_G_\ 6H^KR#Z_#N>E_P#"0:1_T$+?_ONC_A(-(_Z"%O\
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MBBB@ HHHH **** "BBB@ HHHH ****0'*?#;_CRU?_L)W'_H5=P.E</\-O\
MCRU?_L)W'_H5=P.E2:+8****!A1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5Q6E?\E-UG_KG'_Z!7:UQ6E?\E-UG_KG'_P"@4 =K
M1110 UJ@N;A+6!YI" JJ2:L&N0\?3O%HAC1BNYAR/K515V8XBI[.FY'+:WXZ
MN[J9DM#Y4.< ]ZW_  E]CUNQ9[N&.6X0X9G )->7'Y@=P//I6MH6MW&CWRRQ
M<ACAD[$5U2A:.A\Y1QKE5_>;'L'_  C^E_\ /C!_WP*0Z!I?_/C!_P!\"H]%
MUU=6@WK!)'Z[JH^(?%']DHR+;R-(1PW85S:WL>[+V,8\UCG?&%Y'H\T,.FJM
MO(#N?ROER/2CPSXWDDN$M=08'<<*V.GUKB-0OY]2O'N+ALL3GV%5XR4.5[GC
M%=/(N74\'Z[)5KQV/H17#J&!X(R*R_$\TD'AZ\EA<I(L9(8=N*/#MPUSHUN[
M==N/RIGBPG_A&+_C_ED?Y5R-69]-3ESP4CY>M_&_B*&XCD.JW1VL"=TA*X^E
M?4>@ZU!JWANVU,./+>+<Q^G!KY=\.>'6UW3]4:%2TUI!YJ@=6Y KHO#GCLZ1
MX#U719I")VRD SRHP<_K2-;W*GB[Q_K%[XENWL]0N88%<QJD<A XXKL+?7M4
M;X*37YOIC="X8"8N=P'R]Z\XGT!H_",>M3$A[B0B,'O@X-=M;?\ )!)_^OE_
M_9: ,CPU%XY\4P23:=J5W*D;;3F8\?K7>>&M&\9:-;:G<ZU=3M$MK(4W29PV
M.#UKSWP'\09O!UG<016BS>:^\DCVKT[1?B%-XOT;5X9;/R1';.<XZ\4 >7Z+
M?>+O$>M2:?8:K=&3+'!E../QK1OM7\<^ M3@?4;J5T=N/-8LI_#-5/AOJBZ/
MXNGOY())(XP^X)C.,&KOQ&\<Q^.IK.PTNUD"0OO&[JQ(Q0![##X\T]?!<7B*
M?@-'DQ9Y+>GZ5X_=^,?&7CG4I(=&$L4.?E6'Y3CW.:J^-K.\T'P=H>C7(*&2
M+SI$/8Y(_E7LOPRT6WTCPA;&)%\V8;I' ^]Z4 >5)X?^(VB217;37;1AAO'F
MY[^F:N?$;Q5K=AJNE"VO9H/,M4>1%8CYB3FO?",KVQWS7SS\:Q_Q6EF5&<0K
MC_OHT >N7GB:+0/!4>IW<H:7RLKD_>;TKR[P+J'B?QMXE>=]0N(K".0N^UB
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MQI]U/)'IUFVQD4\'&1T]\56\(P'P[\7)-'T"]DNM.:,A@K%DP1^7%2>'+Y?
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MT.Y\0WPBARMNI_>R?X5W/C;3+?2?AAJEK;* B0J,XY/SK74:5I5OI-DEM;H
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M\M7_ .PG<?\ H5=N.E2:+86BBB@84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<5I7_)3=9_ZYQ_^@5VM<5I7_)3=9_ZYQ_^@4 =
MK1110 AK!\5Z4=5T66%/OK\P_#FMXTW ((ZTT[,SJP4XN+/GN:%X9620,I4X
M(QSFNR\#^'EU"5KVY0&.,X53W-=AK'A&PU.3SF39+ZKQG\*YV;77\'D:<EN)
M%7G=G&170ZCDK(\&.$6'J\]38]!CACB7:BJH'H*BN[*"[A9)HU8$<Y%>??\
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M>61_GYRN,?SKU&N+U#_DJVB_]>=Q_(4>TEW#ZM3[$O\ PKG1_P#GK=?]_/\
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M_"N-&_YZW?\ W\_^M1_PKC1O^>MW_P!_/_K5V%%'M)=P^K4^QQ__  KC1O\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** *FJ_\@>]_ZX/_ .@FN?\
MAO\ \B#I'_7!:Z#5?^0/>_\ 7!__ $$US_PW_P"1!TC_ *X+0!U=%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444@.4^&_
M_'EJ_P#V$[C_ -"KMQ7$?#?_ (\M7_["=Q_Z%7<5)HM@HHHH&%%%% !1110
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M2+72H]3L=4\0S:[$/-"O'.89']-I&,5V&L:Q?^(M0T/0$FELUO8#/<.A*/\
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M/^$$T3_GG/\ ]_30!L_VQIO_ #_6_P#W\%']L:;_ ,_UO_W\%8W_  @FB?\
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M ._@H_MC3?\ G^M_^_@K&_X031/^><__ ']-'_"":)_SSG_[^F@#9_MC3?\
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MQIO_ #_6_P#W\%8W_"":)_SSG_[^FC_A!-$_YYS_ /?TT ;/]L:;_P _UO\
M]_!1_;&F_P#/];_]_!6-_P ()HG_ #SG_P"_IH_X031/^><__?TT ;/]L:;_
M ,_UO_W\%']L:;_S_6__ '\%8W_"":)_SSG_ ._IH_X031/^><__ ']- &S_
M &QIO_/];_\ ?P4?VQIO_/\ 6_\ W\%8W_"":)_SSG_[^FC_ (031/\ GG/_
M -_30!L_VQIO_/\ 6_\ W\%']L:;_P _UO\ ]_!6-_P@FB?\\Y_^_IH_X031
M/^><_P#W]- &S_;&F_\ /];_ /?P4?VQIO\ S_6__?P5C?\ "":)_P \Y_\
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M\_UO_P!_!1_;&F_\_P!;_P#?P5C?\()HG_/.?_OZ:/\ A!-$_P"><_\ W]-
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M\Y_^_IH_X031/^><_P#W]- &S_;&F_\ /];_ /?P4?VQIO\ S_6__?P5C?\
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M.ABU"6.6Y5<.\0(#?G7/:CI7BZ._FDT76+,03#[E\KN4_P!W'2NNQ2;>,=J
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M_GRO/^_?_P!>C_A+[7_GRO/^_?\ ]>GRL7M8]SHJ*YW_ (2^V_Y\KS_OW_\
M7H_X2^U_Y\KS_OW_ /7I<K'[6/<Z*BN=_P"$OM?^?*\_[]__ %Z/^$OM?^?*
M\_[]_P#UZ.5A[6/<Z*BN=_X2^U_Y\KS_ +]__7H_X2^U_P"?*\_[]_\ UZ.5
MB]K'N=%17._\)?:_\^5Y_P!^Z/\ A+[7_GRO/^_?_P!>CD8_:Q[G15Q>H?\
M)5M%_P"O.X_D*TO^$OM<X^QWG_?%<M>^(('^(>E7WV>X"Q6TR%"OS'..@I<C
M#VL>YZ717._\)?;?\^5Y_P!^_P#Z]'_"7VO_ #Y7G_?O_P"O3Y6'M8]SHJ*Y
MW_A+[7_GRO/^_?\ ]>C_ (2^U_Y\KS_OW_\ 7HY6'M8]SHJ*YW_A+[7_ )\K
MS_OW_P#7H_X2^U_Y\KS_ +]__7HY6'M8]SHJ*YW_ (2^U_Y\KS_OW_\ 7H_X
M2^V_Y\KS_OW_ /7HY6'M8]SHJ*YW_A+[7_GRO/\ OW_]>C_A+[;_ )\KS_OW
M_P#7HY6'M8]SHJ*YW_A+[7_GRO/^_?\ ]>C_ (2^U_Y\KS_OW_\ 7HY6'M8]
MSHJ*YW_A+[;_ )\KS_OW_P#7H_X2^U_Y\KS_ +]__7HY6'M8]SHJ*YW_ (2^
MV_Y\KS_OW_\ 7H_X2^U_Y\KS_OW_ /7HY6'M8]SHJ*YW_A+[7_GRO/\ OW_]
M>C_A+[7_ )\KS_OW_P#7HY6'M8]SHJ*YW_A+[;_GRO/^_?\ ]>C_ (2^U_Y\
MKS_OW_\ 7HY6'M8]SHJ*YW_A+[;_ )\KS_OW_P#7H_X2^V_Y\KS_ +]__7HY
M6'M8]SHJ*YW_ (2^U_Y\KS_OW_\ 7H_X2^U_Y\KS_OW_ /7HY6'M8]RCX\_U
M_AG_ +"\/]:["O-_%_B&"]ET)EM[A/(U*.5MZXR!G@>]=-_PE]M_SY7G_?NE
MR,?M8]SHJ*YW_A+[;_GRO/\ OW_]>C_A+[;_ )\KS_OW_P#7I\C%[6/<Z*BN
M=_X2ZV_Y\KS_ +]__7I&\8VB];.['_ /_KT<C#VL>YT=%<U_PFEE_P ^MW_W
MQ_\ 7H_X32R_Y]+O_O@?XT<C%[:/<Z6BN:_X32R_Y]+O_O@?XT?\)I9?\^EW
M_P!\#_&CD8>VAW.EHKFO^$TLO^?2[_[X'^-'_":67_/K=_\ ?'_UZ.1A[:'<
MZ6BN:_X32R_Y];O_ +XIX\861&?LUR/^ 4<C&JL.YT5%<\?&%BHR8;@?\!IG
M_"::=_SSG_[YHY&'M8=SI**YO_A--._YYS_]\T?\)IIW_/.?_OFCD8>UAW.D
MHKF_^$TT[_GE/_WS3E\9:<W\$P^JT<C#VL.YT5%<Z?&>F+U$H_"A?&>E,<;G
M'U%')(/:P[G145SY\8Z4.LC#G%;-I>6]] )K:19(SW4TFFAJ<7U)ZY7XD_\
M)/-8_P"N2_\ H:UU7'K7*_$G_DGFL?\ 7)?_ $-:DM'167_'A;_]<E_E5BH+
M+_CPM_\ KDO\A4],&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3GC<=12 C-.J#42EI.]+0 4444 %%%% !7%:5_R4W6?^N<?_ *!7:UQ6E?\
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M:PM:$LGE1!=Q 8_-Z]*S(=?\>ZAH+:[!-86MM%RT$EOO:0#J00>,B@#U6BN
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M^N2_RJ>H++_CQM\\$Q+Q^ J>N0]1A1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK_W[%'_".Z-_T#+7_OV*/K7D"RQ[W/%=P_O*:3<O]X#\:]L_X1W1O^@9:_\
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M_?L4?6_(/[,?<\3WK_>'YT;U_O#\Z]L_X1S1?^@;:_\ ?L4?\(YHO_0-M?\
MOV*/K7D']F/N>)[U_O#\Z-Z_WA^=>V?\(YHO_0-M?^_8H_X1S1?^@;:_]^Q1
M]:\@_LQ]SQ/>O]X?G1O3U'YU[9_PCFC?] RU_P"_8H_X1S1O^@;:_P#?L4?6
MQ?V8^YXF'0G@^U=5X?\ !ESJ5U'<7ORV8^8#NU>A+X=T8?=TVWX''R#BM)$5
M$"(%4 8P!43Q+:L;TL HN[8RWMXK6!(X5"HHP .U<U\2,?\ "O=8X_Y9+C_O
MM:ZJN6^)/_)/-8_ZY+_Z&M<LG<].-DK(Z*R_X\8.?^6:_P A4]067_'A;_\
M7)?Y"IZ0] HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@"IJO_('O?^N#_P#H)KG_ (;_ /(@Z1_UP6N@U7_D#WO_ %P?_P!!
M-<_\-_\ D0=(_P"N"T@.KHHHI@%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1112 Y3X;?\ 'EJ__83N/_0J[@=*X?X;?\>6K_\
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M76 <<8KDJUE+8]/#X;DU8HI:!2USG:%%%% !1110 4444 %<5I7_ "4W6?\
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MZYX)WZG94:Y-&CF^_<8_6BCCMGCUHKK1Y[W-7PU_R,NG_P#785[8*\3\-?\
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M *] '6?Q8HY[<G/:JT][!;V)NY'(A";RP';&:YR/XC>'995C6X<LY"J-O?\
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M3"4W X[8H L]Z/7GI7*-\1?#J.8VN9-RG;]SO^=='!?07%@EY&Q,+KO!([4
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M &3[U6\'ZS9Z)\-](N;UV2/R%Y49[4@.Z[4=3QS7-V/CK0M2O([6VN)&ED.
M-O\ ]>M36-:LM$M#=7KE8\@9 ]:8&A].?2C^5<YIGCC0]6OH[&TN)&FD^Z"F
M/ZUHZUKUCH%M'<7[E8Y&V# S0!I=AS17.Z;XVT35KU;6TG=IF&0"N/ZU?UG7
MK#0H$EOI&17/&!F@#3'6D[$^E<]IGC71=8O%L[2=FE<\97%7M9U^PT&%9K^1
MD5S@8% &I@YX&?>CMG!Q7/Z1XRT?6[T6=E,[3%2V"N.!5K6_$>G>'UA>_E9%
ME)"X7/(H UO\:!R,U@Z3XPTC7+HVUE,S2@9P5Q5C6O$FFZ 8OMTK)O'RX7-
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MV9)MK2"$GJ8XPN?RJS10!5N--L;M]]S9P3-ZR1AC^M.MK"SLRQM;6&$MU\M
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M4?\ "7V__/C>?]\"O.O^$CU#_GHO_?(H_P"$CU#_ )Z+_P!\BCZL']HGHO\
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M*** "BBB@ HHHH **** *FJ_\@>]_P"N#_\ H)KG_AO_ ,B#I'_7!:Z#5?\
MD#WO_7!__037/_#?_D0=(_ZX+2 ZNBBBF 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%%(#E/AM_QY:O\ ]A.X_P#0J[@=*X?X
M;?\ 'EJ__83N/_0J[@=*DT6P4444#"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KBM*_Y*;K/_7./_T"NUKBM*_Y*;K/_7./_P!
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M6_$*&.W^&^K11($C6%0%'^^M=3!!';PK%"@5$&  *YKXD_\ )/-8_P"N2_\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q6E?\
M)3=9_P"N<?\ Z!7:UQ6E?\E-UG_KG'_Z!0!VM%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?/M%
M%%>PCY=AW]O2MK3O%&I:;;^3 R,OJZY.*Q:EMX)+F=(85W2.<*!2E%-:EPE)
M.R'7EY-?W#3W#EF8\U-+JES-81V+L/(C^Z .OUK>C\!W[ ,;B ?4G(JGJOA.
MZTBR-S//"Z;@,*3GFLU*%[&KISU;,#L,CFBC![XR**U3.?J:OAK_ )&73_\
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M_P (]H__ $#+7_OV*/\ A'M'_P"@9:_]^Q6E11S,/9Q[&;_PCVC_ /0,M?\
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M444 %%%% %35?^0/>_\ 7!__ $$US_PW_P"1!TC_ *X+70:K_P @>]_ZX/\
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M:*/QSZT5UG":OAK_ )&73_\ KL*]L%>)^&O^1ET__KL*]L':O/Q7Q'L9?\#
MU'+M\MMPR,<U)33@CD5S=3O>QYS/>^"_/<26<Y8$@_*>OYU']L\$8_X\I_\
MOD_XUZ VF6)))L[<GK_JQ2?V788_X\K?_OV*UYSE=*7D8'A>XT"6XG&D021R
M!1OW CCMWKJQ6)9[(O$5S:Q10QPI"C )&%.23G)[UN5$]3:FFEJ)5:_NEL=/
MN+MONPQM)@]\#-63S6=KMBVH:'>6B9W2PNJC..<&I-3A/#WAW_A.8)-=\133
M31SL3:VRR%%C3MRI!/![UU.B>$K7P[J#RZ;<31VCKAK9V+@M_>R23TKD?!^H
M:?-X7E\):W<2:?=6@\I]TIA+*,8*OQZ=J9X1MH-+\?W]MIE_=WMBEL6'F7;3
MKNR.,DF@#J=2^(.EZ;/+$+/4KM8OOS6EL9(Q_P "!K3_ .$HTO\ L(:R9\69
M'!/WL_W<>O;%>;+KVKZMIVIW-KK>F:-;)O4V$EJC2-C.>X))QZ=ZN>"]/L-;
M^%TEMJUVD<+W<C>:[>6 X;*GGISVH ZW3/'5IJMU'!%I6L1;QD23V91?SS7+
M6OQ'N1X^O+&:TU62R4$)$EIDJ>.3[5)8Z[K'A_6=+TV;6+/7;.Y?R5%K&H:#
M )W,023TQ3["[@M/BY?&ZE2 2PG896"@].A/6@#H+[X@Z/8ZA)I[QWDU[&JL
M8(8=SD$9X&>W>LU9].O?B#8WOVK4(+J6 ;+22+:N-I^]SP:K:-'%)\7M:F"(
MS+%'M? ) *=J75,GXO6&.OD<?]\F@#?U7QQINE7YLO(O;RX49=;*#S=GUP>*
MUM+U>VUBP2\MBPC;M(,,OU':N&\(7EKI/BOQ)!JLT5O=27+2H\S! T?'0GKS
M6KX@U^S7P9>3Z/M5YP8H"J;-SG.,>M %3PM_Q4'C+4_$#IF&$_9[8]@1E7_E
M5WQ_K5[86EGINF2".^U&4Q))W0#DG\LUJ>$-*_L?PU:VY&)&7S9/]YN3^M<S
M\2[.ZMY]'U^WB>9-.G+S(@).TC&0/QH MQ?"_06MU-[]IN+QAE[@SNI9O7 .
M*WX/+\,:$HOKUYTAR!(X 9O10.Y[5R?B3_A&?%6C+JW]MS03)!F-(K\P$?5
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MK.J>$[W4(M=TS3;5D)&F?9$:51_=QG)/X5/(2WP3L226_>9W=.<M0!ZOH_\
MR!;'_KWC_P#015VJ6C_\@6Q_Z]X__015V@ HHHH **** #M32>:=3>_TH \D
M'B*33?B=KKIIMW.6MH4Q'$3C!;GZ5N_\)Q<_] '4?_ =J721_P 74\09_P"?
M*W/ZM7952,V<9_PG%S_T =1_\!VH_P"$XN/^@#J/_@.U=G13$<9_PG%Q_P!
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M9?+,)W'..0*];_']*XS4/^2K:+GG-G<?R%*PP_X3BX_Z .H_^ [4?\)Q<?\
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M':NSHHL!QG_"<7'_ $ =1_\  =J/^$XN/^@#J/\ X#M79T46 XS_ (3BX_Z
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MG%Q_T =1_P# =J/^$XN/^@#J/_@.U=G10!QG_"<7'_0!U'_P':C_ (3BX_Z
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M .*_X3RY_P"@!J7_ (#M1_PGES_T -2_\!VKM:* .*_X3RY_Z &I?^ [4?\
M">7/_0 U+_P':NU_&C\10!Q7_">7/_0 U+_P':C_ (3RY_Z &I?^ [5VOXT?
MC0!Q7_">7/\ T -2_P# =J/^$\N?^@!J7_@.U=K^-'/K0!Q?_">7/_0 U+_P
M':D_X3RY_P"@!J7_ (#M7:\T4 <5_P )Y<_] #4O_ =J/^$\N?\ H :E_P"
M[5VM% '%?\)Y<_\ 0 U+_P !VH_X3RY_Z &I?^ [5VM% '%?\)Y<_P#0 U+_
M ,!VI?\ A/+G_H :E_X#M7:4<T <5_PGES_T -2_\!VK)\*:S)J7Q&U5Y+*X
MMR\:9$D9&,+7I?-<5I0/_"R]9]?+C[_[- ': FG4VG4 %%%% !1110 4444
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M]#%#_P!]_P#UJ/[7U#_H8H/^^_\ ZU/V,C-XN!Z/17G']KZA_P!#%#_WW_\
M6H_M?4/^ABA_[[_^M1[&0?6X'H]%><?VOJ'_ $,4/_??_P!:C^U]0_Z&.'_O
MO_ZU/V,@^MP/2.U)7G:ZO>?Q>)(O^^Q_A2_VM<_]#)'_ -]C_"E[&0?6X'H=
M%>>?VM=?]#)'_P!]C_"C^UKK_H9(_P#OL?X4>PD'UJ!Z'17GG]K77_0R1_\
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MU#_H8H?^^_\ ZU/76KX#GQ! ?^!__6H]C(/K<#T0@^M%>>'7+['&NV^?=_\
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MJ_\ ('O?^N#_ /H)KG_AO_R(.D?]<%I =71113 **** "BBB@ HHHH ****
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M"BBB@ HHHH *XK2O^2FZS_USC_\ 0*[6N*TK_DINL_\ 7./_ - H [6BBB@
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M$SWKHM#TO^S-/6-V+RL=[N>I)YJUIJ8-2EHRKH5W=">;3KTEYH%#%S_%GO\
MI70"L#28;I];OKRYB:-6 C0$=0">:Z#M4R-8*RL!JAJVG/J=@]K'>W-DS$'S
MK9MKC\:OTM26<]X>\*VOAV"X5+B>[EG8M+/<,&=\]B:RF^'5BUY<RKJ%]%9W
M+[YM/5QY#CT*XZ5VU% '+6_@;3;7PY!HD4DRVL,WG(<C.<DX^G-7-=\,6FOZ
M;#8W4DHCB='4J><J01_*MVB@#F?$/@ZSUV>VN1<W-C>6Y^2YM6"OC'3/IS4F
MD>%+33;:Y2:>XOY+H_O9;I@SD8Q@GTKHJ* .2T7P/#HB7$$.JW\MI,' MI)
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M !1110 4444 %%%% !24II.U '@_C/\ Y*5J/_7M%_6J$?\ KDSCD@8[5?\
M&?\ R4G4?^O:+^M9N<%2O\)R#Z5ZE!7I'S..=J]SLM9U1+;4XHSI]I,=H&]T
MRW05IXMW\22S2)ADM RA.H^3/%<#/>7%S*)996>0=&]*E.JWINUN3.WGJH4/
M[42HOH*.)CL;U]K5M?00VYAO7E60%)9V!(.13_$>H7,NKI8M,ZVWW60'K]:P
M+G6=0O$ GFWA3E< <&H+BZGNYFFGD,DG]_WIQIM;D2K(Z'Q#?ZA9W?V2UEEB
MM @"JG0C S6E%>VVEZ'9R*UV=[$M]F8#<>X.:Y?^WM3,'E&[?8!MV[0>/RIM
MMK.H6<?EP7#*A)., _SJ73=BXUHJ5SIM-OA<W&L7=A;,CF $*WWB=W6JT5[?
M3^'[BZNYI3/%+F)V/*\=JS=.UV2U74))9'-Q.@5&"C@YS5*\U:]OP$N+@R =
ML  ?E1[.5QJM%*YT6OWUY)J5I"TTA@.QBI/&>*EB<IXT5Q_!;Y_\=-<P^L7\
MD"027!9%(*C X(Z4S^TKS[4;GSV$VW;N[XJ_9.QFZRO<Z*WU.XU6QUA;M]ZI
M%OC4]$^8#BN9MC:BXS=I*T7I&0#^M)#>3P1RK%(425=L@[L*AYP<G(-.,&DR
M)U%)IG5ZL^D?V19;HKLC:WEC<O7WJEX4=/[7*]"Z,$SZX-8TMU--%%'*Y9(_
MNKZ4Q':.0/&VU@<AJ:A:(>U3E<M/87?V]X/L[F4-R,=#756D U:VL;QR"UGQ
M-^=<W+K^IS1-&]VYC<8/RC^>*L6&L+9:)=6R,_GSL.@^7&.:CD=C2,XWN;-A
MJDVS6+R,_,,(K'J!R!BJ6BSW<XN]1GO;O]T@W>4_SL,]*P(KV>"&2*.3;')C
M>!WI]GJ%UI[,UK,8]W#''6G[)V%[;W[G4:Y(EYX<M[DI<,QD 5[@@L1CV[5>
M.I7!\20V18_9O( :/L^0.M<;=ZSJ%]"(KFY9T!R!@4W^T[P7@NOM#&<# ;C@
M#M4*DRY5XW.F-[/J%GJUO,Q:.!P(E'\(#'%1IJ-]IFA[;B>:26X7$<9/"+V-
M<VFHW<32E)2OG'<^.YZU;_X2+5O*6,W)V 8P5'^%-TV*-6,CHK*:73+6PBEN
M+]WN%W)' X"KR>.:QO%*11>(&"JR(RJ74=3QS^-4X->U.VA6**[=47[HP#BJ
MEU=W%[,T]PY>4X!)IPIM,52M%QLCI;%]&_X1^\(BO/+ 7>I9<]>,5S%P8#.W
MV<2"(GY?,.3CWH2ZFC@D@20B*0#>OK4?0\<X]:M0:9E.LI)(ZZZO-1M?#.E_
M8G= R$&1.N<GBK<EK)-K5O.DS03+;[Y6C.&X7/ZUA-XAFBTZQM[*9XVB0B3Y
M003GWK.75+U;S[6D["?&"]9*FV=#JQ.ON+B+4?#EZ["\E6,C:]RP/.1TJAJ=
MW>:7INGIITCQ1O#N<Q=SDUBSZ]J=U T,MVQB;[RD 9IL&MZC;0"&*[=8Q]T;
M0<?G1&FT*5:+1J:,[RZ?J;R,2Q7)9NIXID#E/"+R*VUA*,,/]ZLA=1ND\[$I
M'G<.,?>I@NYA:&T$A$!.2GO6CA<R59)G4:M>ZA/:Z;"EU*%GC7?SU-:]E<?\
M3?\ LV:6_N2O#[G!C/X>E<,-7O\ [)]E%PWD@?=P.*LKXEU=<;;QA@=-H_PK
M-TV;1KQN=5IT*7%I*;U$\R%V-GN').3_ %Q5/2IEALM2O;CSQ=A\.(B Z\]J
MYB75;Z:2&26X8O$<H>F.<TL>L7\5R]PER1(_WFP,&CV3L+V\+[&W-J=OJ6JZ
M?LBN%EC;!EG(+,,'TK(U[_D-W70?,.!]*BGU6^N94EEFS)'RK8 Q5:>:2XF:
M:9RSMU)[UK"%C&K4YB.BC-%:F 4444 %%%%&@!1111H 4444: %%%%&@!111
M0 4444 %%%%&H!1111J 4444:@%%%%&H!1111J 4444:@%%%%&H!1110 4<_
M7VHX')Y'>FNQ0A2,LWW0.])M#C%MV!B=P1!N=C@*.YKIM6\,R6/PYU;4+\EK
MIK=0JM_ -Z\"MSP7X1,&-2U%?WS#*1D?=K4^)/\ R3S6/^N2_P#H:UY]:JI.
MQ[N!PKA[S.CLA_H%L/2)?Y5/4%E_QX6__7)?Y"IZYK6/1"BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH J:K_ ,@>]_ZX/_Z"
M:Y_X;_\ (@Z1_P!<%KH-5_Y ][_UP?\ ]!-<_P##?_D0=(_ZX+2 ZNBBBF 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%(#E/
MAM_QY:O_ -A.X_\ 0J[@=*X?X;?\>6K_ /83N/\ T*NX'2I-%L%%%% PHHHH
M **** .$^*-NTNA0RC_EC(6-<SJ^;CPUHMRO(,&T_P#?1KTOQ%IO]JZ'=6G&
M73BO,M*#W_ARYTB3(N[%MT:=R!_^NNBB[,X,3!M-F+!/);3K-$^'4Y&*](T;
M6+3Q-IS6-Z%\['(/>O,R"I(/8X-207$MK.DL3E"O(YKKG3YE='GT:W([,[K3
M_!#6VMF2<A[2,[E!Z'V-4O&NO"XD_LZV;$*<2$=S4+^/K][+R?)CWE<&3)S]
M:Y5W9W9V.6)YK.G3DW>1K5K12M#J)U]O2J6H<HB_WCCBKGI]*AL[:35M=MK2
M%<Y<'CVZUO4:43FHP;F>V>$HFA\*Z;$P(980#FMNHH(UAA6-1@*, 5+7E/5G
MT,-%8*6BBD4%%%% !1110 5Q6E?\E-UG_KG'_P"@5VM<5I7_ "4W6?\ KG'_
M .@4 =K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'S[1117L(^88=ZO:3>+8:C%<.,JN<@>XJC
M6CH=G%?:M#!.3Y9R3@X/ S2E:VHX7;T+NG:M8VFL7#2(S6-Q\C#G(6K>M:MH
M_P#99L=)23:[AW+YX(^OUJ[)XDT&UE>#^QDD"':'P/F_2LS6-?TN_L?)M=)%
MM)N!WC''Y5S+5IV.UR2C:YSE%'_ZZ*ZS@ZFKX:_Y&73_ /KL*]L':O$_#7_(
MRZ?_ -=A7M@KS\5\1[&7_ P-)SBEHKF/0&X/7%&WUIU% #0"/>G48I: $I:*
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D-+33
MUH \+\7PS3?$K4O)AEE(M8L[$+8Z^E4?L5[G_CQNA_VQ;_"O1=)_Y*GX@[_Z
M%;_S:NRKIIUG&-D>9B,'&K.[/"/L=[G/V&Z_[\M_A1]BO>GV"Z^ODM_A7N]%
M:?6I&/\ 9L#PC['>_P#/A=#_ +8M_A2?8;S_ )\+OC_IBW^%>\44?69!_9L3
MPC['>_\ /A=?]^6_PI/L5[WL;L^_DM_A7O%%'UF0++8GA'V*]SG[!=C_ +8M
M_A1]BO.AL+HC_KBW^%>[T4?69!_9T3PC[%?#_EQNO^_#?X4GV*]Q@6%V/4^2
MW^%>\44?69!_9T3PC[%>GG[#=9_ZXM_A1]BO?^?&ZS_UQ;_"O=Z*/K,@_LV)
MX1]BON3]ANL_]<&_PH^Q7N,?8;KCH?);_"O=Z*?UF0?V;$\(^Q7W_/C==<_Z
MAO\ "C[%>]?L%U_WY;_"O=Z*7UF0++8]SP?[%>C_ )<+KG_IBW^%*+*^_P"?
M&Z^GDM_A7N]%'UF0?V;#N>$?8K[_ )\;K('7R&_PI/L5[T^P7>3W\EO\*]XH
MH^LR#^S87N>$?8KWM8W?_?EO\*/L5YGBPNP/^N3?X5[O11]9D/\ LV'<\(^P
MWA_Y<+OW_<M_A41CF6Y2W:VG\Y@2J&,AF Z\5[Y_+O7%W_\ R5?11_TYW'\A
M1]9D+^S8VM<\\^Q7O_/C=#_MBW^%'V*]Y_T&ZY_Z8M_A7N_X44?69 LNBCP?
M[%?$8^P70]?W+<_I1]BOL?\ (/NO^_3?X5[Q126(D-9=$\'^Q7IZZ?=<?],6
M_P */L5]G)L+HY_Z8M_A7O%%5]9D']FQ[G@_V*]'2PNO^_+?X4?8KX];"Z'_
M &Q;_"O>**7UF0O[-B>#_8KX\?8+H?\ ;%O\*/L5\?\ EPNNO'[EO\*]XHH^
MLR#^S8]SP?['?!L_8+H_]L6_PH^Q7W&;"Z./^F+?X5[Q13^LR!Y;$\'^Q7QZ
MV%UGU\EO\*/L5]_SXW7_ 'Y;_"O>**2Q,A_V;$\'^Q7W_/A=?]^6_P */L5]
M_P ^%U_WY;_"O>**?UF0?V;#N>#_ &*^_P"?"Z_[\M_A1]BOO^?"Z_[\M_A7
MO%%'UF0?V;$\'^Q7W_/A=?\ ?EO\*/L5]_SX77_?EO\ "O>**/K,@_LV)X/]
MBOO^?"Z_[\M_A1]BOO\ GPNO^_+?X5[Q11]9D']FQ/!_L5]_SX77_?EO\*/L
M5]_SX77_ 'Y;_"O>**7UF0?V;$\"FBN+?9YUK.F]MB[HR,GT'O4OV*^_Y\+K
M_ORW^%>D>.SB?PW@?\QB'/Y&NP%'UJ0_[-CW/!_L5]_SX77_ 'Y;_"C[%??\
M^%U_WY;_  KWBBCZS(7]FQ/!_L5]_P ^%U_WY;_"C[%??\^%U_WY;_"O>**?
MUF0?V;$\'^Q7W_/A=?\ ?EO\*/L5]_SX77_?EO\ "O>**7UF0?V;$\'^Q7W_
M #X77_?EO\*/L5]_SX77_?EO\*]XHH^LR#^S8G@_V*^_Y\+K_ORW^%'V*^_Y
M\+K_ +\M_A7O%%'UF0?V;$\'^Q7W_/A=?]^6_P */L5]_P ^%U_WY;_"O>**
M/K,@_LV)X/\ 8K[_ )\+K_ORW^%'V*^_Y\+K_ORW^%>\44?69!_9L3P?[%??
M\^%U_P!^6_PH^Q7W_/A=?]^6_P *]XHH^LR#^S8G@_V*^_Y\+K_ORW^%'V*^
M_P"?"Z_[\M_A7O%%'UF0?V;$\'^Q7W_/A=?]^6_PH^QWP_Y<+K_ORW^%>\4?
MAG\:/K,A?V=$\(6ROC(H^P7(SU!B;'\J[[PWX&CMI8[V^^>3&Y8ST%=Q@?GU
MS2_2HG7E)6-J>!A!W$ VC"UR_P 2?^2>ZQ_UR7_T-:ZFN5^)/_)/-8_ZY+_Z
M&M<YW(Z.R_X\;?\ ZY+_ "%3U!9?\>%O_P!<E_D*GI@%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4U7_D#WO\ UP?_ -!-
M<_\ #?\ Y$'2/^N"UT&J_P#('O?^N#_^@FN?^&__ "(.D?\ 7!:0'5T444P"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI <I
M\-O^/+5_^PG<?^A5W Z5P_PV_P"/+5_^PG<?^A5W Z5)HM@HHHH&%%%% !11
M10 UAFN(\2^&+B*^&MZ/A;E/FDCZ!Z[FFD<<TXNS(G!25F>-7]E'?1F]LU*N
M#B:W(PRMZXZXK$((RIX(/>O7M5\*6M]*US;N]M=$8WQG /U'>N2O_!VK[\LD
M-SZ&%=GYY-=D*ZZGEUL&[WB<<>HH_P FM>3PCXB+XCTY@OJ7%6K7X?ZY=L!<
M.ELIZG&?Y&MGB(V.=86I?4Y::=B?)A!:1C@ #->E> /"3Z7&=1O4Q<RCY5Z[
M1ZUIZ%X&TS1V6=E,UP.KN<C/L*ZI1Z5RU:W-HCT,/A>1\S%I:.]+7,=X4444
M %%%% !1110 5Q6E?\E-UG_KG'_Z!7:UQ6E?\E-UG_KG'_Z!0!VM%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU\9'Y54\.P^+8]19M;D@:U*$!8WR=WY4 =5VR>/K1TKGO$T7B222W_L!X$4
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M:[9SWH_R*X[6K?QK)JTSZ5+:BSX\M9),'I]*V/#L>MQV9_MUXFGR<>4V[^E
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MH:==Z;X+:.[8EC*I"$_<'-<\79K4ZIP7*TT<510/QHKKZGG]35\-?\C+I_\
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M %[O_P"@FL#X;_\ (@Z1_P!<%KH-5_Y ][_UP?\ ]!-<_P##?_D0=(_ZX+2
MZNBBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH *Y7XD_\ )/-8_P"N2_\ H:UU5<K\2?\
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MKV\=EKGA[IG+'%<\N1%+2K::34(?*5N&&<5ZQ%D( <_C44-C;P',<2J?4"K
M&*\O 8+ZM&USLC#E'4445Z)04444 %%%% !1110 4444 ?/M%%%>PMCYB6X5
MK^&E1]>MPX!')P1UXK(J_H]_%INIPW4T9=$/*CO2FO=95.RDKF]>^,]9MKN6
M-/+C1#@*T>2*S-2\4:GJUJ;>Y:(QYW'" 5NW'BS0+J5II]#:23NS;<FLK5]8
MT6]LC%9:2;>7<#Y@QTKFAT]T[*CTTD<[Z?X44=0.E':NLX+W9J^&O^1ET_\
MZ["O;!VKQ/PU_P C+I__ %V%>V#M7GXKXCV,O^!AWI:2EKF/0"BBB@ HHHH
M*J:G_P @J[S_ ,\7_P#035NJNHC.FW2@98PN!CZ&@#YA\%>.)_!WB+6Y(=&N
M=1$[%=L.<ISG)X-;7PXOK36/BO=ZOJ.ZPO+F3,-H\9!)X[UE^"_&Z> ?$^M2
M7FD7MSY[E5\D 8PV><UN:9_:'Q%^*6F^([+2)K"QM)0TDD@&X\]\=Z )_B1J
M?B!/B?;:?H^H2PF=/+"[SM .!G&>M=0L>K_#'P5J&H:EK#ZG<.,Q[P?D8GW)
M]:YWQ?#(?CAI3"-RH*C=MXZK7HWQ,\/W/B3P1>6-HNZ<X95_O8.: /GL^(Y-
M8A?4[_QW<V=\WS?98H9 H/IP<5ZS\.O&6I>*? FJ1O=(M]9CRX[EQ@=,[CFO
M.M"\0^&_#^FII?B'P USJ,/RM*(EY^OO7?6-A=:K\,]?.G>&X])^U(?L\,*!
M6E7;WY]: /-M=O)+*::<_$&YDOE.?L\22!21VR#BO1M/\=ZW=_!2;6(N=0B<
MPAPF[@$#./7FO+]*O=,B\*W&B/X/DNM< ?==M&/E S^/%>@^ +[4-#^#,L]O
MIC7;K<R"2!EZKD9X/MF@# \'P:WJH@U>P\:&:^R&?3YW*C/I\S8-7OCKH-^D
M-OJ\VI.T+E4-ISM#$=>N.U<MK5YIGB:_LE\)^%KS3M460$E JK7J'Q?T35+[
MX;69VM/<6[(TRJ.< ')H V/A;X1U3P_8+>7NN2ZA%=0HT<3[L1#;TY/O7!?$
M9SK/QDTW2;ARUJJHP1NF>?\ "O0?A=XYC\3Z8NGKIUS:R6,21L\N,-@8X_*N
M:^+_ (-U-]7M/%6C1M-<0X$D:=0J]_UH ]?CM+=+)+801B$+M$84;?IBO._B
MDEQ!96T5MKD6BV&T^8R+\V<_P@$'UZ5S\/QXD-HMG_PCE^VIE=F0!LW?3TK
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MZ-JL.KZ?'=1 C(^8$=Z\D\/:!<>(K\* 4M$.9'_H*]BL+&#3[2.WMD"1H,#
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M_037/_#?_D0=(_ZX+70:K_R![W_K@_\ Z":Y_P"&_P#R(.D?]<%I =71113
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M\:-C^\N:EHH ACMXHCF.)$)[JH%*88V;>T:LPZ$J,BI:* $Q@4M%% !1110
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M2_\ /O;?]_Q1_P ()XE_Y][;_O\ BE[6F'U:MV,%9'4?*Q4GL#Q078L"23Z
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MCGZ*Z#_A!/$O_/M;?]_Q1_P@GB7_ )]K;_O^*/;0[A]4J=CGZ*Z#_A!/$O\
MS[6W_?\ %'_"">)?^?:V_P"_XH]M#N'U2IV.?)['IZUH:%H5SXAO1#&"MNAR
M\G;Z5O:3X"U5KU1J:11V^#DI(&/TQ7HFG:;;:7:K;VL851U..:QJUU:T3LPV
M#;E>0:=IMOI=FEK;(%C4=0.35SJ3FBBN%MO4]E1459!]:***!A1110,****
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M7?\ _?I*/^$%U#_H:[__ +])7:T4 <5_P@NH?]#7?_\ ?I*/^$%U#_H:[_\
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M'_0UW_\ WZ2C_A!=0_Z&N_\ ^_25VM% '%?\(+J'_0UW_P#WZ2C_ (074/\
MH:[_ /[])7:T4 <5_P (+J'_ $-=_P#]^DH_X074/^AKO_\ OTE=K10!Q7_"
M"ZA_T-=__P!^DH_X074/^AKO_P#OTE=K10!Q7_""ZA_T-=__ -^DH_X074/^
MAKO_ /OTE=K10!Q7_""ZA_T-=_\ ]^DH_P"$%U#_ *&N_P#^_25VM% '%?\
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M /0T7W_?I*[*B@#C?^$'O_\ H:+_ /[])1_P@]__ -#1?_\ ?I*[*BD!QO\
MP@]__P!#1?\ _?I*/^$(O\_\C1??]^DKLJ* /)_%_A2]M)=#W^(+R;S=3BC7
M=&HV$Y^8>]=-_P (1?\ ;Q1??]^DIWCS_7>&N>FKP\?G78#VIV'H<;_P@]__
M -#1?_\ ?I*/^$(O_P#H:+[_ +])79446%Z'&_\ "$7_ /T-%_\ ]^DH_P"$
M(O\ _H:+[_OTE=E10%[G&_\ "#W_ /T-%_\ ]^DH_P"$'O\ _H:+_P#[])79
M44 <;_P@]_\ ]#1?_P#?I*/^$'O_ /H:+_\ [])7944 <;_P@]__ -#1?_\
M?I*/^$'O_P#H:+__ +])7944 <;_ ,(/?_\ 0T7_ /WZ2C_A![__ *&B_P#^
M_25V5% '&_\ "#W_ /T-%_\ ]^DH_P"$'O\ _H:+_P#[])7944 <;_P@]_\
M]#1?_P#?I*/^$'O_ /H:+_\ [])7944 <;_P@]__ -#1?_\ ?I*/^$'O_P#H
M:+__ +])7944 <;_ ,(/?_\ 0T7_ /WZ2C_A![__ *&B_P#^_25V5% '&_\
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M#W__ $-%_P#]^DH_X0>__P"AHO\ _OTE=E10!QO_  @]_P#]#1?_ /?I*/\
MA![_ /Z&B_\ ^_25V5% '&_\(/?_ /0T7_\ WZ2C_A![_P#Z&B__ ._25V5%
M '&_\(/?_P#0T7__ 'Z2C_A![_\ Z&B__P"_25V5% '&_P#"#W__ $-%_P#]
M^DH_X0>__P"AHO\ _OTE=E10!QO_  @]_P#]#1?_ /?I*/\ A![_ /Z&B_\
M^_25V5% '&_\(/?_ /0T7_\ WZ2C_A![_P#Z&B__ ._25V5% '&_\(/?_P#0
MT7__ 'Z2C_A![_\ Z&B__P"_25V5% '":AX*ODTVZ<^)[Y@L+DJ8EYX/%8W@
M;PE>7G@[3KA/$5Y KP@B)8U(7VKTG5/^0/>\_P#+O)_Z":Y_X;_\B%I'O;J0
M*0$'_"$7_P#T-%]_WZ2C_A"+_P#Z&B__ ._25V5%,#C?^$'O_P#H:+__ +])
M1_P@]_\ ]#1?_P#?I*[*B@#C?^$'O_\ H:+_ /[])1_P@]__ -#1?_\ ?I*[
M*B@#C?\ A![_ /Z&B_\ ^_24?\(/?_\ 0T7_ /WZ2NRHH XW_A![_P#Z&B__
M ._24?\ "#W_ /T-%_\ ]^DKLJ* .-_X0>__ .AHO_\ OTE'_"#W_P#T-%__
M -^DKLJ* .-_X0>__P"AHO\ _OTE'_"#W_\ T-%__P!^DKLJ* .-_P"$'O\
M_H:+_P#[])1_P@]__P!#1?\ _?I*[*B@#C?^$'O_ /H:+_\ [])1_P (/?\
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M&RM\;CCNU=?]JMQ_RWB_[[%>4>(+JUM?B9JIN;2.X#6D.T/GCDTG]KZ3_P!
M>W_7_&NB%)R5SSZ^*C3E9GK'VJW_ .>\7_?8H^U6_P#SWB_[Z%>3_P!KZ3_T
M![?]?\:7^U])_P"@/;_K_C5_5Y&7UZ'<]7^U6_\ SWB_[Z%'VJW_ .>\7_?0
MKR?^U])_Z ]O_P"/?XT?VOI/_0'M_P#Q[_&CZO(/KT.YZQ]JM_\ GO%_WT*/
MM5O_ ,]XO^^A7D_]KZ3C_D$6_P"O^-+_ &OI/_0'M_\ Q[_&CZO(7UZ'<]7^
MU6__ #WB_P"^A2?:K?\ Y[Q?]]BO*/[8TG_H$6__ (]_C1_:^E?] >#]?\:/
MJ\A_7H]SU?[5;_\ />+_ +[%'VJW_P">\7_?8KRC^U])_P"@1;_K_C1_:^D<
M?\2BWYZ=?\:/J[%]>AW/6/M5O_SWB_[Z%'VJW_Y[Q?\ ?0KR?^U])_Z ]O\
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M2_R%3U!9?\>%O_UR7^0J>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHHHT#4****- U"BBBC0-0HHHHT ****- "BBBC0 HHHHT ****- "BBBC0
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MHHH **** "BBB@ HHHH J:K_ ,@>]_ZX/_Z":Y_X;_\ (@Z1_P!<%KH-5_Y
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M5EZ-JJ:K:>:L9BD!PT;')%:BUG(ZJ:LA:J:E_P @N\_ZX/\ ^@FK=,8!U*L
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MM_\ KDO\A4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC9SS1I&@Z9H4<L6FVPMUE8,X!)R1WYJKJ/A'0]7O&N[ZQ6:=@%+EB,@=.AH
MT+'4[+48R]E<).HZE.U07?B#2+&=H+F_ABE'56)S2Z5H6FZ'&R:=;"!6^\ 2
M<_G574?!^@ZK=&ZO;!9IFZL6(_D: -*QU*RU*-GL[A)T4X)7M5:[\0Z38W!@
MN;Z**0#)5C3M)T33M%A>+3K<0(Y!8*2<_G5/4?!V@ZM=M=7U@LTS#!8LPZ?0
MT :=E?V>IPF:TG6>,'&Y>QJK<>(]'M+A[>?4(8Y4.&0DY!J32]'L-%MC;:?
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MZ.5VE/:@#/\ ^$IT/?M_M*'/0C)K2:XA2#SVD CV[MW;%8'_  @7AK?Y@TQ
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MQ*UIK>99!LC V^R\UVEM96]K9I:0Q[+=%VJ@["N&\.:18Z;\2M96T@$0V(V
M2>2N3UH ]"S2TT=?:G4 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!\^T445["/F);BCC!Z>_7-=79>
M+[:UM(H3H\$A10I=L<_I7)^@XXZ58M[*XNY52&%W+'C X-3.,7\1I3E)/W3K
M/^$YM/\ H!V_/L/\*HZQXICU+3VM(M/C@#,&+(1V_"EL_!-].2+N5+9LY56Y
MS^51ZW8Z!:69%C<2/>*P4@MQ[]JP2AS:'3*53E]XYSO11GO1758X>IJ^&O\
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MGNL?]<E_]#6NJKE?B3_R3S6/^N2_^AK0".CLO^/&W_ZY+_(5/4%E_P >%O\
M]<E_D*GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@"IJO_ "![W_K@_P#Z":Y_X;_\B#I'_7NM=!JO_('O?^N#_P#H)KG_
M (;_ /(@Z1_UP6D!U=%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ****0'*?#;_CRU?_ +"=Q_Z%7;CI7$?#;_CRU?\ ["=Q
M_P"A5W Z5)HM@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !7%:5_P E-UK_ *YQ_P#H%=K7%:5_R4W6?^N<?_H% ':T444
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M\0>*='T:&!;87%KM$VZ7 XQTXYK6\:^"9_$O@"#2(A%]NAC14+-@ C&>?PH
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M *":Y_X;_P#(@Z1_UP6D!U=%%%, HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ****0'*?#;_ (\M7_["=Q_Z%7<#I7#_  V_X\M7
M_P"PG<?^A5W Z5)HM@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7%:5_R4W6?^N<?_ *!7:UQ6E?\ )3=9_P"N<?\ Z!0!
MVM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?/M%%%>PMCYAA11130@HHHH **** -7PU_R,NG_
M /785[8.U>)^&O\ D9=/_P"NPKVP=J\_$_$>QE_P,*BG_P!0_P#NFI33'&8V
M'J,5S+<[GL<!8'Q8+1!8+ ;7)\O=MSC)JSO\<]TMA_WS5]-=L-!M!9-.)[F+
M.8X^IYS6=<^)M5U%8SIUOY4<IV'S!\R]LULK]CC:CW-K03KYEE_M@1!,#9L
MZ]^E= O2L+0=+U*P,C7^H?:MX 4<\?G6[6<CJIIV%I,4M)S]:DT#&.,TAXX_
M6LK5O$NDZ'+!%J-ZEN]PVV,,"=Q].*U VX*5Y!YH =3>_/Y4[K24 &<'IUH]
M\<GMFE[=135D20'8ZMCK@YQ0 O>E/ZTGM0#VH 6G5AGQ;HBZZ-$.H1C4B<"
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MKTKP+9Z);Z.\FB65]:022-N6]5E<MW.&YH \R\26+#QWK.N6P/VO3!YZ,/\
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M=&B64L25YQRW.:]/H **** "BBB@ HHHH **** "DI:;2=@/"/&G'Q)U'/\
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M>M?\('X?_P"?1O\ OX:/^$#\/_\ /HW_ '\-+ZU'L']F3[GDM%>M?\('X?\
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MR&O_ !&T?P[J36-T)#(!_".*T/#'BVP\50RR62N%A/.\=S0!OT=L_E7':_\
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M@T 7S_*CBO/X?B_H,]Q'&B3;F.!QW_*NQU+5H-*TF34)@3"B>8P7KTS0!?\
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MF4;^O!Q7*7_Q<T#3=0N+*9)_,@<HV!W% 'H.:-W-96A:Y;:]I,>H6H812#<
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M[G[-#J-I)/G'E),I;\LYJS<75O9PF:YGCAB'5Y&"@?B: $6TMD;<EO$K>JH
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MM=59?0C(IU% $(M+92"+>($="$%2.B2+M=59?1AD4ZB@"%;2V4@K;Q*1T(0
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M8EB!^\'7ZB@#WFBF+(C<*RD^QI] !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M-/6G4AH \GNK[4++XH:T; 1%FM(-WF8]6K4_MWQ'_P!.GZ?XUQGC,X^)6HX[
MVL7]:S2<'DXKNHT5*%SQL5BW3J-'HO\ ;OB+TM/T_P :/[=\1_\ 3I^G^->=
M;C^F1[T;C6OU='-]>D>B_P!N^(_^G3]/\:/[=\1_].GZ?XUYUDGI^/M1N/X]
MAZT?5D+Z](]%_MWQ'Z6GZ?XT?V]XB_Z=/T_QKSHD^YHW<=>*/JR#Z](](&L^
M(6&=]H/R_P :=_;'B#_GI9_D/\:\TR?4BEW$]"31]60?7I'I7]L>(/\ GI9_
MD/\ &C^V/$'_ #TL_P A_C7FNXXZT;CW.#Z4?5D'U^1Z5_;'B#_GI9_D/\:/
M[8\0?\]+/\A_C7FNX^IHW'U-'U=#^OR/2O[8\0?\]+/\A_C1_;'B#_GI9_D/
M\:\UW'UHW'U-'U=!]?DCTK^V/$'_ #TL_P A_C1_;'B#_GI9_D/\:\UW'UHW
M'UH^KH7]H2/2O[8\0?\ /2S_ "'^-']L>(/^>EG^0_QKS7<?4T;CZT?5T'U^
M1Z5_;'B#_GI9_D/\:/[8\0?\]+/\A_C7FNX^M&X^M+ZN@^OL]*_MCQ!_STL_
MR'^-']L>(/\ GI9_D/\ &O-=Q]:-Q]33^KH/K\CTK^V/$'_/2S]^!_C7.W5_
MJ[>.-/N&:W-REO*J, -H!QG/-<ODT9.<Y.?7O2^KH?\ :$CTK^V-?_YZV?Y#
M_&C^V/$'_/2S_(?XUYKN-&X^M/ZN@^OL]*_MCQ!_STL_R'^-']L>(/\ GI9_
MD/\ &O-=Q]:-Q]:7U="^OL]*_MCQ!_STL_R'^-']L>(/^>EG^0_QKS7<?6C<
M?6CZN@^OL]*_MCQ!_P ]+/\ (?XT?VQX@_YZ6?Y#_&O-=Q]:-Q]:/JZ#Z^ST
MK^V/$'_/2S_(?XT?VQX@_P">EG^0_P :\UW'UHW'UH^KH/K[/2O[8\0?\]+/
M\A_C1_;'B#_GI9_D/\:\UW'UHW'UH^KH/K[/2O[8\0?\]+/\A_C1_;'B#_GI
M9_D/\:\UW'UHW'UI_5T'U]GI7]L>(/\ GI9_D/\ &C^V/$'_ #TL_P A_C7F
MNX^M&X^M+ZN@^OL]*_MCQ!_STL_R'^-']L>(/^>EG^0_QKS7<?6C<?6CZN@^
MOL]*_MCQ!_STL_R'^-']L>(/^>EG^0_QKS7<?6C<?6CZN@^OL]*_MCQ!_P ]
M+/\ (?XT?VQX@_YZ6?Y#_&O-=Q]:-Q]:/JZ#Z^STK^V/$'_/2S_(?XT?VQX@
M_P">EG^0_P :\UW'UHW'UH^KH/K[.K\37^L7$NCFX:W;R[^-X]@'#C.,\]*W
MAK'B'O+9_@H_QKS;<:-Q]2?K1]70_P"T&>D_VQX@_P">EG^0_P :7^V/$'_/
M2S_(?XUYKN-&3ZFG]70OK[/2O[8\0?\ /2T_(?XU&VM^(5/#6A_+_&O.=Q]3
M1D^M'U=!]?9Z+_;OB+_IT_3_ !H_MWQ'_P!.GZ?XUYUN/K1DT?5T'U]GHO\
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M **** "N*TK_ )*;K/\ USC_ /0*[6N*TK_DINL_]<X__0* .UHHHH ****
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M 4444 %%%% !1110 4444 %%%% !1110 4444""BBB@84444 %%%% !1110
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MZX/_ .@FN?\ AO\ \B#I'_7!:0'5T444P"BBB@ HHHH **** "BBB@ HHHH
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MO(6Z]LT >A:1J2:QI%KJ,:-&EQ&) C')&?6KXKR]]>O;#P;X7TG3F$5YJ:K
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MJ;0N->U[&RWB&\>ZFN-D0EE7;O"\@8J"35[F:UBMY"CB)MRN1\V?K6;YL?\
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ME?B3_P D]UG_ *Y+_P"AK7G3DY,]^E34(V1T=E_QX6P](E_E4]067_'C;_\
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MA_[]BIZ*+L.2'8K_ &&T_P"?6'_OV*/L-I_SZP_]^Q5BBB[#DAV*_P!AM/\
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M0?8K3_GU@_[]BC[%:?\ /K!_W[%3T478<D.Q!]BM/^?6#_OV*/L5I_SZP?\
M?L5/11=AR0[$'V*T_P"?6#_OV*/L5I_SZP?]^Q4]%%V')#L0?8K3_GU@_P"_
M8H^Q6G_/K!_W[%3T478<D.Q!]BM/^?6#_OV*3[#:?\^L/_?L58HIW8>SCV(5
ML[9&#+;Q9'.0@!%3=J**3;92BEL''':N5^)'_)/=9_ZY+_Z&M=57*_$G_DGF
ML?\ 7)?_ $-:!G1V7_'C;_\ 7)?Y"IZ@LO\ CPM_^N2_R%3T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!4U7_ ) ][_UP
M?_T$US_PW_Y$'2/^N"UT&J_\@>]_ZX/_ .@FN?\ AO\ \B#I'_7!:0'5T444
MP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI
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M_P"A3O/^^D_^*I?^$H\4_P#0IWG_ 'TG_P 57;T4 <1_PE'BG_H4[S_OI/\
MXJC_ (2CQ3_T*=Y_WTG_ ,57;T4 <1_PE'BG_H4[S_OI/_BJ/^$H\4_]"G>?
M]])_\57;T4 <1_PE'BG_ *%.\_[Z3_XJD_X2CQ3_ -"G>?\ ?2?_ !5=Q10!
MP_\ PD_BG'_(IWG_ 'TG_P 51_PD_BG_ *%.\_[Z3_XJNXHH XC_ (2CQ3_T
M*=Y_WTG_ ,52?\)/XI_Z%.\_[Z3_ .*KN** .''B?Q2/^93O/^^D_P#BJ/\
MA)_%(_YE.\_[Z3_XJNXHH XC_A*/%/\ T*=Y_P!])_\ %4?\)1XI_P"A3O/^
M^D_^*KMZ* .(_P"$H\4_]"G>?]])_P#%4?\ "4>*?^A3O/\ OI/_ (JNWHH
MXC_A*/%/_0IWG_?2?_%4?\)1XI_Z%.\_[Z3_ .*KMZ* .(_X2CQ3_P!"G>?]
M])_\51_PE'BG_H4[S_OI/_BJ[>B@#B/^$H\4_P#0IWG_ 'TG_P 51_PE'BG_
M *%.\_[Z3_XJNWHH XC_ (2CQ3_T*=Y_WTG_ ,51_P )1XI_Z%.\_P"^D_\
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M -])_C7;44!H<3_PDWBC_H5;O_OI/\:/^$F\4?\ 0JW?_?2?XUVU% :'$_\
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M=?\ =-8'PW_Y$'2.3_Q[K^-(94_X2;Q/_P!"K=_]])_C2?\ "3>*/^A5N_\
MOI/\:[;IQ13$<3_PDWBC_H5;O_OI/\:/^$F\4?\ 0JW?_?2?XUVU% '$_P#"
M3>*/^A5N_P#OI/\ &C_A)O%'_0JW?_?2?XUVU% '$_\ "3>*/^A5N_\ OI/\
M:/\ A)O%'_0JW?\ WTG^-=M10!Q/_"3>*/\ H5;O_OI/\:/^$F\4?]"K=_\
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M^*KMZ* .(_X2CQ3_ -"G>?\ ?2?_ !5'_"4>*?\ H4[S_OI/_BJ[>B@#B/\
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M HHI,T +129HR* %HHS29% "T44F: %HI,BES0 44F:,T +11FB@ HI,BEH
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M1110 4444 %%%% !1110 4444 %%%% !1110!3U7_D#WO_7!_P#T$U@?#?\
MY$'2/^O=:Z#5?^0/>_\ 7!__ $$US_PW_P"1!TC_ *X+2 ZNBBBF 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%(#E/AO_P >
M6K_]A.X_]"KN*X?X;_\ 'EJ__83N/_0J[@5)HM@HHHH&%%%% !1110 4444
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MOB)+[2=3FCGOK*,M]HC;(D[9KCK+Q?\ $+Q'XAU30M&NP724[)Y, 1+@<=*
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MU% %R!0]C&CC(:, C'M7SQ875S\)?B1>2:A;RR:;<,S&5$) W?3TS7TB%"@
M  #I5/4-)T_58O*O[.&YC'\,J!A0!Y\OQHT+4[N"ST**ZO;B5MI4PLH4>O2O
M)M7FT5_B;K@\<M?&S$C?9UCW]<]@.U?2&G^%]"TJ?S]/TFTMI?[\404TM_X8
MT+5;@7%_I5I<S#H\L88T > ?!Y;)/BO>#3898K/R&\I)00P''KS6_P##$?\
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MBB@ HHHH ****0'*?#;_ (\M7_["=Q_Z%7<#I7#_  V_X\M7_P"PG<?^A5W
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M -^GH_L;QO\ ]!S3_P#OT] ';45Q/]C>-_\ H.:?_P!^GH_L;QO_ -!S3_\
MOT] ';45Q/\ 8WC?_H.:?_WZ>C^QO&__ $'-/_[]/0!VU%<3_8WC?_H.:?\
M]^GH_L;QO_T'-/\ ^_3T =M17$_V-XW_ .@YI_\ WZ>C^QO&_P#T'-/_ ._3
MT =M17$_V-XW_P"@YI__ 'Z>C^QO&_\ T'-/_P"_3T =M17$_P!C>-_^@YI_
M_?IZ/[&\;_\ 0<T__OT] ';45Q/]C>-_^@YI_P#WZ>C^QO&__0<T_P#[]/0!
MVU%<3_8WC?\ Z#FG_P#?IZ/[&\;_ /0<T_\ []/0!VU%<3_8WC?_ *#FG_\
M?IZ/[&\;_P#0<T__ +]/0!VU%<3_ &-XW_Z#FG_]^GH_L;QO_P!!S3_^_3T
M=M17$_V-XW_Z#FG_ /?IZ/[&\;_]!S3_ /OT] ';45Q/]C>-_P#H.:?_ -^G
MH_L;QO\ ]!S3_P#OT] ';45Q/]C>-_\ H.:?_P!^GH_L;QO_ -!S3_\ OT]
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M?]!RP_[]O1_PC_C3_H.6'_?MZ+ARG0ZI_P @B]_ZX2?^@FN?^''_ "(.D?\
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M.6'_ '[>BX<IUE%<G_PC_C3_ *#EA_W[>C_A'_&G_0<L/^_;T7#E.LHKD_\
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M .@YI_\ WZ>C^QO&_P#T'-/_ ._3T =M17$_V-XW_P"@YI__ 'Z>C^QO&_\
MT'-/_P"_3T =M17$_P!C>-_^@YI__?IZ/[&\;_\ 0<T__OT] ';45Q/]C>-_
M^@YI_P#WZ>C^QO&__0<T_P#[]/0!VU%<3_8WC?\ Z#FG_P#?IZ/[&\;_ /0<
MT_\ []/0!VU%<3_8WC?_ *#FG_\ ?IZ/[&\;_P#0<T__ +]/0!VN:XK2SCXF
M:T?^F<6?^^:/[%\;_P#0<T_'_7)Z;X;\,Z[I_BB\U75+^WG2= I$:L"<# ZT
M =OGFEIO/>G4 %%%% !1110 4F*6B@!,48I:* $Q1BEHH 0KD8I"N>_2G44
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MH1>VS7)MA/&9P,F,,-P_"@">BHI[F&VC\R>5(DR!N=L#)Z4]75U#*05/0@T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ P****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK6MN\F]X8RX_B9!FK&*,"@"*2&&4!9(D<=@R@BF"U@CC;R8(T8J1E5 JQBC
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-** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gvvh0m1pmdf2000008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -9!YX# 2(  A$! Q$!_\0
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M&<LOUKWEQB-O]TUX3\+O^2L:W_P/^0K0R/5_!NLZMKN@)>:UI9TV[+LI@.>
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M#+G)R/PKG+[Q7=?$75M(T;2)9K=559;F6/(P<9*Y'THL,]NSS1QQ7 ^.[+Q
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MO[4T_3O/E^TZ@@>W7RC@@YZGMT-6-6\7:3HNK66F7LLBW5Z?W 6,D'G')[4
M;M49M:TV#4H]/FO84O9!E(2WS,/I63XD\<Z#X4,8U2Z9'<?*L:[R/J!7E]UK
MNG^(OC/H%]ILID@9!R1@_=;J*+ >Z45Q^N_$SPSX;OVLM1NI5G'WECB+X_*M
MK0/$FF>)K'[9I<_F19QR,,/J*+ :U%%% @HHHH ;)_JV_P!TUR/P]_Y 3_\
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MI=1L8IVMCNA+9^0^WY5ICY1CMVJ923&E8**.GN:*S&%%'>BA@<9X[_UND?\
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M'M[32=5OM+ \0Z#;3121[4MK*1'8Y'!/K75_$"VF\)^(]-\5VY=L+Y4Y4X!
M'!_6N]A^'7A"VN4N8=!M%F1@ZN-W!ZYZUE?%6PO]5\+#3K"QENWF<#,:YV#(
MY-%P.;^'.GKXKUW6/$VH0"6WG8QQQN,C'!K#\.?\(SI7Q*U&WU:"VB4R@6R/
M%GYL<8_&O7?!FB_V!X5L+ QXFBB D..II]YX.\/7^IKJ5SI4$MXK!A,<Y!'X
MT7 \R\5Z?9ZK\7]-M;B-9;9X5.PCC 7CBK?QDTJWT[POIR:=9)!;QW6]UB7
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MDA-O)AK.$QQGY>P-?0O4"L/3O"'A_2KF.ZT_2X+>>,%4=,Y /7O6YV(_2DV
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M.U)M0L]*@AO#G]ZN<\]>]6['P_I.G7L][:6,45Q.?WLHSEJ+@>2>/);7P_\
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M@8QD8KW,#/ZCBD151=J*%SZ#K4\V@^4P_%RX\':FO4?9V&1V%>%Z5\/+?5_
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M%T?B:Q2-+HRK&PD7<O7#<4>S8N8]-]S^%&,=,5X7>?$WQW:65IK+Z;!'I,@
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MP]_Y 3_]=6_]"-==)_JV_P!TUR'P]_Y 4G_75O\ T(T,TAN==1114&X4444
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M%PWA#Q)]@M)FW;&8@]>G KM/ W@S5=!GGU#6]7DU#4IUVNV<J.<^E=UBC&*
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MYL@#*_CC%,\$>'7F\%FP\1Z<2TDK,\,P]<5W7.,^M'>BX6.8_P"%=>#_ /H
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MQW_K=)_Z_8O_ $*NSIB04444AL****!7"BBB@84444 %%%% !1110 44=:*
M"BBB@84444 %%%% @HHHH **** "BBB@ HHHH **** L%%%% !1110 4444
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MH .]%%% !1110 4444 %%%% PHHHH$%%%% !1112 ;)_JV_W37(_#W_D!/\
M]=6_]"-==)_JV_W37(_#W_D!/_UU;_T(TV:0W.MHHHJ+FX4444"N%%%% PHH
MHH **** "BBB@ HHHH ****8!1112 **** "BBB@ /3BBBB@ ZT444 %%%%
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M7R6E0'YBO) ^E%KA>Q;_ $HZ53L]5L[Y0T4F,]$<;6_(\U:9U12TCA57[Q/
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M'XXJG::I:7R;H9<-_<<;6/X&K4CI$I>1@J 9R3P*+,7,AU%83^+]+1V3_26
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MR;% Y-2^GTK-U>"[EB4V=M;S2*0?W[$#]*<=R9;&+>*NM.6TNU:.5O\ E^'
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M(!R#4JQH^:YT$,HEA67'!4&N2TV-M3N=8E#'S&_=K_P$G KJK-"EC"LBE2$
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M V.E2T5/,[@XIHI:5IR:99BW5MWS%F;'4GK5VBBFW=@E9!67HG_'I)_UV?\
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M(/\ R ;7_K^A_F:ZRN3^(/\ R ;7_K^A_F:J.XI;'1VW_'K#_N#^52U%;?\
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M^$L\._\ 0<T[_P "4_QH_P"$L\._]!S3O_ E/\: -BBL?_A+/#O_ $'-._\
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M<=G<W3-:BLG_ (2C0/\ H-6/_?\ 7_&C_A*- _Z#5C_W_7_&E9]@N:U%9/\
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M +_K_C18#6K.LO\ D)7A[?+_ "J+_A)]!_Z#5A_X$+_C5"S\2:&NHW;-J]B
MVW:3.O/'UIV Z7Z45D_\)/H(/_(:L/\ O^O^-'_"4:#_ -!JP_[_ *_XTK :
MU%9/_"4:#_T&K#_O^O\ C1_PE&@_]!JP_P"_Z_XT[,#6HK)_X2C0?^@U8?\
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MO*_"J&.3^E;UOJEC=W4UM!<QR30G$B*>5^M &?\ \(9X8_Z .G?^ Z_X4?\
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M$,\,_P#0!T[_ ,!U_P */^$,\,_] '3O_ =?\*W:* ,+_A#/#/\ T =._P#
M=?\ "C_A#/#/_0!T[_P'7_"MVB@#"_X0SPS_ - '3O\ P'7_  H_X0SPS_T
M=._\!U_PK=HH PO^$,\,_P#0!T[_ ,!U_P */^$,\,_] '3O_ =?\*W:* ,+
M_A#/#/\ T =._P# =?\ "C_A#/#/_0!T[_P'7_"MVB@#"_X0SPS_ - '3O\
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MP,7_ (1'PY_T!+#_ +\+_A1_PB/AS_H"6'_?A?\ "MJBCF?<#%_X1'PY_P!
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M(CX<_P"@)8?]^%_PK:H[XI\S[B,7_A$?#G_0$L/^_"_X4?\ "(^'/^@)8?\
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M'_?A?\*/^$2\._\ 0$L/^_"_X5LT47 QO^$2\._] 2P_[\+_ (4?\(EX=_Z
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MPO\ A6S11<#&_P"$2\._] 2P_P"_"_X4?\(EX=_Z EA_WX7_  K9HHN!C?\
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M9G :QJUW=>)M0LM#T.PU"YAA4W;W\Q0*I!QMX/O69X/+W7@?Q$M[;VZM'=R
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M":Q:35YEC2%$9AODP "5!Z ^U<[:V.J:/J\=A;7SV.H7$+7$]P$#G[I8)ST
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MHH YE[WQB-6\M-%TTZ?O \XW9W[>YVXKI1G:,]<<TN#S[^]% !1110 4444
M%%%% !1110!SGCC_ )%B?_>']:UM(_Y UE_UP3^0K)\<?\BQ/_O#^M:VD?\
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MZ* .(_MGQE_T!E_[Y_\ KT?VSXR_Z R_]\__ %Z[>B@#B/[9\9?] 9?^^?\
MZ]']L^,O^@,O_?/_ ->NWHH XC^V?&7_ $!E_P"^?_KT?VSXR_Z R_\ ?/\
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M $!E_P"^?_KT?VSXR_Z R_\ ?/\ ]>NWHH XC^V?&7_0&7_OG_Z]']L^,O\
MH#+_ -\__7KMZ* .'&L^,L\Z,HY_N_\ UZY'Q1J7B63Q'I#W&F*LBA@@QUY'
MO7LO>N#\98_X2S0OHW_H0J9;#6Y7_MCQ=_T"5P/]G_Z]']L>+_\ H$+_ -\_
M_7KLJ*XV]39(XW^V/%W_ $"%_P"^?_KT?VQXO'_,(7_OG_Z]=ES1SBD%CC?[
M8\7_ /0)4_\  ?\ Z])_;'B[H-(''3Y?_KUV??&:,9'\J=P.-&K^+P<_V0N?
M4K_]>D_M?Q=VT=?<[?\ Z]=/;:K87MS);VUW#+-%]^-&R5^M7*&!QG]L>+O^
M@0N/]W_Z]']L>+O^@0O_ 'S_ /7KL\<T?RI; <9_:_B[_H$+_P!\_P#UZ/[7
M\7?] A?^^?\ Z]=G_DT>O-- <9_;'B[_ *!"_P#?/_UZ/[8\78P=(4#_ '?_
M *]=!<^(=(LKU;.YU*VAN&( C>0!CGVJW=7MK9VQN+FXCBA&,NYP.>E '*?V
MQXNX_P")0N3_ +/_ ->C^V/%V2?[(7_OG_Z]=+<ZSIMI#%-<7L$4<W",[@!O
MIZU=5@P!!R",@CO1<#C?[7\7<?\ $I7)_P!G_P"O1_:_B[_H$+_WS_\ 7KLQ
MTHI7 XS^V/%PY_LA?^^?_KU0TG5?%20N(]*4KYC$_+WS]:]"K,T3_CSD'_39
M_P#T*J30'/\ ]L>+_P#H$+_WS_\ 7H_M?Q=_T"%_[Y_^O79T4KH#C/[7\7?]
M A?^^?\ Z]']K^+O^@0O_?/_ ->NSHHN@L<9_:_B[_H$+_WS_P#7H_M?Q=_T
M"%_[Y_\ KUV=%%PLSC/[7\7?] A?^^?_ *]+_;'B_P#Z!"_]\_\ UZ[*BBZ
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M[_H$+_WS_P#7KLJ* .-_M?Q=_P! A?\ OG_Z]']K^+O^@0O_ 'S_ /7KLJ*
M.-_M?Q=_T"%_[Y_^O1_:_B[_ *!"_P#?/_UZ[*B@#C?[7\7?] A?^^?_ *]
MU?Q=_P! A?\ OG_Z]=E10!YCXLU/Q.^@2I<:6JQ[ADX^OO6EINK>*UTNU6/2
ME9!"NT[>V/K6SXYY\,3_ %']:UM(_P"0+8_]<$_D*8'-?VMXN_Z!"_\ ?/\
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M'7_OG_Z])_:_B[_H$+_WS_\ 7KLJ*DVL<=_:_B[_ *!"_P#?/_UZ/[7\7?\
M0(7_ +Y_^O79=:3MFBX''?VQXN_Z!"Y_W?\ Z])_:_BT#_D$)_WS_P#7KL^U
M&<?4=/>@#C?[7\7?] A?KM_^O1_:_BW_ *!"_P#?/_UZZNZO+>Q@:>YG2*)?
MO.YP!2V]S!=P+/;S++$PR'4Y!H Y+^U_%W_0(7_OG_Z]']K^+NO]D+_WS_\
M7KL_Z_E2>@]: .._M?Q=_P! A?\ OG_Z])_:_BW.?['7_OG_ .O79#G@=JCN
M+B&UMVFGE6.*,9:1C@ >IH0,Y+^V/%PX_LA?^^?_ *]']K^+?^@0O_?/_P!>
MNCT[6M,U;?\ V??077EG#^4X;!I\FJV$5S);O>0K/&N]XRW*KUS0(YC^U_%O
M7^R%_P"^?_KTO]K^+L?\@A1GU7_Z]=39:A9ZE!]HLKF*>+. \;9%60>._% '
M&_VOXN_Z!"_]\_\ UZ3^U_%O_0(7_OG_ .O7944#.-_M?Q;_ - A?^^?_KU2
M;5?%7]JQG^REW%#_  __ %Z[^LYO^0[%_P!<VIH33.?_ +7\6Y_Y!*_]\_\
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M65KJD:R:2D#!2R%@TNSD_4G%&@M3K/B786U_X N9K7RY%MH_-A>+&!]"*U_
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M#TKPL=+OOM(UG5+DD$>5<3[E_+% '0=.*/QH_/\ &B@ HHHH **** "BB@4
M-D_U;?0UR/P^_P"0$_\ UU;_ -"-==)_JW^AKD?A]_R G_ZZM_Z$:3-8;G6T
M445)L'MZT;L\@<#BBCFA >/>-;X_\)Y'9Z_<7EKI)BS"UM*T8+8/4K^'%:GP
MEN;VXAU,^?-<:<D^+>29BS$8'<\^M9/B,P-\0I8_%<DG]E1Q[K9&!:/<<CH
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M_OO_  (?_&BR"YV7X4?7BN-_X5W9_P#/_??^!#_XT?\ "O+,?\O][[?Z0_\
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MT=^E<;_PKNS_ .?^^_\  A_\:/\ A7=G_P _]]_X$/\ XT] N=E^%'X5QO\
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M_A7EG_S_ %[_ .!#_P"- '9?B*/Q%<;_ ,*\L_\ G^O?_ A_\:/^%>V?_/\
M7O\ X$/_ (T@.Q_&L^RXU*]SQ]WK]*Y[_A7MGC_C^O?_  (?_&J5KX"LVU"Z
M4WU[QM_Y;OZ?6F!W_P"(H_$5QO\ PKVS_P"?Z]_[_O\ XT?\*\L_^?Z]_P#
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MO?\ P(?_ !H [+\11^(KC?\ A7EG_P _U[_X$/\ XT?\*\L_^?Z]_P# A_\
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M/^%>6?\ S_7O_@0_^- '9?E1^5<;_P *\L_^?Z]_\"'_ ,:/^%>6?_/]>_\
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MG_S_ %[_ .!#_P"-2;G8T8KC?^%?6?\ S_7W_@0_^-'_  KZS_Y_K[_P(?\
MQHL(Z]H8I3\\:-GNRY-*J(H 4!1CL,8KD/\ A7MG_P _U[_X$/\ XT?\*^M,
MD_;KW_P(?_&@5BQXY\+OXFT98+5TCNXI%DB=CP"#FMC2K*5-*M8]0C@:[CC"
MR.@R"0/>N?\ ^%>V?_/]>_\ @0_^-'_"OK/_ )_KW_P(?_&BX6.N6*./_5QH
MI/!*J!2F*-FW&-2V.25%<A_PKVS_ .?Z]_\  A_\:/\ A7UGC'VZ^Q_U\/\
MXT7"QUGV>$\&!,#IE!2BWA'(@0-WP@KDO^%?6?\ S_7O_@0_^-'_  KZS_Y_
MKW_P(?\ QHN!V"JJKA4"CT JM<V_^B3"VBB$[(P0D8Y(XYKF/^%?6G_/]>_^
M!#_XT?\ "OK3_G^O?_ A_P#&@8[P+X5N_#\%Y<:C)&]_=REY#&<CG'>NOX]!
M7'?\*^L_^?Z]_P# A_\ &C_A7UG_ ,_U[_X$/_C0!V-%<=_PKZS_ .?Z]_\
M A_\:/\ A7MG_P _U[_X$/\ XT =CQZUG/\ \AN(^B-7/CX>V?\ S_7O_@0_
M^-4F\!6@U:-?MUYC8W_+=O\ &@1WW'K17'?\*^L_^?Z]_P"_[_XT?\*^L_\
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MLK=H'N8+AC;HT@P\6[Y03V^6HWT;Q3XFUJPN->L+/3;:QD\U?L\_G-(<$8/
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M.>N ,5QDO@KQ7-X7'A_^R=,188PBWOFJTDV#U;(X/XUU_P#PM+PMC_CXN_\
MP#D_PH'Q2\+C.)[O_P  Y/\ "@"751XFM[:TM-/T#3=1A2("0W5QMVL/08.:
MQ['X?W-QX0N;#4"D-U+<FY6)'WHA#;@N?3M6F?BEX7SC[1=_^ <G^%'_  M+
MPO\ \][O_P  Y/\ "@"A;0>+XGCBE\':#(JD!IOM"@D>N-M7?$F@ZT-=L=?T
M&"WDO((O)>VED"(RDY/S8IW_  M+POG_ (^+O_P#D_PH_P"%I^%LY\^[_P#
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M!VE%<7_PM/PO_P ][O\ \ Y/\*/^%I^%_P#GO=_^ <G^% ':45Q?_"T_"_\
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M,?\ "R_#?_/>Z_\  23_  I/^%E^&_\ GO=?^ DG^%/DD!UZJJ*%10JC@ #
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M-K\0_#L=_=.TUSM?;C%K)_A18#O**Y'_ (65X:_Y[W7_ ("2?X4?\+*\-?\
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M+M(GFNMZ0JIQ:R=0![46 [BBN1_X65X;_P">]U_X"2?X4G_"R_#7_/:Z_P#
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M @CC\Z[B;S(;-A:1*SJOR(S8!-<Q_P +*\-9QY]S]?LDG^%'_"R_#7:>Z_\
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M_"C_ (63X;_Y[W7_ ("2?X46"YUM'X5R7_"R?#?_ #WNO_ 23_"C_A9/AO\
MY[77_@+)_A18+G6,H9=K*"I[&H(K"S@D\R*U@1_[RQ@'\ZYK_A9/AO\ Y[77
M_@+)_A1_PLCPW_SVNO\ P%D_PHL!UM%<E_PLGPW_ ,]KK_P%D_PI/^%D^&_^
M>]U_X"R?X46"YUU%<E_PLGPW_P ][K_P$D_PH_X63X;_ .>]U_X"2?X46"YU
MM%<E_P +)\-_\][K_P !)/\ "C_A9/AO_GO=?^ DG^%%@N=;17)?\+)\-_\
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M<C'.35<MQ7/:N",X^I%'RD?P_7M7DFG>)M1/A>ST.S_>ZI=2.B9;E(>,,?\
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M*0R@^M+1^%% !11^%'X4 %%'X4?A0 44?A1WH /6LZR_Y"=Y]%_E6B*SK/\
MY"E[G_9_E3 T:**/PI %%'X4?A0 44?A1^% !1W%'X44 9.M6VM742KH^HP6
M3J<LTL'F U-I$&J6]F(]5OH;RY!),D4/EC';BM#\** #O111^% !11^%'X4
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M;?B!_P \=-_[_G_"NRAN(;A"T$T<J@X+(P(S^%2<_C0!Q./'X_Y9:;_W_/\
MA1CX@?\ /+3?^_Y_PKMJ"<4 <5M^('_/'3?^_P"?\*3'C_\ YY:;_P!_S_A7
M;=!1GGVH XK'Q _YXZ;_ -_S_A28^('_ #RTW_O^?\*[;M1VH XG'C__ )Y:
M;_W_ #_A1CX@?\\M-_[_ )_PKMJ,^G2@#B<>/_\ GEIO_?\ /^%&/B!_SRTW
M_O\ G_"NVSS]:IZIJEKH]A->WCE8(AN8JN2!0!RN/B!_SRTW_O\ G_"C;\0/
M^>.F_P#?\_X5V5M<1W-O'/$28Y%#J2,<$9%34 </M^('_/'3?^_Y_P *-OQ
M_P">.F_]_P _X5W%% '#[?B!_P \=-_[_G_"C;\0/^>.F_\ ?\_X5W%% '#[
M?'__ #QTW_O^?\*-OC__ )XZ;_W_ #_A7<44 <1M^('_ #RTW_O^?\*3;\0/
M^>.F_P#?\_X5W%% '#[?B!_SQTW_ +_M_A1M^('_ #QTW_O^W^%=Q10!P^WX
M@?\ /'3?^_[?X4;?B!_SQTW_ +_M_A7<44 </M^('_/'3?\ O^W^%&WX@?\
M/'3?^_[?X5W%% '#[?B!_P \=-_[_M_A1M^('_/'3?\ O^W^%=Q10!P^WX@?
M\\=-_P"_[?X4;?B!_P \=-_[_M_A7<44 </M^('_ #QTW_O^W^%&WX@?\\=-
M_P"_[?X5W%% '#[?B!_SQTW_ +_M_A1M^('_ #QTW_O^W^%=Q10!P^WX@?\
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M_P *[2BGS!8XO;X\_P">6G?]_P _X4NWQY_SRT[_ +_G_"NSHHN%CB]OCO\
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M48\>=HM._P"_Y_PKL^]&.:=Q-'DOA0>+_M>I?9(K+?YO[S=*0.I]JZ?'CO\
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M_P#[_'_"C;XZ_P">6G_]_C_A79?C10!QNWQU_P \M/\ ^_Q_PHQXZ_YYZ?\
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M'XUSD\_C!=3Q;V>E-8[A\SRN'V]^.F: .C[44B[MHW8SCG%+0 4444 %%%%
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M  @7AW_H'Q_D/\*/^$"\._\ 0/C_ "% &I_;ND?]!2S_ ._Z_P"-(=<T@_\
M,4L_^_Z_XUF?\(%X=_Z!\?Y"C_A O#O_ $#X_P#OD4 :?]N:1_T%++_O^O\
MC0=<TCMJEG_W_7_&LS_A _#O_0/C_P"^11_P@7AW_H'Q_P#?(H T_P"W-(!)
M_M2SR?\ INO^-._MW2/^@I9?]_U_QK*_X0+P[_T#X_\ OD4?\(%X=_Z!\?\
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MW9[).)7 X'K5(#H_[;TK_H)6?_?]?\:/[;TK_H)6?_?]?\:S/^$'T#O81_\
M?(H_X0?P_P#\^$?_ 'R*0&G_ &WI7_02L_\ O^O^-']MZ5_T$K/_ +_K_C69
M_P (/X?_ .?"/_OD4?\ "#^'_P#GPC_[Y% &G_;>E?\ 02L_^_Z_XT?VWI7_
M $$K/_O^O^-9G_"#^'_^?"/_ +Y%'_"#^'_^?"/_ +Y%(#3_ +;TK_H)6?\
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MH_MO2O\ H)6?_?\ 7_&LS_A!_#__ #X1_P#?(H_X0?P__P ^$?\ WR* -/\
MMO2O^@E9_P#?]?\ &C^V]*[ZE:?]_E_QK,_X0?P__P ^$?\ WR*/^$'\/_\
M/@GY"@#"\;ZKITLND^7?VS[;R(DK*IP-WUKL/[;TK_H)6?\ W_7_ !K@?&7A
M/1K673/)LXU$EU&K# Y!:NK_ .$'\/\ _/A'_P!\BJLK"-/^V]*_Z"5G_P!_
MU_QH_MO2O^@E9_\ ?]?\:S/^$'\/_P#/A'_WR*/^$'\/_P#/A'_WR*6@V:?]
MMZ5_T$K/_O\ K_C1_;>E?]!*S_[_ *_XUF?\(/X?_P"?"/\ [Y%'_"#^'_\
MGPC_ .^119 :?]MZ5_T$K/\ [_K_ (TO]MZ5_P!!*S_[_K_C67_P@V@=/L$?
M/L*/^$(\/]?L$?\ WR*$D!I_VWI7_03L_P#O^O\ C1_;>E?]!*S_ ._Z_P"-
M9G_"#^'S_P N$?\ WR*/^$'\/_\ /A'_ -\BBR T_P"V]*_Z"5G_ -_U_P :
M/[;TKI_:5G_W_7_&LS_A!_#_ /SX1_\ ?(H_X0?P_P#\^$?_ 'R*+(#3_MO2
MO^@E9_\ ?]?\:/[;TK_H)V?_ '_7_&LS_A!_#^?^/"/_ +Y%'_"#^'^^GQ_7
M:*5D!I_VWI7_ $$K/_O^O^-']MZ5_P!!*S_[_K_C69_P@_A_I]@C_P"^11_P
MA'A__GPC_P"^13L@-/\ MO2O^@E9_P#?]?\ &C^V]*_Z"5G_ -_U_P :S/\
MA!_#_P#SX1_D*/\ A!_#_P#SX1_]\BBR U/[;TK_ *"5G_W_ %_QH_MO2O\
MH)6?_?\ 7_&LO_A!_#__ #X1_D*/^$'T#_GPCY_V13L#,/P7JNG17NK&2_ME
M#2\;I5&>3[UU_P#;>E8_Y"5G_P!_U_QK@?"/A/1KJ\U19K-&5)<+P/4UU?\
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M0?P__P ^$?\ WR* -/\ MO2O^@G9_P#?]?\ &C^V]*_Z"5G_ -_U_P :S/\
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M_P O^-9G_"$:!_SXQ_D*/^$(T#_GQC_(4 :?]M:7_P!!*S_[_K_C1_;6E_\
M02L_^_Z_XUE_\(1H'_/A'^0H_P"$(T#_ )\(_P A3 U/[:TO_H)6?_?]?\:/
M[:TO_H)6?_?]?\:R_P#A"- _Y\(_R%'_  A&@?\ /A'^0H U/[:TO_H)6?\
MW_7_ !H_MO2L_P#(2L_^_P"O^-9?_"$:!_SX1_D*7_A"- S_ ,>$?Y"@#2_M
MO2N?^)E9_P#?]?\ &L^SUG3!J-XQU"T .W'[Y?3ZTW_A!_#Y./L$8_ 50M/!
MFA-J%VAL8\+MQP* .B_MK2O^@E:?]_E_QH_MK2_^@E9_]_U_QK,_X0C0/^?"
M/\A2?\(1H'_/A'^0H U/[:TO_H)6?_?]?\:/[:TO_H)6?_?]?\:R_P#A"- _
MY\(_R%'_  A&@?\ /A'^0H U/[:TO_H)6?\ W_7_ !H_MK2_^@E9_P#?]?\
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MY\(_R%+_ ,(1X?\ ^?!/R%(!T.LZ9_;%P3J%IM(&#YR^GUK1_MO2O^@E:?\
M?Y?\:YV'P9H9U:>/[#'M4#L/2K__  A&@?\ /C'^0IL#3_MK2_\ H)6?_?\
M7_&C^V]*_P"@E9_]_E_QK+_X0C0/^?"/\A1_PA&@?\^$?Y"D!J?VWI6<_P!I
M6G_?Y?\ &C^W-*_Z"5IQ_P!-E_QK+_X0C0/^?!/R%'_"$:!G_CPC_(4P-/\
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MA;P/,RLRH,E4&2?H*PM*\86>KW_V2"PU.*3!.Z>T9$X]S0!T-&!VHZ#C]:*
M"BBB@ HHHH *.*** &OCRV^AKD?A[_R G_ZZM_Z$:ZZ3_5M]#7(_#[_D!/\
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MRC_^*H_X3O6/^A#U[\H__BJ .XHKA_\ A.]8_P"A#U[\H_\ XJC_ (3O6/\
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M R18,&01Q^?Z5H?\)KJPY_X0C6\_2/\ QH_X3;5A_P R1KGY1_XT>\&A!:>
MIV\'3Z'K6J/?RO(72X.<KTP.?3%4[/X=ZK+>::VO:Q!>VNG8,,4410Y!_B.3
MGK6E_P )KJPZ>"-<QUQB/_&@>-=5 X\#ZV/H$_QH]X-"YJ_A236M<LKBZNE;
M3+09%IM(+/P5)/MBJOB7P;>:CJ<.I:/>P6-PB&)S+%Y@*D8P ",=32'QMJYY
M/@G7/RC_ ,:3_A-=5'3P/K?Y)_C2]X-##\4:?%X-^%5SI@G:2XFB\LR9Y=_:
MNJ\ Z8VD^#=/M6!#;-QS[G/]:PM2UR35Q&-1^'FK7*Q-OC$BQG:?4?-5Y?&F
MJHH5? ^MA0, 8CX_\>IM.P':45QG_";:O_T)&M_DG^-'_";:M_T)&M_E'_\
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MUO\ )/\ &C_A-M7_ .A(US\H_P#&CV;"YV? ]:*XW_A-M7'3P1KGY)_C2?\
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M%<;_ ,)KJW_0D:W^4?\ C1_PFNJ]_!&M_DG^-%@+_CC/_",3\=QW^M:^C_\
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MZ#\2*XW_ (375O\ H2-;_*/_ !H_X375L?\ (D:W^4?^-%@.R."<XYHKC?\
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ME:.-L\'!!KU&N"TW7I]'M1:Z?\/M6MX <A$5 ,_]]5<_X335O^A)UO\ )/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;:C?>!+CQG_:EV-2#>?M6=A&!CILSBG7NJ-?WVFZOK%G-<6]QI\R)LB,JA^
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M,T <5_PB?B/_ *&?_P EQ_C1_P (GXC_ .AG_P#)?_Z]=K10!Q7_  B?B/\
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MM*DC\16V2!DL0% SGTH=PL<<?"_B#_H9?_)?_P"O1_PBWB#!_P"*DZ_]._\
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M(OX@_P"AD_\ )?\ ^O7944".-_X1?Q!_T,G_ )+_ /UZ/^$7\0?]#)_Y+_\
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M1?Q!_P!#)_Y+_P#UZ[*BDP.-_P"$7\0?]#)_Y+__ %Z/^$7\0?\ 0R?^2_\
M]>NRHH XW_A%_$'_ $,G_DO_ /7H_P"$7\0?]#)_Y+__ %Z[*B@#C?\ A%_$
M'_0R?^2__P!>C_A%_$'_ $,G_DO_ /7KLJ* .-_X1?Q!_P!#)_Y+_P#UZ/\
MA%_$'_0R?^2__P!>NRHH XW_ (1?Q!_T,G_DO_\ 7H_X1?Q!_P!#)_Y+_P#U
MZ[*B@#C?^$7\0?\ 0R?^2_\ ]>C_ (1?Q!_T,G_DO_\ 7KLJ* .-_P"$7\0?
M]#)_Y+__ %Z/^$7\0?\ 0R?^2_\ ]>NRHH XW_A%_$'_ $,G_DO_ /7I?^$7
M\0?]#)_Y+_\ UZ[&B@#S+Q9X=UNWT&62;7O-0$93R<>OO6EIOAG7GTNU=?$6
MU6B4A?(Z#'UK8\<?\BQ/_O#^M:VD?\@:R_ZX)_(4P.;_ .$7\0?]#)_Y _\
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MB#_H9/\ R7_^O1_PB_B#_H9/_)?_ .O7944@.-_X1?Q!_P!#)_Y+_P#UZ/\
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M_P (OX@_Z&+_ ,@?_7KL**+A8X__ (1?Q!_T,7_D#_Z]'_"+^(/^AB_\@?\
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M]7M9[KG]U&^6XZULE0P*L,@\8(JM%IUC#)YL5E;QR#^)(U!_/%/0-2U1112
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MWNAMN+>*8'IYB @?G3H;:"U3R[>&.),\*BA1^E $GX44?YQ10 4444 %%%%
M!1110!SGCC_D6)_]X?UK6TC_ ) UE_UP3^0K)\<?\BQ/_O#^M:VD?\@:R_ZX
M)_(4P+M%%%( KG/$?A&#Q+<VSWM[.MK;MN:V&-DG'?O71UY_\1_%6J:1 FGZ
M5874LLXP]Q%"SB)3]!R:: PO#D$.F_%J\L=!++IZ1GSHD.55N..?:O5KV7R+
M&>;H5C9OI@5YYX$U+0=*$=C:V.KM?7##S;FXLG7<WJ2>@KO]3C,VDWB#J\+
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M-0#QEH7/^G#_ +Y-7+G0-*O)FFN;&&25N69AS47_  BVA9_Y!EO^1K0S(/\
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M&@#%AU7PM#K4NK+?/]JE4*Q.=N ,=,5I_P#"9:%_S_#_ +Y-3_\ "*Z'_P!
MR#CVI?\ A%="_P"@9!^5 $'_  F6@_\ /\/^^32?\)EH7_/\/^^35C_A%=#_
M .@9!^5'_"*Z'_T#(/R- %?_ (3+0O\ G]'_ 'R:/^$RT+_G]'_?)JQ_PBNA
M_P#0,M_R-'_"*Z'_ - RW_(T 5_^$RT+'_'\/^^31_PF6A?\_P /^^35C_A%
M=#Q_R#(/R-'_  BNA_\ 0,@_(T 0?\)GH7_/\/\ ODT?\)GH/_/\/^^34_\
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M31_PE^B?\_H_[Y-3?\(SHG_0.A_*C_A&=$_Z!T/Y4] U(?\ A+]$_P"?T?\
M?)H_X2_1/^?T?]\FIO\ A&=$_P"@=#^5'_",Z)_T#H?RHT#4A_X2_1/^?T?]
M\FC_ (2_1/\ G]'_ 'R:F_X1G1?^@;#^5'_",Z+_ - V'\J- U(?^$OT3/\
MQ^C_ +Y-'_"7Z)_S^C_ODU-_PC.B?] V'\J/^$9T3_H&P_E1H&I#_P )?HG_
M #^C_ODT?\)?HG_/Z/\ ODU-_P (SHG_ $#H?RH_X1G1/^@=#^5&@:D/_"7Z
M)_S^C_ODT?\ "7Z)_P _H_[Y-3?\(SHG_0.A_*C_ (1G1/\ H'0_E1H&I#_P
ME^B?\_H_[Y-'_"7Z)_S^C_ODU-_PC.B?] Z'\J/^$9T3_H'0_E1H&I#_ ,)?
MH?>\'_?)K.T?Q7HT=LZO=@'S7(^4^M:Y\,:+_P! Z'\JSM&\.:.]M(S6$);S
M7 X]Z:L+4M_\)AH?_/X/^^31_P )?HG_ #^#_ODU-_PC&B?] Z'\J/\ A&=$
M_P"@=#^5+0>I#_PE^B?\_H_[Y-'_  E^B?\ /Z/^^34W_",Z)_T#H?RH_P"$
M9T3_ *!T/Y4:!J0_\)?HG_/Z/^^31_PE^B?\_H_[Y-3?\(SHG_0.A_*C_A&=
M$_Z!T/Y4:!J0_P#"7Z)_S^C_ +Y-'_"7Z'_S^C_ODU-_PC.B?] Z'\J/^$9T
M7_H&P_E1H&I#_P )?H?_ #^C_ODT?\)?H?\ S^C_ +Y-3?\ ",Z)_P! V'\J
M/^$9T3_H'0_E2T#4A_X2_1/^?T?]\FC_ (2_1/\ G]'_ 'R:F_X1G1/^@=#^
M5'_",Z)_T#H?RIZ!J0_\)?HG_/Z/^^31_P )?HG_ #^C_ODU-_PC.B?] Z'\
MJ/\ A&=$_P"@=#^5&@:D/_"7Z)_S^C_ODT?\)?HG_/Z/^^34W_",Z)_T#H?R
MH_X1G1/^@=#^5&@:D/\ PE^B?\_H_P"^32?\)?HG_/Z/^^34_P#PC.B?] Z'
M\J/^$9T3_H&P?E1=!J<9XT\2Z5<R:7Y5T#LNXV)*GH&KK?\ A+]$_P"?P?\
M?)KE_&N@Z7!)I?EV42[KN(-@=1NKKO\ A&=$_P"@=#^5-V#4A_X2_1/^?P?]
M\FC_ (2_1/\ G\'_ 'R:F_X1G1/^@=#^5'_",Z)_T#H?RI:!=D/_  E^B?\
M/X/^^31_PE^B?\_H_P"^34W_  C&B_\ 0-A_*C_A&=$X/]FP_E0F@NR'_A+]
M$/\ R^KD?[!K#>7PBWB5=>%Y)'>A-A*$A6&,<C%=%_PC.BY'_$OA'''%'_",
MZ)_T#H/J!33L&I#_ ,)?HG'^F@8_V31_PE^B$_\ 'X/^^34W_"-:)WTZ#\J!
MX9T7_H'0_E4W @_X2_0_^?T?]\FE/B_0\_\ 'X/^^34W_",:+_T#H/RH_P"$
M9T7_ *!L/Y4[I@0_\)?HG_/Z/^^30/%^B?\ /Z/^^34W_",Z)WTZ #UQ1_PC
M.B_] V'\J/0"'_A+]#S_ ,?H_P"^35+5=;\.ZSILUA<W[I#,NUC%E3CV.*T_
M^$9T7_H&PY^E'_",Z+C_ )!T/)ZXHN&IE:/J_AC0M-BT^QN=L$8P-P)/XG%7
MO^$OT,G_ (_!Q_LFI_\ A&=%[Z;!^5'_  C&BXQ_9T(_"BZ!7(?^$OT3M>C/
M^Z:/^$OT3J+U??Y34W_",Z+G_D'09^E'_",Z)_T#8.?:FK [G&^#_$NDV]YJ
MIEN@H>7*_*?4UUG_  F&B?\ /Z/^^37+^#M!TN:]U42V43A)<*".G)KKO^$9
MT7_H'0?E0[ KD/\ PE^B?\_H_P"^31_PE^B?\_H_[Y-3?\(SHG_0-A_*C_A&
M=$_Z!T/Y5.@:D/\ PE^B?\_H_P"^31_PE^B?\_H_[Y-3?\(SHG_0.A_*C_A&
M=$_Z!T/Y4] U(?\ A+]$_P"?T?\ ?)H_X2_1/^?T?]\FIO\ A&=$_P"@=!^5
M'_",Z)_T#H?RHT#4A_X2_1/^?T?]\FC_ (2_1/\ G]'_ 'R:F_X1G1/^@=#^
M5'_",Z)_T#H?RHT#4A_X3#1/^?P?]\FC_A+]$_Y_!_WR:F_X1G1/^@=#^5'_
M  C.B?\ 0.A_*C0-2'_A+]$_Y_1_WR:/^$OT3_G]'_?)J;_A&=$_Z!T/Y4?\
M(SHG_0.A_*C0-2'_ (2_1/\ G]'_ 'R:/^$OT3_G]'_?)J;_ (1G1/\ H'0_
ME1_PC.B?] Z'\J- U(?^$OT3_G]'_?)H_P"$OT3_ )_1_P!\FIO^$9T3_H'0
M_E1_PC.B?] Z'\J- (?^$OT3_G]'_?)KF/'7B;2;K1+=(KL%Q>Q,1M/0$YKK
M?^$9T3_H&P?E7+^.] TJWT.V>&QB5C>Q G';)JHVN$MC:M_%NB"VB!O!P@_A
M-2?\)=HG_/Z/^^33K?PUHIMHB=.AR4';VJ3_ (1G1?\ H'0?E6YSD/\ PE^B
M?\_H_P"^31_PE^B?\_H_[Y-3?\(SHO\ T#H/RH_X1G1?^@=!^5,1#_PE^B?\
M_H_[Y-'_  E^B?\ /Z/^^34W_",Z+_T#H/RH_P"$9T7_ *!T'Y4 0_\ "7Z)
M_P _H_[Y-'_"7Z)_S^C_ +Y-3?\ ",Z+_P! Z#\J/^$9T7_H'0?E2 A'B[1,
M?\?@_P"^31_PE^B?\_@_[Y-3?\(SHO\ T#H/RH_X1G1?^@=!^5 $/_"7Z)_S
M^#_ODT?\)?HG_/Z/^^34_P#PC.B_] Z#\J3_ (1G1?\ H'0?E0!#_P )?HG_
M #^C_ODT?\)?HG_/Z/\ ODU-_P (SHO_ $#H/RH_X1G1?^@=!^5,"'_A+]$_
MY_1_WR:/^$OT3_G]'_?)J;_A&=%_Z!T'Y4?\(SHO_0.@_*@"'_A+]$_Y_1_W
MR:/^$OT3_G]'_?)J;_A&=%_Z!T'Y4?\ ",Z+_P! Z#\J (3XOT3_ )_1_P!\
MFJ%IXKT8:C>,;P;6VX^4^E:O_",Z+_T#H/RJA9^'-'.I7:G3X=J[<#'M0!9_
MX2[1/^?P?]\FC_A+]$_Y_1_WR:G_ .$9T7_H'0_E2?\ ",Z+_P! Z#\J (?^
M$OT3_G]'_?)H_P"$OT3_ )_1_P!\FIO^$9T7_H'0?E1_PC.B_P#0.@_*@"'_
M (2_1/\ G]'_ 'R:/^$OT3_G]'_?)J;_ (1G1?\ H'0?E1_PC.B_] Z#\J (
M?^$OT3_G]'_?)H_X2[1/^?T?]\FIO^$9T7_H'0?E1_PC.B_] Z#\J0$/_"7:
M(?\ E]'_ 'R:/^$OT3_G\'_?)J;_ (1G1?\ H'0_E2_\(SHO_0.A_*@"#_A+
M]$_Y_!_WR:/^$OT3_G]'_?)J?_A&=%_Z!T/Y4G_",Z+_ - Z#\J (?\ A+]$
M_P"?T?\ ?)H_X2_1/^?T?]\FIO\ A&=%_P"@=!^5'_",Z+_T#H/RI@0_\)?H
MG_/Z/^^31_PE^B?\_H_[Y-3?\(SHO_0.@_*C_A&=%_Z!T'Y4 0_\)?HG_/Z/
M^^31_P )?HG_ #^C_ODU-_PC.B_] Z#\J7_A&=%_Z!L'Y4 <SXQ\4:1<>')8
MX[H%R1QM/O6II?BS18])LT:\ 984!^4^@JAXT\/Z3#X<F>*PA5@1R!]:U=*\
M-Z.^D6;OI\)8PH2<>PH E_X2[1/^?T?]\FC_ (2_1/\ G]'_ 'R:G_X1K1?^
M@=!^5)_PC.B_] Z#\J (?^$OT3_G]'_?)H_X2_1/^?P?]\FIO^$9T7_H'0?E
M2_\ ",Z+_P! V#\J (/^$OT7D"\'3^Z:#XNT,@@W@*D8^Z:G_P"$9T;_ *!L
M/Y4?\(UHW;38/RH X7P_;Z5X?\6:CJMOK*&TO "UOY;94Y))STKL_P#A+]$S
M_P ?@^NTU/\ \(UHW7^SH1^%)_PC.B_] V$_A0!#_P )?HG_ #^C_ODT?\)?
MHG_/X/\ ODU/_P (SHO_ $#8?RI/^$:T4?\ ,-@_*A#(?^$NT3_G\'_?)H_X
M2_1/^?T?]\FI_P#A&M&_Z!L'OQ2?\(UHO_0.A_*@"'_A+M$_Y_1_WR:Y",:=
M)XZ?Q!>ZU#+$B[;>$1,"G/?\Z[;_ (1G1O\ H'0_E1_PC.C?] V$GZ4 0?\
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M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !24M)0 5P?C/\ Y&W0O]UO_0A7>5P?C/\
MY&W0O]UO_0A42V''<ZJCO117%U-[A1110,**** "BBBBP@H_&FRLZQLT:;V
MX7.,FL#3]9UZYU'R+OPV]K;Y/[\W*M].!ZT^4+G14E'%%*P7"BBB@=PHHHH
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M.M=%N-*CGG%K/<&XP2/E8MNX]LUIZGX=M=4T5=+EDD6$ #<IYXK _M+XE?\
M0OZ%_P"!S_\ Q-']H_$K_H7]"_\  Y__ (F@#9UGPM::S%!F:6VNK< 17<!
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MXA_] +1/_ U__B:HZ3?^/A!)Y.B:,4,C9W7C#G//:J4!7/0J*XS^T/B)_P!
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M^!K_ /Q-']H?$3_H Z)_X&O_ /$T_9A<[3\*/PKB_P"T/B)_T =$_P# Y_\
MXFE_M#XB?] '1/\ P.?_ .)HY N=G^%'X5Q?]H?$3_H Z)_X'/\ _$T?VA\1
M/^@#HG_@<_\ \31[,39VE<G\0?\ D VO_7]#_,U7_M#XA_\ 0"T3_P #7_\
MB:Y[QG>^-GTB 7VCZ3%%]KB*F.[9CNR<#ITIQAJ#V/3+7_CUA_W!_*IJX:#4
M/B%]GCVZ%HI7:,$WK_\ Q-2?VA\0O^@#HO\ X&O_ /$UM8YSM.?2CGTKC/[0
M^(?_ $ =%_\  U__ (FC^T/B%_T =%_\#7_^)IV [/\ "C\*XS^T/B'_ - '
M1?\ P-?_ .)H_M#XA?\ 0!T7_P #7_\ B:+ =G^%'3VKC/[0^(?_ $ =%_\
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M =%_\#7_ /B:/[0^(7_0!T7_ ,#7_P#B:+ =G^%%<9_:'Q"_Z .B_P#@:_\
M\31_:'Q#QC^PM%'_ &^O_P#$T6 O^./^18G_ -X?UK7TC_D#67'_ "P3^0KS
M[Q9?>.'T*47FCZ3% 2,F.[9C_*M+3;_Q^NE6JQ:'HS1B)=I-XX)&./X:8'><
M^E']:XS[?\0_^@%HO_@:_P#\31_:'Q#_ .@#HO\ X&O_ /$TK =F/:N4UWP)
MI^M:O#JRW5Q8WT7'G6I"M^9^M5_[1^(?_0!T7_P-?_XFC^T/B'_T M$_\#7_
M /B:8Q]I\/K1-9AU34M0O=5N(%Q +U@PCYSD8'6NJGA6:VDA[2(5&>G3%<E_
M:'Q#_P"@%HO_ (&O_P#$T?VA\1/^@%HH/I]M?_XF@#G?AM+-IOB77O#URIB"
MNTL+@8SN8\C\JZ6\\"W%\DJ3>*=;,4HPT7FKC'ITZ5"+KQ^LID'AW0@YZL+M
ML_GMI_\ :'Q#_P"@%HO/_3Z__P 30!JZ7X3L=#T9].TUI+;S =T\> Y/KGUJ
M.Z\(VNI: =)U&[N;]2<B><@NI^M9W]H?$,#C0=%]O]-?_P")H_M#XA_] +1?
M_ U__B:0%8_"^UEM8;.YUS5+FQAZ6TL@*8^F*TK+P#I5GX@35EDD>2*/9%$^
M-D8X^[^55O[0^(?_ $ =%^GVU_\ XFC^T/B%@?\ $BT3_P #7_\ B:8#=2^&
MVGZAJMS?QZA>V;7*A9XK=@%<#UXKD#HMC<?$C2M'TY&^R:2@+G'?D?UKL?[0
M^(>?^0%HF?\ K]?_ .)J,7/CX2&1?#N@AVZN+MLG_P =H [90 H'I2UQG]H?
M$,CG0M%/_;Z__P 32?VA\0O^@#HO_@:__P 32$=ISZ45QG]H?$/_ * .B_\
M@:__ ,31_:'Q#_Z .B_^!K__ !-%@.BA/_$ZN/H/Y5H]Z\_BO_'PU.;&B:,9
M<#</MC8Z?2KO]H?$(?\ ,"T3G_I]?_XFFT!V?X4<^E<9_:'Q#_Z .B_^!K__
M !-']H?$/_H Z+_X&O\ _$TK =-JE@^HV#V\=[<V>[_EM P#+7(:?\,(=,U2
M748-?U874QS*PD7,GUXJS_:'Q#_Z 6B_^!K_ /Q-']H?$/\ Z 6B_P#@:_\
M\33&=DJX0#)( P6/>O)M&M#X?^*&J:>2]O'J48>.6/CG!)Q[\UT_]H?$/_H
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MI$FCVGV=]1NKT#&U[E@2H'85@?VA\0O^@%HO_@:__P 31_:'Q"Q_R ]%_P#
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M49DDDGDEW%YY>7=F]<4[^T/B%_T ]%_\#7_^)ILEYX_E7;)X?T-E]&O&(_\
M0:+ 5_A-HS:9X/CEDCVR71\YN.?2N\_#-<8M[\0$4*F@:(JCH!>-_P#$TO\
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M3;JU0K'J("2E3P>IS^E*P'K/;(Z44F<HIQC<,XI?2D 4444",V'C6KGCLO\
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MN;(Q>5F#R\8V<8_*@#/\)Y/A32R>]LG\A6S4*2VT:!$DA50,!58 "G?:(/\
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M"C[3#_SVC_[Z%%@)**C^TP_\]H_^^A2?:(>GG1\_[0HL!R/CO_6Z1_U^1?\
MH5=G7$^.9XFDTG$B'%Y%SN']ZNR^T0_\]H_^^A5V$245']IA_P">T?\ WT*/
MM,/_ #VC_P"^A46'<DHJ/[3#_P ]H_\ OH4?:8?^>T?_ 'T*+!<DHJ/[3#_S
MVC_[Z%'VF'_GM'_WT*+,1)4<L;21,J2&-R,!QU%'VB'_ )[1_P#?0H^TP_\
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M .^A2L.Y)7/:UX?U+4[Q9K/Q+?:<@&/+@1"/U%;GVB'_ )ZQ_P#?0H^T0_\
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M$%WJEQJ,H)/G3JH8^W%7?M$/_/:/_OH4?:(?^>T?_?0H DHJ/[1#_P ]H_\
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M 'T*+ 245']HA_Y[1_\ ?0H^T0_\]H_^^A0!)14?VB'_ )[1_P#?0H^T0?\
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M?^>T?_?0H%<DHJ/[1#_SVC_[Z%'VB'_GM'_WT* N0:E:37UG)!!>RVCMTEB
M)'YUGZ)HNH:6\C7FOWFI!ONB=%&WZ8%:_P!HA_YZQ_\ ?0H^T0_\]H_^^A0.
MY)V/O13/M$/_ #VC_P"^A2?:(?\ GK'_ -]"@+DE%1_:(?\ GK'_ -]"C[1#
M_P ]8_\ OH4!<DHJ/[1#_P ]8_\ OH4?:(?^>T?_ 'T*+ 245']HA_Y[1_\
M?0H^T0_\]H_^^A18!MW_ ,><I_V36CHW_(-CK*NYX6M)?WJ9*D8#"M/1CG38
M\#]:TB93,K4_!=IJ=[)=2WVH1LYSMBGVJ/PQ53_A7FGY_P"0GJO'_3S_ /6K
MJ[BXAM;=YKB18X4&6=CP!5;3-7T[68#<:;>Q7,(.TM$V1FM#,YW_ (5WI_\
MT$M5_P# G_ZU'_"O-/\ ^@GJO_@3_P#6KIK?4;.ZN);>"Y226+_6(IY7ZU9X
MQF@#D/\ A7FGX_Y"6J_^!/\ ]:C_ (5WI_\ T$]5_P# G_ZU=?QUI: ./_X5
MWI__ $$]5_\  G_ZU'_"N]/_ .@EJO\ X$__ %JZ:74;*"\CLY;B-+B7[D9/
M+?2K0]* ./\ ^%>:?_T$M5_\"?\ ZU'_  KS3_\ H)ZK_P"!/_UJZ^C\: .0
M_P"%=Z?_ -!/5?\ P)_^M1_PKNP_Z"6J_P#@3_\ 6KK\44 <A_PKO3^G]I:K
M_P"!/_UJ/^%=Z?\ ]!/5?_ G_P"M77\8SFB@#D/^%>:?_P!!/5?_  )_^M1_
MPKS3_P#H):K_ .!/_P!:NOS5.TU;3[^XFM[2[BFF@XE1#DI]: .<_P"%=Z?_
M -!+5?\ P)_^M2?\*\T\'/\ :6J_^!/_ -:NPI/3F@#D?^%>:?T_M/5?_ G_
M .M1_P *\T__ *">J_\ @3_]:K=GXCN;WQE=:3#;H;.U0&2?G.XC(%:-]XAT
M?3;V*SO=0MX+B4XCC=L%OI0!A_\ "N]/_P"@EJO_ ($__6H_X5YI_P#T$M5_
M\"?_ *U=1>7]K86YN+N=(81U=C@"ID=7175MRL,@CN* .1_X5WI__02U7_P)
M_P#K4?\ "O-/_P"@EJO_ ($__6KL*.U ''_\*\T\?\Q+5?\ P)_^M1_PKS3_
M /H)ZK_X$_\ UJZUY%C1F<A549)/85#9W]K?P&>TGCFB#%=R'(R.HH YC_A7
MFG_]!/5?_ G_ .M1_P *[T_/_(3U7_P)_P#K5U_Y49&: .0_X5YI_P#T$M5_
M\"?_ *U)_P *\L"/^0GJO_@3_P#6KL?2FG/3G/K0!R/_  KRP/\ S$M5_P#
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M#+.V\2Z1 M[?NL@8EGFR5Y'3BO8._P!.M<)XS_Y&S0\D]&X'?YA4SV&MQ/\
MA +$_P#,2U,XY_X^/_K4?\(#8'G^T-4_\"/_ *U=9^@HKB;U-DCD_P#A +#_
M *"&J?\ @1_]:C_A +#_ *"&J?\ @1_]:NLHHN%CD_\ A +#_H(:I_X$?_6H
M_P"$ L/^@AJG_@1_]:NLHHN%CD_^$ L/^@AJG_@1_P#6H_X0"P_Z"&J?^!'_
M -:NLHHN%CD_^$!L/^@CJG_@1_\ 6H_X0&P_Z".J?^!'_P!:NLHHN%CD_P#A
M +#_ *"&J?\ @1_]:C_A +#_ *"&J?\ @1_]:NLHHN%CD_\ A +#_H(:I_X$
M?_6H_P"$ L/^@AJG_@1_]:NLHHN%CD_^$ L/^@AJG_@1_P#6H_X0"P_Z"&J?
M^!'_ -:NLHHN%CD_^$ L/^@AJG_@1_\ 6H_X0"P_Z"&J?^!'_P!:NLHHN%CD
MO^$ L.O]HZGQ_P!/'_UJH:5X%LIK=R=0U( 2,!BX]_I7>5F:)_QZO_UV?^=4
MF%C%_P"$ L/^@CJ?_@1_]:C_ (0"P_Z".I_^!'_UJZW-'YU-PL<G_P (!8?]
M!#5/_ C_ .M1_P (!8?]!#5/_ C_ .M76447"QR?_" 6'_00U3_P(_\ K4?\
M(!8?]!#5/_ C_P"M76447"QR?_" 6'_01U/_ ,"/_K4?\(!8?]!#5/\ P(_^
MM76447"QR?\ P@%A_P!!#5/_  (_^M1_P@-A_P!!'5/_  (_^M768H[9I7"Q
MR?\ P@%A_P!!#5/_  (_^M1_P@%A_P!!#5/_  (_^M7644[A8Y/_ (0"P_Z"
M&J?^!'_UJ/\ A +#_H(:I_X$?_6KK**+A8Y/_A +#_H(:I_X$?\ UJ/^$ L/
M^@CJ?_@1_P#6KK**+A8Y/_A +#_H(:I_X$?_ %J/^$ L,9_M'4__  (_^M76
M447"QY5XP\&V=G+IBI?7[^9=1J=\^<9;MQ74_P#" 6'_ $$=4_\  C_ZU0>.
M\>;I'_7Y%U_WJ[.JOH%CD_\ A +#_H(ZI_X$?_6H_P"$ L/^@AJG_@1_]:NL
MHJ>8=CD_^$ L/^@CJ?\ X$?_ %J/^$ L/^@CJ?\ X$?_ %JZRLS5O$.D:$J-
MJFHP6@<X4RMC)H3NQ61C?\(!8?\ 01U/_P "/_K4G_" 6'_01U/_ ,"/_K5T
M.FZM8:S;?:=.NX[F'IOC.14]U<QV=K+<RL!'$A=L^@&:;O<-#E_^$ L,?\A#
M5/?_ $C_ .M2_P#" 6'_ $$=3/\ V\?_ %JT?#GB:U\26$E_:PRQ0(Y7>XQN
MQW%,3QIX9>_6Q36K0W9;8(M_S$^E/4"C_P (!8=M0U3_ ,"/_K4?\(!88R=1
MU/\ \"/_ *U=47&PN2-H&2:YZ;Q_X2MYWAFUZQ25#M93)R".U)78K%;_ (0"
MQX_XF.IG/_3Q_P#6H_X0"PZ?VEJ?_@1_]:I+_P >:-:V=O<6DS:C]I?9!':X
M8L?:KVA>)K/7=.FNXDDMQ"?WT<PPR?6G9@9G_" V&/\ D):G_P"!'_UJ7_A
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MG_P@-A_T$-4_\"/_ *U'_" V'_00U3_P(_\ K5UE% ')_P#" V'_ $$-4_\
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M=%>Q->(,M"#\P'TJ\,^IHU Y3_A ;#_H(ZG_ .!'7]*3_A ;#_H(ZG_X$?\
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M "W]OI5[_A K#_H(ZG_X$?\ UJVX?^0S<>X7^5:)H8')_P#" V'_ $$-4_\
M C_ZU'_" V'_ $$=3_\  C_ZU=910!R?_" V'_01U/\ \"/_ *U'_" V'_01
MU/\ \"/_ *U=6Q"*2QP ,DUGV7B#2M2O)K2RU"&>XA_UD:-DK]:8&)_P@-A_
MT$=3_P# C_ZU!\ V(_YB&I_^!'_UJZSGUKGY?%MC%XJCT!(I9+MUW,T8R%&,
M\T@*A\ V'_01U/\ \"/_ *U)_P (#8]?[0U/_P "/_K5LOX@TA-572VU" 7[
M'Y8-WS'\*T7944LQP ,G/:C4#E?^$!L?^@AJ?_@1_P#6H_X0&QQ_R$-3_P#
MC_ZU7[;QIX:N;LVD&M6CW(+ QH_S<=?RK*'Q'TPZD;86EVUN)C ;P*/*W#MG
M-&H$W_" V&/^0CJG_@1_]:C_ (0&Q[ZCJ?X7'_UJTM9\26FBO:1R+)-/<N$C
MCC&6.>_TJO'XOL6\4#09(9H+IH_,7S  K#&>*-0*O_" V&/^0CJG_@1_]:C_
M (0&P_Z"&J?^!'_UJZRC% ')_P#" V'_ $$-4_\  C_ZU'_" V'?4=3_ / C
M_P"M7644 <B_@*P"-_Q,M3X!_P"7C_ZU<WX*\'6=[I#2O>W\9$C#:DV!U/M7
MJ#Y\MO\ =-<C\/?^0$_M,W_H1I-FD-QW_"!6/_01U+_P(_\ K4?\(%8_]!'4
MO_ C_P"M75T5-S:QRG_"!6/_ $$=2_\  C_ZU'_"!6.,_P!HZE_X$?\ UJZO
MFC//]*=PL<I_P@5A_P!!#4__  (_^M1_P@5AU_M'4_\ P(_^M6SJOB#2-""'
M5+^"T$APOFMC)J;3M6L=8M?M&G745Q"?XXSD47T$8'_"!6/_ $$=2_\  C_Z
MU'_"!6/;4-3_ / C_P"M72WEU#8VDUS*VV.)"S'O@"LSP[XDM?$>G/?6L4J6
MZ,5WRC&<=_I0F!F_\(#8Y_Y".I\=?](_^M1_P@-B?^8CJ9_[>/\ ZU7D\:>&
MY;[[%'K-FUTS;!$)/F)]*W!@_=.>]%V.R.5_X0*QS_R$=3'_ &\?_6H_X0*Q
M[ZAJ?'7_ $C_ .M6U?Z_I6EW$=M?:A!!+*<)'(V"Q]JI^(/%-IX>%LDL4UQ/
M<-LBMX0"['&>!1J!1_X0*Q!Q_:.I9_Z^/_K4?\(#8]/[0U//_7Q_]:M+1?$M
MEK6F2WD:O;K"<31S##1_6H]*\46VKV%W>VMM<&&W9U!*C]YMSG;^5&H%'_A
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MLO7O&UEH5[]C-K<W=P(S*Z6ZAC&H.,FC4-"/_A K'/&HZGQU_P!(_P#K4?\
M"!6/;4-3/M]H_P#K5J?\)'8?\(__ &R9,6X4L<]21V^M5Y?%5O%X9_MUK.Z\
MD@,$VC?@]_IS0)6*?_"!6.,_VAJ?_@1_]:C_ (0*Q_Z"&I_^!'_UJW-&U:UU
MO2X-0LR?)F7<N>M7_P 31<JQRG_"!6/_ $$=3_\  C_ZU'_"!6/_ $$=2_\
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M\0Z+;K<WEH#&T' +HQ&[!/ X%0);:YXIUZPN]3TE])M+!BXCED60RDC'5>E
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MO@=OUKG)]>UJ+4Q;Q^%[B6WW!?M N$ P>^.O% '1T4BYV@LN#W&:6@ HHHH
M**** "BBB@ ]:SK+_D)WGT7^5:-9UE_R$[W_ (#_ "H T:*** "BBB@ HHHH
M */YFBB@"M=ZA9V"AKN[@MU/ ,T@4'\Z=:WMK?1>9:7$4\9/WXW##\Q4=]I=
MCJ<:I?6<%RJG($J!L?G3K+3[/3H/(LK:.WBSG9&H49H L\9HHHH **** "BB
MB@ HHHH YSQQ_P BQ/\ [P_K6MI'_(&LO^N"?R%9'CC_ )%B?_>']:U](_Y
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M4O\ A ,#_D,W7Y?_ %ZLS.SRN.M)N&,Y'UKC?^$ _P"HS=_E_P#7H_X5^/\
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M_P *_P#^HS=_E_\ 7I/^$ '_ $&;O\O_ *] '99%<)XR/_%6Z'W^5OYBK0\
M8(/]LW1Q[?\ UZX[Q1X.^S>(M(@_M*X?S-QW'J.1[U,MAK<]1R.,D8HR/45R
M'_""?]1>YY[8_P#KTO\ P@G_ %%[G\O_ *]<;W-D==D>U&1[5R'_  @G_47N
M?\_C1_P@G_47N?\ /XT =?D>U&1[5R'_  @G_47N?\_C1_P@G_47N?\ /XT
M=?D>U&1[5R'_  @G_47N?\_C1_P@G_47N?\ /XT60'7Y'M1D>U<A_P ()_U%
M[G_/XT?\()_U%[G_ #^-%D!U^1[49'M7(?\ ""#_ *"]S_G\:/\ A!/^HO<_
MY_&BP'7Y'M1D>U<A_P ()_U%[G_/XT?\()_U%[G_ #^-%@.OR/:C(]JY#_A!
M/^HO<_Y_&C_A!/\ J+W/^?QH Z_(]J,CVKD/^$$_ZB]S_G\:/^$$_P"HO<_E
M_P#7H Z_<,=:S-$(^S2#.")7_G6'_P ()_U%[G_/XU0TGP1YUO)C5KD8D;M[
M_6J2$=]D>U&1[5R'_""?]1>Z_P _C1_P@G_47NO\_C4V&=?D>U&1[5R'_""?
M]1>Y_P _C1_P@G_47N?\_C18#K\CVHR/:N0_X03_ *B]S_G\:/\ A!/^HO<_
MY_&@#K\CVHR/:N0_X03_ *B]S_G\:/\ A!/^HO<_Y_&BR Z_(]J,CVKD/^$$
M_P"HO<_Y_&C_ (03_J+W/^?QHL@.OR/:C(]JY#_A!/\ J+W/^?QH_P"$$_ZB
M]S_G\:+(#K\CVHR/:N0_X03_ *B]S_G\:/\ A!/^HO<_Y_&BP'7Y'M1D>U<A
M_P ()_U%[G_/XT?\()_U%[G_ #^- '7Y'M1E<YXKD/\ A!/^HO<_Y_&C_A!/
M^HO<_E_]>@!GCO!DTCG/^F1<#_>KLLCVKR?Q?X0^RR::/[2N'WW4:Y/;+?6N
MI_X03_J+W7^?QIM"ZG7Y'M1D>U<A_P ()_U%[G_/XT?\()_U%[G_ #^-*R&=
M?N'M1GT.3U]JY#_A!!_T%[K\O_KT?\()ZZO=8[<=?UI60'8;AC.>E07=O#>V
M<UM* 8Y4*,#[C%<L? H[ZO=>O _^O1_P@F?^8Q<D?Y]ZK0#4\,^&[;POI[65
MM<S2PERX20CY<]ACM6WQ@#(//Y5R'_"!YP/[6NOR_P#KT?\ ""#_ *"]UD^W
M_P!>EI<#K\CL0<<9H! Z$#WKD/\ A!..=7NL_3_Z]'_""<\ZO<_@/_KT)(#K
MLK@9Z4NX=R!7(?\ ""#H=7NL>N/_ *]'_""9Y_M>Z_+_ .O19 =5<QK=6LL/
MFLF]2I*'D9[UC>%_"]CX6LY(;>5YFE??))+C<Q]\5G?\((#UUBZ]SC_Z]+_P
M@N>?[6N?R_\ KTU:PCK@PQR0*,CU%<A_P@@_Z"]U^7_UZ/\ A!/^HO<_E_\
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M^O0!WN?>C(]JY#_A!?\ J+W/^?QH_P"$%_ZB]S_G\: .OR/:C(]JY#_A!?\
MJ+W/^?QH_P"$%_ZB]S_G\: .OR/:C(]JY#_A!?\ J+W/^?QH_P"$%_ZB]S_G
M\: .OR/:C(]JY#_A!?\ J+W/^?QH_P"$%_ZB]S_G\: .OX]J,CU%<A_P@O\
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M9Z=/_KT ==\N,': .U)\I/8C'X5R7_""#_H+W7'M_P#7H_X07GC5[K\O_KT
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M\?\ UZ/^$&XR-7NOH1_]>CH'4Z[<, Y^E&[WX]*Y'_A!A_T%KGGV_P#KT?\
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M)[T >KBEKGO!.JRZWX0TW49VW2SPAF;U-=!]: %HHHH **** "BBB@ HHHH
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M4HK>4C.U@<_H*8&U14=O<17<"3P2*\;J&1AW!J2E9 %%%%&@!1111H 4444
M%<G\0?\ D VW.?\ 3H?YFNLKD_B#_P @&U_Z_H?YFJCN*6QT5K_QZ1?[@_E4
MU16O_'K#_N#^52UTG.%%%% @HHHH **** "BBC&>._7% !11UYHH **** "B
MBB@ HHHH /6LZS_Y"E[_ , _E6CZUG67_(3O/HO\J -'^5%%% !1110 4444
M %%%'?\ QH **S=6U_2]#B634[Q+97. 6!Y_*I-+U?3]:M1=:==)<0$D!U!Z
MCZT 7J*/K10 4444 %%%% !1SVHHH YSQQ_R+$Y]Q_6M;2/^0-9?]<$_]!%9
M'CC_ )%B?_>']:U](_Y UE_UP3^0I@7:***0!4<US!;(&GFCB4]#(P4?K4E<
M_P"(/"5CXCN;>34I9I+>W.[[-D>6W&/F%,#:@O+6Y/\ H]S#*1U\MPW\JFZ=
M3^->0>&;6UL?BS>6WAY1'8(A$Z1_ZL-QQ^5>KWLWD:?<2]TC9OI@4#,^U\3:
M5>:U-I%O.9+R 9D0*<*/K^%7I-2L(9&22]MT93R&F4'\LUYS\*M.\^76M:DR
MLMW.Z!^^,Y'\ZK:IIOP[TBYU-]9N4O\ 4F<NZW*EG!QT!QBBP'JL,T4Z"2&1
M)$/1D8$?I3I)(XHR\CK'&O5F; KSKX007$&A73DRK8O,3:Q.1\JY.<8[5?\
MBE8:EJ'AC;II=U1@TL49P77(SU]LT =6NK::QP+^U9B>@F7/\ZYYOB5X86]-
MI]M?>9 FX1-MW=ANZ5Y+J4?AC6-(L-/\-:,8]:8 LZ !HS_M'_"JVH:9K^@>
M![C3+SP_,V)TF^V$#9@ Y[Y[T[ >[ZKXJTC1Y;2.[N?WEV<0HB%B?R^M.MO$
M^E7>N2:1%.WVV(99&0KQTXSUKQWX?>(M$N[]=;\3ZM:PW4$:P06[AOD"C;GI
MW%;OB>_BM_B-X?U>P9)+>\PGF+T=<,:+ >N]O7WHI%.45L#YAD>U+4@%%%%
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M112&+6:__(;B_P!QJT:SG_Y#D7_7-J8F:-'-%%(8<T<T44 '-'-%% !1110
M456O[^UTRT>ZO)A#"G)=N@JGI7B71M<=QIM_'<%/O;0>/S% &K1S1V']:* "
MBBB@ HHHH *.:** (;O_ (])O78:T-&_Y!L=9]W_ ,>DW^Z:T=&_Y!L=:1,I
MD>O6,NI:%=VD!42RQ[4)/&:S(?#7VGP9_8M^$WM&R$J<[2<\BG:CXWT?2[U[
M2Y-UYB'!V6S,/S JG_PLCP_GK>_^ C_X5H9F%X0\!:SI6FZS9ZG=(WVI#%!(
MCY(49"Y_#%9TO@KQ=<>&E\/FTTJ*"!52.[67,LH!'WLCBNO_ .%D>'_6]_\
M 1_\*/\ A9'A_P!;W_P$?_"@"#Q%X<U9SI>I:,()-1LE6,Q3/M1UZGFJ>F>'
MO%$_C"UU_6#:IY<4B&VBEW*F1@8.,G/>M/\ X61X?];W_P !'_PH_P"%D>'_
M %O?_ 1_\* ,O7],\8:]Y^GRZ/HR64C@"Y%PWFA0<@XQU_&K6L^$KZ&>PU+2
M%M[J^M8?(,5V<)(N<G)P>]6O^%D>'_6]_P# 1_\ "C_A9'A_UO?_  $?_"@
MT2/Q-+=LFKZ'HUE;E"/-M)2S@_B!7.+X2\46,6H:79VNFS6=U-)*+V:3]\N[
M^$#&,5T?_"R/#_K>_P#@(_\ A1_PLCP_ZWO_ ("/_A0!H>#-(N=!\):?IEX4
M,]O$$<H<C-;]<A_PLCP_ZWO_ ("/_A1_PLGP_P"M[_X"/_A0!U]%<A_PLCP_
MZWO_ ("/_A1_PLCP_P"M[_X"/_A0!U]%<A_PLCP_ZWO_ ("/_A1_PLCP_P"M
M[_X"/_A0!U]%<A_PLCP_ZWO_ ("/_A1_PLCP_P"M[_X"/_A0!U]%<A_PLCP_
MZWO_ ("/_A1_PLCP_P"M[_X"/_A0!U]%<A_PLCP_ZWO_ ("/_A1_PLCP_P"M
M[_X"/_A0!U]%<A_PLCP_ZWO_ ("/_A1_PLCP_P"M[_X"/_A0!U]%<A_PLCP_
MZWO_ ("/_A1_PLCP_P"M[_X"/_A0!U]%<A_PLCP_ZWO_ ("/_A1_PLCP_P"M
M[_X"/_A0!U]%<A_PLCP_ZWO_ ("/_A1_PLCP_P"M[_X"/_A0!U]%<A_PLCP_
MZWO_ ("/_A1_PLCP_P"M[_X"/_A0!U]%<A_PLCP_ZWO_ ("/_A1_PLCP_P"M
M[_X"/_A0!U]%<A_PLCP_ZWO_ ("/_A1_PLCP_P"M[_X"/_A0!U]%<A_PLCP_
MZWO_ ("/_A1_PLCP_P"M[_X"/_A0!U]%<A_PLCP_ZWO_ ("/_A1_PLCP_P"M
M[_X"/_A0!U]%<A_PLCP_ZWO_ ("/_A1_PLCP_P"M[_X"/_A0!U]%<A_PLCP_
MZWO_ ("/_A1_PLCP_P"M[_X"/_A0!U]%<A_PLCP_ZWO_ ("/_A1_PLCP_P"M
M[_X"/_A0!UW>N#\9?\C;H7T;_P!"%7A\1] SQ]MST'^BO_A7&^*?&VCW?B31
MYXC=>7$&#;K=@>H]JB6PUN>G45RO_"Q-!SUO>>/^/5_\*3_A8>@CC-YQ_P!.
MK_X5QVU-DSJZ*Y3_ (6'H7K>?^ K_P"%'_"P]"];S_P%?_"BP7.KHKE/^%AZ
M%ZWG_@*_^%'_  L/0O6\_P# 5_\ "CE"YU=%<I_PL/0O6\_\!7_PH_X6'H7K
M>?\ @*_^%%@N=60",$ Y]:A6UMD<NEO"K=F5 #7-?\+#T+UO/_ 5_P#"C_A8
M>A>MY_X"O_A3L%SJ_P :*Y3_ (6'H7K>?^ K_P"%'_"P]"];S_P%?_"ERA<Z
MNBN4_P"%AZ%ZWG_@*_\ A1_PL/0O6\_\!7_PHY0N=717*?\ "P]"];S_ ,!7
M_P */^%AZ%ZWG_@*_P#A1RA<ZNBN4_X6'H7]Z\_\!7_PH_X6'H7K>?\ @*_^
M%#0'5UEZ)_QZR?\ 79_YUDCXAZ%ZWG_@*_\ A6=I'C[0X;=PWVSF5\?Z*_<_
M2J2 [NBN4_X6%H0[WG_@*_\ A1_PL/0?6\_\!7_PJ>4=SJZ*Y3_A8>A>MY_X
M"O\ X4?\+#T+UO/_  %?_"CE%<ZNBN4_X6'H7K>?^ K_ .%'_"P]"];S_P !
M7_PHY0N=71Z>WZURG_"P]"];S_P%?_"C_A8>@^MY_P" K_X4687.EDMK>5MT
MD$4A]70&I55478J@*.F.,5RW_"P]!];S_P !'_PI/^%AZ#ZWG_@*_P#A1J%S
MJ_QHKE/^%AZ%ZWG_ ("O_A1_PL/0O6\_\!7_ ,*+!<ZNBN4_X6'H7K>?^ K_
M .%'_"P]"];S_P !7_PHY0N=717*?\+#T+UO/_ 5_P#"C_A8>A>MY_X"O_A1
MRA<ZNBN4_P"%AZ%ZWG_@*_\ A1_PL+03@9O/_ 5_\*.4=ROX[_UVD?\ 7Y%_
MZ%79UY7XP\:Z1>R::83=8BNHV;=;L. WTKJO^%AZ#ZWO_@*_^%4T3?4ZJBN4
M_P"%AZ#ZWG_@*_\ A1_PL/0?6\_\!7_PJ>4=SJZ\S\<^%_%?B+Q!:RP1V5SI
M%N=WV2:<H)#SUP,^E=#_ ,+#T+UO/_ 5_P#"C_A8>A?WKS_P%?\ PJEH#+'A
M]_$J2BWU72]-L[1%^3[).7.>PP15'XG:;)JG@:\A0X9")<CT7FIO^%AZ#ZWO
M_@*_^%1S^/?#US!)#*+QHY%*L#:/R#QZ4[ZB,?2=+3QG\)[2Q$VQUA5 P[,,
M52C\%>)]8@TO3->2SBT^P8-O@F+/)@GJ"/>M30O$'A'PY;R0:<NH+$[ERCPR
M-@GTR.*U?^%AZ#ZWN/\ KU?_  IN3"PVVT[Q1#XU$OVR,^'D@V)!N&[<% '&
M/7WK)O/!>J:M\2H=<OGB_LZV0"*(/DDX(Z?E6Q_PL/0?6]_\!7_PI?\ A8F@
MYZWG_@*_^%*[0S5\11:G+HD\6CF,7DB[4:1MH7WKG)O :+X+DTNW93>N1*TC
M'[[\G!/IDU=_X6'H7K>?^ K_ .%'_"P]"];S_P !7_PI)L1E>&?#.MVVNOK&
MMK;0^1:I#'';R;P0H(R2163X B?4/B/XDUA7/D;S&F.G4&NGN/'GA^YMI(':
M]V2*5;;;.#@_A6;H&O\ A#PU9M:Z;'?K&S;F,D#LS'W)%5=B/03UZG-':N5_
MX6)H/K>?^ K_ .%)_P +#T+UO/\ P%?_  K.Q=SJZ*Y3_A8>A9ZWG_@*_P#A
M2GXAZ%US>?\ @*_^%-(5ROX(_P"/[6/^NW]379=J\K\)^-='LKO4VE-UMEER
M-MNQ[GVKJO\ A8>A>MY_X"O_ (4- F=517*?\+#T+UO/_ 5_\*/^%AZ%ZWG_
M ("O_A4V'<ZNBN4_X6'H7K>?^ K_ .%'_"P]"];S_P !7_PI\HKG5T5RG_"P
M]"_O7G_@*_\ A1_PL/0O6\_\!7_PIV"YU?XU%);6\K R012$=W0$US/_  L/
M0?6\_P# 5_\ "C_A8>@^MY_X"O\ X4K!<ZH*%7:!P.F!BEKD_P#A8>A>M[_X
M"O\ X4O_  L/0O6\_P# 5_\ "CE"YU=%<I_PL/0O6\_\!7_PH_X6'H7K>?\
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MV88W6[ =_:M/3/'VAQ:5:1M]KW)"JG%L_8#VI@=I17*_\+!T+_I\_P# 5_\
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M_P# 5_\ "J#>/-$.KQ2 W>-C?\NK_P"%,39W%%<M_P +!T+'6\_\!7_PI/\
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M%ZDO8VK:PM/LL1-O']P=O:IOL%I_S[Q_E3[7_CUA_P!P?RJ6N@P*_P!@M?\
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M:?\ /O'^5']GVG_/O'^56:* L5_L%KG/V>/\JSGL;7^V8T\A,%&/2MJLU_\
MD.1?[C4R;%C[!:8_X]X_RH_L^T_Y]X_RJS10RK%;^S[3_GWC_*C^S[3_ )]X
M_P JLT4A6*W]GVG_ #[Q_E1_9]I_S[Q_E5FB@+%;^S[3_GWC_*C^S[3_ )]X
M_P JLT4!8K?V?:?\^Z?E1_9]I_S[I^56:* L5O[/M/\ GWC_ "H_L^T_Y]X_
MRJS10%BM_9]I_P ^\?Y4?V?:?\^\?Y59HH"Q6_L^T_Y]X_RH_L^T_P"?>/\
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M]^E_PH_LVP_Y\;;_ +]+_A0!S,?Q%\+QQJBW\:JHP%W4_P#X61X9_P"?^/\
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M^JZ3^S+#_GQMO^_2_P"%']F6'_/C;?\ ?I?\* .;_P"%D^&?^@A'_P!]4?\
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M_GSM_P#OTO\ A1_9UC_SYV__ 'Z7_"EH&ISW_"Q/#O\ S_1_]]4?\+$\._\
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M^=O_ -^E_P */[.L?^?.W_[]+_A1H&ISW_"Q/#O_ #_1_P#?5'_"Q/#O_/\
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M (_H_P#OJL_QQ8VB2Z3LM85!O(@0(P,_-78?V=8_\^=O_P!^E_PINP:G/_\
M"Q/#G_/]'_WU2?\ "Q/#G_/]'_WU70_V=8_\^=O_ -^E_P */[.L?^?.W_[]
M+_A4Z#U.>_X6)X<_Y_H_^^J/^%B>'/\ G^C_ .^JZ'^SK'_GSM_^_2_X4?V=
M8_\ /G;_ /?I?\*>@:G/?\+$\.?\_P!'_P!]4?\ "Q/#G_/]'_WU70_V=8_\
M^=O_ -^E_P */[-L?^?.W_[]+_A1H&ISW_"Q/#G_ #_1_P#?5'_"Q/#O_/\
M1_\ ?5=#_9UC_P ^=O\ ]^E_PH_LZQ_Y\[?_ +]+_A1H&ISW_"Q/#O\ S_1_
M]]4O_"Q/#G_/]'_WU70?V;8_\^=O_P!^E_PH_LZQ_P"?.W_[]+_A1H&ISW_"
MQ/#O_/\ 1_\ ?5'_  L3PY_S_1_]]5T/]G6/_/G;_P#?I?\ "C^SK'_GSM_^
M_2_X4:!J<]_PL3P[_P _T?\ WU1_PL3P[_S_ $?_ 'U70_V=8_\ /G;_ /?I
M?\*/[.L?^?.W_P"_2_X4:!J<]_PL3PY_S_1_]]4?\+$\.?\ /]'_ -]5T/\
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M.W_[]+_A1_9UC_SYV_\ WZ7_  HT#4Y[_A8GAS_G^C_[ZH_X6)X=_P"?Z/\
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MV/\ [ZH_X6'X=_Y_H_\ OJNA_LZQ_P"?*W_[]+_A1_9UC_SY6_\ WZ7_  H
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M )\K?_OTO^%']G6/_/G;_P#?I?\ "D!SW_"P_#O_ #_1_P#?5'_"P_#O_/\
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M/_/E;_\ ?I?\* ./B\?>'QJUQ)]NCPP 'S>U7_\ A87AW_G^C_[ZK0AL+/\
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M?^?*W_[]+_A1H&IS_P#PL+P[_P _T?\ WU1_PL+P[_S_ $?_ 'U70?V=8_\
M/E;_ /?I?\*/[.L?^?*W_P"_2_X4:!J<_P#\+"\/?\_T?_?5'_"PO#O_ #_1
M_P#?5=!_9UC_ ,^5O_WZ7_"C^SK'_GRM_P#OTO\ A2N@U.?_ .%A>'?^?Z/_
M +ZH_P"%A>'?^?Z/_OJN@_LZQ_Y\K?\ []+_ (4?V=8_\^5O_P!^E_PIZ!J<
M_P#\+"\._P#/]'_WU1_PL+P[_P _T?\ WU70?V=8_P#/E;_]^E_PH_LZQ_Y\
MK?\ []+_ (4:!J<__P +"\._\_T?_?5'_"PO#O\ S_1_]]5T']G6/_/E;_\
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MX]*\[TF35]8\%:=X=B\.7D*R (;]POE@<_-US72^-8C#K?A>)CDQLBDCV84
M==K?BS2?#WEKJ,[HS]!'$SG\=HXJ[H^M66N6*WFGS>; W1L$$>Q!Z5Q>I:WJ
M-UXNU'3]"M=.CNK>W1KF>]#8=#G &/3!IOPGEEEM]<,S0,_V]LFWSY><#[N>
M<4 >CT4@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *2EHH 3O7!^,_^1MT+Z-_Z$*[SO7!^,_\
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M:5.C'3/L^.?M(?=G\*:0&_14-KY_D1_:=GG;?G\O[N?:IJ+ %%%% !11118
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M): .VHKB?.\=_P#/&V_):/.\=_\ /&V_): .VHKB?.\=_P#/&V_):/.\=_\
M/&V_): .VHKB?.\=_P#/&V_):/.\=_\ /&V_): .VHKB?.\=_P#/&V_):/.\
M=_\ /&V_): .VHKB?.\=_P#/&V_):/.\=_\ /&V_): .VHKB?.\=_P#/&V_)
M:/.\=_\ /&V_): .VHKB?.\=_P#/&V_):/.\=_\ /&V_): .VHKB?.\=_P#/
M&V_):/.\=_\ /&V_): .VHKB?.\=_P#/&V_):/.\=_\ /&V_): .VHKB?.\=
M_P#/&V_):/.\=_\ /&V_): .VHKB?.\=_P#/&V_):/.\=_\ /&V_): .VHKB
M?.\=_P#/&V_):/.\=_\ /&V_): .U/6N#\9?\C;H7^ZW_H0J;S_'.X9AM^OH
MM<AXHE\6GQ'I1N(X!(,[,!?45,MAK<]3HXKC?.\;9_U-O^2T>=XV_P">-O\
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M!(Y&:6H?MEM_S\P_]_!1]LMO^?F'_OX* )J*A^V6W_/S#_W\%'VRV_Y^8?\
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MW/-6_MEM_P _,/\ W\%'VRU_Y^(O^_@H GI*A^V6O_/Q#_W\%'VRV_Y^8?\
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MBXYV@4^H?MEK_P _,/\ WV*3[9:_\_,/_?P4A$]%0_;+7_GYA_[^"C[9:_\
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MHL!-6<_.N1#T1JM_;+;_ )^8?^^Q6<]W;?VW$?M$7W&S\XIV)9KT5#]LM?\
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MW_H!P_\ ?Q__ (JC_A6/@W_H!P_]_'_^*KKJ* .1_P"%8^#?^@'#_P!_'_\
MBJ/^%8^#?^@'#_W\?_XJNNHH Y'_ (5CX-_Z </_ '\?_P"*H_X5CX-_Z </
M_?Q__BJZZB@#D?\ A6/@W_H!P_\ ?Q__ (JC_A6/@W_H!P_]_'_^*KKJ* .1
M_P"%8^#?^@'#_P!_'_\ BJ/^%8^#?^@'#_W\?_XJNNHH Y'_ (5CX-_Z </_
M '\?_P"*H_X5CX-_Z </_?Q__BJZZB@#D?\ A6/@W_H!P_\ ?Q__ (JC_A6/
M@W_H!P_]_'_^*KKJ* .1_P"%8^#?^@'#_P!_'_\ BJ/^%8^#?^@'#_W\?_XJ
MNNHH Y'_ (5CX-_Z </_ '\?_P"*H_X5CX-_Z </_?Q__BJZZB@#D?\ A6/@
MW_H!P_\ ?Q__ (JC_A6/@W_H!P_]_'_^*KKJ* .1_P"%8^#?^@'#_P!_'_\
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MSX2_Z L/_?Q_\:ZFBCG861RW_"N?"7_0%A_[^/\ XT?\*Y\)8P-%AS_UT?\
MQKJ:*.=A9'EOC'P1X<L9-,%OI<:"2ZC1P';D%N>]=3_PKGPE_P! 6'_OX_\
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M%<^$O^@+#_W\?_&NIHHYV%D<M_PKGPE_T!8?^_C_ .-'_"N?"7_0%A_[^/\
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M]0NXWT>)E3;M^=_3ZUVWK6=9?\A.\_X#_*G<#'_X5SX2_P"@-$?^VC_XT?\
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MQ_\ &NIHHN!RW_"N?"7_ $!8?^_C_P"-+_PKGPEG_D"P_P#?Q_\ &NHH[T7
MY1_AUX2$3$:-"#@_\M'_ ,:YOP5X)\-ZAI#RW.E12.)&&=[<#)]Z]-?_ %3?
M0UR/P^_Y ,G_ %V;_P!"-#;-(;DO_"NO">/^0/%_WV_^-'_"NO"?_0&B_P"^
MW_QKJ./_ *]%3=FUCE_^%=>$O^@-%_W\?_&C_A77A+_H#0_]_'_QKJ,4G>CF
M861S'_"N_"77^QHO^_C_ .-'_"NO">,_V-%_WV_^-7-;\6Z=H#JERMQ*QZK:
MPF4K[D+T%2:!XGTSQ-:-<:=,S(IPRNNU@?<4[NPM#/\ ^%=>$NVC19_WW_QH
M_P"%=>$^VC0_]_'_ ,:W=4U"+3--N+V8?)#&6QTS@5C^%_%!UW09-6NK9;.V
M5FV[GZJ._/K2NPT(O^%=>$L_\@>+C_;?_&@?#KPEU_L:+\7?_&FVGQ!T>_OD
MM;:'47:1MB2BS<QGWW=,>]=2.1P,9YYIML=D<Q_PKKPGU.BQ8]=[_P"-'_"N
MO"8'_(&B/_;1^?UI^K>//#^C:E#I]U>$W$S;56)=^#[XZ4WQ1XIDT.>QM+*S
M%U?7;[(XV?:O0GD]NE%V&@G_  KKPG_T!XOJ'?\ QI?^%=>$^G]C0_7S'_QH
MT+QA#J6CW5Y?1I9R6;8N$#[@O?@]ZDT/Q%>:SI%UJ*Z<(HT+^0&?_6!<X/MF
MC4-"+_A77A(\_P!CQ8]I'_QI?^%=>$^?^)-%]-[_ .-.\(>*QXGM;AI+<6MQ
M;R&.6$-G&/>NEI7861R__"NO"?\ T!HO^^W_ ,:/^%=>$_\ H#1?]]O_ (UU
M%%%V.R.7_P"%=>$_^@-%_P!]O_C5%_ 'A;^UXH?[(BV%&)&]_P#&NVK.?_D.
M1?[C479-C(_X5UX3_P"@-%G_ 'W_ ,:/^%=>$_\ H#1?]]O_ (UU'N>M%%V.
MR.7_ .%=>$_^@-%_WV_^-'_"NO"?_0&B_P"^W_QKJ**.9A9'+_\ "NO"?_0&
MB_[[?_&C_A77A/\ Z T7_?;_ .-=111=A9'+_P#"NO"?_0&B_P"^W_QH_P"%
M=>$_^@-%_P!]O_C74447861R_P#PKKPE_P! :+_OM_\ &C_A77A+_H#1?]]O
M_C74?C1CFB["R.7_ .%=>$O^@-%_WV_^-'_"NO"?_0&B_P"^W_QKJ**+L+(Y
M?_A77A/_ * T7_?;_P"-'_"NO"?_ $!HO^^W_P :ZBBB["R.7_X5UX3_ .@-
M%_WV_P#C1_PKKPG_ - :+_OM_P#&NHHHNPLCE_\ A77A/_H#1?\ ?;_XT?\
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M///YU@7O@SQ9JVGV-A=RZ;#!931,A@+9D5&!^;(ZX% %O63GXK:.^,Y0<_\
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M^N*>@#J***0!1110 4444M0"BBB@ K+T3_CTD_Z[/_Z%6I69HG_'I)Z^<_\
MZ$:I"L:=%%%(84444 %%%%+4 HZ<XZ=Z*,#TIH+&'JWB[1M#N5M[^Z>.1AD
M1,W\A6M:W45Y;QW$#;HW&5)&,@U(R*_WE4_44[  QCCTIW06#O1112 ****
M"BBBC4 HHH[T:A8XSQW_ *[2/^OR+_T*NSKC/'?^MT@X/_'[%_Z%79U6H@HH
MHJ1V"BBB@ HHHHU *J:EJ=KI-D]U>.4B4<D*6_05;[4A4$<CCO0!D:-XFTK7
MS(-/G:3R\;MT;+C\Q6Q2*B+]U ,^@I?YT %%%% !1111J%@HHHH ***.!UXH
M0'&^"/\ C^U?_KM_4UV7:N-\$?\ ']J_'_+;^IKLJ;$%%%%(=@HHHH ****
ML%8>K>+]&T2Z%M?W+12D9P(F;^0K<P/3KUII1&^\H/U%4K ,MKF.[@CGA;,;
MKN7(QD&I:  . ,#M[45(!1110 4444:A8**** "N3^(/_(!M?^OZ'^9KK..]
M<G\0?^0!:G_I^A_F:J.XGL=':_\ 'I#_ +@_E4M16O\ QZ0_[@_E4M=)SL**
M.*.*!!11Q1Q0 44<4<4 ';O^='OW'K1QG/?L?2N:N/#.HSZI]K7Q5JD488-]
MG39LQZ=,X- '2T4B@A0"V<#&3WI: "BCBCB@ HHXHXH **.*.] !ZUG67_(3
MO/HO\JT?6LZR_P"0I>_\!_E3 T:**.*0!11Q1Q0 44<4<4 %']>]'%'% &9K
M&OZ=H4:RZA,T*-PI$;-G\A4FE:Q8ZW:"YL)3)"3C<4*Y(]C5XJK#! /U% 55
M&%4 >@% "]SQ11]31Q0 44<4<4 %%'%'% !11Q1]* .<\<?\BQ/_ +P_K6MI
M'_(&LO\ K@G\A63XX_Y%B?\ WA_6M;2/^0-9?]<$_D* +M%%'% !6??VFF!_
M[0O+> O;C<LTBC*_0]JT.*X7X@>&_$GB40VNE7EO#8@YFCD8@2>QQVI@8?AA
M&\2_$F\\0VL)BTZ$&)9<8\T\'->EZG(8M*NY!U6%V_0US>@V?BO3!;6<MGHL
M.GQX5A S[MOMFNGO8O/L+B+KOC90#[BBXS@/A/8I_9>H7T@#27-S)N^F:NZG
M?7^BB_@T7P6[*Y)%S&\:JY_O$=:Q_A=>,6US0#,Z7%M,[*>Z G (_*M2PTSX
MA:8]S%_:&GZG"[YC>\=MRKZ?**8%#X1/9?8[\+<1F_DFW3P(A7RSD\<UI_%.
MQLKWPV#=WR6<D3AXC(I8$@CC Y-,\*>"]2\/I?ZE<3PW&LW3%OF)\M>N!ZXI
M/$_A#6_%6DVDMQ/;0:M:2[T$)/EL..#GGM0P//\ 5]=U/7O#^FZ=K%O'IVF.
MH#7;0$A_=0.5_&HO$GA*^\/>"VAMO$-J^ESR(\40B8R,V#@ Y_I7?ZMHGCG6
M]);3+A](@A<;6EA9]V/;(Q5>R^&UZ=;L#J%VD^EV"_NHLY8MD')_'-.X'"_#
MSQ+)X<BN[B[T&]U"^C5?-N!,OR1_PCGGI6UXCUR'5/%'A37[-FC2=P"F>5^5
MC@UN7O@'7[75M3;1KBR%E?H%99R04ZYQ@>]<Y)X;-AXO\,Z!#,DK6>V2<*>^
M"*5P/<8SF-#SEE!.:=34!$:C(.!C-.J1!110: ,Z'_D-7'T7^5:-9T/_ "&;
MCGLO\JT?Y4, HHXHXH **.*.* "BCBCB@".>>.VA>:4[409)QG%8NE^,=%UB
M]-E97+O/@D@Q,O3W(K>//O31'&.0BCZ"@!W':BCZT4 %%'%'% !11Q1Q0 44
M<44 -D_U;?[IKD?A]_R G_ZZM_Z$:ZZ3_5M]#7(?#[_D O\ ]=6_]"-)LTAN
M==11TX-%3<W"C\:/QHH Q==OM+\/Z==:I<K''NCVL^.7]OUKB_A1I-RIU#7)
MX3!#?R[X8B,?+C&<?A4_C#P?XF\0^([:[2>PETVW.Y+2X9MC-ZG'?I75:%_P
MD:2,FJPZ;';JN$%H6S^M5T)L8?Q9N9[7P)<>2PW22HF2.Q.#7/\ B5GTSX.6
M$,#;?-BC#$>ORUU/Q.TQM3\#WD<>X&,B7C_9R:S=+TR+QK\+K6T\W:PB50P[
M,H%-"L84'B#Q'X.L=#:YEL9='N&6-8X8"KHO/?->MQOY\"./NNH8#N,BO-X?
M NOZFFF6>O3V9LM/(93;EBTA&>N>.]=!;Z/XD@\8M>'4P="$.Q+0GHV  >GU
MH8(\\^(GAS3]$UW1I+16,UQ>,\CN<DY(.,^E>A>*O"]YK4FG7VF7T-K>V<F\
M-,A9&X(Q@?6N>\7>$/%WB?4[68OI4<5G*9(0&?)';=^5=5=0>);WPU-;L]A!
M?N-HDB9M@'KS0%CRR:*:U:ZLY)TN+."42ZA)"-HFD'*HN>F1FO1O"_BR'4KE
MM$DTB;3'C@1XHY'5MZ$9'3VI+CP)"/!S:/;;5N"1(9&Z,_/7\ZA\/^&M6L-8
MDUC6I[96BMUBC2W)*X5<9.?:BX6,+P(SVOQ0\36@8>2V7"XZ$M7JM>6_#N$W
MOCGQ)K(8^3(YC3TX8&O4N])E(****D85G/\ \AR+_KFU:-9S_P#(<A_ZYM3N
M)FC1112;&%%%%%P"BBB@ HHHHN%BKJ&H6VF6C7-VVR).2P4G^54M(\3:5KK2
M+I]PTGE_>W1LN,_45K$!E(/(/8T*J(<A0#["G<!>N #FB@G-%*X!1110 444
M47 **** (;O_ (\YO]TUHZ-_R#(ZSKO/V.;_ '#6AHQ_XEL?TK2)E,Q-4\9?
MV=?26RZ7?3!#@ND#$'Z&J7_"P2?^8+J7/3_17KMJ,^]:&9Q ^(/'&BZF/^W5
MZSM5\2V.KR6IOO#^I2&VD\R/]P^ V,<^M>D$T@Y&>QH XE?'^WY5T34L#_IV
M>E_X6"3TT74OQMGKML]J#R.E '$'X@'OHNH\_P#3JU<KJ*^'M3O)+NX\.:RL
MDC9D\D2H"?H.*]A'(IBR1LY19%9UX(#<B@#@--\6VNDVHM;+0-1CB4<#[,Y)
M^IJW_P +!.WC1-2'_;L]=MWR*=0!Q'_"P>?^0+J7_@*]'_"P3CG1-2_\!GKM
M^]&: .(_X6$?^@+J7_@*]'_"PC_T!=2_\!7KN** .'_X6$?^@+J7_@*]'_"P
MC_T!=2_\!7KN** .'_X6$?\ H"ZE_P" KT?\+"/_ $!=2_\  5Z[BB@#A_\
MA81_Z NI?^ KT?\ "PC_ - 74O\ P%>NXHH X?\ X6$?^@+J7_@*]'_"PC_T
M!=2_\!7KN** .'_X6$?^@+J7_@*]'_"PC_T!=2_\!7KN** .'_X6$?\ H"ZE
M_P" KT?\+"/_ $!=2_\  5Z[BB@#A_\ A81_Z NI?^ KT?\ "PC_ - 74O\
MP%>NXHH X?\ X6$?^@+J7_@*]'_"PC_T!=2_\!7KN** .'_X6$?^@+J7_@*]
M'_"PC_T!=2_\!7KN** .'_X6$?\ H"ZE_P" KT?\+"/_ $!=2_\  5Z[BB@#
MA_\ A81_Z NI?^ KT?\ "PC_ - 74O\ P%>NXHH X?\ X6$?^@+J7_@*]'_"
MPC_T!=2_\!7KN** .'_X6$?^@+J7_@*]'_"PC_T!=2_\!7KN** .'_X6$?\
MH"ZE_P" KT?\+"/_ $!=2_\  5Z[BB@#A_\ A81_Z NI?^ KT?\ "PC_ - 7
M4O\ P%>NXHH XC_A81_Z FI?^ KTG_"PC_T!-2_\!7KN*2@#B!\0&W #1=2Y
MZ?Z,]<AXH\9?:?$6D3?V7?(8PPVM;L">1TKV:N#\9_\ (VZ']&_]"%3+8:W*
MW_">-_T!M1S_ ->S4G_">G'_ "!M1_\  9J[2BN-O4V2.+_X3P_] ;4?_ 9J
M/^$\/_0&U'_P&:NTH'YT7"QQ?_">'_H#:C_X#-2_\)X?^@-J/_@,U=GF@LJ
MEB !U)[4F%CC/^$\/_0&U'_P&:C_ (3P_P#0&U'_ ,!FKL(IXITW12)( <91
M@1^E/_F33%8XS_A/#_T!M1_\!FH_X3P_] ;4?_ 9J[/I]:,?A[YH8['&?\)X
M?^@-J/\ X#-1_P )X?\ H#:C_P" S5V=''4\8H"QQG_">'_H#:C_ . S4?\
M">'_ * VH_\ @,U=8E[:22&)+B)I!_ L@)'X5(\T49422HA8_*&8#- 6./\
M^$\/_0&U'_P&:C_A/#_T!M1_\!FKKVN(%F$32QB1NB%QG\JDH"QQG_">'_H#
M:C_X#-2?\)Z?^@-J/_@,U=I12;"QQG_">'_H#:C_ . S50TKQPT5NX&D7[ R
M,>+=O6O0JS-$_P"/60_]-G_G5IBL<_\ \)X?^@/J/_@,U'_">'_H#:C_ . S
M5V=%1=#LSC/^$\/_ $!M1_\  9J/^$\/_0&U'_P&:NSHHN%F<9_PGA_Z VH_
M^ S4?\)X?^@-J/\ X#-79T4[A9G&?\)X?^@-J/\ X#-1_P )Z?\ H#:C_P"
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M (3TY_Y VH_^ S5V?/6CBBX69Q?_  GK?] ;4?\ P&:E_P"$\/\ T!M1_P#
M9J[/K^%&<TKH+,XS_A/3_P! ;4?_  &:C_A/#_T!M1_\!FKLZ*=PLSC/^$\/
M_0&U'_P&:C_A/#_T!M1_\!FKLZ*+A9G&?\)X?^@-J/\ X#-1_P )X?\ H#:C
M_P" S5V=%*Z"S.,_X3TY_P"0-J/_ (#-1_PGIS_R!M1_\!FKL^]'(IIZA9GD
MOA3Q@;6[U)O[,O9/,ESA8&.WDUU!\>G_ * VH_\ @,U'@@G[=J_'_+;^IKLJ
M;8DF<7_PGI_Z VH_^ S4O_">'_H#:C_X#-79T5-T.S.,_P"$\/\ T!M1_P#
M9J/^$\/_ $!M1_\  9J[.BBZ"S.,_P"$\/\ T!M1_P# 9J/^$\/_ $!M1_\
M 9J[.BG=!9G&?\)Z?^@-J/\ X#-1_P )Z?\ H#:C_P" S5V=%%T%F<9_PGA_
MZ VH_P#@,U'_  GA_P"@-J/_ (#-79T4KH+,XS_A/#_T!M1_\!FH_P"$\/\
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M[)?W3'2;]MVW@6[<5W]9UC_R$[W_ (#_ "H Y[_A/#_T!]0_\!VH_P"$\/\
MT!M0_P# =J[(=** .-_X3P_] ;4/_ =J/^$\/_0&U#_P':NRHH XW_A/#_T!
MM0_\!VH_X3P_] ;4/_ =J[*B@#C?^$\/_0&U#_P':C_A/#_T!M0_\!VKLJ*
M.-_X3P_] ;4/_ =J/^$\/_0&U#_P':NRHH XW_A/#_T!M0_\!VH_X3P_] ;4
M/_ =J[*B@#C?^$\/_0&U#_P':C_A/#_T!M0_\!VKLJ* .-_X3P_] ;4/_ =J
M/^$\/_0&U#_P':NRHH XW_A/#_T!M0_\!VH_X3L_] ;4/_ =J[*CO0!YCXL\
M9-=Z%+%_95['D\LT# 5I:;XX,6EVL8TC4&"PJ,BW;GBMGQQ_R+$_^\/ZUK:1
M_P @:R_ZX)_(4P.:_P"$\/\ T!]0_P# =J/^$\/_ $!M0_\  =J[*BD!QO\
MPGA_Z ^H?^ [4?\ "=D\?V-J'/?[.U=E13 XW_A.S_T!]0S_ ->[4G_">'K_
M &-J'I_Q[M79T9QS2&>;6VJZ79ZU-JT'A[4%O9@%DD$+@,![=.]:_P#PG9_Z
M VH?^ [5V73IWH_"@#C?^$[;_H#:AS_T[MQ1_P )X?\ H#ZAD?\ 3LU=E1TH
M XW_ (3L\?\ $GU ?]N[4?\ ">-_T!M0SV_T=J[*CZT <;_PGG7_ (D^H@'_
M *=FK(M]5TRUUJ;6(_#VH"]E&'D,+G(SG ':O2?;MZ44 <;_ ,)X>3_8^H<]
MOLS4?\)X?^@/J'_@.U=E10!QO_">'_H#:A_X#M1_PG9_Z ^H?^ [5V5'2@1P
M$/C<KJL\@TF^.0./L[>E7?\ A.R/^8/J&?\ KW:NA@_Y#%P/8?RK1H8'&_\
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M8'1]1Z'_ )=FKF_!GC V>E/$=,OI"9&.Y(&(ZFO5I/\ 5M]#7(_#[_D!2?\
M75O_ $(T-FD-R/\ X3L_] ?4/_ =J/\ A.S_ - ?4/\ P':NQHJ;HVL<=_PG
M9_Z ^H?^ [4?\)V<?\@?4/\ P':NQHHN@L<</'1S_P @;4,_]>[4G_"=D_\
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M'U#_ ,!VKL:*+A8X[_A.S_T!]0_\!VH_X3L_] ?4/_ =J[&BBX6.._X3L_\
M0'U#_P !VH_X3L_] ?4/_ =J[&BBZ"QQW_"=G_H#ZA_X#M1_PG9_Z ^H?^ [
M5V-%%PL<=_PG9_Z ^H?^ [4?\)V?^@/J'_@.U=C11<+''?\ "=G_ * ^H?\
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MX5WVCK+XW\1#6[S:-*M7*VD;'AV'!;\>*3Q"?^$G\0KX>TJ"%;>)@][<H@!
M'.W/N,UP^KV]I;7NJQ74SPWEJ84L8UD*L5#X&%!YXHT8'5_% +HFNZ'XBBPL
ML=P(Y".A&">:]/M91/:Q2@YWH&X]Q7DWQ4FED\ Z2MT':ZEE'!7D-BO4M)4K
MI-J",?ND_D*B0T7**/PHK,H*S-$_X])/^NS_ /H5:=9>B?\ 'I)_UV?_ -"J
MT(U****@84444 %%%% !0>>V:*._7']: #J.*.V<?C67K.FW^HPI'8ZO+IS*
M>6BC5\_G4FCV%YI]IY5YJDNH2Y)\V2,*?I@4] -#D=:*.W>BD 4444 %%%%
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M4 %%%% !1110 4444 <WXX_Y%B?_ 'A_6M?2/^0-9?\ 7!/Y"LGQQ_R+$_\
MO#^M:VD?\@:R_P"N"?R%,"[1112 **** "BBB@8>U'U_.BC H .O YH]O2N;
MGT#6I=3^U)XINHH-X/V9;=",>F>M=&HVJ%R3CK0(6BBB@ HHHH **** "BBB
M@#.@_P"0U<?0?RK1K.A_Y#5Q]%_E6C0P"BBB@ HHHH **** "CG&?PHK U?1
M-6U"Z$MEXDN=/B YCC@1@??F@#?H_G45M%)!;I'+,9G4 &0C!;WJ6@ HHHH
M**** "BBB@!LG^K;Z&N1^'O_ " I/^NK?^A&NND_U;?0UR/P]_Y 4G_75O\
MT(T,T@=;1114&X4444 %%%% !111^&: #\J.^,9-,G5Y(61)3&Q7 <#)!^E8
M.FZ#J]GJ'VBY\27-Y#S^X>!%'YCGB@#H>O([44?7\,44 %%%% !1110 4444
M %9S_P#(<B_W&K1K.?\ Y#D7_7-J:$S1HHHI#"BBB@ HHHH **** #\*.*J:
ME:SWEG)#;7DEG(W25$#%?P-4=%TG4].:0WVO3ZB&QM$D*KM_*@#9HHSW/%%
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M(#L:*X[_ (1WQ+_T'OU:C_A'?$O_ $'OU:BP'8T?TKCO^$=\2_\ 0>_5J/\
MA'?$O_0>_5J+(#L?\FCFN._X1WQ+_P!![]6H_P"$=\2_]![]6HL@.QHKCO\
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M-%<=_P ([XE_Z#WZM1_PCOB7_H/?JU%@.QHKCO\ A'?$O_0>_5J/^$=\2_\
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M'_".^)?^@]^K4[(+G8T5QW_".^)?^@]^K4?\([XE_P"@]^K4K!<[')HKCO\
MA'?$O_0>_5J/^$=\2_\ 0>_5J+ =C17'?\([XE_Z#WZM1_PCOB7_ *#WZM18
M#L:*X[_A'?$O_0>_5J/^$=\2_P#0>_5J=@.QHKCO^$=\2_\ 0>_5J/\ A'?$
MO_0>_5J5@.QKD_B"/^)!:_\ 7]#_ #-1?\([XE_Z#_ZM7.^--#UZ'1K=I]9\
MU3>1 #)ZY.*J"U$]CTFU_P"/2+_<'\JFKB[?P]XD-M'C7<#:,#+<5)_PCWB3
M_H/?JU=!@=A17'_\(]XD_P"@]^K4?\(]XD_Z#WZM0(["BN/_ .$>\2?]![]6
MH_X1[Q)_T'OU:F!V%%<?_P (]XD_Z#WZM1_PCWB3_H/?JU '8?C1QGO7'_\
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MC_D#67_7!/\ T$5Y_P"+="U^'097GUK?&",KDUI:9X?\1-I=JR:YA3$I RW
MQ3 [JBN/_P"$=\2_]!W]6H_X1[Q)_P!![]6H ["BN/\ ^$>\2?\ 0>_5J/\
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MC/!'_']J_P#UV_J:[+\*XWP3_P ?VL?]=OZFNR[4, _"BBBD,**** "BBB@
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MPF_AC_H.6?\ W\H_X3?PQ_T'+/\ [^4 ;]%8'_";^&/^@Y9_]_*/^$W\,?\
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M%@-O/YG]:QY?"F@3WOVN;2;1[G<&\TQC.13/^$P\._\ 08M/^_E'_"8>'/\
MH,6G_?RBP&T  ,   = *6L3_ (3#P[_T&+3_ +^4?\)AX=_Z#-I_W\HL!MT5
MB?\ "8>'?^@S:?\ ?RC_ (3#P[_T&;3_ +^46 VZ*Q/^$P\._P#09M/^_E'_
M  F'AW_H,VG_ '\HL!MT5B?\)AX=_P"@S:?]_*/^$P\._P#08M/^_E%@-OFL
MZR_Y"=[_ ,!_E57_ (3#P[_T&+3_ +[K/M/%OA]=2O&.KV@!VX^?VHL!U=%8
MG_"8>'/^@S:?]_*/^$P\._\ 09M/^_E%@-NBL3_A,/#O_09M/^_E'_"8>'?^
M@S:?]_*+ ;=%8G_"8>'?^@S:?]_*/^$P\._]!FT_[^46 VZ/\X]:Q/\ A,/#
MO_09M/\ OY1_PF'AW_H,VG_?RBP%W4=&T[5XU34;&&Z13E5E4-BI-/TVQTNW
M%OI]K#;0@Y$<2X )ZUF_\)AX=_Z#%H?^VE+_ ,)AX=_Z#%I]/,HL!M]S16)_
MPF'AW_H,VGT\RC_A,/#O_09M/^_E%@-NBL3_ (3#P[_T&;3_ +^4?\)AX=_Z
M#-I_W\HL!MT5B?\ "8>'?^@S:?\ ?RC_ (3#P[_T&;3_ +^46 VZ*Q/^$P\.
M_P#09M/^_E'_  F'AW_H,VG_ '\HL!7\<?\ (L3_ .\/ZUK:1_R!K+_K@G\A
M7)>,?%&AW/AV:*'5+:1\CY5?GO6II?B[P^FDV:-K%H&6% 07Z' I68'345B?
M\)AX=_Z#-I_W\H_X3#P[_P!!FT_[^4[ ;=%8G_"8>'?^@S:?]_*/^$P\._\
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M;0K##&L<:#"JHX J2L3_ (3#P[_T&;3_ +^4?\)AX=_Z#-I_W\HL!MT5B?\
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M,6G_ '\H_P"$P\._]!BT_P"_E'*PYD;?%'%8G_"8>'?^@Q:?]_*/^$P\._\
M08M/^_E'*PYD:EY96M_ UO=PI-$_5'&01573=!TK1F=M/T^WM2_WO*0#-5?^
M$P\/?]!BTY[>91_PF'AW_H,6G_?RGRL.9&V!P.E'%8G_  F'AW_H,6G_ '\H
M_P"$P\._]!BT_P"_E+E8<R-OBCBL3_A,/#O_ $&+3_OY1_PF'AW_ *#%I_W\
MHY6',C;XHXK$_P"$P\._]!BT_P"_E'_"8>'?^@Q:?]_*.5AS(V^*.*Q/^$P\
M._\ 08M/^_E'_"8>'?\ H,6G_?RCE8<R-2\_X])O]PUHZ,?^);%]*Y6Z\7>'
MS:2@:O:D[#T>ND\/7,%WI$,MO*LD9Z,IXK6"L9S=QUUH&F7D[37%I$\C'EBH
M)-0_\(KHN?\ CPBY_P!D5M459F8W_"*Z+_SX1?\ ?(H_X171?^?"+_OD5LT4
M 8W_  BNB_\ /A%_WR*/^$5T7_GPB_[Y%;-% &-_PBNB_P#/A%_WR*3_ (13
M1?\ GPB_[Y%;5% &-_PBNB_\^$7_ 'R*/^$5T7_GPB_[Y%;-% &-_P (KHO_
M #X1?]\BC_A%=%_Y\(O^^16S10!C?\(KHO\ SX1?]\BC_A%=%_Y\(O\ OD5L
MT4 8W_"*Z+_SX1?]\BC_ (171?\ GPB_[Y%;-% &-_PBNB_\^$7_ 'R*/^$5
MT7_GPB_[Y%;-% &-_P (KHO_ #X1?]\BC_A%=%_Y\(O^^16S10!C?\(KHO\
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M_P"$5T7_ )\(O^^16S10!C?\(KHO_/A%_P!\BC_A%=%_Y\(O^^16S10!C?\
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M_P"?"+_OD5LT4 8W_"*Z+_SX1?\ ?(H_X171?^?"+_OD5LT4 8W_  BNB_\
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C118+F(WA/16!4V$6".?E%:=I:065NL%O&(XUZ*!5BB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gvvh0m1pmdf2000004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,)!X8# 2(  A$! Q$!_\0
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MK[4]'FT35$M[6.Y5KJ/?L,B C(R/O9':J_CCQS/X8U#2[&WMHY6O9TC+L_W
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MFC-KR?,R,9YZ4 =M=ZE9V";[NXCA7.,NV*DM[J"[B66WE22-N0RG(KQ_X?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD8)SDG!]>G:O;N/048]J+!<\=\$^%]9UCQI-XO\ $=O]G?;_ *- ZD,OH?;
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MYJ>3&-S,OS!1@=\8KK<#TI: /';NWU?4_@(^G2V5])JD01&BD@8.V) 1@8Y
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M@[1]3MOC=KU]/I]S'9RM.8YWB(1LL,8/3FO8Z* /(;+P_JUSK'Q(BCLYHVU
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M>R8_K2['J_\ PM_P3_T&!_WXD_\ B:3_ (6_X)_Z# _[\2?_ !->1M;6K?\
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MD_\ B:\V_LNP_P"?.#_OV*/[+L/^?.#_ +]BCV+#ZTNQZ3_PM_P3_P!!@?\
M?B3_ .)H_P"%O^"?^@P/^_$G_P 37FW]EV'_ #YP?]^Q1_9=A_SYP?\ ?L4>
MQ8?6EV/2?^%O^"?^@P/^_$G_ ,31_P +?\$_]!@?]^)/_B:\V_LNP_Y\X/\
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M!C_QY6X^D8I/[+L/^?.#_OV*/8L/K2['I/\ PM_P3_T&!_WXD_\ B:/^%O\
M@G_H,#_OQ)_\37FW]EV'_/G!_P!^Q1_9=A_SYP?]^Q1[%A]:78])_P"%O^"?
M^@P/^_$G_P 31_PM_P $_P#08'_?B3_XFO-O[+L/^?.#_OV*/[,L/^?.#_OV
M*/8L/K2['I/_  M_P3_T&!_WXD_^)H_X6_X)_P"@P/\ OQ)_\37G)TBRQG[%
M!_W[%,_LNP_Y\X/^_8H]B^X?6EV/2?\ A;_@G_H,#_OQ)_\ $T?\+?\ !/\
MT&!_WXD_^)KS;^R[#_GS@_[]BC^R[#_GS@_[]BCV+#ZTNQZ3_P +?\$_]!@?
M]^)/_B:/^%O^"?\ H,#_ +\2?_$UYM_9=A_SYP?]^Q52_P!%M)(=T5K"&7L$
M'-'L6'UI=CU/_A;_ ()_Z# _[\2?_$TO_"W_  3_ -!@?]^)/\*\U\%7.E6&
ML>1J=A:26DWRDR0*VP]CTS7M*>%O#SJ&71]/*D9!%NG^%9233.BG-35S _X7
M!X)_Z# _[\2?_$T?\+@\%?\ 08'_ 'XD_P#B:Z'_ (1/P_\ ] :P_P# =/\
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M  HU Y[_ (7!X)_Z# _[\2?X4?\ "X/!/_08'_?B3_"NA_X1/P__ - :P_\
M =/\*/\ A$_#_P#T!K#_ ,!T_P *-0.>_P"%P>"?^@P/^_$G^%'_  N#P3_T
M&!_WXD_PKH?^$3\/_P#0&L/_  '3_"C_ (1/P_\ ] :P_P# =/\ "C4#GO\
MA<'@G_H,#_OQ)_A1_P +@\$_]!@?]^)/\*Z'_A$_#_\ T!K#_P !T_PH_P"$
M3\/_ /0&L/\ P'3_  HU Y[_ (7!X)_Z# _[\2?X4?\ "X/!/_08'_?B3_"N
MA_X1/P__ - :P_\  =/\*/\ A$_#_P#T!K#_ ,!T_P *-0.>_P"%P>"?^@P/
M^_$G^%'_  N#P3_T&!_WXD_PKH?^$3\/_P#0&L/_  '3_"C_ (1/P_\ ] :P
M_P# =/\ "C4#GO\ A<'@G_H,#_OQ)_A1_P +@\$_]!@?]^)/\*Z'_A$_#_\
MT!K#_P !T_PH_P"$3\/_ /0&L/\ P'3_  HU Y[_ (7!X)_Z# _[\2?X4?\
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M_P#08'_?B3_"C_A<'@G_ *# _P"_$G^%=#_PB?A__H#6'_@.G^%'_")^'_\
MH#6'_@.G^%&HCGO^%O\ @G_H,#_OQ)_\31_PM_P3_P!!@?\ ?B3_ .)KH?\
MA$_#_P#T!K#_ ,!T_P */^$3\/\ _0&L/_ =/\*-0.>_X7!X)_Z# _[\2?X4
M?\+@\$_]!@?]^)/\*Z'_ (1/P_\ ] :P_P# =/\ "C_A$_#_ /T!K#_P'3_"
MC4>ASW_"X/!/_08'_?B3_"C_ (6_X)_Z# _[\2?_ !-=#_PB?A__ * UA_X#
MI_A1_P (GX?_ .@-8?\ @.G^%&HCGO\ A;_@G_H,#_OQ)_\ $T?\+?\ !/\
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M-'_"W_!/_08'_?B3_P")KH?^$3\/_P#0&L/_  '3_"C_ (1/P_\ ] :P_P#
M=/\ "C4#GO\ A;_@G_H,#_OQ)_\ $T?\+?\ !/\ T&!_WXD_^)KH?^$3\/\
M_0&L/_ =/\*/^$3\/_\ 0&L/_ =/\*-0.>_X6_X)_P"@P/\ OQ)_\31_PM_P
M3_T&!_WXD_\ B:Z'_A$_#_\ T!K#_P !T_PH_P"$3\/_ /0&L/\ P'3_  HU
M Y[_ (6_X)_Z# _[\2?_ !-'_"W_  3_ -!@?]^)/_B:Z'_A$_#_ /T!K#_P
M'3_"C_A$_#__ $!K#_P'3_"C4#GO^%O^"?\ H,#_ +\2?_$T?\+?\$_]!@?]
M^)/_ (FNA_X1/P__ - :P_\  =/\*/\ A$_#_P#T!K#_ ,!T_P *-0.>_P"%
MO^"?^@P/^_$G_P 31_PM_P $_P#08'_?B3_XFNA_X1/P_P#] :P_\!T_PH_X
M1/P__P! :P_\!T_PHU Y[_A;_@G_ *# _P"_$G_Q-'_"W_!/_08'_?B3_P")
MKH?^$3\/_P#0&L/_  '3_"C_ (1/P_\ ] :P_P# =/\ "C4#GO\ A;_@G_H,
M#_OQ)_\ $T?\+?\ !/\ T&!_WXD_^)KH?^$3\/\ _0&L/_ =/\*/^$3\/_\
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M"?\ H,#_ +\2?_$T?\+?\$_]!@?]^)/_ (FNA_X1/P__ - :P_\  =/\*/\
MA$_#_P#T!K#_ ,!T_P *-0.>_P"%O^"?^@P/^_$G_P 31_PM_P $_P#08'_?
MB3_XFNA_X1/P_P#] :P_\!T_PH_X1/P__P! :P_\!T_PHU Y[_A;_@G_ *#
M_P"_$G_Q-'_"W_!/_08'_?B3_P")KH?^$3\/_P#0&L/_  '3_"C_ (1/P_\
M] :P_P# =/\ "C4>ASW_  N#P3_T&!_WXD_PH_X7!X)_Z# _[\2?X5T/_")^
M'_\ H#6'_@.G^%'_  B?A_\ Z UA_P" Z?X4:B.>_P"%O^"?^@P/^_$G^%'_
M  M_P3_T&!_WXD_^)KH?^$3\/_\ 0&L/_ =/\*/^$3\/_P#0&L/_  '3_"C4
M#GO^%P>"?^@P/^_$G_Q-'_"W_!/_ $&!_P!^)/\ XFNA_P"$3\/_ /0&L/\
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M@P/^_$G_ ,31_P +?\$_]!@?]^)/_B:Z'_A$_#__ $!K#_P'3_"C_A$_#_\
MT!K#_P !T_PHU Y[_A;_ ()_Z# _[\2?_$T?\+?\$_\ 08'_ 'XD_P#B:Z'_
M (1/P_\ ] :P_P# =/\ "C_A$_#_ /T!K#_P'3_"C4#GO^%O^"?^@P/^_$G_
M ,31_P +?\$_]!@?]^)/_B:Z'_A$_#__ $!K#_P'3_"C_A$_#_\ T!K#_P !
MT_PHU Y[_A;_ ()_Z# _[\2?_$T?\+?\$_\ 08'_ 'XD_P#B:Z'_ (1/P_\
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MX/!/_08'_?B3_"NA_P"$3\/_ /0&L/\ P'3_  H_X1/P_P#] :P_\!T_PHU
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTZ&&."/8@ '6I**HS"BBB@ HHHH K7<WEIM!^9JSO>I;EBUPWMP*BH&@JS9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MCEZH='(LB[E.0:?62UO<63EX263N*MVU['/A2=KXZ46!2Z,MT4F:6D6%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@\/ZI<2*BV<H+' +*0/SJ\/!.MG_ )81_P#?P4G)+<I4YOH<]171CP1K>/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "FX&<XYIU% !1110 4444 %%%% !1110 4444 %%%% !4<TJPQEV.
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MXJA1@4"*&#W%%7G0.,8JDPP2/2@8E%%% !1110 4444 %%%% !1110 4444
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M%8;>)-9%Q',NM+<;;I9!RJY.W\?O9KUH* <]S0 M%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 >-Z__ ,ENO/\ L$)_Z&M%&O\ _);K
MS_L$)_Z&M%,1Q/@G_D7%_P"NK5T5<[X)_P"1<7_KJU=%75#X4>95^-A1115&
M84444 %%%% !4D0R<^E1U-#WH G5<]:1EQ3D/%#]*!#.U5Y%VM[58I&7<,4#
M*M%*00<'M24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%%  2 ,GM5;[;'NV\]>M62-RD'O5'["P?[PQF@"]11
MTHH *:T:/]Y0:=10 @4*,*,"EHHH ****8!1110!UGBD9^%5J?0Q_P ZH?![
M_D(:H/\ IDG\S6AXH&?A1;9.!F,_J:S_ (/_ /(1U3_KDG\S7._A9VK^)$];
MHHHK$Z@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM&$M7H2:2A+NXQ@<5K55L;?R( #]X\FK52S6*L@HHHI%!1110 4444 %%%%
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MUK=7>GW4O,AMI,!CZD8ZUT/AKP[%X:TZ2UCNKBY:24RO)</N8L0!Z=.*S_\
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MCF&4;-2TBD[A1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4M/%^A7LPFGU".$'G;(<'Z5LGQIX=5?^0O;8_P!ZI<6D5&46[MF_2%@H))
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M5A_Z18R=]OZ&M*VO8[@8^ZWI2L.,[Z,M44E+2+"BBB@ HHHH **** "BBB@
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MG[O&:ZN*-8HPB] ,5@]#L7O6?0D%%%%2:A1110 4444 %%%% !1110 4444
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M_I74 >U+6,IMG9"C&)#';0P_ZN)$_P!U0*EQ2T5!J)BBEHH ***9)(L<9=B
M ,DF@$KA)(L:EF( '4DUR6K^.K6TE:WL4-S-T^7[H_&L+Q#XAN-9NGLK%S':
M(</(/XJS;>UCMEVHN3W8]37/.MT1Z^'P$4N:K]QHSZYK]]*"]W%9J1P(QNQ3
MX)]3+KCQ Y;MOC^7/Y52I#TZXQSFLE.1UNA!JR5COM$U.>Z$EM>(JW40&2IX
M<?WA6V.E<#X4OI;W6V5.8X(-C/Z\DX_6N^'2NJG*Z/%Q5+V=3E"BBBK.<***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &O&LBE6&0:
MR;NQ>%C)#G;UP.HK8H/3%-,F44S)M-1(/ES_ (-6FTBK'YA/RXSD51O-/#@O
M$,-W'K5."[> F-QE.X-.R9%W'1FW'(LBAE.0:=6)8S%+O;N.QC^%;6:35BXR
MN+1112*"BBB@ HHHH **** "BBB@ HI*BGFC@B:21PJJ,EB>E %;5=3MM(L)
M;R[E$<,0R6)Z^P]Z^<?&/BZ[\4ZF\K%TM%/[F'.<>_N:U_B-XV?Q!?M96KXL
M(&P,'_6'U^E<?;08Q*V2Q' ]*1Z>%P[6K'V\ C&YOO'VJ>BB@]:,5%604444
M%!1110 4N:2B@!<TE%% !12$@=333*H[T"NA]%1&8>E)YQ["@7.B:BH///\
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M^$KNO^@1=?FO^-'_  E=U_T![G\U_P :.>(?5:IU-%<M_P )7=?] BY_-?\
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MC,YZF@"Q+*%4XZUEW3$D#GGK5BD(!ZC- $$$6/G8<]JL444 %%%% !112XH
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M=D=$*6@45U'BA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!9& JRTJ@9S51VW,3ZT 9SDER3ZTVK$T)R66HA&S'&#0!/;,2A![5*LR!_O
MD5'Y12$JOWCUJ%87+#/% &FUP2.!BH223DTG2B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *4#)%)3H_\ 6+]: +JC"@4M HH$4YO]8:CI\O\ K&^M
M,IC"NVDW3?"6[4?>V,/_ !\5Q-=UX>VZCX(U"Q<$+&K9(/7JU9U-C>ANS<\$
M7<=YX2L7BSA$$9R.Z\&NBKBOA=(&\'QIG+)*^?Q-=K7-)69W0=XIA1112+"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EJEA'J>G
MRVDGW77&?3WKR\QW_A:^>*>,O;D_>[$>U>NU7NK*WO(C'<1*Z'L128TSB+/4
MK:^7]S(-W=3UJW4&K> _F:?2Y3')U"$\5A)J>H:1-Y&IV[$ XWX_KWI%7.DH
MJK::A:WJYAE!/]WO^56J0!67X4&/'-WM.5*.3CH.15V\NDL[5IGZ#H/4UB^!
M/%^A_P!M7EA=7'DZI+(<B5=JG!Z GOSTIH#U-B%&37AMG)_PLKXMM=89M(TG
M:5&[&2"=IQ[D8/TKJ?B]XH.D>%3I]H=UYJ684 !)V_Q8QWY&*V_AUX53PMX7
MAMVPUS,/-G?'5C_2GN3L=:BA4"KT'2GT44Q!28%+10 THIZ@4PV\3=8U/X5+
M10.[*<FE6$O^LM8V^HJK)X9T:08.GP_]\UK44#522ZG,W'@30ISN-KM]E.*M
M6OA#0;6:.>+385F3I)CFMNEH&ZLWNP'3%%%%! 4444 %%%% !112&@"&ZN$M
M;>2:1@$12S'VKYB\8>('\1^(9[S=F+=L@!X^7M^->L?%SQ+]@TA-*@?$UWR^
M/[@Z_KBO#(5W/O/W1P/K2._"T]+D\,0553N>I]:N5#".2:FH/8IQM$****#0
M**** "CI13'/:@3=AK')I***1F->F4]Z900PHHHH$%%%% !1110 4444 %&*
M** -CP%_R.UU_P!>!_\ 0THH\!_\CM=?]>!_]#2BJ1X5?^(R+PA_R 5_ZZM6
M]7.>$9D&CK&3@^8U='77#X4>-5^-A1115D!1112 **** "BBB@!DL:RQE2.*
MRDS%*T;>M;%9NH)M=9!QG^=#&B&=.C#OUJ&K)^>+\*JTBD+13A'E-V:;0 44
M44@+-E<_9Y<'F-N&%6YX_+?@_*>5-9=:-I(9[=H6Y=.5^E-":-"RG\Q-C'YA
MTJW6+&YCD5AV-;*L&0,.A%,ABU6NYFB"[>IJS5+4!D(: 'VUUYIV/][UJU6,
MK%6##J*V%.5!]J %HHHH **** "BBB@ HHHI@6K"SDO;M8E!V#F1A_"HY)_*
MJ6H/+XI\0P:9IL4GV2%O*C4'H!]YSVYY/XUI:S<'0/#BVZD"]U 9;!.Y(OY<
MD?K73_##P\;#3&U.=,37(PF<Y5,_UQFL92TN=-*FV['9:-I-OHNFPV5JN(XQ
M^9[G\36A117.=R5E8****!A5'4XK":QDAU+R/LLHV.)F 4YXQS5ZL?Q+H%OX
MET>33;IG2-V5MR'!!!!'\J3!'BWCO0+'P!K&G:MX8O'MKF>Y53:1R!E"X].I
M!]_6NC\3327/Q4\ SRKMDEMV=U]"5)(K9T;X1Z-IVI+?7EU=ZG)&<P_:GSY?
MTKHM4\)V>J>(],UR1W6YT]2(5'3GUI%'FNO^&;;Q7\;]1TZYGG@7^SD<20-A
M@0%_QIG@>"+P)\3K[PW=?.+PAK:YDP7(YVC/J<\_2O4(_"UG'XRF\2AY/M<L
M @*_P[1C_"JWB#P58Z]J^GZJTLEO>6)S%)&!D].N>O2@$>6:SX>7Q/\ '&YT
MYKVXLP;8OYMNVU^.V?2NTL/AQ9>$;+4M3M;JYN]1-N_ESW!W.IP>F*Z&V\&6
M5OXP?Q+YDC7K1F+!Z8-=(R*ZX89'I1;0+GCOABQT/_A4&IW4L-LUTT<YGDD(
MW"7!QR>AZ<5I_ _3VLO!\EV\ZR&]E\P#/*X^7!_*KO\ PJ+03J4DWF70LY'\
MQ[,3,(V;U(S6UX<\#Z?X8U"XN-.DG6*9=HMV<E$YSP#0!U=(>1B@# I:HDYO
M7_#4.I*9(P%F[_[5<'<VFH:3(4EC:2,'C(Y'^->OFH9[2"X7;-&K ^HK*=)2
MU1WX?'2I+EEJCR)-2@;AR4;T88J1KZV5=QE7'UKO[OPEI=R&_<[2>I'-5;?P
M'I,,PD=&DP<X8\5E[&1W+'T&KNYE>"5GN]1FOG5EMTC\N+/0\Y_K7H Z5#!;
MQ6\0CBC5$' "C J:NB$>56/)Q%;VM3FM8****HP"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K*\0:O%HFB75]*0!'&=N>A;' _$UJUX_P#&;7<1VVC12??_ 'LP'0C/
M _,4&E*'/*QY)>W4E_J$MQ(<R3.7/?'-28Q@"H+=<YDXYX!]JLH,L!2/:I1L
M6%&% I:**#M"BBB@ HHHH :YP*CI6.324&;=V%%%%(0QOO4VG/U%-H(>X444
M4""BBB@ HHHH **** "BBB@#UKX+_?U'\*]=KR+X+_?U'\*]=IH\;%_Q6%(>
ME+2-TIG,?/D(SXS\39[7']*TH(P_)K-@./&7B;_KO_2M&&0(<'H:Z:7P(\[$
M_P 1DDD QE?RJOCFKAD7'WA4$:[YB>U:F!)#%@9;K4P&*WO#6CV^JR3+.6 0
M<8JCK6G_ -F:D]N#E/O*?8U/,KV*<&H\Q0HKI_#_ (<AU#3VN;EF&XD(![5S
M7ELTI2-68@D8 R:%)-V$X-*XVBGR6\T.#)$Z ]V4BFI&\K;8T9F]%&:=Q68P
MJ&'(S566'8<CI5]H)DD"-#(&/12IR::T$VQF:%P@X+%3@47"S,VBI_L=PY)B
M@E=?54)%1,C(VUU96[@C!HN%F-HJ<6=T7V_9YMPY(V&GV<&_4H()T(!E564C
M'>AL:3*M%:NM:<T.M7,-G;2&)&  52V.!68R,CE74JPZAA@T)I@TUN-HJ;[)
M<[-XMIBN,YV'%0CDX'7TH%J%%3_8[H<FVF&3CF,U$RLC[64A@<$$8-%T.S&T
M5+);3Q)OD@D5?[S(0*BHN*P4444P"BBBD 4444 %%%% !1110 4 XYHHH NQ
MOO7WI]44<H<BI&G++@#F@")CEB?>DHHH *Z[P+<YNKJPD=1%-&2 3U/3^6:Y
M&K.GW;6.H07*=8VS2DKHNG+EDF=/X$D&D>)M8T)D9 7,D6[IM!Q_45Z.*\N\
M72&PUC3/%MB=T;[4EYXZ< X]LUZ38WD-_9Q7=NP>*50RGV-<TNYZ%-[HLT44
M5!J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 E5KNPM;Z,QW,*2*?[PJS2T <)J'@'$QFTRY,+9R$/04V'PWXA&%>^CQZLO
M2N]I,"E8=S!T_P ,00.LUY(UW<+@@R=%/L!_6L+QQ\-]-\36KW%K&MIJJ_-%
M<1C&3Z'';]:[OI0:+!<^9/#JS6/Q,L+/QM(X^R+Y<(G;*A@?D.>F/>OIB$J8
MU*8*XX(KB?B)X$M_%^EDILBOH@3#-CDG^Z?:N5\%_$\Z?I$VF:];S+>V.(U8
M#F7_ .O_ /6H*C&4M$>R45YL?B[9*,G2K\+ZD+_C6SH_Q%T/5V$?GFWE8X"2
MC&?QZ4RWAZD5=H["BF(X=0RL"",@@]:?08A1110 4444 %%%% !1110 4444
M %%%% !4-S*L%O),YPJ*6)]A4U<)\4M?_LCPN\$;,)[MO*7:>1W)^G&*"H1Y
MI)'BGC#77U[Q#=7A8LA?9$/]D<#]*S44(@7TZFJ\:[IB<\(.GO5GOBD>U2B6
M(AA/KS3Z0#  I:#N6P4444#"BBB@!"<"HJ<YR:;2,Y,****!#7IE/?I3*"&%
M%%% @HHHH **** "BBB@ HHHH V/ ?\ R.UU_P!>!_\ 0THH\!_\CM=?]>!_
M]#2BJ1X5?^(S)\.QEM(4J?FWM6];WA0A)?SKG_#CE-+&/[YK;(69?>NJ'PH\
MBK\;-4,&&0<TM9,4[VS8/*5IQR+*H93D59E8?1110 4444 %%%% !5'4?]6G
MUJ]5'4L>6GUH8(@AYBQ59OO'ZU8AXCJNWWC]:12#) QDXHHI*0Q0I8@#O4P@
MXY/-0_2K:L"HZ4Q,K.A0X-/M93!<(PZ9P?I1.P) %0T :LRA)2!T/(J[8R;H
MRA['BJ!;S+>&3'5<'\*ELVVW"CUXIDLU:CGB\V(KW[&I**!&:EG(7PPPOK6B
M!A0/2EHH **** "BBB@ HHHH *U-#LTNKYI9\BUME,TIP.@YQSZXQ675[7;I
M=)\(PVL;+]KU ^9)CAEC!X'T)!I2>FA<%K=E&PBF\:>-U+D^1OS[*B]![9Q^
MM>Z0QK%"D2#"(H4#T K@/A9HGV32I-3D4;[HX0YZ(/\ ZXKT,5S3>MCOHQM&
M[ZA1114&P4444 %!HHH ,4F*6B@ HHHH ,4444 &!1110 4444 %%%% !BBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".:01(SL> ,FOEKQ=JK:QX
MDOKPY >78JYR%'3_ .O7OOQ#U7^RO!][(N0\B^4N.HW<9KYK0[KC);D#)]Z1
MVX6'4L*NU0HQQ4L(R]1U-#T)H/7@M26BBB@W"BBB@04UC@4ZHW/- GL-HHHI
M$!1110 UZ94C=*CH(D%%%% @HHHH **** "BBB@ HHHH ]:^"_W]1_"O7:\B
M^"_W]1_"O7::V/&Q?\5A2-TI:1NE,YCYX1L>-/$@];BM"LU?^1W\1_\ 7Q6E
M732^!'G8G^(PJS;#AC5:K5N?D;ZUH8'8>#20E\1U$9Q4>IQ_VKH=C?(&,B$0
MOQDD^OZ53T#5[?3%N1.KGS4PNT9J7PYK\6DI-%<([QORNWG!K)IWNCIC./*H
MLZ&TD6WUJUTN-B5M[9MQSPQXZCUKE]$@U!]4DEL&1&CSODD *J#3M.UJ*#7I
MM1N5;;(&X09QFET75;2T6\AO%D,-R,?(.>^::35Q.:DU=G1M#=W&FWPU*ZM;
MH+$2GE 94X//2LF*7^Q/#%O=6RC[3=.?WA4';CT_*F6VJ:+I]A=06J3F2:,J
M7=1W''>JMEJ]J^E-INI1LT2\Q21CYE-))V*<HWWU)]'U*ZU/Q+9273J[(&48
M4#C!I-3UNYN[Z6P 1+5I=A15'/S<\U7M+O3=/U2TN+?SWCC!\PLH!)YZ#-9E
MQ/OOI;B(XS*9%R/?-4HZF3FU'<Z#Q%K=SH5Y'I^F[(88T!/R@[OK5;5Q'J>A
M66L,H2YWB.3"XWGN:BO-5TC5DCEU))TNTP'>%00P'XBJNKZU#>_9+.Q1X[*W
MP%#'EO<TE&W0MS3OKH=!XCUZ]T_58[:T"1@1*SOM!+9[5!JJ1W*:+JGEHEQ-
M*!)MXW<BK7B:ZT5;Z&&^2<3HBL7B4?,OH>:PM5\06EU<6$=K"Z6EHX89')_#
M\*E*ZT1<I)2:;-3Q)XDN-.U,0:<\:80&7Y!DM[\>F*I>+8C-J&FO'$#-/ K,
M OWF)K"UF\CO]6GNH@0DA!&X<] *V;KQ);OJFF7<$;D6L(C<..OKBJ46K-$.
M?-=-G06JZ[!)#'<WU@L( #6[ 9QCITJC!I5HGC2['E QPQ><J=L\=OQJI<:M
MH$^L'4Y4N9)#C$908!'?K5>3Q(!XG?4+2-GBD4(Z,O+#'(J4I%RE NZ1XLO[
MW7X8+CRVMY9,!-@^3TP:LZ;I\-WXOU6XFVLL$C85QD$GO^E,TN?09-;C?3[&
MX%PTF3Y@PJ>_6JIU$:5XNOIV4O&\C*Z@]B>M%KWL*]DN9WU-RV6\EDDBU;4+
M">S92/+4 $>F.*\XF14GD53D!B!742'PTUR\I2Z*$<1@#@_7-<M*%$K!,A<\
M9]*N":W,ZLD]AE%%%68A1110 448JU'"  3UH K8/H:,'T-7@ .PI<#TH SZ
M*GG0+AAWJ"@ HHHH **** "BBB@"O$SB5E/3-6*:S!%W'I2JRN,@T ;VD:A;
M3:?+HFI(K6<^=CG^!O6G^&->O/"&K'0-:(%HQS%-G('I@_W37/UK">TUK3UT
MS5,*RC$%UCF/V/M6<XF].ITZGL".LB*Z,&5AD$'@TZO(=%\6:GX.N_[+UF)I
MK-<"-TY('L>XKTS3-<T_5[=9K.ZCD4G'!Z'TK"46CMA-2-*BFAA3JDT"BBB@
M HHHH **** "BBB@ HHHH **** "H+N[AL;.:YN'V11(7=O0 9-3UYK\9_$?
M]C>#VM(9&2YOF\I2O]W^+/U&:&!P>D?&777\91I>W"R:/)<F(*D*@[2<*=V,
M^AKW+6;R2U\/WEY;./,2 R1MU'3@U\K76I:#)X#L=.MXYX]6AF,TS^6-LA.0
M/FSGICM7N'A3Q!_PD'PCN)9'4SP6S0R*#]W:,+GZ@ U)2W%^$'B_6?%NG:G-
MJ]PLTD$J+&5C5, @D]*M?%#4/%&B:3'JV@SJ(8#_ *3$8PQ(_O<CH,?K7,?L
M^$#2-:_Z[Q_^@FO4?$EY8V?AV]FU'9]E$1\P2="/2F(X"?XL0_\ "M4UJ)D&
MI2#RO*!!VRXZX/\ #3])\<ZEHO@F/7_%EUYLUWEK2!(0N0!T. .?K7A&GK;V
M^J66IW]A+_8K7)RJG<"H(RH/KR*^LH(M(\1:%;DP07=A*JO&DB!E..G!I#/*
M? 7Q,\0^)OB,FGWC)%8R)(PM_+ *X7(YQFN^^(OC)?"'AR2X@>-K^4[+>)N2
MQ/?'MU_"O-=#5(OVC[Y(U"HID 4# '[H5E7WB'3/%/Q.FN]=ODM]*TXE;>.0
M;2Q7MQU^;)^E%P2NSK?A'X\\0>*M;U&WUBZ26."V\Q56)4(;<!V%9LGCOQQX
MG\4ZAI_APP6L5DTBL&56R%.,G(ZFLKX0:QIUEX]UMI;A$CNXY!!_MC?NX_ $
MUDP:=JFN^.M:N/!#R6\:EV=FD*[^?F''7)Y I7'8]0^%WCS5_$-S?:5KD0-]
M:D[I54 <'!! XXKT\=*\.^!U_;VVHZKHUW:NFL;C)+*[9)"G!!]""1]:]Q_A
MJD2SC/'GBP^']/:.U8?:G'R\?=]Z\TTW3O,S>WH\VYE.YB_.*L?$F=Y=;^=B
M0LC+] ,5<B'[I/3:,5:1[6'IJ%-=V*R(R[612OH1Q523P_97[[,_9Y3]R1!@
M ]LU=HJFD;/8F\,>+=0\,:F-%UTNT.[:DK'.T=CGN*]>BF26-71@RL,@CO7D
MMW90^)-+^PS8%]",VLA/)_V2?SJ;X>>*YK*Z/A[5F9)$)6(R'D$?PUG:QYV(
MH\WO):H]8HIH8&G4'GA1110 4444 %%%% !1110 4444 -/W:^?/BQK7]I>*
M#;(VZ&T7:N#P2>37O&J78L=*NKHX_=1,XSW(%?*-]</?ZA+.^09Y6<X[9)-#
M.O"QNVQ+=-L>>[<FIXQEQ3:DA'S_ $J3UX+H3T444SI"BBB@ I"<"EICGM0)
M[#****1F%%%% "-TJ.I#TJ.@B04444""BBB@ HHHH **** "BBB@#8\!_P#(
M[77_ %X'_P!#2BCP'_R.UU_UX'_T-**I'A5_XC,7P_\ \@L9_OFM96*G(-9/
MA_\ Y!8_WS6I73#8\FI\3+(991@]::K/;/N4Y4_K4(..E3QR!QM:K,[&C#<+
M,N1U]*FK&(>%]\9_*KD5\C8#_*:8K%VBD!!&0<BEH$%%'O2'IF@!>E9-Y+YL
MV ?E7@5/=W8"[(SSW-5(4R=Q'% UH2_<B_"JU23/D@#M45(:%HI**0Q:/I24
M4 +Q124M %ZV):S([*]21G;(I]ZCL6S;SH>F U._I3)9N44R(YA0^U/IDA11
M10 4444 %%%% !1113 N:59M?ZE!; $AW&[']WO69KUP_B+Q@+>$L8A(MO$<
M<JO0_KFMS2Y$L=.U347D,;Q0%(F!_C8$"J7PUB23Q-)?3,3Y$98#&=Q;(K*3
MU;-X1T2[GLNG6JV5A!;( !&@7@>U6ZS#JJ@_+$3^-1MJLASL0#ZUA9G;SQ1K
MT5C#4;IONJI_"I!=7Y'$/_CM+E8^=&K165]IU#_GC_X[0;G4/^>/_CM%F'.C
M5HK+^U7XZP<?[M']I3+R\/%%@YT:E%9?]KCO"?SJ1=5B/WD8?K19ASHT**I#
M4[<]V_*I1>6Y /FJ,^II68^9%BBHTN(GX613]#3\B@=Q:3O2T4#"BBB@ HHH
MH **** "BBB@ HIDD@C0NV<#TJLNI6['&XCZB@3:6Y<HIB2)(NY&# ]P:=18
M!:***!A1110 4444 %%%% !1110 4444 %%%% !1110 444G'K0 M%5KB^MK
M49FF1/\ >.*JC7],S@W<7_?0I<R*5.;6B-.BJ\%Y;W*[H9D<>JG-39]*=Q--
M;E+5-7L=&LVN]1N8[>W7J[G K@'^.'AD2$1Q:@Z D;A;\'Z<UB?$+[1XE^*&
MC>%G7_0$"3S*3MWJ3AOKPO%>LV.D:?I]C%9VMI%';QKM1 HP!2!6.7USXHZ!
MX?>S2^6\WW< GC$<.[Y22.>>O%1:9\7?"NI70M_/N+5SC:;J+8&)[ YZURWC
M^)%^,/A=-HV_9QQC_IHU=SXW\+:7KWAR[2ZMUW01/+&Z##(P!(P:0]#J8Y5E
MC5U8%6&017)^)OB3X?\ "FHQ6-_+.UQ(N=L$8?;T^]R,=:X[X;>-?LGPSO+S
M4R\BZ62A<G<7!/R@?3@5PGB;3+N_\*MXRU1)%NM0U!%@20<QPX8@9[C&,47%
M8]JUSXDZ'X?@LI;Q+QEO(_,B\J'=QQUYXZUGZ=\8O#.J:I;:? M^)[F01Q^9
M;[1D].]=-X=CA?POIID16Q;)]X9[5YE:1_\ ":?&5YD4IIVAD8"L,&0'ANG0
MXY^E [%CXU:H-EAIL<A#',DB#N.WZ@UY';@[68]">/I76?%#4&O/&EV#_P N
MRB$#Z9/]:Y:)0D:J#P!0>KAXVBA]3Q?<J"K,?""F=U/<=1110;!1110 5">2
M:E/2HJ")!1112)"BBB@ /2HJEJ,]:"9"4444$A1110 4444 %%%% !1110!Z
MU\%_OZC^%>NUY%\%_OZC^%>NTUL>-B_XK"D;I2TC=*9S'SLO_([^(_\ KXK2
MK-7_ )'?Q'_U\5I5TTO@1YV)_B,*L6QZBJ]20MMD'O6A@7****!!Q1@444 +
MQ2444 %(Q &:6H+A\?** (&.YBWK2*2K CJ#244#+>I:E<ZI=_:+DJ7"A?E&
M.!52BBBUM >KNPHHHH *LV-[+872W$.WS$Z;ER!5:B@#>'BR_3<T45O'(PPS
MI'@FLX3&;,DC[I&Y8D]:I44)68W)O<N/*JC@@FJC')SZTE%,04444@"BBB@!
MRXW#-7ATK/J5)RO!Y% BY14'VA?2F/<=EXH 6Y8<"J]*23R324#"BBB@ HJ2
M% [\]*L&)"/NT 4Z*G> KRO(J$]<=Z (Y1NC852#%#D&M"JLT)W90<4 2Q3"
M08/WJEJI#$^\$@@"I_.4.5)Y% ,M_:G:T:TF59H#T1QG:?5?0UG'3$CG%QIU
MR]K-O&Q6/"C_ 'O_ *U6LY''-%*RZ%*31:MO%'C#2Q,J3?;(XSEY''F #V)K
MH-/^+2,574;!HEV\R1G=D_3 KE><$9QFI&E\UHS<I'<B,8191D 5+@C15I)[
MGJ.F>.-!U41B&]1)9#A8I?E;\JZ%&5QE2"/4&O CI6G2C'[RWD9B3(IRJ^P7
M_P"O5[3;OQ'H(W:5<_:K5<DQ#YL#/4KVK)T^QT0KWW/<:*XOPQ\0+#7)8[2X
M_P!'O3P%8_*Y]C_2NS!!Z5FU;<Z(R4M4+10**104444 %%%% !1110 5Y/X[
M\ Z_XO\ &EA='[.-'MV0-&TIRX#98[<=2.*]8I* .2O/AOX5FTV:"'0M/BE>
M,JDH@&5., _6N.\$_#[Q/X:LM=TVXDM&LKV%A"5<DE\@ GC@;:]?I*+ F?/6
MD_"[XE:''*FE:I!9)*076&\90Q'3.!6QK7@;XA:]X=LM'O;FSF2.7S9II;DL
M[MV[=@37MU%*P7//-2^&=G+\.AX<M%431J'CE^[NE ^\?K2_#+P_XE\-Z?+I
M^N2026\9!MC'*6('=3QP!QCZFO0J*+#N>7:;X"UFW^,5UXHE^S_V=*7*XE._
ME,#C'K[UU-Q\/O"DOFR'0+ RODEC",[CWKJ*.]%A7/'_  '\*[K0O$VI7VKV
MUD]M(CK:^6VXQY;L,<?*2*H+\-?&?AK7KVZ\*ZA:>1<[LB=BNT$YQCGD>M>W
MT=Z+#YF>8_#;X<7OAN\NM8UJX$^JW!96*2%@ 3DDGN20#7IO:EHIH1XW\2M&
MD6ZDN%0D,?,4_P _Z5BZ%J*W5HL+-^]C&"">2*]KUG2HM5LFA?AOX6QT->#:
M]I%UX<U9IHT* -T';_ZU4F>QA*RG'EZHZ2BJMC>QWMJLJ$<_>&>AJU5'4*K%
M&#*2&!X(HU[2CK]E_:5FH&J6P!D4=95'?W/2DJ6WN)+6=)HSAE-#1G.-]5N=
M-\/_ !DNMVHL;R0"_B'()YD'K_GUKO:\/\0Z;)!.GB;1!L*-NN$4\QMZ_3K7
MI7@_Q3;^(M)67>JW"8$T>>0?7Z5GL>9B*-O>B=-130ZGH12Y&*#D$9MHR3VK
M(N/%.BVEP+>XU*".;. C-S7"?%SQ%J-NVG^'-)G,5UJ;!9"GWO+)V\>@]?:K
MFF?!SPU!I'D7<,L]Q(@\R9WRRMWVG' I7'9'??;[;Y<S(-PRN3U%*+VW9MJS
M(6[ ,,UX3\4]%M[+Q#X4T6*2;[+Y+1<O\V-P[UTNJ?!K3+.PDNM#OM0M[^$>
M9'))-N P/3 H'H>L@Y%02W4<!'F.JYZ;CBO/_A1XQF\0^&98M0D9[ZQ.R9V'
M)'\)/J>#FO,/B#J=]XN6_P!>@DECT?3Y4MK<<[968G<0?7@47$D?1WVV *&\
MU,'H<]:;]NMR<>='ST^85Q_AOPWI6O\ @;1#JEJMQY<&5W]LUP?B/0])E^)N
MB^'_  _;PV\D+BXN'C;D;3N*G\!G\:5V5:)W/Q6U1;+P=)#N(>Z8(F/8@G]!
M7S]" TK-G[HVXQ7JOQJOF^UZ;IX.46/S?QY%>66_,9;&"2<TST<+&T435+#W
M-15/#]S\:#T(;DE%%%!N%%%% !4;_>J2H3U-!,@HHHI$!1110 5&>M24QASF
M@EC:***"0HHHH **** "BBB@ HHHH V/ ?\ R.UU_P!>!_\ 0THH\!_\CM=?
M]>!_]#2BJ1X5?^(S'\/H?[)#8XWM6G5'PV0-$&3_ !M5VNF.QY-3XF+12451
M!.DW&&_.@QJ_*FH: 2#P:8B97GAX4G'I4ZZ@P^^E51,X]Z=YP[K0!8;43GY4
MQ]34+SSS]>!Z"F^:O_/.D,S=AB@!5AQRYHDE&-J<5$6+=33HU!?!H 92U8E1
M=F>F*K4 A:*2BD,6BDHH"XM%)10!=L?]7/\ [O\ 45)4=@/W=Q_N_P!14E-$
MFQ;_ /'NGTJ2H[?_ %$?TJ2F2%%%% !1110 4444 %%%']:8%WQ%*]CX(LK7
MY2+V9I&XYP,8_7-=+\,-(4^'Y;B>,JTLV4;^\N!_7-<7X\VPZI:64;LT=O:J
MN#_>R<_TKU[PA:-8^%=/MW(++'DD>Y)_K7/-VB=M*/OZ]#4%E;C_ )9"I1$@
M& HP/:GT5B=5D)M']T?E2XHHH&%&!110 8INT'J!^5.HH ;L7^Z/RIKP12##
M(#^%244"L5_L-O\ \\EJ-]-@;H"OT-7**=V'*C/.E1 ?*[@_6HSI<G:?BM2B
MBY/(C+-M>H,1RDBA4U%!G=GZFM2DQ1<.1&8;J_!P81G_ '30+ZZ7)> [1_LF
MM2@@'J* Y7W,S^U<#YHCGZTO]K+_ ,\C^=:'EIW4?E2>5'_<'Y4] M+N4/[7
M7_GD?SH_M=?^>1_[ZJ]Y,?\ <'Y4>3'_ '!^5+0+2[E#^UU_YY'_ +ZIK:L?
MX8R/J:T?)C_N+^5+Y2?W%_*BZ"TNYD_VE<-QL0_A5:;S6;S)$(!]L5T&Q1T4
M?E5">PFG?+2C;Z8IW(E%F= LK2 0D[NV.U;T*LL0#MN;N:;!;I FU!^-2TFR
MXQL+1112+"BBB@ HHHH **** "BBB@ HHHH **** "BBDH 1F"@D]JX?Q#XO
ME$[6.D /(.'E[+5[QCJTMK;)8V[$3W'4C^%>YKCH(5A3:O7J3ZFL*M2SLCU,
M%A8M>TF5I+.XNW\R\O))&/)P::=)AQP\@/\ O5H45SW/64VMC.C74=,<26EP
MS!>=M=MX8\7KJ&VUNQLN!QD]S7-50O(&BD6[M_EEC.3CO51FXLSJT85XVDM>
MYH_%#PKJ+:C8^+-"C,M_9$,\84DLJG(X'/K3K+XW:"MDJZA!=07X7#P>43\W
MUQ73:5XQTYM,A^US@2[<,*<=;\+EF8QVI9CDDPC/\JZ5)=SPY8:JG;E/-OB%
MK"+\0?#.N/!-]E6S61MJEB!O;TK7U_XHS:Y9RZ5X7T>\NKBXCV-*\3!8]QP<
MC'H>M=L_B+P[(!O,#X&!N0'%$?B/P]$VZ)H8VZ$HF/Y4<R[D_5ZO\K.+L_A"
MTW@&UT2>\$%U]H^T7$B _,<'"GZ9_2N;^(O@[6M"\*6<4NOW%_:I<1QQVQ3A
M.#@_A7L'_"8:.#_Q\C\JBE\4:#.,2R1N,YPRYYHYH]Q?5ZW\K.4DU&_\%_"9
M;B>[DO;R2,+;EDSL+#Y5('88J[\)=!;1_!L=W<8-U?$SN2,$*>BGZ<UNR>)]
M!EB$<DL;(.BLN0*K:IXTTBST>X>"=08XR5 ' _"GS1'["KUBSY\UZ]?4-<N[
MJ7!:6<[L=.N*BZ<56\Y+B\)!SN8M5FF>I1V"K2_='TJK5I>@^E,ZJ8M%2"&0
MKN$;D>H4U&>.M!HF@HHHH :WW34=2-]VG2VL\"HTT,D:N,J64C</:@B;UL0T
M5)%#)/*L42,[MP%49)HGMY;:0QS1M&XZJPP12)N1T5)##)/*L42,\C'"JHR3
M1-!+;RF.:-HY%ZJPP10%UL1TUZ=2$9% ,CHHHH("BGQQO+(L<:%W8X"J,DT2
MPR02-'*C(Z]588(H%=#****!A114MO;3W4HBMX7ED(R%12Q_(4";(J*GBLKF
M<RB&"20Q#=(%4G8/?TJ"@+IGK7P7^_J/X5Z[7D7P7^_J/X5Z[36QX^+_ (K"
MD;I2TC=*9S'SLO\ R._B/_KXK2K-7_D=_$?_ %\5I5TTO@/.Q/\ $84#K116
MA@7HW#H#3ZI12;&Y/!JX",4"%HI** %I,T5')*$XZF@!9) B^_:J9))R:5B7
M;)IZP,PSG% R*BE92K8-)0 4444 %%%2B!R,T 144I!!P:2@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** 'Q/L?)Z5=!!&16?4D<I3CM0(N]J@F
MB##(ZU(CJPX-*2 .30!0-%*W+&DH&%0RP;SN7K4W'>FNX12W6@""))%?G.*L
MU3-Q(3P<4+<.&Y.10,N44#D9]:*!!4D$\MM*)89"CCH14=% &@^EV_B*'-MM
MMM9C.Y64X6?_  :NI\$>,);B7^Q-8RFH1?*&?@OCL?>N)BD>&59(V(=#E2.U
M;GB.U;4-(M_%>GJ(;ZV;$Y3C.._X5E.*.FE-GK .1FEK)\.ZJNL:':WHQND0
M;P#T/I6M6!W+57"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH 0USGBGP[%K-BY" S*/3[P]*Z2D(S07";A*Z/FZ1+CPYJI#*?)8X(
M/^>U=-!,EQ"LJ'*L,UV'CGPI%J%K)<PQ_,/O #]:\HT^[ET>^:TN<^6QQD]O
M>J3/;I555C='5U1U+44L(QQNE;[B^M:*^5'9S7TS?N($W'!^]G@#]:RM(LGO
M[AM4O5RSG]U&>BBIJ5%%7-(V;L4X].U?55S<2F*)NL><5I6&@2:<&-O=LC-U
M(K; P*6N*51R-U9;(I17>M:<_F17+28ZUUOA_P ;)=N+:^&R7IFN?JE>60E'
MFQG;,O(([THS:,ZE&E65I+43XQPS:=K6@>*X-[QVSK%($'10V[.??.*[_2_'
MOAW4],6\CU.UC78&=)955H^W(/3FLWPOJMMJNEO8:H(W\OY6$N,$?C5.Z^&O
M@>XN#*D,<(;[Z1S8#<YYR:ZE)-7/"JT)4YN+.0^+-_:3>-?"EVD\;6^PMYH8
M;<;QSFO0/$'Q$\,Z;I,T@U:UN&*E5CMY0[$D>@I=0\&^#=4BM(KNUMY$M(_+
MA'FGY5].M0V?@+P)8W,=Q#IUF)8SE6,A.#]"<4[F?(^QYUX7\*^(+CX7ZB^D
MPE=0UB8!UE/ECR1GD$^N:Q_%&E^,?#_PZ72M2T[3[?2HYD+21/ND9^Q//]*^
MB$O;&) B30JJ\ *P %4-:L]"\06!L=3\BXMRP<HTF.1TZ&GH'++L<KX"U74=
M,^&8OM9BB6&VA9X/*ZM$!GGWZUE_"+3+C4+K5/%VH%GFOY"L3./X!T(_E^%=
MQ<:5X>NM"71)1"=/0 +")<# [9!S5W35TC2-.AL+%X(;:%<(@<<#KZT7#E?8
M\%^*5V]QXTO8R<K  J_]\@_S-<K%_JDX_A%7/%%\;WQ)?W!<.6G(SGL#BJU,
M]:@K*P5/#_JZ@JQ%]V@ZZ>X^BGK%(XRL;L/4*332I4X(((H-;H2BBB@ /2H:
ME/2E-K.MJMRT,@@9MHDVG:3Z9H)F[;D-%* 2< 9)J:YL[FS?9<0O$V,X=2#B
MD1<@HHJ6XMI[5PEQ"\3,NX!U(R/6@+D5-89%.H[4#W(J*#P:*#,** "3@#-3
M7-K/9R^5<PR128SM=2#C\:!76Q#1110,***549W"(I9B<  <DT"V$HJRVGWB
M7@M&M9A<GI$8SN]>G6H)(WAE:.1&1T.&5A@@T FF:W@/_D=KK_KP/_H:44>
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M% %Q2 PSZU=!!&15"G!V7H30!+<8W#Z5!2DDG)-)0 4H5CT!J2%-[\]!5L#
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MO[I_*C4/:,S/[,E_Y^Y?SH_LR7_G[E_.M/#?W3^5&UO[I_*EJ'M&9G]F2_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ5Z/\/KQ+KP?9*K;FA4H_P!<D_UKGGK&YVTM)M'175U#96TEQ<.L<48W,S'
M ]:YC_A9?A#_ *#MG_W]%:/C'_D4=4_Z]W_]!->&^"]>^&MGX6M8/$.GB74U
M+^:_V=FSECCD>V*P=[V.Q6M<^B+6[AO+>*X@</#*@='4\,",@U/7F?B/X@Q:
M/;:5I/A>U2XO[V%#:1$?+&A4%=R]>G:M;PI<^/)=2<>)K;3H[/RR5:V.6W<<
M=3QUIW$T=M17+>/_ !#>>&?"EQJ=B(C/&0 )5++W[9%<WX3\7>+M;9=9O[2R
ML_#GE,YE<[7X'WN3T]Z+A8]-HKQ\>.O'?B);O4?"VFV+:9;L4S/DNY')QR,U
ML:;\5;2;P7=:Y>0-'-9-Y,\(')EXP![9(HN%CT?O2UY/HWB'XGZT+?4(M,TR
M+39I 0LF5D$>[TW=<5)J?C_Q%K/B6ZT7P79VLS60/GS71^4D'! Y&,'BBXK'
MJE%><^$/'NIWUSJ.B:_:);ZW9QO*/+4^6Z#N/T[\US/AWXB>/?%]DZZ-I^G-
M<6[?OY),JA!^Z ,]>#WHN.Q[63BHUGC=F57#%>H!Z5Y9I?CWQ7KEEJ.DVNGV
M<?B2PD59%E;$; YW8&>",>O>N?\ AW<^.6UF\6UAL'M_M@%Z96Y4<;MG/I1<
M:1[Q17F&N^/-?O?$[>'/!]C#/>6PS=2W*GRUXSC.1CZ_A3]!\<Z]9^)4T#QC
M;6UO=W*[[62W^XWL>3Z&BXK,],HKR#6_'GC(^/[SPYH%G9S^6JE6D0_("H)+
M'. *]-T1]3?2H&UA(4OBO[P0G*Y]J$P:L:5%%%,04444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 444&@!*P-=UP6@-M;G=<,.O]VC7-=6S4
MVUN0UPW_ ([7)@'>SNVZ1CDL>IK@Q.)M[L!-@ =Q>1BSMRS'O3J**\ZY(4R2
M1E&V/_6-\H'UH=]O'5CT KIO#^A-$RWMV,R$91?[M:4J;J2LAHKQ^!]/NK.%
MKH2>?M^9E.WK2+\.])#9+W#>QDKK^@I:]B-.*C:QT1Q%6*LF9&G>'=-TL#[-
M;J''\9Y;\ZU5&!BG45:26QG*<I.\G<****9(4444 %%%% !4%Y"EQ:R12*&1
MU((/>IZ:_P!V@%N?(UU^YOI5 QB4C'XU)6KXXM5L?&.IQQIA%E+(*R1T!I'N
M4I70M30GJ*AI\1P_UH.B.C+%%%%!N%%%% @J'O4U1,,-0*0E%%%(@**<HR:>
M5![4#2(J*5EQ24">@4444 ,84VI3R*B/!H(:"BBB@04444 %%%% 'K7P7^_J
M/X5Z[7D7P7^_J/X5Z[36QXV+_BL*0]*6D/2F<Q\[+_R._B/_ *^*TJSHU9O'
M'B/:/^7C^E:C1L@Y%=-+X$>=B?XC*]PY1..]4_J<U?9 XPPJ/[,F>I%:&!4J
M["N(0&I!#&G)_6F-=H/EC4N1_=% "FV4]&(IOV7_ &OTI";J3HH0'\Z8;6=O
MO3_I0!:W)#& 6 QZU 9I)>(AA?[YJ%A:VW,LF]AVS_2J%SJ,DWR1CRX_3O0-
M(O//;VA)9O,E_E5636)B?W:*H]^:SOK12N58O?VO=?['_?--;5+IA]X#Z"J=
M%%PLBTNI72?\M,_458BUB13^]0-[CBLVBBX6.E@NH;H?(<D=5/:HKBR4@O'P
M?3UK!1VC<.APPK>L+T72;6XD7K[T)DM%))'ADR,@CJ*U89EF3</QJM>P<>:@
MY'WA5:UF\J49/RG@TP-;O5@1F,!E//<57'."*O\ !44"&B5"OWJ@FE#?*M-E
M4HY':HZ "BBB@"&Y.(Q]:IFKLZ[H_IS50 D@"@"[%S$OTI](HPH%+0 4444
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M+'U-8.:CON=D,/*:M%>Z=S$@BB5%Z*,"GUR__">Z'_SW?_OBC_A/=#_Y[O\
M]\&L^9'3["IV.HJEJE_'IVGS7,I 5%SSW/:L3_A/=#_Y[O\ ]\&N?\4>)+37
M(;>SL)6(:3,F5QP.:F<TEH:T,-.=1)K0Q4:74;R34;O+22$E0?X1VJU2 !5
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MDV(26^E)ML%2Y=4BU6KX7L_.\0B>1<I'$=I/8Y%95=)X?E$5S;R$@(ZM&?\
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M_P! R/\ [^O_ (T8T_\ Z!D?_?U_\:BQ1BF7S,EQI_\ T#(_^_K_ .-&-/\
M^@9'_P!_7_QJ+%&* YB7&G_] R/_ +^O_C1C3_\ H&1_]_7_ ,:BQ1B@.8EQ
MI_\ T#(_^_K_ .-&-/\ ^@9'_P!_7_QJ+%&* YB7&G?] R/_ +^O_C1C3_\
MH%Q_]_6_QJ*C% <Q+C3_ /H&1_\ ?U_\:,:?_P! R/\ [^O_ (U%BC% <Q+C
M3_\ H&1_]_7_ ,:,:=_T#(_^_K_XU%BDHU#F";["Q$,6F)YLG"XE;CWZUNZ'
MX9>T\N\>X6!Q]V1B>OL!65I$8;4'F8 ["  ?SKJY9FGD+D\= OH*\?'8J2DZ
M:>P7N2M;2$Y.MC\&?_"D^RR?]!O_ ,>?_"J]%>9[06A8^RR?]!O_ ,>?_"C[
M+)_T&_\ QY_\*KT4<[#0L?97_P"@W_X\_P#A1]E?_H-_^//_ (57HHYV&A8^
MRO\ ]!O_ ,>?_"C[+)_T&_\ QY_\*KT4>T8:%C[+)_T&_P#QY_\ "C[*_P#T
M&_\ QY_\*KT4>T8:%C[*_P#T&_\ QY_\*/LK_P#0;_\ 'G_PJO11SL-"Q]ED
M_P"@W_X\_P#A1]E?_H-_^//_ (57HHYV&A8^RR?]!O\ \>?_  H^RO\ ]!O_
M ,>?_"J]%'M&&A8^RR?]!O\ \>?_  H^RR?]!O\ \>?_  JO11SL-"Q]ED_Z
M#8_[Z?\ PJ.2"X1"RZN'(_A5GS_*HZ*3G<8Q$()9F+.>K$]:?114""FL^" H
M+,>BBB1PB;C71>&-,@DC%_*RR2$X5?[O_P!>KIP]I+E0T3Z#H(M]MW=C,Y&5
M0]$_^O714N**]FG34(V0PHHHK084444 %%%% !1110 4444 %%%% !1110!4
MU&SCO[&:TF&8ID*./4$5\KZS82Z3K-U9RKL:"0C![#_]5?65>)?&+0?L^H0:
MQ%& LXV28'\0[G\,4K'5AIVE8\VSG'OTHJ*!N"GITJ6@]9.Z'Q-AL=C5BJE6
M5.Y0:#>#Z#J***"PHHHH&1N.]-J8C(J(C!H(DA*E4Y%14H.#0*+L2T4@8&EH
M-!CCO35P3S3WZ5'2(>XYEP,TVEW'&*2@3"F,M/HH):(J*<5[TV@BP4444 >M
M?!?[^H_A7KM>1?!?[^H_A7KM-;'C8O\ BL*1NE+2'I3.8^=E_P"1W\1_]?%:
M7:LU?^1W\1_]?%6+R?RX]J_>;]*Z:7P(\[$?Q&5[B1KB81ID@<?6HK^<6\*V
MT9Y(^8BID*VEL9W^^P^45BR.TKEV.6)R:T9DD-I:**DH*%!9@!UHIT;^7(&H
M >;:3'45$00<$8J[Y\>,Y%59'#OD4Q(91112&%'7BBE7EP* +4$(EFP1E4'(
MK0$28QL&/I4-F/W;'U8U9JB64KFV 'F1#!'4"J+@$!AWK;/(K*FC\N9T_A;E
M:3!,N:*_,L?_  *K>H+^[5@.AK&M)S;7"OV/#"NA<+/!@'((R#30F4;&3;-M
M)X-:58I#128/#+6G;3B9.?O#J*!-$]%%% !1110 58@CXW$9J%5W,!5X#  H
M /PIKHK#!%/I#0(HNI5B*ADF$?N:M7'^L_"J$\3%MPYH&.2Y5C@BIZSL=N]:
M"\(H]J %HHHH **** "BBB@ HHJ.5]B'U- #99PF5'6JQD=OXC^%-[Y/6I[>
M+<=QZ#I0!/"&$8W=:?15_1K!M2U6"U"EE9@7P<?+WH;L.*N['4^&?#MK_9<N
MH:JGR,I90W15'?\ G7(V.E1^-/%DB6\;0Z9 W.!V'OZG^M=3\2-6>QTFWT6S
M.)K@A2%8A@O;\^E=%X.T&+0-"BB /FR@22D]R?\ ZW%<SM\3W/0@Y?PD]%N3
M1>$=%CC5%LE"J,#DT_\ X131O^?-?S-:;7ELCE&GC##J"W-/::., O(J@G )
M.,UERQ.Q5JB5E)F3_P (IHW_ #YK^9H_X131O^?-?S-:KW$,1 DE1">FXXI4
MFBD&4D5A[&ERQ[![>K_,S)_X131O^?-?S-'_  BFC?\ /FOYFM5[B&,X>5%/
MH6Q3EE1P"CA@?0T^6(>WJ_S,R/\ A%-&_P"?-?S-<SXHTB#2C%-9PA(SPV!7
MH%9^K6"ZA8R0L.2,K]:B<$XZ&U#$SC43E)M'FP(89!R",UH:=.H#6SML$ARC
M_P!QNQK)8-8W36TP*_,0I/KZ5/T-<B=F>U.*G&QVVG^(0)!9:B1#<KT8_=D]
MP:W4FC< JZL#Z'->;"\$D'V>ZB6>'L&ZCZ'J*8([4 +!=WUL.@"2$A?UKHC5
M/-G@KZH]0S2UR>BWMS:SQP3W?VJVEXCF(Y!]#75KTK:+N<%2FZ;LQ:***9F%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 T@$8-?-?Q$T3^Q?%ETBJ1%.WFH3WSR?UKZ5/2O-OBYX?\
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M][N!#POR0#PX]17>6-[#?VZS0L&4_I[5ZE"NJBL]QIEJBBBND84444 %%%%
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MRN[8QYQZU:M?$ND7UZ+.TOHIIS&)0B')VGH:\L^'^F:7XGUGQ->:_;07-_\
M:F0K(OW8P  <=J7X+Z4B:]XBOXY!Y4,[VD<7]T;]PQ1=CL>C>(O#<>IQ&:,
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MZZM715UP^%'C57[[,YM/<?=<&HVM9TYP3]#6K15&=S)\VXC')8?6I$OY!]X
MBM$@'J!4;6\3=4% $"Z@I/*$#ZT\7T)[D?44C6$1Z$CZ5&=/_NO^8H LBYA/
M_+04&XB ^^OX&J1L)!T8&FFRG_NC\Z +4E_&H^7+&J,LSS-ECQZ5(+*8]@/Q
MJ5-//\;_ )4#*B*78*H)-:EO;B!/5CU-.BA2(845)0(**** )8GQP:FJI4JR
MXZT 344@8&EH **** "H9A\V:FJ.4?)0!!1110 4444 %%%% !1110 4444
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M_P CQXE_W+3_ - >NDKB/[=LM!\<:\=0\^-9X[;RF2VDD#;5;/*J1QD5H?\
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ME1YC=3T%+%;%V\V8Y)Y ]*MT""BBB@ HHHH ,GU-%%% !1110 4444 %%%%
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M/2EI#TIG(?.P_P"1W\1_]?%7;B$31[3U'0U27_D=_$?_ %\5I5TTO@/.Q/\
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MV.7S0>Y)_P#K5Z%7-+<]"G\(4445)84444 %%%% !1110 4444 %%)FESQ0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4UES3J* /*_B%\.5U$/J>DQ
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M<T77_P!UKVGPARNU9L!L?X5Q]%2X(TC5E$Z'4?AI'*@O_#MZ&Y#1HQX_!O\
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MJ@=&C;:X(([4WITH-E-HMT5 LI7KR*E5PPX-!JI)CJ***"@HHHH <#2TRC-
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MFBFF344T.I[TZ@JX4444#"BBB@#0\$?\CU=_]>!_]#2BCP1_R/5W_P!>!_\
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M^#F@-I-AI\[W$B6;.ZL'VDLQ!)/Y"M/7_AIH?B/4(;^\69+J) @DBD*G Z4
MCQTV^JR_&35SIEW86VH+*QC-Z,HPQSC@C-=7X-\&:YI_Q$77=0U'2Y#*'\V*
MS?&25('R@ 5UGB#X5Z-XDVW%TK0WP4*9HC]['KZFG^$/AEIW@^[:[M)I9;EQ
MM9W.!CZ4*X:'FWPHT?3]6^('B-=0LX+I8B[*LR!@#YI'0U] Q1I#$L4:!(T
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M%4D]JK&Z;/ XJPRAU(/>HA:KD<DT 2HVY V.M.J9+8X'84V2,Q]^* (Z***
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M PHHHH **3BFO+'']]U&?4T"N.J"XDFC'[J/=QZU%)J4"$@98CTJE+J<CY"
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MI*5V4H)&=>ERPA@B('0D"G6-B8FWR@;NP]*OTHHN'+K<****184444 %%%%
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MO5:B@#0SZ4M44D9>]2BY]5H$6:*@^TK_ '31]I7T- $])FJYN?1:C>5F[XH
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MF9.V\\?H:I3_ !%\27T86TTWR23PZ1LV?S&*]0&@Z0#D:99@^H@7_"K<5K#
M@2&-(U'\** *?-'H@]G/JSR+^P_''B>5?MTTEO%MX9V"J?P7_"NCT7X7:=9!
M9-1<W4N 2HX4&N_ Q2TN=]"E2CUU(8;>&VC$<$21H.BHH J6EHJ#0**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \;U_P#Y+=>?]@A/_0UHHU__ )+=>?\ 8(3_ -#6BF(XGP3_ ,BXO_75
MJZ*N=\$_\BZO_75JZ*NJ'PH\RK\;"BBBJ,PHJ"XD9< '%1),ZGDY% %RBD4A
MEW#O2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 4[NV9VWH,\<BJRVTK,!M(^M:M% #(HQ%&%':GT44 %%%% !11
M10 4444 %%%% $-S!YR<?>'2L\V\H.-AK6HH IVMJRMO<8QT%7*** "BBB@
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M94PH_&NEL-5L=2B,EG=Q3(#C*-FE9E*29>HI,C'6C-(H6BBB@ HHHH ****
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M1 J@  8 %9-\NB.J,.=W>Q'!;0VT*PPQJD:C"JHX J:DQ2UD;A1110,****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!XWK_ /R6Z\_[!"?^AK11K_\ R6Z\_P"P0G_H:T4Q')^
M?^197_KJ]=0:Y?P$0/#"D_\ /5ZWY9L_*M=4/A1Y=7XV12'=(Q%-HHJR HHH
MI %%%% !1110 4448S0 4H4GH*F2(#DU)CTH @$34>4U3T4 5BC#M3:MTQHP
M: *]%.92M-H **** "BBB@"C-_K6IE23#$K>]1T#+5J?E(]ZGJ&V7"9]3FIJ
M!!1110 4444 %%%-9P@R30 ZBJYNN>%H6Z'=: +%%(K!AD'-+0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444P
M"BBBD 4V1UC0LW %.J&ZC,L)"]1S0!4EO'+_ "<+5JVN/.3YAAAUK.\M\XV'
M\JT+2 Q*6;[QH L4444 %%%% !1110 4444 %(P#*0>AX-+10!S]U#)87:R0
ML5P=R,.U>V^!/$;>(-%#3D?:H#LEQW]#7E-] L]JP(Y'(]JE\ :O)I?BBW0N
M%AN#Y<@8\ =<_7BLZD;JYT4:G+(]\IKR+&N68 >YK/GU+G9 ,GUQ4,=G<71W
M3,54\\USV.USZ(FFU09VPJ6/KBH5MKJ[.Z5RJGUK0@M(H!\JY/J:GIW0E%O<
MK06,,/.-S>IJSC'2EHJ2TD@HHHH&%%%% !1110 4444 %%%% !1110 4444
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MG_/I7I&.*C@ACMX5AB4*B#"J!P*EK%N[.J,>56"BBBD4%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 >-Z__P ENO/^P0G_ *&M%&O_ /);KS_L
M$)_Z&M%,1Q7@DG_A'%&>/-:NAKG?!/\ R+B_]=6KH68*,L<5U0^%'F5?C8M(
M6"]3BJ[W))P@_&H&8L>35F99:Y4'"C-1FY?MQ4-%("87+CK5B.42#WJC3XFV
MR T 7J*** "IHEXR:AJTGW10 M%%% !1110 4444 (1D<U"\9'(Z5/1VH J4
M5(\>.:CH **** &O&L@P:A%J,\GBK%%  !@8'2BBB@ HHHH **** "J4K%W/
MH.E73TK//4_6@!****!CD<HV0:NHX=<BJ%36[;9-O8T 6Z***!!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1156:
M\$;%57)'>@"U16?]O?\ N#\ZMPSK,,C@^E $M%%% !1110!2FO2KE4' XS5F
M%S)$K$8)J$V*%R2QY/2K(4*H Z"@!:*** "BBB@ HHHH 0C(Q7/(-NK(HX_?
M#'YUT5<^#G64_P"NP_G2>Q<-['T;:VD<2*P&6(SDU;J./.Q<^E25R,]-)):!
M1112*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#S/X<_\CCXL_Z^J],KS/X<_P#(X^+/
M^OJO3*4=BI;A2-TI:0]*9)\[+_R._B/_ *^*TJS1_P COXC_ .OBM*NFE\)Y
MV)_B,****T, HJ2.&68XCC9R3C@5T&G^"]3NV5IT%O'GYMY^;'L*3DEN5&$I
M;(YO&:MVFF7M^VVVMI)#C(P,#'UKNH_#>@:%";C4+A9&C&6:4X'_ 'S6=J7Q
M+TG3(3;:3;^>R8";1MCQ['_ZU0ZC?PFZH6^)D6G^ [N<(]Y*L"$<J.6']*U!
MX8\.:?$WVZZ5V7J6EVD?@#7%OX@\9^*69+&.:*+/_+ ;=OU;@FK=G\+M5OKE
MYM7O@F\9+J2[$^^<5+OU9<8Q7PQN=2NO>![8>6+BS.WCF(G^E./BCP2W_+:R
M_P"_'_UJIV?PIT:%,74T]P?4'9_(U;_X5AX:_P"?>?\ [_M4-HU49=D4[C4/
M -^ZF2ZA4C@!-R?R%3-X:\-WL6ZSOEB'8B3/\S4=S\*M%D3%O)/ ?7<7_F:Q
M[SX2/'$7L=2+RXX$B;1GZC--27<F4'UB:5S\/Y]VZRO(Y(R.K\']*YV]T#4[
M#F:TD"DX# 9!_*IFT'Q]H9CEM[J6Y"GB.*4N/Q!P*DMOB/KNF3F#6=.$C*V'
M;;L*CZ 8-6I2]3)TX/I8Q""IP001U!I*[.+7_!OB-MLRBUF9@,LH0NQXZBF7
M_@:3._2[F.>/J58\CZ8SFJ4UU,G1>\=3CZ*M7>G7=C(4N;>2-AZBJN*O<S::
MW"BBBF(**** "H?('F;B:FI55G;:JDD]!2 3V%=OX1\, A=2OU&U>8XV''U-
M'ACPB2!?:JFT#F.(_P S5+QAXQENYO[ \/AFE<^7))'_ "7_ !K*4KNR.FE3
MY5SR*_C/Q!+XAU./PYI+,Z%\2LG1C]?2N\\-:!;^'M)CLX 2WWI'/5FK*\$^
M#XO#UD)IT5[^1?G?KM]A77UC)Z61UPCKS,****DT"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-L^>"*06S^PH AJ>WC);?C@5(MLHY;FIN!P.!0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -<XC8^QK'R2<
MGO6R1N4CUK*EA:)B"..QH&1U-:,1<*/7BH:N6<#!O,88':@&7J***!!1110
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M;ZFM4"LY2Z(WA!IWEN '&*6BBH-0HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!BBBBD4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >9_#G_D<?%G_7U7IE
M>9_#G_D<?%G_ %]5Z92CL5+<*0]*6D/2F2>9?#O_ )'7Q=_U\"O3J\Q^'?\
MR.OB[_KX%>G4H[%2W"BBBF2%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 >-Z__ ,ENO/\ L$)_Z&M%&O\ _);KS_L$
M)_Z&M%,1Q/@G_D7%_P"NK5T5<[X)_P"1=7_KJU=%77#X4>95^-A1113,PHHH
MH **** "BBB@ HHHH **** "BBB@!0Q'0U()CW%144 61(I[XI<@]ZJTN3ZT
M 6J*J[F]31N;U- %DL!U-1/+GA:BHH **** "BBB@ IDD@C7)I]0W"%D!% $
M)GD)ZU/#*9!SU%4^?2K-LI&XGB@"Q5B,82H.I%60.!0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 44A('4TTR*.] #Z*A,WH*:9&]: +%)N'K
M5;<QZFDH L&11WJ-Y-W Z5'10 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%1S3)!$TC' % #;FY2VB+L1GL*TO"?A.Y\4W8O;\,FGQG&!QO\ 8?XU
M3\*^'I_%>L>;*I^Q0M^\.<?117N-I:PV=K'! @2-!M50. *RJ3MHCJH4;ZR"
MVMH;2!(8(UCC0;551@ 5/117.=H4444#"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#S/X<_\CCXL_P"OJO3*\S^'/_(X^+/^OJO3*4=BI;A2'I2T
MAZ4R3S+X=_\ (Z^+O^O@5Z=7F/PZ_P"1U\7?]? KTZE'8J6X4444R0HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"?Z+_OJC_A(=)_Y_HO^^J]6HH]K(/JT3RG_A(=)_Y_HO\ OJC_ (2'2?\
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M2?\ G^B_[ZH_X2'2?^?Z+_OJO5J*/:L/JT3RC^WM'_Y_(?\ OJE_X2'2<?\
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M_P"?Z+_OJC_A(=)_Y_HO^^J]6HH]K(/JT3RG_A(=)_Y_HO\ OJC_ (2'2?\
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MBS"Z+'_"R?"7_0<L_P#OX*/^%D^$O^@Y9_\ ?P57HHLPNBQ_PLGPE_T'+/\
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MZ#EG_P!_!1_PLGPE_P!!RS_[^"J]%%F%T6/^%D^$O^@Y9_\ ?P4?\+)\)?\
M0<L_^_@JO119A=%C_A9/A+_H.6?_ '\%'_"R?"7_ $'+/_OX*KT468718_X6
M3X2_Z#EG_P!_!1_PLGPE_P!!RS_[^"J]%%F%T6/^%D^$O^@Y9_\ ?P4?\+)\
M)?\ 0<L_^_@JO119A=%C_A9/A+_H.6?_ '\%'_"R?"7_ $'+/_OX*KT46871
M8_X63X2_Z#EG_P!_!1_PLGPE_P!!RS_[^"J]%%F%T6/^%D^$O^@Y9_\ ?P4?
M\+)\)?\ 0<L_^_@JO119A=%C_A9/A+_H.6?_ '\%'_"R?"7_ $'+/_OX*KT4
M68718_X63X2_Z#EG_P!_!1_PLGPE_P!!RS_[^"J]%%F%T6/^%D^$O^@Y9_\
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/%>DZ9_Q\M_N'^8HIB/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gvvh0m1pmdf2000011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 1X!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HI*6@ HI** %HI,T9H 6BDHS0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@8T <?X]^)&F^"+-@Y$^H,F8[8'GZD]A4OPV\9S^./#TFISVJVS),8]BMN[
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M2UP'MK8****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME"F5 Q&>F:\$^-7A71_#FF6$FFVB127%TSR-CD]./I7NF@_\@&Q_ZXK_ "H
MT:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *\C^+?A#6?$?B?PW=Z9:^=#:;_.;/W<LI_I7KE% #.W KRG0O"6
ML6GQFU'7)K;;I\JL$DSUKUC%+B@#R#QCX/UK4_C-HNN6EKOL+=(1))GIM<D_
MH:FTOPGK%O\ &F\UV2VQI\BD+)GK\N*]9HH \@\.^$-:L_C)J&N3VNVPE!V2
M9Z_+BH=*\$:VOQ \2WLL!BM;ZW>.&7/<CBO9,4N* /G;0/#'CWP[I=_X=M-'
MM&^T,V;YUR<<]ZT=,\">(;;X/:AH$EEB]>XW(N[[PYYKW? HP* .7^'^EW>C
M^"=.L+V/R[B*(*Z^AQ7A/Q?\-7D7Q(2+3N?[8"JJ*>68DY!_,5],W,1FMWB5
MRA=2-PZBO.O#GPI32O$JZ[JFJSZC=1']QYG1* .U\.Z4FB>'[+3HQ@0Q!3]:
MX?XPZ'KOB72;+2M'MS)&\P:=LX '&*],%+B@#SJQ^#OA2/2X8KC3E>X$0#OG
M^+'/ZUS'@7P=XC\+:CXETXVN=+O(91 <_P 1!"_IQ7MN*3% 'A_@CX<ZK#\-
M->T35;7R;FY8- ">XIWPC^'FKZ$=5OM:M_+NFA\F $Y)!!S_ "%>WXI,4 >+
M_#+P7KNA>#?$5CJ%IY5Q=*!"N?O<-_C6!X6L?BKX/TI],TO2;;[.96E_>@DY
M.,]QZ5]$8HQ0!C>&9]6N-!MY-;B2/4"O[U4& #7E?Q&\->+)OB-9^(/#UBLY
MM[<*&<\;LG_&O;<44 > 7_@OXC?$"ZMXO$<L%G8QN&9$Z8[\9ZUU?C[X92:K
MX6TRUT0JMUI94Q!N-V/_ *_->J44 ?/^J:7\2_&>GVOA_4K"&VM(RHEFP1N
MXSUYK7\;?#O4G3PG::1;^?#IJ[97SCNO/Z5[1BC% 'E_QD\+ZMXFTG3X=*M_
M.DBFW.,XP*]&T]&AL+>-QAE0 CWJWBC% &-XMLI]1\(:Q96R;YY[.6.-?5BI
M %<E\&_#NI^&/",UEJL'DSM<EPN<\;0/Z5Z-10 4444 %%%% !1110 4444
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M^#Y]/T*$R7-R0C$'&%SS6#X6^#GAZ#P[:)J^GK)?;,S,3W/:O4^*6@#Q'0/
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M/>KU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY31O^1_\2?\ ;'_T 5U=:+8QEN'XT4451(4444 %%%% !1110 4444 %%%%
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ME)$H*D/UR>V,G\J]HP*,"@#G_!>DS:)X2T^PG_UT<0W\]\<UF:Q_R4K1N/\
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MQ!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK'8QGN%%%%,D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8<$8YJY0:29C"LIR<4MC8Q12T5!L%%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M+$'W34U0P?=-35E+<WCL%%%%(84444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5QWQ$M-!N_#Y'B"[>UMT?<DL;88-CM785Y!\7/&>BV5U9Z
M/?V8N72=9)$D#!=F.HQUZT <%I7BOQ-I^M"U\'7U]K=@#]VYB) 'NV!_.O</
M WC"7Q59W:7=D;/4+&017,.> QST]N#7 O\ %30;>*ST_P &6"_:99E0H(,
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MD/\ K!5D=*K0_P"L%61TK.6YK#86BBBI+"BBB@ HHHH **** "BBB@ HHHH
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M.<*>?I2O(J<,<?A0 ^BFJP=<CI3?/CW;=W/TH DHIK,%&YC@4B2K)]TYQ[4
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M)/\ D>?#?UD_FM=B.E7+9&-/XI"T445!L%%%% !1110 4444 %%%% !1110
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M .O7?^,/AKHGB*]EU?4;JYB\N/+>7(0  /8UY#+:?#&.9T74-6<*<;E)(/\
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M4<X%+10 F >HS0 !TXI:* $VJ3RH_*EQQC'Z444 )M .< ?A05!Z@&EHH 0
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M3_?*GJ( !TXI54>8#@44Y/OK5O8X%N6Q2T45B;A1110 4444 %%%% !1110
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M:[ZN!^+7_(JQ_P#7=?Y&F=6"_CQ/$**04M!]>%%%% !1110!I>'_ /D/V/\
MUU%?3?:OF3P__P A^Q_ZZBOIOL*1X&<?%$****#Q2S!]VI:B@^[4M92W-X[!
M1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !2&EICR+&I9V"J.23V
MH \Q^*?B#Q%;:CI&A>'6$-S?.09F_#@&N>B\(_%L3(9-=BV!@6'FCI^==#\5
M?#>M>)FTJ;0[NWA:UD9Q(TJJ0>,8)/M7+P:#\4TDC#^(+8HK#/[].1^= 'N=
MHLB6<*3',JHH<^IQS7 _%ZUFN/#4$BV\EQ:P7"R7,4?5HQUKO;02+9P"5@T@
MC4.1W..:\C^+7BKQ)I.HV=I8V3FT:92LJ#/F_P"P: /.]"U"UUHSZ#H5C(9)
M]42YBPIQ%&N>OYXKZG'2O#)=0\;Z]=6MK8^&%T8&=7EN%CVDJ.HS7N0Z4 !K
MA_%,'C3[9/<Z5JVGVEC$FY5GB))/.<G<,5W%><^/[KP9J8GLM<U8VT]LARD<
MNUAGT'?I0!3_ .%@ZK=> M-N[>&+^V-0N/LL61\F_(&[Z<^M3^'_ !7KND>)
M+K0/%DD$LJVANX9X5*@J 201D_W37)P7$\'@7PKK-U 5M-.U#+,$(_=97#$?
M@:T[F[A\<_$:XET9Q/:P:/) \RCC>X? S_P(4 #>-O%T=I_PE;-;?V";CR_L
MVP[_ "]VW=NS_2O7K2Y2\LX+J/[DT:R+]",BO!Y]?LW^%?\ PB:MG63<"V^S
M8^;/F9SCTQWKV_1+5[+0M/M9,AXK>-&SZA0#0!RVC?\ (_\ B3_MC_Z *ZK/
M%<GI,8D\?^),DC'D]/\ <%=6%PN.:UCL8SW'=J.U1" !MVXT]T#CDD?2F2+1
MFFI&$Z$FD:$,<[B* 'YI>:3;\NW)IBPA6R"3]:!CZ6F/'O[D?2E1 @P"3]:!
M60ZDS49A!;)8U(5RN* %S29IJQ!6SDFAXPYR210 ^C--5=HQR:9Y(W9RV:!Z
M$N:.::R;AC)I$B"'@D_6@0^L'Q7_ ,@U?]\5M/$'.22*Q/%(VZ8@_P!L5QYA
M_N\CIP?\:)QF:,\T&IK><6[[O+23/9Q7Q22;U/IWIL0UHVY_XD=Q_P!=!_*F
M_P!I#_GSM_R/^-/&L,L31BU@V$Y(VG_&NBGR1O[QC-S?0SLTF>E7_P"TQ_SY
MV_Y'_&J]Q<"X*GRHX\#^ =:R<8I:,M2D^A >E=7X0_U=Q]17*'I75^$/]7<?
M45VY5_O*.;'_ ,%G3?K149A!;.XT]ERNW)K[$^;%I>M1I$$.02?K2O$'.22/
MI0.PX]*X'5O^0I/_ +QKO0NU<5P6JC&IS_[QKS<R^!"*=%%%>,(**** "BBB
M@!\7^N3_ 'A7HJ?<7Z5YU%_KD_WA7H2P@JI+'I7K99]H:)O>C--VY7;DTU8@
MK9#$_6O5 DHICQA^I(^E*J[!C)/UH EA_P!8*M"J<$0$V[)JX*SEN:PV%HHH
MJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ***2@#C-:_Y*)HO_ %S?
M^:UVE<WJ6CW-SXNTW48P/(@1@YSZX_PKHQTJI/1&5--2D+1114FH4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% "&O/[C3/&OVK77748E@FC L<M_
MJVR.OX9KT&N4^)%M=W7P_P!8BL YN3$"@0\\,"?T!H \RO-)^*6G1":\\26%
MO&QP&DF"@G\Z]2\"0:Q;^&(5UV[CNKTNS>;&V592?EP?I7A.GR2?$_4]/TIS
M=6^FZ39'SR&Y+A1DDGWKU7X+33/X(:)YFFBANI8X9&.=RAL4 >B2HLL3(XRK
M#!KQV\^$&NPW-Q;:-XIDL]'G<LUKL)V@]0#FO8)YD@@>5SA$&XFO(9OC7>27
M.+#PM=W$#AFA<'F15ZD#% 'IGAO0;;PWHEMIEKDQPK@L>K'N:UZY_P &Z]-X
ME\-VVJ3VX@>;)\L'I704 %%%% !7&:Q_R4K1?^O&?_T*.NSKB]8_Y*5HW_7C
M/_Z%'3CN*6QTU%%%:F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:^>M>_Y#U[_ -=3
M7T*:^>M>_P"0]>_]=37/B-D?2\-_Q)>AG4445RGUX4444 %(:6D- SU_X6?\
MBS-_U\M_Z"M=S7#_  L_Y%F?_KY;_P!!6NXKOI_ C\ZS3_?*GJ%.3[ZTVG)]
M]:MG MRY1116)N%%%% !1110 4444 %%%% "-]TXKS.YT?X@>3K&S4X5,KC[
M$2X^0<YSS]*]-KA/B];7US\/;S^SQ(98W61A&3G8.3C% ' WFE?%'355KOQ+
M8VZN<*9)@H8_G7K/@ZWU:V\.6L>MW"7%]@EY$.0W/&*\&M=WQ3U262X:ZM-)
MTBP(R&_C )R3]:]@^$MQ=7'@"R^TNT@0ND;L>64,0#0!V5U;QW=I-;2C,<J%
M&'L1@UX_)\'=?CEDLK'Q9)!HDCDFU\LDA2<E<YKU^^NDL;"XNY,[((VD;'H!
MFO(I/C5J3LS6OA.[>(QF6-B?O1@XW=.E 'JFBZ3;Z'I-MIUHI$,"!5SWQWK1
MK&\,:O)KOA^SU*6(1-<1ARBG(&16S0 4444 %9^O?\B]J7_7K)_Z":T*S]>_
MY%[4O^O63_T$T 97A;_D6;'_ *Y"M>LCPO\ \BS8_P#7(5KULC![A1110(**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *X'XM?\BK'_P!=U_D:[ZN!^+7_ "*L?_7=?Y&F=6"_
MCQ/#Q2T@I:#Z_H%%%% !1110!I>'_P#D/V/_ %U%?3?85\R>'_\ D/V/_745
M]-]A2/ SCXHA1110>*68/NU+44'W:EK*6YO'8****0PHHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *P/&*6<OA34(KZ\DL[9X65YX_O(".HK?JEJFEVFL
M:=-87L?F6\R[77.,B@#P?44\#W^@Z=I9\;WT?V,M^]7=N?..O'M65!H'@<7,
M17Q_J;,&&!D\G/\ NUUGC?P_X!\$?9?M7AVXN?M!('DL3C'KS7)0>(OAK]LB
MC7PI?K(S#;EO?TS0!])V*HNGVZQN701*%8]6&.M<1\5]4O-,\/VWV".(W,]R
ML222*"(R>AYZ5V]D4:PMS&I6,Q+M4]0,# KS7XD:KX2U^U;0[_Q)]@F@D#/L
M0D@_E0!1T_PQ\3EO+>:Y\10/"'#2( .1W%>OCI7S_H]KH$.H6B0?$J_F*R*%
MB;<=WM]VOH!>E "UF7?AW1[^Y^T76G6\TW]]T!)K3HH KO8VLEH;1[>)K<C'
MEE1MQ]*BL=)L-,1DL;2&W5NOEJ!FKM% &=_86EB^^V_8+?[3_P ]?+&:T,4M
M'>@#A]&_Y'_Q)_VQ_P#0!755RFC?\C_XD_[8_P#H KJZUCL8SW"BBBF2%%%%
M !1110 4444 %%%% !1110 4444 %%%% !6#XK_Y!J_[XK>K!\5_\@U?]\5Q
MYA_N\CIP?\:)QE%%%?$GTX4444AA1113$(>E=7X0_P!7<?45RAZ5U?A#_5W'
MU']:]'*O]Y1QX_\ @LZ>BBBOL3YL**** $/2N"U;_D*3_P"\:[X]*X'5O^0I
M/_O&O-S+X$!2HHHKQA!1110 4444 /B_UT?^\*]&3[B_2O.8O]='_O"O14^X
MOTKULL^T,?1117J@%%%% $D/^L%615:'_6"K(Z5G+<UAL+1114EA1110 444
M4 %%%% !1110 4444 %%(31F@!:2HY)DB4M(X51R237.W_C6PLY#&BM*1P=M
M5&+ELB)U(05Y,Z:BN4LO'>G7,OERJ\&>A89!_*I=4\8V5DI$1$K]O2G[.5[6
M(^L4[7N=+2CI7G#_ !"N_,^2VC^AS5ZQ^(<3G;>6NS_:C/ JG1FE>QFL92;M
M<[FEJE8:G:ZE );6577N >15P<UDU8Z4TU="T444#"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K)\2ZS#X?\.WVJW"[H[>/<5QUSP!^9%:M87C'1T\0
M>$M1TN241+<18#DX (((_4"@#Q:UD^)5];R:_I5G:VMG-F001HB[DZ\]SQ7K
M'PX\0Q^(_"4%XMK':RJS1S0QIM4..#Q]:\JL_$7Q+T32%\.0Z'%.J+Y4=X.?
MEZ9!SC&*]-^%^AR:#X12"XGCFNI96EF9&# ,3DCCTH Z?4+FR=&L)[J".6="
M%C>0!F^@SDUXY>:'-I>CZ6NC>*=#?4-/:5%/VI &C;;P<GJ,&NC\?Z]HNA^)
M[&ZOM#O[Z[BC)CEMT)"@XZUY;_:WPWD$DW_")ZHR@G>P)PI]^: /=?AUI;:/
MX1MK9[R&[D)+O+"X=,GL".*ZVN3^'4^EW/@ZTET:UDMK)L[(Y#DBNLH ****
M "N,UC_DI6C?]>,__H4==G7&:Q_R4K1?^O&?_P!"CIQW%+8Z6BBBM3 ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** $-?/6O?\AZ]_ZZFOH4U\]:]_R'KW_KJ:Y\1LCZ7A
MO^)+T,ZBBBN4^O"BBB@ I#2TAH&>P?"S_D69_P#KY;_T%:[BN'^%G_(LS_\
M7RW_ *"M=Q7?3^!'YUFG^^5/4*<GWUIM.3[ZU;.!;ERBBBL3<**** "BBB@
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M>370Z;+)/I=I++_K'A1G^I4$UY+\5]<\8Z;JUG%I<#?83,ACDC8@LW]TX[4
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M?D]/X?UKVC%&V@#SG08=8U_QY;:[J&E2Z=;V-J88TF*EG=@03P3QR*[;7O\
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M,@&@!U%1>>N<;3UQTI[OL7)!H =13$D#YP"/J*1Y@IQAORH DHI-V5R,TP3
MMMVM^5 $E8?BP?\ $CE^H_G6T[[!DAC]*PO%+[]"F(!'(ZCWJH?$BH[GGE%%
M%=QU!1110 4444 2V_\ Q]0_[Z_SKUJ+B%/]T?RKR2W/^E1>SC^=>LV\@>)
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MNO\ (UWU<#\6O^15C_Z[K_(UJ=6"_CQ/#Q2T@I:#Z_H%%%% !1110!I>'_\
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M'Z5XW_PE_P 1XM%_X1I?"\AFV&W^T_9WV;3QG/3\:]8^'WA^7PWX/LK&Y/\
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M%+2"EH/K^@4444 %%%% &EX?_P"0_8_]=17TWV%?,GA__D/V/_745]-]A2/
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MH FAGFMW5HY74CIAC7KOAZ^>_P!%@FD.7QAC[UXXVXMG=CU%:^G>(K[2HS'
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M TC31X3^)NGZ7933&SO[-F>.20L Z@G(SZ\5W^O?\B]J7_7K)_Z": ,OPO\
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M=J6JUHX=#@$<]ZLUE+<WCL%%%%(84444 %%%% !1110 4444 %%%% !1110
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MWTKV#P[')%X;TR.7_6+:Q!O^^16'_P *V\-_VM_:/V,^9YGF[,_)O]<5UJC
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MZF+T&.&*_(0&I(Q*#\[ CV%244BB)UEW9C90/<5B^*<_V8FXC.\5OU@^*_\
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MKG,3D/%W_'S!]#7.=JZ/Q=_Q]0?0USE?%YC_ +Q(^FP7\"(M%%%<)UA1110
M5M^%O^0J?]P_TK$K;\+?\A4_[A_I77@/]XB<V+_A,[:BBBOMT?+B&OGK7O\
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M (KG_CWD_P!TUYV_WV_WC7HES_Q[2?[IKSI_OM_O&O)S+= )1117E""BBB@
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MTJM#_K*LCI6<MS6&PM%%%26%%%% !1110 4444 %%%% !1110 4444 %%%%
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M<Y70^*WW7,/!& >M<\.E?%YC_O$CZ;!?P(BT445PG6%%%% !6WX6_P"0J?\
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M;BW)'/\ C7M]&* /G73/!/Q3T?4;R_LIH8[B[.9F#?>->U^$(];B\.6Z>()
M^HC/F$'KS_A6_BDQ0!0UFT:]T:]MH@/-E@=%..Y4@5XC9W?CS2?"[^%AX2\Y
M\-$MT(CL()ZGC^M=WXQ\!ZSK^K-?V?B:33H F#$J\#'>O*)Q;V^J?8'^(\QD
M#["PC)4'ZT >[>!-(N]#\'Z?87K9N(H_G ['T_"NEK'\,VKV?A^SA>^^VLL8
M_P!(_O\ '6MB@ HHHH *S]>_Y%[4O^O63_T$UH5GZ]_R+VI?]>LG_H)H RO"
MW_(LV/\ UR%:]9'A?_D6K'_KD*UZV1@PHHHH$%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% $5S_Q[R?[IKSI_OM_O&O1;C_CWD_W3
M7G;_ 'V_WC7DYEN@&T445Y0@HHHH *0TM(:.H'?:1_R"X/\ =J]5'2/^07!_
MNU>KZ>C_  X^@PK@?BU_R*L?_7=?Y&N^K@?BU_R*L?\ UW7^1K4ZL%_'B>'B
MEI!2T'U_0**** "BBB@#2\/_ /(?L?\ KJ*^F^PKYD\/_P#(?L?^NHKZ;[4C
MP,X^*(4444'BEF#[M2U%!]VI:REN;QV"BBBD,**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 2O(->^#VJ:GKFI7]GXB^R0WQ_>1!3R..#Q[
M5[!7.^+_ !99^#])^WWD<DH+;$CC&69O04 >?Z-\)/$>CS6JQ>+I/LL#@^2J
M\$>G2O81TKRJQ^,[7M[!;CP?KD?FN%$C0_*,]S7JHZ4 +1110 4444 %'>BC
MO0!PVC?\C_XD_P"V/_H KJZY31O^1_\ $G_;'_T 5U=:QV,9[A1113)"D/2E
MI#TIH4MCR+5/^0I<_P"^:J5;U3_D*7/^^:J5]'3^!'QM;^(_4****HS"BBB@
M J>Q_P"0C;?]=5_G4%3V/_(1MO\ KJO\ZF?PLNG\:/8$^XOTIU-3[B_2G5\X
MS[..R"BBBD,*P?%?_(-7_?%;U8/BO_D&K_OBN/,/]WD=.#_C1.,HHHKXD^H"
MBBB@ HHHH 0]*ZOPA_J[CZC^M<H>E=7X0_U=Q]1_6O1RK_>4<6/_ (+.GHHH
MK[$^;"BBB@!#TK@M6_Y"D_\ O&N]/2N"U;_D*3_[QKS<R^! 4J***\804444
M %%%% #XO]='_O"O14^XOTKSJ+_71_[PKT5/N+]*];+/M#'T445ZH!1110!)
M#]^K(Z56A^_5D=*SEN:PV%HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@
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M@#U3X<6]W:^!=+BO0PF$0.&Z@=A^5=969H=_)J6D6]W+:O:.Z@F!Q@I[5I4
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M.,^U!XI:M_NFIJK6C[D/RD<]ZLUD]S>.P4444AA1110 4444 %%%% !1110
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M#Q2Q;_=-35#;_=J:LGN;QV"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH :W>O.-;\3SWVE7;77A.>Z%K>>7'$PR7 Y#BO1V!P<>E>
M#^-+?X@^'7-U_P )$/)NKOR[>)2>-S<#KV%  DUGJ?BJVU.X\ WD=P9%!D)^
M4=LD5[T.E> ZE'\1/"TVFWFJZ\LEI+.B2!')(S7OPZ4 %%%% !1110 4=Z*.
M] '#:-_R/_B3_MC_ .@"NKKE-&_Y'_Q)_P!L?_0!75UK'8QGN%%%%,D*0]*6
MD/2FA2V/(M4_Y"ES_OFJE6]4_P"0I<_[YJI7T=/X$?&UOXC]0HHHJC,****
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ML?\ )2M&_P"O&?\ ]"CIQW%+8Z:BBBM3 **** "BBB@ HHHH **** "BBB@
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M.3[ZTVG)]]:MG MRY1116)N%%%% !1110 4444 %%%% !1110 4444 %%%%
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MO_7-_P":UVE<EJUG<R^.M)N4A=H8T<.X' SMKK :N6R,J?Q2%HHHJ#4****
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MH$%%%% !1110 4444 %%%% !1110!YAXB_Y&"\_W_P"@K,K3\1?\C!>_[_\
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MW10!S6C?\C_XD_[8_P#H KJZXV9=7T7QAJU[#HT][;W8C*-$ZC&% .<FK?\
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M?]"O??\ ?V/_ !K2Z,N5G22?ZIOI7C]W_P ?DW^^:[M_$6L%"/\ A%[[D?\
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MK"QJI\+WO Q_K8_\:PK3C+8SJ*^QU-%<Q_PD>L?]"O??]_8_\:7_ (236/\
MH5K[_O['_C6-S+ED5O%W_'S!_NFN<K0UNZUW4YHWC\-7BA1CF6/_ !K*^R^(
M?^A=N?\ OXG^-?+8[!UJE>4HK0]["XBG"DHR9-14/V7Q#_T+MS_W\3_&C[+X
MA_Z%VY_[^)_C7']0K_RG1]:I=R;\:*A^R^(?^A=N?^_B?XT?9?$/_0NW/_?Q
M/\:/J%?^4/K5'N2UN>%O^0J?]P_TKGOLOB'_ *%VY_[^)_C6AH\VO:=>><_A
MN[8;<8$B?XUTX/!5H5HRDM#'$XBG*DTGJ>CT5S'_  D>L?\ 0K7P_P"VL?\
MC1_PD>L?]"O??]_8_P#&OK.9'S_*SIC7SUKW_(>O?^NIKU__ (2/6/\ H5[[
M_O['_C7F&I>&/%%YJ5Q<IH,X61RP!D3_ !K"MJM#W<CKTZ%23J.QSU%:W_"'
M^*O^@%-_W\3_ !H_X0_Q5_T IO\ OXG^-<_)+L?3?VGA?YC)HK6_X0_Q5_T
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M_P#?5']NZ;_S]Q_]]5Y7_9/B3_H7[C_OXG^-']D^)/\ H7[C_OXG^-'LL/\
MS![?%_R'K$.K6-Q*L<5RC.>@!J[7E&D6WB'3]3ANI/#MTRH<D"1/\:[#_A(]
M8_Z%:^_[^Q_XUS55"+]QW.W#NK.-ZBL=/17,?\)'K'_0KWW_ ']C_P :/^$C
MUC_H5[[_ +^Q_P"-971T<K.7\1?\C!>?[_\ 05F5=U2#Q#?:G/<IX<N@LC9
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M:Y'P+XZL_&^G37-O$\$D+[7B?J!V-5[#XC66H_$"3PK!;R%XU?-QQM)49(%
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M]!0!W&10*Y'QUXYM/!&GPW-Q \[2MA8TZX[FNBTB_75-)MKY%*K/&'"GJ,T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;P[IYU]-:\L_;$B\H-G@+Q_A6M0 M%%% !1110 4444 %%%% !1110 4444
M%%%% !1124 %>9>.Y7.L&,N2!&,)G@#G^?\ 2O3:\W\>HHU17 RS1J&^@SBM
MJ'QG)C?X3.-CD.2-HP.E-\]3)M YI^W!R#@8Z4FR-&)&,XR:] \(GW*(\ 9:
ME41;<OR:SY[Z.(;<_,>@J&._(D_>!@OHU 7-#< VQ0<4]0I!S1&\,L>Y<TF.
M,YYH&(.>F3[4AC9V$0B+.YP% YI<,?N?>%=+X'2&37B]Q@R!,QY]:B<N57+I
M0YYJ)V7@_29=)T01S<22N9&7TR ,?I6[))'& 9&"@^IIPZ5B>*;*&\TAS+*(
MC'\RL>F:\UN[NSZ&$5"*2.8\5ZM//>RV(<>0I' &2>AKELMN8  X/'UIY?<6
M+,,CC/K4;+-YZ&,@ ]<55B6*C+O8,K%L>M*,@%NYZ<<BE+CS'C:3#'TIH*E
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MAC6"%(DX1%"C\*D% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&O%=6MSX/T&#5K<,-/U?3O)NE X67:0K?CA17K/@#_D1M)_ZX+0!TF*6BB@
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M<TN#D,?Y5R7@RR']H7!GMF#*HVEUZ=:[L5++BAU%%%(H**** "BBB@ HHHH
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MS.0<_I5;P9<CQ9XIUKQ2OS6J*;2T;L5&<D?D* +ND^/M9UU)IM.\*-+;13M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\"I<W9!F<9RV*74='LM4>W>[@$C6\@DB)_A8=ZT:* .>UGP;HNO72W-[:9G
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M:S#:(E](,/*,Y:M@4M% !1110 TC-9]CHMCI][=7=O"%N+IMTLG=C_DUI44
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*H_M#QY_T"=+_P"^V_\ BJ .RHKC?[0\>?\ 0)TO_OMO_BJ/[0\>?] G2_\
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M#LJ*XW^T/'G_ $"=+_[[;_XJC^T/'G_0)TO_ +[;_P"*H [*BN-_M#QY_P!
MG2_^^V_^*H_M#QY_T"=+_P"^V_\ BJ .RHKC?[0\>?\ 0)TO_OMO_BJ/[0\>
M?] G2_\ OMO_ (J@#LJ*XW^T/'G_ $"=+_[[;_XJC^T/'G_0)TO_ +[;_P"*
MH [*BN-_M#QY_P! G2_^^V_^*H_M#QY_T"=+_P"^V_\ BJ .RHKC?[0\>?\
M0)TO_OMO_BJ/[0\>?] G2_\ OMO_ (J@#LJ*XW^T/'G_ $"=+_[[;_XJC^T/
M'G_0)TO_ +[;_P"*H [*BN-_M#QY_P! G2_^^V_^*H_M#QY_T"=+_P"^V_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q?@O_D9
M/%7_ %]K_P"S5VE<7X,_Y&3Q5_U]K_[-0!VE%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7%^#/\ D9/%7_7VO_LU=I7%^#/^1D\5?]?:_P#L
MU ':4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<7X,_Y&3Q5
M_P!?:_\ LU=I7%^#/^1D\5?]?:_^S4 =I1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF'!CEN45A^!-:=?*OQ-T>?6_B_JEI;'$BQ-,/HD>X_RH ^IDE1XQ(CJR$9#
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MS75J2)5*D 8.*Z6O!?A5_P E>\2_5_\ T*O>J "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?_#^Y\+:MJVJ:A<0SW5[*60QDG:I.2#D#VKI]>\,:5XEBB35+83+$VY 3T-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>M%F%T245'YR>M'G)ZT6871)14?FKZT\'(S2L%Q:***!A1110 4444 %%%%
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M^E-H0V%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MIZ?=;Z4RGK]UJ'L-#****!!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 ^+_6"K=5(?\ 6"K=9RW-8;!1114EA1110 4444 %%%%
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MM?>--4\4ZK9O9B>-88('^\%&.3^5=CX@_P"1?OO^N1K3P*S/$'_( OO^N1H
MRO!__(I:9S_RP7^5;?XUB>#_ /D4M,_ZX+_*MNMD8/</QH_&BB@0?C1^-%%
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MH .]7$^Z*I]ZN)]T5$S2 ZBBBH- HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *Y+Q?\ \ACP_P#]?7]176UR7B__ )#'A_\
MZ^OZBFMQ/8WZJ-$3J2R>>!A,>5GKUYJW5-A!_:J,6/G>7P.V.:U,!]\AEM64
M2B+)'SDXQS4R#$:Y.>!R.]5]0\DV;"<D1Y&<?6K$>/+7;]W Q0,@M8RCS$S"
M3<V< _=]J6>,M<0,)@FT\KG[U-LQ")+CRB2Q?Y_8T7 A-U;^8V'S\GO0(L2C
M,3 -C(ZGM45FGEVD:&02$#[X/6I)<&)PWW2.:AL1$+*(0G,>WY2: &0Q%=3G
MD-PK;D4>4#RO7FGWL9D2,"818D4Y)QGGI4< MQJMRR',Y1=X/IDXIU^(3%'Y
M[$ 2*1CUR,4#+=5[-#'"P,HE.XG<#[]*L=JK6"Q"!A"<KO.?KF@ EC+7\+^<
M%PI'ED\M[TZ^0R64JB419'WR>E1S"#^T82Q(FVG:/:G7XB:QF$[8B(^;'I0(
MFC^2%<N" /O>M9]A>6TM[<+'=I*6.0@/2K,T0FTQHHV*AH\*WI7%>%-.D;5V
MF$J[820<-R:VITXR@Y-['+6KSA4C!*Z9V]S&7EAQ*$VMT)^]4[\HPSCCKZ57
MNA"9;<R,0V_Y/<U.^/+;/3!S6)UD5FA2V"F028)^8'KS3$C/]I22><"#'CR\
M\CWIUEY2VRB$Y3G&?K3$$']JR$$^?Y>"/;(H$7**2N/\2Z[>6>HBWMWV*J@G
MWJHQ<G8<8W=CLUZ-3:IZ-=O>Z7%/)]]EYJY4[.PVK!111024;_5K;3BHG8Y;
MH%JS;7"74"RQG*-T-8>OZ8+VYMRK[7;Y>?SK7T^T%C9QP!MVWO7%3J5I5Y1D
MO=1TSA35)26Y:HHHKM.8**** "BBB@ HHHH **** "BBB@ HHHH **** "GK
M]UJ93U^ZU#&AE%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ?#_K!5NJD/^L%6ZSEN:PV"BBBI+"BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX?\ 6"K=5(?]8*MUG+<UAL%%%%26%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q?@S_D9/%7_7VO\
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M+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M444 %%%% !1110 4444 %//^J'UIE//^J'UI,:&4444Q!1110 4444 %%%%
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M2.%&L$)>8G9YG8$FI=2MVM-.9!,"DD:KLSSDD$FA)IZC2L2F,CP]9P]Y"O\
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MUJYUWP3:W-V=UQ&[P.Q_B*';G\<52OOB)<1>(-0T;3]"GNY[(;I'#J%Q^)H
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MBBB@ HHHH **** "BBB@ IP^ZU-IP^ZU#V&AO>BCO10(**** "BBB@ HHHH
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MOI0QK<91110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ4RGK]UJ&-;C****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q?@S_D9/%7_7VO\
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M'4445!H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-0-?6J1"5[F%8CT<N #^-9^K:A(^CW,FCW%O+>)&7C7>&!Q0!K@YI:P/!_B
M>)O#UOJ13RY6&V6/^XXZBM^@ HHHH **** "BBB@ HHHH **** "BBB@ KB_
M!G_(R>*O^OM?_9J[2N+\&?\ (R>*O^OM?_9J .THHHH **** "BBB@ HHHH
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M% !1110 =ZN)]T53[U<3[HJ)FD!U%%%0:!1110 4444 %%%% !1110 4444
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M_'FK5-1=B*H["G5ZU-<L4CSYN\FPHHHJR0HHHH **** "BBB@ HHHH ****
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M4NN^%M5N? 6@FTMB=2TN5)Q >"=K D?7BI;.WUGQ7XWL=3O](N-/L["U>/\
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MHHH **** "BBB@ HHHH *<OW6^E-IR]&^E#&MQM%%% @HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ?#_ *P5;JI#_K!5JLY;FL-A
M:**9)(L2%W.% R2:AM)798^DK'3Q-IKW'D^=@DX!/2M=6##*G(-1"K"?PNY4
MH2C\2%HS[5#=3I:6LUQ*<1Q(78^P&37*^#?B!9>,;F^MX+:2VEM6X61LET[,
M..G(K0D["C-<KK'BC5M+OI8;?PS<WD"+N\])MH/&3_":3P3XT'C.UO+A=-EL
MH[:41!G?<)#SG!P.F* .KS17$CXCZ>?'1\,"WD+!@GVG=\F\_P /3K^-=L*
M T;<TM% "8H(I:* &[:4"EHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "N+\&?\C)XJ_Z^U_\ 9J[2N+\&?\C)XJ_Z^U_]FH [2BBB@ HHHH ****
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M^]7$^Z*B9I =1114&@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^&'AN]O?MDMM*+C8J%UF=3@# Z'VJ:/X<Z EE+9F&:2"5UD99)W;)7..I]Z
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MSDWK&DBDL?08H ]P'2EI!TI: "BBB@ HHHH *S/$'_( OO\ KD:TZS/$'_(
MOO\ KD:$!D^#_P#D4M,_ZX+_ "K;K$\'_P#(I:9_UP7^5;=;&#W"BBB@0444
M4 %%%% !1110 4444 %.C^]3:=']ZA[#0VBBB@04444 %%%% !1110 4444
M%%%% !3A]UJ;3A]UJ'L-#>]%'>B@04444 %%49-6L8I&CDN$#J<$$TW^VM/_
M .?F/\ZKE9#J13U9H44R*5)HQ)&VY3T(I]24G<****!A1110 5E)_P C)+_U
MP7^9JUJ-_'I]E)</SL'3U-<"OBR[&J&\*(00%*^U=%&A.HFXG%B<53I22D>D
M9X]*Q]2\26.GY3?YLG]Q.:Q5?7/$7S(?LMJW0CC(K9TWPU96.'=/.FZEWYH]
MG"G\;N^P>VJ5?X2LN[,=GUW7B?+'V2V/3C!(K6T[PQ960#R*9YNI=^>:VP .
M  !Z"EJ95G:T=$7##13YIZL0*%&   .F*6DK)U77[;3AL!\R<]$7FLDFSJ4>
MB-"ZNH;2W:6:144#J37E-]*9[N24L3N?.3WKK[;2KW6IA=:FYC@)RL72KFKV
M%E&M@B0Q@"X53CTR*WI-0D*K)0@T0^"X98["5W4A';*Y%=13(Q&BA(P  . *
M?6,G=W'S<VH4445(!3FZ+]*;3FZ+]*.HQM%%% @HHHH **** "BBB@ HHHH
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MWQ@\V-PEEL)&62&/D?@* /9;!98].MDG_P!<L2A\?WL#/ZU8J*V,OV2'S_\
M7;%WX_O8Y_6JVJZO8Z+8R7FH7"001C)9C0!>HK(B\2Z5+H UO[4JV!7=YK=,
M50T+Q[H'B&Z:VL;O,ZKN".A4LOJ,CI0!TN:X7X@;Q?:"8P"WVGC/X5NZ=XFA
MU74YK6UMY7BB8H9^-I(ZCKG]*P_B '-]H(1MK?:>#^5-;BEL9'B(O]ACW <M
MSBLO2+R2VD9$5/G[MVK4\0AQ8Q[FSSS7-#., X->S1AS8?0^<Q$^7%W\BV]W
M/'?%W8N5;."<@U.3<ZE(SMP .3V45G1C=*H+8YZUT5Q EII9S.!O7C:/O4\3
M4=/EC%:O\#+"T_:\TIOW5T[F')'%& JMN<G\,4DL?EG!(8X&*6&%O-4L/<YJ
M)^9#@Y /%.G)RM'FO;J:1<:3E-PT>B78VK3R[>WQ<# QE<YY_I5>X<A5D<AF
M;H >%%2PS+<VV^ZD 2(81!U)JC,4,:D-\V?N^E>7+"PDVK;[GT&&E*=I/9;$
MGF/.%11\HSD5);P^7<*RMG![5!!</;Q3E .4.21TJ..61,,I8;AZ5C4H3C:E
M2E9(]"+4DY21/>32/<LQ8\],^E+'<'R=K,?EZ"HRBO&LGF@YHFC\N--Q56/W
M5[FIJ1PV)C[*_J5'GI/F)H)-\IPH+'Y5S5VZD^P&/RQ&S%=KCJ,UDIYBOA8R
MWT/2K-Y.3%&CQQ(2<@@\MCUITG0I3]A$FI3JS_>,O6VKR):D>6O%4HKN0W"R
M; 63D 4VUC>YB\M6^4\8%/MRMI<ASAB."IK..)H0K>S:UV0WAI\CE'YFO>//
M-8!G1<'D%:RXU>:[C  9ASS4_P!HG-N\#-\J'GZ4VR$DE]\CA"J\$BN%\M3,
M/1%14J>%9K);L3')Y$8/\6<\5.&F^V,NQ?+VYW=S2)'<[8\S#C[W'6E"S_:R
M3(/*QTKU84XP^%6/*E.4G[SN-DCFG1TD5 /X"N<U7@FDCLI1@;XSSFK@2<%]
MTN<_=XZ5CWC3032(SABX^; Q7!CY*C^^^1UX1.I^[+D4DL&GK(@0D\G-/BMW
M:4221QD-R<YR*AMQ+=0QB,[4C]1U-:!$GG@B50@'*XJ\-!58J4EHB:TG3DXQ
MW*ES9R7)P5C0 \$=:?9VTUK;NORER<C-6%2;S6+2@J>@QTI!'/Y; R@L?NG'
M2MUA:2J>U2U,77J.'(WH#&X\H$*GF=QSBE8S[DVA-I'S9I"D_E "4;P>3BE9
M)RZ%90% ^88ZUTF-A0TWG8VIY?KSFFJ9_G+JG^S@FE"S>=N,@V?W<4BI,-^Z
M4'/W>.E  &N?)SMC\S/3G%*QN B[50G^+.:;LG\G'G#S,_>Q2LDY50LP##[Q
MQUH <3/YP&$\LCD]Z13/O8,J;?X2,\T%9O.4^8/+ Y&.M(J3;V+2 J?NC'2@
M 4W'EL2L>_/R]<4,;CRE*JF_N#G%($G\M@9AN)X.WI5674(8Y%M7OHEN.X(Z
MTF[%1IRG\*N7&,X=,*FW'S?_ %J 9O-(*IY>.#SFN>\1^(GTA8OL\J2R-U'!
MQ4GA_P 0_P!J1%KB:.*1>#'T_'-3[2-['5]0KJC[:VAN*UQ\^Y4R/NX)Y^M&
M;CR<A(_,S^%59K^&S4FYOHEW_<-6%\V2V!CG!8\AP!BJNCFE3FES-#G,X5-J
MIG^+.:7,WF@ +Y?<]Z&2?:@64 C[QV]:"DWF@^8-@ZC%,@%,^]MRIM ^4CJ:
M0-<>6V5C#YX'.*55F#ONE!4CY1CI2*EP(V!E!?L=HXH &:X\M2JQ[^XYP*5C
M-O0 )M_BZTC)<>4H68!^YQUI2DV^/$@VC[PQUH  9O-((3R^QYS2*UP0Y98P
M1]W!/ZTH283%C("G9<4U4G D#2@DCY3CI0 %KCR<[4\S/3G%.8S@)M5.3\V2
M>*;LN/)QYH\S^]BE=9B$VR 8/S?+UH 7,WG8VIY?KGFD4SEFW*FW^'K2[9O.
MR)!Y?]W%4-3U$Z3:2W,TH91PB #.:3=BZ=.522C%:LO!KGR22L>_L!G%!-P(
MU(6/?WR3BN=T?Q5'J4,B32B"9>A8<$5K'48'152_B#]SCK24T]C6KA*M*7+)
M:EXM-YBX5-G\6>M ,QE((3R^Q[U4DOX%(?[;%L4<C/6L>U\864]^T3RLD8^Z
M2O'Z<T.:04\)6J)N,=CH5:XVL66//\/6FL\Z0;V\H.#SDX&*RUUF:17%M!-<
M'^%@@ 'YXJAJ\.O:CI;Q"%$!Y(5L,WM2<[+0NEA'*:C-V.B$[RA3 T+C^(AL
MX_*I,S>=C:OE^O>N,\,Z-K=J)3YS6H[*X#9_G71?9-:_Z"2?]^A_A2C-M;&E
M?"4Z=1QC43-%#/N;>J!?X<5&LTC1L 8#*#]T-Q6;/:ZR+>0G4DP%.?W8';Z5
MPN@I<WNM"#[8Z[L[FWGFE*I9VL;X;+%5IRJ.?P]CT&\UB.T15W1O,>J)EC^E
M1&[U:]XMK=;:,]9).OX"K%OI4=HB^0$$@^](R[F/XFKA6;S%(D 4=1CK5V;W
M.+VE*GI!7?F8%SX8;4%9+ZY=V_A<'I^'2K6B:+_8MK)''M9V.=Q[UJJLWFL3
M("IZ#'2D5+@*P:4%B?E..E+DC>X3QE:5/V;>G8"USY0(6/S.XYQ2L9\IM5.G
MS<FD,<_DA?-'F9Y;'6ADGRF) ,?>XZU9S&AI)F_M11M3R\=>]=4*Y72%E_M1
M6\P>7C[N*ZH5E/<WI_"+1114%B44M)0!RGCSQ-+X<TF+[)&)+^[E6&W0_P!X
MD#/X5B2^-=>M]?\ ^$?MM*CO;R&W26:0MM&2!GN.YIWCHK'XZ\(RW./LHG<'
M=TW%&Q^N*F\2^#M+O=6O=9_MJ6QOFAQF.?;MP!C(S[4 =;HMU?W>FK-J5HMK
M<EB#$K9 &>*FN=5T^S9EN;VWA91DK)*JD#Z$UR?POUC4-8\*L^HN9G@GDA2X
M(QYJJQ /Y"N>U/1;+6OC3<1WT0EB33PPC;[I.!U% 'I#ZYI,<<;OJ5HJR_<)
MF7YOIS5B>^M+6W\^XN88H?[[N #^->':'X4TN\T+Q>]Q$TGV25X[8,Q/D@$_
M=]/PJUOBU)? ]CK4A.F2QN7\QB%D<;=H8_XT >QV^J6%Z56UOK>9F&0L<H8D
M?05P/BKXB7>G7>KVNFV\;C3H4:25NSL>GY8K!LX]#T#XP7+Z7*BVL.G&654;
M*(PW9QVZ 57O-/<?";7];E'^DZI<>=D]0H8*!_X[G\: /6='UF&YTC3Y[NX@
MCN+F)7"%P"Q([ U9FUG3(;C[/+J%K'-_SS:90?RS7BOPV,5QJ$I\1ESK4-OF
MPCF'[O9LX*#IFIM%TKPUJ?@K7-1UF9/[6$L_FR2R8DC(9@H'?ICI0!WWB+Q1
M-H>M:3<B:*71;MO)E=2"$<]#D=N/UKM%P1D5X7J+Q?\ "B-+0\RO+&(O7=FO
M:=*65-)M5FSYHB4/GUQ0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MXOP9_P C)XJ_Z^U_]FKM*XOP9_R,GBK_ *^U_P#9J .THHHH **** "BBB@
MHHHH **** "BBB@ KG/&'A1/%VDKI\E_<V2A]_F6S8;Z5T=(: / ?$_PU\-^
M$K59M5\;ZW&7^X@<%F_"F^ -!\*:EXBM9M.\8:Q+=6[^8MM<-@28_"M'QV^E
M6WQ@M9_%2$Z2;8"!G!,8;C.?UK-U:X\+W_Q#\._\(4$:\6?,DENI5-ON.* /
MH(=**0=*6@ HHHH **** "LSQ!_R +[_ *Y&M.LSQ!_R +[_ *Y&A 9/@_\
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M<P[#0I[.[69[V20 'Y2:W***ER<M6"26P4444AA3FZ+]*;3FZ+]*.HQM%%%
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MFKE1NBNI5@"K<$'O0!\NP>.+&R^%E_X=4SIJ+W+.I48&/K^%>A^%_C+X>LM
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M[Y(1_P M)?\  9->B 4"EH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/<****!!1110 4444 %%%% !1110 4Z/[U-IT?WJ'L-#:***!!1110 4444
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MNB_2CJ,;1110(**** "BBB@ HHI,T +249K*U#6X;4F.'][-T 'K43J1@KR
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M=;:Y _B1B./YUZ@AW*#ZB@!]%%% !1110 4444 %%%% !1110 4444 %%%%
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M'4G<!TKD_'?A)KFW6ZTR%5*DF1%&-WO7<2F<7L01082IW''0TZ\,HM9#  9
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M%% !1110 ?C24M% !1110 4]?NM]*93U^ZU#V&MR/'K2T44(5PHHHH ****
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M5','5?$#GY-,*?[PIINO%,G2")/JM=311SKL',NQRWE^)W'+QK]#0=/\2/\
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MY<],4^GG_5#ZT@1!(KM]QMM*@=5^=MQI]%,1#Y<V[/F#'IBI&#%<*<'UIU%
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MVN^&M-\16L=OJ$)=8V#HRL592/0CFG7OAZQU"33Y+F-G>PE66 [CPPQCZ]*
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MVAQ:7J\\DB6DC?9I()GC8(2< XQT&!6YH7@[2/#WGM8VY\V?_622.79OQ/-
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M!#EZ-]*;3EZ-]*;0AA1110(**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *>OW6IE/7[K4,:W&4444""BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@!\/^L%6ZJ0_ZP5;K.6YK#8****DL**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KB_!G_(R>*O^OM?_ &:NTKB_!G_(R>*O^OM?_9J .THHHH ****
M"BBB@ HHHH **** "BBB@ KD?B?_ ,DVUO\ ZXC_ -"6NNJM>V<&H6DEK=1"
M6"08=&Z$4 >"^%_!7C^\\-V-QI_B4P6KQ*T<>X_*,=.M=/HG@GX@66MV=S?^
M)3/:QR!I8MQ^8>G6O4[2S@L+6.VMHECAC&$11P!5CM0 HZ4444 %%%% !111
M0 5F>(/^0!??]<C6G69X@_Y %]_UR-" R?!__(I:9_UP7^5;=8GA#_D4=,_Z
MX+_*MH]*V,'W(9[RVML>?,D>>FXXJ19$= RL"IZ$5Y3K,\TVJS^<Q+!^F>E0
MKJ<T%OY<EZ88,_Q-@5VSPL84^>4CR89A.=5TXQN>H7FL6%CQ/<HK?W<\UB7/
MC2W!V6L#S.>!GBN4L]2\/(P,\J7$G7F<8/X8KH+'Q1HL9V6MM"&[!9 3_*N+
MZSA8]V=OL<7/=60IN/$^I'Y(C;QMTR,4Z+PA<W,@DU&]9C_='^-:@\1KC'V2
M0?C_ /6H_P"$GMN\3@T/,(6M'3Y"6#BG>;;);;PQI=K@BW#D=WYK5CABA7;&
M@0>PK('B:SSRKC\*</$ECWWC\*S>+C+>1M&G&/PHV1161_PD5A_?8?A3QK^G
MG_EJ?RI>WI]RS4IR??K,&MV!_P"6ZCZU+'K-AN_X^8Q]31[:#6XUN7**J#5+
M$\_:X?IO%.^WVF,BXC/'9J?M8=Q%FBN>D\41),52 M&#UW5IQZM9/&LAN(TW
M#H6&:B&)I2=DP+U%9[:S8+_R\H?H:B/B#3Q_RU)_"J=>FNH&K16,?$ED.FX_
MA67JOB!KE%2U+(I^\3UK.IBZ<5>X'69I:XC3M9GM;@&1V>,]16ZOB6R/9Q^%
M32QD)J[T VJ*RE\0Z>>KL/PJ1=;L&Z3J/K6WMZ?<#1IP^ZU4%U2Q;_EZBS_O
M"K*74#JVV9#GT:J]I!]1HD[T4@8'D$4M5S)B"BBBG= %%-=TC0N[!5'4FHH+
MRWN21#,CD==II.44[7 GHR*1F5%W,0 *HS:S8PYS.K'T4YJ74C'=@7Z*PV\2
M0,=MO!)*WH*B:ZUNZ/[FW$*'^\.:R>)AM'4#H:K3WUM;\2SHI]":Q_[)U.X_
MX^+TJ.X'-68O#MF@S(7D;ON-3[6K+X8_>!#?>(;=8)$MV8R$8! XKEQ<S";S
M1(V_.=V:[1[6UM1M2S+AO[BYK+&F0"],OV*X,6.%*]_RKBQ%.K.2NP'0VFK7
M\:M)=>6C#M5N'P[;+\T[/*WJ3BM&VE\Q=HADC"] XQ5BNVGAX63>H%6&PM;?
M'EP*#ZXJSTZ4M%="A&.R ****H!,>U'X4M%*R 3%+113LD 4444 %.?HOTIM
M.?HOTI=1]!M%%%,04444 %%%':@ HK/U#6M-TM<WMY##Z!W )KE[[XHZ%;9$
M!EN6]%&,T&T:%26R.XHR.YKS:;Q7XNUG:=%T5K:%O^6DZDY^AXJ/_A$_&6KM
MG4M:%O&>JH,_UH-EA>7^))([C4?$>D:5D7E_#$W]PMR:YB\^*>D0MMM(IKE\
MX 48!/UJ:Q^&.B6^U[KS[J7^(R/QG\JZ2ST+3-.'^B6,,9'<+R:!KZM#NSQ/
MQSJFK:U/;WM]ITME;8VPANC>^:E^&4%_)XMA>S)$:*?-/;&._P".*]4U7[=J
M$$MI)X?CFC((1FN!^!Z5'H%MJ.A6*P0>'8PW\4BW &?TI-Z'>L6O8."C8;+9
M_$0S.8=8TI8RQV V>2!_WU3?L/Q)_P"@UI/_ (!?_95VT+.\*M(FQR,E<YQ4
ME9'EG&36/BJ3PSJL&JWMK<7$L!6#[/#Y>#@^YKY^>WF2Y:!XV\T/MVXYS7UF
MPS5 Z-IQNOM+641F_O[>:I2L=N%Q?L$U:]RCX.M[FT\(Z;!=@B=(OGSUZFN
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MVE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2@#M!2T@ZTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+>RRB6=9'4 L;>3!Z_[-.NO'WAN94#S3L%<,,6\G!!_W:+H+,[ ]*KV2*D#
M2>9\Q.<^_2N=_P"%A^'<$?:9O_ :3_XFHK;Q_P"&XHR$FF4%B<&WD_\ B:+H
M5F=++&IU"%_-((4@)G[U.OD$EE*C2>6"/O9Z5R[^/O#37<<AFG+*,!OL\F!_
MX[2W/C[PW-;NC33.K#E1;R<_^.T7'9G60C$*#=NP.OK4%M&%NKAA-O+-DKG[
MM<['\0?#JQJHGF  QC[/)Q_X[4</C[PTDTKK-.K.>2;>3G_QVBZ"S.HND#R0
M$R[-K9 _O>U3.,HPSCCKZ5R,_C[PV[Q$S3L5;((MY./_ !VI6^(7ATJP^T3'
M(_Y]I/\ XFBZ"S.DLT"6ZJ)-X&?F_&F1QJ-3DD\XD^7@QYZ<]:YJW\?^&XH5
M59YE49X-O)_\335\?>&A>M+YTX<IC=]GDP1_WS1=!9G945RO_"P_#O\ S\S?
M^ TG_P 31_PL/P[_ ,_,W_@-)_\ $T70N5G6+T:FURP^(GAT _Z3-_X#2?\
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M_/S-_P" TG_Q-%T'*SJJ*Y7_ (6'X=_Y^9O_  &D_P#B:/\ A8?AW_GYF_\
M :3_ .)HN@Y6=517*_\ "P_#O_/S-_X#2?\ Q-'_  L/P[_S\S?^ TG_ ,31
M=!RLZJBN5_X6'X=_Y^9O_ :3_P")H_X6'X=_Y^9O_ :3_P")HN@Y6=53U^ZU
M<E_PL/P[_P _,W_@-)_\32CXB>'0#_I,W3_GVD_^)H;0TF=317*_\+#\._\
M/S-_X#2?_$T?\+#\._\ /S-_X#2?_$T70N5G545RO_"P_#O_ #\S?^ TG_Q-
M'_"P_#O_ #\S?^ TG_Q-%T'*SJJ*Y7_A8?AW_GYF_P# :3_XFC_A8?AW_GYF
M_P# :3_XFBZ#E9U5%<K_ ,+#\._\_,W_ (#2?_$T?\+#\._\_,W_ (#2?_$T
M70<K.JHKE?\ A8?AW_GYF_\  :3_ .)H_P"%A^'?^?F;_P !I/\ XFBZ#E9U
M5%<K_P +#\._\_,W_@-)_P#$T?\ "P_#O_/S-_X#2?\ Q-%T'*SJJ*Y7_A8?
MAW_GYF_\!I/_ (FC_A8?AW_GYF_\!I/_ (FBZ#E9U5%<K_PL/P[_ ,_,W_@-
M)_\ $T?\+#\._P#/S-_X#2?_ !-%T'*SJJ*Y7_A8?AW_ )^9O_ :3_XFC_A8
M?AW_ )^9O_ :3_XFBZ#E9U5%<K_PL/P[_P _,W_@-)_\31_PL/P[_P _,W_@
M-)_\31=!RLZJBN5_X6'X=_Y^9O\ P&D_^)H_X6'X=_Y^9O\ P&D_^)HN@Y6=
M;%_K!5NN6T?QAH^K7ZVMI-(TK#(#0NOZD5U J);FL%H+1114E!1110 4444
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MQD*DKJ%SGO\ A//$D9S-X:;;_L@G^M'_  LC4X^)O#=WG_8C8UT/_"P?"_\
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MB^@AE_PIW0O8T/YF>P"Y@/2>(Y]'%/\ ,3^^OYUXR=,\* _+XTU%1V AD_\
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M_P#B:ZVTGCN;6.>)MT;J&4XQD&ID7!$]%%%0:!1110 4444 %)BEHH ****
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M@DAD7<C+T(KCY)-7_P"$J$P@;V3/\'^<T =>\%K&NYXH@/4J*<+:W(R(8_\
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M %93DOGT]:;X=\6Z1XHBDDTRX+F(XD1AAE^HH V/LMO_ ,\(_P#OD4?9;?\
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M^Q65XB\8Z3X8DC34'E#2C*K&FXX%/TCQ;HNN:5-J5C>*]M!GS2>#'@9.?PH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 ,DR$)'7%>4^$=-L=2TGQ?/?1H\]Q=RQ3[NNP#@?J:]8(
MS7FNM_#34;G5+^;1->.GVFI?\?<'EEMW7)!R,=: -'X2RO)X LMY)VLRKD]@
M:Z-_^1FB_P"N'^-3:'H]MH.CV^FV@(AA7:">I]ZD:S+:JEYOX6/9MQ]?\: (
M==_Y!,G^\O\ Z$*O0?\ 'O%_N#^50W]J;VT: -MR0<XST.:GC79&JYSM % &
M?I7^OOO^NM&H?\A&Q_WZL6EH;:2=B^[S7W=.E%Q:&>Y@EWX\HYQCK0!-=?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*&7Z&O.IOA]X@UBZ2+Q#XG^V:6DF\6\<)0MCIDEC_*O1H(D@A6*,81!A1[4
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MZ"IZBD194:-U#(PP0>XH ^;_ !!XDTKQ-#J&NWVIVPN1.L5E:E_F2(-RV/?
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MJ-SJUA93V\-S=PQ2W!VQ([@%SZ#UKS?0?$FJW/QJU31YKMFL8HR4B.,#Y<T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MMA/>VVIVTD, S(PD&%^OI7->%?BII7B76KRP!CMA$_EPF249F/JM 'H-%%%
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M^%UN-'^+'B+2K8E+11\L0)P,9KW2N6TGP/IVD>*KWQ!!)(;J['[P-T'TKJ:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HC:V[3"8P1F4='*C/
MYU+10 4444 %&!110 4444 %%%% !1110 4444 %%%% !1110 8'I1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% "'I52TTZULKBXF@B"27#;I2/XCZ_
MK5RB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 1E5E*LH*D8((ZU'#;P6X(AACC!.2$4"I:* "BBB@
MHHHH **** "C ]*** "BBB@ IJQHK%E10QZD#K3J* "C ]*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>gvvh0m1pmdf2000009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" .K!YX# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!16-IOC7PUK%X+/3=;LKJY(R(HI037@'Q$\8^*?&6NW&@65G<6UO;DAH%'+
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MSZ8KQ;X(?$"]CU9?#>HS-);RJ3 SGE".WX\5ROQ4TP^'?BA)<1KLAEE2>/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M $KO]0_Y!EU_UQ?^1K"\ Z&_ASP9I^FR@":.(&4#^]CFMS4#_P 2VZ_ZXO\
MR- 'R+X%T*V\0_$N&PNQF'S6D9?[P!Z5W?Q]\-Z1HUGI-SIUA!:R,_E'R4"@
MC!/('?WKF?A'_P E=C^DG]*[S]I _P#$GT@>MP?_ $%J %^!O@O1=1\'RZMJ
M%C#=33S/%^^0,%"^F>G6O,]-M8]*^,L5K:9CCBO2$QV!'_UZ]N^ 7_),(O\
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MQI$(QUEDQSD>@YKHOVB#GQ=:?]>R_P S7,>*/"%YX2@T;Q!IK.+>>))!(O\
MRS? R/QYH ^A? '@:S\ ^'&9PKWS1[[F7Z#.![5\\3)>?$;XIM:SS'%Q=-$&
MSD(BD@?H*^@/A[XU@\>>$WAEE5-16(Q3IWR1C</;_"OGC2[^3P1\4/M5Y$P6
MUO'+KZID\_R- 'JWC;X*:)IOA&XOM$$\=Y:(9&9I"P=0,G]!7+_LZ'/CG4._
M^@G_ -#6O0/'GQ5\/-X)NH].O!<7%["8DC"G(##!)].M>?\ [.G_ ".^H?\
M7B?_ $-: /IG%?,/[0<DK^,[9'4A$@PAKZ?[UX7^T%X7N+ZWLM=M8C(+<&*5
M5'(!R=QH ]%^%T$4'PUT'RE WVB.V/[Q'-=3<*K6TH;&TH0?IBO"_@[\4=-L
M]%B\/:Q-Y$D!Q#*WW67T]L8_6NP\;_%C0=%T2Y2SO([J]D0K$D9R.>Y/2@#P
M72D2Q^,EK#:-^Z75512O3;O%>D_M&Z0##I>KJO()@8C\6KC_ (,^&[KQ!XX3
M5)T8V]H?->0CJ_4?J*]T^*VCC6/A]J,:INFB3S(N.X(S^F: /-(?%1_X9R;]
MX/-5OL6W/.W&*Q? _A;[?\'/$UTT>9Y"# <=AMS_ "->:#6[@>'7T?\ Y8-+
MYH^M?5OP^T06?PLM+!T^>6V?=D==V<?S% 'E_P "O$:Z;HGB"&:0;;:(3Q@G
MT#$_R%8OP?TUO$'Q2FU-_F%JSW!XX.25_K7$FZN?">LZQI\9(W)+:2+]>*]L
M_9VT<P:-J.JR+AIY/+0XZK@'^8H ]M^E.I .*6@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I#CUH/TKCOBG?W6E
M_#C5[VRG>"XB1"DB]1EU% '7Y'K3NU?(GA_7/B/XCDE_L?5+R=X<%\.HQ^=;
M&E_%GQIX5UH6WB"26Y16Q+'<#YL>HQB@#Z:O=0M-/B\V[N(X8R<;G.!2V=_:
MW\1EM)TFC!P60Y&:\<^-6KQ:O\,M/U*S=ECN)8W7!Y (SBM/X"2_\4+,TC]+
M@C+'_9% 'K-%1))')G8ZL!UPV:?G% #J*B::-"%>5%/H6Q3E8,H((.>XH ?1
M3<\=:B^T0C $J9]-PH GHIA/J*:\J)C>RKZ$G% $M%1JZNN592/4'-/!H 6F
MDTV65(HV>1@J*,DGH!7A'Q*^-9C>72?##_.,B6[';V6@#WH$'O52^U.RTU4:
M]N8X%<X4NV,FO#/@5XHUO6_$=Y#J>I374:P%E60C@Y%7?VD7=-'T'8Y4_:)<
MD''\*T >UVEW;WUNL]M,DL3='0Y!J>O.?@I+_P 6JTUY'ZO+EF/^V:]"65'&
M596 ZD'- $E(:0&LKQ3-+;^$]7GA<I+'9RNC#J"$)!H U<CUI:^-]'^)WBBQ
MU>UN9]7N9X8Y 6B<C##WKZWT35K?7-%M=3M6S#<('7U&: -#BC(]J^9--\9>
M(I/C!%ISZM<-9F^9#$2-NWGCI71?'7Q/K6A:U8Q:9J,UJCQY81D<T >\C'8T
M9]37*?#B]N-1\!Z9=W<S332(2[MU/S&N-^.^NZGH6D:9+I=[+:L\C!C&>HXH
M ]=R,=:,C.,UY?\ "G6=1U7X;WEW?7<D]PBR8D8\C@UYG\)/&/B'5OB!:6E_
MJMQ/ T;DHY&* /IZBD[T4 +12=J8\L<;89U7ZG% $E&:C5U<94AA[&@R*HRS
M!5SU8XH DJ&XN8;6%YIY%CC499F. *<DBNN496]U.:Y#XIDK\.-996(80-@C
MMP: .FL=6L-19A9W<4Y49;8V<5=KYZ_9RE=M0UC>[$>2/O'W%?0"S1,V%=&/
M?#4 2T4W/--:1$'S.J_4XH DHIBNCC*.&'J#FC/I0 ^BF,P R3@=ZRO$.N1Z
M#X;U#6-GGI9PF4HC#+ =J -BBO+_ (8_$^\\>ZUJ=O+:16]M;0K)&!G=DMCD
MYKTW('7@4 /HJ'[1%T$J$GL&%2 T .HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:!;Z3:N9(X01O(P6R2?ZUM$48H 44444 %%%% !1110 4444 %%%% !1110
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M9!L&!'_ UJ'Q]IMS\.OBC%K=BA2SFE$R[>G7YD_+'YT 9.E?\ERA_P"P@_\
M[-74?M%#.OZ?C_GE7&>%K]-3^+NGWL8(6>\+X],@FNS_ &BO^0_I^/\ GE0!
M>\&_&S0_#OA6QTJYM;II;=2"40$'DGU]ZYKXK?$O3/'.G65O8P3QM;NS,9%Q
MG./?VKT[X=_#SPEJW@73;V^T*TGN)4)>1P<GYC[UQWQR\(Z!X<TG39-'TJWL
MWFD8,8P><8]_>@#J_@S_ ,DJO/\ <D_]!->2?!/_ )*99?\ 7-_Z5ZW\&?\
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MKKC7EW@33+VU^(OB.YN+:2.&9OD=E.&Z=* /412TE+0 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1124
M+1244 +1110 4444 %%%% !1110 44F:,T +124M !1244 +1244 +1244 +
M1244 +129I: "BBDH 6BDHSF@!:*2B@!:*2B@!:**2@!:*** "BBB@ HHHH
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M* "BBB@ HHHH ***:3B@!:,U&\BQJ69@H Y).!7/ZCXXT+3'*3WJLWI&-_\
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ML5X(W])1M_G4NG)=#2.(IRZG2TM1I(DBAD8,IY!4Y!I^:@V6HM%%% !1110
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ME>^;+1E  OXUU1K TKQ9IVL:W>Z5:ES<69_>94@4 ;XI:04M !1110 4444
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M='_Z!UO_ -\"C_A&='_Z!UO_ -\"M>BCFD'LX]C(_P"$9T?_ *!UO_WP*/\
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M_P#? H_X1G1_^@=;_P#? K7HHYI![./8R/\ A&='_P"@=;_]\"C_ (1G1_\
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MUO.;:5R8W"':#]?I2<N>++C3]G.+Z,]06G4T>U*.E8'<+1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 (:\L^+Y8C3T!X)Z>_
M->J5Y;\6N9], '.[_&M:/QG-BOX3.X\+Q"'PSIR[<'[.F?KBMFL[0@1H5B#U
M$"9_*M*LWN;4U:*"BBBD6%%%% !1129H 6BFY&:7- "T4E% "T4W/_ZJ,YH
M=124=Z %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!K?=/TKQ[PH ?B?<<?QOS_P !
M->PO]TUX]X3_ .2G7'^\_P#(UM3^%G'B?CAZGL5+116)V"4V2:.(9DD1!ZLP
M%.[USGBWP9IGC2RBM-5:Y6*)]Z^1)L.?R- &Y]NM/^?J#_OX*/MUI_S]0?\
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M\%'VZT_Y^H/^_@KS/_AG_P '?\]M6_\  H?_ !-'_#/_ (._Y[:M_P"!0_\
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M/^_@H^W6G_/U!_W\%>9_\,_^#O\ GMJW_@4/_B:/^&?_  =_SVU;_P "A_\
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M_B:/^&?_  =_SVU;_P "A_\ $T >F?;K3_GZ@_[^"C[=:?\ /U!_W\%>9_\
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M#_OX*/MUI_S]0?\ ?P5YG_PS_P"#O^>VK?\ @4/_ (FC_AG_ ,'?\]M6_P#
MH?\ Q- 'IGVZT_Y^H/\ OX*/MUI_S]0?]_!7F?\ PS_X._Y[:M_X%#_XFC_A
MG_P=_P ]M6_\"A_\30!Z9]NM/^?J#_OX*/MUI_S]0?\ ?P5YG_PS_P"#O^>V
MK?\ @4/_ (FC_AG_ ,'?\]M6_P# H?\ Q- 'IGVZT_Y^H/\ OX*/MUI_S]0?
M]_!7F?\ PS_X._Y[:M_X%#_XFC_AG_P=_P ]M6_\"A_\30!Z9]NM/^?J#_OX
M*/MUI_S]0?\ ?P5YG_PS_P"#O^>VK?\ @4/_ (FC_AG_ ,'?\]M6_P# H?\
MQ- 'IGVZT_Y^H/\ OX*/MUI_S]0?]_!7F?\ PS_X._Y[:M_X%#_XFC_AG_P=
M_P ]M6_\"A_\30!Z9]NM/^?J#_OX*/MUI_S]0?\ ?P5YG_PS_P"#O^>VK?\
M@4/_ (FC_AG_ ,'?\]M6_P# H?\ Q- 'IGVZT_Y^H/\ OX*/MUI_S]0?]_!7
MF?\ PS_X._Y[:M_X%#_XFC_AG_P=_P ]M6_\"A_\30!Z9]NM/^?J#_OX*/MU
MI_S]0_\ ?P5YG_PS_P"#O^>VK?\ @4/_ (FC_AG_ ,'8_P!=JW_@4/\ XF@#
MTHWUIC_CZ@_[^"N3T#QY'K/BK5M'>.*)+!]HF,GW^3_A6!_PH'P<!_KM5_\
M H?_ !-<KH7P2LKGQ3JUOJ45]'IL3XM'28!G&3U./I0![L+ZT_Y^H?\ OX*7
M[=:?\_4'_?P5YG_PH#P=_P ]=5_\"A_\31_PS_X._P">VK?^!0_^)H ],^W6
MG_/U!_W\%'VZT_Y^H/\ OX*\S_X9_P#!W_/;5O\ P*'_ ,31_P ,_P#@[_GM
MJW_@4/\ XF@#TS[=:?\ /U!_W\%'VZT_Y^H/^_@KS/\ X9_\'?\ /;5O_ H?
M_$T?\,_^#O\ GMJW_@4/_B: /3/MUI_S]0?]_!1]NM/^?J#_ +^"O,_^&?\
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M\30!Z9]NM/\ GZ@_[^"C[=:?\_4'_?P5YG_PS_X._P">VK?^!0_^)H_X9_\
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M  *'_P 30!Z9]NM/^?J#_OX*/MUI_P _4'_?P5YG_P ,_P#@[_GMJW_@4/\
MXFC_ (9_\'?\]M6_\"A_\30!Z9]NM/\ GZ@_[^"C[=:?\_4'_?P5YG_PS_X.
M_P">VK?^!0_^)H_X9_\ !W_/;5O_  *'_P 30!Z9]NM/^?J#_OX*/MUI_P _
M4'_?P5YG_P ,_P#@[_GMJW_@4/\ XFC_ (4!X._Y[:M_X%#_ .)H ],^W6G_
M #]0_P#?P5.#GFO+%^ ?A!6#+-JN1T_TH?\ Q->H0QB&%(ESM10HS[4 2444
M4 %%%% !1110 4444 %%%% !1110 4444 %>7?%?_C\TK_?'\S7J->7?%?\
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M>PM]TUX]X3_Y*?<?[S_R-;4]I')B?CAZGL5+24M8G6%)BEHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@!#678^'M,TW4KB_M+;R[FYYE?
M<3NK4-<5X:\97&N>+M8TB2!4CLCA6!ZT =J*6D%+0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% &1XDT.+Q)H%WI,TSPQW*%&= "1GZT_P_H\?A
M_0+/28I6F2V38'88+<D_UI=>UFVT#1KG4[S=]G@0LVT9/%.T758-=T>VU.UW
M>1<+N3<.<9Q_2@#1[4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 T_2FB1&8J&!(Z@'D4X]*\M\
M#7UU/\3_ !9!-<.\44H"(3PHRU 'J?>EI.]+0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %<G\1M)O-:\$:A86,9DN)4PJCO765%+-'!&TDLBHB\EF.
M * ,?P?8SZ9X1TNRNDV3PP!74]C6[3(W21%DC961N0RG(-/H **** "BBB@
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M=*6N ]X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!N>*\G\ PRQ_%3Q<[Q.J/*"K%2 W+5ZQ2;0>W?-
M #J6D%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %8GBK7X_#/A^ZU
M:6)I4MUW%%ZFMNN+^*=M/>?#[5(;:)Y96CP$09)_"@#H]"U1-;T2TU*.,QI<
MQB0*W49K1KG? L,EOX'T>&:-HY$ME#*PP0?<5T5 !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ'XCTUCVDKZ$3[BGVK#%?$CLRRW(V/I:04M<AZH4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 UONFO'O"?_)3[C_>?^1KV%ONFO'O"?_)3[C_>?^1K
M:GM(Y,3\</4]BI:2EK$ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@!#7,Z)XSL]<\0ZAH\%M/'-8G#N^-I^F#73=Z\I\ VMQ#\2?$
MTDD$B([95F7ANG2@#U84M(*6@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** (+N[@L;9[BYE6*%!EG;H*+:YAN[>.XMY%DA<95QT(KD_BI_R3C6?
M^O=NOT-3_#4_\6YT3K_J/_9C0!UE%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AI:2@!#7G/@[Q)JVI
M_$'Q+IEW=F6SM) L$94#:,MZ#VKT8]*XSPWX,GT3QCK6MR7(D74)-RIMQMY/
M^- ':=\4M)WI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ -1L WRL
M01WZ4\UQ_P 3K^ZTSP%J5W93RP7"1Y22,X(- '7K@  4ZN?\$W4][X*TBYNI
MGEGDMPSR.<LQ]ZZ"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.!T K/$5%-Z&^!H2I1]X=2T45SG>%%%% !1110 4444 %%%% !1110 4444
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M'C(JW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSB@'WS7RJGQP\5C5]YN8C:&8D)Y?.S/3/TKZ?TN_@U32[:^MG#PSH'1AW!H
ML23Q0D"25$STW-C-'G1^7YA=1&>CY&#7A?[0NH7MC<:3]ENI8=T;9V,1GFM7
M5KVZ7]G/3[L3R"X-M"3(&YSGUH ]@CFCER8Y%<#KM.<5)7B_[.]]=W^@ZTUW
M<23,MT@4NV<#;7M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0<]ORH =13<YY%&>,T .HI,TF: '44S/I1N]: 'TTFC.:0G]: !75L@,"1U
M-.[5XQ\+]5O[SXD^(X+F\FFACW[$=R57YAT%==\4_%D_A+PD]U8N!?2R*D(/
M?GD_AF@#N,FEKP_Q;XZ\8^&]+\-P6TUN]]J$.^4RPYR2>/IQBH]2\4_%_0+<
MWVHV=E+:QC=*(8>0HZD^E 'NE+7'_#[QM#XX\/B_6/RKB-MDT8.=K=OTYKK<
M^QH <:*;GUKFO'VL3Z%X+U&^MCMG6(A&Z$$@X- '0BZA+[/.CWY^[N&:FKQ/
MX6^"[S6-/T_Q=J&N7<LTKM*L1<E>I7!YKVK/2@!]%,R>?TH)H ?13<_I1WH
M=13,]37&7OQ CM/B+!X16S+RR(LC3%\8!]L4 =M13:,_SQ0 ZBF>QI<T .HI
MN?7\A03CD]* '4E)SC.*.U !TZT5XI\6OB7XB\&>*K:PTF2 6\ELLK"2$,2=
MQ!Y_"O1O WBN'QAX8MM2C*B8KMF5?X7'!^F3F@#I:*\QU/QOK5I\7['PW"\/
M]G30EV4QY;OW_"G_ !9\;:QX.M]/?27A5IY-KF6,-QF@#TOGUI3TJ&W8R6\;
MGJR GZXKR_X@>/-<\.>.]%TFPD@6TNQ^]5X@S=NAH ]6HKSWXK^+=5\(>%H-
M0TJ2)9WD"DR1[AV_QKK/#%_/JGARPOKD@S30J[E5P,D9- &L*6D%+0 4444
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M>_\ )3O% _VO\*];/6J-MI.G65W-<VME#%<3<R2(@#/]30!>%+2"EH ****
M"BBB@ J/RT$A<(H<]6 &33SQ7F7Q0^*=IX2M)-.L66;59%QM!_U6>Y]Z .*_
M:"\26=T]GH4 62YB8O*1SMSC _0UZ!\'M%FTKX>VB72G?<9<QL/NC)Q7E'PT
M^'5]XQU9?$NOL[V>_P S=*<F=NO?M7T?+-;Z=9&25EBMX4Y/0*HH 2XN+72[
M&2:5DM[:%<EN  !7RC%+)XV^,8N;" A9KL,-HX"J,9_''ZUO?$OXE7?C34AX
M=\/!WL6<)E/O3G/\O\:]1^%/PXC\'Z:+V\4-JEPOS\?<7^[0!Z4/YTM(*6@
MHHHH **** ..^)\DD/PZUAXG9'$#893@C@]ZG^',CS?#W1I)'9V,'+,<D_,:
MU]?T:VU_1;G2[LL(+A"K;3@\T[1-)@T+1[;3+7=Y%NFU-QR<9S_6@#1HHHH
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M'^M?1H\1Z.=0-C_:5M]K#[/(\P;]WIBOG/XW69T_XD6UXX*I<!)23Z @?TH
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MBIX:6-%4'KM&.XH Z']H$_\ %!6I_P"FR_\ LM=_X'_Y$O2?^O9/_017 ?M
M_P#(A6O_ %V7_P!EKKO!FO:3#X/TN.34+=76V0%2XR/E% '945FOKVE1V$E\
M^H6ZVD9P\Q<;5^IJ33-7T_6;476FWD-W;DX$D+AE/XT 7J*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :WW37CWA/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ::8$16R
M 3U(')IYZ5YEX)UC4+WXE>*+*XNI)+:WE BC9B0O+=/RH ].[TM)^-+0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<=\3K&YU'P#J5K:1-+-(F%5>I
MKL3TIIH PO!5M-9^#-)M[B,QRQVX5D/\)K?I!2T %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>4_%_[^G_C_ %KU:O*?B_\ ?T_\
M?ZUK1^-'+C/X3.^\+_\ (KZ7_P!>R?R%;%8_A?\ Y%?2_P#KV3^0K8K.6YO3
M^!!1112+&GBO/9_C%X:M;R_M9WD2:SX*[22[>@P*]#-?.?P_\.66O?&'79+Z
M-9$LF\T(XR&)XH [RQ^.&@7%_':WEI=V D^[).AP?TKMO$'B6R\/>'I-;N6+
M6<84EDYR"0!_.N*^,OAS3;KP%=W@MXHKBS'F1R(@!  /'TKE+_4)M1_9F=IR
MQ>-8TW$_>_>#F@#J[SXW^'H988[6"YO&=0Q$*D[<^O%3^,]7\%P>(M(&O:6+
MC4)C&;9VSE"6^7IZ&JWP<\):99^![:[DM(9KJY)=Y70$X[#]:Y#XSJ%^)7A@
M#M)#@?\ ;2@#W#5]8L="T^2^U&X6"W0<LU></\=]##LT.F7\UNK8,Z(=N/7I
M7/\ QSN)K_Q)H&@&5DM9R6D4'@G(P?U->M:;X7T:ST&+38].@^S>7M*F,'=Q
MU/O0 _PYXJTGQ5IPO=*N5ECZ,.A4^A!KFM4^+GAW1]4U+3[MY$GL&VNH&=[>
M@XKSWP5&_A+XW7^A6C8LIU+F/.0-Q!'Y9JMIOAZU\0?M#:W'>QK);V]PTI1A
MG<=O'ZB@#V#P7XVMO&MM=3VMI<6R6[JI$PQNR">*Z=W"1LY^ZH)_*HK:SM;-
M2EK;Q0J>HC0+G\J==$?99O9&_E0!YS<?&SPU ET,3//;S&+R4'S.1GIQ[5TG
MAWQO8:_X<GUQT>QM8)&1_M'!& #_ %KQOX0>&;/5_'FNZC>P),EI<2*JNN0&
M+G!Q^==1\>Y3IO@NTLK*)88+FXQ(L:XSC:1TH T)_CIH23.+>QO;FW0X,\:'
M;]>E=QX9\5:7XKTT7VF7 DCSAE(PRGT(KRGP_P"(X],\,V^G0^ [N6%H1O<P
M9\PD<FJOPJM=8T7Q)X@F_LFZLM.E@:2)9E("X#$4 >A>*OBIH7A>_%@XEN[S
MO# ,D5E1_'#PY]BFFNH;FUEB*CR)4(8@GKTKE/@QHUMKGB/Q!KVHHMQ<PW31
MIYGS8R<YY],8JY^T!X<T\>';?6(H(XKF*78S(H&X' YH ]&\0:EH=YX$N-5U
M6U%QI1@$LD;9Y4X]/K47AG5]!@\"?VIH]M]GTF")Y1$H/"J,GK[5SGB0_P#&
M/UWGOIR?S6JG@L9_9_O/^O&?_P!%T 77^.'APV<<UM%<W,SYQ!$A+ >O2K6F
M?&3PQJ%A=7,LSVDEMR\$H._VQQ7)_L_^'+(Z#>:I/;Q2SRR[49U!*KCD?F*P
M=8\,:=>_M!QZ<846V=1<-&% 4D$G&* ._L_C?H-QJ$-M<6EY:1S-M2:9"%/I
MVKT6YOK:TL9+RXG2.W12QD)X KRKXYZ+9IX(M[B"WBBDM9P4** < $8K!\?Z
MO=_\*)\/$2-_I<$1E.[D\#O^- '4S_'30DN)$MK"^NX8SAIXD.T>_2NW\,>+
M-*\6Z=]LTNX$B@X=3P5/O7E'ACQ$NC^&;?38O UU-&T0WR>1_K,]_>CX3V.J
MV'Q!U9_[(N=/TF[W.B2IM"==H_6@#MKKXM^'+.ZO[>>5TELSM*8)+GC@<>]9
MVG_&[0;K48K2ZM+NQ\TX62=2 3^5<-X*\/6>N_&O6VO8UECLP9E1AD,<A>GX
MUU'QYT:Q3P&NH16T<5Q!<1HC(@! 8\_RH ]>C=98ED1@5894CN*Q/%7B>T\)
M:0VIWRR-;APA*#.">E,\$SO/X-TN21MSF 9/Z4GC;1AKW@_4M/V[FDA;R^.C
M8XH T=(U>VUK1K?4[5\V\Z;U/M_D5S&F?%#0M4\5R>'H7<72.R9_A)!Q7!?#
MGQ<-,^$^MQ73_/I1>%!GL>/YM7&?V#<^%_#_ (;\<.'^TF\\ZX8]&#$%<_K0
M!]%^)_$]CX4THZCJ#'R@< +U-<CXRU[P;?:5HUYXBTO[7#>KOMA(#\H./3\*
MYKXKW[>)-9\*>'[8AQ=,ETX4]1SD?I3/CE;1V<'AJUA $<+%$4#L-M '2?$7
MQ[8Z%HDNDPQ7"3S6H,+HAVJ.W.*Y?X0_$:TL_#]EHEZEW->37;_OMK,OS-QS
MBO0?&MG;3?#NZFDMXWD6S7#E 2.!7/? JQM9?AK;3R6T32BZE_>%!D8;CF@#
MF?'>HVNE_''1[^[D"6\5N79CV^]73M\==!2;Y["^6V9L"Y,9"'W'%<E\1-(A
MUOXW:/83C,+Q L,=<$G^E>F>//#VF/\ #S5+=+*%%AM6:(K&,H0."* .KTS4
M;75=/@OK.82V\R[D<=Q5H]*\P^!-Q++X",<A)6&<HF>PP*]/)X_"@#YNT3PY
MIGB;XVZ[9ZI;B> 2%MI/&<4_XL>"-&\$P6FJ:#<O:7?G!1;H_;^]^GZUFPZ+
MJNM_&/7;;2-0:QN!(2958@XQ48T2XT3XHZ?8>.YY;^WD;]U)),S+SC!.>WM0
M![DM[:7GPQ@O?$=M]H@>V#W$3]\5EZ1XL\*^'_A_#K.C:<\&E2W#1K%"K$[L
MG/KW!K7^(,<<?PZU)(@JQB'Y0!P!7/\ P2MH;KX3V*3Q)(GVB8[77(SO- 'G
M?A3XEPV/Q$UK4[[[9/:SC$,84DI^&*]CU/XBZ3I'AVSUJYCF6WNG"(I7!R:\
MW^'5E:3?&3Q3%);1-&A^5&0$+]*U/C]$D/A;3DC5407:84# '6@#U^UN%N[2
M*XCR%D4,*YO3O'>F:GXIN_#T"R?;+:-I'STP"!_6MG0CG0K(]1Y*\UXSX#DC
MD^/^NNC J+:0$^X9: /1=$^(VDZUXCFT%5EM[^+.8Y1C)'6I-:^(.E:-XBMM
M"<23WT_1(AG;Z9KSCXVZ3'H&H:?XQTRX%OJ D",JG&_!'/OUY]JD^"NEKX@O
M[[QCJ=PMSJ+/L12<^7_@>./:@#T?Q9X]TOPA'"+T2RSS?ZN"-"6;]*YO3_C;
MH5WJ,-G=V=YIYE.%>X0@?RI_CKQWX;T+6(K:33DU/65&$B\L,5SVSU%>9_$O
M7=0U_0;:>Z\&3:8L<P*7A7 [\9Q_G% 'T!X@\0VGAS1)-6N]S6\>,[>>O2N,
MOOC3H%NL7V2"ZOI'7<T<"$[/J<5F>,)WG^ $$LK[I'@B+$GKS5[X,^&M.M?
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MN4\G\>!6#:?&75;/2EL;[PIJ+ZK&NS<D9V,W0'Z5[9CK49@C+B0QH7'\1'-
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MD8_'->K-$D@ D16QZC-."X&.W:@#PO0?BOK%CX<AT1O"^HR:K$GDI((R$W=
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MCTKAOBV"WPYU10,DQ]/6@#K-+U"#5M,M[^V),,Z;T)':KM<UX !'@/10<_\
M'LM=+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MY3\7_OZ?^/\ 6O5J\I^+_P!_3_Q_K6M'XT<N,_A,[[PO_P BOI?_ %[)_(5L
M5C^%_P#D5]+_ .O9/Y"MBLY;F]/X$%%%%(L:>:3;SFGT4 (*6BB@ HHHH **
M** "BBB@ HHHH **** "DI:* &E5(P0,4@4#I@?A3Z* $Q[TM%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF]']I7/_ #YO0!J45E_VE<_\^;T?VE<_\^;T :E%9?\ :5S_ ,^;T?VE<_\
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M #\)^= %NBJG]I6?_/PGYT?VE9_\_"?G0!;HJI_:5G_S\)^=']I6?_/PGYT
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M # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C
M]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P
M/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH 0XJO':6\
M4SRQQ(CN?F91R:L&N!\)>+=1UGQKKFEW13[/9MB/"@&@#OOPI?PI!2T &!Z4
M8'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444
M&!Z48'I110 8'I24M% &?K&D6NMZ7/IUXFZWF4JX'<4_2M,MM'TRWT^T7;!
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MTHHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** #
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M-HYHX<.C#E3DUTA(H!STH =1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 -;[IKQ[PG_R4^X_WG_D:]A;[IKQ[
MPG_R4^X_WG_D:VI[2.3$_'#U/8J6DI:Q.L**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH 0_2N1\.^-!KGBC5-'^RF/[$<;RV<UUQKS'
MP-H^HV7Q#\1W=S:216\[9CD8<-TZ4 >G"EI!2T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!GZSJ]GH.E3ZE?NR6T"EI&52Q 'L*=I6J6NLZ5;
MZC9.7MKA=\;,I!(Z=*YOXI GX<:R "<V[# 'L:G^&_\ R3O1<@@^1T(_VC0!
MU8Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1124 (:\M\#:A=W/Q.\5V\MP[Q12@1HQX7ENE>HGI[
MUR^A>"X-#\3:KK<=Y)+)J+!FC90 AYZ?G0!U7>EIO-.H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "F,ZH-SLH [DXIW:N*^*TTL'P[U26&1XY%CR&0
MX(H [12"H(.0>XIU<YX#D>7P+HTDCL[M;*2S')-='0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5Y3\7_OZ?^/\ 6O5J\I^+_P!_
M3_Q_K6M'XT<N,_A,[[PO_P BOI?_ %[)_(5L5C^%_P#D5]+_ .O9/Y"MBLY;
MF]/X$%%%%(L*3-!II- "L0!G.!WKSC7]5;Q)?M86[E=+MF_TB0=)6'\(]>U:
M/B[7)9IO[!TV3$\HS/*#_JD^OKS6(D<-M;K:P<11]_[Q]3713AU9P8FMKRH[
M;0M1LI;6.V@C$'EC:L9]JVA7F*N\;AD)##W[UU.D>(PY6"[(4G@/_C2J4FM4
M50Q*?NR.D=@JEB< #DFN'EOKKQ5KQL[&1X=,M6_?2K_RT/H/TJ7Q+JUQJE\G
MA[26/FRC]_,O2-?\FNET?2K;1[".TMUP%'S'N3ZFLTN5&S?M)66R+L2!451T
M48'X5)1]*@NY_LMI/<$$B*-G('4X&:@VV18I,UYU_P +5M,?\@Z[_P"^/_KT
MB_%FR==R:?<L.^%R?YUI[*=C'ZS3[GH^:,USGAGQ5%XE$YAMYH1$0#YBXSFN
M@K-IIV9K&2DKH?13 ?>EH90ZBFT9H =29I"35"]UBRTZ6..ZN4B>4A4!ZDT+
M43DEN:&:,TU6W $=#T/K2\T#'44VCF@!<TM-S1F@!U%-S03Q0 ZDS2=J#0 N
M:7-4;_4[/2XEEO;A(48X4OW-3P3QW,"31-NC=0RMZBC45UL3T4VEH&+1110
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M<S(P5Y@5)'!Y:@#UJEI*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M0UE>(-#M/$FCSZ5>F06\ZX<QM@_G6M6/XDUZW\-:)/JMW'(\, RRQ]: +6D:
M;#H^E6VG6Q<P6Z!$WG+8'J:O50T?5(=:T>TU*W1TBN8PZJX&X#WJ_0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y3\7_OZ?^/\
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M(?\ A'(XP)1;^8O;;(1DG\R:PO@-XD:ZT:Z\.W;$7.GME588.P\ #Z8-9_\
MPH_7SP?%UY@]O/>N2MM.OOA%\4=/^T7#3V]SM5INS!R5.?IUH Z_XVZ]J-WJ
M^F>$M-D91=_ZT XW>WTQ6Y%\#?#']@+;.DOVWR^;@.,[_7ITKD?C%Y^D>.M#
M\3PJ9;4J&#@<#I_3FO5T^(?AC_A'QJW]IP^1Y>=N?FSCICUH \6^$5G<Z?\
M%N_L[IV>6")DW,<Y 8 ?IBM/XDWM]XT^)EKX.MYV2RB(\U0>IS\Q_(51^%6J
M#6_C'J.H*FU)HV90?[NX8IWBV5_!/QTCUN\C8V=PP;S,< ,2#^5 '::S\#_#
M@\/3#3TFAOX8]T<WF#EAZ\5S'[.PF&M>)!.290D08GURV:]/UKXB>&['PW+?
MC4X9-\1\J-3EG)[8KS+]GFYDO-=\37$JXDD6)F &.K-0!S.NZ/=>(/C=?:1;
MS/%'=2*DS+_<V@\_E7L</@_0/AOHNH:SI<,GVF"V8Y=L[B <=JX/0^?VBM0]
ML?\ H(KV'QEITFJ^$=4LX<^;);.$ [MM.!0!\^^"X/#GB_4=0UWQOJRF5I<1
M0R3!<CWSV'2F>)6T'P1XNTO6/!^IK) \G[Z%)0VT C(X['-+\+-&\%:E->:3
MXJM$74HY<1M)*Z!@.".#US7IEY\/OA397%O!-:P"6XD$<2+=.2S$X X- '&?
M'+4+BZU+PY]K\Q-(FA69]IX))Y_'%=OX2\$_#V^FLM6\/2%YK<B1-LPW ]?G
M7&:ZO7M/\+ZA;PZ!K ML-$/)BD;#!1P"#^'K7@E_IR> _BG86_AC4WGBEE3=
M"K9P">5/8B@"S\0+BWNOC9]E\4/.-%20*F. $V=1[;J]?\(>"_".F7HUOPZV
MYFCV9CE#)@^P'6G>(]&\)^,$DL=6DM_MT"@.=P5XB0#[9ZUY)X ,_ACXOOH6
ME7\EYIWS*<MD 9ZXZ9% &C=\_M.V7.?WIR/^V1I/B+"W@OXO:5XCCREI<LOF
MD=#@C?\ SHO./VGK/_KL?_11KN?C1X?76O EQ.BYFL_WRG'.!R: )_BOXE72
M_AU-+"^)K]52 @]<X)_3->?FXNOAY\#K=K5S%J6I.'\P<$*PS^8S7.)KL_Q%
MO/!_AX!B;49N<]-REC_Z#@5Z5\<M!DG\!0R6499+*1?W:CHGK^&* .0\)>&?
MAW+X?BN=?U:*74KE2TI-PH\LD]AZU'\/-1B\+_%=]!TS4!=:-=Y"8?<,D_+R
M.XS6M\/O"_PU\4>'K>2XL8EU%%Q<(]PZG.>O7Z5V&A^#_AUI_B>%='@B_M2#
M]XNR9VVX^IQ0!Z.O>G4@I: "BBB@ HHHH **** "BBB@ HHHH **** $KR?X
M?1NOQ-\4.R,%9N&(Z]*]8J&.V@BE:2.&-'?[S*H!- $PI:0=*6@ HHHH ***
M* "FLBMC*@XY&:=24 >!1?\ )RTF/[C_ -:]VNT,EG.B<LT; ?7%>$P_\G+R
M=/N.?YU[W(Z1QM(YVJH+$^@H ^=M$^'GQ*T%K^ZT:6&T-VP9@)P&8#.._'6M
M3PK\4_$6C^*4\.^,X0&=]BS $$'L2?XA7KUKXHT.]M#=6^J6SP 9W;\<?C7@
M?Q%U&U\<_%31[;0/](-OMCDEC'#$-N)_*@#Z4!SVQ3J:#TIU !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<G/''%=A/;Q7,$D$Z+)%(-KHPR"/2IJ* /+-3^!'A.^O&N(5N;=F.2L<F%_
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M$K6@?2O)/AX?^+G^*1T^8?TH ];%+24M !1110 4444 %%%% !1110 4444
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M]2F"K+<0AV"],FM>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=Z[XNU?2)K6&.*P.$D0G<WUH [6EI!2T %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!D^(]$B\1:#=:5,[)'<(49A[T_0-(CT'0K32X69H[=-H9
MNIY)_K2:_K5OX>T6YU2Z5FAMU+,%ZXI^B:M!KFC6NIVP80W*;U#=0,X_I0!H
MT4=J* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH :>AIN>M./3%>4^ KF>7XI>+8I)I6B27"*SDA>6Z
M"@#U?O2TT=:=0 4444 %%%% !1110 4444 %%%% !1110 4444 %<I\1-'O-
M=\%W^GV*![B9-J G%=5TJ.6:.!&DED2-%Y+,< 4 9'A#3[C2O"6EV%TH6>"
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MURW[IO7I7HQJ))XI'9$E1F4_,H89% $HI:04M !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <=\449_AUK"H"6,#  #V-3_  X0Q_#S14=2K"#H
M?]XUTTB)*A21%=#U##(-*B+&@1%"J.BJ, 4 /HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!O:N
M>TCPA8:+K^I:Q TAN+]MT@+<=_\ &N@(..*Y[2/%]EK/B'4=&@CD$]@VV0G&
M">?\* .B'6G4@ZTM !1110 4444 %%%% !1110 4444 %%%% !1110 AZ5P_
MQ;&/AOJQ[^77<UF:[HMKX@TF;3;P$P3##8H S?  QX#T7C'^C+QZ5TM4M*TZ
M#2=+MM/ML^3;H$3/7%7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O*?B_]_3_Q_K7JU>4_%_[^G_C_ %K6C\:.7&?PF=]X7_Y%
M?2_^O9/Y"MBL?PO_ ,BOI?\ U[)_(5L5G+<WI_ @HHHI%D%U:P7EM);7,230
M2#:\;C(8>A%4M+\.Z-HKR/IFF6MFSC#&&(+D?A6I10 VL:7PCX=FU ZA+HEB
M]XSAS.T*EBP[Y]:V\44 8=]X/\.:G=-=7VB6-S.W626%6)_&J_\ P@/A'.?^
M$<TS/_7LO^%=)10!@6W@OPS9W4=U;:%I\4\;;DD2!0RGU!K<QQ3Z* ,)?!WA
MQ;[[:-$L1=;_ #/.$"[MWKGUK;**5VX&",8QVIU% &-:>%- L+XWUIH]E#=D
MDF9(0&R3D\UK]:=10!2U'2K#5[;[/J-I#=09SY<R!ES]#1IVEV.DVWV73[2&
MU@!SY<*!5S]!5VC% '/ZGX+\.:S,9[[2+2:8GF1HP2?QJ?2/"VAZ$Q?3-,M;
M60C!>.,*2/<ULT4 (*,4M% &7)X>T>;4TU.33+5[]#E;@Q@NO;K6ETIU% '.
M:EX&\-:M=-=7NCVDLY.6D:,9;ZFMBQTZSTRT2UL;:.WMT^['&N /PJW10 VJ
ME_I=CJMJ;>_M8KF$_P $JAA5VDH YJQ\ >%M.NQ=6VBVB3+RK>4,CZ5T%Q;0
MW=O);W$22PR*4>-AE6!Z@BI:* *>G:58:3;_ &?3[.&UA_N1(%'Y"KM!I"<=
M30 5FW?A_2=0NXKR\TZVGN8CF.62,%E^AK1!_2E% ##&C1&)E4H1M*XX(]*Y
M=_AMX0DE\TZ#99)R0(EQ_*NKS1F@"I8:99:7;+;6%K%;0CHD2A1^0JU2TA(%
M %";0=)N-1CU";3K>2\C&$G:,%U^AJ74-,L=5M3:ZA:Q7,!.3'*@93^!JWFC
M(H AM;.WLK:.VMH4A@C&$C0851["JEIH6E:==375G86\%Q.2TLL<8!<GU/>M
M#-!Z''- 'F'BOXB^$[/7I]$\4:898X3A7>'S%/YUP?C+Q=X>UO1CX9\"Z2!+
M=N/-,-OL!'IQUZU[_<Z387W_ !]6<$Q]7C!/YTVUT73;)BUM86\3$YW+&,T
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M&9%;Y03P.E>LFN<T;P?8Z)KM]JUO)(TUX<R!L8% '1BEI!2T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!R_Q!U.ZT?P/JE]92^5<0PLR/Z'!J
M;P-?W&J>"M+O;N3S+B:+=(WJ<FG^,=#F\1^%;_2K>:.*6XC**\@.T$COBI?"
MFCR^'_"^GZ5/*DLMM'M9TS@\D\9^M &U1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #3Q7E?@2T
MN(?BEXLFD@D2.24%'*\-RU>J?UIJQ1JQ944,>20.30 ^EI*6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH #TK$\5:^GACP]<ZM)$94@7)4'&:VZXOXI
MVL]Y\/M3AMXVDE:/ 51DF@#HM"U1=;T2SU-8S&MS&) A.<9K2KG? T,EOX'T
M>&6-DD2W4,K=1714 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO >N6D/BQ5O=/NG"B=!C!]O_ *]=_P"//'EKX.\.+J*J+B:?BVC'\9]?IR*
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M\^<?Y_\ UZ/M.J_\^<?Y_P#UZ -2BLO[3JO_ #YQ_G_]>C[3JO\ SYQ_G_\
M7H U**R_M.J_\^<?Y_\ UZ/M.J_\^<?Y_P#UZ -2BLO[3JO_ #YQ_G_]>C[3
MJO\ SYQ_G_\ 7H U**R_M.J_\^<?Y_\ UZ/M.J_\^<?Y_P#UZ -2BLO[3JO_
M #YQ_G_]>C[3JO\ SYQ_G_\ 7H U**R_M.J_\^<?Y_\ UZ/M.J_\^<?Y_P#U
MZ -2BLO[3JO_ #YQ_G_]>C[3JO\ SYQ_G_\ 7H U**R_M.J_\^<?Y_\ UZ/M
M.J_\^<?Y_P#UZ -2BLO[3JO_ #YQ_G_]>C[3JO\ SYQ_G_\ 7H U**R_M.J_
M\^<?Y_\ UZ/M.J_\^<?Y_P#UZ -2BLO[3JO_ #YQ_G_]>C[3JO\ SYQ_G_\
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MP*FJ6_Q$\23?87'F'(+J0IZ=#0![&*6LH76J?\^<?Y__ %Z7[3JO_/G'^?\
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M=MXZ8+$C^=:GB+6$T'0KS4Y%W"",L%_O'' _.K6FVSV>FVMK)(9'AA2-G/\
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M"^-&K3:WJ>E^#--8O-/('N G]W/0_3&:]8\.Z1%H6@VFF0XVV\:H2!U(')H
MU:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M]TUX]X3_ .2GW'^\
M_P#(U["WW37CWA/_ )*?<?[S_P C6U/:1R8GXX>I[%2TE+6)UA1110 4444
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ME,HMHA&)",;L=\5IU3TS4+?5=-M[^U;=!.F]&(QD5<H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $Q2T44
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7E/Q?^_I_X_P!:]6KRGXO_
M ']/_'^M:T?C1RXS^$SOO"__ "*^E_\ 7LG\A6Q6/X7_ .17TO\ Z]D_D*V*
MSEN;T_@04444BPI*,\TR21(T+R.J*!DLQP!0 ^BH+>ZM[N,R6UQ%,F<;HG##
M]*F!H =1110 E%+10 E%+10 F*6BB@!*,"EHH **** "BBB@ I#UZ4M% "4M
M%% "4"EHH **** $P,5!=6L%];26US$LL,B[71QD$>]6*3% %#3-(L-&M?LV
MGVZ00YSL10!FKU+2T 5KNQM;^W:WO+>*>%NJ2H&!_ U'I^E:?I,)AT^R@M8B
M<E(8P@/X"KM% ""EHHH *3O2T4 9*>'M+36&U;[%#]N;K-L&X?C6J!SQ10*
M%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :WW37CWA/_ )*?<?[S
M_P C7L+?=->/>$_^2GW'^\_\C6U/:1R8GXX>I[%2TE+6)UA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% "&N.\.>"WT+Q7JNL-=>:+X
MY";<;:[$UF6.O:;J.H3V-M<K)<V_$B '*T :8I:3O2T %%%% !1110 4444
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M %%%%  >E<-\6QGX<:I_USX'K7<U!<P0W4)AGC62-N&5AD&@#!\ ?\B%HO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 3O7DGP]_Y*AXI/\ M?X5ZV:J6^FV
M=I=27$%M''-+_K' Y:@"V*6D%+0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% ''_$^22'X=ZS)$[(X@;#*<$<&I_AU*\WP_T9Y'9G:#)+')/S&M
M;7='M]?T:YTRZ+"&X4HVWK@T_1M+@T31[;3K;=Y%NNU-W7&: -"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M* "BBDS0 M%)FB@!:*** "BBB@ HHHH **** "BBB@ HHHH **,T9H ****
M"BBB@ HI,TM !1110 444SS4+[0ZEAU&>: 'T444 %%%% !1110 4444 %%%
M% !1110 UONFO'O"?_)3[C_>?^1KV%ONFO'O"?\ R4^X_P!Y_P"1K:GM(Y,3
M\</4]BI:2EK$ZPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU2:]TR_=4VN<YW''/TZUVGQ=\=7OAJWL])T?(U*_/RL!]U>AQ[\B@#T_>O\
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MY0>14QKR7X>NS?$SQ.I=MJMPI/3I0!ZT*6D%+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "'IQ2"N7^(>H7>E>!M4O;&X>"YBA9DD7JIP:F\!
MWUUJ/@C2KR]F:>YEAS)(_5CN- '244=J* "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH[4 --<OH?C&#6
MO$VJZ*D+*^GOM9SWZ_X5TYKROP):74/Q0\6336T\<4LH:-VC(5N6Z$T >K=Z
M6F@\TZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *H:OI-GKFFS:??1
MF2WE&'4'&:OFN?\ &.OMX8\,W>JK$)6A7(4]S0!K:?8P:98065JNR"%=J+G.
M!5JLOP[JAUKP]8ZDR"-KF(2%1VK4H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *\I^+_ -_3_P ?ZUZM7E/Q?^_I_P"/]:UH_&CE
MQG\)G?>%_P#D5]+_ .O9/Y"MBL?PO_R*^E_]>R?R%;%9RW-Z?P(***2D6!Z?
MA7R?X#M;>^^-T=O=6\4\#S3;HY4#*?D;L:^KB,\5P6C?"70]#\5KXBMKB\:\
M5F;:[J5RP(/&/>@#QOXN: ?!'CFTU72$^S0R@2P^6,!'7&<?B:[_ .)>M1^(
M/@C#J<)^6=8R1GI\P']*[[QCX(TOQMIR6FI&5%C<.KPD!A[<@\5DI\*M&3P;
M+X9:[OGL9)1)N9UWKTX!QC'% &'\!/\ DG)/_3:3^9KS'X=7UKH_QBF?4)5M
MT#R*6D. #@U]"^$?"-AX,T;^R].DFDA#E\S$$\G/8"N3\3_!70/$6JOJ2RW%
MK/(<N(F 4^_2@#D/V@7AU'2M)U*TE6:V5FCWIR,Y_P#K5TOAGQYH5I\(K=Y]
M0@6>&S:-HBW(?!P/KR*Z;_A7.CR>"4\+W)FFM4.X2,PWAO4''O7+:=\ _#=G
M=K+-<75Q&IR(G<;3]>* /.O@--]H^*%[/C'F6DS\]LNIK2^,WB+_ (2OQ-9>
M%-*19W@E"NX4$AR<$9]!Q7I_A[X3Z'X8UB[U/3;F^CGN(GBP77"!B#\O';'%
M.\-?"?0?#.OMK4$MW<7ASAKAPV">IX H \/\!:I<?#'XBM8:W L8D'E2N1R@
M.""#Z5V'QU\2ZC'J.FZ3:7C6UE.BR,\;%2<G')';BO1?&/PNT+QK?Q7NH/<P
MSQKMW6[ $CWR#3=5^%NAZSX=M=(O'N9?LB;8;EV!D'MG% 'D?B/P?X.T+P"V
MH'6I;O4YH0T"^<<,Y&>F<>M;GP5F4_#;Q#".&5)F_-*Z+3?@/X;M1)]KFNKK
M<NU1(X.SW''6NF\+_#K2?"FEWVGV,]TT5XC)(96!(R,<8% 'E7[/B*=>UA]H
MWC('TR*H_'T_\5YIW_7&//YFO8_!_P .=)\%7%U/ITUT[7)RXF<$#Z8 J'Q=
M\,-&\9:M#J.HSW:30J%40L .#GG(- '4Z+_R =/Q_P ^L?\ Z"*DO+^VT^W\
M^[G2&+<$WN<#)X J2UMUM;2&W0DI$BHI/7 &*R/%?A:S\7:,VF7[RI"S!LQ-
M@Y!R* %UDZ"-(GEU$61M2A+-(JD?6O&?@?/_ ,5MKD&F/*VD#YD5CP!S@_6N
MB'P T<R8DU;46ASROFCI^5>@>%_".D>$K#[)I<&S/+NWWF^IH Y+XT^)SHO@
MYK&!B+K4&\E=O4#U_2M#X2>&O^$;\"6B21[;JY'GRY'() X/TJWXG^'.D>+-
M:L]3U*>[+VHQ'$C@(><\C%=@%"J%48 ]* ()KZUMYXX9YTCDD^XK'EJX?XMZ
MMHUMX'O8=0EA>29"L$9()+XX(^AQ6GXU\!6'C:*!;RYN8'@^XT#[?SXKE=.^
M!'A^VNUGO;N\O50Y$4L@*GZ\4 2_ >UNK?P&'G5A'-*6ASZ=#^M=UXM_Y%#5
MQ_TZ2?\ H)K2M+2&SMDM[:-8X47:J*. *;J-C'J6FW%E,S".>-HV*]0",<4
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M]OKZ\BB^[#-("I^O% &1\)],N+3X4:]=SHR+=QSR1 CJOE]:N?L](H\&71
M<S\GUZUZE)I=LVCRZ9&GE6SPM"%3C:I!''YUD^#?!MAX)TM[#3I9Y(G?>3,P
M)SSZ >M 'EWQH_Y'GPJ,_P#+U%_Z&*/C2DVE^-O#NOR0E[. D2-C(!R.#^M>
MD^)O .E^*]5T_4;Z6Y2:QD62,1L "5.1G(K9UK0K#Q!ILEAJ=ND\#\[6'3W%
M "Z?K&GZCID-[;744D#*"'#<5X1\;+)$\?:-?7;NFG3H,S1'!4<#KZUUS? ;
M1UD*P:MJ4=NS F/S1_A7=:QX-TC7= AT?4(/.@AC6.-V/SIM& 0?6@#SZ#X2
M^&KW3ENX_$5Z]JZYWBX;!!_X%7:> /"^C>%](ECT6Z-S;3R;C(3GD9!KD#\!
M-)!,::QJ0M]V?+\T=/RKTG0=$MO#NCP:99[C#$#M+G)/UH M:C<&TTV[N47<
MT4+R!?4@$U\]^"M'/Q0UO5KSQ#K%PHMYBJ6JRE?E]@#VZ5]&2(KHR,H96&&!
M[BO,-3^"6A7FJ27UE=7=C)*Q9U@<!>?PH \G\3Z-H?A_XK:'IVBRR2B.ZMS*
MS2E\-Y@XY/:OJCVKS.T^!_AFTN[&[2:]^T6DJRAS("78$$;N/:O3%!QS0!@>
M--%CU_PEJ-@Z[R\+-&/]L E?UKYSL]=N-6\*Z3X$0G[5'J!5\GEE!;(KZL(X
MK@].^$WA_2_%G_"1P/=&[\PR!&8% 3UXQ[T <C\5]*C\-77AOQ#9#8MC,D4I
M''R C _G4/PX=?&WQ/U;Q5(I:WA14A]%?"]/PS7JWB?PU8^*]$ETK4-XMY"#
ME" P(Z8JIX-\%:9X)TZ6RTMIF25][M*06)_ "@#PWQ[IMI'\;"NL3S6ME=J,
M3QL5QDGN"*[>;X/>&C8--/K]XUJZY)>=BN/^^J[SQ9X)T;QE:+!JD&70_),G
M#IGK@UP\7P'TE&5)=7U)X4;*IYHZ>_% %'Q_X0M].^"XL]#D>YM89EN 0<AE
M[G\A6-\/_ 7AWQ;X;M[I-<O8[I01/"D[#RSGTW>E>Z6^DVEOHT>E>4'M$B\G
M8_.Y<8YKSJ_^!NARWSW5A>7ECYART<,@"CZ<4 6/"OPX\-Z#XL-[8ZM+<:C"
MA#H\A8@'UY]J\R\1^%T\7?&SQ#ICN8Y653$XZ!MB]:]G\%_#O3/!4D\UG<7-
MQ/. )'G?=TSTX]ZF@\ Z9;^-KGQ6DUQ]NN,;E+#9P .F,]O6@#SGX8^,[GPK
MJG_"#>)8X[5X6*V\N, GH![Y[&O<58, 0001P17'>,/AOH?C.6&:_$T-Q%TF
MMV"N?J2#71:/IG]D:9!8BZGN5A7:))R"Q'U % &C12"EH **** "BBB@ HHH
MH **** &M]TUX]X3_P"2GW'^\_\ (U["WW37CWA/_DI]Q_O/_(UM3VD<F)^.
M'J>Q4M)2UB=84444 %%%% !125FQZ]I<NJ-ID=]"UXI(,(<;ACD\4 :=%-%+
MF@!:*,TA- !FBJU[<BSL9KEE++$A8@=3BL#P5XTM?&VF27UI!)"B2&,ASGD4
M =312#K2T %)GBHKB7R+>68C(C0N1]!FN8\#^.K/QQ937-G;R1+$VT[SG)H
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M2X\FW4@9"EB2?0#DT :M%5+&^@U&RAN[<L89E#(64J2#[&K5 "T444 %%%%
M!1110 4444 --)P<^M+VKS+P/J]_>_$KQ59W%U));P2@11L>%&6H ]. I:2E
MH **** "BBB@ HHHH 3-+4$\\=M!)-*P6.-2S,>P'6N0TOXJ^$M8UB/2K'4'
MDNY'V*ODN 3]<8H [:BF@TZ@ HHHH **** "N/\ B9IU[JO@34;.PMY+BYE3
M"1QC))KL*8[!!EF  ZD]* ,/P7:W%AX,TFTNXFAN(K<*\;#!4UOTU2" 5(QV
MP:=0 4444 %%%% !1124 +156\O[;3K=I[N>."(=6D8 ?K3-/U.RU2#S[&YC
MGCSC=&P(H N9I<U5O+^UTZV:XO+B.&%1DM(P _6N=L/B-X5U"]%K!JT/FDX
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MYTO54+V<K2%U5RG1"1R/>OI'Z"O'O$?P>U'7O&5_KT.M)9F9CY85#N QSDT
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M **** "BBB@ K+U[6K3P]H\^IWNX00C+;:TS7$_%B)Y?AUJB1H[NT> J#)-
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M9)]!3E 50%& .@J&[MDN[26WER$E4JV.N#0!Y#&LGQ,^*'G,-^@Z(V%_NR2
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M'>DQSDT >:?!OPKJ&@:)>7FL6SP:C?3F21)1\PY/\^M8WQ \#:_9>+D\8^%
M9;H8\Z!>K>OYBO9,4N.* /&S\0?B->1);6_@QH;@X#3%LA??%=GXH\*R^,_
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MWB@LK %N"1UZ4 >M"EI!2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>>> .[#N:VZ "BBB@ HHHH **** "BBB@!"*,4M% !24M% "4M%% !28I:*
M"DI:* #%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>4_%_P"_I_X_UKU:O*?B_P#?T_\ '^M:T?C1RXS^$SOO"_\
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M&@"6BJ3:I8I<M;M>VZSJ,M&9!N'U%5XO$>B37'V>+5[!YB<>6MPA;\LT :E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM:H+6YAO+>.XMY%DAD&Y67D$5/0 4444 %%%% !1110 4444 %%%% !1110
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M@[&+9R"2>OXULUYA\#[O4[KP*IOW=XTDVVY?KL__ %YKTX=* %HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K?
M=->/>$_^2GW'^\_\C7L+?=->/>$_^2GW'^\_\C6U/:1R8GXX>I[%2TE+6)UA
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'K7#>%?!
MU_HGC'6=7N)8&@O6S&J$[A]>*[DU4@U&RNKF2WM[R"6:/[\:2 LOU% %L4M(
M*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .3^(]E<ZCX"U6T
MLX6FGDA8(B]2<&I_ %G<6'@72;6[B:*>.'#HW4'<:Z,X(]*!WXH =1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%(: $/H:Q].\+Z5I6KWFJ6=N8[N\.Z=RY.X\]C]:V#TQFN0\/>,
MSK?BS6M%-KY?]GN%$F[[W)_PH [ 4M-'6G4 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7#?%PG_A6^JX_YY\UW!JIJ&FVFJVCVE];QW%M(,/'(,AJ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%)F@!DK!8V)/ %>,_#[-QXZFG'0%L_K
M7H_C/5TTCPW<S;@)77RXQGDL:XKX3:>[7%[J3*2K#8#[YR?YUM#2#9Q5WS5H
M170]7I:04M8G:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M='(,,*$-[:%'_A)='_Z"$/YT?\)+H_\ T$(?SKEW^%6AO(S!YU!.0 _2F_\
M"I]%_P">MQ_WW6J4.YS\];L=5_PDNC_]!"'\Z/\ A)='_P"@A#^=<M_PJ?1?
M^>MQ_P!]T?\ "I]%_P">MQ_WW1:GW#GK=CJ?^$ET?_H(0_G1_P )+H__ $$(
M?SKEO^%3Z+_SUN/^^Z/^%3Z+_P ];C_ONBU/N'/6['4_\)+H_P#T$(?SH_X2
M71_^@A#^=<M_PJ?1?^>MQ_WW1_PJ?1?^>MQ_WW1:GW#GK=CJ?^$ET?\ Z"$/
MYT?\)+H__00A_.N6_P"%3Z+_ ,];C_ONC_A4^B_\];C_ +[HM3[ASUNQU/\
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MG7+?\*GT7_GK<?\ ?='_  J?1?\ GK<?]]T6I]PYZW8ZG_A)='_Z"$/YT?\
M"2Z/_P!!"'\ZY;_A4^B_\];C_ONC_A4^B_\ /6X_[[HM3[ASUNQU/_"2Z/\
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MSKEO^%3Z+_SUN/\ ONC_ (5/HO\ SUN/^^Z+4^X<];L=3_PDNC_]!"'\Z/\
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M#-K_ -]&C_A-_#/_ $&;7_OHU@_\*;\$_P#0*'YC_"C_ (4WX)_Z!0_,?X4
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MS'^% &]_PF_AG_H,VO\ WT:/^$W\,_\ 09M?^^C6#_PIOP3_ - H?F/\*/\
MA3?@G_H%#\Q_A0!O?\)OX9_Z#-K_ -]&C_A-_#/_ $&;7_OHU@_\*;\$_P#0
M*'YC_"C_ (4WX)_Z!0_,?X4 ;W_";^&?^@S:_P#?1H_X3?PS_P!!FU_[Z-8/
M_"F_!/\ T"A^8_PH_P"%-^"?^@4/S'^% &]_PF_AG_H,VO\ WT:/^$W\,_\
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M'YC_  H_X4WX)_Z!0_,?X4 ;W_";^&?^@S:_]]&C_A-_#/\ T&;7_OHU@_\
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M?\)OX9_Z#-K_ -]&L'_A3?@G_H%#\Q_A1_PIOP3_ - H?F/\* -[_A-_#/\
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M7=E]M6(VYP9'/ROUZ?E4'_"G/!8_YA8'XC_"L'2_@9HEOKE_<7R)/92-FWA
MQY8Y_P#K4 =Y_P )MX9_Z#-K_P!]&E_X3?PS_P!!FU_[Z-8'_"G/!7_0*'YC
M_"E_X4WX)_Z!0_,?X4 ;W_";^&?^@S:_]]&C_A-_#/\ T&;7_OHU@_\ "F_!
M/_0*'YC_  H_X4WX)_Z!0_,?X4 ;W_";^&?^@S:_]]&C_A-_#/\ T&;7_OHU
M@_\ "F_!/_0*'YC_  H_X4WX)_Z!0_,?X4 ;W_";^&?^@S:_]]&C_A-_#/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 &**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>gvvh0m1pmdf2000007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -E!YX# 2(  A$! Q$!_\0
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M1U4G[Q/2@+FE15&XO)(0I2!I<]<=JGMI7FA#O&4)[&@">BBB@84444 %%%%
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M,*H  ]!0$48XZ4Z@ KR[Q7_R7+PI_P!>DO\ [/7J->7>*_\ DN/A3_KTE_\
M9Z!,]'XQ1B@451 4?E110 4M)10 4444 %%%% !3HQ\])3D^^*!C._'%%*>M
M)0 4M)10(*6DHH .W:EI** #%+244 +1244 +2444 %&!110 M)110 4444
M%%%% "TF!WHHH !UIS\-^%)W%+)]_P#"@8VBEI*!!1110 4444 +28%%% "T
M4E% !1110 4444 %%%% "TF!110 M)110 4M)10 M.D ^7Z4RI)/X?I2&1T4
MM)3$+0.*2B@!:*2B@!:*2B@ P/:BBB@ HQ110 4M)10 4444 'Y4<444 '&:
M*** "CBBB@ IY_U8^M,IY_U:_6@8RC\J**!!1110 4444 %+244 +2444 +2
M444 %&!110 M%)10 4M)10 4444 %%%% !1110 ]^B_2F4]^B_2FT#"BDHH$
M%%%% !1110 M)110 ?E1110 4M)10 8%+244 %%%% "T4E% !1110 M'%)10
M 8'M4\?W:@J>/[M)C0^BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJZS3=7M-4@\VUFW@=<C!_(UFXM;G1&<9;&A130<\4ZI+"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *\N\5_P#)<?"G_7I+_P"SUZC7EWBO_DN/
MA/\ Z])?_9Z /1Z6D%%40+1244"%HI** %HI** %HI** %IR??%,IZ??H&,[
MTM)WHH 6BDHH$+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M +1244 +124M !W%+)]_\*;W%.D^_P#A2&MAM+244Q"T4E% "T4E% "T4E%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** '/T7Z4VG/T7Z4V@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I
MX_NU!4T?W:3&A]%%%(L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4_Z])?\ V>O4:\N\5_\ )<?"G_7I+_[/0!Z/2TE%40+1244"%HI** %HI**
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M+]*;3GZ+]*;0 44E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E% "T4E%
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M "TY/OBF4]/OT#&=Z*.]% !1110(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *6DHH 7N*63[_P"%)W%+)]_\*0UL-HHHIB"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!:?)_#]*CJ23^'Z4A
M]!E)2TE,04444 %%%% !1110 4444 %+244 %+3&XYKB_&OC!]""VMHH:Y<9
MR>BB@UI4I59<L3MZ2O"8O'6OQW'FF^9O]AN5_*NC_P"%IRBT519 S;?F;=QG
MZ46.R66UEL>IGI5>:Z@@7,LJJ/<]*\7O?B!KMWD).(%(_P"68P:QQ_:VL3Y'
MVBYD;KC)S18TAELMYNQ[+>^--#L<A[Q68?PIR:YJ_P#BG;H2MC:,_P#M2''Z
M5RMEX"UZ].YK;R5)ZRG!KH['X68(:]O/JJ+_ /7H-/8X2G\3N8=[\1=;NB1$
MZ0J>/D'-8DMUK.L-M>6YN2>Q)(KUNS\ Z!9X)MO.8=Y3FNAM[&UM$5(($0#I
MM%.XGC:-/2G$\1L_ ^O7K#%F8U/\4G KI[#X52E0]]>!>>5C&?UKU'BGG_5K
M]:5S">8U9;:''V?P]T.U +PM,1_?.16_9Z78V Q:VL<7^XH%7Z2@Y)5ZD_B8
M#I111097%I*** "C\***!"TUN1CFEHH&8>K>%=*U@'[3;*)#_P M%X;\Z\_U
MKX9WML6ETU_/0<[",-^%>N4'I0=5'%U:6S/GE)=5\/W>5\ZVE4\CD9KL-'^)
MT\12/4X?,3O(G!'X5Z-?Z58ZE"8KNWCD4^HYKA=9^&,;[I=,F*'M&_\ C3.Y
M8FA75JBLSLM-\1:9JR VMTK$_P )."*V!T'-?/=]HVK:%+NG@EB(/RR ''X&
MMS1OB+JFGE8[MOM,(X^;[WYT6,ZF7IKFI.Z/::*YC1O&VDZL%C6;RIB/]6_&
M3[5TJL&4$'(/I2/.G2G3=I(=11109B4444 +1244#'OT7Z4VG/T7Z4R@0444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "U-']
MVH*GC^[28T/HHHI%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 5[NVBN[:2WF0-'(I5@>X->4:_X?N]%G)DPUF?N3>GLW]*]?JM=VL%
MY;R03QJ\<B[6!JHR<69U*:FM3P\@.O/(I< #'0"M?Q!H3Z#=>6L9-HS?NY<Y
MX]#^-<[#.]Q++&R$*IQGUKJ3NCS91<79DYF0(6W# [BB.9)5)4\#K3%M8EC,
M8S@G)IZ0HB% .#UIDCF;:A8<XID$XF!XY%/"*%VX^7&*;%"L))4=: )Q$Q!(
M[4JR;>"*@CGGA<J5#(>]-@D+AF+$\]Z8AYC3S?,"_-5F/[M09S2@D=#B@8K_
M 'J5,DE1W%#XXQU[TB':V:0AWD\\]*:8R?X<U/O7KFF-*.U,"!G,0R,_2G;F
M< M0>3FF%G$J@*-OK2 ?"@$WH*L7) 4"JAD1#\SA<>IH>9YL)"&G<\*L8W'/
MX4;#2.A\#:*FJZO+?SX:&T.U(R/O-Z_H:]51%5=H4 >@%<_X*TF72O#T4=P
M)Y"9& &,9YQ71C@5RSE=GITH<L4@P*6BBH-0HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O+O%?_)<?"?\ UZ2_^SUZC7EWBO\ Y+CX4_Z])?\
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M*** "BBB@ J:/[M0U-']VDQK<?1112+"BBB@ HHHH **2EH **3-% "T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %)CBEHH J7MA;:A T%S$LD;=0:\\U/P)?V\T
MLE@ZW$1/R1'"L!Z9X'%>FXZT%<U49..Q$Z<9[GB4VEZE;RM%+83AUZ[4+#\Q
MQ3$T_4)9%CCL+@NQP-T94?F:]OVCTHV ]16GM6<_U5'C_P#PBOB$DXTS@?\
M35?\:K7FC:KIZJUU82JK=-@W_P LU[5M&:1D5N".M+VTNI3PL.AX.'5L\\CJ
M.XHV(2<#J.<5Z]JGA;2M20;[9(W!R'C&T_IUKD;[X?WD )L;E)E&?ED&&/L,
M<5:JIF$L--;''HGEKC/YTX=:TG\->($;!TF8CU#I_C0GAGQ!*0%TJ103R6=,
M#]:TYUW,O9S[&7-,1(HV$YI\DBA 2,8ZUU$?P^U67_6W=O&/]D$M^HQ6@WPT
MC*D?VI<'ZHO^%3[2):P\WT.%W ]*8LI+*,9R.HZ5U\OP]U.,?NKJV<=\@Y_E
M6._A?7XF*#2W90>&1UP?UIJI%DRHS70RSNW#ICO4MK:W.I:C#86J;I93R?[J
M]S_.KJ>&O$$DBQKIDB9.-S.N!^M=WX3\)C05DN;AQ+?2C#,.BCT%*4TEH72H
MRD]5H6-'\&:1ID"[K=;B?&&EEY+?ATK:BTZR@;=%:PHWJJ 59'2EKFNV=ZBD
MK(0 #I2T44B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKR[Q7_R7'PI_UZ2_^SUZC7EWBO\ Y+CX4_Z])?\ V>@#T>EI**H@6BDHH$+1
M244 +1244 +1244 +3D^_3*?'_K*!C>]%)WHH 6BDHH$+1244 +1244 +124
M4 +1244 +1244 +1244 +1244 +1244 +1244 +1244 '<4Z3[_X4WN*=)]_
M\*0UL-I:2BF(6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH
M6BDHH 6BDHH 6GR?P_2HZDD_A^E(?091124Q"T4E% "T4E% "T4E% "T4E%
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MX$)_C1_;>D_]!.R_\"$_QH OT50_MO2?^@G9?^!"?XT?VWI/_03LO_ A/\:
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M_P#6K>\1>*=-\+Z<]YJ5RJ*!\B _.Y[ "N9^%/A"+P_X?2_F#'4M03?,68'
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M8]: /3BZ@@$]:=7FFB67Q'M]5TNXU758+NQE<?:H$B56B!4GDX'0X'!KTN@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!" :,"EHH 0C-)MIU%%@$QQ1BEHH ;M%+BEHH ;M%
M+M%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7EWBO_ )+CX4_Z])?_ &>O4:\N\5_\EQ\*?]>DO_L] 'HXHH'2EJB!
M**6B@0E%+10 E%+10 E%+10 E/3[XIM.3[XH&,[T4O>B@!**6B@0E%+10 E%
M+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 =Q2R??\
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M/@G_ *!T_P#X%2?XT?\ "F?!/_0.G_\  J3_ !KOZ* N<!_PIGP3_P! Z?\
M\"I/\:/^%,^"?^@=/_X%2?XUW]% 7. _X4SX)_Z!T_\ X%2?XU*GP6\$%>=.
MG_\  J3_ !KNJFC^[28T<#_PI7P/_P! Z?\ \"I/\:/^%*^!_P#H'3_^!4G^
M->@T4BCS[_A2O@?_ *!T_P#X%2?XT?\ "E? _P#T#I__  *D_P :]!HH X"+
MX->"X94D33YPR,&'^DR=1^-=+XIL7U#PY=VT7+LF%'J:VJ0C(H*A+EDF?,$\
M+V\S12J5=3A@:C .>G/I7O>N> ](UR<SRH8ICU>/C/UJGI_PTT:QN!,^^<CH
M'Z5?,>W',J?)KN1_#/2I=/T$S3*5>X;> ?2NQO;J.QL+B[F.(X8VD;Z 9J2*
M)(45$&% P *IZQI%MK>FS:?=F7R)0 XC<J2/J*@\:K4=2;D?/OAFP\4^-_&U
M_P"*='N[>":"8A+B=/EZ;0NT \[#Z5:^)/A+QQ]BAUO7;^SO5LN UJNPQ*3G
M)X'?'OS7MOASPII7A6R:TTJ%HXF;>VYBQ)]2:O:KI5KK.G36%['YEO,NUU]1
MUIF9YE-KX\1?L_W]T2QECM/)EW-EBRD D_7&:J?"/QCX?T3P+%9:CJD5M<"X
MD<QN#G!(QT%=QI_PY\/Z9H>H:-;Q3BRO\>>C3$DX]#VK'_X4EX*_Y]+K_P "
MFI ;.J>/M$M/#%UK5M>Q7$,>4CVY^>3LHS7E7AGP#<^/[#5?$FK2 7=X3]C+
M$J W8D#C;R/R->DO\*/"[Z7#II@N1:0NTBH+AAECC)/KTKKK/3[;3[2*UM8E
MBAB4*B(, #TH \G^#WBZ0RS>%-6FQ=6C,+;>N"RCJOX<GGUKU#Q#_P BSJW_
M %YS?^@&L2?X<^'YO$K>(#'<IJ+2B4R).R@L,=AVXZ5TUQ:QW5E-:S9:*:-H
MWP<$@C!_G0!Y%^SY_P B]K'_ %]+_P"@"L'_ (1'X@:5XSU/6M)LU,DT\GER
M3*DF$+$C&[..,5['X9\'Z3X2M9[;28Y8XYG#N'D+$G&.];] 'REITOBH?$=Y
M( G]N^:?,&Q<;L\\=*Z3QU-Y_P 4]&@\2R,+%8X3<!B0BY^\0!^'2O88/ .@
MVWB=O$,<,HU!F+%O-.W)Z\=*L>(_!FB>*HDCU6U$A1MRR(=KCVW#G'M0!XQ\
M7K+PQ8S64^A2Q1:D>&CM3@;.QXX!Z^]>X>%Y+Z7PQISZFI6\,(,H( Y_#VQ7
M/:7\)?".DWR7D%@TDB@@">0R+]<'C-=NJA5"J, #  H \:_:&_Y >B_]?+_^
M@BLWXN<?#3PI@_QK_P"BZ]9\3^#](\7V\,&KQ221P,70)(4()&.U0ZUX$T/7
M]'L]+U"*5[6S(,(64J1QCD]^* *EZ,?"A<#KID?3_<%>4?#34;K2?ACXLO[/
MBYA9&0XSVQ_6O=SI%JVCC2F#FT$(@"[N=H&!S^%9>@>!]$\-V=U::=;L(+I@
MTJ2N7#8X[T >0^#]#\.^)O"ESK7BS5)KNZB=\1S7;CRA_L@')S_2K7P8MEGA
M\66]M&T2N(UC63.5^_UKT"+X2^$8=774EL&\U9#($+GR\_[O3'M6_I'AC3-#
MU'4;ZQB9)M0D$D^6)!(ST';J: /&/@GJ%MH_B/6[34)5MKB=4V)+\N=I;/7Z
MBO6O$=_;:CX,U_[).DXCM9HV,9R VPG'ZBJ>O_##PQXDU5]2U"UE-PZ@,8I2
M@;'<@=^>M:OA[PEI'AC2I=-TV%A:RN7=)7+Y) !Z]L"@#S;X"WMM;^&=0MY;
MB*.5KW(1V )^51Q^-9I_Y.9'^]_[0KOQ\)?":ZFFH)9S+.DHF7;,0H8'(X^M
M:O\ P@VB?\)=_P )/Y,IU/\ OF0[?N[?N].E 'G_ ,:=*-C>:/XHA#!K>81R
M^6G)'7)/T&.?6LGP<Y^(7Q9F\2FV>&TM%!0'!R0-JAO<C)_"O:]9T>TU[2;C
M3+Y6:UN%"R!6VDC(/7\*SO#/@S1_",$\.DQ2(D[!G\R0OR.G7ZT >'^(M(2R
M^+U['JNL7&EV]X6DCO+4D$;CD*3QQZUT&K_#O0DMXO[3\?WUQ&[A4CDD$F6[
M<9->J>(?">C^*+,6VJVJS*OW7Z.OT;J*YZP^#W@_3KZ&\@LYS+"X=1).S+D>
MH/6@#N+90EK$JG(5  ?7BO'OVA#C2-%Q_P _$G_H(KV4 !0!T%8/B?P?I'B^
M""#5XI)(X&+IL<H03[B@"EX4\/Z-+X5TV232+!Y&@4L[6R$D^YQ7E?Q9MVT?
MXC:1J#J%LR(R"JG;&%8#'MT[5[Q8V4.G6,-G;@B&%=B G)Q5+7_#NF^)=.:Q
MU2 30,01CAE/J#V- #8?$6E3&T$5];N;L@0A7R7R,].W [UKUQ.D?"GPMH>J
MVVI6-O<+<V[%D9IV89((Z?C7;4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>E(:P_
M%/B&'P_I#W$F/-;Y8E/\34)7$VDKLOW>K65C*L=S<1Q,_P!T.V,U9CG25-R$
M,IY!!KYRU"?4]7U7S+SS'NYL,%/IC(Q[8KO/AKXID,O]C7DI;C_1RQZ8[5I*
MG97,8UKRLT>K44"BLS<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *H:QJL.BZ7<:A<)(\4"@LL2[F.2!P/QJ_37(",6&0!G&* .(D^)"6
M31R:IH>IV-I*X1)Y8@%R>F>:Z/6_$-CX?T=]3U"3R[=<#CDL3T ]2:\Z^('C
M,ZE&GABRM)K:74'\HRWJ>4H4'DJ3^'-3^.(E&H>#/#%T\EU:W5T!,9&R7"8P
M3ZGFF!T&F_$.VNM1M+.^TZ[T]KWBT>X3"RGT!SUY%=I7FWQF467@B&_MP([N
MSNHC;S+]Z,D]C^ KT"UE_P")=;RRMUB5F8_2D!9KR[Q7_P EQ\*?]>DO_L]>
MD#4+0D 3QY/3YJ\U\6NB?&[PH[, OV27G_ON@1Z2*6JXO;8\"9,_6I'E2-=S
ML%'J35$DE)4*WENS!5E4L>  >M/EGCA&9'"@^IH ?14*7D#L%65"QZ &G23Q
M1<R.%SZF@"6BH4NH)&VI*K$]@:62YAB(\R15STR: )**BCNH96VI*K-Z TLE
MS#$V))%4^YH DIZ??JNES#*<1R*Q]C3XYX_M'E[QOQG;GF@!_>DID<\<I;RW
M5L=<'I3'NX$8JTJAAU!- $U+4<<T<P)C<,!W%-:[MT8JTJ@CJ": ):*8DJ2+
MN1@R^H-1F]MU)#3("#@C/2@1/134E21-Z,&7U%1?;K;'^N3\Z!D]+48F0Q[P
MP*D9SVJ/[=;?\]D_.@"Q24A=0F\MA<9S4'VZV/2=/SH L4M,,B"/S"P"XSGM
M4/VZV_Y[)^= BQ13'F2-=SL%7U)J-;RW9@JS(2>@S0,GHIDDT<2[I'"CU-,6
M[@D8*DJECV!H GHJ)YXHP#(X4'U-(EU!(X5)5+'H : ):*CEGBAQYD@7/3)I
M([J&5]D<JLV,X!H EI:ADN8(FVR2JK>A-$=S#*V(Y%8CL#0!-WI9/O?A4#7,
M*2!'D4,>Q-2M(AEV!ANQG'M2 **A>[@C<J\JAAU!-.CGBESY;AL=<&F!+25"
MUY;HQ5I5!'4$T^.:.5=R,&'J* 'TM5VO;=20TR CKD]*ECD250R,&4]"* 'T
M?G5<WMMWF3\ZE6563>IROK0(=2U7^VVW_/9./>IMZE-X/RXSF@8M%5_M]J1Q
M.GYU,945-Q8!1SF@!U%5_MUM_P ]D_.I7E2--[L%7U- #Z6JXO;8G F3)XZU
M+)*D2[G8*/4T .I:KB\MV("S(2>@!I\D\<(!D<*#ZT 2T5 EW;NX59E+'H :
M=)/%#CS'"YZ9/6@"2BHH[F&5MJ2JS>@-+)<10X$D@7/J: )*DD_A^E5X[F&4
MD)(&(ZX-/N+F*(J))%7(XR: '4E1QW$4Q/ER*V.N#39+J")]KRJK>A- B:BH
MXYXI<^6X;'7!Z4UKRW5BK2J&'49H GI*;'+'*FZ-@R^HJ,WMNI(,R CJ,T#)
MZ*9'*DJ[D8,/45$;ZV5B#,H(Z\T 2LX7K7DOQ#\3&^NCIEJ_[B,_O"#U:NJ\
M:>*8M*TOR[:16N)P0N#T'<UYCX?TI]<UA%F;$6[=+(U!ZN!H**]M/9'5_#KP
MUYLW]K7:?*A_=*?7UKU11\O2JUI#!;64:086&-<+CIBG?;K4 _OT_P"^J+G%
MB:SK3N6:*89$"EBP"@9)J,7ML>/.3\Z#G)J*:TB(A=F 4=S40O;8G'G)^= B
MQ13))%B3<[ *.I-1"]MV8*LRDGH,T#)Z6HY)HXEW2.%'J:8EW!(P5)5)/8&@
M">DJ.6XBAQYD@7/3)ZTB74$C;4E5F/8&@"6GG_5K]:@DN(HB!)(JYZ9-2+*D
MD"NC!E)X(I %+4,ES#$V))%4GL31'<PS-MCD5B.P-,"6EJ%[F&)]KR*K8S@F
MECN8IB1'(K$=<&@"6BH&NX$;:\JAAV)I\<T<RDQN& .#@T /HJ%KRW1RC3(&
M'4$U)'*DJ[HV#+ZB@!]%0->6ZL5:9 0<$9IZ2I(NY&!7U!H DI*@^VVPZS(/
MQJ594:/S P*8SGM0(?15?[=;?\]D_.I3*FS>2-O7- Q])4'VZU_Y[)^=2M*B
MQ>86 3&<]J '457^W6W_ #W3\ZF>5(TWNP5?4T /HJO]MMB0!,A)Z<U(\R1)
MN=@J^I- A]%0K>6[N%69"QZ &GRSQP@&1PH/3- R2DJ%+N"1@J2JS'H :=)<
M118\QPN>F30!._1?I3:0S1MY8# EER/<5'+<10D"20*3TR: ):*ACN89F(CD
M5B.N#2R7,,+;9)%4]<$T")**CCN(I21&ZMCK@TU[N!'*/*JL.H)H FHID4T<
MV3&X;'7!IC7ENCE6F0,.Q- $U%,CGCE4LCA@.X-,:\MU8JTJ@CJ":!D])3$F
M25-R,&7.,BHS>VP./.3\Z +%%,61'3>K KZBHOMUL"09DX]Z!%BDIOF*4W@@
MKC.:A^W6Q_Y;)^= RQ133(JIO+ *!G-1?;K;_GNGYT 3TM1O*B+N9@%]348O
M;=B )E)/3F@">BF/-'$NYW"KZDU&+VW9@HF0D]!F@1/2_G4<LT<(!D<*"< D
MTQ;NW=@JRJ6/  - $]31_=JI)<1Q8\QU7/3)JS;R))%N1@P]1292):***104
M444 %%%% !1110 4444 &**J:AJ=EI<'GWUS%;Q9QND; J>&9+B%)HF#1N R
ML#P0>AH DHHKS3XF_$6;PL\&F:6L<FIS'=SSY:]LCWS^E 'I=%>.Z3X4^(FK
M68OKWQ==:=+*-ZVX!.W/8\C'TKT/PM8ZGI>BI!K%\]Y=*26GD;)(H WZ*P4\
M:^&I+U;*/6[)KEFV"(2C<3Z8JSKFO66A:9-=W<T<95&:-7?;YC 9P/>@#5HK
MS;P+\3K;Q(+Z;4YK:P G6.V@>3YB"H[]^:[DZWIJ:D-.:]@6\/2 N-YXSTH
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MG^&=&,L\UW.CS.%QY"J>21^/Z5ZS';JMG' P#*J!.>^!BDBL;2!]\-K#&_\
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M(YR/,16QZTD5I!"^](U5L8R.M3T4#();2&9][QAFQC)HBM8H<F- N>I%3T4
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MQZC- #/C^2+[0<$C[_\ -:Z;Q7X2C\2_#FTE7:E_:VP>"0MCMT)]#Q^5</\
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MJYD\JX:9':-A'(HP2,]#GT'6KWBJX\1_$S4],TH>'KS3K>$DO+<QL "?O'.
M,8' ZT@/;O#]ZVH^'["\?.^6%6;)R2<<FM*JFEV:Z?I=K9IC;#&$X[X%6Z "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@]**#TH
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M 2G)_K*2G)]^@8WO12=Z6@ HHHH$%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "=Q3I/O_A2=Q2R??_"D-;"4444Q!1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4^3^'Z4RGR?P_2D/H,
MHHHIB"BBDR,4#$9@JDD@ >M>+^//$IU?439P.3;0'''1C77>/_$PT^Q.GVS_
M .DS##8/W17#>#O#S:_JVZ8'[-$=TA]?:A'K8*BJ<76J'6?#KPR8(?[6ND^=
MQB)2.@]:]('2H88(X8DB1<(H  ';%3T'GXBLZLW)A11108!1110 4444 %%%
M% !1110 4444 %%%% "4\_ZL?6FTX_ZL?6D,92T44Q!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 .?HOTIM.?HOTIM !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %31_=
MJ&IH_NTF-;CZ***184444 %%%% !1110 444&@"AJVK6FB:?+?W\RPVT0R\C
M \9.!T]S3-#URP\0Z8FH:=,);=R0&'L<&N+\=W,.O>)=$\)K+*J3R^?=;%W*
M8U!(5N>Y K.\&31^$?'^J^%IKC9%=O\ :+-67"G=\VQ?H"?RH ]!U_Q#I_AN
MR2\U*;RH7D$:M@GYB"0./I6,OQ*\- _OKQX%Z;Y8) O_ *#6'\:SCPMIO_83
MA_DU>@WNG6>HVIMKRWBGA/5)%##\C0!);74%W"LUO,DL;=&1LBLO6_%6D>'M
M@U&\CA>3[B8+,WT S7">$U_X1/XF:IX5@:1K*X@%W;HS9$(&<@#WX_*F>"-*
M@\6>,=6\6WJ^=##.;>R2;EH]O))'3OQ0!KZ;\6=+U'58K%M,U*U$CA%FGAPA
M).!T]370:WXRT?P_?PV5_.5N)H_,CC5&8E<D9X'M6U):Q2A0Z*P4@@,O&1T-
M>;^)'2'XY^&6D=406$N68X'\= '6Z3XVT+6;S[':WRFZ SY+HR-C\0*Z*O(_
MB7+9-XB\.MI1A;6/MBL[Q %O*Y!R17KE '.Q>+;63QM-X7$$PN8;87#2G&S!
MQQUSGGTKH0:\9UC4;W3?CS>'3K+[7=3:<D4:%MJ@D+R3V'%;[>-->\,ZY8V'
MBFSM%MKQBJWENY*H>.N0/6@#TBBN33QC(/'_ /PC,UF$CDM_/AN-WWQSQ4VO
M>)KK3O$.D:186*W<U[(?.R^#%&,98>O?\J .FHIH)VY(YK@-2\9ZM?\ BFY\
M/^&M/AEDM5!N+J=RJ(>O& <CD#ZT >@T5SL6L7FC>&Y]0\3""%[<;I&MV+*1
MG QD#U%<J/%/CB[L9=;M-"METU!YD=O+*1--'V8  @9'/6@#TLG'/2F1313I
MOBD21<XRC BN1_X2JZUOP1#K.@VD-W-,NV6%I"HCX.[G'4&N+^#NI^(ET&"W
M@TN&?37O'\VZ>8AUSC/&.<?6@#V:BN3\.^,)=<\7^(=$>S2)-*=5657),F<]
M1VZ4_7_%DNC>)-)TI+1)5OF*ERY!7'H.] '4T5R+^,IK+QLVA:I8K;6TZ;K.
M[WY$I R0WIT-)H?B^YU_Q/J5E:643Z19D)]O60_.^!E0,=02?RH TK#Q/;ZA
MXAOM'C@F6:S4,[L!M;..GYUNUQVB:^E]XXUC25TZ"%K5%8W"'YY,XX/'O6#:
M^/\ Q'K^O:KH^C:+;![*=X?M,LQV@*2,GCJ<=* /3OQI:\LL_B)KES=W&A+H
ML4OB&WEV&,2$1F,9#29QG ..W>M3PWXQU0^+IO"_B&SBBOQ'YT4MNV4=?Q H
M [^C\JY37-0\6MJAL=#TRT, B5S>7,I5=V3E0 #V _.LGP[XRUC_ (3+_A%O
M$.FQV]T\1EAFA?<L@ ))Y P.* .AT[Q;::EXLU/P]%!,MQIR*TDC ;&SCISG
MO705X>-<O=%^,GBF/3=/:^U"\$44$6<*,*I8L>P R:Z9O&?B3P[K-C:^)M-M
M5L[V78MU!(2(R1PN,#)S0!Z56!J_BJUTCQ%I.BRV\[S:D6$<B ;$Q_>YK>4Y
M&:XSQ/XACTWQQX;TE]-@N&U!G N'/S0XQ]WB@#M*.^*X#7O&&LGQC_PB^AV-
MJ]T(//,UQ(5 7\ >:ZG07U22PQK,,$=ZKE3Y#%E8=CR![T :U&:I:OJEMHNE
M7&HW;$00(7;'4X[#WKST^*_&USH[Z_;:'9K8*I<6YF;S60?Q?=]/>@#T^BN+
MU+QXMK\.#XKM+=9R%4^2[;1DL%(S['-8Z^,/%^LZ5_;FCZ-;)I\48<QW$A62
M4@?-@8/ .<<]* /2)Y5M[>69@2L:%SCT S6/X3\3VOB[0TU6SBEBA>1HPLN-
MWRG'8U6T;Q'#XJ\$R:K#$T7F02*Z-_"X!##Z9KS'X7ZOXD?P9'IWA_3K=Q!+
M(\MQ<N54DG(5< Y[T >YT5R/@;Q9<>(HKZUU"T%KJ6GR^5/$#D#KCG\#1K&H
M>+Y-2EMM&L+%8(P")[B4@L?3 4T ==17%^#/&=SK>HZAHNJV8MM5T]L2A#E&
M4]"#Z]>U<_I7Q)U[Q3<W.FZ-HL"7D$[H\TLI\I$7H2<$[B>,8H ]4HKB/"'C
M#4-1UN_\/ZW9I;ZG9*'W1ME)%..F0.>:@\0^,M7_ .$I/AOPYIJ75TD8>XGE
M?:D ."">#D<C\Z .^HKFM+U35]/TN\N/%$=K ML-PFMW+*R_B!["N9C\5>,]
M6L9M:TG1+<Z:N7ABGE(EN$[$  @9'O0!Z7320.]<GH_CNSU#P.WB2>(PI#&Q
MN(EYV.HY49ZUS^F^+/&5_IB>(3HMJ-).6^SK*?.9/[P&W],T ==X3\66OBVR
MN;JU@FB6WN&MV$H&2RXY&#TYKH.]>7_ Y_-\+:I)M*[M3D;!ZC*K7J H ***
M* "BBB@ HHHH **** "BBB@ HHHH *#THH/2@#R'5?\ DL%M_O)_Z#7KW>O(
M=5_Y+!;?[R?^@UZ]WJGT(ANPHHHJ2PHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH :YPO3)KYVT@_$_P -6MWI^EZ#,+26=Y3OM@Q);CKGT KZ"O[J*QLI
M;J=Q'%"I=W/10.]<S\/=7U37O#C:CJJ1!IIV,!C3:&BXP?YTP/(]"N/BKX=L
MWM=.T"58GD,K;[4,2QZ]Z]7^'FH^*M2TVZD\5V?V:Z6?;$ODA,IM'./KFO*;
M?Q/\2]9N;V31VGN+:&X>(LB$A2#T_+%>B?"O7]7U6'4[3Q!*W]J6TP!AD&'5
M-HYQZ9- 'HU%%%( HHHH **** "O+O%?_)<?"G_7I+_[/7J->7>*_P#DN/A3
M_KTE_P#9Z /1Z***H@****!!1110 4444 %%%% "TY/OTRG1_P"LH&-[T4=Z
M* "BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4M)1
M0 O<4LGW_P *;W%.D^_^%(:V&T444Q!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 M/D_A^E1U))_#]*0^@RBBBF(0]*R]<U:'1=,
MENY?X1\HS]XUI2.J1L['"@9)KQ/QOXD?6]3,,#G[)"=J<_>/K0=F#P[K3UV,
M:5[SQ)K9/+S3O@>U>W>&]%AT/2X[:,?.1F0^IKE_AWX9%E:C5+E/W\HQ&#_"
M*]!P*&;X[$)OV4=D&*6DHH/-%I***!!1110 4444 %%%% !1110 4444 %%%
M% "TX_ZM?K3*>?\ 5CZTAC****8@HHHH **** "BBB@ HHHH **** "BBB@
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M_-Z[RUT"QL]7N=3@BVW5R LK>H&/\*-*T#3M&N+Z:QA\N2^E\Z<_WFYY_4T
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M8VBBBF(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=3(P"1Y/!P>N<\U;^'K-HWC3Q+X4B=Y;*R*30M(Y)4,%^4>W- 'HUWJNGV!
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M"WF7$NHSZS+ )3=M!<%_,(R #C& >*]%^&=]J.H>!;*75$D6Z0M$?-4ABJG
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MK'[/#:A-\DS1(I*L?X90N<^^*ZFZ\/:;KOP\L#J$#2^1IJ2QXD9<-Y77@\T
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M7_V>@#T<=*6D%+5$!1110(**** "BBB@ HHHH *<GWQ3:<GWQ0,;WHH/6B@
MHHHH$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !W
M%+)]_P#"D[BED^]^%(:V$HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!"<5C>*M=BT327G9AYI&V,=R:U+F9+>!Y9&"H@+,3
MZ"O#?%OB&7Q#JQV9-O&=D2CO[T'=@\/[6>NR*%K;7?B'6U3+/+-)EB><5[IH
MVEQ:/I\-I"  @YQW/<USO@+PP-)L!=W*_P"E3KG!'W1VKM N#0:8[$*<N2.R
M%HHHH/-"BBB@ HHHH **** "BBB@!"<&N=\2^)/[(3R85#7##(SV]ZWIYH[>
M-I97"(HR2>PKR?7M074-8FFC8F/.$SZ5I3C=ZC+8\8:N) QG4@'E=@YKK].\
M7:?<6:R74RP2="I!ZUYECM6CIVB7VJHSVT6Y5."2<"M90BT!Z/\ \)1HO_/^
MGY'_  IC^*]&1=PO5;V /^%<9%X+U63.51/JQJ3_ (0;4_[T/_?1_P *SY8=
MQG5_\)AI/_/8_E36\9:2JDB5B1V ZURX\#:GD9>$ ]]Q_P *D_X0/4?^>T'_
M 'T?\*?+#N!L_P#">Z=_S[W'Y#_&C_A/=._Y][C\A_C6.G@._P#,4/-"$/4J
M3G^56_\ A !_S^G_ +YH?()*Y:_X3ZSW8^S38_#_ !IQ\?V6W'V:;]/\:I_\
M("/^?QO^^:L?\*]M]@;[?)S_ -,Q_C2_=CV(9/B H?\ =VAV]MQYIO\ PL _
M\^8_[ZJ;_A7UOG_C_E_[X'^-3#P%9!<&XE)]<?\ UZ?[L1GO\0)]W[NS3'NQ
MIO\ PL"Y_P"?2+_OHUI_\('8_P#/>3\JF3P/I2H XD8^N\BB],#$;Q_>?PVL
M0_$U&WCR_9"!;Q#(QG-=#_PA&C_W)?\ OX:#X+T@*0(WR1QESP:+P[ >;SSR
M7,S2RN69CDDT0S26\R2QL593D$'I6CJN@WFF7+*T3-'GY77D$5%8Z)J&H'$$
M#8_O$8 K6ZL,],T?5(-1L8G297E"C>,_Q=ZTZ\?>._T:ZY#P2*>H/6NDTGQO
M('6+4%!7IYB]1^%8RIO=!8[VBJEKJ%O>QA[>59%/H:M9YK*PA:***!!1110
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M>>-=$U34U\)_8[1Y19W<<D^TCY%&W).?H:[#6X);KPUJ-O"A>:6TE1%'=BA
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M .%)W%+)]_\ "D-;#:***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<1B2%PZD9!!J3/K68!1110(**** "BBB@ HHHH >_1?I3:<_1?I3* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *GC^[4%
M3Q_=I,:'T444BPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.>F:F5-K81U%+3(Y$=-R,&'J.:=D5F%A:*3BB@0M%)2T .?HOTIM.?HOTIM
M!1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
M+1244 +4T?W:AJ:/[M)C0^BBBD6%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4F:6JM]=Q6%I+<S,%6-23[^WUH G>5(P69@ .I/:J_
M]IV'_/[;_P#?T5YEK>NW%])YCR,"3E(E8@1CWQU)_'K67_:5SZI_W[7_  K5
M4FU<YI8F*=CV'^U+#_G]M_\ OZO^-9.K>)[2TC MV%R[ X\MAMX]6Z?A7FG]
MI7/K'_W[7_"JN]L%<X&<D#@?E35+N1+%=D;&I:]=7K$R3%VSD!<JB?3O^>:Q
MY7,TC.YRS'D@ 9IO09)J%K@;6V#=BMHI(Y92<]R97DA=7@FDAD4Y4H_3\.E=
M=IGCJ\CLVBO41YE&$EQP?]X?X5Q80OM8DYJ;M2E!2*A5E#8T]1UNZO))'DF>
M3=W8#@>@'3&?7FLM93-\W/U:I%Y5ABD4[ 1@4TDE8B4W)W9$"^\Y7 S@&D>0
M*<,,@\5.$9AP*0Q$<XIB&1.]I(LMM-)!(#E2C=_ITKK-#\>W%EB#6F,L/:Y5
M?F'^\!_A7*, <9 XICLG"-_%VJ7!,N%24'H>ZV]S#<P)+"X>-QE6'0U-7FG@
M/7Y;>[&B7!W1L"T#>GJO^?6O2EY KFE'E=CT:<U.-T+1114F@4444 %%%% !
M1110 4444 %%%% !7(?$G2]7UGP?/8Z+&)+F5U!5BHRN>?O>WXUU]<7\2-?N
M]'T.WM=+D"ZKJ$ZP6JXZDD ^W&1UH \OT[PU\8-)M1;64\D4(.0OGPMC\6S7
MJ'P[B\6PZ;=+XO<R79FS"Q9#\FT?W??-<1X'TK6=#^(_]F:KJLUV\EHTC RL
MR@D-T!KJ? &MWLWB'7]#U"]%[+:3^9',F-@C(&%X[C-,#T*BBBD 4444 %%%
M% !7EWBO_DN/A3_KTE_]GKU&O+O%?_)<O"?_ %Z2_P#L] 'H]+2451 M%)10
M(6BDHH 6BDHH 6BDHH 6G)]\4RGI_K*!C.]%+24 +1244"%HI** %HI** %H
MI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %[BED^_P#A3>XI
MTGW_ ,*0UL-I:2BF(6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6BDHH 6
MBBDR* #.*\^\>>,%LXGTVPF_TAN'=?X15_QKXN31;8VUJZM=R#'^Z/6O,-&T
M>]\2ZKY:9;<V9)6[#UH/4P>&27M:FR'Z!X=O/$EW(D3;0HRTC#BNOT[X6N)@
MU]= QC^%!R:[W2-(MM'L8[6W0 */F..6-:0ZT"K9A-MJGL06=K'9VR6\*!8T
M7 %6Y/X?I3*?)_#]*#SF[N[&444E!(M%)10 M)110 56O+R&RMFGF<*J^O>B
M\O8+*V:>=PJKZ]Z\RUW79]9NMH)6!3\B"KA%R8PUS7[C5[@JI*VX.%0=ZWO"
M_A<_)?7J\]8XS_,TGA?POG;?7J=.8XS_ #-=RHPN ,#TJY325HC!0 , 8 [4
MM)16)(M%)10 M%)10 M%)10 M%)10 M%)10 M./^K7ZTRGG_ %8^M(8VBDHI
MB%HI** %HI** %HI** %HI** %HI** %HI** %II'%+10,R-4\/6.J+F2$))
MCY9%X(KAM4\)W^G#>@,T8/5>M>H4A .0>1Z5<9M >4:=XAU'27"*Y**>8WZ?
MXUVVE>+++4&\N0^1*>SG@U-JGABQU0EBABD/\:#%<1JGA>^TQBX4RQ@\.E:>
MY,9Z@LBD @@Y[CI3Z\ITSQ+?Z8X7>98P>4<YKN=)\46.H@*7\J3NKFHE3:$;
MM+30ZGH0?>EK,![]%^E-I7/"_2FT +1244"%HI** %HI** %HI** %HI** %
MHI** %HI** %HI** %HI** %HI** %HI** %J:/[M058C^[28T.HHHI%A111
M0 4444 %%)FES0 4444 %%%)D#J: %HHHH **;N'K2]J %HHJ&XNK>TC\RYG
MCA3^](X4?F: )J*:LB.@=6!5AD$'@BEH 6BFD@=32]Z %HHHH **** "BBB@
M HHHH **K+?V;W1M5NX&N!UB$@+#\.M6: "BBB@ HHHH ***CGN(;6,RW$T<
M48ZM(P4?F: )**B@N(;F,26\T<J'HT;!@?Q%/=TC1G=E1%&2S'  H =14-O=
MVUVF^VN(IESC=&X89_"IJ "BDR/6EH **** "BDW#)YHW#&<T +129&,YHH
M6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ [4F?>EK$\0ZHVEZ8\T49DG
M8^7$@_B<]!3MJ)NRNR;4=;M=.RKN'FQ\L2_>)]/0?C7!:UXD?49?WBXC7F.
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M4VG)]\4#&=Z6D[TM !1110(**** "BBB@ HHHH **** "BBB@ HHHH ****
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MHHHH **** "BBB@ HHHH **** "BBB@ IQ_U8^M-IQ_U8^M(8VBBBF(****
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M_P!^C6(CNJ*X7_A:_AO_ )Z7'_?HT?\ "U_#?_/2X_[]&@#NJ*X7_A:_AO\
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M/3[],I\?WQ0,;WI*4]:* $HI:*!"4444 %%%% !1110 4444 %%%+0 E%%%
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MLB@Y 89Q4']C:;_SXP_]\"KU%9B*/]CZ;_SXP?\ ? H_L;3?^?&#_O@5>I*
M*7]C:;_SXP?]\"C^QM-_Y\8/^^!5VC(H I?V-IO_ #XP?]\"C^QM-_Y\8/\
MO@5=_&EH H_V-IO_ #XP?]\"C^QM-_Y\8/\ O@5>I* *7]C:;_SXP?\ ? H_
ML;3?^?&#_O@5>I* *7]C:;_SXP?]\"C^QM-_Y\8/^^!5ZC- %'^QM-_Y\8/^
M^!1_8VF_\^,'_? J]10!1_L;3?\ GQ@_[X%']C:;_P ^,'_? J[10!2_L;3?
M^?&#_O@4?V-IO_/C!_WP*NT4 4O['TW_ )\8/^^!1_8VF_\ /C!_WP*NTM %
M'^QM-_Y\8/\ O@5-'HVF[?\ CQM_^_8JQ4T?W*3*14_L;3/^?"W_ ._8H_L;
M3/\ GPM_^_8J]12**/\ 8VF?\^%O_P!^Q1_8NF?\^%O_ -^Q5ZB@"A_8VG9&
M+* 8.1\@I^I6:W^GRVK\+(N#5RBFG8#Q/4=+NM,NFBGB9=IX;L:K16\T\BQP
MQL[L<* *]ON+6"ZC,<\2NIZAA4-KIUI9\06\:#K\JXK;VV@K&=X7TDZ3I2QR
M?ZUSO<'L:V9V=;:5HQF0(2H]3CBI**Q;N[C/([[XD^+[*Y:R;P7,L\@(A<RD
M[N<!L;?TJ3X4^#=9TW4M2\1:X#;W5[N7[,5YY;<6/IR.!Z5ZO@$Y(%+2 \2T
MSPOKD?QJDU=]-G73_/8B<K\I%>ULQ5<XSCL*=10!Y9K'C_Q='JMWIVG>#KAG
MPWV>61^2O9MN,?K5GX6^$-3T=K[6]==_[3U$@O')RR@>I]>3Q["O2L#.<<T4
M -?[N:\)TDKX+^-MS;REK73[YCL=VPK[AD?7Y^*]XKC_ !OX#@\7_8YTN/L=
M_:.&BN0FXC!SCJ._- '-?&K0=6\0Z1IT>E:?/=/'.6=8ES@;3S1XY\*:EK'P
MUT6&RLR^I6$,)* 8D&$P5'OG^5>GVL4D-K%%++YLB(JL^,;B!R?QJ:@#R[X5
M>&]5TGP[JUSJT,R7U^Q9EF^_D!AD_7-9?P>\+ZQI-AKT.IV,]DUR(Q$9%QNP
M&SC\Q7LM%,#Y[\+ZAXF^'.H7FD#PJ+VXN),B5#M+C)QAL?,/3\:U/!/ACQ3#
M\69-:UNQ=%F21I)T'[O<5P #^5>WX&<X&?I2]* /"]0\-^+?!/CVYU7PSISW
M=E<G<T,(X93U##USDUS/C^]U_5/%6B7.N6"V4DFSR+4-ED7S,?-QUSD_2O5_
M$,'Q'3Q'-/H4VFO8,H$:7'&T>_O[US^F_#?Q'KWBN'6?&E_&WV9@T,-N^X<'
M( /\(SS0!!\2_#6M:UKOABXT[3I[F.WA02M&N0F&!YKTWQ+HX\0>%[S2F.QI
MX=H.,D'@_P!*VP,9IU '@6@:_P"+_AO8/HD_ADW4/FLT#JY4$Y^8@X^8$XK7
M\#>%=>UKQO+XM\26?D 9:"*;EE/\.T=@.WUKV4J#U /X4M 'CN@>&M:M?CIJ
M6L2Z=.NG2&7;<E?D;(&*71O#>LP_'N^UJ33IUTUS*5N2OR',8 Y^M>PT4 >+
M)X7UL?'JXUDZ9<#36E)%SM^0CR@.OUJ7XM^&=9UKQCH=UING7%U!!&HE>)<A
M/WF>?PKV2B@#R_XM:'J>M>"]-M--L9KFXCG5GCC&2 $(_G7(^)O!GB*?PCX:
MGMM.FDFL%VS6P'SCH<_3C]:]^HH \+UW5_%OQ!\*RZ=;>%);*%#YOF+*3OV\
M; ,#DY_2MKQ!X?U>Z^"&F:1!I\SZA$D(>W"_., YXKUH #H,44 >">&_$/C#
MX>^'8].NO"MQ<QLYD21Y2NW./DQ@XQC]:V_A-X7U:#6M2\0Z[8F*>?B S\R
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M*%Q!?VEYJ-S?W:'SP_"9P.>/QKU.[^(EO:_$&#P@;"5KB4J!/O&T97=TQZ4
M=M17%^.OB';^!YK&.>PENOM6<&-PNW! [_6JOB;XD?\ ",VEC?2Z-=3VMV@9
M720 (>.#QUY_2@#OJR?$7B/3_"^E/J6IM(MLK*A,:;B"3@<5@>(/B1I6B>%[
M36T!NEN\&&%6"LP[]?2J?BSQ#82_#=-9U[099;29HRUA(^U@2W!)]NM '9:/
MJUGKNDV^J6)9K:Y7<A9<$C..GX5>P,YQ7!P>+],T#X66?B&QTMX=.50([-'Y
M0%RN,GWYK#'QOMIM/6]L_#NH7$2C_2&3[L+9Z%L8Z8/XT >LT5Y;'\:+&]TV
M.;3M'OKN\R3+:0J2T:C^(D#&.GYUL>!_B98>,KNXLUM9;.ZA&X12-NW+W.0.
M.<4 =U17G.J_%"6QUN[T^P\-ZGJ8M7V236ZDJ&].GM6AX1^(MEXHU&XTZ2SN
M+'4(AEK6;E@!U[<?2@#2M/'.B7OBR?PU#),=2@+!U,1"_+UYKI*^<UU^U\-?
M'77=3N@S)&9@J*.68J,#\:[RU^,ML=9MM/U/0[W2UG("S7)P.>AQ@<>] 'J%
M%-C=9(U=2"K#((.013J "BBB@ HHHH **** "BBB@ I" >HI:* $P/2EHHH
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M5PP5C$RJB#.2"1R<9KO_  GH6F6.HZIJ5KJ/]HWEW-^^G+JQ3IA/EXXP/>N
MT"W\/>'OBBD>EW%M'I_V#.\S JQ(;N3U]JUOA3*MQX@\33Z9&8]%:Y^1"0?W
MV!N.>O//M3 ]5HHHI %%%% !1110 5Y=XK_Y+CX4_P"O27_V>O4:\N\5_P#)
M<?"G_7I+_P"ST >CBBCM15$!1110(**** "BBB@ HHHH 6G)]\4RGI]\4#&G
MK24=Z* "BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 +W%+)]_P#"D[BED^_^%(:V&T444Q!1110 4444 %%%% !1110 4C$
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M>=798)8O- X^?=S_ ./4@/._V?;.W?3=8NVB4W'G+%O/785SC\ZS_AJT=O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7$^.FF\W2A"S F4XVG'S<8_&NVK/U32H=5LS;S949W*R]58="/>FG9W
M(G'FBT>,MG>V[[V>:;6YJOA?4M,>1Y8GN(1EA)"N<?4=OKFL:2(Q[<D$,,JP
M.01[5UJ2>QYLH2CN,J&=7."IZ5-4D<7F G/2F00@$H-W7%26Z*GR@4TC#$4
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M+1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244 +1244
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M/,K5I59\TC)C\-Z5%]VSC/U%7XK2")0L<**!T %3T479B-V@= /RHQ]*=12
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MHH **** "BBB@ HHHH **** %I\G\/TJ.I)/X?I2'T&4E+24Q!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4\_ZL?6F4\_ZL?6D,
M;2444Q!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M /BZ?3M)N=+TK1[K4[[SY)"(MH1/G/#$D<XYXKT'PSXU@\0WEUITMG/8:E:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MEH *<GWZYWQ=XE'A725OVM)+H-,L/EQM@Y;//Z5O6[F0JV  5S0,=WHI,\T
M@T +12%@!DU!>W(M;"XNB"PAC:0@=3@9Q0(L45S_ (0\31^+/#T.KQ6[VR2.
MRB-V#$;21UK?H 6BDHH 6BDI: "N8\2>$8-;;SHF6&ZSR^,AOK734M)JZ(G3
MC-6D>96GP[OVF875Q&D8; (^8L/Z5W^G:7:Z99I;6\8"+W(R3[U=I:2BD9TL
M-3I?"-"*#G _*EP*6DJC>R# HQ137=47+,% ZDF@:78=0>*Y?6O'.DZ/E/-%
MQ-V6,Y_,UYWK7Q!U74]T<#?9HCV3J118[*."JU=;61ZAJWBG2M'#"YN5,@Z(
MAR:\]USXE7UVS1Z<HMX>FX\L?\*YS3?#VKZ[+F&&1\GF1^!^9KT#1?AG:6VR
M747,\G78#A:>AV^RPV'^-W9YU;VFK>(+LF-)KAV/+') KM]$^&/2759.O_+)
M#_,UZ/:V-M91".W@2->F%%6, 4KLYZN83>E/1&;INCV.E1B.SMTC'J!R:U'
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M** %HI** %HI** %HI** %HI** %HI** %HI** 'OT7Z4VG/T7Z4V@ HI**
M%HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI** %HI**
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M2TS6-!\<FR$$C0Y*R-_"4S][TS6C46M#",YJ6NQ[/10.E%9'2%%%% !1110
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M32L 8H0PSD'->EZ5,TVF02,3N*#)->=6MN]S<I"@+$GL.E>F6D'V>TBB_NJ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:@HG0#&Y1\PKOM.U>RU6!9;6=7R,E<\C\*I23.ZEB:=38OT4F115&XM%)10
MM%)10 4M)10 4M)10 M)110 M%)10 M./^K7ZTRGG_5K]:0QM%)13$+1244
M+1244 +1244 +1244 %%%% "T4E% "T4E% "T4E% "TE%% !2TE% "T4E% Q
M[]%^E-IS]%^E,H 6DHHH$+1244 %%%% "T4E% "T4E% "T4E% "T4E% "T4E
M% "T4E% "T4E% !2TE% "U-']VH*GC^[28T/HHHI%A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M'I10>E 'D.J_\E@MO]Y/_0:]>[UY#JO_ "6&V_WD_P#0:]>JI="([L****DL
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *\N\5_\ )<?"G_7I+_[/7J->7>*_^2X^%/\ KTE_]GH ]'I:2BJ(%HI*
M*!"T4E% "T4E% "T4E% "TY/OBF4]/OB@8WO11WI* %HI**!"T4E% "T4E%
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M0QM%)13$+1244 +1244 +1110 4444 %%%% !1244 +1244 +1244 +1244
M+1244 +1244 /?HOTIM.?HOTIM PHI**!"T4E% "T4E% "T4E% "T4E% "T4
ME% "T4E% "T4E% "T4E% "T4E% "T4E% "U-']VH*GC^[28T/HHHI%A1110
M4444 %%%)0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !2&EI#TH \CU7)^,=O\ [Z?^@UZ[7D=U(DOQFMBI! D4'ZA3
M7KE7);&5-ZL****@U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "O+O%?_ "7'PI_UZ2_^SUZC7EWBO_DN/A3_ *])
M?_9Z /1^U%%%40%%%% @HHHH **** "BBB@!:<GWQ3*?'_K*!C>])0>M% !1
M110(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** %[B
MED^_^%-[BG2?>_"D-;#:***8@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *DD_A^E1U))_#]*0^@RDHHIB"BBB@ HHHH ****!A5
M'4M)L]5@,-U"KCL<<CZ&KU%)I,EI2T9YIK7@&XM09M.?SH\DF,K\P'MZUSEG
MJ6HZ/-^YDDA96Y0_=/U'>O;JS-5T*QU>+9<Q#(Z.."*AQ['!4P.O-2=F<]I'
MCZUN%6*_7R)2?O\ \)]_:NL:]MH[;[0T\8AQG=N[5YGK'@:^T]6FM6^TQ#D@
M###\*YHSSB$VSR2>6K9V9X!I<S1E];K4?=J(];C\8:+)=& 70![,WW3]#6Y&
MZRH'5@5(R"#G->!XKK/"_BT:+:/;72R3)NRF#]WVIJ95#'N3M4/4Z*XK_A8E
MC_S[2T?\+$L?^?:2JYD=?UJEW.UHKBO^%B6/_/M)1_PL2Q_Y]I*.=#^M4OYC
MM:*XK_A8EC_S[24?\+$L?^?:2CG#ZU2_F.UIQ_U8^M<1_P +%L?^?:3\Z7_A
M8UCM ^S24<R#ZU2[G:45Q7_"Q;'_ )]I*/\ A8EC_P ^TE',A?6J7<[6BN*_
MX6)8_P#/M)1_PL2Q_P"?:3\Z.=!]:H]SM:2N+_X6)8_\^TGYU'-\1+5H'$4$
MBOM.T^]#D@>+H]SI-2\0:;I61=7*JX&=@Y8TNFZ_INJMMM;E&?&=A.#BO&KJ
MZFO;J2XG<N\AR3FDM[B2UN8YXF*NAR"#4<YQ?VC+GO;0]Z[T5Q5G\0K P+]K
M202 #<57.3WJS_PL'1O^F_\ W[_^O5<YW+$T6K\QUE%<H/B!HQZ_:/\ OW_]
M>E_X6!HGK<_]^O\ Z]4FF'UFC_,CJJ*YJW\<Z+<2A/-DCSGYI$P!^.:N?\)5
MHG_01@_[ZI.212KTVKIFS25CCQ3HA_YB5O\ ]]T[_A)M%Q_R$K?_ +[IIIC]
MK#N:U+61_P )-HO_ $$K?_ONK']KZ<1D7L/_ 'W1=#52#ZE^BJ/]KZ?_ ,_L
M/_?56A(C $2*0>G-%T4I1>S)*2F>8G]]?SI=Z?WQ^=%T.Z'T4S>G]X?G534=
M6M-+M#<7,@5 <#'5C[4-B<HI7;-!NB_2FUQQ^(FFF508IA&#C=CG'K73V5_;
M:A )[659(S_$#WI*2(A6A-VBRU24M)5&@4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 +4T?W:@J>/[M)C0^BBBD6%%%% !113)76-
M&=CA5&2:!,=17FFL?$6X-R8]+15C0D%Y!G=_A5/3_B'J=O,OVW9/#W 7:?SJ
M>8XWCZ*E8]8HJGIVH0:E9174#9CD&1[50\4W>JV6@W-QHMM]IOT \N+&<\\\
M?2J1V)IJZ-NBOG[5OB=\2="B275=+BLTD;:C36Q4,?0<UO\ AKQ=\2M2U&V-
M[HFS3Y8V?SA;$ C82I!SW./SH&>Q45X+J'Q"^*.E6CW=_HJVUNGWI)+4@#]:
M-(^(GQ,UJWCNK'2$N;1GVF2*U)''7G- 'O6:*\NU_P =ZOIOQ3TCPU (?L=U
MY/F;DRWSD@X/X5Z@.@H 6BJ>IZA!I6FW%]=/LA@0NY R< 9X]Z\FM?'GC?QA
M-<3^%=.MH-/M\C?<KGS#['UQCB@#V6BN8\+ZCKLOA)K[7K8+J*+(Q@5-F=N<
M#'OC]:X*?Q5\4+NUNM2L]%BL[.(!E@GB+2,N,Y7ID4 >R4&N'^&WCG_A--(E
MDF@\F\MMJS 'AR1U'Y=.U9OQ!^*EGX:2?3M.Q<:LHQ@CY(_<_3TH ]*HKB_A
MCXFO_%GA0ZEJ/EB?[0\6(UP, #_&NR8$J0#@T ._G17F/PU\=ZMXJ\0ZUI^H
M"'RK(?NS&FT_?(Y_*O2V=4ZD4 /HIH8%<BN5\;>.M/\ !E@DMS^\N9?]5;J?
MF?W]A[T =917C>E^)/BEXC26^TO3[&TLV^>);M#ED/(VG^+BNJ^'NL^+=5-^
M/%.GFT,>SR/W/E[LYW?7M0!W5%>;>/OBM9>&3<Z;8H;C557CCY(R?7W'I5_X
M6>*=0\7>&YM0U+RO.CN6B'EKM& JG^M '=4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %(?NFEI&^Z:!/8\3T_)^+<>?^?Q_Z
MU[;7BFGQNOQ9C8JVW[8YSCZU[76E36QC1ZA11169N%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>7>*_^2X^$_P#K
MTE_]GKU&O+O%?_)<?"G_ %Z2_P#L] 'H]+24M40%%%% @HHHH **** "BBB@
M IR?ZRFTY/OT#&=Z6D[TM !1110(**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** $[BG2??_"D[BED^_P#A2&MA****8@HHHH ****
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M%;#_ *"!_P"^/_KTO_"M1MR=0_\ '/\ Z]=[3S_JU^M'*@^I4>QY]_PK4?\
M00/_ 'Q_]>C_ (5L/^@@?^^/_KUWU+1RH/J5'L<!_P *V'_00/\ WQ_]>C_A
M6P_Z"!_[X_\ KUW]%'*A?4J/8X#_ (5J/^@@?^^/_KTG_"M5_P"@@>/]C_Z]
M=_1@4N5#^I4>QXEJNC7FCW#1W,3!-V$EQ\K?C1I&B7FLW*QP(P0'YY"O KVM
MXHY/OHK?[PS0L4:<(BK]!BER(Y_[/CSWOH>>_P#"LY<Y_M&//_7(_P"-(WPV
MG"_+J$;'T\O']:]%I:?*CH^I4>QYJ/AS>?\ /Y'_ -\?_7IK_#J^6-BES$S
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M-?\ A9VN?]"!JW_?9_\ B*/^%G:Y_P!"!JW_ 'V?_B*])VKZ"C:OH* /-O\
MA9VN?]"!JW_?9_\ B*/^%G:Y_P!"!JW_ 'V?_B*])VKZ"C:OH* /-O\ A9VN
M?]"!JW_?9_\ B*/^%G:Y_P!"!JW_ 'V?_B*])VKZ"C:OH* /-O\ A9VN?]"!
MJW_?9_\ B*/^%G:Y_P!"!JW_ 'V?_B*])VKZ"C:OH* /-O\ A9VN?]"!JW_?
M9_\ B*/^%G:Y_P!"!JW_ 'V?_B*])VKZ"C:OH* /-O\ A9VN?]"!JW_?9_\
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MX87]UH]XLT2W$<3/&W0[AD?D:YC1?$?C33? \-SX<TF :-:1GYKA"\LG)+.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2)YC86:%BR#ZDX/Z5V*.'4,I!4C((H::W",E+8?1112*"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR[Q7_
M ,EQ\*?]>DO_ +/7J->7>*_^2Y>%/^O27_V>F!Z.*6D%+3("BBB@04444 %%
M%% !1110 4Y/OBFTY/OB@8SO2T=Z* "BBB@04444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 '<4LGW_ ,*3N*63[_X4AK8;2T44Q!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4^3^'Z4RG
MR?P_2D/H,HHHIB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ IQ_U8^M-IQ_U8^M(8VBBBF(**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!S]%^E-IS]%^E-H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J:/[M0U-']VDQH?1
M112+"BBB@ HHHH **** "BBH+V6:"PN)K>+SIHXF:./.-[ 9 _$T 4M;\0:;
MX=M%NM3N5MX6;:&8$\_@*O6MQ'=VD5S"P:*9 Z-ZJ1D'\J^??B5XF\5:QX>C
M@UKPO_9ENLF1+YN[)]*[+PEXN\9O;Z192>#]E@(8T^U>=_ %&&Q[\4 >J].3
MV[UX1XNU[6O''Q!;PMHMQ-;VMO(4E9'VYVG#,2.=M>[2@M$X'4J0*\ ^'A^P
M?&G5+>Y(20^>B[N,MN'% '6_\*-T'^RQ#]MNUO=V6O ?F(]-N<8KM[[6M'\(
M:3;_ -HWH@MD C1Y26)(_,FMP'BO!?BO=7C?%+3+2.T_M&.*&.9+)V^5V+'/
MYX% ';:)\9/#>L:@UI+Y]B2P2&2X7Y923CC&<?CBJGQ+^(UMHNGSV>CZG&FL
M1NJO'Y>[ .#W&.AKBO$MKXG\0Z3]CC^'4-@X8,EQ;[0R@'IVZUI>/;#_ (M/
M97^H:3#::P=J3,4!DX.T9;KT H [#X<>.;+5_#L,-YJ23:I%&\MPNTY5<GGI
MCIZ5TNB>+M%\1330Z3?)<O#]_:K#'YBN/^&^F6"?"M+Y+.W6[>VG#SB,!V&6
MZGK7+_ 3_D*:SG_/- 'K4_BW1;;Q!%H4U\BZI+MV6^ULG(R.<8_6FW7C#1+#
M68M(O+Y(+^4@)$ZL-V>G.,?K7DWB%E;]I/2RI!PT(.#WV&NB^->CZ?)X<CU9
MI8X=0MI (6)P7!ZK[]!0!W.M>+=%\/RP1:G?QP23G]VA!9C^"@USGC^+P3=I
M9R>*Y@@P3!\SC.1_L_UKS/X=.GC/Q^+_ ,1W!>]LXU:"$KMWE<]?IZ>]:O[0
M.,:1CIE_Y"F!ZI=^*M T!;&TN[Y+<3H@M@X;Y@>!SC^=<_-\8O#$.N)IQF<Q
M'(:["_NT(SP>_4=A7GOQE7=_PC*?WK6-<_45M?%#0M+T_P"&NGSVUA;1S!8\
MR)$%8Y SDB@#K=>^+GAO0YX8?->\:0KN-N,B,$9!)..WI75:9KMAJ^E?VG97
M*2V9!(D /;K7EGACP_I4GP2>YEL+9[AHI6,K1 OG><<]:S_A)K\>D_#[7;J_
M+RVEE("L8YQN!R/Q)I =3J'QO\-V6H"WABNKN$@?Z5$H$8S_ +V#Q]*[K3=9
ML-<TS[;IUPD]NZG#KG^M>-V.IZMX@T9KG2O >E+8!2JR-&O.!UY6I_@%<2O9
MZ] [$QQE"J]@3NS_ "H P?A5XFTWPI-XEOM0EP"J;(@/FD(9^![UZWX1^)>A
M>+W:&W9[6Z#$"WN!AF '48X_6O*O@OH6FZOXFU>>_ACG:V4>7'*H93N+9.#Z
M8J;QOIEIH?QFT)--B%LD\D$CK%\HR9,' '08 XH ^@J*1>E+0 4444 %%%%
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MI"P!H 6BD!S03B@!:*0,"< \UG7^NZ?IEY:6EU-MGNW\N% ,EC_DT :5%%%
M!129_2EH **:)%.<<X]*Y/XC^)[WPEX6&IV"0O,;B.+$JDC#9ST(]* .NHJ*
M"0O;QNW5E!/Y5+0 4444 %%)G'6EH **;N!Z'I2DXH 6BDW<XI: "BD/0FN
MTWXIZ;JOC4^&X+:8-O:-+@GY790=PQC(Q@\^U 'H%%-W J2.<5P,'Q%O[Z^U
M"VT[PO=70LIVAD=;A1D@D9QCVH ] HKC/#_Q$L=4U1=(U"UN-+U5L[;:Y'WA
MVPV "3Z5TFKZO9:'ILFH:A<+!;Q?>8]_8>I]J +]%>>P>-=?\0IY_AOP_))9
MASLN+J41K,O8J"!Q6@/&=Y9^%[_5=5TB:VFLI/+:$M_K.!RK8P1S^E '945Y
MV_Q(U.'35U"3PA?&T*AS)','POK@#TKL]#UBVU_1X-2M'W0S#*G'3U% &C11
M6-XFU.]TG1I;JPM'NIUQMB12Q/X"@#9HJKI\\US8PS3Q&*1T!9",8-6<T +1
M110 4444 %%%% !1110 4444 4[^Y^QV4UR>D:$XKQF>YDN9&N)01=3$M)(>
MO/\ #]!_6O7M=S_8=X ,MY9('K7CL]R;V5K@QB,R_-@=!]*VHHY,7)I)$2 J
M#N;/-6%$>W+-R:HNC,556SCK5CHOT%;G$..,\4G:JLER2<**D@9F4EJ +L40
M8;C43@!R!TIRRE5Q3.^: 'I$STQK;RGWYSFIQ< #[M12RLXX&*!"-(S#!Z4V
MHHVD+89>*EH&/$;%=V*:.#Q4OG?N]H'-0TP'%V/4TW ;BE$9DX!Q3&C,'R$E
ML]Q0(:\ 2;*N-H]*]'^'"DZ'/)M(5[AB"1U&!S7#Z'H-QX@N_L\)9+5#^^G_
M *#WKV'3].@TRQBM+9-D48P!6%:2M8[<-!WYBY24M5KF\M[.,R7$J1KZL:P.
MP?-*L,+S/PB*6)]A7G?B?Q!I^LVD8M]_FQ/N1BO4]/RQ75ZKJT$WARZN+>6-
MU*%0-WX5YAM"Q1E "V!D4K@,(3=NE&WGKZTXX$F]'.SMFDNR& 28?3% B#1B
M, _2@02M*SJRX(/6I'AD"))NVKGL>M5YWEAPJ)FI"9?)'!#>AH&-_=2R[3]X
M5KZ+JMOHNI_:9D)&W: @K-15V;FX;Z4U#^\RRAU[4!<]0T#Q+#KC3*L31-'_
M  L>HK>S7F7@TLVJW"1;5+@?,3R!QT%>EJ<@<YH#H/HHHI@%%%% !1110 44
M44 %%%% !1110 UD5AAAD'M7E/BBSM8_C9X7B6WA$;VLI9!&,,?GZCO7K%>7
M>*_^2X^$_P#KTE_]GIB/1E15"A5 "\ #L*=2"BF0+1244 +1244 %%%% !2T
ME% !3X_OBF4]/OB@8WO24'K10 4444""BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!>XI9/O_ (4G<4LGW_PI#6PVBBBF(**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "I)/X?I3*?)_#]
M*0^@RDI:2F(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** %IQ_U8^M,IY_U8^M(8RBBBF(**** "BBB@ HHHH **** "BBB@ HHHH
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MV2.WD96'8A20:\G\#-XW\::"E]<>(I;2W0.D<L2)OG;=U;(( '3@"O5M;_Y
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M+2_V>>+*-$,2(!G9D@G/OFJOQ,'_ !9[3,#D36_\C7HFN?\ (G7O_7FW_H-
M$/@O7)?$/A>QU&<*LTD?[U5' 8'%=!7#_"C_ )$.R^K?SKN* "BBB@ HHHH
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M:/QH 6BD_&C\: %HI/QH_&@!:*3\:/QH 6BD_&C\: %HI/QH_&@!>XI9/O\
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MPNOP;_SWO/\ P&-'_"Z_!O\ SWO/_ <UZ+_9]E_SYV__ 'Z%']GV7_/G;_\
M?H47"R/.O^%U^#?^>]Y_X#FC_A=?@W_GO>?^ YKT7^S[+_GSM_\ OT/\*/[/
MLO\ GSM_^_0_PHN%CSK_ (77X-_Y[WG_ (#FE_X77X-_Y[WG_@.:]$_L^R_Y
M\[?_ +]#_"C^S[+_ )\[?_OT/\*+A8\[_P"%U^#?^>]Y_P" YI/^%U^#?^>]
MY_X#FO1?[/LO^?.W_P"_0_PH_L^R_P"?.W_[]#_"BX6/.O\ A=?@W_GO>?\
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M.W_[]#_"BX6/._\ A=?@W_GO>?\ @.:3_A=?@W_GO>?^ YKT7^S[+_GSM_\
MOT/\*/[/LO\ GSM_^_:T7"QYU_PNOP;G_7WG_@.:<WQM\&DY$]Y_X#FO0_[/
MLO\ GSM_^_0_PH_L^R_Y\[?_ +]"BX6/.O\ A=?@W_GO>?\ @,?\:7_A=?@W
M_GO>?^ YKT3^S[+_ )\[?_OV*/[/LO\ GSM_^_0HN%CSK_A=?@W_ )[WG_@.
M:/\ A=?@W_GO>?\ @.:]%_L^R_Y\[?\ []C_  H_L^R_Y\[?_OT/\*+A8\[_
M .%U^#?^>]Y_X#FC_A=?@W_GO>?^ YKT3^S[+_GSM_\ OT/\*/[/LO\ GSM_
M^_0_PHN%CSK_ (77X-_Y[WG_ (#FC_A=?@W_ )[WG_@.:]%_L^R_Y\[?_OT/
M\*/[/LO^?.W_ ._0_P *+A8\Z_X77X-_Y[WG_@.:/^%U^#?^>]Y_X#FO1?[/
MLO\ GSM_^_0_PH_L^R_Y\[?_ +]#_"BX6/._^%U^#?\ GO>?^ YH_P"%U^#?
M^>]Y_P" YKT3^S[+_GSM_P#OT/\ "C^S[+_GSM_^_0_PHN%CSK_A=?@W_GO>
M?^ YH_X77X-_Y[WG_@.:]%_L^R_Y\[?_ +]#_"C^S[+_ )\[?_OT/\*+A8\[
M_P"%U^#?^>]Y_P" YH_X77X-_P">]Y_X#FO1/[/LO^?.W_[]#_"C^S[+_GSM
M_P#OT/\ "BX6/._^%U^#?^>]Y_X#FC_A=?@W_GO>?^ YKT3^S[+_ )\[?_OT
M/\*/[/LO^?.W_P"_0_PHN%CSK_A=?@W_ )[WG_@.:7_A=?@W_GO>?^ YKT3^
MS[+_ )\[?_OT/\*/[/LO^?.W_P"_0_PHN%CSO_A=?@W_ )[WG_@.:3_A=?@W
M_GO>?^ QKT7^S[+_ )\[?_OT/\*/[/LO^?.W_P"_8HN%CSK_ (77X-_Y[WG_
M (#&G/\ &WP:V,7%YP/^?<UZ'_9]E_SYV_\ WZ%)_9]E_P ^=O\ ]^A1<+'G
M?_"Z_!O_ #WO/_ <TO\ PNOP;_SWO/\ P'->B?V?9?\ /G;_ /?L4?V?9?\
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M_ <UZ+_9]E_SYV__ 'Z'^%']GV7_ #YV_P#WZ'^%%PL>=?\ "Z_!O_/>\_\
M <T[_A=O@W8!Y]YG_KW->A_V?9?\^<'_ 'Z'^%']GV7_ #YV_P#WZ'^%%PL>
M=?\ "Z_!O_/>\_\  8T?\+K\&_\ />\_\!S7HO\ 9]E_SYV__?L4?V?9?\^=
MO_WZ'^%%PL>=_P#"Z_!O_/>\_P# <T?\+K\&_P#/>\_\!S7HG]GV7_/G;_\
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M@SM;R_=+KM/Y5;_L^R_Y\[?_ +]C_"IDBCB4+&BHHZ!1@47"P^BBBD,****
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M' 49?I73^ O"\O@_PO%I$UREPZ2N_F(NT'<<]*B\.>$9M$U[Q'J,MTDL>KW
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M*.C=&!X(H \NUJ^3QG'X1TFVNSF[ NK@XW!DCYZ^I9"*9H^LMX:\*^*-(OI
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MMZT 8G@#=_PI[Q7N&W:]T-N<A?W8X%=+\)]'T^W\ Z;=I;Q^?<HSS.PR2=Q
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MR'H>HKE?@L<_#*P/_36;_P!&&@#T"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#"\4^)[+PKI@O+O>[.VR*&,9>5NR@5D?#OQI<^-
M++4;FXM%M3;7/DJ@SG&,\Y[UUT]K;W13SX(Y=AW)O0-M/J,]#7FOP;^[XI_[
M"TE 'J%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M37=45BQV@#))["G4UE# AAD$8.: /.K7XFC5?'UEH&GV^;.;S%:YD1E+%0V=
MN>V1C-;?C'Q9-H"V=GIUK]KU6]D\N"(GCH26/MP:YG7K>&V^.'A-(8DC3[),
M=J* /X^PI?%['_A=/@U<G;Y<IQ^#4 :6F^,M;M/$EKHGBC3X+::^'^B2VI)1
MB.H/)Q7?#H,UYO\ %4/9)H&K64)?4(-02*,@%CM8-D8KT@=* %HHHH ****
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M.I8],?C7)>+;:"U^,'@>*WACAC E(2-0H'7L*L>)5^T_&/PVDJ$QP12/&?\
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MA5P .  .E/Q2XHKF/0$Q1BEHH 3%+110(****!A1110 4444 %%%% !1110
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M]\Z_O'XQE02/7!J_XQTG4=/\1Z=XLT>V:YF@!BO($/SRQ''0'CC!]^:]"HH
M\STR#5_&?CFUUK4=-FL=(TU";>&YP':8]QM)Z8'6O2E 48Y_&G44 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4=J** //?%.AZG??%#PIJEM:
M-)960D^T2@C$><XSSG\JE\=:%J4NHZ3XDTF)[F]TN0XM VT2HWWLG\!7>T4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1RSQPC,CJ@]6
M.*>< 9)Q7@>GC4_BQXTNH]1GEAT.T8[K=)#A>2 !ZDD=: /<H]2LY6VI<PLP
M[!Q4ANX5<J\T2D=BXS7#P_"#PO;7-M<V\5S'+!(LBL)>I4@C/'/2O,=7T6S\
M0_'R?2;_ ,S[+.^'$;[3Q%GK]10!]$QSQRY\N1'Q_=;-25X3XL\,:O\ #51J
M_A?4KPZ>' FMB21&,=6/<$_SKU'PEXHB\2^$K?6"I0%2)<C'S+][\,YH Z"2
MYAB.))44GLS 4&XB5 YD0(>C%N*^7/'5Y>^)[W4/$0D)TZ"X%M:MT#+S@@?A
MS7M&@>&[#Q9\)]"T[4_--N;:*0F)]K9'3F@#N?MEM_S\0_\ ?8J5)%D4,C!E
M/0@Y%?/_ ,3_  'X8\':% ^G_;!J%S+MA#S;A@8W9_ U[!X$TZ;2?!6E6-P0
M98H?F(.>I)_K0!?UGQ!I7A^".;5KZ*TBD;:C2' )]*O6]Q%=01SPN'BD4,C#
MH0>AKR']H3_D7='_ .OIO_0:U;+XN>%-(T?3[66XGF>*UB5V@CWJ"%&1G/44
M >A:GJEEH]DUY?W"06Z?>D?H*33=5LM8M$N]/N$N+=\A9$.0<5POQ&U>SUKX
M47U]8RB6WFB5E8?4<'W%1_!JX@M/A;!<7$BQQ)-,6=C@ ;J /2Z*\\N/C1X1
M@NY(/-NY0C;?-CARA]P<]*[>PU.SU2SCO+&XCGMY!N61&R"* +E9&H>)]%TF
M_@L;_48+>ZGQY43GYGR<#'XURU_\8_"5C>2VIFN9VC.UG@BWJ?H<UYY\1=0B
MU7XE^$+Z!)$BG6W=5E7:P'GGJ* /H,'(S17*Z]X_T7P[JUOIEV+F2[N%!CC@
MBWGDXQUZU:UOQCH_AZQ6YU.<P,R!T@(_>M[!>YH Z"BN/\/_ !,\-^)+K[+9
MW,D5P3A(KA-C.?\ 9&>:EU3XA:#HWB%-#O998[M@ISL^1<C(R<T =717-^&/
M&VD>+GNUTHS,+4J)&D3:#NSC'/M71DX% "T5QS?$[PS'<ZC!-<R0R6'^M$B8
MW'L%YY-,T+XH^&=?O_L5M<2P3D#8MRGE[_9>>30!US7,*,5>6-2.S,!3TD60
M91@P]0<U\U_&")KGXC/"K$$Q#'Y9KTOX+ZN+OP8UI(S--8RM'(S'U)(_(4 >
MC/=01MM>:-6]&8"I58,H92"#R"#UKY1^(UU=:YXDU;6,KY%O="S^4XR0"!^B
MU]&^!/\ D0=!_P"O&+K_ +HH Z*BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH R_$
MEE<:EX:U*RM,?:)[=XX\MCYB,#GM7D7P'NTAN=7TN8JMPK;Q\WWN<''Y5[@>
MAKSGQ%\+5O=6&L^'[XZ/J6?F=!E&]\>M 'HI8*.>]>"P_P#)RZ_[Y_\ 1-=C
M%X)\=-=VS7GC;S[>.5'DB$&-X4@D=>^*IZW\*=:O?&T_B73/$,5C<.08R("6
M3Y=IYSZ4 :OQAU>SL/ =Y9S$_:+W$<*J,\@@Y/H, UY?/K]WX=^$&EZ,T;0R
M:E)+([MU$.[/'N<@UZ!9_"%KG4UU'Q-K$VJW"\D ;58CID>F*])33[001Q?9
M8MD:[44H#M'H* /FSQ3XE\-S_#K3] T5Y6FMG1I7,!C#G!RW7J:]<^%'B;3]
M7\'6>G6C2FXTZVCCGW)A0>>A[]*M^/O 0\7Z/'8VDUO8LLH<OY.<@9XXQZUI
M:5X;GT?P7%HUG<11WT5J(5NA'P6 X8B@#S"2Z/C[XS6T<;.VG:4P8,#N0E3G
M/X]/PKW%0%4 # '85P_P^^'P\%1WDLUV+J\NWR\BKM&T<@8^I-=S0!XY^T+_
M ,B[H_\ U]M_Z!6]9:#H?_"I3:Q(DEH]CYC.6!R^-QY]FJ_\2/ T_CK3;*U@
MO8[4V\QD+.A;=D8QP:Y>?X3>)%TDZ+8^+6BTDJ ;>2+//!/([9YH X?P[=W$
MWP4\2VTLK-%!*@B0]%R<G'XT^2XFM_V>['RI&3?J;(V#U'S<5ZBWPRAM_A]+
MX9L+D)+< &6YD7.YLY)P,<>E6-&^'%M:_#\^%M2F6X4LS>=$NW!)R",YYH 9
MX2T?29?A/8V]Q;0K!<V"M<' &XE>237E?@34+V+P%XT@AG?[/;V^Z%<\(2&R
M1^0KLX_A3XHMM)ETBU\8&/37R/(,1/RGL3FNX\,^"M.\/^%SHOE+-'*#YY<?
MZPGKF@#A_@3I]F_A.ZOVMHVNI+MHVE*Y)4!2!^!)_.N>^,IGB^)>@M9(K72P
MQ&%2."_FG;Q]<5T=I\)_$.AWMT_AWQ7]@M9GW"(Q%CCW.<5:U7X7ZOJ^LZ#J
M=[KL<UQIJ()G>$YF*R%\CGC@@?A0!SGPHN-/U7Q?JEYKLS2>)1,WEB5OE"@8
M.WW'(^E4O&\NLWWQM@M+!(KBY@"BTBNO]4N8\G/MU/UKO/$_PSFU+Q-;:_H=
M]%I=['@RGRRPD/J<'TXJUXP^'TWB62PU"#4C9ZO:1!!.B_(QZDXZ]?>@#B]4
M\(?$;6M<T[4[N#2[>6S<;)+60(0N>?7/%9GCK3H=9^/-GIMSN,%P(4<*<$C:
M:[_2_!WC&/5;2XU;Q;]MM87WM!Y6-W&.N?>G:M\.[B]^)=IXM34(DC@V9@:,
MDG:,=<T =9H_A_1] 60:7I\%IYN/,\I<;L=/YFM3.5KR/5-)U37_ (TVLB07
M<.FV:JSR.C".0J>5STYKUQ4"KM48% 'SQX6LK6_^.]S#=0K+&LDD@5AD!E7(
M/X&KOQ5@2W^+/AGRU5-Q@)VC&?WQKM="^&=SH_Q$G\4/J44L<F_$ B((W+CK
MFI?&7PZN?%'C#2=;BOXH$L?+S$T98OM?=P<\4 >>^/0#\:[ 'G,D6?TI\VK6
M7P]\=>+;.1I7@N[8M&H&?WDF#^ &37<^(?AE<ZWXZMO$2:E'$D+(QA:,DG&.
M^:7XA?#*3QMJ=E=Q7T5KY*E'!C)WC.>QI@>3:GHXT[X(V=TZ.MQ>:D)'+="
MK[2/P->_^ _^1!T'_KQB_P#016-XN^'S^(O!6G>'[:\CMOL;1GS'C+!@JE>@
M/O74>'],;1?#NGZ8\@E:TMTA+J,!MHQG%(#2HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** #%&***8@Q1BBB@ Q1BBB@ Q1BB
MB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q
M1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB
M@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1
MBBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@
M Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1B
MBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q1BBB@ Q2T44 %)BBB@ Q2T44 )BC%%% !B
MC%%% !BC%%% !BC%%% !BC%%% !BEHHH 2C%%% !BC'K110 @0#H*7%%% !B
MC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%%
M !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC
M%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%%
M!BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%
M%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !
MBC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%
I% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BC%%% !BEHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>gvvh0m1pmdf2000002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,.!6T# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>"M!;49H6F8G:B#N:K?#CQ1=>+O#AU2ZC6-GD(5%[#)KRG]H&UULW<-SO?\
MLC:!MW<;_I5#X/6OBF!XM2267^PH@S.@;C(SVH ^EJ*^8KGQGXM^(GC.73M)
MU)--B3<8PTFP8! Y/<U>EA^*7@O5K9Q<2ZHDG.(SO4X^M 'T?15'1KR?4-(M
MKJYMFMIY$!>)NJGTJ]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@Z$^1A1116I@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\&_:0)$>@8)'SS?R6O>:\&_:0_U6@?[\W\EH \[\
M'R-]E9"<CK7T#\*_^0'>?]?'_LHKY[\'?ZEOI7OWPKNHCI][:[OWPE\PC'\.
M /YUQUDEC5Z+\CUE=Y=\_P!3T*BBBNP\D**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC=NZ5W5>G3JPJ*\&>-5H5*+M-6"BBBM#(**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\&_:0_U6@?[
M\W\EKWFO!OVD/]5H'^_-_): .&?_ )$K0?\ <;^9KW'X>^(]&L_!&EVUSJ=I
M%.J,&C>50P.\]LUYIX:\$:GXL\!Z/+8/$JPAE;>?>N9U+2)]#\0MIMUL,T$J
M!BO3G!_K7ITX0K45"^J)>C/K%&5T5U(*L,@CN*6JNF?\@JS_ .N"?^@BK5>:
M]R@HHHI %%%% &#XK\/OXBTK['',D+;PVYEST->7^)O!DWANSAN);N.82/L
M5",<9KVZN$^*,<DFBVGEQN^)B3M4G VFN+&4(.#J6U/1P&)J1J1I)^ZQOPL_
MY MW_P!=A_*N]KQKX=WUU'XABM$G86[Y9H^,$XKV6JP4U*BEV(S&FX5VWUU"
MBBBNLX0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM6JW9S/.1^@]J[J@ KS?4_@GX4U;5+K4;E;KS[F5I9-LS ;B<FO2** /+?\
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M<EW$KK;H""W(.*Z)65T#*05(R"*[:<DXK4\^K%QF].HM%%%69!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME(]C,Z7M(QK0U1UE%%%>H>*%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M17G/PXUK4-4U"]2]NGF5(U*ACT.37HU=E&JJL.='GUZ+HS<&%%%%:F(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *RM<\-Z5XC@C@U6T2YCC;<JOV-:M% 'G/Q)N?#&CZ=IT>OZ.U
MY8JQ5-H)\O&.U9>@:%\)O$<:FPL[%G/_ "S9L,/PS7J5W8VM_"8;N".:,]5=
M<UYCXN^&G@N%6O/MJ:+/U5DF"\_0]: .B3X4>"0RNFAV^0<@C-=C#$D$*0QK
MMC10JCT KYCTOQ[XDT+Q"FFZ)J4NOV>X _NB2!G';^=?3%G+)/902RILD>-6
M9?0D<B@">BBB@ HHHH **** "BBB@ HHHH *\&_:0_U6@?[\W\EKWFO!OVD/
M]5H'^_-_): .R^"'_)-[/_?:O1Z\X^"'_)-[/_?:O1Z "BBB@ HHHH ****
M/(/C=#+,-*\J)WPS9VC/8UYO9>)_$>B6T=G:ZA=6L .5C' ZU]2/#%+CS(T?
M'3<H->)?&R*.+6=+$<:H# <[1C^(UZ.%K*5J31+74]BT:62?0[":5B\DEM&S
M,>I)4$FKU9V@_P#(NZ9_UZQ?^@"M&N"6[*"BBBI **** "BBB@ HHHH ****
M "O$?'^GFR\4W#&0-]I42],;>V/TKVZL+5_"6EZW=K<WD;-(J[00>U<V*HNK
M"RW.S XA4*G-+8XG3?B8EAIT%I_9COY2!=WF@9Q^%6O^%KI_T"G_ ._P_P *
MW/\ A7.@?\\7_P"^J9+\.]!2%V$+Y"DCYJYU#%I6YD=3JX"3NXO^OF9$?Q52
M25$_LIQN8#/FC_"O1@<@&OG*8"WU"0(/ECE.!]#7=CXJ70&/L$?Y_P#UZC#X
MVU_:LTQ677Y?81]=3U.BN#\->/9]=UN.P>T2-74MN!]*[RO0IU8U%S1/*K49
MT9<L]PHHHK0R"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /._BKJNMV-G8
M6NBW\5C)=2['F<J,#CU^M86C_!47KI>^*M:N-4D;YC&KD1FF_'R.VCTG3;Z2
M?;/;3%HXST?ID5'I7[07A\:; EY9W,<ZH%94 QQ0!ZCI/AG1M#A6/3M.@@"C
M *KS^9YK6KR>/X_^%I)%007>6( X%>IVMPEU:PW$>=DJ!USZ$9H EHHHH **
M** "BBB@ HHHH **** "O!OVD/\ 5:!_OS?R6NP\?:!XYU368YO#6JI:V@C
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M/2I;FZ@LX3-<2+'&.K-1=6N'*T[6)J*BMKF&[A6:"0/&W1AWJ6F)JVX4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M ',^,-3\*Z;;0-XH%J8F8B/[1#O&?;@UQ_\ PE7P@_NZ1_X!?_8UZ%K/AW2_
M$$<<>IVB7"QG*AQG%8W_  K3PE_T![?_ +Y% '+Q^*OA$TBJ@TC>2 N+/O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]]J]'H **** "BBB@ HHHH **** "O)_B'\/=<\3>)/M^G_9O)\L+^\D*G(
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MVN+U[23HFKRV!E$FP?>QUJ:F*KTU>42J6"PU67+";;]#V_\ X231?^@I:?\
M?Y?\:5?$6C.ZJNIVA9C@ 2KR:\I\,>"6\1Z?)="[$.R39M*Y[ _UK&>R_L[Q
M-'9E]_DW,:[O7D4GC*JBI..C*67T)2<(S=T?0749HIJ?ZM?H*=7I'CA1110
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MD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@A!_WU1_PD&D?]!"#_OJCGCW#V<^S-*BLW_A(-(_Z"$'_?5'_"0:1_T$(/\
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MTJ*S?^$@TC_H(0?]]4^'6M-N)EBAO87D<X50W)HYX]P]G/LR_1115$!1110
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M@\-V6J2PB%[A-QC!R%Y]: -BBBB@ KG6\%:0_BU?$IB;^T%7:&W'&/I7144
M,EBCGB:*5 \;C#*1D$5YY??!;PM>7KW"+/;AVR\4,A56_ &O1J* ,O0O#VF>
M&]/6RTRV2&(=<#ECZDUJ444 %%%% !7@W[2'^JT#_?F_DM>\UX-^TA_JM _W
MYOY+0!V7P0_Y)O9_[[5Z/7G'P0_Y)O9_[[5Z/0 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y5K7P_UF_UJ
M[NH6M_+E?*[F.>GTKU6BL:U&-56D;X?$SH-N'4\:_P"%9:YZVO\ WT?\*/\
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M1]5K?RA='K%%>=^'?BQ9^(=<M]+BTR>%YLX=G4@8&:]$K*=.5-VDAW"BBBH
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M+_OK_P"M7TA11]?J>0<J/F__ (5/XI_Y\XO^^O\ ZU'_  J?Q3_SYQ?]]?\
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MX+_Y$S2/^O6/_P!!%;U87@O_ )$S2/\ KUC_ /016[7GU/C904445 !1110
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M"'\Z/^$CT?\ Z"$/YUY;_P *RU_TM/\ OZ?\*/\ A66O^EI_W]/^%'UG$?\
M/L/JF$_Y^GJ7_"1Z/_T$(?SH_P"$CT?_ *"$/YUY;_PK+7_2T_[^G_"L[6?!
MNJ:#9?:[T0>5N"_(Y)R?PI2Q5>*NX%1P6%D^6-34]QMKJ"\A$UO*LD9Z,O2I
MJY/X=<>$+;ZM_P"A&NLKNISYX*7<\RM!4ZDH+HPHHHJS,**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?$";=7L>LG02+ZUZ70 4444 %>#?M(?ZK0/]^;^2U[S7@W[2'^JT#_?F_DM
M'9?!#_DF]G_OM7H]><?!#_DF]G_OM7H] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4THC'+*#]13J* $  & ,"EHHH **** "O'?CG_J]+^I_K
M7L5>5?&32=1U1--%A8W%SL)W>5&6QUZXKHPC2JJXGL=OX,(_X0S2.?\ EUC_
M /016[D>HKYCCTSQK#&L<=EJZ(HPJB)L ?E3OL'CC_GUUC_OTW^%=$L(FV^=
M"N?361ZBC(]17S+]@\<?\^NL?]^F_P */L'CC_GUUC_OTW^%3]27\Z#F/IK(
M]11D>HKYE^P>./\ GUUC_OTW^%'V#QQ_SZZQ_P!^F_PH^I+^=!S'TUD>HHR/
M45\R_8/''_/KK'_?IO\ "C[!XX_Y]=8_[]-_A1]27\Z#F/IK(]11D>HKYE^P
M>./^?76/^_3?X4?8/''_ #ZZQ_WZ;_"CZDOYT',?361ZBC(]17S+]@\<?\^N
ML?\ ?IO\*SVOO$27WV%KB^%UNV^2<[\^F*:P-]I(.8^JLCU%&1ZBOF7[!XX_
MY]=8_P"_3?X5#=)XOL;=KB[35((4^])(C*H_'%+ZE_?0<Q]09'J*,CU%?+ED
MWBO4H3+8_P!I7,8."T2E@#^ J!;[Q$U]]A6>^-WNV^2,[\^F*?U'^\',?561
MZBC(]17S+]@\<?\ /KK'_?IO\*/L'CC_ )]=8_[]-_A2^I+^=!S'TUD>HHR/
M45\R_8/''_/KK'_?IO\ "C[!XX_Y]=8_[]-_A1]27\Z#F/IK(]11D>HKYE^P
M>./^?76/^_3?X56O6\5Z;");[^TK:-CM#2J5!/IR*:P5_M(.8^H\CU%&1ZBO
MEZT3Q??VZW%HFJ3PL<!XT9@?Q J?[!XX_P"?76/^_3?X4OJ7]]!S'TUD>HI:
M^7[F+QC9V[W%S'JD,*#+.Z, ![G%>K_!V:_N- N9KUYI \Q\MY.XP.E15POL
MX<W-<:9Z31117(,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "N<\<Q23>%+E(D9W)7"J,GK71TA (P1FIG'G
MBX]RZ<^2:EV.(^&-M/;:)=K/"\3&XR XQGY17<4@ '0 ?2EJ:5/V<%'L57J^
MUJ.?<****T,@HHHH *X[XD037'AK9!$\C>:O"C)ZBNQI" >H!^M14ASP<>YI
M1J>SJ*?8YCP!#+!X4MXYHVC<%LJPP>IKJ*0  8  ^E+13AR14>P59^TFY]PH
MHHJS,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR_XW:]<
MZ=X6ATNR9EN=2D\H;>I7N!^8KU"O(OCO83KI6E:[""PTZX^90,_>QR?^^: .
MJ\#> -(\+:);HMK%+>,@:6=UR6-=:]I;2(4>WB93U!0$5F^&==LO$6@VNH64
MR.DB#(!Y4^A]*V* /#?B?X6A\&ZK8>,- 7[*RSJMS%&<*V2!^N<5[1IMU]NT
MRUNL8\V)7(^HKRCXVZY;W=G8>&+1EGOKNYC)1#DH P//Y5ZGHULUGHME;O\
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M_P"NC_SKML#TK/T71K30-,33[%"L"$D G/6M&IJ24IN2&CE/B0!_P@6J\?\
M+$_R-5?A5_R(5E^-=1JVEVVM:9-I]VI:"9=K@''%,T71K30=,CT^Q0K!']T$
MYJ^=>RY.MQ=30HHHK$84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1F8*NI6I8G  E'- &A//%:P/-/(L<:#+,YP *YJV^(GA:[OQ90ZO;F8G:,L
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\&_:0_U6@?[
M\W\EKWFO!OVD/]5H'^_-_): .R^"'_)-[/\ WVKT>O./@A_R3>S_ -]J]'H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%<WXO\ &NE^#;%;B_<F20XCA3EG/L* .DHK
MRB/XTQV\T+ZKH=Y964S +<.. #W->GV5[;ZC917=K*LL$J[D=3P10!8HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%%?,G_"F_B+_ ,_(_P# P?XT?\*;^(O_ #\C_P #!_C0!]-T5\R?\*;^(O\
MS\C_ ,#!_C1_PIOXB_\ /R/_  ,'^- 'TW17S)_PIOXB_P#/R/\ P,'^-'_"
MF_B+_P _(_\  P?XT ?3=%?,G_"F_B+_ ,_(_P# P?XT?\*;^(O_ #\C_P #
M!_C0!]-T5\R?\*;^(O\ S\C_ ,#!_C1_PIOXB_\ /R/_  ,'^- 'TW17S)_P
MIOXB_P#/R/\ P,'^-'_"F_B+_P _(_\  P?XT ?3=%?,G_"F_B+_ ,_(_P#
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M4W\1?^?D?^!@_P : /INBOF3_A3?Q%_Y^1_X&#_&C_A3?Q%_Y^1_X&#_ !H
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MINBOF3_A3?Q%_P"?D?\ @8/\:/\ A3?Q%_Y^1_X&#_&@#Z;HKYD_X4W\1?\
MGY'_ (&#_&C_ (4W\1?^?D?^!@_QH ^FZ*^89/@_\0XHFD:Y&U1D_P"F#_&N
M2\+:+XE\8:C+8Z7>2M-$NYM]P5&/Q/M0!]ET5\R?\*;^(O\ S\C_ ,#!_C1_
MPIOXB_\ /R/_  ,'^- 'TW17S)_PIOXB_P#/R/\ P,'^-'_"F_B+_P _(_\
M P?XT ?3=%?,G_"F_B+_ ,_(_P# P?XT?\*;^(O_ #\C_P #!_C0!]-T5\R?
M\*;^(O\ S\C_ ,#!_C1_PIOXB_\ /R/_  ,'^- 'TW17S)_PIOXB_P#/R/\
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M 4444 %%%% !1110 4444 %%%% !1110 5'/_P >\O\ N'^525'/_P >\O\
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MK#IEA;SF>&QMHICUD2)58_B!5JFNZQJ6=@JCJ2:$D25 \;!E/0@Y% #J***
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M-7CU35+^YU2YB_U7GME5/KTKTD# P.@H **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBF2S101F2:1(T'5G8 #\30 ^BHK>ZM[N/S+:>*9.FZ-PP_,5+0 4
M57EO[."=8);N".5ONQO( Q^@JQ0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>gvvh0m1pmdf2000014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,G!YX# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOB;_ (07P#&+-PT\@%M V<XXZ_D#7G'P[^%__"9VC:]XBN9I4E8E$+?>YZT
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2"X4DHI&T=>V:]XKS[P!X9\4Z9?W&H^)-4^U/,N%B#'"_AT'X5Z%0!F:^/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 44E% "T4E&: #%%&:,T %%)FB
M@!:*2B@!:*2B@!<44E% "T4E% "T4E% !BEQ244 +1244 +1244 +28HHH 6
MC%)10 8I:2B@!:*2B@ P*6DHH 6BDHH 6C-)10 N:,TE% "YHS244 +FC-)1
M0 N:,TE% "YHS244 +FC-)10 N:,TE% "YHS244 +FC-)10 N:,TE% "YHS2
M44 .HIN:7- "T4VES0 M%)FDS0 ZBDS29H =13<T9- #J*04M !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ,)YIDUQ%;Q-)*X1%Y+$\"G2,%4LQP ,
MFO'O$NMZCXNUW^QM,)\A'P<=_4GVJX0YC&K64%YG8:E\2M$L9&2-VG93@[.E
M9J_%6T<92RF8>HK2T#X>Z5I<"-<Q"YN<99GZ ^U=0NEV2*%%K$ /1:J\%H91
MC6EJW8X;_A:=M_SX3TO_  M.V_Y\)_\ /X5W7]G6?_/M'_WS1_9UG_S[1?\
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M^$_^?PKNO[.L_P#GVC_[YH_LZS_Y]H_^^:.:'8/9U?YCA?\ A:=M_P ^$_\
MG\*/^%IVW_/A/_G\*[K^SK/_ )]H_P#OFC^SK/\ Y]H_^^:.:'8/9U?YCA?^
M%IVW_/A/_G\*/^%IVW_/A/\ Y_"NZ_LZS_Y]H_\ OFC^SK/_ )]H_P#OFCFA
MV#V=7^8X7_A:=M_SX3_Y_"C_ (6G;?\ /A/_ )_"NZ_LZS_Y]H_^^:/[.L_^
M?:/_ +YHYH=@]G5_F.%_X6G;?\^$_P#G\*/^%IVW_/A/_G\*[K^SK/\ Y]H_
M^^:/[.L_^?:/_OFCFAV#V=7^8X7_ (6G;?\ /A/_ )_"C_A:=M_SX3_Y_"NZ
M_LZS_P"?:/\ [YH_LZS_ .?:/_OFCFAV#V=7^8X7_A:=M_SX3_Y_"C_A:=M_
MSX3_ .?PKNO[.L_^?:/_ +YH_LZS_P"?:/\ [YHYH=@]G5_F.%_X6G;?\^$_
M^?PH_P"%IVW_ #X3_P"?PKNO[.L_^?:/_OFC^SK/_GVC_P"^:.:'8/9U?YCA
M?^%IVW_/A/\ Y_"C_A:=M_SX3_Y_"NZ_LZS_ .?:/_OFC^SK/_GVC_[YHYH=
M@]G5_F.%_P"%IVW_ #X3_P"?PH_X6G;?\^$_^?PKNO[.L_\ GVC_ .^:/[.L
M_P#GVC_[YHYH=@]G5_F.%_X6G;?\^$_^?PH_X6G;?\^$_P#G\*[K^SK/_GVC
M_P"^:/[.L_\ GVC_ .^:.:'8/9U?YCA?^%IVW_/A/_G\*/\ A:=M_P ^$_\
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M;_OBC_A<?A?_ )ZS?]\5VG]CZ=_SY0?]\"C^Q]._Y\H/^^!0!Q?_  N/PO\
M\]9O^^*/^%Q^%_\ GK-_WQ7:?V/IW_/E!_WP*/['T[_GR@_[X% '%_\ "X_"
M_P#SUF_[XH_X7'X7_P">LW_?%=I_8^G?\^4'_? H_L?3O^?*#_O@4 <7_P +
MC\+_ //6;_OBC_A<?A?_ )ZS?]\5VG]CZ=_SY0?]\"C^Q]._Y\H/^^!0!Q?_
M  N/PO\ \]9O^^*/^%Q^%_\ GK-_WQ7:?V/IW_/E!_WP*/['T[_GR@_[X% '
M%_\ "X_"_P#SUF_[XH_X7'X7_P">LW_?%=I_8^G?\^4'_? H_L?3O^?*#_O@
M4 <7_P +C\+_ //6;_OBC_A<?A?_ )ZS?]\5VG]CZ=_SY0?]\"C^Q]._Y\H/
M^^!0!Q?_  N/PO\ \]9O^^*/^%Q^%_\ GK-_WQ7:?V/IW_/E!_WP*/['T[_G
MR@_[X% '%_\ "X_"_P#SUF_[XH_X7'X7_P">LW_?%=I_8^G?\^4'_? H_L?3
MO^?*#_O@4 <7_P +C\+_ //6;_OBC_A<?A?_ )ZS?]\5VG]CZ=_SY0?]\"C^
MQ]._Y\H/^^!0!Q?_  N/PO\ \]9O^^*/^%Q^%_\ GK-_WQ7:?V/IW_/E!_WP
M*/['T[_GR@_[X% '%_\ "X_"_P#SUF_[XH_X7'X7_P">LW_?%=I_8^G?\^4'
M_? H_L?3O^?*#_O@4 <7_P +C\+_ //6;_OBC_A<?A?_ )ZS?]\5VG]CZ=_S
MY0?]\"C^Q]._Y\H/^^!0!Q?_  N/PO\ \]9O^^*/^%Q^%_\ GK-_WQ7:?V/I
MW_/E!_WP*/['T[_GR@_[X% '%_\ "X_"_P#SUF_[XH_X7'X7_P">LW_?%=I_
M8^G?\^4'_? H_L?3O^?*#_O@4 <7_P +C\+_ //6;_OBC_A<?A?_ )ZS?]\5
MVG]CZ=_SY0?]\"C^Q]._Y\H/^^!0!Q?_  N/PO\ \]9O^^*/^%Q^%_\ GK-_
MWQ7:?V/IW_/E!_WP*/['T[_GR@_[X% '%_\ "X_"_P#SUF_[XH_X7'X7_P">
MLW_?%=I_8^G?\^4'_? H_L?3O^?*#_O@4 <7_P +C\+_ //6;_OBC_A<?A?_
M )ZS?]\5VG]CZ=_SY0?]\"C^Q]._Y\H/^^!0!Q?_  N/PO\ \]9O^^*/^%Q^
M%_\ GK-_WQ7:?V/IW_/E!_WP*/['T[_GR@_[X% '%_\ "X_"_P#SUF_[XH_X
M7'X7_P">LW_?%=I_8^G?\^4'_? H_L?3O^?*#_O@4 <7_P +C\+_ //6;_OB
MC_A<?A?_ )ZS?]\5VG]CZ=_SY0?]\"C^Q]._Y\H/^^!0!Q?_  N/PO\ \]9O
M^^*/^%Q^%_\ GK-_WQ7:?V/IW_/E!_WP*/['T[_GR@_[X% '%_\ "X_"_P#S
MUF_[XH_X7'X7_P">LW_?%=I_8^G?\^4'_? H_L?3O^?*#_O@4 <7_P +C\+_
M //6;_OBC_A<?A?_ )ZS?]\5VG]CZ=_SY0?]\"C^Q]._Y\H/^^!0!Q?_  N/
MPO\ \]9O^^*/^%Q^%_\ GK-_WQ7:?V/IW_/E!_WP*/['T[_GR@_[X% '%_\
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M?]\5VG]CZ=_SY0?]\"C^Q]._Y\H/^^!0!Q?_  N/PO\ \]9O^^*/^%Q^%_\
MGK-_WQ7:?V/IW_/E!_WP*/['T[_GR@_[X% '%_\ "X_"_P#SUF_[XH_X7'X7
M_P">LW_?%=I_8^G?\^4'_? H_L?3O^?*#_O@4 <7_P +C\+_ //6;_OBC_A<
M?A?_ )ZS?]\5VG]CZ=_SY0?]\"C^Q]._Y\H/^^!0!Q?_  N/PO\ \]9O^^*/
M^%Q^%_\ GK-_WQ7:?V/IW_/E!_WP*/['T[_GR@_[X% '%_\ "X_"_P#SUF_[
MXH_X7'X7_P">LW_?%=I_8^G?\^4'_? H_L?3O^?*#_O@4 <7_P +C\+_ //6
M;_OBC_A<?A?_ )ZS?]\5VG]CZ=_SY0?]\"C^Q]._Y\H/^^!0!Q?_  N/PO\
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MPO\ \]9O^^*/^%Q^%_\ GK-_WQ7:?V/IW_/E!_WP*/['T[_GR@_[X% '%_\
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MO6C7C\["V^+P*YYDQ^8K6GJFCDQ&DHR/8!2T@I>U9'6A:*** "BBB@ J.?\
MX]Y/]T_RJ2HY_P#CWD_W#_*@#SGX2?ZG6O\ K^D_]"->E5YK\)/]1K7_ %_2
M?^A&O2J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0
M]*\QN?\ DO=O_P!@\_S2O3CTKS&Z_P"2]V__ &#S_-* /3J6DI: "BBB@!.U
M%+10!PGQ4_Y%-O\ KJO\Q6UX+0KX5L<]X_ZFLCXIJ3X0=O[LJ?SK;\(?\BKI
M_P#UR_J:U?P'*E^^9N"EI*6LCJ"BBDS0 4UCCKVI<U2U5W339WC^^$./RII7
M9,G9-D+Z[81S>4UPH.<$]JT(Y%D0,C J>017EF_S+8AL#J3]:[?PG+*^CKYF
M3@X7/I6LZ7+&YRT,2ZD^5F_4<LJ0HSR,%4=S3\USWBZ21-(^0G!<!L>E915W
M8Z*DG"+9H0ZW8SS>4EP-QZ>]:(.:\HF?:J.G#*PV$5Z?8.SV<+/]XJ,UI4I\
MB,<-7=5NY:I:9FG UD=0M)FCM32W>@!U%1^>G]]?SIP;/H:!70^BDS2YH&%%
M%% !1129H 6BBB@ HHHH **3-+F@ HHS10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1124 )7CNH(7^+@ [3*?Y5[%7D=Q_R6#_@?]*UI=3EQ6R]3UP=*=31
M3JR.I;!1110 4444 %1S_P#'O)_N'^525'/_ ,>\G^X?Y4 ><_"3_4:U_P!?
MTG_H1KTJO-?A)_J-:_Z_I/\ T(UZ50 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>#R*BUC923T0ZBBB@84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(UY'G="3\PQUXH Z&BD%+0 4444 %%%% !1110 4444 %%%% !1110 4444
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M<L2YKK=!UFXU);F<Z4UI'&N8]R_,U.3)IPO9,X#1FTO2=0N;3Q+I^9)'.)9
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MAKJX63!<X()]*^PFF2"Q\Z1ML:1[F)[8%?+7B[5-%/Q(TJ?39T;3[81KO7H
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M%% !1110 AZ5YC=?\E[M_P#L'G^:5Z<>E>8W7_)>[?\ [!Y_FE 'IPI:04M
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M^N*]&Q1B@#Y0\+:1X[\)W#W%CH+M._&]U!(KW'X;ZOXJU6*\/B:T-NR8\H$
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MYHTTEP9"5D5<Y["KGA&UU)O&]W>WMHT(E3(XX'I5:),C5R3+GAK_ )*9J_\
MUP_]F6FZ7Q\5+[_KF/Z58\/V5S%\0]4N'A98GAPK$<'YA5+6H[[P]XV.LQVD
MD]M,NU]G.*G2Y=FDG;J7_BA_R X?^NPK1UJ325\-6RZNY$#!3M!P6QVKC/%F
MH:MXGCA^RZ;.EG&P)+CDFM;QOI=]+9Z/=PVYGCM@3+%CZ?X4)*R0.;;DTC!\
M1S:#<Z*QT[39()(R&24)C\S6YK-S)=?"J&65BS%5!)/7YJJ:WK5YKNA-8:;H
MTL9V@RLRXP!Z>M7KVPNF^%\-J(7,P !3O]ZJ,TG>7H3^$?!NFS>'8;B^A%Q/
M.N2S\[1T %4O"@DT/QKJ&C1.3:E=ZKG[O2DT+Q)JGA_18['4-*G=D7]RRCJ/
M>K?@O2M0N=9O=?U*)HVF!6)&'.*3;UN5%*T>7<9X7;9XSUQ_0$_K7/V6H6%_
MXEO[S68Y+A5D*QIMW*!GTKJ/#5A<1^+]8DEA98I,[6(Z\UEFWU#P=XBNIA8F
MZT^X8M\HY7FBZNQ2C+E13MY[>U\9VESHEO-%!*<2Q[=JUZZG*@^HKC]*\2MJ
MNJQ06^CR1PGEI9!MQ^%=B*SF[G50C:]F>6>.K,W_ (VTVU#E!(H5B#@XR<UM
M>(/!.D1^'93;VZQSP)N60?>R/>L+Q]]J7QII\EDNZ=%#*OK@DXJUK'BS4]6T
MLZ9:Z5.EW*-CEAP/6M-;*QS:<TDT7_#&J0WO@%O[7F/EIF-G)Y(!XK"NY_"T
M^E2P6FER$!?EF"<Y]<U?U#PG>VG@&&SA4R7"-YLB#ODYQ^M0P^(9VT$:;::%
M*MWY>P_+A1[YIJU[A+FM9HN>!K6#7?!YM[^/SHX9"%#>U5/!OA_3+O5-46>V
M5Q#.0GL*VOAQ9W-GX?GBNHF20RMPPK$T_4;WPIXAU))]/FEBGE+(R+UI7W*4
M?A;+OC)0GBO0U P ^!^E9OCS4!=>)+'3+EY!9(JO(J=6.:V/%5K<W?B319XH
M'9%;+'^[TJ/QKH5^-3L]=TV+S9(%"R1^H!S1&V@JD9-.QSOB(:'+IL;:192P
M7D+*4*IC//?%7O&4TU]X1TAY0RS.54YX.>F:U5\:F2)(X] F:Z. 5*X4'ZU)
MXZM;J]T[3#%;DL)$9U49V^M'-J)PO%V);?P1I,?AC$MNKW#P[WE89;=C/6J7
M@.UBU3PQ=6%ZOG00S':'Y]:[=T8Z,4VG<8<8_"N7^'=E<6NG7ZSQ-&S3$C<.
MO6IYKIFOL[25D<]X2T#3;SQ/J]O<6RO' PV*>W6CQ=:?V?XJM[J\M'GTI$"A
M0,@?A4MO<W?A/Q;J$DUA-/!='*NBY]?\:W-3\6^6WDW>BS20R1A@5&[).>"*
MIOWKF:@N2W4TO"K:%/%)<:,B)OQO11C'X5TPZ5YM\/-+NXM2OM0:V:UMIC\D
M9KTD=*QFM=#JH-N&HM%%%2;!1110 4444 %%%% !1110 4444 %%%% !1110
M 4E+24 )VKR.X_Y+!_P/^E>N=J\CN/\ DL'_  /^E:T^IRXK9>IZZ*6FBG5D
M=2"BBB@ HHHH *CG_P"/>3_</\JDJ.?_ (]Y/]P_RH \Y^$G^HUK_K^D_P#0
MC7I5>:_"3_4:U_U_2?\ H1KTJ@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** $/2O,;K_DO=O_V#S_-*]./2O,;K_DO=O_V#S_-* /3A
M2TE+0 4444 %%%% '%_%'_D2I_\ KK'_ .A5;\ _\BG;?2JGQ1_Y$J?_ *ZQ
M_P#H56_ /_(J6WTK7_EV<O\ S$?(Z@44"BLCJ ]*@N(([B-HI4#HPP01P:GH
MQ1>P6ON8:>%-%C5U6PCP_7BKFG:18Z4I2SMUB!Z[15^C JG)M6(5."=TA*BN
M(([B(Q3('C;@@]ZGHJ5H5ON8<?A318UD5;&(!_O<5<T_2+'2T*6=ND0/7:*T
M,44W)]62H13ND-'TJ"ZM(+V!H;B,21L,%2.M6:*2935]#!3PIHJ0M&MA'M;[
MW%:%AIEGID7E6D*Q+W %7<4M-N3ZDJ$4[I"4&EH%(L845NH_,4H4+T %.HIW
M%97N-P#U%%.HI#L,*J3RHS]*  .PI]%,5D-P/3%!4'J,_A3J*06(]@]!^5.P
M",'I3J*+L+(8$4?PBEQVQ^E.HHU"R&;%/\(I< =,4ZBB["R&@8Z#\:" >H'X
MTZBF.PS:HZ#]*=CBEHI7%:QQ>M:!?W?C.PU&*-3;PCYR3]:[ (H[#ZU)1BFY
M-D1II-M#<9I-B^@I]%+4MI#<8Z"DV@_PY_"GT4:A9#<#THXQTIU% [(8$7^Z
M/RI<#TIU%&HDD-ZB@  =.*=10.PPJ#U -)L7^Z#^%24478K(: !TQBG=J**!
MV%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DI:2@!.U>1W'_)8
M/^!_TKUSM7D=Q_R6#_@?]*UI]3EQ6R]3UP4ZD%+61U(**** "BBB@ J.?_CW
MD_W#_*I*CG_X]Y/]P_RH \Y^$G^HUK_K^D_]"->E5YK\)/\ 4:U_U_2?^A&O
M2J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]*\QN
MO^2]V_\ V#S_ #2O3CTKS&Z_Y+W;_P#8//\ -* /3A2T@I: "BBB@ HHHH X
MOXH_\B5/_P!=8_\ T*K?@'_D5+;Z54^*/_(E3_\ 76/_ -"JWX!_Y%2V^E:_
M\NSE_P"8CY'4"B@45D=0M)129H 6BF[J7- "T49I: $HHI,T +13=U+GF@!:
M*3-+F@ HHI: "BBB@!*6BB@ HHHH **** "BBB@ HHHH ***2@!:*3-&: %H
MHHH 2EHHH **** "BBB@ HHHH **** "BBB@ I*6B@!,4M%% !1110 4444
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M'VVZ_P"?4_G0!HT5G?;;K_GU/YT?;;K_ )]3^= &C16=]MNO^?4_G1]MNO\
MGU/YT :-%9WVVZ_Y]3^='VVZ_P"?4_G0!HT5G?;;K_GU/YT?;;K_ )]3^= &
MC16=]MNO^?4_G1]MNO\ GU/YT :-%9WVVZ_Y]3^='VVZ_P"?4_G0!HT5G?;;
MK_GU/YT?;;K_ )]3^= &C16=]MNO^?4_G1]MNO\ GU/YT :-%9WVVZ_Y]3^=
M'VVZ_P"?4_G0!HT5G?;;K_GU/YT?;;K_ )]3^= &C16=]MNO^?4_G1]MNO\
MGU/YT :-%9WVVZ_Y]3^='VVZ_P"?4_G0!HT5G?;;K_GU/YT?;;K_ )]3^= &
MC16=]MNO^?4_G1]MNO\ GU/YT :-%9WVVZ_Y]3^='VVZ_P"?4_G0!HT5G?;;
MK_GU/YT?;;K_ )]3^= &C16=]MNO^?4_G1]MNO\ GU/YT :-%9WVVZ_Y]3^=
M'VVZ_P"?4_G0!HT5G?;;K_GU/YT?;;K_ )]3^= &C16=]MNO^?4_G1]MNO\
MGU/YT :-%9WVVZ_Y]3^='VVZ_P"?4_G0!HT5G?;;K_GU/YT?;;K_ )]3^= &
MC16=]MNO^?4_G1]MNO\ GU/YT :-%9WVVZ_Y]3^='VVZ_P"?4_G0!HT5G?;;
MK_GU/YT?;;K_ )]3^= &C16=]MNO^?4_G1]MNO\ GU/YT :-%9WVVZ_Y]3^=
M'VVZ_P"?4_G0!HT5G?;;K_GU/YT?;;K_ )]3^= &C16=]MNO^?4_G1]MNO\
MGU/YT :-%9WVVZ_Y]3^='VVZ_P"?4_G0!HT5G?;;K_GU/YT?;;K_ )]3^= &
MC16=]MNO^?4_G1]MNO\ GU/YT :-%9WVVZ_Y]3^='VV[_P"?7]: - TM9ZWE
MT74-;8!/6KXH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+_GVB_[YJ%-=C5T)MWN8'@[5K'5K69[*Q%HJM@J%VYJ'XC_\BC<_A7516\,
M(BC5!_LC%9^O:-%KNF/92N41^I%2FN:YI*F_9\IR_P *?^17?_KLU7?$?A[P
M[K-[_ILJQ78')5L$CWK5\-^'X?#FG&S@D:12Q;+5B^(? ,>NZDUZ+Z2%R,$
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MP/4@9JW5:]BDGLIXHFVN\;*I]"10!XKX?T?Q=X[CN-7D\77EA&961(+:0@*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1/SH DHJ/SXO^>B?G1Y\7_/1/SH DHJ/SXO^>B?G1Y\7_/1/SH DHJ/SXO\
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MH **** "BBB@ HHHH **** $/2O,;K_DO=O_ -@\_P TKTX]*\QNO^2]V_\
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MX:>)K.VFD%I%=F.-\YPN[M7L'@;0](7X=62)!!)'-;!Y'*@EB5R<F@#4\/\
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M_P#?1J]10!1_LJU_N'_OHT?V5:_W#_WT:O44 4?[*M?[A_[Z-']E6O\ </\
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MX\7\)ZN5_P 1F]2TE+7GGOA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB@#@?'D"7'Q8\+)(N5Y/ZK70_&%%/PVOLCH!CVKI[[PQINH:Q::I/$3<VO\
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M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0HH S_.U+_GWC_[ZH\[4O^?>/_OJM"B@#/\ .U+_ )]X_P#OJCSM2_Y]X_\
MOJM"B@#/\[4O^?>/_OJCSM2_Y]X_^^JT** ,_P [4O\ GWC_ .^J/.U+_GWC
M_P"^JT** ,_SM2_Y]X_^^J/.U+_GWC_[ZK0HH S_ #M2_P"?>/\ [ZH\[4O^
M?>/_ +ZK0HH S_.U+_GWC_[ZH\[4O^?>/_OJM"B@#/\ .U+_ )]X_P#OJCSM
M2_Y]X_\ OJM"B@#/\[4O^?>/_OJCSM2_Y]X_^^JT** ,_P [4O\ GWC_ .^J
M/.U+_GWC_P"^JT** ,_SM2_Y]X_^^J/.U+_GWC_[ZK0HH S_ #M2_P"?>/\
M[ZH\[4O^?>/_ +ZK0HH S_.U+_GWC_[ZH\[4O^?>/_OJM"B@#/\ .U+_ )]X
M_P#OJCSM2_Y]X_\ OJM"B@#/\[4O^?>/_OJCSM2_Y]X_^^JT** ,_P [4O\
MGWC_ .^J/.U+_GWC_P"^JT** ,_SM2_Y]X_^^J/.U+_GWC_[ZK0HH S_ #M2
M_P"?>/\ [ZH\[4O^?>/_ +ZK0HH S_.U+_GWC_[ZH\[4O^?>/_OJM"B@#/\
M.U+_ )]X_P#OJCSM2_Y]X_\ OJM"B@#/\[4O^?>/_OJCSM2_Y]X_^^JT** ,
M_P [4O\ GWC_ .^J/.U+_GWC_P"^JT** ,_SM2_Y]X_^^J/.U+_GWC_[ZK0H
MH S_ #M2_P"?>/\ [ZH\[4O^?>/_ +ZK0HH S_.U+_GWC_[ZH\[4O^?>/_OJ
MM"B@"@LFH,XW0(%[D-5X4M% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 AZ5YC=?\E[M_\ L'G^:5Z<>E>8W7_)>[?_
M +!Y_FE 'IPI:04M !1110 4444 <7\4?^1*G_ZZQ_\ H56_ /\ R*EM]*J?
M%'_D2I_^NL?_ *%5OP#_ ,BK;?0UK_R[.7_F(^1U I#G''6E%%9'49[6^H;C
MMNT SQ\O_P!:C[/J/_/VG_?/_P!:M&B@#.^SZC_S^)_WS_\ 6H^SZC_S]I_W
MS_\ 6K1HH SOL^H_\_:?]\__ %J/L^H_\_:?]\__ %JT:2@#/^SZC_S]I_WS
M_P#6H^SZC_S]I_WS_P#6JY(^Q&;'09XKG-/\:Z=>ZA+8N);:9&P!, -WTII-
MDRFH[FO]GU'_ )^T_P"^1_A1]GU'_G[3_OG_ .M5U6R,@Y^E/I%&7)9WLJ%)
M+B-T/560$']*([*^B0)'<QJHZ*J  ?I6F*6@#/\ L^HX_P"/M/\ OG_ZU'V?
M4?\ G\3_ +Y_^M6C10!G?9M1_P"?M/\ OG_ZU+]GU'_G[3_OG_ZU:%% &=]G
MU'_G[3_OG_ZU'V?4?^?Q/^^1_A6C10!G?9]1_P"?M/\ OG_ZU'V?4?\ G\3_
M +Y'^%:-% &=]GU'_G[3_OD?X4?9]1_Y_$_[Y_\ K5HT4 9C6M^ZE6NT(/4%
M!S^E,BL+R!-L,\4:]E2, ?H*U<4N* ,X6^HX_P"/Q/\ OG_ZU'V;4?\ G[3_
M +Y_^M6C10!G?9]1_P"?M/\ OG_ZU)]FU#_G[3_OG_ZU:5% &=]GU'_G[3_O
MG_ZU'V;4?^?M/^^?_K5HT4 9WV?4?^?M/^^?_K4?9]1_Y^T_[Y_^M6C10!G?
M9]1_Y^T_[Y_^M1]FU'_G[3_OG_ZU:-% &=]GU'_G[3_OG_ZU'V;4?^?Q/^^1
M_A6C10!G?9]1_P"?M/\ OG_ZU'V?4?\ G[3_ +Y_^M6C10!G?9]1_P"?M/\
MOD?X4?9]1_Y_$_[Y_P#K5HT4 9WV?4?^?M/^^?\ ZU'V?4?^?M/^^?\ ZU:-
M% &=]GU'_G[3_OG_ .M1]GU'_G[3_OG_ .M6C10!G?9]1_Y^T_[Y_P#K4?9]
M1_Y^T_[Y_P#K5HT4 9WV?4?^?M/^^?\ ZU'V?4?^?M/^^?\ ZU:-% &=]GU'
M_G[3_OG_ .M1]GU'_G[3_OG_ .M6C10!G?9]1_Y^T_[Y_P#K4?9]1_Y^T_[Y
M_P#K5HT4 9WV?4?^?M/^^?\ ZU'V?4?^?M/^^?\ ZU:-% &=]GU'_G[3_OG_
M .M1]GU'_G[3_OG_ .M6C10!G?9]1_Y^T_[Y_P#K4?9]1_Y^T_[Y_P#K5HT4
M 9WV?4?^?M/^^?\ ZU'V?4?^?Q/^^?\ ZU:-% &=]GU'_G\7_OG_ .M2K!J
M8%KI2O<;?_K5H44 -&<<TZBB@ I*6DH 3M7D=Q_R6#_@?]*]<[5Y'<?\E@_X
M'_2M:?4Y<5LO4]<%.IHIU9'4%%%% !1110 5'/\ \>\G^X?Y5)4<_P#Q[R?[
MA_E0!YS\)/\ 4:U_U_2?^A&O2J\U^$G^HUK_ *_I/_0C7I5 !1110 E>?^(V
M^((UF7^P_LIL?X/, S7H%5;ZX^R6-Q<A=QBC9P/7 S0!Y@[?%7C=]@S[A?\
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M_A/5RO\ B,WN]+2=Z6O//?"BBB@ HHHH **2EH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQB-6.2,U+:9K3C*&[T-0&EJ,2)_>'YTHD4]#FH-KH?13=PI=U Q:*3-&[G%
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MJ.F!7G-[?>+-0M;/6G\27=O#?WIMUCBD(6-<X]:[;X>?VOI/Q#U'1]7UJYU
M?9%>'S)"P&2IS]>: /7Q3J04M !112;A0 M%)N%&X4 +6?K/_((NO^N9J_FJ
M&L_\@BZ_ZYFJA\2,ZOP,\%%+2=Z6O96Q\A/XF%)2TE,2W/9O!'_(N05T=<YX
M(_Y%R"NCKQJGQL^MPW\)&7X@_P"0'=?[AKPJO=?$'_(#NO\ <->%5V8/8\G-
M?B0M%%%=IY AKVOPA_R+MM_NUXH:]K\(?\B[;?[M<>+^$]7*_P"(S>HS14%W
M=1V=M)/(<(@RU>?:Y[S=E=D^:*Y/_A/]'_YZ/^5'_"?Z/_??\JT]E/L8?6J7
M<ZS-&:Y/_A/]'_OO^5'_  G^C_\ /1_RH]E/L'UJEW.LSS2U5L+Z+4+..YA)
M,;C(S5JLVK&Z::N@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$KVCPE-&OAZV#.H.WN:\7/2O8?"EC;RZ!;,Z9.WUKDQ?PH]7*_XC.D^T0_\
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M/^>7ZT?V7:?\\OUH L_:(?\ GHOYT?:(?^>B_G5;^R[3_GE^M']EVG_/+]:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M%
M#>U>1W'_ "6#_@?]*]<KR.X_Y+!_P/\ I6M/J<N)V7J>N"G4T4ZLCJ"BBB@
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ML5O-/G6:$G&X=J -.BD%+0 4444 -KR.X_Y+!_P/^E>N5Y%<_P#)8/\ @?\
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M1.65,J,FI!0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG=BJ]!P:U?!>?$GQ.UK77^>WM/\ 1X#VZ<X_.@"MX9"VWQT\1)NQ'%%&.3P
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M9^6<[K=@I/Z5R?\ PIU/^AFU?_OZ/\*]/ IU9'4>7?\ "G4_Z&;5_P#OZ/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD+Q124M=IY AKVOPA_R+MM_NUXH:]K\(?\B[;?2N/%_"CU<K_B,WJRO$?_(
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M129HS0 M%)FC- "T444 %%)10 M%)1F@!:*2EH **** "BBB@ HHHH ****
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MX-Y"#Y:_QCTKCQ4D[6/7RN$HMW1KU@>,S_Q2E_\ [@_]"%:/]KZ=_P _D/\
MWV*PO&.IV4GA:^6.ZB9B@P W^T*Y(?$CU*UW39Y#Z45#]J@_Y[)^='VF#_GL
MGYUZZDK'RCI3OL345#]IA_Y[)^='VF#_ )ZI^=#E&VX*E.^Q[SX;_P"1?L_^
MN=:IXKGO#NJV":!9JUY""$Y!8>M:AU?3O^?R'_OL5Y$]V?64O@1E^*O$$GA^
MQAN(H%F,DFS#-C'!/]*Y/_A9MW_T#X_^_A_PJW\2-0LYM(M1'<Q-B?)PW;::
M\T^TP?\ /9/SKJH4X2C[QY6,KUX5;0V/0/\ A9MW_P! ^/\ [^'_  H_X6;=
M_P#0/B_[^'_"O/\ [3!_SU3\Z/M4'_/9/SK?V-(Y/K6*/1+?XD74US'&;",!
MF R)#_A7HL+EXE<C&X XKY^L;N 7T!,R??'?WKW.VU73_L\>;R'.T?Q"N7$0
MC%^Z>G@*E6:?M#3I"0.IQ5(ZOI__ #^0_P#?8KF_&>N0PZ([6M\@DR,;7KGB
MKNQW5)\L7([#S$_O#\Z/,3^\/SKP7_A*+W_H)-_WW1_PE%[_ -!)O^^ZZ?J_
MF>?_ &A_=9[UO3^\/SHWI_>'YUX+_P )1>_]!%O^^ZEM?$]X;J+.HMM+C/ST
MGA[+<<<?=VY6>[T5EVNKV)MHBU[#N*C.7%3_ -K:=_S^0_\ ?8KF>YZ,7=7+
MN: :YW6/&&DZ1&KRW <,<#RR#6./BCHGK)^0_P :M0;,Y58Q=F=U17"_\+1T
M3UE_[Y'^-+_PM'1/67\A_C1[.0O;P.YHKB8/B9HL]Q'$&<%V"@D#'-=0NL:<
M5!^V0\_[8J7%HN,U+8O451_M?3_^?R'_ +[%0S^(-)MES-J$"#W<4BS4HK#_
M .$OT ?\Q6V_[[%'_"7Z!_T%;;_OL4["YD;E%8?_  E^@?\ 05MO^^Z!XMT%
MF"KJEL2>@WTK,7,C=HJ@NKZ<0"+V'G_;%._M?3O^?V'_ +[%!1=HJE_:^G_\
M_L/_ 'V*/[6T_P#Y_(?^^Q0!<KD_'7A.3Q/ID/V240W]K)YMO(>@;WKH/[6T
M_P#Y_(?^^Q2?VMI__/Y#_P!]B@#@=#\&Z_>^++?7_%-S [V<>RWAA^[GU/ Y
MKTH54_M;3_\ G\A_[[%']KZ?_P _D/\ WV* +M%4O[7T_P#Y_(?^^Q1_:^G_
M //Y#_WV* +M8_B--:;2S_8,D"7H<$>>/E*\Y'0^U6_[6T__ )_(?^^Q1_:V
MG_\ /Y#_ -]B@#SC_A#_ !;XFU^PO?$UU:QVEG()$BMQR6_(5U?BWPM'KN@W
M%G;0P+<2#B1U[_6MS^UM/_Y_(?\ OL4G]K:=_P _D/\ WV* (-%TJ'2["WA$
M,2RI&%9D7K6J.E4?[6T[_G\A_P"^Q1_:^G_\_L/_ 'V* +U(:I_VMI__ #^0
M_P#?8H_M;3_^?R'_ +[% '-_$3P]K/B;P]_9VC7B6KO(#(S,5W+SQQ6#X4\,
M^.O#PL['S](738W'FK&OS,O?^'K7H7]K:?\ \_D/_?8H_M?3_P#G\A_[[% '
M.^,/"*^(-/CBMXK=)Q*KL[#&0#]*W]/T^"PA18H(D<(%8HN,XI_]K:?_ ,_D
M/_?8I/[6T_\ Y_(?^^Q0!=%+5'^UM._Y_(?^^Q2_VMI__/Y#_P!]B@"X:Y[Q
M.GB4PQ-X=DM5E4_O%G'##VX-:O\ :VG_ //Y#_WV*/[6T[_G\A_[[% 'G^E>
M#/$6I>,K;Q%XGNK<FT&(((!QGU/ ]*V/&?@L>(4L/L<=O&T%RLLA88+ $>WM
M74?VMIW_ #^0_P#?8H_M;3_^?R'_ +Z% "V=E!9H!#!'&=H#%% S5L52_M;3
MO^?R'_OL4O\ :^G_ //[#_WV* +M(:I_VOI__/[#_P!]BC^UM/\ ^?R'_OL4
M <9\2?".M^*[2VMM+O(H8D?=*DCD!_K@<TOA72/&FE36]K?RZ6-+C7:8[9,-
M_P"@BNR_M;3_ /G\A_[[%']K:=_S^0_]]B@#F?%/@U=;U#1+BVAMHULKQ9Y]
MRX+J""1TYZ5U4%K!;9$$*1@]=JXS47]K:?\ \_D/_?8I?[6T[_G\A_[[% %P
M4M4O[7T__G\A_P"^Q1_:^G_\_D/_ 'V* +E<IXF3Q>+N*7P])9^0%P\<XY)]
M1P:W_P"UM/\ ^?R'_OL4?VMI_P#S^0_]]B@#AO"_@[6AXJN/$OB:ZAEO)(O)
M2*$?*J_I6EXB\%KJOB#0+^VBMDAL)G>=2N"X.W Z<]#73_VMI_\ S^0_]]BC
M^UM/_P"?R'_OL4 306\-NNR"-$7T48%3U1_M;3O^?R'_ +[%+_:^G_\ /Y#_
M -]B@"[2&J7]KZ?_ ,_L/_?8I?[6T_\ Y_(?^^Q0!SWB0>,EOU?0'LC;;<,D
M_P!X'\C67X1\%:G::Y?:_P"(KF*>_NUV,D8^15]*[7^UM/\ ^?R'_OL4?VMI
M_:\A_P"^Q0!R>L^"!?\ C#2M5@BMEMK3/F(5P7SCMBNRA@C@39#&L:_W5&!4
M']K:?_S^0_\ ?8I?[7T__G\A_P"^Q0!<%+5'^U]/_P"?R'_OL4?VOI__ #^P
M_P#?8H NFL_6[%]2T:ZLXB%>:,H"W05)_:VG_P#/Y#_WV*/[5T__ )_(?^^Q
M0!@^!_#4WASP;;:+?&.9XP0^WE2/QJM<^"UF\:6VKI#;"TBC*-'MY)]<8KI_
M[6T__G\A_P"^Q1_:VG_\_D/_ 'V* +$,,<$8CB140=%48 J6J7]K:=_S^0_]
M]BC^U]._Y_8?^^Q0!=I#5+^U]/\ ^?V'_OL4O]K:?_S^0_\ ?8H Y37X_'O]
MJ3_V-+8&P=0(Q*,.AQSV-'@;P;<Z#:7TNKSQW=]?OYD^.5[\?K75_P!K:?\
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M$MNLS-'+';MD@GOQ7IOA'QNWBF_FMSH][9>5'YF^XB*AN<8&0* .R%+313J
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M,G_??_UJ/^%.>#O^?*7_ +^?_6KO<TZE<$DC@/\ A3?@[_GRF_[^_P#UJ/\
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M .M7?9HI7;'8X'_A3G@[_GSE_P"_G_UJ/^%.>#O^?*7_ +^?_6KOJ6@#@/\
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M\Y?^_G_UJ/\ A3G@['_'E+_W\_\ K5WU+0&YP'_"FO!O_/C)_P!]_P#UJ/\
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MZ]<^)OWK/\?ZUYY7H8>G%PNT>!C<15A5<8LQO^$8TW^Y)_WW1_PC&F_W)/\
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M?-X<TW5&LH+&(&:Y4?,[<_X4_2M>UO1?$>H^&M5O?M96S>>VN,8; 4]?Q!H
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ME)KHT5KM1J!&X0[3G'7Z4 :^:6F@TN: %HI,BC- "T4F11F@!:*** "BBB@
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M.10!V.J?$;4K3P3I.LVMA;R75_*(Q$V=H)( [^]1R?$7Q#H0AG\2^'UALI"
M9[=MP3/<\FN5OS_Q;/P<?^GQ#D_[RUZ/X\U#3(/A_?"]>)P]J4C3.27*X7 ^
MN* .KLKR&_LH;NW</#*H9&!Z@U:KC_AC!<6WP[T>*Y5A*(B2&ZX+$C]*[ 4
M%13LZPNT:[I /E7/4U+4<KK'&SNP55&22> * /,=6\;>-/#]H-4U;0K)=+#8
M?RW)D4>OWOZ5Z+I]_'?:;#>J=L<J!^>PKR[Q+JC?$;6E\-:4V=*A<&\N@<*W
ML/UKHO%.IZMX>TI+'1]#>^MQ;E3(K@;./<B@#MX+B*XC$D+JZ'C*G(J6O'/A
MGXF\0_V596?_  CTSVC2L&NC(O +'/\ %GBO8A0 M%%% %:\DFCM)'@0/*JY
M53W->9ZOX\\7^%X8M1U[1+)-,9PC-"Y,BY_X$?Y5ZDY 4Y(7 ZUXA\3M&O\
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M#X$?+8[^,Q<444E;G(=#X+_Y&6W^M>SBO&/!?_(RV_UKV@=:\W%_&?0Y7_"
MUY%\0O\ D/C_ '*]=->1?$+_ )#X_P!REA?C*S+^$<F.E+BD%+7I'S8E=7X
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M5Z<>E>8W7_)>[?\ [!Y_FE 'IPI:04M !1110 4444 <7\4?^1*G_P"NL?\
MZ%5OP#_R*EM]*J?%'_D2I_\ KK'_ .A5;\ _\BI;?2M?^79R_P#,1\CJ!2T@
MHK(ZAK?=-> :I#;:_P#%^ZTWQ/?S6]JG%O$7*HW->_L<(3Z"O!;_ $P_%+XD
M7NGW+1VUGIAVEE0>8_/K^% #-.LT\._&&UTWPS=RSVC ?:(Q(61.?RKWODKS
MU[UX%::=<_"KXB6-K#<+=6FJ.$+.O[P<]S^->_(=R*1W&: .%UOXJZ%H.M7.
MDW27!NH0,!5!WGT'O5.R^,OA^;STOH[FPDB3<$G3!?V'O7-VNF6VH?M%WCW$
M:R""/>JL,C=MX/X4?$C2K.^^*OAJ*:%665OG&/O8R>?RH Z73/B_HU_JL%E/
M9WEG]H.(9)X\*WI74^)?%.F>%=+^WZA+A&.$1>6<^U>?_&:WBC_X1UDC53'=
MHJ[1C:.>*SOB1Y5U\0O"%G?L?L)C+%6^ZQXZT ;\/QLT0*S7MA?VB%=T;2Q8
M#^P]Z[.S\3V%[X6.OIN2T$1E._J !FN:^+FGZ;+\-M0-PL:M;Q[[;@<,.@%<
M/JFJRVWP-TS3+7FYU'$"*.K @ C]: ,62"?4?AQXB\371)DO[DA,GHH]*]6M
M?%^E^$_ .DW.HR$EX55(DY=S["L+QUHT>@_!---C'$,2@^YZUY_X2V/XTT__
M (3;>81"OV /S'[?K0!] V/B*VNM .L7$,ME;!"Y\_ ('KP:XC_A=>B-.?+L
M+^2T5]IN5BR@]\^E2?&J=X?AVZ6S8ADD17*]-N1^E;GAG3=)3X=6T$20FTDM
M 93@8)*\Y]\T 6_"GC?2O&!NSI@D*6S["[# ;W'MQ71NX12S$ #DD]J\=^!,
M<,,WB**V.8$NRL9_V<G%>A>/)KBW\%ZG):Y\X0G;B@#G-4^,&C66HRV5G9WF
MH-%GS'MX]RBN@\*^-](\70L;"1EGCXD@D&'7ZUS?P6L[&+P)#<0JAN9F)G;'
MS;O0USEI%%IO[0)ATQ0D,T!,Z)P,\T =/=_&/P_:WUW8""[DN[9]GE(F2Y]N
M:O>%OB;I/B?4Y-,6*>SOE&1%<+M+?2N(^%^F6UU\3?$][+&KRV\O[LD=,\5;
M\:PQVWQR\-2P($>:V+2,HP6.YASZ\4 =MXL^(6C>$7C@NFDFNY/N6\*[G--\
M->/K3Q"MT7L;NQ6V7>[W*;1BN#\*VMMJGQLUN75 LL]LF;99>W(&1^%=I\5Y
M98?AYJ;V^0S)M8CKB@#*NOC1HB7,@M+*]O+6(X>YABRE=QH&O6/B32HM1TZ3
MS('X]P?0^]>/^ 3XK7P);6^DZ/ITUC+'\S,_+Y'<;>M=;\*_#.K^%[;4HM4\
MN.*:4211HV54\Y_I0!Z2.E8OB3Q!!X:TPWUQ;W$Z XV0)N;\JUU=7&58-]#3
MNU '@7@?XK2#Q'J9U*'4;J.XFVP(D6?*!( W#M4OB/7[/0_CDFJ7C,L*VRM@
M#YCE!@8]>:U?A!_R-_BS_KX;^8JEKFF0:I^T/:Q7*"2-8E?:PXX2@#J=*^,&
MC7NKPZ?=VEY8-.<1/<1[5:NI\3^+=,\)Z=]KU"4\G"1H,LY]!7GOQTMH4TW1
M;A8U$R7B(K@<@<\5@_$J2^F^(7AR&...X'EAHXYFPCMQUH [?2_C!I-]J$%K
M=V5Y8^><123Q[5:N@\4^.-*\(C3VU$OY=\[+&Z $#&"<_G7GOB[0O'/BW3(K
M.YTNP@$;!DDCD.Y?I\M1?%;3GDM? MC?@%C<ND@Z@\)0!O-\:]$CN4$MA?QV
MKOM%R\6$/O\ 2O2K6YBN[:.Y@</%*H9&'<&N$^)>EVC?"NZ@\E0D,2M& OW2
M,'BM3X82-+\.M'=SEC$>?^!&@#KZ*** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EI* $[5Y'<?
M\E@_X'_2O7.U>1W'_)8/^!_TK6GU.7%;+U/7!3J:*=61U!1110 4444 %1S_
M /'O)_N'^525'/\ \>\G^X?Y4 ><_"3_ %&M?]?TG_H1KTJO-?A)_J-:_P"O
MZ3_T(UZ50 4444 )5>^N/LEC<7.,^5&SX]<#-6:AG2.2"1)<>6RD-GT[T >!
M#6/%&IW5CX@N-5,=G/J ACM8^@4,!S7?Z-KU_P#\+0O]&DN?/M!:K*B_W"<5
MQ>L?#2^B,MSHOB../2EG,P61CMB;VKJ_ACX<L;">\U7^V8]5U*<;)958G:,C
MCGZ4 >F"EI!2T %%(:Y[Q#XOTOPT\:WSR[I/NK&F30!T5%<]H'BW2/$J.=/N
M,O&?GC<89?PK+N?B?X9MM2:R>[<NC[&=4R@/H30!VM%0P2I/$DT;;D<;E([B
MIJ "D-+10!P>J?##2]3\1RZZUU=17DG\2.1M^G-;V@>'$T%90E[<W/F?\]G+
M8^F36]1B@#$B\.VD/B.76PS_ &J2/RR,\8K8 I]% !1110 PY[5P=Y\+-+N_
M$-UK7VR[BN[EMS,CGCV'/%=_10!B:!H*Z#;R0I=W%SO;=F9RQ'YT6GARTL_$
M-YK49;[3=*$<$\8%;6!2T %%%% !1110 Q@&7! (/J*\\F^$>DR7LKQW-U':
M32>8]JLA"$_3->C44 5;2UBL[:.W@4)'&H55'859'2EHH **** $-8?B7PS9
M^*;".SOF<1QR"0;3@Y'2MVDQ0!%'&(HU0=%4**Q="\+66@7M_=6I<R7LGF2!
MCQGC_"N@HH :M.I*6@ J*6/S8FC)(##!Q4M% 'G<'PETNSN)IK2_O8'F;<Y2
M0C/ZUV>EZ<-+L$M!-),$_CD.2?QK0-% &-H?AVTT'[5]E+'[3*97W'/)_P#U
M5L 4ZB@ HHHH P_$'ARS\1PPQ7A<+#()%VG'(J+Q+X3T[Q5HW]F:@I,0Z,O4
M?2N@HH XR^^'.E7_ (9LM">29+:S;=$RL0V?KFJ5M\*-&ANHI[JYO;T1GY8[
MB9F4?@37H-% $,4:0QK&@"J@ 4 =!4PZ4F!2T %4M4L(]3TVXLI694G0HS(<
M$ ^E7:* /.;#X2:9I<)BL=1OH%)R0DA&?KS7<1V"II8L&D=T\LQEF/S$5>HQ
M0!DZ'HEOX?TQ+&U+&)"2-QR>3FM44M% !2'I2T4 4=4L%U/39[-I'C$J%2Z'
M##Z&N&_X5/8SS1'4-2O;R&-MPBDE)4_49KT>DQ0!2NM/AN]+ETYAM@EB,1"]
ME(Q3-&TF#1-)M].MB3# NU-QYZD_UK1I.*  4M%% !65K^AP>(=%N-,NG=89
MQABAP:U:* //K'X66&FQ1PVFJ7\42'A%E('\ZZS5-&@U;1)]*N&;R9HC$S \
MX(Q6K24 4-&TN'1=(MM.M]WDVZ[$+'G%7Q2T4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% "44M% "44M% #:6EI* #M7FOQ,_UUK]*])-9.J>'[#665
MKR-G*],-BM*4^25SFQ5)U:?*CPWM2\U[#_P@>A?\^[_]]FC_ (0/0O\ G@__
M 'V:[?K<3Q_[*J]SQT]*V?"G_(QV?^_7I/\ P@>A?\^[_P#?9J>T\':18W*7
M$$+"1#D$N34SQ46FC2EEM2$U)LWU^Z/I2TT4[M7 >YT/.?B9UL_Q_K7GG^%>
MA_$W[UG^/]:\\KU,-\!\SF'\9BTE%%=!PE_1?^0Y9?\ 79?YU[Q']Q?I7@^B
M_P#(;LO^NR_SKWA/N+]*\_%_$CWLI^!CCTKROXD_\ABW_P"N7]:]4/2O*_B3
M_P AFW_ZY?UK/"_Q#?,OX)Q5+S24N:],^;"N@\%?\C/;US]=!X+_ .1GMJSJ
M_ S?"_Q8GLXI>U(*=7D'UJV/*_B7_P ABU_ZY'^=<37;?$K_ )#%K_UQ/\ZX
MFO5P_P##1\MCOXS%YHHS25N<AT/@O_D9;?ZU[0*\7\%_\C+;_6O9Q7FXOXSZ
M'*_X0IKR+XA?\A\?[E>N]J\B^(7_ "'Q_N4L+\969?PCDZ7FDI:],^; UU7@
M#_D81_NURM=5X _Y&$?[M95O@9TX3^-$]>[4=J.U':O(/K.AY/\ $3_D-K_N
M5QW>NQ^(G_(;7_<KCJ]:A_#1\KC?XT@YHHI:V.4Z7P%_R-4/^XU>QUXYX"_Y
M&J'_ '&KV.O,Q7QGT65_P0I:2EKF/2"BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!#TKS&Z_Y+W;_ /8//\TKTX]*\QNO^2]V_P#V#S_-* /3A2T@I: "
MBBB@ HHHH XOXH_\B5/_ -=8_P#T*K?@'_D5+;Z54^*/_(E3_P#76/\ ]"JW
MX!_Y%2V^E:_\NSE_YB/D=0*6D%+61U#3R,5Y=XB^&5^?$4FO^%]5;3[V8_O4
MZ*QKU+&:3 H \LT/X9:I-XCAUWQ5JYOKF YBB'W5/YUZB!@ #C%/QZTF.* .
M)LO!4UM\2KSQ2;A3'/'L$0'(XQ2^(O!<VL^,M(UM+A42Q)+)CD]?\:[4+1B@
M#C?'?@Z;Q9_9WE3K%]EG$IR.H%5?'_A'2/$6G6<5]>K8WL'_ ![7'<'TKO-M
M87B7PCIGBJVCAU!'/E-N1D."IH \4\<>&[NP\)S2^(/%\VH&-=MI:@\,_8GG
M_.:Z/PGX&U#4X?"^HWCHME8H)1"3R6XP?TKJ+3X0^&X+J.XG%Q=M&<H)Y-P'
MZ5W<<*0Q+'&H5%& !V% '-^-_#<GBGPS/I44HB:3^(CI65KOPYM=>\'V>DW,
M@6[LT AN5'*L/2N[Q1M&: .'MO#,H\#7&B>*[V.ZM@NP3'@@=B?<'%<.G@.[
MTW2I[:/QS(F@A2QC4\E>NW[U>RZCIEMJNGS6-VF^"9=KK7#_ /"FO#I(4RWA
MASGRC+\OTQB@#G?@+:+#:ZU);AC:&YVPNW5E!.*]@NH([J"2"5 T<B[6![BJ
M^D:-8Z'IZ6.GP+# G15%7L4 >2'X;^)/#]Y<'PEK@M[.=B3;R@X3Z<UT'@GX
M>IX:NY]4O[MK[5KG_63N.GL*[O;1M% '$>#O!4WAGQ#K6I27"RKJ#AE4#[M'
MB+P5-K7CS1_$"7"I'80F-HR.6Y)_K7;;11M% 'GGB_X;OK&LQZ]HFH-INKQC
M[ZCA^W/-3:'X7\1SP7MMXKU-+ZVN(_+\E/N@>OUKOMHHVT >/VWPV\6^&6EM
M?"_B+R]/D8LL4V<I].:O:_'K/@_X6Z@EYJ<U]J4K,5GYR"PX ^F*]1VU%<6D
M-U'Y<\:R)G.&&: .7^'5C>6/@ZR%_-)+<R+O9I#D\UUF>.M"1JB!%&%'0"G8
MH \H/PWU_1_%EUJ?AW6!;VMY*'GB?KU!(K</@>X;XD0^*6N5*I$J-'CDD+C-
M=UMXI,4 <;\0?!LWC&QLK>&X6$V]PLQ+#KC/^-,\9?#^W\5Z?:@7+6M_:#]S
M<(.0:[;%&* /*[/P?\06EM[>^\4?Z'$P)9,[W ['FM_QEX+G\3W.@R)<A/[-
MG,K9'W\[?\*[7;1MH P?%&AOKWA:YTE)!&TT>P/UQ3_".BOX=\+V.E22"1K9
M"I8=^2?ZUN;: ,4 +1110 4444 %%%% !1110 44F:,T +129I: "BBDS0 M
M%)FEH **** "BBB@ HHHH **3-&: %HHHH **** "BBB@ I*6DH 3M7D=Q_R
M6#_@?]*]<[5Y'<?\E@_X'_2M:?4Y<5LO4]=%+313JR.H**** "BBB@ J.?\
MX]Y/]P_RJ2HY_P#CWD_W#_*@#SGX2?ZC6O\ K^D_]"->E5YK\)/]1K7_ %_2
M?^A&O2J "BBB@ JIJ,+W.FW4$?WY(F1?J15NJU[.+2RGN2I;RHV?'K@9H ^>
M!:>*-0L8_! TN:"+[67N+G)PZ;L^E=GX&\*?\(O\2;ZVTV&9--%FH=G.59_E
MSC\:X[4?%?C[46M]3MK^.RL[V[-O;JGL<9-=E\.=1\4P^-]2T?Q/J7VAXK42
M1+U!R1SGZ&@#UH=:4T@IU &-J_B;2]#DCCU"Y$+2#*@]Z'U'1Y=._MB1XC;J
MFX3,.U7KK3K.\(:YMXY2O0L,XKS+XD>$O%FO:A:VNAI:G1XE#/;R3; [9Y!'
MITH R="2:ZN_%WBVRB^SV;6<BP$#&\JI.[]:?X>T6QN/@;-=21(T]RDD\CD<
M[PQY_05UGAO3_%36TND:[IFG6NF- 8A]FEW'D$5R:>"_'-AIMUX7LS:/H\\I
M*W!?#(A/(Q^= '>?#2ZFNO 6FR3$E@A7GT!('\JZ:YDG0#R8PY[\U3T#28]#
MT2TTZ/D01A2?4]S6IB@#/^T:A_S[K^='VC4/^?=?SK0Q1B@#/^T:A_S[K^='
MVC4/^?=?SK0Q1B@#/^T:A_S[K^='VC4/^?=?SK0Q1B@#/^T:A_S[K^='VC4/
M^?=?SK0Q1B@#/^T:A_S[K^='VC4/^?=?SK0Q1B@#/^T:A_S[K^='VC4/^?=?
MSK0Q1B@#/^T:A_S[K^='VC4/^?=?SK0Q1B@#/^T:A_S[K^='VC4/^?=?SK0Q
M1B@#/^T:A_S[K^='VC4/^?=?SK0Q1B@#.^T:A_S[K^=+]HU#_GW7\ZT,44 9
M_P!HU#_GW7\Z/M&H?\^Z_G6ABC% &?\ :-0_Y]U_.C[1J'_/NOYUH8HH S_M
M&H?\^Z_G1]HU#_GW7\ZT,48H S_M&H?\^Z_G1]HU#_GW7\ZT,48H S_M&H?\
M^Z_G1]HU#_GW7\ZT,48H S_M&H?\^Z_G1]HU#_GW7\ZT,48H S_M&H?\^Z_G
M1]HU#_GW7\ZT,48H S_M&H?\^Z_G1]HU#_GW7\ZT,48H S_M&H?\^Z_G1]HU
M#_GW7\ZT** ,_P"T:A_S[K^='VC4/^?=?SK0Q1B@#/\ M&H?\^Z_G1]HU#_G
MW7\ZT,44 9_VC4/^?=?SH^T:A_S[K^=:&** ,_[1J'_/NOYT?:-0_P"?=?SK
M0Q1B@#/^T:A_S[K^='VC4/\ GW7\ZT** ,_[1J'_ #[K^='VC4/^?=?SK0HH
M S_M&H?\^Z_G1]HU#_GW7\ZT*,4 9_VC4/\ GW7\Z/M&H?\ /NOYUH8HQ0!G
M_:-0_P"?=?SH^T:A_P ^Z_G6ABC% &?]HU#_ )]U_.C[1J'_ #[K^=:&*,4
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ME>8W7_)>[?\ [!Y_FE>G'I7F-U_R7NW_ .P>?YI0!Z=2T@I: "BBB@ HHHH
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MO/Q5^;4][+>7V;Y2:.:*7F.16_W3FO+?'MI<3ZZ&B@D==G55)KT^*VBM\B)
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M2C:,[B.U4?'?AS0-;TZTM=8O19S(<6\^<,#[&@"K\7(],_X5MJ'GK"&"9M\
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M"$^AZ7?6MWJUQ?S7G+RR_P /!''YU!H'P^L-%\-WFBS2F\M[J1I&\Q!QG/\
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M "6#_@?]*UI]3EQ6R]3UP4ZD%+61U!1110 4444 %1S_ /'O)_N'^525'/\
M\>\G^X?Y4 ><_"3_ %&M?]?TG_H1KTJO-?A)_J-:_P"OZ3_T(UZ50 4444 )
M7">-_ATGC*^M;K^U+BQDMP0##@$YKNZ;WH \:'P% N?M/_"4:CY^,>9N&['U
MQ74>!_AJG@[6[K4VU:ZOY;B#RCYY!P,@]?PKH;OQCX>L)S!=:M;12KU4MDC\
MJGTKQ+HVMSO#IM_%<R(NYE3/ Z9H UQ2T@I: "BBC- !13"?2@>AH ?129I:
M "BBB@ HHII(% #J*;N'J/SI=P]?UH 6BDW#U_6C</7]: %HI-P]?UHW#U_6
M@!:2C<OK^M&Y?7]: %I*-P]?UHW#U_6@ I:3</7]:-P]?UH 6BDW#U_6C</4
M4 +12;E]1^=&X>H_.@!:*3(]1^=&1ZC\Z %HI,CU'YT9'J/SH 6BDR/4?G1D
M>H_.@!:*3(]1^=&1ZC\Z %HI,CU'YT9'J/SH 6BDR/4?G1D>H_.@!:*3(]1^
M=)D>H_.@!U%-R/4?G2Y'J/SH 6BFY'J/SI<CU'YT +129'J/SHR/4?G0 M%-
MR/4?G1D>H_.@!U%-R/4?G2Y'J/SH 6BDR/4?G1D>H_.@!:*3(]1^=&1ZC\Z
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MVK!Z-^5 %[;Z48JC_:L'HWY4?VK!Z-^5 %[ HP/2J/\ :L'HWY4?VK!Z-^5
M%[ HVBJ/]JP>C?E1_:L'HWY4 7MHHVBJ/]JP>C?E1_:L'HWY4 7L48%4?[5@
M]&_*C^U8/1ORH O4R2&.5"DB*ZGJK#(JI_:L'HWY4?VK!Z-^5 %M(DB0)&@5
M1T & *=M%4O[5@]&_*C^U8/1ORH M^3'OW[%W>N.:=CVJE_:L'HWY4?VK!Z-
M^5 %W'M2XJC_ &K!Z-^5']JP>C?E0!=Q2XJC_:L'HWY4?VK!Z-^5 %J6WAG
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MA?6/[>\/66HXPTT8+#WZ']:V:Y/X<6$NG>!M-@E!5]A<C_>)/]:ZR@ HHHH
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MXFE:4J,%VZFK51Q?ZM:EJ2T(:J3V9F?<)G7V!JY24 9_]FM_S\2?G1_9K?\
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M$GYTY=/974_:)#CMFKU&*YCT@ P *6BB@ HHHH **** "BBB@ HHHH ****
M"BBB@!#TKS&Z_P"2]V__ &#S_-*]./2O,;K_ )+W;_\ 8//\TH ].%+2"EH
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MJ2HY_P#CWD_W#_*@#SGX2?ZC6O\ K^D_]"->E5YK\)/]1K7_ %_2?^A&O2J
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M?SK?\+: WA[0TL6G,[@DL^,#)]!Z4!<\R:WOKSPA<:BD;R_:-2+78C&6,2L
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M@ HHHH **** "BBB@ HHHH **** $/2O,;K_ )+W;_\ 8//\TKTX]*\QNO\
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M&M?]?TG_ *$:]*H **** "JFHPM<Z==0(</)$R@^Y%6ZK7L[6UG/,H!:.,L
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MPNO_  -F_P#BJ!V.D_&C\:YO_A!- _YX77_@;-_\51_P@F@?\\+K_P #9O\
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M2T %%%% !1110!Q?Q1_Y$J?_ *ZQ_P#H56_ /_(J6WTJI\4?^1*G_P"NL?\
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MW:'6=$N=4:<"U,R3;<$=,C]:RI+/4%^&&AR'4&E><0&'>/\ 5_*>/>BX6/:
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M0?\ /"7\J/[4'_/"7\JO[1Z4;1Z4 4/[4'_/"7\J/[4'_/"7\JO[1Z4;1Z4
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MCT%<AXB\%MK>H_:1<^6 N,;<UO0FHRNSBQU*52GRQ/)LTM>@_P#"LF_Y_O\
MQVC_ (5DW_/]_P".UV_6*?<\3^SZ_8\^ZUTW@:;R==#E2WR]!6W_ ,*R?_G^
M_P#':UO#W@IM%U 7)NO,XQC;45:\)0:3-\/@JT*BDT=%_:@_YX2_E1_:@_YX
M2_E5_ QTHVBO./H>AY'X]G$^L*VUE^7H:Y.NQ^(?_(;7_=KCJ]:A\"/E<;_&
MD+24M)6QRG1^")?)\2Q-M+?(W KU;^U!_P \)?RKRSP'_P C3#_N-7L6T5YF
M*^,^BRO^$4/[4'_/"7\J5=3#,%$$G)QR*O;1Z4;1Z"N8](4'(SBEI,4M !11
M10 4444 %%%% !1110 4444 %%%% "'I7F-U_P E[M_^P>?YI7IQZ5YC=?\
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M_"2:+_T$[7_OX* -2BLO_A)-%_Z"=K_W\%'_  DFB_\ 03M?^_@H U**R_\
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MC#AE/%6!4LT0M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVKR.X_Y+!_P/^E:T^IRXK9>IZZ*6FBG5D=2"BBB@ HHHH *CG_X]Y/\ </\
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MG_GRB_*I=*U2UUG3H;^R<O;S+N0E2#CZ&KPH S/^$=TG_GRB_*C_ (1W2?\
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MC9QE0S8S7E7QQD:./P^%8@FZ.<'_ ':R/BG8RZKXU\+Z>DSQK.BJ[(<':>M
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MZ!XI@B:Y:TM8VEM&F4@A=P 'Y&M3X=_#W2_$WAEM<UT&[OKQF8.QSY8SQ@T
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ML\_\>T7_ 'R* -*RN([FT26)MR,,@U9J"WC6.!450H'85/4,T"BBB@ HHHH
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MJVH64&BW&IZ9<2F2%H 3@G\*71M(\5ZC\6[+Q#JVG20V[Q-C )$0P0%/H?\
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MQVRL2I&,D#D5JZ=?1ZA9PSJ5W.@8J#TS7CNG:5I,'PT\02VX5;TQRHX#_,%
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M_NFC0-1M(:?Y3_W31Y3_ -V@+,MQ?ZL5)4<8(0 U)4EB4453N+];>388G;W
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M$L>  =WM@>]1>.+)?^%B>#;*Y E"E4?/.["__6H [OP9XAUS7O.DU71'TZ+
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M.2.E ';?#.XENO 6F23$E@A7GT#$#]!77UFZ'I<>C:/:Z?%]R",)GU/K6E0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10
ME%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 E%+10 4444 (:3:">0
M*=10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>
M@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+1
M0 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HV
MCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 F
MT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%
M+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@
MHVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@HVCT%+10 FT>@I-H]!3J*
M $I:** "BBB@ HHHH **** "BBB@ HHHH **** $/2O,;K_DO=O_ -@\_P T
MKTX]*\QNO^2]V_\ V#S_ #2@#TZEI!2T %%%% !1110!Q?Q1_P"1*G_ZZQ_^
MA5;\ _\ (J6WTJI\4?\ D2I_^NL?_H56_ /_ "*EK]*U_P"79R_\O_D=0**!
M2UD=04F/:EHH 3 ]*9*BR1LC %6&"#WJ2DQ0!YC<_!O33J,]S8ZI>V$<[;I8
M8C\K?J*VO"_PXTKPEJLVH:?)*7E38ROS^-=IBC H YCP]X+L_#NKZEJ5M-(\
ME^Y>0,. 2<TFO>#+/7_$.EZQ<32)-IP81JHX;)!_I74;11@4 <MXS\#Z;XUL
MX8KUWBD@;=%,@^9:S[;X<V\7A:\T*YU.ZNH[K[TLGWE'MS7<[:,"@#+\/Z-%
MX?T&STFW9GBM8]BLW4\UHNBNA1@"K#!!':GXHP* /-]1^$.F3ZA->:9J-WI<
MDS9D6 _*WX9%6M1^%NDZIH-KIUW<7+RVQS'=;OG!]>OOZUWV*-M 'EK?!73;
MFW":CK%[>RJ04D<D;<>V375:[X*L]?T"STBYGD6*UD2167J2H(&?SKJ,48%
M&?/ID=QHTFF,[")XO*+=\8K+T#P?I^A>''T-<W%HY8L)!USU%=)@4;10!YB_
MP:L(KEWTW6;ZPMW;<T$9)7^8Q70Z_P" =(\2:3;65_O:2V4+%<#[ZX[YKK<"
MC:* /-=.^$=O:7L,]SKNH7<<#AXXG) &/QKH]9\&6>L^(]-UJ::19[!MR*!P
M>,<UT^*,4 )6)XG\,Z?XLTA]-U%"86.X%3@J?45N8HQ0!Y:GP4TR2W>WO]7O
MKN#:5BC<D"//0XSSBNQL/"6G6?A9/#TB_:+-4*$2#DBNAQ1B@#S"+X.6=I=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 (>E>8W7_)>[?_L'G^:5Z<>E>8W7_)>[?_L'G^:4 >G"
MEI!2T %%%% !1110!Q?Q1_Y$F?\ ZZQ_^A5:\ _\BI:_2JGQ1_Y$J?\ ZZQ_
M^A5<\ _\BI:_2M?^79R_\O\ Y'4"BBC-9'4%%)FES0 449HS0 449HS0 449
MHS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0 449HS0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'M%V#ZN_YF>7?:/B)_SS'YK1]H^(G_/,?FM>HXHQ2]HNP?5W_,SR[[1\1/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!,"EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
-BB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>gvvh0m1pmdf2000010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -2!YX# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH IZE>IINFW-[
M*"8[>-I& ] ,FN#A^+=M<1+)!X?U>6-ONND#$']*ZWQ?_P B=K/_ %YR_P#H
M)JA\/HT/@?2R44_N^N/<T 8W_"U(_P#H6M:_\!G_ /B:/^%JQ_\ 0M:U_P"
MS_\ Q->@>5'_ ,\U_*CRH_\ GFOY4 >?_P#"U8_^A:UK_P !G_\ B:/^%JQ_
M]"UK7_@,_P#\37H'E1_\\U_*CRH_^>:_E0!Y_P#\+5C_ .A:UK_P&?\ ^)H_
MX6K'_P!"UK7_ (#/_P#$UZ!Y4?\ SS7\J/*C_P">:_E0!Y__ ,+5C_Z%K6O_
M  &?_P")H_X6K'_T+6M?^ S_ /Q->@>5'_SS7\J/*C_YYK^5 'G_ /PM6/\
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M:L?_ $+6M?\ @,__ ,37H'E1_P#/-?RH\J/_ )YK^5 'G_\ PM6/_H6M:_\
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M_/-?RH\J/_GFOY4 >?\ _"U8_P#H6M:_\!G_ /B:/^%JQ_\ 0M:U_P" S_\
MQ->@>5'_ ,\U_*CRH_\ GFOY4 >?_P#"U8_^A:UK_P !G_\ B:/^%JQ_]"UK
M7_@,_P#\37H'E1_\\U_*CRH_^>:_E0!Y_P#\+5C_ .A:UK_P&?\ ^)H_X6K'
M_P!"UK7_ (#/_P#$UZ!Y4?\ SS7\J/*C_P">:_E0!Y__ ,+5C_Z%K6O_  &?
M_P")H_X6K'_T+6M?^ S_ /Q->@>5'_SS7\J/*C_YYK^5 'G_ /PM6/\ Z%K6
MO_ 9_P#XFC_A:L?_ $+6M?\ @,__ ,37H'E1_P#/-?RH\J/_ )YK^5 'G_\
MPM6/_H6M:_\  9__ (FC_A:L?_0M:U_X#/\ _$UZ!Y4?_/-?RH\J/_GFOY4
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M#/\ _$UZ!Y4?_/-?RH\J/_GFOY4 >?\ _"U8_P#H6M:_\!G_ /B:/^%JQ_\
M0M:U_P" S_\ Q->@>5'_ ,\U_*CRH_\ GFOY4 >?_P#"U8_^A:UK_P !G_\
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M_H6M:_\  9__ (FC_A:L?_0M:U_X#/\ _$UZ!Y4?_/-?RH\J/_GFOY4 >?\
M_"U8_P#H6M:_\!G_ /B:/^%JQ_\ 0M:U_P" S_\ Q->@>5'_ ,\U_*CRH_\
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M_P#/-?RH\J/_ )YK^5 'G_\ PM6/_H6M:_\  9__ (FC_A:L?_0M:U_X#/\
M_$UZ!Y4?_/-?RH\J/_GFOY4 >?\ _"U8_P#H6M:_\!G_ /B:/^%JQ_\ 0M:U
M_P" S_\ Q->@>5'_ ,\U_*CRH_\ GFOY4 >?_P#"U8_^A:UK_P !G_\ B:/^
M%JQ_]"UK7_@,_P#\37H'E1_\\U_*CRH_^>:_E0!Y_P#\+5C_ .A:UK_P&?\
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M^>:_E0!Y_P#\+5C_ .A:UK_P&?\ ^)H_X6K'_P!"UK7_ (#/_P#$UZ!Y4?\
MSS7\J/*C_P">:_E0!Y__ ,+5C_Z%K6O_  &?_P")H_X6K'_T+6M?^ S_ /Q-
M>@>5'_SS7\J/*C_YYK^5 'G_ /PM6/\ Z%K6O_ 9_P#XFC_A:L?_ $+6M?\
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M!Y4?_/-?RH\J/_GFOY4 >?\ _"U8_P#H6M:_\!G_ /B:/^%JQ_\ 0M:U_P"
MS_\ Q->@>5'_ ,\U_*CRH_\ GFOY4 >?_P#"U8_^A:UK_P !G_\ B:/^%JQ_
M]"UK7_@,_P#\37H'E1_\\U_*CRH_^>:_E0!Y_P#\+5C_ .A:UK_P&?\ ^)H_
MX6K'_P!"UK7_ (#/_P#$UZ!Y4?\ SS7\J/*C_P">:_E0!Y__ ,+5C_Z%K6O_
M  &?_P")H_X6K'_T+6M?^ S_ /Q->@>5'_SS7\J/*C_YYK^5 'G_ /PM6/\
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M:L?_ $+6M?\ @,__ ,37H'E1_P#/-?RH\J/_ )YK^5 'G_\ PM6/_H6M:_\
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M_/-?RH\J/_GFOY4 >?\ _"U8_P#H6M:_\!G_ /B:/^%JQ_\ 0M:U_P" S_\
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M*4$YH =1110 444AH 6BF;C_ /6I<T .HJ)YDB ,DBJ#W8XIRN&4,"&!Z$4
M/HHHH **** "BD)J-YXT8*TB*QZ G!H EHI :6@ HHHH **2F23)$NZ1U11W
M8X% $E%1QRK*H:-U93T(.14E !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@!#T->>_#W_D9O%/_7U7H1Z&O/?A[_R,WBG_ *^J /0Z*** "BBB@#%\7_\
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M8EEAD62-AE64Y!J6O&/A[\4M!LO#^E:-*MS]JP(N(_ER3ZYKV56WHK#H1D4
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M9'J6H6]RI76F'#2=2O.0*]VO]+LM4B2.^MHYT1PZAU! (H ^?OA[X[\2Z_\
M$V*#4KN189=S&WZ*ORDCBOH+4K^#2M.GO;E@L4*%V)]J^?- 54_:(N54 *KL
M !V^2M_XW^+&:XL_"EM,(!<,&N96X 7/3^1H X2[^*/B35_&L<UO>RV]A+<A
M(XE.%*9Q7J7Q;\<:IX9T;3[;2W$=S> !I2,X&.U>5>+TT#2]6\,VVD7D$T-L
MJ&:1#QNSDD_K7>_%[6_#FI^#+#8_VNZD.+22$]&'!S^- '.:H?B!X/T6S\2R
MZ^9DF*DQ,Y<#//0\5[MX.UV3Q'X6L=4EB\J2>,%E'3-?,.L67C"QT#2YO$,5
MQ-HBLK+&9#C'8'TXKZ:\%:AINI^$[&XTF/RK/RPJ1X^[@=* ,WXG>+#X3\&W
M-W$1]IE_=0_[Q[_A7-?!W1Y],\*3^(]3FEEGO TH#,6VH/;\ZP_VC9'&F:0@
M)"&20X]_EKUGPG%''X2TR- /+%NN!0!X%X]^,&O:E=.FBK+8V%N^PR@8+G/K
M7M7A:_NKOX9P7\\K/=-9NYD)YR >:X'X\Z99:9X+MDLK:. /=%V"*!DG')KN
M? T+W/PLL8(\;Y;1T7/3)R* /&/"5UX[\:7=^ECXA>(6TA!\QSZU[#X!T/Q/
MHYNO^$AU,7N\CR\,3M_.O+Y/@_XO\.VEW?Z9K*12<R/'%(R[N_8<UU7P6\;Z
MIKZWNDZPYEN+7E9#UQT(- 'KDDJ0QM)(P5%&23V%8[^,?#T=HUTVKVH@4[2^
M[H:G\2#_ (IO4/\ K@U?.OP=\"Z;XM&IRZKYDD,&!'&&P 3G)_04 ?0L7BS0
MI].;4(]5MFM5/S2;N!_6I-*\3Z/KC.NF:C#<E#\P0\C\Z^;/AUX/M==\?:AH
ME[)*VG6Q9FA#$!B,XS^5:_A:PB\+_'Z;2=/+):*S+M)[;,_UH ]^U7Q%I.AH
MKZG?PVRL<#>>3^ JNGC'P_)#'*NKVQ24X0[NIKP);(?$3XU7-CJLKFT@9@J9
M_A49Q^=5OBGX-T_PCXIT9-,W);W#HQC)R =U 'TS<W20V,MT6&Q(R^>V,9KR
M#P)J.K>(8O%6NW%Y.UB-\=K&7.W'/('MBM[XG:^VB_#1(8'VW-[%'!'CJ,@?
MT%6_"FBC0?A,MKL"NUHTC\=V&30!QW[/5]-+HVM27=S(ZI)'\TKDX&&]:]<T
M_P 0:5JDKQ6%]%<.G+!#G%?(&A^*[W2O#-_HEGF/^T)4\R?.-H&1C]:^@O#G
MAVS\ ?#.[U&S=9[QK4S27"_Q''0'TH [2_\ &7A_2[H6M[JUM#.?X"V3^E6(
M/$>DW-XMI#J,$EPPR(U;)-> _"?P1IWCF75-7UTO</YA4#=SGU-5O"6D)H7Q
MU_LZ*1GCA=@A8Y(&V@#Z;).*\6^)7Q,U:W\11^%?#./MKD+)(%#$$C.!7M)Z
M5\S>"%!^/ES_ &ECSQ<S>5O_ .!8_P#': -B\\,?%/1M/;5TUJ2XEC'F/ )"
MV/7@\5U'@GXA7/COPGJ-E(_V?7((3\RC&[_: _SUKU2XV_9I-_W=AS],5\Y_
M"T(WQFU5;0?Z,?.&!TV[Q0!U7P0\8:EK,VJ:;K%T\UU"59 YYQSG^E<7\3?B
M#X@MO'>I6^E7\T-K9L(BJ'C(SS5RVE3P3\>[TG]W;7._ '  8_\ UJH>&-!_
MX2O2/&VJ3*9)7C9HCU^<;L4 >QGQ44^$AU_S?WQLBRN3_'@X_6O--#T_7/&_
MPNU?4M0O[B2XCD,EM\Y& H!./U%<VWBAC\#_ .QFD_?1WAA"Y_@&T_S)KWKX
M?:,FF?#RPLW4+YD!,@(_O9_I0!SOP3\63:[X:DT^[D+W5@VPECDE?\G%>I]J
M^>?@:[0_$?Q+;QJ3#AQQT&)>#7O]U<I9VDUQ)G9$A=L>@YH +J]MK*/S;F=(
MDSC<YP*ECD26-9(V#(PR".XKY]^*'Q-T/Q-X:2RL5N/-$ROF2/ P,^]=KX+^
M*6A7EKI6BQK<_:O*2+F/C('KF@#T\U\Y^*-:\7:E\6K[P]HNJR0#S#Y:%B%&
M*^C!R*^7O$CZW'\=]0;P^JMJ/F'RPPR/>@#1N?&?CSX=>([2VU^Z2ZM9<%@0
M#E<\X.,YKOO'^EG7;_0[V/Q"FEKM23RFD93*"<]ORKRS3/M?BOXH6]CXZGD2
M:%@J1!?E+#D#KQFNE^.L:P^)O"\<8PB>6JCV#F@#O?'OQ%A\#Z'#]F,-W?85
M/*9B.,?>K8\'^,[+Q'HEO.]W!]L:+S)8D/W/6O+_ (X>&].B\+V.N)$1?2>7
M&SYX(VBNF^'O@W2-,\$KK5M 5O+BQ;S&+9!RN: /1=.UO3M6,@L+R*X,9P^P
MYVTW^WM,_M(Z=]NA^V#_ )8Y^:O&?V>/]9X@_P"NJ_UJA"5/[2C<Y_>'/YT
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M?!Z7WA=8M&TE&N//4GR8QG'-==X9\/6%EHFG%].@CNXX$WG8 P;'-=$5!I:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *3%+10 F*6BB@ HHHH 3%&*6B@!,4 8I:* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "DQ2T4 -Q1@TZB@!!2T44 %(12T4 -Q2XI:* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** $/0UY[\/?^1F\4_\ 7U7H
M1Z&O/?A[_P C-XI_Z^J /0Z*** "BBB@#%\7_P#(G:S_ -><O_H)JE\/?^1'
MTO\ ZY?U-7?%_P#R)VL_]><O_H)JE\/?^1'TO_KE_4T =/1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&:
M"BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-&: "BC-
M% !1110 4444 %%)10 M%)10 M%)D4M !1110 4444 %%&:,T %%)FC(H 6B
MBC- !129%&0: %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***3(H 6BDR*,B@!:***
M"BBB@ I"P&23P.M*:Y?QWXB'ASPU-.HW7,O[J!.[,>* -FRUK3=2N)[>SO(9
MYK=MLJ(V2A]ZO9KQ&ST2Z^'>IZ+K\LCF*]7RM3)[.V""?R->UH=RAAT(S0!)
M1110 4444 %)D4M9NM:E#H^CW6H3MB.!"QH <-=TLZK_ &7]NA^W8W>1N^;'
MTJ_FO!X]'OH=&7XC.LG]I-<_:&0]H#D[?Y5[7I6HP:MIEO?VKAX)T#HP[@T
M7J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#3)_RH^T_],G_*K-% %;[3_P!,G_*C[3_TR?\ *K-% %;[3_TR?\J/M/\
MTR?\JLT4 5OM/_3)_P J/M/_ $R?\JLT4 5OM/\ TR?\J/M/_3)_RJS10!6^
MT_\ 3)_RH^T_],G_ "JS10!6^T_],G_*C[3_ -,G_*K-% %;[3_TR?\ *C[3
M_P!,G_*K-% %;[3_ -,G_*C[3_TR?\JLT4 5OM/_ $R?\J/M/_3)_P JLT4
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MA\+[6/-<]=1UD0,C J>A%1W-Q#:6\D\TBQQQC<S,< "J.A$G1;;/]W^M</\
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M_P ^[T?:G_Y]WH MT54^U/\ \^[T?:G_ .?=Z +=%5/M3_\ /N]'VI_^?=Z
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M444 =%H7_'FW^^:U:RM"_P"/-O\ ?-:M(84444 %%%% !1110 4444 %%%%
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MV<]:J0Z=:6]W-=10(D\W,C@<M]30!P>D_#N\M]*U][^]2?5=85A)(!\JY7
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M2X7/L*OTM ""EHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** &$<UQM]X 2;4KV[LM5NK%+[_CXBA"E7_,''X5VM% '$W?P[L)8
M-/%C=W-C/8QF*.:(C<5.,@YZ]!6YX<\/V_AS3OLD#O*68O)+(<L['J36U10
M4444 %07?_'K)_NFIZAN_P#CUD_W30!QU%'>BF(**** "NMT_P#X\(?]VN2K
MK=/_ ./"'_=I#+54-7_Y!TGX?SJ_5#6/^0;)^'\Z .7HHHI@%%%% AR??7ZU
MV47^I3Z"N-3[X^M=E%_J4^@H&/HHHI %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>AKSWX>_\C-XI_Z^
MJ]"/0UY[\/?^1F\4_P#7U0!Z'1110 4444 8OB__ )$[6?\ KSE_]!-4OA[_
M ,B/I?\ UR_J:N^+_P#D3M9_Z\Y?_035+X>_\B/I?_7+^IH Z>BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/0UY[\/?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 4E%% %'5-2BTJQ>ZGR47K@5S?\ PL;2<?=E_P"^:O>-D9_#<ZJ"Q] *\?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *3 I:* $Q2T44 %)2TE #'B21=K@,OH147V&V_Y
MX1_]\BK&:*:;Z$N,7N-2-44*H 4= *S=<\/:=XBL_LNI0F2,'(P[*0?J"*T\
MFHI[J"UC\RXFCA3^](X4?F:11D:#X.T/PV7;3+)8I7^_(S%V/XL347_"#:!_
M;C:N++%TQ+,1(P5B>Y7.#W[5L6^IV-VQ6VO+>9AU$<JL?T-6=U '(_\ "L/"
M7G2N=+!20Y:+S7V9]<9K0U'P3X>U6&SAO=.69+-"EN"[#RP<9Q@^PK>S2YH
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M":I?#W_D1]+_ .N7]35WQ?\ \B=K/_7G+_Z":I?#W_D1]+_ZY?U- '3T444
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MY!T=7JHZ1_R#HZO4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_*O2QTKR/PCI=J_B"TD7P3<Z<\2DM<S8PK8/ KUL=* %HHHH **** "BBB@
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M[*+_ %*?04ACZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYX-^8H\Z;_G@WYBK-% %;SIO^>#?F*/.F_YX-^8JS10!6\Z;_G@WYBCSIO\
MG@WYBK-% %;SIO\ G@WYBCSIO^>#?F*LT4 5O.F_YX-^8H\Z;_G@WYBK-% %
M;SIO^>#?F*/.F_YX-^8JS10!6\Z;_G@WYBCSIO\ G@WYBK-% %;SIO\ G@WY
MBCSIO^>#?F*LT4 5O.F_YX-^8H\Z;_G@WYBK-% %;SIO^>#?F*/.F_YX-^8J
MS10!6\Z;_G@WYBCSIO\ G@WYBK-% %;SIO\ G@WYBCSIO^>#?F*LT4 5O.F_
MYX-^8H\Z;_G@WYBK-% %;SIO^>#?F*/.F_YX-^8JS10!6\Z;_G@WYBCSIO\
MG@WYBK-% %;SIO\ G@WYBCSIO^>#?F*LT4 5O.F_YX-^8H\Z;_G@WYBK-% %
M;SIO^>#?F*/.F_YX-^8JS10!6\Z;_G@WYBCSIO\ G@WYBK-% %;SIO\ G@WY
MBCSIO^>#?F*LT4 5O.F_YX-^8H\Z;_G@WYBK-% %;SIO^>#?F*/.F_YX-^8J
MS10!6\Z;_G@WYBCSIO\ G@WYBK-% %;SIO\ G@WYBCSIO^>#?F*LT4 5O.F_
MYX-^8H\Z;_G@WYBK-% %;SIO^>#?F*/.F_YX-^8JS10!6\Z;_G@WYBCSIO\
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M #T7\Z/-C_YZ+^=1_9(?^>8H^R0_\\Q0!)YL?_/1?SH\V/\ YZ+^=1_9(?\
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MIEF(VOW ^4\4_P .77BZ768EU70M.M;7!W2P2[F'IQM% '>+3J:*=0 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:P6^^WUK>T;_ )!TG^\:P6^^WUH&)1110(.]=%8?\@8_0USO>NBL/^0,?H:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_/#]://N/^>'ZT 6Z*J>?<?\\/UH\^X_YX?K0!;HJIY]Q_SP_6CS[C_GA^M
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M !1110 4444 %%%% !1110 AZ&O/?A[_ ,C-XI_Z^J]"/0UY[\/?^1F\4_\
M7U0!Z'1110 4444 8OB__D3M9_Z\Y?\ T$U2^'O_ "(^E_\ 7+^IJ[XO_P"1
M.UG_ *\Y?_035+X>_P#(CZ7_ -<OZF@#IZ*** "FNJLN& (/4$4ZFM0!6>VM
M$&6AA ]U IT<$"$/'%&#V*J*\G^(%S>ZGXKFTIM7ET^UMK,SHD;;3,W'?/\
MG-7-,UR?^WO"=G;7\DKRVS&Z@#D@KQ\Q'KUH ]3%.IJTZ@ I#TI:#S0!S?B[
MPQ_PE6EK8O>2VT88,WE_Q8['VJE!X+D;2Y],O]3>YLY8_+6+R@@3T(Q78;:,
M"@#BM(\!?8]5L[V_U.>_-BNVU60<)TY]SP.:[4"C%+0 48HHH 3%<IJ7_'_)
M]:ZRN3U+_D(2_6F!4HHHH$%;.@??E^@K&K9T#[\OT% &?J'_ !_2_6JU6=0_
MX_I?K5:@ HHHH W- _U-Q]1_(UCW'_'Q)_O&MC0/]3<?4?R-9%Q_Q\2?[QH
MBHHHH *WM$_X]):P:WM#_P"/27ZT 8DW^OD_WC3*?-_KY/\ >-,H **** -_
M1O\ D'2?4U@M]]OK6]HW_(.D_P!XU@M]]OK0,2BBB@05T5A_R!C]#7.]ZZ*P
M_P"0,?H:!G.GJ:*#U-% @HHH[T#.ITG_ )!T=7JHZ1_R#HZO4@"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9+R6&:94_@B7<Q_"M&F, >H!^M 'DGB76?"_BM$&I^'M6=TX21;?##\<U:\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*.]%,04444 %=;I__'A#_NUR5=;I_P#QX0_[M(9:JAK'_(-D_#^=7ZH:N?\
MB72?A_.@#EZ***8@HHHH <GWQ]:[*+_4I]!7&)]\?6NSB_U*?2D,?1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7_/"X_[Y'^->645V_58'S/\ :=4]3_X65I7_ #PN/^^1_C2_\+)TO_GA<?\
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MA:)_SU?_ +YKR*BNSZI \G^U*AZ[_P +"T3_ )ZO_P!\T?\ "PM$_P">K_\
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MHH **** "BBB@ HHHH **** $/0UY[\/?^1F\4_]?5>A'H:\]^'O_(S>*?\
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MN^.H/YUZ(* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*O\ [E<[71>#O^0J_P#N5V8'^/$YL5_"9WU+24M?8'SX4444 %%%% !1110
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M?_".G[44=J*^H/%"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI#TH
MCGN(;:%I9Y4CC499G; %>/\ C;PX=0O[^[T#Q'81)J"J+J"65=K$=".1ZFO2
M/%.@CQ+X<O-*:=X/M";1(G537CD7PXU;PLQ^WZ/#KMD/^6D,K++CZ;OZ4 =G
MX&\/S#Q"VM:MK-I>ZBL'DPPVKC;&G?C)KTP5YC\/;OP;/K$J:-:36FJ1H1)#
M-OW =^M>G"@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJQ9\MB?XTB&[_P"/27_=KCZ["[_X])?]VN/H, HHHH$%%%% '7:?_P >$/\
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M2^'O_(CZ7_UR_J: .GHHHH *S-?U%])T.\OXH#/);QEUC SN/IQ6G2%0P(8
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M][^1R%%%%4=X5Z3\&_\ D8+O_K@?YBO-J])^#?\ R,%W_P!<#_,5,MCDQO\
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M\A:\_P"NS?S-.!UY7O(J4445H>T%%%% 'O?PE_Y%+_MJ?Y"N^K@?A+_R*?\
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M=IX>\/>-;#5XY]8\26U[9A2&ACA*DGMS0!W(ZTZF+3Z "BBB@ HHHH ****
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M'&;7A+_D:;#_ *Z_T-)\9/\ D.6?_7,_TI?"7_(TZ?\ ]=?Z&D^,G_(<L_\
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M:7H*^9?!G_(WZ;_UW7^8KZ:7H*SF>%F?\1#C7E/Q'_Y#D/\ USKU:O*?B/\
M\AR+_KE6N%_B'SF9?P#C:***],^;"BBBF!UWP[_Y& _[AKUH=*\E^'?_ ",!
M_P!PUZT.E>7BOXA]'EG\$#TKYP^(W_(\7_\ P'_T$5]'GI7SA\1O^1XO_P#@
M/_H(K*!]'EG\4Y6BBBM#W@HHHH ]4^"G_(0U3_KDG\S7LM>-?!3_ )"&J?\
M7)/YFO9:REN?-8[^/(AO/^/2;_<;^5?*^J_\A:\_Z[-_,U]47G_'I-_N-_*O
ME?5?^0M>?]=F_F:<#KROXF5****T/:"BBB@#WOX2_P#(I_\ ;4_R%=]7 _"7
M_D4_^VI_D*[ZL6?+8G^-(AN_^/27_=KCZ["[_P"/27_=KCZ# ****!!1110!
MUVG_ /'A#_NU9JMI_P#QX0_[M6:0SG_%W_((/^\*\^[UZ#XN_P"00?\ >%>?
M=Z^8S;^,>UE_\,****\L[Q*FMO\ CZB_WA4-36W_ !]1?[PJJ?QHB?PL]7@_
MU$?^Z*D[5'!_J(_]T5)VK[:'PH^:>YQ_C7_5V_\ O5Q]=AXU_P!7;_[U<?7R
MV9?[PSW<%_!04445P'6%:.A?\AFW_P!ZLZM'0O\ D,V_^]6N'_BQ]3*O_#9Z
M>.E% Z45]JMCYL\^\7?\AD_[H_E6!6_XN_Y#)_W1_*L"OD,=_'D?0X7^$@HH
MHKC.@*Z+P=_R%G_W*YVNB\'?\A9_]RNS _QXG/B_X3.^I:2EK[ ^>"BBB@ H
MHHH **** "BBB@ HHHH 0]#7GOP]_P"1F\4_]?5>A'H:\]^'O_(S>*?^OJ@#
MT.BBB@ HHHH Q?%__(G:S_UYR_\ H)JE\/?^1'TO_KE_4U=\7_\ (G:S_P!>
M<O\ Z":I?#W_ )$?2_\ KE_4T =/1110 4UJ=330!A:]XNT/PR%.J7BPLW*J
M%+-^0!-6K77=/O/LJQ7"[[J/S(5.076O,/B-'/H_B:;5KC2I=0L[JT,"/&F\
MPO\ 3_/2H_!MY>>*==T'R=-N+6TTB$^;/,FTNQQ\H]N* /9A3J8O6GT %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !2$9I:* (WB1_O*&^HIOV:'_GDG_?(J7%&*
M=V)Q3W(OLT'_ #R3_OD4?9H/^>2?]\BIJ2B[%R1[$7V>'J(DX_V17 ?$S[MG
M]3_6O1*\[^)GW;/ZG^M;4'^\1R8Y)4'8\[HHHKU#Y@*UO#7_ ",-G_UT'\ZR
M:UO#7_(PV?\ UT'\ZFI\+-:/\1'4?$K_ %]G_NUP-=]\2O\ 7V?^[7 UGA_@
M-\=_&84445L<9M>$O^1IL/\ KK_0TGQD_P"0Y9_]<S_2E\)?\C38?]=?Z&D^
M,G_(<L_^N9_I7GXC^(?7<-_$>:T445F?;!7;?"S_ )'*+_<;^1KB:[;X6?\
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M?^O.7_T$U2^'O_(CZ7_UR_J:N^+_ /D3M9_Z\Y?_ $$U2^'O_(CZ7_UR_J:
M.GHHHH *:U.IIH \N\5:CXLU#QXFA>';Z"&$0>9-YL8(7]*Q[E_B1IWB*+2/
M[:L2\T;20D0@*^WJ.G7I72^-]#MX]4AUVT\0+H^I!/+W/]V5?0C-4/">G0WO
MB1=2U/Q5!J>IK&T<$47W44]2/>@#L?!.O2^(?#Z75R@2ZC<Q3A>F\=<?G725
MB^&O#\/AO36M(IFF+R-*\C#!9C[5M4 %%%(: %HJ*25(HVD<@*H)8GM6)IOC
M+1=6L;R]M+L-;VC;99#P!U_PH Z"BN9TKQUHFL:A'96TSK-*-T0D7:)!ZKZU
MTM "T44F: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,
MT9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*
M3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6
MBDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: "O._B9]VS^I_K7HF:\[^)OW
M;/ZG^M;8?^(CCQ_\%GG=%%%>L?+A6MX:_P"1AL_^N@_G616OX9_Y&&S_ .N@
M_G45/A9M0_B(ZCXE?Z^S_P!VN!KO?B5_K[/_ ':X*LL/\!MCOXS"BBBMSC-K
MPE_R--A_UU_H:3XR?\ARS_ZYG^E'A+_D:=/_ .NO]#2_&3_D.6?_ %R/]*X,
M1_$/KN&_B/-****R/M@KMOA9_P CC%_N-_(UQ-=M\+/^1QB_W&_D:3V.?%?P
M9#_BQ_R.#?\ 7,?R%<-7<_%C_D<&_P"N8_D*X:A"PG\&(4AI:0]*9TG=?"?_
M )'%?^N356^)G_(YW/\ NC^M6?A/_P CBO\ UR:JOQ,_Y'.Y_P!T?UJ>IP+_
M 'OY'(44E+5'?U"O2?@W_P C!=_]<#_,5YM7I'P<_P"1@N_^N!_F*F6QR8W^
M SIO$7_(;GK*K5\1_P#(;FK*KX;%?Q9$T/X:"BBBN<V.J\%_ZZX^E8>L?\A:
MX_WZW/!?^NN/I6'K'_(6N/\ ?KU*W^YQ]3AI?[S(HT445Y9W!WKK_!?^HNOP
M_K7(=ZZ_P9_J+K\/ZUZ.6?[PCCQO\(\)\0?\C!??]=36;6EX@_Y&"^_ZZFLV
MOLEL=]+X$%':BD-!H>S?"+_D7[__ 'OZ&J\W^OD_WC4_PA/_ !3]_P#[W]#5
M><_Z1)_O&OG<[^R>72_WB8RBBBOGCM"NZ\%_\@N7_KK_ $%<*:[GP7_R#)O^
MNO\ 05ZF4_QS@Q_\(Z?M2TG:C/%?4'BBT444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% "'I7DVJ7OC/7?'NI:5H.HVT%C9JOF&:(':3GCH?2O63TKS
M'Q=HD6G^()=8TSQ-'I%]<@"6*7E9,=^OO^M '-R:G\1=.UZ\TMM4LY)[6$7"
M1B(!94YR!QQTKU?PIK9\0^&K+4VC\MYTRR>A[UQ/A?0[._OKZ[N?$Z:CK-U
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MZK=PP&65V. B?7!JIX1UYI?%%A;S^$8-+^U0M)#<!QR!V'% 'K2TZF Y-/H
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M;=?WU_*K5)0!6VW7]]?RK@/B0) MGO(/)Z?C7I&*YWQ-X8_X2%80;CRO+/\
M=SFM*4E&=V<V*INI3<8GC.:2O1?^%8C_ *"'_CG_ ->E_P"%8_\ 40_\<_\
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M[N:X2O0O%W_((/\ O"O/N]?,9M_&/:R_^&%%%%>6=XE2VXS<Q#_:%1U+;?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !24M% !24M% 'FOQ,_X^;7_=-<!7
M?_$S_CYM/]TUP%>KAOX9\QC_ .,PHHHK<XC9\)?\C3I__77^AH^,G_(<L_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQK_J[?\ WJX^NP\:_P"KM_\ >KCZ^6S+_>&>[@OX*"BBBN ZPK1T+_D,V_\
MO5G5HZ%_R&;?_>K7#_Q8^IE7_AL]/'2B@=**^U6Q\V>?>+O^0R?]T?RK K?\
M7?\ (9/^Z/Y5@5\ACOX\CZ'"_P )!1117&= 5T7@[_D+/_N5SM=%X._Y"S_[
ME=F!_CQ.?%_PF=]2TE+7V!\\%%%% !1110 4444 %%%% !1110 AZ&O/?A[_
M ,C-XI_Z^J]"/0UY[\/?^1F\4_\ 7U0!Z'1110 4444 8OB__D3M9_Z\Y?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M 'B9'1117SQVA7=>"_\ D%R_]=?Z"N%KNO!?_(+E_P"NO]!7J93_ !S@Q_\
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MBT445Y9WA4MM_P ?47^\*AJ:V_X^HO\ >%53^-$3^%GJ\'^HC_W14G:HX/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_/;]*/)N?^>WZ4 6Z*J>3<_\]OTH\FY_Y[?I0!;HJIY-S_SV_2CR;G_GM^E
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M@O\ UUQ]*PM8_P"0M<?[U;'@]7::?8^WBL75@1JEP&.3NZUZ=;_<X^IPT_\
M>9%.BBBO+.X.]=?X,_U-U^']:Y#O75^$%=H;G8^ ,9&/K7HY9_O"./&_PSPW
MQ!_R,%]_UU-9M:.O C7KW)R?--9U?8K8[Z7P(*#THHIFA[+\(?\ D7[_ /WO
MZ&J\_P#KY/\ >-2?"5)#H-_M;:-W]#44_P#KW[\GFOG<[Z'ET_\ >)C****^
M>.T*[KP7_P @R7_KK_05PM=IX025M-E*2;?WI[>PKT\J_CG#C_X9UG:BJODW
M/_/;]*58KC<"9<CZ5]2>(6J*04M !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]*^</B-_P CQ?\
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M_KSE_P#035+X>_\ (CZ7_P!<OZFKOB__ )$[6?\ KSE_]!-4OA[_ ,B/I?\
MUR_J: .GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "DI:* $/2OG;XF_P#(YW/^Z/ZU]$GI7SM\3/\ D<[G_=']:N!Z.6_Q3CZ*
M**T/?"O2?@W_ ,C!=_\ 7 _S%>;5Z3\&_P#D8+O_ *X'^8J9;')C?X+.E\1?
M\AN>LJM7Q%_R&YZRJ^&Q7\61-#^&@HHHKG-CJO!?^NN/I6'K'_(6N/\ ?K<\
M%_ZZX^E8>L?\A:X_WZ]2M_N<?4X*7^\R*-%%%>6=X=Z[#P9_J+K\/ZUQ_>NP
M\&?ZFZ_#^M>CEG^\(X\=_"/"?$/_ ",%]_UU-9E:?B'_ )&"^_ZZFLROLEL=
M]+X$%'8T4=C0:'LOPB_Y%^__ -[^AJO-_KW^IJQ\(O\ D7[_ /WOZ&J\_P#K
MW^IKYW._LGETO]XF1T445\\=H5W7@O\ Y!<O_77^@KA:[KP7_P @N7_KK_05
MZF4_QS@Q_P#".G[44=J*^H/%"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** &FOG#XC?\CQ?_5?_ $$5]($5DW7AG1+ZX:XNM+M9IF^\[Q D_C51=CJP
MN(5"?-8^6Z,U]/?\(;X<_P"@+8_]^5_PH_X0WPY_T!;'_ORM5SH]#^U5_*?,
M-%?3W_"&^'/^@+8_]^5H_P"$-\.?] 6Q_P"_*T<X?VJOY3S3X+?\A#5/^N2?
MS->SCI6?I^B:9I3.UA8P6S.,,8HPN?KBM"HD[GEUZOM9N9#>?\><W^X?Y5\K
MZK_R%KS_ *[-_,U]47G_ !YS?[A_E7ROJG_(6N_^NS?S-5 ]#*_BD5****T/
M:"BBB@#WOX2_\BG_ -M3_(5WU<#\)?\ D4_^VI_D*[ZL6?+8G^+(AN_^/27_
M ':X^NPN_P#CTE_W:X^@P"BBB@04444 ==I__'A#_NU9JMI__'A#_NU9I#.?
M\7?\@@_[PKS[O7H/B[_D$'_>%>>]Z^8S;^,>UE_\,6BBBO+.\2IK;_CZB_WA
M452VW_'U%_O"JI_&B)_"SU>#_41_[HJ3M4<'^HC_ -T5)VK[:'PH^:>YQ_C7
M_5V_^]7'UV/C7_5V_P#O5QU?+9E_O#/=P7\%!1117 =85HZ%_P AFW_WJSJT
M="_Y#-O_ +U:X?\ BQ]3*O\ PV>GCI10.E%?:K8^;//O%W_(9/\ NC^58%;_
M (N_Y#)_W1_*L"OD,=_'D?0X7^$@HHHKC.@*Z+P=_P A9_\ <KG:Z+P=_P A
M5_\ <KLP/\>)SXK^$SOJ6DI:^P/G@HHHH **** "BBB@ HHHH **** $/0UY
M[\/?^1F\4_\ 7U7H1Z&O/?A[_P C-XI_Z^J /0Z*** "BBB@#%\7_P#(G:S_
M -><O_H)JE\/?^1'TO\ ZY?U-7?%_P#R)VL_]><O_H)JE\/?^1'TO_KE_4T
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M_".G[4M)VHSQ7U!XHM%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4445P'6%:.A?\AFW_P!ZLXUH:)N.KV^TX.ZM</\ Q8^IE7_AL]/%+539=_\
M/1?RI=EU_P ]%_*OM>A\X<1XN_Y#)_W1_*L"MSQ5O&KD.03M'3Z5AU\ACOX\
MCZ#"_P )!1117&= 5T7@[_D*M_NUSM;WA,2'5&V, =G<5V8'^/$Y\5_"9Z%1
M579=_P#/1?RHV7?_ #T7\J^P/GBU2U!")@3YC _05/0 4444 %%%% !1110
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M(E_Y[M5FB@"MY$O_ #W:CR)?^>[59HH K>1+_P ]VH\B7_GNU6:* *WD2_\
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M_P ]VH\B7_GNU6:* *WD2_\ /=J/(E_Y[M5FB@"MY$O_ #W:CR)?^>[59HH
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MAEFE;J['J:V]M&*  4M%% "4M%% !1110 4444 %%%% !1110 4444 %%%%
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MP. 551MY&?2NN^$]NEMX$MBEPLIED:5@N<1DXR@^E '<T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 (>E?.WQ,_Y'.Y
M_P!T?UKZ)/2OG7XF_P#(YW'^Z/ZU<#T<M_BG(44E&:T/H!:](^#?_(P77_7
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!,48I:* $Q2XHHH
M3%&*6B@!*">*6D- ''^-?]7;_P"]7'UZ!XDTBXU-81 5&T\YKG_^$0U#^]'^
M=?-X_"U9UG**/8PE>G&DDV<_170?\(AJ']Z/\Z/^$0U#^]'^=<?U*O\ RG3]
M:I=SGZT="_Y#-O\ [U7_ /A$-0_O1_G5O3/#-[:ZA%-(R;5.3BM*.#K1JQ;B
M9UL33<&DSM1THI!TI:^K6QX1Y]XN_P"0R?\ ='\JP*Z'Q:K-K!(5C\HZ#VK
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M>AZNFM:/%J,:%%DSA?H<4NFZLFHK.?)DA\F4Q_O0!NP3R/;B@#GV^'-@T-_
M;NZ^SWCLYB\P[48G.1S4FG^ K:ROYKV2_N;F::$P,97)PI].:ZQ9$?.Q@V.N
M#2F1%^\P'?DT <1IWPSTW3IK0F]O)[>TE\V&WED)0-G/3/M4E]\-["[N;IX[
MZ\MK>[;=/;0R$(YZ'@'N*V?$7B*+0;"&Z*><LLZ1 *?[QQ6NMQ'L1F=5W $
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M'PA_Y%^__P![^AJO-_KY/]XU\[G?V3RZ7^\3(Z***^?.T*[KP7_R"Y?^NO\
M05PM=UX+_P"07+_UU_H*]/*?XYP8_P#A(Z?M11VHKZ@\4**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"1F\4_]?5>A'H:\]^'O_(S>*?^OJ@#T.BBB@ HHHH Q?%__(G:S_UYR_\
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MS>!= N+Y+R6P5I4VD9/!*@ $C\!0!T,#K)!&Z$[64$'V-2TQ%VJ !@#H*?0
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M )!<O_77^@KA:[KP7_R"Y?\ KK_05Z>4_P <X,?_  CI^U%':BOJ#Q0HHHH
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MLA_Y[/0!:HJK]D/_ #V>C[(?^>ST 6J*J_9#_P ]GH^R'_GL] %JBJOV0_\
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 )12T4 )12T4 )12T4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWY7Q0_Y^]*_[]_\ UJ/*^*'_ #]Z5_W[_P#K4 >B45YWY7Q0_P"?O2O^_?\
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M -:CROBA_P _>E?]^_\ ZU 'HE%>=^5\4/\ G[TK_OW_ /6H\KXH?\_>E?\
M?O\ ^M0!Z)17G?E?%#_G[TK_ +]__6H\KXH?\_>E?]^__K4 >B45YWY7Q0_Y
M^]*_[]__ %J/*^*'_/WI7_?O_P"M0!Z)17G?E?%#_G[TK_OW_P#6H\KXH?\
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MROBA_P _>E?]^_\ ZU 'HE%>=^5\4/\ G[TK_OW_ /6H\KXH?\_>E?\ ?O\
M^M0!Z)17G?E?%#_G[TK_ +]__6H\KXH?\_>E?]^__K4 >B45YWY7Q0_Y^]*_
M[]__ %J/*^*'_/WI7_?O_P"M0!Z)17G?E?%#_G[TK_OW_P#6H\KXH?\ /WI7
M_?O_ .M0!Z)17G?E?%#_ )^]*_[]_P#UJ/*^*'_/WI7_ '[_ /K4 >B45YWY
M7Q0_Y^]*_P"_?_UJ/*^*'_/WI7_?O_ZU 'HE%>=^5\4/^?O2O^_?_P!:CROB
MA_S]Z5_W[_\ K4 >B45YWY7Q0_Y^]*_[]_\ UJ/*^*'_ #]Z5_W[_P#K4 >B
M45YWY7Q0_P"?O2O^_?\ ]:CROBA_S]Z5_P!^_P#ZU 'HE%>=^5\4/^?O2O\
MOW_]:CROBA_S]Z5_W[_^M0!Z)17G?E?%#_G[TK_OW_\ 6H\KXH?\_>E?]^__
M *U 'HE%>=^5\4/^?O2O^_?_ -:CROBA_P _>E?]^_\ ZU 'HE%>=^5\4/\
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M:CROBA_S]Z5_W[_^M0!Z)17G?E?%#_G[TK_OW_\ 6H\KXH?\_>E?]^__ *U
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M%>=^5\4/^?O2O^_?_P!:CROBA_S]Z5_W[_\ K4 >B45YWY7Q0_Y^]*_[]_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "DQ2
MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>gvvh0m1pmdf2000016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 2%!L0# 2(  A$! Q$!_\0
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M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9
MUK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C
M_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\
MC1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9U
MK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_
M (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C
M1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK
M_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\
M'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'C_C5JB@"K_9UK_SR_P#'C_C1
M_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_9UK_ ,\O_'C_ (U:HH J_P!G
M6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@"K_9UK_SR_\ 'C_C1_9UK_SR_P#'
MC_C5JB@"K_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JB@"K_9UK_P \O_'C_C1_
M9UK_ ,\O_'C_ (U:HH J_P!G6O\ SR_\>/\ C1_9UK_SR_\ 'C_C5JB@#G[R
M-(KMT0848P,^U%/U'_C^D_#^0HH T]._X\8_Q_F:M55T[_CQC_'^9JU0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% &%J/_ !_2?A_(44:C_P ?TGX?R%% &GIW
M_'C'^/\ ,U:JKIW_ !XQ_C_,U:H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $)
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MC5FATF](NU7<UK.NR4#U Z-[X)Q5FP\ ^$M-LA:6WAS3/*V[&\RV61G'^TS
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MX<\7:!XMM7N-#U*&[6/_ %BKE73.<;D8!AG!P2.<<4 ;=%%% !1110 4444
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M7.NE2+J&ZN&64MD_<4,!MP1@J/3/->O>%?!FB^#+:ZM]$@DAAN9?-='E+X.
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M?7EY;H[A%,]ZJ!F)P%&1R237K<,26\$<,2[8XU"*/0 8% #Z*** /GG]F?\
MX_?$G_7.W_G)7T-7SS^S/_Q^^)/^N=O_ #DKZ&H ^;+?3Y_C1\8-274;J5=#
MTPN$2-AQ&K;55?0N1N)Y[CTKU*Y^"?@&?3VM4T4P''RSQ7$GF*?7)8Y^A!'M
M7F_P<U&'PS\4_$GA[4G$$]U(T<1D^4/)'(V%'^\&)'KCW%?0[NL:,[L%102S
M,<  =S0!\]?"N2^\!_&#4O MQ<M+:7!<(.@+JGF))CL3'U^HZX%3_'[PEH.C
MZ%;:OI^FQ6]_>:B?/F0ME]RNQXSCD\\57\,S1>,OVF;S6]./FV%KND,J_=94
MA$((/H6P1ZBNB_:1_P"1*TO_ +"(_P#1;T =+X3^&G@Z+1]#U1-"M_MRV\%P
M)B[D^9M5MW)QG/-;OBWP1H?C6*SCUN*62.T=I$$<I3.1@@D<XX'Y5;\(S1W'
M@S0YHF#1OI\!4CO^[6O)/V@->U$7NC>%[:[-I9WPWW,F=JOEMH#'^Z.21[CT
MH V;SPE\%+.-["XDT:&095@=3;S$/7D[\@_6N/\ @DT6D_%KQ!HNEW_VO26@
MD\N0,")0DB^6^1P2 S#CCYC75V?[/'A"ULP;Z_U*XD5<R2^<D:#'4@;>!]2:
MX[X.VNG6/QOUFUTBX^T:=%;7"6\N\/O02)@[AP?K0!U?[2/_ ")6E_\ 81'_
M *+>O4/"_P#R*6B_]>$'_HM:\O\ VD?^1*TO_L(C_P!%O7J'A?\ Y%+1?^O"
M#_T6M &M7A7[2W_(*\/?]=YO_05KW6O"OVEO^05X>_Z[S?\ H*T 9%_\3?BW
MI.D_:+KPXEK:H@_T@Z?)A!V))8@?C6A\'_#L'C+6Y/'6NZX-5U>"3_CVV%3
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M?X ZMJES')XJ\87%W$G\$1>1OP>0_+_WR:]R@A2VMXH(P1'$@103V P*DHH
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MQ_NUZ110 5YQXB^'%]K7Q6T?Q;%?6\=K8K$'A96+L49FX[<[A7H]% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 86H_P#'])^'\A11J/\ Q_2?A_(44 :>
MG?\ 'C'^/\S5JJNG?\>,?X_S-6J "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P
MM1_X_I/P_D**-1_X_I/P_D** -/3O^/&/\?YFK55=._X\8_Q_F:M4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!A:C_P ?TGX?R%%&H_\ '])^'\A10!IZ=_QX
MQ_C_ #-6JJZ=_P >,?X_S-6J "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH PM1_
MX_I/P_D**-1_X_I/P_D** -/3O\ CQC_ !_F:M55T[_CQC_'^9JU0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% &%J/_'])^'\A11J/_'])^'\A10!IZ=_QXQ_C
M_,U:JKIW_'C'^/\ ,U:H *\]\:^/]-ATV\TW3+N9M0.$$UOD+&0PS\^1VSTS
M7=WD4DUC<10OLD>-E1O0D<&O./A_KFDZ#:S:/JH33M2CF;>\Z[=_IENV/?\
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M7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\
MG^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?8
M9_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_
MXT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _
MTGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/
M_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15
M#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@
M"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_
M7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\
MG^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?8
M9_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_
MXT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _
MTGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/
M_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15
M#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@
M"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_
M7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\
MG^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?8
M9_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_
MXT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _
MTGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/
M_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15
M#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@
M"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_
M7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\
MG^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?8
M9_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_
MXT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _
MTGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/
M_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15
M#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@
M"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_
M7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\
MG^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?8
M9_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_
MXT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _
MTGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/
M_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15
M#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@
M"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_
M7_&@"_15#[#/_P _TGZ_XT?89_\ G^D_7_&@"_15#[#/_P _TGZ_XT?89_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>;?%C_ )A'_;;_ -DKTFO+
MOBI=[]3T^SV8\J%I=^>N\XQCVV?K79@4W77S_(PQ+_=LP_ /_([:?_VT_P#1
M;5[;7B7@'_D=M/\ ^VG_ *+:O;:TS+^*O3]61A/@?J%%%%>>=04444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8
M6H_\?TGX?R%%&H_\?TGX?R%% &GIW_'C'^/\S5JJNG?\>,?X_P S5J@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK55=._X\8_Q_F:M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !7DGQ1_P"1FMO^O-?_ $-Z];KQ+Q]_R.VH?]L_
M_1:UWY<KUOD<V+?[LS?#W_(S:5_U^0_^ABO?Z\ \/?\ (S:5_P!?D/\ Z&*]
M_K3,_CB1@_A84445YAV!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!A:C_P ?TGX?R%%&H_\ '])^'\A10!IZ
M=_QXQ_C_ #-6JJZ=_P >,?X_S-6J "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ+Q]_P CMJ'_ &S_ /1:U[;7
MB7C[_D=M0_[9_P#HM:]#+?XK]/U1RXOX%ZG.QR/#*DL3LDB,&5U."I'0@]C7
MT?7S=7TC6V:?8^?Z$8/[04445Y)VA1110 4444 %%%% !1110 4444 %%%%
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MCH6]N<=CZYZ\5)HWBW6+?Q''H'B:RAAN)QF">$_*WIZ@YP>>.>,4 =S1110
M4444 %%137$4&WS6V[NG!-1?VC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?V
MC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\
M/7_QT_X4?VC:_P#/7_QT_P"% %JBJO\ :-K_ ,]?_'3_ (4?VC:_\]?_ !T_
MX4 6J*J_VC:_\]?_ !T_X4?VC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC
M:_\ /7_QT_X4 6J*J_VC:_\ /7_QT_X4?VC:_P#/7_QT_P"% %JBJO\ :-K_
M ,]?_'3_ (4?VC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?VC:_\]?\ QT_X
M4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\ /7_QT_X4?VC:
M_P#/7_QT_P"% %JBJO\ :-K_ ,]?_'3_ (4?VC:_\]?_ !T_X4 6J*J_VC:_
M\]?_ !T_X4?VC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4
M 6J*J_VC:_\ /7_QT_X4?VC:_P#/7_QT_P"% %JBJO\ :-K_ ,]?_'3_ (4?
MVC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?VC:_\]?\ QT_X4 6J*J_VC:_\
M]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%
M %JBJO\ :-K_ ,]?_'3_ (4?VC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?V
MC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\
M/7_QT_X4?VC:_P#/7_QT_P"% %JBJO\ :-K_ ,]?_'3_ (4?VC:_\]?_ !T_
MX4 6J*J_VC:_\]?_ !T_X4?VC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC
M:_\ /7_QT_X4 6J*J_VC:_\ /7_QT_X4?VC:_P#/7_QT_P"% %JBJO\ :-K_
M ,]?_'3_ (4?VC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?VC:_\]?\ QT_X
M4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\ /7_QT_X4?VC:
M_P#/7_QT_P"% %JBJO\ :-K_ ,]?_'3_ (4?VC:_\]?_ !T_X4 6J*J_VC:_
M\]?_ !T_X4?VC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4
M 6J*J_VC:_\ /7_QT_X4?VC:_P#/7_QT_P"% %JBJO\ :-K_ ,]?_'3_ (4?
MVC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?VC:_\]?\ QT_X4 6J*J_VC:_\
M]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%
M %JBJO\ :-K_ ,]?_'3_ (4?VC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?V
MC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\
M/7_QT_X4?VC:_P#/7_QT_P"% %JBJO\ :-K_ ,]?_'3_ (4?VC:_\]?_ !T_
MX4 6J*J_VC:_\]?_ !T_X4?VC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC
M:_\ /7_QT_X4 6J*J_VC:_\ /7_QT_X4?VC:_P#/7_QT_P"% %JBJO\ :-K_
M ,]?_'3_ (4?VC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?VC:_\]?\ QT_X
M4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\ /7_QT_X4?VC:
M_P#/7_QT_P"% %JBJO\ :-K_ ,]?_'3_ (4?VC:_\]?_ !T_X4 6J*J_VC:_
M\]?_ !T_X4?VC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4
M 6J*J_VC:_\ /7_QT_X4?VC:_P#/7_QT_P"% %JBJO\ :-K_ ,]?_'3_ (4?
MVC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?VC:_\]?\ QT_X4 6J*J_VC:_\
M]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%
M %JBJO\ :-K_ ,]?_'3_ (4?VC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?V
MC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\
M/7_QT_X4?VC:_P#/7_QT_P"% %JBJO\ :-K_ ,]?_'3_ (4?VC:_\]?_ !T_
MX4 6J*J_VC:_\]?_ !T_X4?VC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC
M:_\ /7_QT_X4 6J*J_VC:_\ /7_QT_X4?VC:_P#/7_QT_P"% %JBJO\ :-K_
M ,]?_'3_ (4?VC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?VC:_\]?\ QT_X
M4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\ /7_QT_X4?VC:
M_P#/7_QT_P"% %JBJO\ :-K_ ,]?_'3_ (4?VC:_\]?_ !T_X4 6J*J_VC:_
M\]?_ !T_X4?VC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4
M 6J*J_VC:_\ /7_QT_X4?VC:_P#/7_QT_P"% %JBJO\ :-K_ ,]?_'3_ (4?
MVC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?VC:_\]?\ QT_X4 6J*J_VC:_\
M]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%
M %JBJO\ :-K_ ,]?_'3_ (4?VC:_\]?_ !T_X4 6J*J_VC:_\]?_ !T_X4?V
MC:_\]?\ QT_X4 6J*J_VC:_\]?\ QT_X4?VC:_\ /7_QT_X4 6J*J_VC:_\
M/7_QT_X4?VC:_P#/7_QT_P"% %JO"?&%W]M\7:G+LV;9C%C.?N )G\=N?QKV
MS^T;7_GK_P".G_"O"=?8/XCU1E.5:[E(/_ S7I98O?D_(Y,8_=1G5](U\W5]
M#)JEE(BNDX9&&5902"/45IFGV/G^A.#^T6Z*J_VC:_\ /7_QT_X4?VC:_P#/
M7_QT_P"%>2=I:HJK_:-K_P ]?_'3_A1_:-K_ ,]?_'3_ (4 6J*J_P!HVO\
MSU_\=/\ A1_:-K_SU_\ '3_A0!:HJK_:-K_SU_\ '3_A1_:-K_SU_P#'3_A0
M!:HJK_:-K_SU_P#'3_A1_:-K_P ]?_'3_A0!:HJK_:-K_P ]?_'3_A1_:-K_
M ,]?_'3_ (4 6J*J_P!HVO\ SU_\=/\ A1_:-K_SU_\ '3_A0!:HJK_:-K_S
MU_\ '3_A1_:-K_SU_P#'3_A0!:HJK_:-K_SU_P#'3_A1_:-K_P ]?_'3_A0!
M:HJK_:-K_P ]?_'3_A1_:-K_ ,]?_'3_ (4 6J*J_P!HVO\ SU_\=/\ A1_:
M-K_SU_\ '3_A0!:HJK_:-K_SU_\ '3_A5J@ HHHH **** ,+4?\ C^D_#^0H
MHU'_ (_I/P_D** -/3O^/&/\?YFK55=._P"/&/\ '^9JU0!'/"ES;RP2#,<B
M%&'L1@UYQIS^)/A_')92Z6=4T@2%TFMOOH#UR.WK@CKWKT'4KU--TRZOI$9T
MMXFE95ZD 9K#M/B!X9N[83?VFD)Q\T<RE67V]_PS0!;\/^*M*\2Q,UA*PE09
MDAD&UU'KCN/<9I?$6I:OIT,#:1I/]H.[$2#?MV#M7&^'I;?6OBC<ZMHT+#3T
M@(FE"%%=R,=/4GG\,UU-UXVT;3]<N-)OYGM9H=N'D0['#*&X(Z=<<XH XF35
MY=5\7:>/&,4VF1V\FZU@$!$;OD8+.3SR!SC'TYKT3Q'K</A_1)[^7#,HVQ1Y
M_P!8YZ+_ )[9K@/B!KNG^)XK#1M%;[=>M<APT2G"C:1C/OD'C@;>:Z?Q1X3O
MM=BTD6NHK;26!+%F4L&?Y<-CU&T]?6@#%NM$FTOX;:S>:@2^J:@HGNG;J"6&
M$_#^9-=!X=F:W^'%K.N=T=@7&/4*37*>)_#_ (IM/#=[/?>)?M5LB R0^7C>
M,BMKP%I6ICP_')>:GY]C<VH6&VV?ZK/O]* '?"N%(_!JNH^:6X=F/OP/Y"JG
MQ(41:OX8NEXECO, _P# D/\ 2J7@7Q!:>&8[[P]KDPM)[>X8HT@(5@0,\_AD
M>H:GZEJ,/C?QOH]II1::QTZ3S[B<*0N<@XY_W0 >^Z@#TNBBB@ HHHH BFMX
MI]OFINV].2*B_LZU_P">7_CQ_P :M44 5?[.M?\ GE_X\?\ &C^SK7_GE_X\
M?\:M44 5?[.M?^>7_CQ_QH_LZU_YY?\ CQ_QJU10!5_LZU_YY?\ CQ_QH_LZ
MU_YY?^/'_&K5% %7^SK7_GE_X\?\:/[.M?\ GE_X\?\ &K5% %7^SK7_ )Y?
M^/'_ !H_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/[.M?^>7_ (\?\:M44 5?
M[.M?^>7_ (\?\:/[.M?^>7_CQ_QJU10!5_LZU_YY?^/'_&C^SK7_ )Y?^/'_
M !JU10!5_LZU_P">7_CQ_P :/[.M?^>7_CQ_QJU10!5_LZU_YY?^/'_&C^SK
M7_GE_P"/'_&K5% %7^SK7_GE_P"/'_&C^SK7_GE_X\?\:M44 5?[.M?^>7_C
MQ_QH_LZU_P">7_CQ_P :M44 5?[.M?\ GE_X\?\ &C^SK7_GE_X\?\:M44 5
M?[.M?^>7_CQ_QH_LZU_YY?\ CQ_QJU10!5_LZU_YY?\ CQ_QH_LZU_YY?^/'
M_&K5% %7^SK7_GE_X\?\:/[.M?\ GE_X\?\ &K5% %7^SK7_ )Y?^/'_ !H_
MLZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/[.M?^>7_ (\?\:M44 5?[.M?^>7_
M (\?\:/[.M?^>7_CQ_QJU10!5_LZU_YY?^/'_&C^SK7_ )Y?^/'_ !JU10!5
M_LZU_P">7_CQ_P :/[.M?^>7_CQ_QJU10!5_LZU_YY?^/'_&C^SK7_GE_P"/
M'_&K5% %7^SK7_GE_P"/'_&C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU
M_P">7_CQ_P :M44 5?[.M?\ GE_X\?\ &C^SK7_GE_X\?\:M44 5?[.M?^>7
M_CQ_QH_LZU_YY?\ CQ_QJU10!5_LZU_YY?\ CQ_QH_LZU_YY?^/'_&K5% %7
M^SK7_GE_X\?\:/[.M?\ GE_X\?\ &K5% %7^SK7_ )Y?^/'_ !H_LZU_YY?^
M/'_&K5% %7^SK7_GE_X\?\:/[.M?^>7_ (\?\:M44 5?[.M?^>7_ (\?\:/[
M.M?^>7_CQ_QJU10!5_LZU_YY?^/'_&C^SK7_ )Y?^/'_ !JU10!5_LZU_P">
M7_CQ_P :/[.M?^>7_CQ_QJU10!5_LZU_YY?^/'_&C^SK7_GE_P"/'_&K5% %
M7^SK7_GE_P"/'_&C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_P">7_CQ
M_P :M44 5?[.M?\ GE_X\?\ &C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_L
MZU_YY?\ CQ_QJU10!5_LZU_YY?\ CQ_QH_LZU_YY?^/'_&K5% %7^SK7_GE_
MX\?\:/[.M?\ GE_X\?\ &K5% %7^SK7_ )Y?^/'_ !H_LZU_YY?^/'_&K5%
M%7^SK7_GE_X\?\:/[.M?^>7_ (\?\:M44 5?[.M?^>7_ (\?\:/[.M?^>7_C
MQ_QJU10!5_LZU_YY?^/'_&C^SK7_ )Y?^/'_ !JU10!5_LZU_P">7_CQ_P :
M/[.M?^>7_CQ_QJU10!5_LZU_YY?^/'_&C^SK7_GE_P"/'_&K5% %7^SK7_GE
M_P"/'_&C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_P">7_CQ_P :M44
M5?[.M?\ GE_X\?\ &C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_YY?\
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M^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_P">7_CQ_P :M44 5?[.M?\
MGE_X\?\ &C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_YY?\ CQ_QJU10
M!5_LZU_YY?\ CQ_QH_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/[.M?\ GE_X
M\?\ &K5% %7^SK7_ )Y?^/'_ !H_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/
M[.M?^>7_ (\?\:M44 5?[.M?^>7_ (\?\:/[.M?^>7_CQ_QJU10!5_LZU_YY
M?^/'_&C^SK7_ )Y?^/'_ !JU10!5_LZU_P">7_CQ_P :/[.M?^>7_CQ_QJU1
M0!5_LZU_YY?^/'_&C^SK7_GE_P"/'_&K5% %7^SK7_GE_P"/'_&C^SK7_GE_
MX\?\:M44 5?[.M?^>7_CQ_QH_LZU_P">7_CQ_P :M44 5?[.M?\ GE_X\?\
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M!6N9_!$C!_$RQ_9UK_SR_P#'C_C1_9UK_P \O_'C_C5JBO'.\J_V=:_\\O\
MQX_XT?V=:_\ /+_QX_XU:HH J_V=:_\ /+_QX_XT?V=:_P#/+_QX_P"-6J*
M*O\ 9UK_ ,\O_'C_ (T?V=:_\\O_ !X_XU:HH J_V=:_\\O_ !X_XT?V=:_\
M\O\ QX_XU:HH J_V=:_\\O\ QX_XT?V=:_\ /+_QX_XU:HH J_V=:_\ /+_Q
MX_XT?V=:_P#/+_QX_P"-6J* *O\ 9UK_ ,\O_'C_ (T?V=:_\\O_ !X_XU:H
MH J_V=:_\\O_ !X_XT?V=:_\\O\ QX_XU:HH J_V=:_\\O\ QX_XT?V=:_\
M/+_QX_XU:HH J_V=:_\ /+_QX_XT?V=:_P#/+_QX_P"-6J* *O\ 9UK_ ,\O
M_'C_ (U:HHH **** "BBB@#"U'_C^D_#^0HHU'_C^D_#^0HH T]._P"/&/\
M'^9JU573O^/&/\?YFK5 !U&#7':AX)M+OQ?8WJZ=9KIT<3FX14"^9(<XRH'/
M8UV-% $-M:6UE L%K!%!"O1(D"J/P%07^D:=JJJ+^QM[G;]TRQABOT/45=HH
M S]/T/2M*8M8:?;6[D8+QQ@,1]>M:%%% $-U:P7UK);742RP2##HXR"*6VMH
M;.VCM[>)8H8UVHBC 45+10!GZAH>E:JRM?Z?;W#J,!I(P6 ],]:FL=-L=,A,
M5A:0VT9.2L2!<GU..IJU10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7S=7TC7S=7K97]OY?J<6,^S\PKW_P]_P BSI7_ %YP_P#H KP"O=O!]W]M
M\(Z9+LV;81%C.?N$IG\=N?QJ\S3Y(OS)P;]YFW1117C'>%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &%J/\
MQ_2?A_(44:C_ ,?TGX?R%% &GIW_ !XQ_C_,U:JKIW_'C'^/\S5J@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH S?$/_(LZK_UYS?^@&O *]_\0_\ (LZK_P!><W_H!KP"O9RSX)'!
MC/B0Z2-X97BE1DD1BK(PP5(Z@CL:]K\ _P#(DZ?_ -M/_1C5Y)XA_P"1FU7_
M *_)O_0S7I?PQD=_"\RN[,L=VZH"<A1M4X'H,DG\358_WJ"EZ"PVE5H[2BBB
MO$/0"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@#"U'_C^D_#^0HHU'_C^D_#^0HH T]._X\8_Q_F:M55T[_CQ
MC_'^9JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 9OB'_D6=5_Z\YO_0#7@%>V^/O^1)U#_MG_ .C%KQ*O:RQ?
MNV_,\_%OWDC;\86GV+Q=J<6_?NF,N<8^^ ^/PW8_"O0/A=_R+-S_ -?C?^@)
M7$>/O^1VU#_MG_Z+6NW^%W_(LW/_ %^-_P"@)2Q+;PD6_(=%6KOYG;4445XQ
MWA1110 4444 %%%% !1110 445FZIX@TK1=HU"]CA9L83EF(.>=HR<<'G&*<
M8N3M%7$VDKLTJ*Q-(\5Z5KFH3V=A)([Q()-S1E5=>,D9YX) Y Z\9K;IRA*#
MM)6!24E=!1114C"BBB@ HHHH **** "BBB@ HHHH **** ,+4?\ C^D_#^0H
MHU'_ (_I/P_D** -/3O^/&/\?YFK55=._P"/&/\ '^9JU0 445G:[JT>A:+<
MZE+&9%@ )0-C=D@ 9_&@#1HJ*UF^TVD,^PIYB*^TG.,C.*EH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4
M4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *
MOT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U
M_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y
M\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]
MNG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K
M_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#S
MXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT
M_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4
M4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *
MOT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U
M_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y
M\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]
MNG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K
M_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#S
MXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT
M_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4
M4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *
MOT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U
M_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y
M\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]
MNG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K
M_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#S
MXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT
M_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4
M4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *
MOT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U
M_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y
M\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]
MNG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K
M_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#S
MXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT
M_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4
M4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *
MOT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U
M_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y
M\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]
MNG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K
M_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#S
MXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT
M_P#SXR?K_A1]NG_Y\9/U_P *OT4 4/MT_P#SXR?K_A1]NG_Y\9/U_P *OT4
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M3)Y,6]Y]S<>%E'3J<#<..F2=HKUNO,Q-'V-1QZ=#KHU/:1N4/MT__/C)^O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q/Q1_P"19MO^OQ?_
M $!ZXCP#_P CMI__ &T_]%M7;_%'_D6;;_K\7_T!ZXCP#_R.VG_]M/\ T6U>
MQAO]SE\S@J_QU\C2^*/_ ",UM_UYK_Z&]3_"RZ=-8OK0!?+EMQ*QQSE6 'X?
M.?TJ/XI1N/$-I*481M:!5?'!(=LC/J,C\Q3/A=_R,US_ ->;?^AI5NSP7R%M
MB/F>MT445XAZ 4444 9^N:D-(T.\OR5#0Q$IN!(+GA0<<X+$"OGZO5/BE?O#
MI5E8IN"W,K.[!\ A /E([C+ _P# 17#>$=,_M;Q/96[)NA5_-ES'O7:O.&'H
M2 O/]ZO:P,53H.H^OZ'GXEN=101B5[[X:D27POI31NKJ+2-25.1D* 1]001^
M%>(:S;Q6FN:A;0+LAAN9(T7).%#$ <^U>L?#JZ2X\'P1(&#6\LD3Y'!);?Q[
M8<?K2S%<U*,D&%TFT=71117C'H&;XA_Y%G5?^O.;_P! -> 5[;X^_P"1)U#_
M +9_^C%KQW2K5+[6+*TE+".>XCB8J>0&8 X]^:]G+M*4I/N<&+UFD>_V=JEC
M8V]I$6,<$2Q*6/)"C S[\5F^*-"'B'0Y+(,J3!A)"[9PKCUQV()'?&<XXK9H
MKR(SE&7,MSN<4URL^=;RSN-/NY;2[B:*>)MKHW4?XCW[UZ;X$\9OJ+1Z/J3,
M]V%/D3GDR #)#?[0 //?'//74\:^%O\ A(-/66U2,:A!RC'@R+SE,_7D9[^F
M2:\;_?V=S_RT@N(7]U9&!_,$&O;BX8RE9[K\#SVI8>>FQ]&T5Q_@SQFFNQ+8
MWS*FI(O!Z"<#N/1O4?B.,@=A7C5*<J<N61WPFIJZ"BBBLRC&\3>($\-Z4+U[
M=IV>41(@;:"2">3S@8!['M7#CXIWS:@A-C;QV6]=Z_,\@7C=@Y )ZXXJ+XHW
MWG:U:62M&RV\)<[3EE9SR#^"J?Q]ZX2O9PF$INDI35VS@K5YJ=HO8^CXY$FB
M26)U>-U#*ZG(8'H0>XIU<)\-_$+7UDVCW!S-:)NA8DDM'GH?]TD <]"!CBN[
MKRZU)TIN#.RG-3BI(****R+"BBB@#"U'_C^D_#^0HHU'_C^D_#^0HH T]._X
M\8_Q_F:M55T[_CQC_'^9JU0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM0!?HJAY6I?\_$?Y?_6H\K4O^?B/\O\ ZU %^BJ'E:E_S\1_E_\ 6H\K4O\
MGXC_ "_^M0!?HJAY6I?\_$?Y?_6H\K4O^?B/\O\ ZU %^BJ'E:E_S\1_E_\
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M?B/\O_K4 7Z*H>5J7_/Q'^7_ -:K] !1110 4444 86H_P#'])^'\A11J/\
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M **** ,+4?\ C^D_#^0HHU'_ (_I/P_D** -/3O^/&/\?YFK55=._P"/&/\
M'^9JU0 5"UK;M=)=-;Q&X12JRE!O4'J >H%344 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\N65(E&><J"3^'SC]:]"J,=*]=E896IH****Y#<**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#"U'_C^
MD_#^0HHU'_C^D_#^0HH T]._X\8_Q_F:M55T[_CQC_'^9JU0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-DD2&)Y97
M5(T4LSL<!0.I)["G5S'C[4CIWA.X"%A)=,+=2 "!NR6SGL5##\1]:NG!SFHK
MJ3.7+%L\@U2_?5-5NKZ3<&GE9PK/N*@GA<^@&!^%>L_#K3/L'AA+ATQ->.93
MF/:P7HHSW&!N'^]^?D5G:O?7UO:1%1)/*L2ECP"QP,^W-?0MO;Q6EM%;0+LA
MA01HN2<*!@#GVKU<QFHTXTU_5CBPL;R<V2T445XYWA7C?Q'M/LWBZ27?N^TP
MI+C&-N!LQ[_<S^->R5YA\5;5$OM-NP6\R6)XF&>,*01^/SG]*[<OE:O;N<^*
M5Z99^%$CF+58B[&-6B94SP"=^3CU.!^0KT:O(/AG<10^*FCD;#36SQQC!^9L
MJV/R4G\*]?I8^-J[?<,,[TT%%%5M0OH-,T^>]N6Q#"A=N1D^PSW)X'N:Y$FW
M9'0W8\I^)&K+?^(%M(I-\-DFPXQCS#RV"/;:#GH5-2?#/2_M>O2Z@SX6R3@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MD_Q/U(7.N6]@A4K:19;@@AWP2/0C:$/'J?P]8KP7Q3<2W/BK5))FW,+EXP<
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MX1Z_J8T5*I5YI'5T445X1Z04444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A:C_Q_2?A_(44:C_Q
M_2?A_(44 :>G?\>,?X_S-6JJZ=_QXQ_C_,U:H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** (+RZ2QL;B[E#&.")I6"CD
MA1DX]^*^=:]T\9W3V?@_4I8PI9HA$=PXP[!#^.&->'V]O+=W,5M N^:9Q&BY
M RQ. .?>O8RR-H2D<&+=Y)'NGA.U2S\)Z7%&6*M;K*=QYR_SG\,L:V:**\F<
MN:3D^IW15E8****D851UFWEN]#U"V@7?--;21HN0,L5( Y]ZO44T[.XFKJQ\
MW5]#:5=/?:/97<H423V\<K!1P"R@G'MS7@6HVGV#4[NSW^9]GF>+?C&[:2,X
M[=*UX_&FN0:1!IMO=^3#"C1[U&9&4]!N.<8' VXP/H*]W%X=XB,>0\VA55)O
MF/5/&&KC1O#5U,&99I5\B$JQ4AV!Y!'0@9;\*\/M[>6[N8K:!=\TSB-%R!EB
M< <^]%Q<3W<[3W,TDTS8W22,68X&.2?:NP^'N@7%WKD.I36["SMU+H\D>5D?
ME0%SW!R<C."O;(HITXX2DVWK_6@2FZ\TD>I:78)I>E6MC'M*P1*A94VAB!RV
M/4G)_&K=%%>$VV[L])*RL@HHHI#"BBB@ HHHH **** &K&B,[(BJTC;G(&"Q
MP!D^IP /P%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,+4?^/Z3\/Y"BC4?^/Z3
M\/Y"B@#3T[_CQC_'^9JU573O^/&/\?YFK5 !37=(T+NRJHZLQP!2LP12S$!0
M,DGM7F6N^*M0\7Z;?:9X>T6YN+1B$:\/ .&!X!&.0.YS@]!0!Z:"& (((/((
MI:YGPEK-]>Q-I]_HMQITMI$B@N#MD&,<$@>GO3=?\6SZ;J2Z7IFDW&I7Y0.R
MIPD:GH2<'^@]Z .HHKAM.^(%PNMPZ3K^CR:;-.0L<A8E23TSD=,\9!/-=1KF
MLP:#I<E_<))(JD*J1C+.Q. !0!HT5Y[<^/?$%E"+V[\)3PV&>69R&4>I^7C\
M0*[31]6MM<TJ#4+0DPS#(##E2."#[@T 7J*XK4O'=P=8FTK0-(DU.> D32!L
M(A'4=/J,G'/K4N@^.&O]9_L;5M-ETW42"45SE7XSWP0>N.H..M '84444 %%
M%% !137DCCQO=5STW'%,^TP?\]X_^^Q0!+147VF#_GO'_P!]BC[3!_SWC_[[
M% $M%1?:8/\ GO'_ -]BC[3!_P ]X_\ OL4 2T5%]I@_Y[Q_]]BC[3!_SWC_
M .^Q0!+147VF#_GO'_WV*/M,'_/>/_OL4 2T5%]I@_Y[Q_\ ?8H^TP?\]X_^
M^Q0!+147VF#_ )[Q_P#?8H^TP?\ />/_ +[% $M%1?:8/^>\?_?8H^TP?\]X
M_P#OL4 2T5%]I@_Y[Q_]]BC[3!_SWC_[[% $M%1?:8/^>\?_ 'V*/M,'_/>/
M_OL4 2T5%]I@_P">\?\ WV*/M,'_ #WC_P"^Q0!+147VF#_GO'_WV*/M,'_/
M>/\ [[% $M%1?:8/^>\?_?8H^TP?\]X_^^Q0!+147VF#_GO'_P!]BC[3!_SW
MC_[[% $M%1?:8/\ GO'_ -]BC[3!_P ]X_\ OL4 2T5%]I@_Y[Q_]]BC[3!_
MSWC_ .^Q0!+147VF#_GO'_WV*/M,'_/>/_OL4 2T5%]I@_Y[Q_\ ?8H^TP?\
M]X_^^Q0!+147VF#_ )[Q_P#?8H^TP?\ />/_ +[% $M%1?:8/^>\?_?8H^TP
M?\]X_P#OL4 2T5%]I@_Y[Q_]]BC[3!_SWC_[[% $M%1?:8/^>\?_ 'V*/M,'
M_/>/_OL4 2T5%]I@_P">\?\ WV*/M,'_ #WC_P"^Q0!+147VF#_GO'_WV*/M
M,'_/>/\ [[% $M%1?:8/^>\?_?8H^TP?\]X_^^Q0!+147VF#_GO'_P!]BC[3
M!_SWC_[[% $M%1?:8/\ GO'_ -]BC[3!_P ]X_\ OL4 2T5%]I@_Y[Q_]]BC
M[3!_SWC_ .^Q0!+147VF#_GO'_WV*/M,'_/>/_OL4 2T5%]I@_Y[Q_\ ?8H^
MTP?\]X_^^Q0!+147VF#_ )[Q_P#?8H^TP?\ />/_ +[% $M%1?:8/^>\?_?8
MH^TP?\]X_P#OL4 2T5%]I@_Y[Q_]]BC[3!_SWC_[[% $M%1?:8/^>\?_ 'V*
M/M,'_/>/_OL4 2T5%]I@_P">\?\ WV*/M,'_ #WC_P"^Q0!+147VF#_GO'_W
MV*/M,'_/>/\ [[% $M%1?:8/^>\?_?8H^TP?\]X_^^Q0!+147VF#_GO'_P!]
MBC[3!_SWC_[[% $M%1?:8/\ GO'_ -]BC[3!_P ]X_\ OL4 2T5%]I@_Y[Q_
M]]BC[3!_SWC_ .^Q0!+147VF#_GO'_WV*/M,'_/>/_OL4 2T5%]I@_Y[Q_\
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M%1?:8/\ GO'_ -]BC[3!_P ]X_\ OL5XIZ!+147VF#_GO'_WV*/M,'_/>/\
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M'_/>/_OL4?:8/^>\?_?8H EHJ+[3!_SWC_[[%'VF#_GO'_WV* ):*B^TP?\
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M:W#_ +N1@N1WQGJ00<TSQ1>0>)?&V@:3ITJ7"VLQGN'C.Y5 ()&1W 4_B0*
M/1Z*** "BBB@"*:WBGV^:F[;TY(J+^SK7_GE_P"/'_&K5% %7^SK7_GE_P"/
M'_&C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_P">7_CQ_P :M44 5?[.
MM?\ GE_X\?\ &C^SK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_YY?\ CQ_Q
MJU10!5_LZU_YY?\ CQ_QH_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/[.M?\
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MZU_YY?\ CQ_QH_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/[.M?\ GE_X\?\
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MK7_GE_X\?\:M44 5?[.M?^>7_CQ_QH_LZU_YY?\ CQ_QJU10!5_LZU_YY?\
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MJU10!5_LZU_YY?\ CQ_QH_LZU_YY?^/'_&K5% %7^SK7_GE_X\?\:/[.M?\
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M'!_&K6B^&M)\/(XTVT$32??D+%F;\3V]NE:U% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!RWQ#N(H?!MU'(V&F>..,8/S-N#8_)2?PKRGP]_R,VE?]?D/_ *&*
M])^*/_(LVW_7XO\ Z ]<%X,M4O/&&FQ2%@JRF4;3SE%+C\,J*]G!VCA9/U//
MKW=9+T/;H;>"W\SR(8XO,<R/L4+N8]6..I/K4M%%>,>@%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 86H_\?TGX?R%%&H_\?TGX?R%% &GIW_'C'^/\S5JJNG?\>,?X_S-
M6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M._BM<2K;:7;!L0R/)(RX'+*% /Y,WYUS?P\MY9O&5K)&N5@2220Y'RKM*Y_-
M@/QK9^*MTCWVFV@#>9%$\K''&&( _'Y#^E4_A=_R,US_ ->;?^AI7M4_=P7R
M9Y\M<0>MT445XIZ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!A:C_ ,?TGX?R%%&H_P#'
M])^'\A10!IZ=_P >,?X_S-6JJZ=_QXQ_C_,U:H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH \D^*/_(S6W_7FO_H;UH?"B-#+
MJLI13(JQ*KXY ._(SZ' _(5SOC[_ )';4/\ MG_Z+6NK^%5JZ6.I79*^7+*D
M2C/.5!)_#YQ^M>U5]W!)>2//AKB/O/0J***\4] **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M**HZS<2VFAZA<P-LFAMI)$; .&"D@\^]-*[L)NRN?/E>\>$[5+/PGI<498JU
MNLIW'G+_ #G\,L:\'KZ#T:WEM-#T^VG79-#;1QNN0<,% (X]Z]C,W[D5YG#@
MU[S9>HHHKQCO"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]%
M%#^UH/[DGY#_ !H_M:#^Y)^0_P :OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4
M 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4
M/[6@_N2?D/\ &C^UH/[DGY#_ !J_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!
M0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_
MM:#^Y)^0_P :/[6@_N2?D/\ &K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#
M^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^U
MH/[DGY#_ !H_M:#^Y)^0_P :OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[
M6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@
M_N2?D/\ &C^UH/[DGY#_ !J_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:
M#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^
MY)^0_P :/[6@_N2?D/\ &K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/
M[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[D
MGY#_ !H_M:#^Y)^0_P :OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N
M2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?
MD/\ &C^UH/[DGY#_ !J_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)
M^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0_QH_M:#^Y)^0_QJ_10!0_M:#^Y)^0
M_P :/[6@_N2?D/\ &K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY
M#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_&C^UH/[DGY#_&K]% %#^UH/[DGY#_
M !H_M:#^Y)^0_P :OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/
M\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\:/[6@_N2?D/\:OT4 4/[6@_N2?D/\
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MH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH
MH?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?
MVM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM
M!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_
M<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D
M_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(
M?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?X
MT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?
MVM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM
M!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_
M<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D_(?XU?HH H?VM!_<D_(?XT?VM!_<D
M_(?XU?HH H?VM!_<D_(?XU?HHH **** "BBB@#"U'_C^D_#^0HHU'_C^D_#^
M0HH T]._X\8_Q_F:M55T[_CQC_'^9JU0!5U*>XMM,NI[2#S[B.)GCB_OL!P*
MXN'XK:4D934+"^M;I!\\.P-SZ D@_F!7?5BWF@_:_%5AK+3KLLXG182F<ELC
M.<^] '*^&TO/$?CN3Q1]ADL[!(?+B,HPTIQC/OWYZ=!72>(/&6E>&KF*WO\
MS_,E3>OEIN&,X]:Z"FM&CG+HK8]1F@#R'PEXWTG1;[6YKL7&R]NC-%LC!^7+
M'GG@\BNG^(ME=ZSX8L[K3H6N$BE6X:':264J<';WQGI[FNU^SP_\\8_^^14E
M ' Q_%C1?LV9+.^2X'!A"*?F] <]/R^E'P]TN\9M;U6]M&M(=4EW1V[#!"Y8
MGCT^; _&N\\M-^_8N[^]CFG4 >5Z#K;?#NXO-$UJVN3:M,9+:XC7(88QZ]"
M.G0YJS#<3_$'QAIM]!9RPZ-IC>8))A@N^0<#L<E5X[ 'UQ7I3*KC#*&'H1FE
M  & , 4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<Q?>/M L;N
M.W^TM<%FP\ENN](^G)/<<_PYZ'O6]8ZA9ZG;+<V5Q'/"?XD.<' .#Z'!'!YK
M25*<5>2LB5.+=DRS1116904444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@#"U'_ (_I/P_D**-1_P"/Z3\/Y"B@#3T[_CQC_'^9JU573O\
MCQC_ !_F:M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWBSO+?4+2*[M)5E@E7<CKT/^!]NU3UXEX0\4S^']06.1\Z?,X$Z-G"=MXQW
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M #[Q_G_]>@"_15#S=2_Y]X_S_P#KT>;J7_/O'^?_ ->@"_15#S=2_P"?>/\
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M>N0,$9/OQZC2:ITFZTB8\\TJ:,"TTZ^O]_V.SN+G9C?Y,3/MSTS@<=#6[9^
M/$5VT6ZS6WCD7=YD\B@+QGD#+ ]L8^M>N>;J7_/O'^?_ ->CS=2_Y]X_S_\
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MO'^?_P!>@"_15#S=2_Y]X_S_ /KT>;J7_/O'^?\ ]>@"_15#S=2_Y]X_S_\
MKT>;J7_/O'^?_P!>@"_15#S=2_Y]X_S_ /KT>;J7_/O'^?\ ]>@"_15#S=2_
MY]X_S_\ KT>;J7_/O'^?_P!>@"_15#S=2_Y]X_S_ /KT>;J7_/O'^?\ ]>@"
M_15#S=2_Y]X_S_\ KT>;J7_/O'^?_P!>@"_15#S=2_Y]X_S_ /KT>;J7_/O'
M^?\ ]>@"_15#S=2_Y]X_S_\ KT>;J7_/O'^?_P!>@"_15#S=2_Y]X_S_ /KT
M>;J7_/O'^?\ ]>@"_15#S=2_Y]X_S_\ KT>;J7_/O'^?_P!>@"_15#S=2_Y]
MX_S_ /KT>;J7_/O'^?\ ]>@"_15#S=2_Y]X_S_\ KT>;J7_/O'^?_P!>@"_1
M5#S=2_Y]X_S_ /KT>;J7_/O'^?\ ]>@"_15#S=2_Y]X_S_\ KT>;J7_/O'^?
M_P!>@"_15#S=2_Y]X_S_ /KT>;J7_/O'^?\ ]>@"_15#S=2_Y]X_S_\ KT>;
MJ7_/O'^?_P!>@"_6%XQU)]*\+7D\,JQSLHBB);!RQP=N"#N R1CTSVJ]YNI?
M\^\?Y_\ UZ\^^)>I7+?8=.E*IC,[QJ.O\*G/_??&?KVKHPM/VE:,3*M+E@V<
M!)(\TKRRNSR.Q9G8Y+$]23W-;FD>,-;T9E$-VTT*J%$%P2Z  $ #G*@9[$=!
M1X0T<:UKJP20I-#'&TDD;.5W#H.00>K#O70ZM\-KHEYM+ &<G[/(XXZG"MGZ
M  _B:]FM6HJ7LJG_  #@A3J-<\#I=%^(6D:IB.Z;^S[@_P ,S?NSUZ/P.@[X
MY.!FNKDD2&)Y975(T4LSL<!0.I)["OGF^T^\TRY:VO;>2"8?PNN,C)&1ZC(/
M(XHBU"\ALIK*.XD%K-_K(<_*QR#G'KE1SUXQ7-/+H2=Z;LC6.*DM)(U_%_B%
MO$.M-(AQ:09CMP"<%<_?P>A;Z#@ =JY^M#1='N-<U2.QM@=S99WQD(HZD_R^
MI [UZM?^%K>^TM;+^RK6+RH]D$B##1]<'.[)Y8G!/)Y-;U,13PW+3,XTIUKR
M.2\)>.[VUOHK+5;AKBSE8()96&Z$D_>+'JO/.3P.G3!]8KYVO[&?3;^>RN4*
MS0N588//N/8]0?0UVFB_$233= 2UGA6>XM]L<*[=NZ/'&2/3&.GIUY-<^+PG
M/:=);_U<UH5^6\9L]5HKQ23X@>)7E=UOUC5F)"+ F%]AD$X^I--_X3[Q-_T$
M_P#R!'_\36']FU>Z_KY&GUN'9GMM%>-VGQ'\0VV_S9+>ZW8QYT(&WZ;-OZYZ
M59_X6CK?_/KI_P#W[?\ ^+J7EU9/H-8JF>MT5P6B_$9-0=;>\C@M)R/ONV(S
M@>I/R]^#^>:Z[S=2_P"?>/\ /_Z]<M2E.F[35C>$XS5XE^BJ'FZE_P ^\?Y_
M_7H\W4O^?>/\_P#Z]9E%^BJ'FZE_S[Q_G_\ 7H\W4O\ GWC_ #_^O0!?HJAY
MNI?\^\?Y_P#UZ/-U+_GWC_/_ .O0!=DD2&)Y975(T4LSL<!0.I)["O$/%_B%
MO$.M-(AQ:09CMP"<%<_?P>A;Z#@ =JZ[Q_XCO+2S_LC8D<ETFZ1E)!6//08.
M/FP0?8'CFO/=)TV;5]4M[" ?O)FQGC@#DGDCH 3^%>O@**A%UI_TCAQ-1R?L
MXG8_#KPT;J[&M7<;""!O]'#*-LC\@MSV7^??Y2*]4K'T^VN],T^"RMK6,0PH
M$7ID^YP>I/)]S5GS=2_Y]X_S_P#KUY^(K.M4<ON.JE35.-B_15#S=2_Y]X_S
M_P#KT>;J7_/O'^?_ ->L#0OT50\W4O\ GWC_ #_^O1YNI?\ /O'^?_UZ +]%
M4/-U+_GWC_/_ .O1YNI?\^\?Y_\ UZ +]%4/-U+_ )]X_P __KT>;J7_ #[Q
M_G_]>@"_15#S=2_Y]X_S_P#KT>;J7_/O'^?_ ->@"_15#S=2_P"?>/\ /_Z]
M'FZE_P ^\?Y__7H OT50\W4O^?>/\_\ Z]'FZE_S[Q_G_P#7H OT50\W4O\
MGWC_ #_^O1YNI?\ /O'^?_UZ +]%4/-U+_GWC_/_ .O1YNI?\^\?Y_\ UZ +
M]%4/-U+_ )]X_P __KT>;J7_ #[Q_G_]>@"_15#S=2_Y]X_S_P#KT>;J7_/O
M'^?_ ->@"_15#S=2_P"?>/\ /_Z]'FZE_P ^\?Y__7H OT50\W4O^?>/\_\
MZ]'FZE_S[Q_G_P#7H OT50\W4O\ GWC_ #_^O1YNI?\ /O'^?_UZ +]%4/-U
M+_GWC_/_ .O1YNI?\^\?Y_\ UZ +]%4/-U+_ )]X_P __KT>;J7_ #[Q_G_]
M>@"_15#S=2_Y]X_S_P#KT>;J7_/O'^?_ ->@"_15#S=2_P"?>/\ /_Z]'FZE
M_P ^\?Y__7H OT50\W4O^?>/\_\ Z]'FZE_S[Q_G_P#7H OT50\W4O\ GWC_
M #_^O1YNI?\ /O'^?_UZ +]%4/-U+_GWC_/_ .O1YNI?\^\?Y_\ UZ +]%4/
M-U+_ )]X_P __KT>;J7_ #[Q_G_]>@"_15#S=2_Y]X_S_P#KT>;J7_/O'^?_
M ->@"_15#S=2_P"?>/\ /_Z]'FZE_P ^\?Y__7H OT50\W4O^?>/\_\ Z]'F
MZE_S[Q_G_P#7H OT50\W4O\ GWC_ #_^O1YNI?\ /O'^?_UZ +]%4/-U+_GW
MC_/_ .O1YNI?\^\?Y_\ UZ +]%4/-U+_ )]X_P __KT>;J7_ #[Q_G_]>@"_
M15#S=2_Y]X_S_P#KT>;J7_/O'^?_ ->@"_15#S=2_P"?>/\ /_Z]'FZE_P ^
M\?Y__7H OT50\W4O^?>/\_\ Z]'FZE_S[Q_G_P#7H OT50\W4O\ GWC_ #_^
MO1YNI?\ /O'^?_UZ +]%4/-U+_GWC_/_ .O5^@ HHHH **** ,+4?^/Z3\/Y
M"BC4?^/Z3\/Y"B@#3T[_ (\8_P ?YFK55=._X\8_Q_F:M4 %<EK'P]TG4KMK
MZT>;3;XDMYULV!N]2O\ ABNCU*VEO=,NK6&=K>6:)D29>J$C /'I7GAU/Q[I
M.J6NA-)87MQ<(S12L,_*HY)/'ZC\Z -#PSJ^MZ;XLE\+ZW<"\_=F2WN?XB ,
MC/<Y&>O((ZD5WM<?X:\*ZA;:U-K^O7J76I2)L18Q\D0]NG;C@>O7-7?$4WBJ
M.ZA'A^VLY8"G[PSGD-GMR.U &-\//^0KXI_["!_]">IOB3KC:=I-MIR2F ZD
MYCDGQGRXAC><#D_>'X9K$TC2O'NB3WTUK8V!:]E\Z7S) 0&R3Q\W3FO1C9Q7
MMM!_:-K;RS*@W!D#A6(&<9[9H \YUKQ7X7'@6?0]*N7)$*QQ(86&XA@222,9
M/)K7\)ZU8:IX+.D6DY:]M[!ED381M)!'![\GM6MXF\,VU_X<O;73].LUNY$
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MZW9<.H\Q V3&^.5/3D?3G@]#6A7)*+B[,V335T%%%%(84444 %%%% !1110
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MVGZ];&>PFW[,"2-AAHR1G!']1D<'!.*TJ^;JU+/Q)K=@T1M]4NE6)=J(TA9
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!A:C_ ,?TGX?R
M%%&H_P#'])^'\A10!IZ=_P >,?X_S-6JJZ=_QXQ_C_,U:H *JOIUI)J,6H/
MINXD,:2G.54]15JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB'X=7UC.9-(22\M-A8@LOF(0.1CC=GM@9[8]?6Z*WH8F=%^Z9U*4:BU/ /\
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M:KL8U:,:F^Y\W45]$7>G6-_L^V6=O<[,[/.B5]N>N,CCH*K?\(]HG_0'T_\
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MO.ZGD\_MR^X]2C\1:/+.\*ZA"&3.2QVKP<<,>#^!J?\ MC2_^@E9_P#?]?\
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M& H'0 =A3J\JO7E6ES2.VG35.-D%%%%8F@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%5'U73HW9'O[574
MX96F4$'T/-)R4=V4HRELBW15!];TI$9SJ-J0HR=LJD_@ <FL/4/'%G"KI8Q/
M/)T5W&U.G7U.#VP/K6-3$T::O*2-J>%K5':,6=717EMUXGUB[R&O'C4MN"P_
M)CVR.<?4U0M+^[L7WVMQ)"203L; ;'3(Z'\:X)9M3OI%V.^.3U''62N>PT5G
MZ+JB:OID=RO#CY)5Q@!P!G'MSQ]:T*]2$U.*E'9GE3@X2<9;H****HD****
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M_P!"[_PG_P#U#/\ R/\ _8T?\)__ -0S_P C_P#V-4O^$%U3_GO9_P#?;?\
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MJ45VPPM&'PQ1P3Q=>?Q284445T'.%%%% !1110 4444 %%%% !1110 4444
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M*OZ;H]]JKXM8"R9PTC<(O3J?QZ#GVKUJBM(Y3%/WI77H92SB37NPL_4X_3_
ML* /J-P9'R#Y<)PO7H2>3GCICO65XKT!-*ECN;1-MI)A"I?)5^?7G! ]^_M7
MHM07EK%?6<MK,,QRJ5/ R/<9[CJ*Z:F7TG2<(*S[G+2S&LJJG-W78\T\.ZP=
M'U-78_Z/+A)@2< 9^]@=Q_B.]>GPS17$2RPR))&W1T8$'\17E&JZ3<Z1=&*=
M#L)/E28&'4'&>"<?3J,U!:7]W8OOM;B2$D@G8V V.F1T/XUYN&QD\+>G46GY
M'J8K!0Q5JM-Z_@SV&BO/[+QS?0@+=P1W( /S#Y&)SWQQ^E;]CXRTN[VK,SVT
MAVC$@^7)]&'8>IQ7JT\=0J;2MZGD5<OQ%/>-_37_ ()T-%107,%TA>WGCF0'
M!:-PP!].*EKK335T<;33LPHHK/N-=TNUG6&:^A$C,4P&SM(./FQ]W\<4I3C%
M7D[#C"4W:*N:%%-1UD171@R,,JRG((]13JHD**** "BBJE[JECIP)N[J.(@
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MX7UJ")I'L'*CJ$97/Y DT?7,:U?ET]!/!8%.W-KZG5_\)UI?_/"\_P"^%_\
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M147)/X42Q202&.6-XW'577!'X4 >K(ZR(KHP96&0P.012UY,CM&ZNC%64Y#
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MY@\O\MV,_A7JM%:QRF"^*5_Z^9E/.)OX8I?C_D>7OX5UM$9S8DA1D[9$)_
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M*** "L^;0M)GB:-].M@IZE(PA_,8-:%%3*$9?$KE1G*.L78H6VBZ9:!!#8P
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MBC&%4=JEHHKV$DE9'BMMN["BBBF(**** "BBB@ HHHH **** "BBB@ HHHH
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MS[^U<+X>MH] ^*%SI&E3NVGR0EY8=VX1MC./J#CGKSBO3* .#^'G_(5\4_\
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M* *']DP?WY/S'^%']DP?WY/S'^%7Z* *']DP?WY/S'^%']DP?WY/S'^%7Z*
M*']DP?WY/S'^%']DP?WY/S'^%7Z* *']DP?WY/S'^%']DP?WY/S'^%7Z* *'
M]DP?WY/S'^%']DP?WY/S'^%69[JWMMOVBXBBW?=\QPN?SJC+XBTF&0HUXI(Z
ME%9A^8&* )?[)@_OR?F/\*/[)@_OR?F/\*R9?&=D(R8K:X=^P?"@_CD_RHL_
M&-K-)MNH'MQV<'>/QXS^AH UO[)@_OR?F/\ "C^R8/[\GYC_  J674K*& 3O
M=PB-@2K;P=V.N/7\*HP^)]*F<J;@QG?M&]" ??/8?7% %G^R8/[\GYC_  H_
MLF#^_)^8_P *OT4 4/[)@_OR?F/\*/[)@_OR?F/\*OT4 4/[)@_OR?F/\*/[
M)@_OR?F/\*OT4 4/[)@_OR?F/\*/[)@_OR?F/\*OT4 4/[)@_OR?F/\ "C^R
M8/[\GYC_  J_10!0_LF#^_)^8_PH_LF#^_)^8_PJ_10!0_LF#^_)^8_PH_LF
M#^_)^8_PJY++'!&9)9%C0=6=L ?C6'<^+M.AR(1+.=N057:N?0YY_0T :']D
MP?WY/S'^%']DP?WY/S'^%<S+XSO3(3%;0(G8/EB/QR/Y4S_A,M1_YXVO_?+?
M_%4 =3_9,']^3\Q_A1_9,']^3\Q_A7/1>-9!&!+8J[]RDFT'\,'^=1S>-+MG
M!@M847'(<ECGZC% '2_V3!_?D_,?X4?V3!_?D_,?X5SUMXTD&!=6BMEN6B;&
M!]#G)_$5J0>+-+EW;WEAQT\R/.?^^<T 7?[)@_OR?F/\*/[)@_OR?F/\*GMK
M^TO,?9[F*0E=VU6&X#W'458H H?V3!_?D_,?X5G77@[3+N4RDSQN3EC&P&X_
MB*V6O;5)_(:YA6;('EF0!LGIQ4]14IPJ*TU<TIU9TW>#L<RO@;2PP)FNV /0
MNN#_ ..UHV_AZPM$V0*Z ]<$9/U.,FM6BHIX>E3=X12*J8BK45IR;10_LF#^
M_)^8_P */[)@_OR?F/\ "I7U*PC=D>]ME93@J95!!_.D_M73O^?^U_[_ "_X
MUL8D?]DP?WY/S'^%']DP?WY/S'^%12^(M)AD*->*2.I168?F!BF?\)-H_P#S
M^?\ D)_\* +']DP?WY/S'^%']DP?WY/S'^%59?%.DQQEEG>0CHB1MD_F /UJ
ME-XTM50&"UF=L\AR%&/J,T :_P#9,']^3\Q_A1_9,']^3\Q_A7+77C"^EW+;
MQQ0*<;3C<P_$\?I4NG^,)H\)?Q^:O_/2, -W[=#V]/QH Z3^R8/[\GYC_"C^
MR8/[\GYC_"JTWB?2HH@ZW!E)&0B(<GG'?&/QK N_&-Y*"MM#';@C[Q^=@<]L
M\?I0!TTNGVD$9DEF:-!U9W  _'%8DVL:)$X5'NYAC.Y%  ]OFQ7*S7$URX>>
M:25@,!G8L<?C3X;*[N4+P6TTJ@X+)&6&?PH [6&;1)T+)J*@ X^=PA_)@*PM
M1UNW!,>GI(<<>;+CGKT'Y')_*L%U:-V1U*LIP5(P0:NZ=I-WJDFVWCP@SF5\
MA!CMGUY'% "?VM>_\]__ !Q?\*ADO;F4MOGD(88(!P/R'%=9!X+MUW?:+N63
M^[Y:A,?GG-6H?".F1.6?SIAC&UWP![_*!0!P5%>FII&FHBJ+"VPHP,Q G\SU
MJ>"UM[;=]GMXHMWWO+0+G\J /*ZF@M;BYW?9[>67;][RT+8_*O5** /-(=$U
M.=RJ6,P(&?G78/S;%5)K>:V<)/#)$Q&0KJ5./QKU:F2Q1SQF.6-9$/577(/X
M4 >86M[-:-F-OE[H>A_"NB76](\E&=+P.?O(H4[>G?C(_P .@IVJ>$"H:736
M+<_ZAR/7LQ]..#^=<]_96H_\^%U_WY;_  H W_[<T?\ YYWWY)_C5B+5-"DC
M#-=3QD]4=#D?D"/UK!E\.ZM#&9&LW('9&5C^0.:HSVMQ;;?M%O+%N^[YB%<_
MG0!WL4.ESR".*^21ST5)E)/X58_LF#^_)^8_PKS2IH+JXMMWV>XEBW?>\MRN
M?RH ]%_LF#^_)^8_PH_LF#^_)^8_PKB(O$6K0QA%O'('=U5C^9&:U;'QE*A"
MWT =< ;XAANG4@\'/'I0!T7]DP?WY/S'^%']DP?WY/S'^%9EQXPL8XP8(Y9G
M*@X(V@'N"?4>P(K*?QG?EV*6]L%SP"&) ^N: .H_LF#^_)^8_P */[)@_OR?
MF/\ "N4_X3'4MX;R[; !&W8<'ISU_P YIW_"9:C_ ,\;7_OEO_BJ .I_LF#^
M_)^8_P */[)@_OR?F/\ "L!/&S!%#V +8Y(EP"?IBI8?&L+.1/92(N."CACG
MZ'% &U_9,']^3\Q_A1_9,']^3\Q_A6$_C90[!+ E<\$RX)'TQ5FQ\7VUS.(K
MF$V^X@*^_<OXG QV_P#K4 :G]DP?WY/S'^%']DP?WY/S'^%7D=9$5T8,K#(8
M'((I: *']DP?WY/S'^%']DP?WY/S'^%7Z* *']DP?WY/S'^%']DP?WY/S'^%
M7Z* *']DP?WY/S'^%07EI9V-I)<S/-Y<8R<8)/8#IZUK5PGBG5#>7QM$_P!3
M;L0<$_,W?(]N1^?K0!6EUV4R$Q0HB=@Y+$?CQ_*D379PZEXHRN>0,@D?6F:-
MHTNL3NJN(XXQEW(SC/0 =^E:ESX,N8TW6US',0"2K+L/L!U_7% %G3]3TF\P
MDTDEK+Z2,-IZ_P 6/;OCKWK1QH__ $$H?^_Z5PUS97-F^VY@DB.2!N7 ..N#
MW_"H* /1X;&QN4+P7!E4'!9'5AG\*D_LF#^_)^8_PKS2B@#TO^R8/[\GYC_"
MH+FVTZS3=<W1B&"1N< G'7 QS^%>=T4 =;+K.BQR%5-Y(!T=%7!_/!_2HGUW
M20C%(KTMC@'8 3]:Q+32;^^ :WM9'4C(<C:IYQP3Q5K_ (1G6/\ GS_\BI_C
M0!'<:W/(Q\A1"F>,_,WYXQ^E0_VM>_\ /?\ \<7_  K9MO!ES(FZYN8X20"%
M5=Y]P>GZ9K2_X0W3O^>UU_WTO_Q- '*?VM>_\]__ !Q?\*/[6O?^>_\ XXO^
M%=7_ ,(;IW_/:Z_[Z7_XFC_A#=._Y[77_?2__$T <JFKWBL"9 X]"HP?RJW;
M:Z1,/M4(:(]?*.&'OSG/TX^M:\O@J,R$Q7SHG8/'N(_'(_E67J'A:^L\O"/M
M47K&/F'3^'\>V>G:@#H[ :7J29MKERV,F,D!EZ=L>_7I5M],MHT9WE=549+%
M@ !^5>:T4 =Y--HD"!GU%2"<?(X<_DH-0?VCH'_/])_WPW_Q-<54\-E=W*%X
M+::50<%DC+#/X4 ==_:.@?\ /])_WPW_ ,31_:.@?\_TG_?#?_$URO\ 96H_
M\^%U_P!^6_PH_LK4?^?"Z_[\M_A0!U7]HZ!_S_2?]\-_\35I#HSHK#48\,,C
M,R@_D>E<3+87L$9DEM+B-!U9XR /QQ5:@#LY]1T. /BZFE93C;&N<\]B1C]:
MP;K6Y9"/LT?D+WRP<D_7 X_"LZ&WFN7*00R2L!DJBECC\*V['PE?7*J\[+;(
M>S<OC'''^)!H PG=I&+.Q9CU).34\5A>SQB2*TN)$/1DC)!_'%=[8^'].L&5
MXX/,E7I)*=QZYSCH#[@5J4 >;0:#JEQNV64HV]?,&S_T+&:L1>%M6DD"M L8
M/\;R+@?D2?TKT&B@#A_^$-U'_GM:_P#?3?\ Q-6_^$)_ZB'_ )!_^RKK:* .
M.F\%3*@,%[&[9Y#H5&/J,U:@\%VZ[OM%W+)_=\M0F/SSFNGHH R(O#6FPMN2
M-LYSDG./IGI5C^R8/[\GYC_"K]% %#^R8/[\GYC_  H_LF#^_)^8_P *OT4
M4/[)@_OR?F/\*/[)@_OR?F/\*OT4 4/[)@_OR?F/\*/[)@_OR?F/\*OT4 4/
M[)@_OR?F/\*/[)@_OR?F/\*OT4 4/[)@_OR?F/\ "C^R8/[\GYC_  J_10!0
M_LF#^_)^8_PH_LF#^_)^8_PJ_10!0_LF#^_)^8_PH_LF#^_)^8_PJ_10!0_L
MF#^_)^8_PH_LF#^_)^8_PJ_10!0_LF#^_)^8_P */[)@_OR?F/\ "K]% %#^
MR8/[\GYC_"C^R8/[\GYC_"K]% %#^R8/[\GYC_"C^R8/[\GYC_"K]% %#^R8
M/[\GYC_"C^R8/[\GYC_"K]% %#^R8/[\GYC_  H_LF#^_)^8_P *OT4 4/[)
M@_OR?F/\*/[)@_OR?F/\*OT4 4/[)@_OR?F/\*/[)@_OR?F/\*OT4 4/[)@_
MOR?F/\*OT44 %%%% !1110!A:C_Q_2?A_(44:C_Q_2?A_(44 :>G?\>,?X_S
M-6JJZ=_QXQ_C_,U:H AN[6&^LYK2X3?#,ACD7.,J1@\BO,;KP&EIXKL]*TZ]
MU*'3[F-Y9W5^$P#@ @8]!S7JE% &'X=\)Z7X9B<6,;M+(,//*<NP]/0#Z"H?
M$7A3_A(+J&?^U;VS\M-FR!\ \YR?>NBHH X"+X6P0,[0Z]J,9<Y<HP&X^I]:
M[*XTNUO-).FWB?:+=HQ&_F');'?/KQG/K5VB@#@C\*M.PT*ZKJ2VA;)@$BX_
MEC]*[+3-,M-(L(K*QA$4$8X4=_4D]S5NB@#D=7^'NF:EJ3ZC;W%SI]U(29&M
MF #$]3CL3WQUJWX<\%Z9X;FDN86EN+N3AIYR"P!Z@8'&?SKHZ* "BBB@ HHH
MH **** "BBB@ HHHH **** ,W4M"LM4(:9"D@.3)%@,W&,'CGM65!X+MUW?:
M+N63^[Y:A,?GG-=/10!G0:#I=ONV641W=?,&_P#]"SBM!%6-%1%"JHP% P *
M6B@ J"YLK:\3;<P1RC! W+DC/7![?A4]% &%-X1TR5PR>=",8VH^0??Y@:B_
MX0W3O^>UU_WTO_Q-=%10!P^I>$KJVW26;?:(ASMZ.!SV[]NG)]*RXM&U.:01
MK8W )[NA4?F>*],HH X>U\'WTNUKB2*!3G<,[F'X#C]:V;;PCIT.#,99SMP0
MS;5SZC'/ZFM^B@""VLK:S3;;01Q# !VK@G'3)[_C5>;1-,G0*]C" #GY%V'\
MUQ5^B@#(_P"$9T?_ )\__(K_ .-5Y?"&F22%E:XC!Z(CC _,$_K6_10!RTW@
MJ%G!@O9$7'(= QS]1BH)?!4@C)BOE=^P>/:#^.3_ "KL** .'_X0W4?^>UK_
M -]-_P#$U4_X1G6/^?/_ ,BI_C7H=% 'F=SHVHVF?.LY0 NXLHW*![D9 JO;
M74]G,);>5XW'=3U[X/J/:O5*P]0\+6-YEX1]EE]8Q\IZ?P_AVQU[T <7=ZC>
M7Q)N;F209SM)PH.,< <"JM=U:>$+"$ W#27#8P<G:O7J .?UK<AMX;9"D$,<
M2DY*HH49_"@#RFBO5IK>&Y0)/#'*H.0KJ&&?QJ#^RM._Y\+7_ORO^% 'F%7H
MM&U.:01K8W )[NA4?F>*])BBC@C$<4:QH.BHN /PI] '!0^$=3E0L_DPG.-K
MODGW^4&DG\)ZI%MV)%-GKY<F,?\ ?6*[ZB@#R^[TZ\L21<VTD8SC<1E2<9X(
MX-5:]:JI_96G?\^%K_WY7_"@#S.*62"0212/&XZ,C8(_&KD.MZG Y9+Z8DC'
MSMO'Y-FNYF\/Z5.X9[*,$#'R$H/R4BJ4OA#3))"RM<1@]$1Q@?F"?UH YQ/%
M&KJZL;D, <E3&N#[<"K7_"9:C_SQM?\ OEO_ (JKTO@J,R$Q7SHG8/'N(_'(
M_E4$W@J94!@O8W;/(="HQ]1F@!Z>-F"*'L 6QR1+@$_3%9U]XHU"\!2-A;1Y
M/$60V,\9;_#%2OX.U)49A);,0,A0YR?;D5/9^#9WVM>7"Q#@E(QN;W&>@/YT
M 80U*_4L5O;D%CEB)6Y.,<\^@'Y4O]JZC_S_ -U_W^;_ !KMT\+Z0J*IMBQ
MP6,C9/OP:7_A&='_ .?/_P BO_C0!P_]JZC_ ,_]U_W^;_&FRZA>SQF.6[N)
M$/57D)!_#-=U_P (SH__ #Y_^17_ ,:/^$9T?_GS_P#(K_XT >>5)#;S7+E(
M(9)6 R512QQ^%>EQ:7I\&SR[*!2F-K>6-PQT.>N?>K= 'G,7AW5IHQ(MFX![
M.RJ?R)S4%_I5YIKXN82%S@2#E6Z]_P .G6O3:1U61&1U#*PP5(R"* /)J?)%
M)%M\R-TWJ&7<N,@]"/:O34TVPC=72RME93D,(E!!_*H]4TN#5;7RI1M=>8Y
M.4/^'J* .5T3Q-)9^7:W?SVHX#XRR#M]0/3K^6*ZJ+6=,FC#K?0 'H'<*?R/
M-<%=Z+J%D[B6UD95!8R(I9<#OD=.G>J% 'J\4L<\8DBD61#T9&R#^-/KR6IX
M;V[MD*07,T2DY*I(5&?PH ]3HKS:#7M4M]VR]E.[KYAW_P#H6<5;@\6:I%NW
MO%-GIYD>,?\ ?.* .^J&2ZMXIEADN(DE?&U&<!CG@8%<)>>*-3NX]@D6 =S"
M"I/XY)'X8K&H ]:HKSJP\1:AIZ>6D@EC P$E!8+TZ=^W3.*?/XGU6<OBX$2L
M,;8T QQV)Y_6@#N+O4;.Q!-S<QQG&=I.6(SC@#DUS-]XR=E9+&WV9Z22G)Z?
MW>F<^Y^E<L[M([.[%F8Y+$Y)-:VF^';[4=K[/)@//F2#&1QT'4\'Z>] &?<W
MMS>/NN9Y)3DD;FR!GK@=OPI]IIUY?$"VMI)!G&X#"@XSR3P*[33_  M8V>'F
M'VJ7UD'RCK_#^/?/3M6VBK&BHBA548"@8 % '#)X.U)D5C);*2,E2YR/;@59
M;P5,(,K>QF; ^0H0N>_/_P!:NQHH X?_ (0W4?\ GM:_]]-_\32IX,ORZA[B
MV"YY(+$@?3%=O10!P4WA'4XD#)Y,QSC:CX(]_F K,GTV]M0[3VDR*APSE#M'
M..O2O4** /):D-Q,T"P--(85.5C+':#[#\3^=>G7-A:7F?M%M%(2NW<RC<![
M'J*H?\(SH_\ SY_^17_QH \\J[::M?V("V]U(B@8"$[E'.> >*] ?2--=&4V
M%MAA@XB /YCI63=^#K.4EK::2W)/W3\Z@8[9Y_6@#/@\:7"[OM%I%)_=\MBF
M/SSFLG4-;OM2RLTNV(_\LH^%[?GTSSFKUSX1U&')A,4XW8 5MK8]3GC]35[3
M?!_W9-0D]_)C/TX+?F./SH Y*BO34TC3415%A;848&8@3^9ZU=H \EJTFFW\
MB*Z65RRL,AA$Q!'Y5ZA10!YA_96H_P#/A=?]^6_PJTGAO5W16%F<,,C+J#^1
M/%>BT4 <9!X+N&W?:+N*/^[Y:E\_GC%9NJ:!>:6&D8"6W!QYJ=N>,CM_+GK7
MHM% 'E,-O-<N4@ADE8#)5%+''X5N6GA"_F(-PT=NN<')W-TZ@#C]:[JB@#'M
M/#.F6A#&$SL#D&8[NW3'3]*V*** (9[6WN=OVBWBEV_=\Q V/SJ5%6-%1%"J
MHP% P *6B@ HHHH **** "BBB@ HHHH **** "BBB@"":RM;EP\]M#*P& SQ
MACC\:SY?#.DR[S]EV,^>4=A@GT&<?IBM>B@#FI?!ED8R(KFX1^Q?# ?A@?SK
M#OO#&HVC,8XOM$0Z-%R>N/N]<_3/UKT&B@#S.+1M3FD$:V-P">[H5'YGBMBV
M\&7,B;KFYCA) (55WGW!Z?IFNTHH Y+_ (0G_J(?^0?_ +*H9_!=PNW[/=Q2
M?WO,4IC\LYKLZ* .'_X0W4?^>UK_ -]-_P#$U4_X1G6/^?/_ ,BI_C7H=% '
M 0^%-5E<J\4<(QG<\@(/M\N:SK[3[G3IS%<QE>2%;'RO[@]^HKU"H;FU@O(3
M%<1+(A[,.G;(]#[T >:1:A>P1B.*[N(T'14D( _#-,CNKB*9IH[B5)7SN=7(
M8YY.37;KX1TQ9_,/G,N2?++_ "_3@9X^M-O/"6GSQXMM]LX[@E@?J"?Y$=:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_,=*J_\ ",Z/_P ^?_D5_P#&M>B@#G?^$-T[_GM=?]]+_P#$U4_X0G_J(?\
MD'_[*NMHH X^#P7)YS?:+M1$&^7RURS#\?NG\ZW(_#VEQVOV<VBN#C+M]\GC
M^+J.G; K4HH Y:;P5"S@P7LB+CD.@8Y^HQ1#X*A5R9[V1UQP$0*<_4YKJ:*
M,[3]$L=-PT,6Z4?\M9.6[_EUQQBM&BB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#"U'_C^D_#^0HHU'_C^D_#^0HH T]._X\8_Q
M_F:M55T[_CQC_'^9JU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &%J/\ Q_2?
MA_(44:C_ ,?TGX?R%% &GIW_ !XQ_C_,U:JKIW_'C'^/\S5J@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** ,+4?^/Z3\/Y"BC4?^/Z3\/Y"B@#3T[_CQC_'^9JU
M573O^/&/\?YFK5 !1110 4444 %%4[/5+*_N;NWM9O,EM)/+G7:1L;TY'/X5
M<H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_GA'_P!\"C[-!_SPC_[X% $7]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\
MGA'_ -\"C[-!_P \(_\ O@4 1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H
M/^>$?_? H^S0?\\(_P#O@4 1?VC:_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/
M^>$?_? H^S0?\\(_^^!0!%_:-K_SU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'
M_P!\"C[-!_SPC_[X% $7]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_
M -\"C[-!_P \(_\ O@4 1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$
M?_? H^S0?\\(_P#O@4 1?VC:_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/^>$?
M_? H^S0?\\(_^^!0!%_:-K_SU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'_P!\
M"C[-!_SPC_[X% $7]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"
MC[-!_P \(_\ O@4 1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$?_?
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M% $7]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"C[-!_P \(_\
MO@4 1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$?_? H^S0?\\(_P#O
M@4 1?VC:_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/^>$?_? H^S0?\\(_^^!0
M!%_:-K_SU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'_P!\"C[-!_SPC_[X% $7
M]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"C[-!_P \(_\ O@4
M1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$?_? H^S0?\\(_P#O@4 1
M?VC:_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/^>$?_? H^S0?\\(_^^!0!%_:
M-K_SU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'_P!\"C[-!_SPC_[X% $7]HVO
M_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"C[-!_P \(_\ O@4 1?VC
M:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$?_? H^S0?\\(_P#O@4 1?VC:
M_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/^>$?_? H^S0?\\(_^^!0!%_:-K_S
MU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'_P!\"C[-!_SPC_[X% $7]HVO_/7_
M ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"C[-!_P \(_\ O@4 1?VC:_\
M/7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$?_? H^S0?\\(_P#O@4 1?VC:_P#/
M7_QT_P"%']HVO_/7_P =/^%2_9H/^>$?_? H^S0?\\(_^^!0!%_:-K_SU_\
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M_GA'_P!\"C[-!_SPC_[X% $7]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\
MGA'_ -\"C[-!_P \(_\ O@4 1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H
M/^>$?_? H^S0?\\(_P#O@4 1?VC:_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/
M^>$?_? H^S0?\\(_^^!0!%_:-K_SU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'
M_P!\"C[-!_SPC_[X% $7]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_
M -\"C[-!_P \(_\ O@4 1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$
M?_? H^S0?\\(_P#O@4 1?VC:_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/^>$?
M_? H^S0?\\(_^^!0!%_:-K_SU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'_P!\
M"C[-!_SPC_[X% $7]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"
MC[-!_P \(_\ O@4 1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$?_?
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M% $7]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"C[-!_P \(_\
MO@4 1?VC:_\ /7_QT_X4?VC:_P#/7_QT_P"%2_9H/^>$?_? H^S0?\\(_P#O
M@4 1?VC:_P#/7_QT_P"%']HVO_/7_P =/^%2_9H/^>$?_? H^S0?\\(_^^!0
M!%_:-K_SU_\ '3_A1_:-K_SU_P#'3_A4OV:#_GA'_P!\"C[-!_SPC_[X% $7
M]HVO_/7_ ,=/^%']HVO_ #U_\=/^%2_9H/\ GA'_ -\"C[-!_P \(_\ O@4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#@^A]#5JO-;6RC\)?%6WL[$&.PU. DQ;CM4_-P/HR_@&->E4 %%%% !1110
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MGA^61G2QN/W18]B6!^@^4'\37H% !1110 4444 %%%% !1110 4444 %%%%
M!6>NMZ8^K?V6E[$U]@DPJ<D8YY]/I3=;T^ZU/3_LEI?O8EW'F2QC+;.X'H3Z
MUPUEH]EH7Q7T^RL8RD0L68EF)9F(?))]: /2ZR=1\3Z)I,WDWVI00R]XRV6'
MU Y%3:[?MI>@W]\@!>"!G0'INQQ^N*X[P-X2TV[T"/5=5M4O;R^+2NUP-V 6
M., ^O7/O0!V]AJ5EJEOY]C=17$6<%HV!P?0^AJU7FMK91^$OBK;V=B#'8:G
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MJW8ENIY]: .G!! (.0>A%+7$_"_4)KOPL]K<,2]E.T*[CDA< @?ADCZ 5VU
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M^CTS3+J^F_U=O$TA'K@=/QK*\&7VIZGX;AO]596FN&9T"IMPF<#^6?H16/\
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M0-8\16%M9Z9<0QPARUPDCE=_3;T!R!SQ]/2LJUTKXA6-K';6MUI$,$8VHB(
M /\ OB@#HO&=N&\$:I#$H54M\A5' "X/\A3? DZ7'@G2V0Y"Q;#[%20?Y5<T
M>WU1]':#Q ]O/<.65_)'RE#V/ ]ZY*'PCXK\/2S0>&]7M_[/D8LL5R.4)_X"
M1^(Z^E #M>(N?BYH$$>2T4!=\=A\Y_I^HKT&N4\+^$9]*O[C6-6O/MNKW VM
M(/NH..!TST'.!P, 5U= !1110 4444 %%%% !1110 4444 %%%% !1110 V1
MUBC:1SA5!8GT KS>UTS_ (6;.VJWY%KIL$C16\4*KYSXP<LYSQST_P#UGTET
M61&1P"K#!![BO.X?!OBCPY<3+X9UBW%C*Y?R+D<@_P#?)'3'(QG H 9:?:OA
MWK]AI)E2ZT?4Y=L9*!98WR 22.OWEZ]NF,5O_$'56TSPG<)$3]HO"+:(+U.[
MK_X[G\<5G:=X-UB]UVVU?Q1J<=T]J=T%O ,(ISD=@.#CMS@9--U4?\)#\3=/
MTW[UKI,?VF8=O,."!_Z!^M '4^'M*71?#]EIX W0Q .1W<\L?S)J_<?\>TO^
MX?Y5)7*:_;>,Y]1D_L:[L([%D 59A\V<<_PF@"E\*?\ D3C_ -?+_P EKN*\
MV\/^&_'&@01V=K>::MIYN]U.6/.,_P .>@KT.Z^T"SF^R!#<;#Y0D.%W8XS[
M9H X'42?%OQ*M].7+:=HX\V;^ZTG''Y[1@^C5Z)7,>"O#,WAW3K@WKQRZA=2
MF2>1"3GT&2!GN?J36GXCU4:+X>OM0) :*(^7GNYX7]2* .7TC_BH?B9J.IGY
MK72D^RP''&_D$C_Q_P#,5WA( R3@"N7^'^E'2_"=NTH/VB[)N92>I+=.O^SC
M\<U8\9:7JFL^'WL-*GCADE<"4NQ4-'@Y7('<X_#- '.:SJ$WCS4O[ T:0C2H
MF#7UZHX;!X5?7I^)YZ#GLI=-AMO#DVFV<>R);5H8U'./E('U-<1IF@>/='L4
ML["YTB&%.P7DGU)V<GWKKO#D7B&*"<>()[660L/*-N,8&.<\"@#"^%<Z2^#O
M+4_-#<.K#ZX/]:J_$4B?6O"]FF3+)>9P.PW(/\_0TZ;P=KVC:M<WGA74H(+>
MZ;=);3CY0?;@C'/'0]N:N:#X/U!==&O>([]+W4$7;"D8^2,<^P]3QC')/- '
M57]_:Z992WE[,L-O$,N[=O\ $^U<+IMK<>//$$>N7T31:+9-_H,##!F(/WC[
M9 SVX [&K7CKPOKGB*_LS8SVWV*!=QAG<@&3)Y( ((Q@?GZU$EC\1HHUCCO=
M)1%&%54  'H!LH M?%&)I/!4KCI%/&Y^F<?UKI]'G2ZT2PGC.4DMXV'XJ*KK
MIL^I>&O[/UTQRSS1%+AH>!GU''4<'IU%<?;>&/'&BP'3])UNS:Q!/E&9?F0'
MZJ<?F: )+$BY^-&H/'DK;V8#GMG:@_K^AKT&N<\)^%5\.0W$L]P;K4+MM]Q.
M>YR3@?B3SWKHZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".X@BNK:6
MWG0/%*A1U/1E(P17!Q_#K4=/DD31O%%W9VCG/E;2<?DP!/O@5WEPCRVTL<4A
MBD="JR 9VDC@_A7"G2?B,0;;^W;#RLX\_8 ^W_OCK_G- &9X?TA;/XJM!'?7
M%\]I:EKFXG.XER ,9_X$.Y[UM_$>ZDFL+#0+9C]HU2X6/@9P@(R?S*_@#6OX
M6\+0>&K27]ZUS>W#;KBY?JY]/IR:PM-'_"0_$^^U _-:Z/']GA]/,.0?_9_T
MH [:TM8K*S@M85VQ0QK&@] !@5F>+?\ D4-7_P"O23_T$ULUPVOZ7XWU*2_M
M;>[TX:;/N1$;AMAXP3MZT :W@/\ Y$?2_P#KF?\ T(UT=<)X:T;QIH[6-G/=
MZ>=+@;#HO+;<DD [1SSZUU6NPW]SHEW;Z8T:W<L91&D8J%SP3D \@9Q[T <9
MHI/BWXBW>KG+:?I0\FV]&;D9'8_Q-^*UZ&2%4LQ  &23VK$\): /#GA^"Q.Q
MI\F2=TZ,YZ_D,#\*J>/]5.E>$KKRR?/NL6T0'4ENN/\ @.Z@#+\# ZSKNM^)
MY 2L\OV>V)&,1KC^@7\0:[B::*W@>::18XHU+.[G 4#J2:S?#6DC1/#MEI^
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M>.G:@P$K(I,L8^Y(/XA[9S^!KE(_#WC^WM!IL.NV8M%&Q93GS GIG9G]?QH
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M5K>'M*71?#]EIX W0Q .1W<\L?S)KEM5'_"0_$W3]-^]:Z3']IF';S#@@?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU:%% !1110 4444 %9^I:+8:M-:2WL)D:TD\V'YR &XY(!P>@ZUH44 %%%%
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH PM1_P"/Z3\/Y"BC4?\
MC^D_#^0HH T]._X\8_Q_F:M55T[_ (\8_P ?YFK5 !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 86H_\?TGX?R%%&H_\?TGX?R%% &GIW_'C'^/\S5JJNG?\>,?
MX_S-6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH PM1_X_I/P_D**-1_X_I/P_
MD** -/3O^/&/\?YFK55=._X\8_Q_F:M4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%4=8U.+1](N=0F&5A3(7GY
MFZ*.AQDD#/;->:R?%+6#*YBL[%8RQVJRNQ [ G<,GWP*Z*.&J5E>*,JE:$':
M1ZQ17DG_  M'6_\ GUT__OV__P 71_PM'6_^?73_ /OV_P#\76W]GUB/K5,]
M;HKR3_A:.M_\^NG_ /?M_P#XNC_A:.M_\^NG_P#?M_\ XNC^SZP?6J9ZW17D
MG_"T=;_Y]=/_ ._;_P#Q='_"T=;_ .?73_\ OV__ ,71_9]8/K5,];HKR3_A
M:.M_\^NG_P#?M_\ XNC_ (6CK?\ SZZ?_P!^W_\ BZ/[/K!]:IGK=%>2?\+1
MUO\ Y]=/_P"_;_\ Q='_  M'6_\ GUT__OV__P 71_9]8/K5,];HKR3_ (6C
MK?\ SZZ?_P!^W_\ BZW/"WQ"GU75TL-3@MXO/^6&2+*@-Z-N)Z]!CO@8.>)G
M@:T8N36PXXBG)V._HHK/UW5$T;0[S47Q^XB+*#W;HH_$D"N,W,N#QOI-QXH;
M0$\_[4KM'YA4>6649(!SG/!'3J*Z2O(;KP]/IW@#3?$,:YU2"Y%_(Y&20Y&,
M_DA_[ZKU:PO(M1T^WO83^ZGC61?H1F@#/TGQ)9:QJFI:?;).LNGR>7*TB@*3
MDCY<$]U/7%:TCF.)W",Y52=J]3[#WKS_ ,!_\CIXP_Z^S_Z,DKT*@#'\/>);
M#Q+:RS60E1H7V213*%=#VR 3P?Z&FZ[XGLM ELX;B.>>XNY/+AAMU!9CP.Y
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M;@F3A5P!R?7DCCZ\BHJ5(TXN<MD73IRJS4(;LVJ*\]_X3K5/^>%G_P!\-_\
M%4?\)UJG_/"S_P"^&_\ BJXO[3P_G]QW?V7B.R^\]"HKSW_A.M4_YX6?_?#?
M_%4?\)UJG_/"S_[X;_XJC^T\/Y_<']EXCLOO/0J*\]_X3K5/^>%G_P!\-_\
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MR1PK'E46-3C<Y)ZY^@J[HOC+5_\ A(X]"\1Z7'9W4ZEHGB/RGT'4YS@\@]:
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MRW_Q5'_"9:C_ ,\;7_OEO_BJ .XHKA_^$RU'_GC:_P#?+?\ Q5'_  F6H_\
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MD62\,^3=,OEA%QR,M@GUP/3BNZ\7ZS<:!X;N-1M4B>:-D"K*"5Y8 ]"#W]:
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M[0OXUS*S'"1].#TSUYY'IUH [.BO/T\;Z]HMY!%XKT6.UMYWVK<6[95/K\S
M_F#CUKJ?$?B"W\.:))J4RF7!"Q1J<>8QZ#/8=\^@H UZ*\SO_&'CJQT_^TI?
M#]G#8D!@SJS,H/3< ^1^(%79O%GB>T\%C7;FPT]6\]"%7+*T# 888<X.X@<G
M\* ._HJ"TO(;VPAO8F_<S1B52?0C-8'@_P 17GB5-0NY888[%+CRK0HK!F Y
M);)]"O0#O0!TU9'B+Q%9^&=.2]O4F>-Y1$%A4%LD$]R.P-:]<#\7?^14M?\
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M2Q)>,@,JP@A5)[#)/3IUH MT444 %%%% !1110 4444 %%%% !1110 4444
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M^HG_ .2__P!E1_P@'_43_P#)?_[*NUHH_L_#?R_B_P#,/[2Q7\WX+_(XK_A
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MF@"KXPFB;X@>%85D4RI,2Z@\J"RXS]<&KWB;Q)JT.OVOA[08(3?7$?FM-/\
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M3[KONEW$<#@G/85JZCX0U"UU>YUCPSJ8LKJX.Z>WE7=%*V<Y[X[]CU."*O\
MACPC;^%[K47M;AG@N_+V1,O,>T-_%GYL[O05D7'P^O?M4SV'BK4;."61G:%=
MQ')R1PP'<]J $MO$EYX@\)>)+2ZME@U.P@EBF6(Y5CM8<>^588R?UK0^'$D#
M^!K$08RA=9 .H;>2<_@0?H16CX>\,V7ARPDMK<O,TS;IY93EI#[^WM7.R_#7
MR;R631]?OM,MIFS)!%G!]@0PX^H- #)IHI?C1:B.17,=D4?:<[6PQP??!%3Z
MOXBU_4/%%QX?\.1VT4EM&'FN;CGJ >.O'S =#5O2O 5EHVOVFIV=RX6"!HWC
M==S2N<Y<MGKSTQV%&O\ @9-5U8ZK8:I<Z7?,H622'/S@<=B#G '?L* ..UBU
M\2VOBSPN/$6HVMX6OE\@0*!L_>1[LX1>O'KT-;WQ 9(O$_A.:Y_X]$NCO)^Z
M#N3D_P">QJ>'X;QI>V%_-K%U<W]M<I/)/."_F!3G8!N^7ZDFND\0>'[+Q)IA
MLKT, #NCD3[R-ZB@"[?316]A<33R+'$D;%F<X &.]<?\*?\ D3C_ -?+_P E
MJ*'X=%8\:KKU]J-I"-T=J[,J# XR-QX^F*E^%/\ R)Q_Z^7_ )+0!W%>:PV5
MI?\ QFU:&\M8;F(6JL$FC#KG9%S@]Z]*KB=:\!7.H^([C6;'7[C3IIU56$49
MSPH7[P<<':.* (/'WAK0[;PM<WT%E;V=S!M,3P((\DL!C Z]:A\27,]Y\'H;
MFZ)::2&!G8]6.Y>?QZU/%\-C<S1MKOB"_P!4BC.5B=F4?JS'\L5T?B+0$UWP
M])I$<PM4;9M98]P4*00-N1Z8H XWQZ/^*!T!G!,*R0&3'IY1_P#KUZ1#)'+#
M')"RM$RAD9>A!Z8JA-HEI=Z FCWJ^?;B%8F.,$[0,$>AXS7(K\-;J &WM/%6
MHP6'_/N,]/P8#_QV@!?"Q2?XE^)I[8AK<*JLR]-^1G]0U29 ^,PR>NG\5TV@
M>'K#PWI_V.Q1L$[I)'.6=O4UE>)?!2:]J,&IVNI3Z=?PKL$T0SE>?0@@\GD&
M@#+^+*N?#=DR_<6]4L2,@?*V"1Z4BZ7\260,GB+2RI&00BX(_P"_5=+;^&X/
M^$:_L74;B;4(V!\R6<G>Q)SG/48/3GM7-#X<W]MB&P\7:E;68X$(W<#TX<#]
M* $LO#>IZ!X(\2QWT\$T]U%++_HY)'W#GJ!U] *U_AW)"_@?3Q"5^0.K@=FW
MG.?SS^-:6@:!%H.FR6:W$UT99#))).<EB0 ?PP!7-3?#8P7DDNBZ_>Z7#*V7
MABR1] 0PX^N: .UEFBDBN$21&>-2'56!*G&<'TXKC?A0JCP>S!0"UT^2!UX6
MM[P_X9MO#VG3VL$TTSW#%YII3EF8C&:3PIX>_P"$8T;^S_M7VG]ZTGF>7LZX
MXQD^E '/W0 ^,]E@#FP.??AZ2\56^,]AN4'%@2,CH</6_+X;\WQG!XA^UX\J
MW,'D>7U^]SNS_M=,42^&_-\9P>(?M>/*MS!Y'E]?O<[L_P"UTQ0!G_$P ^!K
MS('#QX]OG%87CT?\4#H#."85D@,F/3RC_P#7KM/$NB?\)%H4^F?:/L_FE3YF
MS?C# ],CT]:EFT2TN] 31[U?/MQ"L3'&"=H&"/0\9H OPR1RPQR0LK1,H9&7
MH0>F*X/PL4G^)?B:>V(:W"JK,O3?D9_4-2+\-;J &WM/%6HP6'_/N,]/P8#_
M ,=KJ] \/6'AO3_L=BC8)W22.<L[>IH YC0/^2K^(_\ K@G\DJ+P \2>)_%<
M,AQ=M>%B&ZE=[_U/ZBNCL/#?V'Q7J6N?:]_VU%3R?+QLQM_BSS]WT%4=?\"V
MNL:C_:=I>SZ;J.,&>#^+C&2,@YQZ$4 0?%&6!/!<J2E?,DFC$0/4L#DX_#-4
M/'D.? FDVLC.+[S8!!$!DO)MVD'\"?QQ5[3OAY%%J,-]K.K7>KS0G,8G)V@]
MN"23^>*J?%*ZQ9:7IY6*-+NYYNY <6^TCD$=/O'\ : *>IZUXNU_39-"_P"$
M6EMYYU\N:Y<GR\=R"1@?]]&NRM] B3PE'H,[>8GV7R'<#J<<D?CR*X,V+6D+
M3Q_%)6(7(4S;_P!/,)_2NL^'^LZAKGA@7.H_-*DS1K+MQYB@#YO3J2/PH XZ
MR\12Z7\-]5TF9L:C9SM8HH//SD]/IB3'^Z*]$\,:2-$\.6-AC#QQ@R?[YY;]
M2:X2YT:UU;XQE;<%HK<)<W8[!U P!ZY)3/U:O4: "N!^+O\ R*EK_P!?R?\
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M5T[_ (\8_P ?YFK5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &%J/\ Q_2?
MA_(44:C_ ,?TGX?R%% %[^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH
M_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[
M\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\
M*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /
M[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_
M)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"
MC^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_
MOR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_
MPHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@
M_LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[
M\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\
M*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#
M^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC
M_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\***
M#^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_
MOR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_
MPH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8
M/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F
M/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH
M /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#
M^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC
M_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)
M@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^
M8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB
M@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8
M/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F
M/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_L
MF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\G
MYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\**
M* #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)
M@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^
M8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^
MR8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR
M?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PH
MHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _L
MF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\G
MYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/
M[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_
M)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"
MBB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^
MR8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR
M?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH
M_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[
M\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\
M*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /
M[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_
M)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"
MC^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_PHHH /[)@_OR?F/\*/[)@_
MOR?F/\*** #^R8/[\GYC_"C^R8/[\GYC_"BB@ _LF#^_)^8_PH_LF#^_)^8_
GPHHH /[)@_OR?F/\*/[)@_OR?F/\*** #^R8/[\GYC_"BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>gvvh0m1pmdf2000012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,M!YX# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)ZI?W'C/P@9/"EX8YI77]XV%(7/S=?:O'O'7PVO_  =I:^(%U^XFNQ*-P;
M;VYH ^DS(BJ7+ *.K$\4D<T4JEHY%=?56S7FMKJEYJ?P8NKNYD8S_9L;CP3T
MJM\#9'D\+S&21G/FOG<<X^:@#U7O[8J-YX8\"25$)Z!F J0=.M>%_&FX>'Q;
MHN)6C7*DD-@=: /<]P W%AMIJ7$4F3'*C;>I5@<5S9UO2O\ A%U']J67F&W
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M%=WIG- 'O((QUSGO4)O;13\US"#Z%Q7EWC+Q/K/@7P%:VUQ+YFJW#&&.4'.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^$'T3_GU_E1[H6F+_P )IH?_ #_0_P#?5'_"::'_ ,_T/_?5)_P@^B?\^O\
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M_@/_ /7KO** .#_X63)_T*6O?^ __P!>C_A9,G_0I:]_X#__ %Z[RB@#@_\
MA9,G_0I:]_X#_P#UZ/\ A9,G_0I:]_X#_P#UZ[RB@#@_^%DR?]"EKW_@/_\
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M63)_T*6O?^ __P!>N\HH X/_ (63)_T*6O?^ _\ ]>C_ (63)_T*6O?^ _\
M]>N\HH X/_A9,G_0I:]_X#__ %Z/^%DR?]"EKW_@/_\ 7KO** .#_P"%DR?]
M"EKW_@/_ /7H_P"%DR?]"EKW_@/_ /7KO** .#_X63)_T*6O?^ __P!>C_A9
M,G_0I:]_X#__ %Z[RB@#@_\ A9,G_0I:]_X#_P#UZ/\ A9,G_0I:]_X#_P#U
MZ[RB@#@_^%DR?]"EKW_@/_\ 7H_X63)_T*6O?^ __P!>N\HH X/_ (63)_T*
M6O?^ _\ ]>C_ (63)_T*6O?^ _\ ]>N\HH X/_A9,G_0I:]_X#__ %Z/^%DR
M?]"EKW_@/_\ 7KO** .#_P"%DR?]"EKW_@/_ /7H_P"%DR?]"EKW_@/_ /7K
MO** .#_X63)_T*6O?^ __P!>C_A9,G_0I:]_X#__ %Z[RB@#@_\ A9,G_0I:
M]_X#_P#UZ/\ A9,G_0I:]_X#_P#UZ[RB@#@_^%DR?]"EKW_@/_\ 7H_X63)_
MT*6O?^ __P!>N\HH X/_ (63)_T*6O?^ _\ ]>C_ (63)_T*6O?^ _\ ]>N\
MHH X/_A9,G_0I:]_X#__ %Z/^%DR?]"EKW_@/_\ 7KO** .#_P"%DR?]"EKW
M_@/_ /7H_P"%DR?]"EKW_@/_ /7KO** .#_X63)_T*6O?^ __P!>C_A9,G_0
MI:]_X#__ %Z[RB@#@_\ A9,G_0I:]_X#_P#UZ/\ A9,G_0I:]_X#_P#UZ[RB
M@#@_^%DR?]"EKW_@/_\ 7H_X63)_T*6O?^ __P!>N\HH X/_ (63)_T*6O?^
M _\ ]>C_ (63)_T*6O?^ _\ ]>N\HH X/_A9,G_0I:]_X#__ %Z/^%DR?]"E
MKW_@/_\ 7KO** .#_P"%DR?]"EKW_@/_ /7H_P"%DR?]"EKW_@/_ /7KO**
M.#_X63)_T*6O?^ __P!>C_A9,G_0I:]_X#__ %Z[RB@#@_\ A9,G_0I:]_X#
M_P#UZ/\ A9,G_0I:]_X#_P#UZ[RB@#@_^%DR?]"EKW_@/_\ 7H_X63)_T*6O
M?^ __P!>N\HH X/_ (63)_T*6O?^ _\ ]>C_ (63)_T*6O?^ _\ ]>N\HH X
M/_A9,G_0I:]_X#__ %Z/^%DR?]"EKW_@/_\ 7KO** .#_P"%DR?]"EKW_@/_
M /7H_P"%DR?]"EKW_@/_ /7KO** .#_X63)_T*6O?^ __P!>C_A9,G_0I:]_
MX#__ %Z[RB@#@_\ A9,G_0I:]_X#_P#UZ/\ A9,G_0I:]_X#_P#UZ[RB@#@_
M^%DR?]"EKW_@/_\ 7H_X63)_T*6O?^ __P!>N\HH X/_ (63)_T*6O?^ _\
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M (63)_T*6O?^ _\ ]>N\HH X/_A9,G_0I:]_X#__ %Z/^%DR?]"EKW_@/_\
M7KO** .#_P"%DR?]"EKW_@/_ /7H_P"%DR?]"EKW_@/_ /7KO** .#_X63)_
MT*6O?^ __P!>C_A9,G_0I:]_X#__ %Z[RB@#@_\ A9,G_0I:]_X#_P#UZ/\
MA9,G_0I:]_X#_P#UZ[RB@#@_^%DR?]"EKW_@/_\ 7H_X63)_T*6O?^ __P!>
MN\HH X/_ (63)_T*6O?^ _\ ]>C_ (63)_T*6O?^ _\ ]>N\HH X(_$B0G(\
M*:\/^W>HY_BA':6[SW7AK6X((QNDED@ 51ZDUZ!BN3^)H_XMKX@/_3FW]* .
MHM;A+NSAN8\[)8UD7/H1D5+6?H/_ "+NF?\ 7I%_Z *T* &#@5POQ-U5['1%
MMXC\UP2C >F*[O'/UKROXA'[5XHL+$\@D$C\#5P6IA7=HV.H\#: FDZ-&[(!
M/*-S,>20>175C.?Y5#9)Y=E GI&H_2IQVJ9.[+IQ48BT444C0**6D)Q0 M%)
M2?C0 ZDI.?:EH **3FB@$+129-+B@ HHQ12 ***2F M%)1VH 6B@44 %%%%
M!1110 M%)10 M%%% !1124 +1244 %%%% !BBBBD M)113 2EI/ZTM 6"EI,
MT4 +124E(!:**2BX"T4"BF 4444 +1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N3^)O_)-/
M$'_7HW]*ZRN3^)O_ "33Q!_UYM_2@#<T'_D7=,_Z](O_ $ 5H5GZ#_R+NF?]
M>D7_ * *T* &FO+/&"[OB-IB]_E_K7JE>7^*UW?$W2AZE/ZUI3W.?$;'ID/$
M$8_V14F*9&,1*/:GU#-ULA:2EI#2&%(2>U%)^.:+ 1S2I#&SR-M11DL>U91\
M16GF!6W*A/$O\-.\1!FTJ7&< 9;'I7#WSL8!DC8J#  K6$$T<=:LXNR/3$<.
M@9<$$9XI_:LCPYY@T>+S2=QSUK7]/6LY*S.FF[QN,FF2&-GD8*BCDUD#Q':F
M;RV#JN?]8>E.\1Y_LN4#(7^(^U<3>2':O]T*-OO6D()HYZU9Q=D>FHV]00<Y
M%/S6=HX=-.A$A.['.:OY_*LY*S.B#O&['44@/O2]J18AJE?ZM8::%-[=1P!O
MN[SC-73TKA?&BQOK>EB0*4WJ"&&1UII$3E9'3VOB#2K^;R+74()9?[J-DUI
M_I7">+;>SMHK1K"...\\S]V(0%+''0XKI;K5X]*TN"6X!:9D&(P>6..E-Q(C
M4N:PP!0*Y>'Q;*MY%%J.DW%C'+]V65P03VZ5>UGQ FF2);PV[W=W)R((V ;'
MKS2L7[16-OJ:*QM)UF74'>&XL);*9!N,<C G'X5F_P#"912W$MM:V,UQ<QG
MB1ADT<H<YU=%8&C>)$U.[EM)[62SNXNL,C D^_%&I^)!:78M+2REOKKJT43
M%1Z\T6#G1OT5SVG>*%NM0^PWME+87) *I,P._P"F*34O%4&G:C]A-N\DS#Y
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M- "T4E% "T4E&: %HI*,T +1110 4444 %%%% !1110 4444 %%%% !1110
M444E "T444 %%%% !1124 +124M !1124 +1110 44E% "T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 A/-!KB?%OB34-*U>VMK:ZM[2-T9B9HM_F$= /3TIB>(M:U!-.MK/RK
M>[N+1KB3S4W $'&W H [BBL?P]JCZI8LTP_?PN8I2.!N'7BM.XNH;909I @/
M<T 3T5%#/'.@>)PZGH0:DS0 M%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7)_$W_
M ))IX@_Z\V_I765R?Q-_Y)IX@_Z\V_I0!N:#_P B[IG_ %Z1?^@"M"L_0?\
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MYT5E#]GM(X@^X*H /K4]-B01QJB_=48%/J&="V%HHHI#"BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#B/$NA7][JK2K9)>PR(54L^WR<C'XU2M?#&LZ*NF7-DHN9+>S:
MV>)GQR3G=GVKT(GG%' '% &-X<TJ32["19C^]GD,KCT)JSJVDVFK6QBNT9D
M.-K$5HTU_P#5M]#0!Q7@2%;2]U>TC+F&*11&&8G Q7;=\G\JX[P9_P AG7/^
MNJ_RKL>] "YHS110 9HHHH 6BBD% "T444 %%%% !1110 4444 %%%% !111
M0 4444 %%(:0GUH =12"B@!:*;GG%!8*,DX% #J*A^T1;@OFIN/09ZU+G!Q0
M M%-) !)X'J:19$D4,C*RGH0<YH ?13<TWS$#!2P#'H* )**;G\O>D+ #))%
M #Z*9N4MMR,^E!=5(!;!/3/>@!]%-XS2\=J %HI/>EH **** "BBB@ HHHH
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M%=S;OYEI#(3RR Y]\5Y[/R9C_M8KO+)O]$A0]/)7\.*4RJ6B.<FNC-/<,[<
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MVH%+10 G6@Y]*6B@!"*0 BG44  I:04M !1110 4444 %%%% !1110 4444
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M9)I!:19F^_\ (.:DL--M=/C*VR;5H M_2E%%+0 4444 %%%% !1110 4444
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MUEHVA?#*'4&T2TO+BXA4.9P0K< _,1VH ]<AU"SN QANX)0OWBD@8#ZXIO\
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MF\V:)?F<5T QGMSS3$4I&J]2 !GUIP]J$K'/)W=QU I*4=:9(M%%% !1110
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MAG_L'W7]* .[HHHH **** "BBB@ HHHH **** "C%%% !1110 4444 %%%%
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MLV%RA)QSWKF7=I(Y)[)=L3W<?EG';=S0![#FE'2DI10 M%%% !1110 4444
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MJ,HYN6WH#U0=,5NTV)" <TZBBD,**** "BBB@ HHHH *,444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<G\3?^2:>(/^O-OZ5UE<G\3?\ DFGB#_KS;^E &YH/_(NZ9_UZ
M1?\ H K0K/T'_D7=,_Z](O\ T 5H4 )7E7C7_DH>G?1?ZUZK7E7C7_DH>G?1
M?ZUI3W.?$?">H6__ ![Q_P"Z/Y5-4-O_ ,>\?^Z/Y5-4,VCL%(<]J6D-(H0T
M 44HH ,4F*=246 *3'.:444 %'X4446 *3%+1WH ,4444 %&**6@!,48I:*
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MA,L<T\<VT[=T:D!3V!KI++2K6QB9(5;YA@EFR?SIZV%O';-;A#L<?-DY/YT
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MHH **** "BBB@ KD_B;_ ,DT\0?]>;?TKK*Y/XF_\DT\0?\ 7FW]* -S0?\
MD7=,_P"O2+_T 5H5GZ#_ ,B[IG_7I%_Z *T* $KRKQK_ ,E#T[Z+_6O5:\J\
M:_\ )0].^B_UK2GN<^(^$]0M_P#CWC_W1_*IJAM_^/>/_='\JFJ'N;1V"D;[
MI-+37 *$'N*11RWA;Q3-K^I:C:S6T<0M#A65B2W)'-=1TZ5YGX F6WUCQ%-(
M>$.2?8$U/#XG\7>(C<7?AVVL5T^-L1FZ!W/],4 >CY[TF?2N6\.^*9=3TJ[:
MYMC_ &A9,8YXHAU<#G;6-J&K^/8K.?4;:UTR.T3YA%,&\S% 'H7-+7&3^.HH
MO!0UY8'8Y\LJ!P'SC\LU7T>[\>WQM[J4Z,;*3YB8RV[;0!VCWEM',L+SQK(Q
MPJLP!/T%3=#7C/C;_A)A\0],-N; '>OD;L^O&ZO6-*.I?V>IU7[/]JR=WD9V
M8_&@"\*,UP^J^*M7O?$$FC>%X;>2X@'[^6X!\M<\CI3-#\7:O'XD;0/$]M!'
M>.I>"6W!\MU'7K[T =WD49[9->;#QAXHU/6[[2](LK;S+>4KYTX/E[1].]:?
MA+Q=?W]S?Z=KD,45_9+YDGD@["I)QC/TH [;/:@=^>*\ZB\4>+/$<US/X;M[
M%;"(E5:[!W/],5T'A'Q%+K=O<6U]&L6I63^3<HOW2V,\>U '2@\XHR"U<OXU
M\37'A>TLYX+;[1YLVQHU&6(QV]ZYR\\5^+]&@AU75;.R_LEF!80@^:@/3.>.
M] 'I>?6LK7?$%CX<LUNK]I!$SA043<<UR?BKQY>Z1J6D6VFVJW2ZA$S# R0W
M !^G/-1:]?>(++PR\WB.STNZ?S1LCC!*XQU.>] 'H-K=1WEI%<PY,<JADR,<
M&I>]<9JGBX:)X:TPV]NK7]ZBI;6Z#C=C.,>E9%YXH\8^'&M[[7K2R?39"/,^
MR!MZ9Z9S]: /2CUXH'7WKS[Q7X\O=(U?2;33+1;E=0A9EXR0V0 ?ISS73Z!_
MPD)MW.O"S$F?E^S9Z?C0!M=\YI:R/$>LIX?T&[U.2-G6W3>0*Y;2-2\>ZJL5
MXG]BFRD.1C=NV_XXH [^C/XUQEUXKU&P\>VNB7<$0LKF%Y$E .<C  _6IM8\
M4W5MXKL]%LHHY-X#S;NH3.#B@#K>U,EGB@C,DTBH@ZLQP*\ZM?%7BOQ'?W8\
M/1Z:EM;N8F6ZW>9E3@GCM3O'G_"3_P#"#'S?L FR//VYQUXQ0!Z'#+'/$LL4
MBR(W1E.0:?GBO.O =YK^G^#[>[U;[#_9D-L7C\K._ SUS38?$7C;7;274M$M
M=/6P!_=K<!M[CU&* /1PP/KQ1]*X2?QU(? -YKMM"/MEJ3&\3CC>I ;\,YK#
MN_&_C.+P]%XBBT^S&G,RAH75O.QGGCI0!ZOVS^>*R=?\2:?X;M8[G4&D6.1M
MJF--QS7#7/C7Q4=+C\06MC:QZ*Y#%)5/G;/7TK0\7Z_;R^#]/U3[#!=1SX<1
MSKD#(H [N"9+BWCGC)V2*&7(YP1FI?>N.\0>*FT72-.CM( ]]>QJ+>(#Y0=H
M//M3-*U#QE!J4$>MVMG);3*2&M 24],YH [)W5$9G(51R6)X J**XAN8VEMY
M8Y5'&Y&!&:QO&/\ :/\ PC=Y_9OV?S/+.X39QMQS7#_"K_A)SIQ\P:>--^T-
MO SOSWQ0!VOA;Q'+KZW+2VZ1>3(R#8Q.<'%=%P/_ *U>->%K_P 2";4;?P_:
MP;HYI&DEN@=C?,>%QWKLO"?C*74].U$ZK$D-YIV1<"/A<X)X_"@#LR>U'0?6
MO-[?Q'XTU^WFU#0K:P2P!S$+D-O<?A5^3QS*W@'4M:AA7[=8!EDB8<;U(!_#
MF@#N,^G-.S7!^&]=\5Z\L.IFTM(-*=26B<$3$@=NW)HO-5\<77GW6EV=C!:1
M@D)>!A(0/I0!W= KCM+\83W_ (-O=2,2+>V2$3(?N[P.WM6);^*/&NL:<=3T
MG3[.*W08*72L'<CKMQV]* /32>.M)GFO-KOXA7Q\*V^M65LC[9A%<QN.5.[:
M<?K70^(O%?\ 9?AJ'4K8)))<.J1!NA+<#]: .I%+5+29[BYTJVFNU5+AT!D5
M>@-7: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2@]**#TH$SR
MF7_DKT'T7^1KU4=*\JE_Y*]!]%_D:]5'2KF84=V+2TE+4'0)WI:3O2T %%%%
M !7":S_R67PS_P!@^Z_I7=UPFL_\EE\,_P#8/NOZ4 =W1110 4444 -/7^M<
MUXMTO4[Q;&[TB.*:\L93+'%,^Q')&,$]JZ;VKB?B)J2V%KI\4NIMIMO<3%)9
MT?:RC&>#0!5;PA?W?AZ47=O -5N94>4B3( 5L\'Z5WD,?EQ(N>@P:\FM5\-^
M?$R_$V_D8L,1FZ'S'/3I7K40'EIAMRXX)[T 24444 %%%% !1110 4444 %)
M2TE !2TE% "T444 %%)10 M)110 4444 +1110 4444 )BC%+10 F**6B@!,
M48I:* $HI:* $Q0!2T4 %%%% "44M% "8YHQ2T4 )BC%+10 F*,4M% "48I:
M* $QBCFEHH 2C%+10 4444 %%%% "8HQ2T4 )BC%+10 F*,4M% "8&:,<TM%
M "8HQ2T4 )12T4 )BC%+10 F*6BB@ HHHH **** "BBB@ HHHH **** "DI:
M* .*^*8SX'N,EL>;'D+_ !?-TKG_  18VL>LQ2Q>&+>RD,9_?)(Y('X\5U?Q
M#2Q?PA<+J+SI!O3F#&_=GC&?>N-\!RK%XE2"YN-?BE>)C%%J! 1U]10!ZU2]
M?I2=!QT%5+Z\:R@\U;>:<G^",9- #[C4+.T(%S=PPDG $CA<_G1+?VENJM-=
M0QJW*EG R*Y;Q.=+O;&-9],6>^FXBB=,NO\ M?AUK*32476=-T?666X$6G2-
MA^<X/WOK0!Z)')',@>-U=#R&4Y!H<CRVQGI7-^"S)_9ES$V?+CN&2'V3M6CK
MM[=V-IYEI;-.P!RJC- '/^$D$FJZ^IZ/(H/MQ6A86HD2]TB[4")&Q;]\ICK6
M/\/)Y;J\UJ6>)HY&E7<K#IQ70:OFSU"VU!0S*Q$+ = ">M4B7H<5>Z(^GWKP
M>7@J=ZXZ$=BOJWM6 ]]H>CW?E:G%+A#NCN8XRSECU!';%>OZIIR:K9@(VV9?
MFAE7JI]17D?C5#:M#<P6(DN$;$T$J_+QT;'O3YK+0Z:;C/XSJ;7Q=JIME:PL
MWO+3(5;BX!1\'O@5OVVFW6JQ":ZU-F1CEH(R&4>V:Q] \3S_ -@6HFT&[)=<
M,(8_DI\FH2V;>?86%U;'.##(N$/O4;[DR5GH=58Z-I^G9%M;K&6ZGKFKPC13
M\JC\JYJR\;:;*A6\D%I*@Y68XR?:JVC_ !"TG6]7_LZV$GFDD G&.*+$\LGL
M=@.A[FG"HU8'^M2#I00TT%%'%% !2'UI::<=*+ 9.O7#I:"VB/[VX.U*O6=J
MEM9QPH-J@9/UK)LQ_:>M27A.;:#Y8O9QP:WZ8@&<TZDS12&+1249H 6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD_B;_R33Q!_UYM_2NLKD_B;
M_P DT\0?]>;?TH W-!_Y%W3/^O2+_P! %:%9^@_\B[IG_7I%_P"@"M"@!*\J
M\:_\E#T[Z+_6O5:\J\:_\E#T[Z+_ %K2GN<^(^$]0M_^/>/_ '1_*IJAM_\
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M(OA[_8EE<JVIK9NCVX!R#S_C7'Z'IW@[3]/%GXAUO5]-U"$['A%[(HX[@ 8
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M\W_[^&C_ (1O3?\ GF__ '\- &IYB?WU_.CS$_OK^=9?_"-Z;_SS?_OX:/\
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MN4\2:OINF:2T^F7&GK<^8BJ8F0M@G!Z5U5NYDMXRW+%<F@">BBB@!,"EHHH
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M HHHH ***2@!:*3-)F@!U%)GFEH **** "BBB@ HHHH **** "BBB@ HHHH
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M@WFC-HVA307%T\ZM';V_WL!LDX^E>P6X801[L[@!G- $]%%% !1110 4444
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MO\20=*4&F%USR:3S5'>ERLCE=R2BF>:GK2>:OK19ARLDHI P/2EI""EI*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ --SWS2FF\GC% '-^.5TX^&I/
M[3F>&W61&+1@%B0>!@^M<7X6%C>>/Y+^V?5PDD;;8;FW"11]. :O^-=+U/Q#
MK(T>"_M5BD(=8G!W*5YYJ;0HM8T7Q5::7JM]:2F6W>10@.2 <=Z /1.<"J=_
MJ"Z? 97AED4=HEW'\JN48H \TUF[N]6\1JZV4,UM!&S>3=DH<8R<"FV;66OZ
MCIL=W:Q1V;Z=(R0<[5&>HKMM6\.6FK2QS2/+%(G&Z(X)'H:BN?"NGW$-NBAX
M3 GEHT9P=O<?2@"MX):3^R[B(Y\F&=HX0>FP=,5H:[J5QIMH)+>V:X+9!"@G
M'Y5>M+2*SMD@A7"*,?6I7'[ML>AH X;X>7,MW>:S-+%Y3M*N01[5W?7KZUQO
M@P?\3G7.O^M3^5=G0 4M)2T )Q0<4M% #:SM4TZ.^BW@%;B($Q2 <J?:M+ H
M(IIB.#T7Q%KTVH3Z?<:?DQGB5\X./>N@%SX@;[EG9X]Y#6R(U#$A0">M. Q3
M;06,,)KLQ_>^3"/^F;YK(U_PSJVJ0HL>J2C# E21BNTII':A2"QBZ?X=M;2"
M%IT$]R@QYK]:V@!@# Q2XI0,"DV%A!Z&EHHI#"BBB@!*8T:N"K#[PP:D[4F*
M NT<[=>&HX7:;2I&L93RWD_QGWS7%W'Q U_3/$\&DW&EI+&6"M,FXDC_ !KU
M;;FJC:;9M.)VMXS*#D.5Y%)HUA-6U1BKXNA PVG:AG'.(#BG?\)?!_T#]1_[
M\&NB"C%+@4:D-J^QPGB+XBQ:-IZW*V%R,N%/G1%16GH/C.PUBP6XDD2 D='.
M*W+_ $JRU.(17EO'/&#G:ZY&:@3P]I,<81=/MPHZ#8.*1?-"Q*FKV#MA;R%B
M>F'&:LM<1)%YK.JI_>)XK.N/#NFR@;;=(F[,@P:QM7\&27>GS06VIW22,/EW
MR?**=R4HLZ>"]MKI2T$R2@'!*'.*FW#U-><>$_A_J>B6TT=[JTCL[;AY+D5T
MW_"-3?*/[2N\'K^\H0W%+9G19'2JLFI6D4OE/<1))G 5FP:QF\-38XU.[QV_
M>5Q>K?#W6W\0)JD&I>9;Q2"7RF)+, 0<#WXH8XP3W9ZP#Q0#FLW2M7@U2%FC
MRDB';)&WWD/H:T1]*#-JP[BBBBF(,4<444 '%&!12T )BEHI* %I.**6@!.*
M*6B@!**6B@!*6BB@ HHHH **** "BBB@ HHHH *Y/XF_\DT\0?\ 7FW]*ZRN
M3^)O_)-/$'_7FW]* -S0?^1=TS_KTB_] %:%9^@_\B[IG_7I%_Z *T* $KRK
MQK_R4/3OHO\ 6O5:\J\:_P#)0].^B_UK2GN<^(^$]0M_^/>/_='\JFJ&W_X]
MX_\ ='\JFJ'N;1V"BBBD4%%%% !2'K2TTT +36_K2.X1"S' '.:P4\8:4^J_
MV?YQ$G/S,,*?H>AIV)<DBAKOB'5-#U)))+4R:<3@L .*Z#3=5M=4M5N;:165
MNOL:9JUQ9QZ9))<A7BV_=Z[OI7GMOI&MZ*KZSIJ8B9BS6N[JG8_7FJL8RFTS
MU,<]/QIV:Y_PYXFMM<BVKF.X3B2-A@@^V:Z"I9O%W0M%)2TAA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% "4'I10>E F>4R_\ )7H/HO\ (UZJ.E>52_\ )7H/HO\ (UZJ
M.E7,PH[L6EI*6H.@3O2TG>EH **** "N$UG_ )++X9_[!]U_2N[KA-9_Y++X
M9_[!]U_2@#NZ*** "BBB@!C9&2!DCMZUPVH^*O$"O/"_@>>XM@Q7<\\>UQZX
M-=R>M<1XXU"PN18V,FI6RV<TQ2]19UW;,?7/6@#.L?$6H+>Q&W^'J0N3CS(I
M80RCN>.:]'C8NJLRE6QROI7E>J:3X3\-P0:CH-W#'?[T5"MUO)!(!XS7J<!+
M0(6.6(&: ):*** "BBB@ HHHH **** $[4'I10>E 'S%\2O^1^U/_?'\A7)U
MUGQ*_P"1^U/_ 'Q_(5R==<=C['!_P(^@"B@4=ZHZ.A[5\"_^/#5?^NR?RKU^
MO(/@7_QX:K_UV3^5>OURU-SY+'?QY'D7QS_Y!6E_]?#?^@UXE7MOQS_Y!6E_
M]?#?^@UXE6]/8]O*_P""%%+25;W/4'Q?ZV/_ 'A7UYI?_(+M?^N2_P A7R'%
M_K4_WA7UWI?_ ""[7_KDO\A6-4\#.-XEI_NFO"-?_P"0_??]=FKW=_NFO"-?
M_P"0_??]=FK3"_$?'9E\!G4445Z'4^?6P5VWPT_Y#5S_ -<1_.N)KMOAI_R&
MKG_KB/YUAB/@9V8'^,CU3M7GWQA_Y$6?_KM'_.O017GWQ@_Y$:?_ *[1_P Z
M\Z&Y]?AOXJ/G?M2445U(^SCL@HHHH"6Q]2^ ?^1&TC_KW6NAF.(7/M7/> ?^
M1&TC_KW6NAF_U#_2N1_$?%U/XK]3Y/U#5-2&IW8%_=@><_'G-Q\Q]ZJG5M2_
MZ"-W_P!_F_QINH_\A2\_Z[O_ .A&JU=,8JQ]92H4^1.Q;_M74O\ H(7?_?YO
M\:4:KJ0Y%_=G_MNW^-4C3@:=D:?5Z6NA[+\%+RZN&U,7%S--C;M\QRV/SKV/
MM7BWP-'S:I_P"O:/2N:IHSY3&14:K2%I:8S$<GB@2+CK469RI,?13-X]:-X]
M:=F.S'T4SS!ZTN:5A/0=13>].H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #3?I2FB@#B?%'
MA[5GU>#6]"G1+F,$21NF[?GCCTJKHOA_Q#=^*(==UZ>+=;PM#%$L>TX;GJ/>
MN_H'3I0 JG(Y&#2TE'XT !H[5ROB'Q3<Z5J,5M;6\,F49F,TFSIZ>M5D\7:A
M=6UD+33T>[N+4W#1.^T+@XQF@#LZ:_\ JV^AK-T+5CJ^GB=XQ'*K;)8U.0K#
MJ,U?FE2*,[W500>6.* .2\&?\AC7?^NJ_P J[*N,\%LK:MK;*P93*N"#GM79
MT +1110 4444 %%%% "4M%% !1110 E+110 4444 %)2T4 )12T4 %)Q2T4
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MX&<;Q+3_ '37A&O_ /(?OO\ KLU>[O\ =->$:_\ \A^^_P"NS5IA?B/CLS^
MSJ***]'J?/\ 0!7;?#3_ )#5S_UQ'\ZXD5VWPT_Y#5S_ -<1_.N?$? SLP/\
M9'J@KS[XP?\ (C3_ /7:/^=>@BO/OC!_R(T__7:/^=>=#<^OPW\5'SMVHH[4
M5U+8^SCL@HHHH"6Q]2^ ?^1&TC_KW6NAF_U#_2N>\ _\B-I'_7NM=#-_J'^E
M<C^(^+J?Q7ZGR'J/_(4O/^N[_P#H1JKWJUJ/_(4O/^N[_P#H1JK77'8^QI?
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M ))IX@_Z\V_I765R?Q-_Y)IX@_Z\V_I0!N:#_P B[IG_ %Z1?^@"M"L_0?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "4'I10>E F>4R_\
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M_P">B_G0!)13/-C_ +Z_G1YL?]]?SH ?13/-C_OK^='FQ_WU_.@!]%,\V/\
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M?*45X=KRA=>O@  /.;I7N[_=->$^(/\ D/7W_79JTPOQ'QN9_ 9M%%%>AU/
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M52B?,.O4OHS1_MW5/^?Z;_OJI;;7-3:ZA5KZ8@N 1GWK)J:T_P"/R#_KHO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@!*#THH/2@3/*9?^2O0?1?Y&O51TKRJ7_DK
MT'T7^1KU4=*N9A1W8M+24M0= G>EI.]+0 4444 %<)K/_)9?#/\ V#[K^E=W
M7":S_P EE\,_]@^Z_I0!W=%%% !1110 T@YZ]ZYKQA%:1P6FHW5W]G6QE,H.
MS<3QC@5TN>:Y/QM#.B:=JBP&:WL)FEG1 68KMQPHZG/:@#FI8;;65_M2SUWR
M]'G=!+"]N=S,#QR>1S7IT2JL:!>@&!S7C]OKIU^V.B:;I=\ES/,K[[FV:)%
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MWD'TKR>YU_Q!YFHPV=\\$=C&TH"XY"C.WZ&H+S6[W5W,RR&.>?1$E+*>0Q-
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2@]**#TH$SRF
M7_DKT'T7^1KU4=*\JE_Y*]!]%_D:]5'2KF84=V+2TE+4'0)WI:3O2T %%%%
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MI1117L=#Y1[A4UKS=PC_ *:+_.H:FM/^/R#_ *Z+_.E/8JE\2/?K:-4MU"J
M-O04V2WB"EA&H;UQ4L'^H7Z"B;_5FO'^T?84]D?(^M?\A[4/^OB3_P!"-4:O
MZU_R'M0_Z^)/_0C5"NJ.Q]IAOX2$I>])1WIG0]CUCX'*&U35-P'^J3^9KVYH
MDD&'0$#IFO$_@9_R%M4_ZY)_.O<*Y:NY\EF/^\,\R^,L:1>$$"( /M"]/QKP
M/MTKW[XT_P#(H)_U\+7@':MJ>QZV5?P@[4O:D[4O:M#UT)7U?X2C5?"VFE5
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M*QV\?EX3H5]/I73T4 <@GA IXJMKU2BZ?:0*L$0ZAQW_ "KKATI:* "BBB@
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M/8JG\2/H"#_4I]!2S?ZLT0?ZE/\ =%)-_JS7C]3["GLCY)UK_D/:A_U\2?\
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M'W:1@H% $^:,U3LM3L=0#&SO(+A5ZF*0-_*H6U[2H[G[-)J5JL^<>691G\J
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ML@7/YT 7LTM103Q7$2RPR))&W(=#D&I: "BBB@ HHHH **** "BBB@ HHHH
M*Y/XF_\ )-/$'_7FW]*ZRN3^)O\ R33Q!_UYM_2@#<T'_D7=,_Z](O\ T 5H
M5GZ#_P B[IG_ %Z1?^@"M"@!*\J\:_\ )0].^B_UKU6O*O&O_)0].^B_UK2G
MN<^(^$]0M_\ CWC_ -T?RJ:H;?\ X]X_]T?RJ:H>YM'8*0TM1SRI#"TKG:JC
M))[4BCQ?XJ-)XH\56/A2WD<* SS!3UXR*G^#%XVFW>J>&;ECYEM*!$K=@!D_
MSKA;?4O&NL>.-2UWPOIZW3H_EEGC#  $CN:ALKWQ3X;^)EKK'B6R-G-?-M("
MA5;)"YP* .R^+_\ R/>@$CD.N!^->S6T23Z7"CJ"K1 $'Z5XE\9+RWA\7Z#=
MRR 0)M<R=L9->D:#\0O"VK+!966K12W(0#8,YZ?2@#RNYOKCX2^/KLF,_P!D
MWH+# ZM@GC\36S\,])N?%GB6[\;:HC;68BVC8<;6'4?B*Q_$-O+\6?&L]I;Y
M2PT]6 ?_ &L>WN*V/@]XBETB^N_!NK.J3V[8@&,?*!S]>30!7^,7AS5'TZZU
M.\U)S;JQ\FW1OEQ[CUKTGX?D+X'L"3@",$G\!7#?&;Q=H<WAZ?1TU"-KY6(,
M(!R.*N>$O$NGZQX!;1]'O5GU6.W \E,@@X H YCX@7EU\0-;N=-LBRZ;IB,9
MG7HQQD9_*M'X2BZ'POU@66[[3C";.N=IQ7'V]A\3O#6EZA!%HP2UGW&622)6
M8CGOG/2I?AGK?BG2O"VJ26MNITU(V;?Y8)#[>.: ,&WTCP_?Z/JMYXBU.XBU
MV%FVPNX!=AVQ7M_P:M]6A\&(=3,H#2-Y0E^]MSQ^&*\?TU? >K^';Z_\0WS)
MKTK,X17*@L?;%>G_  .U6_O="N+:<L]K#(WD2-U(W8QGZ4 =EXTTK6=7TG[)
MI-XEJK<RR9(;;W _"N2^#UBNF3^)K)9'D6"_"!W.2WR#K7IL\BI!)O95^4_>
M.*\Z^&<T7]N>+<R("=2X&X<_(* (]02/Q=\2VT:])>PLH%G\@_=9LX.14>N:
M7:>#/&>C7>CVZV=M=.8[B.(;58 <9_&I(%BT;XQW$DY*)>VJI&['@MNSBI_&
ML@U?Q;H.FVC"0I*S3$<[1CB@#T&>Z2VL)+IP2L<1D8#T S7!K\6K"?3_ +=9
M:/J%W;JNZ9X5!$7LU=CK(V>'+X=,6KC_ ,<-<!X#@B7X43D1H-]N2Q"CGCOZ
MT :<OQ5T\V2WEAIM[?P! \CVX!$7J&]Q721^*M,?P]_;7GJ+0#DD]#Z?7/%<
MC\/[: > KY5AC ::0'Y1R.*Y" [O@K=JH8RB^DV)GKB7I0!V%S\7(;6V2YE\
M-:NMM(X1)2@VL2<#'/>NZTK43JFG179M9K;S%SY<PPP^M>6&XU_Q+HFGZ'/X
M??3TCDCD:[ED1DPIS@ '()KU(M'I6D[I'_=V\>=Q/84 <3XG9_$/CK3=#C4-
M!9N+BYQ_=8$<_C3K1HK7XF7S%@D4<*9)[ +2_#JSGNKC4]?O ?-N9GA3/7RP
MV5-<GXVT;5]:\::A'I=SY2QJCRH =S@#. 10!Z3I7C2QUB>\^S0R_9;7.Z[.
M/*8 9R#6#=?%BV@CN+B'0=4N;* G-U$H,9 [@^E1:/K6EZE\/=1MK> 6D]M;
MO'/;C 97VG .*Y7P_J7B"X\"KH*^&Y0ES%Y:7ID38JD=2N<F@#U;PSXB'B32
MUOTL+FT1S\JS@ D>M.\0^);+PY:":ZR\CG$<*???Z5)X=T]M+T*UM'<.R(,L
M.F<"N&\7RQVOQ+T">_8?8ML@^<97.!C]: -BQ^)%M+JD-CJ.DWVE>>/W<MVH
M56/0 >YJ[KWCK3O#VH+8W$4LD\B!XU3'SG^Z/>L+XIS6MSINFVL+1R7K7D3Q
MJ@RVT-R<^E17%L'^(6F+<Q*[1VJ$[US@YH V]%^(%KJNK_V9<Z;>:=<L 8UN
M@!YF?2K.N^-;71KY+"&SN-1O""3!:@%E^HKFO&2[/B/X6*+MW3L"P]-E)X;>
M.U^)VMIJ#JL\I4P%_0+S@T =9H?BVUUBVN)9K>;3WMSB2*Z #+QDFL2X^)L*
M-.]IH&IWMK$Q!N;= 4./>K_B:YLKW0=9AT]HWO$A<2>6O.<>M</X,M/&4_AJ
M)=.\2:)# !M:&:RRP/H>>30!ZQI6JVNL6,=W:.'C<<X/W3W!]Q577?$-MH<"
MM)&\]P_^KMXOOO\ 05E>!/#EYX:TJ6VO-0@O'DE>0M"I506.>!6=XY\0W5IK
M&GZ1IJ6T-_<@M'=W$0=(P",C'O0!<TSX@PWVKQZ?>Z/?Z9+(,HUVH4-["NQS
M[5X=XA/B*#QEH4.N:WIUZYG1E6TMS&0-W<YKV]3E: ,73O%%IJ.N7FDB*2*X
MM%#/O_B!]*BL?%]G?^)+G1(H95F@S^\;&UL#/%<OXH:/P[XYM-5/[N*\1DE;
ML-J\?K6.9/[&M--\8\^8P:.7GA@S8S^5 'H)\86 \0S:05<-!$999C]Q #R#
M6'-\38@TKVN@:I>6D;%3=0(#'Q[UST-K-J7ACQ5K$:%I+HN8&7J4(J+PE9^,
MKGPS"EAXET.&U(VF*6RR0<<@\\F@#TV+Q%ITFB?VL+A%M0N2Q/0^GU[5RX^)
M\;!)?^$?U3[$[!1>%!Y>,]<^E<UKOAC5-!^&%S:-?Q7DOGA_,A0A1E\GCTJU
M8Z5XSU3PW%;1>*-!%E-$5"_8<8!X]>M &YX^NH+W1](N+>1)(I+I2KJ>",5I
M7'C*RTRZT_2DBEN[R9%!B@P3&,<$^U<AXHT2^T?P)H^F?;X9;F.=4CG"';G'
M7%0^ YAX6U[^R/$"B34KO#P7[CY9-W(1<\C H ]>1MR*V",C.#VKSL3-J_Q>
M1' :&QMY(RO^UP17H@Y7(KS'PY$;;XNZVLC_ #3.SH#Z;10!8\83W&N^+[3P
MS%=2P6Q02W!C;&Y2<%:V+KX;^%Y=.>%-(MDDV8$RQC?D=\^M87B*0Z!\3++5
MYT*V5Q$MNTIZ*<YKO;K5[&VL'NY+J(1!-V[=VH \]\&S75[I^O>&]1E>X-DI
M5'D.200<5;^&NIBT\+WNGRC:=(/E-ZC S_6H?ABLFHZIKFN8 MKZ1?*/J%R#
M7.^);W_A%/%VK68RD>M([+[L1M&* (/"EQ=6/Q$?5YIP;?5+DV\88]LYKL/&
M@;6/&>A:4@S''*7F'L5XK/\ $.BIIOP\TF_$16;30+AB.NX+BI?A_=GQ-XHO
M?$ 8/;FVBCC..C+PU %OQ4?[&\=:#J,;(J&)XG!_B+8 KT7\:\U^*$BM?:/;
M ?O))D92.P#C->E+Q@9&: '4444 %%%% !1110 4444 %%%% "4'I10>E F>
M4R_\E>@^B_R->A:IX>TC6_+.IZ=;W9C^YYJ9Q7GLO_)7H/HO\C7JHZ5<S"CN
MSG/^%?\ A+_H7[#_ +]"C_A7WA'_ *%ZP_[]"NDI:@Z#FO\ A7WA'_H7K#_O
MT*/^%?>$?^A>L/\ OT*Z6B@#FO\ A7WA'_H7K#_OT*/^%?>$?^A>L/\ OT*Z
M6B@#FO\ A7_A+_H7K#_OT*YF;1=-T;XO^'(M-LH;9&L+DLL2X!Z5Z77!ZS_R
M67PU_P!>%U_2@#NQTI:** "BBB@!OX=36;KEQI%OI<HUJ6!+)AB3S_ND>]:+
M'%<5X_\ M;1Z7/9:6=4$-PQEA5UVD;>X;@T 5=.U/X7V-_'/I]UHT-UG"-&0
M&R?2N_0AD5EYST->8V^M.9XE/PR\LE@#)N@^7WKTV(YB4[=F1]WTH DHHHH
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MI3V*I_$CZ!@_U*?043?ZLTD/^H3Z"EF_U9KQ_M'V%/9'R/K7_(>U#_KXD_\
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MJ?,&XS73ZOXHUVQE5+/PA?7@9<EXY4 4^G- %CP?>Z/=Z6RZ18BQ1'*R6^T
MHW<$5TJ].F*X_P %:3J%I'=WVI1B":[E:3R N"@/.#CJ?>NO&<4 .HI** %K
MS:ST2Q\2^(-9N-7@2Z\M L22C(CQD9'H:](KSB[&O^&_$6H-IVB3ZC9WB*$:
M-E'EMW)SUZT :OP]S!IMQIX8M%:/LC)ZX.379US7@W2[O3M*,E^NV\G.^50,
M8-=)0 M%)2T %%%)GF@!:*;GFES0 M%)FC- "T4@Z4M !7)_$W_DFGB#_KS;
M^E=97)_$W_DFGB#_ *\V_I0!N:#_ ,B[IG_7I%_Z *T*S]!_Y%W3/^O2+_T
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M<TM(P^E 'S)\2>?'^I_[X_E7)=Z]=\9_#/7M;\57FH6GV;R)F!0-)@]*P?\
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MWBCTM/\ O[_]:E_X4]XH]+3_ +^__6K3G1W_ %^AW//C7UQH6!H=A_U[Q_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% "4'I10>E F>4R_\ )7H/HO\
M(UZJ.E>52_\ )7H/HO\ (UZJ.E7,PH[L6EI*6H.@3O2TG>EH **** "N$UG_
M )++X9_[!]U_2N[KA-9_Y++X9_[!]U_2@#NZ*** "BBB@!O.?6N4\81LVHZ#
M(8VDACNF,BJNX8V]ZZH]^_UKAM2\5:^NKW*:5I]K+IUJ@:9Y682=<':!UH Y
MS6!9PW5QHXTZ074TL;PLEN2N,Y.6Q@5ZS;J5MXU;J%%>>6?C;Q(\4>IW.FV:
M:.S^67#MYH.<=/K7HL;B5%< X(S0!)1110 4444 %%%% !1110 4444 %8'B
M7Q'I>@0*VI03RHQX$5L9OT K?IASNP* /-=!NO[=\93:UI%C)%8K J9EC,19
M@>1M(_6JNO\ BC3/$=G)I-KI5T-5:4*N;5D7AN3OQ7JH'O28]LF@"II4$MOI
MD$4QS(B@,:O4WMQ3J $/2D_&G'I3?\YH Q?$?B'3="M!+J4,\L3$#;%;F7GZ
M"N0T2[B\2>.%U72K*6WLX8?+=Y8C$2<YQM(_6O2 ,4$<#GD4 .'US2TU?H*=
M0 4444 -8X&:X'7_ !SX?CDNM/?3[R:]*F,'["Q4DC ^;%=\PYSZ4G.,T <S
MX!L;JP\+6D5VGEML&(\YV^U=1S110 M%%% #"/>N%\:S2:+K&EZV899[6.4"
M81(69% /( Y-=UQTQ2]\_G0!Y_H-Z?%/B]]6M8)HK*%5VO-&49SC!&#7H(ZT
MT9Q[TX 9^E "T444 -Z$UYWXIFBT+QM9ZSJ%G)/IH@D1VCA,K*Y(V_*!7HM(
M<^E 'F7A[4[2&;5/$3V5Q%IKNP6,6[;F'7.S%076M6'C#7=)BT'3KA&M9S))
M-+;-!L!&.XY^E>I].E+C\* &(I6)0WW@ #4@Z4F*4=* %JCJHN3IMQ]D/[_;
M\AS5ZFGT'% 'AAN] :S^SOI-\=?:<;G^S/MSNX.[&*Z2;4;GPEX@L]1UBWGD
MBGMV\^2",R,KD\#"^U>G>U+C\Z .)\%>=J6HWVM&!X8)G*Q*X*LRYR"0>E=Q
M2#TI: "BBB@"*XF6WA:5P2JC) &37EWB3Q9HWB"QFTC2M,NI+Z60*"]FT8!#
M<_/BO53TIH&.!P/:@"II$$EOI=O%*<NJ &KU(.*6@ HHHH :>M8'B3Q+I6@1
M(=3@N)4<_*(K8RX_ "M\]:3F@#SGPS.NO^-;C6M-LY;:P\E(RTD9B+D$Y&T_
MSKT;  &*,$]_PI<>G&* '4AZ4M(>GI0 W(Y'H*\I\7>-H9/$3:/>V^H16$+!
MFE@M7?>>O85ZN.E)CDT <<WCCP];Z%#=-;7S69P%C^PL3_WSBLC0;J/Q%XV_
MM;2;*6WL4A$;/)$8B2#TVD?K7I..,"D7B@!WI^M HHH 6FFG4E &9K&AV&NV
M9MM0C:2'T5BO\J72-$L=#M!:V$3)$O0,Y;^=:7>C'O0 @&!@4ZBB@ IM.I.]
M '/>,[.:[\.W!@3S)(E+JG]XCM7$/XA3Q5%H^B6-E=K/&P6Z,L#(L8VXR"1@
M\BO6.M)TH C@C\J*.//W5 _2IJ3O2T %%%% "-7&>/O$UEI&ERV%Q'=O-<0M
ML\BW:0>G)'2NS;V IN"?PH Y+X?:[:ZGX9M((8[E)+>,1N)H&CY'UKKLYZ4F
M#]?K2XZ<]* %'(I:!THH **** "BBB@ HHHH **** "D-+2&@!:*** *]W_Q
M[2?[IKY$O_\ D)77_79_YFOKN[_X]I/]TU\B7_\ R$KK_KL_\S6](]G*/C97
MHHHK8^A"O9/@7TU7ZI7C=>R? OIJOU2HJ;'GYG_N[/9JX3XE_P#()MO^NW]*
M[NN$^)?_ "";;_KM_2LJ/QH^+Q?\)GF [T4#O17K(^5>X=Z/6CO2TGU*A\1[
M]IO_ "#;7_KDO\A5ENAJMIO_ "#;7_KDO\A5EONFO&?Q'UL?X:/#?$__ ",V
MH?\ 78UDUK>)_P#D9M0_Z[&LFO7H_"CY?$_Q&%%%%:=3!'9?#?\ Y&"3_KD?
MYUZQ7D_PW_Y&"3_KD?YUZQ7EXG^(?2Y;_ .7\>?\BO<?5?YUX[WKV+QY_P B
MO<?5?YUX[WKHPGPL\[-/C"BBBNOH>636?_'[;_\ 71?YU] 0_P"J7Z5\_P!G
M_P ?MO\ ]=%_G7T!#_JE^E>?B]SW,K^%CF^Z:\ U'_D)W7_79_YFO?V^Z:\
MU'_D)W7_ %V?^9IX3=AFOPHK4445Z!X85WOPR_X^[[_<7^=<%7>_#+_C[OO]
MQ?YUS8GX3NP'\5'IM>:_&G_D48?^OA:]*[UYK\:?^11A_P"OA:\P^OP?\:/J
M> _XT4?XT5EU/LT%'>BCO1U(J? SZP\+?\BUIW_7NG\A6S6-X6_Y%K3O^O=/
MY"MFM3XFI\;"BBB@@**** "BBB@ HHHH *Y/XF_\DT\0?]>;?TKK*Y/XF_\
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MKZYN03;N/8U\EW]K<?VE=$6\O^N?^ ^IK>F>OE4HQF^9E&BIOLES_P ^\O\
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MZ77#?##P??>#- FT^^ECD=IV=2ASP:[F@ HHHH **** "BBB@ HHHH ****
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M_P"O2+_T 5H5GZ#_ ,B[IG_7I%_Z *T* $KRKQK_ ,E#T[Z+_6O5:\J\:_\
M)0].^B_UK2GN<^(^$]0M_P#CWC_W1_*IJAM_^/>/_='\JFJ'N;1V"BBBD4%)
MBBC/I0 8H/\ ^JC-'% '+:EX"T?5_$4.MW?GM<P_<4O\@_"NI P /2@]:,\4
M &*,49XI: $Q2TF:7- !129YHS0 N*3%&1BC- "T4A.*,T +129HS0 M%)FC
M- "T49YI,B@!:*** "BDS1F@!:*3-&: %HHI,T +129HSZ4 +129YHS0 M%)
MFEH **3-&: %HHI,T +129HS0 M%)FC- "T4@-'>@!:**3- "T4F:,T +111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 )0>E%!Z4"9Y3+_P E>@^B
M_P C7JHZ5Y5+_P E>@^B_P C7JHZ5<S"CNQ:6DI:@Z!.]+2=Z6@ HHHH *X3
M6?\ DLOAG_L'W7]*[NN$UG_DLOAG_L'W7]* .[HHHH **** $ZY[5R7C6XDV
MZ=IOGO!#?S-%-+&VUE7;G(/:NL/6L?Q%%I=SIQM=6;;#-\H8':1]#VH X@S'
M1_",D2ZE<.Z7"!'EE+,07]:]+MV+0QL>I49K@X/"/@OPNHUL23M'#SE[EIEY
M_P!GFNOT;6[#7;,7-A*7B/3*E2/PH TZ*** "BDS1F@!:*3-+0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !574/\ D'S_ .Y5JJNH?\@^?_<H
M ?;9%K&0#]T5+Z>E0V__ ![1?[H_E5#Q'J;:1H-U>JN7C0[?KCB@#4WC\?3-
M)N&<%@,^]>4>#?!__"2:)#XGU#4+EM3O,3QE)F5(SZ;0<'I5/6=*M]5^(_V#
M6+^<11V2,6CN#$"V<$\&@#V3(QUXHSM.>U>!6NHZC'\/M8@6YF>V@N"MO,6.
MX_O,8SUZ5T7Q+>Y/P]TY;>>5)9)85WHY!R6 H ];+#C)_&ER?I]:\0U+6;F/
MPM8Z1--*EU8:A%;NVXY<=2<UU>L>.]5\.60E.@K/9PPAVF-TH./]WK0!Z&6
M."1DTH/_ ->O,=8U+1[[4-/F>UNI9-73DQW+($V+G %7=/\ B':6^DWX:S>*
M2PE2#RGDRS%NG- 'H0- KSV\^)$T4EG:6>D"XOYX/.D@:<)Y8S@\GK6]X/\
M%L/BFRED$7D7$,C1R1;MVT@XZT =+1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% "51TW[]W_P!=35^J&G?>NO\ KJ:
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MF?I5OQ1KMMH.C2SS-\[@K&G=B>*X*RTV_P!(^&VJWMQ'MN;Y2[1D?=&TC^5
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MX2_E1]K/_/"7\J +-%5OMA_YX2?E2?;#_P \)/RH M455^V'_GA)^5'VP_\
M/"7\J +5(*K?;#_SPE_*E^UG_GC)^5 %BN$^)8_XE5M_UU_I79&[/_/"3\JX
MCXCS&32K;,;K^][CVK6C\:.7&?PV>:]Z*,<]117K)H^6<7<***.@)P>E3)JS
M+A%\ZL>_:;_R#+;_ *Y+_(5:;[IK.T^X*Z?;#RI#^Z7H/859-T2,>3(/J*\A
M_$?5P_AGBOB?_D9=0_Z[&LFM7Q*=WB74#@C]\>M95>M2^%'RV)_B,****T,3
MLOAO_P A^3_KD?YUZQ7DGP[D\O7I#L9OW)Z#WKU+[7G_ )82_E7E8GXSZ7+?
MX)@>._\ D5[CZK_.O'>AKUSQQ/O\,7(\IQRO4>]>1]_\:Z<)L>=F?Q!11177
MT/+)K/\ X_+?_KHO\Z^@(?\ 5+]*^?K0XO(#@G]XO3ZU[S'<D1J/)DZ>E>?B
M]SW,K^%EIONFO -1_P"0G=?]=G_F:]V-T2,>3(/PKPC4#G4KHX(_?/U^IIX3
M=AFGPHKT445WL\,*[WX9?\?=]_N+_.N"KNOAM)LNK[Y&/R+T'O6&)^$[L!_%
M1ZAWKS;XT_\ (HQ?]?"UZ!]K/_/&3\J\Y^,D_F>$8OW;K_I"]17EGU^"_C1]
M3P>DI>E)6/4^S0444'UZ_2GU,ZOP,^K_  O_ ,BUI_\ U[I_(5LUS_AFXV^'
M-.'E2'_1TYQ["M?[6?\ GA+^5;,^+J?$RS2U%%)O&=I7ZU+2,PHHHH ****
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MO51TJYF%'=BTM)2U!T"=Z6D[TM !1110 5PFL_\ )9?#/_8/NOZ5W=<)K/\
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MI,TM !1110 E(:=10 F/_P!5+110 4444 %%%% !1110 AH/K2T4 ':BBB@
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MLID58K279&PZD8!YK.L?&%Q-XHDL9X42S+>7%)CEGH&=C@T4<X.<>U'';.*
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MW_P(-;-+0!B_\(U:?\][W_P(-'_"-6G_ #WO?_ @UM44 8O_  C5I_SWO?\
MP(-'_"-6G_/>]_\  @UM44 8O_"-6G_/>]_\"#1_PC5I_P ][W_P(-;5% &+
M_P (U:?\][W_ ,"#1_PC5I_SWO?_  (-;5% &+_PC5I_SWO?_ @T?\(U:?\
M/>]_\"#6U10!B_\ "-6G_/>]_P# @T?\(U:?\][W_P "#6U10!B_\(U:?\][
MW_P(-'_"-6G_ #WO?_ @UM44 8O_  C5I_SWO?\ P(-'_"-6G_/>]_\  @UM
M44 8O_"-6G_/>]_\"#1_PC5I_P ][W_P(-;5% &+_P (U:?\][W_ ,"#1_PC
M5I_SWO?_  (-;5% &+_PC5I_SWO?_ @T?\(U:?\ />]_\"#6U10!B_\ "-6G
M_/>]_P# @T?\(U:?\][W_P "#6U10!B_\(U:?\][W_P(-'_"-6G_ #WO?_ @
MUM44 8O_  C5I_SWO?\ P(-'_"-6G_/>]_\  @UM44 8O_"-6G_/>]_\"#1_
MPC5I_P ][W_P(-;5% &+_P (U:?\][W_ ,"#1_PC5I_SWO?_  (-;5% &+_P
MC5I_SWO?_ @T?\(U:?\ />]_\"#6U10!B_\ "-6G_/>]_P# @T?\(U:?\][W
M_P "#6U10!B_\(U:?\][W_P(-'_"-6G_ #WO?_ @UM44 8O_  C5I_SWO?\
MP(-'_"-6G_/>]_\  @UM44 8O_"-6G_/>]_\"#1_PC5I_P ][W_P(-;5% &+
M_P (U:?\][W_ ,"#1_PC5I_SWO?_  (-;5% &+_PC5I_SWO?_ @T?\(U:?\
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MQKOPK21X&90;EH% ZT?C177S1N>5RR[$UG_Q^V__ %T7^=?0$/\ JE^E?/\
M9_\ ']  ,_O%_G7OT'^K ]JX,4TV>YEB:6I(_P!TUX!J/_(3NO\ KL_\S7O[
M?=-> :C_ ,A.Z_Z[/_,T\)NQYKLBM1117H'@A7>_#+_C[OO]Q?YUP5=[\,O^
M/N^_W%_G7-B?A._ ?Q4>F]Z\U^-/_(HP_P#7PM>E=Z\U^-/_ "*,/_7PM>8?
M7X/^-'U/ ?\ &BC_ !HK'J?9H****?4BI\#/K#PM_P BUIW_ %[I_(5LUC>%
MO^1:T[_KW3^0K9K5GQ-3XV%%%%! 4444 %%%% !1110 5R?Q-_Y)IX@_Z\V_
MI765R?Q-_P"2:>(/^O-OZ4 ;F@_\B[IG_7I%_P"@"M"L_0?^1=TS_KTB_P#0
M!6A0 E>5>-?^2AZ=]%_K7JM>5>-?^2AZ=]%_K6E/<Y\1\)ZA;_\ 'O'_ +H_
ME4U0V_\ Q[Q_[H_E4U0]S:.PE%':D;I2*L+129XK)UCQ!8Z+!ONIE#G[J9Y;
MZ4TA2DD:Q(%1B:,RF(.ID49*YY KBXO$>O:N=^F:?Y,)^Z]PO!_*J%J_B1?&
M=X&DM#<"UC9U .TKDXQ[TU$R=1GHU.'2L73M4NI;@6MW921R?\],84_2MKM2
M:-8RN@I:2BD,6BDS10 M%)2T %%%)F@!:**2@!:*04M !1129H 6BBDH 6BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*#THH
M/2@3/*9?^2O0?1?Y&O51TKRJ7_DKT'T7^1KU4=*N9A1W8M+24M0= G>EI.]+
M0 4444 %<)K/_)9?#/\ V#[K^E=W7":S_P EE\,_]@^Z_I0!W=%%% !1110
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M/RH M455S=>B?E1FZ]$_*@"U157-UZ)^5&;KT3\J +5%5<W7HGY49NO1/RH
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M^E=97)_$W_DFGB#_ *\V_I0!N:#_ ,B[IG_7I%_Z *T*S]!_Y%W3/^O2+_T
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MCQ&VDV=W)9PPCYYHC\V<9'6LG4;34K#Q#8PW5VUW$7&V20_/U]!5Z2XA\/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<* N29RO(XH],_P\U'Y\> -PH\^/GYA0%R7J<]S29_/L:C\^/CYA1Y\?]X4
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M[T#% $/V2WS_ *I*/LEO_P \DJ;BC\10!#]DM_\ GDE'V2W_ .>25-^M'X4
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M!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %)2TE "UYI\:O^11B_Z^%_K7I=>:?&K_ )%&'_KX7^M!
MTX/^/'U/ 1_6BC_&BL>I]F@H[T44^IG4^!GUAX7_ .1:T[_KW3^0K9K&\+?\
MBUIW_7NG\A6S6I\54^-A11100%%%% !1110 4444 %<G\3?^2:>(/^O-OZ5U
ME<G\3?\ DFGB#_KS;^E &YH/_(NZ9_UZ1?\ H K0K/T'_D7=,_Z](O\ T 5H
M4 )7E7C7_DH>G?1?ZUZK7E7C7_DH>G?1?ZUI3W.?$?">H6__ ![Q_P"Z/Y5-
M4-O_ ,>\?^Z/Y5-4/<VCL%(312-2W*#-&>*\_P#$OQ'_ +%U,V=M:K.4QO+D
MC'TKK-!U>+6]*BO(^-XR5]#3Y;(SC5C)V1IBG#I3,XY-<;/\4/#L!DVB]G:*
M5HI$@MF=E*]3@=O>D:':9I>U<5_PM'PX^F)?0M>3*Q(\N*W+2+CKE1R*W]#\
M1:;X@TP:A8R-Y.,D2C8R_P"\#TH ULTG>N+U'XGZ!I=S)#)%J4@C.&E@LVD3
M_OH<5LW7BC3+301K3M*]GM#9B0LPSCJ!WYH W,TQYHXV"O(@9N@+ $UBWGBO
M2;+1XM4DG+6LI54V#<Q)..E<YXJ32[SQ#H=Y=7]U;28'DQK%D/\ -_%Z4 =_
MNI>U<WK'CC1M#U)M/O'F%P(O-")&6+#T'J?:LZR^*7AV]-RJF\BEMU#-%/;L
MCL#TVJ>6_"@#M<T9KF?#_CG1_$MS+;61N8YH^L=U"8F/T!ZUHVFNV5_J=UI\
M#.9[5]D@*X /M0!J_C1GTK&@\2Z=<>()M$C>3[;%&)7!3Y0I..M84WQ2\.1Q
MR.OVV;RW:-U@MF=E*G!R!T% ';9H)KBF^*/AP:9#?QM>31R@G9#;,[IC^\HY
M'XUT.AZ]8>(M/2_T]V:%AT==K+[$=C0!IYQ[YZ4H/-5;^]CTZPENIED*1+N(
MB0LWX 5Y7X1^*2W6NWUM?_VG-&7VP!;1B%Y[X'% 'KV:,\<US6O>.-(\/21Q
M7?VF69QGR[6$RL/J!R*E\.^,=)\3"06+S))&<-%<QF-_^^3S0!<L==T_4K^X
MLK6??<0#,BXZ<XK3KS7P+_R/&OY 'R\'/^V:W-7^(^AZ-?O9RB^N9$'SFTMF
MF4?BM '7@_E1FL6P\3:;J>A/J]O(YMHT+NK)AT YY7J#QTK'M_B5H-Y<VL-J
M+Z<W.-CQ6K,JY[,1P/QH [+-&:Y/6/B#HNBW'D3)?3O@$FTMFE ^I7H:E3QM
MI=YX8EUFU^TM$%(V"$^8I[93J* .GS1S7D_@#XF+J<]S::D=2GF>8"%OLC;4
M&.A(Z5U^N>/=%T"\^R7 N[B;&2MG 9MOUV]* .I[]::S *6/05C:#XGT[Q)9
M&YL6E55)#1S)LD&/53R!6)J7Q-T"RO[C3BFH32Q_*[V]HTD8)_VAQ0!T>FZ]
MI^KSW<%C/YLEI)Y4PQC:V,XK1[UYE\*KB.[U3Q7<0MNC?4 5/ML%==XB\8Z5
MX6$/V\SN\K86.WB,C_D.: +UUKVGV6J6NFSS[;FZ)$28^\0,UI GTKQV_P#$
MFG^)/B-X9ELQ<+B5\I<1&-Q\O<'FN_U_QKI/AN6*&\^TS3.,^7:PF5A]0.10
M!TF:,USOAWQEI'B82BR>>.2)L-%<Q&)_^^3SBJ&J_$C0M)U![*2/4+B1!\QM
M+1I5'ME>] '8YH![5E6&OV5_H_\ :@\V&V&?^/B,QL,>QKFO^%K^'A<K#Y.I
M[6<(LOV)_+R3C[W3% '=9I:B@F2>)98F5XW&593D&I: "BBB@ HHHH ****
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M KE/A_+JDN@R#4+6&WQ*^/*DW;CGFL5O#5AK>L>(;B_4SF  P@L1L.T],>]
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M^'M2*&\TFUG**%7>N< < 5LTN: .5M_!UI;ZW#/%;0065LC)%#$.H8<YJR/
MOA9;GSQH=H)0VX/LYSZUT';I2_4@T 8'_"$>&?MGVO\ L6T^T;MWF;.<^M:D
M&F65M=O=06T<<\BA&D4<D#H*MT4 4KVPCE22:**/[4T;(LC=1D8J'0=,?2])
M@MYB&N O[UQ_$U:?&?\ 9HSQ[T %%%% !1110 4444 6[/[K?6K55;3[K?6K
M/:D9,6BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !24M)0 5YK\:?\ D48O^OA?ZUZ57FGQJQ_P
MB,7_ %\+_6@Z<'_'CZG@7>B@9S161]DF@HHHH6YG4:Y&?6'A;_D6]/\ ^O=/
MY"MFL7PM_P BWIW_ %[I_(5M5LSXNI\3"BBBD0%%%% !1110 4444 %<G\3?
M^2:>(/\ KS;^E=97)_$W_DFGB#_KS;^E &YH/_(NZ9_UZ1?^@"M"L_0?^1=T
MS_KTB_\ 0!6A0 E>5>-?^2AZ=]%_K7JM>5>-?^2AZ=]%_K6E/<Y\1\)ZA;_\
M>\?^Z/Y5-4-O_P >\?\ NC^535#W-H[!1112*"DHI: $Q12T4 )28IU% #<&
MEQ2T4 )B@"EHH ;BC%.HH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!I%+CBEH
MH 3%&*6B@!,48I:* $YHYI:* $HYI:* $ -&*6B@!,48I:* $Q1@TM% "8-&
M*6B@!,4F#3J* &X.:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 E!Z44'I0)GE,O_ "5Z#Z+_ "->JCI7E4O_
M "5Z#Z+_ "->JCI5S,*.[%I:2EJ#H$[TM)WI: "BBB@ KA-9_P"2R^&?^P?=
M?TKNZX36?^2R^&?^P?=?TH [NBBB@ HHHH **** "BBB@ HHI#TH 6BFT4 +
MTI:;GG%** %J*X$A3]TV&J6B@#/\N_S_ *]?IMI?*O\ _GL/^^:O>Y%% %'R
M[_\ Y[#_ +YH\N__ .>P_P"^:OT4 4/+O_\ GL/^^:/+O_\ GL/^^:OT4 4/
M*O\ _GL/^^:/+O\ _GL/^^:O\44 4/+O_P#GL/\ OFCR[_\ Y[#_ +YJ_10!
M0\N__P">P_[YH\N__P">P_[YJ_10!0\N_P#^>P_[YH\N_P#^>P_[YJ_10!0\
MN^_Y[#_OFH+R.]%G,6F!&W^[6KS5;4?^0?.?]DT 94*W1B7$@Z>E2;+O_GH/
MRJ:#_4)_NBI*H@J[+O\ YZ#\J-EW_P ]!^56J*!%79=_\]!^5&R[_P">@_*K
M5% %79=_\]!^5&R[_P">@_*K5% %79=_\]!^5&R[_P">@_*K5% %79=_\]!^
M5&R[_P">@_*K5% %79=_\]!^5&R[_P">@_*K5% %79=_\]!^5&R[_P">@_*K
M5% %79=_\]!^5&R[_P">@_*K5% %79=_\]!^5&R[_P">@_*K5% %79=_\]!^
M5&R[_P">@_*K5% %79=_\]!^5&R[_P">@_*K5% %79=_\]!^5&R[_P">@_*K
M5% %79=_\]!^5&R[_P">@_*K5% %79=_\]!^5&R[_P">@_*K5% %79=_\]!^
M5&R[_P">@_*K5% %79=_\]!^5&R[_P">@_*K5% %79=_\]!^5&R[_P">@_*K
M5% %39=XSY@Q]*JVPN"TV)!]\]JU?ITJE:?>GQ_ST-!I 39=?\]!^5&RZ_YZ
M#\JM44C4J[+K_GH/RHV77_/0?E5JB@"KLNO^>@_*C9=?\]!^56J*!E79=?\
M/0?E1LNO^>@_*K5% %79=?\ /0?E1LNO^>@_*K5% BKLNO\ GH/RHV77_/0?
ME5JB@"KLNO\ GH/RHV77_/0?E5JB@+%79=?\]!^5&R[_ .>@_*K5% 6*NRZ_
MYZ#\J-EU_P ]!^56J* *NRZ_YZ#\J-EU_P ]!^56J* *NRZ_YZ#\J-EU_P ]
M!^56J* *NRZ_YZ#\J-EU_P ]!^56J* *NRZ_YZ#\J-EU_P ]!^56J* *NR[_
M .>@_*C9=?\ /0?E5JB@"KLNO^>@_*C9=?\ /0?E5JB@"KLNO^>@_*C9=?\
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MEKDOB#X@O?#?AZ2^T_;YX(4%UW 9('2@#J\C&<U#=WEO8V[W%U,L,*#+.YP
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M(K$?%=U<-9'1KAX @TU\9 S]_P"7CFNRL;?4?LLD>J74$KLS8,*%/ESP/RH
MC@\4:'=7YLH-4MI+D9_=*_S5%=>,/#ME>-:7.LVD4Z':8VDP0?>N:UO1=-DU
M&ST[2K8+=+()'GCP& !!()ZG-8Y%UH.OZU=WO@V34+>6Y,JW9$954QUYYH ]
M32XAEMUGCD5HF&X.#P16./&7AYYV@AU6VEN%S^Z1\MQUK&\5:Q%+\.KFZL$<
M"2#Y8XCM93QP#VK%T/5;6P%I!=^"I].65.+VX,;9)'7(YYH ]$TO4X-6L8KN
M %4D&0#U%7/45RG@R;S'U2V4;8K>950>Q&:ZOWH$%%%% !VJC:??G_ZZ&KW:
MJ-IG?/C_ )Z&@T@6O?\ A]:RK[Q)HNF7*VU[J<$,Q. DCX-:O&".U<EXGT_1
MX()IKBV2>]N"%4, 6!Z CTI&IU:.LBAE8%",Y]:K6VJ6-Y<206UU')+$=KJI
MR5/O7':KJG_")^#;&RO;@QSNHB>1LDJ"3S6;X'U;0AXCDM['4$FD>(!FP<R-
MGKR* /3@>,_S[U4CU2REOGLEN8C=)]Z+/S"L[Q5KD>@Z+-=R,%;&%..GO7 >
M&-:T&/Q7;"#5$N;B56+R8;DGH.10.YZWU)(S^-'..._K7&Z[J?B.;Q+%I&B3
MVUONA:1IIX=ZC!Z8S7/IKOCN?3[ZY6\L%6P=DD)M?];M_N\\4!<]2QS@')H'
M)]J\YMO$'BGQ+<O'HEU9V4=O$K2FX@W[VQSC!XYIU]XQU:#PR)8A&=22=(';
M9\I+-C.*!7/1._N:AN;J"S@>>XE6*)!EF<X KS75M2\:6,,]G>ZC8N9;9I$>
M*W*E.V.O6B\&O)\,KN;5KZWO,VV46&(JV..I/4T!<].1UD160[E894^M.QSW
MX_*O-K'4_%^CIIXU">TNK6YB_=Q0P;73"\9)//:IO"^NZ[J6N?9[WQ!IDFT$
MO9):LLB_\"Z4 =K<ZI!:W<5NV6DE/"KV'K51_%F@1WOV1]6M1<$[1$7^;-8E
MY;R7WCUPLFW%BRH/3GK7(7T=[I6C:A;3>#+J:7S&8:CN3@$\$$\T >I:EKVD
MZ0D;ZA?PVRR<H9&QFJR^+O#[63W@U:T-NC!3('^4$]!7$:O::E=1>']0&AS:
MJD"OYUNNW/(&/O<5'=WXU&UD6S\*M%<6SA)M.VID]]WIP* /21JEBUBM\+J/
M[*PR)<_*1ZU:CD65%>-E*,-P8="*\C.MW MX$_L>XFAAD!:QC905;T/;'M7H
MD6K+>>&I+VVA,>U-HB[H1U'X4 .N?%>@V5Y]DNM5MHKC('E,^&R>E:!O[07B
M69G07$B%TC)Y*CJ17(^$M TN^T 7%W#%<W$KONG=06'/8GGBH9K6.S^(VAVT
M3.R1Z=*%9VW'&X=3WH [F6:.WC:69E2-!DL>@%165_::C;^?:3I-#N*[D.1D
M=:J:WI=MJMEY=RTRHAW#RWV[C[^H]JP?AXHB\,W 495+J8 #V:@#=U'Q)HNE
M2K#?ZE;6\C=%=\$UH07$-U!'/!(LD+C*,AX(KB=%TNQU5M5NM0MTGF;/^M ;
M9@'IGI5_P,ICTVZME<O##($C]EQ0!K2>)M%CU%=/?4[9;MC@1;_F)J]=WMM8
MVINKJ9(8%ZR,<"N,\4Z1I?E?8K:V#ZC=2$K*N-Z$]\]16!XB\0Z5)=KI>I:B
M+>&RA3]VX8^:V,$<?3O0!ZK;W$-U$LT$BR1,,JZG@U#>ZA9Z=$LEW<)"C,%&
M\XYK"\$ZI8WGA:%K6=9(X@<[1TYKAO$OB?1M1U.\-]J21&T8Q10%6PW?=TQ0
M!Z;%K=M/J3V,89I%B$N[L0:ETK5(=7M#<0AE =HRK=05.*XNVU*VEU/P_<6D
M@?S]D+,HP" ,\UK>%Y@FNZK9(I6./#CZDG- '68HICS1Q_>;%1_:X/\ GH*!
MD]%0_:X/^>@H^UP?\]!0!HVGW6^M6JSK2\@VM^\'6K7VRW_YZ"D9/<FI:K_;
M+?\ YZ"E^V6__/04")Z*@^V6_P#ST%'VRW_YZ"@">BH/MEO_ ,]!1]LM_P#G
MH* )Z*@^V6__ #T%'VRW_P">@H GHJ#[9;_\]!1]LM_^>@H GHJ#[9;_ //0
M4?;+?_GH* )Z*@^V6_\ ST%'VRW_ .>@H GHJ#[9;_\ /04?;+?_ )Z"@">B
MH/MEO_ST%'VRW_YZ"@">BH/MEO\ \]!1]LM_^>@H GHJ#[9;_P#/04?;+?\
MYZ"@">BH/MEO_P ]!1]LM_\ GH* )Z*@^V6__/04?;+?_GH* )Z*@^V6_P#S
MT%'VRW_YZ"@">BH/MEO_ ,]!1]LM_P#GH* )Z2H?MEO_ ,]!1]LM_P#GH* )
MJ*A^V6__ #T%'VRW_P">@H FHQ4'VRW_ .>@H^VV_P#ST% $]%0_;+?_ )Z"
MC[9;_P#/04 34M5_MD'_ #T%'VRW_P">@H L45''(DGW6S4E !1110 4444
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MD[<9Z]:ZNQ\/Z5IIE^QV44(F4+)MS\P' J>STNQT^V:WM+=(HCU5>E 'F'A
M;O#OB]54\7<@ 'T%;OPQO+<^$'@$\?G"XERA8;NOI77V.BZ=IBSBSM(X?/<R
M2[?XV/4FL^R\%>'--U!M0L])@BNV8L95SDD]>] ''^ 89KBY\0):S^3(T@VR
M;<[3SVKH=-T+Q5;71DO_ !.+R#:1Y7V8+S]:Z"PT;3],>9[*U2%ICF0K_$?>
MKW?K0!YEX N[;3=<UVTU"1(;MKIY 92%W(3Q@FMS7O%MG:>&KZ_TVW6Y,7&T
M)P3G'7O6IK/@SP[K]T+G5-+AN90-H9\YQ^!JY;:%IEII9TV"SC2S.?W0Z<T
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M[2]+M-(LUM;*(1PKT%7,<TM !1110 5SWB_PT/%.D-8FX\C+ AMN>A!KH:*
M.3NO!@N-?TO5#=D?886BV;?O9QS^E4+CX=B>376-_M.JNS?<_P!7D8KNJ* ,
M;2/#\6G>&XM'E?SXTC$;,1C=@5QB_##4H[6338_$)72))3(UKY(_O9QNKTS%
M&* .2F\$PMXBTW4H;CRTL[=X1%MSNW8YS50?#JW>WUN">Y\P:E*TH^7'EDC%
M=QBC'- 'GEG\.]2^U:<-5UW[;9:>^Z"W\D+CC'7OQ5W5_A_'JFO)J$=WY,)
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MX6*7E/\ W31Y;_W35VBBX6*7E/\ W31Y;_W3Q5VBBX6*7EOUVFCRG_NFKM%
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M (I_Z%S_ ,=>C_A/_%/_ $+G_CKT<H>V1ZCFC->7?\)_XI_Z%S_QUZ/^$_\
M%/\ T+G_ (Z]'*'MD>HYHS7EW_"?^*?^A<_\=>C_ (3_ ,4_]"Y_XZ]'*'MD
M>HYHS7EW_"?^*?\ H7/_ !UZ/^$_\4_]"Y_XZ]'*'MD>HYHS7EW_  G_ (I_
MZ%S_ ,=>C_A/_%/_ $+G_CKT<H>V1ZCFC->7?\)_XI_Z%S_QUZ/^$_\ %/\
MT+G_ (Z]'*'MD>HYHS7EW_"?^*?^A<_\=>C_ (3_ ,4_]"Y_XZ]'*'MD>HYH
MS7EW_"?^*?\ H7/_ !UZ/^$_\4_]"Y_XZ]'*'MD>HYHS7EW_  G_ (I_Z%S_
M ,=>C_A/_%/_ $+G_CKT<H>V1ZCFC->7?\)_XI_Z%S_QUZ/^$_\ %/\ T+G_
M (Z]'*'MD>HYHS7EW_"?^*?^A<_\=>C_ (3_ ,4_]"Y_XZ]'*'MD>HYHS7EW
M_"?^*?\ H7/_ !UZ/^$_\4_]"Y_XZ]'*'MD>HYHS7EW_  G_ (I_Z%S_ ,=>
MC_A/_%/_ $+G_CKT<H>V1ZCFBO+O^$^\4_\ 0N?^.O2CQ]XISSX<./\ =>CE
M#VJ/4*:>O6O.1X]US:,Z#+G_ *YM0?'NMJ,MH4H^J-3Y0]LCT;..]<GXW\20
M:3I$T2R W$JE54=0:YBY\:^)K[=#::/)%DX\S:PIVD^!=2U6^34->FWY.=A.
M<CT--)(SE4E-61?^&6CR6]I/J=PI$EP2,'ZYKT.H(($MX4BB&U$& !5BID[L
MVI0Y8V$IU)2U)H%%%% !1110 AK@]9/_ !>7PU_UX7/]*[P]*\[\37MIIWQ;
M\-W-[<1V\ L;D&21MH!.,<T >BBBL(>,?#??6[#_ +_K3O\ A,?#?_0<L/\
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M]:/^$Q\-_P#0<L/^_P"M &W16)_PF/AO_H.6'_?]:/\ A,?#?_0<L/\ O^M
M&W16)_PF/AO_ *#EA_W_ %H_X3'PW_T'+#_O^M &W16)_P )CX;_ .@Y8?\
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M]:/^$Q\-_P#0<L/^_P"M &Y16'_PF/AO_H.6'_?]:/\ A,?#?_0<L/\ O^M
M&Y16'_PF/AO_ *#EA_W_ %H_X3'PW_T'+#_O^M &Y16'_P )CX;_ .@Y8?\
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M]:/^$Q\-_P#0<L/^_P"M &Y16'_PF/AO_H.6'_?]:/\ A,?#?_0<L/\ O^M
M&Y16'_PF/AO_ *#EA_W_ %H_X3'PW_T'+#_O^M &Y16'_P )CX;_ .@Y8?\
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M]:/^$Q\-_P#0<L/^_P"M &Y16'_PF/AO_H.6'_?]:/\ A,?#?_0<L/\ O^M
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M16)_PF/AO_H.6'_?]:/^$Q\-_P#0<L/^_P"M &W16)_PF/AO_H.6'_?]:/\
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MSX\#>%L?\@&P_P"_(I?^$&\+?] &P_[\BN@Q10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\
M"#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?\(-X6_Z -A_WY%=!10!S
M_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '/_\ "#>%O^@#8?\ ?D4?
M\(-X6_Z -A_WY%=!10!S_P#P@WA;_H V'_?D4?\ "#>%O^@#8?\ ?D5T%% '
M/?\ "#>%L_\ ( L/^_(H_P"$'\+?] &P_P"_(KH,<YHQ0 D:)%&L<:A40!54
)= !3J** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>gvvh0m1pmdf2000003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +P!YX# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MUC1X/%>F:QX9TB[TJ6&8220SG,;D,#\H!R 02",]QTYSWOQU_P"0[X7^K_\
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MZG+#GVH ]?O=1LM.M_M%]>6]K#G;YD\@1<^F3Q61=>.?"UG=06T^O6*RSX*
M2AA@X()(X P0<DCCFO)/$FJ76L_L_:7=WC^9,+M8R^22P0NH)]3@"IM,^%VF
M7'PD;5#%)/K$]H;J*59=NS@E4 /&,<'ZGGI@ ]?U7Q1H>B0+-J6JVMNKJ&0,
M^6<$X!"CDCGL*N6.I6.IV_VBPO(+J'./,AD#KGTR._M7AWPH\":=XJT:YU77
M4DNE1_LML&F;Y5"\\#IC<,?2K?P>!T;X@>*/#:,TD,)?#EB!F*79G;ZD-^E
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M8W"^9DC(&W.<XJ6^U33],A6:_OK:TB9MBO<2K&I;KC)/7@U\NZE-J=[J4_Q
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MW&N>&3##(X4ODHA('S)UQTKVK ]*,#TH \E^+?A;5)[[3O%>A0RRWUB5$J1
MLX4'*D#O@DYQSSGH.,G6/BOJ^N: VDZ;X<O8M3O$$32!6*C/#;0!G/8?UKW#
M:/04;1Z"@9X_IWA"[\,?!36K>\BQJ%W"\TD:$L5R %7Z@>GZUV'POB>'X<:/
M&\;(PC;*L,$'>U=A@>E+@>E CRCPE%,GQN\62M$ZHT&%9E.#RG0]^]<MJVE:
MK\/?B!>:Q_8IU/1+V1BS/") 0QW$=]K GC(&>>M>_P"!Z4;1Z"@#R;P_XTMO
M$?BK3],L_!<=K;R%VN)Y[=<H%4D8  Q\V!DUL#QIKO\ PM]?"_V*#^R#UN/*
M;>/W'F?>W;?O<=*]!P/2C '04 +1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4R618HGD<X5%+,<9X%/HH \ \*>'F^)7C[5M7\0V<YTU<[(R6C&>
MB*#@' 4$\8.<9ZFO0F^#O@A0-ND/_P"!4O\ \57>8 Z"EH \0^%*:GX5\<:Q
MX7O(YOL[EFC8*2I=.C YP R?CPHKC? /C#5? @OQ%H,MW]L,>=^Y-NW=Z+S]
M[]*^H-H]!2XH \FT+XOWNHW-R-2\.R6=M!;/.9$WNQ*XPH&T<DG%<]X$T'4/
M'7C>X\6>(()%@MI@T43[@I?JJC/55'./IZG/O.!Z4;1Z4 >*_%GP?<V.H1>,
M] \Q;M)4-RL?)# @+(J]_<#Z^IKTCP9XE;Q1X;@U"2UDMYQF.:.1<?.,9(Z<
M'-=%@>E&T>@H \6^'%M.GQJ\62R02K&QNRLA4A6S<+C'X5T.H?!/PSJ6I75]
M/=:H);F5YG5)D"@L23CY.G->D  =*6@#YLO?AU8P?%BW\-Q#4&TN3;NG)7>/
MW98_-MQU]JZ#X@^#-4\/:CX>US0;9[ZST6"*,HXWNOE2-)N? 'RG/)'3%>Y8
M'I1@>E [G@OBCX@ZKXV\/#P]I_AB[2ZO"HF^4M@*0^%X'=>I[ UZK\/M&NO#
M_@72],OE"W4*,94&/E+.S8XXXW8XKI<#TI:!' ?%7P=<>+O#L8T] ^HV<OF0
MJ6VAU/#KR0!G .3_ '<=ZY73OBUJFC:3%IVL>&=0?5+:,1.^"H8@<%LC.3QG
M\Z]HP/2C:,8Q0!X?XGTCQ'HGBG3_ !_HVE2R">W2>_M023$Q4;U8?>QCN!P0
M<CUK^*O'FM>/;!?#NA^'+R+[2P\\RIG<H(( .,*,CDFO>,#THVCT% 'B_C?P
MS-X=^"EAHPW3SPW*-(8QN^9BY;&!TR:[GPRCK\*]/C>-E<:6%*$<@[/2NOP/
M2EP/2@#S3X(PRV_@)TDB:-C>R'#*0>B\\US_ ,.X)X_C;XLE>&18W^UE7*$*
M?](3&">M>U8'I1@>E 'S'X#US6_!FJZAJ4>D75UIK%8KM%0KC)8HP]QAO;DC
MJ16QJMQK'Q9\9:7''HUS::79.!*S<&-&8%F+$8!(7 '/3ZU]"8'I1@'M0.YX
MK\1;>XD^-?A.5+>5HT^R9D"DJN+AB<_A1X]MYY/CEX7F6WE:-!:[G5<@?OWZ
MD5[5@8QBC ]*!'$_%R.27X8ZND4;2.3#A$&2?WR5QT'A.^\4? 72M.ME*7EO
M(]Q'"X"F0B24;#DC&0V<GVKVBDVJ>PH \"\/>./^$?TJ/2/$'@MI[RS B61;
M158H!P&R/O8[]^OO79)I,_COX97D<NBP:1>7AWPQ",QCY3F-F..1UYQCGI7I
M>!Z4;1Z4#N>!^%/B%K?@S1IO#VI^'KN>YM&9+?&?EZ_*W7(![KVJ'X6KJ\OQ
M7N[W5[2XANIHIC,)8BNUB0<<U]!8'I1@>E "BO!_C#I6HZ3XOMO$6DI(LEY;
MM;RR0Q[CNVE#TYR4;&?:O>*3 ]*!'E]GX0 ^!ITB>+9=26ANW!5E;S<^8-PZ
M[AA1CVKC?@[I=]J/B]M1U.*;R]+L_*A>1 ,$G"KR,G WX],#GU^@MH]*,#TH
M'<\5^)UO<2?%GPI(D$KHAM]SJN0,3GK6Q\;[*^O/#%C<6=K).+6[$LFQ<[1M
M(!P.>M>I8'I1@>E CRM/'DOC'P9XDL6T>ZM+F'296=G'RR,4((4=>O2K/P,A
MEA\"W"S0O$WV^0A7&#C8G->EX'I2T >5:+#*G[0_B&=HI!&U@H#E3M/RP=_P
M->IN<+G%.P** /G&.XN?!/Q4UC5-5\-W%Y%-/.]N?+S@-)N613@@\?ED^E6K
M'7-8\1_%_0M8U/3IK.UW%+7?&0/*(8#+8Y)8GGUZ5]!X'I1@>E SQ:_M[@_M
M(VD_V>7RALS)M^7_ %!'6NB^-T4LW@%4AB>5OML1*H,G&&KT? ]*6@1R7A6&
M=_A?IML(CYITM4"G@[BF,<]/QKR[X<>-+WP=;'PYJ&@7KN]YPRIM\LL0K;L]
M<$=J]]P/2C:!T H \6T^VG_X:0NIVMY1%\P\S:=O^H'>O6WT32I)&DDTZT>1
MCEF:!22>^3BKV!Z4M 'FGQ:\%7&N^'[.71[<&YTYF9(8_E)C.-P51P3E5..O
M''7G$TOXR7]II4-GJ/AN_EU*%/*=E4@.PX!((SGCGWKV4@'J*,#TH ^?_&T5
MWH_Q8M_$]UH<U]ILRQ2B(Q'!_=!-K9& ZD9P?050\8^+M3\6:GHUU_85Y9:1
M9W \LM$6RPVENB]AV&>*^C\ ]11@>E [GBGQ7BFN?'OA6:&WEEC'EDLJ' _>
M@\UZ!\1E>7X>:W&B%F-L0 !DDY%=6% Z"C ]*!'B/A_PA+XG^!PT]8F2]BN)
M9K<2)@EP3QSC&X<9]Z3P_P#$K6/!^E+H.M^&+YY[-?+1T!R1SUR#GMR"0>U>
MWX'I1@>E 'AGC_1?$?B%] \:V.EEKB.UC\ZSVAS"P<LIVGEP=W(QT'I3T^)4
M%Q91PVW@ 2:K(JJ$^S#RV?C/\.2/05[A@8QBC ]*!GB7QJLY7\/>'%M[(H5>
M1FBAA("$JI. !QSFO9K#_CPM\C!\M?Y5/@9Z4M ACQ)(&#J&5A@@C((]*^?]
M!OM:^$'B#4K&]T:ZOM-NCF*6)3\P3.UE/(Y#?,.O3TKZ#I-H]!S0!\XWNH:Y
MXF^)WAK7[W1[FTLY+ZWBM59.D:2J2<XZ9?.3QU /''2>/H+B3XX>%Y4@D:-5
MM=TBJ2HQ.^<U[5@>E&!Z4#N9/B'37UKPYJ.EJVQKNW>(-CID8KQ3P=XSU;X=
M6=]X=U+P[<RR13ED,?9B.<GH5X!!'8U] X'I1@>E CYY^'YUF]^,XU+6+.X@
MN9_.DD62)E"9C.T<]@, 9[5+<67B'X6>/KS4]/TJ:ZT2Y?+"*,E#$S9"Y&=K
M*<@?3WKW]A@<#K7F^OR?%&Q\07C:';V6H:9)AK=93&#" ,$<LA))]<]N>M [
MGE?Q!\0:WXIN].U+4--_L_3@[1V,<F [\J6;G!;^'D#:.G7.?9?B5XNUCPGI
MEE<Z/:PW$D\YC=987DPNW/ 4CO7&_P#"#^-_&_B6SO/&B6UI8V;+B"%U(=<Y
M8*%)QG !)(/3'3CVE%QVH$0:;<27>F6MQ,H626%'=0, $@$U:HHH **** "B
MBB@ HHHH SO^$@T;_H+6//\ T\)_C1_;^C?]!>P_\"4_QKROX6^ _#.O>![>
M_P!3TM+BZ>616D:1QD!B!T(KL_\ A57@G_H P_\ ?V3_ .*H Z'^W]&_Z"]A
M_P"!*?XT?V_HW_07L/\ P)3_ !KGO^%5>"?^@##_ -_9/_BJ/^%5>"?^@##_
M -_9/_BJ .A_M_1O^@O8?^!*?XT?V_HW_07L/_ E/\:Y[_A57@G_ * ,/_?V
M3_XJC_A57@G_ * ,/_?V3_XJ@#H?[?T;_H+V'_@2G^-']OZ-_P!!>P_\"4_Q
MKGO^%5>"?^@##_W]D_\ BJ/^%5>"?^@##_W]D_\ BJ .A_M_1O\ H+V'_@2G
M^-']OZ-_T%[#_P "4_QKGO\ A57@G_H P_\ ?V3_ .*H_P"%5>"?^@##_P!_
M9/\ XJ@#H?[?T;_H+V'_ ($I_C1_;^C?]!>P_P# E/\ &N>_X55X)_Z ,/\
MW]D_^*H_X55X)_Z ,/\ W]D_^*H Z'^W]&_Z"]A_X$I_C1_;^C?]!>P_\"4_
MQKGO^%5>"?\ H P_]_9/_BJ/^%5>"?\ H P_]_9/_BJ .A_M_1O^@O8?^!*?
MXT?V_HW_ $%[#_P)3_&N>_X55X)_Z ,/_?V3_P"*H_X55X)_Z ,/_?V3_P"*
MH Z'^W]&_P"@O8?^!*?XT?V_HW_07L/_  )3_&N>_P"%5>"?^@##_P!_9/\
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MOZ-_T%[#_P "4_QKGO\ A57@G_H P_\ ?V3_ .*H_P"%5>"?^@##_P!_9/\
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M_"JO!/\ T 8?^_LG_P 57*:YX2T/PS\0_!1T:P6T-S<S>;M=CNVJN.I/3)H
M]=I"0 23@"@=*BN_^/*?_KFW\J *G]OZ-_T%K#_P)3_&C^W]&_Z"]A_X$I_C
M7CWP@\$^'/$?A*XO=6TR.YN$O7B5V=AA0B$#@CU->@?\*J\$_P#0!A_[^R?_
M !5 '0_V_HW_ $%[#_P)3_&C^W]&_P"@O8?^!*?XUSW_  JKP3_T 8?^_LG_
M ,51_P *J\$_] &'_O[)_P#%4 =#_;^C?]!>P_\  E/\:/[?T;_H+V'_ ($I
M_C7/?\*J\$_] &'_ +^R?_%4?\*J\$_] &'_ +^R?_%4 =#_ &_HW_07L/\
MP)3_ !H_M_1O^@O8?^!*?XUSW_"JO!/_ $ 8?^_LG_Q5'_"JO!/_ $ 8?^_L
MG_Q5 '0_V_HW_07L/_ E/\:/[?T;_H+V'_@2G^-<]_PJKP3_ - &'_O[)_\
M%4?\*J\$_P#0!A_[^R?_ !5 '0_V_HW_ $%[#_P)3_&C^W]&_P"@O8?^!*?X
MUSW_  JKP3_T 8?^_LG_ ,51_P *J\$_] &'_O[)_P#%4 =#_;^C?]!>P_\
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M_C7/?\*J\$_] &'_ +^R?_%4?\*J\$_] &'_ +^R?_%4 =#_ &_HW_07L/\
MP)3_ !H_M_1O^@O8?^!*?XUSW_"JO!/_ $ 8?^_LG_Q5'_"JO!/_ $ 8?^_L
MG_Q5 '0_V_HW_07L/_ E/\:/[?T;_H+V'_@2G^-<]_PJKP3_ - &'_O[)_\
M%4?\*J\$_P#0!A_[^R?_ !5 '0_V_HW_ $%[#_P)3_&C^W]&_P"@O8?^!*?X
MUSW_  JKP3_T 8?^_LG_ ,51_P *J\$_] &'_O[)_P#%4 =#_;^C?]!>P_\
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M_C7/?\*J\$_] &'_ +^R?_%4?\*J\$_] &'_ +^R?_%4 =#_ &_HW_07L/\
MP)3_ !H_M_1O^@O8?^!*?XUSW_"JO!/_ $ 8?^_LG_Q5'_"JO!/_ $ 8?^_L
MG_Q5 '0_V_HW_07L/_ E/\:/[?T;_H+V'_@2G^-<]_PJKP3_ - &'_O[)_\
M%4?\*J\$_P#0!A_[^R?_ !5 '0_V_HW_ $%[#_P)3_&C^W]&_P"@O8?^!*?X
MUSW_  JKP3_T 8?^_LG_ ,51_P *J\$_] &'_O[)_P#%4 =#_;^C?]!>P_\
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M=(BC799("W^TW^-5[;0M+\]0]FI4\?>;_&G]6D+^T:?9GTA_;^C?]!>P_P#
ME/\ &C^W]&_Z"]A_X$I_C7@/_",:,.!8K_WTW^-'_",Z/_SY)_WTW^-+ZM(/
M[1I=F>_?V_HW_07L/_ E/\:/[?T;_H+V'_@2G^-> _\ ",Z/_P ^2?\ ?3?X
MT?\ ",Z/_P ^2?\ ?3?XT?5I#_M&EV9[]_;^C?\ 07L/_ E/\:/[?T;_ *"]
MA_X$I_C7@/\ PC.C_P#/DG_?3?XT?\(SH_\ SY)_WTW^-'U:0?VC2[,]^_M_
M1O\ H+V'_@2G^-']OZ-_T%[#_P "4_QKP'_A&='_ .?)/^^F_P :/^$9T?\
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M_P :/JT@_M&EV9[]_;^C?]!>P_\  E/\:/[?T;_H+V'_ ($I_C7@/_",Z/\
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M/^$9T?\ Y\D_[Z;_ !H^K2#^T:79GOW]OZ-_T%[#_P "4_QH_M_1O^@O8?\
M@2G^-> _\(SH_P#SY)_WTW^-'_",Z/\ \^2?]]-_C1]6D']HTNS/?O[?T;_H
M+V'_ ($I_C1_;^C?]!>P_P# E/\ &O ?^$9T?_GR3_OIO\:/^$9T?_GR3_OI
MO\:/JT@_M&EV9[]_;^C?]!>P_P# E/\ &C^W]&_Z"]A_X$I_C7@/_",Z/_SY
M)_WTW^-'_",Z/_SY)_WTW^-'U:0?VC2[,]^_M[1CTU:P_P# E/\ &@^(-&'7
M5K'_ ,"$_P :^>KOPOI;6S^59J) ,CYCS^M6? >B^&KK7Q8:OIR3)<+MBW2,
M-KCGL1UZ?7%*5"25RH8ZG.2BD]3WS_A(-%_Z"]A_X$I_C1_;^C?]!>P_\"4_
MQKG1\*O!/?08?^_LG_Q5+_PJKP3_ - &'_O[)_\ %5@=IT/]OZ-_T%[#_P "
M4_QH_M_1O^@O8?\ @2G^-<]_PJKP3_T 8?\ O[)_\51_PJKP3_T 8?\ O[)_
M\50!T/\ ;^C?]!>P_P# E/\ &C^W]&_Z"]A_X$I_C7/?\*J\$_\ 0!A_[^R?
M_%4?\*J\$_\ 0!A_[^R?_%4 =#_;^C?]!>P_\"4_QH_M_1O^@O8?^!*?XUSW
M_"JO!/\ T 8?^_LG_P 51_PJKP3_ - &'_O[)_\ %4 =#_;^C?\ 07L/_ E/
M\:/[?T;_ *"]A_X$I_C7/?\ "JO!/_0!A_[^R?\ Q5'_  JKP3_T 8?^_LG_
M ,50!T/]OZ-_T%[#_P "4_QH_M_1O^@O8?\ @2G^-<]_PJKP3_T 8?\ O[)_
M\51_PJKP3_T 8?\ O[)_\50!T/\ ;^C?]!>P_P# E/\ &C^W]&_Z"]A_X$I_
MC7/?\*J\$_\ 0!A_[^R?_%4?\*J\$_\ 0!A_[^R?_%4 =#_;^C?]!>P_\"4_
MQH_M_1O^@O8?^!*?XUSW_"JO!/\ T 8?^_LG_P 51_PJKP3_ - &'_O[)_\
M%4 =#_;^C?\ 07L/_ E/\:/[?T;_ *"]A_X$I_C7/?\ "JO!/_0!A_[^R?\
MQ5'_  JKP3_T 8?^_LG_ ,50!T/]OZ-_T%[#_P "4_QH_M_1O^@O8?\ @2G^
M-<]_PJKP3_T 8?\ O[)_\51_PJKP3_T 8?\ O[)_\50!T/\ ;^C?]!>P_P#
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M$L.N!5.35926\M% QU)JE%LAU(HUZ6H;9G>VC:0Y8C)-35)2U"BBB@84444
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M@HHHJ2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[58  H ;Y8IKQ\<5+2<4#*M.#D#%+)P^*90(,DT444 %%%% !4L/6HJEAZT
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M2_\ H2T CN/@K_R3:S_Z[3?^A&O0J\]^"O\ R3:S_P"NTW_H1KT*@ HHI*
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M44 %%%% !1110 4444 %%%% !7GGCG_DH7@'_KYN/_04KT.O//'/_)0O /\
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M* "BBB@ HHHH *\\\<_\E"\ _P#7S<?^@I7H=>>>.?\ DH7@'_KYN/\ T%*
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@O[07_(4T/\
MZX2_^A+7O5>"_M!?\A30_P#KA+_Z$M (O?#WQUI?AOX=6EK*))[SS96\B,=
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M>5!1112*"BBB@ HI*6@ HI":4=* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\F^*/_)0?A]_
MU_C_ -&PUZS7DWQ1_P"2@_#[_K_'_HV&@#UFJ>K?\@:^_P"O>3_T$U<JGJW_
M "!K[_KWD_\ 030!\]>%?^1:M/HW_H1K8[5C^%?^1:L_HW_H1K97[P^M>G3^
M%'S=?^++U+44*A0Q^\:2>(;=PXJ>FR?<8^QJB;:%.+A_PJQ54'!S5D'(XH)%
MI*6FLV 30,KMRQ_*J$U@68M&1SVJ]W-''I0(SXM/8R RC"CM6@   %& ***!
M6"BBB@85*LH'6HJ* +'F)_>IDD@(P/SJ+\** "BBB@ HHHH *=&,R*#W--H!
MP<T :& ..PJM<MD@#I3?/?;CBJ,]YY4FTKGGGF@;>A9H[4@8, 1T(S5J"-2N
MXC- D5J*FN$"L"!@&H: "@D#J<45TF@>$KC5D^T32^1:] 0,L_T]O>E*2BKL
MN%*51VBCF^X'<]JTK3P_J]Z T%A*RL,AFPH/XMBNTFU#PCX2/E226ZW '*@>
M9(?\X^E5V\:ZK?A?[$\,WDJL0/-NL1K[_AR.<U@Z\GLCMCA(+2<_N,N#P%JK
ME?.D@B4CG#%B/Z?K5^#X>'YC/J ']TQQ\_K2RQ_$;4HR5ETW3,N2JYW.!Z9P
MPQ^O%,?P9XIN9O-G\8W(W$%A$&4>^ "!^E0ZLGO(V6'IK:#9?@^'VG*&$]W.
M^>FT!<?H<TC^$/#<3E)+YU8<%6N%!'Z5G?\ "K(VR3K^H9)R<G_Z]26_PGT8
M!OM5W>7#LV2X8+_0U//_ 'BU0[4T:,/ACPI%'M>>.8Y^\]U@_P#CI J3_A'/
M"/\ T[_^!;?_ !54?^%3^'/[U[_W^'^%'_"I_#G]Z]_[_#_"ES+^9E>RDO\
MEVOZ^1?_ .$<\(^EO_X%M_\ %4?\(YX1]+?_ ,"V_P#BJH?\*G\.?WKW_O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8U'JV75H0M&,?F<P00.01Z9% !) 4%OIVKTQX;_4/#U]!K(MI9(T+1R1$<D
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MK0ABP@)')]:SDG3<%"D+[5HQ3+MPQYH!$_-5;Q@J!N.":E:=5'<U1NM\Z@#
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M&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;H=3H6NP)XJNM2U"8QI+&P!VD]UP,#/8?I4_AK5;"*VU*SN;UK5KJ0^7( >
M1USV_&N/HI.E%CAB91=[;7_$[JTNM!T/2]0M8-3$]S.C#<(S@_*< $ COZU1
MTS5=,U#0UT;5R+?RS^YF )P?PZ'D^U<G12]BNX_K4KZ+3:QU$*Z/HFOZ=)#J
M7VA49VGD"Y5<CY<8_'IFLK5;\/X@N+ZTEX\XO&X!Z]O>LRBKC"SNW<SE5;7*
ME;6YW4]]H7B58I+F\:SND3#;A@$=^>G?CG/M6;XBUFQDTR#2=+9F@A8$R8QN
M_P >2<\=:Y>@>YR#QBH5)+=FDL2VMM6>D>(+/1[Y+*'4+P6EQY>4<C@KW!/3
M]:P?$>K6']E6^CZ7*\D,+9>3/#=?7KDDGCVQ63K6M2:R\#20K&88_+&TYSS6
M72A2T7,_D75Q.K4%\SHO%^IVFJ:A!):2^<JP;"<%<')]:GFUNR&CZ&B2;YK.
M9)98PA!POOC'ZURU%7[-647T,OK$N9ON=]J$_AW5[J+4IM5D$<.-UN<C<1TP
M.O?G'_UZS]1\2VZ>+;74[1WE@2$)(HRN0=V1^&0?PKD:FM+C[)>0W 17,3A]
MK=#CM4JBD:/%REY:G9>9X7NM?&H+=2R22-G[.(VP9#C!Z?C]33-=U :5XZAN
MV4NB1+N&.W()_(FJZ>+K&-A<QZ';K>YSY@P,?IFN6U/6/[0OY)[N8&5CTQPO
MH!Z"HA3=_>V-*M>*C[MKWOHCL;ZR\+:G=OJ)U7R8WYEB7(9F[D C/Z5RFI+:
MKJ,RV+%K8-^[//(Q[U5HK6%/EZG-5J\_V;$-W(8X"P[\57T^21ED5CE0.#5U
ME5QAAD&F1PI$"$[U9B24444 %%%':F!)\1P%O]'"@ ?V9%P/JU>S:)_R M/_
M .O:/_T$5XU\2/\ D(:./73(OYM7K7A&X>Z\)Z9-( &:W4''3@8_I7%5_AH]
MC"O]],VJ***YCT HHHH \W\2?/X^B5V^4!,#/3BM;FJ/C[3)(;V#68,XX60C
M^%A]T_Y]J--U*'480R820##)FF!>HI.O3FBD O--=5=2C@%6X((X-.I.U '-
MV<Q\-^+8BNX6\I"D'^Z>WX8K9OM;U/6I-FF$V]F,@RL,%OI7/^(BMWK4-NA^
M; C;V)/_ ->NIBC2*)(T&U54 #TIH#(M](OA>QSW.HR,$Z[&.35R^U/Q!;70
M-A\UNBY(.&W$]?>KU'U- &9'XZU:T"B_T]3ZD H36I9_$+3IL"XBFA)SD@;@
M*9M4C#*#ZY[U3N])LKQ&#V\:L>0ZC!!]?>A@=S:W=O>PB:WF26,\;D;(J>O*
M=-N[GPMKJ1F0O:3$ @G 8'N?<5ZHO7MCM2 6F22)%&\DCA44$LS'  I_>O._
MBWJD]EX=6T@)473;9&!(^7N/QII79I1INK-074P]6\<:GXENY[32)FL=-B8H
MUPAS)+]/0?3M68FDV:L'DB-RX389+EC*S G/1N,CIP!46A0I%HUMM7!9=S>Y
M-:5;)6/<5.%-<L%H1Q0QVZ1B&-$$>0NU0,9Z^_>I#^'X444T,,^IK#UBU^U^
M*]!LIO\ 57#IN"\$!I=IY^BBMRLOQ1/]AU[PSJAB)@@1/X@"[12EF_#!')]:
M3"[3LO/\CWI?NBEID;J\:LK!E(R".].S6!\\+1110 4444 13PI/&4<9'KZ5
MBND^GS@@\>OJ*WZAN+=;B)D;OT/I51E;1[&<X<VJW&VUPEQ'E>O<5/6$#+I]
MSST[CU%:ZW49M_.&2H&3ZBB4>P0G=6>Y/13(YDEC#H<J:?4F@4444 %%%% !
M1110 4444 %>"_M!?\A30_\ KA+_ .A+7O5>"_M!?\A30_\ KA+_ .A+0",3
MP<S+X=CP<9=C^M;G4Y)YKG/",X30XD(Z.W\ZZ,=OK7I4_A1\[B/XLEYDB0L_
M3I1+&8ZMC"#IQZU5GD#G JS&Q%1110 4A ((/0TM% %8V_S@J3M%6:/ZT4 %
M%%% !1110 5+%%O//W:BJ^B[%V^E TB">-43*C%5ZM7)Q'S57L/I0)F]X/C$
MOB6!3TVMG_ODUT'PUG2ZAURYB4K'-J+R(#Z'D5A>"?\ D9X/]Q__ $$UJ?"0
M8T?4O^OL_P#H(KFQ#^+Y'I8+[/JST,4M(*6N,]8**** "BBB@!#TJO=W MX2
MYY/11ZFK#8VG/ K%F9KZ]"KPO0'V[FJBKLB<K+06QMVN)S-+R ><]S6R.@ID
M,:11A$&%%24I.X0CRH****184444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"/G*_P#%EZA1115&04444 %%%% !1110 4444 %%%% !115&^N) WE)P,<T
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M!3G'\/J*X:E)Q=UL>SA\5&:L]SK**0$8ZTN:Q.P**** "BBB@ HHHH ****
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MR>7'=/Y9ZHY#+_WR>#64J=_,WIXAQVNCL]/^*>@W95;@RVC'.3(NY1SZC/\
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MBJP:ZTNY\P(0)(V!5XF/9@?YC(XX- &W161XCUZV\-:)<ZK>$F&!>%! +L>
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MBB-#AC^E3VA<P+OZXH*<;*Y8HI*,T$BT5 MW$TWE!LM4U VFA:***!!1110
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M:+4D]AU%1^<GF%-PW#MFGYI%"T4E+0 4457N;ZVLX3-=3Q01 X+RN%&3TY-
M%BBH+6[M[V'SK::.:(D@21N&4XZX(]^*BN=6TZRG6"ZO[6"9@"L<LRJQSTP"
M<T 7**:SJD9=F"J!DDG  JG:ZQI][(8[2]M9Y -Q2*97('K@'W% %B:VAN%V
MS1)(IZAAD5C7/@[1;GK9B/KCRV*UHW6L:=8R".[OK6W=AE5FF5"?P)J5[ZVC
MM?M4D\:6^T-YK. F#T.[IB@#D;CX<VS?\>]Y(G^^,UGMX*U^V;-I?(P;D_O"
MO->@6UY;WD FMIXIXB<!XG#+^8J*[U6PL"@O+RVMRX)432JA./3)YH XR+PU
MXIE(CFOHHHS]Y@P)'Y+G]:Z?1= M]%A81YEN)/\ 63/]YO;Z5I)=0R0">.6-
MX2NX2*P*D>N>F*I+XBT9V"KJU@S$X"BY0DGTZ]: -(C*XKS[QE\)=!\4(]Q!
M$FF:ID%+NW7&XCIN48![<]>.M>@!PW2J6LW9L=(N;I1EHTR/K30TKNR/!=)\
M6^/?#T5WX6OIXYKJ!Q#!/PSQ*/0XP5(Q@MR/Y+)X<N;[=)J.IS33,VX[B6&?
MJ>_:F>&I3>WVHWTFYYI'#;G;)^8DGK]!^5=)].E;))'OTZ2H)1COW.<B\,7=
MM.KZ;J9@D!!4N[1\CG.Y>_3M^(K=TKXBZ_X9O4T_Q) ]S #CS&QY@&."K='[
M'.>?6IN]$PAN[0VM];I<VY/W7'S(3W5NH/ Z4G$*B53XU?\ /[SU/1=:L-;L
M%N["Z2>-NNWJIQG!'8UJ#I7SZ]AK/A"9M7\/W[S6@.95S]WK@2)GD#(YZ<]J
M]*\'_$C3_$?EV<Z?9=1*\1DY63 &2I_/@\\=ZS<3RZ^$<5SPUB=Q7"_%W5)]
M*^']V]LS(\[I 75BI56/."/88_&NW#DMC%8GB_0(_%'AJ[TB1E1IDS'(4#;'
M!R#S^7T)J3C.>^$_A^PTOP/I]U;P+]JO8Q/-,1\Q)[9] .,=/S-;'CJ!$\"^
M(91&@D:PE#.!R1M/7UKR[PKX^U/X>V(T/Q9H]]Y-NQ6"=/F([A!N(5ASV/ Q
M717'Q$MO&W@_Q9#9:;<P6UMISLL\S#+DJ01@9 .0>YXH V_A3%'-\*M'CEC2
M12)<JXR/]<_:N$\B+PA\?;:TTL&&UU +YD",50;P<C'< C<!T_*HO!?Q:T[P
M]X*T_1(]*O[W4H2X5(PH20M(S<');HW]WK6IX(T#7O$?CU_&WB"T%M %;[-!
M+G(;[J@*W*A1DYXR<$9H B\471^)OQ#MO"UE/(-'T\M)>2Q-Q(1P2,9''"@G
MN35_X.QQVWB7QQ#$BQQ1WJ*B*N H#S  #TQBKEA\&8M,EEET[Q5K5DTN-YMI
M!&6QTSCKUKG/A1H4\GC/Q%*-:U!1IMZ$D19/EN\M*,RCN>,_4F@#J_C/XB.E
M^$/[-MI2MWJ3^2%7J8_X^_H0/QQ72^ _#L?A?P?8Z>JXF*^;.2N"TC %L_3I
M] *\RM3_ ,)[\<FN2-]AHV=B2>L9P,=#_K.>_3'(KV]1@8_K0 ZN=\9Z2VK^
M&KB*--TT1$L8]2.N/J"1^-=%2-]TT)V ^>+&3R[GRV&-QP<^U;K6,JKO4;AZ
M BJOB[1?[#\131QKB"3][#ST4GI^!XJ:QU"1(4;.X$?=/:K?=&/D1\HV<$$=
MNAK3358[RV6RUF WEN#\LN?WL7&,JW?')P:J7<\5PJL$99!UXZU5XI#'7?AJ
MY1&OM)?[;: [@T>1+&/]I>HQSR*30?%5WX?:X*0QRO(H7YR<C&:DM[B:TF6:
MWE:*0='1B#3+MS?73W-R$DF?&YB@&<#';Z55[[@4KBXNM<U.6]NB-SG)PN
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MR_\ 7PW_ *"M=-7,^!_^0'+_ -?#?^@K735Z-+X$?/8K^-+U"BBBM3 ****
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M%O09H48-,N3BVD/M6YX"=WJ9M@-UTSGL"?SK7K,TL?-(?8"M2@NK\5@I"P!
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M3[AA>E0T4#N%%%% @HHHH **** "BBB@ H_S]:!U]JS]4O3;Q^5&?WS#MV%
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M*Z@O9K38TR$J;8JRYSZ$@XKM/@MQ\-[8'J+B;/\ WU1\5O\ D2=9_P"N<?\
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M[!5P,Y)H W?#6E074D^IWY"V%FN^1NF2!G\>^:2S@N?B3XG:XN!+'H-F2(E
MP&]OJ>^.F,4[Q8SQQ:9X+TM1YUQM:ZVX)R2",\>HW'V [5Z+H.D6^AZ7!86R
M@)&O+8P7;NQ]S7'.H_B[['K4*"OR=%OYLNVUO':P)!#&L<4:A51!@ #L!4]%
M%<QZ25M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !161K?B/3M!BW7LX5V4E(U&6;Z"
ML"#XGZ-(Y$D%U$H&=Q4'/Y&G9BNCM)'6*-G<X51DD]A389DGA26/)1U#*2.Q
MKG=;UVQN_#-U)97<<V]0F8VR?F.,$=1D9ZUT40"H%5=JKP !T%(9)2'D8I:0
M]* /$_&D3V.K2V"R-]G64RQH>@W 'C^6?:J-EE;6(]P,UI_$.ZCN_%4D<)5C
M#&L3D'.&ZX_6J**$C5/[J@5IT,NIK0WD,L!65P" 0<UET=L45*0,HZ@CLL9!
M.T=<56M(G>=& 8*IY-:_TI/IQ57T)ZBG&<9I..QJ_8VHF8RN 4 QBJDX1;B0
M1_=SQ4W*(^^.]-,B X+ 'ZU#>RO'"-AQN.":R>2>N3[U25Q7-U65AE3D>U.K
M.TX-N;.0M:-( HHHH&)VI]O_ ,C;X+_["%Q_Z!'3>M/@4CQ9X+W C_B87'7_
M '(Z3*AN>X#H*BN_^/.?_KFW\JE'05%=_P#'G/\ ]<V_E4EGS-X'_P"0'+_U
M\-_Z"M=-7,^!_P#D!R_]?#?^@K735Z-+X$?/8K^-+U"BBBM# *.]%% &C4<N
M!&Q/3'%0I<!5PPILLI=<=J"KD5%%%!(4444 %30.$+ ]"*A/0\=JHK(_F YS
MD]* 1K3R@\+TJO1CCJ!]:/Q!^E , =IW>E:"D%0?45GU/#+M&T]*!HM4QV"J
M2333/&/XA]*H7=R0<<9/2@;'DY))//I15*%BTZY/7K5V@D*ANIOL]N\O=1Q]
M:FK)UN<!(X1SD[FYI@=!X*\&7&NV,VH"<1(7\M"<_-_>/3UX_"NF_P"%:7/_
M #_+_P!]'_"NS\.6']F>'-/L\%6BA4."V?FQEN?J36J.E>352G-MGUV"Q=?#
M4(TH/1>1YO\ \*TN?^?Y?^^C_A1_PK2Y_P"?Y?\ OH_X5Z316?LXG5_:F*_F
M_ \QNOA[/:6[3O>AEC!8J&//Z56MF1H J @1_(0>HQQ7J<R!XV0]&&#7E^JV
MSZ-J\JOQ#(P!)/?^%OZ&HG!1U1VX/&3Q%XU'JMB>,12MY-P<0R QO@=CQ706
M=['K6G7_ (>U&7RKUK=H)&4_?5EQO7UX.?QKF\@CKD'H11+''<HBR-)'+%S#
M/$?GC_Q'/2G&5AXB@JBU,\? /0R#_P 3B_)/?:G^%=#X9^$?A[PY=K>8EO[I
M'WQ/<D$1GC!"@8R/4_T%1P:SXDLV:)9[._0)\K2?(QQ^7/XUKZ5XON)KR"TU
M33S:23<1S!@8V;GC/8\=,FM%),\N>$J15]&OZZ#_ !EX%TSQG8+%>9BNHCF&
MZC'SIZCW!]*\]@^ B1/NU#Q#+<V\:DB**#8<\=RQP,<=*]JSG&:;(,QL/4&J
M.9;GGFJ_#?2_$VF6&F>=+8VNG!C"EN!_%C/7Z9_&NGN_"MO>>"_^$8DGD%M]
MD2T\U<;]J@ 'TS\HJUIK;;@KZKBM:@NJK2,'PEX7M_".A1Z3:SR31([,'EQG
MYCGMQ3/$FFVVJ6\UA=KO@N8MCK_7ZC@CT(%=#6;JJG,;@=.* I_$>::%\$QH
M_B.SU6+7G:VMIUG6#R,,VTY +;L>F>.E>LSPI<V\D$JAHY%*LI[@]:CM&WVL
M9SGC%6*"&K.QXUK7P*M/M+W6CZQ+8P[>8GC\PCIT;(..M:WA7X6:;8>'M6TV
MZNI+M]155FE*A=N,E2H.<$$YR2:]+F7=$P]0169I[&.X:,]QC\:"XJ\&>86_
MP M8]0S+KT[Z?N!,"PA7/U;./QQ7:^"?A[9>"$OUM+N>X6]V;Q-CC;NQC ']
MXUV-%!F>*ZK\#HH-3DO=-UIK6S,@9;8P%RG?&[<,\^WYUZ]I[YM0N22I(J6Z
M3S('7U'%4=.DV2M$3][F@U6L#G/"_P ,]/\ "WB*YUFVOKF::X1T9)-N &8,
M<8&>U,T[X8:=IWC>;Q2E[<O=2RRRF%MNP&0-D=,\;C7=4M!E=GF6O?#RRU+Q
M=!KEQ=W4<L#1LJ1A=K;#GN*L^,OA1I?BZ[&IP7+Z?J#+\TD:!ED/&"PXY ]"
M*[^2".4Y=0V/45( %4*. *"Y24CRWPI\'5\.^(+?6+C7);N:V;=$JP[!R"#G
M)/J.F.E6_$$!TKQ.TCMML]07);!PL@]?\_Q>U>CXXQ6;K6CV^L:=):7 .&Y5
MAU4CH:F2NC7"UE2J7ELS@B"C;3G/2D_&JDRWGAV5;'5(':U#$17,8R<=OJ,X
MX//I5B.ZLIP#!>P-D9"R-L;KCOBL>I[U[J^Z[DE'?%127-O$H:2X@ +;<"56
MQ^1-44O+K5+H6>E0.\A'+]@/7Z?6D4HW5^B)_LTNMZI%I5M)L!!>9]N=H%:W
M_"M+DC_D,_\ D(__ !5;&FV6F^"=(DGOKE1+-_K9<G+L,\*.OK5.+XGZ.TXC
M,%VJ9P9"H_ XSGFMHT[K4\O$9G.,[47[OYE5/AU?0.)(M<9''1EC((_)JD@\
M(:I=1^9'XIN"H8IG#]02#_'Z@UTMIXDTS5[60V-XCN(]X7.&'X&I?#BJ- LR
MHQNC#G'<GDG\22:?(D<WU^N]6_P1S7_"#ZO_ -#/<_\ C_\ \75_2/"VH:=J
M N;G6IKN, _N3NP2?JQ%=7B@C@\T**)EBZLE9_DCRCX@V#V-\TZR-Y=YACV
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MZE%"KM X%/I*6N@^>"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M603K5)_')L\?^)=W+-XD6U=E\FVA'EJ!T+<D_H!^%,M]&\.:C:V\'VJXT^[
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MT^02>*/!3=_[0N,_7RXZB:LBX/4]V'05%=_\>4__ %S;^52CI45W_P ><_\
MUS;^50:'SE\/_P#D 3?]?+?^@I75UQW@.;R]#E!_Y^&_]!6NI^U#^Z:]&E\"
M/ Q+_>R]2?C_ !JC*0TK$=,TYYV?IP*CK0YVPHH_#-.V/C.TT"&T4<CJ,44
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MO_07L/\ P)3_ !K/E9T\\>YI45%'<0RHKQR*Z,,JRG((]C4FX4BKBT4F:6@
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M7  ' ':J;N"%HHHI 4M14F%#_=:LRMV6,2Q%#WK%D0Q.R,,8/!JXB8RBBBF
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M3;75 ;AV*)NC8*Y'8,1@Y[>M<AXH\&VG@'X8ZTFD?:)YKMHUN9I1N8Q[O88
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M[;Q+X7U_YA%<1?89\D*@&<=^>IS^ KU'AJ\=N4-S\/;_ *K)87,<Z,/F/S$
M@>@[UZIHMV+_ $>RNU9F$T"/EA@G([UP5HV/=PD[W\]1;K0M)OY_/O=,LKF7
M 7?-;J[8';)%2V>F6.G(R6-G;VJ,<LL$2H"??%6Z*Q.PJ6VFV-G+/+:VEO!)
M.VZ9XHE4R'GEB!R>3U]:6STVRTZ)HK"TM[5&;<5@B5 3ZX'? %6CTIC-@>E
M%'^PM)%Z;T:;9B[)),X@7S"2,$[L9Y%2V=A9:;"8;*U@MHRVXI!$$!/K@=ZS
M];\36.AQ$SR!YB,K"C#<?3CL/>N'N/$_B/6&+0E;& GC8.?Q/7T]*B4TCLP^
M!JUES+1=V>FR&.2,I(%*.,$-T(K/@\/Z+$)!#I-@GFH4D\NW0;T_NGCD<#BO
M-1IIN"3J5Y<W/=0KXVGU^;/Z5H6,TWA\?:M.N)YH(QB:SG<'*9Y*].1]/SH5
M0WJ9=RK25V>BV6F66GQNEE:06J.=S+!$J G'4XZU;J*WE6>WCFB8,CJ&4@Y!
M!Y%2U9YFQF:D^9$0=AG%7;5/+MD7OCFLV3]]J./]H+^5:Z]/I0:STBD.H/ H
MJ.X+"WDV9W8XQ09(R6S=7V.Q; ^E;*@*H Z"L[3X&5V9D9<# #"M$4&E1J]D
M+5>ZF\J$D=3P.:L5D:@YDG$8/3C\:!4X\S':?#OD,QZ#I]:U*C@C\N)5]!4M
M IRNPHHJ*:98(R['ITH)):*@MK@7*%E!&#@@U/0-JP4444""N5^(FB7'B/P5
MJ&F6G_'S(%:-?[S*P8+UXSC&:ZJD*@\T >/?"[Q]I.FZ'!X:UJ4:=?6;O&!.
M"B_>SAB?NMDD<XZ5O>-_$VC>(/AYXDBTJ_BNFMHE$WEDD+EP!ST/W3TKHM:\
M#^'/$$KRZEI<,L[KM,P&U_\ OH<Y]ZCT_P !>&=*T^>QM=*C%O/&(YU+,3*
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M 3]*=&H9]IZ&KH '  % TBB8W'53^5-K1_#-5KB,!2P 'K0%BO1110(****
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M#WV\53TM0?,;T.*#6&D6S2%+24%@#C-!D%9-W(]Q<>7&> <#ZUH3S+'"SYP
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MR:1=)J5B3& ?G"]!7J&G:]8W6GP3R7,<;.@)#'!S6L)WT9X^-P7LVIT]8O\
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M<XS_ %IB!AM8CTJ>T^\WTJ6:#S.1@-_.E@B\M><;CZ4ADP4MP 3]*&5E&6!
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M>@SG%=&1GCUJG_9T'F;RI8^C'(IJ9,J3L9]I9/.RNV50'KWK;48&!VI0H4
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M CU[$$9(Z]W\&=:TS3O <T=[J-G;N+R1RLLRJ=NU><'G'6O.?&&J6WQ ^)4
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M$8J*204444B@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;&^N;F$6P8)Y&WD-C/4'TK1\1_#S1_%FCVEO=&9);2(1V]RA^91@ Y'0]/\
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MDVT5!:GN(Z5%=_\ 'E/_ -<V_E4HZ"HKO_CRG_ZYM_*H-#Y,T!]NFN!WD/\
M(5H]365H/_'@_P#UT/\ (5J5Z-+X$?/8K^-+U+=NX*[2>AXIMV1E1WS5;\<4
M9..N?K6A@%2V\AAN(Y/[K#_/Y5%1WH Z5SMU./U*8JW5-B&GM6_B9?Z5<[T
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M@#T]!S7T"RY/6N0\0^ +#5A)<6A%I>$9RHPCGG[P'J>XJU+HR)1ZH\[^TBY
M;S&<C@9))_6BJVJ^']5T*7%U Z+G"RKRC?0_XXJO%J#*0LJY_P!JG;L1?N;/
MVN;R5B!PH&..M0?C44<\<P^0Y/I4G0X/%*P7N+1110 4Z.1HG#+U%-HH&6+B
M\DN  P 4>E5CZ#\Z6BD!C72%+A@>I)(J6SN)%=8V.Y6Z9[5>GMXYQ\PY'>HX
M;&*%P^2S#IDU;:L(M4445 %#4L[(QV[UG5N31"9-C=.WL:RYK22-N!E?4"KB
MQ%>IK5BMU&5[G!I@BD)P$;\JO6=J4822C!'W1CI3;!%_M3K?_D;?!?\ V$+C
M_P! CIG:GV__ "-O@O\ ["%Q_P"@1UF:0W/<1T%17?\ QY3_ /7-OY5*.@J*
M[_X\I_\ KFW\JDL^2-!_X\'_ .NA_D*U*R]!_P"/!_\ KH?Y"M2O1I? CY[%
M?QI>H^*(R/C.*E>V*CY6Z5%&^QP:O;T(SGK6ECG;,ZBG-C>^.F>*;2&7]+G\
MNZ$9/R2#!K1@'V:^,0Z,.,U@ X(/<'(K?N#YD%O=9YXR1[\TT)EJ2 2<YP33
MHD\M,9S3F;"9'8<50\Q]V[=R:!FC14,$OF)S]X5-0 4444 %%%% !1110 4J
MMM<'&>:2JLETX8A<8% &H;E><+4#R,YZX'I4,3%XPQZFGT!<*HWU]Y \F'YI
MGX  S4EW?I9*&*B1CT0_U]JZ_P !>!'DE36]94[F/F00-U]0[?T%1.:@KLUH
MT9596B6/!?P[6$1:MK2,]T2'CMV/">[#U]NU>EK]VFKD#&<T^O/G-S=V>_2I
M1I1Y8H****DT"BBB@ HHHH **** "BBB@ HHH/2@"AJ<F(E3^\?T%2V";+5>
M/O<U3U([IE7/1:TXAMC5?08K*.LVQ(?6?J.YE10IP3FKV\9J(W$7G>5D;JN2
MNK#$LX_*MU&,$\FK%)1G'--*RL!EZ@YDN!$.<=/K6A;QB*%5%9EMFXO]YZ9+
M5L5G3U;D)!37<(I8G '6G5F:E-\ZP@^Y JY.RN-EJWNUN&( 8$<U9JM9P>3$
M,\L>IQ5BB+;5V M%)FEJ@"BBD8X&3C% !FD:1%&68 >]<QJ?B5VE:WTV,.>A
ME/(S[?XUCM!?W!W3W3;CZDFN.>+2=H*Y+E8[U9XF.%D4D]@:?D9Q7GGV.ZB'
M[J[;/;G%6K3Q#>V$BQW1+IG'(_K4QQJO:<; I&CXW\.R>(-,06Q7[5;DM&#Q
MNR.5SVSQ^(%>1P7MYIKM;,\T:JQW1$E2&X!S[\"O>[6ZBO(1+$V5[BLGQ!X2
MT_Q @:?=%<(,+-'UQZ'U%=\)IJZV%*-]4>4)?_:5P9RV3]TOFGT:WX1U30W9
MS$\]L.EQ$,@CU(_A_P#K5E17\J84_,!WJ[=B&WU-R.[FBA\N-@%)SG%0DLSE
MF;<35>*ZAEX!*GT88J:E8+BT444 % )!R#R***0RT]_+)%L(ZC!JK110!E:@
MC"XW$Y##BH[>X>)UP<KG&*UI8DF3:XX[>U5DT^)'#;B<=CBKOH(M@YYS2T=L
M>E%2!7O<_9&V\9/-8];[*KIM89!ZUES6,D;$QJ64GM51!HJ4H8@Y'!]:=Y4F
M<;&_*K%O9N[J9!A![55Q(TU):($]3R:Q;W_D??!__80B_P#1J5MXQGZ5B7O_
M "/O@_\ ["$7_HU*S9I#<^CQTJIJW_(&OO\ KWD_]!-6QTJIJW_(&OO^O>3_
M -!-06?//A10/#5KZG=GW^8UM $]!63X13=X:LR>F&'_ (\:WQP,#%>G3^!'
MSE;^)+U*VUO2D[XJWD^U1N@()[U1D04444 %%0RW4,+%6)+#J *2.[CE. =I
M/9N*!7)Z*.,XHH&%'3GT.:*,9XXY]:8B_P",+?[5X,T34E7_ %#-;,-PX';C
MKD[:[#X6:C'<^$4M!@/:2LIQGD,2V?S)'X5S]I!_:W@C6M+55::("YB&S)R,
M$X]^,?B:H?"C4OL_B"?3VD 2XB+J"3]Y>>!TZ%ORKEG&\&NS/3HSY:L9=U8]
MI'2BD'04M<9ZP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !24M-;@$^E &3)F?42!_>Q],5KCCBLFR&^]R3TR?UK7K*EU8D
M(>U9)B>>_P#F4[<\\=JU7<(A8] *CCGCFW;&SM/.*J23T&2]J21@D98]!UIW
M:JFH/MM67NQQ52=E<"G:+Y]V7;MEC]:UQTJCIJ?N2YZL:O5%->[<2"J]S=I;
M@ @LQ["IV("DGH*Q\F^N^ORD\<=J<Y-;#-:&021*X! /K3Z:BA$"@8 Z4ZK0
M!12 YI: "BBDH 6BF%PH)8@#US51]7L8QS<H3Z*<FI<DMV!Q'Q%\,7%Y-_;%
MFGF;(PL\2CYB!GYAZG''T K@K;6+J)%1YY#&H"J=Q^4#M7NJ:A9W'W+A&XZ9
MKF_$/@*PUDM<6C"UNF^8LHRCGCJ.W3J*TA--6(E'JCSO[2;D!C*SXZ;CF@]!
M]:AU;P[JV@29NH7$?.)H_F0\^O;MU]:J1:@P.V4 CID55B+]S:-W+Y8C#84#
MM5>HHIXI>$;)]*EQ@\TK!>X4444@"G12O"X9#@BFT4QD]S=R7(VL ![5!VHH
MI 8MR&6XDW#))XJ>RG<2+$6W!N!5V>W2=1G@CH13(;..&0.&8D>M6VK"+ Z4
MM)2U %#4L^7'_O&LZMR6)94VM67-:2QGA=R]L"KBP:*]36KLMS&1_>P?I3!%
M(QP$8GZ5>M+-T;S)%P<<#TIMB1?['Z5POC[_ (^;'_KFW\Q7<]C]*X;Q]_Q\
MV/\ US;^8K,N.YK^#_\ D78O]YOYUO5@^#_^1=B_WF_G6]7H4O@1X&)_C2]2
M.>/S$QW%0PPNK[CP!Z5:HJS(8\:./F 'O2+!&O(YHN%9D&WK3;='5/G- $U)
MD#C<,TM46W&YXR>: +U !/"C)H';CMWKJ/#FGP65E)XBU/Y;2V4R1#=RS#V^
MO0>M3.7*KETJ;G*P^_N1X)\*@1@'6M0&U,#)3^HP#^=;?@+PT=#TK[1= F_N
M\/.23E>X4Y[C//O7/>&=.N/&/B>3Q1J4)%G&VVTC=00V,@?4+^IKU( =<5Q5
M)/;JSV:%--\W1;?YB@8I:**Q.P**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH ****  UFZC <B51[&M*D(##!&:"HRY7<KV4IEMP3_"<9]:
MLTU45%PJ@#T IU F[NX53O+3SR&0A7'4^M7** C)IW1'#&8H50G.!4E)2T""
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (Y((YHVCE021L
M,,KC((]Q7'Z_X TB]5I[<_8) -S,@_=@#J2O;CTQ79MTK%U32WU>_BCN1G3X
M5$A3G,KY/!]@ /SHO8329XK?Z<^GW3QPW"7$:XVRPYPWYTV&_:, .N\>O2O>
M5T?30H']GVO _P">*_X5R7C+P=87-A+?V8@L[B(;B.%1P.Q[ ^F.]6I)[F;A
M8X..195#*>#3QU ]:RK"3;<>6&.&XQ6H3SD?A0U82*;ZBBR,NPD*<&K@(95(
M[C-4Y;#?)E)-H/WABK:KL15_N\4W8!U%%-9U3[S*OU.*0#J*C\Z+_GJG_?0J
M0<C(Y^E%@"BBB@ HHHH *.IR>:**0PZ\>M2Q1E?%?@ELY#7]P1_WQ'47/:GP
M,S>+/!0/\.H7 '_?$=#*AN>X#H*BN_\ CRG_ .N;?RJ4=!45W_QY3_\ 7-OY
M5)9\D:#_ ,>#_P#70_R%:E9_A] ^G28ZB0\?@*T3P<5Z-+X$?/8K^-+U$HR?
M6BBM# ****0!6Y"=^A\\8''X$UAUM\PZ-$AZOSS]<TT!?3+6BX^\4%4JOP<0
M1^RBHIK?/S#\A0!';$^<!Z@YJ[5:VB(;<01CUJS0 4444 %%%% !1110 R5M
ML1/X50"EVP.I-6;IL;%_$TEK'CYR/I0!95=JA?2H;NY6UMVD8 GHHSSFIBP4
M%C@8&234?AO0I_%^OJK(ZV$#9EE &% _A^IQCVZTI245=E0A*<E&)N_#WPBV
MJ7T?B#4D4VP8M#&PSYC9QGZ Y_\ U5Z^% Z<4R""*W@2&&-8XT4*JJ,  =!4
ME>=4FYNY]!0HQI1Y4+BBBBH-@HHHH **** "BBB@ HHHH **** "D/W32TC?
M=/TH Q[_ #]L(!QD5X'X9\3_ !,\674UKI&LR2S0Q^8X<1)@9QU(KWV^_P"/
MX5\S_#^R\57NIW2>%+GR+I8<S-O5<ID>OOBLX;L2/;O 5KX[M+Z\?QA=![;R
MAY/[R,@-GD_+[>M32>/?"D6J.LFN6P*.=QW9QCW Y%5_"Z^(M%\/ZU/X\U)?
M("@K*9%;8N#NZ#J25P.YKQ;=X4GM)+/1O#VLZC=!'W3M-M9%&?G 56'&1G('
M:G)7L,^C]5\5Z3I&@_VQ-?6[6C9$4BOE9&P2%!&>?E/Y5YYX1^,4>K3ZDWB*
MXL].B5(_LL:AOF)W;N>_\-<W\.M$M/$?PWU^TU+S9(;.X^U0QK(5V.L3#/'U
MK*^%?A#1O%9U?^UDDD^RK$T820K@DMG..O053V#H?0VE@9D?/8<^U4'\<^&D
MDO$;6K539?\ 'P"3^[PVW^?'%:&DC:)!V  _G7SOX>\.V7BCXO:EINH^8;8W
M5U(RQMM+$.<#-12^% CWJT\;>'+ZUN[JVUBUDAM$WSMOQY:^IS6=I7BO0=?U
M?R+#5;6>8G<$5OF(]@>O3M7A4/A&RE^+K>&!)(+$7;(<\L44%BN>.H&,_P Z
MNKIEOX>^-VF6&FM+'!'>VP7+G=APNX9]#N(_&G)<SL%CZ#U;Q'I.@HCZKJ-O
M:"0X42-\Q^@ZU7T[Q?H>LI)_9FJVUT\8R41OF'OCKBOG'6-:TW6?B/J&H>(8
M]0NM.$TBK!$1O"C(10<@*!UXST]R:2PU/3M.^(.GW_AVUO8+,R(ODW+#=\WR
ML-PSQS]>M4UHT@/IBR66:X,C.<#K@]ZU>U5K  6B^I))^M6JF"L@$[5S?B2_
MD9X].@8@N-TI'9?3^==(W2N):3[1J-W<'O(47/7 _P _I6&*FU&RZDR"*%(%
M"H ,#J.]/_$T45PV)"F21)*A1P"".II]%#[ 0Z/>-I.HB"1OW$GY"NK_ +7T
M_O>1?]]5R=Q;+<!0W&/3K4']E0C@-)^8JJ=:I25DKH+M'9'5--(P;R+G_:%<
MYK6@^&-88RF:&WF/)EA(4M]1T-4/[+A_O2?F*@N-)61HXT9PK'YVX.!Z?CTK
M:.+JWV0V[[G&ZOH0TZYV6MY'>Q8X:/@KC PP_P ,UGPW<L#$$%AZ'J*]$&AV
M@ &TGZX_PJM?>&+&ZB+,3$X'WQCCZUT1QEY6E'0AKL<M#.DZY0_45+6/'FVO
MMF02K%#@YSCWK8[D5UNW0"I<7RP2% A9@,FK$4@FC5U[]JKW5GYYWAN>E30Q
M>3&$Z^IINU@):**1F"C+$ >I-(!:*C\Z+_GJG_?0IRNK?=8'Z&@!U%%% !0,
MCH3110,**** #ZUB7JD>._!Q/?48Q_Y%C_QK;K#O"3X[\'CG_D(Q?^C(Z3*A
MN?1XZ54U;_D#7W_7O)_Z":MCI535O^0-??\ 7O)_Z":DL\"\(_\ (KV?MO\
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M9_"3_+\*[<<UPRCRRL>W2GSP4NXZBBBI- HHHH **** "BBB@ HHHH ****
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MBKEPJB(D#G-4^] $MM$9YTCQ]YAD^U;%V=\\<"D$)\M5]+C$44MTPZ#:OO\
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MD5]&%!^=9%T#%?[AP"0V<4ZCLD.]CS'X2^"M:T8Z]%K6GR6<5[;K$I+H2?O
MXP3TSWKFM.\(?$?P9J>H+H=H98)3L,RF)EE0'(8!CG/7MW-?1*J"/:C8!GOF
MK>J S=)8_,'^\5!->6>"O!WB#3/BS?ZQ>:;)%8227)28NI!#L=O .>?I7J%J
M3#?[/<J>*U=OIQ44G[M@1XS;>#M?C^-[Z^^G.-+-U))]IWKC:8V .,YZGTJK
MJ?A/7+GXT6NKPV#O8)=VSM,'7 50NXXSGC![=J]QV=>3@]JR;@?9KX$9'.1]
M*4WRV8FSR?Q+X!\4:!X[_P"$C\'1F<3R-*T2LJ^66/S(P) *'M_];-;FC3?$
MC5_%%O+KVGQ:?I<,;F2.(KM=MN%_B9B<D>W!KU%<, P/7D4ZM'JAW,W3[@AS
M"W?I6AG''ZFHFBBC<S8 8<YKC]<\3/=N;'2\DL=IE'?UQ[>]1'W(ZF52K&DK
ML[)IH\X\Q<_45QL:>7/=QMG>MPV?0 ].?SKGVT>0Y<SAF//4]?:IM.N9+:ZD
M%T&(^ZY/7!Z'\ZY,3*Z3.>GB>>7*T;W;-%'RX&#D$9##H1ZT5SG2%%%&0!DF
M@!&=4&78*/4G%1_:(/\ GM%_WV*+2R&N7WE$N+6(9=D.,MV%;'_"':?_ ,]K
MG_OH?X40IU)ZQ2L.S,?[1!_SWB_[[%'VB#'^OB_[[%:__"':?_SVN?\ OH?X
M4O\ PAVG_P#/6Y_[Z7_"K^KU^R#E9D?:(?\ GM%_WV*:T$%^NPQI.J#<0.0M
M-U/0%TFY\XQ7-U8-]XQD>9%QZ8Y'Y5CW^IVL$$T.CI=&62,I,\RX(7J0 ._
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M-??]>\G_ *":MBJFK?\ (&OO^O>3_P!!-0:G@/A#_D5K/_@?_H;5N5A^$/\
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M^%'SE9_O9>I8HI <BEJC,3M59OO5:[56;[U AM%%% !1110 4444 %';%%%
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M;NZQ%+=8W(64 [?7 7//K0%CUBDKQ.#X7ZK<>&EUQO$][_;<D0NT<RMM!QN
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M@L 1[TM( YI02IR."*2B@"?[;<!<;^/H*@))ZT44 (0&!!&0>HJ$VD#'F/\
M4U/13U 8D4<8^1 *X?Q]_P ?-C_US;^8KNZXCXA121W&GE^-T;$#\12;*CN>
MT_!7_DFUG_UVF_\ 0C7H5>>_!7_DFUG_ -=IO_0C7H52:!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% $4L"S@K(J.A&"K#(->:?$G1H;6.RN[6WBAC
MW-'((H@H)(R"2.IX/ZUZA56^L+;4+26VNHA+#(N&1N1_^NFG9W):N>#6-R(T
M$;$J1T)JW+>)@%Y\_C77W_PLC=Y'L-1\M2,K%*F[G_>!Z?@:CM?A4Q$;7>J
M'^-(HL_DQ/\ 2KNF1:1Q;:C$OW$)]S47]HOW11[$FO6K'X=^'[51YL#W+8P3
M,_'Y#%5_&.FZ-:^'I@-.MHII2!$T4*J=WU'MFES(?*SS>VN%G4X&UAVJ>LFT
M/EW:#!!Z'-:WMZ4,DI7EFTCAXUY/WJLVZ-'"JNV6J7Z4E%QBU6N[@P*NT99N
ME6:BE@CFV[QTH7F!G?;Y<_P'VQ4R:D.CQX]Q4C:=">A9?I2+IT>>6:JT%J7
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M5+4M/$NQ9XWVN%SG;[CD]:K^&OAQH/A74I-0T^.<W+H8RTTN[ )R<<>U7O\
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M8%O<_P!:$F)DM)1GWH_(_6F M*%<_=7/>KUJ]FL8,@'F=RPJQ)?0+&0I#'T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444TG&.<4 <WXO\
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M;;EE0,#^'2O#S*BHS51=3UL#5YHN#Z$]%%%><=P4444 %%%% !1110 4444
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M5][+EMX<TJ294;6[=\GA8R,G]:[2PT^UTZW$-LFU .3W/U-><SZ-\A,4F3U
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M?^A&MBL?PK_R+5G]&_\ 0C6Q7IT_A1\W7_BR]0HHHJC,**** "BBB@ HHHH
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MZ@O/*%N?.8A2> O4GM2>FJZ$R5TT9-I>P0P+!*WE2+P0PZFK?VNW_P">T?\
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M<#I5PAU9TT,.IOGF[B)&L:*B* JC  Z 5(.E)2UJ>BM@HHHH **** "BBB@
MHHHH ***1B1C'>@#EO&7B=/#]CLBVM>3 B-2?N?[1YKS'38" VJ77[UG)\G+
M#)?@[CWP.?Q^E/U^_&M>+YGN'983-Y:\'Y$''],_4T^5P[#:H0!0J(#P%'0?
ME6EK(R;NQG/<D^N3W[TM123I$,L1] :I27LD[".!#D\  98GZ4K7%<NS7$<
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M'<]L^"O_ "3:S_Z[3?\ H1KT*O/?@K_R3:S_ .NTW_H1KT*I- HHHH ****
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M_/.7]/\ &C^V+?\ YYR_I_C7:_\ "*Z/_P ^*?\ ?3?XT?\ "*Z/_P ^*?\
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MHV+L?*TJ%$/0^:Y8#ZY_I4M-;F-6,Z6DI*YI6]S'<INC/3J,8(IEU9QW6-V
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MW7_BR]0HHHJC,**** "BBB@ HHHH ****  @$'/2JXLH=^Y5)]NU6**  <
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M !1110 53OFOE"_8HX'/.X2N5^F, ]ZN44 >'^(?"^KZ;J<DIM6=)7+HT&9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"OAO\ T%:Z:O1I? CY[%?QI>H444<GHM:& 4444 %%%% !S3#$C')6GT4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MSSQS_P E"\ _]?-Q_P"@I7H=>>>.?^2A> ?^OFX_]!2@#T(=!45W_P ><_\
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M_P *Y\*?] K_ ,CR_P#Q5/@^'_ABWF$J:5&6])'9U_)B16@NKOGYHU_ T_\
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MB77BS0+.W:>?6K%(UQDBX4]3CH#5J/6M-GTY=1BU&V-FP!$_FJ$&??L>>AH
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M@&+$ZY?/3 S6HIR.N: %HHHH **** "BBB@ HHHH **** "BBB@ KR;XH_\
M)0?A]_U_C_T;#7K->3?%'_DH/P^_Z_Q_Z-AH ]9JGJW_ "!K[_KWD_\ 035R
MJ>K?\@:^_P"O>3_T$T ?/7A7_D6K3Z-_Z$:V*Q_"O_(M6GT;_P!"-;%>G3^%
M'S=?^++U"BBBJ,PHHHH **** "BBB@ HHHH *EAZD>E15)$?FH GHHHH&%%%
M% $,JXY%158D^[^%5Z!!1110 4444 %%%% !7>'_ ))%<?\ 7M+_ .AFN#KT
M&"![GX4S0QC+M;2X&<?Q-6-?9>IV8-:R]#GO@W_Q\:S_ +L7\WKU@5X]\(+K
M9K&H6NW_ %MNLN[=TVMC'X[_ -*]A%<U?^(ST<%_!0M%%%8G6%%%% !1124
M+13'D5!EF"_6J,NJQ+Q&"Y_*FDV2YQ6Y?)Q52XU&&'*@[V]!6<9;J]/ ;!/
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MY[\%?^2;6?\ UVF_]"->A4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW/@[4?B7<^(8X_$MD(=-\MR[B.-?FQ\O(.>M CH->^)GA?P[J;:??WS_ &E
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M!7 P>XX'- 'TA1110(**** "BBB@ HHHH **** "O!?V@O\ D*:'_P!<)?\
MT):]ZKP7]H+_ )"FA_\ 7"7_ -"6@$=Q\%?^2;6?_7:;_P!"->A5Y[\%?^2;
M6?\ UVF_]"->A4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5YYXY_Y*%X!_Z^;C_T%*]#
MKSSQS_R4+P#_ -?-Q_Z"E 'H0Z"HKO\ X\I_^N;?RJ4=!45W_P >4_\ US;^
M5 'S/X&.W1)3Z7+?^@K7:(ZNH.:XOP/_ ,@27_KX;_T%:Z8,5Z'%>C2^!'SV
M)?[Z7J7R0*AEFQ\JX+&H#*Y&"QQ3*T,;A11QWI_E2;<@9% BO<9,6!ZY-5(D
MWRX[5H$=B*8$13P #0 ^BBB@#/UEL6..[-BO7OAW;);>"; H6/F[I#GU+'_"
MO&]<?$$<?JQ;^G]:]T\+VRVOA;2HE4H!:QL1D]2,GK[DUS8I^ZD>AER]]OR-
MKO2TE+7&>P%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 (0",&DVCU-.HH .V*3:*6B@!-HQBDV#!'K3J* &[12A<'K
M2T4 %(5!.2*6B@!NP>_%&T$8IU% #=@]Z"H/6G44 -V#'TZ4I4'K2T4 (!@4
MFT$Y-.HH 0* <TM%% !3=HSGFG44 )C%!&3FEHH ;L&<UQ/BSX6:%XPU9=2O
MI[Z&=4$9^SN@# 9QD,I]:[BB@#A_"WPJ\/>%-2_M"V>[NKE5Q$UVZMY7J5PH
MY/J<UW%%% !1110 4444 %%%% !1110 4444 %%%% !7DWQ1_P"2@_#[_K_'
M_HV&O6:\F^*/_)0?A]_U_C_T;#0!ZS5/5O\ D#7W_7O)_P"@FKE4]6_Y U]_
MU[R?^@F@#YZ\*_\ (M6GT;_T(UL@E3P36-X5_P"1:M/HW_H1K8KTZ?PH^<K_
M ,67J3+<.." :'G8\#%0T51E=A1110 4444 %%%% !5*[NBC!$.&/)/I5VLJ
M\C*7)/\ >YIH3)+:[?S LC94^M:-8L:EY44>M;7<T %.#L!US3:*0QV\FF]:
M** "BBB@!KL%1F/89K&=R[ECU/>MF1=\3)_>&*Q2-K%?3BF)EBRD99@N?E8\
M"M2LJRB+SANR'-:M($%%%% PHHHH [?PEXJCBC33;]E5%&(IF/'T)IWBWX>6
MVMJ]_ICI;WKDNW/R2Y'Z'W'KS7#>GM70Z)XMO=)58I/](MQQY;'E!['_ #^%
M82I23YX;G=2Q,7'V=;8QM-\3>(O ER-.O;4R6RL<12@@8]4;T)'N.OX>EZ'X
MZT772$AN1#.>D4_R,?7'8_AZ5+%>Z'XGM&@D\F=/XH9EPP/T/X<BN6U?X3V$
MX:32;A[9MO$<A+J3QWZCOZU@W&3]Y69UQ56FKTWS1/2%;*YH!KQR.'X@^$]J
M1B>ZMD( 51YZ8ZGC[P].U:%E\7)D/EZII)5Q@$Q,1SW.#T^F:ET7TU-%BX[3
M37J>J9HKDK#XB>'+\J#J'V=CD!;A2G3U/3]:Z&TU.QO(T>WO()5?[A20-N^E
M0XM;F\:D)?"R[12#I2U)H%%%% !2-]VEHH \X7X612>/V\4WFJM<2&X,XMOL
MP4<#"@G)R%&.W;-=CK^CP^(-!O=)F?;'=1%"R]5/8]NA /X5JX%'% 'E5O\
M!T0>$;W0#K\CP7-S'<J_V8?(R@@\;N<_+W_A%;L?P^1/AH_@S^TF*/S]J\CG
M_6^9]W/X=:[C HXH XOP[\/[?0O!5]X;EO6NH+QI"\ACV$!U"XP">F,]:YCP
MU\)-0\/:S-(/$)DT]X)(_+",I<O&4RRYQQN)ZGH.G;UO HP/2@#AOA_\/(_
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M?@K_ ,DVL_\ KM-_Z$:]"H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>3?%'_DH/P^_P"O\?\ HV&O6:\F^*/_ "4'X??]
M?X_]&PT >LU3U;_D#7W_ %[R?^@FKE4]6_Y U]_U[R?^@F@#YZ\*_P#(M6?T
M;_T(UL5C^%?^1:L_HW_H1K8KTZ?PH^;K_P 67J%%%%49A1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]:!)#J***!A1110 4457N+I(,#;N/L:!%C)__5144,R31EER"#R*EI@%%%%
M] HQZ<444!H.5W1@R.RD'((-7Y=134[3[%K4;7L(YCDW?O8S[-W^A]*SJ*EI
M,J,Y1V92TK6;[P;KTCV<IEMBV"C_ "K,G;('1L?B#GWKW/1-9MM>TV._M"?*
MD'1A@J>X/N*\.U&T%U;X S(@^6M/X9^(#I>NMITTF+>]P!EL!9.<'\>GY5C7
MI*4>9;G9@\0XSY'LSW 4M-3[M.KA/:"BBB@ HHHH **** "BBB@ HHI&( R3
M@4 +15-]0MU8@N2?89H74;=OXR,>HIV9//'N7**CCFCE^XX;C/!J2D4%%%%
M!1110 4444 %%%% !1110 4444 %>"_M!?\ (4T/_KA+_P"A+7O5>"_M!?\
M(4T/_KA+_P"A+0".X^"O_)-K/_KM-_Z$:]"KSWX*_P#)-K/_ *[3?^A&O0J
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\\\<_P#)0O /_7S<?^@I7H=>>>.?^2A> ?\
MKYN/_04H ]"'05%=_P#'E/\ ]<V_E4HZ"HKO_CRG_P"N;?RH \R^ H_XH2Z_
M[",G_HN.O4J\N^ O_(B7?_81D_\ 1<=>I4 %)BEHH 3%-9<]*?10 T+@=*,4
MZB@+"8H%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KSSQS_ ,E"\ _]?-Q_Z"E>AUYYXY_Y*%X!_P"OFX_]!2@#T(=!
M45W_ ,>4_P#US;^52CH*BN_^/*?_ *YM_*@#S/X"_P#(B7?_ &$9/_1<=>I5
MY;\!?^1$N_\ L(R?^BXZ]2H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR;XH_P#)0?A]
M_P!?X_\ 1L->LUY-\4?^2@_#[_K_ !_Z-AH ]9JGJW_(&OO^O>3_ -!-7*IZ
MM_R!K[_KWD_]!- '@/A$;O"MF#_M_P#H;5INNTUF^$/^17L_^!_^AM6RR[AB
MO3I_"CYRO_$EZE:BE(*G!I*HR"F-$C')6GYHQ0 @ 48'2EHHH **** "HYVV
MP_6I*AN?]3^(H IT444  R.G6M"-M\:M^=9_:K5K]QOK0!8HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C>>*/[[[?PI9Y/*B9O:
ML8DL<F@#921).48-3ZQHI/*E5O?FM@=*!(6BBB@91OXY'*%%W#'3WJ>UA,46
M#_%R:GHH **** "BBB@ [5E:XP\B)<98N3G&>.]:M8FN28E@0=54GZ?YQ37<
M1[%\+P1X'M\@\RR$$C&1NZ_2NRK%\(VC6/A33;=_O+ I/R[<9YQC\:VJ\N;O
M)L^EI*U-(****DT(+F*21/W<K(WMWK.:QO'.6E_\>-:]%-2L1*"EN9*Z2Q/S
MR#'L*F72H1C<S''7'%:%'X4^=B5***\=C;+R(P3[DFIPBJ,* /I3J*5V6DEL
M)BEQ112&)BEHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O!?V@O^
M0IH?_7"7_P!"6O>J\%_:"_Y"FA_]<)?_ $): 1W'P5_Y)M9_]=IO_0C7H5>>
M_!7_ ))M9_\ 7:;_ -"->A4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YYXY_P"2A> ?
M^OFX_P#04KT.O//'/_)0O /_ %\W'_H*4 >A#H*BN_\ CRG_ .N;?RJ4=!45
MW_QY3_\ 7-OY4 >9_ 7_ )$2[_[",G_HN.O4J\M^ O\ R(EW_P!A&3_T7'7J
M5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^U8N/Z4)/X@\M?,\'Z_O[[;&3G]*?M8=P^J5OY30HJAY^N_]"?XA_P# %_\
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MGZ[_ -"?XA_\ 7_PH\_7?^A/\0_^ +_X4>VI]P^J5OY2_15#S]=_Z$_Q#_X
MO_A1Y^N_]"?XA_\  %_\*/;4^X?5*W\I?HJAY^N_]"?XA_\  %_\*//UW_H3
M_$/_ ( O_A1[:GW#ZI6_E+]%4//UW_H3_$/_ ( O_A1Y^N_]"?XA_P# %_\
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M?6KW_"R[_P#Z$/Q3_P" 3?X5QU*G.[GK8>@J4;'H(I:\]_X67?\ _0A^*?\
MP";_  H_X67?_P#0A^*?_ )O\*S.@]"HKSW_ (67?_\ 0A^*?_ )O\*/^%EW
M_P#T(?BG_P  F_PH ]"HKSW_ (67?_\ 0A^*?_ )O\*/^%EW_P#T(?BG_P
MF_PH ]"HKSW_ (67?_\ 0A^*?_ )O\*/^%EW_P#T(?BG_P  F_PH ]"HKSW_
M (67?_\ 0A^*?_ )O\*/^%EW_P#T(?BG_P  F_PH ]"HKSW_ (67?_\ 0A^*
M?_ )O\*/^%EW_P#T(?BG_P  F_PH ]"HKSW_ (67?_\ 0A^*?_ )O\*/^%EW
M_P#T(?BG_P  F_PH ]"HKSW_ (67?_\ 0A^*?_ )O\*/^%EW_P#T(?BG_P
MF_PH ]"HKSW_ (67?_\ 0A^*?_ )O\*/^%EW_P#T(?BG_P  F_PH ]"HKSW_
M (67?_\ 0A^*?_ )O\*/^%EW_P#T(?BG_P  F_PH ]"HKSW_ (67?_\ 0A^*
M?_ )O\*/^%EW_P#T(?BG_P  F_PH ]"HKSW_ (67?_\ 0A^*?_ )O\*/^%EW
M_P#T(?BG_P  F_PH ]"HKSW_ (67?_\ 0A^*?_ )O\*/^%EW_P#T(?BG_P
MF_PH ]"HKSW_ (67?_\ 0A^*?_ )O\*/^%EW_P#T(?BG_P  F_PH ]"KP7]H
M+_D*:'_UPE_]"6NW_P"%EW^/^1#\4_\ @$W^%><_$N77O&]YI\UGX/\ $%N+
/6-U836+Y8L0>,#VH&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>gvvh0m1pmdf2000013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gvvh0m1pmdf2000013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,U!X$# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?/&A>&+?Q=\3O%4%[=74?V=@\312XVG'6OH>OG30/#EWXC^*GB
MJ"VU:?3PKC>8<9<$=.E &WX,UG4IO#/C'1+ZYDNX["*417#=QMZ9J'X8^/\
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M1'^A-=Q7A>H^&-2UW3;)[KQII)MPZO#MC .>P'->VV<4D-E#%*X>14 9AW-
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MX1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.:
M/0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;
M?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?
M^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q_
M_P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__
M -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_
M (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_
MX1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.:
M/0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;
M?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?
M^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q_
M_P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__
M -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_
M (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_
MX1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.:
M/0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;
M?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?
M^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q_
M_P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__
M -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_
M (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_
MX1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.:
M/0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;
M?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?
M^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q_
M_P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__
M -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_
M (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_
MX1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.:
M/0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;
M?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?
M^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q_
M_P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__
M -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_
M (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_
MX1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.:
M/0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;
M?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?
M^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q_
M_P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__
M -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_
M (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_
MX1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.:
M/0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;
M?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?
M^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q_
M_P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__
M -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_
M (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_
MX1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.:
M/0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;
M?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?
M^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q_
M_P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__
M -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_X1?Q_P#]#?;?^ YH ]#HKSS_
M (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.: /0Z*\\_X1?Q__P!#?;?^ YH_
MX1?Q_P#]#?;?^ YH ]#HKSS_ (1?Q_\ ]#?;?^ YH_X1?Q__ -#?;?\ @.:
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MTC[4GVY$WM%W ]: -*BJ]M?VEXTBVUQ'*8SAPISM-6* "BBB@ HHHH ****
M"BBB@ HHHH *PT\46<EU+&D<QAB#%[C;\@P,FM+4Q,VEW0MO]>8F\O\ WL<5
MY1-=ZNGAB*S@NHY;B7>L]FB8**"23GOQ0!Z+9>*K"^NHX%66/S3B)W7"R?2M
MRN"DOK74;;0+2Q?-Q%(I90O,>%YSZ=Z[BY\[[-)]FV^=CY-_3/O0!+17*:?J
M^NP^*8=)U:*TV36SSJ\#DD;6 QT'K75T %%%8^D:M-J6H:C$T:K#;2^6K \D
MCK_2FHMIL5S8HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N:^(/_ "(>L?\ 7 _S%=+7-?$'_D0]8_ZX
M'^8H ^::*** /ICQIX@_X1_0I)HV N)/EB'OZUYSX8\#W?BEVU/4YF2&0Y#'
MEGK0\<&3Q!XZL=&0GRX\ X[9Z_RKU*TM8K*SBMH5"QQJ%4"M^;V<%;=G#R*O
M5?-\,3CQ\+M VX(E)'?=1_PJWP__ '9O^^J[>BL_:S[G1]7I?RHXC_A5OA_^
M[-_WU1_PJWP__=F_[ZKMZ*/:3[A]7I?RHXC_ (5;X?\ [LW_ 'U1_P *M\/_
M -V;_OJNWHH]I/N'U>E_*CB/^%6^'_[LW_?5'_"K?#_]V;_OJNWHH]I/N'U>
ME_*CB/\ A5OA_P#NS?\ ?5'_  JWP_\ W9O^^J[>BCVD^X?5Z7\J.(_X5;X?
M_NS?]]4?\*M\/_W9O^^J[>BCVD^X?5Z7\J.(_P"%6^'_ .[-_P!]4?\ "K?#
M_P#=F_[ZKMZ*/:3[A]7I?RHXC_A5OA_^[-_WU1_PJWP__=F_[ZKMZ*/:3[A]
M7I?RHXC_ (5;X?\ [LW_ 'U1_P *M\/_ -V;_OJNWHH]I/N'U>E_*CB/^%6^
M'_[LW_?5'_"K?#_]V;_OJNWHH]I/N'U>E_*CB/\ A5OA_P#NS?\ ?5'_  JW
MP_\ W9O^^J[>BCVD^X?5Z7\J.(_X5;X?_NS?]]4?\*M\/_W9O^^J[>BCVD^X
M?5Z7\J.(_P"%6^'_ .[-_P!]4?\ "K?#_P#=F_[ZKMZ*/:3[A]7I?RHXC_A5
MOA_^[-_WU1_PJWP__=F_[ZKMZ*/:3[A]7I?RHXC_ (5;X?\ [LW_ 'U1_P *
MM\/_ -V;_OJNWHH]I/N'U>E_*CB/^%6^'_[LW_?5'_"K?#_]V;_OJNWHH]I/
MN'U>E_*CB/\ A5OA_P#NS?\ ?5'_  JWP_\ W9O^^J[>BCVD^X?5Z7\J.(_X
M5;X?_NS?]]4?\*M\/_W9O^^J[>BCVD^X?5Z7\J.(_P"%6^'_ .[-_P!]4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<S\*_P#DG>F_[\W_ *->@#LJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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MM_QZQ?[@_E4M16W_ !ZQ?[@_E4M !1110 57OO\ CRE_W35BJ]]_QY2_[IH
M33_^/"'_ ':LU6T__CPA_P!VK- !7FWCK0]1M?%ND>*=*B,S0-Y5Q&O4H>_\
MJ])HH P=3L=7U!XKG2]6-G&T?,;0JV<]^15+0/!::,][>O>/<ZK>#]Y=NO(^
M@Z 5U=% '"ZCX$U#7_(M]<UQ[JQB<.85B5-Y'KBNQDMFCTXVUFPB8)MC;'"^
ME6:* .,M?A_;+X4O='NKAIIKTLT]Q_$S'O46@?#\Z9KD&J7VH->36L/DVX*@
M!%Y_7FNXHH 1T61&1U#*PP0>A%<)%\.FT?4;J\\-ZK+IOVEBSP[0Z9)R2 <@
M5WE% '!>(/ %[XE\/0Z;J6M/+-'=I<^=Y8'W0>,#ZUG^+M$U7Q%XMT/1HX6&
MD6>)[B<]&(Q@?7DUZ;10 BJ%4*.@&*6BB@ JA#_R%Y_]P5?JA#_R%Y_]P4 7
MZ*** "N%^*'B.XT7P_':6.\7M_(((F0X*Y[UW5>2_%Z%XM<\,Z@[D6T5T%<=
MN>_Z4 6/$.OZAX&\/Z'HUE,\VH7C",SW+ER#QDDG-3/XDU[PKXLTK3M9OXKV
MSU+"A_+",C_@.G(K=\:Z!HOB+3;0ZC>?9&1PUO<*<$-7F^K:*VN?$;0;>#6)
M=4-FZO*X7"1JI&._7K0!L^&?$NO^)/&.N:;)KJ6D%I)B%1$F2/Q'-=3XY\0Z
MAX1\(QS0R>?>22+")V08&Y@-Q'XUS/BSP[X,L](U.^M;K[/JJY=9(I2)/- X
M'KZ5T7A2PG\5?#>TMO$L1D>5/FW?>P#P?KTH P]-\<:GH^N7ECK5]%=PK9BX
MCD5 I5B 0IP/4UU_@J35[S2#J&KS9DNF,D46T#RT)^4?EBO-IO!^EWGBN>QT
MJ2XG@L8_-O)9)"Y9U&43)[#"UDZ=XCUF"?2]1AU6ZFOIM0>WDTXN=@C!8#Y>
M@X - 'T*3@9/:O-I?&.M^(_&=UH/APPP6UGQ<7<B[OF] ,&O1F!DA*G@LN*\
M:\'72^!OB#KVGZNC06]]-YL%RX^5N3CG\: .MUM_$_AKPAK>HSZQ'=/;VCR0
MMY*J58#K@#%<IJ>LZ]=_"O1?&<5W,;^T FG6-MJ2+WW*.#TKK/'NN:9J7P[\
M20V5Y%/(MA(2$.<<5RMI=0VO[-1\X@>9ISQIGNQ!Q0!ZIH6IIK.AV>H(,">,
M/BM"N3^&MK+9_#W1X9V9I!#R6Z]3764 %%%% !5>]N19VK3F)Y G)5!S5BL[
M7)[VVT>XET^(27*K\BF@#F=<\2RO>01VEZUK9LA+7"0[VW<?*5(R*WO#-W=W
MNCK->G=)O(5RNTNO&#CM7':;'J&HZW"]O/.203-,;98PAXP#@_-WKT"Q^UB#
M;>;#(IP&3H1ZT 6J*** "BBB@#EKW_DI6F?]@Z;_ -&)6YJ]T++2+JX/\$9-
M8=[_ ,E*TS_L'3?^C$J;QQ*R>&9XU^],PC ]<U<%>20I.R;$\"P&'PE9EOO2
MKYA_&NDJMIULMGIUO;I]V- HJS2G+FDV$59)!1114C"BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N:^(/_(AZ
MQ_UP/\Q72US7Q!_Y$/6/^N!_F* /FFBBB@#WCX3_ /()O?\ KJ/ZUZ%WKSWX
M3_\ ()O?^NH_K7H7>M*WQLPPO\&(M%%%9FX4444 %%%% !1110 4444 %%%<
MIX@UB\N;Y=$T9L73C,TP_P"62TTKLF<U%79U=<]XF\)Z?XAMB9E$=P@^28=1
M7(0:YKO@G4?LNME[NQD;Y9\YQFMW5?$?]M&'2]!D\V2Y7,DRGB)/\:T4)1=T
M8.K"<6I+7L<KH?BZ^\+WK:;J+FZT^)_+$ZG.W%>JV5];:A;+<6LJR1L,@J:S
M(?"^F1Z&-*>!9(<?,6')/K]:Y*U\-^(?"NMJ-&;[1I\K?-&YX6G+EGMHR8>T
MHV3U7Y'I%%(FXHNX8;'(I:Q.L**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K@/BA_QY:=_U\+7?UY]\42?LNFC_ *>%K2E\:.?%?PF=U8_\
M@^V_ZY+_ "%3U!8_\@^V_P"N2_R%3UFS=;!1110,**** *>K?\@:^_Z]Y/\
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M)_Z":YGX5_\ ).]-_P!^;_T:] '94444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 AZ&N(OO^/V7_ 'C7;GH:XB^_X_9?]XT 5Z*** "BBB@
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MX4 6;;_CUB_W!_*I:BMO^/6+_<'\JEH **** "J]]_QY2_[IJQ5>^_X\I?\
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M;22V%N]M"T Z1E!M_*DFL+.Y@6">UADB7@(Z @?A0!YEX.E&N_%76M<LU8V
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M_P"\:[<]#7$7W_'[+_O&@"O1110 4444 %%%% !1110 4444 %%%% !1110
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M<Q/UR:]THHH *HZO_P @Z3\*O51U?_D'2?A0!9MO^/6+_<'\JEJ*V_X]8O\
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MH@8JH*VD1)"@Y/!ZYH [./Q_&?&X\,S:7=0R,3Y<[A=C@#.1SFNDA_Y"\_\
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MCB2)=L:A1Z 4^L:E1S9V4*"I+S"BBBLS<**** "BBB@ HHHH **** "BBB@
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M )*5IG_8.F_]&)732Q)-$T<BAD88(/>N9O?^2E:9_P!@Z;_T8E=30!XYXO\
M"4OAR].IZ>KBR9LMY?#1'VKI?#7C9BD,&IMNA<8CNQT/LWH:[J>"*YA:&9 \
M;C#*1P:\B\0Z#<>#;][NWA^TZ-.<2P'D+7=3FJT>2>YSRBZ;YH['KZ.LB!T8
M,I&013J\WT/69]+L4O+&1KW1V^_'G,D'_P!:N]T_4;74[5;BTE62-AV/2N6I
M2</0VC-2+=%%%9E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<U\0?^1#UC_K@?YBNEKFOB#_R(>L?]<#_ #% 'S31
M110![Q\)_P#D$WO_ %U']:]"[UY[\)_^03>_]=1_6O0N]:5OC9AA?X,1:***
MS-PHHHH *"<#)HK%\0C4KBV%EIR;6FX>8G[@II78I.RN8VJ7$_BC5CI%D2+"
M%O\ 2IE[G^Z/UKK;6VAL[=(($"1H,!1531='@T73H[6'D@?.YZL?4UHTY/HM
MB*<6O>ENPHHHJ30**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\]^*7_'MIO\ U\+7H5>>_%+_ (]M-_Z^%K2C
M\:.?%?P6=W8_\@^V_P"N2_R%3U!8_P#(/MO^N2_R%3UFS=;!1110,**** *>
MK?\ (&OO^O>3_P!!-<S\*_\ DG>F_P"_-_Z->NFU;_D#7W_7O)_Z":YGX5_\
MD[TW_?F_]&O0!V5%%% !1110 5%<"0VT@B_UFT[?K4M1SR&*WDD"[BJD@>M
M''F75M=*:>%N+)(<^?-C!8]@/TK?T W7]FA+HLS(Q56<8+#/4UCQVGB+4%^U
M1:I';J_2-$SBM_2K>\MK3R[VY^T2Y^_C% %ZBBB@ HHHH BAMX;<,(8U0,VY
ML#J?6HO[-L_M'G_9H_-_O8YJU10 4444 %%%% "'H:XB^_X_9?\ >-=N>AKB
M+[_C]E_WC0!7HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!
MR??7ZUW4/^HC_P!T5PJ??7ZUW</^HC_W10!0OFTZ\3R+R$3(K9VLN1D5*NH6
MJJ%7< !@#;5ORT/\(_*D\I/[@_*@#D=5\*^%]9OC>7EH[3-]XKD!OK5J\T7P
M[>Z5#IDEIBTA8,D:+@ CI72>4G]P?E1Y2?W!^5 %-+VT2)8EW; , ;>U<K=^
M"/!]Y>/<R6!5W.75.%8^XKMO*3^X/RH\I/[@_*@"A:3Z?86L=M:Q^5#&,*BK
MP!3+AM+NKB&>> 22PG,;LG*_2M+RD_N#\J/*3^X/RH I3ZA ]M*J[LLA ^7V
MKRCP;X!TZ1=4D\1V#>8]ZTD7^TNXD9_2O9/*3^X/RH\I/[@_*@#G9](\/W&H
M6-Z]L?.L5VVY"\*/2LFX\">#+FYGGDT\[IF+,!TSZXKN/*3^X/RH\I/[@_*@
M#E]5\/>&]96U%Y;,QM1B)@,%135\->&5FOIA:MOOH_*G./O+S_C75>4G]P?E
M1Y2?W!^5 ',3Z!X<N=(M-+EMF-I:,'A3'W2#D?K4>J>&?"^L7D5W>69>:)0H
M8#&0.QKJ_*3^X/RH\I/[@_*@#D?^$4\*C3?[/%F1;><)]@'\8.<UH2Z?HDVJ
MVNIO"QNK5/+B?'W1C%;WE)_<'Y4>4G]P?E0!@Z9IVB:1?WE[9PM'/=MNF;'W
MC6K_ &E;^K?]\U9\I/[@_*CRD_N#\J *W]I6_JW_ 'S1_:5OZM_WS5GRD_N#
M\J/*3^X/RH K?VE;^K?]\U4U.^@EL752V3CM6IY2?W!^54M6C0:?(0H'3M0
M0:C;K;QJ2V0H_AJ3^TK?U;_OFI;:-/LT7RC[@[>U2>4G]P?E0!6_M*W]6_[Y
MH_M*W]6_[YJSY2?W!^5'E)_<'Y4 5O[2M_5O^^:AO-0@>TE4%LE3_#5_RD_N
M#\J@O8T%E+A1]T]J *UEJ$"6<2L6R!_=J?\ M*W]6_[YI;"-#80DJ.GI5CRD
M_N#\J *W]I6_JW_?-']I6_JW_?-6?*3^X/RH\I/[@_*@"M_:5OZM_P!\T?VE
M;^K?]\U9\I/[@_*CRD_N#\J *W]I6_JW_?-']I6_JW_?-6?*3^X/RH\I/[@_
M*@"M_:5OZM_WS1_:5OZM_P!\U9\I/[@_*CRD_N#\J *W]I6_JW_?-']I6_JW
M_?-3(;>1F5#&S+U (.*<%B+%0%)'4>E %?\ M*W]6_[YH_M*W]6_[YJSY2?W
M!^5'E)_<'Y4 5O[2M_5O^^:/[2M_5O\ OFK/E)_<'Y4>4G]P?E0!6_M*W]6_
M[YJG%?0C4YG);:5':M7RD_N#\JHPQI_:TXVC&P=J )?[2M_5O^^:/[2M_5O^
M^:L^4G]P?E1Y2?W!^5 %;^TK?U;_ +YH_M*W]6_[YJSY2?W!^5'E)_<'Y4 5
MO[2M_5O^^:/[2M_5O^^:L^4G]P?E1Y2?W!^5 %;^TK?U;_OFC^TK?U;_ +YJ
MSY2?W!^5'E)_<'Y4 5O[2M_5O^^:/[2M_5O^^:L^4G]P?E1Y2?W!^5 %;^TK
M?U;_ +YH_M*W]6_[YJSY2?W!^5'E)_<'Y4 5O[2M_5O^^:/[2M_5O^^:L^4G
M]P?E1Y2?W!^5 %;^TK?U;_OFC^TK?U;_ +YJSY2?W!^5'E)_<'Y4 5O[2M_5
MO^^:/[2M_5O^^:L^4G]P?E1Y2?W!^5 #89X[A2T9) ]14M(%5?N@#Z4IZ4 <
M1>:QK$^L75M!JNG6"PMA89TRY'][[PXKIM$>ZDTY6N[N"ZEW',D"X4_J:\_O
M3'I_B*__ +0T".Z$LI:.XDN0K,/3'I7=^'2C:0C1V'V)2QQ#NW?CF@#5) !)
MZ"LFU\3:9=7DUJLS1RP@LPE7;D#J1GJ*FCN-0%_*MQ;1QV2C*R^8,GZBN%U:
MY/B47]_I[1)!:1/''@C?)P=YQZ8)H [.Q\3Z5J%X;6"X_>9PI88#_P"Z>];%
M<'-+9S67AQ-/:+[1O7 3J!M^;/ZUW$YD6%S"H:0#Y5)QDT <U>_\E*TS_L'3
M?^C$KJ:X>.749?B3I_\ :%M'"1I\NW8X;/SI7<4 %0W=I!?6SV]Q&)(G&&4U
M-11L!X[J6F:CX UO[99AI=-F;!0\@CT-=#8I]J0:WX7E"/UN+)NA]>.QKN+Z
MQM]1M)+:ZC#QN,$&O*KK3M1\$:XDMM(Q@<_(3]UQ_=/O7="I[56?Q?F<\H\C
M\CT30_$=MK"M&08+N,XD@?A@?\*VJXI8+'Q?9K>V$AL]3B/)7A@WH1Z5<TSQ
M++;7HTO7$\BZ'"38^27\?6N>=/\ E^XT4NYU-% ((R.0:*Q- HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YKX@_\B'K'_7
M_P Q72US7Q!_Y$/6/^N!_F* /FFBBB@#WCX3_P#()O?^NH_K7H7>O/?A/_R"
M;W_KJ/ZUZ%WK2M\;,,+_  8BT445F;A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*** ')]]?K7=P_ZB/_=%<(GWU^M=W#_J(_\ =% #Z*9--%;Q-+-(L<:]68X
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MSO+>_M4N;:020O\ =8#K0!/116=/K%O;:Q;Z;*&$MPI:-L<'&./UH T:***
M"J.K_P#(.D_"KU4=7_Y!TGX4 6;;_CUB_P!P?RJ6HK;_ (]8O]P?RJ6@ HID
MLT4$9DFD2-!U9C@4J2)+&KQL&1AD,IR"* '57OO^/*7_ '35BJ]]_P >4O\
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MOUYQ0!KT5C:=K=S?/(LNCW5J$7<#(RG=[#!JJ/$U[YVS_A';_&[&[>F/KUH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7GOQ2_X]M-_
MZ^%KT*O/?BE_Q[:;_P!?"UI1^-'/BOX+.[L?^0?;?]<E_D*GJ"Q_Y!]M_P!<
ME_D*GK-FZV"BBB@84444 4]6_P"0-??]>\G_ *":YGX5_P#).]-_WYO_ $:]
M=-JW_(&OO^O>3_T$US/PK_Y)WIO^_-_Z->@#LJ*** "BBB@ JE<7=S%=B*.T
M:2,QEO,!&,CM5VH[@R"VD,0S)M.WZT <5<7$\]UYTG@^1Y ?O?)S^M=5I%S/
M=62O/9-9L#@1-C@?A7-?VCJ>NE=.MC/9M$";FX*]#Z"N@T"6YDTX"Z8NZ,5$
MA&"P!ZT :E%%% !1110 4444 %%%% !1110 AZ&N(OO^/V7_ 'C7;GH:XB^_
MX_9?]XT 5Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH <GW
MU^M=W#_J(_\ =%<(GWU^M=W#_J(_]T4 <+\0+HWU]I?AR.4)]L<M-DXP@!/\
MP*I^%;^0^#];TF>4/-I[RQJ0<_)D[?TQ70R>$8K_ ,3W.K:CME4QB.! ?N#C
M/]:K#P2+/6+^YTYTBM[VV\J2,_WN,']* +_@Y%F\%:?'(,JUNH(/TKSFX$EE
MXH;P+%> :7<S^<9-Q^12>8L_C^E=[I&G>(]+TJ'3@+'RXH]BR"1L],9QMJDO
MP_1O#LMO-.&U627[0;ON)/4>W)H =X\\/0W/A2Y8SRI;VEJ^R!&*J3C@G'6K
M^F:I#HWP_M;Z=@$BML@$]3S@4[6M-UG4/#C:9&;9I)H#%-([$8)'4<4[3-!E
MDT"/2=;@MIH8@ H0ELX[G(H X[0+7R?'UEJ5W<A[N_A>23+\+P0%'Y52UN_.
MD>(-?/V(:VD^&+JNXVF5 P<]N_&>M=HW@:Q7Q+::E$@6&!"NS)Z\XJO:^%M4
MT2YU0:5);RV^H.9&^T$AD) ''!STH M>'66S^'RR1W?VH+;NXD!/'4XY].GX
M56\):6+KP ((IW@>[9Y6E3[P+/N/\R*U=%\.)HWAA]*60R%UD+,>[.23^&36
M5X&N;H^%;BRBC07ME<20[)"0.'./TH SOAK91Z?JWBBTA+%([I5!9B2?O=S3
M$TV\\-W&LZA>:)!?V\MTTX< %PA)/>M;PSH&M:/K&I75P;1H]0E\V38Y)3&>
MG'/6K>HV/B2_M[BP,]HEO,2OGC.]4_W<8S^- %+4O$5[/>:##HDL:6^HJV69
M0=J\<CCMFJ%GJ7BBYUO4]!;5(UDLU$RWH@7<RG.%*XQ_"?SK=7PHMO>:(UM(
M!!IJ%<'JV<?X5):>'9;?Q3J>K&52EW"D:KW&"W^- '/2>--0E\,V$D31Q7ES
M<_97G91M0[@-V.G>K'A;4==D\5ZG8:CJZWUK:H"C)"B@Y ZD#KS6#KWAR33=
M/TG29;M8O-O3)YYC#HO((R#WJ0:G/X8EU+3H9HK]9;?(GAMA&5D;Y0#MZ]J
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M3_UZQ_RI_B"VU*\L7M;!;<K*I5S*Q&/I@&F^&;*_TW1H+&^$.;>-8T:)B=P
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M@#U-&X;=V>,9S0 M%<K!XYLKOQ8FAVT,KY5B9\83(."!742.L4;2.<*HR30
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M_BZ/^%>^)/\ H?\ 4_\ OV?_ (NO1:*S-SSK_A7OB3_H?]3_ ._9_P#BZ/\
MA7OB3_H?]3_[]G_XNO1:* /.O^%>^)/^A_U/_OV?_BZ/^%>^)/\ H?\ 4_\
MOV?_ (NO1:* /.Q\/?$>1GQ]J9_X ?\ XNN^M(7M[2*&29IG10&D;JQ]:FHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "O/?BE_P >VF_]?"UZ%7GOQ2_X]M-_Z^%K2C\:.?%?P6=W
M8_\ (/MO^N2_R%3U!8_\@^V_ZY+_ "%3UFS=;!1110,**** *>K?\@:^_P"O
M>3_T$US/PK_Y)WIO^_-_Z->NFU;_ ) U]_U[R?\ H)KF?A7_ ,D[TW_?F_\
M1KT =E1110 4444 %1W$OD6\DN,[%+8]<5)2,H=2K#((P10!R5K<:HVJ65Q<
M7P,-SOQ JX"@ XR>];>BWLU[;2--R4D*A@,;A6/=>#6>Z26VU6YMX4)/E Y
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MUN(8?BTR1;%0:>  N,#YFKN4A1+=8 /D"[<>U8R^#]#2^^VK8H+D?\M._7-
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M'Z"@#SK7+#4_#O@"^T7S;6:S$;10/G,C ]%VXZ_C6I?P26Q\&PRC$B3 ,/\
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M&[($6J6Y8_PEQFLG2FMT6IQ?4VJ*A2Z@E *3(P/3!J7(/>LRA:*** "BBB@
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MKJ%I=QV;M)>%U'5<5NU1U?\ Y!TGX4 5X;*]:",B_8 J,#;TI_V"^_Z"#?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[+_O&NW/0UQ%]_Q^R_[QH KT444 %%%% !1110 4444 %%%% !1110 4444
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M<T <U>_\E*TS_L'3?^C$KJ:X>*>_G^)%A]NM5@(T^7;M;.?G3WKN* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@"-[>"3_60QM_O*#5*;0-)G_UEA <_[.*T:*:DUL*R,"7P;HLGW;8QGU21
MA_6J,G@<*<VFL7\![ ."/U%=;15JK-=1<D>QPM]H/BFRL9WM=?:<*AQ&Z#)_
M2O%EEU :H&#S?:M_OG.:^H^HP:H?V)IGVK[3]BA\[.=VP5T4<7R7YE<RG1YM
MF<Y8OXU^PPYCT\G8.7W9_'FK&_QI_P \M-_\>_\ BJZJBL'5_NHTY/,Y7?XT
M_P">6F_^/?\ Q5&_QI_SRTW_ ,>_^*KJJ*/:^2#D\SE=_C3_ )Y:;_X]_P#%
M4;_&G_/+3?\ Q[_XJNJHH]KY(.3S.5W^-/\ GEIO_CW_ ,51O\:?\\M-_P#'
MO_BJZJBCVOD@Y/,Y7?XT_P">6F_^/?\ Q5<SXYD\6CP\_P!I6V6#/SFVW;L?
MF:]0IDL4<T;1RHKHW!5AD&JA6Y9)\J%*G=6N?/G@%[__ (2RT%NTFTN/,'.-
MO?-?0U4K32-/L)#):VD43GJ57FKM/$5E5E=*P4H<BL%%%%<YH%%%% !1110
M4444 %<U\0?^1#UC_K@?YBNEKFOB#_R(>L?]<#_,4 ?--%%% 'O'PG_Y!-[_
M -=1_6O0N]>>_"?_ )!-[_UU']:]"[UI6^-F&%_@Q%HHHK,W"BBB@ HHI"0
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M2SE&+1SGS>G0?A0!VGASXC:-XCO_ .SXS+;7F,K#.I5F'J*ZXD*"20 .I->
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MZUZ728 Z 4 >4?'&PN[[3-%6UMY)BE^C,$&<#FN@\4?#^W\:66EFYOI[5K1
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MVYZ&N(OO^/V7_>- %>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(':&QV/CL?FKJ8?^0O/_ +@J>.QM8KI[F.WC6=_O2 <FHXHG74YI"IVE1@T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *YKX@_P#(AZQ_UP/\Q72US7Q!_P"1#UC_ *X'^8H ^::*** /
M>/A/_P @F]_ZZC^M>A=Z\]^$_P#R";W_ *ZC^M>A=ZTK?&S#"_P8BT445F;A
M1110 4444 %%9&J^(['2-1L;&Y+":\?9%@=ZUZ (;J[M[* S74R0Q#J[M@"E
M6XA:W^T+*AAQNW@\8]:X#XVLR_#.]*D@^8G(/O7!R>);_P 4Z)H_@OPU,?-:
M$?;9UYV+W&: /=[34+._5FM+F*<*<,8V!P:LUS>B:/IO@7POL#;8H(]\TK'E
MCC)-<Z/B[8E#=#2+\Z:&P;S8=@YQGITH ]&HKB];^)&G:+<:0K6\DUOJ8!BN
M%/RC/3-7?%GC6S\*I8B6%KB:]E$<4:-@G/>@#IZ*\4^*?C[6=+UW2K&RM;FW
MB\S,C#_EOTX'%=EJ/Q%CT7P4OB'4=)NH%\Y83 YPW/?ITH [FBN*TKXCV&LR
MWWV2SN&@M(?-:?'R/P3@''/2K7AWQU:>(O#-YK<%K)'%;%PR,V2=HS0!U=5K
M^^M]-LI;R[D$<$0W.YZ 5S6@_$#3=;\,7>O-&]M:VKLKASD\5Q'B?XI:=KO@
MW4XTT^[@MID,<-TZ'8Y^N* /6-*U6SUK3X[^PF6:VDSM=3P<5=KS?X8:@FE_
M""QO)(WD6(.=B#+'YST%6+?XJ6G]I6]GJ.D7NGBY;;#+.IVM^G% 'H%%("",
MCH:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O/?BE_Q[:;_ -?"UZ%7GOQ2
M_P"/;3?^OA:TH_&CGQ7\%G=V/_(/MO\ KDO\A4]06/\ R#[;_KDO\A4]9LW6
MP4444#"BBB@"GJW_ "!K[_KWD_\ 037,_"O_ ))WIO\ OS?^C7KIM6_Y U]_
MU[R?^@FN9^%?_).]-_WYO_1KT =E1110 4444 %,E0R0NBL5+*0&':GU%<;#
M;2>8=J;3N(["@#FI?#.I;'9->N <$C/2M#PP\C:65EN6N)$<JSMZYK$U#2]#
ML+5+J>ZO&64_*JODM^&*Z;1C9MID)L!B#' [_C0!?HHHH **** "BBB@ HHH
MH **** $/0UQ%]_Q^R_[QKMST-<1??\ '[+_ +QH KT444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 Y/OK]:[N'_ %$?^Z*X1/OK]:[N'_41
M_P"Z* 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXC(VQ(6C.]C[#K5S2=8M=8MC-;%AM;:Z.,,I]"* ,_\ MG6?^A?;_P "1_\
M$T?VSK/_ $+[?^!(_P#B:WZ* ,#^V=9_Z%]O_ D?_$T?VSK/_0OM_P"!(_\
MB:WZ* ,#^V=9_P"A?;_P)'_Q-']LZS_T+[?^!(_^)K?HH P/[9UG_H7V_P#
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ME(P5([$4 9W]LZS_ -"^W_@2/_B:/[9UG_H7V_\  D?_ !-;]% &!_;.L_\
M0OM_X$C_ .)H_MG6?^A?;_P)'_Q-;]% &!_;.L_]"^W_ ($C_P")H_MG6?\
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MDM?&&EW>H+:1M)B1BL<Q0['([!NAKH* ,#^V=9_Z%]O_  )'_P 31_;.L_\
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M\*Q\*_\ 0._\BM_C0,Z#^WM'_P"@M8_^!*?XT?V]H_\ T%K'_P "4_QKG_\
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MH **** "BBB@ HHHH **** ')]]?K7=P_P"HC_W17")]]?K7=P_ZB/\ W10
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-%XD@EDBL;RU$1 (N8PI/TY-5O$'A(:YK>DZC]J\G[!)OV>7G?T[YXZ5TH
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M0 4444 %%%% !1110 Y/OK]:[N'_ %$?^Z*X1/OK]:[N'_41_P"Z* 'T444
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M?(S2.P.X8STYKNZ "BBLFT\2:7?:U<:3;W DO+<9E0?PT :U%<P?%DX\;?\
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M_P!T4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***IZIJ,&DZ9<7]RVV&!"S&@"K=>)-*LM:M](GNT6^N!
MF.+/)I=0\0Z=IUVMI-,6NF7>(8QN?;ZX]*\MCUC2+C5='UNYU&S^VW=X'D'G
M+F*/(VJ>>,9-=9X6,=WX^\1SLRR.JQHAZX3+8Q^M '8:=J5IJMHMU9S++$W&
M0>A]#5NN,\#*8[[Q!&HQ"M\=@[#Y5KLZ "BBB@ HHHH **** "BBB@ HHHH
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M&VN&"Q3,>&/T[?C3?'7F_P#"(WGE?W?F_P!WO5'Q1C_A"[7R,>9OB\K'KD4
M=CU&:*BM=WV2'?\ >V#/UQ4M !1110 AZ&N(OO\ C]E_WC7;GI7,W.BW<MS(
MZH,,V1S0!C45I_V%>_W!^8H_L*]_N#\Q0!F45I_V%>_W!^8H_L*]_N#\Q0!F
M45I_V%>_W!^8H_L*]_N#\Q0!F45I_P!A7O\ <'YBC^PKW^X/S% &80#U&:,
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M=7(6D:,&5 K=P* ,C_A$/#YU,ZD=*MS=DY,A!/Z9Q6T  , 8 [4M% !1110
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MNS!_$SR,W_AQ]3*HHHKT#P@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** %'45[[I'_((M/\ KD*\"'45[[I'_((M/^N0KBQFR/7RCXY%VBBBN ]T
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LG^J?_=->!:M_R%KK
M_KJW\Z]]D_U3_P"Z:\"U;_D+77_75OYUVX/=GCYO\,2G1117>>&%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5]"67_ !X6_P#UR7^0KY[KZ$LO
M^/"W_P"N2_R%<.,V1[&4;S^7ZD]%%%<)[@4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% $%Y_QY3_ /7-OY5\BZG_ ,A2Z_ZZM_.OKJ\_X\I_^N;?
MRKY%U/\ Y"EU_P!=6_G6]'J>[DOV_D5:***V/>"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH L6'_'_;_P#70?SKZ\L_^/&W_P"N:_RKY#L/^/\
MM_\ KH/YU]>6?_'C;_\ 7-?Y5C6Z'@YU]CYD]%%%8'A!1110 4444 %%%% !
M7-?$'_D0]8_ZX'^8KI:YKX@_\B'K'_7 _P Q0!\TT444 >\?"?\ Y!-[_P!=
M1_6O0N]>>_"?_D$WO_74?UKT+O6E;XV887^#$6BBBLS<**** "BBB@ HHHH
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M'^=>ZM]T_2O"O$O_ ",-[_UT/\Z[,'\3/(S?^''U,JBBBO0/""BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 4=17OND?\@BT_P"N0KP(=17OND?\
M@BT_ZY"N+&;(]?*/CD7:***X#W0HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** &R?ZI_]TUX%JW_(6NO^NK?SKWV3_5/_ +IKP+5O^0M=?]=6_G7;
M@]V>/F_PQ*=%%%=YX84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 -D_U3_[IKP+5O^0M=?\
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MKSWX3_\ ()O?^NH_K7H7>M*WQLPPO\&(M%%%9FX4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB@ HHHH **** "BBB@""\_X\I_\ KFW\J^1=3_Y"EU_UU;^=?75Y_P >4_\
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M_E^I/1117">X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_E^I/1117">X%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!!>?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>F_[\W_HUZ .RHHHH **** "H;J(SVDT0."Z%0?3-35%<2F&WDD4995)"^M
M'+7VGRZ?I]E<QZ<)Y+8D21(!E@>_ZUK^'(YTTL-/%Y1=BRQ'^ $]*RXK?Q!J
M$8N4U>*!7Z1B,';^E;VEP7=O:;+VZ%Q+G[X4"@"[1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C?=/TKP
MKQ+_ ,C#>_\ 70_SKW5ONGZ5X5XE_P"1AO?^NA_G79@_B9Y&;_PX^IE4445Z
M!X04444 %%%% !1110 4444 %%%% !1110 4444 %%%% "CJ*]]TC_D$6G_7
M(5X$.HKWW2/^01:?]<A7%C-D>OE'QR+M%%%<![H4444 %%%% !1110 4444
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MKT8CD4 >,^-=+L;3X'P1:/9W$%O+=)*L,I)=<@GFI?B%!(_P+TZ-(V+CR?E
MYZ&O9)8(IH_+EC5T_ND<4CVT$D(A>)&C'12.* /+_&.D7FK? R*UM8B\R0I*
M4[D+DFMGX8^)K/5?#MKIL22I=6D(69)%QM.37=*BJ@15 4#  J.*UMX'9XH4
M1FZE1C- $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %<#\4%_XE^GMZ7*UWU<+\3U_P")58MZ7*UI2^-&&)_A2.SL
M?^0?;?\ 7)?Y"IZ@L?\ D'VW_7)?Y"IZS9LM@HHHH&%%%% %/5O^0-??]>\G
M_H)KF?A7_P D[TW_ 'YO_1KUTVK?\@:^_P"O>3_T$US/PK_Y)WIO^_-_Z->@
M#LJ*** "BBB@ KFM7T9+_5E4ZO=6\DJ_+%&Q X_&NEKG-=G_ +*U:TU5T9K=
M08Y2HSM![_K0!3C\#"W1O+UJ^1>IPY_QK:T"**'3]D5[)=J&(\R0Y.:KW?BO
M2(;)I4NDD9E^1%Y)/85)X:M7MM)5I%*R3,9"I[9/'Z4 ;-%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]TUX%JW_ "%KK_KJW\Z[<'NSQ\W^&)3HHHKO/#"BBB@ HHHH **** "BBB@
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M17BOAC7+[QEXYOKQ_$2VMG:7.R"S5P/-&3^?2O8+K4;*P0-=W4,"^LCA?YT
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MCQ]: +=%,??Y?R@;\=ZAC:\WC>B!>^#0!9HJ*8S #R0I/?-) ;@D^<J@=L4
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M_2[738RMNA!;[S$DD_G5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M L6'_'_;_P#70?SKZ\L_^/&W_P"N:_RKY#L/^/\ M_\ KH/YU]>6?_'C;_\
M7-?Y5C6Z'@YU]CYD]%%%8'A!1110 4444 %%%% !7-?$'_D0]8_ZX'^8KI:Y
MKX@_\B'K'_7 _P Q0!\TT444 >\?"?\ Y!-[_P!=1_6O0N]>>_"?_D$WO_74
M?UKT+O6E;XV887^#$6BBBLS<**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N"^*#?
M\2[3U];E:[VO.OBA)^\TB$=6G!K2E\:.?%/]TSOK'_CPMO\ KDO\A4]0V@Q9
M0#TC7^535FS=;!1110,**** *>K?\@:^_P"O>3_T$US/PK_Y)WIO^_-_Z->N
MFU;_ ) U]_U[R?\ H)KF?A7_ ,D[TW_?F_\ 1KT =E1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/6@!:*3(]:,CUH 6BDR/6C(]: %HI,CUHR/6@!:*3(]:,CUH 6BDR/6C(]:
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M]]5>HH H_P!F1_\ /:;_ +ZH_LR/_GM-_P!]5>HH H_V9'_SVF_[ZH_LR/\
MY[3?]]5>HH H_P!F1_\ /:;_ +ZH_LR/_GM-_P!]5>HH H_V9'_SVF_[ZH_L
MR/\ Y[3?]]5>HH H_P!F1_\ /:;_ +ZH_LR/_GM-_P!]5>HH H_V9'_SVF_[
MZH_LR/\ Y[3?]]5>HH H_P!F1_\ /:;_ +ZH_LR/_GM-_P!]5>HH H_V9'_S
MVF_[ZH_LR/\ Y[3?]]5>HH H_P!F1_\ /:;_ +ZH_LR/_GM-_P!]5>HH H_V
M9'_SVF_[ZH_LR/\ Y[3?]]5>HH H_P!F1_\ /:;_ +ZH_LR/_GM-_P!]5>HH
M H_V9'_SVF_[ZH_LR/\ Y[3?]]5>HH H_P!F1_\ /:;_ +ZH_LR/_GM-_P!]
M5>HH H_V9'_SVF_[ZH_LR/\ Y[3?]]5>HH H_P!F1_\ /:;_ +ZH_LR/_GM-
M_P!]5>HH H_V9'_SVF_[ZH_LR/\ Y[3?]]5>HH H_P!F1_\ /:;_ +ZH_LR/
M_GM-_P!]5>HH H_V9'_SVF_[ZH_LR/\ Y[3?]]5>HH H_P!F1_\ /:;_ +ZH
M_LR/_GM-_P!]5>HH H_V9'_SVF_[ZH_LR/\ Y[3?]]5>HH H_P!F1_\ /:;_
M +ZH_LR/_GM-_P!]5>HH H_V9'_SVF_[ZH_LR/\ Y[3?]]5>HH H_P!F1_\
M/:;_ +ZH_LR/_GM-_P!]5>HH H_V9'_SVF_[ZH_LR/\ Y[3?]]5>HH H_P!F
M1_\ /:;_ +ZH_LR/_GM-_P!]5>HH H_V9'_SVF_[ZH_LR/\ Y[3?]]5>HH H
M_P!F1_\ /:;_ +ZH_LR/_GM-_P!]5>HH H_V9'_SVF_[ZH_LR/\ Y[3?]]5>
MHH H_P!F1_\ /:;_ +ZH_LR/_GM-_P!]5>HH H_V9'_SVF_[ZH_LR/\ Y[3?
M]]5>HH H_P!F1_\ /:;_ +ZH_LR/_GM-_P!]5>HH H_V9'_SVF_[ZH_LR/\
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MO-%*HVYB(&1[Y%=/10I.+NA3A&:M)7//O^%1:)_S^7W_ 'TO^%'_  J+1/\
MG\OO^^E_PKT&BK]K/N9?5:/\IY]_PJ+1/^?R^_[Z7_"C_A46B?\ /Y??]]+_
M (5Z#11[6?</JM'^4\^_X5%HG_/Y??\ ?2_X4?\ "HM$_P"?R^_[Z7_"O0:*
M/:S[A]5H_P IY]_PJ+1/^?R^_P"^E_PH_P"%1:)_S^7W_?2_X5Z#11[6?</J
MM'^4\^_X5%HG_/Y??]]+_A1_PJ+1/^?R^_[Z7_"O0:*/:S[A]5H_RGGW_"HM
M$_Y_+[_OI?\ "C_A46B?\_E]_P!]+_A7H-%'M9]P^JT?Y3S[_A46B?\ /Y??
M]]+_ (4?\*BT3_G\OO\ OI?\*]!HH]K/N'U6C_*>??\ "HM$_P"?R^_[Z7_"
MC_A46B?\_E]_WTO^%>@T4>UGW#ZK1_E//O\ A46B?\_E]_WTO^%'_"HM$_Y_
M+[_OI?\ "O0:*/:S[A]5H_RGGW_"HM$_Y_+[_OI?\*/^%1:)_P _E]_WTO\
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MF_[\W_HUZ .RHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Y#XE7ES8>#;F>UF:*4$89>M=?7$_%7_D1KKZBJC\2.C"I.O!/N>"?\
M)?X@_P"@K<?F*7_A+O$'_05N/S%8E'>NNR/K_94_Y5]Q]9>%9I;CPQI\TSEY
M'A4LQZDU:UG5[;0]*FU"[;$42Y('4^PJEX._Y%+3?^N"_P JQ?B>C_\ "-PS
M#)@@N4DG &<I_P#KQ7&]SXRK_$EZE>#7O'&LQPWVEZ196]C)\P2\)\PKZ_>&
M/Q%=Q#(_V9'N0L<A'S#/ -1Z?=VM[80W%I(CP.@*%#D8KB+V%O$GQ$GTR]N9
M8[&S@#+;H^T2EN^1SQCU[TC,] 5E894@CU!IOFQ\?O%YX'-<#I'F:!\19-"M
M)99=/FMA+L=]WDL,]SSS_2N6\+Z(M_X#UK5+N\NI;B)YF@)F8>60,C&#_.@#
MV@N@8*64$]!FE+*N-S 9Z9->,Q6DTGPI_P"$HN+VYEU18S*DID(V[20!@<8X
MK0^($UQ?:9X(_P!,EMFNKE/->-MN<QY(H ]55U;.U@<=<&N7\/ZM>7GC#Q%9
M3S%[>T>$0IC[N4!/ZU@:Y:?\(GXF\.S:5-.?MMP8+B$R%@Z[&.[GW Z4EO=S
MV&N^/+JV4M-$L+(!Z^6* /2/,3=MWKN],\UEZYXALM BMWNV_P!?,L* ==QS
MC^5>8Z5IFKZMX:M=1@T^XDU">-9A>&\&-QY/R[L8]L5?^(FCI=:1X?N]1B(O
MI+V".?;(<#(.1P<4 >IK(CH'5@5/<&A71_NL&^AKS?QIY^CQZ%H>EPR_9+N?
M$NV7!/3Y=S'C.?6IM&T?6K#Q-:7%KI\EG8$%;F.2Y\P-Z$?,: /1*\Q7Q?XT
MO]<UF+3++3)+'39=C!PPD8;0W7=COZ5Z=7@Z:?XDN-:\7W.CZK]GM8KG,]N$
M!:0;%S@X]* /6_"7B./Q/H::@L7E/N9)(R<[64D'^5;8D1CA74D=@:\TNM1B
MTOX5PS>'HB%E*JY4X96+ /G/?.:@BT+6DFT^ZTO39[6575I97NPXE4CG(W'Z
M\4 >I,Z*0&903TR:4NH."P!],UYEKD<VE^);C4O$%M<7.FN5\F:"1@L'U4']
M:C\4J-3^(GANVBOY8;2:!V/EO@2+E>* /45=7&58'Z&D:1%.&=03V)KSX(?#
M'CR&STXS26MU;/))"TA8*RXP>3GG/Z5#X7T"#Q3HTVKZK=W$EW<2,1B8KY'H
M  0./>@#T@LJC+$ >I-)YB%MN]<^F:\8U;5M1O?A'?1R7$PEMK^.WCN0V&==
MZ\Y'UQ^%:OBG1DT'P1::Y;7-S_:$#6Y,IE)WAG4$$9QT/I0!ZDSHGWF5<],F
ME+ #)( ]<UY?KJW4.K+K>L6MQ>:.]O&R?9Y"# 2!DD Y/.:D\37\VI:WHFGV
M,4MQILUKYX1)A'YG3 ))!Z'UH ],5E<95@1Z@TM<-X6TO5M.U^0_8I+33'B.
M8I)_,P^1@CDGUKN: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH ;)_JG_W37@6K?\A:Z_ZZM_.O?9/]4_\ NFO M6_Y
M"UU_UU;^==N#W9X^;_#$IT445WGAA1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% #9/]4_^Z:\"U;_ )"UU_UU;^=>^R?ZI_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"GJW_(&OO\ KWD_]!-<S\*_
M^2=Z;_OS?^C7KIM6_P"0-??]>\G_ *":YGX5_P#).]-_WYO_ $:] '94444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH^N0[!_9-7NCP_!]*^A++_CPM_\ KDO\A67_ ,(EHG_/C'^0K:50B*BC"J,
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M(5M>7UM:7NF7FGO=?Z@SJ=K_ (X%=E0,3:N,8&/3%+110 FU<YP,^N*  !@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH @O/^/*?_KFW\J^1
M=3_Y"EU_UU;^=?75Y_QY3_\ 7-OY5\BZG_R%+K_KJW\ZWH]3W<E^W\BK1116
MQ[P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %BP_P"/^W_ZZ#^=
M?7EG_P >-O\ ]<U_E7R'8?\ '_;_ /70?SKZ\L_^/&W_ .N:_P JQK=#P<Z^
MQ\R>BBBL#P@HHHH **** "BBB@ KFOB#_P B'K'_ %P/\Q72US7Q!_Y$/6/^
MN!_F* /FFBBB@#Z[HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH IZM_P @:^_Z]Y/_ $$US/PK_P"2=Z;_ +\W_HUZZ;5O
M^0-??]>\G_H)KF?A7_R3O3?]^;_T:] '94444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %9^L_\@Z2M"J6JQO+8NB*2Q["@#C*5?O#Z
MU:_LV[_YXM^5 TZ[R/W+=?2@#K;'_CRB^E<G\4VV>!+QL$X9#@=_F%=;9J4M
M(U88('-8_C'1)_$'AV;3[9U21V4@MTX(- '%I)JGC/\ L.WCT>>QM;-TEEN)
M^"<#&%_.K$MSXBUCXC:IH]IJ)MM/AC1F8#YE// ^M>B64+6UC! Q!:.,*2/8
M5@:7X>N;+QIJVL.Z&"\1%11U&W.<_G0!DZC?:OJ_BC_A&M-O?LL=I"LEU<X^
M=LYP!V['M3-.UV_\-^)+C0M:N_M<(MC<P3D8;:,Y#?E6EKOAK43K:Z[H-S'#
M?;/+ECE'R2@=,]_7\Z9HWA2[DU*XU?Q#-%<7L\/D".,?)&G.0._.30!DZ,/$
MOBG3VU^'5?LRR,QM;95^0J#@;OKBL(^+]?F^'-]J"W 744U%+=#C@?O%4CZ5
MKV>GZMH%M/9Z?KVGC0U+,)'<&2$=2!V]:R/"?AB]UKX<RVL4@#2:F+A))!]]
M5E#$_CM- '57=YJOA3P?=:MJ%\UY=R*A"[?EC9B!@ <]ZYNUUW7[6XM;M;K4
M+MY& G@>S<)@_P!TXXQ]:]*U?1X]8T*339FVAT ##^%A@@_F*YO3=,\:6T\%
MK/>V#V4) ,VP^8ZCL>V?PH SM=UF^_X3(V=YJ4NE6(53;N$^64]\L1@4[QCK
M&IV>M:?:/>R66D/$3)?1INR_& 3T ZUI>+-!U[7I6LH38C3I0 SR(3(GKBG:
MQH.N?V3;:3I3V<MHD(A<WBEFX&,_6@"KXHU:\TSPYHLMGJ'G&:]AC:=<'S%)
MYJQ:ZU=V'CRYT^_G+6ES;":VR.%(SN&?IBJL_@*XC\):/HUM="1[*[CGDDD/
M4*><5:\=^$+SQ'96CZ9<K;7]N<"0_P!PX##\A0!A-XSU*T\*ZCKLC.RW-X(;
M)2A.P$A<X[\YJM8Z]KMEJ-E*D^H7R3.%N(I;1E5<]U.!P*[>Z\)6USX0BT,-
MY?E*#&X_A<'.?SK.TO3_ !G%>00WMU8&RA."Z(=\@'KVH [-3N4'&,C-<!X#
M_P"1K\5?]?(_E7H%>9'POXTTSQ'JEYHMW8);7TH<^:I+"@"^Z_9/B_$MFJA;
MBS8W*KZ@K@TW3]=U:35/%T<1,[V;XMHL=/O<?I6QX9\+3Z5>7&J:I>?;=3N!
MAI,8"K_=%1:5X<U#3-8\0W\<L6Z_DWP9_AZ]?SH RO!6KR7*375YK,L]TD9:
M>RD7:8S[#&<5SB>*=;UN&;4X;R^@.\_9X(;1F3 [$X.?P-=7H_A/59?$_P#;
M>M/:(Z1F)8[52 X/=O6H8_#/BC099K;0;RS?3Y7+(MRIW0Y],4 7IO$1?PA9
M75]<R:=<W V[=AWELXX4\UF>$_$5Z?$=UH\MQ<W4?V;[1"US$4?.2,<@9'%:
M7B'POJNI1Z7>VUU!_:5ADXE7,;D]>*31_#.LQ>)EUS4[J"28VGDE(EPJ')(Q
M[<T 8_AK6+_4?$<B:MJ\EI>),P&GNFU60$XP2.>,'BJ6H^+K[6O$6I6MK<WM
MI:V#^4OV:W9RS]\G!XSFMF\\(ZYKOB&TN=4FLXK6SF\V-[=2)7ZX!/I5G4?#
M.M:=KESJGAJ>V7[9@W%O<+\NX#&X8[T 7O NKZCJNDS+JD,J7%O*4$DD93S%
MR<-@^PKJ:S-"@U.#3@-6EBENBQ+&(84#L*TZ "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P"?RV_6C_A26N?\_EM^M'/'N'U_#?SH\QHKT[_A26N?\_EM^M'_  I+7/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% %/5O\ D#7W_7O)_P"@FN9^%?\ R3O3?]^;_P!&O73:M_R!K[_K
MWD_]!-<S\*_^2=Z;_OS?^C7H [*BBB@ HHHH **** "BBB@ HHHH *0D 9)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!3U;_ ) U]_U[R?\ H)KF?A7_ ,D[TW_?F_\ 1KUTVK?\
M@:^_Z]Y/_037,_"O_DG>F_[\W_HUZ .RHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKFOB#_R(>L?]<#_,5TM<U\0?^1#UC_K@?YB@#YIHHHH ^NZ*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *>K?\@:^_Z]Y/
M_037,_"O_DG>F_[\W_HUZZ;5O^0-??\ 7O)_Z":YGX5_\D[TW_?F_P#1KT =
ME1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7-?$'_D0]8_ZX'^8KI:YKX@_P#(AZQ_
MUP/\Q0!\TT444 ?7=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% %;4$\W3;J,G&^%US]0:\'TSQ)X@\.60TJQU&(6\$C[-
MUN">6)]?>BB@"Y_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#
MQ7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P
M/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%%
M !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''
M^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <
M?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!
M&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T
M$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#
MQ7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P
M/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%%
M !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''
M^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <
M?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!
M&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T
M$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#
MQ7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P
M/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%%
M !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''
M^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <
M?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!
M&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T
M$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#
MQ7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P
M/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%%
M !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''
M^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <
M?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!
M&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T
M$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#
MQ7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P
M/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%%
M !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''
M^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <
M?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!
M&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T
M$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#
MQ7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P
M/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%%
M !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''
M^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <
M?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!
M&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T
M$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#
MQ7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P
M/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%%
M !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''
M^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <
M?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!
M&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T
M$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#
MQ7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P
M/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%%
M !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''
M^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <
M?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!
M&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T
M$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P/%?_ $$8?_ <?XT44 '_  L#
MQ7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%% !_PL#Q7_P!!&'_P''^-'_"P
M/%?_ $$8?_ <?XT44 '_  L#Q7_T$8?_  ''^-'_  L#Q7_T$8?_  ''^-%%
M !_PL#Q7_P!!&'_P''^-4]4\6^)-8TR?3[G48O)G78^+<9Q^=%% %+_A#8_^
-?UO^_?\ ]>BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>24
<FILENAME>alxo-20201231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Instance Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-18T17:24:36.2205867+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 11fbbc32b9104e6cbcd92c96d6313ce7 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2020-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:alxo="http://www.alxoncology.com/20201231" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="alxo-20201231.xsd" />
  <xbrli:unit id="U_xbrlishares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_iso4217USD_xbrlishares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="U_xbrlipure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_alxoSegment">
    <xbrli:measure>alxo:Segment</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="U_alxoInvestor">
    <xbrli:measure>alxo:Investor</xbrli:measure>
  </xbrli:unit>
  <xbrli:context id="C_0001810182_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20210312">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-03-12</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:ShareOptionsGrantedToEmployeesAndNonemployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20200708_20200708">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-08</xbrli:startDate>
      <xbrli:endDate>2020-07-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201613Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201813Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_alxoWarrantLiabilityMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alxo:WarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_alxoCompoundDerivativeLiabilityMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alxo:CompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_alxoWarrantLiabilityMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alxo:WarrantLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_alxoCompoundDerivativeLiabilityMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alxo:CompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoComputerHardwareAndSoftwareMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alxo:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoComputerHardwareAndSoftwareMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alxo:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoLabEquipmentAndOtherAssetsMember_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alxo:LabEquipmentAndOtherAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoLabEquipmentAndOtherAssetsMember_20200701_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alxo:LabEquipmentAndOtherAssetsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20191220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapLongtermDebtTypeAxis_alxoFirstTrancheMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alxo:FirstTrancheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapLongtermDebtTypeAxis_alxoSecondTrancheMember_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">alxo:SecondTrancheMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20191220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20191220_20191220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-20</xbrli:startDate>
      <xbrli:endDate>2019-12-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20191220_20191220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-20</xbrli:startDate>
      <xbrli:endDate>2019-12-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20191220_20191220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-20</xbrli:startDate>
      <xbrli:endDate>2019-12-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20191220_20191220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-12-20</xbrli:startDate>
      <xbrli:endDate>2019-12-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20191220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200716">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200716">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200716">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200716">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200817">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200716">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-16</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200816_20200817">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-08-16</xbrli:startDate>
      <xbrli:endDate>2020-08-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapFairValueByLiabilityClassAxis_alxoCompoundDerivativeLiabilityMember_20191220">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">alxo:CompoundDerivativeLiabilityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20201201_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">alxo:LoanAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20200721">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_alxoUndesignatedPreferredStockMember_20200721">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:UndesignatedPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_alxoUndesignatedPreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:UndesignatedPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_alxoUndesignatedPreferredStockMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:UndesignatedPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200721_20200721">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-21</xbrli:startDate>
      <xbrli:endDate>2020-07-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200721">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_alxoFollowOnPublicOfferingMember_20201201_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">alxo:FollowOnPublicOfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-12-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoConvertiblePreferredStockIssuedAndOutstandingMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:ConvertiblePreferredStockIssuedAndOutstandingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoStockOptionsIssuedAndOutstandingMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoStockOptionsIssuedAndOutstandingMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:StockOptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoStockOptionsAuthorizedForFutureIssuanceMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:StockOptionsAuthorizedForFutureIssuanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoStockOptionsAuthorizedForFutureIssuanceMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:StockOptionsAuthorizedForFutureIssuanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoWarrantsIssuedAndOutstandingMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:WarrantsIssuedAndOutstandingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoWarrantsAuthorizedForFutureIssuanceMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:WarrantsAuthorizedForFutureIssuanceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesCConvertiblePreferredStockMember_20200229">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-02-29</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesCConvertiblePreferredStockMember_20200201_20200229">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-02-01</xbrli:startDate>
      <xbrli:endDate>2020-02-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200721">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200721">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20200817">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-08-17</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBAndCConvertiblePreferredStockMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">alxo:SeriesBAndCConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200720_20200720">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-20</xbrli:startDate>
      <xbrli:endDate>2020-07-20</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200720">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-20</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_alxoTwoThousandAndFifteenShareAwardSchemeMember_20150101_20151231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alxo:TwoThousandAndFifteenShareAwardSchemeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPlanNameAxis_alxoTwentyThousandAndTwentyEquityIncentivePlanMember_20200401">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alxo:TwentyThousandAndTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-04-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPlanNameAxis_alxoAmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alxo:AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPlanNameAxis_alxoAmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">alxo:AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201709Member_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201709Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoTwentyThousandAndTwentyEmployeeStockPurchasePlanMember_20200701_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:TwentyThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoTwentyThousandAndTwentyEmployeeStockPurchasePlanMember_20200731">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:TwentyThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_alxoTwentyThousandAndTwentyEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:TwentyThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2021-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoTwentyThousandAndTwentyEmployeeStockPurchasePlanMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:TwentyThousandAndTwentyEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:ShareOptionsGrantedToEmployeesAndNonemployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:ShareOptionsGrantedToEmployeesAndNonemployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:ShareOptionsGrantedToEmployeesAndNonemployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:ShareOptionsGrantedToEmployeesAndNonemployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:ShareOptionsGrantedToEmployeesAndNonemployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:ShareOptionsGrantedToEmployeesAndNonemployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:ShareOptionsGrantedToEmployeesAndNonemployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:ShareOptionsGrantedToEmployeesAndNonemployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:ShareOptionsGrantedToEmployeesAndNonemployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">alxo:ShareOptionsGrantedToEmployeesAndNonemployeesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMinimumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMinimumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMinimumMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMaximumMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMaximumMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMaximumMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_deiLegalEntityAxis_alxoStanfordJuniorUniversityMember_us-gaapTypeOfArrangementAxis_alxoExclusiveEquityAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:ExclusiveEquityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxo:StanfordJuniorUniversityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_deiLegalEntityAxis_alxoStanfordJuniorUniversityMember_us-gaapTypeOfArrangementAxis_alxoExclusiveEquityAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:ExclusiveEquityAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxo:StanfordJuniorUniversityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_deiLegalEntityAxis_alxoSelexisSAMember_us-gaapTypeOfArrangementAxis_alxoCommercialLicenseAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:CommercialLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxo:SelexisSAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_deiLegalEntityAxis_alxoSelexisSAMember_us-gaapTypeOfArrangementAxis_alxoCommercialLicenseAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:CommercialLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxo:SelexisSAMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_deiLegalEntityAxis_alxoCrystalBioscienceIncMember_us-gaapTypeOfArrangementAxis_alxoCommercialAntibodyAgreementMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:CommercialAntibodyAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxo:CrystalBioscienceIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_deiLegalEntityAxis_alxoCrystalBioscienceIncMember_us-gaapTypeOfArrangementAxis_alxoCommercialAntibodyAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:CommercialAntibodyAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">alxo:CrystalBioscienceIncMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:ResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxo:TollnineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:ResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxo:TollnineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:ResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxo:TollnineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20180601_20180630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:ResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxo:TollnineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-06-01</xbrli:startDate>
      <xbrli:endDate>2018-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20180630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:ResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxo:TollnineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxo:TollnineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxo:TollnineMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2019-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTallacTherapeuticsMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20200701">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:ResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxo:TallacTherapeuticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2020-07-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTallacTherapeuticsMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20200701_20200701">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:ResearchAndDevelopmentServicesAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">alxo:TallacTherapeuticsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-07-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoWarrantToPurchaseConvertiblePreferredStockMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:WarrantToPurchaseConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoCommonStockSubjectToRepurchaseMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoCommonStockSubjectToRepurchaseMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoCommonStockSubjectToRepurchaseMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:CommonStockSubjectToRepurchaseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoOptionsIssuedAndOutstandingMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoOptionsIssuedAndOutstandingMember_20190101_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoOptionsIssuedAndOutstandingMember_20180101_20181231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">alxo:OptionsIssuedAndOutstandingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoOfficeAndLaboratorySpaceMember_20200101_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alxo:OfficeAndLaboratorySpaceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapTypeOfArrangementAxis_alxoMasterServiceAgreementMember_20151101_20151130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:MasterServiceAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-11-01</xbrli:startDate>
      <xbrli:endDate>2015-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapTypeOfArrangementAxis_alxoMasterServiceAgreementMember_20151130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:MasterServiceAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoSecondDrugProductManufacturerMember_us-gaapTypeOfArrangementAxis_alxoMasterServiceAgreementMember_20151130">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">alxo:MasterServiceAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alxo:SecondDrugProductManufacturerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoOfficeSpaceMember_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alxo:OfficeSpaceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoOfficeSpaceMember_20170101_20171231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">alxo:OfficeSpaceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20200101_20200331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-01-01</xbrli:startDate>
      <xbrli:endDate>2020-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20200401_20200630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-04-01</xbrli:startDate>
      <xbrli:endDate>2020-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20200701_20200930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-07-01</xbrli:startDate>
      <xbrli:endDate>2020-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20201001_20201231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2020-10-01</xbrli:startDate>
      <xbrli:endDate>2020-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20190101_20190331">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-01-01</xbrli:startDate>
      <xbrli:endDate>2019-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20190401_20190630">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-04-01</xbrli:startDate>
      <xbrli:endDate>2019-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20190701_20190930">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-07-01</xbrli:startDate>
      <xbrli:endDate>2019-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="C_0001810182_20191001_20191231">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001810182</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2019-10-01</xbrli:startDate>
      <xbrli:endDate>2019-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <dei:DocumentType id="F_000000" contextRef="C_0001810182_20200101_20201231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001810182_20200101_20201231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001810182_20200101_20201231">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001810182_20200101_20201231">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001810182_20200101_20201231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:CurrentFiscalYearEndDate id="F_000005" contextRef="C_0001810182_20200101_20201231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001810182_20200101_20201231">ALX ONCOLOGY HOLDINGS INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001810182_20200101_20201231">0001810182</dei:EntityCentralIndexKey>
  <dei:EntityFileNumber id="F_000008" contextRef="C_0001810182_20200101_20201231">001-39386</dei:EntityFileNumber>
  <dei:EntityTaxIdentificationNumber id="F_000009" contextRef="C_0001810182_20200101_20201231">85-0642577</dei:EntityTaxIdentificationNumber>
  <dei:EntityIncorporationStateCountryCode id="F_000010" contextRef="C_0001810182_20200101_20201231">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityAddressAddressLine1 id="F_000011" contextRef="C_0001810182_20200101_20201231">866 Malcolm Road</dei:EntityAddressAddressLine1>
  <dei:EntityAddressAddressLine2 id="F_000012" contextRef="C_0001810182_20200101_20201231">Suite 100</dei:EntityAddressAddressLine2>
  <dei:EntityAddressCityOrTown id="F_000013" contextRef="C_0001810182_20200101_20201231">Burlingame</dei:EntityAddressCityOrTown>
  <dei:EntityAddressStateOrProvince id="F_000014" contextRef="C_0001810182_20200101_20201231">CA</dei:EntityAddressStateOrProvince>
  <dei:EntityAddressPostalZipCode id="F_000015" contextRef="C_0001810182_20200101_20201231">94010</dei:EntityAddressPostalZipCode>
  <dei:CityAreaCode id="F_000016" contextRef="C_0001810182_20200101_20201231">650</dei:CityAreaCode>
  <dei:LocalPhoneNumber id="F_000017" contextRef="C_0001810182_20200101_20201231">466-7125</dei:LocalPhoneNumber>
  <dei:EntityCurrentReportingStatus id="F_000018" contextRef="C_0001810182_20200101_20201231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityInteractiveDataCurrent id="F_000019" contextRef="C_0001810182_20200101_20201231">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityFilerCategory id="F_000020" contextRef="C_0001810182_20200101_20201231">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntitySmallBusiness id="F_000021" contextRef="C_0001810182_20200101_20201231">false</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany id="F_000022" contextRef="C_0001810182_20200101_20201231">true</dei:EntityEmergingGrowthCompany>
  <dei:IcfrAuditorAttestationFlag id="F_000023" contextRef="C_0001810182_20200101_20201231">false</dei:IcfrAuditorAttestationFlag>
  <dei:EntityExTransitionPeriod id="F_000024" contextRef="C_0001810182_20200101_20201231">false</dei:EntityExTransitionPeriod>
  <dei:EntityCommonStockSharesOutstanding id="F_000025" contextRef="C_0001810182_20210312" decimals="INF" unitRef="U_xbrlishares">40127198</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat id="F_000026" contextRef="C_0001810182_20201231" decimals="-8" unitRef="U_iso4217USD">1500000000</dei:EntityPublicFloat>
  <dei:EntityShellCompany id="F_000027" contextRef="C_0001810182_20200101_20201231">false</dei:EntityShellCompany>
  <dei:Security12bTitle id="F_000028" contextRef="C_0001810182_20200101_20201231">Common Stock, par value $0.001 per share</dei:Security12bTitle>
  <dei:TradingSymbol id="F_000029" contextRef="C_0001810182_20200101_20201231">ALXO</dei:TradingSymbol>
  <dei:SecurityExchangeName id="F_000030" contextRef="C_0001810182_20200101_20201231">NASDAQ</dei:SecurityExchangeName>
  <dei:EntityVoluntaryFilers id="F_000031" contextRef="C_0001810182_20200101_20201231">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer id="F_000032" contextRef="C_0001810182_20200101_20201231">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:DocumentAnnualReport id="F_000033" contextRef="C_0001810182_20200101_20201231">true</dei:DocumentAnnualReport>
  <dei:DocumentTransitionReport id="F_000034" contextRef="C_0001810182_20200101_20201231">false</dei:DocumentTransitionReport>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000035" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">434219000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000036" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">9017000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:DueFromRelatedPartiesCurrent id="F_000037" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">536000</us-gaap:DueFromRelatedPartiesCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000038" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">1773000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000039" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">256000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000040" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">435992000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000041" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">9809000</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000042" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">52000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000043" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">860000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="F_000044" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000045" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000046" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">436054000</us-gaap:Assets>
  <us-gaap:Assets id="F_000047" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">10676000</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="F_000048" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">4000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000049" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">3748000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities id="F_000050" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">6200000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities id="F_000051" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">1236000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:LiabilitiesCurrent id="F_000052" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">6204000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000053" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">4984000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebtNoncurrent id="F_000054" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">5421000</us-gaap:LongTermDebtNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000055" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="F_000056" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">547000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:Liabilities id="F_000057" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">6209000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000058" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">10952000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000059" xsi:nil="true" contextRef="C_0001810182_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000060" xsi:nil="true" contextRef="C_0001810182_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000061" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">60933000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000062" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">9430000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:PreferredStockValue id="F_000063" xsi:nil="true" contextRef="C_0001810182_20201231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:PreferredStockValue id="F_000064" xsi:nil="true" contextRef="C_0001810182_20191231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000065" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">40000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000066" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000067" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">548327000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000068" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">2140000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000069" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">-118522000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000070" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">-72782000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="F_000071" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">429845000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000072" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">-70639000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000073" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">436054000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000074" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">10676000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000075" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000076" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000077" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000078" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">9421633</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000079" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000080" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">9297081</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000081" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000082" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">9297081</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="F_000083" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">73571000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000084" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare id="F_000085" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000086" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000087" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">2145370</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued id="F_000088" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued id="F_000089" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">1016727</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000090" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000091" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">1016727</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityLiquidationPreference id="F_000092" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">10014000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000093" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare id="F_000094" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized id="F_000095" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_xbrlishares">100000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized id="F_000096" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_xbrlishares">100000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued id="F_000097" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued id="F_000098" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding id="F_000099" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding id="F_000100" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000101" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000102" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_iso4217USD_xbrlishares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000103" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_xbrlishares">1000000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000104" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_xbrlishares">1519618271</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000105" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_xbrlishares">39844522</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000106" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_xbrlishares">3166946</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000107" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_xbrlishares">39844522</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000108" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_xbrlishares">3166946</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000109" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1182000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000110" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000111" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2067000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:TypeOfRevenueExtensibleList id="F_000112" contextRef="C_0001810182_20200101_20201231">alxo:RelatedPartyMember</us-gaap:TypeOfRevenueExtensibleList>
  <us-gaap:TypeOfRevenueExtensibleList id="F_000113" contextRef="C_0001810182_20190101_20191231">alxo:RelatedPartyMember</us-gaap:TypeOfRevenueExtensibleList>
  <us-gaap:TypeOfRevenueExtensibleList id="F_000114" contextRef="C_0001810182_20180101_20181231">alxo:RelatedPartyMember</us-gaap:TypeOfRevenueExtensibleList>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000115" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">28961000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000116" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">16306000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000117" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">11270000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000118" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">14809000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000119" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3313000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000120" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2601000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:CostsAndExpensesRelatedParty id="F_000121" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1075000</us-gaap:CostsAndExpensesRelatedParty>
  <us-gaap:CostsAndExpensesRelatedParty id="F_000122" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4360000</us-gaap:CostsAndExpensesRelatedParty>
  <us-gaap:CostsAndExpensesRelatedParty id="F_000123" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1880000</us-gaap:CostsAndExpensesRelatedParty>
  <us-gaap:OperatingExpenses id="F_000124" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">44845000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000125" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">23979000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000126" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">15751000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000127" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-43663000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000128" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-19183000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000129" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-13684000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestIncomeExpenseNonoperatingNet id="F_000130" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-811000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet id="F_000131" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-21000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:OtherNonoperatingExpense id="F_000132" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">404000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="F_000133" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense id="F_000134" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:OtherNonoperatingExpense>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000135" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-621000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000136" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-45499000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000137" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-19209000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000138" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-13686000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000139" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">241000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000140" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">34000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000141" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">45000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="F_000142" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-45740000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000143" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-19243000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000144" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-13731000</us-gaap:NetIncomeLoss>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="F_000145" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5202000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="F_000146" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4028000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact id="F_000147" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">3671000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000148" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-50942000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000149" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-23271000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000150" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-17402000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000151" contextRef="C_0001810182_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.76</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000152" contextRef="C_0001810182_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-7.56</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000153" contextRef="C_0001810182_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-6.33</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000154" contextRef="C_0001810182_20200101_20201231" decimals="0" unitRef="U_xbrlishares">18485343</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000155" contextRef="C_0001810182_20190101_20191231" decimals="0" unitRef="U_xbrlishares">3076461</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000156" contextRef="C_0001810182_20180101_20181231" decimals="0" unitRef="U_xbrlishares">2750838</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000157" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231" decimals="INF" unitRef="U_xbrlishares">9297081</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000158" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20171231" decimals="-3" unitRef="U_iso4217USD">60933000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:SharesOutstanding id="F_000159" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="INF" unitRef="U_xbrlishares">3205421</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000160" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000161" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" unitRef="U_iso4217USD">1390000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000162" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" unitRef="U_iso4217USD">-39808000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000163" contextRef="C_0001810182_20171231" decimals="-3" unitRef="U_iso4217USD">-38415000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="F_000164" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">6914</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000165" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000166" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockRepurchasedDuringPeriodShares id="F_000167" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">-43689</us-gaap:StockRepurchasedDuringPeriodShares>
  <alxo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions id="F_000168" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">92000</alxo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions>
  <alxo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions id="F_000169" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">92000</alxo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions>
  <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares id="F_000170" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20180101_20181231" decimals="INF" unitRef="U_xbrlishares">-6899</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000171" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">269000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000172" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">269000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000173" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-13731000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000174" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">9297081</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000175" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">60933000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:SharesOutstanding id="F_000176" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="INF" unitRef="U_xbrlishares">3161747</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000177" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20181231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000178" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20181231" decimals="-3" unitRef="U_iso4217USD">1758000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000179" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20181231" decimals="-3" unitRef="U_iso4217USD">-53539000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000180" contextRef="C_0001810182_20181231" decimals="-3" unitRef="U_iso4217USD">-51778000</us-gaap:StockholdersEquity>
  <alxo:TemporaryEquityStockIssuedDuringPeriodShareNewIssues id="F_000181" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">1016727</alxo:TemporaryEquityStockIssuedDuringPeriodShareNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000182" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9430000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="F_000183" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">5199</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000184" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000185" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <alxo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions id="F_000186" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">75000</alxo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions>
  <alxo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions id="F_000187" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">75000</alxo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000188" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">297000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000189" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">297000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000190" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-19243000</us-gaap:NetIncomeLoss>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000191" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">10313808</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000192" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">70363000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:SharesOutstanding id="F_000193" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">3166946</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000194" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000195" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20191231" decimals="-3" unitRef="U_iso4217USD">2140000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000196" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20191231" decimals="-3" unitRef="U_iso4217USD">-72782000</us-gaap:StockholdersEquity>
  <alxo:TemporaryEquityStockIssuedDuringPeriodShareNewIssues id="F_000197" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">11055966</alxo:TemporaryEquityStockIssuedDuringPeriodShareNewIssues>
  <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues id="F_000198" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">104680000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
  <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount id="F_000199" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-1019000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
  <us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount id="F_000200" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-1019000</us-gaap:WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000201" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">-21369774</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000202" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-175043000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000203" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">21369774</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000204" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">21000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000205" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">175022000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities id="F_000206" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">175043000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:CommonStockDividendsShares id="F_000207" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">-2564759</us-gaap:CommonStockDividendsShares>
  <us-gaap:Dividends id="F_000208" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-3000</us-gaap:Dividends>
  <us-gaap:Dividends id="F_000209" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:Dividends>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000210" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">12512000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000211" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">13000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000212" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">364387000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000213" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">364400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <alxo:StockIssuedDuringPeriodSharesWarrantExercise id="F_000214" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">48932</alxo:StockIssuedDuringPeriodSharesWarrantExercise>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="F_000215" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">182111</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000216" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">299000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000217" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">299000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <alxo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions id="F_000218" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">27000</alxo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions>
  <alxo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions id="F_000219" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">27000</alxo:StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000220" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5436000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000221" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5436000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:NetIncomeLoss id="F_000222" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-45740000</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding id="F_000223" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">39844522</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity id="F_000224" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20201231" decimals="-3" unitRef="U_iso4217USD">40000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000225" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20201231" decimals="-3" unitRef="U_iso4217USD">548327000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000226" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20201231" decimals="-3" unitRef="U_iso4217USD">-118522000</us-gaap:StockholdersEquity>
  <us-gaap:ProfitLoss id="F_000227" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-45740000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000228" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-19243000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss id="F_000229" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-13731000</us-gaap:ProfitLoss>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000230" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">202000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000231" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">429000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000232" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">431000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:ShareBasedCompensation id="F_000233" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5436000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000234" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">297000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000235" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">269000</us-gaap:ShareBasedCompensation>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="F_000236" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">421000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <us-gaap:AmortizationOfFinancingCostsAndDiscounts id="F_000237" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">11000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
  <alxo:ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants id="F_000238" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">650000</alxo:ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants>
  <alxo:GainOnAssignmentOfLease id="F_000239" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">126000</alxo:GainOnAssignmentOfLease>
  <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent id="F_000240" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-536000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
  <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent id="F_000241" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-396000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
  <us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent id="F_000242" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">932000</us-gaap:IncreaseDecreaseInDueFromRelatedPartiesCurrent>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000243" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">1514000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000244" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-744000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000245" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-897000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <alxo:IncreaseDecreaseInOtherAssets id="F_000246" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">10000</alxo:IncreaseDecreaseInOtherAssets>
  <alxo:IncreaseDecreaseInOtherAssets id="F_000247" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-7000</alxo:IncreaseDecreaseInOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000248" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-3744000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000249" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2976000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="F_000250" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-269000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities id="F_000251" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">4983000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities id="F_000252" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">134000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities id="F_000253" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="F_000254" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-4000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities id="F_000255" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">136000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000256" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-38289000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000257" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-14249000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities id="F_000258" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-13190000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000259" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">31000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000260" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">353000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000261" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">653000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyHeldForSale id="F_000262" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">641000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000263" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">610000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000264" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-353000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities id="F_000265" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-653000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000266" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">368256000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000267" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3848000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000268" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">299000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000269" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">10000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised id="F_000270" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000271" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">104680000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock id="F_000272" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">9430000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:PaymentsForRepurchaseOfCommonStock id="F_000273" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">6000</us-gaap:PaymentsForRepurchaseOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfDebt id="F_000274" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">5917000</us-gaap:ProceedsFromIssuanceOfDebt>
  <us-gaap:PaymentsOfDebtExtinguishmentCosts id="F_000275" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">6506000</us-gaap:PaymentsOfDebtExtinguishmentCosts>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000276" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">462881000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000277" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">15357000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities id="F_000278" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="F_000279" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">425202000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="F_000280" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">755000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect id="F_000281" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-13842000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000282" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">9017000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000283" contextRef="C_0001810182_20181231" decimals="-3" unitRef="U_iso4217USD">8262000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000284" contextRef="C_0001810182_20171231" decimals="-3" unitRef="U_iso4217USD">22104000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents id="F_000285" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">434219000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:InterestPaidNet id="F_000286" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">427000</us-gaap:InterestPaidNet>
  <us-gaap:IncomeTaxesPaid id="F_000287" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">47000</us-gaap:IncomeTaxesPaid>
  <alxo:VestingOfEarlyExercisedStockOptions id="F_000288" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">27000</alxo:VestingOfEarlyExercisedStockOptions>
  <alxo:VestingOfEarlyExercisedStockOptions id="F_000289" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">75000</alxo:VestingOfEarlyExercisedStockOptions>
  <alxo:VestingOfEarlyExercisedStockOptions id="F_000290" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">92000</alxo:VestingOfEarlyExercisedStockOptions>
  <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 id="F_000291" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">7000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
  <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 id="F_000292" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
  <alxo:NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable id="F_000293" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">95000</alxo:NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable>
  <us-gaap:ConversionOfStockAmountConverted1 id="F_000294" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">175043000</us-gaap:ConversionOfStockAmountConverted1>
  <alxo:NonCashAccumulatedDividendOnConvertiblePreferredStock id="F_000295" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">3000</alxo:NonCashAccumulatedDividendOnConvertiblePreferredStock>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="F_000296" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1) ORGANIZATION&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Organization&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;ALX Oncology Holdings Inc., or the Company, was formed as a Delaware corporation on April&amp;#160;1, 2020, or Inception. The Company was formed for the purpose of completing the Company&amp;#8217;s initial public offering of its common stock and related transactions in order to carry on the business of ALX Oncology Limited. After Inception, ALX Oncology Limited became a wholly-owned subsidiary of the Company as a result of the internal reorganization. As part of the internal reorganization, all of the equity, option and warrant holders of ALX Oncology Limited became equity, option and warrant holders of the Company, holding the same number of corresponding shares, options and/or warrants in the Company as they did in ALX Oncology Limited immediately prior to the internal reorganization. The information included herein is presented as that of ALX Oncology Holdings Inc. unless such information refers to a date prior to April 1, 2020, in which case it will reflect that of ALX Oncology Limited, the predecessor company. The Company is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company owns subsidiaries, consisting of ALX Oncology Limited, incorporated in Ireland; ALX Oncology Inc., incorporated in the United States, Alexo International Holdings Ltd, incorporated in Malta; Alexo Therapeutics International, incorporated in the Cayman Islands, which is a wholly-owned subsidiary of Alexo International Holdings Ltd., and Sirpant Therapeutics, incorporated in the Cayman Islands, which is a wholly-owned subsidiary of Alexo Therapeutics International, or collectively, the Subsidiaries.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of&amp;#160;December 31, 2020, the Company has devoted substantially all of its efforts to the formation and financing of the Company, as well as product development, and has not realized product revenues from its planned principal operations. The Company has no manufacturing facilities and all manufacturing related activities are contracted out to third-party service providers.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Management expects to incur additional losses in the future to conduct product candidate research and development and to conduct pre-commercialization activities and recognizes that the Company will likely raise additional capital to fully implement its business plan. The Company intends to raise such capital through the sale of additional equity, debt financings or strategic alliances with third parties. However, there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms acceptable to the Company. If the Company is unsuccessful in its efforts to raise additional financing, the Company could be required to significantly reduce operating expenses and delay, reduce the scope of or eliminate some of its development programs or its future commercialization efforts, out-license intellectual property rights to its product candidates and sell unsecured assets, or a combination of the above, any of which may have a material adverse effect on the Company&amp;#8217;s business, results of operations, financial condition and/or its ability to fund its scheduled obligations on a timely basis or at all. &lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;The Company believes that the existing capital resources will be sufficient to fund the projected operating requirements for at least the next twelve months.&lt;/font&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="F_000297" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2) SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Preparation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, and the applicable rules and regulations of the U.S. Securities and Exchange Commission, or SEC.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 8, 2020, the Company&amp;#8217;s board of directors approved an amendment to the Company&amp;#8217;s certificate of incorporation to effect a 1-for-6.5806 reverse split of its common stock and convertible preferred stock. The par values of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All authorized, issued and outstanding common stock, convertible preferred stock, stock options, warrants, and related per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. The reverse stock split was effected on July 9, 2020.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, Series B convertible preferred stock warrant liability, term loan compound derivative liability, term loan, valuation of the Company&amp;#8217;s common stock, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company holds its cash and cash equivalents in checking and money market accounts. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and are stated at fair value.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk, Credit Losses and Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits, and invests in money market funds. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents. The Company has not experienced any losses on its deposits of cash and cash equivalents. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&amp;#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&amp;#8217;s potential product candidates, uncertainty of market acceptance of the Company&amp;#8217;s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s product candidates require approvals from the U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives of the assets. Upon sale or retirement of assets, the cost and related accumulated depreciation or amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations and comprehensive loss. Maintenance and repairs are charged to the consolidated statement of operations and comprehensive loss as incurred.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Deferred Offering Costs&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&amp;#8217; equity (deficit) as a reduction of additional paid-in capital generated as a result of the equity financing. &amp;#160;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the asset or asset group are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds its fair value. Fair value is determined using various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. The Company has not recorded impairment of any long-lived assets. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the consolidated financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Where observable prices or inputs are not available valuation models are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments&amp;#8217; complexity.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s financial instruments consist of cash and cash equivalents, receivables due from related-party, accounts payable, the term loan compound derivative liability and the Series B convertible preferred stock warrant liability. The term loan compound derivative liability and the Series B convertible preferred stock warrant liability are re-measured at the end of every period and carried at fair value (Note 3). The recorded value of the Company&amp;#8217;s receivables due from related-party and accounts payable approximates its current fair value due to the relatively short-term nature of these items.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Term Loan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for the Loan and Security Agreement, dated as of December 20, 2019, as amended, with Silicon Valley Bank, or SVB, and WestRiver Innovation Lending Fund VIII, LP, or WestRiver, collectively as lenders, and SVB, as administrative agent and collateral agent, as a liability measured at net proceeds less debt discount and is accreted to the face value of the term loan over its expected term using the effective interest method. The Company considers whether there are any embedded features in its debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to Accounting Standards Codification, or ASC, Topic 815, &lt;font style="font-style:italic;"&gt;Derivatives and Hedging&lt;/font&gt;.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records convertible preferred stock net of issuance costs on the dates of issuance, which represents the carrying value. In the event of a change of control of the Company, proceeds will be distributed in accordance with the liquidation preferences set forth in its organization documents unless the holders of convertible preferred stock have converted their convertible preferred stock into common stock. Convertible preferred stock is classified outside of stockholders&amp;#8217; equity (deficit) on the accompanying consolidated balance sheets as events triggering the liquidation preferences are not solely within the Company&amp;#8217;s control. The Company has elected not to adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because of the uncertainty of whether or when such an event would occur. Upon the consummation of the Company&amp;#8217;s initial public offering in July 2020, all shares of convertible preferred stock outstanding and accrued cumulative dividends automatically converted into&amp;#160;23,934,533&amp;#160;shares of common stock.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Series B Convertible Preferred Stock Warrant Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has issued freestanding warrants to purchase its Series B convertible preferred stock. Freestanding warrants for the Company&amp;#8217;s convertible preferred stock that are classified outside of permanent equity are recorded at fair value, and are subject to re-measurement at the end of every period until the earlier of the exercise of the warrants or the completion of a liquidation event, including the completion of an initial public offering. Upon exercise, the Series B convertible preferred stock warrant liability would be reclassified to additional paid-in capital, with any change in fair value recognized as a component of other expense, net. Following the Company&amp;#8217;s initial public offering, the warrants were automatically converted to warrants to purchase shares of common stock (Note 5). The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance to additional paid-in capital with no further re-measurement required as common stock warrants are considered permanent equity. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To date, the Company has derived revenue from providing research and development services on a time and materials basis to a related-party.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes such revenues over time as services are delivered, and invoices the customer as the work is incurred in arrears.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt; (Topic 606), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the Company&amp;#8217;s consideration as to whether the Company has entered into a contract with a customer, it considers whether it is probable that it will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cost of Services for Related-Party Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company incurs costs associated with related-party services including direct labor and associated employee benefits, laboratory supplies, and other expenses. These costs are recorded in cost of services for related-party revenue as a component of total operating expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Costs &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred and consist primarily of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to nonemployees and entities that conduct certain research and development activities on behalf of the Company and expenses incurred in connection with license agreements (Note 9). Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and recorded in prepaid expenses and other current assets, and then expensed as the related goods are delivered or the services are performed.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Clinical and Manufacturing Accruals&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records accruals for estimated costs of research, preclinical studies and clinical trials, and manufacturing development, which are a significant component of research and development expenses. A substantial portion of the Company&amp;#8217;s ongoing research and development activities are conducted by third-party service providers, including contract research organizations, or CROs, and contract manufacturing organizations, or CMOs. The Company&amp;#8217;s contracts with CROs generally include pass-through fees such as regulatory expenses, investigator fees, travel costs and other miscellaneous costs, including shipping and printing fees. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company accrues the costs incurred under agreements with these third parties based on estimates of actual work completed in accordance with the respective agreements. The Company determines the estimated costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fees to be paid for such services.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company makes significant judgments and estimates in determining the accrual balance at the end of each reporting period. As actual costs become known, the Company adjusts its accruals. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&amp;#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in the Company reporting amounts that are too high or too low in any particular period. To assist in its estimates the Company relies upon the receipt of timely and accurate reporting from its clinical and non-clinical studies and other third-party vendors. Through December 31, 2020, there have been no material differences from the Company&amp;#8217;s accrued estimated expenses to the actual clinical trial expenses. However, variations in the assumptions used to estimate accruals, including, but not limited to, the number of patients enrolled, the rate of patient enrollment, and the actual services performed, and related costs may vary from the Company&amp;#8217;s estimates, resulting in adjustments to clinical trial expense in future periods. Changes in these estimates that result in material changes to the Company&amp;#8217;s accruals could materially affect its financial position and results of operations.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-based Compensation Expense &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all stock-based payments made to employees, directors and non-employees based on estimated grant-date fair values. The Company uses the straight-line method to allocate compensation expense to reporting periods over each optionee&amp;#8217;s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards using the Black-Scholes option-pricing model. The Black-Scholes model requires the input of subjective assumptions, including expected volatility, expected dividend yield, expected term, risk-free rate of return and the estimated fair value of the underlying common stock on the date of grant. Prior to the Company&amp;#8217;s initial public offering, the fair value of the common stock underlying the stock-based awards was determined on each grant date by the board of directors, with input from management, considering the most recently available third-party valuation of common shares. The Company accounts for the effect of forfeitures as they occur. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Foreign Currency Transactions &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of the Company&amp;#8217;s operation and each of its subsidiaries is U.S. dollars. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate prevailing on the balance sheet date. Expenses are translated at the average exchange rates prevailing during the applicable period. Foreign currency transaction gains and losses are included in the consolidated statement of operations and comprehensive loss and recorded in other expense, net, and were immaterial for the years December 31, 2020, 2019 and 2018.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for the period in which the temporary differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&amp;#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss is equal to net loss for all periods presented.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies the two-class method to compute basic and diluted net loss per share when it has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires net loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all net loss for the period had been distributed. The Company&amp;#8217;s convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt; (ASU 2016-02). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU No. 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. In June 2020, the FASB issued ASU No. 2020-05, which extends the effective date of ASU No. 2016-02 for non-public business entities, including smaller reporting companies, to fiscal years beginning after December 15, 2021. The new standard is effective for the Company beginning January 1, 2022 (or earlier if the Company ceases to be an emerging growth company). Early adoption is permitted. The Company is currently evaluating the effects of the adoption of this guidance on its consolidated financial statements and related disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2021. ASU 2019-12 is effective for the Company beginning January 1, 2022. Early adoption is permitted. The Company is currently in the process of evaluating the effects of the adoption of this guidance on the Company&amp;#8217;s financial statements and does not expect it to have a material impact on its consolidated financial statements.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements Recently Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. The Company early adopted this guidance on January 1, 2020. &lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;For trade receivables and other instruments, the Company uses a new forward-looking &lt;/font&gt;&lt;font style="color:#000000;"&gt;expected loss model that generally results in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses are recognized as allowances rather than as reductions in the amortized cost of the securities. &lt;/font&gt;&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;The adoption of the guidance did not have a material impact on the Consolidated Financial Statements and related disclosures and there was&amp;#160;no&amp;#160;allowance for losses for the year ended December 31, 2020.&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&amp;#8212;Changes to the Disclosure Requirements for Fair Value Measurement. The FASB issued final guidance that eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. Under the ASU, entities will no longer be required to disclose the amount of transfers between Level 1 and Level 2 of the fair value hierarchy. Public companies will be required to disclose changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. ASU 2018-13 is effective for public business entities for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2019, with early adoption permitted. The Company adopted this guidance on January 1, 2020. The adoption of ASU 2018-13 did not have a material impact on its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000298" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3) FAIR VALUE OF FINANCIAL INSTRUMENTS&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of the Company&amp;#8217;s financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC Topic 820, Fair Value Measurements and Disclosures. ASC Topic 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&amp;#8212;Observable inputs, such as quoted prices in active markets;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&amp;#8212;Inputs, other than the quoted prices in active markets, which are observable either directly or indirectly such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&amp;#8217;s anticipated life; and&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&amp;#8212;Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s financial instruments consist of cash and cash equivalents, receivables due from related-party, accounts payable, the term loan compound derivative liability and the Series B convertible preferred stock warrant liability.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash and cash equivalents are reported at their respective fair values on the Company&amp;#8217;s consolidated balance sheets. Where quoted prices are available in an active market, securities are classified as Level 1. The Company classifies money market funds as Level 1. When quoted market prices are not available for the specific security, then the Company estimates fair value by using quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third-party data providers, including but not limited to benchmark yields, reported trades and broker/dealer quotes. Where applicable the market approach utilizes prices and information from market transactions for similar or identical assets.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures its Series B convertible preferred stock warrant liability and term loan compound derivative liability at fair value on a recurring basis and these are classified as Level 3 liabilities. The fair value of the Series B convertible preferred stock warrant liability was determined using an option-pricing model. The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance to additional paid-in capital with no further re-measurement required as the common stock warrants are considered permanent equity effective with the completion of the initial public offering. The Company calculated the fair value of the term loan compound derivative liability by computing the difference between the fair value of the term loan with the compound derivative using the &amp;#8220;with and without&amp;#8221; method under the income approach, and the fair value of the term loan without the compound derivative. The valuation methodology and underlying assumptions are discussed further in Note 5. The compound derivative liability was extinguished upon the extinguishment of the host instrument in December 2020 (Note 5).&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the Company&amp;#8217;s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;424,115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;424,115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Non-current liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compound derivative liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.56%;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table is a reconciliation of all financial liabilities measured at fair value using Level 3 unobservable inputs (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compound&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value at beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification to equity&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Extinguishment of compound derivative liability upon extinguishment of host instrument&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value at end of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;There were no transfers of assets or liabilities between the fair value measurement levels during the years ended December 31, 2020 and 2019.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying values of the Company&amp;#8217;s financial instruments, such as accounts payable and accrued expenses and other current liabilities, approximate fair value due to the short-term nature of these items.&amp;#160;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock id="F_000299" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4) BALANCE SHEET COMPONENTS&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment, Net&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the components of property and equipment, net as of December 31, 2020 and 2019 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,698&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,309&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,449&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;860&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization expense was $0.2 million, $0.4 million and $0.4 million for years ended December 31, 2020, 2019 and 2018, respectively. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At June 30, 2020, certain lab equipment and other assets for an aggregated net book value of $0.6 million relating to the asset transfer with Tallac Therapeutics, Inc. (formerly known as Tollnine, Inc., or Tollnine), or Tallac Therapeutics, a related-party (Note 10), met the criteria as assets held for sale. Those assets were reported at the lower of carrying value or fair value less costs to sell. In July 2020, the Company received $0.6 million cash in exchange for the transfer of such assets. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Accrued Expenses and Other Current Liabilities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the components of accrued expenses and other current liabilities as of December 31, 2020 and 2019 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;122&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,974&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;924&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical and nonclinical study costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,473&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued contract manufacturing&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,123&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued federal income tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;151&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,200&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,236&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
  <us-gaap:DebtDisclosureTextBlock id="F_000300" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5) TERM LOAN&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s wholly-owned subsidiaries Alexo Therapeutics International and Sirpant Therapeutics, as borrowers, entered into a Loan and Security Agreement, or the Loan Agreement, dated as of December 20, 2019, with SVB and WestRiver, collectively as lenders, and SVB, as administrative agent and collateral agent. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As a result of the internal reorganization, in May 2020 the Company entered into a Joinder and First Amendment to the Loan and Security Agreement, or the Joinder Amendment, and Amended and Restated Warrants to Purchase Stock, or the Amended Warrants. The purpose for entering into the Joinder Amendment was to add the newly established ALX Oncology Holdings Inc. as additional borrower to the Term Loan. Concurrently, the Company modified the Amended Warrants to change the issuer from ALX Oncology Limited to ALX Oncology Holdings Inc. The Company accounted for the First Amendment to the Loan and Security Agreement as a modification.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Loan Agreement provided for term loans in an aggregate principal amount of up to $10.0 million funded in two tranches, subject to the satisfaction of a certain milestone. The first tranche, in the amount of $6.0 million, was funded on the closing date of the Loan Agreement in December 2019. A second tranche of $4.0 million was available on or before March 31, 2020, upon the Company&amp;#8217;s achievement of an equity financing resulting in net cash proceeds in an amount of at least $30.0 million to the Company. The Company elected not to draw down on the second tranche, which is no longer available.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The loans under the Loan Agreement bore interest at a floating per annum interest rate equal to the greater of 7.0% or 2.0% plus the prime rate as reported in The Wall Street Journal.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company was required to make interest-only payments for the first 12 months after the closing of the Loan Agreement, followed by consecutive equal monthly payments of principal and interest commencing on January 1, 2021 and continuing through the maturity date of September 1, 2022. The Loan Agreement also provided for a final payment equal to 6.0% multiplied by the aggregate principal amount of the term loans funded, which was due on the maturity date, upon the acceleration of the term loans, or upon prepayment of the term loans. If the Company elected to prepay the term loans, there was also a prepayment fee of between 1.0% and 3.0% of the principal amount being prepaid depending on the timing and circumstances of prepayment.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In conjunction with the Loan Agreement, the Company issued warrants to purchase 61,292 Series B convertible preferred stock to SVB and WestRiver with an exercise price of $9.4972 per share. Following the Company&amp;#8217;s initial public offering, these warrants were automatically converted to warrants to purchase 61,292 shares of common stock at an exercise price of $9.4972 per share. The estimated fair value of the warrants at the date of issuance was approximately $0.4 million. The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance of $1.0 million to additional paid-in capital with no further re-measurement required as the common stock warrants are considered permanent equity effective July 16, 2020. The fair value of the common stock warrant was determined using a Black-Scholes option-pricing model with the following assumptions: an expected term of 9.8 years, a volatility of 84.2%, a dividend rate of zero and a risk-free rate of 0.6%. The changes in fair value in warrant liability were recognized as a component of other expense, net in the accompanying consolidated statement of operations and comprehensive loss. On August 17, 2020, SVB and WestRiver delivered the Notice of Exercise for net exercise of 61,292 warrants at an exercise price of $9.4972 per share. Accordingly, the Company issued 48,932 shares of the Company&amp;#8217;s common stock (Note 6). &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The loans under the Loan Agreement were secured by substantially all of the Company&amp;#8217;s assets, except the Company&amp;#8217;s intellectual property, which is the subject of a negative pledge.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company determined that certain loan features were embedded derivatives requiring bifurcation and separate accounting. Those embedded derivatives were bundled together as a single, compound embedded derivative and then bifurcated and accounted for separately from the host contract. The Company recorded a term loan compound derivative liability of approximately $51,000 which was marked-to-market until the extinguishment of the host instrument. The Company calculated the fair value of the compound derivative by computing the difference between the fair value of the term loan with the compound derivative using the &amp;#8220;with and without&amp;#8221; method under the income approach, and the fair value of the term loan without the compound derivative. The Company calculated the fair values using a probability-weighted discounted cash flow analysis. The key valuation assumptions used consist of the discount rate and the probability of the occurrence of a change in control event. The term loan compound derivative liability was re-measured at each financial reporting period with any changes in fair value being recognized as a component of other expense, net in the consolidated statement of operations and comprehensive loss. The compound derivative liability was extinguished upon the extinguishment of the host instrument in December 2020.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value of Series B convertible preferred stock warrant liability at issuance, fair value of embedded derivatives, which were bifurcated and other debt issuance costs were treated as debt discounts on the Company&amp;#8217;s consolidated balance sheet and together with the final payment were amortized to interest expense throughout the life of the term loan using the effective interest rate method.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2020, the Company used approximately $6.5 million of the net proceeds from the Company&amp;#8217;s follow-on public offering to repay the outstanding principal amount of $6.0 million and early extinguish the outstanding Term Loan with SVB and WestRiver. As a result, the Company recognized a $0.6 million loss on early debt extinguishment, representing the difference between the&amp;#160;reacquisition&amp;#160;price of debt and the net carrying amount of the loan as of the date of the payoff. &lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000301" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6) STOCKHOLDERS&amp;#8217; EQUITY &lt;font style="font-style:italic;"&gt; &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On&amp;#160;July 21, 2020, the Company&amp;#8217;s amended and restated certificate of incorporation became effective, authorizing 1,000,000,000&amp;#160;shares of common stock and&amp;#160;100,000,000&amp;#160;shares of undesignated preferred stock. As of&amp;#160;December 31, 2020&amp;#160;and&amp;#160;2019, the Company had&amp;#160;39,844,522&amp;#160;and&amp;#160;3,166,946&amp;#160;shares of common stock outstanding, respectively. As of&amp;#160;December 31, 2020&amp;#160;and&amp;#160;2019, the Company had zero and 10,313,808 shares of preferred stock outstanding, respectively.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Common Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&amp;#160;July&amp;#160;2020, the Company consummated its initial public offering and issued&amp;#160;9,775,000&amp;#160;shares of common stock for net proceeds of approximately&amp;#160;$169.5 million, after deducting underwriting discounts and commissions of $13.0 million and offering-related expenses of $3.2 million. Upon the closing of the initial public offering, all shares of convertible preferred stock outstanding and accrued cumulative dividends were automatically converted into 23,934,533 shares of common stock.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In&amp;#160;December&amp;#160;2020, the Company consummated its follow-on public offering and issued&amp;#160;2,737,000&amp;#160;shares of common stock for net proceeds of approximately&amp;#160;$194.9 million, after deducting underwriting discounts and commissions of $12.5 million and offering-related expenses of $0.7 million. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock reserved for future issuance, on an as if converted basis, as of December 31, 2020 and 2019, consists of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,313,808&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,857,308&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,183,745&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options authorized for future issuance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,835,443&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;566,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,292&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants authorized for future issuance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,646&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,692,751&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,156,391&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019, the Company&amp;#8217;s convertible preferred stock consisted of the following (in thousands, except share amounts):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued And&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Proceeds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preference&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares designated as:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,421,633&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,297,081&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,933&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73,571&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series&amp;#160;B convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,145,370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,016,727&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,430&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,567,003&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,313,808&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;83,585&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Net proceeds are gross proceeds from the offerings net of issuance costs&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:9pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Series C Convertible Preferred Stock Issuance&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:4pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2020, the Company entered into a Series C Preferred Stock Purchase Agreement, or the Series C Agreement, with certain existing investors, employees and new investors, or collectively, the Series C Investors. Under the terms of the Series C Agreement, the Company authorized the sale and issuance of up to 11,055,981 Series C convertible preferred stock at a purchase price of $9.4972 per share. All authorized Series C convertible preferred stock have been purchased with gross proceeds of $105.0&amp;#160;million.&amp;nbsp;&amp;nbsp;The Series C convertible preferred stock and related accumulated dividends automatically converted into shares of the Company&amp;#8217;s common stock upon the consummation of the Company&amp;#8217;s initial public offering.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Preferred Stock Warrant Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 21, 2020, the warrants to purchase 61,292 Series B convertible preferred stock issued to SVB and WestRiver with an exercise price of $9.4972 per share were automatically converted to warrants to purchase 61,292 shares of common stock at an exercise price of $9.4972 per share. The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance to additional paid-in capital with no further re-measurement required as the common stock warrants are considered permanent equity.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On August 17, 2020, SVB and WestRiver delivered the Notice of Exercise to net exercise 61,292 warrants at an exercise price of $9.4972 per share. Accordingly, the Company issued&amp;#160;48,932&amp;#160;shares of the Company&amp;#8217;s common stock. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Dividends&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior to the Company&amp;#8217;s initial public offering, cumulative dividends of 6.0% per annum of the original issue price for each convertible preferred stock series were payable when and as declared by the Company&amp;#8217;s Board of Directors, or Board of Directors, upon the occurrence of a liquidation event or upon a contingent mandatory conversion of the convertible preferred stock in connection with a qualified initial public offering as described below. The Series A original issue price was $6.58, and the Series B and Series C original issue price was $9.4972. The original issue price was subject to adjustment in the event of any share dividend, share split, combination, consolidation or other recapitalization. The dividends accrued from day to day from the issue date of such preferred stock whether or not declared and were cumulative. In addition, the preferred stockholders participated on an as-converted basis in any dividends payable to common stockholders. As of July 20, 2020, there were approximately $18.0 million of accrued cumulative dividends on the Series A, Series B and Series C convertible preferred stock, which became payable upon the consummation of the Company&amp;#8217;s initial public offering and automatically converted into 2,564,759 shares of the Company&amp;#8217;s common stock.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000302" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7) STOCK-BASED COMPENSATION &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Equity Incentive Plans&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2015 Share Award Scheme&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2015, the Company adopted an equity compensation plan, the 2015 Share Award Scheme, or the 2015 Share Award Scheme, for eligible employees, officers, directors, advisors, and consultants. The 2015 Share Award Scheme provided for the grant of incentive and non-statutory share options. The 2015 Share Award Scheme permitted the Company to grant up to 2,143,117 common stock awards, including incentive share options, non-statutory share options, conditional share awards and restricted share awards.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2020 Equity Incentive Plan&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On April 1, 2020, the Board of Directors approved a new equity incentive plan, or the 2020 Equity Incentive Plan, that replaced the 2015 Share Award Scheme. The 2020 Equity Incentive Plan is for employees, non-employee directors and consultants covering 4,379,139 shares of the Company&amp;#8217;s common stock and authorizes the award of stock options, restricted stock awards, stock appreciation rights and restricted stock units.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;2020 Amended and Restated Equity Incentive Plan&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, the Company adopted the Amended and Restated 2020 Equity Incentive Plan, or the 2020 Plan. The 2020 Plan replaced the Company&amp;#8217;s 2020 Equity Incentive Plan and&amp;#160;a total of 7,874,862&amp;#160;shares were reserved under the 2020 Plan.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The terms of the stock option agreements, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the 2020 Plan. The term of the options generally expire, upon the earliest of (i) termination of continuous service for cause (ii) three months after the termination of continuous service for reasons other than cause, death or disability (iii) twelve months after the termination of continuous service due to disability (iv) eighteen months after the employee&amp;#8217;s death if the employee died during the period of continuous service (v) expiration date in the grant notice or (vi) the day before the tenth anniversary of the date of grant. The exercise price of the incentive share options must equal at least the fair market value of the share on the date of grant.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All awards that are canceled, forfeited or expired are returned to the 2020 Plan and are available for grant in conjunction with the issuance of new awards. Share options granted are exercisable over a maximum term of 10 years from the date of grant and generally vest over an agreed service period, usually four years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain share options granted under the 2020 Plan provide option holders the right to elect to exercise unvested options in exchange for common stock. Such unvested common stock is subject to a repurchase right held by the Company at the original issuance price in the event the optionee&amp;#8217;s service to the Company is terminated either voluntarily or involuntarily. The right lapses as the underlying repurchase right expires. These repurchase terms are considered to be a forfeiture provision. The cash received from employees for exercise of unvested options is treated as a refundable deposit and is classified as a liability on the consolidated balance sheets. At December 31, 2020 and 2019, there were unvested early exercised options of 63 and 34,024, respectively, and the liability related to these unvested options was approximately $0 and $27,000, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Option Modification&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In connection with the transfer of employees to Tallac Therapeutics, Dr. Hong Wan, the Company&amp;#8217;s former Chief Scientific Officer, and eight of the Company&amp;#8217;s employees, or Transferred Employees, terminated their employment with the Company effective as of June 30, 2020 and became employees of Tallac Therapeutics effective as of July 1, 2020. The options to purchase shares of the Company&amp;#8217;s common stock that were previously granted to the Transferred Employees will continue to vest and be exercisable subject to the Transferred Employees remaining service providers under the original terms of the award. The Company evaluated the change in status from an employee to a consultant in accordance with ASC 718. While the Company concluded that the change in status did not affect the vesting condition or the classification of the initial awards, the significant reduction in the level of services that the grantees were expected to provide under the original awards as compared to the level of services expected under the Tallac Services Agreement will no longer meet the substantive service condition requirements and therefore the compensation cost for the unvested awards was recognized immediately with no future service requirement. In September 2020, in connection with the resignation of the Company&amp;#8217;s former Chief Business Officer and the entry into a consulting agreement with him, the Company evaluated the change in status from an employee to a consultant in accordance with ASC 718. While the Company concluded that the change in status did not affect the vesting condition or the classification of the initial awards, the significant reduction in the level of services that the grantee was expected to provide under the original awards as compared to the level of services expected under the consulting agreement will no longer meet the substantive service condition requirements and therefore the compensation expense for the unvested awards expected to vest during the consultancy was recognized immediately with no future service requirement. The Company recorded $1.7 million in stock-based compensation expenses related to the modifications for the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, the Board of Directors and stockholders approved the ALX Oncology Holdings Inc. 2020 Employee Stock Purchase Plan, or the ESPP. The ESPP allows eligible employees to have up to&amp;#160;15&amp;#160;percent&amp;#160;of their eligible compensation withheld and used to purchase common stock, subject to a maximum of&amp;#160;$25,000&amp;#160;worth of stock purchased in a calendar year or no more than&amp;#160;3,000&amp;#160;shares in an offering period, whichever is less. An offering period consists of a&amp;#160;six-month purchase period, with a look back feature to our stock price at the commencement of the offering period. Eligible employees can purchase the Company&amp;#8217;s common stock at the end of the offering period at&amp;#160;85%&amp;#160;of the lower of the closing price of our common stock on The Nasdaq Global Select Market on the first and last day of the offering periods.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The initial number of shares of common stock available for issuance under the ESPP, was&amp;#160;400,000. Unless the Board of Directors provides otherwise, beginning on January 1, 2021, the maximum number of shares which shall be made available for sale under the ESPP will automatically increase on the first trading day in January of each calendar year during the term of the ESPP by an amount equal to the least of:&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.42%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.27%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;800,000 shares; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.42%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.27%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;one percent of the outstanding shares of our common stock on the last day of our immediately preceding fiscal year; or &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:3.42%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.27%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;such number of shares as our board of directors may determine no later than the last day of our immediately preceding fiscal year.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2021, the Board of Directors approved the first offering period beginning February 1, 2021. As of&amp;#160;December 31, 2020, there were&amp;#160;no purchases under the ESPP.&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Option Activity&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a summary of share option activity under the Plan and related information:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available&amp;#160;to&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in&amp;#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;566,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,183,745&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;638&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,124,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,857,655&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,857,655&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.92&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(182,111&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.65&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Canceled/forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,981&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,981&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,835,443&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,857,308&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.94&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.86&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;375,270&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,776,399&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.85&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.65&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;310,999&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020, there was unrecognized share-based compensation expense of $25.0 million, related to unvested share options which the Company expects to recognize over a weighted-average period of 3.2 years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate intrinsic values represent the total pre-tax intrinsic value, of options outstanding and exercisable calculated as the difference between the exercise price of the options and the fair value of the Company&amp;#8217;s common stock as of December 31, 2020 and 2019. The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018 were $4.4 million, immaterial and immaterial, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-based Compensation Expenses&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compensation cost for share options granted is based on the grant-date fair value estimated and is recognized over the vesting period of the applicable option on a straight-line basis. The weighted-average grant-date fair value per share for share options granted during the years ended December 31, 2020, 2019 and 2018 was $7.74, $1.27 and $1.14, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense includes share options granted to employees and nonemployees and has been reported in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,551&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of services for related-party revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;297&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;269&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock Option Valuation Assumptions&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company uses the Black-Scholes option pricing model to determine the estimated fair value of stock options at the date of the grant, and stock-based compensation is adjusted for actual forfeitures as they occur. The fair value of each option grant during the years ended December 31, 2020, 2019 and 2018 was estimated with the&lt;font style="letter-spacing:-0.4pt;"&gt; &lt;/font&gt;following assumptions:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8 - 6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.4 - 6.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.2 - 6.0&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3% - 0.8%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7% - 2.1%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.6% - 3.0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78.7% - 89.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75.2% - 80.5%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66.5% - 68.7%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Expected Term. &lt;font style="font-style:normal;"&gt;The expected term of the options represents the average period the share options are expected to remain outstanding. As the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior, the expected term of options granted is derived from the average midpoint between the weighted average vesting and the contractual term, also known as the simplified method.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Risk-Free Interest Rate. &lt;font style="font-style:normal;"&gt;The risk-free interest rate is based on the yield of U.S. Treasury notes as of the grant date with terms commensurate with the expected term of the option.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Dividend Yield. &lt;font style="font-style:normal;"&gt;The expected dividends assumption is based on the Company&amp;#8217;s expectation of not paying dividends in the foreseeable future.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Volatility. &lt;font style="font-style:normal;"&gt;Since the Company does not have sufficient trading history for its common stock, the expected volatility is based on the historical volatilities of the common shares of comparable publicly traded companies. The Company selected companies with comparable characteristics, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the Company&amp;#8217;s share-based awards.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;font style="font-style:normal;"&gt;. Historically, for all periods prior to our initial public offering, the fair value of the shares of common stock underlying our stock option was determined by the Company&amp;#8217;s board of directors. Because there was no public market for the Company&amp;#8217;s common stock, the board of directors determined fair value of the common stock at the time of grant of the options by considering a number of objective and subjective factors including important developments in the Company&amp;#8217;s operations, valuations performed by an independent third party, sales of convertible preferred stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company&amp;#8217;s common stock, among other factors. Since the completion of our initial public offering, the fair value of each share of common stock underlying stock option grants is based on the closing price of our common stock on the Nasdaq Global Select Market as reported on the date of grant.&lt;/font&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000303" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8) INCOME TAXES&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The U.S. domestic and international components of pre-tax loss for the years ending December 31, 2020, 2019 and 2018 are as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;855&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;International&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,042&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,541&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,209&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The federal and state provision for income taxes consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current provision for income taxes:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;239&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;International&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;241&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax provision:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;International&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;241&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the effective tax for the years ended December 31, 2020, 2019 and 2018 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,555&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,874&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,098&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(332&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research &amp;amp; Development credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(512&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,733&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;321&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign rate differential&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,380&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,899&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior period true ups&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;241&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets as of December 31, 2020 and 2019 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,283&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,259&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research &amp;amp; other credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,260&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;261&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;696&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,299&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;166&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;166&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Realization of deferred tax assets is dependent upon the Company generating future taxable income, the timing and amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $4.6 million and $4.5 million for the years ended December 31, 2020 and 2019, respectively.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses and tax credit carryforwards as of December 31, 2020 are as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expiration Years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses, federal (Post December 31, 2017)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,919&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Do Not Expire&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses, state&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2038-2040&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits, federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,327&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2039-2040&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits, state&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,893&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;N/A&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses, foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,086&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;N/A&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Utilization of the Company&amp;#8217;s U.S. net operating loss and credit carryforwards may be subject to substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitation could result in the expiration of the U.S. net operating loss and credit carryforwards before utilization. To date, the Company has not performed an analysis to determine whether there would be a substantial annual limitation due to a change in ownership.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Unrecognized Tax Benefits&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations and comprehensive loss. If the Company is eventually able to recognize its uncertain tax positions, the Company&amp;#8217;s effective tax rate would be reduced. The Company currently has a full valuation allowance against its net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The unrecognized tax benefits as of December 31, 2020, 2019 and 2018 were $0.8 million, $0.7 million and $0.4 million, respectively. Future changes in the unrecognized tax benefits will not impact the effective tax rate due to the Company&apos;s full valuation allowance.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will file income tax returns in the U.S. federal and California jurisdiction, is not currently under examination, and all years since inception are open to examination. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has the following activity relating to unrecognized tax benefits (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:89.6%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;692&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;418&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions/reversals based on tax positions of prior years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions based on tax positions related to the current year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;272&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lapses in statutes of limitations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;842&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;692&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;418&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next 12 months due to tax examination changes, settlement activities, expirations of statute of limitations or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months. During the years ended December 31, 2020, 2019 and 2018, no interest or penalties were required to be recognized relating to unrecognized tax benefits.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000304" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9) LICENSE AGREEMENT&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2015, the Company entered into a license agreement, or the Stanford Agreement, with the Board of Trustees of the Leland Stanford Junior University, or Stanford, under which the Company obtained a worldwide, royalty-bearing, sublicensable license under certain patents relating to the Company&amp;#8217;s current product candidates, to develop, manufacture and commercialize products for use in certain licensed fields, the scope of which would include the application of the licensed intellectual property in oncology. The license granted to the Company in the Stanford Agreement includes an exclusive grant, subject to certain pre-existing non-exclusive or exclusive rights that Stanford retained for grant to third parties with respect to certain categories of the licensed patents in certain fields of use and retained rights by Stanford and all other nonprofit institutions to use and practice the licensed patents and technology for internal research and other nonprofit purposes. The license granted to the Company in the Stanford Agreement also includes non-exclusive grants to certain Stanford patents.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In consideration for the rights granted to the Company under the Stanford Agreement, the Company paid Stanford a nonrefundable license royalty and reimbursed Stanford for past patent expenses, together totaling less than $0.1 million, and granted Stanford a specified number of shares of common stock of the Company. In addition, the Company is obligated to pay Stanford ongoing patent expenses and an annual license maintenance fee, which are nominal and will be creditable against any royalties payable to Stanford in the applicable year. The Company is required to make milestone payments up to an aggregate of $5.0 million in respect of a specified number of licensed products that successfully satisfy certain clinical and regulatory milestones. No milestone payments have been made through December 31, 2020. The Company also agreed to pay Stanford tiered royalties on a specified percentage of net sales made by the Company, its affiliates and its sublicensees of licensed products at rates ranging within low single-digit percentages, subject to certain reductions and offsets. The license, on a licensed product-by-licensed product and country-by-country basis, shall become royalty-free and fully paid-up upon the later of the date on which the last valid claim included in the exclusively or non-exclusively licensed patents expires and ten years after the first commercial sale of the licensed product in such country.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may terminate the Stanford Agreement, on a licensed product-by-licensed product basis, at any time for any reason by providing at least 60 days&amp;#8217; written notice to Stanford. Stanford may terminate the Stanford Agreement, if the Company is in breach of any provision of the Stanford Agreement and fails to remedy such breach within 60 days after written notice of such breach by Stanford. In addition, Stanford has the right to terminate the Stanford Agreement, on a licensed product-by-licensed product basis, if the Company is not diligently developing and commercializing such licensed product under certain conditions or if the Company fails to achieve specified development milestones for such licensed product by certain dates, subject to the Company&amp;#8217;s extension rights.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Commercial License Agreement with Selexis SA&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the Company entered into a license agreement with Selexis SA, or Selexis, under which the Company obtained a worldwide, royalty-bearing, sublicensable license under certain patents, know-how and other intellectual property, to use Selexis generated cell lines to manufacture ALX148 and to make, use and sell licensed product containing such compound in all fields of use. The rights granted under this agreement include the rights to grant sublicenses to contractors or other collaboration partners, in each case to develop production processes or manufacture licensed product containing ALX148.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In consideration for the rights granted to the Company under the agreement, the Company paid Selexis a nominal one-time fee and will pay Selexis an annual maintenance fee. The Company also agreed to pay Selexis milestone payments up to an aggregate of 1.2 million Swiss Francs in respect of all licensed products developed and/or commercialized under the grant that successfully satisfies certain milestone events. The Company also agreed to pay Selexis a flat royalty of a very low single-digit percentage on net sales made by the Company, its affiliates and sublicensees of products. This royalty obligation, on a product-by-product and country-by-country basis, shall terminate and become fully paid-up upon the passing of ten years after the first commercial sale of the product in such country, or the Company&amp;#8217;s exercise of the royalty buyout option exercisable at any time prior to the first commercial sale of a licensed product.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may terminate the license agreement at any time for any reason with at least 60 days&amp;#8217; written notice to Selexis. Either party may terminate the license agreement if the other party enters into a bankruptcy event or in the event of a material breach of the agreement (that cannot be cured or remains uncured for 60 days after the date that the defaulting party is provided with written notice of such breach). The Company&amp;#8217;s obligations to pay royalties that are accrued or accruable will survive any termination of the agreement, and in certain circumstances the licenses granted under the agreement will terminate unless they have become fully paid up as described in the previous paragraph.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Commercial Antibody Agreement with Crystal Bioscience Inc. (Now a Subsidiary of Ligand Pharmaceuticals Incorporated)&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2017, the Company entered into an agreement with Crystal Bioscience Inc. (now a subsidiary of Ligand Pharmaceuticals Incorporated), or Crystal, under which the Company obtained an assignment of certain patents, covering certain SIRP&amp;#945; antibodies. Under this agreement, the Company also received a worldwide, royalty-bearing non-exclusive license, with the right to grant sublicenses through multiple tiers of sublicenses, under certain of Crystal&amp;#8217;s background patents and know-how necessary to commercialize the rights under the assigned patents.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In consideration for the rights granted to the Company under the agreement, it agreed to pay Crystal milestone payments up to $11.1 million in respect of all licensed products developed under the assigned patents, that successfully satisfy certain clinical and regulatory milestones, each milestone being paid only once for all products. The Company also agreed to pay Crystal tiered royalties on net sales made by the Company, its affiliates and sublicensees of products at rates ranging within low single-digit percentages, subject to certain potential reductions. This royalty obligation, on a product-by-product and country-by-country basis, shall terminate and become fully paid-up upon the later of the date on which the last valid claim included in the licensed patents expires and ten years after the first commercial sale of the product in such country.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company agreed to use commercially reasonable efforts to develop and commercialize licensed products, including meeting defined development milestones by certain specified dates.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company may terminate the agreement at any time for any reason with at least 60 days&amp;#8217; written notice to Crystal. Either party may terminate the agreement if the other party enters into a bankruptcy event or in the event of material breach of the agreement (that remains uncured for 60 days after the date that it is provided with written notice of such breach). The Company&amp;#8217;s obligations to pay royalties and milestone payments which accrued pre-termination or accrue post-termination will survive any termination.&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock id="F_000305" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10) RELATED-PARTY TRANSACTIONS&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Related-party revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2018, the Company entered into a Research and Development Services Agreement, or Tollnine Agreement, with Tollnine, a related-party of the Company, to provide research and development services to Tollnine. The Company&amp;#8217;s Chief Executive Officer was also the Chief Executive Officer of Tollnine until April 2020 and two of the Company&amp;#8217;s investors are also investors in Tollnine. As such, Tollnine was deemed to be a related-party. The Tollnine Agreement had an initial term of 3 years, to be automatically renewed for additional one-year terms unless terminated by either party. The services were to be provided at a price based on the costs incurred by the Company plus a mark-up equal to 10% of such costs. The Company recognized revenue when Tollnine, as the Company&amp;#8217;s customer, obtained control of promised goods or services, in an amount that reflects the consideration which the Company expected to receive in exchange for those goods or services. The Company recognized related-party revenues of $1.2 million, $4.8 million and $2.1 million for the years ended December 31, 2020, 2019 and 2018, respectively, under the Tollnine Agreement. Effective as of July 1, 2020, the Company terminated the Tollnine Agreement and entered into the Tallac Services Agreement with Tallac Therapeutics. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Receivables due from related-party&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2020 and 2019, the Company had outstanding related-party receivables from Tollnine of zero and $0.5 million, respectively.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Tallac Service Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company entered into a research and development services agreement, or the Tallac Services Agreement, with Tallac Therapeutics effective as of July 1, 2020. The Tallac Services Agreement provides that Tallac Therapeutics will provide certain preclinical research services to the Company for a service fee based on the costs incurred by Tallac Therapeutics plus a mark-up equal to 10.0% of such costs. The Tallac Services Agreement has an initial term of four years and is renewed automatically for additional one year terms thereafter. The Company records the payments for the research and development services as research and development costs within the consolidated statement of operations and comprehensive loss. The Company has recorded $0.6 million as research and development costs for the year ended December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Tallac Collaboration Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 4, 2021, the Company entered into a Collaboration Agreement with Tallac Therapeutics pursuant to which the Company and Tallac Therapeutics expect to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. T&lt;font style="color:#000000;"&gt;he key economic components of the collaboration transaction include that both parties &lt;/font&gt;will share equally (a) in the cost and expenses of research and development and (b) any profit or loss.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock id="F_000306" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11) NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,740&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,243&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,731&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: cumulative preferred dividends allocated to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; preferred stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,028&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(50,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23,271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,402&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares of common stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,485,343&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,076,461&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,750,838&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; stockholders, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods presented as the inclusion of all potential common stock outstanding would have been anti-dilutive. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding potentially dilutive securities were excluded from the computation of diluted net loss per share for the years ended December 31, 2020, 2019 and 2018, because including them would have been anti-dilutive:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,313,808&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,297,081&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,292&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;229,912&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,857,308&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,183,745&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;864,819&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,857,371&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,592,869&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,391,812&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000307" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12) COMMITMENTS AND CONTINGENCIES&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Guarantees and Indemnifications&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&amp;#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company also has indemnification obligations to its officers and directors for specified events or occurrences, subject to some limits, while they are serving at the Company&amp;#8217;s request in such capacities. There have been no claims to date and the Company has director and officer insurance that may enable the Company to recover a portion of any amounts paid for future potential claims. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2020.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Contingencies&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;From time to time, the Company may be a party to various claims in the normal course of business. Legal fees and other costs associated with such actions will be expensed as incurred. The Company will assess, in conjunction with its legal counsel, the need to record a liability for litigation and contingencies. Reserve estimates will be recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. For the years ended December 31, 2020, 2019 and 2018, the Company had no pending or threatened litigation.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Contractual Obligations and Other Commitments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has contractual obligations from its operating lease, manufacturing and service contracts and other research and development activities. The following table aggregates the Company&amp;#8217;s material expected contractual obligations and commitments as of December 31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.68%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022 - 2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024 - 2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease obligations&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; (1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;346&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing and service contracts&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; (2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,320&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,292&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,028&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,666&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,432&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,234&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.29%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Payments due for the office space in Burlingame, California under a single operating sub-lease agreement that expires in 2023. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.29%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In November 2015, the Company entered into a Master Service Agreement, or the MSA, with KBI Biopharma, Inc. relating to formulation development, process development and cGMP manufacturing of ALX148 for use in clinical trials on a project basis. The MSA had an initial term of three years with successive one-year renewal periods, is cancellable upon notice and is non-exclusive. Statements of work under the MSA commit the Company to certain purchase obligations of approximately $9.9 million. In addition, the Company has commitments with a second drug product manufacturer that commits the Company to certain purchase obligations of approximately $0.4 million. These amounts are based on non-cancellable commitments and forecasts that include estimates of future market demand, quantity discounts and manufacturing efficiencies that may impact timing of purchases.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company enters into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation. These payments are not included in the table of contractual obligations above.&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Facilities&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2017, the Company entered into a lease agreement for office space for a period of five years and four months, commencing February 1, 2018 and ending May 31, 2023.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In July 2020, the Company (i) assigned to Tallac Therapeutics, a related party (Note 10), the Company&amp;#8217;s lease with respect to the premises located at 866 Malcolm Road, Burlingame, California, and (ii) received a sub-lease for premises from Tallac Therapeutics.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Minimum rent payments under operating leases are recognized on a straight-line basis over the term of the lease including any periods of free rent. Rent expense was $0.6 million, $0.8 million and $1.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. Sub-lease expenses are recorded within rent expense. &amp;#160;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000308" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13) SUBSEQUENT EVENTS&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Tallac Collaboration Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On March 4, 2021, the Company entered into a Collaboration Agreement with Tallac Therapeutics pursuant to which the Company and Tallac Therapeutics expect to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. The collaboration builds on the Company&amp;#8217;s expertise in developing therapies that block the CD47 checkpoint pathway and expands its immuno-oncology pipeline. The companies will leverage their respective scientific and technical expertise to advance an anti-SIRP&amp;#945; antibody conjugated to a Toll-like receptor 9, or TLR9, agonist for targeted activation of both the innate and adaptive immune systems. T&lt;font style="color:#000000;"&gt;he key economic components of the collaboration transaction include that both parties &lt;/font&gt;will share equally (a) in the cost and expenses of research and development and (b) any profit or loss. The Company is currently evaluating the accounting for the collaboration.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock id="F_000309" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14) SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following presents certain unaudited quarterly consolidated financial information for the&amp;#160;years ended December 31,&amp;#160;2020&amp;#160;and&amp;#160;2019. This information has been prepared on the same basis as the audited consolidated financial statements and includes all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the unaudited quarterly results of operations set forth herein. Net loss per share for all periods presented has been retroactively adjusted to reflect the 1-for-6.5806 reverse stock split effected on July 8, 2020.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,897&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,314&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,809&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,437&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,972&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,759&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,774&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,259&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,946&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,143&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,178&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,835&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000310" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Basis of Preparation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, and the applicable rules and regulations of the U.S. Securities and Exchange Commission, or SEC.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock id="F_000311" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Principles of Consolidation&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <alxo:ReverseStockSplitPolicyTextBlock id="F_000312" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Reverse Stock Split&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On July 8, 2020, the Company&amp;#8217;s board of directors approved an amendment to the Company&amp;#8217;s certificate of incorporation to effect a 1-for-6.5806 reverse split of its common stock and convertible preferred stock. The par values of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All authorized, issued and outstanding common stock, convertible preferred stock, stock options, warrants, and related per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. The reverse stock split was effected on July 9, 2020.&lt;/p&gt;</alxo:ReverseStockSplitPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000313" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Use of Estimates&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, Series B convertible preferred stock warrant liability, term loan compound derivative liability, term loan, valuation of the Company&amp;#8217;s common stock, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000314" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company holds its cash and cash equivalents in checking and money market accounts. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and are stated at fair value.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <alxo:ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock id="F_000315" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Concentration of Credit Risk, Credit Losses and Other Risks and Uncertainties&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits, and invests in money market funds. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents. The Company has not experienced any losses on its deposits of cash and cash equivalents. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&amp;#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&amp;#8217;s potential product candidates, uncertainty of market acceptance of the Company&amp;#8217;s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s product candidates require approvals from the U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</alxo:ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000316" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Property and Equipment&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives of the assets. Upon sale or retirement of assets, the cost and related accumulated depreciation or amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations and comprehensive loss. Maintenance and repairs are charged to the consolidated statement of operations and comprehensive loss as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <alxo:DeferredOfferingCostsPolicyTextBlock id="F_000317" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Deferred Offering Costs&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&amp;#8217; equity (deficit) as a reduction of additional paid-in capital generated as a result of the equity financing. &amp;#160;&lt;/p&gt;</alxo:DeferredOfferingCostsPolicyTextBlock>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock id="F_000318" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Impairment of Long-Lived Assets&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the asset or asset group are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds its fair value. Fair value is determined using various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. The Company has not recorded impairment of any long-lived assets. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="F_000319" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Fair Value of Financial Instruments&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the consolidated financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Where observable prices or inputs are not available valuation models are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments&amp;#8217; complexity.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s financial instruments consist of cash and cash equivalents, receivables due from related-party, accounts payable, the term loan compound derivative liability and the Series B convertible preferred stock warrant liability. The term loan compound derivative liability and the Series B convertible preferred stock warrant liability are re-measured at the end of every period and carried at fair value (Note 3). The recorded value of the Company&amp;#8217;s receivables due from related-party and accounts payable approximates its current fair value due to the relatively short-term nature of these items.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:DebtPolicyTextBlock id="F_000320" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Term Loan&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for the Loan and Security Agreement, dated as of December 20, 2019, as amended, with Silicon Valley Bank, or SVB, and WestRiver Innovation Lending Fund VIII, LP, or WestRiver, collectively as lenders, and SVB, as administrative agent and collateral agent, as a liability measured at net proceeds less debt discount and is accreted to the face value of the term loan over its expected term using the effective interest method. The Company considers whether there are any embedded features in its debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to Accounting Standards Codification, or ASC, Topic 815, &lt;font style="font-style:italic;"&gt;Derivatives and Hedging&lt;/font&gt;.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
  <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy id="F_000321" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Convertible Preferred Stock&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records convertible preferred stock net of issuance costs on the dates of issuance, which represents the carrying value. In the event of a change of control of the Company, proceeds will be distributed in accordance with the liquidation preferences set forth in its organization documents unless the holders of convertible preferred stock have converted their convertible preferred stock into common stock. Convertible preferred stock is classified outside of stockholders&amp;#8217; equity (deficit) on the accompanying consolidated balance sheets as events triggering the liquidation preferences are not solely within the Company&amp;#8217;s control. The Company has elected not to adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because of the uncertainty of whether or when such an event would occur. Upon the consummation of the Company&amp;#8217;s initial public offering in July 2020, all shares of convertible preferred stock outstanding and accrued cumulative dividends automatically converted into&amp;#160;23,934,533&amp;#160;shares of common stock.&lt;/p&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
  <alxo:ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock id="F_000322" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapSeriesBPreferredStockMember_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Series B Convertible Preferred Stock Warrant Liability&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has issued freestanding warrants to purchase its Series B convertible preferred stock. Freestanding warrants for the Company&amp;#8217;s convertible preferred stock that are classified outside of permanent equity are recorded at fair value, and are subject to re-measurement at the end of every period until the earlier of the exercise of the warrants or the completion of a liquidation event, including the completion of an initial public offering. Upon exercise, the Series B convertible preferred stock warrant liability would be reclassified to additional paid-in capital, with any change in fair value recognized as a component of other expense, net. Following the Company&amp;#8217;s initial public offering, the warrants were automatically converted to warrants to purchase shares of common stock (Note 5). The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance to additional paid-in capital with no further re-measurement required as common stock warrants are considered permanent equity. &lt;/p&gt;</alxo:ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock>
  <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock id="F_000323" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Revenue Recognition&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To date, the Company has derived revenue from providing research and development services on a time and materials basis to a related-party.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes such revenues over time as services are delivered, and invoices the customer as the work is incurred in arrears.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt; (Topic 606), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the Company&amp;#8217;s consideration as to whether the Company has entered into a contract with a customer, it considers whether it is probable that it will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
  <alxo:CostOfServicesForRelatedPartyRevenuePolicyTextBlock id="F_000324" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Cost of Services for Related-Party Revenue&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company incurs costs associated with related-party services including direct labor and associated employee benefits, laboratory supplies, and other expenses. These costs are recorded in cost of services for related-party revenue as a component of total operating expenses in the accompanying consolidated statements of operations and comprehensive loss.&lt;/p&gt;</alxo:CostOfServicesForRelatedPartyRevenuePolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000325" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Research and Development Costs &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred and consist primarily of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to nonemployees and entities that conduct certain research and development activities on behalf of the Company and expenses incurred in connection with license agreements (Note 9). Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and recorded in prepaid expenses and other current assets, and then expensed as the related goods are delivered or the services are performed.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <alxo:ClinicalAndManufacturingAccrualsPolicyTextBlock id="F_000326" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Clinical and Manufacturing Accruals&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company records accruals for estimated costs of research, preclinical studies and clinical trials, and manufacturing development, which are a significant component of research and development expenses. A substantial portion of the Company&amp;#8217;s ongoing research and development activities are conducted by third-party service providers, including contract research organizations, or CROs, and contract manufacturing organizations, or CMOs. The Company&amp;#8217;s contracts with CROs generally include pass-through fees such as regulatory expenses, investigator fees, travel costs and other miscellaneous costs, including shipping and printing fees. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company accrues the costs incurred under agreements with these third parties based on estimates of actual work completed in accordance with the respective agreements. The Company determines the estimated costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fees to be paid for such services.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company makes significant judgments and estimates in determining the accrual balance at the end of each reporting period. As actual costs become known, the Company adjusts its accruals. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&amp;#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in the Company reporting amounts that are too high or too low in any particular period. To assist in its estimates the Company relies upon the receipt of timely and accurate reporting from its clinical and non-clinical studies and other third-party vendors. Through December 31, 2020, there have been no material differences from the Company&amp;#8217;s accrued estimated expenses to the actual clinical trial expenses. However, variations in the assumptions used to estimate accruals, including, but not limited to, the number of patients enrolled, the rate of patient enrollment, and the actual services performed, and related costs may vary from the Company&amp;#8217;s estimates, resulting in adjustments to clinical trial expense in future periods. Changes in these estimates that result in material changes to the Company&amp;#8217;s accruals could materially affect its financial position and results of operations.&lt;/p&gt;</alxo:ClinicalAndManufacturingAccrualsPolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="F_000327" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Stock-based Compensation Expense &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all stock-based payments made to employees, directors and non-employees based on estimated grant-date fair values. The Company uses the straight-line method to allocate compensation expense to reporting periods over each optionee&amp;#8217;s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards using the Black-Scholes option-pricing model. The Black-Scholes model requires the input of subjective assumptions, including expected volatility, expected dividend yield, expected term, risk-free rate of return and the estimated fair value of the underlying common stock on the date of grant. Prior to the Company&amp;#8217;s initial public offering, the fair value of the common stock underlying the stock-based awards was determined on each grant date by the board of directors, with input from management, considering the most recently available third-party valuation of common shares. The Company accounts for the effect of forfeitures as they occur. &lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000328" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Segment Reporting &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. &lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock id="F_000329" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Foreign Currency Transactions &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The functional currency of the Company&amp;#8217;s operation and each of its subsidiaries is U.S. dollars. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate prevailing on the balance sheet date. Expenses are translated at the average exchange rates prevailing during the applicable period. Foreign currency transaction gains and losses are included in the consolidated statement of operations and comprehensive loss and recorded in other expense, net, and were immaterial for the years December 31, 2020, 2019 and 2018.&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000330" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for the period in which the temporary differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&amp;#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock id="F_000331" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Comprehensive Loss&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Comprehensive loss is equal to net loss for all periods presented.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000332" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share Attributable to Common Stockholders&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company applies the two-class method to compute basic and diluted net loss per share when it has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires net loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all net loss for the period had been distributed. The Company&amp;#8217;s convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <alxo:RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock id="F_000333" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), &lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt; (ASU 2016-02). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU No. 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. In June 2020, the FASB issued ASU No. 2020-05, which extends the effective date of ASU No. 2016-02 for non-public business entities, including smaller reporting companies, to fiscal years beginning after December 15, 2021. The new standard is effective for the Company beginning January 1, 2022 (or earlier if the Company ceases to be an emerging growth company). Early adoption is permitted. The Company is currently evaluating the effects of the adoption of this guidance on its consolidated financial statements and related disclosures.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2021. ASU 2019-12 is effective for the Company beginning January 1, 2022. Early adoption is permitted. The Company is currently in the process of evaluating the effects of the adoption of this guidance on the Company&amp;#8217;s financial statements and does not expect it to have a material impact on its consolidated financial statements.&lt;/p&gt;</alxo:RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000334" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;New Accounting Pronouncements Recently Adopted&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. The Company early adopted this guidance on January 1, 2020. &lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;For trade receivables and other instruments, the Company uses a new forward-looking &lt;/font&gt;&lt;font style="color:#000000;"&gt;expected loss model that generally results in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses are recognized as allowances rather than as reductions in the amortized cost of the securities. &lt;/font&gt;&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;The adoption of the guidance did not have a material impact on the Consolidated Financial Statements and related disclosures and there was&amp;#160;no&amp;#160;allowance for losses for the year ended December 31, 2020.&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In September 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&amp;#8212;Changes to the Disclosure Requirements for Fair Value Measurement. The FASB issued final guidance that eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. Under the ASU, entities will no longer be required to disclose the amount of transfers between Level 1 and Level 2 of the fair value hierarchy. Public companies will be required to disclose changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. ASU 2018-13 is effective for public business entities for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2019, with early adoption permitted. The Company adopted this guidance on January 1, 2020. The adoption of ASU 2018-13 did not have a material impact on its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <dei:DocumentsIncorporatedByReferenceTextBlock id="F_000335" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Certain portions of the registrant&apos;s definitive proxy statement relating to the Company&apos;s 2021 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days of the registrant&apos;s fiscal year ended December 31, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="F_000336" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the Company&amp;#8217;s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Cash equivalents&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;424,115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;424,115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Financial liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Non-current liabilities&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compound derivative liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="F_000337" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table is a reconciliation of all financial liabilities measured at fair value using Level 3 unobservable inputs (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Compound&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrant&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Derivative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value at beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;361&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in fair value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reclassification to equity&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Extinguishment of compound derivative liability upon extinguishment of host instrument&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(43&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair value at end of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000338" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the components of property and equipment, net as of December 31, 2020 and 2019 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Computer hardware and software&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;146&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,698&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;429&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,309&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,449&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;52&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;860&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <alxo:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock id="F_000339" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table presents the components of accrued expenses and other current liabilities as of December 31, 2020 and 2019 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;300&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;122&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,974&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;924&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued clinical and nonclinical study costs&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,473&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued contract manufacturing&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,123&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued federal income tax&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;179&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;151&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;136&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,200&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,236&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</alxo:ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock>
  <alxo:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock id="F_000340" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock reserved for future issuance, on an as if converted basis, as of December 31, 2020 and 2019, consists of the following:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,313,808&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,857,308&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,183,745&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options authorized for future issuance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,835,443&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;566,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,292&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants authorized for future issuance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,646&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,692,751&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,156,391&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</alxo:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
  <us-gaap:TemporaryEquityTableTextBlock id="F_000341" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2019, the Company&amp;#8217;s convertible preferred stock consisted of the following (in thousands, except share amounts):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Issued And&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Liquidation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Proceeds&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Preference&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares designated as:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series A convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,421,633&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,297,081&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60,933&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73,571&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Series&amp;#160;B convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,145,370&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,016,727&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,430&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,014&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,567,003&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,313,808&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;70,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;83,585&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.24%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Net proceeds are gross proceeds from the offerings net of issuance costs&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000342" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table provides a summary of share option activity under the Plan and related information:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available&amp;#160;to&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Grant&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual Life&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(in&amp;#160;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;566,900&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,183,745&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;638&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Authorized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,124,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,857,655&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,857,655&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10.92&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(182,111&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.65&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Canceled/forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,981&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,981&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Outstanding at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,835,443&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,857,308&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.94&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.86&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;375,270&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercisable at December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,776,399&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.85&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.65&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;310,999&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000343" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation expense includes share options granted to employees and nonemployees and has been reported in the Company&amp;#8217;s consolidated statements of operations and comprehensive loss as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,551&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;105&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;195&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost of services for related-party revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;58&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,436&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;297&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;269&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000344" contextRef="C_0001810182_20200101_20201231">The fair value of each option grant during the years ended December 31, 2020, 2019 and 2018 was estimated with the&lt;font style="letter-spacing:-0.4pt;"&gt; &lt;/font&gt;following assumptions:
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="5" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.66%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.8 - 6.1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.4 - 6.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.2 - 6.0&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.3% - 0.8%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.7% - 2.1%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2.6% - 3.0%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;-&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected stock price volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;78.7% - 89.0%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75.2% - 80.5%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;66.5% - 68.7%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock id="F_000345" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The U.S. domestic and international components of pre-tax loss for the years ending December 31, 2020, 2019 and 2018 are as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;United States&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,457&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;813&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;855&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;International&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,042&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(20,022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14,541&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss before income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,209&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock id="F_000346" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The federal and state provision for income taxes consist of the following (in thousands):&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current provision for income taxes:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;239&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;44&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;International&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total current&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;241&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax provision:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;International&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;241&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000347" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A reconciliation of the U.S. federal statutory income tax rate to the effective tax for the years ended December 31, 2020, 2019 and 2018 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At federal statutory income tax rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,555&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,034&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,874&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,098&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,875&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(332&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;60&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;57&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research &amp;amp; Development credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(512&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(499&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,710&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,733&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;732&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;321&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;100&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Foreign rate differential&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,380&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,899&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Prior period true ups&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(950&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Provision for income taxes&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;241&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000348" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets as of December 31, 2020 and 2019 are as follows (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,283&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,259&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research &amp;amp; other credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,861&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,260&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;383&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;261&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;696&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,299&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,852&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;166&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;166&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(11,288&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,686&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <alxo:SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock id="F_000349" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses and tax credit carryforwards as of December 31, 2020 are as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amount&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expiration Years&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses, federal (Post December 31, 2017)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,919&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Do Not Expire&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses, state&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,363&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2038-2040&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits, federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,327&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2039-2040&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax credits, state&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,893&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;N/A&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating losses, foreign&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,086&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;N/A&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</alxo:SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock>
  <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock id="F_000350" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has the following activity relating to unrecognized tax benefits (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:89.6%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at beginning of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;692&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;418&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions/reversals based on tax positions of prior years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(64&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions based on tax positions related to the current year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;240&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;272&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;160&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Lapses in statutes of limitations&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;Balance at end of year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;842&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;692&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;418&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock id="F_000351" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(45,740&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(19,243&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,731&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less: cumulative preferred dividends allocated to&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; preferred stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,202&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,028&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(3,671&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(50,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(23,271&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(17,402&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-average shares of common stock&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,485,343&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,076,461&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,750,838&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&amp;nbsp; stockholders, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7.56&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock id="F_000352" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following outstanding potentially dilutive securities were excluded from the computation of diluted net loss per share for the years ended December 31, 2020, 2019 and 2018, because including them would have been anti-dilutive:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December&amp;#160;31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,313,808&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,297,081&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Warrants to purchase convertible preferred stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;61,292&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Common stock subject to repurchase&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;63&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;34,024&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;229,912&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options issued and outstanding&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,857,308&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,183,745&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;864,819&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,857,371&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,592,869&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,391,812&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:RegistrationPaymentArrangementTextBlock id="F_000353" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has contractual obligations from its operating lease, manufacturing and service contracts and other research and development activities. The following table aggregates the Company&amp;#8217;s material expected contractual obligations and commitments as of December 31, 2020 (in thousands):&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="18" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.68%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022 - 2023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2024 - 2025&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.28%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating lease obligations&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; (1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;346&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;140&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Manufacturing and service contracts&lt;sup style="font-size:85%;line-height:120%;vertical-align:top"&gt; (2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,320&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,292&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,028&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,666&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,432&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,234&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.29%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(1)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;Payments due for the office space in Burlingame, California under a single operating sub-lease agreement that expires in 2023. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:5.29%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;(2)&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"&gt;In November 2015, the Company entered into a Master Service Agreement, or the MSA, with KBI Biopharma, Inc. relating to formulation development, process development and cGMP manufacturing of ALX148 for use in clinical trials on a project basis. The MSA had an initial term of three years with successive one-year renewal periods, is cancellable upon notice and is non-exclusive. Statements of work under the MSA commit the Company to certain purchase obligations of approximately $9.9 million. In addition, the Company has commitments with a second drug product manufacturer that commits the Company to certain purchase obligations of approximately $0.4 million. These amounts are based on non-cancellable commitments and forecasts that include estimates of future market demand, quantity discounts and manufacturing efficiencies that may impact timing of purchases.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RegistrationPaymentArrangementTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock id="F_000354" contextRef="C_0001810182_20200101_20201231">
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following presents certain unaudited quarterly consolidated financial information for the&amp;#160;years ended December 31,&amp;#160;2020&amp;#160;and&amp;#160;2019. This information has been prepared on the same basis as the audited consolidated financial statements and includes all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the unaudited quarterly results of operations set forth herein. Net loss per share for all periods presented has been retroactively adjusted to reflect the 1-for-6.5806 reverse stock split effected on July 8, 2020.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,897&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,314&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,809&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;17,825&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(7,437&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,972&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(10,759&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,774&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.36&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;(in thousands, except per share data)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,259&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,484&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,946&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss attributable to common stockholders&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,143&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,178&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,115&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8,835&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.71&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.68&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1.33&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <us-gaap:StockholdersEquityReverseStockSplit id="F_000355" contextRef="C_0001810182_20200101_20201231">On July 8, 2020, the Company&#8217;s board of directors approved an amendment to the Company&#8217;s certificate of incorporation to effect a 1-for-6.5806 reverse split of its common stock and convertible preferred stock.</us-gaap:StockholdersEquityReverseStockSplit>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000356" contextRef="C_0001810182_20200708_20200708" decimals="9" unitRef="U_xbrlipure">0.151961827</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:AssetImpairmentCharges id="F_000357" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AssetImpairmentCharges>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000358" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200731" decimals="INF" unitRef="U_xbrlishares">23934533</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:NumberOfOperatingSegments id="F_000359" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_alxoSegment">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted id="F_000360" contextRef="C_0001810182_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate id="F_000361" contextRef="C_0001810182_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect id="F_000362" contextRef="C_0001810182_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201613Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted id="F_000363" contextRef="C_0001810182_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate id="F_000364" contextRef="C_0001810182_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">2020-01-01</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate>
  <us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect id="F_000365" contextRef="C_0001810182_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201813Member_20201231">true</us-gaap:ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000366" contextRef="C_0001810182_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">424115000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000367" contextRef="C_0001810182_us-gaapFairValueByAssetClassAxis_us-gaapMoneyMarketFundsMember_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20201231" decimals="-3" unitRef="U_iso4217USD">424115000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:DerivativeLiabilities id="F_000368" contextRef="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">51000</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="F_000369" contextRef="C_0001810182_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">51000</us-gaap:DerivativeLiabilities>
  <alxo:WarrantLiabilityFairValueDisclosure id="F_000370" contextRef="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">361000</alxo:WarrantLiabilityFairValueDisclosure>
  <alxo:WarrantLiabilityFairValueDisclosure id="F_000371" contextRef="C_0001810182_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20191231" decimals="-3" unitRef="U_iso4217USD">361000</alxo:WarrantLiabilityFairValueDisclosure>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000372" contextRef="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_alxoWarrantLiabilityMember_20191231" decimals="-3" unitRef="U_iso4217USD">361000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000373" contextRef="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_alxoCompoundDerivativeLiabilityMember_20191231" decimals="-3" unitRef="U_iso4217USD">51000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease id="F_000374" contextRef="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_alxoWarrantLiabilityMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">658000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease id="F_000375" contextRef="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_alxoCompoundDerivativeLiabilityMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-8000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
  <alxo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity id="F_000376" contextRef="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_alxoWarrantLiabilityMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-1019000</alxo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity>
  <alxo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment id="F_000377" contextRef="C_0001810182_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel3Member_us-gaapFairValueByLiabilityClassAxis_alxoCompoundDerivativeLiabilityMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-43000</alxo:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="F_000378" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount id="F_000379" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="F_000380" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount id="F_000381" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueAssetsLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount id="F_000382" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount id="F_000383" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel1ToLevel2TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount id="F_000384" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount id="F_000385" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueLiabilitiesLevel2ToLevel1TransfersAmount>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 id="F_000386" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3 id="F_000387" contextRef="C_0001810182_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 id="F_000388" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3 id="F_000389" contextRef="C_0001810182_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 id="F_000390" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3 id="F_000391" contextRef="C_0001810182_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 id="F_000392" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3 id="F_000393" contextRef="C_0001810182_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000394" contextRef="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoComputerHardwareAndSoftwareMember_20201231" decimals="-3" unitRef="U_iso4217USD">63000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000395" contextRef="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoComputerHardwareAndSoftwareMember_20191231" decimals="-3" unitRef="U_iso4217USD">146000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000396" contextRef="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapMachineryAndEquipmentMember_20191231" decimals="-3" unitRef="U_iso4217USD">1698000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000397" contextRef="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20201231" decimals="-3" unitRef="U_iso4217USD">9000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000398" contextRef="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20191231" decimals="-3" unitRef="U_iso4217USD">36000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000399" contextRef="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20201231" decimals="-3" unitRef="U_iso4217USD">5000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000400" contextRef="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20191231" decimals="-3" unitRef="U_iso4217USD">429000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000401" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">77000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000402" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">2309000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000403" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">25000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000404" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">1449000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:DepreciationAndAmortization id="F_000405" contextRef="C_0001810182_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">200000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="F_000406" contextRef="C_0001810182_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization id="F_000407" contextRef="C_0001810182_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:DepreciationAndAmortization>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000408" contextRef="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoLabEquipmentAndOtherAssetsMember_20200630" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="F_000409" contextRef="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoLabEquipmentAndOtherAssetsMember_20200701_20200731" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000410" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">300000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000411" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">122000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000412" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">1974000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent id="F_000413" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">924000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <alxo:AccruedClinicalAndNonClinicalCostsCurrent id="F_000414" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">1473000</alxo:AccruedClinicalAndNonClinicalCostsCurrent>
  <alxo:AccruedContractManufacturingCurrent id="F_000415" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">2123000</alxo:AccruedContractManufacturingCurrent>
  <alxo:AccruedContractManufacturingCurrent id="F_000416" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">53000</alxo:AccruedContractManufacturingCurrent>
  <alxo:AccruedFederalIncomeTax id="F_000417" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">179000</alxo:AccruedFederalIncomeTax>
  <alxo:AccruedFederalIncomeTax id="F_000418" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">1000</alxo:AccruedFederalIncomeTax>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000419" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">151000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent id="F_000420" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">136000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:DebtInstrumentFaceAmount id="F_000421" contextRef="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20191220" decimals="INF" unitRef="U_iso4217USD">10000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount id="F_000422" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapLongtermDebtTypeAxis_alxoFirstTrancheMember_20191231" decimals="-5" unitRef="U_iso4217USD">6000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount id="F_000423" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapLongtermDebtTypeAxis_alxoSecondTrancheMember_20200331" decimals="-5" unitRef="U_iso4217USD">4000000</us-gaap:DebtInstrumentFaceAmount>
  <alxo:ProceedsFromEquityFinancing id="F_000424" contextRef="C_0001810182_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20200101_20200331" decimals="-5" unitRef="U_iso4217USD">30000000</alxo:ProceedsFromEquityFinancing>
  <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis id="F_000425" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20200101_20201231">The loans under the Loan Agreement bore interest at a floating per annum interest rate equal to the greater of 7.0% or 2.0% plus the prime rate as reported in The Wall Street Journal.</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
  <us-gaap:LongTermDebtPercentageBearingVariableInterestRate id="F_000426" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20191220" decimals="3" unitRef="U_xbrlipure">0.070</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
  <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 id="F_000427" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapVariableRateAxis_us-gaapPrimeRateMember_20191220_20191220" decimals="INF" unitRef="U_xbrlipure">0.020</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
  <alxo:DebtInstrumentInterestOnlyPaymentTerms id="F_000428" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20200101_20201231">Interest-only payments for the first 12 months after the closing of the Loan Agreement</alxo:DebtInstrumentInterestOnlyPaymentTerms>
  <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment id="F_000429" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20200101_20201231">monthly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
  <us-gaap:DebtInstrumentDateOfFirstRequiredPayment1 id="F_000430" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20191220_20191220">2021-01-01</us-gaap:DebtInstrumentDateOfFirstRequiredPayment1>
  <us-gaap:DebtInstrumentMaturityDate id="F_000431" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20191220_20191220">2022-09-01</us-gaap:DebtInstrumentMaturityDate>
  <alxo:FinalPaymentFeeAsPercentageOfFundedPrincipalAmount id="F_000432" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20191220_20191220" decimals="3" unitRef="U_xbrlipure">0.060</alxo:FinalPaymentFeeAsPercentageOfFundedPrincipalAmount>
  <alxo:DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount id="F_000433" contextRef="C_0001810182_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20191220_20191220" decimals="INF" unitRef="U_xbrlipure">0.010</alxo:DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount>
  <alxo:DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount id="F_000434" contextRef="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20191220_20191220" decimals="INF" unitRef="U_xbrlipure">0.030</alxo:DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000435" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20191220" decimals="INF" unitRef="U_xbrlishares">61292</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000436" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20191220" decimals="4" unitRef="U_iso4217USD_xbrlishares">9.4972</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="F_000437" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191220" decimals="INF" unitRef="U_xbrlishares">61292</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:SharePrice id="F_000438" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20191220" decimals="INF" unitRef="U_iso4217USD_xbrlishares">9.4972</us-gaap:SharePrice>
  <alxo:EstimatedFairValueIssuanceOfWarrants id="F_000439" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20191220" decimals="-5" unitRef="U_iso4217USD">400000</alxo:EstimatedFairValueIssuanceOfWarrants>
  <us-gaap:WarrantsAndRightsOutstandingTerm id="F_000440" contextRef="C_0001810182_srtRangeAxis_srtMinimumMember_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20201231">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm id="F_000441" contextRef="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedTermMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200716">P9Y9M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="F_000442" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputPriceVolatilityMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200716" decimals="3" unitRef="U_xbrlipure">0.842</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="F_000443" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputRiskFreeInterestRateMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200716" decimals="3" unitRef="U_xbrlipure">0.006</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput id="F_000444" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapMeasurementInputTypeAxis_us-gaapMeasurementInputExpectedDividendRateMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200716" decimals="0" unitRef="U_xbrlipure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000445" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200817" decimals="INF" unitRef="U_xbrlishares">61292</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000446" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200817" decimals="4" unitRef="U_iso4217USD_xbrlishares">9.4972</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <alxo:ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock id="F_000447" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200716" decimals="-5" unitRef="U_iso4217USD">1000000</alxo:ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities id="F_000448" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200816_20200817" decimals="INF" unitRef="U_xbrlishares">48932</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue id="F_000449" contextRef="C_0001810182_us-gaapFairValueByLiabilityClassAxis_alxoCompoundDerivativeLiabilityMember_20191220" decimals="0" unitRef="U_iso4217USD">51000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <alxo:NetProceedsFromFollowOnPublicOffering id="F_000450" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20201201_20201231" decimals="-5" unitRef="U_iso4217USD">6500000</alxo:NetProceedsFromFollowOnPublicOffering>
  <us-gaap:RepaymentsOfLongTermDebt id="F_000451" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20201201_20201231" decimals="-5" unitRef="U_iso4217USD">6000000</us-gaap:RepaymentsOfLongTermDebt>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt id="F_000452" contextRef="C_0001810182_us-gaapDebtInstrumentAxis_alxoLoanAgreementMember_20201201_20201231" decimals="-5" unitRef="U_iso4217USD">-600000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <us-gaap:CommonStockSharesAuthorized id="F_000453" contextRef="C_0001810182_20200721" decimals="INF" unitRef="U_xbrlishares">1000000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000454" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoUndesignatedPreferredStockMember_20200721" decimals="INF" unitRef="U_xbrlishares">100000000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000455" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoUndesignatedPreferredStockMember_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding id="F_000456" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoUndesignatedPreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">10313808</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000457" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200721_20200721" decimals="INF" unitRef="U_xbrlishares">9775000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000458" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200721_20200721" decimals="-5" unitRef="U_iso4217USD">169500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000459" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200721_20200721" decimals="-5" unitRef="U_iso4217USD">13000000</us-gaap:PaymentsOfStockIssuanceCosts>
  <alxo:PaymentForOfferingCost id="F_000460" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200721_20200721" decimals="-5" unitRef="U_iso4217USD">3200000</alxo:PaymentForOfferingCost>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion id="F_000461" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200721" decimals="INF" unitRef="U_xbrlishares">23934533</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000462" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_alxoFollowOnPublicOfferingMember_20201201_20201231" decimals="INF" unitRef="U_xbrlishares">2737000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering id="F_000463" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_alxoFollowOnPublicOfferingMember_20201201_20201231" decimals="-5" unitRef="U_iso4217USD">194900000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:PaymentsOfStockIssuanceCosts id="F_000464" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_alxoFollowOnPublicOfferingMember_20201201_20201231" decimals="-5" unitRef="U_iso4217USD">12500000</us-gaap:PaymentsOfStockIssuanceCosts>
  <alxo:PaymentForOfferingCost id="F_000465" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_alxoFollowOnPublicOfferingMember_20201201_20201231" decimals="-5" unitRef="U_iso4217USD">700000</alxo:PaymentForOfferingCost>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000466" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoConvertiblePreferredStockIssuedAndOutstandingMember_20191231" decimals="INF" unitRef="U_xbrlishares">10313808</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000467" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoStockOptionsIssuedAndOutstandingMember_20201231" decimals="INF" unitRef="U_xbrlishares">4857308</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000468" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoStockOptionsIssuedAndOutstandingMember_20191231" decimals="INF" unitRef="U_xbrlishares">1183745</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000469" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoStockOptionsAuthorizedForFutureIssuanceMember_20201231" decimals="INF" unitRef="U_xbrlishares">2835443</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000470" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoStockOptionsAuthorizedForFutureIssuanceMember_20191231" decimals="INF" unitRef="U_xbrlishares">566900</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000471" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoWarrantsIssuedAndOutstandingMember_20191231" decimals="INF" unitRef="U_xbrlishares">61292</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000472" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoWarrantsAuthorizedForFutureIssuanceMember_20191231" decimals="INF" unitRef="U_xbrlishares">30646</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000473" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_xbrlishares">7692751</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000474" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_xbrlishares">12156391</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000475" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_xbrlishares">11567003</us-gaap:TemporaryEquitySharesAuthorized>
  <alxo:TemporaryEquitySharesIssuedAndOutstanding id="F_000476" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">9297081</alxo:TemporaryEquitySharesIssuedAndOutstanding>
  <alxo:TemporaryEquitySharesIssuedAndOutstanding id="F_000477" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20191231" decimals="INF" unitRef="U_xbrlishares">1016727</alxo:TemporaryEquitySharesIssuedAndOutstanding>
  <alxo:TemporaryEquitySharesIssuedAndOutstanding id="F_000478" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_xbrlishares">10313808</alxo:TemporaryEquitySharesIssuedAndOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent id="F_000479" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">70363000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityLiquidationPreference id="F_000480" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">83585000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquitySharesAuthorized id="F_000481" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesCConvertiblePreferredStockMember_20200229" decimals="INF" unitRef="U_xbrlishares">11055981</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:SaleOfStockPricePerShare id="F_000482" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesCConvertiblePreferredStockMember_20200229" decimals="4" unitRef="U_iso4217USD_xbrlishares">9.4972</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock id="F_000483" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesCConvertiblePreferredStockMember_20200201_20200229" decimals="-5" unitRef="U_iso4217USD">105000000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000484" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200721" decimals="INF" unitRef="U_xbrlishares">61292</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000485" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBConvertiblePreferredStockMember_20200721" decimals="4" unitRef="U_iso4217USD_xbrlishares">9.4972</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight id="F_000486" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200721" decimals="INF" unitRef="U_xbrlishares">61292</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:SharePrice id="F_000487" contextRef="C_0001810182_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20200721" decimals="INF" unitRef="U_iso4217USD_xbrlishares">9.4972</us-gaap:SharePrice>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="F_000488" contextRef="C_0001810182_20200817" decimals="INF" unitRef="U_xbrlishares">61292</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="F_000489" contextRef="C_0001810182_20200817" decimals="4" unitRef="U_iso4217USD_xbrlishares">9.4972</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:CommonStockSharesIssued id="F_000490" contextRef="C_0001810182_20200817" decimals="INF" unitRef="U_xbrlishares">48932</us-gaap:CommonStockSharesIssued>
  <us-gaap:PreferredStockDividendRatePercentage id="F_000491" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200101_20201231" decimals="INF" unitRef="U_xbrlipure">0.060</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:SharesIssuedPricePerShare id="F_000492" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesAConvertiblePreferredStockMember_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">6.58</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare id="F_000493" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_alxoSeriesBAndCConvertiblePreferredStockMember_20201231" decimals="4" unitRef="U_iso4217USD_xbrlishares">9.4972</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:PreferredStockAmountOfPreferredDividendsInArrears id="F_000494" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200720_20200720" decimals="-5" unitRef="U_iso4217USD">18000000</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>
  <alxo:CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion id="F_000495" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200720" decimals="INF" unitRef="U_xbrlishares">2564759</alxo:CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000496" contextRef="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapPlanNameAxis_alxoTwoThousandAndFifteenShareAwardSchemeMember_20150101_20151231" decimals="INF" unitRef="U_xbrlishares">2143117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000497" contextRef="C_0001810182_us-gaapPlanNameAxis_alxoTwentyThousandAndTwentyEquityIncentivePlanMember_20200401" decimals="INF" unitRef="U_xbrlishares">4379139</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000498" contextRef="C_0001810182_us-gaapPlanNameAxis_alxoAmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_20200731" decimals="INF" unitRef="U_xbrlishares">7874862</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod id="F_000499" contextRef="C_0001810182_us-gaapPlanNameAxis_alxoAmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 id="F_000500" contextRef="C_0001810182_us-gaapPlanNameAxis_alxoAmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_20200101_20201231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
  <alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised id="F_000501" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">63</alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised>
  <alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised id="F_000502" contextRef="C_0001810182_20190101_20191231" decimals="INF" unitRef="U_xbrlishares">34024</alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000503" contextRef="C_0001810182_20201231" decimals="0" unitRef="U_iso4217USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions id="F_000504" contextRef="C_0001810182_20191231" decimals="0" unitRef="U_iso4217USD">27000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000505" contextRef="C_0001810182_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201709Member_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_000506" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoTwentyThousandAndTwentyEmployeeStockPurchasePlanMember_20200701_20200731" decimals="2" unitRef="U_xbrlipure">0.15</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount id="F_000507" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoTwentyThousandAndTwentyEmployeeStockPurchasePlanMember_20200701_20200731" decimals="0" unitRef="U_iso4217USD">25000</alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000508" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoTwentyThousandAndTwentyEmployeeStockPurchasePlanMember_20200731" decimals="INF" unitRef="U_xbrlishares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage id="F_000509" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoTwentyThousandAndTwentyEmployeeStockPurchasePlanMember_20200701_20200731" decimals="2" unitRef="U_xbrlipure">0.85</alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000510" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoTwentyThousandAndTwentyEmployeeStockPurchasePlanMember_20200731" decimals="INF" unitRef="U_xbrlishares">400000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000511" contextRef="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapAwardTypeAxis_alxoTwentyThousandAndTwentyEmployeeStockPurchasePlanMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20210101" decimals="INF" unitRef="U_xbrlishares">800000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000512" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoTwentyThousandAndTwentyEmployeeStockPurchasePlanMember_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000513" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_xbrlishares">566900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized id="F_000514" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">6124217</alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized>
  <alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted id="F_000515" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">3857655</alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted>
  <alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled id="F_000516" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1981</alxo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="F_000517" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_xbrlishares">2835443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000518" contextRef="C_0001810182_20191231" decimals="INF" unitRef="U_xbrlishares">1183745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="F_000519" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">3857655</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000520" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">182111</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod id="F_000521" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_xbrlishares">1981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000522" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_xbrlishares">4857308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000523" contextRef="C_0001810182_20201231" decimals="INF" unitRef="U_xbrlishares">3776399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000524" contextRef="C_0001810182_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000525" contextRef="C_0001810182_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">10.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000526" contextRef="C_0001810182_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000527" contextRef="C_0001810182_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">0.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000528" contextRef="C_0001810182_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">8.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000529" contextRef="C_0001810182_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">3.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000530" contextRef="C_0001810182_20190101_20191231">P8Y21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000531" contextRef="C_0001810182_20200101_20201231">P8Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000532" contextRef="C_0001810182_20200101_20201231">P8Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding id="F_000533" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">638000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding id="F_000534" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">375270000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000535" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">310999000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000536" contextRef="C_0001810182_20201231" decimals="-5" unitRef="U_iso4217USD">25000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000537" contextRef="C_0001810182_20200101_20201231">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000538" contextRef="C_0001810182_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">4400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000539" contextRef="C_0001810182_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">7.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000540" contextRef="C_0001810182_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000541" contextRef="C_0001810182_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000542" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2551000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000543" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">105000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000544" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">195000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000545" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2885000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000546" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">33000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000547" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000548" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">159000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000549" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_us-gaapIncomeStatementLocationAxis_us-gaapCostOfSalesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">58000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000550" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5436000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000551" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">297000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000552" contextRef="C_0001810182_us-gaapAwardTypeAxis_alxoShareOptionsGrantedToEmployeesAndNonemployeesMember_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">269000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000553" contextRef="C_0001810182_srtRangeAxis_srtMinimumMember_20200101_20201231">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000554" contextRef="C_0001810182_srtRangeAxis_srtMinimumMember_20190101_20191231">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000555" contextRef="C_0001810182_srtRangeAxis_srtMinimumMember_20180101_20181231">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000556" contextRef="C_0001810182_srtRangeAxis_srtMaximumMember_20200101_20201231">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000557" contextRef="C_0001810182_srtRangeAxis_srtMaximumMember_20190101_20191231">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000558" contextRef="C_0001810182_srtRangeAxis_srtMaximumMember_20180101_20181231">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000559" contextRef="C_0001810182_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000560" contextRef="C_0001810182_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum id="F_000561" contextRef="C_0001810182_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000562" contextRef="C_0001810182_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000563" contextRef="C_0001810182_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum id="F_000564" contextRef="C_0001810182_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000565" contextRef="C_0001810182_20200101_20201231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000566" contextRef="C_0001810182_20190101_20191231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000567" contextRef="C_0001810182_20180101_20181231" decimals="2" unitRef="U_xbrlipure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000568" contextRef="C_0001810182_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.787</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000569" contextRef="C_0001810182_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum id="F_000570" contextRef="C_0001810182_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.665</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000571" contextRef="C_0001810182_20200101_20201231" decimals="3" unitRef="U_xbrlipure">0.890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000572" contextRef="C_0001810182_20190101_20191231" decimals="3" unitRef="U_xbrlipure">0.805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum id="F_000573" contextRef="C_0001810182_20180101_20181231" decimals="3" unitRef="U_xbrlipure">0.687</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign id="F_000574" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-9457000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign id="F_000575" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">813000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign id="F_000576" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">855000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic id="F_000577" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-36042000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic id="F_000578" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-20022000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic id="F_000579" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-14541000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_000580" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">239000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_000581" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">33000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentFederalTaxExpenseBenefit id="F_000582" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">44000</us-gaap:CurrentFederalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="F_000583" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="F_000584" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit id="F_000585" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="F_000586" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">241000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="F_000587" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">34000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:CurrentIncomeTaxExpenseBenefit id="F_000588" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">45000</us-gaap:CurrentIncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000589" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-9555000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000590" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-4034000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000591" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-2874000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes id="F_000592" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-3098000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes id="F_000593" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-1875000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes id="F_000594" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-332000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost id="F_000595" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-5000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost id="F_000596" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">60000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost id="F_000597" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">57000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch id="F_000598" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">512000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch id="F_000599" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">861000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch id="F_000600" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">499000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000601" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5710000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000602" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3733000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000603" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">732000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000604" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">321000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000605" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">75000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000606" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">100000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential id="F_000607" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">7380000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential id="F_000608" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">3886000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential id="F_000609" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">2899000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
  <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes id="F_000610" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">-950000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes id="F_000611" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">-38000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000612" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">7283000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000613" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">3259000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="F_000614" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">2861000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment id="F_000615" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">3260000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsOther id="F_000616" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">76000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="F_000617" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">69000</us-gaap:DeferredTaxAssetsOther>
  <alxo:DeferredTaxAssetsAccruedExpenses id="F_000618" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">383000</alxo:DeferredTaxAssetsAccruedExpenses>
  <alxo:DeferredTaxAssetsAccruedExpenses id="F_000619" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">261000</alxo:DeferredTaxAssetsAccruedExpenses>
  <alxo:DeferredTaxAssetsStockOptions id="F_000620" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">696000</alxo:DeferredTaxAssetsStockOptions>
  <alxo:DeferredTaxAssetsStockOptions id="F_000621" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">3000</alxo:DeferredTaxAssetsStockOptions>
  <us-gaap:DeferredTaxAssetsNet id="F_000622" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">11299000</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet id="F_000623" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">6852000</us-gaap:DeferredTaxAssetsNet>
  <alxo:DeferredTaxLiabilitiesPropertyPlantAndEquipment1 id="F_000624" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">11000</alxo:DeferredTaxLiabilitiesPropertyPlantAndEquipment1>
  <alxo:DeferredTaxLiabilitiesPropertyPlantAndEquipment1 id="F_000625" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">166000</alxo:DeferredTaxLiabilitiesPropertyPlantAndEquipment1>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_000626" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">11000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredIncomeTaxLiabilities id="F_000627" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">166000</us-gaap:DeferredIncomeTaxLiabilities>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000628" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">11288000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000629" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">6686000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="F_000630" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet id="F_000631" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000632" contextRef="C_0001810182_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">4600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000633" contextRef="C_0001810182_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">4500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:OperatingLossCarryforwards id="F_000634" contextRef="C_0001810182_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" unitRef="U_iso4217USD">7919000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards id="F_000635" contextRef="C_0001810182_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-3" unitRef="U_iso4217USD">71363000</us-gaap:OperatingLossCarryforwards>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000636" contextRef="C_0001810182_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20201231" decimals="-3" unitRef="U_iso4217USD">1327000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:TaxCreditCarryforwardAmount id="F_000637" contextRef="C_0001810182_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20201231" decimals="-3" unitRef="U_iso4217USD">2893000</us-gaap:TaxCreditCarryforwardAmount>
  <us-gaap:OperatingLossCarryforwards id="F_000638" contextRef="C_0001810182_us-gaapIncomeTaxAuthorityAxis_us-gaapForeignCountryMember_20201231" decimals="-3" unitRef="U_iso4217USD">5086000</us-gaap:OperatingLossCarryforwards>
  <alxo:OperatingLossCarryforwardsExpirationPeriod id="F_000639" contextRef="C_0001810182_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2038</alxo:OperatingLossCarryforwardsExpirationPeriod>
  <alxo:OperatingLossCarryforwardsExpirationPeriod id="F_000640" contextRef="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20200101_20201231">2040</alxo:OperatingLossCarryforwardsExpirationPeriod>
  <alxo:TaxCreditCarryforwardExpirationPeriod id="F_000641" contextRef="C_0001810182_srtRangeAxis_srtMinimumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2039</alxo:TaxCreditCarryforwardExpirationPeriod>
  <alxo:TaxCreditCarryforwardExpirationPeriod id="F_000642" contextRef="C_0001810182_srtRangeAxis_srtMaximumMember_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20200101_20201231">2040</alxo:TaxCreditCarryforwardExpirationPeriod>
  <us-gaap:UnrecognizedTaxBenefits id="F_000643" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">842000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="F_000644" contextRef="C_0001810182_20191231" decimals="-3" unitRef="U_iso4217USD">692000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="F_000645" contextRef="C_0001810182_20181231" decimals="-3" unitRef="U_iso4217USD">418000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="F_000646" contextRef="C_0001810182_20171231" decimals="-3" unitRef="U_iso4217USD">247000</us-gaap:UnrecognizedTaxBenefits>
  <alxo:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions id="F_000647" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">-64000</alxo:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
  <alxo:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions id="F_000648" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">2000</alxo:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
  <alxo:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions id="F_000649" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">11000</alxo:UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="F_000650" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">240000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="F_000651" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">272000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="F_000652" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">160000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations id="F_000653" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense id="F_000654" contextRef="C_0001810182_20200101_20201231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense id="F_000655" contextRef="C_0001810182_20190101_20191231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense id="F_000656" contextRef="C_0001810182_20180101_20181231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
  <alxo:NonrefundableLicenseRoyaltyAndPatentExpenses id="F_000657" contextRef="C_0001810182_deiLegalEntityAxis_alxoStanfordJuniorUniversityMember_us-gaapTypeOfArrangementAxis_alxoExclusiveEquityAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">100000</alxo:NonrefundableLicenseRoyaltyAndPatentExpenses>
  <alxo:ClinicalAndRegulatoryMilestonesPayments id="F_000658" contextRef="C_0001810182_deiLegalEntityAxis_alxoStanfordJuniorUniversityMember_us-gaapTypeOfArrangementAxis_alxoExclusiveEquityAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">5000000</alxo:ClinicalAndRegulatoryMilestonesPayments>
  <alxo:AgreementExpiryDescription id="F_000659" contextRef="C_0001810182_deiLegalEntityAxis_alxoStanfordJuniorUniversityMember_us-gaapTypeOfArrangementAxis_alxoExclusiveEquityAgreementMember_20200101_20201231">licensed patents expires and ten years after the first commercial sale of the licensed product in such country</alxo:AgreementExpiryDescription>
  <alxo:TerminationOfAgreementWrittenNoticePeriod id="F_000660" contextRef="C_0001810182_deiLegalEntityAxis_alxoStanfordJuniorUniversityMember_us-gaapTypeOfArrangementAxis_alxoExclusiveEquityAgreementMember_20200101_20201231">P60D</alxo:TerminationOfAgreementWrittenNoticePeriod>
  <alxo:NoticePeriodToRemedyBreachOfAgreement id="F_000661" contextRef="C_0001810182_deiLegalEntityAxis_alxoStanfordJuniorUniversityMember_us-gaapTypeOfArrangementAxis_alxoExclusiveEquityAgreementMember_20200101_20201231">P60D</alxo:NoticePeriodToRemedyBreachOfAgreement>
  <alxo:ClinicalAndRegulatoryMilestonesPayments id="F_000662" contextRef="C_0001810182_deiLegalEntityAxis_alxoSelexisSAMember_us-gaapTypeOfArrangementAxis_alxoCommercialLicenseAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">1200000</alxo:ClinicalAndRegulatoryMilestonesPayments>
  <alxo:AgreementExpiryDescription id="F_000663" contextRef="C_0001810182_deiLegalEntityAxis_alxoSelexisSAMember_us-gaapTypeOfArrangementAxis_alxoCommercialLicenseAgreementMember_20200101_20201231">shall terminate and become fully paid-up upon the passing of ten years after the first commercial sale of the product in such country, or the Company&#8217;s exercise of the royalty buyout option exercisable at any time prior to the first commercial sale of a licensed product</alxo:AgreementExpiryDescription>
  <alxo:TerminationOfAgreementWrittenNoticePeriod id="F_000664" contextRef="C_0001810182_deiLegalEntityAxis_alxoSelexisSAMember_us-gaapTypeOfArrangementAxis_alxoCommercialLicenseAgreementMember_20200101_20201231">P60D</alxo:TerminationOfAgreementWrittenNoticePeriod>
  <alxo:NoticePeriodToRemedyBreachOfAgreement id="F_000665" contextRef="C_0001810182_deiLegalEntityAxis_alxoSelexisSAMember_us-gaapTypeOfArrangementAxis_alxoCommercialLicenseAgreementMember_20200101_20201231">P60D</alxo:NoticePeriodToRemedyBreachOfAgreement>
  <alxo:ClinicalAndRegulatoryMilestonesPayments id="F_000666" contextRef="C_0001810182_deiLegalEntityAxis_alxoCrystalBioscienceIncMember_us-gaapTypeOfArrangementAxis_alxoCommercialAntibodyAgreementMember_20201231" decimals="-5" unitRef="U_iso4217USD">11100000</alxo:ClinicalAndRegulatoryMilestonesPayments>
  <alxo:AgreementExpiryDescription id="F_000667" contextRef="C_0001810182_deiLegalEntityAxis_alxoCrystalBioscienceIncMember_us-gaapTypeOfArrangementAxis_alxoCommercialAntibodyAgreementMember_20200101_20201231">licensed patents expires and ten years after the first commercial sale of the product in such country</alxo:AgreementExpiryDescription>
  <alxo:TerminationOfAgreementWrittenNoticePeriod id="F_000668" contextRef="C_0001810182_deiLegalEntityAxis_alxoCrystalBioscienceIncMember_us-gaapTypeOfArrangementAxis_alxoCommercialAntibodyAgreementMember_20200101_20201231">P60D</alxo:TerminationOfAgreementWrittenNoticePeriod>
  <alxo:NoticePeriodToRemedyBreachOfAgreement id="F_000669" contextRef="C_0001810182_deiLegalEntityAxis_alxoCrystalBioscienceIncMember_us-gaapTypeOfArrangementAxis_alxoCommercialAntibodyAgreementMember_20200101_20201231">P60D</alxo:NoticePeriodToRemedyBreachOfAgreement>
  <alxo:NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell id="F_000670" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20200101_20201231" decimals="INF" unitRef="U_alxoInvestor">2</alxo:NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000671" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">1200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000672" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">4800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax id="F_000673" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">2100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
  <alxo:InitialTermOfAgreementWithRelatedParty id="F_000674" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20180601_20180630">P3Y</alxo:InitialTermOfAgreementWithRelatedParty>
  <alxo:RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated id="F_000675" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20180601_20180630">P1Y</alxo:RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated>
  <alxo:RelatedPartyMarkupCostPercentage id="F_000676" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20180630" decimals="2" unitRef="U_xbrlipure">0.10</alxo:RelatedPartyMarkupCostPercentage>
  <us-gaap:DueFromRelatedParties id="F_000677" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_20201231" decimals="-6" unitRef="U_iso4217USD">0</us-gaap:DueFromRelatedParties>
  <us-gaap:DueFromRelatedParties id="F_000678" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTollnineMember_20191231" decimals="-5" unitRef="U_iso4217USD">500000</us-gaap:DueFromRelatedParties>
  <alxo:RelatedPartyMarkupCostPercentage id="F_000679" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTallacTherapeuticsMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20200701" decimals="3" unitRef="U_xbrlipure">0.100</alxo:RelatedPartyMarkupCostPercentage>
  <alxo:InitialTermOfAgreementWithRelatedParty id="F_000680" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTallacTherapeuticsMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20200701_20200701">P4Y</alxo:InitialTermOfAgreementWithRelatedParty>
  <alxo:RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated id="F_000681" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTallacTherapeuticsMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20200701_20200701">P1Y</alxo:RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000682" contextRef="C_0001810182_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_alxoTallacTherapeuticsMember_us-gaapTypeOfArrangementAxis_alxoResearchAndDevelopmentServicesAgreementMember_20200701_20200701" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:PreferredStockDividendsAndOtherAdjustments id="F_000683" contextRef="C_0001810182_20200101_20201231" decimals="-3" unitRef="U_iso4217USD">5202000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
  <us-gaap:PreferredStockDividendsAndOtherAdjustments id="F_000684" contextRef="C_0001810182_20190101_20191231" decimals="-3" unitRef="U_iso4217USD">4028000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
  <us-gaap:PreferredStockDividendsAndOtherAdjustments id="F_000685" contextRef="C_0001810182_20180101_20181231" decimals="-3" unitRef="U_iso4217USD">3671000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000686" contextRef="C_0001810182_20200101_20201231" decimals="0" unitRef="U_xbrlishares">18485343</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000687" contextRef="C_0001810182_20190101_20191231" decimals="0" unitRef="U_xbrlishares">3076461</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic id="F_000688" contextRef="C_0001810182_20180101_20181231" decimals="0" unitRef="U_xbrlishares">2750838</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000689" contextRef="C_0001810182_20200101_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.76</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000690" contextRef="C_0001810182_20190101_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-7.56</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000691" contextRef="C_0001810182_20180101_20181231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-6.33</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000692" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">10313808</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000693" contextRef="C_0001810182_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20180101_20181231" decimals="0" unitRef="U_xbrlishares">9297081</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000694" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoWarrantToPurchaseConvertiblePreferredStockMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">61292</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000695" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoCommonStockSubjectToRepurchaseMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">63</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000696" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoCommonStockSubjectToRepurchaseMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">34024</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000697" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoCommonStockSubjectToRepurchaseMember_20180101_20181231" decimals="0" unitRef="U_xbrlishares">229912</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000698" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoOptionsIssuedAndOutstandingMember_20200101_20201231" decimals="0" unitRef="U_xbrlishares">4857308</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000699" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoOptionsIssuedAndOutstandingMember_20190101_20191231" decimals="0" unitRef="U_xbrlishares">1183745</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000700" contextRef="C_0001810182_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_alxoOptionsIssuedAndOutstandingMember_20180101_20181231" decimals="0" unitRef="U_xbrlishares">864819</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000701" contextRef="C_0001810182_20200101_20201231" decimals="0" unitRef="U_xbrlishares">4857371</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000702" contextRef="C_0001810182_20190101_20191231" decimals="0" unitRef="U_xbrlishares">11592869</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="F_000703" contextRef="C_0001810182_20180101_20181231" decimals="0" unitRef="U_xbrlishares">10391812</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:PurchaseObligation id="F_000704" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">10320000</us-gaap:PurchaseObligation>
  <us-gaap:PurchaseObligationDueInNextTwelveMonths id="F_000705" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">6292000</us-gaap:PurchaseObligationDueInNextTwelveMonths>
  <us-gaap:PurchaseObligationDueInSecondAndThirdYear id="F_000706" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">4028000</us-gaap:PurchaseObligationDueInSecondAndThirdYear>
  <us-gaap:ContractualObligation id="F_000707" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">10666000</us-gaap:ContractualObligation>
  <us-gaap:ContractualObligationDueInNextTwelveMonths id="F_000708" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">6432000</us-gaap:ContractualObligationDueInNextTwelveMonths>
  <us-gaap:ContractualObligationDueInSecondAndThirdYear id="F_000709" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">4234000</us-gaap:ContractualObligationDueInSecondAndThirdYear>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue id="F_000710" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">346000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
  <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths id="F_000711" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">140000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
  <alxo:LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree id="F_000712" contextRef="C_0001810182_20201231" decimals="-3" unitRef="U_iso4217USD">206000</alxo:LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree>
  <alxo:OperatingSubLeaseExpirationYear id="F_000713" contextRef="C_0001810182_srtStatementGeographicalAxis_stprCA_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoOfficeAndLaboratorySpaceMember_20200101_20201231">2023</alxo:OperatingSubLeaseExpirationYear>
  <alxo:InitialTermOfAgreement id="F_000714" contextRef="C_0001810182_us-gaapTypeOfArrangementAxis_alxoMasterServiceAgreementMember_20151101_20151130">P3Y</alxo:InitialTermOfAgreement>
  <alxo:RenewalPeriodsOfAgreement id="F_000715" contextRef="C_0001810182_us-gaapTypeOfArrangementAxis_alxoMasterServiceAgreementMember_20151101_20151130">P1Y</alxo:RenewalPeriodsOfAgreement>
  <us-gaap:PurchaseObligation id="F_000716" contextRef="C_0001810182_us-gaapTypeOfArrangementAxis_alxoMasterServiceAgreementMember_20151130" decimals="-5" unitRef="U_iso4217USD">9900000</us-gaap:PurchaseObligation>
  <us-gaap:PurchaseObligation id="F_000717" contextRef="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoSecondDrugProductManufacturerMember_us-gaapTypeOfArrangementAxis_alxoMasterServiceAgreementMember_20151130" decimals="-5" unitRef="U_iso4217USD">400000</us-gaap:PurchaseObligation>
  <us-gaap:LesseeOperatingLeaseTermOfContract id="F_000718" contextRef="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoOfficeSpaceMember_20171231">P5Y4M</us-gaap:LesseeOperatingLeaseTermOfContract>
  <alxo:LesseeOperatingLeaseCommencingEndDate id="F_000719" contextRef="C_0001810182_us-gaapPropertyPlantAndEquipmentByTypeAxis_alxoOfficeSpaceMember_20170101_20171231">2023-05-31</alxo:LesseeOperatingLeaseCommencingEndDate>
  <us-gaap:OperatingLeaseExpense id="F_000720" contextRef="C_0001810182_20200101_20201231" decimals="-5" unitRef="U_iso4217USD">600000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense id="F_000721" contextRef="C_0001810182_20190101_20191231" decimals="-5" unitRef="U_iso4217USD">800000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingLeaseExpense id="F_000722" contextRef="C_0001810182_20180101_20181231" decimals="-5" unitRef="U_iso4217USD">1000000</us-gaap:OperatingLeaseExpense>
  <us-gaap:OperatingExpenses id="F_000723" contextRef="C_0001810182_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">5897000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000724" contextRef="C_0001810182_20200401_20200630" decimals="-3" unitRef="U_iso4217USD">11314000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000725" contextRef="C_0001810182_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">9809000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000726" contextRef="C_0001810182_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">17825000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000727" contextRef="C_0001810182_20200101_20200331" decimals="-3" unitRef="U_iso4217USD">-7437000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000728" contextRef="C_0001810182_20200401_20200630" decimals="-3" unitRef="U_iso4217USD">-13972000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000729" contextRef="C_0001810182_20200701_20200930" decimals="-3" unitRef="U_iso4217USD">-10759000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000730" contextRef="C_0001810182_20201001_20201231" decimals="-3" unitRef="U_iso4217USD">-18774000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000731" contextRef="C_0001810182_20200101_20200331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.37</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000732" contextRef="C_0001810182_20200401_20200630" decimals="2" unitRef="U_iso4217USD_xbrlishares">-4.41</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000733" contextRef="C_0001810182_20200701_20200930" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.36</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000734" contextRef="C_0001810182_20201001_20201231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-0.50</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:OperatingExpenses id="F_000735" contextRef="C_0001810182_20190101_20190331" decimals="-3" unitRef="U_iso4217USD">5259000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000736" contextRef="C_0001810182_20190401_20190630" decimals="-3" unitRef="U_iso4217USD">5484000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000737" contextRef="C_0001810182_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">4290000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000738" contextRef="C_0001810182_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">8946000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000739" contextRef="C_0001810182_20190101_20190331" decimals="-3" unitRef="U_iso4217USD">-5143000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000740" contextRef="C_0001810182_20190401_20190630" decimals="-3" unitRef="U_iso4217USD">-5178000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000741" contextRef="C_0001810182_20190701_20190930" decimals="-3" unitRef="U_iso4217USD">-4115000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic id="F_000742" contextRef="C_0001810182_20191001_20191231" decimals="-3" unitRef="U_iso4217USD">-8835000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000743" contextRef="C_0001810182_20190101_20190331" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.71</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000744" contextRef="C_0001810182_20190401_20190630" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.68</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000745" contextRef="C_0001810182_20190701_20190930" decimals="2" unitRef="U_iso4217USD_xbrlishares">-1.33</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
  <us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare id="F_000746" contextRef="C_0001810182_20191001_20191231" decimals="2" unitRef="U_iso4217USD_xbrlishares">-2.83</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>25
<FILENAME>alxo-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-18T17:24:36.2205867+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 11fbbc32b9104e6cbcd92c96d6313ce7 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:alxo="http://www.alxoncology.com/20201231" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.alxoncology.com/20201231" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2020-01-31" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/negated" />
  <xsd:import schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" namespace="http://www.xbrl.org/2009/role/net" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd" namespace="http://fasb.org/srt-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31" />
  <xsd:import schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2018-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd" namespace="http://fasb.org/us-roles/2020-01-31" />
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd" namespace="http://fasb.org/us-types/2020-01-31" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.alxoncology.com/20201231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alxo-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alxo-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alxo-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="alxo-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100040 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders&apos; Equity (Deficit)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100050 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureOrganization" id="Role_DisclosureOrganization">
        <link:definition>100060 - Disclosure - Organization</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies" id="Role_DisclosureSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments" id="Role_DisclosureFairValueOfFinancialInstruments">
        <link:definition>100080 - Disclosure - Fair Value of Financial Instruments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100090 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureTermLoan" id="Role_DisclosureTermLoan">
        <link:definition>100100 - Disclosure - Term Loan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100110 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100120 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100130 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureLicenseAgreement" id="Role_DisclosureLicenseAgreement">
        <link:definition>100140 - Disclosure - License Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100150 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>100160 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100170 - Disclosure -  Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100180 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnaudited" id="Role_DisclosureSelectedQuarterlyFinancialDataUnaudited">
        <link:definition>100190 - Disclosure - Selected Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" id="Role_DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>100200 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" id="Role_DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>100210 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100220 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100230 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100240 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100250 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>100260 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100270 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables" id="Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables">
        <link:definition>100280 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>100300 - Disclosure - Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsReconciliationOfFinancialLiabilitiesMeasuredAtFairValueUsingLevel3UnobservableInputsDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsReconciliationOfFinancialLiabilitiesMeasuredAtFairValueUsingLevel3UnobservableInputsDetails">
        <link:definition>100310 - Disclosure - Fair Value of Financial Instruments - Reconciliation of Financial Liabilities Measured at Fair Value Using Level 3 Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" id="Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfPropertyAndEquipmentDetails" id="Role_DisclosureBalanceSheetComponentsScheduleOfComponentsOfPropertyAndEquipmentDetails">
        <link:definition>100330 - Disclosure - Balance Sheet Components - Schedule of Components of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsComponentsOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureBalanceSheetComponentsComponentsOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
        <link:definition>100350 - Disclosure - Balance Sheet Components - Components of Accrued Expenses and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails" id="Role_DisclosureTermLoanAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Term Loan - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="Role_DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Stockholders&apos; Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceOnConvertedBasisDetails" id="Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceOnConvertedBasisDetails">
        <link:definition>100380 - Disclosure - Stockholders&apos; Equity - Common Stock Reserved for Future Issuance on Converted Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfConvertiblePreferredStockDetails" id="Role_DisclosureStockholdersEquitySummaryOfConvertiblePreferredStockDetails">
        <link:definition>100390 - Disclosure - Stockholders&apos; Equity - Summary of Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100410 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseIncludesShareOptionsGrantedToEmployeesAndNonemployeesDetails" id="Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseIncludesShareOptionsGrantedToEmployeesAndNonemployeesDetails">
        <link:definition>100420 - Disclosure - Stock-Based Compensation - Share-Based Compensation Expense Includes Share Options Granted to Employees and Nonemployees (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionGrantUsingBlackScholesOptionPricingModelDetails" id="Role_DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionGrantUsingBlackScholesOptionPricingModelDetails">
        <link:definition>100430 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Each Option Grant Using Black-Scholes Option-Pricing Model (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesDomesticAndInternationalComponentsOfPreTaxLossDetails" id="Role_DisclosureIncomeTaxesDomesticAndInternationalComponentsOfPreTaxLossDetails">
        <link:definition>100440 - Disclosure - Income Taxes - Domestic and International Components of Pre-Tax Loss (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" id="Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
        <link:definition>100450 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfStatutoryAndEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfStatutoryAndEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100460 - Disclosure - Income Taxes - Schedule of Statutory and Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" id="Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails">
        <link:definition>100470 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100480 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsDetails" id="Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsDetails">
        <link:definition>100490 - Disclosure - Income Taxes - Schedule of Net Operating Losses and Tax Credit Carryforwards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" id="Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails">
        <link:definition>100500 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - License Agreement - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Related-Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100530 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesWereExcludedFromComputationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesWereExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>100540 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Were Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsDetails">
        <link:definition>100550 - Disclosure - Commitments and Contingencies - Summary of Company&apos;s Commitments and Contractual Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsParentheticalDetails" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsParentheticalDetails">
        <link:definition>100560 - Disclosure - Commitments and Contingencies - Summary of Company&apos;s Commitments and Contractual Obligations (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSELECTEDQUARTERLYFINANCIALDATAUNAUDITEDAdditionalInformationDetails" id="Role_DisclosureSELECTEDQUARTERLYFINANCIALDATAUNAUDITEDAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Additional Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSELECTEDQUARTERLYFINANCIALDATAUNAUDITEDScheduleOfCertainUnauditedQuarterlyConsolidatedFinancialInformationDetails" id="Role_DisclosureSELECTEDQUARTERLYFINANCIALDATAUNAUDITEDScheduleOfCertainUnauditedQuarterlyConsolidatedFinancialInformationDetails">
        <link:definition>100590 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Schedule of Certain Unaudited Quarterly Consolidated Financial Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="alxo_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" name="StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" name="TemporaryEquityStockIssuedDuringPeriodShareNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_StockIssuedDuringPeriodSharesWarrantExercise" name="StockIssuedDuringPeriodSharesWarrantExercise" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants" name="ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alxo_GainOnAssignmentOfLease" name="GainOnAssignmentOfLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_IncreaseDecreaseInOtherAssets" name="IncreaseDecreaseInOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_VestingOfEarlyExercisedStockOptions" name="VestingOfEarlyExercisedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable" name="NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock" name="NonCashAccumulatedDividendOnConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alxo_ReverseStockSplitPolicyTextBlock" name="ReverseStockSplitPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock" name="ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" name="ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock" name="CostOfServicesForRelatedPartyRevenuePolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock" name="ClinicalAndManufacturingAccrualsPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" name="RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" name="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" name="ShareOptionsGrantedToEmployeesAndNonemployeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock" name="SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_WarrantLiabilityFairValueDisclosure" name="WarrantLiabilityFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_WarrantLiabilityMember" name="WarrantLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_CompoundDerivativeLiabilityMember" name="CompoundDerivativeLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_ComputerHardwareAndSoftwareMember" name="ComputerHardwareAndSoftwareMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_ScheduleOfBalanceSheetComponentsLineItems" name="ScheduleOfBalanceSheetComponentsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_ScheduleOfBalanceSheetComponentsTable" name="ScheduleOfBalanceSheetComponentsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_LabEquipmentAndOtherAssetsMember" name="LabEquipmentAndOtherAssetsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_AccruedClinicalAndNonClinicalCostsCurrent" name="AccruedClinicalAndNonClinicalCostsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_AccruedContractManufacturingCurrent" name="AccruedContractManufacturingCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_AccruedFederalIncomeTax" name="AccruedFederalIncomeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_ProceedsFromEquityFinancing" name="ProceedsFromEquityFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alxo_FirstTrancheMember" name="FirstTrancheMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_SecondTrancheMember" name="SecondTrancheMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_LoanAgreementMember" name="LoanAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount" name="FinalPaymentFeeAsPercentageOfFundedPrincipalAmount" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount" name="DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_DebtInstrumentInterestOnlyPaymentTerms" name="DebtInstrumentInterestOnlyPaymentTerms" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_EstimatedFairValueIssuanceOfWarrants" name="EstimatedFairValueIssuanceOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock" name="ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_NetProceedsFromFollowOnPublicOffering" name="NetProceedsFromFollowOnPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alxo_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_FollowOnPublicOfferingMember" name="FollowOnPublicOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_SeriesBAndCConvertiblePreferredStockMember" name="SeriesBAndCConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_PaymentForOfferingCost" name="PaymentForOfferingCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_ConvertiblePreferredStockIssuedAndOutstandingMember" name="ConvertiblePreferredStockIssuedAndOutstandingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_StockOptionsIssuedAndOutstandingMember" name="StockOptionsIssuedAndOutstandingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_StockOptionsAuthorizedForFutureIssuanceMember" name="StockOptionsAuthorizedForFutureIssuanceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_WarrantsIssuedAndOutstandingMember" name="WarrantsIssuedAndOutstandingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_WarrantsAuthorizedForFutureIssuanceMember" name="WarrantsAuthorizedForFutureIssuanceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_TemporaryEquitySharesIssuedAndOutstanding" name="TemporaryEquitySharesIssuedAndOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion" name="CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="alxo_TwoThousandAndFifteenShareAwardSchemeMember" name="TwoThousandAndFifteenShareAwardSchemeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_TwentyThousandAndTwentyEquityIncentivePlanMember" name="TwentyThousandAndTwentyEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" name="AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember" name="TwentyThousandAndTwentyEmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_DeferredTaxAssetsAccruedExpenses" name="DeferredTaxAssetsAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alxo_DeferredTaxAssetsStockOptions" name="DeferredTaxAssetsStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <xsd:element id="alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1" name="DeferredTaxLiabilitiesPropertyPlantAndEquipment1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" name="NetOperatingLossAndTaxCreditCarryforwardsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" name="NetOperatingLossAndTaxCreditCarryforwardsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_OperatingLossCarryforwardsExpirationPeriod" name="OperatingLossCarryforwardsExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_TaxCreditCarryforwardExpirationPeriod" name="TaxCreditCarryforwardExpirationPeriod" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_NonrefundableLicenseRoyaltyAndPatentExpenses" name="NonrefundableLicenseRoyaltyAndPatentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_ClinicalAndRegulatoryMilestonesPayments" name="ClinicalAndRegulatoryMilestonesPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_AgreementExpiryDescription" name="AgreementExpiryDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_ExclusiveEquityAgreementMember" name="ExclusiveEquityAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_StanfordJuniorUniversityMember" name="StanfordJuniorUniversityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_CommercialLicenseAgreementMember" name="CommercialLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_SelexisSAMember" name="SelexisSAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_CommercialAntibodyAgreementMember" name="CommercialAntibodyAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_CrystalBioscienceIncMember" name="CrystalBioscienceIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_TerminationOfAgreementWrittenNoticePeriod" name="TerminationOfAgreementWrittenNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_NoticePeriodToRemedyBreachOfAgreement" name="NoticePeriodToRemedyBreachOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell" name="NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_InitialTermOfAgreementWithRelatedParty" name="InitialTermOfAgreementWithRelatedParty" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated" name="RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_RelatedPartyMarkupCostPercentage" name="RelatedPartyMarkupCostPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <xsd:element id="alxo_ResearchAndDevelopmentServicesAgreementMember" name="ResearchAndDevelopmentServicesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_TollnineMember" name="TollnineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_TallacTherapeuticsMember" name="TallacTherapeuticsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_WarrantToPurchaseConvertiblePreferredStockMember" name="WarrantToPurchaseConvertiblePreferredStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_CommonStockSubjectToRepurchaseMember" name="CommonStockSubjectToRepurchaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_OptionsIssuedAndOutstandingMember" name="OptionsIssuedAndOutstandingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree" name="LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive" name="LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <xsd:element id="alxo_OperatingSubLeaseExpirationYear" name="OperatingSubLeaseExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_OfficeAndLaboratorySpaceMember" name="OfficeAndLaboratorySpaceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_MasterServiceAgreementMember" name="MasterServiceAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_SecondDrugProductManufacturerMember" name="SecondDrugProductManufacturerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <xsd:element id="alxo_InitialTermOfAgreement" name="InitialTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_RenewalPeriodsOfAgreement" name="RenewalPeriodsOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_LesseeOperatingLeaseCommencingEndDate" name="LesseeOperatingLeaseCommencingEndDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <xsd:element id="alxo_OfficeSpaceMember" name="OfficeSpaceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>26
<FILENAME>alxo-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-18T17:24:36.2205867+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 11fbbc32b9104e6cbcd92c96d6313ce7 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef xlink:type="simple" xlink:href="alxo-20201231.xsd#TemplateLink" roleURI="http://www.alxoncology.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="alxo-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10180.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10190.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="alxo-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingExpense" order="10070.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="10130.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="alxo-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_IncreaseDecreaseInOtherAssets" xlink:type="locator" xlink:label="alxo_IncreaseDecreaseInOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_GainOnAssignmentOfLease" xlink:type="locator" xlink:label="alxo_GainOnAssignmentOfLease" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants" xlink:type="locator" xlink:label="alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyHeldForSale" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyHeldForSale" order="10120.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="10130.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10140.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="10150.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="10160.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants" order="10170.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alxo_GainOnAssignmentOfLease" order="10180.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10190.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="10200.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="alxo_IncreaseDecreaseInOtherAssets" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="10230.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="10240.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="10250.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfPropertyAndEquipmentDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfComponentsOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsComponentsOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureBalanceSheetComponentsComponentsOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsComponentsOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AccruedFederalIncomeTax" xlink:type="locator" xlink:label="alxo_AccruedFederalIncomeTax" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AccruedContractManufacturingCurrent" xlink:type="locator" xlink:label="alxo_AccruedContractManufacturingCurrent" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AccruedClinicalAndNonClinicalCostsCurrent" xlink:type="locator" xlink:label="alxo_AccruedClinicalAndNonClinicalCostsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="alxo_AccruedClinicalAndNonClinicalCostsCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="alxo_AccruedContractManufacturingCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="alxo_AccruedFederalIncomeTax" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10060.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesDomesticAndInternationalComponentsOfPreTaxLossDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesDomesticAndInternationalComponentsOfPreTaxLossDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesDomesticAndInternationalComponentsOfPreTaxLossDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10020.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfStatutoryAndEffectiveIncomeTaxRateReconciliationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfStatutoryAndEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfStatutoryAndEffectiveIncomeTaxRateReconciliationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="10080.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails">
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DeferredTaxAssetsStockOptions" xlink:type="locator" xlink:label="alxo_DeferredTaxAssetsStockOptions" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DeferredTaxAssetsAccruedExpenses" xlink:type="locator" xlink:label="alxo_DeferredTaxAssetsAccruedExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1" xlink:type="locator" xlink:label="alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="alxo_DeferredTaxAssetsAccruedExpenses" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="alxo_DeferredTaxAssetsStockOptions" order="10090.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="10020.00" priority="2" use="optional" weight="-1.00" />
  </link:calculationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsDetails" xlink:type="simple" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueAfterFifthYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInFourthAndFifthYear" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInFourthAndFifthYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondAndThirdYear" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInSecondAndThirdYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive" xlink:type="locator" xlink:label="alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree" xlink:type="locator" xlink:label="alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="10010.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree" order="10020.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive" order="10030.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="10040.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="10050.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInSecondAndThirdYear" order="10060.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueInFourthAndFifthYear" order="10070.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear" order="10080.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" order="10090.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInSecondAndThirdYear" order="10100.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueInFourthAndFifthYear" order="10110.00" priority="2" use="optional" weight="1.00" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligationDueAfterFifthYear" order="10120.00" priority="2" use="optional" weight="1.00" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>27
<FILENAME>alxo-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-18T17:24:36.2205867+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 11fbbc32b9104e6cbcd92c96d6313ce7 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <link:roleRef xlink:type="simple" xlink:href="alxo-20201231.xsd#TemplateLink" roleURI="http://www.alxoncology.com/20201231/role/TemplateLink" />
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="alxo-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10210.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10240.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_2" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesAConvertiblePreferredStockMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesBConvertiblePreferredStockMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10980.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11580.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="alxo-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesAConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesBConvertiblePreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10940.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10980.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="alxo-20201231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:type="locator" xlink:label="alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StockIssuedDuringPeriodSharesWarrantExercise" xlink:type="locator" xlink:label="alxo_StockIssuedDuringPeriodSharesWarrantExercise" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsShares" xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends" xlink:type="locator" xlink:label="us-gaap_Dividends" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:type="locator" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:type="locator" xlink:label="alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10280.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" order="10580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10760.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends" order="10900.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="10960.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_StockIssuedDuringPeriodSharesWarrantExercise" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" order="11700.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12180.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:href="alxo-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock" xlink:type="locator" xlink:label="alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:type="locator" xlink:label="alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DeferredOfferingCostsPolicyTextBlock" xlink:type="locator" xlink:label="alxo_DeferredOfferingCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ReverseStockSplitPolicyTextBlock" xlink:type="locator" xlink:label="alxo_ReverseStockSplitPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_ReverseStockSplitPolicyTextBlock" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_DeferredOfferingCostsPolicyTextBlock" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtPolicyTextBlock" order="10620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock" order="10820.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock" order="10920.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10970.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="11070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="11120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="11170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="11320.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="alxo-20201231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" xlink:type="locator" xlink:label="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="alxo_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="alxo_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="alxo_SignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alxo_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alxo_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alxo_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10680.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantLiabilityFairValueDisclosure" xlink:type="locator" xlink:label="alxo_WarrantLiabilityFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_2" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="10710.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="alxo_WarrantLiabilityFairValueDisclosure" order="10950.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsReconciliationOfFinancialLiabilitiesMeasuredAtFairValueUsingLevel3UnobservableInputsDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsReconciliationOfFinancialLiabilitiesMeasuredAtFairValueUsingLevel3UnobservableInputsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsReconciliationOfFinancialLiabilitiesMeasuredAtFairValueUsingLevel3UnobservableInputsDetails">
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment" xlink:type="locator" xlink:label="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" xlink:type="locator" xlink:label="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CompoundDerivativeLiabilityMember" xlink:type="locator" xlink:label="alxo_CompoundDerivativeLiabilityMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantLiabilityMember" xlink:type="locator" xlink:label="alxo_WarrantLiabilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="alxo_WarrantLiabilityMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="alxo_CompoundDerivativeLiabilityMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" order="10340.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment" order="10380.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfPropertyAndEquipmentDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfComponentsOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ComputerHardwareAndSoftwareMember" xlink:type="locator" xlink:label="alxo_ComputerHardwareAndSoftwareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alxo_ComputerHardwareAndSoftwareMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10400.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10440.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LabEquipmentAndOtherAssetsMember" xlink:type="locator" xlink:label="alxo_LabEquipmentAndOtherAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ScheduleOfBalanceSheetComponentsTable" xlink:type="locator" xlink:label="alxo_ScheduleOfBalanceSheetComponentsTable" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ScheduleOfBalanceSheetComponentsLineItems" xlink:type="locator" xlink:label="alxo_ScheduleOfBalanceSheetComponentsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alxo_ScheduleOfBalanceSheetComponentsLineItems" xlink:to="alxo_ScheduleOfBalanceSheetComponentsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alxo_ScheduleOfBalanceSheetComponentsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alxo_LabEquipmentAndOtherAssetsMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_ScheduleOfBalanceSheetComponentsLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_ScheduleOfBalanceSheetComponentsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_ScheduleOfBalanceSheetComponentsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10250.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureTermLoanAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NetProceedsFromFollowOnPublicOffering" xlink:type="locator" xlink:label="alxo_NetProceedsFromFollowOnPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock" xlink:type="locator" xlink:label="alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_EstimatedFairValueIssuanceOfWarrants" xlink:type="locator" xlink:label="alxo_EstimatedFairValueIssuanceOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount" xlink:type="locator" xlink:label="alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount" xlink:type="locator" xlink:label="alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DebtInstrumentInterestOnlyPaymentTerms" xlink:type="locator" xlink:label="alxo_DebtInstrumentInterestOnlyPaymentTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ProceedsFromEquityFinancing" xlink:type="locator" xlink:label="alxo_ProceedsFromEquityFinancing" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CompoundDerivativeLiabilityMember" xlink:type="locator" xlink:label="alxo_CompoundDerivativeLiabilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LoanAgreementMember" xlink:type="locator" xlink:label="alxo_LoanAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SecondTrancheMember" xlink:type="locator" xlink:label="alxo_SecondTrancheMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FirstTrancheMember" xlink:type="locator" xlink:label="alxo_FirstTrancheMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="alxo_FirstTrancheMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="alxo_SecondTrancheMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_2" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="alxo_LoanAgreementMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_2" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_2" order="10270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10520.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_2" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="10630.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="10650.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10840.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesBConvertiblePreferredStockMember" order="10890.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="11130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="alxo_CompoundDerivativeLiabilityMember" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_ProceedsFromEquityFinancing" order="11440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" order="11510.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_DebtInstrumentInterestOnlyPaymentTerms" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" order="11620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11640.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount" order="11660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount" order="11680.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11810.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="11870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" order="11930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_EstimatedFairValueIssuanceOfWarrants" order="11990.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="12050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="12170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock" order="12470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="12620.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_NetProceedsFromFollowOnPublicOffering" order="12670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="12690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="12710.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion" xlink:type="locator" xlink:label="alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:type="locator" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_PaymentForOfferingCost" xlink:type="locator" xlink:label="alxo_PaymentForOfferingCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBAndCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBAndCConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="alxo_FollowOnPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_UndesignatedPreferredStockMember" xlink:type="locator" xlink:label="alxo_UndesignatedPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_UndesignatedPreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10120.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10310.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alxo_FollowOnPublicOfferingMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesCConvertiblePreferredStockMember" order="10690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesBConvertiblePreferredStockMember" order="10750.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10910.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesAConvertiblePreferredStockMember" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesBAndCConvertiblePreferredStockMember" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11020.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11250.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="alxo_PaymentForOfferingCost" order="11270.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="11580.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="11600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11690.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="11740.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" order="11860.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion" order="11900.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceOnConvertedBasisDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceOnConvertedBasisDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceOnConvertedBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantsAuthorizedForFutureIssuanceMember" xlink:type="locator" xlink:label="alxo_WarrantsAuthorizedForFutureIssuanceMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="alxo_WarrantsIssuedAndOutstandingMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StockOptionsAuthorizedForFutureIssuanceMember" xlink:type="locator" xlink:label="alxo_StockOptionsAuthorizedForFutureIssuanceMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StockOptionsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="alxo_StockOptionsIssuedAndOutstandingMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ConvertiblePreferredStockIssuedAndOutstandingMember" xlink:type="locator" xlink:label="alxo_ConvertiblePreferredStockIssuedAndOutstandingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_ConvertiblePreferredStockIssuedAndOutstandingMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_StockOptionsIssuedAndOutstandingMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_StockOptionsAuthorizedForFutureIssuanceMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_WarrantsIssuedAndOutstandingMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_WarrantsAuthorizedForFutureIssuanceMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10200.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfConvertiblePreferredStockDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockholdersEquitySummaryOfConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfConvertiblePreferredStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TemporaryEquitySharesIssuedAndOutstanding" xlink:type="locator" xlink:label="alxo_TemporaryEquitySharesIssuedAndOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesAConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesBConvertiblePreferredStockMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="alxo_TemporaryEquitySharesIssuedAndOutstanding" order="10300.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10620.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201709Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201709Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TwentyThousandAndTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="alxo_TwentyThousandAndTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TwoThousandAndFifteenShareAwardSchemeMember" xlink:type="locator" xlink:label="alxo_TwoThousandAndFifteenShareAwardSchemeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alxo_TwoThousandAndFifteenShareAwardSchemeMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alxo_TwentyThousandAndTwentyEquityIncentivePlanMember" order="10230.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" order="10290.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201709Member" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10470.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember" order="10490.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10560.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10570.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10590.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10610.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10830.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10880.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10930.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="10950.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised" order="11000.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount" order="11180.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11200.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage" order="11220.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11500.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11550.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseIncludesShareOptionsGrantedToEmployeesAndNonemployeesDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseIncludesShareOptionsGrantedToEmployeesAndNonemployeesDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseIncludesShareOptionsGrantedToEmployeesAndNonemployeesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" xlink:type="locator" xlink:label="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionGrantUsingBlackScholesOptionPricingModelDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionGrantUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionGrantUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10260.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10380.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10440.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10500.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TaxCreditCarryforwardExpirationPeriod" xlink:type="locator" xlink:label="alxo_TaxCreditCarryforwardExpirationPeriod" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OperatingLossCarryforwardsExpirationPeriod" xlink:type="locator" xlink:label="alxo_OperatingLossCarryforwardsExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" xlink:type="locator" xlink:label="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:type="locator" xlink:label="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" xlink:to="srt_RangeAxis" order="10320.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10350.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10370.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10390.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10420.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10460.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="alxo_OperatingLossCarryforwardsExpirationPeriod" order="10550.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="alxo_TaxCreditCarryforwardExpirationPeriod" order="10670.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" order="10790.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureLicenseAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails">
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NoticePeriodToRemedyBreachOfAgreement" xlink:type="locator" xlink:label="alxo_NoticePeriodToRemedyBreachOfAgreement" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TerminationOfAgreementWrittenNoticePeriod" xlink:type="locator" xlink:label="alxo_TerminationOfAgreementWrittenNoticePeriod" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AgreementExpiryDescription" xlink:type="locator" xlink:label="alxo_AgreementExpiryDescription" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ClinicalAndRegulatoryMilestonesPayments" xlink:type="locator" xlink:label="alxo_ClinicalAndRegulatoryMilestonesPayments" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NonrefundableLicenseRoyaltyAndPatentExpenses" xlink:type="locator" xlink:label="alxo_NonrefundableLicenseRoyaltyAndPatentExpenses" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CrystalBioscienceIncMember" xlink:type="locator" xlink:label="alxo_CrystalBioscienceIncMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommercialAntibodyAgreementMember" xlink:type="locator" xlink:label="alxo_CommercialAntibodyAgreementMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SelexisSAMember" xlink:type="locator" xlink:label="alxo_SelexisSAMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommercialLicenseAgreementMember" xlink:type="locator" xlink:label="alxo_CommercialLicenseAgreementMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StanfordJuniorUniversityMember" xlink:type="locator" xlink:label="alxo_StanfordJuniorUniversityMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain_2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ExclusiveEquityAgreementMember" xlink:type="locator" xlink:label="alxo_ExclusiveEquityAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_2" order="10050.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alxo_ExclusiveEquityAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="alxo_StanfordJuniorUniversityMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alxo_CommercialLicenseAgreementMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="alxo_SelexisSAMember" order="10530.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alxo_CommercialAntibodyAgreementMember" order="10770.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="alxo_CrystalBioscienceIncMember" order="10850.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alxo_NonrefundableLicenseRoyaltyAndPatentExpenses" order="11060.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alxo_ClinicalAndRegulatoryMilestonesPayments" order="11080.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alxo_AgreementExpiryDescription" order="11100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alxo_TerminationOfAgreementWrittenNoticePeriod" order="11150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alxo_NoticePeriodToRemedyBreachOfAgreement" order="11170.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_RelatedPartyMarkupCostPercentage" xlink:type="locator" xlink:label="alxo_RelatedPartyMarkupCostPercentage" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated" xlink:type="locator" xlink:label="alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_InitialTermOfAgreementWithRelatedParty" xlink:type="locator" xlink:label="alxo_InitialTermOfAgreementWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell" xlink:type="locator" xlink:label="alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TallacTherapeuticsMember" xlink:type="locator" xlink:label="alxo_TallacTherapeuticsMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TollnineMember" xlink:type="locator" xlink:label="alxo_TollnineMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ResearchAndDevelopmentServicesAgreementMember" xlink:type="locator" xlink:label="alxo_ResearchAndDevelopmentServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alxo_ResearchAndDevelopmentServicesAgreementMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_2" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alxo_TollnineMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alxo_TallacTherapeuticsMember" order="10450.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell" order="10540.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10600.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alxo_InitialTermOfAgreementWithRelatedParty" order="10660.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated" order="10720.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alxo_RelatedPartyMarkupCostPercentage" order="10780.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="10870.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="11000.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesWereExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesWereExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesWereExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OptionsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="alxo_OptionsIssuedAndOutstandingMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommonStockSubjectToRepurchaseMember" xlink:type="locator" xlink:label="alxo_CommonStockSubjectToRepurchaseMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantToPurchaseConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_WarrantToPurchaseConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_WarrantToPurchaseConvertiblePreferredStockMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_CommonStockSubjectToRepurchaseMember" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_OptionsIssuedAndOutstandingMember" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10170.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10220.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsParentheticalDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsParentheticalDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsParentheticalDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_RenewalPeriodsOfAgreement" xlink:type="locator" xlink:label="alxo_RenewalPeriodsOfAgreement" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_InitialTermOfAgreement" xlink:type="locator" xlink:label="alxo_InitialTermOfAgreement" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OperatingSubLeaseExpirationYear" xlink:type="locator" xlink:label="alxo_OperatingSubLeaseExpirationYear" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SecondDrugProductManufacturerMember" xlink:type="locator" xlink:label="alxo_SecondDrugProductManufacturerMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_MasterServiceAgreementMember" xlink:type="locator" xlink:label="alxo_MasterServiceAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain_2" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OfficeAndLaboratorySpaceMember" xlink:type="locator" xlink:label="alxo_OfficeAndLaboratorySpaceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="alxo_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="alxo_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="alxo_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alxo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alxo_OfficeAndLaboratorySpaceMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alxo_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10100.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_2" order="10110.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10130.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10150.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alxo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10190.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alxo_MasterServiceAgreementMember" order="10210.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alxo_SecondDrugProductManufacturerMember" order="10330.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="alxo_OperatingSubLeaseExpirationYear" order="10360.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="alxo_InitialTermOfAgreement" order="10410.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="alxo_RenewalPeriodsOfAgreement" order="10430.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PurchaseObligation" order="10450.00" priority="2" use="optional" />
  </link:definitionLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LesseeOperatingLeaseCommencingEndDate" xlink:type="locator" xlink:label="alxo_LesseeOperatingLeaseCommencingEndDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OfficeSpaceMember" xlink:type="locator" xlink:label="alxo_OfficeSpaceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="alxo_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="alxo_CommitmentsAndContingenciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="alxo_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="alxo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alxo_OfficeSpaceMember" order="10090.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10140.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="alxo_LesseeOperatingLeaseCommencingEndDate" order="10160.00" priority="2" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10210.00" priority="2" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>28
<FILENAME>alxo-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-18T17:24:36.2215862+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 11fbbc32b9104e6cbcd92c96d6313ce7 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd#axisDefault" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line2</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntitySmallBusiness_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Icfr Auditor Attestation Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityShellCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentAnnualReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentTransitionReport_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Class Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Domain]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesAConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_SeriesAConvertiblePreferredStockMember" xlink:to="alxo_SeriesAConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_SeriesBConvertiblePreferredStockMember" xlink:to="alxo_SeriesBConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables due from related-party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan - non-current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 12)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Carrying Amount Attributable To Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.001 par value; 100,000,000 shares authorized, no shares issued or outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 1,000,000,000 and 1,519,618,271 shares authorized as of December 31, 2020 and 2019, respectively; 39,844,522 and 3,166,946 shares issued and outstanding as of December 31, 2020 and 2019, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock, liquidation preference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related-party revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Revenue [Extensible List]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRevenueExtensibleList" xlink:to="us-gaap_TypeOfRevenueExtensibleList_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfRevenueExtensibleList_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Revenue Extensible List</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of services for related-party revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Costs And Expenses Related Party</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Income Expense Nonoperating Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss on early debt extinguishment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gains Losses On Extinguishment Of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss and comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cumulative dividends allocated to preferred stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividends Income Statement Impact</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss Available To Common Stockholders Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Per Basic And Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares of common stock used to compute net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:type="locator" xlink:label="alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value vesting of early exercised stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:to="alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:type="locator" xlink:label="alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" />
    <link:label xml:lang="en-US" xlink:label="alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, stock issued during period, share, new issues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:to="alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StockIssuedDuringPeriodSharesWarrantExercise" xlink:type="locator" xlink:label="alxo_StockIssuedDuringPeriodSharesWarrantExercise" />
    <link:label xml:lang="en-US" xlink:label="alxo_StockIssuedDuringPeriodSharesWarrantExercise_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares warrant exercise.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_StockIssuedDuringPeriodSharesWarrantExercise" xlink:to="alxo_StockIssuedDuringPeriodSharesWarrantExercise_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Temporary equity, balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of convertible preferred stock, net of issuance costs, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Issued During Period Share New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:type="locator" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reclassification of warrants from liability to equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Down Round Feature Increase Decrease In Equity Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock in to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends" xlink:type="locator" xlink:label="us-gaap_Dividends" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Dividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cumulative dividends</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_Dividends_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsShares" xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cumulative dividends, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsShares" xlink:to="us-gaap_CommonStockDividendsShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockDividendsShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Dividends Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with equity offerings, net of underwriter discounts and issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with equity offerings, net of underwriter discounts and issuance costs, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_StockIssuedDuringPeriodSharesWarrantExercise_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon net exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_StockIssuedDuringPeriodSharesWarrantExercise_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Warrant Exercise</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under equity incentive plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under equity incentive plans, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of common stock, shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased During Period Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of early exercised stock options</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Vesting Of Early Exercised Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of unvested early exercised stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchased And Retired During Period Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, shares</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Temporary equity, balance</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants" xlink:type="locator" xlink:label="alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants" />
    <link:label xml:lang="en-US" xlink:label="alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in fair value of compound derivative liability and warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants" xlink:to="alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_GainOnAssignmentOfLease" xlink:type="locator" xlink:label="alxo_GainOnAssignmentOfLease" />
    <link:label xml:lang="en-US" xlink:label="alxo_GainOnAssignmentOfLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain on assignment of lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_GainOnAssignmentOfLease" xlink:to="alxo_GainOnAssignmentOfLease_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_IncreaseDecreaseInOtherAssets" xlink:type="locator" xlink:label="alxo_IncreaseDecreaseInOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="alxo_IncreaseDecreaseInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (Decrease) In Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_IncreaseDecreaseInOtherAssets" xlink:to="alxo_IncreaseDecreaseInOtherAssets_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_VestingOfEarlyExercisedStockOptions" xlink:type="locator" xlink:label="alxo_VestingOfEarlyExercisedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="alxo_VestingOfEarlyExercisedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of early exercised stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_VestingOfEarlyExercisedStockOptions" xlink:to="alxo_VestingOfEarlyExercisedStockOptions_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable" xlink:type="locator" xlink:label="alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash or Part Noncash Debt Issuance Costs in Accounts Payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable" xlink:to="alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock" xlink:type="locator" xlink:label="alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash accumulated dividend on convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock" xlink:to="alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProfitLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of term loan discount and issuance costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Financing Costs And Discounts</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value of compound derivative liability and warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Changes In Fair Value Of Compound Derivative Liability And Warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_GainOnAssignmentOfLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gain on assignment of lease</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_GainOnAssignmentOfLease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain On Assignment Of Lease</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on early debt extinguishment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Receivables due from related-party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Due From Related Parties Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_IncreaseDecreaseInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_IncreaseDecreaseInOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyHeldForSale" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyHeldForSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from assets held for sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:to="us-gaap_ProceedsFromSaleOfPropertyHeldForSale_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyHeldForSale_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Held For Sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from common stock offerings, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of common stock under equity incentive plans</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of convertible preferred stock, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for repurchase of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Repurchase Of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of term loan, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for early debt extinguishment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Debt Extinguishment Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_InterestPaidNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Paid Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of non-cash investing and financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_VestingOfEarlyExercisedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of early exercised stock options</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_VestingOfEarlyExercisedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Early Exercised Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of property and equipment in accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Acquisition Fixed Assets Acquired1</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs in accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Or Part Noncash Debt Issuance Costs In Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock into common stock upon closing of initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Stock Amount Converted1</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated dividend on convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Accumulated Dividend On Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ORGANIZATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">FAIR VALUE OF FINANCIAL INSTRUMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">BALANCE SHEET COMPONENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TERM LOAN</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCK-BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LICENSE AGREEMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RELATED-PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selected Quarterly Financial Data (Unaudited)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation Policy [Text Block]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ReverseStockSplitPolicyTextBlock" xlink:type="locator" xlink:label="alxo_ReverseStockSplitPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="alxo_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ReverseStockSplitPolicyTextBlock" xlink:to="alxo_ReverseStockSplitPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ReverseStockSplitPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reverse Stock Split Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of credit risk, credit losses and other risks and uncertainties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Of Credit Risk, Credit Losses And Other Risks And Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Of Credit Risk Credit Losses And Other Risks And Uncertainties Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DeferredOfferingCostsPolicyTextBlock" xlink:type="locator" xlink:label="alxo_DeferredOfferingCostsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="alxo_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_DeferredOfferingCostsPolicyTextBlock" xlink:to="alxo_DeferredOfferingCostsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Or Disposal Of Long Lived Assets Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Financial Instruments Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Redeemable Preferred Stock Issue Policy</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:type="locator" xlink:label="alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock warrant liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:to="alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrant Liability Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Policy [Text Block]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock" xlink:type="locator" xlink:label="alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cost of services for related party revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock" xlink:to="alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Services for Related-Party Revenue</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Services For Related Party Revenue Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and manufacturing accruals.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock" xlink:to="alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and Manufacturing Accruals</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Manufacturing Accruals Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Reporting</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Recently issued accounting pronouncements policy.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Recently Issued Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Accounting Pronouncements Recently Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated By Reference [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Financial Liabilities Measured at Fair Value Using Level 3 Unobservable Inputs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued expenses and other current liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:to="alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Accrued Expenses and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Expenses And Other Current Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator" xlink:label="alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of common stock reserved for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Reserved for Future Issuance on Converted Basis</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Common Stock Reserved For Future Issuance Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Convertible Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityTableTextBlock" xlink:to="us-gaap_TemporaryEquityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" xlink:type="locator" xlink:label="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share options granted to employees and nonemployees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" xlink:to="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Options Granted To Employees And Nonemployees</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Options Granted To Employees And Nonemployees [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation Expense Includes Share Options Granted to Employees and Nonemployees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Each Option Grant Using Black-Scholes Option-Pricing Model</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Components of Loss Before Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Income Tax Provision (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Statutory and Effective Income Tax Rate Reconciliation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock" xlink:type="locator" xlink:label="alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock" />
    <link:label xml:lang="en-US" xlink:label="alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of net operating loss and tax credit carryforwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock" xlink:to="alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Net Operating Loss and Tax Credit Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Net Operating Loss And Tax Credit Carryforwards [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computation of Basic and Diluted Net Loss per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Outstanding Potentially Dilutive Securities Were Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegistrationPaymentArrangementTextBlock" xlink:type="locator" xlink:label="us-gaap_RegistrationPaymentArrangementTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RegistrationPaymentArrangementTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Company&apos;s Commitments and Contractual Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RegistrationPaymentArrangementTextBlock" xlink:to="us-gaap_RegistrationPaymentArrangementTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RegistrationPaymentArrangementTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Registration Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Certain Unaudited Quarterly Consolidated Financial Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Quarterly Financial Information Table [Text Block]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="alxo_SignificantAccountingPoliciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="alxo_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="alxo_SignificantAccountingPoliciesLineItems_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="alxo_SignificantAccountingPoliciesTable" />
    <link:label xml:lang="en-US" xlink:label="alxo_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant accounting policies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_SignificantAccountingPoliciesTable" xlink:to="alxo_SignificantAccountingPoliciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_SignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IPOMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">I P O [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2016-13</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201613Member" xlink:to="us-gaap_AccountingStandardsUpdate201613Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201613Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201613 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU 2018-13</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201813Member" xlink:to="us-gaap_AccountingStandardsUpdate201813Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201813Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201813 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_SignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Reverse Stock Split</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split, conversion ratio</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible shares converted in to common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Shares Issued Upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adopted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Adoption Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Principle Accounting Standards Update Immaterial Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value on Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantLiabilityFairValueDisclosure" xlink:type="locator" xlink:label="alxo_WarrantLiabilityFairValueDisclosure" />
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantLiabilityFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant liability fair value disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_WarrantLiabilityFairValueDisclosure" xlink:to="alxo_WarrantLiabilityFairValueDisclosure_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compound derivative liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantLiabilityFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantLiabilityFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability Fair Value Disclosure</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" xlink:type="locator" xlink:label="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" />
    <link:label xml:lang="en-US" xlink:label="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, reclassification to equity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" xlink:to="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment" xlink:type="locator" xlink:label="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment" />
    <link:label xml:lang="en-US" xlink:label="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, loss on extinguishment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment" xlink:to="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Liability Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantLiabilityMember" xlink:type="locator" xlink:label="alxo_WarrantLiabilityMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrant Liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_WarrantLiabilityMember" xlink:to="alxo_WarrantLiabilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant Liability [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CompoundDerivativeLiabilityMember" xlink:type="locator" xlink:label="alxo_CompoundDerivativeLiabilityMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_CompoundDerivativeLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Compound derivative liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_CompoundDerivativeLiabilityMember" xlink:to="alxo_CompoundDerivativeLiabilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_CompoundDerivativeLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Compound Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_CompoundDerivativeLiabilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compound Derivative Liability [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Fair value at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification to equity</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification To Equity</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Extinguishment of compound derivative liability upon extinguishment of host instrument</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Loss On Extinguishment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Fair value at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets transferred from level 1 to level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets transferred from level 2 to level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities transferred from level 1 to level 2</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level1 To Level2 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities transferred from level 2 to level 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Level2 To Level1 Transfers Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets transferred into level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value assets transferred out of level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities transferred into level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value liabilities transferred out of level 3</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ComputerHardwareAndSoftwareMember" xlink:type="locator" xlink:label="alxo_ComputerHardwareAndSoftwareMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_ComputerHardwareAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer hardware and software.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ComputerHardwareAndSoftwareMember" xlink:to="alxo_ComputerHardwareAndSoftwareMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ComputerHardwareAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Hardware And Software</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ComputerHardwareAndSoftwareMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Computer Hardware And Software [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Machinery and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Machinery And Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ScheduleOfBalanceSheetComponentsLineItems" xlink:type="locator" xlink:label="alxo_ScheduleOfBalanceSheetComponentsLineItems" />
    <link:label xml:lang="en-US" xlink:label="alxo_ScheduleOfBalanceSheetComponentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of balance sheet components.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ScheduleOfBalanceSheetComponentsLineItems" xlink:to="alxo_ScheduleOfBalanceSheetComponentsLineItems_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ScheduleOfBalanceSheetComponentsTable" xlink:type="locator" xlink:label="alxo_ScheduleOfBalanceSheetComponentsTable" />
    <link:label xml:lang="en-US" xlink:label="alxo_ScheduleOfBalanceSheetComponentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of balance sheet components.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ScheduleOfBalanceSheetComponentsTable" xlink:to="alxo_ScheduleOfBalanceSheetComponentsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ScheduleOfBalanceSheetComponentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Balance Sheet Components [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ScheduleOfBalanceSheetComponentsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Balance Sheet Components [Table]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LabEquipmentAndOtherAssetsMember" xlink:type="locator" xlink:label="alxo_LabEquipmentAndOtherAssetsMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_LabEquipmentAndOtherAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lab equipment and other assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_LabEquipmentAndOtherAssetsMember" xlink:to="alxo_LabEquipmentAndOtherAssetsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_LabEquipmentAndOtherAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab Equipment and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_LabEquipmentAndOtherAssetsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lab Equipment And Other Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ScheduleOfBalanceSheetComponentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Balance Sheet Components [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ScheduleOfBalanceSheetComponentsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Balance Sheet Components [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Property and equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from transfer of assets for cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Plant And Equipment</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AccruedClinicalAndNonClinicalCostsCurrent" xlink:type="locator" xlink:label="alxo_AccruedClinicalAndNonClinicalCostsCurrent" />
    <link:label xml:lang="en-US" xlink:label="alxo_AccruedClinicalAndNonClinicalCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued clinical costs and non clinical costs current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_AccruedClinicalAndNonClinicalCostsCurrent" xlink:to="alxo_AccruedClinicalAndNonClinicalCostsCurrent_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AccruedContractManufacturingCurrent" xlink:type="locator" xlink:label="alxo_AccruedContractManufacturingCurrent" />
    <link:label xml:lang="en-US" xlink:label="alxo_AccruedContractManufacturingCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued contract manufacturing current.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_AccruedContractManufacturingCurrent" xlink:to="alxo_AccruedContractManufacturingCurrent_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AccruedFederalIncomeTax" xlink:type="locator" xlink:label="alxo_AccruedFederalIncomeTax" />
    <link:label xml:lang="en-US" xlink:label="alxo_AccruedFederalIncomeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued federal income tax.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_AccruedFederalIncomeTax" xlink:to="alxo_AccruedFederalIncomeTax_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Related Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_AccruedClinicalAndNonClinicalCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued clinical and nonclinical study costs</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_AccruedClinicalAndNonClinicalCostsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Clinical And Non Clinical Costs Current</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_AccruedContractManufacturingCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued contract manufacturing</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_AccruedContractManufacturingCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Contract Manufacturing Current</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_AccruedFederalIncomeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accrued federal income tax</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_AccruedFederalIncomeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Federal Income Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued expenses and other current liabilities</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ProceedsFromEquityFinancing" xlink:type="locator" xlink:label="alxo_ProceedsFromEquityFinancing" />
    <link:label xml:lang="en-US" xlink:label="alxo_ProceedsFromEquityFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from equity financing.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ProceedsFromEquityFinancing" xlink:to="alxo_ProceedsFromEquityFinancing_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Longterm Debt Type [Domain]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FirstTrancheMember" xlink:type="locator" xlink:label="alxo_FirstTrancheMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_FirstTrancheMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">First tranche.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_FirstTrancheMember" xlink:to="alxo_FirstTrancheMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_FirstTrancheMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Tranche</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_FirstTrancheMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">First Tranche [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SecondTrancheMember" xlink:type="locator" xlink:label="alxo_SecondTrancheMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_SecondTrancheMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second tranche.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_SecondTrancheMember" xlink:to="alxo_SecondTrancheMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_SecondTrancheMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Tranche</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_SecondTrancheMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Tranche [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Name [Domain]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LoanAgreementMember" xlink:type="locator" xlink:label="alxo_LoanAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_LoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_LoanAgreementMember" xlink:to="alxo_LoanAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_LoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_LoanAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Loan Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Time to Liquidity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Price Volatility [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan, principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ProceedsFromEquityFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from equity financing</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ProceedsFromEquityFinancing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Equity Financing</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt instrument, description of variable rate basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Description Of Variable Rate Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan, annual floating interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Long Term Debt Percentage Bearing Variable Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan, interest rate above prime rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Basis Spread On Variable Rate1</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount" xlink:type="locator" xlink:label="alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount" />
    <link:label xml:lang="en-US" xlink:label="alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Final payment fee as percentage of funded principal amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount" xlink:to="alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount" xlink:type="locator" xlink:label="alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount" />
    <link:label xml:lang="en-US" xlink:label="alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, prepayment fee, percentage of principal amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount" xlink:to="alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DebtInstrumentInterestOnlyPaymentTerms" xlink:type="locator" xlink:label="alxo_DebtInstrumentInterestOnlyPaymentTerms" />
    <link:label xml:lang="en-US" xlink:label="alxo_DebtInstrumentInterestOnlyPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt instrument, interest-only payment terms.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_DebtInstrumentInterestOnlyPaymentTerms" xlink:to="alxo_DebtInstrumentInterestOnlyPaymentTerms_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_DebtInstrumentInterestOnlyPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan interest-only payments, term</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_DebtInstrumentInterestOnlyPaymentTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Interest Only Payment Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Frequency of periodic payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Frequency Of Periodic Payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan principal and interest payment commencement date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Date Of First Required Payment1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Maturity Date</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of principal amount as final payment</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Final Payment Fee As Percentage Of Funded Principal Amount</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayment fee percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument Prepayment Fee Percentage Of Principal Amount</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_EstimatedFairValueIssuanceOfWarrants" xlink:type="locator" xlink:label="alxo_EstimatedFairValueIssuanceOfWarrants" />
    <link:label xml:lang="en-US" xlink:label="alxo_EstimatedFairValueIssuanceOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated fair value issuance of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_EstimatedFairValueIssuanceOfWarrants" xlink:to="alxo_EstimatedFairValueIssuanceOfWarrants_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock" xlink:type="locator" xlink:label="alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock" />
    <link:label xml:lang="en-US" xlink:label="alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock warrants value converted into common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock" xlink:to="alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants issued to purchase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock exercise price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_EstimatedFairValueIssuanceOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of warrants</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_EstimatedFairValueIssuanceOfWarrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Fair Value Issuance Of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and rights outstanding, measurement input term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants and rights outstanding, measurement input</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants And Rights Outstanding Measurement Input</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding preferred stock warrant liability converted into common stock</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Warrants Value Converted Into Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock issued upon warrants exercise</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of compound derivative liability</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NetProceedsFromFollowOnPublicOffering" xlink:type="locator" xlink:label="alxo_NetProceedsFromFollowOnPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="alxo_NetProceedsFromFollowOnPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from follow-on public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_NetProceedsFromFollowOnPublicOffering" xlink:to="alxo_NetProceedsFromFollowOnPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_NetProceedsFromFollowOnPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from follow-on public offering</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NetProceedsFromFollowOnPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Follow On Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of outstanding principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RepaymentsOfLongTermDebt_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repayments Of Long Term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Stock By Class [Table]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_UndesignatedPreferredStockMember" xlink:type="locator" xlink:label="alxo_UndesignatedPreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_UndesignatedPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Undesignated preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_UndesignatedPreferredStockMember" xlink:to="alxo_UndesignatedPreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_UndesignatedPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Undesignated Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_UndesignatedPreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Undesignated Preferred Stock [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="alxo_FollowOnPublicOfferingMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on public offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_FollowOnPublicOfferingMember" xlink:to="alxo_FollowOnPublicOfferingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_FollowOnPublicOfferingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Public Offering [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesCConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series C convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_SeriesCConvertiblePreferredStockMember" xlink:to="alxo_SeriesCConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series C Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series C Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBAndCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBAndCConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_SeriesBAndCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B and C convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_SeriesBAndCConvertiblePreferredStockMember" xlink:to="alxo_SeriesBAndCConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_SeriesBAndCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B and C Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_SeriesBAndCConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Series B And C Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible preferred stock, shares outstanding</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_PaymentForOfferingCost" xlink:type="locator" xlink:label="alxo_PaymentForOfferingCost" />
    <link:label xml:lang="en-US" xlink:label="alxo_PaymentForOfferingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for offering cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_PaymentForOfferingCost" xlink:to="alxo_PaymentForOfferingCost_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from initial public offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Underwriting discounts and commissions paid</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_PaymentForOfferingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for offering related expense</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_PaymentForOfferingCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Offering Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ConvertiblePreferredStockIssuedAndOutstandingMember" xlink:type="locator" xlink:label="alxo_ConvertiblePreferredStockIssuedAndOutstandingMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_ConvertiblePreferredStockIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock, issued and outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ConvertiblePreferredStockIssuedAndOutstandingMember" xlink:to="alxo_ConvertiblePreferredStockIssuedAndOutstandingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ConvertiblePreferredStockIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ConvertiblePreferredStockIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Issued And Outstanding [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StockOptionsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="alxo_StockOptionsIssuedAndOutstandingMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_StockOptionsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options issued and outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_StockOptionsIssuedAndOutstandingMember" xlink:to="alxo_StockOptionsIssuedAndOutstandingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_StockOptionsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_StockOptionsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Issued And Outstanding [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StockOptionsAuthorizedForFutureIssuanceMember" xlink:type="locator" xlink:label="alxo_StockOptionsAuthorizedForFutureIssuanceMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_StockOptionsAuthorizedForFutureIssuanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock options authorized for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_StockOptionsAuthorizedForFutureIssuanceMember" xlink:to="alxo_StockOptionsAuthorizedForFutureIssuanceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_StockOptionsAuthorizedForFutureIssuanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Authorized for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_StockOptionsAuthorizedForFutureIssuanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Options Authorized For Future Issuance [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="alxo_WarrantsIssuedAndOutstandingMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants issued and outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_WarrantsIssuedAndOutstandingMember" xlink:to="alxo_WarrantsIssuedAndOutstandingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Issued And Outstanding [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantsAuthorizedForFutureIssuanceMember" xlink:type="locator" xlink:label="alxo_WarrantsAuthorizedForFutureIssuanceMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantsAuthorizedForFutureIssuanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants authorized for future issuance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_WarrantsAuthorizedForFutureIssuanceMember" xlink:to="alxo_WarrantsAuthorizedForFutureIssuanceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantsAuthorizedForFutureIssuanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants Authorized for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantsAuthorizedForFutureIssuanceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Authorized For Future Issuance [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock reserved for future issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TemporaryEquitySharesIssuedAndOutstanding" xlink:type="locator" xlink:label="alxo_TemporaryEquitySharesIssuedAndOutstanding" />
    <link:label xml:lang="en-US" xlink:label="alxo_TemporaryEquitySharesIssuedAndOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity shares issued and outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_TemporaryEquitySharesIssuedAndOutstanding" xlink:to="alxo_TemporaryEquitySharesIssuedAndOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Authorized Shares</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_TemporaryEquitySharesIssuedAndOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares Issued And Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_TemporaryEquitySharesIssuedAndOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Shares Issued And Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net Proceeds</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Aggregate Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Preferred Stock And Preference Stock</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion" xlink:type="locator" xlink:label="alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion" />
    <link:label xml:lang="en-US" xlink:label="alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative preferred stock dividend convertible shares issued upon conversion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion" xlink:to="alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, cumulative dividends percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividend Rate Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares original issue price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:type="locator" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued cumulative dividends on the Series A, Series B and Series C convertible preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:to="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Amount Of Preferred Dividends In Arrears</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative preferred stock dividend convertible shares issued upon conversion</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Preferred Stock Dividend Convertible Shares Issued Upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TwoThousandAndFifteenShareAwardSchemeMember" xlink:type="locator" xlink:label="alxo_TwoThousandAndFifteenShareAwardSchemeMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_TwoThousandAndFifteenShareAwardSchemeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and fifteen share award scheme.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_TwoThousandAndFifteenShareAwardSchemeMember" xlink:to="alxo_TwoThousandAndFifteenShareAwardSchemeMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_TwoThousandAndFifteenShareAwardSchemeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Share Award Scheme</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_TwoThousandAndFifteenShareAwardSchemeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Fifteen Share Award Scheme [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TwentyThousandAndTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="alxo_TwentyThousandAndTwentyEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_TwentyThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">twenty thousand and twenty equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_TwentyThousandAndTwentyEquityIncentivePlanMember" xlink:to="alxo_TwentyThousandAndTwentyEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_TwentyThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Equity Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_TwentyThousandAndTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Thousand And Twenty Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated 2020 equity incentive plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" xlink:to="alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Plan</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated Two Thousand Twenty Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201709Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201709Member" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201709Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option Modification</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201709Member" xlink:to="us-gaap_AccountingStandardsUpdate201709Member_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201709Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201709 [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty thousand and twenty employee stock purchase plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:to="alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Thousand And Twenty Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share option granted during the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of share option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share options, maximum term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share options, service period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised" />
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options nonvested exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested early exercised options</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability related to these unvested options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock-based compensation expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount" />
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, authorized amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage" />
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based compensation arrangement by share-based payment award, purchase of common sock at lower of closing price, percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of eligible compensation withheld</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, authorized amount</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation, number of shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation, lower of closing price, percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Purchase Of Common Sock At Lower Of Closing Price Percentage</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" />
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Authorized.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted" />
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" />
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled" />
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Canceled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Shares Available to Grant Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available to Grant, Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Authorized</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Shares Available to Grant, Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available to Grant, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares Available to Grant, Canceled/forfeited</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Canceled</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Shares Available to Grant Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options, Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options, Canceled/forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options, Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options, Exercisable at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Canceled/forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercisable at December 31, 2020</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life (Years), Outstanding Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Life (Years), Outstanding Options Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options Aggregate Intrinsic Value, Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options Aggregate Intrinsic Value, Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized share-based compensation expense, weighted-average period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total intrinsic value of options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant-date fair value per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of Services for Related-party Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CostOfSalesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cost Of Sales [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">International</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current provision for income taxes:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">International</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax provision:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">International</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At federal statutory income tax rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation State And Local Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research &amp; Development credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign rate differential</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Foreign Income Tax Rate Differential</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prior period true ups</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Prior Year Income Taxes</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DeferredTaxAssetsAccruedExpenses" xlink:type="locator" xlink:label="alxo_DeferredTaxAssetsAccruedExpenses" />
    <link:label xml:lang="en-US" xlink:label="alxo_DeferredTaxAssetsAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets accrued expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_DeferredTaxAssetsAccruedExpenses" xlink:to="alxo_DeferredTaxAssetsAccruedExpenses_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DeferredTaxAssetsStockOptions" xlink:type="locator" xlink:label="alxo_DeferredTaxAssetsStockOptions" />
    <link:label xml:lang="en-US" xlink:label="alxo_DeferredTaxAssetsStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_DeferredTaxAssetsStockOptions" xlink:to="alxo_DeferredTaxAssetsStockOptions_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1" xlink:type="locator" xlink:label="alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1" />
    <link:label xml:lang="en-US" xlink:label="alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities, property, plant and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1" xlink:to="alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research &amp; other credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets In Process Research And Development</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_DeferredTaxAssetsAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_DeferredTaxAssetsAccruedExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_DeferredTaxAssetsStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_DeferredTaxAssetsStockOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Stock Options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Components Of Deferred Tax Liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Property Plant And Equipment1</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Liabilities Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, increase in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:type="locator" xlink:label="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" />
    <link:label xml:lang="en-US" xlink:label="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss and tax credit carryforwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" xlink:type="locator" xlink:label="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" />
    <link:label xml:lang="en-US" xlink:label="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net operating loss and tax credit carryforwards.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" xlink:to="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Loss And Tax Credit Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss And Tax Credit Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Country [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Operating Loss And Tax Credit Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Operating Loss And Tax Credit Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Amount</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OperatingLossCarryforwardsExpirationPeriod" xlink:type="locator" xlink:label="alxo_OperatingLossCarryforwardsExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="alxo_OperatingLossCarryforwardsExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_OperatingLossCarryforwardsExpirationPeriod" xlink:to="alxo_OperatingLossCarryforwardsExpirationPeriod_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TaxCreditCarryforwardExpirationPeriod" xlink:type="locator" xlink:label="alxo_TaxCreditCarryforwardExpirationPeriod" />
    <link:label xml:lang="en-US" xlink:label="alxo_TaxCreditCarryforwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_TaxCreditCarryforwardExpirationPeriod" xlink:to="alxo_TaxCreditCarryforwardExpirationPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_OperatingLossCarryforwardsExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses, Expiration Years</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_OperatingLossCarryforwardsExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_TaxCreditCarryforwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credits, Expiration Years</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_TaxCreditCarryforwardExpirationPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating losses, Expiration Years</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefit that would impact effective rate if recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits That Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of year</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions/reversals based on tax positions of prior years</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Decreases Resulting From Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions based on tax positions related to the current year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Lapses in statutes of limitations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized interest and penalties expense (benefit) related to unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Expense</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NonrefundableLicenseRoyaltyAndPatentExpenses" xlink:type="locator" xlink:label="alxo_NonrefundableLicenseRoyaltyAndPatentExpenses" />
    <link:label xml:lang="en-US" xlink:label="alxo_NonrefundableLicenseRoyaltyAndPatentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Nonrefundable license royalty and patent expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_NonrefundableLicenseRoyaltyAndPatentExpenses" xlink:to="alxo_NonrefundableLicenseRoyaltyAndPatentExpenses_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ClinicalAndRegulatoryMilestonesPayments" xlink:type="locator" xlink:label="alxo_ClinicalAndRegulatoryMilestonesPayments" />
    <link:label xml:lang="en-US" xlink:label="alxo_ClinicalAndRegulatoryMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestones payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ClinicalAndRegulatoryMilestonesPayments" xlink:to="alxo_ClinicalAndRegulatoryMilestonesPayments_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AgreementExpiryDescription" xlink:type="locator" xlink:label="alxo_AgreementExpiryDescription" />
    <link:label xml:lang="en-US" xlink:label="alxo_AgreementExpiryDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement expiry description.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_AgreementExpiryDescription" xlink:to="alxo_AgreementExpiryDescription_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ExclusiveEquityAgreementMember" xlink:type="locator" xlink:label="alxo_ExclusiveEquityAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_ExclusiveEquityAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Exclusive equity agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ExclusiveEquityAgreementMember" xlink:to="alxo_ExclusiveEquityAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ExclusiveEquityAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exclusive Equity Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ExclusiveEquityAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Exclusive Equity Agreement [Member]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LegalEntityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StanfordJuniorUniversityMember" xlink:type="locator" xlink:label="alxo_StanfordJuniorUniversityMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_StanfordJuniorUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stanford Junior University.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_StanfordJuniorUniversityMember" xlink:to="alxo_StanfordJuniorUniversityMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_StanfordJuniorUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stanford Junior University</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_StanfordJuniorUniversityMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stanford Junior University [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommercialLicenseAgreementMember" xlink:type="locator" xlink:label="alxo_CommercialLicenseAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_CommercialLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_CommercialLicenseAgreementMember" xlink:to="alxo_CommercialLicenseAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_CommercialLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_CommercialLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial License Agreement [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SelexisSAMember" xlink:type="locator" xlink:label="alxo_SelexisSAMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_SelexisSAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Selexis SA.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_SelexisSAMember" xlink:to="alxo_SelexisSAMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_SelexisSAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selexis SA</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_SelexisSAMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selexis S A [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommercialAntibodyAgreementMember" xlink:type="locator" xlink:label="alxo_CommercialAntibodyAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_CommercialAntibodyAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial antibody agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_CommercialAntibodyAgreementMember" xlink:to="alxo_CommercialAntibodyAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_CommercialAntibodyAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Antibody Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_CommercialAntibodyAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Antibody Agreement [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CrystalBioscienceIncMember" xlink:type="locator" xlink:label="alxo_CrystalBioscienceIncMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_CrystalBioscienceIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Crystal Bioscience Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_CrystalBioscienceIncMember" xlink:to="alxo_CrystalBioscienceIncMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_CrystalBioscienceIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Crystal Bioscience Inc</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_CrystalBioscienceIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Crystal Bioscience Inc [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NonrefundableLicenseRoyaltyAndPatentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nonrefundable license royalty and patent expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NonrefundableLicenseRoyaltyAndPatentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Nonrefundable License Royalty And Patent Expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ClinicalAndRegulatoryMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and regulatory milestones payments</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ClinicalAndRegulatoryMilestonesPayments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestones Payments</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_AgreementExpiryDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement expiry description</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_AgreementExpiryDescription_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Agreement Expiry Description</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TerminationOfAgreementWrittenNoticePeriod" xlink:type="locator" xlink:label="alxo_TerminationOfAgreementWrittenNoticePeriod" />
    <link:label xml:lang="en-US" xlink:label="alxo_TerminationOfAgreementWrittenNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination of agreement written notice period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_TerminationOfAgreementWrittenNoticePeriod" xlink:to="alxo_TerminationOfAgreementWrittenNoticePeriod_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NoticePeriodToRemedyBreachOfAgreement" xlink:type="locator" xlink:label="alxo_NoticePeriodToRemedyBreachOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="alxo_NoticePeriodToRemedyBreachOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Notice period to remedy the breach of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_NoticePeriodToRemedyBreachOfAgreement" xlink:to="alxo_NoticePeriodToRemedyBreachOfAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_TerminationOfAgreementWrittenNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination of agreement written notice period</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_TerminationOfAgreementWrittenNoticePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Termination Of Agreement Written Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NoticePeriodToRemedyBreachOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Notice period to remedy the breach of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NoticePeriodToRemedyBreachOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Notice Period To Remedy Breach Of Agreement</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell" xlink:type="locator" xlink:label="alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell" />
    <link:label xml:lang="en-US" xlink:label="alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of company&apos;s investors who are investors in related party as well.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell" xlink:to="alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_InitialTermOfAgreementWithRelatedParty" xlink:type="locator" xlink:label="alxo_InitialTermOfAgreementWithRelatedParty" />
    <link:label xml:lang="en-US" xlink:label="alxo_InitialTermOfAgreementWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial term of agreement with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_InitialTermOfAgreementWithRelatedParty" xlink:to="alxo_InitialTermOfAgreementWithRelatedParty_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated" xlink:type="locator" xlink:label="alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated" />
    <link:label xml:lang="en-US" xlink:label="alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party agreement automatically renewal additional term unless terminated.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated" xlink:to="alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_RelatedPartyMarkupCostPercentage" xlink:type="locator" xlink:label="alxo_RelatedPartyMarkupCostPercentage" />
    <link:label xml:lang="en-US" xlink:label="alxo_RelatedPartyMarkupCostPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Related party markup cost percentage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_RelatedPartyMarkupCostPercentage" xlink:to="alxo_RelatedPartyMarkupCostPercentage_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ResearchAndDevelopmentServicesAgreementMember" xlink:type="locator" xlink:label="alxo_ResearchAndDevelopmentServicesAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_ResearchAndDevelopmentServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development services agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_ResearchAndDevelopmentServicesAgreementMember" xlink:to="alxo_ResearchAndDevelopmentServicesAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_ResearchAndDevelopmentServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Services Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_ResearchAndDevelopmentServicesAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Services Agreement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions By Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TollnineMember" xlink:type="locator" xlink:label="alxo_TollnineMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_TollnineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tollnine.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_TollnineMember" xlink:to="alxo_TollnineMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_TollnineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tollnine</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_TollnineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tollnine [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TallacTherapeuticsMember" xlink:type="locator" xlink:label="alxo_TallacTherapeuticsMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_TallacTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tallac therapeutics.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_TallacTherapeuticsMember" xlink:to="alxo_TallacTherapeuticsMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_TallacTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tallac Therapeutics</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_TallacTherapeuticsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tallac Therapeutics [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of company&apos;s investors who are investors in related party as well</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Company S Investors Who Are Investors In Related Party As Well</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_InitialTermOfAgreementWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial term of agreement with related party</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_InitialTermOfAgreementWithRelatedParty_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Term Of Agreement With Related Party</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement automatically renewal additional term unless terminated</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Agreement Automatically Renewal Additional Term Unless Terminated</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_RelatedPartyMarkupCostPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Markup cost in percentage</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_RelatedPartyMarkupCostPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Markup Cost Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding related-party receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_DueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Due From Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: cumulative preferred dividends allocated to preferred stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Dividends And Other Adjustments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares of common stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Outstanding Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantToPurchaseConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_WarrantToPurchaseConvertiblePreferredStockMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantToPurchaseConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants to purchase convertible preferred stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_WarrantToPurchaseConvertiblePreferredStockMember" xlink:to="alxo_WarrantToPurchaseConvertiblePreferredStockMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantToPurchaseConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_WarrantToPurchaseConvertiblePreferredStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Warrant To Purchase Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommonStockSubjectToRepurchaseMember" xlink:type="locator" xlink:label="alxo_CommonStockSubjectToRepurchaseMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_CommonStockSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock subject to repurchase.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_CommonStockSubjectToRepurchaseMember" xlink:to="alxo_CommonStockSubjectToRepurchaseMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_CommonStockSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Subject to Repurchase</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_CommonStockSubjectToRepurchaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Subject To Repurchase [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OptionsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="alxo_OptionsIssuedAndOutstandingMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_OptionsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Options issued and outstanding.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_OptionsIssuedAndOutstandingMember" xlink:to="alxo_OptionsIssuedAndOutstandingMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_OptionsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_OptionsIssuedAndOutstandingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Options Issued And Outstanding [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree" xlink:type="locator" xlink:label="alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree" />
    <link:label xml:lang="en-US" xlink:label="alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, liability, to be paid, year two and three.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree" xlink:to="alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive" xlink:type="locator" xlink:label="alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive" />
    <link:label xml:lang="en-US" xlink:label="alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease, liability, to be paid, year four and year five.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive" xlink:to="alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive_lbl" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Manufacturing and service contracts, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligation" xlink:to="us-gaap_PurchaseObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing and service contracts, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation Due In Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondAndThirdYear" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInSecondAndThirdYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligationDueInSecondAndThirdYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing and service contracts, 2022 - 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInSecondAndThirdYear" xlink:to="us-gaap_PurchaseObligationDueInSecondAndThirdYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligationDueInSecondAndThirdYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation Due In Second And Third Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInFourthAndFifthYear" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInFourthAndFifthYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligationDueInFourthAndFifthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing and service contracts, 2024 - 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueInFourthAndFifthYear" xlink:to="us-gaap_PurchaseObligationDueInFourthAndFifthYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligationDueInFourthAndFifthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation Due In Fourth And Fifth Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueAfterFifthYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligationDueAfterFifthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Manufacturing and service contracts, Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PurchaseObligationDueAfterFifthYear" xlink:to="us-gaap_PurchaseObligationDueAfterFifthYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligationDueAfterFifthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Obligation Due After Fifth Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contractual Obligation, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual Obligation, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation Due In Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual Obligation, 2022 - 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:to="us-gaap_ContractualObligationDueInSecondAndThirdYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation Due In Second And Third Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual Obligation, 2024 - 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:to="us-gaap_ContractualObligationDueInFourthAndFifthYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation Due In Fourth And Fifth Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual Obligation, Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueAfterFifthYear" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Obligation Due After Fifth Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating lease obligations, Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease obligations, 2021</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease obligations, 2022 - 2023</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability To Be Paid Year Two And Three</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease obligations, 2024 - 2025</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability To Be Paid Year Four And Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease obligations,Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Five</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OperatingSubLeaseExpirationYear" xlink:type="locator" xlink:label="alxo_OperatingSubLeaseExpirationYear" />
    <link:label xml:lang="en-US" xlink:label="alxo_OperatingSubLeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating sub-lease expiration year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_OperatingSubLeaseExpirationYear" xlink:to="alxo_OperatingSubLeaseExpirationYear_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="alxo_CommitmentsAndContingenciesLineItems" />
    <link:label xml:lang="en-US" xlink:label="alxo_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="alxo_CommitmentsAndContingenciesLineItems_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="alxo_CommitmentsAndContingenciesTable" />
    <link:label xml:lang="en-US" xlink:label="alxo_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and Contingencies.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_CommitmentsAndContingenciesTable" xlink:to="alxo_CommitmentsAndContingenciesTable_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OfficeAndLaboratorySpaceMember" xlink:type="locator" xlink:label="alxo_OfficeAndLaboratorySpaceMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_OfficeAndLaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office and laboratory space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_OfficeAndLaboratorySpaceMember" xlink:to="alxo_OfficeAndLaboratorySpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_OfficeAndLaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office and Laboratory Space</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_OfficeAndLaboratorySpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office And Laboratory Space [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xml:lang="en-US" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Burlingame, California</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="stpr_CA" xlink:to="stpr_CA_lbl" />
    <link:label xml:lang="en-US" xlink:label="stpr_CA_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">CALIFORNIA</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_MasterServiceAgreementMember" xlink:type="locator" xlink:label="alxo_MasterServiceAgreementMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_MasterServiceAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Master service agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_MasterServiceAgreementMember" xlink:to="alxo_MasterServiceAgreementMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_MasterServiceAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Master Service Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_MasterServiceAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Master Service Agreement [Member]</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SecondDrugProductManufacturerMember" xlink:type="locator" xlink:label="alxo_SecondDrugProductManufacturerMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_SecondDrugProductManufacturerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Second drug product manufacturer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_SecondDrugProductManufacturerMember" xlink:to="alxo_SecondDrugProductManufacturerMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_SecondDrugProductManufacturerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Drug Product Manufacturer</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_SecondDrugProductManufacturerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Second Drug Product Manufacturer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_OperatingSubLeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating sub-lease expiration year</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_OperatingSubLeaseExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Sub Lease Expiration Year</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_InitialTermOfAgreement" xlink:type="locator" xlink:label="alxo_InitialTermOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="alxo_InitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial term of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_InitialTermOfAgreement" xlink:to="alxo_InitialTermOfAgreement_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_RenewalPeriodsOfAgreement" xlink:type="locator" xlink:label="alxo_RenewalPeriodsOfAgreement" />
    <link:label xml:lang="en-US" xlink:label="alxo_RenewalPeriodsOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Renewal periods of agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_RenewalPeriodsOfAgreement" xlink:to="alxo_RenewalPeriodsOfAgreement_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_InitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial term of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_InitialTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Term Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_RenewalPeriodsOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Renewal periods of agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_RenewalPeriodsOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Renewal Periods Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_PurchaseObligation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Purchase obligations</link:label>
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LesseeOperatingLeaseCommencingEndDate" xlink:type="locator" xlink:label="alxo_LesseeOperatingLeaseCommencingEndDate" />
    <link:label xml:lang="en-US" xlink:label="alxo_LesseeOperatingLeaseCommencingEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee, operating lease commencing end date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_LesseeOperatingLeaseCommencingEndDate" xlink:to="alxo_LesseeOperatingLeaseCommencingEndDate_lbl" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OfficeSpaceMember" xlink:type="locator" xlink:label="alxo_OfficeSpaceMember" />
    <link:label xml:lang="en-US" xlink:label="alxo_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Office space.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="alxo_OfficeSpaceMember" xlink:to="alxo_OfficeSpaceMember_lbl" />
    <link:label xml:lang="en-US" xlink:label="alxo_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Space</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_OfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Office Space [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, term of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Term Of Contract</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_LesseeOperatingLeaseCommencingEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease commencing end date</link:label>
    <link:label xml:lang="en-US" xlink:label="alxo_LesseeOperatingLeaseCommencingEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Commencing End Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" />
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>29
<FILENAME>alxo-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date      : 2021-03-18T17:24:36.2215862+00:00 -->
<!-- Version            : 5.0.1.571 -->
<!-- Package ID         : 11fbbc32b9104e6cbcd92c96d6313ce7 -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/role/TemplateLink" xlink:href="alxo-20201231.xsd#TemplateLink" xlink:type="simple" />
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="alxo-20201231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="locator" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:type="locator" xlink:label="dei_DocumentTransitionReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport" xlink:type="locator" xlink:label="dei_DocumentAnnualReport" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:type="locator" xlink:label="dei_EntityShellCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag" xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:type="locator" xlink:label="dei_EntitySmallBusiness" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="alxo-20201231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:type="locator" xlink:label="us-gaap_LongTermDebtNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesAConvertiblePreferredStockMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesBConvertiblePreferredStockMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DueFromRelatedPartiesCurrent" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="alxo-20201231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesAConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesBConvertiblePreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="alxo-20201231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpensesRelatedParty" xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfRevenueExtensibleList" xlink:type="locator" xlink:label="us-gaap_TypeOfRevenueExtensibleList" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_TypeOfRevenueExtensibleList" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="alxo-20201231.xsd#Role_StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" xlink:type="locator" xlink:label="alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StockIssuedDuringPeriodSharesWarrantExercise" xlink:type="locator" xlink:label="alxo_StockIssuedDuringPeriodSharesWarrantExercise" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockDividendsShares" xlink:type="locator" xlink:label="us-gaap_CommonStockDividendsShares" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends" xlink:type="locator" xlink:label="us-gaap_Dividends" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:type="locator" xlink:label="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" xlink:type="locator" xlink:label="alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding" xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockDividendsShares" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_StockIssuedDuringPeriodSharesWarrantExercise" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="12330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_li0l2" order="12350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_li0l2" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_li0l2" order="12390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="alxo-20201231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock" xlink:type="locator" xlink:label="alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable" xlink:type="locator" xlink:label="alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:type="locator" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_VestingOfEarlyExercisedStockOptions" xlink:type="locator" xlink:label="alxo_VestingOfEarlyExercisedStockOptions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDebtExtinguishmentCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfDebtExtinguishmentCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="locator" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyHeldForSale" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_IncreaseDecreaseInOtherAssets" xlink:type="locator" xlink:label="alxo_IncreaseDecreaseInOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_GainOnAssignmentOfLease" xlink:type="locator" xlink:label="alxo_GainOnAssignmentOfLease" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants" xlink:type="locator" xlink:label="alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:type="locator" xlink:label="us-gaap_ProfitLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="alxo_GainOnAssignmentOfLease" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="alxo_IncreaseDecreaseInOtherAssets" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyHeldForSale" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtExtinguishmentCosts" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="12300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_li0l2" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="alxo_VestingOfEarlyExercisedStockOptions" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" order="12960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable" order="13020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="13080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock" order="13140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureOrganization" xlink:href="alxo-20201231.xsd#Role_DisclosureOrganization" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureOrganization">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies" xlink:href="alxo-20201231.xsd#Role_DisclosureSignificantAccountingPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments" xlink:href="alxo-20201231.xsd#Role_DisclosureFairValueOfFinancialInstruments" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents" xlink:href="alxo-20201231.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureTermLoan" xlink:href="alxo-20201231.xsd#Role_DisclosureTermLoan" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureTermLoan">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="alxo-20201231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquity">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="alxo-20201231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensation">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxes">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureLicenseAgreement" xlink:href="alxo-20201231.xsd#Role_DisclosureLicenseAgreement" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureLicenseAgreement">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions" xlink:href="alxo-20201231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="alxo-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="alxo-20201231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="alxo-20201231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSubsequentEvents">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnaudited" xlink:href="alxo-20201231.xsd#Role_DisclosureSelectedQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnaudited">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:href="alxo-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock" xlink:type="locator" xlink:label="alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock" xlink:type="locator" xlink:label="alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:type="locator" xlink:label="alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DeferredOfferingCostsPolicyTextBlock" xlink:type="locator" xlink:label="alxo_DeferredOfferingCostsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:type="locator" xlink:label="alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ReverseStockSplitPolicyTextBlock" xlink:type="locator" xlink:label="alxo_ReverseStockSplitPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_ReverseStockSplitPolicyTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UseOfEstimates" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_DeferredOfferingCostsPolicyTextBlock" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtPolicyTextBlock" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="11060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables" xlink:href="alxo-20201231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables" xlink:href="alxo-20201231.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables">
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="alxo-20201231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityTableTextBlock" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="locator" xlink:label="alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_TemporaryEquityTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="alxo-20201231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" xlink:type="locator" xlink:label="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock" xlink:type="locator" xlink:label="alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="alxo-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="alxo-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RegistrationPaymentArrangementTextBlock" xlink:type="locator" xlink:label="us-gaap_RegistrationPaymentArrangementTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_RegistrationPaymentArrangementTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:href="alxo-20201231.xsd#Role_DisclosureSelectedQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:type="locator" xlink:label="us-gaap_AssetImpairmentCharges" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="alxo_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201813Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201813Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201613Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201613Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="alxo_SignificantAccountingPoliciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="alxo_SignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_SignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_SignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201613Member" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201813Member" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_SignificantAccountingPoliciesTable" xlink:to="alxo_SignificantAccountingPoliciesLineItems" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantLiabilityFairValueDisclosure" xlink:type="locator" xlink:label="alxo_WarrantLiabilityFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="alxo_WarrantLiabilityFairValueDisclosure" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsReconciliationOfFinancialLiabilitiesMeasuredAtFairValueUsingLevel3UnobservableInputsDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsReconciliationOfFinancialLiabilitiesMeasuredAtFairValueUsingLevel3UnobservableInputsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsReconciliationOfFinancialLiabilitiesMeasuredAtFairValueUsingLevel3UnobservableInputsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment" xlink:type="locator" xlink:label="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" xlink:type="locator" xlink:label="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CompoundDerivativeLiabilityMember" xlink:type="locator" xlink:label="alxo_CompoundDerivativeLiabilityMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantLiabilityMember" xlink:type="locator" xlink:label="alxo_WarrantLiabilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="alxo_WarrantLiabilityMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="alxo_CompoundDerivativeLiabilityMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfPropertyAndEquipmentDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfComponentsOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfPropertyAndEquipmentDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:type="locator" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ComputerHardwareAndSoftwareMember" xlink:type="locator" xlink:label="alxo_ComputerHardwareAndSoftwareMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alxo_ComputerHardwareAndSoftwareMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ScheduleOfBalanceSheetComponentsLineItems" xlink:type="locator" xlink:label="alxo_ScheduleOfBalanceSheetComponentsLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LabEquipmentAndOtherAssetsMember" xlink:type="locator" xlink:label="alxo_LabEquipmentAndOtherAssetsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ScheduleOfBalanceSheetComponentsTable" xlink:type="locator" xlink:label="alxo_ScheduleOfBalanceSheetComponentsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="alxo_ScheduleOfBalanceSheetComponentsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_ScheduleOfBalanceSheetComponentsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alxo_LabEquipmentAndOtherAssetsMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_ScheduleOfBalanceSheetComponentsTable" xlink:to="alxo_ScheduleOfBalanceSheetComponentsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_ScheduleOfBalanceSheetComponentsLineItems" xlink:to="us-gaap_DepreciationAndAmortization" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_ScheduleOfBalanceSheetComponentsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_ScheduleOfBalanceSheetComponentsLineItems" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsComponentsOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureBalanceSheetComponentsComponentsOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsComponentsOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AccruedFederalIncomeTax" xlink:type="locator" xlink:label="alxo_AccruedFederalIncomeTax" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AccruedContractManufacturingCurrent" xlink:type="locator" xlink:label="alxo_AccruedContractManufacturingCurrent" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AccruedClinicalAndNonClinicalCostsCurrent" xlink:type="locator" xlink:label="alxo_AccruedClinicalAndNonClinicalCostsCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="alxo_AccruedClinicalAndNonClinicalCostsCurrent" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="alxo_AccruedContractManufacturingCurrent" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="alxo_AccruedFederalIncomeTax" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureTermLoanAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLongTermDebt" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NetProceedsFromFollowOnPublicOffering" xlink:type="locator" xlink:label="alxo_NetProceedsFromFollowOnPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock" xlink:type="locator" xlink:label="alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_EstimatedFairValueIssuanceOfWarrants" xlink:type="locator" xlink:label="alxo_EstimatedFairValueIssuanceOfWarrants" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount" xlink:type="locator" xlink:label="alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount" xlink:type="locator" xlink:label="alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DebtInstrumentInterestOnlyPaymentTerms" xlink:type="locator" xlink:label="alxo_DebtInstrumentInterestOnlyPaymentTerms" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:type="locator" xlink:label="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ProceedsFromEquityFinancing" xlink:type="locator" xlink:label="alxo_ProceedsFromEquityFinancing" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CompoundDerivativeLiabilityMember" xlink:type="locator" xlink:label="alxo_CompoundDerivativeLiabilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByLiabilityClassAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember" xlink:type="locator" xlink:label="us-gaap_PrimeRateMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain" xlink:type="locator" xlink:label="us-gaap_VariableRateDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis" xlink:type="locator" xlink:label="us-gaap_VariableRateAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LoanAgreementMember" xlink:type="locator" xlink:label="alxo_LoanAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SecondTrancheMember" xlink:type="locator" xlink:label="alxo_SecondTrancheMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FirstTrancheMember" xlink:type="locator" xlink:label="alxo_FirstTrancheMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:type="locator" xlink:label="us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:type="locator" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="alxo_FirstTrancheMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="alxo_SecondTrancheMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="alxo_LoanAgreementMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_VariableRateAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesBConvertiblePreferredStockMember" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="10030.14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="alxo_CompoundDerivativeLiabilityMember" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="11360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_ProceedsFromEquityFinancing" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtPercentageBearingVariableInterestRate" order="11500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_DebtInstrumentInterestOnlyPaymentTerms" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentDateOfFirstRequiredPayment1" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount" order="11670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" order="11920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_EstimatedFairValueIssuanceOfWarrants" order="11980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="12040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="12160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock" order="12460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="12520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="12610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="alxo_NetProceedsFromFollowOnPublicOffering" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" order="12680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="12700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion" xlink:type="locator" xlink:label="alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:type="locator" xlink:label="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:type="locator" xlink:label="us-gaap_SharePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_PaymentForOfferingCost" xlink:type="locator" xlink:label="alxo_PaymentForOfferingCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBAndCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBAndCConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesCConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesCConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_FollowOnPublicOfferingMember" xlink:type="locator" xlink:label="alxo_FollowOnPublicOfferingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:type="locator" xlink:label="us-gaap_IPOMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_UndesignatedPreferredStockMember" xlink:type="locator" xlink:label="alxo_UndesignatedPreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_UndesignatedPreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="alxo_FollowOnPublicOfferingMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesCConvertiblePreferredStockMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesBConvertiblePreferredStockMember" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesAConvertiblePreferredStockMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesBAndCConvertiblePreferredStockMember" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="alxo_PaymentForOfferingCost" order="11260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" order="11850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceOnConvertedBasisDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceOnConvertedBasisDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceOnConvertedBasisDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantsAuthorizedForFutureIssuanceMember" xlink:type="locator" xlink:label="alxo_WarrantsAuthorizedForFutureIssuanceMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="alxo_WarrantsIssuedAndOutstandingMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StockOptionsAuthorizedForFutureIssuanceMember" xlink:type="locator" xlink:label="alxo_StockOptionsAuthorizedForFutureIssuanceMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StockOptionsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="alxo_StockOptionsIssuedAndOutstandingMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ConvertiblePreferredStockIssuedAndOutstandingMember" xlink:type="locator" xlink:label="alxo_ConvertiblePreferredStockIssuedAndOutstandingMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_ConvertiblePreferredStockIssuedAndOutstandingMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_StockOptionsIssuedAndOutstandingMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_StockOptionsAuthorizedForFutureIssuanceMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_WarrantsIssuedAndOutstandingMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_WarrantsAuthorizedForFutureIssuanceMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfConvertiblePreferredStockDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockholdersEquitySummaryOfConvertiblePreferredStockDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfConvertiblePreferredStockDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TemporaryEquitySharesIssuedAndOutstanding" xlink:type="locator" xlink:label="alxo_TemporaryEquitySharesIssuedAndOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesBConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesBConvertiblePreferredStockMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SeriesAConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_SeriesAConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesAConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="alxo_SeriesBConvertiblePreferredStockMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="alxo_TemporaryEquitySharesIssuedAndOutstanding" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201709Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201709Member" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TwentyThousandAndTwentyEquityIncentivePlanMember" xlink:type="locator" xlink:label="alxo_TwentyThousandAndTwentyEquityIncentivePlanMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TwoThousandAndFifteenShareAwardSchemeMember" xlink:type="locator" xlink:label="alxo_TwoThousandAndFifteenShareAwardSchemeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alxo_TwoThousandAndFifteenShareAwardSchemeMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alxo_TwentyThousandAndTwentyEquityIncentivePlanMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201709Member" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="10870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="10940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount" order="11170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="11420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="11540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_li0l2" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" xlink:type="locator" xlink:label="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantExercised" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_li0l2" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="11690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="12410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="12530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="12770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseIncludesShareOptionsGrantedToEmployeesAndNonemployeesDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockBasedCompensationShareBasedCompensationExpenseIncludesShareOptionsGrantedToEmployeesAndNonemployeesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseIncludesShareOptionsGrantedToEmployeesAndNonemployeesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfSalesMember" xlink:type="locator" xlink:label="us-gaap_CostOfSalesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" xlink:type="locator" xlink:label="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionGrantUsingBlackScholesOptionPricingModelDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionGrantUsingBlackScholesOptionPricingModelDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionGrantUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesDomesticAndInternationalComponentsOfPreTaxLossDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesDomesticAndInternationalComponentsOfPreTaxLossDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesDomesticAndInternationalComponentsOfPreTaxLossDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfStatutoryAndEffectiveIncomeTaxRateReconciliationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfStatutoryAndEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfStatutoryAndEffectiveIncomeTaxRateReconciliationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1" xlink:type="locator" xlink:label="alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DeferredTaxAssetsStockOptions" xlink:type="locator" xlink:label="alxo_DeferredTaxAssetsStockOptions" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_DeferredTaxAssetsAccruedExpenses" xlink:type="locator" xlink:label="alxo_DeferredTaxAssetsAccruedExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:type="locator" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="alxo_DeferredTaxAssetsAccruedExpenses" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="alxo_DeferredTaxAssetsStockOptions" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TaxCreditCarryforwardExpirationPeriod" xlink:type="locator" xlink:label="alxo_TaxCreditCarryforwardExpirationPeriod" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OperatingLossCarryforwardsExpirationPeriod" xlink:type="locator" xlink:label="alxo_OperatingLossCarryforwardsExpirationPeriod" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator" xlink:label="us-gaap_TaxCreditCarryforwardAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:type="locator" xlink:label="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:type="locator" xlink:label="srt_MaximumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:type="locator" xlink:label="srt_MinimumMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:type="locator" xlink:label="srt_RangeMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:type="locator" xlink:label="srt_RangeAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCountryMember" xlink:type="locator" xlink:label="us-gaap_ForeignCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" xlink:type="locator" xlink:label="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" xlink:to="srt_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsTable" xlink:to="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="alxo_OperatingLossCarryforwardsExpirationPeriod" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="alxo_TaxCreditCarryforwardExpirationPeriod" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" order="10780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureLicenseAgreementAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails">
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NoticePeriodToRemedyBreachOfAgreement" xlink:type="locator" xlink:label="alxo_NoticePeriodToRemedyBreachOfAgreement" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TerminationOfAgreementWrittenNoticePeriod" xlink:type="locator" xlink:label="alxo_TerminationOfAgreementWrittenNoticePeriod" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_AgreementExpiryDescription" xlink:type="locator" xlink:label="alxo_AgreementExpiryDescription" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ClinicalAndRegulatoryMilestonesPayments" xlink:type="locator" xlink:label="alxo_ClinicalAndRegulatoryMilestonesPayments" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NonrefundableLicenseRoyaltyAndPatentExpenses" xlink:type="locator" xlink:label="alxo_NonrefundableLicenseRoyaltyAndPatentExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CrystalBioscienceIncMember" xlink:type="locator" xlink:label="alxo_CrystalBioscienceIncMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommercialAntibodyAgreementMember" xlink:type="locator" xlink:label="alxo_CommercialAntibodyAgreementMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SelexisSAMember" xlink:type="locator" xlink:label="alxo_SelexisSAMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommercialLicenseAgreementMember" xlink:type="locator" xlink:label="alxo_CommercialLicenseAgreementMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_StanfordJuniorUniversityMember" xlink:type="locator" xlink:label="alxo_StanfordJuniorUniversityMember" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain" xlink:type="locator" xlink:label="dei_EntityDomain" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis" xlink:type="locator" xlink:label="dei_LegalEntityAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ExclusiveEquityAgreementMember" xlink:type="locator" xlink:label="alxo_ExclusiveEquityAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alxo_ExclusiveEquityAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="dei_LegalEntityAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="alxo_StanfordJuniorUniversityMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alxo_CommercialLicenseAgreementMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="alxo_SelexisSAMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alxo_CommercialAntibodyAgreementMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="alxo_CrystalBioscienceIncMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alxo_NonrefundableLicenseRoyaltyAndPatentExpenses" order="11050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alxo_ClinicalAndRegulatoryMilestonesPayments" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alxo_AgreementExpiryDescription" order="11090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alxo_TerminationOfAgreementWrittenNoticePeriod" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="alxo_NoticePeriodToRemedyBreachOfAgreement" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_DueFromRelatedParties" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_RelatedPartyMarkupCostPercentage" xlink:type="locator" xlink:label="alxo_RelatedPartyMarkupCostPercentage" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated" xlink:type="locator" xlink:label="alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_InitialTermOfAgreementWithRelatedParty" xlink:type="locator" xlink:label="alxo_InitialTermOfAgreementWithRelatedParty" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell" xlink:type="locator" xlink:label="alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TallacTherapeuticsMember" xlink:type="locator" xlink:label="alxo_TallacTherapeuticsMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_TollnineMember" xlink:type="locator" xlink:label="alxo_TollnineMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_ResearchAndDevelopmentServicesAgreementMember" xlink:type="locator" xlink:label="alxo_ResearchAndDevelopmentServicesAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alxo_ResearchAndDevelopmentServicesAgreementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alxo_TollnineMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="alxo_TallacTherapeuticsMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alxo_InitialTermOfAgreementWithRelatedParty" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="alxo_RelatedPartyMarkupCostPercentage" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DueFromRelatedParties" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAbstract" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesWereExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesWereExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesWereExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OptionsIssuedAndOutstandingMember" xlink:type="locator" xlink:label="alxo_OptionsIssuedAndOutstandingMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommonStockSubjectToRepurchaseMember" xlink:type="locator" xlink:label="alxo_CommonStockSubjectToRepurchaseMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_WarrantToPurchaseConvertiblePreferredStockMember" xlink:type="locator" xlink:label="alxo_WarrantToPurchaseConvertiblePreferredStockMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_WarrantToPurchaseConvertiblePreferredStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_CommonStockSubjectToRepurchaseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="alxo_OptionsIssuedAndOutstandingMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive" xlink:type="locator" xlink:label="alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree" xlink:type="locator" xlink:label="alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueAfterFifthYear" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueAfterFifthYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInFourthAndFifthYear" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInFourthAndFifthYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInSecondAndThirdYear" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInSecondAndThirdYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation" xlink:type="locator" xlink:label="us-gaap_ContractualObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueAfterFifthYear" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueAfterFifthYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInFourthAndFifthYear" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInFourthAndFifthYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInSecondAndThirdYear" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInSecondAndThirdYear" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligationDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_PurchaseObligationDueInNextTwelveMonths" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligation" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInNextTwelveMonths" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInSecondAndThirdYear" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueInFourthAndFifthYear" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_PurchaseObligationDueAfterFifthYear" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligation" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueInSecondAndThirdYear" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueInFourthAndFifthYear" order="10930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ContractualObligationDueAfterFifthYear" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="11230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="alxo_LesseeOperatingLeaseLiabilityToBePaidYearFourAndFive" order="11430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="11530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsParentheticalDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsParentheticalDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsParentheticalDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PurchaseObligation" xlink:type="locator" xlink:label="us-gaap_PurchaseObligation" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_RenewalPeriodsOfAgreement" xlink:type="locator" xlink:label="alxo_RenewalPeriodsOfAgreement" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_InitialTermOfAgreement" xlink:type="locator" xlink:label="alxo_InitialTermOfAgreement" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OperatingSubLeaseExpirationYear" xlink:type="locator" xlink:label="alxo_OperatingSubLeaseExpirationYear" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="alxo_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_SecondDrugProductManufacturerMember" xlink:type="locator" xlink:label="alxo_SecondDrugProductManufacturerMember" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_MasterServiceAgreementMember" xlink:type="locator" xlink:label="alxo_MasterServiceAgreementMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:href="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd#stpr_CA" xlink:type="locator" xlink:label="stpr_CA" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:type="locator" xlink:label="srt_SegmentGeographicalDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:type="locator" xlink:label="srt_StatementGeographicalAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OfficeAndLaboratorySpaceMember" xlink:type="locator" xlink:label="alxo_OfficeAndLaboratorySpaceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="alxo_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="alxo_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alxo_OfficeAndLaboratorySpaceMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesTable" xlink:to="srt_StatementGeographicalAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="stpr_CA" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="alxo_MasterServiceAgreementMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alxo_SecondDrugProductManufacturerMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesTable" xlink:to="alxo_CommitmentsAndContingenciesLineItems" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="alxo_OperatingSubLeaseExpirationYear" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="alxo_InitialTermOfAgreement" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="alxo_RenewalPeriodsOfAgreement" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PurchaseObligation" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:type="locator" xlink:label="us-gaap_OperatingLeaseExpense" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_LesseeOperatingLeaseCommencingEndDate" xlink:type="locator" xlink:label="alxo_LesseeOperatingLeaseCommencingEndDate" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="alxo_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_OfficeSpaceMember" xlink:type="locator" xlink:label="alxo_OfficeSpaceMember" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:href="alxo-20201231.xsd#alxo_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="alxo_CommitmentsAndContingenciesTable" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="alxo_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="alxo_OfficeSpaceMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesTable" xlink:to="alxo_CommitmentsAndContingenciesLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="alxo_LesseeOperatingLeaseCommencingEndDate" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="alxo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSELECTEDQUARTERLYFINANCIALDATAUNAUDITEDAdditionalInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureSELECTEDQUARTERLYFINANCIALDATAUNAUDITEDAdditionalInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSELECTEDQUARTERLYFINANCIALDATAUNAUDITEDAdditionalInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:roleRef roleURI="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSELECTEDQUARTERLYFINANCIALDATAUNAUDITEDScheduleOfCertainUnauditedQuarterlyConsolidatedFinancialInformationDetails" xlink:href="alxo-20201231.xsd#Role_DisclosureSELECTEDQUARTERLYFINANCIALDATAUNAUDITEDScheduleOfCertainUnauditedQuarterlyConsolidatedFinancialInformationDetails" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSELECTEDQUARTERLYFINANCIALDATAUNAUDITEDScheduleOfCertainUnauditedQuarterlyConsolidatedFinancialInformationDetails">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_OperatingExpenses" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630019822888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ALX ONCOLOGY HOLDINGS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001810182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39386<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-0642577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">866 Malcolm Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Burlingame<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">466-7125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,127,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ALXO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain portions of the registrant's definitive proxy statement relating to the Company's 2021 Annual Meeting of Stockholders, to be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2020, are incorporated by reference into Part III of this Annual Report on Form 10-K where indicated.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630019838616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 434,219<span></span>
</td>
<td class="nump">$ 9,017<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Receivables due from related-party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,773<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">435,992<span></span>
</td>
<td class="nump">9,809<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">436,054<span></span>
</td>
<td class="nump">10,676<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">3,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">6,200<span></span>
</td>
<td class="nump">1,236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,204<span></span>
</td>
<td class="nump">4,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Term loan - non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">6,209<span></span>
</td>
<td class="nump">10,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 100,000,000 shares authorized, no shares issued or outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 1,000,000,000 and 1,519,618,271 shares authorized as of December 31, 2020 and 2019, respectively; 39,844,522 and 3,166,946 shares issued and outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">548,327<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(118,522)<span></span>
</td>
<td class="num">(72,782)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">429,845<span></span>
</td>
<td class="num">(70,639)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 436,054<span></span>
</td>
<td class="nump">10,676<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,933<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,430<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alxo_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630022883400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,567,003<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,519,618,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">39,844,522<span></span>
</td>
<td class="nump">3,166,946<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">39,844,522<span></span>
</td>
<td class="nump">3,166,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,421,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,297,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,297,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Convertible preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,145,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,016,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,016,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alxo_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630022833176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Related-party revenue</a></td>
<td class="nump">$ 1,182<span></span>
</td>
<td class="nump">$ 4,796<span></span>
</td>
<td class="nump">$ 2,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfRevenueExtensibleList', window );">Type of Revenue [Extensible List]</a></td>
<td class="text">alxo:RelatedPartyMember<span></span>
</td>
<td class="text">alxo:RelatedPartyMember<span></span>
</td>
<td class="text">alxo:RelatedPartyMember<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 28,961<span></span>
</td>
<td class="nump">$ 16,306<span></span>
</td>
<td class="nump">$ 11,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">14,809<span></span>
</td>
<td class="nump">3,313<span></span>
</td>
<td class="nump">2,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Cost of services for related-party revenue</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">4,360<span></span>
</td>
<td class="nump">1,880<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">44,845<span></span>
</td>
<td class="nump">23,979<span></span>
</td>
<td class="nump">15,751<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(43,663)<span></span>
</td>
<td class="num">(19,183)<span></span>
</td>
<td class="num">(13,684)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense</a></td>
<td class="num">(811)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expense, net</a></td>
<td class="num">(404)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early debt extinguishment</a></td>
<td class="num">(621)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(45,499)<span></span>
</td>
<td class="num">(19,209)<span></span>
</td>
<td class="num">(13,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(241)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">(45,740)<span></span>
</td>
<td class="num">(19,243)<span></span>
</td>
<td class="num">(13,731)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Cumulative dividends allocated to preferred stockholders</a></td>
<td class="num">(5,202)<span></span>
</td>
<td class="num">(4,028)<span></span>
</td>
<td class="num">(3,671)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (50,942)<span></span>
</td>
<td class="num">$ (23,271)<span></span>
</td>
<td class="num">$ (17,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (2.76)<span></span>
</td>
<td class="num">$ (7.56)<span></span>
</td>
<td class="num">$ (6.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares of common stock used to compute net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="nump">18,485,343<span></span>
</td>
<td class="nump">3,076,461<span></span>
</td>
<td class="nump">2,750,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfRevenueExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates type of revenue from product and service. Includes, but is not limited to, revenue from contract with customer and other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfRevenueExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630016782696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="num">$ (38,415)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 1,390<span></span>
</td>
<td class="num">$ (39,808)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,297,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,205,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43,689)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Repurchase of unvested early exercised stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,731)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="num">(51,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
<td class="num">(53,539)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,297,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, balance at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,161,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,243)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,243)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="num">(70,639)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
<td class="num">(72,782)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Temporary equity, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,313,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Temporary equity, balance at Dec. 31, 2019</a></td>
<td class="nump">70,363<span></span>
</td>
<td class="nump">$ 70,363<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,166,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues', window );">Issuance of convertible preferred stock, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,055,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Reclassification of warrants from liability to equity</a></td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock in to common stock</a></td>
<td class="nump">175,043<span></span>
</td>
<td class="num">$ (175,043)<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">175,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock into common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,369,774)<span></span>
</td>
<td class="nump">21,369,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Cumulative dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsShares', window );">Cumulative dividends, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,564,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in connection with equity offerings, net of underwriter discounts and issuance costs</a></td>
<td class="nump">364,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">364,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with equity offerings, net of underwriter discounts and issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,512,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_StockIssuedDuringPeriodSharesWarrantExercise', window );">Issuance of common stock upon net exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,740)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 429,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 548,327<span></span>
</td>
<td class="num">$ (118,522)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,844,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_StockIssuedDuringPeriodSharesWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares warrant exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_StockIssuedDuringPeriodSharesWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value vesting of early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, stock issued during period, share, new issues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_TemporaryEquityStockIssuedDuringPeriodShareNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued as dividends during the period. Excludes stock splits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL109261756-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630023859768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (45,740)<span></span>
</td>
<td class="num">$ (19,243)<span></span>
</td>
<td class="num">$ (13,731)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">202<span></span>
</td>
<td class="nump">429<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">5,436<span></span>
</td>
<td class="nump">297<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of term loan discount and issuance costs</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants', window );">Changes in fair value of compound derivative liability and warrants</a></td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_GainOnAssignmentOfLease', window );">Gain on assignment of lease</a></td>
<td class="num">(126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early debt extinguishment</a></td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent', window );">Receivables due from related-party</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="num">(932)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,514)<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_IncreaseDecreaseInOtherAssets', window );">Other assets</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,744)<span></span>
</td>
<td class="nump">2,976<span></span>
</td>
<td class="num">(269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">4,983<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(38,289)<span></span>
</td>
<td class="num">(14,249)<span></span>
</td>
<td class="num">(13,190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(353)<span></span>
</td>
<td class="num">(653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale', window );">Proceeds from assets held for sale</a></td>
<td class="nump">641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">610<span></span>
</td>
<td class="num">(353)<span></span>
</td>
<td class="num">(653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offerings, net</a></td>
<td class="nump">368,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of offering costs</a></td>
<td class="num">(3,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of common stock under equity incentive plans</a></td>
<td class="nump">299<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of convertible preferred stock, net</a></td>
<td class="nump">104,680<span></span>
</td>
<td class="nump">9,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Cash paid for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuance of term loan, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtExtinguishmentCosts', window );">Cash paid for early debt extinguishment</a></td>
<td class="nump">6,506<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">462,881<span></span>
</td>
<td class="nump">15,357<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">425,202<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="num">(13,842)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">9,017<span></span>
</td>
<td class="nump">8,262<span></span>
</td>
<td class="nump">22,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">434,219<span></span>
</td>
<td class="nump">9,017<span></span>
</td>
<td class="nump">8,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_VestingOfEarlyExercisedStockOptions', window );">Vesting of early exercised stock options</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Acquisition of property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable', window );">Debt issuance costs in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of convertible preferred stock into common stock upon closing of initial public offering</a></td>
<td class="nump">175,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock', window );">Accumulated dividend on convertible preferred stock</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Changes in fair value of compound derivative liability and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ChangesInFairValueOfCompoundDerivativeLiabilityAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_GainOnAssignmentOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on assignment of lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_GainOnAssignmentOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_IncreaseDecreaseInOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Other Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_IncreaseDecreaseInOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non cash accumulated dividend on convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_NonCashAccumulatedDividendOnConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Debt Issuance Costs in Accounts Payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_NoncashOrPartNoncashDebtIssuanceCostsInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_VestingOfEarlyExercisedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Vesting of early exercised stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_VestingOfEarlyExercisedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate increase (decrease) during the reporting period in the amount due from the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtExtinguishmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtExtinguishmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630022101032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1) ORGANIZATION</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Organization</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALX Oncology Holdings Inc., or the Company, was formed as a Delaware corporation on April&#160;1, 2020, or Inception. The Company was formed for the purpose of completing the Company&#8217;s initial public offering of its common stock and related transactions in order to carry on the business of ALX Oncology Limited. After Inception, ALX Oncology Limited became a wholly-owned subsidiary of the Company as a result of the internal reorganization. As part of the internal reorganization, all of the equity, option and warrant holders of ALX Oncology Limited became equity, option and warrant holders of the Company, holding the same number of corresponding shares, options and/or warrants in the Company as they did in ALX Oncology Limited immediately prior to the internal reorganization. The information included herein is presented as that of ALX Oncology Holdings Inc. unless such information refers to a date prior to April 1, 2020, in which case it will reflect that of ALX Oncology Limited, the predecessor company. The Company is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company owns subsidiaries, consisting of ALX Oncology Limited, incorporated in Ireland; ALX Oncology Inc., incorporated in the United States, Alexo International Holdings Ltd, incorporated in Malta; Alexo Therapeutics International, incorporated in the Cayman Islands, which is a wholly-owned subsidiary of Alexo International Holdings Ltd., and Sirpant Therapeutics, incorporated in the Cayman Islands, which is a wholly-owned subsidiary of Alexo Therapeutics International, or collectively, the Subsidiaries.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of&#160;December 31, 2020, the Company has devoted substantially all of its efforts to the formation and financing of the Company, as well as product development, and has not realized product revenues from its planned principal operations. The Company has no manufacturing facilities and all manufacturing related activities are contracted out to third-party service providers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management expects to incur additional losses in the future to conduct product candidate research and development and to conduct pre-commercialization activities and recognizes that the Company will likely raise additional capital to fully implement its business plan. The Company intends to raise such capital through the sale of additional equity, debt financings or strategic alliances with third parties. However, there can be no assurance that the Company will be successful in acquiring additional funding at levels sufficient to fund its operations or on terms acceptable to the Company. If the Company is unsuccessful in its efforts to raise additional financing, the Company could be required to significantly reduce operating expenses and delay, reduce the scope of or eliminate some of its development programs or its future commercialization efforts, out-license intellectual property rights to its product candidates and sell unsecured assets, or a combination of the above, any of which may have a material adverse effect on the Company&#8217;s business, results of operations, financial condition and/or its ability to fund its scheduled obligations on a timely basis or at all. <font style="Background-color:#FFFFFF;color:#000000;">The Company believes that the existing capital resources will be sufficient to fund the projected operating requirements for at least the next twelve months.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630102209416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2) SIGNIFICANT ACCOUNTING POLICIES</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Preparation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, and the applicable rules and regulations of the U.S. Securities and Exchange Commission, or SEC.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, the Company&#8217;s board of directors approved an amendment to the Company&#8217;s certificate of incorporation to effect a 1-for-6.5806 reverse split of its common stock and convertible preferred stock. The par values of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All authorized, issued and outstanding common stock, convertible preferred stock, stock options, warrants, and related per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. The reverse stock split was effected on July 9, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, Series B convertible preferred stock warrant liability, term loan compound derivative liability, term loan, valuation of the Company&#8217;s common stock, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company holds its cash and cash equivalents in checking and money market accounts. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and are stated at fair value.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Credit Losses and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits, and invests in money market funds. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents. The Company has not experienced any losses on its deposits of cash and cash equivalents. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s potential product candidates, uncertainty of market acceptance of the Company&#8217;s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives of the assets. Upon sale or retirement of assets, the cost and related accumulated depreciation or amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations and comprehensive loss. Maintenance and repairs are charged to the consolidated statement of operations and comprehensive loss as incurred.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Offering Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in capital generated as a result of the equity financing. &#160;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the asset or asset group are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds its fair value. Fair value is determined using various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. The Company has not recorded impairment of any long-lived assets. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the consolidated financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Where observable prices or inputs are not available valuation models are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments&#8217; complexity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of cash and cash equivalents, receivables due from related-party, accounts payable, the term loan compound derivative liability and the Series B convertible preferred stock warrant liability. The term loan compound derivative liability and the Series B convertible preferred stock warrant liability are re-measured at the end of every period and carried at fair value (Note 3). The recorded value of the Company&#8217;s receivables due from related-party and accounts payable approximates its current fair value due to the relatively short-term nature of these items.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Term Loan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for the Loan and Security Agreement, dated as of December 20, 2019, as amended, with Silicon Valley Bank, or SVB, and WestRiver Innovation Lending Fund VIII, LP, or WestRiver, collectively as lenders, and SVB, as administrative agent and collateral agent, as a liability measured at net proceeds less debt discount and is accreted to the face value of the term loan over its expected term using the effective interest method. The Company considers whether there are any embedded features in its debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to Accounting Standards Codification, or ASC, Topic 815, <font style="font-style:italic;">Derivatives and Hedging</font>.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records convertible preferred stock net of issuance costs on the dates of issuance, which represents the carrying value. In the event of a change of control of the Company, proceeds will be distributed in accordance with the liquidation preferences set forth in its organization documents unless the holders of convertible preferred stock have converted their convertible preferred stock into common stock. Convertible preferred stock is classified outside of stockholders&#8217; equity (deficit) on the accompanying consolidated balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. The Company has elected not to adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because of the uncertainty of whether or when such an event would occur. Upon the consummation of the Company&#8217;s initial public offering in July 2020, all shares of convertible preferred stock outstanding and accrued cumulative dividends automatically converted into&#160;23,934,533&#160;shares of common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Series B Convertible Preferred Stock Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has issued freestanding warrants to purchase its Series B convertible preferred stock. Freestanding warrants for the Company&#8217;s convertible preferred stock that are classified outside of permanent equity are recorded at fair value, and are subject to re-measurement at the end of every period until the earlier of the exercise of the warrants or the completion of a liquidation event, including the completion of an initial public offering. Upon exercise, the Series B convertible preferred stock warrant liability would be reclassified to additional paid-in capital, with any change in fair value recognized as a component of other expense, net. Following the Company&#8217;s initial public offering, the warrants were automatically converted to warrants to purchase shares of common stock (Note 5). The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance to additional paid-in capital with no further re-measurement required as common stock warrants are considered permanent equity. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the Company has derived revenue from providing research and development services on a time and materials basis to a related-party.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes such revenues over time as services are delivered, and invoices the customer as the work is incurred in arrears.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (Topic 606), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the Company&#8217;s consideration as to whether the Company has entered into a contract with a customer, it considers whether it is probable that it will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Services for Related-Party Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurs costs associated with related-party services including direct labor and associated employee benefits, laboratory supplies, and other expenses. These costs are recorded in cost of services for related-party revenue as a component of total operating expenses in the accompanying consolidated statements of operations and comprehensive loss.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and consist primarily of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to nonemployees and entities that conduct certain research and development activities on behalf of the Company and expenses incurred in connection with license agreements (Note 9). Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and recorded in prepaid expenses and other current assets, and then expensed as the related goods are delivered or the services are performed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical and Manufacturing Accruals</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records accruals for estimated costs of research, preclinical studies and clinical trials, and manufacturing development, which are a significant component of research and development expenses. A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including contract research organizations, or CROs, and contract manufacturing organizations, or CMOs. The Company&#8217;s contracts with CROs generally include pass-through fees such as regulatory expenses, investigator fees, travel costs and other miscellaneous costs, including shipping and printing fees. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company accrues the costs incurred under agreements with these third parties based on estimates of actual work completed in accordance with the respective agreements. The Company determines the estimated costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fees to be paid for such services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company makes significant judgments and estimates in determining the accrual balance at the end of each reporting period. As actual costs become known, the Company adjusts its accruals. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in the Company reporting amounts that are too high or too low in any particular period. To assist in its estimates the Company relies upon the receipt of timely and accurate reporting from its clinical and non-clinical studies and other third-party vendors. Through December 31, 2020, there have been no material differences from the Company&#8217;s accrued estimated expenses to the actual clinical trial expenses. However, variations in the assumptions used to estimate accruals, including, but not limited to, the number of patients enrolled, the rate of patient enrollment, and the actual services performed, and related costs may vary from the Company&#8217;s estimates, resulting in adjustments to clinical trial expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect its financial position and results of operations.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-based Compensation Expense </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all stock-based payments made to employees, directors and non-employees based on estimated grant-date fair values. The Company uses the straight-line method to allocate compensation expense to reporting periods over each optionee&#8217;s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards using the Black-Scholes option-pricing model. The Black-Scholes model requires the input of subjective assumptions, including expected volatility, expected dividend yield, expected term, risk-free rate of return and the estimated fair value of the underlying common stock on the date of grant. Prior to the Company&#8217;s initial public offering, the fair value of the common stock underlying the stock-based awards was determined on each grant date by the board of directors, with input from management, considering the most recently available third-party valuation of common shares. The Company accounts for the effect of forfeitures as they occur. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Currency Transactions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of the Company&#8217;s operation and each of its subsidiaries is U.S. dollars. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate prevailing on the balance sheet date. Expenses are translated at the average exchange rates prevailing during the applicable period. Foreign currency transaction gains and losses are included in the consolidated statement of operations and comprehensive loss and recorded in other expense, net, and were immaterial for the years December 31, 2020, 2019 and 2018.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for the period in which the temporary differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is equal to net loss for all periods presented.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share Attributable to Common Stockholders</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method to compute basic and diluted net loss per share when it has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires net loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all net loss for the period had been distributed. The Company&#8217;s convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), <font style="font-style:italic;">Leases</font> (ASU 2016-02). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU No. 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. In June 2020, the FASB issued ASU No. 2020-05, which extends the effective date of ASU No. 2016-02 for non-public business entities, including smaller reporting companies, to fiscal years beginning after December 15, 2021. The new standard is effective for the Company beginning January 1, 2022 (or earlier if the Company ceases to be an emerging growth company). Early adoption is permitted. The Company is currently evaluating the effects of the adoption of this guidance on its consolidated financial statements and related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2021. ASU 2019-12 is effective for the Company beginning January 1, 2022. Early adoption is permitted. The Company is currently in the process of evaluating the effects of the adoption of this guidance on the Company&#8217;s financial statements and does not expect it to have a material impact on its consolidated financial statements.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Accounting Pronouncements Recently Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. The Company early adopted this guidance on January 1, 2020. <font style="Background-color:#FFFFFF;color:#000000;">For trade receivables and other instruments, the Company uses a new forward-looking </font><font style="color:#000000;">expected loss model that generally results in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses are recognized as allowances rather than as reductions in the amortized cost of the securities. </font><font style="Background-color:#FFFFFF;color:#000000;">The adoption of the guidance did not have a material impact on the Consolidated Financial Statements and related disclosures and there was&#160;no&#160;allowance for losses for the year ended December 31, 2020.</font> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement. The FASB issued final guidance that eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. Under the ASU, entities will no longer be required to disclose the amount of transfers between Level 1 and Level 2 of the fair value hierarchy. Public companies will be required to disclose changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. ASU 2018-13 is effective for public business entities for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2019, with early adoption permitted. The Company adopted this guidance on January 1, 2020. The adoption of ASU 2018-13 did not have a material impact on its consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630021703448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE OF FINANCIAL INSTRUMENTS</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(3) FAIR VALUE OF FINANCIAL INSTRUMENTS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of the Company&#8217;s financial assets and liabilities are determined in accordance with the fair value hierarchy established in ASC Topic 820, Fair Value Measurements and Disclosures. ASC Topic 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy of ASC Topic 820 requires an entity to maximize the use of observable inputs when measuring fair value and classifies those inputs into three levels:</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1&#8212;Observable inputs, such as quoted prices in active markets;</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2&#8212;Inputs, other than the quoted prices in active markets, which are observable either directly or indirectly such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the instrument&#8217;s anticipated life; and</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3&#8212;Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of cash and cash equivalents, receivables due from related-party, accounts payable, the term loan compound derivative liability and the Series B convertible preferred stock warrant liability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents are reported at their respective fair values on the Company&#8217;s consolidated balance sheets. Where quoted prices are available in an active market, securities are classified as Level 1. The Company classifies money market funds as Level 1. When quoted market prices are not available for the specific security, then the Company estimates fair value by using quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be corroborated by observable market data for substantially the full term of the assets. Where applicable, these models project future cash flows and discount the future amounts to a present value using market-based observable inputs obtained from various third-party data providers, including but not limited to benchmark yields, reported trades and broker/dealer quotes. Where applicable the market approach utilizes prices and information from market transactions for similar or identical assets.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures its Series B convertible preferred stock warrant liability and term loan compound derivative liability at fair value on a recurring basis and these are classified as Level 3 liabilities. The fair value of the Series B convertible preferred stock warrant liability was determined using an option-pricing model. The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance to additional paid-in capital with no further re-measurement required as the common stock warrants are considered permanent equity effective with the completion of the initial public offering. The Company calculated the fair value of the term loan compound derivative liability by computing the difference between the fair value of the term loan with the compound derivative using the &#8220;with and without&#8221; method under the income approach, and the fair value of the term loan without the compound derivative. The valuation methodology and underlying assumptions are discussed further in Note 5. The compound derivative liability was extinguished upon the extinguishment of the host instrument in December 2020 (Note 5).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Cash equivalents</font></p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424,115</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424,115</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Non-current liabilities</font></p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compound derivative liability</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-right:2.56%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table is a reconciliation of all financial liabilities measured at fair value using Level 3 unobservable inputs (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compound</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrant</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at beginning of year</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">658</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification to equity</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of compound derivative liability upon extinguishment of host instrument</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at end of year</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no transfers of assets or liabilities between the fair value measurement levels during the years ended December 31, 2020 and 2019.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of the Company&#8217;s financial instruments, such as accounts payable and accrued expenses and other current liabilities, approximate fair value due to the short-term nature of these items.&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630026360824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">BALANCE SHEET COMPONENTS</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(4) BALANCE SHEET COMPONENTS</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment, Net</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the components of property and equipment, net as of December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware and software</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,698</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,309</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,449</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense was $0.2 million, $0.4 million and $0.4 million for years ended December 31, 2020, 2019 and 2018, respectively. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At June 30, 2020, certain lab equipment and other assets for an aggregated net book value of $0.6 million relating to the asset transfer with Tallac Therapeutics, Inc. (formerly known as Tollnine, Inc., or Tollnine), or Tallac Therapeutics, a related-party (Note 10), met the criteria as assets held for sale. Those assets were reported at the lower of carrying value or fair value less costs to sell. In July 2020, the Company received $0.6 million cash in exchange for the transfer of such assets. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Accrued Expenses and Other Current Liabilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the components of accrued expenses and other current liabilities as of December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,974</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">924</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical and nonclinical study costs</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,473</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued contract manufacturing</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,123</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued federal income tax</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,200</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,236</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630102256024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">TERM LOAN</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(5) TERM LOAN</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s wholly-owned subsidiaries Alexo Therapeutics International and Sirpant Therapeutics, as borrowers, entered into a Loan and Security Agreement, or the Loan Agreement, dated as of December 20, 2019, with SVB and WestRiver, collectively as lenders, and SVB, as administrative agent and collateral agent. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As a result of the internal reorganization, in May 2020 the Company entered into a Joinder and First Amendment to the Loan and Security Agreement, or the Joinder Amendment, and Amended and Restated Warrants to Purchase Stock, or the Amended Warrants. The purpose for entering into the Joinder Amendment was to add the newly established ALX Oncology Holdings Inc. as additional borrower to the Term Loan. Concurrently, the Company modified the Amended Warrants to change the issuer from ALX Oncology Limited to ALX Oncology Holdings Inc. The Company accounted for the First Amendment to the Loan and Security Agreement as a modification.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Loan Agreement provided for term loans in an aggregate principal amount of up to $10.0 million funded in two tranches, subject to the satisfaction of a certain milestone. The first tranche, in the amount of $6.0 million, was funded on the closing date of the Loan Agreement in December 2019. A second tranche of $4.0 million was available on or before March 31, 2020, upon the Company&#8217;s achievement of an equity financing resulting in net cash proceeds in an amount of at least $30.0 million to the Company. The Company elected not to draw down on the second tranche, which is no longer available.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loans under the Loan Agreement bore interest at a floating per annum interest rate equal to the greater of 7.0% or 2.0% plus the prime rate as reported in The Wall Street Journal.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company was required to make interest-only payments for the first 12 months after the closing of the Loan Agreement, followed by consecutive equal monthly payments of principal and interest commencing on January 1, 2021 and continuing through the maturity date of September 1, 2022. The Loan Agreement also provided for a final payment equal to 6.0% multiplied by the aggregate principal amount of the term loans funded, which was due on the maturity date, upon the acceleration of the term loans, or upon prepayment of the term loans. If the Company elected to prepay the term loans, there was also a prepayment fee of between 1.0% and 3.0% of the principal amount being prepaid depending on the timing and circumstances of prepayment.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In conjunction with the Loan Agreement, the Company issued warrants to purchase 61,292 Series B convertible preferred stock to SVB and WestRiver with an exercise price of $9.4972 per share. Following the Company&#8217;s initial public offering, these warrants were automatically converted to warrants to purchase 61,292 shares of common stock at an exercise price of $9.4972 per share. The estimated fair value of the warrants at the date of issuance was approximately $0.4 million. The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance of $1.0 million to additional paid-in capital with no further re-measurement required as the common stock warrants are considered permanent equity effective July 16, 2020. The fair value of the common stock warrant was determined using a Black-Scholes option-pricing model with the following assumptions: an expected term of 9.8 years, a volatility of 84.2%, a dividend rate of zero and a risk-free rate of 0.6%. The changes in fair value in warrant liability were recognized as a component of other expense, net in the accompanying consolidated statement of operations and comprehensive loss. On August 17, 2020, SVB and WestRiver delivered the Notice of Exercise for net exercise of 61,292 warrants at an exercise price of $9.4972 per share. Accordingly, the Company issued 48,932 shares of the Company&#8217;s common stock (Note 6). </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loans under the Loan Agreement were secured by substantially all of the Company&#8217;s assets, except the Company&#8217;s intellectual property, which is the subject of a negative pledge.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that certain loan features were embedded derivatives requiring bifurcation and separate accounting. Those embedded derivatives were bundled together as a single, compound embedded derivative and then bifurcated and accounted for separately from the host contract. The Company recorded a term loan compound derivative liability of approximately $51,000 which was marked-to-market until the extinguishment of the host instrument. The Company calculated the fair value of the compound derivative by computing the difference between the fair value of the term loan with the compound derivative using the &#8220;with and without&#8221; method under the income approach, and the fair value of the term loan without the compound derivative. The Company calculated the fair values using a probability-weighted discounted cash flow analysis. The key valuation assumptions used consist of the discount rate and the probability of the occurrence of a change in control event. The term loan compound derivative liability was re-measured at each financial reporting period with any changes in fair value being recognized as a component of other expense, net in the consolidated statement of operations and comprehensive loss. The compound derivative liability was extinguished upon the extinguishment of the host instrument in December 2020.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of Series B convertible preferred stock warrant liability at issuance, fair value of embedded derivatives, which were bifurcated and other debt issuance costs were treated as debt discounts on the Company&#8217;s consolidated balance sheet and together with the final payment were amortized to interest expense throughout the life of the term loan using the effective interest rate method.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2020, the Company used approximately $6.5 million of the net proceeds from the Company&#8217;s follow-on public offering to repay the outstanding principal amount of $6.0 million and early extinguish the outstanding Term Loan with SVB and WestRiver. As a result, the Company recognized a $0.6 million loss on early debt extinguishment, representing the difference between the&#160;reacquisition&#160;price of debt and the net carrying amount of the loan as of the date of the payoff. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630027559528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(6) STOCKHOLDERS&#8217; EQUITY <font style="font-style:italic;"> </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On&#160;July 21, 2020, the Company&#8217;s amended and restated certificate of incorporation became effective, authorizing 1,000,000,000&#160;shares of common stock and&#160;100,000,000&#160;shares of undesignated preferred stock. As of&#160;December 31, 2020&#160;and&#160;2019, the Company had&#160;39,844,522&#160;and&#160;3,166,946&#160;shares of common stock outstanding, respectively. As of&#160;December 31, 2020&#160;and&#160;2019, the Company had zero and 10,313,808 shares of preferred stock outstanding, respectively.</p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Common Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In&#160;July&#160;2020, the Company consummated its initial public offering and issued&#160;9,775,000&#160;shares of common stock for net proceeds of approximately&#160;$169.5 million, after deducting underwriting discounts and commissions of $13.0 million and offering-related expenses of $3.2 million. Upon the closing of the initial public offering, all shares of convertible preferred stock outstanding and accrued cumulative dividends were automatically converted into 23,934,533 shares of common stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In&#160;December&#160;2020, the Company consummated its follow-on public offering and issued&#160;2,737,000&#160;shares of common stock for net proceeds of approximately&#160;$194.9 million, after deducting underwriting discounts and commissions of $12.5 million and offering-related expenses of $0.7 million. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance, on an as if converted basis, as of December 31, 2020 and 2019, consists of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock issued and outstanding</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313,808</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857,308</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,745</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options authorized for future issuance</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,835,443</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants issued and outstanding</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,292</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants authorized for future issuance</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,646</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,692,751</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,156,391</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, the Company&#8217;s convertible preferred stock consisted of the following (in thousands, except share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued And</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Proceeds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preference</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Shares designated as:</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,421,633</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,297,081</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,933</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,571</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series&#160;B convertible preferred stock</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145,370</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,016,727</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,430</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,567,003</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313,808</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,363</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,585</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net proceeds are gross proceeds from the offerings net of issuance costs</p></td></tr></table></div></div>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:9pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Series C Convertible Preferred Stock Issuance</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:4pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2020, the Company entered into a Series C Preferred Stock Purchase Agreement, or the Series C Agreement, with certain existing investors, employees and new investors, or collectively, the Series C Investors. Under the terms of the Series C Agreement, the Company authorized the sale and issuance of up to 11,055,981 Series C convertible preferred stock at a purchase price of $9.4972 per share. All authorized Series C convertible preferred stock have been purchased with gross proceeds of $105.0&#160;million.&nbsp;&nbsp;The Series C convertible preferred stock and related accumulated dividends automatically converted into shares of the Company&#8217;s common stock upon the consummation of the Company&#8217;s initial public offering.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Preferred Stock Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 21, 2020, the warrants to purchase 61,292 Series B convertible preferred stock issued to SVB and WestRiver with an exercise price of $9.4972 per share were automatically converted to warrants to purchase 61,292 shares of common stock at an exercise price of $9.4972 per share. The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance to additional paid-in capital with no further re-measurement required as the common stock warrants are considered permanent equity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 17, 2020, SVB and WestRiver delivered the Notice of Exercise to net exercise 61,292 warrants at an exercise price of $9.4972 per share. Accordingly, the Company issued&#160;48,932&#160;shares of the Company&#8217;s common stock. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to the Company&#8217;s initial public offering, cumulative dividends of 6.0% per annum of the original issue price for each convertible preferred stock series were payable when and as declared by the Company&#8217;s Board of Directors, or Board of Directors, upon the occurrence of a liquidation event or upon a contingent mandatory conversion of the convertible preferred stock in connection with a qualified initial public offering as described below. The Series A original issue price was $6.58, and the Series B and Series C original issue price was $9.4972. The original issue price was subject to adjustment in the event of any share dividend, share split, combination, consolidation or other recapitalization. The dividends accrued from day to day from the issue date of such preferred stock whether or not declared and were cumulative. In addition, the preferred stockholders participated on an as-converted basis in any dividends payable to common stockholders. As of July 20, 2020, there were approximately $18.0 million of accrued cumulative dividends on the Series A, Series B and Series C convertible preferred stock, which became payable upon the consummation of the Company&#8217;s initial public offering and automatically converted into 2,564,759 shares of the Company&#8217;s common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630026438840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(7) STOCK-BASED COMPENSATION </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Equity Incentive Plans</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2015 Share Award Scheme</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2015, the Company adopted an equity compensation plan, the 2015 Share Award Scheme, or the 2015 Share Award Scheme, for eligible employees, officers, directors, advisors, and consultants. The 2015 Share Award Scheme provided for the grant of incentive and non-statutory share options. The 2015 Share Award Scheme permitted the Company to grant up to 2,143,117 common stock awards, including incentive share options, non-statutory share options, conditional share awards and restricted share awards.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2020 Equity Incentive Plan</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On April 1, 2020, the Board of Directors approved a new equity incentive plan, or the 2020 Equity Incentive Plan, that replaced the 2015 Share Award Scheme. The 2020 Equity Incentive Plan is for employees, non-employee directors and consultants covering 4,379,139 shares of the Company&#8217;s common stock and authorizes the award of stock options, restricted stock awards, stock appreciation rights and restricted stock units.</p>
<p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">2020 Amended and Restated Equity Incentive Plan</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company adopted the Amended and Restated 2020 Equity Incentive Plan, or the 2020 Plan. The 2020 Plan replaced the Company&#8217;s 2020 Equity Incentive Plan and&#160;a total of 7,874,862&#160;shares were reserved under the 2020 Plan.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The terms of the stock option agreements, including vesting requirements, are determined by the Board of Directors, subject to the provisions of the 2020 Plan. The term of the options generally expire, upon the earliest of (i) termination of continuous service for cause (ii) three months after the termination of continuous service for reasons other than cause, death or disability (iii) twelve months after the termination of continuous service due to disability (iv) eighteen months after the employee&#8217;s death if the employee died during the period of continuous service (v) expiration date in the grant notice or (vi) the day before the tenth anniversary of the date of grant. The exercise price of the incentive share options must equal at least the fair market value of the share on the date of grant.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All awards that are canceled, forfeited or expired are returned to the 2020 Plan and are available for grant in conjunction with the issuance of new awards. Share options granted are exercisable over a maximum term of 10 years from the date of grant and generally vest over an agreed service period, usually four years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain share options granted under the 2020 Plan provide option holders the right to elect to exercise unvested options in exchange for common stock. Such unvested common stock is subject to a repurchase right held by the Company at the original issuance price in the event the optionee&#8217;s service to the Company is terminated either voluntarily or involuntarily. The right lapses as the underlying repurchase right expires. These repurchase terms are considered to be a forfeiture provision. The cash received from employees for exercise of unvested options is treated as a refundable deposit and is classified as a liability on the consolidated balance sheets. At December 31, 2020 and 2019, there were unvested early exercised options of 63 and 34,024, respectively, and the liability related to these unvested options was approximately $0 and $27,000, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Option Modification</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the transfer of employees to Tallac Therapeutics, Dr. Hong Wan, the Company&#8217;s former Chief Scientific Officer, and eight of the Company&#8217;s employees, or Transferred Employees, terminated their employment with the Company effective as of June 30, 2020 and became employees of Tallac Therapeutics effective as of July 1, 2020. The options to purchase shares of the Company&#8217;s common stock that were previously granted to the Transferred Employees will continue to vest and be exercisable subject to the Transferred Employees remaining service providers under the original terms of the award. The Company evaluated the change in status from an employee to a consultant in accordance with ASC 718. While the Company concluded that the change in status did not affect the vesting condition or the classification of the initial awards, the significant reduction in the level of services that the grantees were expected to provide under the original awards as compared to the level of services expected under the Tallac Services Agreement will no longer meet the substantive service condition requirements and therefore the compensation cost for the unvested awards was recognized immediately with no future service requirement. In September 2020, in connection with the resignation of the Company&#8217;s former Chief Business Officer and the entry into a consulting agreement with him, the Company evaluated the change in status from an employee to a consultant in accordance with ASC 718. While the Company concluded that the change in status did not affect the vesting condition or the classification of the initial awards, the significant reduction in the level of services that the grantee was expected to provide under the original awards as compared to the level of services expected under the consulting agreement will no longer meet the substantive service condition requirements and therefore the compensation expense for the unvested awards expected to vest during the consultancy was recognized immediately with no future service requirement. The Company recorded $1.7 million in stock-based compensation expenses related to the modifications for the year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Board of Directors and stockholders approved the ALX Oncology Holdings Inc. 2020 Employee Stock Purchase Plan, or the ESPP. The ESPP allows eligible employees to have up to&#160;15&#160;percent&#160;of their eligible compensation withheld and used to purchase common stock, subject to a maximum of&#160;$25,000&#160;worth of stock purchased in a calendar year or no more than&#160;3,000&#160;shares in an offering period, whichever is less. An offering period consists of a&#160;six-month purchase period, with a look back feature to our stock price at the commencement of the offering period. Eligible employees can purchase the Company&#8217;s common stock at the end of the offering period at&#160;85%&#160;of the lower of the closing price of our common stock on The Nasdaq Global Select Market on the first and last day of the offering periods.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The initial number of shares of common stock available for issuance under the ESPP, was&#160;400,000. Unless the Board of Directors provides otherwise, beginning on January 1, 2021, the maximum number of shares which shall be made available for sale under the ESPP will automatically increase on the first trading day in January of each calendar year during the term of the ESPP by an amount equal to the least of:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">800,000 shares; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one percent of the outstanding shares of our common stock on the last day of our immediately preceding fiscal year; or </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.42%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.27%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such number of shares as our board of directors may determine no later than the last day of our immediately preceding fiscal year.</p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2021, the Board of Directors approved the first offering period beginning February 1, 2021. As of&#160;December 31, 2020, there were&#160;no purchases under the ESPP.</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Option Activity</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a summary of share option activity under the Plan and related information:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available&#160;to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,745</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.06</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,124,217</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,857,655</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,857,655</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.92</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(182,111</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.65</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled/forfeited</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,981</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,981</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.99</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,835,443</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857,308</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.94</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.86</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375,270</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,776,399</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.85</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.65</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,999</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, there was unrecognized share-based compensation expense of $25.0 million, related to unvested share options which the Company expects to recognize over a weighted-average period of 3.2 years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate intrinsic values represent the total pre-tax intrinsic value, of options outstanding and exercisable calculated as the difference between the exercise price of the options and the fair value of the Company&#8217;s common stock as of December 31, 2020 and 2019. The total intrinsic value of options exercised during the years ended December 31, 2020, 2019 and 2018 were $4.4 million, immaterial and immaterial, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-based Compensation Expenses</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compensation cost for share options granted is based on the grant-date fair value estimated and is recognized over the vesting period of the applicable option on a straight-line basis. The weighted-average grant-date fair value per share for share options granted during the years ended December 31, 2020, 2019 and 2018 was $7.74, $1.27 and $1.14, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense includes share options granted to employees and nonemployees and has been reported in the Company&#8217;s consolidated statements of operations and comprehensive loss as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,551</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,885</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of services for related-party revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,436</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock Option Valuation Assumptions</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company uses the Black-Scholes option pricing model to determine the estimated fair value of stock options at the date of the grant, and stock-based compensation is adjusted for actual forfeitures as they occur. The fair value of each option grant during the years ended December 31, 2020, 2019 and 2018 was estimated with the<font style="letter-spacing:-0.4pt;"> </font>following assumptions:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="5" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 - 6.1</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4 - 6.0</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2 - 6.0</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3% - 0.8%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7% - 2.1%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6% - 3.0%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend rate</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected stock price volatility</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78.7% - 89.0%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.2% - 80.5%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.5% - 68.7%</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Expected Term. <font style="font-style:normal;">The expected term of the options represents the average period the share options are expected to remain outstanding. As the Company does not have sufficient historical information to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior, the expected term of options granted is derived from the average midpoint between the weighted average vesting and the contractual term, also known as the simplified method.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Risk-Free Interest Rate. <font style="font-style:normal;">The risk-free interest rate is based on the yield of U.S. Treasury notes as of the grant date with terms commensurate with the expected term of the option.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Dividend Yield. <font style="font-style:normal;">The expected dividends assumption is based on the Company&#8217;s expectation of not paying dividends in the foreseeable future.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Volatility. <font style="font-style:normal;">Since the Company does not have sufficient trading history for its common stock, the expected volatility is based on the historical volatilities of the common shares of comparable publicly traded companies. The Company selected companies with comparable characteristics, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the Company&#8217;s share-based awards.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Fair Value<font style="font-style:normal;">. Historically, for all periods prior to our initial public offering, the fair value of the shares of common stock underlying our stock option was determined by the Company&#8217;s board of directors. Because there was no public market for the Company&#8217;s common stock, the board of directors determined fair value of the common stock at the time of grant of the options by considering a number of objective and subjective factors including important developments in the Company&#8217;s operations, valuations performed by an independent third party, sales of convertible preferred stock, actual operating results and financial performance, the conditions in the biotechnology industry and the economy in general, the stock price performance and volatility of comparable public companies, and the lack of liquidity of the Company&#8217;s common stock, among other factors. Since the completion of our initial public offering, the fair value of each share of common stock underlying stock option grants is based on the closing price of our common stock on the Nasdaq Global Select Market as reported on the date of grant.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630100492456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(8) INCOME TAXES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. domestic and international components of pre-tax loss for the years ending December 31, 2020, 2019 and 2018 are as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,457</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">813</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">855</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,042</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,541</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,499</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,209</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,686</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal and state provision for income taxes consist of the following (in thousands):</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Current provision for income taxes:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax provision:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the effective tax for the years ended December 31, 2020, 2019 and 2018 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At federal statutory income tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,555</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,034</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,874</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,098</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,875</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(332</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; Development credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(512</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(861</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,710</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,733</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">732</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign rate differential</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,380</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,899</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior period true ups</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(950</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets as of December 31, 2020 and 2019 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,283</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,259</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; other credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,861</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,260</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">696</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,299</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,288</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,686</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Realization of deferred tax assets is dependent upon the Company generating future taxable income, the timing and amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by approximately $4.6 million and $4.5 million for the years ended December 31, 2020 and 2019, respectively.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses and tax credit carryforwards as of December 31, 2020 are as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration Years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, federal (Post December 31, 2017)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,919</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Do Not Expire</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, state</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,363</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2038-2040</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits, federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,327</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2039-2040</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits, state</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,893</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, foreign</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,086</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilization of the Company&#8217;s U.S. net operating loss and credit carryforwards may be subject to substantial annual limitation due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. Such annual limitation could result in the expiration of the U.S. net operating loss and credit carryforwards before utilization. To date, the Company has not performed an analysis to determine whether there would be a substantial annual limitation due to a change in ownership.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Unrecognized Tax Benefits</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s policy is to include interest and penalties related to unrecognized tax benefits, if any, within the provision for taxes in the consolidated statements of operations and comprehensive loss. If the Company is eventually able to recognize its uncertain tax positions, the Company&#8217;s effective tax rate would be reduced. The Company currently has a full valuation allowance against its net deferred tax asset which would impact the timing of the effective tax rate benefit should any of these uncertain tax positions be favorably settled in the future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The unrecognized tax benefits as of December 31, 2020, 2019 and 2018 were $0.8 million, $0.7 million and $0.4 million, respectively. Future changes in the unrecognized tax benefits will not impact the effective tax rate due to the Company's full valuation allowance.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will file income tax returns in the U.S. federal and California jurisdiction, is not currently under examination, and all years since inception are open to examination. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the following activity relating to unrecognized tax benefits (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:89.6%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">247</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions/reversals based on tax positions of prior years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to the current year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lapses in statutes of limitations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">842</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although it is reasonably possible that certain unrecognized tax benefits may increase or decrease within the next 12 months due to tax examination changes, settlement activities, expirations of statute of limitations or the impact on recognition and measurement considerations related to the results of published tax cases or other similar activities, the Company does not anticipate any significant changes to unrecognized tax benefits over the next 12 months. During the years ended December 31, 2020, 2019 and 2018, no interest or penalties were required to be recognized relating to unrecognized tax benefits.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630026430392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">LICENSE AGREEMENT</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(9) LICENSE AGREEMENT</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Exclusive (Equity) Agreement with The Board of Trustees of the Leland Stanford Junior University</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2015, the Company entered into a license agreement, or the Stanford Agreement, with the Board of Trustees of the Leland Stanford Junior University, or Stanford, under which the Company obtained a worldwide, royalty-bearing, sublicensable license under certain patents relating to the Company&#8217;s current product candidates, to develop, manufacture and commercialize products for use in certain licensed fields, the scope of which would include the application of the licensed intellectual property in oncology. The license granted to the Company in the Stanford Agreement includes an exclusive grant, subject to certain pre-existing non-exclusive or exclusive rights that Stanford retained for grant to third parties with respect to certain categories of the licensed patents in certain fields of use and retained rights by Stanford and all other nonprofit institutions to use and practice the licensed patents and technology for internal research and other nonprofit purposes. The license granted to the Company in the Stanford Agreement also includes non-exclusive grants to certain Stanford patents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the rights granted to the Company under the Stanford Agreement, the Company paid Stanford a nonrefundable license royalty and reimbursed Stanford for past patent expenses, together totaling less than $0.1 million, and granted Stanford a specified number of shares of common stock of the Company. In addition, the Company is obligated to pay Stanford ongoing patent expenses and an annual license maintenance fee, which are nominal and will be creditable against any royalties payable to Stanford in the applicable year. The Company is required to make milestone payments up to an aggregate of $5.0 million in respect of a specified number of licensed products that successfully satisfy certain clinical and regulatory milestones. No milestone payments have been made through December 31, 2020. The Company also agreed to pay Stanford tiered royalties on a specified percentage of net sales made by the Company, its affiliates and its sublicensees of licensed products at rates ranging within low single-digit percentages, subject to certain reductions and offsets. The license, on a licensed product-by-licensed product and country-by-country basis, shall become royalty-free and fully paid-up upon the later of the date on which the last valid claim included in the exclusively or non-exclusively licensed patents expires and ten years after the first commercial sale of the licensed product in such country.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may terminate the Stanford Agreement, on a licensed product-by-licensed product basis, at any time for any reason by providing at least 60 days&#8217; written notice to Stanford. Stanford may terminate the Stanford Agreement, if the Company is in breach of any provision of the Stanford Agreement and fails to remedy such breach within 60 days after written notice of such breach by Stanford. In addition, Stanford has the right to terminate the Stanford Agreement, on a licensed product-by-licensed product basis, if the Company is not diligently developing and commercializing such licensed product under certain conditions or if the Company fails to achieve specified development milestones for such licensed product by certain dates, subject to the Company&#8217;s extension rights.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Commercial License Agreement with Selexis SA</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the Company entered into a license agreement with Selexis SA, or Selexis, under which the Company obtained a worldwide, royalty-bearing, sublicensable license under certain patents, know-how and other intellectual property, to use Selexis generated cell lines to manufacture ALX148 and to make, use and sell licensed product containing such compound in all fields of use. The rights granted under this agreement include the rights to grant sublicenses to contractors or other collaboration partners, in each case to develop production processes or manufacture licensed product containing ALX148.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the rights granted to the Company under the agreement, the Company paid Selexis a nominal one-time fee and will pay Selexis an annual maintenance fee. The Company also agreed to pay Selexis milestone payments up to an aggregate of 1.2 million Swiss Francs in respect of all licensed products developed and/or commercialized under the grant that successfully satisfies certain milestone events. The Company also agreed to pay Selexis a flat royalty of a very low single-digit percentage on net sales made by the Company, its affiliates and sublicensees of products. This royalty obligation, on a product-by-product and country-by-country basis, shall terminate and become fully paid-up upon the passing of ten years after the first commercial sale of the product in such country, or the Company&#8217;s exercise of the royalty buyout option exercisable at any time prior to the first commercial sale of a licensed product.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may terminate the license agreement at any time for any reason with at least 60 days&#8217; written notice to Selexis. Either party may terminate the license agreement if the other party enters into a bankruptcy event or in the event of a material breach of the agreement (that cannot be cured or remains uncured for 60 days after the date that the defaulting party is provided with written notice of such breach). The Company&#8217;s obligations to pay royalties that are accrued or accruable will survive any termination of the agreement, and in certain circumstances the licenses granted under the agreement will terminate unless they have become fully paid up as described in the previous paragraph.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Commercial Antibody Agreement with Crystal Bioscience Inc. (Now a Subsidiary of Ligand Pharmaceuticals Incorporated)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2017, the Company entered into an agreement with Crystal Bioscience Inc. (now a subsidiary of Ligand Pharmaceuticals Incorporated), or Crystal, under which the Company obtained an assignment of certain patents, covering certain SIRP&#945; antibodies. Under this agreement, the Company also received a worldwide, royalty-bearing non-exclusive license, with the right to grant sublicenses through multiple tiers of sublicenses, under certain of Crystal&#8217;s background patents and know-how necessary to commercialize the rights under the assigned patents.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In consideration for the rights granted to the Company under the agreement, it agreed to pay Crystal milestone payments up to $11.1 million in respect of all licensed products developed under the assigned patents, that successfully satisfy certain clinical and regulatory milestones, each milestone being paid only once for all products. The Company also agreed to pay Crystal tiered royalties on net sales made by the Company, its affiliates and sublicensees of products at rates ranging within low single-digit percentages, subject to certain potential reductions. This royalty obligation, on a product-by-product and country-by-country basis, shall terminate and become fully paid-up upon the later of the date on which the last valid claim included in the licensed patents expires and ten years after the first commercial sale of the product in such country.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company agreed to use commercially reasonable efforts to develop and commercialize licensed products, including meeting defined development milestones by certain specified dates.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company may terminate the agreement at any time for any reason with at least 60 days&#8217; written notice to Crystal. Either party may terminate the agreement if the other party enters into a bankruptcy event or in the event of material breach of the agreement (that remains uncured for 60 days after the date that it is provided with written notice of such breach). The Company&#8217;s obligations to pay royalties and milestone payments which accrued pre-termination or accrue post-termination will survive any termination.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630027715192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED-PARTY TRANSACTIONS</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(10) RELATED-PARTY TRANSACTIONS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Related-party revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the Company entered into a Research and Development Services Agreement, or Tollnine Agreement, with Tollnine, a related-party of the Company, to provide research and development services to Tollnine. The Company&#8217;s Chief Executive Officer was also the Chief Executive Officer of Tollnine until April 2020 and two of the Company&#8217;s investors are also investors in Tollnine. As such, Tollnine was deemed to be a related-party. The Tollnine Agreement had an initial term of 3 years, to be automatically renewed for additional one-year terms unless terminated by either party. The services were to be provided at a price based on the costs incurred by the Company plus a mark-up equal to 10% of such costs. The Company recognized revenue when Tollnine, as the Company&#8217;s customer, obtained control of promised goods or services, in an amount that reflects the consideration which the Company expected to receive in exchange for those goods or services. The Company recognized related-party revenues of $1.2 million, $4.8 million and $2.1 million for the years ended December 31, 2020, 2019 and 2018, respectively, under the Tollnine Agreement. Effective as of July 1, 2020, the Company terminated the Tollnine Agreement and entered into the Tallac Services Agreement with Tallac Therapeutics. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Receivables due from related-party</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020 and 2019, the Company had outstanding related-party receivables from Tollnine of zero and $0.5 million, respectively.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Tallac Service Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company entered into a research and development services agreement, or the Tallac Services Agreement, with Tallac Therapeutics effective as of July 1, 2020. The Tallac Services Agreement provides that Tallac Therapeutics will provide certain preclinical research services to the Company for a service fee based on the costs incurred by Tallac Therapeutics plus a mark-up equal to 10.0% of such costs. The Tallac Services Agreement has an initial term of four years and is renewed automatically for additional one year terms thereafter. The Company records the payments for the research and development services as research and development costs within the consolidated statement of operations and comprehensive loss. The Company has recorded $0.6 million as research and development costs for the year ended December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Tallac Collaboration Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 4, 2021, the Company entered into a Collaboration Agreement with Tallac Therapeutics pursuant to which the Company and Tallac Therapeutics expect to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. T<font style="color:#000000;">he key economic components of the collaboration transaction include that both parties </font>will share equally (a) in the cost and expenses of research and development and (b) any profit or loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630102149096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(11) NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,740</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,243</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,731</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: cumulative preferred dividends allocated to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stockholders</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,202</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,028</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,671</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,942</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,271</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,402</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,485,343</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076,461</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,750,838</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders, basic and diluted</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company was in a loss position for all periods presented, basic net loss per share is the same as diluted net loss per share for all periods presented as the inclusion of all potential common stock outstanding would have been anti-dilutive. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive securities were excluded from the computation of diluted net loss per share for the years ended December 31, 2020, 2019 and 2018, because including them would have been anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313,808</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,297,081</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase convertible preferred stock</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,292</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229,912</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857,308</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,745</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">864,819</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857,371</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,592,869</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,391,812</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630102132216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(12) COMMITMENTS AND CONTINGENCIES</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Guarantees and Indemnifications</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future but have not yet been made. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. However, the Company may record charges in the future as a result of these indemnification obligations. The Company also has indemnification obligations to its officers and directors for specified events or occurrences, subject to some limits, while they are serving at the Company&#8217;s request in such capacities. There have been no claims to date and the Company has director and officer insurance that may enable the Company to recover a portion of any amounts paid for future potential claims. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of December 31, 2020.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may be a party to various claims in the normal course of business. Legal fees and other costs associated with such actions will be expensed as incurred. The Company will assess, in conjunction with its legal counsel, the need to record a liability for litigation and contingencies. Reserve estimates will be recorded when and if it is determined that a loss related matter is both probable and reasonably estimable. For the years ended December 31, 2020, 2019 and 2018, the Company had no pending or threatened litigation.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Other Commitments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has contractual obligations from its operating lease, manufacturing and service contracts and other research and development activities. The following table aggregates the Company&#8217;s material expected contractual obligations and commitments as of December 31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022 - 2023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2024 - 2025</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligations<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">346</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing and service contracts<sup style="font-size:85%;line-height:120%;vertical-align:top"> (2)</sup></p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,320</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,292</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,028</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,666</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,432</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,234</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Payments due for the office space in Burlingame, California under a single operating sub-lease agreement that expires in 2023. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In November 2015, the Company entered into a Master Service Agreement, or the MSA, with KBI Biopharma, Inc. relating to formulation development, process development and cGMP manufacturing of ALX148 for use in clinical trials on a project basis. The MSA had an initial term of three years with successive one-year renewal periods, is cancellable upon notice and is non-exclusive. Statements of work under the MSA commit the Company to certain purchase obligations of approximately $9.9 million. In addition, the Company has commitments with a second drug product manufacturer that commits the Company to certain purchase obligations of approximately $0.4 million. These amounts are based on non-cancellable commitments and forecasts that include estimates of future market demand, quantity discounts and manufacturing efficiencies that may impact timing of purchases.</p></td></tr></table></div></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination upon notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation. These payments are not included in the table of contractual obligations above.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Facilities</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, the Company entered into a lease agreement for office space for a period of five years and four months, commencing February 1, 2018 and ending May 31, 2023.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, the Company (i) assigned to Tallac Therapeutics, a related party (Note 10), the Company&#8217;s lease with respect to the premises located at 866 Malcolm Road, Burlingame, California, and (ii) received a sub-lease for premises from Tallac Therapeutics.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum rent payments under operating leases are recognized on a straight-line basis over the term of the lease including any periods of free rent. Rent expense was $0.6 million, $0.8 million and $1.0 million for the years ended December 31, 2020, 2019 and 2018, respectively. Sub-lease expenses are recorded within rent expense. &#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630026110152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(13) SUBSEQUENT EVENTS</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Tallac Collaboration Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 4, 2021, the Company entered into a Collaboration Agreement with Tallac Therapeutics pursuant to which the Company and Tallac Therapeutics expect to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics. The collaboration builds on the Company&#8217;s expertise in developing therapies that block the CD47 checkpoint pathway and expands its immuno-oncology pipeline. The companies will leverage their respective scientific and technical expertise to advance an anti-SIRP&#945; antibody conjugated to a Toll-like receptor 9, or TLR9, agonist for targeted activation of both the innate and adaptive immune systems. T<font style="color:#000000;">he key economic components of the collaboration transaction include that both parties </font>will share equally (a) in the cost and expenses of research and development and (b) any profit or loss. The Company is currently evaluating the accounting for the collaboration.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630133129624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Selected Quarterly Financial Data (Unaudited)</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(14) SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following presents certain unaudited quarterly consolidated financial information for the&#160;years ended December 31,&#160;2020&#160;and&#160;2019. This information has been prepared on the same basis as the audited consolidated financial statements and includes all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the unaudited quarterly results of operations set forth herein. Net loss per share for all periods presented has been retroactively adjusted to reflect the 1-for-6.5806 reverse stock split effected on July 8, 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q1</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q2</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q3</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q4</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,897</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,314</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,809</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,825</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,437</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,972</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,759</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,774</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.41</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.36</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.50</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q1</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q2</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q3</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q4</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,259</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,484</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,290</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,946</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,143</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,178</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,115</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,835</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.71</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.68</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.83</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630017242824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Basis of Preparation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, and the applicable rules and regulations of the U.S. Securities and Exchange Commission, or SEC.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Principles of Consolidation</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ReverseStockSplitPolicyTextBlock', window );">Reverse Stock Split</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reverse Stock Split</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 8, 2020, the Company&#8217;s board of directors approved an amendment to the Company&#8217;s certificate of incorporation to effect a 1-for-6.5806 reverse split of its common stock and convertible preferred stock. The par values of the common and convertible preferred stock were not adjusted as a result of the reverse stock split. All authorized, issued and outstanding common stock, convertible preferred stock, stock options, warrants, and related per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented. The reverse stock split was effected on July 9, 2020.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, Series B convertible preferred stock warrant liability, term loan compound derivative liability, term loan, valuation of the Company&#8217;s common stock, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cash and Cash Equivalents</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company holds its cash and cash equivalents in checking and money market accounts. The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash equivalents consist primarily of amounts invested in money market accounts and are stated at fair value.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock', window );">Concentration Of Credit Risk, Credit Losses And Other Risks And Uncertainties</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentration of Credit Risk, Credit Losses and Other Risks and Uncertainties</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits, and invests in money market funds. The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents. The Company has not experienced any losses on its deposits of cash and cash equivalents. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#8217;s future operating results and cause actual results to vary materially from expectations include, but are not limited to, uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#8217;s potential product candidates, uncertainty of market acceptance of the Company&#8217;s product candidates, competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s product candidates require approvals from the U.S. Food and Drug Administration, or FDA, and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">
<p style="margin-top:8pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Property and Equipment</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost less accumulated depreciation. Depreciation of property and equipment is provided using the straight-line method over the estimated useful lives of the assets. Upon sale or retirement of assets, the cost and related accumulated depreciation or amortization are removed from the consolidated balance sheet and the resulting gain or loss is reflected in the consolidated statement of operations and comprehensive loss. Maintenance and repairs are charged to the consolidated statement of operations and comprehensive loss as incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Deferred Offering Costs</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of the equity financing, these costs are recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in capital generated as a result of the equity financing. &#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Impairment of Long-Lived Assets</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company reviews property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount to the future undiscounted net cash flows which the asset or asset group are expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured as the amount by which the carrying amount of the assets exceeds its fair value. Fair value is determined using various valuation techniques including discounted cash flow models, quoted market values and third-party independent appraisals, as considered necessary. The Company has not recorded impairment of any long-lived assets. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Fair Value of Financial Instruments</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies fair value accounting for all financial assets and liabilities and nonfinancial assets and liabilities that are required to be recognized or disclosed at fair value in the consolidated financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Where observable prices or inputs are not available valuation models are applied. These valuation techniques involve some level of management estimation and judgment, the degree of which is dependent on the price transparency for the instruments or market and the instruments&#8217; complexity.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s financial instruments consist of cash and cash equivalents, receivables due from related-party, accounts payable, the term loan compound derivative liability and the Series B convertible preferred stock warrant liability. The term loan compound derivative liability and the Series B convertible preferred stock warrant liability are re-measured at the end of every period and carried at fair value (Note 3). The recorded value of the Company&#8217;s receivables due from related-party and accounts payable approximates its current fair value due to the relatively short-term nature of these items.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Term Loan</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Term Loan</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for the Loan and Security Agreement, dated as of December 20, 2019, as amended, with Silicon Valley Bank, or SVB, and WestRiver Innovation Lending Fund VIII, LP, or WestRiver, collectively as lenders, and SVB, as administrative agent and collateral agent, as a liability measured at net proceeds less debt discount and is accreted to the face value of the term loan over its expected term using the effective interest method. The Company considers whether there are any embedded features in its debt instruments that require bifurcation and separate accounting as derivative financial instruments pursuant to Accounting Standards Codification, or ASC, Topic 815, <font style="font-style:italic;">Derivatives and Hedging</font>.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Convertible Preferred Stock</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records convertible preferred stock net of issuance costs on the dates of issuance, which represents the carrying value. In the event of a change of control of the Company, proceeds will be distributed in accordance with the liquidation preferences set forth in its organization documents unless the holders of convertible preferred stock have converted their convertible preferred stock into common stock. Convertible preferred stock is classified outside of stockholders&#8217; equity (deficit) on the accompanying consolidated balance sheets as events triggering the liquidation preferences are not solely within the Company&#8217;s control. The Company has elected not to adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because of the uncertainty of whether or when such an event would occur. Upon the consummation of the Company&#8217;s initial public offering in July 2020, all shares of convertible preferred stock outstanding and accrued cumulative dividends automatically converted into&#160;23,934,533&#160;shares of common stock.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Revenue Recognition</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To date, the Company has derived revenue from providing research and development services on a time and materials basis to a related-party.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes such revenues over time as services are delivered, and invoices the customer as the work is incurred in arrears.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods or services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font> (Topic 606), the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the Company&#8217;s consideration as to whether the Company has entered into a contract with a customer, it considers whether it is probable that it will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock', window );">Cost of Services for Related-Party Revenue</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Cost of Services for Related-Party Revenue</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company incurs costs associated with related-party services including direct labor and associated employee benefits, laboratory supplies, and other expenses. These costs are recorded in cost of services for related-party revenue as a component of total operating expenses in the accompanying consolidated statements of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Research and Development Costs </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred and consist primarily of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to nonemployees and entities that conduct certain research and development activities on behalf of the Company and expenses incurred in connection with license agreements (Note 9). Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are capitalized and recorded in prepaid expenses and other current assets, and then expensed as the related goods are delivered or the services are performed.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock', window );">Clinical and Manufacturing Accruals</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Clinical and Manufacturing Accruals</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records accruals for estimated costs of research, preclinical studies and clinical trials, and manufacturing development, which are a significant component of research and development expenses. A substantial portion of the Company&#8217;s ongoing research and development activities are conducted by third-party service providers, including contract research organizations, or CROs, and contract manufacturing organizations, or CMOs. The Company&#8217;s contracts with CROs generally include pass-through fees such as regulatory expenses, investigator fees, travel costs and other miscellaneous costs, including shipping and printing fees. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to the Company under such contracts. The Company accrues the costs incurred under agreements with these third parties based on estimates of actual work completed in accordance with the respective agreements. The Company determines the estimated costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fees to be paid for such services.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company makes significant judgments and estimates in determining the accrual balance at the end of each reporting period. As actual costs become known, the Company adjusts its accruals. Although the Company does not expect its estimates to be materially different from amounts actually incurred, the Company&#8217;s understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in the Company reporting amounts that are too high or too low in any particular period. To assist in its estimates the Company relies upon the receipt of timely and accurate reporting from its clinical and non-clinical studies and other third-party vendors. Through December 31, 2020, there have been no material differences from the Company&#8217;s accrued estimated expenses to the actual clinical trial expenses. However, variations in the assumptions used to estimate accruals, including, but not limited to, the number of patients enrolled, the rate of patient enrollment, and the actual services performed, and related costs may vary from the Company&#8217;s estimates, resulting in adjustments to clinical trial expense in future periods. Changes in these estimates that result in material changes to the Company&#8217;s accruals could materially affect its financial position and results of operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation Expense</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Stock-based Compensation Expense </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for stock-based compensation by measuring and recognizing compensation expense for all stock-based payments made to employees, directors and non-employees based on estimated grant-date fair values. The Company uses the straight-line method to allocate compensation expense to reporting periods over each optionee&#8217;s requisite service period, which is generally the vesting period, and estimates the fair value of stock-based awards using the Black-Scholes option-pricing model. The Black-Scholes model requires the input of subjective assumptions, including expected volatility, expected dividend yield, expected term, risk-free rate of return and the estimated fair value of the underlying common stock on the date of grant. Prior to the Company&#8217;s initial public offering, the fair value of the common stock underlying the stock-based awards was determined on each grant date by the board of directors, with input from management, considering the most recently available third-party valuation of common shares. The Company accounts for the effect of forfeitures as they occur. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Segment Reporting </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Foreign Currency Transactions </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The functional currency of the Company&#8217;s operation and each of its subsidiaries is U.S. dollars. All assets and liabilities denominated in a foreign currency are translated into U.S. dollars at the exchange rate prevailing on the balance sheet date. Expenses are translated at the average exchange rates prevailing during the applicable period. Foreign currency transaction gains and losses are included in the consolidated statement of operations and comprehensive loss and recorded in other expense, net, and were immaterial for the years December 31, 2020, 2019 and 2018.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the consolidated financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for the period in which the temporary differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the consolidated statements of operations and comprehensive loss in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that it believes these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, it would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company recognizes benefits of uncertain tax positions if it is more likely than not that such positions will be sustained upon examination based solely on their technical merits, as the largest amount of benefit that is more likely than not to be realized upon the ultimate settlement. The Company&#8217;s policy is to recognize interest and penalties related to the underpayment of income taxes as a component of income tax expense or benefit.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Comprehensive Loss</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss is equal to net loss for all periods presented.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:5.24%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Net Loss Per Share Attributable to Common Stockholders</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share, since the effects of potentially dilutive securities are antidilutive given the net loss for each period presented.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applies the two-class method to compute basic and diluted net loss per share when it has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common stock and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires net loss available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all net loss for the period had been distributed. The Company&#8217;s convertible preferred stock participate in any dividends declared by the Company and are therefore considered to be participating securities. The participating securities are not required to participate in the losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU No. 2016-02 (Topic 842), <font style="font-style:italic;">Leases</font> (ASU 2016-02). ASU 2016-02 requires an entity to recognize assets and liabilities arising from a lease for both financing and operating leases. ASU No. 2016-02 will also require new qualitative and quantitative disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases. In June 2020, the FASB issued ASU No. 2020-05, which extends the effective date of ASU No. 2016-02 for non-public business entities, including smaller reporting companies, to fiscal years beginning after December 15, 2021. The new standard is effective for the Company beginning January 1, 2022 (or earlier if the Company ceases to be an emerging growth company). Early adoption is permitted. The Company is currently evaluating the effects of the adoption of this guidance on its consolidated financial statements and related disclosures.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which is intended to simplify various aspects related to accounting for income taxes. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2021. ASU 2019-12 is effective for the Company beginning January 1, 2022. Early adoption is permitted. The Company is currently in the process of evaluating the effects of the adoption of this guidance on the Company&#8217;s financial statements and does not expect it to have a material impact on its consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements Recently Adopted</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">New Accounting Pronouncements Recently Adopted</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326), which requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This replaces the existing incurred loss model and is applicable to the measurement of credit losses on financial assets measured at amortized cost. The Company early adopted this guidance on January 1, 2020. <font style="Background-color:#FFFFFF;color:#000000;">For trade receivables and other instruments, the Company uses a new forward-looking </font><font style="color:#000000;">expected loss model that generally results in the earlier recognition of allowances for losses. For available-for-sale debt securities with unrealized losses, the losses are recognized as allowances rather than as reductions in the amortized cost of the securities. </font><font style="Background-color:#FFFFFF;color:#000000;">The adoption of the guidance did not have a material impact on the Consolidated Financial Statements and related disclosures and there was&#160;no&#160;allowance for losses for the year ended December 31, 2020.</font> </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement. The FASB issued final guidance that eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. Under the ASU, entities will no longer be required to disclose the amount of transfers between Level 1 and Level 2 of the fair value hierarchy. Public companies will be required to disclose changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period and the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. ASU 2018-13 is effective for public business entities for annual reporting periods, and interim periods within those annual periods, beginning after December 15, 2019, with early adoption permitted. The Company adopted this guidance on January 1, 2020. The adoption of ASU 2018-13 did not have a material impact on its consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock', window );">Convertible Preferred Stock Warrant Liability</a></td>
<td class="text">
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Series B Convertible Preferred Stock Warrant Liability</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has issued freestanding warrants to purchase its Series B convertible preferred stock. Freestanding warrants for the Company&#8217;s convertible preferred stock that are classified outside of permanent equity are recorded at fair value, and are subject to re-measurement at the end of every period until the earlier of the exercise of the warrants or the completion of a liquidation event, including the completion of an initial public offering. Upon exercise, the Series B convertible preferred stock warrant liability would be reclassified to additional paid-in capital, with any change in fair value recognized as a component of other expense, net. Following the Company&#8217;s initial public offering, the warrants were automatically converted to warrants to purchase shares of common stock (Note 5). The Company revalued the Series B convertible preferred stock warrants as of the completion of the initial public offering and reclassified the outstanding preferred stock warrant liability balance to additional paid-in capital with no further re-measurement required as common stock warrants are considered permanent equity. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical and manufacturing accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ClinicalAndManufacturingAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk, credit losses and other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ConcentrationOfCreditRiskCreditLossesAndOtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ConvertiblePreferredStockWarrantLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of services for related party revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_CostOfServicesForRelatedPartyRevenuePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recently issued accounting pronouncements policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_RecentlyIssuedAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ReverseStockSplitPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ReverseStockSplitPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116854557&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630026298856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Financial Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the Company&#8217;s financial assets and liabilities that are measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial assets</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Cash equivalents</font></p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424,115</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424,115</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financial liabilities</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Non-current liabilities</font></p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Compound derivative liability</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrant liability</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Financial Liabilities Measured at Fair Value Using Level 3 Unobservable Inputs</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table is a reconciliation of all financial liabilities measured at fair value using Level 3 unobservable inputs (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Compound</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Warrant</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Derivative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at beginning of year</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">658</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reclassification to equity</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Extinguishment of compound derivative liability upon extinguishment of host instrument</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(43</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value at end of year</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630020844584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property and Equipment</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the components of property and equipment, net as of December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer hardware and software</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">146</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,698</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, gross</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,309</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: accumulated depreciation and amortization</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,449</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">860</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock', window );">Components of Accrued Expenses and Other Current Liabilities</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the components of accrued expenses and other current liabilities as of December 31, 2020 and 2019 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">300</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,974</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">924</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued clinical and nonclinical study costs</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,473</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued contract manufacturing</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,123</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued federal income tax</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">179</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">151</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued expenses and other current liabilities</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,200</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,236</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued expenses and other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630022865320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Common Stock Reserved for Future Issuance on Converted Basis</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock reserved for future issuance, on an as if converted basis, as of December 31, 2020 and 2019, consists of the following:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock issued and outstanding</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313,808</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options issued and outstanding</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857,308</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,745</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options authorized for future issuance</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,835,443</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants issued and outstanding</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,292</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants authorized for future issuance</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,646</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,692,751</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,156,391</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Summary of Convertible Preferred Stock</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019, the Company&#8217;s convertible preferred stock consisted of the following (in thousands, except share amounts):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.42%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31, 2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Issued And</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Net</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Proceeds<sup style="font-size:85%;line-height:120%;vertical-align:top">(1)</sup></p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Preference</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Shares designated as:</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series A convertible preferred stock</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,421,633</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,297,081</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,933</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73,571</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Series&#160;B convertible preferred stock</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,145,370</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,016,727</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,430</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,014</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,567,003</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313,808</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,363</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,585</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.24%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Net proceeds are gross proceeds from the offerings net of issuance costs</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630020806824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Share Option Activity</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a summary of share option activity under the Plan and related information:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Available&#160;to</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Grant</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Life</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Years)</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in&#160;thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2019</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566,900</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,745</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.06</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">638</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Authorized</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,124,217</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,857,655</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,857,655</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.92</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(182,111</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.65</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canceled/forfeited</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,981</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,981</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.99</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,835,443</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857,308</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.94</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.86</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">375,270</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable at December 31, 2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,776,399</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.85</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.65</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.94%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">310,999</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Each Option Grant Using Black-Scholes Option-Pricing Model</a></td>
<td class="text">The fair value of each option grant during the years ended December 31, 2020, 2019 and 2018 was estimated with the<font style="letter-spacing:-0.4pt;"> </font>following assumptions:
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="5" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.66%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (in years)</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.8 - 6.1</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4 - 6.0</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2 - 6.0</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.3% - 0.8%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.7% - 2.1%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.6% - 3.0%</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend rate</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected stock price volatility</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78.7% - 89.0%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.2% - 80.5%</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.9%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66.5% - 68.7%</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember', window );">Share Options Granted To Employees And Nonemployees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Compensation Expense Includes Share Options Granted to Employees and Nonemployees</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation expense includes share options granted to employees and nonemployees and has been reported in the Company&#8217;s consolidated statements of operations and comprehensive loss as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,551</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,885</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of services for related-party revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,436</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">269</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630109631720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule Components of Loss Before Income Taxes</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The U.S. domestic and international components of pre-tax loss for the years ending December 31, 2020, 2019 and 2018 are as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,457</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">813</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">855</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,042</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,022</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14,541</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,499</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,209</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,686</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Provision (Benefit)</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The federal and state provision for income taxes consist of the following (in thousands):</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Current provision for income taxes:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">239</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax provision:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Statutory and Effective Income Tax Rate Reconciliation</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A reconciliation of the U.S. federal statutory income tax rate to the effective tax for the years ended December 31, 2020, 2019 and 2018 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.02%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At federal statutory income tax rate</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,555</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,034</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,874</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State income taxes</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,098</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,875</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(332</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; Development credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(512</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(861</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(499</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,710</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,733</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">732</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.6%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign rate differential</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,380</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,886</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,899</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior period true ups</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(950</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.6%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provision for income taxes</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">241</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Components of Deferred Tax Assets</a></td>
<td class="text">
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant components of the Company&#8217;s deferred tax assets as of December 31, 2020 and 2019 are as follows (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,283</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,259</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research &amp; other credits</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,861</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,260</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">383</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">696</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,299</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,852</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax liabilities:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liabilities</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">166</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,288</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,686</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock', window );">Summary of Net Operating Loss and Tax Credit Carryforwards</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses and tax credit carryforwards as of December 31, 2020 are as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Expiration Years</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, federal (Post December 31, 2017)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,919</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Do Not Expire</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, state</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,363</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2038-2040</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits, federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,327</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2039-2040</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax credits, state</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,893</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating losses, foreign</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,086</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">N/A</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has the following activity relating to unrecognized tax benefits (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:89.6%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at beginning of year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">247</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions/reversals based on tax positions of prior years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:59.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to the current year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">272</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.12%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">160</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lapses in statutes of limitations</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:59.74%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance at end of year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">842</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">692</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.12%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">418</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.78%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of net operating loss and tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_SummaryOfNetOperatingLossAndTaxCreditCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=121610041&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630023858040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Loss per Share</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth the computation of the basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(45,740</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(19,243</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,731</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: cumulative preferred dividends allocated to</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; preferred stockholders</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,202</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,028</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,671</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50,942</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(23,271</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,402</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted-average shares of common stock</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; outstanding</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,485,343</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,076,461</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,750,838</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; stockholders, basic and diluted</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7.56</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6.33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of Outstanding Potentially Dilutive Securities Were Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following outstanding potentially dilutive securities were excluded from the computation of diluted net loss per share for the years ended December 31, 2020, 2019 and 2018, because including them would have been anti-dilutive:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.74%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,313,808</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,297,081</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Warrants to purchase convertible preferred stock</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61,292</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock subject to repurchase</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34,024</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">229,912</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options issued and outstanding</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857,308</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,183,745</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">864,819</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,857,371</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,592,869</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.5%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,391,812</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630026350440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RegistrationPaymentArrangementTextBlock', window );">Summary of Company's Commitments and Contractual Obligations</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has contractual obligations from its operating lease, manufacturing and service contracts and other research and development activities. The following table aggregates the Company&#8217;s material expected contractual obligations and commitments as of December 31, 2020 (in thousands):</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.29%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.68%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2022 - 2023</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2024 - 2025</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:34.28%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease obligations<sup style="font-size:85%;line-height:120%;vertical-align:top"> (1)</sup></p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">346</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.02%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing and service contracts<sup style="font-size:85%;line-height:120%;vertical-align:top"> (2)</sup></p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,320</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,292</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,028</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:34.28%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,666</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,432</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,234</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.02%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Payments due for the office space in Burlingame, California under a single operating sub-lease agreement that expires in 2023. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:5.29%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-style:italic;font-weight:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">In November 2015, the Company entered into a Master Service Agreement, or the MSA, with KBI Biopharma, Inc. relating to formulation development, process development and cGMP manufacturing of ALX148 for use in clinical trials on a project basis. The MSA had an initial term of three years with successive one-year renewal periods, is cancellable upon notice and is non-exclusive. Statements of work under the MSA commit the Company to certain purchase obligations of approximately $9.9 million. In addition, the Company has commitments with a second drug product manufacturer that commits the Company to certain purchase obligations of approximately $0.4 million. These amounts are based on non-cancellable commitments and forecasts that include estimates of future market demand, quantity discounts and manufacturing efficiencies that may impact timing of purchases.</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RegistrationPaymentArrangementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent obligations arising from commitments made to the recipient of the entity's financial instruments to endeavor (a) to file a registration statement for the resale of those financial instruments (demand or "piggyback" rights granted to the recipient) or for the resale of equity shares that are issuable upon exercise or conversion of those financial instruments and (b) for the registration statement to be declared effective by the SEC within a specified grace period. This disclosure does not include information about the contingent obligation to make future payments or otherwise transfer consideration under a registration payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99383193&amp;loc=d3e16207-108621<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99383193&amp;loc=d3e16242-108621<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RegistrationPaymentArrangementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630026410936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Selected Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of Certain Unaudited Quarterly Consolidated Financial Information</a></td>
<td class="text">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following presents certain unaudited quarterly consolidated financial information for the&#160;years ended December 31,&#160;2020&#160;and&#160;2019. This information has been prepared on the same basis as the audited consolidated financial statements and includes all adjustments (consisting only of normal recurring adjustments) necessary to present fairly the unaudited quarterly results of operations set forth herein. Net loss per share for all periods presented has been retroactively adjusted to reflect the 1-for-6.5806 reverse stock split effected on July 8, 2020.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q1</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q2</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q3</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q4</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,897</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,314</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,809</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,825</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(7,437</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,972</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,759</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,774</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.37</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.41</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.36</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.50</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.72%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(in thousands, except per share data)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q1</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q2</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q3</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q4</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,259</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,484</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,290</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,946</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to common stockholders</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,143</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,178</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,115</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,835</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.72%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to common stockholders, basic and diluted</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.71</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.68</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.33</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.83</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630017124856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 08, 2020</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 21, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On July 8, 2020, the Company&#8217;s board of directors approved an amendment to the Company&#8217;s certificate of incorporation to effect a 1-for-6.5806 reverse split of its common stock and convertible preferred stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.151961827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member', window );">ASU 2016-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member', window );">ASU 2018-13</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted', window );">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate', window );">Change in Accounting Principle, Accounting Standards Update, Adoption Date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect', window );">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible shares converted in to common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,934,533<span></span>
</td>
<td class="nump">23,934,533<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether accounting standards update was adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date accounting standards update was adopted, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121329987&amp;loc=SL120154346-209984<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121483254&amp;loc=SL120254523-199619<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120320025-210437<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL120254519-210437<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120240428&amp;loc=SL120254526-165497<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31010-122693<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201613Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201813Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630017034296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value on Recurring Basis - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Compound derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_WarrantLiabilityFairValueDisclosure', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 424,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 424,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Financial liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Compound derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_WarrantLiabilityFairValueDisclosure', window );">Warrant liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_WarrantLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant liability fair value disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_WarrantLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630017211624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Reconciliation of Financial Liabilities Measured at Fair Value Using Level 3 Unobservable Inputs (Details) - Level 3<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at beginning of year</a></td>
<td class="nump">$ 361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="nump">658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity', window );">Reclassification to equity</a></td>
<td class="num">(1,019)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Compound Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value at beginning of year</a></td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Change in fair value</a></td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment', window );">Extinguishment of compound derivative liability upon extinguishment of host instrument</a></td>
<td class="num">$ (43)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, loss on extinguishment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityLossOnExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, reclassification to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alxo_WarrantLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alxo_WarrantLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alxo_CompoundDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alxo_CompoundDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630022899384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount', window );">Fair value assets transferred from level 1 to level 2</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount', window );">Fair value assets transferred from level 2 to level 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount', window );">Fair value liabilities transferred from level 1 to level 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount', window );">Fair value liabilities transferred from level 2 to level 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Fair value assets transferred into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Fair value assets transferred out of level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Fair value liabilities transferred into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Fair value liabilities transferred out of level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of liabilities measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630017036328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Components of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 2,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(1,449)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_ComputerHardwareAndSoftwareMember', window );">Computer Hardware And Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630016729928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule Of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_LabEquipmentAndOtherAssetsMember', window );">Lab Equipment and Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ScheduleOfBalanceSheetComponentsLineItems', window );"><strong>Schedule Of Balance Sheet Components [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from transfer of assets for cash</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ScheduleOfBalanceSheetComponentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of balance sheet components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ScheduleOfBalanceSheetComponentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_LabEquipmentAndOtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_LabEquipmentAndOtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630021650712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Components of Accrued Expenses and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">1,974<span></span>
</td>
<td class="nump">924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_AccruedClinicalAndNonClinicalCostsCurrent', window );">Accrued clinical and nonclinical study costs</a></td>
<td class="nump">1,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_AccruedContractManufacturingCurrent', window );">Accrued contract manufacturing</a></td>
<td class="nump">2,123<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_AccruedFederalIncomeTax', window );">Accrued federal income tax</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">151<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="nump">$ 1,236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_AccruedClinicalAndNonClinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical costs and non clinical costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_AccruedClinicalAndNonClinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_AccruedContractManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued contract manufacturing current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_AccruedContractManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_AccruedFederalIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued federal income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_AccruedFederalIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630013925176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 17, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 20, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 21, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 16, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase | shares</a></td>
<td class="nump">61,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share | $ / shares</a></td>
<td class="nump">$ 9.4972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 621,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=alxo_CompoundDerivativeLiabilityMember', window );">Compound Derivative Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value of compound derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon warrants exercise | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,369,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember', window );">Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt instrument, description of variable rate basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The loans under the Loan Agreement bore interest at a floating per annum interest rate equal to the greater of 7.0% or 2.0% plus the prime rate as reported in The Wall Street Journal.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Term loan, annual floating interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_DebtInstrumentInterestOnlyPaymentTerms', window );">Term loan interest-only payments, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Interest-only payments for the first 12 months after the closing of the Loan Agreement<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Frequency of periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">monthly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1', window );">Term loan principal and interest payment commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Term loan maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount', window );">Percentage of principal amount as final payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NetProceedsFromFollowOnPublicOffering', window );">Net proceeds from follow-on public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember', window );">Loan Agreement | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock issued upon warrants exercise | shares</a></td>
<td class="nump">48,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember', window );">Loan Agreement | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase | shares</a></td>
<td class="nump">61,292<span></span>
</td>
<td class="nump">61,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share | $ / shares</a></td>
<td class="nump">$ 9.4972<span></span>
</td>
<td class="nump">$ 9.4972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_EstimatedFairValueIssuanceOfWarrants', window );">Estimated fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock', window );">Outstanding preferred stock warrant liability converted into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember', window );">Loan Agreement | Volatility | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember', window );">Loan Agreement | Risk-free Rate | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember', window );">Loan Agreement | Dividend Rate | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember', window );">Loan Agreement | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Term loan, interest rate above prime rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember', window );">Loan Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember', window );">Loan Agreement | Maximum | Time to Liquidity | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, measurement input term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember', window );">Loan Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ProceedsFromEquityFinancing', window );">Proceeds from equity financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount', window );">Prepayment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember', window );">Loan Agreement | Minimum | Time to Liquidity | Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding, measurement input term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=alxo_FirstTrancheMember', window );">First Tranche | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=alxo_SecondTrancheMember', window );">Second Tranche | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan, principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock warrants value converted into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ConvertiblePreferredStockWarrantsValueConvertedIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_DebtInstrumentInterestOnlyPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, interest-only payment terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_DebtInstrumentInterestOnlyPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, prepayment fee, percentage of principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_DebtInstrumentPrepaymentFeePercentageOfPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_EstimatedFairValueIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_EstimatedFairValueIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final payment fee as percentage of funded principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_FinalPaymentFeeAsPercentageOfFundedPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_NetProceedsFromFollowOnPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from follow-on public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_NetProceedsFromFollowOnPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ProceedsFromEquityFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from equity financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ProceedsFromEquityFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDateOfFirstRequiredPayment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDateOfFirstRequiredPayment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=alxo_CompoundDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=alxo_CompoundDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=alxo_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=alxo_FirstTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=alxo_FirstTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=alxo_SecondTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=alxo_SecondTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630015378248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 21, 2020</div></th>
<th class="th"><div>Jul. 20, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 17, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,519,618,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,567,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,844,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,844,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,166,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts and commissions paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,844,522<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,844,522<span></span>
</td>
<td class="nump">48,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,166,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with equity offerings, net of underwriter discounts and issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,512,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrants to purchase common stock</a></td>
<td class="nump">61,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock exercise price per share</a></td>
<td class="nump">$ 9.4972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with equity offerings, net of underwriter discounts and issuance costs, shares</a></td>
<td class="nump">9,775,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering</a></td>
<td class="nump">$ 169,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts and commissions paid</a></td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_PaymentForOfferingCost', window );">Payment for offering related expense</a></td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible shares converted in to common stock</a></td>
<td class="nump">23,934,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,934,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=alxo_FollowOnPublicOfferingMember', window );">Follow-on Public Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in connection with equity offerings, net of underwriter discounts and issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,737,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Net proceeds from initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Underwriting discounts and commissions paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_PaymentForOfferingCost', window );">Payment for offering related expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alxo_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,313,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,055,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,145,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase</a></td>
<td class="nump">61,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share</a></td>
<td class="nump">$ 9.4972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,313,808<span></span>
</td>
<td class="nump">9,297,081<span></span>
</td>
<td class="nump">9,297,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred stock, cumulative dividends percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears', window );">Accrued cumulative dividends on the Series A, Series B and Series C convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion', window );">Cumulative preferred stock dividend convertible shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,564,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,421,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,297,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesBAndCConvertiblePreferredStockMember', window );">Series B and C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares original issue price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.4972<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative preferred stock dividend convertible shares issued upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_CumulativePreferredStockDividendConvertibleSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_PaymentForOfferingCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment for offering cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_PaymentForOfferingCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of cumulative preferred dividends in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAmountOfPreferredDividendsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=alxo_FollowOnPublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=alxo_FollowOnPublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alxo_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alxo_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alxo_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alxo_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesBAndCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alxo_SeriesBAndCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630019924984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Common Stock Reserved for Future Issuance on Converted Basis (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">7,692,751<span></span>
</td>
<td class="nump">12,156,391<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_ConvertiblePreferredStockIssuedAndOutstandingMember', window );">Convertible Preferred Stock Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,313,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_StockOptionsIssuedAndOutstandingMember', window );">Stock Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">4,857,308<span></span>
</td>
<td class="nump">1,183,745<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_StockOptionsAuthorizedForFutureIssuanceMember', window );">Stock Options Authorized for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">2,835,443<span></span>
</td>
<td class="nump">566,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_WarrantsIssuedAndOutstandingMember', window );">Warrants Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,292<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_WarrantsAuthorizedForFutureIssuanceMember', window );">Warrants Authorized for Future Issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,646<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_ConvertiblePreferredStockIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_ConvertiblePreferredStockIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_StockOptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_StockOptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_StockOptionsAuthorizedForFutureIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_StockOptionsAuthorizedForFutureIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_WarrantsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_WarrantsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_WarrantsAuthorizedForFutureIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_WarrantsAuthorizedForFutureIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630022910040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Convertible Preferred Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Authorized Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,567,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_TemporaryEquitySharesIssuedAndOutstanding', window );">Shares Issued And Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,313,808<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Authorized Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,421,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_TemporaryEquitySharesIssuedAndOutstanding', window );">Shares Issued And Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,297,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,933<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Authorized Shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,145,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_TemporaryEquitySharesIssuedAndOutstanding', window );">Shares Issued And Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,016,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Net Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Aggregate Liquidation Preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,014<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_TemporaryEquitySharesIssuedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity shares issued and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_TemporaryEquitySharesIssuedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alxo_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=alxo_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630014521272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Apr. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,692,751<span></span>
</td>
<td class="nump">12,156,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised', window );">Unvested early exercised options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">34,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Liability related to these unvested options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense, weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.74<span></span>
</td>
<td class="nump">$ 1.27<span></span>
</td>
<td class="nump">$ 1.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share option granted during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of eligible compensation withheld</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount', window );">Share-based compensation, authorized amount</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage', window );">Share-based Compensation, lower of closing price, percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201709Member', window );">Stock Option Modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | ESPP | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alxo_TwoThousandAndFifteenShareAwardSchemeMember', window );">2015 Share Award Scheme | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share option granted during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,143,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alxo_TwentyThousandAndTwentyEquityIncentivePlanMember', window );">2020 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of share option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,379,139<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember', window );">2020 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance</a></td>
<td class="nump">7,874,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share options, maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Share options, service period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, authorized amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardAuthorizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options nonvested exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based compensation arrangement by share-based payment award, purchase of common sock at lower of closing price, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchaseOfCommonSockAtLowerOfClosingPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alxo_TwentyThousandAndTwentyEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201709Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201709Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alxo_TwoThousandAndFifteenShareAwardSchemeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alxo_TwoThousandAndFifteenShareAwardSchemeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alxo_TwentyThousandAndTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alxo_TwentyThousandAndTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=alxo_AmendedAndRestatedTwoThousandTwentyEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630019870696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available to Grant Balance</a></td>
<td class="nump">566,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized', window );">Shares Available to Grant, Authorized</a></td>
<td class="nump">6,124,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted', window );">Shares Available to Grant, Granted</a></td>
<td class="num">(3,857,655)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled', window );">Shares Available to Grant, Canceled/forfeited</a></td>
<td class="nump">1,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares Available to Grant Balance</a></td>
<td class="nump">2,835,443<span></span>
</td>
<td class="nump">566,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Balance</a></td>
<td class="nump">1,183,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Options, Granted</a></td>
<td class="nump">3,857,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options, Exercised</a></td>
<td class="num">(182,111)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options, Canceled/forfeited</a></td>
<td class="num">(1,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options, Balance</a></td>
<td class="nump">4,857,308<span></span>
</td>
<td class="nump">1,183,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options, Exercisable at December 31, 2020</a></td>
<td class="nump">3,776,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">10.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Canceled/forfeited</a></td>
<td class="nump">0.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Balance</a></td>
<td class="nump">8.94<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable at December 31, 2020</a></td>
<td class="nump">$ 3.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Life (Years), Outstanding Options</a></td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
<td class="text">8 years 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Life (Years), Outstanding Options Exercisable</a></td>
<td class="text">8 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding Options Aggregate Intrinsic Value, Balance</a></td>
<td class="nump">$ 375,270<span></span>
</td>
<td class="nump">$ 638<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Outstanding Options Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 310,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Canceled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantCanceled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630017034760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Share-Based Compensation Expense Includes Share Options Granted to Employees and Nonemployees (Details) - Share Options Granted To Employees And Nonemployees - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 5,436<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">2,551<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,885<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember', window );">Cost of Services for Related-party Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=alxo_ShareOptionsGrantedToEmployeesAndNonemployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630017035944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Fair Value of Each Option Grant Using Black-Scholes Option-Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">78.70%<span></span>
</td>
<td class="nump">75.20%<span></span>
</td>
<td class="nump">66.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="nump">80.50%<span></span>
</td>
<td class="nump">68.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630021677944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Domestic and International Components of Pre-Tax Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">United States</a></td>
<td class="num">$ (9,457)<span></span>
</td>
<td class="nump">$ 813<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">International</a></td>
<td class="num">(36,042)<span></span>
</td>
<td class="num">(20,022)<span></span>
</td>
<td class="num">(14,541)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (45,499)<span></span>
</td>
<td class="num">$ (19,209)<span></span>
</td>
<td class="num">$ (13,686)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630022866648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision for income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred tax provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630016705976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Statutory and Effective Income Tax Rate Reconciliation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">At federal statutory income tax rate</a></td>
<td class="num">$ (9,555)<span></span>
</td>
<td class="num">$ (4,034)<span></span>
</td>
<td class="num">$ (2,874)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="num">(3,098)<span></span>
</td>
<td class="num">(1,875)<span></span>
</td>
<td class="num">(332)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research &amp; Development credits</a></td>
<td class="num">(512)<span></span>
</td>
<td class="num">(861)<span></span>
</td>
<td class="num">(499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">5,710<span></span>
</td>
<td class="nump">3,733<span></span>
</td>
<td class="nump">732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">7,380<span></span>
</td>
<td class="nump">3,886<span></span>
</td>
<td class="nump">2,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Prior period true ups</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(950)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630022822472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Loss carryforwards</a></td>
<td class="nump">$ 7,283<span></span>
</td>
<td class="nump">$ 3,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research &amp; other credits</a></td>
<td class="nump">2,861<span></span>
</td>
<td class="nump">3,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_DeferredTaxAssetsAccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_DeferredTaxAssetsStockOptions', window );">Stock options</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">11,299<span></span>
</td>
<td class="nump">6,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1', window );">Fixed assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(11,288)<span></span>
</td>
<td class="num">(6,686)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_DeferredTaxAssetsAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_DeferredTaxAssetsAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_DeferredTaxAssetsStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_DeferredTaxAssetsStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities, property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_DeferredTaxLiabilitiesPropertyPlantAndEquipment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630022873176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets, increase in valuation allowance</a></td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">842,000<span></span>
</td>
<td class="nump">692,000<span></span>
</td>
<td class="nump">$ 418,000<span></span>
</td>
<td class="nump">$ 247,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Recognized interest and penalties expense (benefit) related to unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630022913768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Operating Losses and Tax Credit Carryforwards (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net Operating Loss And Tax Credit Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 7,919<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 1,327<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net Operating Loss And Tax Credit Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_TaxCreditCarryforwardExpirationPeriod', window );">Tax credits, Expiration Years</a></td>
<td class="text">2039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net Operating Loss And Tax Credit Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_TaxCreditCarryforwardExpirationPeriod', window );">Tax credits, Expiration Years</a></td>
<td class="text">2040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net Operating Loss And Tax Credit Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 71,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 2,893<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net Operating Loss And Tax Credit Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_OperatingLossCarryforwardsExpirationPeriod', window );">Net operating losses, Expiration Years</a></td>
<td class="text">2038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net Operating Loss And Tax Credit Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_OperatingLossCarryforwardsExpirationPeriod', window );">Net operating losses, Expiration Years</a></td>
<td class="text">2040<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems', window );"><strong>Net Operating Loss And Tax Credit Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 5,086<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net operating loss and tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_NetOperatingLossAndTaxCreditCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_OperatingLossCarryforwardsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_OperatingLossCarryforwardsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_TaxCreditCarryforwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_TaxCreditCarryforwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630022866680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">$ 418<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions', window );">Additions/reversals based on tax positions of prior years</a></td>
<td class="num">(64)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">272<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapses in statutes of limitations</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">$ 418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increases (decreases) resulting from prior period tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_UnrecognizedTaxBenefitsIncreasesDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630016755128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alxo_ExclusiveEquityAgreementMember', window );">Exclusive Equity Agreement | Stanford Junior University</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NonrefundableLicenseRoyaltyAndPatentExpenses', window );">Nonrefundable license royalty and patent expenses</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ClinicalAndRegulatoryMilestonesPayments', window );">Clinical and regulatory milestones payments</a></td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_AgreementExpiryDescription', window );">Agreement expiry description</a></td>
<td class="text">licensed patents expires and ten years after the first commercial sale of the licensed product in such country<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_TerminationOfAgreementWrittenNoticePeriod', window );">Termination of agreement written notice period</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NoticePeriodToRemedyBreachOfAgreement', window );">Notice period to remedy the breach of agreement</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alxo_CommercialLicenseAgreementMember', window );">Commercial License Agreement | Selexis SA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ClinicalAndRegulatoryMilestonesPayments', window );">Clinical and regulatory milestones payments</a></td>
<td class="nump">$ 1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_AgreementExpiryDescription', window );">Agreement expiry description</a></td>
<td class="text">shall terminate and become fully paid-up upon the passing of ten years after the first commercial sale of the product in such country, or the Company&#8217;s exercise of the royalty buyout option exercisable at any time prior to the first commercial sale of a licensed product<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_TerminationOfAgreementWrittenNoticePeriod', window );">Termination of agreement written notice period</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NoticePeriodToRemedyBreachOfAgreement', window );">Notice period to remedy the breach of agreement</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alxo_CommercialAntibodyAgreementMember', window );">Commercial Antibody Agreement | Crystal Bioscience Inc</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_ClinicalAndRegulatoryMilestonesPayments', window );">Clinical and regulatory milestones payments</a></td>
<td class="nump">$ 11.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_AgreementExpiryDescription', window );">Agreement expiry description</a></td>
<td class="text">licensed patents expires and ten years after the first commercial sale of the product in such country<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_TerminationOfAgreementWrittenNoticePeriod', window );">Termination of agreement written notice period</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NoticePeriodToRemedyBreachOfAgreement', window );">Notice period to remedy the breach of agreement</a></td>
<td class="text">60 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_AgreementExpiryDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement expiry description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_AgreementExpiryDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_ClinicalAndRegulatoryMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical and regulatory milestones payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_ClinicalAndRegulatoryMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_NonrefundableLicenseRoyaltyAndPatentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nonrefundable license royalty and patent expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_NonrefundableLicenseRoyaltyAndPatentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_NoticePeriodToRemedyBreachOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Notice period to remedy the breach of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_NoticePeriodToRemedyBreachOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_TerminationOfAgreementWrittenNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Termination of agreement written notice period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_TerminationOfAgreementWrittenNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alxo_ExclusiveEquityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alxo_ExclusiveEquityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alxo_StanfordJuniorUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alxo_StanfordJuniorUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alxo_CommercialLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alxo_CommercialLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alxo_SelexisSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alxo_SelexisSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alxo_CommercialAntibodyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alxo_CommercialAntibodyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=alxo_CrystalBioscienceIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=alxo_CrystalBioscienceIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630021952248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>Investor</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Related-party revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,182<span></span>
</td>
<td class="nump">$ 4,796<span></span>
</td>
<td class="nump">$ 2,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,961<span></span>
</td>
<td class="nump">16,306<span></span>
</td>
<td class="nump">11,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxo_TollnineMember', window );">Tollnine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Outstanding related-party receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alxo_ResearchAndDevelopmentServicesAgreementMember', window );">Research and Development Services Agreement | Tollnine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell', window );">Number of company's investors who are investors in related party as well | Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Related-party revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_InitialTermOfAgreementWithRelatedParty', window );">Initial term of agreement with related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated', window );">Agreement automatically renewal additional term unless terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_RelatedPartyMarkupCostPercentage', window );">Markup cost in percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alxo_ResearchAndDevelopmentServicesAgreementMember', window );">Research and Development Services Agreement | Tallac Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_InitialTermOfAgreementWithRelatedParty', window );">Initial term of agreement with related party</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated', window );">Agreement automatically renewal additional term unless terminated</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_RelatedPartyMarkupCostPercentage', window );">Markup cost in percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development costs</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_InitialTermOfAgreementWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial term of agreement with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_InitialTermOfAgreementWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of company's investors who are investors in related party as well.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_NumberOfCompanySInvestorsWhoAreInvestorsInRelatedPartyAsWell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party agreement automatically renewal additional term unless terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_RelatedPartyAgreementAutomaticallyRenewalAdditionalTermUnlessTerminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_RelatedPartyMarkupCostPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related party markup cost percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_RelatedPartyMarkupCostPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxo_TollnineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxo_TollnineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alxo_ResearchAndDevelopmentServicesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alxo_ResearchAndDevelopmentServicesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxo_TallacTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=alxo_TallacTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630015361208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45,740)<span></span>
</td>
<td class="num">$ (19,243)<span></span>
</td>
<td class="num">$ (13,731)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Less: cumulative preferred dividends allocated to preferred stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,202)<span></span>
</td>
<td class="num">(4,028)<span></span>
</td>
<td class="num">(3,671)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (18,774)<span></span>
</td>
<td class="num">$ (10,759)<span></span>
</td>
<td class="num">$ (13,972)<span></span>
</td>
<td class="num">$ (7,437)<span></span>
</td>
<td class="num">$ (8,835)<span></span>
</td>
<td class="num">$ (4,115)<span></span>
</td>
<td class="num">$ (5,178)<span></span>
</td>
<td class="num">$ (5,143)<span></span>
</td>
<td class="num">$ (50,942)<span></span>
</td>
<td class="num">$ (23,271)<span></span>
</td>
<td class="num">$ (17,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,485,343<span></span>
</td>
<td class="nump">3,076,461<span></span>
</td>
<td class="nump">2,750,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.76)<span></span>
</td>
<td class="num">$ (7.56)<span></span>
</td>
<td class="num">$ (6.33)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630017035752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Were Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">4,857,371<span></span>
</td>
<td class="nump">11,592,869<span></span>
</td>
<td class="nump">10,391,812<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,313,808<span></span>
</td>
<td class="nump">9,297,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_WarrantToPurchaseConvertiblePreferredStockMember', window );">Warrants to Purchase Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_CommonStockSubjectToRepurchaseMember', window );">Common Stock Subject to Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">34,024<span></span>
</td>
<td class="nump">229,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_OptionsIssuedAndOutstandingMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">4,857,308<span></span>
</td>
<td class="nump">1,183,745<span></span>
</td>
<td class="nump">864,819<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_WarrantToPurchaseConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_WarrantToPurchaseConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_CommonStockSubjectToRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_CommonStockSubjectToRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_OptionsIssuedAndOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=alxo_OptionsIssuedAndOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630021924424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Company's Commitments and Contractual Obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Manufacturing and service contracts, Total</a></td>
<td class="nump">$ 10,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInNextTwelveMonths', window );">Manufacturing and service contracts, 2021</a></td>
<td class="nump">6,292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligationDueInSecondAndThirdYear', window );">Manufacturing and service contracts, 2022 - 2023</a></td>
<td class="nump">4,028<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual Obligation, Total</a></td>
<td class="nump">10,666<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">Contractual Obligation, 2021</a></td>
<td class="nump">6,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondAndThirdYear', window );">Contractual Obligation, 2022 - 2023</a></td>
<td class="nump">4,234<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Operating lease obligations, Total</a></td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Operating lease obligations, 2021</a></td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree', window );">Operating lease obligations, 2022 - 2023</a></td>
<td class="nump">$ 206<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease, liability, to be paid, year two and three.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_LesseeOperatingLeaseLiabilityToBePaidYearTwoAndThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondAndThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second and third fiscal years following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondAndThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in next fiscal year following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligationDueInSecondAndThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase arrangement to be paid in second and third fiscal years following current fiscal year. Includes, but is not limited to, recorded and unrecorded purchase obligations, long-term purchase commitment, and short-term purchase commitment. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligationDueInSecondAndThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630019860536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Company's Commitments and Contractual Obligations (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=alxo_MasterServiceAgreementMember', window );">Master Service Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_InitialTermOfAgreement', window );">Initial term of agreement</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_RenewalPeriodsOfAgreement', window );">Renewal periods of agreement</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligations</a></td>
<td class="nump">$ 9,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_OfficeAndLaboratorySpaceMember', window );">Office and Laboratory Space | Burlingame, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_OperatingSubLeaseExpirationYear', window );">Operating sub-lease expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_SecondDrugProductManufacturerMember', window );">Second Drug Product Manufacturer | Master Service Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligations</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_InitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_InitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_OperatingSubLeaseExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating sub-lease expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_OperatingSubLeaseExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_RenewalPeriodsOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Renewal periods of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_RenewalPeriodsOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=alxo_MasterServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=alxo_MasterServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_OfficeAndLaboratorySpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_OfficeAndLaboratorySpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_SecondDrugProductManufacturerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_SecondDrugProductManufacturerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630023845896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_OfficeSpaceMember', window );">Office Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_alxo_LesseeOperatingLeaseCommencingEndDate', window );">Lessee, operating lease commencing end date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_alxo_LesseeOperatingLeaseCommencingEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, operating lease commencing end date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">alxo_LesseeOperatingLeaseCommencingEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>alxo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_OfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=alxo_OfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630026338472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Additional Information (Details)<br></strong></div></th>
<th class="th"><div>Jul. 08, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.151961827<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139630017141064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Schedule of Certain Unaudited Quarterly Consolidated Financial Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 17,825<span></span>
</td>
<td class="nump">$ 9,809<span></span>
</td>
<td class="nump">$ 11,314<span></span>
</td>
<td class="nump">$ 5,897<span></span>
</td>
<td class="nump">$ 8,946<span></span>
</td>
<td class="nump">$ 4,290<span></span>
</td>
<td class="nump">$ 5,484<span></span>
</td>
<td class="nump">$ 5,259<span></span>
</td>
<td class="nump">$ 44,845<span></span>
</td>
<td class="nump">$ 23,979<span></span>
</td>
<td class="nump">$ 15,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (18,774)<span></span>
</td>
<td class="num">$ (10,759)<span></span>
</td>
<td class="num">$ (13,972)<span></span>
</td>
<td class="num">$ (7,437)<span></span>
</td>
<td class="num">$ (8,835)<span></span>
</td>
<td class="num">$ (4,115)<span></span>
</td>
<td class="num">$ (5,178)<span></span>
</td>
<td class="num">$ (5,143)<span></span>
</td>
<td class="num">$ (50,942)<span></span>
</td>
<td class="num">$ (23,271)<span></span>
</td>
<td class="num">$ (17,402)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (0.50)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (4.41)<span></span>
</td>
<td class="num">$ (2.37)<span></span>
</td>
<td class="num">$ (2.83)<span></span>
</td>
<td class="num">$ (1.33)<span></span>
</td>
<td class="num">$ (1.68)<span></span>
</td>
<td class="num">$ (1.71)<span></span>
</td>
<td class="num">$ (2.76)<span></span>
</td>
<td class="num">$ (7.56)<span></span>
</td>
<td class="num">$ (6.33)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MY78\SGV0ML7$B_QX(NV.IS$YADY6;)8E>A6Q8B<C8"&T.$/X8RM,IB@.=Z*
MYU7AD"^.(?5L2$>%'EOY2>Q/(.UD <_KPBV3!<H%+4'T2U&>-IBM4FU1 U"O
M"02='N!Y0=AS0F_MH_4:$WPP+);%Q)_@"=R) 'Z)"AQ#-R9WV,VAQ%NLL)OT
M*/@08B<">%X%KD51<&V8?__(I*+4O+QG90IPT;L_A68(D_=6X+.1S51QKG8T
M99<+&!L4DP]LL4+6<_+_ QUFWZD+GI<7Z&D?0 ,YT!F"V!L&YRE#T$JGWZQ
M+5KB>J$WL0F=H.!DEK/79L&MR#,FU:^_Q 1''VI%!G%^!X,&3[E^/]?,=N)
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M$7+_9G-_H\6N?CEX)[0617VY910>*V, OV\$](K-C7G?V+Y?7OT'4$L#!!0
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M7XV0%Y\ABH9DA_PD_\2D9&E^&1,<$:X-U/,=8_*EH3\.5!^#%K\ 4$L#!!0
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MY#)1* /Y_9(Q\?A&/="P?Z;FZG]02P,$%     @ ,H-R4@1^].7=!P  X"
M !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6R=6MN.XS82_17"R,,$B,<6
M*=G6H+N!'GMG-T NC>E-]IF6:)L[DNB05%_R]2E*LB2+E^[D8=JR7"3K%*OJ
M5)%S\RSD-W5B3*.7LJC4[>RD]?G38J&R$RNI^BC.K()?#D*65,-7>5RHLV0T
M;P:5Q0(OEZM%27DUN[MIWCW(NQM1ZX)7[$$B59<EE:^?62&>;V?1[/+B*S^>
MM'FQN+LYTR-[9/JW\X.$;XM^EIR7K%)<5$BRP^WL/OJTBV,SH)'XG;-G-7I&
M!LI>B&_FRX_Y[6QI-&(%R[29@L+'$]NRHC S@1Y_=)/.^C7-P/'S9?8O#7@
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MQ@C [P<A].6+6:#_3PUW?P%02P,$%     @ ,H-R4B+!6U-@!P  Y1$  !@
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MEG%Z\12M.^[^MLZ4Z8;X1+W,["UQR8KU.57Q6G*IN>61%O40(S= R (* S+
MY7G$CL:TS<#>)\FTFV]CI=[*8MJ'B].-!\*^V,XZEF3&I6P]4A7_@E"TFLL4
MO@*6O<"P3P1\V".2^)Y6D6@H%)DR3LX,L4)<!M6 [KH)H<]08+6M2]G59\4#
M@:<9R_Y#J6)N5-,)K$ZS40*A2?ITEJ$[7*!;@,TZ?N/N/O:U.!M\>D,?R_@#
M W_@X*,S?85OGFY^PUBD3_?M\O0#R'OIE@H$:2JQ=6_WY8M)$DY_$VP3/^0S
M&X*MXV5%$B6>%^!]:=$TNQL^8//+SLF_4$L#!!0    ( #*#<E(,64USYA\
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MH++6L8%,MRH.'4TW@1$)^(K5D;Z?627J!LK\@]J1+P$DD5!0-!V(9$#TF>/
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MAK9&."Z*3BHSB$,(YJ+'IMBLUJL^>%E.QE' !K%01/YK5>E<3*+84\!%&?:
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M&M74\C11%* DNX_5N*)1*RI>U^D(&AR>/6ILO6TA(L*,(#W'=7_I2!"F9>#
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MO#<%/V8*P[JE!?A]9M XXA=2T/[3Y/Q_4$L#!!0    ( #*#<E(1%I-KY@0
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M'.!CL!-52NH!P%>P.NP&W2.WENU$P-U_1:T !0QTDZ_5F,H&61,V<' :%<A
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M5N@F--<N6& *5OTV>$VD]WH\/[:+%(ZVZ$E70EV@&^B.9] 8HQ](V2&Y:JO
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M_N5)\/'HF-+"JW,%Y9WK(6Z.C@N.'R&@X#2DBN#\Z9R/,@+E4AN;&:N9P7$
M=X9<V.RV6..)UF:3HF3@DQ03GRE$"[H*0Q@]I_LHQ(*V@#R [G&.L(F5Z+1L
M?]HZP,F3>7\^B:B!&\W-T'C8'TX>L\515S=GP+#)<0[I",;7TO;J2/<+Y$OX
MA>(C;W0AIN<X#O1@4L]'[*9[9MRJ4K:.0XR6:DWWXK948U=<E)A$6XEN>GG1
MHWQD+F1U%-<S49@2#.FL]Q&10B*]\PX)C0N*#3& .#J*IM,AIPE.%I?3WO?F
M7,P<YB4H=S3!@91*<1T1>#SN#6<]NDO5&3J8XV(.'^<;6?(IP%;E2(HNY0RG
M2'B4"9 ;QI0%1I=S^G=VV>O4&+_R\(BK#=3HF35+V,,WE;UY<9VBA3J_B]$+
M4[5HWJ>H1-A"?ZZX,FT+-XY>WE^Z$:IS><.U0^[<T+M?U#;@Q[ %]Y/)[PTG
M"=*(+1_:TR1W9H72*(Z;TOA5EQ&NQJTLYKSRWW&65EPW'_Q6V+SSPQEJ  A[
M.U/_3/L+<2YF_6&/HB0]#?#=R#Y]U-7G\Q5=.D"85G2910 _"K7#^"F6#/J+
MIR@XYO0\Z@^?]D;]&3V/^X.G[9:)IDJ2BD)Z]9S_\S^&/?*V .3XU*DW7QBJ
MBTLB-0='_&G0GS[MS6;XEQCD-9[2)TCFSN%#8?=2FL^V]KY/-W'7Z_UC>KDW
M[#:G#F'RY;H\K!B2 M"@"24/5*J&)K%TR"36\#^4?S&G/5\8&UBS)]M+&AS%
MS:8NGBRQH9N+M3E;UA#1AIL-O/C<Y8;@J"F\J[%48$D7961S_YZ>CB0M5/;M
MV6BHL$PGFP*HZ%03+JGX58X?5TC$01U.N\(%TZH0G_/B(7>52J7!O#DLS11"
M9-(7C,/O"(?O'0X_ DSN%/DH2 ]2[D[3F IB_M*_PYNDZ@9M#0QEV\4@-)A@
M8;R,SXW,X 8OM-\_CK0^VCZ+^[_1QGO0=$Y!.[O >,#QP;%C"PF^8P&(;20?
ME;?D;-JB&6ZEE)DV,&SZXE?O7\BH="WEVU#K9@T&O3LS<:FKO=E>1QVM)Q_(
M%/B 7Z7;DT='-!S[( 69GK19HL1!%TX<V6@M<VTO!'A!S$WR\'=CL( 2VF-"
M(;!=F4/C]@Z9(@PA'L&];,E-^*)^>*53.M;E@WTW^;3:UGF"/%': W1[D.+E
M- '%7;%H_3[4<=&.[+T64VI43]3;8?/C[ME\1ZF'FU?1%S_X_>E<G_-7FKII
M&S%# V(SIW13-Z-?/Y&(3I3^)T9RP<6-=OAI4Q\EK\,K>/LR'<YJ^N):F?MO
M;0_( PYFU%Z2<M/ZQUH2(\N185# U:&DQX:JR,#![:.]Y++<^?LG'/6"L53!
MHV]W==E.PNGC2AI.@@O%&96@'(7: J\Z59"V56<DMJ[<JLC2?#"8V!$?(*HV
M5&MPGZFA!Z[L(IY#6FNB)2YK;<8_RIZW6_79F&TWX\LY=*)C4L\*^26/&4)F
M5QH_1"[@F[,FS_]2(^#&Z]R<:SC/:<\I\4:1\5337NNRYW-!H1#LPN\%X>98
MQ&@#07#!A>;U6)SJ/QJ=V#>_CB*9T<T2<X72&BZ,I;11JEQ\_A=]BVM%6WR<
M]JV.7S$(JX,8^TTC_/HK(WP^IK.]T-%+A\?^O.(B^ .73)7W_&<\I,0FK\W?
MNOAO_5\*79D_D&F7FS\S AOW.J=SFA5>'?3GTS-S#<Q]J(L-_[G,LJCK(N/'
MM4)B*&D!?E\5 )K]0!OXOY]Z\[]02P,$%     @ ,H-R4GID^!.V"0  WQD
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MN6A1)6\4N5;!,T:1U-BRFYK>DAD%\H$<0%Y[]&Q\U :"3FM+'J^V!Z"OLQ:
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MX6.UZ2"H*W(@0@&!R,]$9SE>:R26OF.3-H2O$FO0@&B;IP)8.[%S*YRB<=8
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MXRIE5Y"6ND0G.G8/\R(ARV9+0^1?]9DV;*ZE5,#=?;T2+F\_]*'4;&#261<
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MA(N?7^--L!5_\L39)-B"+Y=*(H^T ._G%BA--Z2@_09^]5]02P,$%     @
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MAQ%M$*#SM=;^L @&CD_M[ =02P,$%     @ ,H-R4B)8;[P9!   4 D  !D
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M$! [WETBQW))#9W/E-P39;T1S1JN5!>-Y)BPBW)O%,XRC#/S>Z</5&354F5
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MY*UB;Y5XJ]3[I2L5!81G?%@T:.\G+_.+:8YM%/E)E*(Q]8MP:@=ROX@SKY>
M&J/8NC5TS<'64LJF06:.<2UYA?R]8>ZG2>Z-O&&4^-,\=E;HY]G4686?YRE:
MK\CZ+]!]M^%*MW\JQEN4!FD.X\!E1"L-TJBSPB"9'*TL1,ON[Q^G6)Q-79L6
M5K#4CZ<AMH4_32?_4:_,C]+$:H-&7E@C]:,HLT;A%TGVH\6*@OP@411,BJ.5
M))T5!P5:KUVPXY-7K@&U=6\YWD^R%:9[\/K1_G=AT;V2_[AW_QI?J-HR/&T<
M-A@:!GDV(*I[O[N.D3OW9JZEP1?8F37^\H"R#CB_D=(<.S9!_Q,U_QM02P,$
M%     @ ,H-R4D/X2.>1(0  1W$  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&ULO5U;<]O&DOXK*&_55EQ%T1(=.W9.DBI9MO?XE).XI#AY'@)#<F(0
MP\P DGE^_?9M+@ !2';.[HLMBL!<>OKZ=??HASOK/OF=UFWQ>5\W_L='N[8]
M?/_DB2]W>J_\TAYT ]]LK-NK%CZZ[1-_<%I5]-*^?K(Z/W_^9*],\^BG'^AW
M']Q//]BNK4VC/[C"=_N]<L=7NK9W/SZZ>!1^<6VVNQ9_\>2G'PYJJV]T^_'P
MP<&G)W&4RNQUXXUM"J<W/SZZO/C^U>H%OD!/_&[TG<]^+G K:VL_X8=WU8^/
MSG%%NM9EBT,H^.]67^FZQI%@'7_)H(_BG/AB_G,8_2UM'C:S5EY?V?H/4[6[
M'Q^]>%14>J.ZNKVV=__4LJ%G.%YI:T__%G?\['?P<-GYUN[E95C!WC3\O_HL
MA,A>>'$^\<)*7EC1NGDB6N5KU:J??G#VKG#X-(R&/]!6Z6U8G&GP5&Y:!]\:
M>*_]Z<9L&[,QI6K:XK(L;=>TIMD6'VQM2J-]\4WXZ?$/3UJ8#]]Z4LK8KWCL
MU<38%ZOB9]NT.U^\:2I=]0=X @N-JUV%U;Y:S8[X6I?+XNG%HEB=K\YGQGL:
M=_^4QOMV8KQ7RAM?V$WQP6FOFU8AIXQM].'#')2C48K?=C!D4=K& P4KU>JJ
MV)A&-:51=>%A*@W,W?IBIVYUL=:Z*0[T-CQGD%M+ZRIX6@-#M#OZ+&=S< 8&
M.=1P.EO=:*?J^HC?ZT/+[[8[77QL#'ZZP7EH:9=[[>"8%X5UQ<?ES;+XG\O+
M#XM"-14]KPX'.&>UKG7A.AP:OW!ZV]6T&QJ"QL57;W39.=,:>>S-YW*GFJTN
MKNQ^;SP*+$US\^9J.7-(W\9#^G:6NA_2?F$15Y&@$T?UU8,5EW4-Y&NU*^W^
MH)HCB'N-)\"[;)UJO"J9&NG0=&U +)60OLP'G-O\L[CY9[/KO=:WV@$?W;2V
M_%3<P"&U8YO^XD&*7YOB7QTPS@L6I@6=[A5O_+__Z\7JXKM_^&)ME:N04)5Q
MH$:M\\@HSM[";A4P*7!PA5Q<M';T_5*[EK1+JW$4(+UU!RL" N_HS0:&+51Q
M<08&YNSY\MF+\^? =KQ<3PO%]T!,X$SV\)*G+>!Y *EO<7AD69"<C78H.O3]
M$H6O %DJ;E7=Z<B\,L8];Q=WVNFBL;"NZD_0P+A7V#<LRX.J#V/%1=(KM-0E
M<9#JVIUUYM^Z6A0@#!V1"HC8M2#T3842G.]E,;>4A0QO#\1VB^)..6##UB]$
M/FMBO(,&.[L#U0$G@EH"J07*#+@@ZH,OT4-.M\ZRN43-$H@ YP6K0W,*(X*^
M&Z%  :=8@#["%1E;>=P/ZE5=\9&,O7('Q&4^@#FL<.5+YLHY"7H>)>CY+/-_
M],1[;WQK]J@,Q\3GRT9@[LI4?62O^VC,&@)]*=,>6;%'70S$^:L#,?-@WAMP
MB()<[=4G7>@X-YZ[ K;:,TO Q H8E>6(^1($C'A66 $6!\_KEE^MC5J;.NGN
MROBRMKYSM$5D&V!0G'GJ'9ZE$HE^V+:#D1E;&[)$T\EJ]&?P-CU\J,"^@*"D
ME\CP,5,M47>!]K'-UN*OUVA]%SG5-(H]40LU1Z3= A50W54\LO4Z"I"HK_!D
M571>;[H:=G[+VJ.&R<[P4R6$ ;$%-@'-5H-AP.V" 7:=JN&+C3*B>*9IOP ;
MZI">K^8U$8M[?/,(:EJ[/2Q'(2?M#T!&.$,8ZE:AN(X^N"B8'!FGGNCIGD)"
M-;W71:L^R['0[\_0^:UH5C@C-G#%SXGH^/6 X"C.H"G ;A"A\'1AT^C3D$9L
M8&%PHAT\!XMR<(+NDV[/_$&7:#2"BH/39'[L\WQVWFLPPAI/"LYQC:>JO&W(
MEP'RP,#$I<:5W1Y5,!ATT-1E"Z<E.AT)T-4H#"!'KM@XNQ<&B5N9TT3?14WT
MW:P>N5)^1YNB']Z M,/!H(",J:2O'(ITDQQOL;-UQ4=2AN?I!YT]CRIII\M/
M*!3X /"!/LI1!*_3+WO#HL ;H*LG5;^#N <T=FU@4#0W< XMBSWI-SC[+>B$
M&H9L@]-(7.BTQLDP/ "C 0Z9#X1/ZN70.7 MX1SX8(>+7_+V\^W0VGR+3C+L
MP<#"4 9%W?#BV"B.[I.UJ].LO"K4=DF:YUC@162!%_/G9H']FE;LQJ_@@8*P
M@Q&\-AX$3SZ\MQY%Z1+6\BL)!G[+GS\VZ%*!94<ZCK'-[/08XG_O#ZK4/SXB
MR^QN]:/!FNSLFM1@36JXIN)M- "F\:WKF!5(8@^VA0^&XA7?K?\,)BOP%1RR
MP@/LKZ;D!3B8;_QT)WF[S[4(4> JP;B 1?&&>7^C*XF@X)O.]2P8;L"T'>L<
M>%9_+I%+8<K3MS *"&X9LYD_X;(-:*/!HL"- JUH/=N@?*OBMZ%U))]3D(9B
M?:3?3ZP2)1XE>5;F^TL ^2)G-VEG=%A!H/G$X1!PL$BS!Q,\&I=-UZ)[$50M
M#&!A)A7(>FMK,%RJ:+K]&O@*OR8&<Y'!NIS!EL5;Q9$(\10K[LS_F9A=I@32
MA'7P!L#0(S*4VP(X"+!+>&I@0IE;23$A@<HVKAL]";THUEU+&@-)2$Q 1[G(
M%GUD-R?NON\XA$A;E3M<W=Z )FR!:_S($!2-6U@:!V$PQ(0]CY(&DF*K#DA3
M8NA1L1<T&#?I0'T@\S@YZLA8Y X _Z&P$I5 L)D?=7A>G!_EMG"J'%J3!^0)
M11"S \^V"-01OF%!OG6+9P"_VS6VMMLCAD)P@GH+C@&Y;7@,.W,0-U:#4U*1
M:P$+^:11,"MS:RITR="^@(>JS[P%>P+*O4.P ^S7.+^>;C.XYI'NF:DB__VM
MM1SEO7;=MKBL]G#"7G0802%O7U\N).[<8]B O@F$ =ILF]ZY@NM-L!L0 -Y"
ME0">F7;L4"M$+5@O@$T"CD)^1*_O3Z"CKPQC$[0IA\:R09O96'*='!TL!PL@
MW"-[O#,URD"I<43<6:-1W:F,W6#L=SW6H. -R&Y09\A#B\2=_&VMCAC9N9,7
M._;1*,9AW9Q>I4!R;*'@G@:IIXA5Y7*J*HXO#4P"+]DFGW-9S!CPE]& O[P'
M/T)- H)#P!=PQ0$-W)@E_IIQBMZO=?QUWR4I+9A <IA 9KM]QS$,B "<GA''
M_'7VB3RI\8$-L3O("<4\(>1"UD4T^PQ77>PU^,)P@+?B24]'200D4KRS+#X>
M,*  EL63=Z B'/OJ,21:2/#HVQZ6,;4E' ;\. B4_LV?%=F4/6%141I[L:C
M=P6G-U(0BIH8M[I%CD/?$RQ=08 &H1L3H$F,9P<6+$BUTSM,5F 0!N-A:(18
M8J-"N(-X@4&?&65SA]HPQIU_8QZ$IL 6=1@TSCFH%^<I(7 ^RYFO0PCZ*P9#
M2*<K.*-19W-^I'%O<V+X?H"A#J95M?FW9@@1SZG66]0MP*T;31 SQ]P!%*>
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MKJY_]:$@39[N$VODE9]_G2B8*P<>+XR==29*I23(K_=G[<[9;KMC#249XKP
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MVK_X@$I4U4N@ZABY=K=O+ W>Y:Z9X^,)E%V \YF4INE8@/8Y-OT74$L#!!0
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M@?</#G\*V-JC,?65K+3^[(W?BEDO]H1 0NX\ L>?KW +4GH@I/%EC]GK4OK
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M<VAE970R-"YX;6R-5EMOVS84?N>O(+QB2P B$G6U4\> G;9H@'4+XFY]&/9
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MB2%AF]3<RMVO4!G4LWR13'7Q2W;57K]%HHTV,JO J$'&1?G/OE6.. #0[A%
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MA\2P8&6J/XGU#50)=8V_2*3*_I)U9>LY)"J5%ED%1@89SS?_[*$28@] .R<
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MFF>GE><=*'6)]S$JLS)E&F*\1MA2(LXV%Q79LTQ(S7_;@R;FFP#=/5KG?O>
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MSZ>5;U*^*1XKNN=IRL/B<LW<!8MS ?']DO-T]R9_4JE^2O#\/U!+ P04
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M_FH$1X>!NWBS%<6 ,9WL\(8LB;C?W3)Y9]1:HC@E&8]I!AA97XUF\'*![$)
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M9"^;/1(F/QKK5 .W+ Z)WK^EZJ#MMK$U4.)A4^.AOLB_BJ1;E:5J:+69S'&
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M&Z!I@SAM#T4/C#2VA$BD2M)V_/<=4K*B*+*02X!<;"[S'F?FC<@9[[FXES&
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MYP,L(U$TBL5$\=RT3G=<82-FAC$VUR"T >ZO.5?'B3Z@:M>G_P%02P,$%
M  @ ,H-R4IL!TA*@ P  E0X  !D   !X;"]W;W)K<VAE971S+W-H965T-#0N
M>&ULS5=;C]HZ$/XKHTA':J5N;D" "I 6V)Y3J:N#=M6>AZH/WF0 :YV88YME
M^?>UG1"@3;QT^](7\.W[,O/-^#*C'1>/<HVHX#EGA1Q[:Z4V[X- IFO,B?3Y
M!@L]L^0B)TIWQ2J0&X$DLZ"<!7$8)D%.:.%-1G9L(28COE6,%K@0(+=Y3L1^
MBHSOQE[D'0;NZ&JMS$ P&6W("N]1?=XLA.X%-4M&<RPDY04(7(Z]Z^C]/.H:
M@%WQA>).GK3!N/+ ^:/I?,S&7F@L0H:I,A1$_SWA#!DS3-J._RM2K_ZF 9ZV
M#^P?K//:F0<B<<;9?S13Z[$W\"##)=DR=<=W_V#E4,_PI9Q)^PN[:FWH0;J5
MBN<56%N0TZ+\)\^5$"> N-<"B"M ?"F@4P$ZEP*Z%<!*'92N6!WF1)')2/ =
M"+-:LYF&%=.BM?NT,'&_5T+/4HU3DWO%T\>KJ58N@QG/=3I)8@-R!?<ZQ[(M
M0^!+^$"H@"^$;6WOAJ1K^'=CU_TM2*'@LZ3%"J:,:#*-XPQEM>!J(6AJ)F]Y
MA@S>S%$1RN3;4:"T^<:((*U,G9:FQBVF1K'F*-1:PDV1879.$&B_:^?C@_/3
MV,DXQ]2'3O0.XC .&PR:70R/A@WP^>7P@<.;3AW*CN7KM(5R301"0RBOA8[1
M"O5N53#=P^FZ!=G;X>L=$1E\_:0IX:/"7'YS&-2M#>I:@[HM!MU1^7BU%(A
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M1T+*MX4J7Z_U:%U;7=N*XH?QJ:FY;!UPI"D+MELB5K20P'"I*4._KZ]X4=9
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ME5W>=:#=0+):]V2/3*H.3[_FJFM'W@+4]QUC\F70.AC^!ZS^!U!+ P04
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M==\LN=DW2]O[BL+NGMEXWRR*.T=U)XWNY*3NQU?53" HT$BHR(F9.90C,PT
M-F9M2GE19^32C ).T:9)DO)_TI;L*7B?L0\MTE,650+\G<97@)J[B:-))DN!
M51MI3INA-G2]_-WY*+Q-J]GT2E--R@>JYDQHPF%F*(/KCJF-JJ9/M4&Y=.UU
M*M$T:[=<F($-RAJ8]S,I<;NQ#IJ_ (-_4$L#!!0    ( #*#<E(_@MSG3 ,
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MTW.XX=AT>2#M!O-^*(1>3JR#HF_L_ 902P,$%     @ ,H-R4B2<E+47 P
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M;"]W;W)K<VAE971S+W-H965T-3(N>&ULS5A9;QLW$/XK S4H$B#1'CZDI+(
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;+58VV[C-A#]%<+8HKM
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MB!6K+V3UBZ#[JBG>4 %-=O68P!V6, F [UM*Q>E%3M#>BF?_ U!+ P04
M"  R@W)2^VCGOJP#   K#@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-2YX
M;6S-5TMOVS@0_BN$3EN@&XF2;$N%;2"Q4VR MC%B;'-8]$!+8XN-)&I)*D[_
M_0XI17Y$]@:])!=;HN:;US?D#,=;(1]4!J#)4Y&7:N)D6E>?7%<E&11,78@*
M2ORR%K)@&E_EQE65!)9:4)&[ON<-W8+QTIF.[=I"3L>BUCDO82&)JHN"R5]7
MD(OMQ*'.\\(=WV3:++C3<<4VL 3]=[60^.9V6E)>0*FX*(F$]<2YI)_F=&@
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M1&4/T/NME.9Y80T,P^SL;U!+ P04    "  R@W)2P>?JG-H"  !("   &0
M 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6RU5DUOVS ,/7>_@C!Z:($N3IS/
M%4F ? TKT&!%@VZ'80?59A*AEI1)2M/^^U&RXZ6=8P0#=HDEF>_QD93)]'=*
M/YDUHH47D4HS"-;6;J[#T,1K%,S4U 8EO5DJ+9BEK5Z%9J.1)1XDTC"JUSNA
M8%P&P[X_N]/#OMK:E$N\TV"V0C#].L94[09!(]@?W//5VKJ#<-C?L!4NT#YL
M[C3MPH(EX0*EX4J"QN4@&#6N9SUG[PV^<=R9@S6X2!Z5>G*;FV00U)T@3#&V
MCH'1XQDGF*:.B&3\RCF#PJ4#'J[W[)]][!3+(S,X4>EWGMCU(.@%D."2;5-[
MKW9?,(^G[?ABE1K_"[O<MAY O#56B1Q,"@27V9.]Y'DX #0Z1P!1#HC> UI'
M ,T<T#P5T,H!K?> [A% .P?XT,,L=I^X*;-LV-=J!]I9$YM;^.Q[-.6+2W=/
M%E;36TXX.YPH(;BEPEL#3"8P4=)RN4(9<S3P$49)PEU%60HW,KN6KKX74[2,
MI^:23!X64[@XOX1SX!+F/$W)P/1#2^J<CS#.E8PS)=$1)8T(YN1\;6 F$TS>
M$H045A%;M(]M'%4R3C&N0;-Q!5$]JI<(FIP,;WPJ@4]/A_=*X+/3X=V*9#2+
M0C<]7_.$0H_^*O2/6S*'&XO"_*QPUBJ<M;RSUA%G]^0&\(6:F<&RFY"A.Q[M
M.MGSL%[K],/GP^*4V?3>VDPSF^Z!3:.P>".\70AO5PK_NESR&&&Q83%6Y*%3
MT'7^?]*[A;-NI?9;- ;Q"FB&:.;<0(K40J_ HA:@EA"3=TV=N>PR5E.WX169
M-M "X3_1"K6]0FWO7]222"%<?N@ *6,)LV4W:%9-/F>O[MOY<'9&GWZS3&UX
MT#(%ZI6?58:\;Z7-.DQQ6HS#D9\"[\['-":SJ?:')INQ<Z977!J*:TF4]5J7
MKI[.YE:VL6KC&_.CLM3F_7)-HQZU,Z#W2Z7L?N,<%'\>AK\!4$L#!!0    (
M #*#<E)DPYW3(@(  !H$   9    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM
M;'U4VX[:,!#]%2M/N]*67%AVZ2I$"@14*HI8+JVJJ@\F&8B%8Z>V0W;_OK83
M(EJ5OL2>\9PS9\;CA#47)YD#*/164"9'3JY4^>*Z,LVAP++'2V#ZY,!%@94V
MQ=&5I0"<65!!W<#SGMP"$^9$H?6M1!3R2E'"8"60K(H"B_<Q4%Z/'-^Y.-;D
MF"OC<*.PQ$?8@-J5*Z$MMV/)2 %,$LZ0@,/(B?V7<=_$VX"O!&IYM4>FDCWG
M)V/,LY'C&4% (56& >OE#!.@U!!I&;]:3J=+:8#7^PO[S-:N:]EC"1-.OY%,
MY2-GZ* ,#KBB:LWK3]#6,S!\*:?2?E'=QGH.2BNI>-&"M8*"L&;%;VT?K@#^
MXPU T ("J[M)9%4F6.$H%+Q&PD1K-K.QI5JT%D>8N92-$OJ4:)R*-M/%=+*=
M)NAU%Z^WT_7B.YK-E_%R,H\7*(FW,;K;+>-=,M<Q]^@#BK.,F'9BBN:LF0G3
MW+L$%"94WH>NTJH,MYNV"L:-@N"&@L\5[2%O^( "+_#^A+NZF*ZBH*LHL'S]
M&WRO%18*!'U',\(P2\E?4A,B4\IE)0#]B/=2"3T8/_^3M]_E[=N\CS?RKN$,
M0@+25Y:>D"PI40\HY<QX[02;]/]J3T/K>Y;7/*)SY/7\@?_QR1\&SZ%[OA;E
M7EVU>35?L#@2)A&%@T9[O>>!@T0SB8VA>&EO?\^5GB6[S?7C!6$"]/F!<W4Q
MS$!UOX/H-U!+ P04    "  R@W)2)TU9ZT,$  !_#P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970V,"YX;6RE5VUOXC@0_BL6V@]=J4O>25)1)$IH"V5[W5+N
M=#K=!T,,1$UBSG9*]]_?Y(4L&!-%VB\0.\\SXYEY[(S[>\K>^980@3Z3..6W
MG:T0NQM-XZLM23#OTAU)X<V:L@0+&+*-QG>,X+ @);%FZGI/2W"4=@;]8NZ%
M#?HT$W&4DA>&>)8DF/V\(S'=WW:,SF'B-=IL13ZA#?H[O"%S(A:[%P8CK;82
M1@E)>413Q,CZMC,T;F:]'%\ _HS(GA\]HSR2):7O^6 2WG;T?$$D)BN16\#P
M]T%&)(YS0[",_RJ;G=IE3CQ^/EB_+V*'6):8DQ&-_XI"L;WM>!T4DC7.8O%*
M]X^DBL?)[:UHS(M?M*^P>@>M,BYH4I%A!4F4EO_XL\K#$0'LJ EF13!E@GV!
M8%4$JRW!K@AV6X)3$9RVA%Y%Z+4EN!7!;4OP*H+7EN!7!%\F]"X53C]43F_K
MPZB+?5;MBY1#N8VBWEHIK$*5 19XT&=TCUB.!WOY0R'M@@]BC-)\$\X%@[<1
M\,1@/IZ-1V_C /U8#%_?QJ^SO]']Y'GX/)H,9R@8O@W1U>)YN @F@/F*OJ$Y
MG )A%A-$UVA$F(!MCA8ISL)(D!#]R# 3A,4_T8BFG,91B//I^RC%Z2K",9JD
MY;F1;\"K@  ]YKG9Q3Q 5U^^HB](0WR+&>&H,!P)?@V3\/RVI1G':<C[FH"X
M\]5KJRK&NS)&\T*,%OI.4['E:)R&)%3PI\U\PVPPH$'"ZZR;AZS?F8T6 [+J
M(LNX1J9NZHH%C9KI<[(#NGZ1'C33IUG:2!\WT[]CUKCX^]:Q&[Z"_M Z=B7]
ML77L2OJD=>Q*^O3WZO[T>ZF;M:=[#2JVZK/#*NQ9%^S]VNWJ#1Y$?!53GC&"
M_ADNN6#PR?VWP:]=^[4+O_8%OW_L" ,/Z0:13VA&.%&>":4-M["1MR(? \/U
M3*>O?1QOM'.4[^G^*2A0F#(LPSY%C<]1CN>[IZ#[<Y#GV[U3T,,YR#9]_13T
MJ'!G>]*:)@J0Z4CA317NP)*4J:=SE&GYKF1KIDB5XSI&C3HIN%,7W&DL^#,T
MHR DCK 0+%IF B_A"R0H6M$D :'!=W+UOJ5Q2)A2"L[9HKX9GNM*R1JI8+HK
MIRM0P2 3IB0'!<RU+5D/"I3G65+N'Q0HVS DU*,"Y8#F)4DH4;8E:4*%TGU;
M"O)) 3,MTS4D5:A2YMJZJ99%KY9%KYTLX#PHNX8V KG.N_9HA:"70&$49T+9
M$MR5KOWC)>M=^?10@BQI.P<*E-VUI1R-%2BS>Z87)<J3JO>@0!E=2T(]*E$]
M62]*E%SAJ7)=KI2))P7*[3H2:J9 ]8Y77XI%.VIZ$\(VQ56.0\6S5)3?L'JV
MOBT.BZ99FK\S;B:&8GX*M\OR,OC+?'DUA2Y@$Z4<Q60-KO2N"_IFY76O' BZ
M*UKN)170PA>/6[@A$Y8#X/V:4G$8Y [J._?@?U!+ P04    "  R@W)28M\W
M%V\"  !2#@  #0   'AL+W-T>6QE<RYX;6S5EUUOFS 4AO^*Y4Y3*DT%DB9I
M5D#:*E6:M$Z5FHO=50X8L.0/9DQ&^NMG8P))6J*H%VO(17P^[.>\F",P?J$V
M%#]E&"M0,<J+ &9*Y5\=IX@RS%!Q)7+,=281DB&E79DZ12XQB@NSB%%G[+HS
MAR'"8>CSDMTS58!(E%P%<-Z&@!U^Q 'T9M<06-R=B'$ GT>?_Y1"W7X"=KSX
M<G'A7KG/E[>'F5&3NH3.F^#I">!>;!]T=I):]YA>MQ<^/PU^C-V'OME'MU+L
M3Q-'!Z$^T.+$#3B^ WWXN=NC<T]AO=AIVBOT$\&[+IM &]!TQ#!8(QK .T3)
M2A*S*D&,T(T-CTT@$E1(H'1[ZW*>B10O-NU9SW1^PV&$"UG7MA7L_ZJ9?I#8
M>D8@H;05.(8V$/HY4@I+?J^=>G(=?)4"C;W<Y%IA*M'&&T]AMZ >=)&5D#&6
M;1D/;D.A3W%BY$B29F94(G=,4BG!M!$3E J.:@W;%8VAL1&F],D\%GXG>^PJ
MV;EO]5WCK:D%-:;%6,?P=VF6O8N]?A<7Y&0MU/=27PZO?=-K^%'BA%2U7R6M
M@#ZZUT]'>4XWWRA).</VXD\N&/IHNPYD0I(77<VT2J0#6$*PQE*1:#?R5Z)\
MB2NU;:<JZ=<\'J#F_[O/*>98(KHK6O?^.>_RNQ5/YA\EN7ZJ' I^4V/SKC]W
MD=,AB)P-0>0@>O)F""(7 Q Y_["GYNDB)^>YD4YS$MHY;NT=MMHH,(?: /XR
M1V3:%06KDE!%>.-E)(XQ?W7FTGB%5OH#;X^OY\<X0255RS89P,Y^P#$IV:*=
M]6@VHIG5V3_-Y7FSNF#W%1G^ U!+ P04    "  R@W)2EXJ[',     3 @
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M;',O=V]R:V)O;VLN>&UL+G)E;'/-VDMNHT 4A>&M6"P@Y?LB22O.J">91MD
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MK%W]]=\>W3UO3-4>\UG_2\WL#5!+ 0(4 Q0    ( #*#<E('04UB@0   +$
M   0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @ ,H-R4DPH17SN    *P(  !$              ( !KP   &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @ ,H-R4IE<G",0!@  G"<  !,
M     ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  R@W)2
MJV+-+*T&  #]&@  &               @($-"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @ ,H-R4JK+:6J2!0  :Q8  !@
M     ("!\ X  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M #*#<E(X%;=AU0,  !@2   8              " @;@4  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    "  R@W)2W"ZQWF,%  #V$P  &
M            @('#&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @ ,H-R4C?/.C3S!@  7R,  !@              ("!7!X  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    ( #*#<E($?O3EW0<  . @
M   8              " @84E  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    "  R@W)2(L%;4V '  #E$0  &               @(&8+0
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ,H-R4@Q937/F
M'P  ^&(  !@              ("!+C4  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    ( #*#<E)3\QN0*@D  $ 9   8              "
M@4I5  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  R@W)2
M$1:3:^8$  #4"@  &0              @(&J7@  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    ( #*#<E)2OS 0^0H  'T=   9
M      " @<=C  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @ ,H-R4IL,\_N]"    QD  !D              ("!]VX  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  R@W)2,Q39S$D2  !+-0
M&0              @('K=P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    ( #*#<E)Z9/@3M@D  -\9   9              " @6N*  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ ,H-R4M(OSH+K
M"@  V",  !D              ("!6)0  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    "  R@W)2JVK0>\4%  !&#P  &0
M@(%ZGP  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( #*#
M<E*N+*1SGP0  &$*   9              " @7:E  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @ ,H-R4E(A;<!S"0  #Q<  !D
M         ("!3*H  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    "  R@W)240#>ZY4#  !V!P  &0              @('VLP  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( #*#<E(B6&^\&00  % )
M   9              " @<*W  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @ ,H-R4D/X2.>1(0  1W$  !D              ("!$KP
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  R@W)2,4X7
M4\H#  ":"0  &0              @(':W0  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    ( #*#<E)9<X;,K@,  +,(   9
M  " @=OA  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M,H-R4AAJ^N+N P  #0D  !D              ("!P.4  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    "  R@W)2/0GBE4L%  #+"P  &0
M            @('EZ0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    ( #*#<E)D;7QRC 8  "T2   9              " @6?O  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ ,H-R4L9T0HY5!
M%PH  !D              ("!*O8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    "  R@W)2I%K ]]X$  "N"@  &0              @(&V
M^@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( #*#<E)X
M?>@X!P0  $,)   9              " @<O_  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @ ,H-R4HS7)XH[!   ]0\  !D
M     ("!"00! 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #*#<E*8.R,_!@,  ( )   9              "
M@6D5 0!X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ ,H-R
M4MT?S\_U @  BP@  !D              ("!IA@! 'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    "  R@W)2_E(>6'\(  "S+   &0
M        @('2&P$ >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   ( #*#<E*)TS96=0<  #$H   9              " @8@D 0!X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @ ,H-R4FMO?1P= P  X@L
M !D              ("!-"P! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    "  R@W)2B].O!$4#  #;"P  &0              @(&(+P$
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( #*#<E).>KGF
MR@4  'P9   9              " @00S 0!X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @ ,H-R4DW $=*A!   :Q(  !D
M ("!!3D! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  R
M@W)2*^0GU&8#  "Z"P  &0              @('=/0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( #*#<E*; =(2H ,  )4.   9
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M970T."YX;6Q02P$"% ,4    "  R@W)2D*X[3-8"   ."   &0
M    @(&64@$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M #*#<E(_@MSG3 ,  $,.   9              " @:-5 0!X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @ ,H-R4B2<E+47 P  Y @  !D
M             ("!)ED! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    "  R@W)2_!;0>&($  #!$   &0              @(%T7 $ >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( #*#<E*P-$1P&P0
M #<0   9              " @0UA 0!X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @ ,H-R4MT+96HD!   (0\  !D              ("!
M7V4! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  R@W)2
M^VCGOJP#   K#@  &0              @(&Z:0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    ( #*#<E)FGPXYQ@(  *<(   9
M      " @9UM 0!X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @ ,H-R4E:]F)1@ P  V H  !D              ("!FG ! 'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  R@W)2P>?JG-H"  !("
M&0              @($Q= $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    ( #*#<E)DPYW3(@(  !H$   9              " @4)W 0!X
M;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L! A0#%     @ ,H-R4B=-6>M#
M!   ?P\  !D              ("!FWD! 'AL+W=O<FMS:&5E=',O<VAE970V
M,"YX;6Q02P$"% ,4    "  R@W)28M\W%V\"  !2#@  #0
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:+GAM;%!+!08     1 !$ ),2  #AB@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>174</ContextCount>
  <ElementCount>423</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>70</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Fair Value of Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments</Role>
      <ShortName>Fair Value of Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureTermLoan</Role>
      <ShortName>Term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureLicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure -  Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Selected Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnaudited</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstruments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponents</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Selected Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Selected Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSelectedQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Fair Value of Financial Instruments - Reconciliation of Financial Liabilities Measured at Fair Value Using Level 3 Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsReconciliationOfFinancialLiabilitiesMeasuredAtFairValueUsingLevel3UnobservableInputsDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Reconciliation of Financial Liabilities Measured at Fair Value Using Level 3 Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Fair Value of Financial Instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair Value of Financial Instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Balance Sheet Components - Schedule of Components of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsScheduleOfComponentsOfPropertyAndEquipmentDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Components of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Balance Sheet Components - Components of Accrued Expenses and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureBalanceSheetComponentsComponentsOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Components of Accrued Expenses and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Term Loan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureTermLoanAdditionalInformationDetails</Role>
      <ShortName>Term Loan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Stockholders' Equity - Common Stock Reserved for Future Issuance on Converted Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquityCommonStockReservedForFutureIssuanceOnConvertedBasisDetails</Role>
      <ShortName>Stockholders' Equity - Common Stock Reserved for Future Issuance on Converted Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stockholders' Equity - Summary of Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockholdersEquitySummaryOfConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stock-Based Compensation - Share-Based Compensation Expense Includes Share Options Granted to Employees and Nonemployees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseIncludesShareOptionsGrantedToEmployeesAndNonemployeesDetails</Role>
      <ShortName>Stock-Based Compensation - Share-Based Compensation Expense Includes Share Options Granted to Employees and Nonemployees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stock-Based Compensation - Schedule of Fair Value of Each Option Grant Using Black-Scholes Option-Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureStockBasedCompensationScheduleOfFairValueOfEachOptionGrantUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Fair Value of Each Option Grant Using Black-Scholes Option-Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Income Taxes - Domestic and International Components of Pre-Tax Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesDomesticAndInternationalComponentsOfPreTaxLossDetails</Role>
      <ShortName>Income Taxes - Domestic and International Components of Pre-Tax Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Income Taxes - Schedule of Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfProvisionForIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Income Taxes - Schedule of Statutory and Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfStatutoryAndEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Statutory and Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesSignificantComponentsOfDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Income Taxes - Schedule of Net Operating Losses and Tax Credit Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfNetOperatingLossesAndTaxCreditCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Schedule of Net Operating Losses and Tax Credit Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureIncomeTaxesScheduleOfUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - License Agreement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureLicenseAgreementAdditionalInformationDetails</Role>
      <ShortName>License Agreement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Related-Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related-Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Were Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonStockholdersSummaryOfOutstandingPotentiallyDilutiveSecuritiesWereExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Summary of Outstanding Potentially Dilutive Securities Were Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Commitments and Contingencies - Summary of Company's Commitments and Contractual Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Company's Commitments and Contractual Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Commitments and Contingencies - Summary of Company's Commitments and Contractual Obligations (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfCompanySCommitmentsAndContractualObligationsParentheticalDetails</Role>
      <ShortName>Commitments and Contingencies - Summary of Company's Commitments and Contractual Obligations (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSELECTEDQUARTERLYFINANCIALDATAUNAUDITEDAdditionalInformationDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="alxo-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Schedule of Certain Unaudited Quarterly Consolidated Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.alxoncology.com/20201231/taxonomy/role/DisclosureSELECTEDQUARTERLYFINANCIALDATAUNAUDITEDScheduleOfCertainUnauditedQuarterlyConsolidatedFinancialInformationDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) - Schedule of Certain Unaudited Quarterly Consolidated Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>alxo-20201231.xml</File>
    <File>alxo-20201231.xsd</File>
    <File>alxo-20201231_cal.xml</File>
    <File>alxo-20201231_def.xml</File>
    <File>alxo-20201231_lab.xml</File>
    <File>alxo-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/stpr/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0001564590-21-014169-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-21-014169-xbrl.zip
M4$L#!!0    ( #*#<E(55MUZ,H4! /??'P 1    86QX;RTR,#(P,3(S,2YX
M;6SLO6MSXT:2*/I](O8_X&IG-MQQ)34?$D5UCWU"K6YY--MN]95D>_=\F8"
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M$TBE9A\+Z*A2#J="LD#K=3M]M%,VL1P@._WQZ/;;S9$1>0Z__-=_L,T/96\
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MC8106(+]G;J3G*!?B>$J9 _!= I]F)_)6F#]6QHZE;N9V7:=/] ;"4SL$JK
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MZ<?OR;(SL\ %[Q,%/XS%?:6]AXW'OT7]I]J-/_,L>$> 5&)>'VLD''?9(6:
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M#9L$SHL9.B\D3J#-&INVUOY M4B_+B#8$&5TD_86$$D/ FDV::IKMFU[ -K
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M3L]>DU<[/6NF^0\]G<9O YW>:8/80*JT0&-J@[C7Y-4&<=T&L7M\=J9+ -I
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MW\!_F4.9T406.,6'E%6(<T-XJ8[/9351^U-P1J55J"TP#JC(VU0'KZQ876/
M-W]GQ:*5JX%LM ^RY6-=_TQXZ\L/*/H/UCW4U-,Z9"4&7E#-FJK,)L;J^@PV
M*%/6T%:0&U3^=X&7^#&,.$P<Z)WT2U]H-:8;JW9@1MD:K1IO;ZD)=JU;6@ZU
M,XY?%K]K#E];R85&3D <,UE.PA+9Z@8X/)IAH%[(NRP27VQ 4OY*!A[N_'F
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MKS]LX1!E8QZ4<T3Y+HQXL4_,X9Z3:-  ?RS7E=,IS ??$6PBXGLA?/5U^A)
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M\2[[XSW3&N.\6SX&MGF-Y[D7Z$:CSL6XZJT,-;<$3[VW9-2K&I!MO#$VDS<
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M^(_(WHX8])$ET"!H1=::M(TNFTKAN2DG1$ZP4)RE!^(^2#Q$"&:[*]0#?+&
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M!O#Q!48:1H=%&M:'1$<&],>7# Q8['<_N#^;@550N%P;G6HK\_"R1H/$HN,
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M_2TPSBY15RO]EC]EK?EA\&LZ;BNZ;L*=WV]#Y?B4U\UR9\T7:-\A0LIC*2_
MEHSJDE92PRUH&6NW9P&&ZZKAFTG*5EO_M6T7"TT'&O3;X;%.LN9A:=^T:/M$
M:%J6N!*%T6[E\B!3>MZ*A;W3&<C&9--"Q^D,_=.M8"P"'%.IEI>SM0P#W(BG
M+EN<=EVB7<L1Q83&:%0Q)-ZRV/@)-O04RM61HBRN\W"_RP,!MU*D<,K.A5"6
M,!C%BOBVQ)A+D>12/!HG?T/'_Z'W\US>5ZJL'O6^3NQU[>ES'>I@Z;W)+^!.
MJ6W!#SDOW8"0NEBXV6G%D4I=+H%;IN.5GW8Y8!LWQ1ZPU75UC^PWO6/Y*P)W
M@W.3:XW_R![987OVR-K=M^S;QU\O;SY^./MZ^>WF'^SFV^7GZ\NKFT]?/E\W
M8[=L.@O.M/R&*)>):)+GEZT[C7>N.WTK[Z?[4"*?:P&BB-&,\FINR&Y ZGQ@
MJ@?[7K,?+"@T7!G;U8U1:I4HU4^KN_G*U!=EM</#6<G;%=753(HI^_A=. DJ
M _8%#$@''4P>:?-4U;_E(=RFFW4*+!KIL<M%"/^/HJPMI?M@K0\KE4O_#I4@
M&E(87-)[![.O0.L7S;^,E.*UBOKN53 'U^_3XP)K8Z>[_'#,V8PK'UGB&0VN
MK4IL8U^;=%966@+SDRMW7-DMOKA/*21;W4\70O M54B4!Z$R[G/1]A E:M1M
MR@%2AQYT=3GK($%C6!G(IKBU$2]G!*6/8Z+V$;MKMC];@$NM@I'A[V@&BW_C
MT@N4;'=_R#E+E;#J?ZR<L%!2#"0D_/*$C';L: :<P%:SBM"#6MT+O-33F$ML
M_VT0N&IU+NNV6M?#(,4<K6"64O44ET2CM*MEA_-AI ,W]CFITYG&'=12X7=]
MJ"5U40/<OKI>]X[N;U!IRF5Z75I@LMCK06><.Z0XPU_W2AYJYAP?=B@F=6K5
MABBKY+<^G+M@:$VG^E%$!EKWUP1F9UYP>91*LW!S8:H%*RI-/0?SG3L;5%BJ
MJO3/,(HA7ZAP%8QI0^*EW]1<0N=$GQF;PA1>G1B-X;A+-7D>3,UL4EZL3B74
MF$$28XQ>.5[KPE(,FQJR?*I!%?\18:#EI-L9%F)4GO)-";>O2DXA.(V9-#?;
M3:''C9&'QX"V:AIKJZK!H,%6]9<2_E;]E5)LNIJUJ72]C2&UKTJ'3O)@8-[-
MLHVUL@,.[8/L5[4]XA$2W]2,[63>V4SGV_N,VPXWV#K3( FS"!:NQD6Y@;-J
M]CPT=UC)W$&[1BA'^B&MAFZ4+N>GSFT>-WY\ID3;'](#6#KJB[8"YC)0/(='
M=$6VZH$;JWBQM1JW.H5BAML#<>DAB-9L@9FJ%ALNE+(:%2S_:'O*M+^-]1NF
MY:Y6MFPU3]=]R9;_!@H^>Z<CN&4PMJNQ11)&27H"[:%]BY-LH_+[GIU+^U<@
MRQMZ5TX-6AO"J+AU"Y[$6'>D3]_@:GO(Y'R>^"H65QASZD0O#DR&W6HV!S4Z
MT-C?!0P#2!]8^8[>1^@K.4^]O=4M?7$1*BIM%@0M##-@EI^^4Y,':\8J=$P+
MCPMI!0B]?</?,EDH4FV_9H=\H-ZM4HJ?WTS>9EO$\;@;2*S2 9NB8P<$N5:C
M8Q]YB/L+HZ\BO,:6;XR%C5H4"[/?LL\?;]BO7ZZOV=>/W]CU7RZ_?627-S??
M/OW\MYO+GW_]R&Z^L*LOO_WVY3.[OOER]3]_^?+KAX_?3A,G,T&/(,5,01:"
M>W4^6*U\X!$?Y(QTT1N%)XE7=LO@LI>CI['T$J0V7/K#"8OK<:E8\#@.Y22)
MLU-GY1-U,X :@^IOE+P$201EJ906CEC$V?N^6RH-&)2_???(N+]\RI-R A;=
M4YWLYJ=7W5=J:S2FLX&AS3^GN7+4YS0+CZ/4=9YS)\V6HS34(A+OLC_>,YU4
M9]PM7\6Z.2?Z7+JN)Y[Q@K[S3K_R"_JJE9P#$Z8]-R*/7^7V"" OE!-+83(V
M,]%2^0H/NUOI'1Z#KB*'I]_AH97+*<!\0-5/0O<)4/X#W9B/*VZ,#OS:H^Y[
M\&>.3'UV8GE\P3L]C$'F-!=ZM(*\ZJ<:B<EJ!=>FRZB>#[I=EU&='Y'<DY@.
M^XINMADR26Q6O471&3Y1CHC52$TV4TW:%Z0F24T>H"9)_9'Z:XH XBXM4]2?
M<3?:&X/2:6(CT/$7O9LAC94T_W:,S\D<]V- >XX4I1>Z_Z2%MUG4X&J:/:BK
ME7?.U "Z[GZ6!UTL4Q,\Z2YU8_EKV 9#HA8B0FQ54^B(K9J%)[$5L56-@""V
M(NB(K5J+)['5Z4*WS[ZFTI[0;7KVH.(U$ K<&KLR3!KM1'>!/S\@VF0@BP![
M^V8PM,X'^^T ).%Y,5C>&@L(^:R& -%2R2!:J0-*;^P+JS?H&XM52X6':(5H
MA22#:*6N*+VQ^]9YWS86JY8*SPY:J6R[J=GG<"N#ZE<11>^8D\SQ-@=, [8(
MQ52H5&RNQ*1OOHM);[W 2>\7+Z!M]+B4F#G_JS0VY8PR%2\GU^L$LPF FKO4
MM<]9DU8R2@W06UUX?CJ"31?(-T.KU^U5#*>YAXA,@NK8,,&I*6Y(EENM5"(1
M6IW1(T([=.G4ZO;V.Q5+A$:$1H16/Y5(A%9G](C0#B2TOC4Z/S:X3H1F"*%5
MMDMX5\3=#1),7-WKM(_FLJW#^R0KKWA[\8[0\B$ -EU/UF(5_] \1RL M]JR
M,7TKP LBVW1)?C/L6A>#8X/2SYW9:JO.;:585KUW;;L/WV+CAJBPT? 2%;:'
M"GM]JW>T]T]42%1(5$A4V%QXB0K;0X7VN34X>JL24:$A5$B9CBM#Y8/ 2W%]
MRG5L(C@U6+E=I3,R0FH$W4-KA"R-.N/9TB-M-4"&CDP; @2Q56VA([9J%I[$
M5J8B0VQE"!#$5K6%CMBJ67@26YFWBYF"MW]7I0GWC-^)D-\*%LUX"&T(IBM;
ME@OL&CT:&Q.#!$D<Q=S'B5+QEFT*;]=R'9[TOIG(4+*U BY[; W&0ZM/:3Q-
M0Z8&@D3NOB% D(B8B@QQ30%7W^J>CZS!J.K]QR1']9,CHAI#@" 1,149HIH"
MKIYU/NQ:X_ZQF9M(CNH4%GZ)=-(M/O22)[=8B%#'B;>DN6ASM+B<X<-B$QY)
MAW$?$VY[22S<BC=(4]*/YBPGTNFM$Y_>JBA)&2WK;T7R3:]S/JH833J:5>^D
MFRTVV(C&ZHP>T5A3D'QSWAD2C=4!*:(Q T$A&JLS>D1C34'RS:C3/W9[$-&8
M(316#JK_J.*V^5.NO#MB9%8&XH=#.KY5N6]L =;76VP2JG(+AIW>X*!&/,/H
M7TO?$2R>"785S!?<7[)['C'I,YZ&SX-(QC+P&12&UR]B/%T&;H17$$;0">%F
M@6/_8<1=1JKDB,\%@U+3L/*F)[>6CN]A&=!,+XFP(<%4/QG$\(#DWLK>[_(&
M:'8?))[+9OQ.L(D0T"5X_DPU0MZ)#ML#0[L>(-[,< 0]+[C';I>'(!\E;\FR
MGK-(.$D(J$(K[P4,OO@.8^O"6$_#8*Y&&X9TD<0\3L?[$>#PC:7@8<2$C\5\
M$(Z83^"1OFVQ7K?7Q?^W+]32 OPQAADC')Y$*:JJH5#&?#=@[Q[!Z^6EOJR#
M]*J2UO,_O>J^8H[P/-3DT+G\<\H1ZG/*/@[.\C#GFI0H0#][?!&)=]D?[YDF
MDW&WO*5D\T+C<V=^>OK5M27C0_?_%-9'W0W_%\B57SE&Y7&?!)Z[R1!1*(TS
MD';B^>QH0?-@B  N&R2VPIT7@ZYBF7UNC&D=E!G;*$C_8(^Z[X%VS)#!%]PO
M8PP<I]DLTU(.JQ6*Q&8U0RMGLUZE9&;;1^6%);93FT3!G3)#)(G<JL>@O/9R
ME!R1VB2UV0:H,?YDALB2VJP>@[W49NMDY GJL(HT(J0.GZ0.]SME].Q7>AIX
MG:XQ*)TFE%)!!OO69*2Z"OP[$<82UWX6H9B*,!3N>A:J2@[/[#B53.F73-WD
MLP>=M7*+2 V@>Y@!\PGPM4(4_S#NV3US :6SSL82&*75,$5$B*YJ"AW1U2'Y
M!KM6W^Y;X^ZQF3F(K<R0-&(K0X @MB+HB*V>!\\+JW=Q;G7'QV8L)+*J4-".
M">?2!0.G0NCO/(1'XPBS0RV2T)GQ",]"G#K&2RGVC>4RRJ'77F0H%^4I([0D
M269(4B7T0SXOB0@A0V2S'UPC&US6GK%0D1 1S]0("!(10H9XAIR:^D%#6UT-
M1NBJG&4G2B;_$DZ,<=)09)%2<Y=@*1I*2T&$#!D.1SNH56<2) &BC3^- ()$
MA) ACMEXT>C ZO8&QD)%0D0\4R,@2$0(&>*9C4?_>Q?6A7WL:AM)4<T"H*:E
M36P8;%\6F",[8C**$DQ6[KOE]-L5+YR>/G=B(S5B#5;Q]DO]2XK33/2ZF^YN
MH1,L6R$=6./AN=4_^KAE\U,4F826,?N$MM]'UF(#I0;JD<BMSN@1N1V83,"R
MQWWK?# D<JL!6D1N#4*'R(W0(W)[3DC'(_#=S,FT3=160<3YM+>G;HXX/]L%
MT[TN%MD Y%X0HHT!YD,0:KI6K,$*Z>&)U.G2\!K!NV<");I>_, 0]7G529;H
MBO%:$N9#+_[9+)K&H4/T2/ 2/9J-N6U;PXN>-1X=&PH@?C181(D?34:'^)'@
M)7XT&W/,*']A6^/*]V'7BA\U)!DBN\"K-E+^8\QA\/*G7'EWQ BM#,@/A\S7
MK6W^XX])=';+^>+=1Q[Z,!.BKR*\G@&P-U#9SU[@_/ZG__XOQOZ8/88Y'V0\
MAR9$E[Y[!=7 2\)WI(@^R,CQ@B@IO<ND^].K7_X)</6[YZ\P;R[VX9N8_O3J
M"K^UQS;\Z_T3K[#NPI_J#[O7MU_]:>/8X$B,%YMD?]/8E"_L.U2XGS WWMB]
MM^SJRV^_?;KY[>/GFVMV^?D#?/Y\\^GSGS]^OOKT\;H8_ZV]'#W:RV&G-_BA
MW%@9@VYPGJC&#NOJGQ..V9$%5(+[W#]!R^:^G$J'JSWPI^YG9<KYD\_BF4B_
M@FF<A)%@P91-DDCZ(HHL]3/(QH+[2Z8N!XV8].- 3?F0.[$>('X;"J&$!U[@
ML?J52Y]QAM6*>(F%AF(1B@@>TH.H7KS7::AE.M"+,+B3KF#0=@;2)T)HE5P;
M_ Z[*=J4YSDZ?Q\Q\7VAQ)0E\$J(38?>E)HF(_CE=U#E/IL(AR?PJXRA_+O
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MOQ)?JUM5+NHJ3S4#&@AE>;J3OM!Z.-6F/)_T2S7E<?;?IB+ENXH6<_P[[)M
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M2R>DF1O?RM'*^0IT/CJ#C:LS-*M9;^FC,9@@)HR<.P]NQVD6S09PODX5RRY
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MY;%NA8)#>1FE?CX]>D6I0D[*N5;NPJ/RM5Z5-_DY8=3XFGS,241%G%ZD<H%
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MA:V[MNA34'#;94JJ,%?SW8;Q#>%74$+A]L79ZOS\.+J$2@_@2KE>7&#M+_.
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M/]8]!-)(R+\STIV]V11@[QDCPZ; NJ: T^DYAV2A:JD0K3 'F%]8B[59-"Q
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MRI8%:I$)B@H2P_74W7.9[930>Q^)/Z-4* -^Q:&REG5 H8308K,]2=UTTT.
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MZQWP;)ST-B,1&I;*Y*;=C%0[#-2H+T*OPFU:Q*YHYBIL:VQ#UZG4\OHT-CL
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M,Y?/VB&QZL1'G;0BW6Z%Q(I=^4&MPQP#?A+)V-UR!2A)C)P$)3>H^/" DBS
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M>C#4! /V(??5DEAME*CX!W,+ S!E]"8C9\,O1&,7;9YH#'MCUIV>!E/)_@A
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MIOX]PU'!V7WW;MKI8N]FOOVR=8)H^VQF,5U7-K$J[.%DE,D[\F\@>IOJ:B?
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M>%==*W,.B(.U<MDXGT.<TA2>?'\M0X]7Z H[X_W"[Z%)/!U#?_D_4$L#!!0
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M_/;JY/CTY/C-\?&KHR4),:$^QV^OJ,!G"<4(+XLH-067IP8_^SA.T7-Z&>6
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M%JSAW^0AR:>208B1A6CN[A9%H5, JJT"L:^7)P%,!TU?<8Q67SWR Z5?LC@
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M 1!RD;<9\><4>;4L<>\XV,S!I ']')8.]K4@H*0'\P$7&;L9>]>J7 &O'Y.
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M]27U767EY17@][2E<9.&LK%"7S3YHU8OUU#G[& .&(%NM1PT& %8Q<2RIN?
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M_<6+),CB T\25._&CENMKLI,Y"\SD4@ B7_]7R_;!#S#+(]1^F^_._[VP^\
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MDJ!!!4J&@0,OP?Q D$8@)#_ FK,?_J*&(])2YR(P2P2X,$M ?Q"8@E4!2K:
M\IW8X\[V\ )#=PL3G*]%-P%>J,!<H;.;'!U]K(;HVG>K6QA"# U>JN4@VD-
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M@ _;0Z)]B\/MV1L"21P\L(Z" ]M#;T,UY5I.V#&K9 &43UWQ8<E4)0\YQ(T
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M;![IUGPE)I4^OT=%D(C_?HKRXAH5?X'%+0S18TK>>1"??53)3B<22#_+F$1
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MAJH29FTC_149I4*XS37?2GUC0;>4WK^XJRC9C%:N).D,T=>WO:5Y;-9F"-9
M_.NR3_N!N!K$VXW%0O7;NVBL+-N,]JXHZPP1>;&[<:Y,V&9PUH+_:S-7^P%:
MW+NS$*+?:D6HO<-G7I[TLE0NU/I]*95+B^3%3HYG,]97MW\X=?5<"?JOQ$*=
M[D!ZN'AX&,?E07D.NX7;($[Q[T]16F1!6.R#Y!YFVX_*L7=J\69X9T!?W EB
M<L4;",S!5;R!X)N_P"#+?W_4V!\:?3AP\M \DX';>!;#U#*^0F,6P_>#7/1^
MT-WZ[/8-.IB%1?+^&;8/KN,I([F6>/,9OX:X_D9R,7]Y&U'=Q-@M1G5M*_D*
M#=MR5!],R?NC^O%2HOKYW_=Q\7J9YD5&FU;FZ^()9O=/0<HUL'I\S.CMC4L\
MPCC-X_"7(-E#P?TG">]6Y)S!'2S(;3_@=\7N2@Y0"0*H)#Z>0)S;TFW$=FN6
M\35;M:5HS\8#A $!.B) AC3N(F(RM+!".'D*$$_-]!86#/&/]XC\2ICV>J"<
MLC1N(.1\I4AMH6>/]WZF\;,:N<5*NJ%=?+4&;;W:SL937N2D(P+WB/ZZD?;W
M>LK$H?Y\NTO0*X1W,'N.0]@-YS5*GQE.9*SY/2J"1/SW4Y07UZCX"RQN88@>
M4]4G,!T*H6_9SH2R'XH_IUE%O?$.?./-#_A"?O8D^KJW.S09E&_6QGAT+*4$
M7$S0&RXK45E4S $5MOD9(B[^8 &PP*"6^*W$/78&Z )E_%?D<TK%ZJDE\]!Z
M.R6=.6P>@2^\4O<NX)6ZG41KAL7'TV%[GB+(#EC#UV6[4X;C\BPCZ?,KCF1A
ME8B#:P!4 _,5'>3DF?VHTZ!\]@,Q,\NX6@@]T_H7V@#$5U75 W-^!-M)K=+^
M>3L)=+\&"W1UTJYQ%IR9]KQK?%-(!F^TTG\\"PIX$<39Y/%4631?VJZ.BNKN
M1$:5O]+'.]]%I BUP6QYV,59+4N&WT:LU35>9^U_)9'_R@S5>C >O\3.7FH@
M8P%D,+.$YLL4KS7A78&%(&.X(L&2@/42YRIA=)",OB4-D+4?GA@S4'$#)3L_
MXI ,4DA!=1ZCDHP  GXCO/Z/'ZYRALAQ*0O.4A*R#@PC_-\.TXG7N,N(ZO,:
MFW&W8=RF=IQ;F$.,V],JC<[@,TS0CHAUSLJ:GZ!J8U(I<OI 29"W[THE4Q"D
M$1#8^N%)*@ B#4TN *RDA=.JB1/@+,%OC.G4+O8S3'%.F6"I5M$V3N.\(!V<
MGZ&VDTD2U$=.BH%]1^-LJ9\U&?OA:FI (BU]+@*TI(G7Z@"ON5V.[%NL-W=!
M G-U]^KXLCXJ!\3LNPW=I$&;<L<G!QNZ+9.0]P_>[8*L>,5_>X;IT/IU2C?J
M!P>-ZLT[(!(! _(4)J$O8?4*@J\2:JXPZB[=<$]SM>^2D^=9M X,^77KI*I(
MK?)\ORUW$_BIPLFN#$I(,</9^E&I[!M7=?P1_W(+OHE3\$IO^?D1H2:P,AOW
M.21Q>[L69>DN1EW@!8*\PA'=N:[7Z=3INU1_&^=_N\@@.20-L9Z+6SR=?,+I
MVG:_G60_3EFF&?8W%&5T4&; S-YM,#=RUH&R SB9AD=@RSAZ%!JGM$L;6VU:
MV'XM-FAM<ZTGC)(! #("4 X!D#& 3V-FO="X&KSX%U=+F7RV:2;CE'&5<?Q:
MXFK++B>-JR*V7XL-SA97Q\S:_[A:9MYG\7,<P30BXYHMH'8+XXD5=PGG<+4>
M<38T@K[!P#EH>*XB9C^&;][(7,?(RG!+T6F(? NA\1>48#))7+SZL)@?D<HS
M.^Z4TF'4I#5TL"--5,%SQ?LM+^SEK-1U0!W ^>NQR,E";#V&-[.^[X%GYA7^
MB%1^F[:K5?YXL'VSJWTY*YTXV'JXXI_ (N<+MK,L^MEIUBN4YQ?8O$E'RCC=
MQ^GC>@<S.N#\!&Y0!MGG[H,72-YV@?&CQI%L/2ZF9X)UN+KH14!>1&*GACWI
M7FX!^H/3W?K*7B[,S7/A1 Y ! &U)* 6!3!9 /\TE09P<?QW_3/\0U[$H6/?
MK]E,:A4E6Q=7.?#?4LHV2!;K_0?HF[E_4]T+1MH\ )3R3'W&=I]E.&&I%,,/
M(I[ %&[BHDN3JX><MJQ6.HQKP,7@L*@V5P?'>YDL>$F#GN.<9)'D?&_,+* @
M%O"3'T'!@D$@>Q L%_RDB7OMZ]6I>BY*3XSXK11G\E/W3.(+&)%K 0>:TW#[
M?E+&\/:1MN_ G)-73CJ*T:$G#BO,<SQ:/L69=3G5/#Y#EW:K-"+70:UXSAA!
M8[R&&=CW(LK/*Q^2Q.S0DV14MPA\6EY%6=+;8)2I!]YU!C<0RQ9Q?^^9TE7<
M2Y:B/GYR'+Z*9:8B?$A/B<N BOM:R;*:POK30Z_6@_;6?.Y2>TL^1>[-<9]B
M=^A"QM4/GY*$27HEYG:U-?&*:J;IR7$-Q8B->73THHI2Q<T"HUZ54CRIG-BP
M@X[);X;:R>R8MZ?)Y51/2I$;B;O%C%6.KCGT,GS>]/)0"\@.]Y57Y)) :SMH
M>]'HW>3,]U=MKAU'*%I8D QR^+K6CG+P=:T=)92X#*@.UHZ,IW^^9M')''K7
MQ,O'B+/URZ\T',JQ)TWJ0CJNHWPL80(3N^G=59[E0!$>,7E0) WC)*;328\B
M5N5^$4D?]C@:O-;?5[PL:)FQZ5$42X+8G^-7!=CPFF->LA0,QJ,K@6Y,Z>"\
MDE6DWI39-,\TD1C9E&UH5;ZJ=V<K$<7/SW"!KT?#W6LFJ-&;78&T=3OI8^5H
MB2XYQ7@0+D;A'0\(P[I=&)2C3MV_DO<EF;A&:02C?5C$#TG9%[7[B@GIYVC!
MCU496C<)-0%<^'QW^TBO/5_33,;C@0X:;\(D1F-'0Z@J)^B]1T4D\R.DX%^<
MXO5@7.1E^W$+8:.+J'4[.&1BB/6/#.N4OEP>\0!0-67_YV"[^U.C+7O(N'L=
M"@;@'7?W/@W[#Z6LVY)?<<Z@9.V'7YX^D8N6EVE9L,$?6.4Y+')RJ9+=(DT2
M]"5(0QO% B5NUN%7X.[@>@)ECM-Z^D(<,XN@9.>U;^N8R+C3*X.Q?',8#1/<
M1BY34-5/R:>85* 2"ZS&[6;*&+(NGF"VBOYKGQ=DPK*QL#\D:1W^-@O[+D\Y
M>.W:O<B-^V^W^A:"TJ@G4K9 X.N'I[4W04F1[RS>X%B!98R#Q(+GC;.PCO$8
M2P=7C?C&+JG%@TA@Y;6W2J,_[KUR*E\HTJ/>W;&O3[N#G$E9PI0.?Y/%*/L+
M7B_8K9MWD[4.=Q<;^\Y,N9 7E\D#M46VAV"_\WNU/(CJN//VJW5!"(XZ*8.5
M\-:KD ?)"Z+>=OR1^QKYS5\/LOU5&&*;B7@M3<J[) FIHR%%V([^(Q3N269#
ME=TZ]QVP!4? ^)9/&.7?SNM4:O A)6V^MV)*M(K/W\[6MZ,F%5M&)%*=S()8
MDSG$N'II/IV0]=K.H1)-#><J#AY(?[(8YC<9PI-8\7J#H2U6:73^]WU,*\!2
M;VYI$C8W+RE&[BTNJ<4X(A=7J"#X)R(*?2D3EL)X9H=J%M!AF@H #%NKK3<E
MMSN4DC7S>G,8?'5:V\@1-'GR4(*!XZM6+&!Z<L]*#4*DI<E%P,63U)HC>;NR
MJS8[^VVH2@'\BE;Z2%IDG099]KI!&>F5J;1N5")K?B19@HU]_Z,]Q$*1AQ_>
MIP-IQRER:9TN"+ZD%3D%#ZQ8L]YPIW*X3N.3EW@=C4*85]O.S:?>C1QSE+9%
M>$=X.7B3JGDJ M&JO%?G(;2Q'O)8*3TO#=<!W[TDU1XJ0'4Z@IZ/%&28VX7I
MAI#9#,HHV(RVA.*;WK8<@6%PUJN5XZ?*A^:R<03\*20V[KZT*H9+&<, %N60
MSMT-R7YI[N!H<5F#6X3T VBPP:S'!C/-G' -S5(W^GV+P0G3<WVW5JA5>#I#
MB* ,S0^5LGP$8, #,(^I&Y9UUUN$LJ/%JEXG5>NUH@XNCNM[0GG:[R+?$*SC
ME;Y>Q2X'PO&:G\!:JO#G]Z9*XUQ4_(+'*!/?_1U/5^P4$2OY RH 76?6(LS=
MST,05">UZ*9CL66$0'>25$,(FWY$32G$AGIZ'&C09W3:OB2<UKF206::/-SL
MJHKCNRCN;Q=TWB?[Q==+)IJW2":X)C+U/1 _[W@<:$%P=-,%;YN41:R:I.W/
M39CH@A;!/9@-^5.7 CW'9\"/Q(1O^A7S8>!HZZ.\>[;:HKW:!J Z;7T457E-
M<D;FB+1&R6"0^WV94ML&D*G^EX9WTLY8*NX=1VV$.Y),!M/SX#@Z-$XMX/7@
M?7E-O'&(X"I.X64!M_(G>W5(:Y['5&?EY$0FF251=1 C(0<QR-%+XKQLU[YY
MWL:'DY@&^"-#Y6N='99F=A\\)%(+(2VRKNV4LOEO&]4#1]<^!:4O"%\Q7R#@
MMDZ"D0+??=5_HWDP#/Q&Y;!0NYUCX(FC,;N]X+C:%T\HBXO7U4NL=Y>Q1<'"
MI;<&11=MOZNR6<7)CRQU!)6NNX@=NO(3@:1?^> WPF9^%SA#VR!.S9R@I&$3
M!$;SZW:$%C:#KB#JRU<<!MV!,9K\\@)B+W*?DH5<]OH);A\4#UEV$S"H6W41
M?.-/W0ZC@*24XZ7&R_H@YP X"_ ;8S*UM3?:SOY_^RS.HS@D:Q)UNQ\EI8_'
M".DW_2*1+$)(45V>HY$(0 A]B45V<_D,[]2B/4%T?U\?CRYZSMH3^>$4@Q @
M&=7XJ.ZDH6F%J<'WBJQ1-83( J@P"]: ;EE$:O!.HIR=.[MNKNA.>2/WL#3K
MR[$OM2NX[F[<3G3!UJ/+M)TA0WW;?)",/AX#9.V[QWVU1>&)5\A@@Q24Y3$.
M20U!Q^QA:2^ZW[O/7W8Q>WGWAO:YD][74R&IN><CS\+)?MZZN9?7V+PC%Q&Y
M!+Q!H _;>1HP(TU=:VTQ=SJ3M@5*4M,T/BGJ3NSNOGO#V$^34X,4J2MW(;%C
M+-L\ C5?VGO2PC68J<<HD<.)HV2LS8<YH2?V)$4NP)MP5",IA@)D$R]2:\G.
M%-\4E:?I8LG4Y.%G@)E_@=N#KM1RMTO#2T%2,8R>3?_>YN<T@R%Z3.-_T .Z
M_&50I9I1+PE]E'I(VG<OD1$]OO? 6?GA46/H($F5>8I$T@$"F;I.1D&8TA?N
MGX+B5[1/HLOM+@B+\\T&AD7\K//^M2X'Z_B-<)S.T4"!)0%?B"@@IK( 6 K#
MGM:(-Z#^JM=N*6LHXUXK!<\RC6+,YP&1 E Q ),#5(*H/TK=4YWH4< EOQ24
MGT'^PRW,]PF9N2^P =#7!%C>C+]T@_)8K4N[9:Z:RV6K4CBIBO1.RM6MK1Q\
M$Y5B_AZ'!RXH(&X*=HVW//#7=Z6T/E11W)@><@>NI[D#P_>N"+*"3S$G04(O
M?.'P\0 ?XS0E%H$VX!6OD,P7\1ZZ3:-K7A0QTN\S^(Q_'R0Y8$]!XW5%PPF(
M2IB+O-HI;WBHF=%)IA(.5-*!2CQ Y.-OQS )Z9<K&?U(2ZLA_/_M75EO(S<2
M_BM\6NP"G@39 UAD@07D(PLM-&/#4C!8Y"%HM6BK$ZHI]&&/_GUX],%N]4&R
MR5;)V)?$UECU5=57Q9O%AEOO\H0_/F772[E&=-YT&&K@,<WZDBO!A%?00!EE
M(UN,0JF:1AMTX;&K;32-CV6M./L8D6/0#+4:GT(QP,W/LWQ"GNG3\.@J.*;X
M\65Q/)(HY'?$^(G0/&,?K:)#)$=X+MJB:?#.PVN*.CY*]PA@/EY&J404W3ZI
M04$W1DYB:[QEFD[:1XHCW3:K5K'=: DM>:7#6D]4*,H_7>E&'YSIQ4-<)I0R
MN<#Q;GQ:,?-(4-[Y>L)Q0$0URWBWC-FX!:=947/:S?!/ \9'SST*Z^/5B"KZ
MHP)+7/$_EDJ4]<G1GXO5B;^H8[_\*O<5C )):^2GR=P5!XW.&*^\+%DI(TZ1
ME^J49>$G5Z&A3(>7/-[QAG<5A5SF,STQQ!.#>V*A&9>F&]2?,1)J6_'! ,1/
M/0]5 39,$AJ@1*H@\UXH >H94RN^J;7+K8X!WK$_82,!PF0^X]><\# [?8X(
M"WL:X_0I.'$6],-16YYE)&K*]Q*$);:(MZ1"1X<*GD6AQ(<0?J;44AL76P7=
MXC7!^" #.$I.]S@-DT@\]Z =9T,B+$.K7Z27:*K@Y&'2$]K5@!#"1X,DJNFY
M.5XD78=[-N\A;,9U1PFSB?(C.V]XD22\E)R(6!;0K%4->_YYPWY* SEQTBZK
MY1-]PH5BY]IXN!%>Z,@GG@TMD:JF&(>U%57_ JFJZE5ZFNVBN;^(I/ZY_GC1
M1RX9>'ZNS3%?/+XH2IE6V^H1,.&*5I= ]XU'+V]B:*;^+EY9XV>8XB;9,)J(
M80*IEE]!DE7D&D<0ZXT*(Q>IRG7>^ 3=[8UY]0ECT?:$&4+]/^_Z\LXV'.A$
M+JZ,^B*+N_K%H+<G-*TATS-'?/@6DCQE$</?[<E.U11#/T&UQ%C.%8?%>IDO
M5I ("TP4E* 09HN:=%$#_P&F1FT3:UXD(*H0IY_<FL,6,F:&75FHM.RT4QQ^
M]TK?OM_A2/;7[(=V-\T^^G6%7P/R$&<&16,[OV8>-AUBW(>) $ 2X;+Y.N1L
M.N -0(XEYSZU&5<:QZB$TB_H>OX=.R>J,CRT8$""LM.[M,\#4#Q)5">:%UGM
M&?ZLLR!^H<GNOWD<T>3G..)GAAF X?!G3(QE'SLLULOPIX1$$A/5H!"&/YIT
M40/_ ::F5=FSAY?IPY\Y;"%C9CB;T=S1PP$G81208CO7=DXS+LAV<W5$L)]=
MU0JTVM<'-;/1IHT:>1$T1<TUGXJ? M+E#&<>>\BX*<[2?(T)9B/1]<*TJVY_
MS[8#:,KQTQE+#+1>0,C0/H_3(8] \FZC/ZU<ZZ#_]*$L:>F)%AYZR 4;36_I
MSGK93T/2Y :X1[+O3C(H8*'VDF/4G7>3@XZ$35-/1UEB^NDIO5ITWE6>&^,N
MX9-3F@7D-J)I&&$68<LX-,WT 1&VL=,KTD]N2SA4X_$CR2"2>IP>JNDSH%0T
M\K>3!P>)Z]D&,J3^I=YT<'#T9V7R%JL?7/O]6I=ZS+B/;WSN::7[F,!<6_M>
M H_Z)/8C!1FY6'S!O,;2J!1I>H?E&@TF7;:6BRT%M(@!"5Y>K7)@ZZPW0QJ-
M*=&^%G)E5I*6@9RW&A75L.C)F8&^;V$TBH4,7,& ;PEI&R%QT+V.$9I%XG%R
MB&(Q3WE\J8"^)E'&DO<+S5A>FQ:*UY=H6RQ>%\%/P?@:G=]!K]9HT+M4 ,5"
M TA5XXTYIG:>MKHJIHK9T&>&L#O=)C@(]PJD=O1I2K.^):LAW=/U6"6H^/7V
M1("+"D=;H4$C&"&$G1FQU-S%U]%\-*K<&[4=#LK>SVLJ.;>27PVHK"R 41',
MKIXLF#$KFZ-]HY2\*CM)P\2R!!9%$A1)U :YDTLGY'P1B]\H.QR#^+1>QF]\
MZ)FD7_=TD>#JUV7\+&M\/ 4)F^.D7S$A^KW#)!#;3F,"J)^^1"C$@S.4*OTI
M.-+T7[Q65:$*>M]3%"18^22*J^(J1ZX?"MA?,0U!]#0N8H<ZH\MJ&+2,HRP*
M"&\[U:8ZRO8JC':DZXJSC&D]\5ZBMX!&K"D^M#I1!M\,4@C!:4@LM?"P5< U
MHK>4O\@S>F".#@-"3L\XQN\!*0MN2F5^C@E.T[*+Q_KS0F=XEB'K"-]+3#\W
M6]8JH@-5/1;:0C\45 K*),B%BN)GJ2.$L'<=7M0'C9,3YW.0_)X?[VC*"YB&
MG-!7K:H2FH(<A'J7X!EB^"!@V0 CS?@(N0"&%IB#]'5%7+\WYZV HNJD;J?<
MGAK_8E_DQ C 124) T"_I4K*.!9XS;VJVU/K7X%6([&)CLZ"(\:D7&4D$,]!
MH-NMI)BQO5_$NWO\A@D]\L9UC9,W-@5/;8])&DJU[G ,4#SU/E(#L46WJW5
M::$$K+51.[*IO;NOA]AF"5B%544!5&K@\OCE!6PE+3,7HV9>ZK277J-L6IW(
M1*I]UZ*/XB."E:X"QCC!@DIJ[\SKH8UT,#;6]5^BTI%JO?Y%]:%ON^'(U^5U
MX"ET?IM]S#GPW-T9^JXNNF\H(7$48\.1:_MKMKN]#3%^3H04$! &ECW.I@/>
M .38QEYY(=_!+K@'34E326?W938!(4&XV>,D..(\BT*#>G4C FQY[A'H)Y4$
M&-]"K]! 9-48*U3+62 9:.2<=+\*Y2#]O*I/>C4'-E5:V5QV&9?E?'R]\G<I
MI7=H#?"6B3:+XW.CE:O;(/,P-C8/<GUEX^+'8QJ'NER>C?D(SB$-OXB*VD(5
MM$85.F+:(*:.\LDR;DV5%^ROG+ADSJ,G:F28G#NY+BM)TT".V3JWR0TTF(9?
MW7&,[BLCEJ<O/IAO.KN#VDD-M5"A%ZH5D^$D54,;3T[R=\A!C8S/RID&UN37
MQQJNQ9A.*@NK.!YZTC#)RYCY/L?\_4K%#9'>"VDC NS'6IT"W<?48YZE61#O
M^ N>11?R28XA$ASBZ(UO+0-YL7"8(ZKE.I!\%&G!$.0CJFI^1!,OKM9#]Z[-
M1:?/(+[A9$N[MT[5#7'>?,W]@/47G,DW&%<T31?;-$O85,(DO7L$V(=3IT O
MTPF<<+M^A)'#PT10+?^ ='HY3<%9^=HGQT"_E"AS+P(],5DX2?!NG='P]_OH
M+=KA>,?+-HAW,Q:[W_(T$Q>J3=+ 1*H]3?HH7MY-9P/%'U&8'_@E=%XZXEBJ
M@W:E*H@--KFCY$N_]1^D7.$])3N6@C 2SB(.J#T35\!Y,U\K6"1P404LCL+(
M)V84[)F3^"N.7O<LR!:L:V5CXG(Q9KT/F,G*R,VF1S.7;4^N*9;[?O >QU3,
M_,#TA-;<TJE^O38>BU0MP5&!CNHE0:D 4N<R%^MX=7UT&Z11Z"-A"\'^619
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M11KM +RM%X.EV)5NE6]8%NJMR3HU;I:-V.XC$+V[L%=B%6D;Q,"*3?X:SNS
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MWI:NX6?")E8%@=;99> T8#;W>8NLII @]T#)QRVP.8%AG 03Q,5U[Z,V?=+
M"=H/G7S3QLFF+R28/#/Y80M?G/8^VF4K_THR">P=DE9@;\G!'P^>2'8?OS:_
M\6YE,=GQUEZX7N8UF05T6<C+9C1:!!\-'!+\Y:?3DY/3DY]/3GYZLX*=R#R
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M10"H-%T$?[[9H)BIE-/0L[O3/9!NF\W0>6Z0K2/$Z&E9F^V(<I*R\'.M?&_
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M''KJO(L\MT$=SE]3G'TR9PP>-]+5WNLV:_O3R/+Z]_"C,+] ?H">/^=TG4T
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MGF<6>VTGK^0OKD-\AYER$I5-$52[F.6#&_X)-\0=J[SY+*NH=C'+Q%OX&_5
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M[[6LBO.W.(R230ZVZQWYP5&]#Z@/?[33(X#>83C"4C)SLDQ>(>'P@?W-8N!
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M9.D/SSWQ^K*+2V.K-G."._&,N"S8H,S*;P]NY;P=!>('U][>X(WD["C0KKS
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M/4&7#<?/;+V$QJ_ =<>Q&C5(/[KKGAG>YEB=1[Y!>[$3'7U@^O%TF&W\K.G
M='9EV8O4UDQ,S>^L9\ZY9]E_PF\#T3#]-Q8Y!/_PC3K$4_I>V I+?7\D5#OI
M/OA8RTYJ-L%)&,;+;51-^LK_&_6 C <G[@&.ZS?KU5W&2RUO;!)<]<*3K6 ^
M8"KU$.4M5T>+\J7[XCH@/-AL.@=WEYFCP_3!#?^\#@B+]2$@KJ,^2(=*GLQ
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MI0+;G1?D#-OQ/J5&-.Q%&F3XZKAA'7D8T'VRB@N2E.?M1TQ0%4O&!@@53MI
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M<:.'/M8<VZ\CMM78-E 6W"'QN4O[</,O['^>X>[_K_\?4$L! A0#%     @
M,H-R4A56W7HRA0$ ]]\? !$              ( !     &%L>&\M,C R,#$R
M,S$N>&UL4$L! A0#%     @ ,H-R4LE)89& %P  I@,! !$
M ( !884! &%L>&\M,C R,#$R,S$N>'-D4$L! A0#%     @ ,H-R4LND,A\4
M$   3/$  !4              ( !$)T! &%L>&\M,C R,#$R,S%?8V%L+GAM
M;%!+ 0(4 Q0    ( #*#<E+9L ]O[C$   ** P 5              "  5>M
M 0!A;'AO+3(P,C Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  R@W)2=\\'V$>)
M   K4 @ %0              @ %XWP$ 86QX;RTR,#(P,3(S,5]L86(N>&UL
M4$L! A0#%     @ ,H-R4@CN)HD14@  QU,& !4              ( !\F@"
L &%L>&\M,C R,#$R,S%?<')E+GAM;%!+!08     !@ & (H!   VNP(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
